PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Acharya, P; Goenrich, M; Hagemeier, CH; Demmer, U; Vorholt, JA; Thauer, RK; Ermler, U				Acharya, P; Goenrich, M; Hagemeier, CH; Demmer, U; Vorholt, JA; Thauer, RK; Ermler, U			How an enzyme binds the C-1 carrier tetrahydromethanopterin - Structure of the tetrahydromethanopterin-dependent formaldehyde-aactivating enzyme (Fae) from Methylobacterium extorquens AM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; RAY-DIFFRACTION DATA; METHYLOTROPHIC BACTERIA; METHANOPYRUS-KANDLERI; METHANOGENIC ARCHAEA; ANAEROBIC OXIDATION; MOLECULAR-HYDROGEN; METHANE; PROTEIN; DEHYDROGENASE	Tetrahydromethanopterin (H4MPT) is a tetrahydrofolate analogue involved as a C-1 carrier in the metabolism of various groups of microorganisms. How H4MPT is bound to the respective C1 unit converting enzymes remained elusive. We describe here the structure of the homopentameric formaldehyde-activating enzyme (Fae) from Methylobacterium extorquens AM1 established at 2.0 angstrom without and at 1.9 angstrom with methylene-H4MPT bound. Methylene-H4MPT is bound in an "S"-shaped conformation into the cleft formed between two adjacent subunits. Coenzyme binding is accompanied by side chain rearrangements up to 5 angstrom and leads to a rigidification of the C-terminal arm, a formation of a new hydrophobic cluster, and an inversion of the amide side chain of Gln(88). Methylene-H4MPT in Fae shows a characteristic kink between the tetrahydropyrazine and the imidazolidine rings of 70 degrees that is more pronounced than that reported for free methylene-H4MPT in solution (50 degrees). Fae is an essential enzyme for energy metabolism and formaldehyde detoxification of this bacterium and catalyzes the formation of methylene-H4MPT from H4MPT and formaldehyde. The molecular mechanism of this reaction involving His(22) as acid catalyst is discussed.	Max Planck Inst Biophys, D-60438 Frankfurt, Germany; Max Planck Inst Terr Mikrobiol, D-35043 Marburg, Germany; INRA, CNRS, F-31326 Castanet Tolosan, France	Max Planck Society; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); INRAE	Ermler, U (corresponding author), Max Planck Inst Biophys, Max von Laue Str 3, D-60438 Frankfurt, Germany.	ulrich.ermler@mpibp-frankfurt.mpg.de	Vorholt, Julia/K-3514-2016	Vorholt, Julia/0000-0002-6011-4910; Acharya, Priyamvada/0000-0002-0089-277X				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; Bartoschek S, 2001, CHEMBIOCHEM, V2, P530, DOI 10.1002/1439-7633(20010803)2:7/8<530::AID-CBIC530>3.3.CO;2-S; Boetius A, 2000, NATURE, V407, P623, DOI 10.1038/35036572; BREITUNG J, 1992, EUR J BIOCHEM, V210, P971, DOI 10.1111/j.1432-1033.1992.tb17502.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chistoserdova L, 2004, MOL BIOL EVOL, V21, P1234, DOI 10.1093/molbev/msh113; Chistoserdova L, 1998, SCIENCE, V281, P99, DOI 10.1126/science.281.5373.99; COWTAN KD, 1994, JOINT CCP4 ESF EACBM, V31, P83; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Ermler U, 2002, STRUCTURE, V10, P1127, DOI 10.1016/S0969-2126(02)00802-X; ESCALANTESEMERENA JC, 1984, J BIOL CHEM, V259, P9447; GORRIS LGM, 1991, BIOFACTORS, V3, P29; Graham DE, 2002, NAT PROD REP, V19, P133, DOI 10.1039/b103714p; Hagemeier CH, 2003, J MOL BIOL, V332, P1047, DOI 10.1016/S0022-2836(03)00949-5; Hinrichs KU, 1999, NATURE, V398, P802, DOI 10.1038/19751; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KALLEN RG, 1966, J BIOL CHEM, V241, P5851; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kruger M, 2003, NATURE, V426, P878, DOI 10.1038/nature02207; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laukel M, 2004, PROTEOMICS, V4, P1247, DOI 10.1002/pmic.200300713; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Maden BEH, 2000, BIOCHEM J, V350, P609, DOI 10.1042/0264-6021:3500609; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Michaelis W, 2002, SCIENCE, V297, P1013, DOI 10.1126/science.1072502; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POE M, 1980, BIOCHEMISTRY-US, V19, P4576, DOI 10.1021/bi00561a006; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; Romanowski MJ, 2002, PROTEINS, V47, P568, DOI 10.1002/prot.10118; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLEUCHER J, 1994, BIOCHEMISTRY-US, V33, P3986, DOI 10.1021/bi00179a027; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shima S, 2002, J BIOSCI BIOENG, V93, P519, DOI 10.1016/S1389-1723(02)80232-8; Shima S, 2000, J MOL BIOL, V300, P935, DOI 10.1006/jmbi.2000.3909; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; THAUER RK, 1995, BIOTECH HAN, V8, P33; VANBEELEN P, 1984, BIOCHEMISTRY-US, V23, P4448, DOI 10.1021/bi00314a032; Vorholt JA, 2002, ARCH MICROBIOL, V178, P239, DOI 10.1007/s00203-002-0450-2; Vorholt JA, 1999, J BACTERIOL, V181, P5750, DOI 10.1128/JB.181.18.5750-5757.1999; Vorholt JA, 2000, J BACTERIOL, V182, P6645, DOI 10.1128/JB.182.23.6645-6650.2000	48	16	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13712	13719		10.1074/jbc.M412320200	http://dx.doi.org/10.1074/jbc.M412320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15632161	hybrid			2022-12-27	WOS:000228095500066
J	Bilecen, K; Ozturk, UH; Duru, AD; Sutlu, T; Petoukhov, MV; Svergun, DI; Koch, MHJ; Sezerman, UO; Cakmak, I; Sayers, Z				Bilecen, K; Ozturk, UH; Duru, AD; Sutlu, T; Petoukhov, MV; Svergun, DI; Koch, MHJ; Sezerman, UO; Cakmak, I; Sayers, Z			Triticum durum metallothionein - Isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; BIOLOGICAL MACROMOLECULES; EXPRESSION; STRESS; COPPER; PLANT; ZINC; IDENTIFICATION; INDUCTION; PATTERNS	A novel gene sequence, with two exons and one intron, encoding a metallothionein (MT) has been identified in durum wheat Triticum durum cv. Balcali85 genomic DNA. Multiple alignment analyses on the cDNA and the translated protein sequences showed that T. durum MT (dMT) can be classified as a type 1 MT. dMT has three Cys-X-Cys motifs in each of the Nand C-terminal domains and a 42-residue-long hinge region devoid of cysteines. dMT was overexpressed in Escherichia coli as a fusion protein (GSTdMT), and bacteria expressing the fusion protein showed increased tolerance to cadmium in the growth medium compared with controls. Purified GSTdMT was characterized by SDS- and native-PAGE, size exclusion chromatography, and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. It was shown that the recombinant protein binds 4 +/- 1 mol of cadmium/mol of protein and has a high tendency to form stable oligomeric structures. The structure of GSTdMT and dMT was investigated by synchrotron x-ray solution scattering and computational methods. X-ray scattering measurements indicated a strong tendency for GSTdMT to form dimers and trimers in solution and yielded structural models that were compatible with a stable dimeric form in which dMT had an extended conformation. Results of homology modeling and ab initio solution scattering approaches produced an elongated dMT structure with a long central hinge region. The predicted model and those obtained from x-ray scattering are in agreement and suggest that dMT may be involved in functions other than metal detoxification.	Sabanci Univ, Fac Engn & Nat Sci, TR-34956 Istanbul, Turkey; DESY, EMBL, D-22607 Hamburg, Germany; Res Inst Genet Engn & Biotechnol, TUBITAK, TR-41470 Gebze, Kocaeli, Turkey	Sabanci University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)	Sayers, Z (corresponding author), Sabanci Univ, Fac Engn & Nat Sci, TR-34956 Istanbul, Turkey.	zehra@sabanciuniv.edu	Crawford, Troy/H-3862-2015; Petoukhov, Maxim V/R-7371-2016; SEZERMAN, OSMAN U/X-6441-2018; Cakmak, Ismail/A-2257-2009; Sutlu, Tolga/E-1190-2012; Bilecen, Kivanc/E-3308-2019	Crawford, Troy/0000-0001-5403-1476; Petoukhov, Maxim V/0000-0001-6760-4595; Sutlu, Tolga/0000-0002-7813-8734; Bilecen, Kivanc/0000-0002-6254-3516; Duru, Adil/0000-0002-5844-913X; Cakmak, ismail/0000-0002-3183-5524; Sezerman, Osman Ugur/0000-0003-0905-6783; Svergun, Dmitri/0000-0003-0830-5696				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BINZ PA, 1997, METALLOTHIONEIN, V4, P7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BRAUN W, 1992, P NATL ACAD SCI USA, V89, P10124, DOI 10.1073/pnas.89.21.10124; Brouwer M, 2002, J INORG BIOCHEM, V88, P228, DOI 10.1016/S0162-0134(01)00381-6; Butt A, 1998, PLANT J, V16, P209, DOI 10.1046/j.1365-313x.1998.00286.x; Cakmak I, 2000, J EXP BOT, V51, P221, DOI 10.1093/jexbot/51.343.221; Choi D, 1996, PLANT PHYSIOL, V112, P353, DOI 10.1104/pp.112.1.353; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; DEFRAMOND AJ, 1991, FEBS LETT, V290, P103, DOI 10.1016/0014-5793(91)81236-2; DEMIRANDA JR, 1990, FEBS LETT, V260, P277, DOI 10.1016/0014-5793(90)80121-X; Dunaeva M, 2001, EUR J BIOCHEM, V268, P5521, DOI 10.1046/j.1432-1033.2001.02471.x; Ebadi M, 1996, NEUROCHEM INT, V29, P159, DOI 10.1016/0197-0186(95)00116-6; EVANS KM, 1992, PLANT MOL BIOL, V20, P1019, DOI 10.1007/BF00028889; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P203; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guinier A., 1939, ANN PHYS-NEW YORK, V11, P161, DOI DOI 10.1051/ANPHYS/193911120161; Hart JJ, 2002, PHYSIOL PLANTARUM, V116, P73, DOI 10.1034/j.1399-3054.2002.1160109.x; Hsieh HM, 1996, PLANT MOL BIOL, V32, P525, DOI 10.1007/BF00019104; HSIEH HM, 1995, PLANT MOL BIOL, V28, P381, DOI 10.1007/BF00020388; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KAWASHIMA I, 1992, EUR J BIOCHEM, V209, P971, DOI 10.1111/j.1432-1033.1992.tb17370.x; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KILLE P, 1991, FEBS LETT, V295, P171, DOI 10.1016/0014-5793(91)81411-Z; Kim S, 2001, MOL PLANT MICROBE IN, V14, P1340, DOI 10.1094/MPMI.2001.14.11.1340; Klaassen C. D., 1999, METALLOTHIONEIN; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE B, 1987, BIOCHEM CELL BIOL, V65, P1001, DOI 10.1139/o87-131; Ma M, 2003, PLANT SCI, V164, P51, DOI 10.1016/S0168-9452(02)00334-5; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MEYERS MW, 1982, AGRONOMY ABSTRACTS; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; Murphy A, 1997, PLANT PHYSIOL, V113, P1293, DOI 10.1104/pp.113.4.1293; OKUMURA N, 1994, PLANT MOL BIOL, V25, P705, DOI 10.1007/BF00029608; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Peterson CW, 1996, FEBS LETT, V379, P85, DOI 10.1016/0014-5793(95)01492-6; Petoukhov MV, 2002, BIOPHYS J, V83, P3113, DOI 10.1016/S0006-3495(02)75315-0; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Rauser WE, 1999, CELL BIOCHEM BIOPHYS, V31, P19, DOI 10.1007/BF02738153; Robinson NJ, 1996, PLANT MOL BIOL, V30, P1169, DOI 10.1007/BF00019550; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sayers Z, 1999, EUR J BIOCHEM, V262, P858, DOI 10.1046/j.1432-1327.1999.00451.x; Simons KT, 1997, J MOL BIOL, V268, P209, DOI 10.1006/jmbi.1997.0959; SNOWDEN KC, 1995, PLANT PHYSIOL, V107, P341, DOI 10.1104/pp.107.2.341; SNOWDEN KC, 1993, PLANT PHYSIOL, V103, P855, DOI 10.1104/pp.103.3.855; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; TOMMEY AM, 1991, FEBS LETT, V292, P48, DOI 10.1016/0014-5793(91)80831-M; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; VALLEE BL, 1991, METHOD ENZYMOL, V205, P3; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; WRIGHT CF, 1987, J BIOL CHEM, V262, P12912; Yu WH, 2002, J PROTEIN CHEM, V21, P177, DOI 10.1023/A:1015324717115	62	51	56	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13701	13711		10.1074/jbc.M412984200	http://dx.doi.org/10.1074/jbc.M412984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15632113	hybrid			2022-12-27	WOS:000228095500065
J	Parra, M; Kasler, H; McKinsey, TA; Olson, EN; Verdin, E				Parra, M; Kasler, H; McKinsey, TA; Olson, EN; Verdin, E			Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-D; II HISTONE DEACETYLASES; MEF2 TRANSCRIPTION FACTOR; ORPHAN STEROID-RECEPTOR; CARDIAC-HYPERTROPHY; IN-VIVO; MUSCLE DIFFERENTIATION; ANTIGEN RECEPTOR; APOPTOSIS; NUR77	HDAC7, a class II histone deacetylase that is highly expressed in thymocytes, inhibits both transcription of the orphan steroid nuclear receptor Nur77 and induction of apoptosis in response to activation of the T-cell receptor (TCR). Here, we report that HDAC7 is exported to the cytoplasm by a calcium-independent signaling pathway after TCR activation. Protein kinase D1 (PKD1) was activated after TCR engagement, interacted with HDAC7, and phosphorylated three serines (Ser(155), Ser(318), and Ser(448)) at its N terminus, leading to its export from the nucleus. Mutation of Ser(155), Ser(318), and Ser(448) blocked the nucleocytoplasmic shuttling of HDAC7 in response to TCR activation, as did overexpression of a kinase-inactive form of PKD1. Consistent with the regulatory role of HDAC7 in Nur77 expression, PKD1 activation led to the transcriptional activation of Nur77 via myocyte enhancer factor 2-binding sites in its promoter. In a mouse model of negative selection, PKD1 was activated during thymocyte activation. These observations indicate that PKD1 regulates the expression of Nur77 during thymocyte activation at least in part by phosphorylating HDAC7.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; Myogen Inc, Westminster, CO USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Verdin, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, 1650 Owens St, San Francisco, CA 94158 USA.	everdin@gladstone.ucsf.edu	Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183; Parra, Maribel/0000-0002-9072-5763				Asada A, 2000, IMMUNOLOGY, V101, P309, DOI 10.1046/j.1365-2567.2000.00110.x; Cantrell DA, 2003, CURR OPIN IMMUNOL, V15, P294, DOI 10.1016/S0952-7915(03)00052-9; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Esau C, 2001, J EXP MED, V194, P1449, DOI 10.1084/jem.194.10.1449; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Marklund U, 2003, IMMUNITY, V19, P491, DOI 10.1016/S1074-7613(03)00260-7; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Sambrook J., 2002, MOL CLONING LAB MANU; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Sohn SJ, 2003, CURR OPIN IMMUNOL, V15, P209, DOI 10.1016/S0952-7915(03)00004-9; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	37	118	128	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13762	13770		10.1074/jbc.M413396200	http://dx.doi.org/10.1074/jbc.M413396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15623513	hybrid			2022-12-27	WOS:000228095500072
J	Pushkar, YN; Karyagina, I; Stehlik, D; Brown, S; van der Est, A				Pushkar, YN; Karyagina, I; Stehlik, D; Brown, S; van der Est, A			Recruitment of a foreign quinone into the A(1) site of photosystem I Consecutive forward electron transfer from A(0) TO A(1) to F-X with anthraquinone in the A(1) site as studied by transient EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORRELATED RADICAL PAIRS; PHOTOSYNTHETIC REACTION CENTERS; BIOSYNTHETIC-PATHWAY MUTANTS; BACTERIAL REACTION CENTERS; SYNECHOCOCCUS SP PCC-7002; IRON-SULFUR CENTERS; HIGH-FIELD EPR; W-BAND EPR; SPIN POLARIZATION; RHODOBACTER-SPHAEROIDES	In photosystem I ( PS I), phylloquinone (PhQ) acts as a low potential electron acceptor during light-induced electron transfer ( ET). The origin of the very low midpoint potential of the quinone is investigated by introducing anthraquinone (AQ) into PS I in the presence and absence of the iron-sulfur clusters. Solvent extraction and reincubation is used to obtain PS I particles containing AQ and the iron-sulfur clusters, whereas incubation of the menB rubA double mutant yields PS I with AQ in the PhQ site but no iron-sulfur clusters. Transient electron paramagnetic resonance spectroscopy is used to investigate the orientation of AQ in the binding site and the ET kinetics. The low temperature spectra suggest that the orientation of AQ in all samples is the same as that of PhQ in native PS I. In PS I containing the iron sulfur clusters, (i) the rate of forward electron transfer from the AQ(.-) to F-X is found to be faster than from PhQ(.-) to F-X, and (ii) the spin polarization patterns provide indirect evidence that the preceding ET step from A(0)(.-) to quinone is slower than in the native system. The changes in the kinetics are in accordance with the more negative reduction midpoint potential of AQ. Moreover, a comparison of the spectra in the presence and absence of the iron-sulfur clusters suggests that the midpoint potential of AQ is more negative in the presence of FX. The electron transfer from the AQ(.-) to F-X is found to be thermally activated with a lower apparent activation energy than for PhQ in native PS I. The spin polarization patterns show that the triplet character in the initial state of P(700)(.+)AQ(.-) increases with temperature. This behavior is rationalized in terms of a model involving a distribution of lifetimes/redox potentials for A(0) and related competition between charge recombination and forward electron transfer from the radical pair P(700)(.+)A(0)(.-).	Free Univ Berlin, Inst Expt Phys, D-14195 Berlin, Germany; Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada	Free University of Berlin; Brock University	Stehlik, D (corresponding author), Free Univ Berlin, Inst Expt Phys, Arnimallee 14, D-14195 Berlin, Germany.	stehlik@physik.fu-berlin; avde@brocku.ca						Agalarov R, 2003, BBA-BIOENERGETICS, V1604, P7, DOI 10.1016/S0005-2728(03)00024-0; BIGGINS J, 1988, BIOCHEMISTRY-US, V27, P1494, DOI 10.1021/bi00405a015; Bixon M, 1999, ADV CHEM PHYS, V106, P35, DOI 10.1002/9780470141656.ch3; BLANKENSHIP RE, 2002, MOL MECH PHOTOSYNTHE, P95; BONNERJEA J, 1982, FEBS LETT, V148, P313, DOI 10.1016/0014-5793(82)80831-4; Bratt PJ, 1997, J PHYS CHEM B, V101, P9686, DOI 10.1021/jp9725238; BURGHAUS O, 1993, J PHYS CHEM-US, V97, P7639, DOI 10.1021/j100131a037; Carrington A., 1967, INTRO MAGNETIC RESON; Cohen RO, 2004, BIOCHEMISTRY-US, V43, P4741, DOI 10.1021/bi035633f; Cramer W.A., 1990, ENERGY TRANSDUCTION; Edens GJ, 2000, J AM CHEM SOC, V122, P1479, DOI 10.1021/ja991791b; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fursman CE, 2002, J PHYS CHEM B, V106, P9679, DOI 10.1021/jp0257202; Golbeck JH, 1999, PHOTOSYNTH RES, V61, P107, DOI 10.1023/A:1006281802710; GUIGLIARELLI B, 1993, J BIOL CHEM, V268, P900; GUNNER MR, 1991, CURR TOP BIOENERG, V16, P319; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; Hartwich G, 1998, J PHYS CHEM B, V102, P3815, DOI 10.1021/jp973472h; Hore PJ, 1996, MOL PHYS, V89, P1195, DOI 10.1080/002689796173598; Hulsebosch RJ, 2001, J PHYS CHEM B, V105, P10146, DOI 10.1021/jp012272+; Hulsebosch RJ, 1999, J PHYS CHEM B, V103, P6815, DOI 10.1021/jp990677c; Itoh S, 2001, BBA-BIOENERGETICS, V1507, P115, DOI 10.1016/S0005-2728(01)00199-2; Iwaki M, 1996, J PHYS CHEM-US, V100, P10802, DOI 10.1021/jp960221k; Johnson TW, 2001, J BIOL CHEM, V276, P39512, DOI 10.1074/jbc.M104040200; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Jortner J., 1999, ADV CHEM PHYS, V107; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kamlowski A, 1998, J PHYS CHEM B, V102, P8266, DOI 10.1021/jp9817022; Kamlowski A, 1998, J PHYS CHEM B, V102, P8278, DOI 10.1021/jp9824611; Kandrashkin Y, 2001, SPECTROCHIM ACTA A, V57, P1697, DOI 10.1016/S1386-1425(01)00436-X; Kandrashkin YE, 1998, APPL MAGN RESON, V15, P417, DOI 10.1007/BF03162027; Kandrashkin YE, 2002, MOL PHYS, V100, P1431, DOI 10.1080/00268970110118240; Kandrashkin YE, 1997, APPL MAGN RESON, V12, P141, DOI 10.1007/BF03162183; Li JL, 2000, BIOCHEMISTRY-US, V39, P7445, DOI 10.1021/bi992591f; Link G, 2001, J AM CHEM SOC, V123, P4211, DOI 10.1021/ja003382h; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; LUNEBERG J, 1994, FEBS LETT, V338, P197, DOI 10.1016/0014-5793(94)80364-1; MacMillan F, 1997, BIOCHEMISTRY-US, V36, P9297, DOI 10.1021/bi971097d; MCCRACKEN JL, 1983, BIOCHIM BIOPHYS ACTA, V724, P83, DOI 10.1016/0005-2728(83)90028-2; MOENNELOCCOZ P, 1994, BIOCHEMISTRY-US, V33, P10037, DOI 10.1021/bi00199a030; MORRIS AL, 1995, J PHYS CHEM-US, V99, P3854, DOI 10.1021/j100011a063; NORRIS JR, 1990, J CHEM PHYS, V92, P4239, DOI 10.1063/1.457782; O'Malley PJ, 1999, BBA-BIOENERGETICS, V1411, P101, DOI 10.1016/S0005-2728(99)00036-5; PEDERSEN JB, 1979, FEBS LETT, V97, P305, DOI 10.1016/0014-5793(79)80108-8; Poluektov OG, 2002, J PHYS CHEM B, V106, P8911, DOI 10.1021/jp021465+; PRISNER TF, 1993, P NATL ACAD SCI USA, V90, P9485, DOI 10.1073/pnas.90.20.9485; Pushkar YN, 2004, J MOL STRUCT, V700, P233, DOI 10.1016/j.molstruc.2004.02.015; Pushkar YN, 2004, J PHYS CHEM B, V108, P9439, DOI 10.1021/jp0361879; Pushkar YN, 2002, J PHYS CHEM B, V106, P12052, DOI 10.1021/jp0265743; Rigby SEJ, 1996, BIOCHEMISTRY-US, V35, P6651, DOI 10.1021/bi952619x; RUSTANDI RR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P311, DOI 10.1016/0005-2728(92)90087-I; Sakuragi Y, 2005, J BIOL CHEM, V280, P12371, DOI 10.1074/jbc.M412943200; Sakuragi Y, 2002, BIOCHEMISTRY-US, V41, P394, DOI 10.1021/bi011297w; Salikhov KM, 2003, APPL MAGN RESON, V24, P467, DOI 10.1007/BF03166949; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; Schlodder E., 2001, PS2001 P 12 INT C PH, pS6; Semenov AY, 2000, J BIOL CHEM, V275, P23429, DOI 10.1074/jbc.M000508200; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; SIECKMAN I, 1991, FEBS LETT, V284, P98, DOI 10.1016/0014-5793(91)80771-T; SNYDER S, 1993, BIOPHYS J, V64, pA216; STEHLIK D, 1989, J PHYS CHEM-US, V93, P1612, DOI 10.1021/j100341a084; STEHLIK D, 1992, PHOTOSYNTH RES, V34, P129; Tang J, 1999, J PHYS CHEM B, V103, P5145, DOI 10.1021/jp990236t; Tang J, 1996, CHEM PHYS LETT, V253, P293, DOI 10.1016/0009-2614(96)00176-5; Utschig LM, 1997, BIOCHEMISTRY-US, V36, P8548, DOI 10.1021/bi9630319; van der Est A, 2004, BIOCHEMISTRY-US, V43, P1264, DOI 10.1021/bi035431j; van der Est A, 2001, BBA-BIOENERGETICS, V1507, P212, DOI 10.1016/S0005-2728(01)00204-3; VANDEREST A, 1995, CHEM PHYS, V194, P349, DOI 10.1016/0301-0104(95)00046-Q; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; vanderEst A, 1997, J PHYS CHEM B, V101, P1437, DOI 10.1021/jp9622086; Xu Q, 2000, J PHYS CHEM B, V104, P8035, DOI 10.1021/jp000543v; Xu Q, 2002, BIOCHEMISTRY-US, V41, P10021, DOI 10.1021/bi025573y; Xu W, 2003, J BIOL CHEM, V278, P27876, DOI 10.1074/jbc.M302965200; Xu W, 2003, J BIOL CHEM, V278, P27864, DOI 10.1074/jbc.M302962200; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; Zech SG, 2000, J PHYS CHEM B, V104, P9728, DOI 10.1021/jp002125w; Zech SG, 1997, BIOCHEMISTRY-US, V36, P9774, DOI 10.1021/bi970754z; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	79	17	18	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12382	12390		10.1074/jbc.M412940200	http://dx.doi.org/10.1074/jbc.M412940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15640524	hybrid			2022-12-27	WOS:000227922000039
J	Fioriti, L; Dossena, S; Stewart, LR; Stewart, RS; Harris, DA; Forloni, G; Chiesa, R				Fioriti, L; Dossena, S; Stewart, LR; Stewart, RS; Harris, DA; Forloni, G; Chiesa, R			Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO GENERATION; BIOCHEMICAL-PROPERTIES; PROTEASOME INHIBITION; ENDOPLASMIC-RETICULUM; MUTANT; FORM; DEGRADATION; METABOLISM; DEATH; TRANSMEMBRANE	Inherited prion diseases are linked to mutations in the prion protein (PrP) gene, which favor conversion of PrP into a conformationally altered, pathogenic isoform. The cellular mechanism by which this process causes neurological dysfunction is unknown. It has been proposed that neuronal death can be triggered by accumulation of PrP in the cytosol because of impairment of proteasomal degradation of misfolded PrP molecules retrotranslocated from the endoplasmic reticulum (Ma, J., Wollmann, R., and Lindquist, S. (2002) Science 298, 1781-1785). To test whether this neurotoxic mechanism is operative in inherited prion diseases, we evaluated the effect of proteasome inhibitors on the viability of transfected N2a cells and primary neurons expressing mouse PrP homologues of the D178N and nine octapeptide mutations. We found that the inhibitors caused accumulation of an unglycosylated, aggregated form of PrP exclusively in transfected N2a expressing PrP from the cytomegalovirus promoter. This form contained an uncleaved signal peptide, indicating that it represented polypeptide chains that had failed to translocate into the ER lumen during synthesis, rather than retrogradely translocated PrP. Quantification of N2a viability in the presence of proteasome inhibitors demonstrated that accumulation of this form was not toxic. No evidence of cytosolic PrP was found in cerebellar granule neurons from transgenic mice expressing wild-type or mutant PrPs from the endogenous promoter, nor were these neurons more susceptible to proteasome inhibitor toxicity than neurons from PrP knock-out mice. Our analysis fails to confirm the previous observation that mislocation of PrP in the cytosol is neurotoxic, and argues against the hypothesis that perturbation of PrP metabolism through the proteasomal pathway plays a pathogenic role in prion diseases.	Dulbecco Telethon Inst, I-20157 Milan, Italy; Ist Ric Farmacol Mario Negri, Dept Neurosci, I-20157 Milan, Italy; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Fondazione Telethon; Dulbecco Telethon Institute (DTI); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Washington University (WUSTL)	Chiesa, R (corresponding author), Dulbecco Telethon Inst, Via Eritrea 62, I-20157 Milan, Italy.	chiesa@marionegri.it	Fioriti, Luana/AAN-7207-2021; Forloni, Gianluigi/AAB-2115-2020; Chiesa, Roberto/G-1561-2017	Forloni, Gianluigi/0000-0001-5374-3914; Chiesa, Roberto/0000-0002-3842-3733; fioriti, luana/0000-0003-2429-8967; Harris, David/0000-0002-6985-5790	Telethon [TCP00083] Funding Source: Medline	Telethon(Fondazione Telethon)		Asante EA, 2004, NEUROSCI LETT, V360, P33, DOI 10.1016/j.neulet.2004.01.049; Barmada S, 2004, NEUROBIOL DIS, V16, P527, DOI 10.1016/j.nbd.2004.05.005; Biasini E, 2004, J NEUROCHEM, V88, P545, DOI 10.1046/j.1471-4159.2003.02152.x; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Bush KT, 1997, J BIOL CHEM, V272, P9086; Capellari S, 2000, AM J PATHOL, V157, P613, DOI 10.1016/S0002-9440(10)64572-5; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Chiesa R, 2000, J NEUROCHEM, V75, P72, DOI 10.1046/j.1471-4159.2000.0750072.x; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 2001, NEUROBIOL DIS, V8, P279, DOI 10.1006/nbdi.2001.0400; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Chiesa R, 2004, TECHNIQUES PRION RES, P176; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fioriti L, 2005, MOL CELL NEUROSCI, V28, P165, DOI 10.1016/j.mcn.2004.09.006; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kikuchi S, 2003, BRAIN RES, V964, P228, DOI 10.1016/S0006-8993(02)04030-1; Kim BH, 2004, MOL BRAIN RES, V124, P40, DOI 10.1016/j.molbrainres.2004.02.005; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lang-Rollin I, 2004, J NEUROCHEM, V90, P1511, DOI 10.1111/j.1471-4159.2004.02684.x; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; McLennan NF, 2004, AM J PATHOL, V165, P227, DOI 10.1016/S0002-9440(10)63291-9; Miller TM, 1996, J NEUROSCI, V16, P7487; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Mishra RS, 2003, J ALZHEIMERS DIS, V5, P15, DOI 10.3233/JAD-2003-5103; Negro A, 2001, MOL CELL NEUROSCI, V17, P521, DOI 10.1006/mcne.2000.0953; Nishimura T, 2004, BIOCHEM BIOPH RES CO, V323, P218, DOI 10.1016/j.bbrc.2004.08.087; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Porcile C, 2002, ANN NY ACAD SCI, V973, P402, DOI 10.1111/j.1749-6632.2002.tb04673.x; Rachidi W, 2003, J BIOL CHEM, V278, P9064, DOI 10.1074/jbc.M211830200; Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462; Roucou X, 2004, J NEUROSCI RES, V75, P153, DOI 10.1002/jnr.10864; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Stewart RS, 2003, J BIOL CHEM, V278, P45960, DOI 10.1074/jbc.M307833200; Stockel J, 2001, J MOL BIOL, V313, P861, DOI 10.1006/jmbi.2001.5085; Wang XH, 2005, J BIOL CHEM, V280, P317, DOI 10.1074/jbc.M410649200; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	60	96	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11320	11328		10.1074/jbc.M412441200	http://dx.doi.org/10.1074/jbc.M412441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15632159	hybrid			2022-12-27	WOS:000227761800053
J	He, XY; Li, F; Chang, WP; Tang, J				He, XY; Li, F; Chang, WP; Tang, J			GGA proteins mediate the recycling pathway of memapsin 2 (BACE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETASE CYTOSOLIC DOMAIN; AMYLOID-PRECURSOR-PROTEIN; TRANS-GOLGI NETWORK; ALZHEIMERS-DISEASE; GAMMA-ADAPTIN; VHS DOMAINS; BETA; TRAFFICKING; CLEAVAGE; MATURATION	Memapsin 2 ( BACE, beta-secretase) is a membrane-associated aspartic protease that initiates the hydrolysis of beta-amyloid precursor protein (APP) leading to the production of amyloid-beta (A beta) and the progression of Alzheimer disease. Both memapsin 2 and APP are transported from the cell surface to endosomes where APP is cleaved by memapsin 2. We described previously that the cytosolic domain of memapsin 2 contains an acid cluster-dileucine motif (ACDL) that binds the VHS (Vps-27, Hrs, and STAM) domain of Golgi-localized gamma-ear-containing ARF-binding (GGA) proteins ( He, X., Zhu, G., Koelsch, G., Rodgers, K. K., Zhang, X. C., and Tang, J. ( 2003) Biochemistry 42, 12174-12180). Here we report that GGA proteins colocalize in the trans-Golgi network and endosomes with memapsin 2 and a memapsin 2 chimera containing a cytosolic domain of a mannose-6-phosphate receptor. Depleting cellular GGA proteins with RNA interference or mutation of serine 498 to stop the phosphorylation of ACDL resulted in the accumulation of memapsin 2 in early endosomes. A similar change of memapsin 2 localization also was observed when a retromer subunit, VPS26, was depleted. These observations suggest that GGA proteins function with the phosphorylated ACDL in the memapsin 2-recycling pathway from endosomes to trans-Golgi on the way back to the cell surface.	Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Tang, J (corresponding author), Oklahoma Med Res Fdn, Prot Studies Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jordan-tang@omrf.ouhsc.edu	LI, FENG/D-1379-2012		NIA NIH HHS [AG-18933] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018933] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Ghosh P, 2003, J CELL BIOL, V163, P755, DOI 10.1083/jcb.200308038; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Huang XP, 2004, J BIOL CHEM, V279, P37886, DOI 10.1074/jbc.M402130200; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Mathews PM, 2002, J BIOL CHEM, V277, P5299, DOI 10.1074/jbc.M108161200; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Steinhilb ML, 2002, J NEUROCHEM, V80, P1019, DOI 10.1046/j.0022-3042.2002.00764.x; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	29	198	202	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11696	11703		10.1074/jbc.M411296200	http://dx.doi.org/10.1074/jbc.M411296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15615712	hybrid			2022-12-27	WOS:000227761800098
J	Terada, M; Khoo, KH; Inoue, R; Chen, CI; Yamada, K; Sakaguchi, H; Kadowaki, N; Ma, BY; Oka, S; Kawasaki, T; Kawasaki, N				Terada, M; Khoo, KH; Inoue, R; Chen, CI; Yamada, K; Sakaguchi, H; Kadowaki, N; Ma, BY; Oka, S; Kawasaki, T; Kawasaki, N			Characterization of oligosaccharide ligands expressed on SW1116 cells recognized by mannan-binding protein - A highly fucosylated polylactosamine type N-glycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE MOIETY; MASS-SPECTROMETRY; INNATE IMMUNITY; SERUM LECTIN; SIALIC-ACID; MANNOSE; COMPLEMENT; CHAIN; LACTOSAMINOGLYCAN; CHROMATOGRAPHY	Mannan-binding protein (MBP) is a C-type serum lectin and activates complement through the lectin pathway when it binds to ligand sugars such as mannose, N-acetyl-glucosamine, and fucose on microbes. In addition, the vaccinia virus carrying the human MBP gene was shown to exhibit potent growth inhibitory activity toward human colorectal carcinoma, SW1116, cells in nude mice. We have proposed calling this activity MBP-dependent cell-mediated cytotoxicity (MDCC) (Ma, Y., Uemura, K., Oka, S., Kozutsumi, Y., Kawasaki, N., and Kawasaki, T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 371-375). In this study, the MBP ligands on the surface of SW1116 cells were characterized. Initial experiments involving plant lectins and anti-Lewis antibodies as inhibitors of MBP binding to SW1116 cells indicated that fucose plays a crucial role in the interaction. Subsequently, Pronase glycopeptides were prepared from whole cell lysates, and oligosaccharides were liberated by hydrazinolysis. After being tagged by pyridylamination, MBP ligand oligosaccharides were isolated with an MBP affinity column, and then their sequences were determined by mass spectrometry and tandem mass spectrometry after permethylation, in combination with endo-beta-galactosidase digestion and chemical defucosylation. The MBP ligands were shown to be large, multiantennary N-glycans carrying a highly fucosylated polylactosamine type structure. At the nonreducing termini, Le(b)/Le(a) or tandem repeats of the Lea structure prevail, a substantial proportion of which are attached via internal Le(x) or N-acetyllactosamine units to the trimannosyl core. The structures characterized are unique and distinct from those of other previously reported tumor-specific carbohydrate antigens. It is concluded that MBP requires clusters of tandem repeats of the Le(b)/Le(a) epitope for recognition.	Kyoto Univ, Fac Med, Sch Hlth Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto 6068501, Japan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 106, Taiwan	Kyoto University; Kyoto University; Academia Sinica - Taiwan; National Taiwan University	Kawasaki, N (corresponding author), Kyoto Univ, Fac Med, Sch Hlth Sci, Sakyo Ku, 53 Kawaharamachi, Kyoto 6068507, Japan.	nobukokw@hs.med.kyoto-u.ac.jp	Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X				CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; DELL A, 1994, METHOD ENZYMOL, V230, P108; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; FERNANDES B, 1991, CANCER RES, V51, P718; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; Granovsky M, 2000, NAT MED, V6, P306; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2001, ADV EXP MED BIOL, V491, P369; Hart ML, 2002, AIDS RES HUM RETROV, V18, P1311, DOI 10.1089/088922202320886352; HARTLEY CA, 1992, J VIROL, V66, P4358, DOI 10.1128/JVI.66.7.4358-4363.1992; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; IKEDA K, 1987, J BIOL CHEM, V262, P7451; Ito M, 2002, ANAL BIOCHEM, V300, P260, DOI 10.1006/abio.2001.5470; Jack DL, 2003, BIOCHEM SOC T, V31, P753, DOI 10.1042/BST0310753; KANNAGI R, 1985, J BIOL CHEM, V260, P6410; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; Kawasaki T, 1999, BBA-GEN SUBJECTS, V1473, P186, DOI 10.1016/S0304-4165(99)00178-6; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LEE RT, 1992, ARCH BIOCHEM BIOPHYS, V299, P129, DOI 10.1016/0003-9861(92)90254-T; Ma Y, 1999, P NATL ACAD SCI USA, V96, P371, DOI 10.1073/pnas.96.2.371; Malhotra R, 1994, Clin Exp Immunol, V97 Suppl 2, P4; Muto S, 1999, BIOL PHARM BULL, V22, P347; OHTA M, 1994, GLYCOCONJUGATE J, V11, P304, DOI 10.1007/BF00731203; Sharon N., 2003, LECTINS, P63; STROUD MR, 1992, EUR J BIOCHEM, V203, P577, DOI 10.1111/j.1432-1033.1992.tb16586.x; STROUD MR, 1991, J BIOL CHEM, V266, P8439; SUPER M, 1989, LANCET, V2, P1236; SUZUKI J, 1991, AGR BIOL CHEM TOKYO, V55, P283, DOI 10.1080/00021369.1991.10870520; Uemura K, 1996, J BIOL CHEM, V271, P4581; Varki A, 1999, ESSENTIALS GLYCOBIOL, P455; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414	35	42	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10897	10913		10.1074/jbc.M413092200	http://dx.doi.org/10.1074/jbc.M413092200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15634673	Green Published, hybrid			2022-12-27	WOS:000227761800005
J	Yu, WX; Gong, JS; Ko, MH; Garver, WS; Yanagisawa, K; Michikawa, M				Yu, WX; Gong, JS; Ko, MH; Garver, WS; Yanagisawa, K; Michikawa, M			Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-DERIVED CHOLESTEROL; DISEASE TYPE-C; ALZHEIMERS-DISEASE; INTRACELLULAR-TRANSPORT; NEUROFIBRILLARY TANGLES; TAU-PHOSPHORYLATION; LIVER MITOCHONDRIA; CULTURED NEURONS; PLASMA-MEMBRANE; LIPID RELEASE	Niemann- Pick type C1 (NPC1) disease is a fatal hereditary disorder characterized by a defect in cholesterol trafficking and progressive neurodegeneration. Although the NPC1 gene has been identified, the molecular mechanism responsible for neuronal dysfunction in brains of patients with NPC1 disease remains unknown. This study demonstrates that the amount of cholesterol within mitochondria membranes is significantly elevated in NPC1 mouse brains and neural cells. In addition, the mitochondrial membrane potential, the activity of ATP synthase, and henceforth the level of ATP are markedly decreased in NPC1 mouse brains and neurons. Importantly, reducing the level of cholesterol within mitochondrial membranes using methyl-beta-cyclodextrin can restore the activity of ATP synthase. Finally, NPC1 neurons show an impaired neurite outgrowth, which can be rescued by exogenous ATP. These results suggest that mitochondrial dysfunctions and subsequent ATP deficiency, which are induced by altered cholesterol metabolism in mitochondria, may be responsible for neuronal impairment in NPC1 disease.	Natl Inst Longev Sci, Dept Alzheimers Dis Res, Obu, Aichi 4748522, Japan; Pharmaceut & Med Devices Agcy, Tokyo 1000013, Japan; Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA	University of Arizona	Michikawa, M (corresponding author), Natl Inst Longev Sci, Dept Alzheimers Dis Res, 36-3 Gengo, Obu, Aichi 4748522, Japan.	michi@nils.go.jp						AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; Bu BT, 2002, J NEUROSCI, V22, P6515; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Colell A, 2003, J BIOL CHEM, V278, P33928, DOI 10.1074/jbc.M210943200; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Garren L D, 1971, Recent Prog Horm Res, V27, P433; Garver WS, 2000, J LIPID RES, V41, P673; Garver WS, 2002, J LIPID RES, V43, P579; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; Gong JS, 2002, J NEUROSCI RES, V70, P438, DOI 10.1002/jnr.10347; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; HIGASHI Y, 1993, ACTA NEUROPATHOL, V85, P175; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOVE S, 1995, BRAIN, V118, P119, DOI 10.1093/brain/118.1.119; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Mattson MP, 1999, J NEUROSCI RES, V56, P8, DOI 10.1002/(SICI)1097-4547(19990401)56:1<8::AID-JNR2>3.3.CO;2-7; Michikawa M, 2003, J NEUROSCI RES, V72, P141, DOI 10.1002/jnr.10585; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; MORRIS MD, 1982, AM J PATHOL, V108, P140; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; Ribeiro I, 2001, HUM GENET, V109, P24, DOI 10.1007/s004390100531; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; RINDINA FC, 1986, FEBS LETT, V198, P353, DOI 10.1016/0014-5793(86)80435-5; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; Sawamura N, 2003, J NEUROCHEM, V84, P1086, DOI 10.1046/j.1471-4159.2003.01596.x; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Skladchikova G, 1999, J NEUROSCI RES, V57, P207; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; Walkley SU, 1998, ANN NY ACAD SCI, V845, P188, DOI 10.1111/j.1749-6632.1998.tb09671.x; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; ZHENG X, 1989, NEUROLOGY, V39, P1203, DOI 10.1212/WNL.39.9.1203	46	152	160	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11731	11739		10.1074/jbc.M412898200	http://dx.doi.org/10.1074/jbc.M412898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644330	hybrid			2022-12-27	WOS:000227761800102
J	Avila-Flores, A; Santos, T; Rincon, E; Merida, I				Avila-Flores, A; Santos, T; Rincon, E; Merida, I			Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; INDUCED ACTIVATION; IN-VIVO; ALPHA; ZETA; PHOSPHORYLATION; TRANSLOCATION; INHIBITION; RECEPTOR	The protein known as mammalian target of rapamycin (mTOR) regulates cell growth by integrating different stimuli, such as available nutrients and mitogenic factors. The lipid messenger phosphatidic acid (PA) binds and positively regulates the mitogenic response of mTOR. PA generator enzymes are consequently potential regulators of mTOR. Here we explored the contribution to this pathway of the enzyme diacylglycerol kinase (DGK), which produces PA through phosphorylation of diacylglycerol. We found that overexpression of the DGK zeta, but not of the alpha isoform, in serum-deprived HEK293 cells induced mTOR-dependent phosphorylation of p70S6 kinase (p70S6K). After serum addition, p70S6K phosphorylation was higher and more resistant to rapamycin treatment in cells overexpressing DGK zeta. The effect of this DGK isoform on p70S6K hyperphosphorylation required the mTOR PA binding region. Down-regulation of endogenous DGK zeta by small interfering RNA in HEK293 cells diminished serum-induced p70S6K phosphorylation, highlighting the role of this isoform in the mTOR pathway. Our results confirm a role for PA in mTOR regulation and describe a novel pathway in which DGK zeta-derived PA acts as a mediator of mTOR signaling.	CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC)	Merida, I (corresponding author), CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	imerida@cnb.uam.es	Avila, Antonia/AAA-4617-2019; Merida, Isabel/A-9713-2014; Rincón, Esther/L-5047-2014; Santos-Mendoza, Teresa/AAK-8528-2021	Avila, Antonia/0000-0001-6278-2472; Merida, Isabel/0000-0003-2762-6241; Rincón, Esther/0000-0003-3870-1868; Santos-Mendoza, Teresa/0000-0003-1015-5631; Santos, Teresa/0000-0003-3765-5863				Abramovici H, 2003, MOL BIOL CELL, V14, P4499, DOI 10.1091/mbc.E03-03-0190; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Ballou LM, 2003, FEBS LETT, V550, P51, DOI 10.1016/S0014-5793(03)00816-0; Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Bonham L, 2003, EXPERT OPIN THER TAR, V7, P643; Brose N, 2004, CURR OPIN NEUROBIOL, V14, P328, DOI 10.1016/j.conb.2004.05.006; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen J, 2003, CURR TOP MICROBIOL, V279, P245; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Cipres A, 2003, J BIOL CHEM, V278, P35629, DOI 10.1074/jbc.M305635200; Davidson L, 2004, J BIOL CHEM, V279, P11906, DOI 10.1074/jbc.M310784200; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jones DR, 1999, J BIOL CHEM, V274, P16846, DOI 10.1074/jbc.274.24.16846; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Litosch I, 2000, BIOCHEMISTRY-US, V39, P7736, DOI 10.1021/bi000022y; Lopez-Andreo MJ, 2003, MOL BIOL CELL, V14, P4885, DOI 10.1091/mbc.E03-05-0295; Luo B, 2004, CELL SIGNAL, V16, P891, DOI 10.1016/j.cellsig.2004.01.010; Maestre Nicolas, 2003, J Exp Ther Oncol, V3, P36, DOI 10.1046/j.1359-4117.2003.01065.x; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Outram SV, 2002, IMMUNOLOGY, V105, P391, DOI 10.1046/j.1365-2567.2002.01385.x; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pettitt TR, 1999, J BIOL CHEM, V274, P36181, DOI 10.1074/jbc.274.51.36181; Sanjuan MA, 2003, J IMMUNOL, V170, P2877, DOI 10.4049/jimmunol.170.6.2877; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; SIDDIQUI RA, 1995, CELL SIGNAL, V7, P247, DOI 10.1016/0898-6568(94)00083-N; Springett GM, 2004, BIOESSAYS, V26, P730, DOI 10.1002/bies.20057; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Zhong XP, 2003, NAT IMMUNOL, V4, P882, DOI 10.1038/ni958; Zhong XP, 2002, J BIOL CHEM, V277, P31089, DOI 10.1074/jbc.M203818200	60	120	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10091	10099		10.1074/jbc.M412296200	http://dx.doi.org/10.1074/jbc.M412296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632115	hybrid			2022-12-27	WOS:000227559600044
J	Barragan, MJL; Blazquez, B; Zamarro, MT; Mancheno, JM; Garcia, JL; Diaz, E; Carmona, M				Barragan, MJL; Blazquez, B; Zamarro, MT; Mancheno, JM; Garcia, JL; Diaz, E; Carmona, M			BzdR, a repressor that controls the anaerobic catabolism of benzoate in Azoarcus sp CIB, is the first member of a new subfamily of transcriptional regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SHIKIMATE KINASE; PHENYLACETIC ACID; CRYSTAL-STRUCTURE; PROTEIN; SEQUENCE; DEGRADATION; HOMOLOGY; PROGRAM; CLONING	In this work, we have studied the transcriptional regulation of the bzd operon involved in the anaerobic catabolism of benzoate in the denitrifying Azoarcus sp. strain CIB. The transcription start site of the P-N promoter running the expression of the bzd catabolic genes was identified. Gel retardation assays and P-N:: lacZ translational fusion experiments performed both in Azoarcus sp. CIB and Escherichia coli cells have shown that bzdR encodes a specific repressor that controls the inducible expression of the adjacent bzd catabolic operon, being the first intermediate of the catabolic pathway (i.e. benzoyl-CoA, the actual inducer molecule). This is the first report of a transcriptional repressor and a CoA-derived aromatic inducer controlling gene expression in the anaerobic catabolism of aromatic compounds. DNase I footprinting experiments revealed that BzdR protected three regions ( operators) at the PN promoter. The three operators contain direct repetitions of a TGCA sequence that forms part of longer palindromic structures. In agreement with the repressor role of BzdR, operator region I spans the transcription initiation site as well as the -10 sequence for recognition of the RNA polymerase. Primary sequence analyses of BzdR showed an unusual modular organization with an N-terminal region homologous to members of the HTH-XRE family of transcriptional regulators and a C-terminal region similar to shikimate kinases. A three-dimensional model of the N-terminal and C-terminal regions of BzdR, generated by comparison with the crystal structures of the SinR regulator from Bacillus subtilis and the shikimate kinase I protein from E. coli, strongly suggests that they contain the helix-turn-helix DNA-binding motif and the benzoyl-CoA binding groove, respectively. The BzdR protein constitutes, therefore, the prototype of a new subfamily of transcriptional regulators.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28040 Madrid, Spain; CSIC, Inst Quim Fis Rocasolano, Grp Cristalografia Macromol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Carmona, M (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Ramiro Maeztu 9, E-28040 Madrid, Spain.	mcarmona@cib.csic.es	Castiñeira, Blas Blázquez/J-1353-2014; Diaz, Eduardo/F-8605-2016; Mancheno, Jose/K-4984-2014; Garcia Lopez, Jose Luis/G-9139-2015	Diaz, Eduardo/0000-0002-9731-6524; Mancheno, Jose/0000-0001-6943-3291; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Blazquez, Blas/0000-0003-4099-6909; Carmona, Manuel/0000-0002-1591-7618	NATIONAL CANCER INSTITUTE [K22CA093873] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barragan MJL, 2004, J BACTERIOL, V186, P5762, DOI 10.1128/JB.186.17.5762-5774.2004; Barragan MJL, 2004, MICROBIOL-SGM, V150, P2018, DOI 10.1099/mic.0.27186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY LI, 1995, BIOCHEMISTRY-MOSCOW+, V60, P923; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cervin MA, 1998, NUCLEIC ACIDS RES, V26, P3806, DOI 10.1093/nar/26.16.3806; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Coschigano PW, 1997, APPL ENVIRON MICROB, V63, P652, DOI 10.1128/AEM.63.2.652-660.1997; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Egland PG, 1999, J BACTERIOL, V181, P2102, DOI 10.1128/JB.181.7.2102-2109.1999; Egland PG, 2000, J BACTERIOL, V182, P100, DOI 10.1128/JB.182.1.100-106.2000; Felsenstein J., 1993, PHYLIP PHYLOGENETIC; Ferrandez A, 2000, J BIOL CHEM, V275, P12214, DOI 10.1074/jbc.275.16.12214; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; FISCHER D, 2000, PACIFIC S BIOCOMPUTI, V96, P119; Gescher J, 2002, J BACTERIOL, V184, P6301, DOI 10.1128/JB.184.22.6301-6315.2002; Gibson J, 2002, ANNU REV MICROBIOL, V56, P345, DOI 10.1146/annurev.micro.56.012302.160749; Gu YJ, 2002, J MOL BIOL, V319, P779, DOI 10.1016/S0022-2836(02)00339-X; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Harwood CS, 1998, FEMS MICROBIOL REV, V22, P439, DOI 10.1016/S0168-6445(98)00026-6; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KOUDELKA GB, 1993, J BIOL CHEM, V268, P23812; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krell T, 1998, J MOL BIOL, V278, P983, DOI 10.1006/jmbi.1998.1755; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Ladero V, 2002, J GEN VIROL, V83, P2891, DOI 10.1099/0022-1317-83-11-2891; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leuthner B, 1998, FEMS MICROBIOL LETT, V166, P35, DOI 10.1111/j.1574-6968.1998.tb13180.x; MANDICMULEC I, 1995, J BACTERIOL, V177, P4619, DOI 10.1128/jb.177.16.4619-4627.1995; MARTIN AC, 1995, VIROLOGY, V211, P21, DOI 10.1006/viro.1995.1375; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Peters F, 2004, J BACTERIOL, V186, P2156, DOI 10.1128/JB.186.7.2156-2163.2004; ROBERTS TM, 1977, NATURE, V270, P274, DOI 10.1038/270274a0; Romanowski MJ, 2002, PROTEINS, V47, P558, DOI 10.1002/prot.10099; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schuhle K, 2003, J BACTERIOL, V185, P4920, DOI 10.1128/JB.185.16.4920-4929.2003; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Silhavy T. J., 1984, EXPT GENE FUSIONS; Speicher David W., 1994, Methods (Orlando), V6, P262, DOI 10.1006/meth.1994.1028; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WHIPP MJ, 1995, J BACTERIOL, V177, P1627, DOI 10.1128/jb.177.6.1627-1629.1995	57	55	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10683	10694		10.1074/jbc.M412259200	http://dx.doi.org/10.1074/jbc.M412259200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15634675	hybrid, Green Published			2022-12-27	WOS:000227559600114
J	Barret, A; Forestier, L; Deslys, JP; Julien, R; Gallet, PF				Barret, A; Forestier, L; Deslys, JP; Julien, R; Gallet, PF			Glycosylation-related gene expression in prion diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; CREUTZFELDT-JAKOB-DISEASE; CELL-ADHESION MOLECULE; CIRCULATORY HALF-LIFE; HEPARAN-SULFATE; TENASCIN-R; N-ACETYLGALACTOSAMINE; EXTRACELLULAR-MATRIX; ALZHEIMERS-DISEASE; INCUBATION PERIOD	Several lines of evidence indicate that some glycoconjugates are efficient effectors of the cellular prion protein (PrPC) conversion into its pathogenic (PrPSc) isoform. To assess how glycoconjugate glycan moieties participate in the biogenesis of PrPSc, an exhaustive comparative analysis of the expression of about 200 glycosylation-related genes was performed on prion-infected or not, hypothalamus-derived GT1 cells by hybridization of DNA microarrays, semiquantitative RT-PCR, and biochemical assays. A significant up- (30-fold) and down- (17-fold) regulation of the expression of the ChGn1 and Chst8 genes, respectively, was observed in prion-infected cells. ChGn1 and Chst8 are involved in the initiation of the synthesis of chondroitin sulfate and in the 4-O-sulfation of non-reducing N-acetylgalactosamine residues, respectively. A possible role for a hyposulfated chondroitin in PrPSc accumulation was evidenced at the protein level and by determination of chondroitin and heparan sulfate amounts. Treatment of Sc-GT1 cells with a heparan mimetic (HM2602) induced an important reduction of the amount of PrPSc, associated with a total reversion of the transcription pattern of the N-acetylgalactosamine-4-O-sulfotransferase 8. It suggests a link between the genetic control of 4-O-sulfation and PrPSc accumulation.	Inst Sci Vie & Sante, INRA, UMR 1061, F-87060 Limoges, France; CEA, Grp Innovat Diagnost & Therapeut Infect Prions, F-92265 Fontenay Aux Roses, France	INRAE; CEA	Julien, R (corresponding author), Inst Sci Vie & Sante, INRA, UMR 1061, 123 Ave Albert Thomas, F-87060 Limoges, France.	rjulien@unilim.fr; francois.gallet@unilim.fr		Gallet, Paul-Francois/0000-0003-0681-5561				Adams I, 2001, NEUROSCIENCE, V108, P285, DOI 10.1016/S0306-4522(01)00419-5; Adjou KT, 2003, J GEN VIROL, V84, P2595, DOI 10.1099/vir.0.19073-0; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Barbosa I, 2003, GLYCOBIOLOGY, V13, P647, DOI 10.1093/glycob/cwg082; Barret A, 2003, J VIROL, V77, P8462, DOI 10.1128/JVI.77.15.8462-8469.2003; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Bodo M, 1996, CYTOKINE, V8, P772, DOI 10.1006/cyto.1996.0103; Bruckner G, 1999, NEUROSCIENCE, V92, P791, DOI 10.1016/S0306-4522(99)00071-8; Caceres J, 1997, J CELL BIOCHEM, V65, P145, DOI 10.1002/(SICI)1097-4644(199705)65:2<145::AID-JCB2>3.0.CO;2-U; Caughey B, 2002, BIOCHEM SOC T, V30, P565, DOI 10.1042/bst0300565; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Dealler S, 2003, IDRUGS, V6, P470; Desgranges P, 1999, FASEB J, V13, P761, DOI 10.1096/fasebj.13.6.761; Doh-Ura K, 2004, J VIROL, V78, P4999, DOI 10.1128/JVI.78.10.4999-5006.2004; Eberl H, 2004, J BIOL CHEM, V279, P25058, DOI 10.1074/jbc.M400952200; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; Elimova E, 2004, FASEB J, V18, P1749, DOI 10.1096/fj.03-1436fje; Evers MR, 2001, J BIOL CHEM, V276, P36344, DOI 10.1074/jbc.M105848200; FARQUHAR CF, 1986, J GEN VIROL, V67, P463, DOI 10.1099/0022-1317-67-3-463; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; GUIROY DC, 1991, ACTA NEUROPATHOL, V82, P87, DOI 10.1007/BF00293949; Hartig W, 2001, NEUROBIOL AGING, V22, P25, DOI 10.1016/S0197-4580(00)00179-2; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Jeffrey M, 1996, NEURODEGENERATION, V5, P101; Kang HG, 2002, J BIOL CHEM, V277, P34766, DOI 10.1074/jbc.M204907200; KIMBERLIN RH, 1986, ANTIMICROB AGENTS CH, V30, P409, DOI 10.1128/AAC.30.3.409; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Martinez-Pomares L, 1999, J BIOL CHEM, V274, P35211, DOI 10.1074/jbc.274.49.35211; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; Milhiet PE, 1998, J ENDOCRINOL, V158, P389, DOI 10.1677/joe.0.1580389; Montagna P, 2003, LANCET NEUROL, V2, P167, DOI 10.1016/S1474-4422(03)00323-5; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Moudjou M, 2004, J VIROL, V78, P9270, DOI 10.1128/JVI.78.17.9270-9276.2004; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; NORENBERG U, 1995, J CELL BIOL, V130, P473, DOI 10.1083/jcb.130.2.473; OKAMOTO M, 1994, NEUROSCI LETT, V172, P51, DOI 10.1016/0304-3940(94)90660-2; Okuda T, 2003, J BIOCHEM, V134, P111, DOI 10.1093/jb/mvg118; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Perez M, 1998, BIOCHEM J, V335, P369, DOI 10.1042/bj3350369; Pesheva P, 2000, PROG NEUROBIOL, V61, P465, DOI 10.1016/S0301-0082(99)00061-1; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PRIOLA SA, 1994, MOL NEUROBIOL, V8, P113, DOI 10.1007/BF02780661; Probstmeier R, 2000, J NEUROSCI RES, V60, P21, DOI 10.1002/(SICI)1097-4547(20000401)60:1<21::AID-JNR3>3.0.CO;2-H; Probstmeier R, 2000, BRAIN RES, V863, P42, DOI 10.1016/S0006-8993(00)02075-8; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Rudd PM, 2001, BIOCHEMISTRY-US, V40, P3759, DOI 10.1021/bi002625f; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Schatzl HM, 1997, J VIROL, V71, P8821; Schonberger O, 2003, BIOCHEM BIOPH RES CO, V312, P473, DOI 10.1016/j.bbrc.2003.10.150; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SNOW AD, 1988, AM J PATHOL, V133, P456; SNOW AD, 1990, LAB INVEST, V63, P601; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Supattapone S, 2004, J MOL MED, V82, P348, DOI 10.1007/s00109-004-0534-3; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Tzaban S, 2002, BIOCHEMISTRY-US, V41, P12868, DOI 10.1021/bi025958g; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; WOODS AG, 1995, BRAIN RES, V697, P53, DOI 10.1016/0006-8993(95)00775-L; Woodworth A, 2004, J BIOL CHEM, V279, P10413, DOI 10.1074/jbc.M312466200; Woodworth A, 2002, J BIOL CHEM, V277, P50941, DOI 10.1074/jbc.M209876200; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Xiao ZC, 1997, J BIOL CHEM, V272, P32092, DOI 10.1074/jbc.272.51.32092; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Ye X, 1997, NEUROTOXICOLOGY, V18, P533	85	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10516	10523		10.1074/jbc.M412635200	http://dx.doi.org/10.1074/jbc.M412635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632154	hybrid			2022-12-27	WOS:000227559600095
J	Cui, J; Holgado-Madruga, M; Su, WW; Tsuiki, H; Wedegaertner, P; Wong, AJ				Cui, J; Holgado-Madruga, M; Su, WW; Tsuiki, H; Wedegaertner, P; Wong, AJ			Identification of a specific domain responsible for JNK2 alpha 2 autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; MAP KINASES; CELL-DEATH; JNK; ACTIVATION; PROTEIN; APOPTOSIS; PHOSPHORYLATION	c-Jun N-terminal kinases (JNKs) are a group of mitogen-activated protein kinase family members that are important in regulating cell growth, proliferation, and apoptosis. Activation of the JNK pathway has been implicated in the formation of several human tumors. We have previously demonstrated that a 55-kDa JNK isoform is constitutively activated in 86% of human brain tumors and more recently demonstrated that this isoform is either JNK2 alpha 2 or JNK2 beta 2. Importantly, we have also found that among the 10 known JNK isoforms, the JNK2 isoforms are unique in their ability to autophosphorylate in vitro and in vivo. This does not require the participation of any upstream kinases and also leads to substrate kinase activity in vitro and in vivo. To clarify the mechanism of JNK2 alpha 2 autoactivation, we have generated a series of chimeric cDNAs joining portions of JNK1 alpha 2, which does not have detectable autophosphorylation activity, with portions of JNK2 alpha 2, which has the strongest autophosphorylation activity. Through in vivo and in vitro kinase assays, we were able to define a domain ranging from amino acids 218 to 226 within JNK2 alpha 2 that is required for its autophosphorylation. Mutation of JNK2 alpha 2 to its counterpart of JNK1 alpha 2 in this region abrogated the autophosphorylation activity and c-Jun substrate kinase activity in vivo and in vitro. Notably, switching of JNK1 alpha 2 to JNK2 alpha 2 at this 9-amino acid site enabled JNK1 alpha 2 to gain the autophosphorylation activity in vivo and in vitro. We also found two other functional sites that participate in JNK2 alpha 2 activity. One site ranging from amino acids 363 to 382 of JNK2 alpha 2 is required for efficient c-Jun binding in vitro, and a site ranging from amino acids 383 to 424 enhances autophosphorylation intensity, although it is not required for triggering the autophosphorylation in vitro. These findings have uncovered the regions required for JNK2 alpha 2 autophosphorylation, and this information could be used as potential targets to block JNK2 alpha 2 activation.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Wong, AJ (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, BLSB 1002,233 S 10th St, Philadelphia, PA 19107 USA.	awong@mail.jci.tju.edu			NCI NIH HHS [CA96539, CA69495] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096539, R01CA069495] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481; Bost F, 1999, MOL CELL BIOL, V19, P1938; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen NY, 2001, CANCER RES, V61, P3908; Cioffi CL, 2000, METHOD ENZYMOL, V314, P363; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Garay M, 2000, BIOCHEM PHARMACOL, V59, P1033, DOI 10.1016/S0006-2952(99)00412-8; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hreniuk D, 2001, MOL PHARMACOL, V59, P867, DOI 10.1124/mol.59.4.867; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang ZH, 2004, J NEUROCHEM, V89, P168, DOI 10.1111/j.1471-4159.2004.02319.x; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Masuda K, 2003, J BIOL CHEM, V278, P32448, DOI 10.1074/jbc.M213254200; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Senger DL, 2002, CANCER RES, V62, P2131; Tsuiki H, 2003, CANCER RES, V63, P250; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	32	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9913	9920		10.1074/jbc.M412165200	http://dx.doi.org/10.1074/jbc.M412165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637069	hybrid			2022-12-27	WOS:000227559600022
J	Jiang, Y; Bhattacharjee, H; Zhou, TQ; Rosen, BP; Ambudkar, SV; Sauna, ZE				Jiang, Y; Bhattacharjee, H; Zhou, TQ; Rosen, BP; Ambudkar, SV; Sauna, ZE			Nonequivalence of the nucleotide binding domains of the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; P-GLYCOPROTEIN; CATALYTIC SUBUNIT; PUMP; METALLOACTIVATION; HYDROLYSIS; SITE; MUTAGENESIS; MECHANISM; TURNOVER	The arsRDABC operon of Escherichia coli plasmid R773 encodes the ArsAB pump that catalyzes extrusion of the metalloids As(III) and Sb(III), conferring metalloid resistance. The catalytic subunit, ArsA, is an ATPase with two homologous halves, A1 and A2, connected by a short linker. Each half contains a nucleotide binding domain. The overall rate of ATP hydrolysis is slow in the absence of metalloid and is accelerated by metalloid binding. The results of photolabeling of ArsA with the ATP analogue 8-azidoadenosine 5'-[alpha-P-32]-triphosphate at 4 degrees C indicate that metalloid stimulation correlates with a > 10-fold increase in affinity for nucleotide. To investigate the relative contributions of the two nucleotide binding domains to catalysis, a thrombin site was introduced in the linker. This allowed discrimination between incorporation of labeled nucleotides into the two halves of ArsA. The results indicate that both the A1 and A2 nucleotide binding domains bind and hydrolyze trinucleotide, even in the absence of metalloid. Sb( III) increases the affinity of the A1 nucleotide binding domain to a greater extent than the A2 nucleotide binding domain. The ATP analogue labeled with P-32 at the gamma position was used to measure hydrolysis of trinucleotide at 37 degrees C. Under these catalytic conditions, both nucleotide binding domains hydrolyze ATP, but hydrolysis in A1 is stimulated to a greater degree by Sb(III) than A2. These results suggest that the two homologous halves of the ArsA may be functionally nonequivalent.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; NCI, Cell Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Wayne State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu	Ambudkar, Suresh V/B-5964-2008; Sauna, Zuben E./AAA-7149-2019; Ambudkar, Suresh V/L-1317-2016; Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM55425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010030, Z01BC010030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055425, R37GM055425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; Bhattacharjee H, 2000, BIOMETALS, V13, P281, DOI 10.1023/A:1009200215328; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; HSU CM, 1989, J BIOL CHEM, V264, P17349; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1992, J BIOL CHEM, V267, P19272; Kaur P, 1999, J BIOL CHEM, V274, P25849, DOI 10.1074/jbc.274.36.25849; Kuroda M, 1998, METHOD ENZYMOL, V292, P82; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JX, 2000, MOL MICROBIOL, V35, P361, DOI 10.1046/j.1365-2958.2000.01696.x; Meng YL, 2004, J BIOL CHEM, V279, P18334, DOI 10.1074/jbc.M400037200; Ramaswamy S, 1998, J BIOL CHEM, V273, P9243, DOI 10.1074/jbc.273.15.9243; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Walmsley AR, 2001, BIOCHEM J, V360, P589, DOI 10.1042/0264-6021:3600589; Yang RY, 2003, J BIOL CHEM, V278, P30764, DOI 10.1074/jbc.M304118200; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731; Zhou TQ, 2002, J BIOL CHEM, V277, P23815, DOI 10.1074/jbc.M203432200	27	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9921	9926		10.1074/jbc.M413391200	http://dx.doi.org/10.1074/jbc.M413391200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637064	hybrid			2022-12-27	WOS:000227559600023
J	Nobukuni, Y; Kohno, K; Miyagawa, K				Nobukuni, Y; Kohno, K; Miyagawa, K			Gene trap mutagenesis-based forward genetic approach reveals that the tumor suppressor OVCA1 is a component of the biosynthetic pathway of diphthamide on elongation factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN-RESISTANT MUTANTS; PSEUDOMONAS EXOTOXIN-A; HAMSTER OVARY CELLS; DIPHTHERIA-TOXIN; FACTOR-II; SACCHAROMYCES-CEREVISIAE; CHROMOSOME 17P13.3; ADP-RIBOSYLATION; EXPRESSION; CANCER	OVCA1 is a tumor suppressor identified by positional cloning from chromosome 17p13.3, a hot spot for chromosomal aberration in breast and ovarian cancers. It has been shown that expression of OVCA1 is reduced in some tumors and that it regulates cell proliferation, embryonic development, and tumorigenesis. However, the biochemical function of OVCA1 has remained unknown. Recently, we isolated a novel mutant resistant to diphtheria toxin and Pseudomonas exotoxin A from the gene trap insertional mutants library of Chinese hamster ovary cells. In this mutant, the Ovca1 gene was disrupted by gene trap mutagenesis, and this disruption well correlated with the toxin-resistant phenotype. We demonstrated direct evidence that the tumor suppressor OVCA1 is a component of the biosynthetic pathway of diphthamide on elongation factor 2, the target of bacterial ADP-ribosylating toxins. A functional genetic approach utilizing the random gene trap mutants library of mammalian cells should become a useful strategy to identify the genes responsible for specific phenotypes.	Hiroshima Univ, Dept Human Genet, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan; Nara Inst Sci & Technol, Dept Mol & Cell Genet, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	Hiroshima University; Nara Institute of Science & Technology	Nobukuni, Y (corresponding author), Hiroshima Univ, Dept Human Genet, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	nobukuni@hiroshima-u.ac.jp	Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				Arora S, 2003, CANCER RES, V63, P6894; BAGAGLIO DM, 1993, CANCER RES, V53, P2260; Bruening W, 1999, CANCER RES, V59, P4973; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; Chen CM, 2004, GENE DEV, V18, P320, DOI 10.1101/gad.1162204; Chen CM, 2001, BIOCHEM BIOPH RES CO, V286, P1019, DOI 10.1006/bbrc.2001.5488; CHEN JYC, 1985, MOL CELL BIOL, V5, P3357, DOI 10.1128/MCB.5.12.3357; DUNLOP PC, 1983, J BIOL CHEM, V258, P4754; FENDRICK JL, 1989, P NATL ACAD SCI USA, V86, P554, DOI 10.1073/pnas.86.2.554; FOLEY BT, 1995, J BIOL CHEM, V270, P23218, DOI 10.1074/jbc.270.39.23218; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GUPTA RS, 1978, CELL, V14, P1007, DOI 10.1016/0092-8674(78)90354-9; IGLEWSKI WJ, 1994, MOL CELL BIOCHEM, V138, P131, DOI 10.1007/BF00928454; KOHNO K, 1987, EXP CELL RES, V172, P54, DOI 10.1016/0014-4827(87)90092-9; KOHNO K, 1985, SOMAT CELL MOLEC GEN, V11, P421, DOI 10.1007/BF01534836; KOHNO K, 1987, J BIOL CHEM, V262, P12298; Liu SH, 2003, MOL CELL, V12, P603, DOI 10.1016/j.molcel.2003.08.003; MARZOUKI A, 1989, FEBS LETT, V255, P72, DOI 10.1016/0014-5793(89)81063-4; MATTHEAKIS LC, 1992, MOL CELL BIOL, V12, P4026, DOI 10.1128/MCB.12.9.4026; MATTHEAKIS LC, 1993, GENE, V132, P149, DOI 10.1016/0378-1119(93)90528-B; MOEHRING JM, 1979, SOMAT CELL GENET, V5, P453, DOI 10.1007/BF01538880; MOEHRING JM, 1980, P NATL ACAD SCI-BIOL, V77, P1010, DOI 10.1073/pnas.77.2.1010; MOEHRING TJ, 1977, CELL, V11, P447, DOI 10.1016/0092-8674(77)90063-0; PAPPENHEIMER AM, 1983, J BACTERIOL, V153, P1342, DOI 10.1128/JB.153.3.1342-1347.1983; Parmer TG, 1999, BRIT J CANCER, V79, P59, DOI 10.1038/sj.bjc.6690012; Phillips NJ, 1996, CANCER LETT, V102, P85, DOI 10.1016/0304-3835(96)04169-9; ROBBINS AR, 1983, J CELL BIOL, V96, P1064, DOI 10.1083/jcb.96.4.1064; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Schultz DC, 1996, CANCER RES, V56, P1997; Schultz DC, 1998, GENOMICS, V52, P186, DOI 10.1006/geno.1998.5420; SIMINOVITCH L, 1985, MOL CELL GENETICS, P869; Tanaka T, 2004, INT J CANCER, V111, P617, DOI 10.1002/ijc.20289; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; VARMUS HE, 1981, CELL, V25, P23, DOI 10.1016/0092-8674(81)90228-2; VONMELCHNER H, 1990, P NATL ACAD SCI USA, V87, P3733, DOI 10.1073/pnas.87.10.3733; Yang J, 2001, CANCER RES, V61, P4010	36	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10572	10577		10.1074/jbc.M413017200	http://dx.doi.org/10.1074/jbc.M413017200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637051	hybrid			2022-12-27	WOS:000227559600102
J	Song, YH; Jacob, CO				Song, YH; Jacob, CO			The mouse cell surface protein TOSO regulates Fas/Fas ligand-induced apoptosis through its binding to fas-associated death domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; LYMPHOPROLIFERATIVE DISEASE; RECEPTOR; FADD; MODULATION; ACTIVATION; MECHANISMS; CASPASE-8; PATHWAYS	Mouse TOSO, the homologue of human TOSO gene, was cloned and characterized in the present study. Using immunofluorescence confocal microscopy we localized TOSO to the cytoplasmic membrane of expressing cells. Using stably transfected mouse TOSO ( mTOSO)- expressing Jurkat cells, we show that TOSO protects cells from Fas/ Fas ligand- and tumor necrosis factor-induced apoptosis but not from TNF-related apoptosis-inducing ligand-induced apoptosis. The Fas-induced activation of caspase-8 was significantly inhibited by the expression of mTOSO. Using deletion mutants and glutathione S- transferase pull-down approaches, we have shown that mTOSO regulates apoptosis by directly binding to Fasassociated death domain through its C-terminal domain, suggesting the disruption of death-inducing signaling complex formation as mechanism of action. Furthermore, we have expressed mTOSO in transgenic mice and show that mTOSO overexpressing primary T lymphocytes are resistant to Fas/Fas ligand-induced apoptosis.	Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Jacob, CO (corresponding author), Univ So Calif, Sch Med, Dept Med, 2011 Zonal Ave,HMR 705, Los Angeles, CA 90089 USA.	Jacob@usc.edu						Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHINNAIYAN AM, 1995, CELL, V81, P512; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Thorburn J, 2003, MOL BIOL CELL, V14, P67, DOI 10.1091/mbc.E02-04-0207; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	33	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9618	9626		10.1074/jbc.M413609200	http://dx.doi.org/10.1074/jbc.M413609200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632112	hybrid			2022-12-27	WOS:000227453100117
J	West, AP; Dancho, BA; Mizel, SB				West, AP; Dancho, BA; Mizel, SB			Gangliosides inhibit flagellin signaling in the absence of an effect on flagellin binding to toll-like receptor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; GRAM-NEGATIVE FLAGELLIN; TOLL-LIKE RECEPTOR-5; NF-KAPPA-B; INTERLEUKIN-1 RECEPTOR; BACTERIAL FLAGELLIN; EPITHELIAL-CELLS; CPG-DNA; LIPOPOLYSACCHARIDE; PHOSPHORYLATION	A recent study concluded that gangliosides serve as co-receptors for flagellin signaling via toll-like receptor 5 (TLR5). In view of several findings in this study that were inconsistent with a role for gangliosides as co-receptors, we re-examined this important issue. Using TLR5-negative RAW 264.7 cells and a TLR5-enhanced yellow fluorescent protein chimera, we established an assay for specific binding of flagellin to cells. Inhibition of clatherin-mediated internalization of flagellin(.)TLR5-enhanced yellow fluorescent protein complexes did not impair flagellin activation of IRAK-1. Thus flagellin signal occurs at the cell surface and not intracellularly. Exogenous addition of mixed gangliosides (GM1, GD1a, and GT1b) as well as GD1a itself inhibited flagellin-induced interleukin-1 receptor-associated kinase activation as well as tumor necrosis factor alpha production in HeNC2, THP-1, and RAW 264.7 cells. Gangliosides inhibited flagellin signaling in the absence of an effect on flagellin binding to TLR5. Depletion of gangliosides in RAW 264.7 cells did not alter the concentration dependence or magnitude of flagellin signaling as measured by interleukin-1 receptor-associated kinase activation or tumor necrosis factor alpha production. Our findings are consistent with the conclusions that gangliosides are not essential co-receptors for flagellin and that the inhibitory effect of gangliosides is mediated by at least one mechanism that is distinct from any effect on the binding of flagellin to TLR5.	Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Mizel, SB (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	smizel@wfubmc.edu	West, A. Phillip/A-7867-2009; West, A. Phillip/W-8171-2019	West, A. Phillip/0000-0003-2884-6895	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051319] Funding Source: NIH RePORTER; NIAID NIH HHS [AI51319] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Berin MC, 2002, CELL MICROBIOL, V4, P635, DOI 10.1046/j.1462-5822.2002.00218.x; Bharti AC, 2003, NITRIC OXIDE-BIOL CH, V8, P75, DOI 10.1016/S1089-8603(02)00145-3; BIRD TA, 1991, BIOCHEM BIOPH RES CO, V177, P61, DOI 10.1016/0006-291X(91)91948-C; CAVAILLON JM, 1987, CELL IMMUNOL, V106, P293, DOI 10.1016/0008-8749(87)90173-0; CHU JWK, 1995, IMMUNOLOGY, V84, P396; Ciacci-Wooline F, 1999, INFECT IMMUN, V67, P5176, DOI 10.1128/IAI.67.10.5176-5185.1999; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; Crespo PM, 2002, J BIOL CHEM, V277, P44731, DOI 10.1074/jbc.M204604200; DICKSON RB, 1981, J BIOL CHEM, V256, P3454; Donnelly MA, 2002, J BIOL CHEM, V277, P40456, DOI 10.1074/jbc.M206851200; Draberova L, 2003, J IMMUNOL, V171, P3585, DOI 10.4049/jimmunol.171.7.3585; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; FRITZ BMR, 1997, BIOCHIM BIOPHYS ACTA, V1354, P153; GALLIS B, 1989, J IMMUNOL, V143, P3235; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Hybiske K, 2004, CELL MICROBIOL, V6, P49, DOI 10.1046/j.1462-5822.2003.00342.x; HYNDS DL, 1995, J NEUROCHEM, V65, P2251; Krifuks O, 1998, CELL IMMUNOL, V187, P45, DOI 10.1006/cimm.1998.1311; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Liaudet L, 2003, SHOCK, V19, P131, DOI 10.1097/00024382-200302000-00008; Liu YH, 2004, J BIOL CHEM, V279, P36481, DOI 10.1074/jbc.M402880200; Lopez-Boado YS, 2001, J BIOL CHEM, V276, P41417, DOI 10.1074/jbc.M107121200; Maaser C, 2004, J IMMUNOL, V172, P5056, DOI 10.4049/jimmunol.172.8.5056; Madrazo DR, 2003, INFECT IMMUN, V71, P5418, DOI 10.1128/IAI.71.9.5418-5421.2003; McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; MILJAN EA, 2002, SCI STKE, V160, P1; Mirkin BL, 2002, CELL PROLIFERAT, V35, P105, DOI 10.1046/j.1365-2184.2002.00228.x; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; Mizel SB, 2003, J BIOL CHEM, V278, P23624, DOI 10.1074/jbc.M303481200; Mizel SB, 2003, J IMMUNOL, V170, P6217, DOI 10.4049/jimmunol.170.12.6217; Mizel SB, 2002, J BIOL CHEM, V277, P22414, DOI 10.1074/jbc.M201762200; MONDAK JJ, 1995, J POLIT, V57, P62, DOI 10.2307/2960271; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Murthy KGK, 2004, J BIOL CHEM, V279, P5667, DOI 10.1074/jbc.M307759200; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ogushi K, 2004, J BIOL CHEM, V279, P12213, DOI 10.1074/jbc.M307944200; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Pestana ES, 1997, BRIT J CANCER, V75, P213, DOI 10.1038/bjc.1997.36; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Shayman JA, 2000, METHOD ENZYMOL, V311, P373; Shen WP, 2002, CELL IMMUNOL, V220, P125, DOI 10.1016/S0008-8749(03)00004-2; Simons M, 1999, MOL BIOL CELL, V10, P3187, DOI 10.1091/mbc.10.10.3187; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Steiner TS, 2000, J CLIN INVEST, V105, P1769, DOI 10.1172/JCI8892; Takahashi A, 2001, FEBS LETT, V508, P484, DOI 10.1016/S0014-5793(01)03088-5; Triantafilou M, 2002, J CELL SCI, V115, P2603; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; YATES AJ, 1993, EXP CELL RES, V204, P38, DOI 10.1006/excr.1993.1006; Zhang J, 2003, INVEST OPHTH VIS SCI, V44, P4247, DOI 10.1167/iovs.03-0219; Zhou X, 2003, INFECT IMMUN, V71, P2120, DOI 10.1128/IAI.71.4.2120-2129.2003; Zurita AR, 2001, BIOCHEM J, V355, P465, DOI 10.1042/0264-6021:3550465	60	30	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9482	9488		10.1074/jbc.M411875200	http://dx.doi.org/10.1074/jbc.M411875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632166	hybrid			2022-12-27	WOS:000227453100102
J	Wu, JG; Ling, X; Pan, DL; Apontes, P; Song, L; Liang, P; Altieri, DC; Beerman, T; Li, FZ				Wu, JG; Ling, X; Pan, DL; Apontes, P; Song, L; Liang, P; Altieri, DC; Beerman, T; Li, FZ			Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin - Evidence of survivin down-regulation associated with drug sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOZYME-MEDIATED INHIBITION; HUMAN-MELANOMA CELLS; WILD-TYPE P53; APOPTOSIS INHIBITOR; CANCER CELLS; FACTOR-I; EXPRESSION; GENE; GROWTH; INDUCTION	Expression of the antiapoptotic protein survivin is associated with cancer cell viability and drug resistance. Thus, control of its expression in cancer cells has significant consequences for cancer therapeutics. Here we have shown that hedamycin, a GC-rich DNA binding drug, down-regulated survivin expression. Using a series of survivin promoter-luciferase constructs, we have identified an 86-bp GC-rich DNA element (-124 to -39) that mediates the ability of hedamycin to down-regulate survivin expression. Furthermore, both in vivo foot-printing and in vitro gel mobility shift experiments revealed that hedamycin bound to a 21-bp GC-rich DNA element (-115 to -95) in the survivin promoter. This drug-DNA interaction abrogated the binding of Sp-1 or Sp1-like proteins to the 21-bp cis-acting DNA element, and mutagenesis of this region consistently diminished survivin promoter activity. Finally, down-regulation of survivin transcription by hedamycin modulated the viability of cancer cells. These data suggest that abrogation of Sp-1 or Sp1-like protein binding to the 21-bp DNA element in the survivin promoter contributes at least in part to the inhibitory effect of hedamycin on survivin gene transcription. Drug-induced modulation of survivin gene expression may provide novel approaches for cancer therapeutics.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; University of Massachusetts System; University of Massachusetts Worcester	Li, FZ (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton Sts, Buffalo, NY 14263 USA.	fengzhi.li@roswellpark.org	Liang, Ping/S-3790-2018; Li, Fengzhi/GXF-0115-2022; Liang, Ping/D-2709-2009	Liang, Ping/0000-0003-4423-0636; Liang, Ping/0000-0003-4423-0636	NCI NIH HHS [CA101515, R01 CA078810, R01 CA080939, CA109481, CA78810, CA90917, R03 CA101515, R01 CA109481-01, R01 CA109481, R01 CA090917, CA080939] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078810, R01CA109481, R03CA101515, R01CA080939, R01CA090917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Ansell SM, 2004, LEUKEMIA, V18, P616, DOI 10.1038/sj.leu.2403281; BOAM DSW, 1995, J BIOL CHEM, V270, P19487, DOI 10.1074/jbc.270.33.19487; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chiang SY, 1996, J BIOL CHEM, V271, P23999, DOI 10.1074/jbc.271.39.23999; Choi KS, 2003, CANCER GENE THER, V10, P87, DOI 10.1038/sj.cgt.7700531; Fortugno P, 2002, J CELL SCI, V115, P575; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 1999, LAB INVEST, V79, P1121; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; LI F, 2004, IN PRESS ONCOGENE; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; Li HM, 1996, GENOMICS, V32, P253, DOI 10.1006/geno.1996.0112; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MUELLER PR, 2001, CURRENT PROTOCOLS MO, V3; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Olie RA, 2000, CANCER RES, V60, P2805; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; Pennati M, 2003, J INVEST DERMATOL, V120, P648, DOI 10.1046/j.1523-1747.2003.12082.x; Pennati M, 2002, J CLIN INVEST, V109, P285; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shen CX, 2003, CANCER GENE THER, V10, P403, DOI 10.1038/sj.cgt.7700581; Tu LC, 2004, MOL CANCER THER, V3, P577; Tu SP, 2003, CANCER RES, V63, P7724; Turner P. R., 2000, Current Drug Targets, V1, P1, DOI 10.2174/1389450003349407; Wall NR, 2003, CANCER RES, V63, P230; WELCH JJ, 1994, J BIOL CHEM, V269, P31051; White CM, 2000, BIOCHEMISTRY-US, V39, P12262, DOI 10.1021/bi001427l; White CM, 2002, BBA-GENE STRUCT EXPR, V1574, P100, DOI 10.1016/S0167-4781(01)00351-7; Xia CY, 2002, MOL CANCER THER, V1, P687; Yamamoto T, 2002, EUR J CANCER, V38, P2316, DOI 10.1016/S0959-8049(02)00247-2; Younis Tallal, 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P697; Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	48	74	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9745	9751		10.1074/jbc.M409350200	http://dx.doi.org/10.1074/jbc.M409350200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637054	hybrid, Green Accepted			2022-12-27	WOS:000227453100132
J	Audet, N; Paquin-Gobeil, M; Landry-Paquet, O; Schiller, PW; Pineyro, G				Audet, N; Paquin-Gobeil, M; Landry-Paquet, O; Schiller, PW; Pineyro, G			Internalization and Src activity regulate the time course of ERK activation by delta opioid receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-SPECIFIC REGULATION; INVERSE-AGONIST; TYROSINE PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; KINASE; MU; EFFICACY; DESENSITIZATION; TRAFFICKING; BINDING	The present study showed that delta opioid receptor (deltaOR) ligands Tyr-Ticpsi [CH2-NH] Cha-Phe-OH (TICP) and ICI174864 behaved as inverse agonists in the cyclase pathway but induced agonist responses in the ERK cascade. Unlike ligands that behaved as agonists in both pathways, and whose stimulation of ERK was marked but transient (10 min), ERK activation by ICI174864 and TICP was moderate and sustained, lasting for more than 1 h in the case of TICP. Biochemical experiments showed that duration of ERK activation by agonists and "dual efficacy ligands" was inversely correlated with their ability to trigger receptor phosphorylation and degradation. Thus, although TICP stabilized deltaORs in a conformation that did not incorporate P-32, was not a substrate for tyrosine kinase Src, and was not downregulated following prolonged exposure to the drug, the conformation stabilized by D-Pen-2,5-enkephalin (DPDPE) incorporated P-32, was phosphorylated by Src, and suffered degradation within the first 2 h of treatment. Inhibition of endocytosis by sucrose prolonged ERK activation by DPDPE increasing the decay half-life of the response to values that resembled those of dual efficacy ligands (from a 2-min decay t(1/2) increased to 12 min). Src inhibitor PP2 also prolonged ERK stimulation by DPDPE. It did so by maintaining a sustained activation of the kinase at similar to20% of maximum following an initial rapid reduction in the response. These results show that specific kinetics of ERK activation by agonists and dual efficacy ligands are determined, at least in part, by the differential ability of the two types of drugs to trigger mechanisms regulating deltaOR responsiveness.	Univ Montreal, Dept Psychiat, Fac Med, Montreal, PQ H1N 3V2, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H1N 3V2, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H1N 3V2, Canada; Univ Montreal, Inst Rech Clin Montreal, Montreal, PQ H1N 3V2, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Pineyro, G (corresponding author), Univ Montreal, Dept Psychiat, Fac Med, 7331 Rue Hochelaga, Montreal, PQ H1N 3V2, Canada.	graciela.pineyro@crfs.umontreal.ca		Pineyro, Graciela/0000-0001-9709-651X				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alves ID, 2003, J BIOL CHEM, V278, P48890, DOI 10.1074/jbc.M306866200; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Bhowmick N, 1998, ENDOCRINOLOGY, V139, P3185, DOI 10.1210/en.139.7.3185; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; Chidiac P, 1996, MOL PHARMACOL, V50, P662; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Clark RB, 1999, TRENDS PHARMACOL SCI, V20, P279, DOI 10.1016/S0165-6147(99)01351-6; Gbahou F, 2003, P NATL ACAD SCI USA, V100, P11086, DOI 10.1073/pnas.1932276100; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Kramer HK, 2000, MOL BRAIN RES, V79, P55, DOI 10.1016/S0169-328X(00)00097-8; Kramer HK, 2000, BIOCHEM PHARMACOL, V60, P781, DOI 10.1016/S0006-2952(00)00400-7; Law PY, 2000, J BIOL CHEM, V275, P32057, DOI 10.1074/jbc.M002395200; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; Lowe JD, 2002, J BIOL CHEM, V277, P15729, DOI 10.1074/jbc.M200612200; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pineyro G, 2005, MOL PHARMACOL, V67, P336, DOI 10.1124/mol.104.004549; Pineyro G, 2001, MOL PHARMACOL, V60, P816; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; Roettger BF, 1997, MOL PHARMACOL, V51, P357; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Schiller PW, 1999, BIOPOLYMERS, V51, P411, DOI 10.1002/(SICI)1097-0282(1999)51:6<411::AID-BIP4>3.0.CO;2-Z; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Valiquette M, 1996, J BIOL CHEM, V271, P18789, DOI 10.1074/jbc.271.31.18789; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653	39	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7808	7816		10.1074/jbc.M411695200	http://dx.doi.org/10.1074/jbc.M411695200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632168	hybrid			2022-12-27	WOS:000227395700046
J	Gwira, JA; Wei, F; Ishibe, S; Ueland, JM; Barasch, J; Cantley, LG				Gwira, JA; Wei, F; Ishibe, S; Ueland, JM; Barasch, J; Cantley, LG			Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; RENAL INJURY; MOUSE; IDENTIFICATION; RECEPTOR; CELLS; IRON; MET; PROTEINS	Growth factors such as hepatocyte growth factor (HGF) are highly up-regulated during development and following renal injury and are known to induce marked morphogenic actions in cultured tubular epithelial cells, including scattering, migration, single cell branching morphogenesis, and multicellular branching tubulogenesis. In the present study, we demonstrate that HGF stimulates epithelial cells to express neutrophil gelatinase-associated lipocalin (Ngal), a member of the lipocalin family of secreted proteins that has recently been shown to participate in mesenchymal-epithelial transformation via its ability to augment cellular iron uptake. At concentrations below those found to mediate iron transport, purified Ngal can induce a promigratory and probranching effect that is dependent on ERK activation. The suppression of Ngal expression using short hairpin RNA results in increased cyst formation by tubular cells. However, the simultaneous addition of Ngal and HGF leads to direct association of the two proteins, and results in a partial inhibition of HGF-mediated activation of c-Met and the downstream MAPK and phosphatidylinositol 3-kinase signaling pathways. This inhibitory effect down-regulates HGF-stimulated single cell migration, and limits branching morphogenesis at both the single cell and multicellular level. These experiments demonstrate that the local expression of Ngal can play a regulatory role in epithelial morphogenesis by promoting the organization of cells into tubular structures while simultaneously negatively modulating the branching effects of HGF.	Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale Univ, Dept Med, New Haven, CT 06520 USA; Columbia Univ, Div Nephrol, New York, NY 10032 USA	Yale University; Yale University; Columbia University	Cantley, LG (corresponding author), Yale Univ, Sch Med, 333 Cedar St,Box 208029, New Haven, CT 06520 USA.	lloyd.cantley@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065109, U24DK058776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK65109, U24 DK58776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cantley LG, 1996, AM J PHYSIOL-RENAL, V271, pF1103, DOI 10.1152/ajprenal.1996.271.6.F1103; Chu ST, 1998, J PEPT RES, V52, P390; Cowland JB, 2003, J IMMUNOL, V171, P6630, DOI 10.4049/jimmunol.171.12.6630; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Goetz DH, 2000, BIOCHEMISTRY-US, V39, P1935, DOI 10.1021/bi992215v; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; JOANNIDIS M, 1994, AM J PHYSIOL, V267, pF231, DOI 10.1152/ajprenal.1994.267.2.F231; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Liu YH, 2002, CURR OPIN NEPHROL HY, V11, P23, DOI 10.1097/00041552-200201000-00004; Liu ZX, 2001, AM J PHYSIOL-RENAL, V281, pF62, DOI 10.1152/ajprenal.2001.281.1.F62; LONGATI P, 1994, ONCOGENE, V9, P49; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MEHEUS LA, 1993, J IMMUNOL, V151, P1535; Mishra J, 2004, J AM SOC NEPHROL, V15, P3073, DOI 10.1097/01.ASN.0000145013.44578.45; Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Ueland JM, 2004, AM J PHYSIOL-RENAL, V286, pF581, DOI 10.1152/ajprenal.00289.2003; Wojnar P, 2003, J BIOL CHEM, V278, P16209, DOI 10.1074/jbc.M210922200; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4	26	134	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7875	7882		10.1074/jbc.M413192200	http://dx.doi.org/10.1074/jbc.M413192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15637066	hybrid			2022-12-27	WOS:000227395700055
J	Harrison, JR; Huang, YF; Wilson, KA; Kelly, PL; Adams, DJ; Gronowicz, GA; Clark, SH				Harrison, JR; Huang, YF; Wilson, KA; Kelly, PL; Adams, DJ; Gronowicz, GA; Clark, SH			Col1a1 promoter-targeted expression of p20 CCAAT enhancer-binding protein beta (C/EBP beta), a truncated c/EBP beta isoform, causes osteopenia in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; ADIPOCYTE DIFFERENTIATION; GENE-EXPRESSION; C-FOS; REGULATED EXPRESSION; BONE-FORMATION; 3T3-L1 CELLS; I COLLAGEN; ALPHA; FAMILY	CCAAT enhancer-binding protein (C/EBP) transcription factors regulate adipocyte differentiation, and recent evidence suggests that osteoblasts and adipocytes share a common pluripotent progenitor in bone marrow. However, little is known about the role of C/EBP transcription factors in the control of osteoblast differentiation or function. In this study, the function of C/EBP transcription factors was disrupted in osteoblast lineage cells by overexpressing a naturally occurring dominant negative C/EBP isoform. Expression of FLp20C/EBPbeta was driven by a 3.6-kb Col1a1 promoter/first intron construct, and four transgenic ( TG) mouse lines were established. Northern blotting and reverse transcription-PCR indicated that the transgene was targeted to bone, with lower levels of expression in lung, skin, and adipose tissue. TG mice from two lines showed reduced body weight compared with wild type litter-mates. All TG lines showed evidence of osteopenia, ranging from mild to severe, as evidenced by reduced trabecular bone volume. Severely affected lines also showed reduced cortical bone width. Dynamic histomorphometry demonstrated an associated decrease in mineral apposition and bone formation rates. Long bones and calvariae of TG mice showed reduced COL1A1 and osteocalcin mRNA levels and increased bone sialoprotein mRNA, consistent with an inhibition of terminal osteoblast differentiation. Ex vivo analysis of primary osteoblast differentiation showed similar effects on marker expression and reduced expression of the mature osteoblast marker Col2.3-green fluorescent protein, demonstrating a cell-autonomous effect of the transgene. These data suggested that C/EBP transcription factors may be important determinants of osteoblast function and bone mass.	Univ Connecticut, Ctr Hlth, Dept Orthodont, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Orthopaed, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut	Harrison, JR (corresponding author), Univ Connecticut, Ctr Hlth, Dept Orthodont, AM-049, Farmington, CT 06030 USA.	harrison@nso1.uchc.edu		Gronowicz, Gloria/0000-0001-7158-3598	NIAMS NIH HHS [AR40668, P30 AR46026] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040668, P30AR046026] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097-4644(20010401)81:1<23::AID-JCB1021>3.0.CO;2-H; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORTELL R, 1994, J CELL BIOCHEM, V54, P256, DOI 10.1002/jcb.240540214; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Darlington GJ, 1999, CURR OPIN CELL BIOL, V11, P678, DOI 10.1016/S0955-0674(99)00035-6; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Fux C, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh001; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harrison JR, 2000, J BONE MINER RES, V15, P1138, DOI 10.1359/jbmr.2000.15.6.1138; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kalajzic Z, 2002, BONE, V31, P654, DOI 10.1016/S8756-3282(02)00912-2; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Orwoll ES, 2001, J BONE MINER RES, V16, P1962, DOI 10.1359/jbmr.2001.16.11.1962; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pereira RC, 2004, ENDOCRINOLOGY, V145, P1952, DOI 10.1210/en.2003-0868; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	41	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8117	8124		10.1074/jbc.M410076200	http://dx.doi.org/10.1074/jbc.M410076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15598659	hybrid			2022-12-27	WOS:000227395700083
J	Feng, SJ; Lu, X; Kroll, MH				Feng, SJ; Lu, X; Kroll, MH			Filamin A binding stabilities nascent glycoprotein Ib alpha trafficking and thereby enhances its surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DINUCLEOTIDE DELETION; GPIB-BETA; PROTEIN; PLATELETS; COMPLEX	The glycoprotein (Gp) Ib-IX-V complex is essential for platelet-mediated hemostasis and thrombosis. The cytoplasmic domain of its largest polypeptide subunit GpIbalpha possesses a binding region for filamin A, which links GpIb-IX-V to the platelet cytoskeleton. There is evidence that filamin A binding to GpIbalpha directs the surface expression of GpIb-IX. To investigate the mechanism of this effect, we examined GpIbalpha biosynthesis in Chinese hamster ovary (CHO) cells stably co-expressing wildtype or mutant GpIbalpha with GpIbbeta, GpIX with and without filamin A. We observed that surface GpIbalpha expression is enhanced in CHO cells co-expressing human filamin A. In comparison with cells expressing only GpIbalpha, GpIbbeta, and GpIX (CHO-GpIbalpha/betaIX), lysates from CHO-GpIbalpha/betaIX + filamin A-expressing cells showed greater amounts of immature, incompletely O-glycosylated and fully mature GpIbalpha, but lesser amounts of the similar to15-kDa C-terminal peptide released when the extracellular domain of GpIbalpha is cleaved by proteases. When filamin A binding is eliminated by truncation of GpIbalpha at C-terminal residue 557 or by a deletion between amino acids 560-570, the decreased synthesis of mature GpIbalpha is accompanied by decreased immature GpIbalpha and by an increased immunodetectable C-terminal peptide. The synthesis of mature GpIbalpha in CHO-GpIbalpha/betaIX cells is eliminated by brefeldin A (which inhibits transport out of the endoplasmic reticulum (ER)) and restored by lactacystin (which inhibits proteasomal degradation). These results suggest that GpIbalpha binds to filamin A within the ER and that filamin A binding directs post-ER trafficking of GpIbalpha to the cell surface.	Baylor Coll Med, Res Serv 151, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; Rice Univ, Houston, TX 77030 USA	Baylor College of Medicine; Rice University	Kroll, MH (corresponding author), Baylor Coll Med, Res Serv 151, Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.	mkroll@bcm.tmc.edu						AfsharKharghan V, 1997, BLOOD, V90, P2634, DOI 10.1182/blood.V90.7.2634.2634_2634_2643; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Bush KT, 1997, J BIOL CHEM, V272, P9086; Dong JF, 1998, J BIOL CHEM, V273, P31449, DOI 10.1074/jbc.273.47.31449; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Dusseljee S, 1998, J CELL SCI, V111, P2217; Esapa CT, 2003, FEBS LETT, V555, P209, DOI 10.1016/S0014-5793(03)01230-4; Feng SJ, 2003, BLOOD, V102, P2122, DOI 10.1182/blood-2002-12-3805; FOX JEB, 1988, J BIOL CHEM, V263, P4882; Jackson SP, 2003, NAT REV DRUG DISCOV, V2, P775, DOI 10.1038/nrd1198; Kenny D, 1997, BLOOD, V90, P2626, DOI 10.1182/blood.V90.7.2626.2626_2626_2633; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kufrin D, 2003, BLOOD, V102, P926, DOI 10.1182/blood-2003-01-0054; Lin RW, 2002, PHARMACOLOGY, V66, P173, DOI 10.1159/000065531; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; Meyer SC, 1998, J BIOL CHEM, V273, P3013, DOI 10.1074/jbc.273.5.3013; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sadler JE, 2002, SCIENCE, V297, P1128, DOI 10.1126/science.1075452; Shi Q, 2004, J THROMB HAEMOST, V2, P1989, DOI 10.1111/j.1538-7836.2004.00961.x; Strassel C, 2003, BIOCHEMISTRY-US, V42, P4452, DOI 10.1021/bi026213d; Ulsemer P, 2001, BIOCHEM J, V358, P295, DOI 10.1042/0264-6021:3580295; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123	24	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6709	6715		10.1074/jbc.M413590200	http://dx.doi.org/10.1074/jbc.M413590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15623510	hybrid			2022-12-27	WOS:000227332700059
J	Wood, DR; Nye, JS; Lamb, NJC; Fernandez, A; Kitzmann, M				Wood, DR; Nye, JS; Lamb, NJC; Fernandez, A; Kitzmann, M			Intracellular retention of caveolin 1 in presenilin-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE CLEAVAGE; BETA-SECRETASE; LIPID RAFTS; NULL MICE; NOTCH; LOCALIZATION; TRAFFICKING; ASSOCIATION; DEFECTS	Mutations in genes encoding presenilins (PS1 and PS2) are responsible for the majority of early onset familial Alzheimer's disease. PS, a critical component of gamma-secretase, is responsible for the intramembranous cleavage of amyloid precursor protein and Notch. Other physiological functions have been assigned to PS without any clear identification of the mechanisms underlying these multiple biological roles. The early embryonic lethality of PSI and PS2 double knock-out (PS1/2 null) mice prevents the evaluation of physiological roles of PS. To investigate new functions for presenilins, we performed a proteomic approach by using cells derived from PS1/2 null blastocysts and wild type controls. We identified a presenilin-dependent cell-surface binding of albumin. Binding of albumin depends on intact caveolae on the cellular surface. Abnormal caveolin 1 localization in PS1/2 null cells was associated with a loss of caveolae and an absence of caveolin 1 expression within lipid rafts. Expressing PSI or PS2 but not the intracellular form of Notch1 in PS1/2 null cells restored normal caveolin 1 localization, demonstrating that presenilins are required for the subcellular trafficking of caveolin 1 independently from Notch activity. Despite an expression of both caveolin 1 and PS1 within lipid raft-enriched fractions after sucrose density centrifugation in wild type cells, no direct interaction between these two proteins was detected, implying that presenilins affect caveolin 1 trafficking in an indirect manner. We conclude that presenilins are required for caveolae formation by controlling transport of intracellular caveolin 1 to the plasma membrane.	Northwestern Univ, Dept Urol, Chicago, IL 60611 USA; Johnson & Johnson Pharmaceut Res & Dev, Titusville, NJ 08560 USA; CNRS, UPR 1142, Inst Human Genet, Cell Biol Unit, F-34396 Montpellier 05, France; CRBM, FRE2593, Muscle Stem Cells & Facio Scapulo Humeral Dystrop, F-34293 Montpellier 5, France	Northwestern University; Johnson & Johnson; Johnson & Johnson USA; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Kitzmann, M (corresponding author), CRBM, FRE2593, Muscle Stem Cells & Facio Scapulo Humeral Dystrop, 1919 Route Mende, F-34293 Montpellier 5, France.	magali.kitzmann@crbm.cnrs.fr	Nye, Jeffrey/G-6520-2012	Nye, Jeffrey/0000-0002-6056-281X				Berechid BE, 2002, J BIOL CHEM, V277, P8154, DOI 10.1074/jbc.M108238200; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; CAPOZA F, 2004, IN PRESS AM J PHYSL; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nishiyama K, 1999, J NEUROSCI, V19, P6538; Palacino JJ, 2000, J BIOL CHEM, V275, P215, DOI 10.1074/jbc.275.1.215; Razani B, 2001, J BIOL CHEM, V276, P38121; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Sisodia SS, 1999, AM J HUM GENET, V65, P7, DOI 10.1086/302475; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	34	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6663	6668		10.1074/jbc.M410332200	http://dx.doi.org/10.1074/jbc.M410332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15613480	hybrid			2022-12-27	WOS:000227332700053
J	Haites, RE; Morita, YS; McConville, MJ; Jacobe, HB				Haites, RE; Morita, YS; McConville, MJ; Jacobe, HB			Function of phosphatidylinositol in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; PHOSPHOLIPASE-C; ACYLATION STATE; TUBERCULOSIS; BIOSYNTHESIS; LIPIDS; LIPOARABINOMANNAN; MANNOSIDES; SMEGMATIS; ENVELOPE	Phosphatidylinositol (PI) is an abundant phospholipid in the cytoplasmic membrane of mycobacteria and the precursor for more complex glycolipids, such as the PI mannosides (PIMs) and lipoarabinomannan (LAM). To investigate whether the large steady-state pools of PI and apolar PIMs are required for mycobacterial growth, we have generated a Mycobacterium smegmatis inositol auxotroph by disruption of the ino1 gene. The ino1 mutant displayed wild-type growth rates and steady-state levels of PI, PIM, and LAM when grown in the presence of 1 mM inositol. The non-dividing ino1 mutant was highly resistant to inositol starvation, reflecting the slow turnover of inositol lipids in this stage. In contrast, dilution of growing or stationary-phase ino1 mutant in inositol-free medium resulted in the rapid depletion of PI and apolar PIMs. Whereas depletion of these lipids was not associated with loss of viability, subsequent depletion of polar PIMs coincided with loss of major cell wall components and cell viability. Metabolic labeling experiments confirmed that the large pools of PI and apolar PIMs were used to sustain polar PIM and LAM biosynthesis during inositol limitation. They also showed that under non-limiting conditions, PI is catabolized via lyso-PI. These data suggest that large pools of PI and apolar PIMs are not essential for membrane integrity but are required to sustain polar PIM biosynthesis, which is essential for mycobacterial growth.	Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	University of Melbourne; University of Melbourne	Jacobe, HB (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Royal Parade, Parkville, Vic 3010, Australia.	hbj@unimelb.edu.au		Billman-Jacobe, Helen/0000-0001-5713-4657; Morita, Yasu/0000-0002-4514-9242				Alexander DC, 2004, J BIOL CHEM, V279, P18824, DOI 10.1074/jbc.M400791200; Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Billman-Jacobe H, 1999, ANTIMICROB AGENTS CH, V43, P3011, DOI 10.1128/AAC.43.12.3011; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; Gomez A, 2001, J CLIN MICROBIOL, V39, P1396, DOI 10.1128/JCM.39.4.1396-1401.2001; HENRY RJ, 1983, J CHROMATOGR, V256, P419, DOI 10.1016/S0021-9673(01)88259-5; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; Jeevarajah D, 2004, J BACTERIOL, V186, P6792, DOI 10.1128/JB.186.20.6792-6799.2004; Johansen KA, 1996, INFECT IMMUN, V64, P3259, DOI 10.1128/IAI.64.8.3259-3266.1996; KLIG LS, 1991, YEAST, V7, P325, DOI 10.1002/yea.320070403; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; MACALA LJ, 1983, J LIPID RES, V24, P1243; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MENARD R, 1993, J BACTERIOL, V175, P5899; Meyers PR, 1998, J CLIN MICROBIOL, V36, P2752, DOI 10.1128/JCM.36.9.2752-2754.1998; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Movahedzadeh F, 2004, MOL MICROBIOL, V51, P1003, DOI 10.1046/j.1365-2958.2003.03900.x; Onyebujoh P, 2004, NAT REV MICROBIOL, V2, P930, DOI 10.1038/nrmicro1050; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; Raynaud C, 2002, MOL MICROBIOL, V45, P203, DOI 10.1046/j.1365-2958.2002.03009.x; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Salman M, 1999, BBA-MOL CELL BIOL L, V1436, P437, DOI 10.1016/S0005-2760(98)00151-9; Sambrook J, 2001, MOL CLONING LAB HDB, V3rd; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0	36	46	47	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10981	10987		10.1074/jbc.M413443200	http://dx.doi.org/10.1074/jbc.M413443200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15634688	hybrid			2022-12-27	WOS:000227761800014
J	Sarfare, S; Ahmad, ST; Joyce, MV; Boggess, B; O'Tousa, JE				Sarfare, S; Ahmad, ST; Joyce, MV; Boggess, B; O'Tousa, JE			The Drosophila ninaG oxidoreductase acts in visual pigment chromophore production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; POTASSIUM CHANNELS; GENE; PHOTORECEPTORS; SEQUENCE; MELANOGASTER; RHODOPSIN; PATHWAY; PROTEIN; ENZYME	The Drosophila ninaG mutant is characterized by low levels of Rh1 rhodopsin, because of the inability to transport this rhodopsin from the endoplasmic reticulum to the rhabdomere. ninaG mutants do not affect the biogenesis of the minor opsins Rh4 and Rh6. A genetic analysis placed the ninaG gene within the 86E4-86E6 chromosomal region. A sequence analysis of the 15 open reading frames within this region from the ninaG(P330) mutant allele identified a stop codon in the CG6728 gene. Germ-line transformation of the CG6728 genomic region rescued the ninaG mutant phenotypes, confirming that CG6728 corresponds to the ninaG gene. The NinaG protein belongs to the glucose-methanol-choline oxidoreductase family of flavin adenine dinucleotide-binding enzymes catalyzing hydroxylation and oxidation of a variety of small organic molecules. High performance liquid chromatography analysis of retinoids was used to gain insight into the in vivo role of the NinaG oxidoreductase. The results show that when Rh1 is expressed as the major rhodopsin, ninaG flies fail to accumulate 3-hydroxyretinal. Further, in transgenic flies expressing Rh4 as the major rhodopsin, 3-hydroxyretinal is the major retinoid in ninaG(+), but a different retinoid profile is observed in ninaG(P330). These results indicate that the ninaG oxidoreductase acts in the biochemical pathway responsible for conversion of retinal to the rhodopsin chromophore, 3-hydroxyretinal.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame	O'Tousa, JE (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	jotousa@nd.edu		O'Tousa, Joseph/0000-0001-9754-6816	NEI NIH HHS [EY06808] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; CELNIKER SE, 2002, GENOME BIOL; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; FEILER R, 1992, J NEUROSCI, V12, P3862; Franceschini N, 1975, PHOTORECEPTOR OPTICS, P97; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; GLOOR GB, 1993, GENETICS, V135, P81; Gu G, 2004, J BIOL CHEM, V279, P18608, DOI 10.1074/jbc.M400323200; HARDIE RC, 1991, NEURON, V6, P477, DOI 10.1016/0896-6273(91)90255-X; HARDIE RC, 1991, J NEUROSCI, V11, P3079; HARRIS WA, 1977, NATURE, V266, P648, DOI 10.1038/266648a0; Hsu CD, 2002, VISION RES, V42, P507, DOI 10.1016/S0042-6989(01)00231-0; ISONO K, 1988, J GEN PHYSIOL, V92, P587, DOI 10.1085/jgp.92.5.587; Kiefer C, 2002, P NATL ACAD SCI USA, V99, P10581, DOI 10.1073/pnas.162182899; KIRSCHFELD K, 1977, NATURE, V269, P386, DOI 10.1038/269386a0; KOUTZ P, 1989, YEAST, V5, P167, DOI 10.1002/yea.320050306; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; NICHOLS R, 1985, DROSOPH INF SERV, V61, P195; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; OZAKI K, 1993, NEURON, V10, P1113, DOI 10.1016/0896-6273(93)90059-Z; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; Pichaud F, 2001, DEVELOPMENT, V128, P815; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHIFF NM, 1992, MOL BIOL EVOL, V9, P1029; Seki T, 1998, EUR J BIOCHEM, V257, P522, DOI 10.1046/j.1432-1327.1998.2570522.x; SEKI T, 1994, EUR J BIOCHEM, V226, P691, DOI 10.1111/j.1432-1033.1994.tb20097.x; Seki T, 1998, COMP BIOCHEM PHYS B, V119, P53, DOI 10.1016/S0305-0491(97)00322-2; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STEPHENSON RS, 1983, SYM SOC EXP BIOL, P477; SUZUKI T, 1986, VISION RES, V26, P425, DOI 10.1016/0042-6989(86)90185-9; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2001, P NATL ACAD SCI USA, V98, P1130, DOI 10.1073/pnas.031576398; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WASHBURN T, 1992, GENETICS, V130, P585; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834	43	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11895	11901		10.1074/jbc.M412236200	http://dx.doi.org/10.1074/jbc.M412236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15640158	hybrid			2022-12-27	WOS:000227761800119
J	Takashima, H; Yoshida, T; Ishino, T; Hasuda, K; Ohkubo, T; Kobayashi, Y				Takashima, H; Yoshida, T; Ishino, T; Hasuda, K; Ohkubo, T; Kobayashi, Y			Solution NMR structure investigation for releasing mechanism of neocarzinostatin chromophore from the holoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; RIBOSOME RECYCLING FACTOR; MODEL-FREE APPROACH; APO-NEOCARZINOSTATIN; NATURAL-ABUNDANCE; KEY INTERACTIONS; PROTEIN; RELAXATION; SPECTROSCOPY; ENEDIYNE	Holo-neocarzinostatin (holo-NCS) is a complex protein carrying the anti-tumor active enediyne ring chromophore by a scaffold consisting of an immunoglobulin-like seven-stranded anti-parallel beta-barrel. Because of the labile chromophore reflecting its extremely strong DNA cleavage activity and complete stabilization in the complex, holo-NCS has attracted much attention in clinical use as well as for drug delivery systems. Despite many structural analyses for holo-NCS, the chromophore-releasing mechanism to trigger prompt attacks on the target DNA is still unclear. We determined the three-dimensional structure of the protein and the internal motion by multinuclear NMR to investigate the releasing mechanism. The internal motion studied by C-13 NMR methine relaxation experiments showed that the complex has a rigid structure for its loops as well as the beta-barrel in aqueous solution. This agrees with the refined NMR solution structure, which has good convergence in the loop regions. We also showed that the chromophore displayed a similar internal motion as the protein moiety. The structural comparison between the refined solution structure and x-ray crystal structure indicated characteristic differences. Based on the findings, we proposed the chromophore-releasing mechanism by a three-state equilibrium, which sufficiently describes both the strong binding and the prompt releasing of the chromophore. We demonstrated that we could bridge the dynamic properties and the static structure features with simple kinetic assumptions to solve the biochemical function.	Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; POLA Chem Ind Inc, Totsuka Ku, Yokohama, Kanagawa 2440812, Japan; Novartis Inst Biomed Res, Informat Knowledge Management, Tsukuba, Ibaraki 3002611, Japan	Osaka University; Pola Chemical Industries Inc.; Novartis	Kobayashi, Y (corresponding author), Osaka Univ, Grad Sch Pharmaceut Sci, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.	yujik@protein.osaka-u.ac.jp		Yoshida, Takuya/0000-0002-3491-9344				ADJADJ E, 1992, EUR J BIOCHEM, V203, P505, DOI 10.1111/j.1432-1033.1992.tb16576.x; ADJADJ E, 1992, BIOCHIMIE, V74, P853, DOI 10.1016/0300-9084(92)90068-P; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Heyd B, 2003, BIOCHEMISTRY-US, V42, P5674, DOI 10.1021/bi0273664; ISHIDA N, 1965, J ANTIBIOT, V18, P68; Izadi-Pruneyre N, 2001, PROTEIN SCI, V10, P2228, DOI 10.1110/ps.12201; KAPPEN LS, 1993, SCIENCE, V261, P1319, DOI 10.1126/science.8362243; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KIM KH, 1993, SCIENCE, V262, P1043; KIM KH, 1997, NEOCARZIOSTATIN PAST, P109; LEFEVRE C, 1994, J BIOMOL NMR, V4, P689, DOI 10.1007/BF00404278; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Maeda Hiroshi, 1997, NEOCARZINOSTATIN PAS, P227; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MISPELTER J, 1995, J BIOMOL NMR, V5, P233; MOHANTY S, 1994, BIOCHEMISTRY-US, V33, P10579, DOI 10.1021/bi00201a003; NAPIER MA, 1981, BIOCHEMISTRY-US, V20, P5602, DOI 10.1021/bi00522a038; Nicaise M, 2004, PROTEIN SCI, V13, P1882, DOI 10.1110/ps.03540504; Nicaise M, 2003, PROTEIN ENG, V16, P733, DOI 10.1093/protein/gzg099; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P1387, DOI 10.1002/anie.199113873; NOZAKI S, 2002, J BIOCH, V131, P469; Okuno Y, 2000, J AM CHEM SOC, V122, P6848, DOI 10.1021/ja994323a; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PENG JW, 1991, J MAGN RESON, V95, P421, DOI 10.1016/0022-2364(91)90233-J; Perez J, 2001, J MOL BIOL, V308, P721, DOI 10.1006/jmbi.2001.4611; Potts BCM, 1998, J BIOMOL NMR, V11, P45, DOI 10.1023/A:1008245501057; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P4007, DOI 10.1021/bi00517a009; Russo D, 2001, BIOCHEMISTRY-US, V40, P3958, DOI 10.1021/bi002200t; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Smith AL, 1996, J MED CHEM, V39, P2103, DOI 10.1021/jm9600398; SMITH BL, 1994, J BIOL CHEM, V269, P30587; Sternberg U, 2004, ANNU REP NMR SPECTRO, V52, P53, DOI 10.1016/S0066-4103(04)52002-1; Sudhahar GCP, 2000, J BIOL CHEM, V275, P39900; Takashima H, 2004, BIOCHEMISTRY-US, V43, P13932, DOI 10.1021/bi048649u; Takashima H, 2004, J AM CHEM SOC, V126, P4504, DOI 10.1021/ja031637w; TAKASHIMA H, 1991, J BIOCHEM-TOKYO, V109, P807, DOI 10.1093/oxfordjournals.jbchem.a123462; TAKASHIMA H, 1997, NEOCARZINOSTATIN PAS, P83; TANAKA T, 1991, TETRAHEDRON LETT, V32, P3175, DOI 10.1016/S0040-4039(00)79715-2; Tanaka T, 2001, J MOL BIOL, V309, P267, DOI 10.1006/jmbi.2001.4621; TANAKA T, 1993, J CHEM SOC CHEM COMM, P1205, DOI 10.1039/c39930001205; TEPLYAKOV A, 1993, EUR J BIOCHEM, V213, P737, DOI 10.1111/j.1432-1033.1993.tb17814.x; Urbaniak MD, 2004, J MED CHEM, V47, P4710, DOI 10.1021/jm040790d; Urbaniak MD, 2002, BIOCHEMISTRY-US, V41, P11731, DOI 10.1021/bi0262146; Valerio-Lepiniec M, 2002, PROTEIN ENG, V15, P861, DOI 10.1093/protein/15.11.861; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang DW, 1996, J MOL BIOL, V263, P369, DOI 10.1006/jmbi.1996.0581; Yoshida T, 2003, BIOCHEMISTRY-US, V42, P4101, DOI 10.1021/bi027191y; Yoshida T, 2001, BIOCHEMISTRY-US, V40, P2387, DOI 10.1021/bi002474g	55	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11340	11346		10.1074/jbc.M411579200	http://dx.doi.org/10.1074/jbc.M411579200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15640161	hybrid			2022-12-27	WOS:000227761800055
J	Brader, G; Sjoblom, S; Hyytiainen, H; Sims-Huopaniemi, K; Palva, ET				Brader, G; Sjoblom, S; Hyytiainen, H; Sims-Huopaniemi, K; Palva, ET			Altering substrate chain length specificity of an acylhomoserine lactone synthase in bacterial communication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTOVORA SUBSP CAROTOVORA; QUORUM-SENSING SIGNALS; ACYL CARRIER PROTEIN; PATHOGEN ERWINIA-CAROTOVORA; BETA-KETOACYL; RHIZOBIUM-LEGUMINOSARUM; HOMOSERINE LACTONASE; VIBRIO-FISCHERI; TI-PLASMID; AUTOINDUCER	Quorum sensing mediated by specific signal compounds (autoinducers) allows bacteria to monitor their cell density and enables a synchronized regulation of target gene sets. The best studied group of autoinducers are the acylhomoserine lactones (AHSLs), which are central to the regulation of virulence in many plant and animal pathogens. Variation of the acyl side chain of the AHSLs underlies the observed species specificity of this communication system. Here we show that even different strains of the plant pathogen Erwinia carotovora employ different dialects of this language and demonstrate the molecular basis for the acyl chain length specificity of distinct AHSL synthases. Under physiological concentrations, only the cognate AHSL with the "right" acyl chain is recognized as a signal that will switch on virulence genes. Mutagenesis of the AHSL synthase gene expI(SCC1) identified the changes M127T and F69L as sufficient to effectively alter ExpI(SCC1) (an N-3-oxohexanoyl-L homoserine lactone producer) substrate specificity to that of an N-3-oxooctanoyl-L-homoserine lactone producer. Our data identify critical residues that define the size of the substrate-binding pocket of the AHSL synthase and will help in understanding and manipulating this bacterial language.	Univ Helsinki, Viikki Bioctr, Fac Biosci, Dept Biol & Environm Sci,Div Genet, FIN-00014 Helsinki, Finland	University of Helsinki	Palva, ET (corresponding author), Univ Helsinki, Viikki Bioctr, Fac Biosci, Dept Biol & Environm Sci,Div Genet, POB 56, FIN-00014 Helsinki, Finland.	tapio.palva@helsinki.fi		Hyytiainen, Heidi/0000-0002-3109-9600				Andersson RA, 2000, MOL PLANT MICROBE IN, V13, P384, DOI 10.1094/MPMI.2000.13.4.384; BAINTON NJ, 1992, BIOCHEM J, V288, P997, DOI 10.1042/bj2880997; Bao WL, 1999, BIOCHEMISTRY-US, V38, P9752, DOI 10.1021/bi990751h; Bauer WD, 2004, CURR OPIN PLANT BIOL, V7, P429, DOI 10.1016/j.pbi.2004.05.008; Carlier A, 2003, APPL ENVIRON MICROB, V69, P4989, DOI 10.1128/AEM.69.8.4989-4993.2003; Chatterjee A, 2002, J BACTERIOL, V184, P4089, DOI 10.1128/JB.184.15.4089-4095.2002; Dong YH, 2001, NATURE, V411, P813, DOI 10.1038/35081101; Elbing K, 2002, CURR PROTOCOLS MOL B; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; Fray RG, 1999, NAT BIOTECHNOL, V17, P1017, DOI 10.1038/13717; Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907; Gould TA, 2004, MOL MICROBIOL, V53, P1135, DOI 10.1111/j.1365-2958.2004.04211.x; Hanzelka BL, 1997, J BACTERIOL, V179, P4882, DOI 10.1128/jb.179.15.4882-4887.1997; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Hentzer M, 2003, BIODRUGS, V17, P241, DOI 10.2165/00063030-200317040-00003; Hoang TT, 2002, MICROBIOL-SGM, V148, P3849, DOI 10.1099/00221287-148-12-3849; Leadbetter JR, 2000, J BACTERIOL, V182, P6921, DOI 10.1128/JB.182.24.6921-6926.2000; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; Lithgow JK, 2000, MOL MICROBIOL, V37, P81, DOI 10.1046/j.1365-2958.2000.01960.x; Lithgow JK, 2001, PLANT SOIL, V232, P3, DOI 10.1023/A:1010333716277; Loh J, 2002, CURR OPIN PLANT BIOL, V5, P285, DOI 10.1016/S1369-5266(02)00274-1; Mae A, 2001, MOL PLANT MICROBE IN, V14, P1035, DOI 10.1094/MPMI.2001.14.9.1035; More MI, 1996, SCIENCE, V272, P1655, DOI 10.1126/science.272.5268.1655; Nasser W, 1998, MOL MICROBIOL, V29, P1391, DOI 10.1046/j.1365-2958.1998.01022.x; Parsek MR, 2000, P NATL ACAD SCI USA, V97, P8789, DOI 10.1073/pnas.97.16.8789; Parsek MR, 1999, P NATL ACAD SCI USA, V96, P4360, DOI 10.1073/pnas.96.8.4360; Parsek MR, 1997, MOL MICROBIOL, V26, P301, DOI 10.1046/j.1365-2958.1997.5741935.x; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; PIRHONEN M, 1988, MOL GEN GENET, V214, P170, DOI 10.1007/BF00340198; PIRHONEN M, 1991, MOL PLANT MICROBE IN, V4, P276, DOI 10.1094/MPMI-4-276; PIRHONEN M, 1993, EMBO J, V12, P2467, DOI 10.1002/j.1460-2075.1993.tb05901.x; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; SWIFT S, 1993, MOL MICROBIOL, V10, P511, DOI 10.1111/j.1365-2958.1993.tb00923.x; Taga ME, 2003, P NATL ACAD SCI USA, V100, P14549, DOI 10.1073/pnas.1934514100; Val DL, 1998, J BACTERIOL, V180, P2644, DOI 10.1128/JB.180.10.2644-2651.1998; Vannini A, 2004, J BIOL CHEM, V279, P24291, DOI 10.1074/jbc.M401855200; von Bodman SB, 1998, P NATL ACAD SCI USA, V95, P7687, DOI 10.1073/pnas.95.13.7687; Watson WT, 2002, MOL CELL, V9, P685, DOI 10.1016/S1097-2765(02)00480-X; Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631; Whitehead NA, 2002, ANTON LEEUW INT J G, V81, P223, DOI 10.1023/A:1020570802717; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Zhang LH, 2003, TRENDS PLANT SCI, V8, P238, DOI 10.1016/S1360-1385(03)00063-3; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0	44	42	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10403	10409		10.1074/jbc.M408603200	http://dx.doi.org/10.1074/jbc.M408603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15634689	hybrid			2022-12-27	WOS:000227559600081
J	Watanabe, K; Nureki, O; Fukai, S; Ishii, R; Okamoto, H; Yokoyama, S; Endo, Y; Hori, H				Watanabe, K; Nureki, O; Fukai, S; Ishii, R; Okamoto, H; Yokoyama, S; Endo, Y; Hori, H			Roles of conserved amino acid sequence motifs in the SpoU (TrmH) RNA methyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEEP TREFOIL KNOT; ESCHERICHIA-COLI; RIBOSOMAL-RNA; GM18 METHYLTRANSFERASE; MODIFICATION DATABASE; CRYSTAL-STRUCTURE; AQUIFEX-AEOLICUS; ACTIVE-SITE; RECOGNITION; ENZYME	Transfer RNA (Gm18) methyltransferase (TrmH (SpoU)) catalyzes the transfer of a methyl group from S-adenosyl- L-methionine (AdoMet) to the 2'-OH of guanosine 18 in tRNA. This enzyme is a member of the SpoU family of RNA methyltransferases. Recent computational researches have shown that three amino acid sequence motifs are conserved among the SpoU members. Recently, we determined the crystal structures of the apo- and AdoMet bound forms of TrmH (Nureki, O., Watanabe, K., Fukai, S., Ishii, R., Endo, Y., Hori, H., and Yokoyama, S. (2004) Structure 12, 593-602). Furthermore, we clarified the AdoMet binding site and proposed the catalytic mechanism. Since the functions of the conserved amino acid residues in the motifs remain unknown, here we have prepared 17 mutants of TrmH and carried out various biochemical studies, including determination of the kinetic parameters for both AdoMet and tRNA, S-adenosyl- L-homocysteine affinity chromatography, gel mobility shift assay, CD spectroscopy, and analytical gel filtration. Our results show that Asn(35), Arg(41), Glu(124), and Asn(152) are involved in binding tRNA and that the Asn(35) residue is involved in the release of S-adenosyl- L-homocysteine. Several residues of TrmH are important for stability of the enzyme. Taken together, our biochemical studies reinforce the previously proposed catalytic mechanism. We also discuss amino acid substitutions in general within the SPOUT superfamily of methyltransferases.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan; Univ Tokyo, Grad Sch Sci, Tokyo 1130033, Japan; JST, PRESTO, Kawaguchi, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN, Harima Inst, Harima 6795148, Japan; Ehime Univ, Venture Business Lab, Matsuyama, Ehime 7908577, Japan; Ehime Univ, Cell Free Sci & Technol Res Ctr, Matsuyama, Ehime 7908577, Japan	Tokyo Institute of Technology; Ehime University; University of Tokyo; Japan Science & Technology Agency (JST); RIKEN; RIKEN; Ehime University; Ehime University	Nureki, O (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Midori Ku, Nagatsuta 4259, Yokohama, Kanagawa 2268501, Japan.	onureki@bio.titech.ac.jp; hori@eng.ehime-u.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Watanabe, Kazunori/G-6671-2012; Hori, Hiroyuki/AAB-3911-2021; Fukai, Shuya/X-4838-2018	Yokoyama, Shigeyuki/0000-0003-3133-7338; Watanabe, Kazunori/0000-0003-3678-636X; Fukai, Shuya/0000-0002-1241-1443; Ishii, Ryohei/0000-0003-2486-1393				Ahn HJ, 2003, EMBO J, V22, P2593, DOI 10.1093/emboj/cdg269; Anantharaman V, 2002, J MOL MICROB BIOTECH, V4, P71; BYSTROM AS, 1982, MOL GEN GENET, V188, P440, DOI 10.1007/BF00330046; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; Cavaille J, 1999, RNA, V5, P66, DOI 10.1017/S1355838299981475; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; Elkins PA, 2003, J MOL BIOL, V333, P931, DOI 10.1016/j.jmb.2003.09.011; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; HJALMARSSON KJ, 1983, J BIOL CHEM, V258, P1343; HOLMES WM, 1992, J BIOL CHEM, V267, P13440; Hori H, 2003, J BIOL CHEM, V278, P25081, DOI 10.1074/jbc.M212577200; HORI H, 1989, J BIOCHEM-TOKYO, V106, P798, DOI 10.1093/oxfordjournals.jbchem.a122933; Hori H, 2002, GENES CELLS, V7, P259, DOI 10.1046/j.1365-2443.2002.00520.x; Hori H, 1998, J BIOL CHEM, V273, P25721, DOI 10.1074/jbc.273.40.25721; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KIM SH, 1974, P NATL ACAD SCI USA, V71, P4970, DOI 10.1073/pnas.71.12.4970; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; Lim K, 2003, PROTEINS, V51, P56, DOI 10.1002/prot.10323; Liu JY, 2003, PROTEINS, V53, P326, DOI 10.1002/prot.10479; MATSUMOTO T, 1990, J BIOCHEM-TOKYO, V107, P331, DOI 10.1093/oxfordjournals.jbchem.a123047; McCloskey JA, 1998, NUCLEIC ACIDS RES, V26, P196, DOI 10.1093/nar/26.1.196; Michel G, 2002, STRUCTURE, V10, P1303, DOI 10.1016/S0969-2126(02)00852-3; Nureki O, 2004, STRUCTURE, V12, P593, DOI 10.1016/j.str.2004.03.003; Nureki O, 2002, ACTA CRYSTALLOGR D, V58, P1129, DOI 10.1107/S0907444902006601; Persson B. C., 1997, NUCLEIC ACIDS RES, V25, P3969, DOI [10.1093/nar/25.20.4093, DOI 10.1093/NAR/25.20.4093]; Redlak M, 1997, BIOCHEMISTRY-US, V36, P8699, DOI 10.1021/bi9701538; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; Urbonavicius J, 2002, J BACTERIOL, V184, P5348, DOI 10.1128/JB.184.19.5348-5357.2002; Verdino P, 2004, METHODS, V32, P241, DOI 10.1016/j.ymeth.2003.08.017; Zarembinski TI, 2003, PROTEINS, V50, P177, DOI 10.1002/prot.10311	34	54	56	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10368	10377		10.1074/jbc.M411209200	http://dx.doi.org/10.1074/jbc.M411209200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637073	hybrid			2022-12-27	WOS:000227559600077
J	Eisses, JF; Chi, YQ; Kaplan, JH				Eisses, JF; Chi, YQ; Kaplan, JH			Stable plasma membrane levels of hCTR1 mediate cellular copper uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; STIMULATED ENDOCYTOSIS; TRANSPORTER-1 HCTR1; OXYGEN RADICALS; PROTEIN; CTR1; DEGRADATION; MECHANISM	The human copper transporter 1 (hCtr1), when heterologously overexpressed in insect cells, mediates saturable Cu uptake. In mammalian expression systems, a rapid Cu- dependent internalization of hCtr1 has been reported in cells that overexpress epitope-tagged hCtr1 when exposed to Cu in the external medium. This finding led to the suggestion that such internalization may be a step in the hCtr1 transmembrane Cu transport mechanism. We have demonstrated that preincubation in Cu- containing media of sf9 cells stably expressing hCtr1 has no effect on the initial rate of Cu transport. Furthermore, Western blot analyses of fractionated sf9 cell membranes show no evidence of a regulatory Cu-dependent internalization from the plasma membrane. In similar studies on human embryonic kidney (HEK) 293 cells, we showed that incubation with Cu does not alter the initial rate of Cu uptake mediated by endogenous levels of hCtr1 compared with untreated cells. Confirmation that hCtr1 mediates this transport is provided by specific small interfering RNA-dependent decreases in hCtr1 protein levels and in Cu transport rates. Western blot analysis and confocal microscopy of human embryonic kidney 293 cells showed that the majority of hCtr1 protein is localized at the plasma membrane and no significant internalization is detected upon Cu treatment. We concluded that internalization of hCtr1 is not a required step in the transport pathway; we suggest that oligomeric hCtr1 acts as a conventional transporter providing a permeation pathway for Cu through the membrane and that internalization of endogenous hCtr1 in response to elevated extracellular Cu levels does not play a significant regulatory role in Cu homeostasis.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kaplan, JH (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	kaplanj@uic.edu		Kaplan, Jack/0000-0002-7048-6574	NCI NIH HHS [R24 CA86307] Funding Source: Medline; NIGMS NIH HHS [P01 GM067166] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aller SG, 2004, J BIOL CHEM, V279, P53435, DOI 10.1074/jbc.M409421200; Arredondo M, 2004, AM J PHYSIOL-GASTR L, V287, pG27, DOI 10.1152/ajpgi.00297.2003; Arredondo M, 2003, AM J PHYSIOL-CELL PH, V284, pC1525, DOI 10.1152/ajpcell.00480.2002; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Guo Y, 2004, J BIOL CHEM, V279, P17428, DOI 10.1074/jbc.M401493200; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Klomp AEM, 2003, BIOCHEM J, V370, P881, DOI 10.1042/BJ20021128; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2004, PFLUG ARCH EUR J PHY, V447, P752, DOI 10.1007/s00424-003-1092-1; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; Zerounian NR, 2003, AM J PHYSIOL-GASTR L, V284, pG739, DOI 10.1152/ajpgi.00415.2002	23	70	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9635	9639		10.1074/jbc.M500116200	http://dx.doi.org/10.1074/jbc.M500116200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634665	hybrid			2022-12-27	WOS:000227453100119
J	Fox, CA; McConnell, KH				Fox, CA; McConnell, KH			Toward biochemical understanding of a transcriptionally silenced chromosomal domain in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ORIGIN RECOGNITION COMPLEX; TELOMERIC HETEROCHROMATIN; GENE-EXPRESSION; PROTEIN SIR2; YEAST; CHROMATIN; BINDING; ACETYLATION; ACTIVATOR; RAP1		Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fox, CA (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 587 MSC,1300 Univ Ave, Madison, WI 53706 USA.	cfox@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056890] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansari A, 1999, METHODS, V17, P104, DOI 10.1006/meth.1998.0722; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bose ME, 2004, MOL CELL BIOL, V24, P774, DOI 10.1128/MCB.24.2.774-786.2004; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; Buck SW, 2004, J LEUKOCYTE BIOL, V75, P939, DOI 10.1189/jlb.0903424; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Chang JF, 2003, STRUCTURE, V11, P637, DOI 10.1016/S0969-2126(03)00093-5; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Chow JC, 2003, CELL MOL LIFE SCI, V60, P2586, DOI 10.1007/s00018-003-3121-9; DeBeer MAP, 2003, GENE DEV, V17, P1817, DOI 10.1101/gad.1096703; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; Eissenberg JC, 2003, PROG NUCLEIC ACID RE, V74, P275, DOI 10.1016/S0079-6603(03)01016-X; Eissenberg JC, 2001, BIOESSAYS, V23, P767, DOI 10.1002/bies.1111; Gardner KA, 1999, GENETICS, V151, P31; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Georgel PT, 2001, P NATL ACAD SCI USA, V98, P8584, DOI 10.1073/pnas.151258798; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Huang Y, 2002, NUCLEIC ACIDS RES, V30, P1465, DOI 10.1093/nar/30.7.1465; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Moazed D, 2004, NOVART FDN SYMP, V259, P163; Moazed D, 2004, NOVART FDN SYMP, V259, P56; Moazed Danesh, 2004, Novartis Found Symp, V259, P48; Moretti P, 2001, MOL CELL BIOL, V21, P8082, DOI 10.1128/MCB.21.23.8082-8094.2001; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Oki M, 2004, MOL CELL BIOL, V24, P1956, DOI 10.1128/MCB.24.5.1956-1967.2004; Oki M, 2002, CURR OPIN CELL BIOL, V14, P299, DOI 10.1016/S0955-0674(02)00327-7; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Rusche LN, 2002, MOL BIOL CELL, V13, P2207, DOI 10.1091/mbc.E02-03-0175; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Sekinger EA, 1999, EMBO J, V18, P7041, DOI 10.1093/emboj/18.24.7041; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 2004, MOL CELL BIOL, V24, P6931, DOI 10.1128/MCB.24.16.6931-6946.2004; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0	52	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8629	8632		10.1074/jbc.R400033200	http://dx.doi.org/10.1074/jbc.R400033200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623501	hybrid			2022-12-27	WOS:000227453100001
J	Garcia, HH; Brar, GA; Nguyen, DHH; Bjeldanes, LF; Firestone, GL				Garcia, HH; Brar, GA; Nguyen, DHH; Bjeldanes, LF; Firestone, GL			Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR INTERACTIONS; NATURALLY OCCURRING INDOLES; MOLECULAR-WEIGHT FORMS; DIETARY INDOLE-3-CARBINOL; 3,3'-DIINDOLYLMETHANE DIM; ESTRADIOL METABOLISM; PROSTATE-CANCER; CERVICAL-CANCER; TUMOR-CELLS; G(1)	Indole-3-carbinol (I3C), a dietary compound found in cruciferous vegetables, induces a robust inhibition of CDK2 specific kinase activity as part of a G(1) cell cycle arrest of human breast cancer cells. Treatment with I3C causes a significant shift in the size distribution of the CDK2 protein complex from an enzymatically active 90 kDa complex to a larger 200 kDa complex with significantly reduced kinase activity. Co-immunoprecipitations revealed an increased association of both a 50 kDa cyclin E and a 75 kDa cyclin E immunoreactive protein with the CDK2 protein complex under I3C-treated conditions, whereas the 90 kDa CDK2 protein complexes detected in proliferating control cells contain the lower molecular mass forms of cyclin E. I3C treatment caused no change in the level of CDK2 inhibitors (p21, p27) or in the inhibitory phosphorylation states of CDK2. The effects of I3C are specific for this indole and not a consequence of the cell cycle arrest because treatment of MCF-7 breast cancer cells with either the I3C dimerization product DIM or the anti-estrogen tamoxifen induced a G1 cell cycle arrest with no changes in the associated cyclin E or subcellular localization of the CDK2 protein complex. Taken together, our results have uncovered a unique effect of I3C on cell cycle control in which the inhibition of CDK2 kinase activity is accompanied by selective alterations in cyclin E composition, size distribution, and subcellular localization of the CDK2 protein complex.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@berkeley.edu			NCI NIH HHS [R01 CA102360, R01 CA102360-01A1, CA102360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akli S, 2003, CANCER BIOL THER, V2, pS38; Birt DF, 1996, PROG CLIN BIOL RES, V395, P223; BRADFIELD CA, 1987, J TOXICOL ENV HEALTH, V21, P311, DOI 10.1080/15287398709531021; BRADFIELD CA, 1984, FOOD CHEM TOXICOL, V22, P977, DOI 10.1016/0278-6915(84)90147-9; BRADLOW HL, 1991, CARCINOGENESIS, V12, P1571, DOI 10.1093/carcin/12.9.1571; BRESNICK E, 1990, CARCINOGENESIS, V11, P1159, DOI 10.1093/carcin/11.7.1159; Brown KA, 2004, BREAST CANCER RES, V6, pR130, DOI 10.1186/bcr762; Chatterji U, 2004, CARCINOGENESIS, V25, P1119, DOI 10.1093/carcin/bgh121; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; Chen I, 1996, BIOCHEM PHARMACOL, V51, P1069, DOI 10.1016/0006-2952(96)00060-3; CHEN YH, 1995, J BIOL CHEM, V270, P22548, DOI 10.1074/jbc.270.38.22548; Couillard S, 1998, CANCER RES, V58, P60; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Cover CM, 1999, CANCER RES, V59, P1244; Cram EJ, 2001, J BIOL CHEM, V276, P22332, DOI 10.1074/jbc.M010539200; D'Hondt L, 2003, NEW ENGL J MED, V348, P1063; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Firestone GL, 2003, J NUTR, V133, p2448S, DOI 10.1093/jn/133.7.2448S; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; Harwell RM, 2004, J BIOL CHEM, V279, P12695, DOI 10.1074/jbc.M313407200; Harwell RM, 2000, CANCER RES, V60, P481; Hong C, 2002, BIOCHEM PHARMACOL, V63, P1085, DOI 10.1016/S0006-2952(02)00856-0; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; Hudson EA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-2; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; Jin L, 1999, CANCER RES, V59, P3991; Kang Y, 2003, NEW ENGL J MED, V348, P1063; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 2003, NAT MED, V9, P152, DOI 10.1038/nm0203-152; KOJIMA T, 1994, CANCER RES, V54, P1446; Lee TH, 1999, ONCOGENE, V18, P4269, DOI 10.1038/sj.onc.1202755; LIU H, 1994, JNCI-J NATL CANCER I, V86, P1758, DOI 10.1093/jnci/86.23.1758; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; LOUB WD, 1975, J NATL CANCER I, V54, P985; Malumbres Marcos, 2003, Prog Cell Cycle Res, V5, P5; Meng QH, 2000, BREAST CANCER RES TR, V63, P147, DOI 10.1023/A:1006495824158; Meng QH, 2000, J NUTR, V130, P2927, DOI 10.1093/jn/130.12.2927; Meng QH, 2000, J MOL MED, V78, P155, DOI 10.1007/s001090000088; MICHNOVICZ JJ, 1990, J NATL CANCER I, V82, P947, DOI 10.1093/jnci/82.11.947; Moore JD, 2002, MOL BIOL CELL, V13, P4388, DOI 10.1091/mbc.E02-07-0449; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORSE MA, 1990, CANCER RES, V50, P2613; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Rahman KMW, 2000, ONCOGENE, V19, P5764, DOI 10.1038/sj.onc.1203959; Rahman KMW, 2003, NUTR CANCER, V45, P101, DOI 10.1207/S15327914NC4501_12; Sarkar FH, 2003, J NUTR, V133, p2434S, DOI 10.1093/jn/133.7.2434S; SCHOLAR EM, 1989, NUTR CANCER, V12, P121, DOI 10.1080/01635588909514010; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHARMA S, 1994, CANCER RES, V54, P5848; Sherr C J, 2000, Harvey Lect, V96, P73; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Srivastava BH, 1998, CANCER LETT, V134, P91, DOI 10.1016/S0304-3835(98)00247-X; Staub RE, 2002, CHEM RES TOXICOL, V15, P101, DOI 10.1021/tx010056m; Su Tin Tin, 2004, Sci STKE, V2004, ppe11; Sutherland RL, 2002, NEW ENGL J MED, V347, P1546, DOI 10.1056/NEJMNEJMp020124; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Yang ES, 2003, J BIOL CHEM, V278, P46862, DOI 10.1074/jbc.M306340200; Yuan F, 1999, ANTICANCER RES, V19, P1673; Zhang J, 2003, CANCER-AM CANCER SOC, V98, P2511, DOI 10.1002/cncr.11844	67	46	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8756	8764		10.1074/jbc.M407957200	http://dx.doi.org/10.1074/jbc.M407957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611077	hybrid			2022-12-27	WOS:000227453100018
J	Zhang, ZL; Tsujimura, M; Akutsu, J; Sasaki, M; Tajima, H; Kawarabayasi, Y				Zhang, ZL; Tsujimura, M; Akutsu, J; Sasaki, M; Tajima, H; Kawarabayasi, Y			Identification of an extremely thermostable enzyme with dual sugar-1-phosphate nucleotidylyltransferase activities from an acidothermophilic archaeon, Sulfolobus tokodaii strain 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; DTDP-RHAMNOSE; PYROPHOSPHORYLASE; GENE; CRENARCHAEON; PATHWAY	L-Rhamnose is an essential component of the cell wall and plays roles in mediating virulence and adhesion to host tissues in many microorganisms. Glucose-1-phosphate thymidylyltransferase ( RmlA, EC 2.7.7.24) catalyzes the first reaction of the four-step pathway of L-rhamnose biosynthesis, producing dTDP-D-glucose from dTTP and glucose-1-phosphate. Three RmlA homologues of varying size have been identified in the genome of a thermophilic archaeon, Sulfolobus tokodaii strain 7. In this study, we report the heterologous expression of the largest homologue (a 401 residue-long ST0452 protein) and characterization of its thermostable activity. RmlA enzymatic activity of this protein was detected from 65 to 100 degreesC, with a half- life of 60 min at 95 degreesC and 180 min at 80 degreesC. Analysis of a deletion mutant lacking the 170-residue C-terminal domain indicated that this region has an important role in the thermostability and activity of the protein. Analyses of substrate specificity indicated that the enzymatic activity of the full- length protein is capable of utilizing alpha-D-glucose-1-phosphate and N-acetyl-D-glucosamine-1-phosphate but not alpha-D glucosamine1- phosphate. However, the protein is capable of utilizing all four deoxyribonucleoside triphosphates and UTP. Thus, the ST0452 protein is an enzyme containing both glucose- 1-phosphate thymidylyltransferase and N-acetyl-D-glucosamine-1-phosphate uridylyltransferase activities. This is the first report of a thermostable enzyme with dual sugar-1-phosphate nucleotidylyltransferase activities.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan; PSS Co Ltd, Matsudo, Chiba 2710064, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Kawarabayasi, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Higashi 1-1-1, Tsukuba, Ibaraki 3058566, Japan.	kawarabayasi.yutaka@aist.go.jp						BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; Kandler O, 1998, CELL MOL LIFE SCI, V54, P305, DOI 10.1007/s000180050156; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KOPLIN R, 1993, J BACTERIOL, V175, P7786; Li Q, 2000, MICROBIOL-UK, V146, P2291, DOI 10.1099/00221287-146-9-2291; LINDQUIST L, 1993, EUR J BIOCHEM, V211, P763, DOI 10.1111/j.1432-1033.1993.tb17607.x; Ma YF, 1997, MICROBIOL-SGM, V143, P937, DOI 10.1099/00221287-143-3-937; MACPHERSON DF, 1994, MOL MICROBIOL, V11, P281, DOI 10.1111/j.1365-2958.1994.tb00308.x; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MELO A, 1965, J BIOL CHEM, V240, P398; Niemetz R, 1997, EUR J BIOCHEM, V249, P905, DOI 10.1111/j.1432-1033.1997.00905.x; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Sivaraman J, 2002, J BIOL CHEM, V277, P44214, DOI 10.1074/jbc.M206932200; THORSON JS, 1994, J BACTERIOL, V176, P1840, DOI 10.1128/jb.176.7.1840-1849.1994; Zuccotti S, 2001, J MOL BIOL, V313, P831, DOI 10.1006/jmbi.2001.5073	22	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9698	9705		10.1074/jbc.M411211200	http://dx.doi.org/10.1074/jbc.M411211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15598657	hybrid			2022-12-27	WOS:000227453100127
J	Furumatsu, T; Tsuda, M; Taniguchi, N; Tajima, Y; Asahara, H				Furumatsu, T; Tsuda, M; Taniguchi, N; Tajima, Y; Asahara, H			Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CHONDROCYTE-SPECIFIC ENHANCER; AUTOSOMAL SEX REVERSAL; RNA-POLYMERASE-II; SRY-RELATED GENE; TGF-BETA; COLLAGEN GENE; TRANSCRIPTIONAL ACTIVATION; MORPHOGENETIC PROTEINS; CAMPOMELIC DYSPLASIA	The transcriptional activation by SRY- type high mobility group box 9 ( SOX9) and the transforming growth factor beta ( TGF- beta) signals are necessary for chondrogenic differentiation. We have previously shown that CREB- binding protein ( CBP/ p300) act as an important SOX9 co- activator during chondrogenesis. In the present study, we investigated the relationship between TGF- beta- dependent Smad2/ 3 signaling pathways and the SOX9- CBP/ p300 transcriptional complex at the early stage of chondrogenesis. Overexpressed Smad3 strongly induced the primary chondrogenesis of human mesenchymal stem cells. In addition, Smad3 enhanced the transcriptional activity of SOX9 and the expression of alpha1( II) collagen gene ( COL2A1), and small interference RNA against Smad3 ( si- Smad3) inhibited them. We observed that Smad2/ 3 associated with Sox9 in a TGF- beta- dependent manner and formed the transcriptional complexes with SOX9 on the enhancer region of COL2A1. Interestingly, the association between Sox9 and CBP/ p300 was increased by Smad3 overexpression and was suppressed by si- Smad3. Our findings indicate that Smad3 has a stronger potential to stimulate the SOX9- dependent transcriptional activity by modulating the interaction between SOX9 and CBP/ p300, rather than Smad2. This study suggests that the Smad3 pathway presents a key role for the SOX9- dependent transcriptional activation in primary chondrogenesis.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Canc Inst Japanese Fdn Canc Res, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Natl Ctr Child Hlth & Dev, Setagaya Ku, Tokyo 1578535, Japan; Japan Sci & Technol Agcy, PRESTO, SORST, Kawaguchi, Saitama 3320012, Japan	Scripps Research Institute; Japanese Foundation for Cancer Research; National Center for Child Health & Development - Japan; Japan Science & Technology Agency (JST)	Asahara, H (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM161, La Jolla, CA 92037 USA.	asahara@scripps.edu	FURUMATSU, Takayuki/B-2233-2011		NIAMS NIH HHS [AR50631-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050631, R56AR050631] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; BALLOCK RT, 1993, DEV BIOL, V158, P414, DOI 10.1006/dbio.1993.1200; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ferguson CM, 2000, ENDOCRINOLOGY, V141, P4728, DOI 10.1210/en.141.12.4728; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Furumatsu T, 2002, INT J CANCER, V97, P313, DOI 10.1002/ijc.1607; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; KULYK WM, 1989, DEV BIOL, V135, P424, DOI 10.1016/0012-1606(89)90191-7; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149; Liu Y, 2004, DEV BIOL, V270, P411, DOI 10.1016/j.ydbio.2004.03.017; Marquez RM, 2001, GENETICS, V157, P1639; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishimura R, 2003, FRONT BIOSCI, V8, pS275, DOI 10.2741/1049; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012-1606(03)00321-X; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Tuli R, 2003, J BIOL CHEM, V278, P41227, DOI 10.1074/jbc.M305312200; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	65	246	258	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8343	8350		10.1074/jbc.M413913200	http://dx.doi.org/10.1074/jbc.M413913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623506	hybrid			2022-12-27	WOS:000227395700109
J	Lopez, C; Metral, S; Eladari, D; Drevensek, SP; Gane, P; Chambrey, R; Bennett, V; Cartron, JP; Le Van Kim, C; Colin, Y				Lopez, C; Metral, S; Eladari, D; Drevensek, SP; Gane, P; Chambrey, R; Bennett, V; Cartron, JP; Le Van Kim, C; Colin, Y			The ammonium transporter rhbg - Requirement of a tyrosine-based signal and ankyrin-G for basolateral targeting and membrane anchorage in polarized kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; DARBY CANINE KIDNEY; BLOOD-GROUP SYSTEM; INOSITOL 1,4,5-TRISPHOSPHATE; BINDING DOMAIN; NEONATAL CARDIOMYOCYTES; INITIAL SEGMENTS; SORTING SIGNALS; ANION-EXCHANGER; 2-HYBRID SYSTEM	RhBG is a nonerythroid member of the Rhesus (Rh) protein family, mainly expressed in the kidney and belonging to the Amt/Mep/Rh superfamily of ammonium transporters. The epithelial expression of renal RhBG is restricted to the basolateral membrane of the connecting tubule and collecting duct cells. We report here that sorting and anchoring of RhBG to the basolateral plasma membrane require a cis-tyrosine-based signal and an association with ankyrin-G, respectively. First, we show by using a model of polarized epithelial Madin-Darby canine kidney cells that the targeting of transfected RhBG depends on a YED motif localized in the cytoplasmic C terminus of the protein. Second, we reveal by yeast two-hybrid analysis a direct interaction between an FLD determinant in the cytoplasmic C-terminal tail of RhBG and the third and fourth repeat domains of ankyrin-G. The biological relevance of this interaction is supported by two observations. (i) RhBG and ankyrin-G were colocalized in vivo in the basolateral domain of epithelial cells from the distal nephron by immunohistochemistry on kidney sections. (ii) The disruption of the FLD-binding motif impaired the membrane expression of RhBG leading to retention on cytoplasmic structures in transfected Madin-Darby canine kidney cells. Mutation of both targeting signal and ankyrin-G-binding site resulted in the same cell surface but nonpolarized expression pattern as observed for the protein mutated on the targeting signal alone, suggesting the existence of a close relationship between sorting and anchoring of RhBG to the basolateral domain of epithelial cells.	INSERM, U665, Inst Natl Transfus Sanguine, F-75015 Paris, France; INSERM, U356, F-75006 Paris, France; Hop Necker Enfants Malad, APHP, Dept Physiol, F-75015 Paris, France; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Durham, NC 27710 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Colin, Y (corresponding author), INSERM, U665, Inst Natl Transfus Sanguine, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	colin@idf.inserm.fr	colin, yves/O-1910-2017; METRAL, Sylvain/P-5833-2017; le van kim, caroline/O-7030-2017	colin, yves/0000-0001-5196-4254; METRAL, Sylvain/0000-0001-6244-8546; Eladari, Dominique/0000-0003-1067-0844; le van kim, caroline/0000-0002-3251-1310				ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; Alper SL, 1997, AM J PHYSIOL-RENAL, V273, pF601, DOI 10.1152/ajprenal.1997.273.4.F601; Avent ND, 2000, BLOOD, V95, P375, DOI 10.1182/blood.V95.2.375; Bakouh N, 2004, J BIOL CHEM, V279, P15975, DOI 10.1074/jbc.M308528200; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bhattacharyya R, 1999, BIOCHEM J, V340, P505, DOI 10.1042/0264-6021:3400505; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Cartron JP, 1999, BEST PRACT RES CL HA, V12, P655, DOI 10.1053/beha.1999.0047; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chernova MN, 2003, AM J PHYSIOL-CELL PH, V284, pC1235, DOI 10.1152/ajpcell.00522.2002; Devonald MAJ, 2003, NAT GENET, V33, P125, DOI 10.1038/ng1082; Doctor RB, 1998, AM J PHYSIOL-RENAL, V274, pF129, DOI 10.1152/ajprenal.1998.274.1.F129; Eladari D, 2002, J AM SOC NEPHROL, V13, P1999, DOI 10.1097/01.ASN.0000025280.02386.9D; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gane P, 2001, BRIT J HAEMATOL, V113, P680, DOI 10.1046/j.1365-2141.2001.02757.x; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gut A, 1998, J BIOL CHEM, V273, P29381, DOI 10.1074/jbc.273.45.29381; Huang CH, 2001, BLOOD CELL MOL DIS, V27, P90, DOI 10.1006/bcmd.2000.0355; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; JORDAN C, 1995, J BIOL CHEM, V270, P29971; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Kizhatil K, 2004, J BIOL CHEM, V279, P16706, DOI 10.1074/jbc.M314296200; Lemaillet G, 2003, J BIOL CHEM, V278, P27333, DOI 10.1074/jbc.M303327200; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Liu Z, 2000, J BIOL CHEM, V275, P25641, DOI 10.1074/jbc.M003353200; Liu Z, 2001, J BIOL CHEM, V276, P1424, DOI 10.1074/jbc.M007528200; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; Ludewig U, 2004, J PHYSIOL-LONDON, V559, P751, DOI 10.1113/jphysiol.2004.067728; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Mouro-Chanteloup I, 2003, BLOOD, V101, P338, DOI 10.1182/blood-2002-04-1285; Nakatsu F, 2003, CELL STRUCT FUNCT, V28, P419, DOI 10.1247/csf.28.419; Nicolas V, 2003, J BIOL CHEM, V278, P25526, DOI 10.1074/jbc.M302816200; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; Quentin F, 2003, J AM SOC NEPHROL, V14, P545, DOI 10.1097/01.ASN.0000050413.43662.55; Ripoche P, 2004, P NATL ACAD SCI USA, V101, P17222, DOI 10.1073/pnas.0403704101; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; Thevananther S, 1998, J BIOL CHEM, V273, P23952, DOI 10.1074/jbc.273.37.23952; Toye AM, 2004, J CELL SCI, V117, P1399, DOI 10.1242/jcs.00974; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Verlander JW, 2003, AM J PHYSIOL-RENAL, V284, pF323, DOI 10.1152/ajprenal.00050.2002; Weiner ID, 2004, CURR OPIN NEPHROL HY, V13, P533, DOI 10.1097/00041552-200409000-00009; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	63	41	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8221	8228		10.1074/jbc.M413351200	http://dx.doi.org/10.1074/jbc.M413351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611082	hybrid			2022-12-27	WOS:000227395700095
J	Weinglass, AB; Soskine, M; Vazquez-Ibar, JL; Whitelegge, JP; Faull, KF; Kabacko, HR; Schuldiner, S				Weinglass, AB; Soskine, M; Vazquez-Ibar, JL; Whitelegge, JP; Faull, KF; Kabacko, HR; Schuldiner, S			Exploring the role of a unique carboxyl residue in EmrE by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG TRANSPORTER EMRE; ESCHERICHIA-COLI; SUBSTRATE-BINDING; MEMBRANE-PROTEIN; ANTIPORTER; STATE; SITE; H+	EmrE is a small multidrug transporter in Escherichia coli that extrudes various positively charged drugs across the plasma membrane in exchange with protons, thereby rendering cells resistant to these compounds. Biochemical experiments indicate that the basic functional unit of EmrE is a dimer where the common binding site for protons and substrate is formed by the interaction of an essential charged residue ( Glu-14) from both EmrE monomers. Carbodiimide modification of EmrE has been studied using functional assays, and the evidence suggests that Glu-14 is the target of the reaction. Here we exploited electrospray ionization mass spectrometry to directly monitor the reaction with each monomer rather than following inactivation of the functional unit. A cyanogen bromide peptide containing Glu-14 allows the extent of modification by the carboxyl-specific modification reagent diisopropylcarbodiimide ( DiPC) to be monitored and reveals that peptide (2)NPYIYLGGAILAEVIGTTLM(21) is similar to 80% modified in a time-dependent fashion, indicating that each Glu-14 residue in the oligomer is accessible to DiPC. Furthermore, preincubation with tetraphenylphosphonium reduces the reaction of Glu-14 with DiPC by up to 80%. Taken together with other biochemical data, the findings support a "time sharing" mechanism in which both Glu-14 residues in a dimer are involved in tetraphenylphosphonium and H+ binding.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Physiol, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Microbiol & Mol Genet, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Dept Behav Sci, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Hebrew University of Jerusalem; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012; Vazquez-Ibar, Jose-Luis/AAD-8827-2021	Schuldiner, Shimon/0000-0002-4874-6237; Vazquez-Ibar, Jose-Luis/0000-0002-8314-3378; Soskine, Misha/0000-0002-2198-9466	NIDDK NIH HHS [DK51131:07] Funding Source: Medline; NINDS NIH HHS [NS16708] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Butler PJG, 2004, J MOL BIOL, V340, P797, DOI 10.1016/j.jmb.2004.05.014; Elbaz Y, 2004, P NATL ACAD SCI USA, V101, P1519, DOI 10.1073/pnas.0306533101; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Gutman N, 2003, J BIOL CHEM, V278, P16082, DOI 10.1074/jbc.M213120200; HOARE DG, 1967, J BIOL CHEM, V242, P2447; KHORANA HG, 1953, CHEM REV, V53, P145, DOI 10.1021/cr60165a001; Ma C, 2004, P NATL ACAD SCI USA, V101, P2852, DOI 10.1073/pnas.0400137101; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Ninio S, 2003, J BIOL CHEM, V278, P12000, DOI 10.1074/jbc.M213119200; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Rotem D, 2004, J BIOL CHEM, V279, P48787, DOI 10.1074/jbc.M408187200; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; Soskine M, 2004, J BIOL CHEM, V279, P9951, DOI 10.1074/jbc.M312853200; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Weinglass A, 2004, J BIOL CHEM, V279, P41858, DOI 10.1074/jbc.M407555200; Weinglass AB, 2004, CURR OPIN DRUG DISC, V7, P589; Weinglass AB, 2003, EMBO J, V22, P1467, DOI 10.1093/emboj/cdg145; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITELEGGE JP, 1992, EUR J BIOCHEM, V207, P1077, DOI 10.1111/j.1432-1033.1992.tb17144.x; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200	28	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7487	7492		10.1074/jbc.M413555200	http://dx.doi.org/10.1074/jbc.M413555200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623511	hybrid			2022-12-27	WOS:000227395700010
J	Lavelin, I; Geiger, B				Lavelin, I; Geiger, B			Characterization of a novel GTPase-activating protein associated with focal adhesions and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; BINDING PROTEIN; CELL-ADHESION; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; COMPLEX-FORMATION; NERVOUS-SYSTEM; RHOGAP PROTEIN; CDC42 GTPASES; STRESS FIBERS	In the present study we characterize a novel RhoGAP protein (RC-GAP72) that interacts with actin stress fibers, focal adhesions, and cell-cell adherens junctions via its 185-amino acid C-terminal region. Overexpression of RC-GAP72 in fibroblasts induces cell rounding with partial or complete disruption of actin stress fibers and formation of membrane ruffles, lamellipodia, and filopodia. RC-GAP72 mutant truncated downstream of the GTPase-activating protein (GAP) domain retains the ability to stimulate membrane protrusions but fails to affect stress fiber integrity or induce cell retraction. A mutant protein consisting of the C terminus of RC-GAP72 and lacking the GAP domain does not exert any visible effect on cellular morphology. Inactivation of the GAP domain by a point mutation does not abolish the effect of RC-GAP72 on actin stress fibers but moderates its capability to induce membrane protrusions. Our data imply that the cytoskeletal localization of RC-GAP72 and its interaction with GTPases are essential for its effect on the integrity of actin stress fibers, whereas the induction of lamellipodia and filopodia depends on the activity of the GAP domain irrespective of binding to the actin cytoskeleton. We propose that RC-GAP72 affects cellular morphology by targeting activated Cdc42 and Rac1 GTPases to specific subcellular sites, triggering local morphological changes. The overall physiological functions of RC-GAP72 are presently unknown, yet our data suggest that RC-GAP72 plays a role in regulating cell morphology and cytoskeletal organization.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Geiger, B (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	benny.geiger@weizmann.ac.il			NIGMS NIH HHS [U54 GM64346] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fauchereau F, 2003, MOL CELL NEUROSCI, V23, P574, DOI 10.1016/S1044-7431(03)00078-2; Fidyk NJ, 2002, BIOCHEMISTRY-US, V41, P15644, DOI 10.1021/bi026413p; Foletta VC, 2002, MOL BRAIN RES, V107, P65, DOI 10.1016/S0169-328X(02)00448-5; Furukawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P643, DOI 10.1006/bbrc.2001.5022; Furuta B, 2002, J NEUROCHEM, V82, P1018, DOI 10.1046/j.1471-4159.2002.01021.x; Graham DL, 1999, BIOCHEMISTRY-US, V38, P985, DOI 10.1021/bi9821770; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hall C, 2001, J NEUROSCI, V21, P5191, DOI 10.1523/JNEUROSCI.21-14-05191.2001; Harada A, 2000, J BIOL CHEM, V275, P36885, DOI 10.1074/jbc.M004069200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Leonard DA, 1998, J BIOL CHEM, V273, P16210, DOI 10.1074/jbc.273.26.16210; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Moon SY, 2003, J BIOL CHEM, V278, P4151, DOI 10.1074/jbc.M207789200; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Prakash SK, 2000, HUM MOL GENET, V9, P477, DOI 10.1093/hmg/9.4.477; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Richnau N, 2001, J BIOL CHEM, V276, P35060, DOI 10.1074/jbc.M103540200; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; Schaefer L, 1997, GENOMICS, V46, P268, DOI 10.1006/geno.1997.5040; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Seoh ML, 2003, FEBS LETT, V539, P131, DOI 10.1016/S0014-5793(03)00213-8; Shan ZH, 2003, GENE, V303, P55, DOI 10.1016/S0378-1119(02)01143-5; Shibata H, 2001, J BIOCHEM, V130, P23, DOI 10.1093/oxfordjournals.jbchem.a002958; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; Taylor JM, 1999, J CELL SCI, V112, P231; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; VAN AL, 1997, GENE DEV, V11, P2295; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Yamashiro S, 2003, CELL MOTIL CYTOSKEL, V55, P36, DOI 10.1002/cm.10109; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	56	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7178	7185		10.1074/jbc.M411990200	http://dx.doi.org/10.1074/jbc.M411990200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611138	hybrid			2022-12-27	WOS:000227332700109
J	Su'etsugu, M; Shimuta, TR; Ishida, T; Kawakami, H; Katayama, T				Su'etsugu, M; Shimuta, TR; Ishida, T; Kawakami, H; Katayama, T			Protein associations in DnaA-ATP hydrolysis mediated by the hda-replicase clamp complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAA; SLIDING CLAMP; CHROMOSOMAL REPLICATION; IN-VITRO; COUPLED INACTIVATION; SUBUNIT ARRANGEMENT; ORIGIN RECOGNITION; INITIATOR PROTEIN; STRUCTURAL BASIS; POLYMERASE-III	In Escherichia coli, the activity of ATP-bound DnaA protein in initiating chromosomal replication is negatively controlled in a replication-coordinated manner. The RIDA ((r) under bar egulatory (i) under bar nactivation of (D) under bar na (A) under bar) system promotes DnaA-ATP hydrolysis to produce the inactivated form DnaA-ADP in a manner depending on the Hda protein and the DNA-loaded form of the beta-sliding clamp, a subunit of the replicase holoenzyme. A highly functional form of Hda was purified and shown to form a homodimer in solution, and two Hda dimers were found to associate with a single clamp molecule. Purified mutant Hda proteins were used in a staged in vitro RIDA system followed by a pull-down assay to show that Hda-clamp binding is a prerequisite for DnaA-ATP hydrolysis and that binding is mediated by an Hda N-terminal motif. Arg(168) in the AAA(+) Box VII motif of Hda plays a role in stable homodimer formation and in DnaA-ATP hydrolysis, but not in clamp binding. Furthermore, the DnaA N-terminal domain is required for the functional interaction of DnaA with the Hda-clamp complex. Single cells contain similar to50 Hda dimers, consistent with the results of in vitro experiments. These findings and the features of AAA(+) proteins, including DnaA, suggest the following model. DnaA-ATP is hydrolyzed at a binding interface between the AAA(+) domains of DnaA and Hda; the DnaA N-terminal domain supports this interaction; and the interaction of DnaA-ATP with the Hda-clamp complex occurs in a catalytic mode.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Highashi Ku, Fukuoka 8128582, Japan	Kyushu University	Katayama, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Highashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	katayama@phar.kyushu-u.ac.jp	Kawakami, Hironori/H-6792-2017	Kawakami, Hironori/0000-0001-8971-1914; Su'estugu, Masayuki/0000-0001-6695-4032; Katayama, Tsutomu/0000-0001-9994-1684				Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; BRENDLER T, 1995, EMBO J, V14, P4083, DOI 10.1002/j.1460-2075.1995.tb00080.x; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Camara JE, 2003, J BACTERIOL, V185, P3244, DOI 10.1128/JB.185.10.3244-3248.2003; CHIARAMELLO AE, 1989, J BACTERIOL, V171, P4272, DOI 10.1128/JB.171.8.4272-4280.1989; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Fujikawa N, 2003, NUCLEIC ACIDS RES, V31, P2077, DOI 10.1093/nar/gkg309; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; Hishida T, 2004, P NATL ACAD SCI USA, V101, P9573, DOI 10.1073/pnas.0403584101; Ishida T, 2004, J BIOL CHEM, V279, P45546, DOI 10.1074/jbc.M402762200; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Katayama T, 2001, BIOCHIMIE, V83, P13, DOI 10.1016/S0300-9084(00)01206-2; Katayama T, 2001, MOL MICROBIOL, V41, P9, DOI 10.1046/j.1365-2958.2001.02483.x; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; Kawakami H, 2001, MOL GENET GENOMICS, V266, P167, DOI 10.1007/s004380100546; Kitagawa R, 1998, GENE DEV, V12, P3032, DOI 10.1101/gad.12.19.3032; Kitagawa R, 1996, MOL MICROBIOL, V19, P1137, DOI 10.1046/j.1365-2958.1996.453983.x; KORNBERG A, 1992, DNA REPLICATION, P521; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; Kurz M, 2004, J BACTERIOL, V186, P3508, DOI 10.1128/JB.186.11.3508-3515.2004; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; Messer W, 1999, BIOCHIMIE, V81, P819, DOI 10.1016/S0300-9084(00)87165-5; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Neuwald AF, 1999, GENOME RES, V9, P27; Nishida S, 2002, J BIOL CHEM, V277, P14986, DOI 10.1074/jbc.M108303200; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; Ogawa T, 2002, MOL MICROBIOL, V44, P1367, DOI 10.1046/j.1365-2958.2002.02969.x; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Onogi T, 2002, J BACTERIOL, V184, P867, DOI 10.1128/JB.184.3.867-870.2002; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; Su'etsugu M, 2004, GENES CELLS, V9, P509, DOI 10.1111/j.1356-9597.2004.00741.x; Su'etsugu M, 2001, MOL MICROBIOL, V40, P376, DOI 10.1046/j.1365-2958.2001.02378.x; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Takata M, 2000, MOL MICROBIOL, V35, P454, DOI 10.1046/j.1365-2958.2000.01722.x; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; Yao N, 2003, J BIOL CHEM, V278, P50744, DOI 10.1074/jbc.M309206200; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	56	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6528	6536		10.1074/jbc.M412060200	http://dx.doi.org/10.1074/jbc.M412060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611053	hybrid			2022-12-27	WOS:000227332700036
J	Tran, NL; McDonough, WS; Savitch, BA; Sawyer, TF; Winkles, JA; Berens, ME				Tran, NL; McDonough, WS; Savitch, BA; Sawyer, TF; Winkles, JA; Berens, ME			The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NF kappa B pathway activation and BCL-X-L/BCL-W expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HEPATOCELLULAR-CARCINOMA; TWEAK/FN14 INTERACTION; ALPHA PHOSPHORYLATION; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; FAMILY PROTEINS; SCID MICE; DEATH; RECEPTOR	The Fn14 gene encodes a type la transmembrane protein that belongs to the tumor necrosis factor receptor superfamily. We recently showed that fibroblast growth factor-inducible 14 (Fn14) is overexpressed in migrating glioma cells in vitro and in glioblastoma multiforme clinical specimens in vivo. To determine the biological role of Fn14 in brain cancer progression, we examined the activity of Fn14 as a potential mediator of cell survival. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)stimulated glioma cells had increased cellular resistance to cytotoxic therapy-induced apoptosis. Either TWEAK treatment or Fn14 overexpression in glionta cells resulted in the activation of NFkappaB and subsequently the translocation of NFkappaB from the cytoplasm to the nucleus. In addition, Fn14 activation induced BCL-X-L and BCL-W mRNA and protein levels, and this effect was dependent upon NFkappaB transcriptional activity. Substitution of a putative NFkappaB binding site identified in the BCL-X promoter significantly decreased Fn14-induced transactivation. Furthermore Fn14-induced transactivation of the BCL-X promoter was also diminished by the super-repressor IkappaBalpha mutant, which specifically inhibits NFkappaB activity, and by mutations in the NFkappaB binding motif of the BCL-X promoter. Additionally small interfering RNA-mediated depletion of either BCL-XL or BCL-W antagonized the TWEAK protective effect on glioma cells. Our results suggest that NFkappaB-mediated up-regulation of BCL-XL and BCL-W expression in glioma cells increases cellular resistance to cytotoxic therapy-induced apoptosis. We propose that the Fn14 protein functions, in part, through the NFkappaB signaling pathway to up-regulate BCL-XL and BCL-W expression to foster malignant glioblastoma cell survival. Targeted therapy against Fn14 as an adjuvant to surgery may improve management of invasive glioma cells and advance the outcome of this devastating cancer.	Translat Genom Res Inst, Neurogenom Div, Phoenix, AZ 85004 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	Translational Genomics Research Institute; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Berens, ME (corresponding author), Translat Genom Res Inst, Neurogenom Div, 445 N 5th St, Phoenix, AZ 85004 USA.	mberens@tgen.org			NHLBI NIH HHS [HL-39727] Funding Source: Medline; NINDS NIH HHS [NS-42262] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039727, R01HL039727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Chiao PJ, 2002, CANCER, V95, P1696, DOI 10.1002/cncr.10829; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chuang YY, 2004, CANCER RES, V64, P8271, DOI 10.1158/0008-5472.CAN-04-2097; Del Bufalo D, 2001, J CELL BIOCHEM, V83, P473, DOI 10.1002/jcb.1245; Desplat-Jego S, 2002, J NEUROIMMUNOL, V133, P116, DOI 10.1016/S0165-5728(02)00368-5; Ding GR, 2003, RADIAT RES, V160, P232, DOI 10.1667/RR3018; Donohue PJ, 2003, ARTERIOSCL THROM VAS, V23, P594, DOI 10.1161/01.ATV.0000062883.93715.37; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gibson L, 1996, ONCOGENE, V13, P665; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Green DR, 1998, NATURE, V396, P629, DOI 10.1038/25248; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han HY, 2002, CANCER RES, V62, P2890; Han SY, 2003, BIOCHEM BIOPH RES CO, V305, P789, DOI 10.1016/S0006-291X(03)00852-0; Hao CH, 2001, CANCER RES, V61, P1162; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; HOELZINGER DB, 2005, IN PRESS NEOPLASIA, V7; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jiang ZH, 2003, J NEUROCHEM, V84, P273, DOI 10.1046/j.1471-4159.2003.01522.x; Jin L, 2004, J INVEST DERMATOL, V122, P1175, DOI 10.1111/j.0022-202X.2004.22419.x; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Krajewski S, 1997, AM J PATHOL, V150, P805; KRISHNA M, 1995, J NEUROSURG, V83, P1017, DOI 10.3171/jns.1995.83.6.1017; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee HW, 2003, CANCER RES, V63, P1093; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Mariani L, 2001, CANCER RES, V61, P4190; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Middleton G, 2001, DEVELOPMENT, V128, P447; Miyakoshi J, 2000, BRIT J CANCER, V82, P28; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; O'Reilly LA, 2001, CELL DEATH DIFFER, V8, P486, DOI 10.1038/sj.cdd.4400835; Oliver L, 2000, BIOCHEM BIOPH RES CO, V273, P411, DOI 10.1006/bbrc.2000.2952; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PILKINGTON GJ, 1994, BRAIN PATHOL, V4, P157, DOI 10.1111/j.1750-3639.1994.tb00826.x; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Streffer JR, 2002, J NEURO-ONCOL, V56, P43, DOI 10.1023/A:1014448721327; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; Tran NL, 2003, AM J PATHOL, V162, P1313, DOI 10.1016/S0002-9440(10)63927-2; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Weaver KD, 2003, J NEURO-ONCOL, V61, P187, DOI 10.1023/A:1022554824129; Wild-Bode C, 2001, J NEUROSURG, V94, P976, DOI 10.3171/jns.2001.94.6.0978; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhu CJ, 2003, J NEUROSCI RES, V74, P60, DOI 10.1002/jnr.10722	73	159	164	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3483	3492		10.1074/jbc.M409906200	http://dx.doi.org/10.1074/jbc.M409906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15611130	hybrid			2022-12-27	WOS:000226983900044
J	Santilli, G; Schwab, R; Watson, R; Ebert, C; Aronow, BJ; Sala, A				Santilli, G; Schwab, R; Watson, R; Ebert, C; Aronow, BJ; Sala, A			Temperature-dependent modification and activation of B-MYB - Implications for cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; C-MYB; GENE-EXPRESSION; NEUROBLASTOMA-CELLS; CHROMOSOMAL REGION; S PHASE; A-MYB; PROTEIN; CYCLE; PHOSPHORYLATION	B-MYB is a ubiquitous transcription factor with an essential role in mouse development. Because cells with a disrupted B-MYB gene cannot be obtained, it is still unknown what is the critical function(s) exerted by B-MYB in mammalian cells. In this study we have observed that reducing B-MYB expression in primary human fibroblasts by using RNA interference results in a partial block of the cells in the G(2) phase of the cell cycle and cell death. Surprisingly, suppressing B-MYB transcriptional activity with a dominant-negative molecule is without effect, suggesting that its transactivating function is not essential. Only human or murine fibroblasts exposed to high temperature are sensitized to cell death in the presence of dominant-negative B-MYB. This correlates with temperature-dependent binding of endogenous B-MYB to transcriptional regulatory elements of the stress-related gene ApoJ/clusterin. We find that regulation of ApoJ/clusterin by B-MYB is a pro-survival response to thermal stress. Thus, B-MYB is regulated by temperature to activate genes required for cell survival.	UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Div Invest Sci, London W2 1PG, England; Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA	University of London; University College London; Imperial College London; Cincinnati Children's Hospital Medical Center	Sala, A (corresponding author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	a.sala@ich.ucl.ac.uk	sala, arturo/C-4959-2008; Aronow, Bruce J/F-8438-2012	Sala, Arturo/0000-0002-2841-7866				Albrecht B, 2004, J PATHOL, V203, P780, DOI 10.1002/path.1576; Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bar-Shira A, 2002, CANCER RES, V62, P6803; Bergholtz S, 2001, NUCLEIC ACIDS RES, V29, P3546, DOI 10.1093/nar/29.17.3546; Bies J, 1996, ONCOGENE, V12, P355; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Cicchillitti L, 2004, BIOCHEM J, V378, P609, DOI 10.1042/BJ20031110; Grassilli E, 1999, CANCER RES, V59, P2451; Joaquin M, 2003, J BIOL CHEM, V278, P44255, DOI 10.1074/jbc.M308953200; Joaquin M, 2002, ONCOGENE, V21, P7923, DOI 10.1038/sj.onc.1206001; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Long EM, 2003, LUNG CANCER-J IASLC, V42, P9, DOI 10.1016/S0169-5002(03)00279-4; Manalo DJ, 2001, J BIOL CHEM, V276, P23554, DOI 10.1074/jbc.M011300200; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Okada M, 2002, EMBO J, V21, P675, DOI 10.1093/emboj/21.4.675; Pagnan G, 2003, NEUROSCI LETT, V336, P163, DOI 10.1016/S0304-3940(02)01255-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Robinson C, 1996, ONCOGENE, V12, P1855; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; Skotheim RI, 2002, CANCER RES, V62, P2359; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Tanno B, 2002, J BIOL CHEM, V277, P23172, DOI 10.1074/jbc.M200141200; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	43	27	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15628	15634		10.1074/jbc.M411747200	http://dx.doi.org/10.1074/jbc.M411747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15618219	hybrid			2022-12-27	WOS:000228444800022
J	Skasko, M; Weiss, KK; Reynolds, HM; Jamburuthugoda, V; Lee, K; Kim, B				Skasko, M; Weiss, KK; Reynolds, HM; Jamburuthugoda, V; Lee, K; Kim, B			Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VERTICAL-SCANNING MUTAGENESIS; MISPAIR EXTENSION FREQUENCIES; STEADY-STATE; DNTP BINDING; IN-VITRO; POLYMERASE FIDELITY; CRITICAL TRYPTOPHAN; VIRAL MUTAGENESIS; ERROR SPECIFICITY	We compared the mechanistic and kinetic properties of murine leukemia virus (MuLV) and human immunodeficiency virus type 1 (HIV-1) reverse transcriptases (RTs) during RNA-dependent DNA polymerization and mutation synthesis using pre-steady-state kinetic analysis. First, MuLV RT showed 6.5-121.6-fold lower binding affinity (K-d) to deoxynucleotide triphosphate (dNTP) substrates than HIV-1 RT, although the two RTs have similar incorporation rates (k(pol)). Second, compared with HIV-1 RT, MuLV RT showed dramatic reduction during multiple dNTP incorporations at low dNTP concentrations. Presumably, due to its low dNTP binding affinity, the dNTP binding step becomes rate-limiting in the multiple rounds of the dNTP incorporation by MuLV RT, especially at low dNTP concentrations. Third, similar fold differences between MuLV and HIV-1 RTs in the K-d and k(pol) values to correct and incorrect dNTPs were observed. This indicates that these two RT proteins have similar misinsertion fidelities. Fourth, these two RT proteins have different mechanistic capabilities regarding mismatch extension. MuLV RT has a 3.1-fold lower mismatch extension fidelity, compared with HIV-1 RT. Finally, MuLV RT has a 3.8-fold lower binding affinity to mismatched template/primer (T/P) substrate compared with HIV-1 RT. Our data suggest that the active site of MuLV RT has an intrinsically low dNTP binding affinity, compared with HIV-1 RT. In addition, instead of the misinsertion step, the mismatch extension step, which varies between MuLV and HIV-1 RTs, contributes to their fidelity differences. The implications of these kinetic differences between MuLV and HIV-1 RTs on viral cell type specificity and mutagenesis are discussed.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	baek_kim@urmc.rochester.edu			NIAID NIH HHS [R56 AI049781, AI49781, R01 AI049781, T32 AI007362, AI07362] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI049781, T32AI007362, R01AI049781] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avidan O, 2002, EUR J BIOCHEM, V269, P859, DOI 10.1046/j.0014-2956.2001.02719.x; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; BAKHANASHVILI M, 1993, FEBS LETT, V319, P201, DOI 10.1016/0014-5793(93)80067-5; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; BATTULA N, 1974, J BIOL CHEM, V249, P4086; Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Chowdhury K, 1996, BIOCHEMISTRY-US, V35, P16610, DOI 10.1021/bi961462l; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200; Diamond TL, 2003, J BIOL CHEM, V278, P29913, DOI 10.1074/jbc.M211754200; Diamond TL, 2001, J BIOL CHEM, V276, P23624, DOI 10.1074/jbc.M102496200; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; FARAJ A, 1994, ANTIMICROB AGENTS CH, V38, P2300, DOI 10.1128/AAC.38.10.2300; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Fields BN, 1996, VIROLOGY; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; Hamburgh ME, 1998, NUCLEIC ACIDS RES, V26, P4389, DOI 10.1093/nar/26.19.4389; Harris D, 1998, BIOCHEMISTRY-US, V37, P9630, DOI 10.1021/bi980549z; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kaushik N, 1999, BIOCHEMISTRY-US, V38, P2617, DOI 10.1021/bi9824285; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Malboeuf CM, 2001, BIOTECHNIQUES, V30, P1074, DOI 10.2144/01305rr06; Mansky LM, 2000, J VIROL, V74, P9525, DOI 10.1128/JVI.74.20.9525-9531.2000; Mansky LM, 2003, J VIROL, V77, P2071, DOI 10.1128/JVI.77.3.2071-2080.2003; Miller MD, 1999, J INFECT DIS, V179, P92, DOI 10.1086/314560; MONK RJ, 1992, J VIROL, V66, P3683, DOI 10.1128/JVI.66.6.3683-3689.1992; Naeger LK, 2001, ANTIVIR THER, V6, P115; O'Neil PK, 2002, J BIOL CHEM, V277, P38053, DOI 10.1074/jbc.M204774200; Perach M, 1999, VIROLOGY, V259, P176, DOI 10.1006/viro.1999.9761; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; Rezende LF, 1998, J VIROL, V72, P2890, DOI 10.1128/JVI.72.4.2890-2895.1998; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; Sherman MP, 2003, J VIROL, V77, P7582, DOI 10.1128/JVI.77.13.7582-7589.2003; Shi QL, 2002, BIOCHEMISTRY-US, V41, P14831, DOI 10.1021/bi0258389; Singh K, 2000, PROTEIN ENG, V13, P635, DOI 10.1093/protein/13.9.635; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; Wainberg MA, 1996, AIDS, V10, pS3, DOI 10.1097/00002030-199612005-00002; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; Weiss KK, 2004, BIOCHEMISTRY-US, V43, P4490, DOI 10.1021/bi035258r; Weiss KK, 2002, J BIOL CHEM, V277, P22662, DOI 10.1074/jbc.M200202200; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	65	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12190	12200		10.1074/jbc.M412859200	http://dx.doi.org/10.1074/jbc.M412859200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15644314	Green Accepted, hybrid			2022-12-27	WOS:000227922000017
J	Wrigley, JDJ; Schurov, I; Nunn, EJ; Martin, ACL; Clarke, EE; Ellis, S; Bonnert, TP; Shearman, MS; Beher, D				Wrigley, JDJ; Schurov, I; Nunn, EJ; Martin, ACL; Clarke, EE; Ellis, S; Bonnert, TP; Shearman, MS; Beher, D			Functional overexpression of gamma-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; BETA-SECRETASE; ASPARTYL PROTEASE; IN-VIVO; PROTEOLYTIC FRAGMENTS; THYMOCYTE DEVELOPMENT; MISSENSE MUTATIONS; HUMAN BRAIN; PRESENILIN-1	Presenilins appear to form the active center of gamma-secretase but require the presence of the integral membrane proteins nicastrin, anterior pharynx defective 1, and presenilin enhancer 2 for catalytic function. We have simultaneously overexpressed all of these polypeptides, and we demonstrate functional assembly of the enzyme complex, a substantial increase in enzyme activity, and binding of all components to a transition state analogue gamma-secretase inhibitor. Co-localization of all components can be observed in the Golgi compartment, and further trafficking of the individual constituents seems to be dependent on functional assembly. Apart from its catalytic function, gamma-secretase appears to play a role in the trafficking of the gamma-amyloid precursor protein, which was changed upon reconstitution of the enzyme but unaffected by pharmacological inhibition. Because the relative molecular mass and stoichiometry of the active enzyme complex remain elusive, we performed size exclusion chromatography of solubilized gamma-secretase, which yielded evidence of a tetrameric form of the complex, yet almost completely abolished enzyme activity. gamma-Secretase activity was reconstituted upon addition of an independent size exclusion chromatography fraction of lower molecular mass and nonproteinaceous nature, which could be replaced by a brain lipid extract. The same treatment was able to restore enzyme activity after immunoaffinity purification of the gamma-secretase complex, demonstrating that lipids play a key role in preserving the catalytic activity of this protease. Furthermore, these data show that it is important to discriminate between intact, inactive gamma-secretase complexes and the active form of the enzyme, indicating the care that must be taken in the study of gamma-secretase.	Merck Sharp & Dohme Ltd, Dept Mol & Cellular Neurosci, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England; Neurosci Res Ctr, Harlow CM20 2QR, Essex, England	Merck & Company; Merck & Company	Beher, D (corresponding author), Merck Sharp & Dohme Ltd, Dept Mol & Cellular Neurosci, Neurosci Res Ctr, Terlings Pk,Eastwick Rd, Harlow CM20 2QR, Essex, England.	dirk_beher@merck.com		Beher, Dirk/0000-0001-8005-5359				Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Beher D, 2003, BIOCHEMISTRY-US, V42, P8133, DOI 10.1021/bi034045z; Beher D, 1999, J NEUROCHEM, V72, P1564, DOI 10.1046/j.1471-4159.1999.721564.x; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Culvenor JG, 2000, EXP CELL RES, V255, P192, DOI 10.1006/excr.1999.4791; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GEIGER B, 1990, J CELL SCI, V97, P607; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hebert SS, 2004, NEUROBIOL DIS, V17, P260, DOI 10.1016/j.nbd.2004.08.002; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Meredith JE, 2002, BIOCHEM BIOPH RES CO, V299, P744, DOI 10.1016/S0006-291X(02)02747-X; Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wada S, 2003, BIOCHEMISTRY-US, V42, P13977, DOI 10.1021/bi034904j; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Wrigley JDJ, 2004, J NEUROCHEM, V90, P1312, DOI 10.1111/j.1471-4159.2004.02596.x; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	77	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12523	12535		10.1074/jbc.M413086200	http://dx.doi.org/10.1074/jbc.M413086200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15613471	hybrid			2022-12-27	WOS:000227922000056
J	Gao, H; Jin, SQ; Song, YM; Fu, M; Wang, MR; Liu, ZH; Wu, M; Zhan, QM				Gao, H; Jin, SQ; Song, YM; Fu, M; Wang, MR; Liu, ZH; Wu, M; Zhan, QM			B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G(2)-M arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR PROTEIN B23; P53; NUCLEOPHOSMIN/B23; INHIBITION; ACTIVATION; EXPRESSION; INDUCTION; APOPTOSIS; TRANSPORT; INTERACTS	Gadd45a is an important player in cell cycle G(2)-M arrest in response to genotoxic stress. However, the underlying mechanism(s) by which Gadd45a exerts its role in the control of cell cycle progression remains to be further defined. Gadd45a interacts with Cdc2, dissociates the Cdc2-cyclin B1 complex, alters cyclin B1 nuclear localization, and thus inhibits the activity of Cdc2/ cyclin B1 kinase. These observations indicate that Gadd45a nuclear translocation is closely associated with its role in cell cycle G(2)-M arrest. Gadd45a has been characterized as a nuclear protein, but it does not contain a classical nuclear localization signal, suggesting that Gadd45a nuclear translocation might be mediated through different nuclear import machinery. Here we show that Gadd45a associates directly with B23 (nucleophosmin), and the B23-interacting domain is mapped at the central region (61- 100 amino acids) of the Gadd45a protein using a series of Myc tag-Gadd45a deletion mutants. Deletion of this central region disrupts Gadd45a association with B23 and abolishes Gadd45a nuclear translocation. Suppression of endogenous B23 through a short interfering RNA approach disrupts Gadd45a nuclear translocation and results in impaired Gadd45a-induced cell cycle G(2)-M arrest. These findings demonstrate a novel association of B23 and Gadd45a and implicate B23 as an important regulator in Gadd45a nuclear import.	Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Inst Canc, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, QM (corresponding author), Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.	Zhanqimin@chinalab.gov.cn		song, yongmei/0000-0002-7789-0158	NCI NIH HHS [R01 CA93640] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093640] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carrier F, 1999, MOL CELL BIOL, V19, P1673; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1990, PROG CLIN BIOL RES, V340, P315; HALL PA, 1995, ONCOGENE, V10, P2427; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OConnor PM, 1997, CANCER SURV, V29, P151; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; SIPOS K, 1991, BIOCHEM BIOPH RES CO, V177, P673, DOI 10.1016/0006-291X(91)91841-Y; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; Szebeni A, 1999, PROTEIN SCI, V8, P905; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yun JP, 2003, J CELL BIOCHEM, V90, P1140, DOI 10.1002/jcb.10706; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	43	52	65	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10988	10996		10.1074/jbc.M412720200	http://dx.doi.org/10.1074/jbc.M412720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644315	hybrid			2022-12-27	WOS:000227761800015
J	Salinas, K; Wierzbicki, S; Zhou, L; Schmitt, ME				Salinas, K; Wierzbicki, S; Zhou, L; Schmitt, ME			Characterization and purification of Saccharomyces cerevisiae RNase MRP reveals a new unique protein component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA REPLICATION; PRECURSOR RIBOSOMAL-RNA; CELL-CYCLE PROGRESSION; YEAST GENES; IN-VITRO; SUBUNIT; COMPLEX; RIBONUCLEOPROTEINS; ENDORIBONUCLEASE; MUTAGENESIS	In the yeast Saccharomyces cerevisiae, RNase mitochondrial RNA processing (MRP) is an essential endoribonuclease that consists of one RNA component and at least nine protein components. Characterization of the complex is complicated by the fact that eight of the known protein components are shared with a related endoribonuclease, RNase P. To fully characterize the RNase MRP complex, we purified it to apparent homogeneity in a highly active state using tandem affinity purification. In addition to the nine known protein components, both Rpr2 and a protein encoded by the essential gene YLR145w were present in our preparations of RNase MRP. Precipitation of a tagged version of Ylr145w brought with it the RNase MRP RNA, but not the RNase P RNA. A temperature-sensitive ylr145w mutant was generated and found to exhibit a rRNA processing defect identical to that seen in other RNase MRP mutants, whereas no defect in tRNA processing was observed. Homologues of the Ylr145w protein were found in most yeasts, fungi, and Arabidopsis. Based on this evidence, we propose that YLR145w encodes a novel protein component of RNase MRP, but not RNase P. We recommend that this gene be designated RMP1, for RNase MRP protein 1.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Schmitt, ME (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	schmittm@upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064634] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM064634] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AULDS J, 2002, RECENT RES DEV MOL C, V3, P371; Cai T, 1999, MOL CELL BIOL, V19, P7857; Cai T, 2002, GENETICS, V161, P1029; Cai T, 2001, METHOD ENZYMOL, V342, P135, DOI 10.1016/S0076-6879(01)42541-9; CAI T, 2000, THESIS UPSTATE MED U; Chamberlain JR, 1996, NUCLEIC ACIDS RES, V24, P3158, DOI 10.1093/nar/24.16.3158; Chamberlain JR, 1998, GENE DEV, V12, P1678, DOI 10.1101/gad.12.11.1678; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; Dichtl B, 1997, EMBO J, V16, P417, DOI 10.1093/emboj/16.2.417; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; Houser-Scott F, 2002, P NATL ACAD SCI USA, V99, P2684, DOI 10.1073/pnas.052586299; HUANG KN, 1993, MOL CELL BIOL, V13, P3125, DOI 10.1128/MCB.13.6.3125; Lee DY, 1998, J BIOL CHEM, V273, P30614, DOI 10.1074/jbc.273.46.30614; Li X, 2004, NUCLEIC ACIDS RES, V32, P3703, DOI 10.1093/nar/gkh689; Li Y, 2001, P NATL ACAD SCI USA, V98, P441, DOI 10.1073/pnas.021555498; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; REIMER G, 1988, EXP CELL RES, V176, P117, DOI 10.1016/0014-4827(88)90126-7; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sambrook J., 2001, MOL CLONING LAB MANU; SCHMITT ME, 1993, FASEB J, V7, P208, DOI 10.1096/fasebj.7.1.7678563; SCHMITT ME, 1994, GENE DEV, V8, P2617, DOI 10.1101/gad.8.21.2617; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shadel GS, 2000, GENE, V245, P175, DOI 10.1016/S0378-1119(00)00013-5; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Srisawat C, 2001, RNA, V7, P632, DOI 10.1017/S135583820100245X; Stolc V, 1997, GENE DEV, V11, P2414, DOI 10.1101/gad.11.18.2414; TOPPER JN, 1992, CELL, V70, P16, DOI 10.1016/0092-8674(92)90529-L; Welting TJM, 2004, NUCLEIC ACIDS RES, V32, P2138, DOI 10.1093/nar/gkh539; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	37	51	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11352	11360		10.1074/jbc.M409568200	http://dx.doi.org/10.1074/jbc.M409568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15637077	hybrid			2022-12-27	WOS:000227761800057
J	Bonacci, TM; Ghosh, M; Malik, S; Smrcka, AV				Bonacci, TM; Ghosh, M; Malik, S; Smrcka, AV			Regulatory interactions between the amino terminus of G-protein beta gamma subunits and the catalytic domain of phospholipase c beta 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; HETEROTRIMERIC G-PROTEIN; C-BETA; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; INHIBITION; ACTIVATION; EFFECTORS; MEMBRANE	We previously identified a 10-amino acid region from the Y domain of phospholipase C beta 2 (PLC beta 2) that associates with G-protein beta gamma subunits (Sankaran, B., Osterhout, J., Wu, D., and Smrcka, A. V. ( 1998) J. Biol. Chem. 273, 7148-7154). We mapped the site for cross-linking of a synthetic peptide (N20K) corresponding to this Y domain region to Cys(25) within the amino-terminal coiled-coil domain of G beta gamma (Yoshikawa, D. M., Bresciano, K., Hatwar, M., and Smrcka, A. V. ( 2001) J. Biol. Chem. 276, 11246-11251). Here, further experiments with a series of variable length cross-linking agents refined the site of N20K binding to within 4.4-6.7 angstrom of Cys(25). A mutant within the amino terminus of the G beta subunit, G beta(1)(23-27)gamma(2), activated PLC beta 2 more effectively than wild type, with no significant change in the EC50, indicating that this region is directly involved in the catalytic regulation of PLC beta 2. This mutant was deficient in cross- linking to N20K, suggesting that a binding site for the peptide had been eliminated. Surprisingly, N20K could still inhibit G beta 1(23-27)gamma(2)-dependent activation of PLC, suggesting a second N20K binding site. Competition analysis with a peptide that binds to the G alpha subunit switch II binding surface of G beta gamma indicates a second N20K binding site at this surface. Furthermore, mutations to the N20K region within the Y-domain of full-length PLC beta 2 inhibited G beta gamma-dependent regulation of the enzyme, providing further evidence for a G beta gamma binding site within the catalytic domain of PLC beta 2. The data support a model with two modes of PLC binding to G beta gamma through the catalytic domain, where interactions with the amino-terminal coiled-coil domain are inhibitory, and interactions with the G alpha subunit switch II binding surface are stimulatory.	Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Smrcka, AV (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.	Alan_Smrcka@urmc.rochester.edu	Ghosh, Mousumi/D-3180-2011		NHLBI NIH HHS [HL/T3207949] Funding Source: Medline; NIGMS NIH HHS [GM60286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; Dohlman HG, 2002, ANNU REV PHYSIOL, V64, P129, DOI 10.1146/annurev.physiol.64.081701.133448; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; JOURNOT L, 1987, J BIOL CHEM, V262, P15106; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE SB, 1993, J BIOL CHEM, V268, P25952; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; LITOSCH I, 1989, BIOCHEM J, V261, P245, DOI 10.1042/bj2610245; LITOSCH I, 1993, J BIOL CHEM, V268, P8692; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Myung CS, 2000, P NATL ACAD SCI USA, V97, P9311, DOI 10.1073/pnas.97.16.9311; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; SIMMONDS SH, 1985, NEUROSCI LETT, V60, P267, DOI 10.1016/0304-3940(85)90588-9; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Yoshikawa DM, 2001, J BIOL CHEM, V276, P11246, DOI 10.1074/jbc.M006073200; Yoshikawa DM, 2000, BIOCHEMISTRY-US, V39, P11340, DOI 10.1021/bi0005557; Zhang ZX, 2004, J BIOL CHEM, V279, P33937, DOI 10.1074/jbc.M403404200	34	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10174	10181		10.1074/jbc.M412514200	http://dx.doi.org/10.1074/jbc.M412514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15611108	hybrid			2022-12-27	WOS:000227559600054
J	Ferrand, A; Kowalski-Chauvel, A; Bertrand, C; Escrieut, C; Mathieu, A; Portolan, G; Pradayrol, L; Fourmy, D; Dufresne, M; Seva, C				Ferrand, A; Kowalski-Chauvel, A; Bertrand, C; Escrieut, C; Mathieu, A; Portolan, G; Pradayrol, L; Fourmy, D; Dufresne, M; Seva, C			A novel mechanism for JAK2 activation by a G protein-coupled receptor, the CCK2R - Implication of this signaling pathway in pancreatic tumor models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II AT(1) RECEPTOR; JAK/STAT PATHWAY; TRANSGENIC MICE; CELLS; GROWTH; CANCER; PROLIFERATION; DIMERIZATION; ASSOCIATION; INHIBITION	To date very few G protein-coupled receptors (GPCRs) have been shown to be connected to the Janus kinase (JAK)/STAT pathway. Thus our understanding of the mechanisms involved in the activation of this signaling pathway by GPCRs remains limited. In addition, little is known about the role of the JAK pathway in the physiological or pathophysiological functions of GPCRs. Here, we described a new mechanism of JAK activation that involves G alpha(q) proteins. Indeed, transfection of a constitutively activated mutant of G alpha(q) (Q209L) in COS- 7 cells demonstrated that G alpha(q) is able to associate and activate JAK2. In addition, we showed that this mechanism is used to activate JAK2 by a GPCR principally coupled to G(q), the CCK2 receptor (CCK2R), and involves a highly conserved sequence in GPCRs, the NPXXY motif. In a pancreatic tumor cell line expressing the endogenous CCK2R, we demonstrated the activation of the JAK2/STAT3 pathway by this receptor and the involvement of this signaling pathway in the proliferative effects of the CCK2R. In addition, we showed in vivo that the targeted CCK2R expression in pancreas of Elas-CCK2 mice leads to the activation of JAK2 and STAT3. This process may contribute to the increase of pancreas growth as well as the formation of preneoplastic lesions leading to pancreatic tumor development observed in these transgenic animals.	Hop Rangueil, INSERM, U531, TSA 50032, F-31059 Toulouse, France; Hop Rangueil, Histol Facil, IFR 31, TSA 50032, F-31059 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Seva, C (corresponding author), Hop Rangueil, INSERM, U531, TSA 50032, F-31059 Toulouse, France.	sevac@toulouse.inserm.fr	SEVA, Catherine/O-9166-2014; Fourmy, Daniel/AAE-3703-2019; Dufresne, Marlène/M-6332-2014; FERRAND, Audrey/I-5623-2016; Kowalski-Chauvel, Aline/O-9212-2014	SEVA, Catherine/0000-0002-4265-7372; Fourmy, Daniel/0000-0001-9910-4827; FERRAND, Audrey/0000-0002-1057-8151; 				Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Arnould M, 2004, FEBS LETT, V568, P89, DOI 10.1016/j.febslet.2004.05.012; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Burdelya L, 2002, MOL CANCER THER, V1, P893; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Dehez S, 2001, FEBS LETT, V496, P25, DOI 10.1016/S0014-5793(01)02396-1; Ferrand A, 2004, EXP CELL RES, V301, P128, DOI 10.1016/j.yexcr.2004.07.037; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Grippo PJ, 2003, CANCER RES, V63, P2016; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; Saillan-Barreau C, 1998, GASTROENTEROLOGY, V115, P988, DOI 10.1016/S0016-5085(98)70271-9; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Toyonaga T, 2003, CANCER LETT, V201, P107, DOI 10.1016/S0304-3835(03)00482-8; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8	23	59	60	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10710	10715		10.1074/jbc.M413309200	http://dx.doi.org/10.1074/jbc.M413309200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640156	hybrid			2022-12-27	WOS:000227559600116
J	Kusic, J; Kojic, S; Divac, A; Stefanovic, D				Kusic, J; Kojic, S; Divac, A; Stefanovic, D			Noncanonical DNA elements in the lamin B2 origin of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION COMPLEX; ORC-BINDING; TRIPLEX FORMATION; HUMAN-CELLS; SEQUENCES; PROTEIN; PURIFICATION; INITIATION; REQUIRES; GENOME	DNA replication origins of eukaryotes lack linear replicator elements but contain short (dT)(n) (dA)(n) sequences that could build mutually equivalent unorthodox structures. Here we report that the lamin B2 origin of DNA replication adopts an alternative form characterized by unpaired regions CTTTTTTTTTTCC/GGAAAAAAAAAAG (3900-3912) and CCTTTTTTTTC/GAAAAAAAAGG (4141-4151). Both unpaired regions are resistant to DNase and except in central parts of their homopyrimidine strands are sensitive to single strand-specific chemicals. Interactions that protect central pyrimidines probably stabilize the bubble-like areas. Because DNA fragments containing either one or both bubbles migrate in TBM (89 mM Tris base, 89 mM boric acid, and 2 mM MgCl2) PAGE even faster than expected from their linear size, interacting regions are expected to belong to the same molecule. In an origin fragment containing a single bubble, free homopyrimidine strand can only interact with Hoogsteen hydrogen bonding surfaces from a complementary double stranded sequence. Indeed, this origin fragment reacts with triplex preferring antibody. In competition binding experiments control double stranded DNA or single stranded (dT) 40 do not affect origin-antibody interaction, whereas TAT and GGC triplexes exert competitive effect. Because the chosen fragment does not contain potential GGC forming sequences, these experiments confirm that the lamin B2 origin adopts a structure partly composed of intramolecular TAT triads.	Inst Mol Genet & Genet Engn, YU-11010 Belgrade, Serbia And Mont, Serbia		Stefanovic, D (corresponding author), Inst Mol Genet & Genet Engn, Vojvode Stepe 444A,POB 23, YU-11010 Belgrade, Serbia And Mont, Serbia.	stefanovic@yubc.net	Kojic, Snezana/AAF-4873-2019	Kusic-Tisma, Jelena/0000-0002-4167-404X; Divac Rankov, Aleksandra/0000-0001-6282-6746; Kojic, Snezana/0000-0001-5090-1278				Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; Abdurashidova G, 1998, EMBO J, V17, P2961, DOI 10.1093/emboj/17.10.2961; Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; Altman AL, 2001, MOL CELL BIOL, V21, P1098, DOI 10.1128/MCB.21.4.1098-1110.2001; Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; Biamonti G, 2003, CHROMOSOME RES, V11, P403, DOI 10.1023/A:1024910307162; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BLUME SW, 1992, NUCLEIC ACIDS RES, V20, P1777; Blume SW, 1999, NUCLEIC ACIDS RES, V27, P695, DOI 10.1093/nar/27.2.695; BRUKNER I, 1990, NUCLEIC ACIDS RES, V18, P891, DOI 10.1093/nar/18.4.891; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Chuang RY, 2002, J BIOL CHEM, V277, P16920, DOI 10.1074/jbc.M107710200; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; ECKDAHL TT, 1990, NUCLEIC ACIDS RES, V18, P1609, DOI 10.1093/nar/18.6.1609; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; HAMPEL KJ, 1994, BIOCHEMISTRY-US, V33, P5674, DOI 10.1021/bi00185a002; HAMPEL KJ, 1993, BIOCHEMISTRY-US, V32, P1072, DOI 10.1021/bi00055a012; HO PS, 1994, P NATL ACAD SCI USA, V91, P9549, DOI 10.1073/pnas.91.20.9549; HO PS, 1986, EMBO J, V5, P2737, DOI 10.1002/j.1460-2075.1986.tb04558.x; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KLYSIK J, 1991, NUCLEIC ACIDS RES, V19, P7145, DOI 10.1093/nar/19.25.7145; Kong DC, 2003, EMBO J, V22, P3441, DOI 10.1093/emboj/cdg319; Kong DC, 2002, EMBO J, V21, P5567, DOI 10.1093/emboj/cdf546; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Kumar S, 1996, NUCLEIC ACIDS RES, V24, P3289, DOI 10.1093/nar/24.17.3289; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Lee JK, 2001, P NATL ACAD SCI USA, V98, P13589, DOI 10.1073/pnas.251530398; Lu L, 2001, GENE DEV, V15, P134, DOI 10.1101/gad.822101; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; Segurado M, 2003, EMBO REP, V4, P1048, DOI 10.1038/sj.embor.7400008; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Spradling AC, 1999, GENE DEV, V13, P2619, DOI 10.1101/gad.13.20.2619; Stefanovic D, 2003, J BIOL CHEM, V278, P42737, DOI 10.1074/jbc.M307058200; Takahashi T, 2003, EMBO J, V22, P964, DOI 10.1093/emboj/cdg079; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; WELLS RD, 1988, J BIOL CHEM, V263, P1095	41	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9848	9854		10.1074/jbc.M408310200	http://dx.doi.org/10.1074/jbc.M408310200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15611042	hybrid			2022-12-27	WOS:000227559600014
J	Ohkawara, H; Ishibashi, T; Sakamoto, T; Sugimoto, K; Nagata, K; Yokoyama, K; Sakamoto, N; Kamioka, M; Matsuoka, I; Fukuhara, S; Sugimoto, N; Takuwa, Y; Maruyama, Y				Ohkawara, H; Ishibashi, T; Sakamoto, T; Sugimoto, K; Nagata, K; Yokoyama, K; Sakamoto, N; Kamioka, M; Matsuoka, I; Fukuhara, S; Sugimoto, N; Takuwa, Y; Maruyama, Y			Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TISSUE FACTOR; ADHESION; PHOSPHORYLATION; SIGNALS; GTPASES; KINASE; RAC; SPHINGOSINE-1-PHOSPHATE; CYTOSKELETON	RhoA plays a critical signaling role in thrombin-induced endothelial dysfunction. The possible thrombin regulation of geranylgeranylation, a lipid modification, of unprocessed RhoA and the significance of the geranylgeranylation in RhoA activation in endothelial cells (ECs) are not well understood. The amounts of the unprocessed and geranylgeranylated forms of RhoA in non-stimulated cultured human aortic ECs were 31 +/- 8 and 69 +/- 8% total cellular RhoA, respectively (n = 6, p < 0.0001), as determined by the Triton X-114 partition method. Thrombin-induced rapid conversion of most of the unprocessed RhoA into the geranylgeranylated form within 1 min through stimulating geranylgeranyltransferase I ( GGTase I) activity. Thrombin-induced rapid geranylgeranylation was inhibited by acute short term ( 3 min) pretreatment with atorvastatin as well as by an inhibitor of GGTase I (GGTI-286). Thrombin also rapidly stimulated GTP loading of RhoA, which was blocked by acute pretreatment with either atorvastatin or GGTI-286. These observations indicate the dependence of thrombin stimulation of RhoA on the rapid geranylgeranylation of unprocessed RhoA. Importantly, the addition of geranylgeranylpyrophosphate to ECs pretreated with atorvastatin quickly reversed the atorvastatin inhibition of thrombin stimulation of RhoA. These results suggest that geranylgeranylation of unprocessed RhoA may limit thrombin-induced full activation of RhoA in ECs. Cytoskeleton analysis demonstrated that atorvastatin and GGTI-286 inhibited thrombin-induced stress fiber formation. We provide the evidence that, in thrombin-stimulated ECs, the unprocessed form of RhoA is rapidly geranylgeranylated to become the mature form, which then is converted into GTP-bound active RhoA.	Fukushima Med Univ, Dept Internal Med 1, Fukushima 9601295, Japan; Fukushima Med Univ, Dept Pharmacol, Fukushima 9601295, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Osaka 5658565, Japan; Kanazawa Univ, Grad Sch Med, Dept Physiol, Kanazawa, Ishikawa 9208640, Japan	Fukushima Medical University; Fukushima Medical University; National Cerebral & Cardiovascular Center - Japan; Kanazawa University	Ishibashi, T (corresponding author), Fukushima Med Univ, Dept Internal Med 1, 1 Hikarigaoka, Fukushima 9601295, Japan.	masaishi@fmu.ac.jp	Sugimoto, Naotoshi/C-4739-2015	Sugimoto, Naotoshi/0000-0003-1995-5002; Kamioka, Masashi/0000-0001-6588-0764; Matsuoka, Isao/0000-0002-7170-3630; Ohkawara, Hiroshi/0000-0002-3129-1977				Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Ardissino D, 2001, BLOOD, V98, P2726, DOI 10.1182/blood.V98.9.2726; Begum N, 2002, DIABETES, V51, P2256, DOI 10.2337/diabetes.51.7.2256; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chappell J, 2000, J BIOL CHEM, V275, P31792, DOI 10.1074/jbc.M004798200; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Eto M, 2001, CIRC RES, V89, P583, DOI 10.1161/hh1901.097084; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Golovchenko I, 2000, CIRC RES, V87, P746, DOI 10.1161/01.RES.87.9.746; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Ishibashi T, 2003, ARTERIOSCL THROM VAS, V23, P681, DOI 10.1161/01.ATV.0000065194.00822.C7; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Liu L, 1999, J BIOL CHEM, V274, P33334, DOI 10.1074/jbc.274.47.33334; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nagata K, 2001, J HYPERTENS, V19, P775, DOI 10.1097/00004872-200104000-00015; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sonel A, 2000, CIRCULATION, V102, P1107, DOI 10.1161/01.CIR.102.10.1107; VAN AL, 1997, GENE DEV, V11, P2295; Wolfrum S, 2003, ARTERIOSCL THROM VAS, V23, P729, DOI 10.1161/01.ATV.0000063385.12476.A7; Yokoyama K, 2002, CIRCULATION, V105, P962, DOI 10.1161/hc0802.104457	35	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10182	10188		10.1074/jbc.M409547200	http://dx.doi.org/10.1074/jbc.M409547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640525	hybrid			2022-12-27	WOS:000227559600055
J	Passeggio, J; Liscum, L				Passeggio, J; Liscum, L			Flux of fatty acids through NPC1 lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NIEMANN-PICK C1; CHOLESTEROL; FIBROBLASTS; TRANSPORT; DISEASE; CELLS; TRAFFICKING; SUPPRESSION; MUTATIONS	Niemann-Pick type C (NPC) is an autosomal recessive lipid storage disorder characterized by lysosomal accumulation of cholesterol and gangliosides resulting from a defect in intracellular lipid trafficking. The NPC1 gene encodes a 1278-amino acid integral membrane protein involved in the sub-cellular trafficking of lipids. The exact biological function of NPC1 remains unclear. Recent evidence suggests that NPC1 is a eukaryotic member of the RND permease family of transport proteins, which when expressed in bacteria is capable of transporting fatty acids. The goal of this project was to assess the role of NPC1 in the transport of fatty acids in primary human fibroblasts using normal fibroblasts and fibroblasts from patients with three lysosomal storage diseases: NPC, mucolipidosis IV, and Sandhoff disease. If NPC1 is a fatty acid transporter, we expect to find fatty acid accumulation only in NPC fibroblasts. We used three experimental approaches to assess the role of NPC1 as a fatty acid transporter. First, we evaluated the accumulation versus metabolism of low density lipoprotein-derived oleic acid. Second, we assessed the amount of free fatty acid present after growth in lipoprotein-containing media. Third, we assessed the cellular accumulation of acriflavine, a fluorescent substrate for a number of resistance-nodulation-cell division permease transporters. Our results indicate that fatty acid flux through NPC1-deficient lysosomes is normal.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA	Tufts University; Tufts University	Liscum, L (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	Laura.Liscum@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049564] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK49564] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2003, LIPID ANAL; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; FAUST JR, 1977, J BIOL CHEM, V252, P4861; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Greer WL, 1999, AM J HUM GENET, V65, P1252, DOI 10.1086/302620; Groener JEM, 1996, J LIPID RES, V37, P2271; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; Leventhal AR, 2004, J BIOL CHEM, V279, P8084, DOI 10.1074/jbc.M310672200; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Park WD, 2003, HUM MUTAT, V22, P313, DOI 10.1002/humu.10255; PATTERSON MC, 2000, METABOLIC MOL BASES, P2625; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Sugii S, 2003, J BIOL CHEM, V278, P27180, DOI 10.1074/jbc.M300542200; TERUYA J, 1995, J LIPID RES, V36, P266; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107	21	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10333	10339		10.1074/jbc.M413657200	http://dx.doi.org/10.1074/jbc.M413657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632139	hybrid			2022-12-27	WOS:000227559600073
J	Petrou, P; Pavlakis, E; Dalezios, Y; Galanopoulos, VK; Chalepakis, G				Petrou, P; Pavlakis, E; Dalezios, Y; Galanopoulos, VK; Chalepakis, G			Basement membrane distortions impair lung lobation and capillary organization in the mouse model for Fraser syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; TRANSCRIPTION FACTOR; ANCHORING FIBRILS; BLEBBED PHENOTYPE; MORPHOGENESIS; CRYPTOPHTHALMOS; MALFORMATION; VASCULATURE; MODULES; PROTEIN	Fras1 is a putative extracellular matrix protein that has been implicated in the structural adhesion of embryonic epidermis to dermis. Moreover, mutations in Fras1/FRAS1 have been associated with the mouse blebbed phenotype and the human rare genetic disorder Fraser syndrome, respectively. Here we report the mapping of Fras1 within the extracellular space and evaluate the effects of Fras1 deficiency on lung development in the mouse. Expression of Fras1 was detected in the mesothelial cells of the visceral pleura and in the conducting airway epithelia. Immunogold histochemistry identified Fras1 as a component of the extracellular matrix localized below the lamina densa of epithelial basement membranes in the embryonic lung. Embryos homozygous for a targeted mutation of Fras1 exhibited fused pulmonary lobes resulting from incomplete separation during development as well as a profound disarrangement of blood capillaries in the terminal air sacs. We demonstrate that loss of Fras1 causes alterations in the molecular composition of basement membranes, concomitant with local disruptions of epithelial-endothelial contacts and extravasation of erythrocytes into the embryonic respiratory lumen. Thus, our findings identify Fras1 as an important structural component of the sub-lamina densa of basement membranes required for lobar septation and the organization of blood capillaries in the peripheral lung.	Univ Crete, Dept Biol, Iraklion 71409, Crete, Greece; Univ Crete, Fac Med, Dept Basic Sci, Sch Hlth Sci, Iraklion 71409, Crete, Greece	University of Crete; University of Crete	Chalepakis, G (corresponding author), Univ Crete, Dept Biol, Iraklion 71409, Crete, Greece.	chalepak@imbb.forth.gr	Dalezios, Yannis/D-7533-2013	Dalezios, Yannis/0000-0002-9154-4876; Pavlakis, Evangelos/0000-0002-7971-609X				AOYAMA H, 1994, TERATOLOGY, V50, P177, DOI 10.1002/tera.1420500302; Balci S, 1999, PRENATAL DIAG, V19, P856, DOI 10.1002/(SICI)1097-0223(199909)19:9<856::AID-PD628>3.0.CO;2-X; Bruckner-Tuderman L, 1998, J MOL MED-JMM, V76, P226, DOI 10.1007/s001090050213; Bruckner-Tuderman L, 1999, MATRIX BIOL, V18, P43, DOI 10.1016/S0945-053X(98)00007-9; Chinoy MR, 2003, FRONT BIOSCI-LANDMRK, V8, pD392, DOI 10.2741/974; Darling S, 1994, Clin Dysmorphol, V3, P91; deMello DE, 1997, AM J RESP CELL MOL, V16, P568, DOI 10.1165/ajrcmb.16.5.9160839; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; EKBLOM P, 1994, DEVELOPMENT, V120, P2003; FARR AG, 1992, J EXP MED, V176, P1477, DOI 10.1084/jem.176.5.1477; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Hislop AA, 2002, J ANAT, V201, P325, DOI 10.1046/j.1469-7580.2002.00097.x; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; Larrain J, 2000, DEVELOPMENT, V127, P821; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lim L, 2002, AM J PHYSIOL-LUNG C, V282, pL1012, DOI 10.1152/ajplung.00371.2001; Lonai P, 2003, J ANAT, V202, P43, DOI 10.1046/j.1469-7580.2003.00143.x; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; McGregor L, 2003, NAT GENET, V34, P203, DOI 10.1038/ng1142; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Nguyen NM, 2002, DEV BIOL, V246, P231, DOI 10.1006/dbio.2002.0658; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; OZGUNEN T, 1995, INT J GYNECOL OBSTET, V49, P187, DOI 10.1016/0020-7292(94)02335-V; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; Relan NK, 1999, PEDIATR DEVEL PATHOL, V2, P103, DOI 10.1007/s100249900098; Simon-Assmann P, 1998, ANN NY ACAD SCI, V859, P46, DOI 10.1111/j.1749-6632.1998.tb11110.x; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Slavotinek AM, 2002, J MED GENET, V39, P623, DOI 10.1136/jmg.39.9.623; Smyth I, 2004, P NATL ACAD SCI USA, V101, P13560, DOI 10.1073/pnas.0402760101; Takamiya K, 2004, NAT GENET, V36, P172, DOI 10.1038/ng1292; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Vrontou S, 2003, NAT GENET, V34, P209, DOI 10.1038/ng1168; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; WINTER RM, 1990, CLIN GENET, V37, P494; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	38	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10350	10356		10.1074/jbc.M412368200	http://dx.doi.org/10.1074/jbc.M412368200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15623520	hybrid			2022-12-27	WOS:000227559600075
J	Weixel, KM; Blumental-Perry, A; Watkins, SC; Aridor, M; Weisz, OA				Weixel, KM; Blumental-Perry, A; Watkins, SC; Aridor, M; Weisz, OA			Distinct Golgi populations of phosphatidylinositol 4-phosphate regulated by phosphatidylinositol 4-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; OXYSTEROL-BINDING PROTEIN; CANINE KIDNEY-CELLS; BREFELDIN-A; INOSITOL LIPIDS; LIVING CELLS; MDCK CELLS; 4-KINASE; WORTMANNIN; SECRETION	Phosphatidylinositol 4-phosphate (PI4P) regulates biosynthetic membrane traffic at multiple steps and differentially affects the surface delivery of apically and basolaterally destined proteins in polarized cells. Two phosphatidylinositol 4-kinases (PI4Ks) have been localized to the Golgi complex in mammalian cells, type III PI4K beta (PI4KIII beta) and type II PI4K alpha ( PI4KII alpha). Here we report that PI4KIII beta and PI4KII alpha localize to discrete subcompartments of the Golgi complex in Madin-Darby canine kidney (MDCK) cells. PI4KIII alpha was enriched in early Golgi compartments, whereas PI4KII alpha colocalized with markers of the trans-Golgi network (TGN). To understand the temporal and spatial control of PI4P generation across the Golgi complex, we quantitated the steady state distribution of a fluorescent PI4P-binding domain relative to cis/medial Golgi and TGN markers in transiently transfected MDCK cells. The density of the signal from this PI4P reporter was roughly 2-fold greater in the early Golgi compartments compared with that of the TGN. Furthermore, this ratio could be modulated in vivo by overexpression of catalytically inactive PI4KIII beta and PI4KII alpha or in vitro by the PI4KIII beta inhibitor wortmannin. Our data suggest that both PI4KIII beta and PI4KII alpha contribute to the compartmental regulation of PI4P synthesis within the Golgi complex. We discuss our results with respect to the kinetic effects of modulating PI4K activity on polarized biosynthetic traffic in MDCK cells.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NIDDK NIH HHS [R01 DK054407, R01 DK062318, R01 DK064613, T32-DK61296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK054407, R01DK062318, R01DK064613] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; Balla T, 2001, CURR PHARM DESIGN, V7, P475, DOI 10.2174/1381612013397906; Balla T, 2000, TRENDS PHARMACOL SCI, V21, P238, DOI 10.1016/S0165-6147(00)01500-5; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; Cockcroft S, 2001, J MEMBRANE BIOL, V180, P187, DOI 10.1007/s002320010069; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; Ellis MA, 2004, J BIOL CHEM, V279, P52735, DOI 10.1074/jbc.M410533200; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Guo J, 2003, P NATL ACAD SCI USA, V100, P3995, DOI 10.1073/pnas.0230488100; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Levine TP, 2001, MOL BIOL CELL, V12, P1633, DOI 10.1091/mbc.12.6.1633; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; LOW SH, 1991, J BIOL CHEM, V266, P17729; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Pathre P, 2003, EMBO J, V22, P4059, DOI 10.1093/emboj/cdg390; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; WAGNER M, 1994, J CELL SCI, V107, P933; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Waugh MG, 2003, BIOCHEM J, V373, P57, DOI 10.1042/BJ20030089; YANO H, 1993, J BIOL CHEM, V268, P25846	34	103	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10501	10508		10.1074/jbc.M414304200	http://dx.doi.org/10.1074/jbc.M414304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15634669	hybrid			2022-12-27	WOS:000227559600093
J	Duque, J; Fresno, M; Iniguez, MA				Duque, J; Fresno, M; Iniguez, MA			Expression and function of the nuclear factor of activated T cells in colon carcinoma cells - Involvement in the regulation of cyclooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; TRANSCRIPTION FACTORS; CANCER PREVENTION; NF-AT; LYMPHOCYTE-ACTIVATION; MUSCLE-CELLS; INHIBITION; GENE; CALCINEURIN; PROTEIN	Increasing evidence shows a crucial role of the Ca2+/ calcineurin-mediated activation of the nuclear factor of activated T cells (NFAT) in the regulation of a variety of processes in nonimmune cells. Here we provide evidence that NFATc1 and NFATc2 are expressed in human colon carcinoma cell lines. These proteins are translocated from the cytoplasm to the nucleus upon treatment with a combination of phorbol 12-myristate 13-acetate plus the calcium ionophore A23187. Subsequent to translocation to the nucleus, NFATc1 and NFATc2 were able to bind to a NFAT response element in the DNA, regulating transcriptional activation of genes containing a NFAT-responsive element such as cyclooxygenase-2 (COX-2). COX-2 expression and prostaglandin E-2 (PGE(2)) production were induced upon pharmacological stimuli leading to NFAT activation and blunted by inhibition of calcineurin phosphatase with cyclosporin A or tacrolimus (FK506). Expression of NFAT wild type protein or the active catalytic subunit of calcineurin transactivates COX-2 promoter activity, whereas a dominant negative mutant of NFAT inhibited COX-2 induction in colon carcinoma cell lines. Furthermore, mutation or deletion of NFAT binding sites in the human COX-2 promoter greatly diminished its induction by phorbol 12-myristate 13-acetate/calcium ionophore A23187. These findings demonstrate the presence and activation of NFAT in human colon carcinoma cells, with important implications in the regulation of genes involved in the transformed phenotype as COX-2.	Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Iniguez, MA (corresponding author), Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.	Mainiguez@cbm.uam.es	Peña, Miguel Angel Iñiguez/J-8518-2012	Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Fresno Escudero, Manuel/0000-0002-9223-5477				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; HERSCHMAN HR, 1993, J LIPID MEDIATOR, V6, P89; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085; Huls G, 2003, LANCET, V362, P230, DOI 10.1016/S0140-6736(03)13915-3; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Iniguez MA, 1999, J IMMUNOL, V163, P111; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; JIANG H, 1993, CARCINOGENESIS, V14, P67, DOI 10.1093/carcin/14.1.67; Jimenez JL, 2004, CELL SIGNAL, V16, P1363, DOI 10.1016/j.cellsig.2004.04.002; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kawamori T, 1998, CANCER RES, V58, P409; Koshkina NV, 2004, J AEROSOL MED, V17, P7, DOI 10.1089/089426804322994415; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; Martinez-Martinez S, 2004, CURR MED CHEM, V11, P997, DOI 10.2174/0929867043455576; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; MASUHARA M, 1993, CARCINOGENESIS, V14, P1579, DOI 10.1093/carcin/14.8.1579; Mohri T, 1998, CELL STRUCT FUNCT, V23, P255, DOI 10.1247/csf.23.255; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PIONTEK M, 1994, J CANCER RES CLIN, V120, P695, DOI 10.1007/BF01194265; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robida AM, 2000, MOL PHARMACOL, V58, P701, DOI 10.1124/mol.58.4.701; Sakai Manabu, 2004, Journal of Medical Investigation, V51, P63, DOI 10.2152/jmi.51.63; San-Antonio B, 2002, J BIOL CHEM, V277, P27073, DOI 10.1074/jbc.M106983200; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Sugimoto T, 2001, J AM SOC NEPHROL, V12, P1359, DOI 10.1681/ASN.V1271359; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VandeVrie W, 1997, J CANCER RES CLIN, V123, P21, DOI 10.1007/BF01212610; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; YAMAMOTO S, 1994, CANCER LETT, V83, P185, DOI 10.1016/0304-3835(94)90317-4; Yellaturu CR, 2002, BIOCHEM J, V368, P183, DOI 10.1042/BJ20020347	58	99	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8686	8693		10.1074/jbc.M413076200	http://dx.doi.org/10.1074/jbc.M413076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632146	hybrid			2022-12-27	WOS:000227453100010
J	Liu, Y; Sinha, S; McDonald, OG; Shang, YT; Hoofnagle, MH; Owens, GK				Liu, Y; Sinha, S; McDonald, OG; Shang, YT; Hoofnagle, MH; Owens, GK			Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; ALPHA-ACTIN EXPRESSION; DIFFERENTIATION MARKER GENES; MESSENGER-RNA EXPRESSION; GROWTH FACTOR-BB; CELL-DIFFERENTIATION; TRANSCRIPTION FACTOR; IN-VIVO; CARG ELEMENTS; INDUCED STIMULATION	Platelet-derived growth factor BB (PDGF-BB) has been shown to be an extremely potent negative regulator of smooth muscle cell (SMC) differentiation. Moreover, previous studies have demonstrated that the Kruppellike transcription factor (KLF) 4 potently represses the expression of multiple SMC genes. However, the mechanisms whereby KLF4 suppresses SMC gene expression are not known, nor is it clear whether KLF4 contributes to PDGF- BB- induced down- regulation of SMC genes. The goals of the present studies were to determine the molecular mechanisms by which KLF4 represses expression of SMC genes and whether it contributes to PDGF- BB- induced suppression of these genes. Results demonstrated that KLF4 markedly repressed both myocardin- induced activation of SMC genes and expression of myocardin. KLF4 was rapidly up- regulated in PDGF-BB-treated, cultured SMC, and a small interfering RNA to KLF4 partially blocked PDGFBBinduced SMC gene repression. Both PDGF-BB and KLF4 markedly reduced serum response factor binding to CArG containing regions within intact chromatin. Finally, KLF4, which is normally not expressed in differentiated SMC in vivo, was rapidly up- regulated in vivo in response to vascular injury. Taken together, results indicate that KLF4 represses SMC genes by both down- regulating myocardin expression and preventing serum response factor/myocardin from associating with SMC gene promoters, and suggest that KLF4 may be a key effector of PDGF-BB and injury-induced phenotypic switching of SMC.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Owens, GK (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, 415 Lane Rd,MR 5,Rm 1220,POB 801394, Charlottesville, VA 22908 USA.	gko@virginia.edu	Sinha, Sanjay/AAF-1692-2021	Sinha, Sanjay/0000-0001-5900-1209; HOOFNAGLE, MARK/0000-0002-6080-5244	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL057353, R01HL038854, P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL38854, P01HL19242, R37HL57353] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Aikawa M, 1998, CIRC RES, V83, P1015, DOI 10.1161/01.RES.83.10.1015; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; BLANK RS, 1988, J CELL BIOL, V107, P299, DOI 10.1083/jcb.107.1.299; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; CORJAY MH, 1990, J CELL PHYSIOL, V145, P391, DOI 10.1002/jcp.1041450302; Dandre F, 2004, AM J PHYSIOL-HEART C, V286, pH2042, DOI 10.1152/ajpheart.00625.2003; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; Hautmann MB, 1998, J BIOL CHEM, V273, P8398, DOI 10.1074/jbc.273.14.8398; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; HENDRIX JA, 2004, IN PRESS J CLIN INVE; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Liu Y, 2003, J BIOL CHEM, V278, P48004, DOI 10.1074/jbc.M301902200; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; MIANO JM, 1990, AM J PATHOL, V137, P761; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; OWENS GK, 1995, PHYSIOL REV, V75, P487; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Sun JX, 2002, CIRC RES, V90, P1020, DOI 10.1161/01.RES.0000017727.35930.33; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; VAN P, 1994, CIRC RES, V75, P1126; Wamhoff BR, 2004, CIRC RES, V95, P981, DOI 10.1161/01.RES.0000147961.09840.fb; Wamhoff BR, 2004, CIRC RES, V95, P406, DOI 10.1161/01.RES.0000138582.36921.9e; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; WEIR L, 1995, J BIOL CHEM, V270, P5457, DOI 10.1074/jbc.270.10.5457; Weissberg P L, 1995, Blood Press Suppl, V2, P68; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; Yoshida T, 2004, CIRC RES, V94, P1075, DOI 10.1161/01.RES.0000125622.46280.95; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhang XM, 2001, J BIOL CHEM, V276, P40033, DOI 10.1074/jbc.M104934200	54	251	255	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9719	9727		10.1074/jbc.M412862200	http://dx.doi.org/10.1074/jbc.M412862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623517	hybrid			2022-12-27	WOS:000227453100129
J	Schuchner, S; Tembe, V; Rodriguez, JA; Henderson, BR				Schuchner, S; Tembe, V; Rodriguez, JA; Henderson, BR			Nuclear targeting and cell cycle regulatory function of human BARD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRCA1 TUMOR-SUPPRESSOR; RING DOMAIN; UBIQUITIN LIGASE; BREAST-CANCER; PROTEIN; GENE; BRCA1-BARD1; MUTATIONS; LOCALIZATION; REPAIR	The BARD1 gene is mutated in a subset of breast and ovarian cancers, implicating BARD1 as a potential tumor suppressor. BARD1 gains a ubiquitin E3 ligase activity when heterodimerized with BRCA1, but the only known BRCA1-independent BARD1 function is a p53-dependent proapoptotic activity stimulated by nuclear export to the cytoplasm. We described previously the nuclear-cytoplasmic shuttling of BARD1, and in this study, we identify the transport sequences that target BARD1 to the nucleus and show that they are essential for BARD1 regulation of the cell cycle. We used deletion mapping and mutagenesis to define two active nuclear localization signals ( NLSs) present in human BARD1 that are not conserved in rodent BARD1. Site-directed mutagenesis of the primary bipartite NLS abolished BARD1 nuclear import and caused its cytoplasmic accumulation. Using flow cytometry and 5-bromo-2-deoxyuridine incorporation assays, we discovered that transiently expressed BARD1 can elicit a p53-independent cell cycle arrest in G(1) phase, and that this was abrogated by mutation of the BARD1 NLS but not by mutation of the nuclear export signal. Thus, BARD1 regulation of the cell cycle is a nuclear event and may be linked to its induced expression during mitosis and its possible involvement in the DNA damage checkpoint.	Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Sydney, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Darcy Rd,POB 412, Sydney, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au	Rodriguez, Jose Antonio/AAA-1125-2019	Rodriguez, Jose Antonio/0000-0002-2823-3733				Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Boulton SJ, 2004, CURR BIOL, V14, P33, DOI 10.1016/j.cub.2003.11.029; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200; Fabbro M, 2004, EXP CELL RES, V298, P661, DOI 10.1016/j.yexcr.2004.05.004; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jans DA, 1998, MED RES REV, V18, P189, DOI 10.1002/(SICI)1098-1128(199807)18:4<189::AID-MED1>3.3.CO;2-Z; Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Karppinen SM, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.020669; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sarkisian CJ, 2001, J BIOL CHEM, V276, P37640, DOI 10.1074/jbc.M106281200; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; Westermark UK, 2003, MOL CELL BIOL, V23, P7926, DOI 10.1128/MCB.23.21.7926-7936.2003; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200	40	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8855	8861		10.1074/jbc.M413741200	http://dx.doi.org/10.1074/jbc.M413741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632137	hybrid			2022-12-27	WOS:000227453100030
J	Friedler, A; Veprintsev, DB; Rutherford, T; von Glos, KI; Fersht, AR				Friedler, A; Veprintsev, DB; Rutherford, T; von Glos, KI; Fersht, AR			Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; CORE DOMAIN; DNA-BINDING; MUTANT P53; HOMOLOGOUS RECOMBINATION; OLIGOMERIZATION DOMAIN; CRYSTAL-STRUCTURE; DESIGNED PEPTIDE; BRCT DOMAINS; SH3 DOMAINS	Homologous recombination is repressed by the binding of p53 to Rad51. We identified by fluorescence and NMR spectroscopy that peptides corresponding to residues 179-190 of Rad51 bind to the core domain of p53 in a site that overlaps with its specific DNA binding site. The p53 site is quite promiscuous, since it also binds peptides derived from 53BP1, 53BP2, Hif-1alpha, and BCL-X-L in overlapping regions. Binding is mediated mainly by a strong, nonspecific, electrostatic component and is fine tuned by specific interactions. Competition of the different proteins with each other and with specific DNA for a single site in p53 could be a factor in regulation of its activity.	MRC, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge	Fersht, AR (corresponding author), MRC, Cambridge Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	arf25@cam.ac.uk	Fersht, Alan R/B-2189-2008; Veprintsev, Dmitry B/H-2228-2012	Veprintsev, Dmitry B/0000-0002-3583-5409				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Ekblad CMS, 2004, PROTEIN SCI, V13, P617, DOI 10.1110/ps.03461404; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hajduk PJ, 1997, J MED CHEM, V40, P3144, DOI 10.1021/jm9703404; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Henning W, 2003, TOXICOLOGY, V193, P91, DOI 10.1016/S0300-483X(03)00291-9; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Linke SP, 2003, CANCER RES, V63, P2596; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	48	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8051	8059		10.1074/jbc.M411176200	http://dx.doi.org/10.1074/jbc.M411176200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611070	hybrid			2022-12-27	WOS:000227395700075
J	Haugstetter, J; Blicher, T; Ellgaard, L				Haugstetter, J; Blicher, T; Ellgaard, L			Identification and characterization of a novel thioredoxin-related transmembrane protein of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING SITE; DISULFIDE-ISOMERASE; FUNCTIONAL-CHARACTERIZATION; REDOX STATE; B' DOMAIN; ERP57; GLUTATHIONE; OXIDOREDUCTASE; CALRETICULIN; OXIDATION	The endoplasmic reticulum ( ER) contains a number of thiol- disulfide oxidoreductases of the protein- disulfide isomerase ( PDI) family that catalyze the formation of disulfide bonds in newly synthesized proteins. Here we describe the identification and characterization of a novel member of the human PDI family, TMX3 ( thioredoxinrelated transmembrane protein 3). The TMX3 gene encodes a protein of 454 amino acid residues that contains a predicted N- terminal signal sequence, a single domain with sequence similarity to thioredoxin and a CGHC active site sequence, a potential transmembrane domain, and a C- terminal KKKD tetrapeptide sequence that matches the classical KKXX- type consensus sequence for ER retrieval of type I transmembrane proteins. Endogenous TMX3 contains endoglycosidase Hsensitive glycans, localizes to the ER by immunofluorescence microscopy, and is present in the membrane fraction after alkaline extraction of the ER luminal content. The TMX3 transcript is found in a variety of tissues and is not up- regulated by the unfolded protein response. Circular dichroism spectroscopy of the recombinantly expressed luminal domain of TMX3 showed features typical of a properly folded protein of the alpha/beta type. The redox potential of recombinant luminal TMX3 was determined to - 0.157 V, similar to the values previously found for PDI and ERp57. Interestingly, TMX3 showed oxidase activity, and in human tissue- culture cells the protein was found partially in the oxidized form, potentially suggesting a function of the protein as a dithiol oxidase.	ETH, Inst Biochem, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Ellgaard, L (corresponding author), ETH, Inst Biochem, CH-8093 Zurich, Switzerland.	lars.ellgaard@bc.biol.ethz.ch	Ellgaard, Lars/I-9034-2014	Ellgaard, Lars/0000-0002-7018-0137				Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Antoniou AN, 2003, ANTIOXID REDOX SIGN, V5, P375, DOI 10.1089/152308603768295104; Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200; Chakravarthi S, 2004, J BIOL CHEM, V279, P39872, DOI 10.1074/jbc.M406912200; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Ko FCF, 2002, DEVELOPMENT, V129, P1185; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; Matsuo Y, 2004, ARCH BIOCHEM BIOPHYS, V423, P81, DOI 10.1016/j.abb.2003.11.003; Matsuo Y, 2001, J BIOL CHEM, V276, P10032, DOI 10.1074/jbc.M011037200; Mayer M, 2004, J MOL BIOL, V341, P1077, DOI 10.1016/j.jmb.2004.06.068; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Meng XF, 2003, BIOCHEM GENET, V41, P99, DOI 10.1023/A:1022073917044; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Mossner E, 1998, PROTEIN SCI, V7, P1233; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Rozhkova A, 2004, EMBO J, V23, P1709, DOI 10.1038/sj.emboj.7600178; Ruddock LW, 1996, BIOCHEM J, V315, P1001, DOI 10.1042/bj3151001; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Silvennoinen L, 2004, J BIOL CHEM, V279, P13607, DOI 10.1074/jbc.M313054200; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Tabaska JE, 1999, GENE, V231, P77, DOI 10.1016/S0378-1119(99)00104-3; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Urade R, 2004, BIOCHEMISTRY-US, V43, P8858, DOI 10.1021/bi0493315; van Lith M, 2005, J BIOL CHEM, V280, P1376, DOI 10.1074/jbc.M408651200; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wheeler DL, 2004, NUCLEIC ACIDS RES, V32, pD35, DOI 10.1093/nar/gkh073; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	62	64	65	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8371	8380		10.1074/jbc.M413924200	http://dx.doi.org/10.1074/jbc.M413924200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623505	hybrid			2022-12-27	WOS:000227395700113
J	Sheng, SH; Perry, CJ; Kashlan, OB; Kleyman, TR				Sheng, SH; Perry, CJ; Kashlan, OB; Kleyman, TR			Side chain orientation of residues lining the selectivity filter of epithelial Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOAD URINARY-BLADDER; SODIUM-CHANNEL; SUBUNIT STOICHIOMETRY; ION SELECTIVITY; PORE REGION; POTASSIUM CHANNEL; MOLECULAR-BASIS; ENAC; PERMEATION; AMILORIDE	Epithelial Na+ channels (ENaCs) selectively conduct Na+ and Li+ but exclude K+. A three-residue tract (( G/S)XS) present within all three subunits has been identified as a key structure forming a putative selectivity filter. We investigated the side chain orientation of residues within this tract by analyzing accessibility of the introduced sulfhydryl groups to thiophilic Cd2+. Xenopus oocytes were used to express wild-type or mutant mouse alphabetagammaENaCs. The blocking effect of external Cd2+ was examined by comparing amiloride- sensitive Na+ currents measured by two-electrode voltage clamp in the absence and presence of Cd2+ in the bath solution. The currents in mutant channels containing a single Cys substitution at the first or third position within the (G/S) XS tract (alphaG587C, alphaS589C, betaG529C, betaS531C, gammaS546C, and gammaS548C) were blocked by Cd2+ with varying inhibitory constants (0.06-13 mM), whereas the currents in control channels were largely insensitive to Cd2+ at concentrations up to 10 mM. The Cd2+ blocking effects were fast, with time constants in the range of seconds, and were only partially reversible. The blocked currents were restored by 10 mM dithiothreitol. Mutant channels containing alanine or serine substitutions at these sites within the alpha subunit were only poorly and reversibly blocked by 10 mM Cd2+. These results indicate that the introduced sulfhydryl groups face the conduction pore and suggest that serine hydroxyl groups within the selectivity filter in wild-type ENaCs face the conduction pore and may contribute to cation selectivity by participating in coordination of permeating cations.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Sch Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sheng, SH (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Dept Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.	shaohu@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702; Solvi, Cwyn/0000-0003-2517-6179	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK066883, R01DK054354, T32DK061296] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK054354, F32 DK066883, DK061296, DK066883] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN O, 1984, ENVIRON HEALTH PERSP, V54, P249, DOI 10.2307/3429813; BENOS DJ, 1980, J GEN PHYSIOL, V76, P233, DOI 10.1085/jgp.76.2.233; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Berdiev BK, 1998, BIOPHYS J, V75, P2292, DOI 10.1016/S0006-3495(98)77673-8; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; Creighton T. E., 1993, PROTEINS STRUCTURE M; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; HILLE B, 2001, ION CHANNELS EXCITAB, P561; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Jung H, 2002, FEBS LETT, V529, P73, DOI 10.1016/S0014-5793(02)03184-8; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Li JQ, 2003, J BIOL CHEM, V278, P13867, DOI 10.1074/jbc.M300149200; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; PALMER LG, 1982, J MEMBRANE BIOL, V67, P91, DOI 10.1007/BF01868651; PALMER LG, 1990, RENAL PHYSIOL BIOCH, V13, P51; PALMER LG, 1987, J MEMBRANE BIOL, V96, P97, DOI 10.1007/BF01869236; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; Very AA, 2003, ANNU REV PLANT BIOL, V54, P575, DOI 10.1146/annurev.arplant.54.031902.134831; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	36	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8513	8522		10.1074/jbc.M413880200	http://dx.doi.org/10.1074/jbc.M413880200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611061	hybrid			2022-12-27	WOS:000227395700128
J	Welcker, M; Clurman, BE				Welcker, M; Clurman, BE			The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; SCFFBW7 UBIQUITIN LIGASE; CYCLIN-E; DNA-REPLICATION; CELLULAR-TRANSFORMATION; RETINOBLASTOMA PROTEIN; VIRAL ONCOPROTEINS; C-MYC; MULTISITE PHOSPHORYLATION; HISTONE DEACETYLASE	Cell transformation by simian virus 40 (SV40) results mostly from the highly oncogenic activities of the large T antigen ( LT), which corrupts the cellular checkpoint mechanisms that guard cell division and the transcription, replication, and repair of DNA. The most prominent LT targets are the retinoblastoma protein (pRb) and p53. Here we report that LT binds directly to Fbw7, the substrate recognition component of the SCFFbw7 ubiquitin ligase and a human tumor suppressor. LT binding mislocalizes the nucleolar Fbw7gamma isoform to the nucleoplasm. Interestingly, the binding of LT to Fbw7 occurs via a decoy phospho-epitope within the C terminus of LT that closely mimics the consensus Cdc4 phospho-degron found within Fbw7 substrates. We demonstrate that, using this mode of interaction, LT can interfere with Fbw7-driven cyclin E turnover in vivo and causes increased cyclin E-associated kinase activity. Our data suggest that LT competes with cellular proteins for Fbw7 binding in a substrate-like fashion.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Clurman, BE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.	bclurman@fhcrc.org	Clurman, Bruce/AAV-3854-2021	Welcker, Markus/0000-0001-6723-4790	NATIONAL CANCER INSTITUTE [R01CA102742, R01CA084069] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA84069, R01CA102742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2004, J VIROL, V78, P2749, DOI 10.1128/JVI.78.6.2749-2757.2004; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cotsiki M, 2004, P NATL ACAD SCI USA, V101, P947, DOI 10.1073/pnas.0308006100; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JH, 2002, J NEUROCHEM, V82, P1540, DOI 10.1046/j.1471-4159.2002.01105.x; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; Spruck CH, 2002, CANCER RES, V62, P4535; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; VANROY F, 1983, J VIROL, V45, P442, DOI 10.1128/JVI.45.1.442-446.1983; Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S0002-9343(03)00087-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Wu XH, 2004, GENE DEV, V18, P1305, DOI 10.1101/gad.1182804; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	48	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7654	7658		10.1074/jbc.M413377200	http://dx.doi.org/10.1074/jbc.M413377200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611062	hybrid			2022-12-27	WOS:000227395700028
J	Syme, CA; Friedman, PA; Bisello, A				Syme, CA; Friedman, PA; Bisello, A			Parathyroid hormone receptor trafficking contributes to the activation of extracellular signal-regulated kinases but is not required for regulation of cAMP signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; EGF RECEPTOR; CELL-PROLIFERATION; BETA-ARRESTIN; ENDOCYTOSIS; TRANSACTIVATION; INTERNALIZATION; PHOSPHORYLATION; STIMULATION; PEPTIDE	Agonist-mediated activation of the type 1 parathyroid hormone receptor (PTH1R) results in several signaling events and receptor endocytosis. It is well documented that arrestins contribute to desensitization of both G(s)- and G(q)-mediated signaling and mediate PTH1R internalization. However, whether PTH1R trafficking directly contributes to signaling remains unclear. To address this question, we investigated the role of PTH1R trafficking in cAMP signaling and activation of extracellular signal-regulated kinases ERK1/2 in HEK-293 cells. Dominant negative forms of dynamin (K44A-dynamin) and beta-arrestin1 (beta-arrestin1-(319-418)) abrogated PTH1R internalization but had no effect on cAMP signaling; neither acute cAMP production by PTH nor desensitization and resensitization of cAMP signaling were affected. Therefore, PTH1R trafficking is not necessary for regulation of cAMP signaling. PTH-(1- 34) induced rapid and robust activation of ERK1/2. A PTHrP-based analog ([p-benzoylphenylalanine(1), Ile(5), Arg(11,13), Tyr(36)] PTHrP-(1-36) NH2), which selectively activates the G(s)/cAMP pathway without inducing PTH1R endocytosis, failed to stimulate ERK1/2 activity. Inhibition of PTH1R endocytosis by K44A-dynamin dampened ERK1/2 activation in response to PTH-(1-34) by 69%. Incubation with the epidermal growth factor receptor inhibitor AG1478 reduced ERK1/2 phosphorylation further. In addition, ERK1/2 phosphorylation occurred following internalization of a PTH1R mutant induced by PTH-(7-34) in the absence of G protein signaling. Collectively, these data indicate that PTH1R trafficking and G(q) (but not G(s)) signaling independently contribute to ERK1/2 activation, predominantly via transactivation of the epidermal growth factor receptor.	Univ Pittsburgh, Sch Med, Div Endocrinol & Metab, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bisello, A (corresponding author), Univ Pittsburgh, Sch Med, Div Endocrinol & Metab, Dept Med, E1140 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	biselloa@msx.dept-med.pitt.edu			NIDDK NIH HHS [DK-62078] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Ahmed I, 2003, MOL ENDOCRINOL, V17, P1607, DOI 10.1210/me.2002-0040; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; Blind E, 1996, J BONE MINER RES, V11, P578; BLIND E, 1995, ENDOCRINOLOGY, V136, P4271, DOI 10.1210/en.136.10.4271; Castro M, 2002, ENDOCRINOLOGY, V143, P3854, DOI 10.1210/en.2002-220232; Chaudhary LR, 1998, MOL CELL BIOCHEM, V178, P59, DOI 10.1023/A:1006807221545; Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002-0049; Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200; Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Fujita T, 2002, J BIOL CHEM, V277, P22191, DOI 10.1074/jbc.M110364200; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MERENDINO JJ, 1986, SCIENCE, V231, P388, DOI 10.1126/science.2417317; Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Smith J, 2001, MOL ENDOCRINOL, V15, P1539, DOI 10.1210/me.15.9.1539; Sneddon WB, 2000, ENDOCRINOLOGY, V141, P4185, DOI 10.1210/en.141.11.4185; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Stewart AF, 1996, BONE, V19, P303, DOI 10.1016/S8756-3282(96)00221-9; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Tawfeek HAW, 2002, MOL ENDOCRINOL, V16, P1, DOI 10.1210/me.16.1.1; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vilardaga JP, 2002, J BIOL CHEM, V277, P8121, DOI 10.1074/jbc.M110433200; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Whitfield JF, 1999, DRUG AGING, V15, P117, DOI 10.2165/00002512-199915020-00005	49	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11281	11288		10.1074/jbc.M413393200	http://dx.doi.org/10.1074/jbc.M413393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15611080	hybrid			2022-12-27	WOS:000227761800048
J	Chen, MH; Ben-Efraim, I; Mitrousis, G; Walker-Kopp, N; Sims, PJ; Cingolani, G				Chen, MH; Ben-Efraim, I; Mitrousis, G; Walker-Kopp, N; Sims, PJ; Cingolani, G			Phospholipid scramblase 1 contains a nonclassical nuclear localization signal with unique binding site in importin alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; STRUCTURAL BASIS; PLASMA-MEMBRANE; PROTEIN IMPORT; CRYSTALLOGRAPHIC ANALYSIS; TRANSBILAYER MOVEMENT; KARYOPHERIN ALPHA; RECOGNITION; BETA; SEQUENCE	Nuclear import of proteins containing a classical nuclear localization signal (NLS) is an energy-dependent process that requires the heterodimer importin alpha/beta . Three to six basic contiguous arginine/lysine residues characterize a classical NLS and are thought to form a basic patch on the surface of the import cargo. In this study, we have characterized the NLS of phospholipid scramblase 1 (PLSCR1), a lipid-binding protein that enters the nucleus via the nonclassical NLS (257)GKISKHWTGI(266). This import sequence lacks a contiguous stretch of positively charged residues, and it is enriched in hydrophobic residues. We have determined the 2.2 angstrom crystal structure of a complex between the PLSCR1 NLS and the armadillo repeat core of vertebrate importin alpha. Our crystallographic analysis reveals that PLSCR1 NLS binds to armadillo repeats 1-4 of importin alpha, but its interaction partially overlaps the classical NLS binding site. Two PLSCR1 lysines occupy the canonical positions indicated as P2 and P5. Moreover, we present in vivo evidence that the critical lysine at position P2, which is essential in other known NLS sequences, is dispensable in PLSCR1 NLS. Taken together, these data provide insight into a novel nuclear localization signal that presents a distinct motif for binding to importin alpha.	SUNY Upsatate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13078 USA; Scripps Res Inst, La Jolla, CA 92037 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Scripps Research Institute	Cingolani, G (corresponding author), SUNY Upsatate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13078 USA.	cingolag@upstate.edu			NHLBI NIH HHS [HL63819, HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL063819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, STRUCTURE, V7, pR91, DOI 10.1016/S0969-2126(99)80060-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	46	92	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10599	10606		10.1074/jbc.M413194200	http://dx.doi.org/10.1074/jbc.M413194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15611084	hybrid			2022-12-27	WOS:000227559600105
J	Phan, QT; Fratti, RA; Prasadarao, NV; Edwards, JE; Filler, SG				Phan, QT; Fratti, RA; Prasadarao, NV; Edwards, JE; Filler, SG			N-cadherin mediates endocytosis of Candida albicans by endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM INFECTIONS; LISTERIA-MONOCYTOGENES; PROTEIN; RECEPTOR; PENETRATION; DAMAGE; IDENTIFICATION; MECHANISMS; ATTACHMENT; DIMORPHISM	Candida albicans is the most common cause of fungal bloodstream infections. To invade the deep tissues, blood-borne organisms must cross the endothelial cell lining of the vasculature. We have found previously that C. albicans hyphae, but not blastospores, invade endothelial cells in vitro by inducing their own endocytosis. Therefore, we set out to identify the endothelial cell receptor that mediates the endocytosis of C. albicans. We determined that endocytosis of C. albicans was not mediated by bridging molecules in the serum and that it was partially dependent on the presence of extracellular calcium. Using an affinity purification procedure, we discovered that endothelial cell N-cadherin bound to C. albicans hyphae but not blastospores. N-cadherin also co-localized with C. albicans hyphae that were being endocytosed by endothelial cells. Chinese hamster ovary (CHO) cells expressing human N-cadherin endocytosed significantly more C. albicans hyphae than did CHO cells expressing either human VE-cadherin or no human cadherins. The expression of N-cadherin by the CHO cells resulted in enhanced endocytosis of hyphae, but not blastospores, indicating the selectivity of the N-cadherin-mediated endocytosis. Down-regulation of endothelial cell N-cadherin expression with small interfering RNA significantly inhibited the endocytosis of C. albicans hyphae. Therefore, a novel function of N-cadherin is that it serves as an endothelial cell receptor, which mediates the endocytosis of C. albicans.	Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Los Angeles Biomed Res Inst,Div Infect Dis, Dept Med,St Johns Cardiovasc Res Ctr, Torrance, CA 90502 USA; Univ So Calif, Div Infect Dis, Childrens Hosp, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Filler, SG (corresponding author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Los Angeles Biomed Res Inst,Div Infect Dis, Dept Med,St Johns Cardiovasc Res Ctr, 1124 W Carson St, Torrance, CA 90502 USA.	sfiller@ucla.edu	Filler, Scott G/A-2779-2009	Filler, Scott G/0000-0001-7278-3700	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054928] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00425] Funding Source: Medline; NIAID NIH HHS [R01 AI9990, AI054928] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baumgartner W, 2003, J NEUROSCI, V23, P11008; Belanger PH, 2002, CELL MICROBIOL, V4, P805, DOI 10.1046/j.1462-5822.2002.00232.x; Billker O, 2002, EMBO J, V21, P560, DOI 10.1093/emboj/21.4.560; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Chang YC, 2004, INFECT IMMUN, V72, P4985, DOI 10.1128/IAI.72.9.4985-4995.2004; Cloutier M, 2003, FUNGAL GENET BIOL, V38, P133, DOI 10.1016/S1087-1845(02)00520-0; Feng QH, 1999, J BACTERIOL, V181, P6339, DOI 10.1128/JB.181.20.6339-6346.1999; FILLER SG, 1995, INFECT IMMUN, V63, P976, DOI 10.1128/IAI.63.3.976-983.1995; FONZI WA, 1993, GENETICS, V134, P717; Fratti RA, 1996, INFECT IMMUN, V64, P4714, DOI 10.1128/IAI.64.11.4714-4718.1996; Fu Y, 2002, MOL MICROBIOL, V44, P61, DOI 10.1046/j.1365-2958.2002.02873.x; GILBERTSONBEADLING SK, 1993, LAB INVEST, V69, P203; Glee PM, 2001, INFECT IMMUN, V69, P2815, DOI 10.1128/IAI.69.5.2815-2820.2001; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; HEIMARK RL, 1990, J CELL BIOL, V110, P1745, DOI 10.1083/jcb.110.5.1745; IBRAHIM AS, 1995, INFECT IMMUN, V63, P1993, DOI 10.1128/IAI.63.5.1993-1998.1995; IBRAHIM AS, 1995, INFECT IMMUN, V63, P4368, DOI 10.1128/IAI.63.11.4368-4374.1995; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jones M, 2002, ARTERIOSCL THROM VAS, V22, P1972, DOI 10.1161/01.ATV.0000036416.14084.5A; Lambert M, 2000, J CELL SCI, V113, P2207; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; Masai I, 2003, DEVELOPMENT, V130, P2479, DOI 10.1242/dev.00465; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Molinari G, 2000, CELL MICROBIOL, V2, P145, DOI 10.1046/j.1462-5822.2000.00040.x; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; PARK H, 2005, IN PRESS CELL MICROB; Pfaller MA, 2000, ANTIMICROB AGENTS CH, V44, P747, DOI 10.1128/AAC.44.3.747-751.2000; Phan QT, 2000, INFECT IMMUN, V68, P3485, DOI 10.1128/IAI.68.6.3485-3490.2000; Rangel-Frausto MS, 1999, CLIN INFECT DIS, V29, P253, DOI 10.1086/520194; Robinson EE, 2003, J CELL SCI, V116, P377, DOI 10.1242/jcs.00231; ROTROSEN D, 1985, J INFECT DIS, V152, P1264, DOI 10.1093/infdis/152.6.1264; SALOMON D, 1992, J CELL SCI, V102, P7; Santoni G, 2001, MICROB PATHOGENESIS, V31, P159, DOI 10.1006/mpat.2001.0459; Schnadelbach O, 2001, MOL CELL NEUROSCI, V17, P1084, DOI 10.1006/mcne.2001.0961; Sheppard DC, 2004, J BIOL CHEM, V279, P30480, DOI 10.1074/jbc.M401929200; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Sonneborn A, 2000, MOL MICROBIOL, V35, P386, DOI 10.1046/j.1365-2958.2000.01705.x; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Tsuchimori N, 2000, INFECT IMMUN, V68, P1997, DOI 10.1128/IAI.68.4.1997-2002.2000; Wanner IB, 2002, J NEUROSCI, V22, P4066, DOI 10.1523/JNEUROSCI.22-10-04066.2002	42	86	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10455	10461		10.1074/jbc.M412592200	http://dx.doi.org/10.1074/jbc.M412592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632157	hybrid			2022-12-27	WOS:000227559600087
J	Bian, F; Kasumov, T; Thomas, KR; Jobbins, KA; David, F; Minkler, PE; Hoppel, CL; Brunengraber, H				Bian, F; Kasumov, T; Thomas, KR; Jobbins, KA; David, F; Minkler, PE; Hoppel, CL; Brunengraber, H			Peroxisomal and mitochondrial oxidation of fatty acids in the heart, assessed from the C-13 labeling of malonyl-CoA and the acetyl moiety of citrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; DICARBOXYLIC-ACIDS; COENZYME-A; RAT-HEART; METABOLISM; LIVER; CHROMATOGRAPHY; ENRICHMENT; CARNITINE; ACETATE	We previously showed that a fraction of the acetyls used to synthesize malonyl-CoA in rat heart derives from partial peroxisomal oxidation of very long and long-chain fatty acids. The C-13 labeling ratio ( malonylCoA)/( acetyl moiety of citrate) was > 1.0 with C-13-fatty acids, which yields [C-13] acetyl-CoA in both mitochondria and peroxisomes and <1.0 with substrates, which yields [C-13] acetyl-CoA only in mitochondria. In this study, we tested the influence of C-13-fatty acid concentration and chain length on the labeling of acetyl-CoA formed in mitochondria and/or peroxisomes. Hearts were perfused with increasing concentrations of labeled docosanoate, oleate, octanoate, hexanoate, butyrate, acetate, or dodecanedioate. In contrast to the liver, peroxisomal oxidation of 1-C-13- fatty acids in heart does not form [1-C-13] acetate. With [1-C-13] docosanoate and [ 1,12(13)C(2)] dodecanedioate, malonyl-CoA enrichment plateaued at 11 and 9%, respectively, with no detectable labeling of the acetyl moiety of citrate. Thus, in the intact rat heart, docosanoate and dodecanedioate appear to be oxidized only in peroxisomes. With [1-C-13] oleate or [1-C-13] octanoate, the labeling ratio >1 indicates the partial peroxisomal oxidation of oleate and octanoate. In contrast, with [3-C-13] octanoate, [1-C-13] hexanoate, [1-C-13] butyrate, or [1,2-C-13(2)] acetate, the labeling ratio was <0.7 at all concentrations. Therefore, in rat heart, ( i) n-fatty acids shorter than 8 carbons do not undergo peroxisomal oxidation, ( ii) octanoate undergoes only one cycle of peroxisomal beta-oxidation, ( iii) there is no detectable transfer to the mitochondria of acetyl-CoA from the cytosol or the peroxisomes, and ( iv) the capacity of C-2 - C-18 fatty acids to generate mitochondrial acetyl-CoA decreases with chain length.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxb8@case.edu			NIA NIH HHS [2PO1AG015885] Funding Source: Medline; NIDDK NIH HHS [R01DK035543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abbas AS, 1998, J MOL CELL CARDIOL, V30, P1305, DOI 10.1006/jmcc.1998.0693; Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Baes M, 2000, J BIOL CHEM, V275, P16329, DOI 10.1074/jbc.M001994200; BERGSETH S, 1990, BIOCHIM BIOPHYS ACTA, V1042, P182, DOI 10.1016/0005-2760(90)90005-I; CERDAN S, 1988, J BIOL CHEM, V263, P11664; CONNOCK MJ, 1983, BIOCHEM INT, V6, P545; Dyck JRB, 2004, CIRC RES, V94, pE78, DOI 10.1161/01.RES.0000129255.19569.8f; Dyck JRB, 2002, J MOL CELL CARDIOL, V34, P1099, DOI 10.1006/jmcc.2002.2060; Fraser Fiona, 1996, Biochemical Society Transactions, V24, p184S; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Goodwin GW, 1998, AM J PHYSIOL-HEART C, V274, pH1239, DOI 10.1152/ajpheart.1998.274.4.H1239; Ha J, 1996, P NATL ACAD SCI USA, V93, P11466, DOI 10.1073/pnas.93.21.11466; HARRISON EH, 1988, AM J PHYSIOL, V255, pH441, DOI 10.1152/ajpheart.1988.255.3.H441; HOVIK R, 1991, J LIPID RES, V32, P993; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Kasumov T, 2002, ANAL BIOCHEM, V305, P90, DOI 10.1006/abio.2002.5639; KVANNES J, 1994, BBA-GEN SUBJECTS, V1201, P203, DOI 10.1016/0304-4165(94)90042-6; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; LINN TC, 1979, J BIOL CHEM, V254, P1691; Longnus SL, 2001, AM J PHYSIOL-HEART C, V281, pH1561, DOI 10.1152/ajpheart.2001.281.4.H1561; LOPASCHUK GD, 1992, MOL CELL BIOCHEM, V116, P111, DOI 10.1007/BF01270577; LOPASCHUK GD, 1994, BBA-LIPID LIPID MET, V1213, P263, DOI 10.1016/0005-2760(94)00082-4; MINKLER PE, 1995, ANAL BIOCHEM, V231, P315, DOI 10.1006/abio.1995.0057; Mueller S, 2002, BIOCHEM J, V363, P483, DOI 10.1042/0264-6021:3630483; Poirier M, 2002, AM J PHYSIOL-HEART C, V283, pH1379, DOI 10.1152/ajpheart.00244.2002; POWERS L, 1995, J MASS SPECTROM, V30, P747, DOI 10.1002/jms.1190300514; Ramsay Rona R., 2004, Molecular Aspects of Medicine, V25, P475, DOI 10.1016/j.mam.2004.06.002; Reszko AE, 2004, J BIOL CHEM, V279, P19574, DOI 10.1074/jbc.M400162200; Reszko AE, 2001, ANAL BIOCHEM, V298, P69, DOI 10.1006/abio.2001.5349; Reszko AE, 2004, J BIOL CHEM, V279, P34298, DOI 10.1074/jbc.M405488200; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Sambandam N, 2004, EUR J BIOCHEM, V271, P2831, DOI 10.1111/j.1432-1033.2004.04218.x; SKORIN C, 1992, BIOCHEM J, V281, P561, DOI 10.1042/bj2810561; Stanley William C, 2002, Heart Fail Rev, V7, P115, DOI 10.1023/A:1015320423577; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; Taegtmeyer H, 2004, ANN NY ACAD SCI, V1015, P202, DOI 10.1196/annals.1302.017; URNISS BS, 1989, VOGELS TXB PRACTICAL, P680; VAMECQ J, 1989, AM J PHYSIOL, V256, pG680, DOI 10.1152/ajpgi.1989.256.4.G680; VAMECQ J, 1989, J BIOCHEM-TOKYO, V106, P216, DOI 10.1093/oxfordjournals.jbchem.a122835; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VOET D, 1998, FUNDAMENTALS BIOCH, P569; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; ZHANG Y, 1994, J BIOL CHEM, V269, P11025	44	37	37	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9265	9271		10.1074/jbc.M412850200	http://dx.doi.org/10.1074/jbc.M412850200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611129	hybrid			2022-12-27	WOS:000227453100077
J	Fillebeen, C; Rivas-Estilla, AM; Bisaillon, M; Ponka, P; Muckenthaler, M; Hentze, MW; Koromilas, AE; Pantopoulos, K				Fillebeen, C; Rivas-Estilla, AM; Bisaillon, M; Ponka, P; Muckenthaler, M; Hentze, MW; Koromilas, AE; Pantopoulos, K			Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA THERAPY; METAL-ION BINDING; NITRIC-OXIDE; HEMOCHROMATOSIS; IDENTIFICATION; MULTICENTER; EXPRESSION; REDUCTION; REPLICONS; RIBAVIRIN	Clinical data suggest that iron is a negative factor in chronic hepatitis C; however, the molecular mechanisms by which iron modulates the infectious cycle of hepatitis C virus (HCV) remain elusive. To explore this, we utilized cells expressing a HCV replicon as a well-established model for viral replication. We demonstrate that iron administration dramatically inhibits the expression of viral proteins and RNA, without significantly affecting its translation or stability. Experiments with purified recombinant HCV RNA polymerase (NS5B) revealed that iron binds specifically and with high affinity (apparent K-d: 6 and 60 muM for Fe2+ and Fe3+, respectively) to the protein's Mg2+-binding pocket, thereby inhibiting its enzymatic activity. We propose that iron impairs HCV replication by inactivating NS5B and that its negative effects in chronic hepatitis C may be primarily due to attenuation of antiviral immune responses. Our data provide a direct molecular link between iron and HCV replication.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; European Mol Biol Lab, D-69117 Heidelberg, Germany; McGill Univ, Fac Med, Montreal, PQ H3G 1Y6, Canada	Lady Davis Institute; McGill University; University of Sherbrooke; European Molecular Biology Laboratory (EMBL); McGill University	Koromilas, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	antonis.koromilas@mcgill.ca; kostas.pantopoulos@mcgill.ca	Hentze, Matthias W/V-3980-2017; Ponka, Prem/A-4123-2011; Pantopoulos, Kostas/A-9668-2008	Hentze, Matthias W/0000-0002-4023-7876; Pantopoulos, Kostas/0000-0002-2305-0057; Ponka, Prem/0000-0001-5835-1477; Muckenthaler, Martina/0000-0002-3778-510X				Akiyoshi F, 1997, AM J GASTROENTEROL, V92, P1463; Ali N, 2002, J VIROL, V76, P12001, DOI 10.1128/JVI.76.23.12001-12007.2002; Ali S, 2004, J VIROL, V78, P491, DOI 10.1128/JVI.78.1.491-501.2004; Bartenschlager R, 2002, NAT REV DRUG DISCOV, V1, P911, DOI 10.1038/nrd942; BARTON AL, 1995, AM J CLIN PATHOL, V103, P419; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Benzaghou I, 2004, J BIOL CHEM, V279, P49755, DOI 10.1074/jbc.M409657200; Bonkovsky HL, 2002, J HEPATOL, V37, P848, DOI 10.1016/S0168-8278(02)00305-7; Bost AG, 2003, J VIROL, V77, P4401, DOI 10.1128/JVI.77.7.4401-4408.2003; Bougie I, 2003, J BIOL CHEM, V278, P3868, DOI 10.1074/jbc.M209785200; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; DESOUSA M, 1988, ANN NY ACAD SCI, V526, P310; Di Bisceglie AM, 2000, HEPATOLOGY, V32, P135, DOI 10.1053/jhep.2000.8700; Distante S, 2002, LIVER, V22, P269, DOI 10.1046/j.0106-9543.2002.01672.x; Diwakaran HH, 2002, J HEPATOL, V36, P687, DOI 10.1016/S0168-8278(02)00018-1; Fargion S, 2002, AM J GASTROENTEROL, V97, P1204; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Haq F, 2003, MUTAT RES-FUND MOL M, V533, P211, DOI 10.1016/j.mrfmmm.2003.07.014; Hardy RW, 2003, J VIROL, V77, P2029, DOI 10.1128/JVI.77.3.2029-2037.2003; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Ioannou George N, 2002, Semin Gastrointest Dis, V13, P95; Johnson RB, 2000, ARCH BIOCHEM BIOPHYS, V377, P129, DOI 10.1006/abbi.2000.1749; Kakizaki S, 2000, LIVER, V20, P125, DOI 10.1034/j.1600-0676.2000.020002125.x; KARUPIAH G, 1995, J EXP MED, V181, P2171, DOI 10.1084/jem.181.6.2171; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; Pellerin C, 2002, BIOCHEM BIOPH RES CO, V295, P682, DOI 10.1016/S0006-291X(02)00743-X; Pianko S, 2002, J INTERF CYTOK RES, V22, P483, DOI 10.1089/10799900252952271; Pietrangelo A, 1996, SEMIN LIVER DIS, V16, P13, DOI 10.1055/s-2007-1007215; Pietrangelo A, 2003, GASTROENTEROLOGY, V124, P1509, DOI 10.1016/S0016-5085(03)00275-0; PONKA P, 1985, J BIOL CHEM, V260, P4717; Randall G, 2001, CURR OPIN INFECT DIS, V14, P743, DOI 10.1097/00001432-200112000-00013; Rivas-Estilla AM, 2002, J VIROL, V76, P10637, DOI 10.1128/JVI.76.21.10637-10653.2002; Sartori M, 2001, DIGEST LIVER DIS, V33, P157, DOI 10.1016/S1590-8658(01)80072-4; Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806; Sherrington CA, 2002, LIVER, V22, P187, DOI 10.1046/j.0106-9543.2002.00002.x; Shi ST, 2001, CELL MOL LIFE SCI, V58, P1276, DOI 10.1007/PL00000939; Sievert W, 2002, AM J GASTROENTEROL, V97, P982; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Theurl I, 2004, J INFECT DIS, V190, P819, DOI 10.1086/422261; Tung BY, 2003, GASTROENTEROLOGY, V124, P318, DOI 10.1053/gast.2003.50046; Walker EM, 2000, ANN CLIN LAB SCI, V30, P354; Weiss G, 2002, EUR J CLIN INVEST, V32, P70, DOI 10.1046/j.1365-2362.2002.0320s1070.x; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; Wilson JE, 2000, MOL CELL BIOL, V20, P4990, DOI 10.1128/MCB.20.14.4990-4999.2000	48	84	88	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9049	9057		10.1074/jbc.M412687200	http://dx.doi.org/10.1074/jbc.M412687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637067	hybrid			2022-12-27	WOS:000227453100053
J	Iwasaki, T; Kounosu, A; Tao, Y; Li, ZR; Shokes, JE; Cosper, NJ; Imai, T; Urushiyama, A; Scott, RA				Iwasaki, T; Kounosu, A; Tao, Y; Li, ZR; Shokes, JE; Cosper, NJ; Imai, T; Urushiyama, A; Scott, RA			Rational design of a mononuclear metal site into the archaeal Rieske-type protein scaffold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; IRON-SULFUR CLUSTERS; CLOSTRIDIUM-PASTEURIANUM RUBREDOXIN; ABSORPTION SPECTROSCOPIC ANALYSIS; ELECTRON-TRANSFER REACTIONS; FE-S PROTEINS; RESONANCE RAMAN; THERMUS-THERMOPHILUS; PYROCOCCUS-FURIOSUS; 2FE-2S PROTEINS	Proteins containing Rieske-type [2Fe-2S] clusters play essential functions in all three domains of life. We engineered the two histidine ligands to the Rieske-type [2Fe2S] cluster in the hyperthermophilic archaeal Rieske-type ferredoxin from Sulfolobus solfataricus to modify types and spacing of ligands and successfully converted the metal and cluster type at the redox-active site with a minimal structural change to a native Rieske-type protein scaffold. Spectroscopic analyses unambiguously established a rubredoxin-type mononuclear Fe3+/2+ center at the engineered local metal-binding site ( Zn2+ occupies the iron site depending on the expression conditions). These results show the importance of types and spacing of ligands in the in vivo cluster recognition/ insertion/ assembly in biological metallosulfur protein scaffolds. We suggest that early ligand substitution and displacement events at the local metal-binding site(s) might have primarily allowed the metal and cluster type conversion in ancestral redox protein modules, which greatly enhanced their capabilities of conducting a wide range of unique redox chemistry in biological electron transfer conduits, using a limited number of basic protein scaffolds.	Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Chinese Acad Sci, Synchrotron Radiat Facil, Inst High Energy Phys, Beijing 100039, Peoples R China; Rikkyo Univ, Dept Chem, Toshima Ku, Tokyo 1718501, Japan; Univ Georgia, Dept Chem, Athens, GA 30602 USA	Nippon Medical School; Nippon Medical School; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Rikkyo University; University System of Georgia; University of Georgia	Scott, RA (corresponding author), Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	scott@chem.uga.edu	Li, Zhongrui/AAB-9111-2019; Li, Zhongrui/I-4872-2017	Li, Zhongrui/0000-0001-5371-7628; Tao, Ye/0000-0003-4770-4921; Scott, Robert/0000-0003-2236-1336; Iwasaki, Toshio/0000-0001-9562-4649	NIGMS NIH HHS [GM 42025] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MWW, 2002, J BIOL INORG CHEM, V7, P647, DOI 10.1007/s00775-002-0359-x; ADAMS MWW, 1992, ADV INORG CHEM, V38, P341, DOI 10.1016/S0898-8838(08)60068-9; Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; Colbert CL, 2000, STRUCTURE, V8, P1267, DOI 10.1016/S0969-2126(00)00536-0; Cosper NJ, 2002, PROTEIN SCI, V11, P2969, DOI 10.1110/ps.0222402; Cosper NJ, 2001, J BIOCHEM, V130, P191, DOI 10.1093/oxfordjournals.jbchem.a002972; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; CZAJA C, 1995, J BIOL CHEM, V270, P20273, DOI 10.1074/jbc.270.35.20273; Dauter Z, 1996, P NATL ACAD SCI USA, V93, P8836, DOI 10.1073/pnas.93.17.8836; DAY MW, 1992, PROTEIN SCI, V1, P1494, DOI 10.1002/pro.5560011111; DeGrado WF, 1999, ANNU REV BIOCHEM, V68, P779, DOI 10.1146/annurev.biochem.68.1.779; Dikanov SA, 2004, J BIOL INORG CHEM, V9, P753, DOI 10.1007/s00775-004-0571-y; EIDSNESS MK, 1992, PROTEIN ENG, V5, P367, DOI 10.1093/protein/5.4.367; Frazzon J, 2002, BIOCHEM SOC T, V30, P680, DOI 10.1042/BST0300680; FU WG, 1992, J BIOL CHEM, V267, P15502; George GN, 1996, J BIOL INORG CHEM, V1, P226, DOI 10.1007/s007750050047; HAGEN WR, 1992, ADV INORG CHEM, V38, P165, DOI 10.1016/S0898-8838(08)60064-1; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; Hay M, 1996, P NATL ACAD SCI USA, V93, P461, DOI 10.1073/pnas.93.1.461; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Hunsicker-Wang LM, 2003, BIOCHEMISTRY-US, V42, P7303, DOI 10.1021/bi0342719; Iwasaki T, 2000, J BIOL CHEM, V275, P25391, DOI 10.1074/jbc.M909243199; Iwasaki T, 2004, J AM CHEM SOC, V126, P4788, DOI 10.1021/ja031976p; Iwasaki T, 2002, J BIOL CHEM, V277, P39642, DOI 10.1074/jbc.M207312200; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Jones LH, 2003, J BIOL CHEM, V278, P47269, DOI 10.1074/jbc.M308863200; Kounosu A, 2004, J BIOL CHEM, V279, P12519, DOI 10.1074/jbc.M305923200; Li ZR, 2003, BIOCHEMISTRY-US, V42, P15003, DOI 10.1021/bi035078h; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Link TA, 1999, ADV INORG CHEM, V47, P83, DOI 10.1016/S0898-8838(08)60077-X; Lu Y, 2001, CHEM REV, V101, P3047, DOI 10.1021/cr0000574; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; Meyer J, 1997, BIOCHEMISTRY-US, V36, P13374, DOI 10.1021/bi971775w; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Rees DC, 2002, ANNU REV BIOCHEM, V71, P221, DOI 10.1146/annurev.biochem.71.110601.135406; SAITO H, 1991, B CHEM SOC JPN, V64, P829, DOI 10.1246/bcsj.64.829; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Williams PA, 1999, NAT STRUCT BIOL, V6, P509; Wilmanns M, 1995, P NATL ACAD SCI USA, V92, P11955, DOI 10.1073/pnas.92.26.11955; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; Xiao ZG, 1998, J AM CHEM SOC, V120, P4135, DOI 10.1021/ja973162c; Yano T, 2001, J BIOENERG BIOMEMBR, V33, P213, DOI 10.1023/A:1010782903144; Zickermann V, 1997, BIOCHEMISTRY-US, V36, P3232, DOI 10.1021/bi962040e	52	10	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9129	9134		10.1074/jbc.M414051200	http://dx.doi.org/10.1074/jbc.M414051200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632131	hybrid			2022-12-27	WOS:000227453100062
J	Ramakrishnan, SN; Lau, P; Burke, LJ; Muscat, GEO				Ramakrishnan, SN; Lau, P; Burke, LJ; Muscat, GEO			Rev-erb beta regulates the expression of genes involved in lipid absorption in skeletal muscle cells - Evidence for cross-talk between orphan nuclear receptors and myokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; MESSENGER-RNA EXPRESSION; ROR-ALPHA; TRANSGENIC MICE; DEFICIENT MICE; ACTIN GENE; SUPERFAMILY; IDENTIFICATION; RVR; METABOLISM	Rev-erbbeta is an orphan nuclear receptor that selectively blocks trans-activation mediated by the retinoic acid-related orphan receptor-alpha (RORalpha). RORalpha has been implicated in the regulation of high density lipoprotein cholesterol, lipid homeostasis, and inflammation. Rev-erbbeta and RORalpha are expressed in similar tissues, including skeletal muscle; however, the pathophysiological function of Rev-erbbeta has remained obscure. We hypothesize from the similar expression patterns, target genes, and overlapping cognate sequences of these nuclear receptors that Rev-erbbeta regulates lipid metabolism in skeletal muscle. This lean tissue accounts for > 30% of total body weight and 50% of energy expenditure. Moreover, this metabolically demanding tissue is a primary site of glucose disposal, fatty acid oxidation, and cholesterol efflux. Consequently, muscle has a significant role in insulin sensitivity, obesity, and the blood-lipid profile. We utilize ectopic expression in skeletal muscle cells to understand the regulatory role of Rev-erbbeta in this major mass peripheral tissue. Exogenous expression of a dominant negative version of mouse Rev-erbbeta decreases the expression of many genes involved in fatty acid/lipid absorption (including Cd36, and Fabp-3 and -4). Interestingly, we observed a robust induction (> 15-fold) in mRNA expression of interleukin-6, an "exercise-induced myokine" that regulates energy expenditure and inflammation. Furthermore, we observed the dramatic repression (> 20- fold) of myostatin mRNA, another myokine that is a negative regulator of muscle hypertrophy and hyperplasia that impacts on body fat accumulation. This study implicates Rev-erbbeta in the control of lipid and energy homoeostasis in skeletal muscle. In conclusion, we speculate that selective modulators of Rev-erbbeta may have therapeutic utility in the treatment of dyslipidemia and regulation of muscle growth.	Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, St Lucia, Qld 4072, Australia	University of Queensland	Muscat, GEO (corresponding author), Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	g.muscat@imb.uq.edu.au	; Muscat, George/A-6401-2017	Burke, Lez/0000-0002-2932-6843; Muscat, George/0000-0002-5829-5695; Lau, Patrick/0000-0002-9693-390X				Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Attie AD, 2002, J LIPID RES, V43, P1899, DOI 10.1194/jlr.M200189-JLR200; Auwerx J, 1999, CELL, V97, P161; Bois-Joyeux B, 2000, DNA CELL BIOL, V19, P589, DOI 10.1089/104454900750019344; BONNELYE E, 1994, CELL GROWTH DIFFER, V5, P1357; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Bruce CR, 2004, AM J PHYSIOL-ENDOC M, V287, pE616, DOI 10.1152/ajpendo.00150.2004; Burke L, 1996, NUCLEIC ACIDS RES, V24, P3481, DOI 10.1093/nar/24.18.3481; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; Clapham JC, 2001, BIOCHEM BIOPH RES CO, V287, P1058, DOI 10.1006/bbrc.2001.5698; Coste H, 2002, J BIOL CHEM, V277, P27120, DOI 10.1074/jbc.M203421200; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; Delerive P, 2002, J BIOL CHEM, V277, P35013, DOI 10.1074/jbc.M202979200; Di Gregorio GB, 2004, AM J PHYSIOL-ENDOC M, V287, pE182, DOI 10.1152/ajpendo.00189.2003; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; DUNWOODIE SL, 1994, J BIOL CHEM, V269, P12212; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; ENMARK E, 1994, BIOCHEM BIOPH RES CO, V204, P49, DOI 10.1006/bbrc.1994.2424; Esterbauer H, 1999, CLIN CHEM, V45, P331; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Faldt J, 2004, ENDOCRINOLOGY, V145, P2680, DOI 10.1210/en.2003-1319; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Holst D, 2003, BBA-MOL CELL BIOL L, V1633, P43, DOI 10.1016/S1388-1981(03)00071-4; Lau P, 2004, J BIOL CHEM, V279, P36828, DOI 10.1074/jbc.M404927200; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; Migita H, 2004, FEBS LETT, V561, P69, DOI 10.1016/S0014-5793(04)00118-8; Migita H, 2004, FEBS LETT, V557, P269, DOI 10.1016/S0014-5793(03)01502-3; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V283, P785, DOI 10.1006/bbrc.2001.4848; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Pircher P, 2005, AM J PHYSIOL-REG I, V288, pR482, DOI 10.1152/ajpregu.00690.2003; Raspe E, 2002, J LIPID RES, V43, P2172, DOI 10.1194/jlr.M200386-JLR200; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; SHANI M, 1988, MOL CELL BIOL, V8, P1006, DOI 10.1128/MCB.8.2.1006; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Wang S, 2002, ANN NY ACAD SCI, V967, P112; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1	50	68	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8651	8659		10.1074/jbc.M413949200	http://dx.doi.org/10.1074/jbc.M413949200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623503	hybrid			2022-12-27	WOS:000227453100006
J	Miller, F; Kentsis, A; Osman, R; Pan, ZQ				Miller, F; Kentsis, A; Osman, R; Pan, ZQ			Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL(.)hypoxia-inducible transcription factor-1 alpha complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; HIPPEL-LINDAU-DISEASE; RENAL-CELL CARCINOMA; UBIQUITIN LIGASE; MOLECULAR-DYNAMICS; GERMLINE MUTATIONS; PROLYL HYDROXYLATION/; REGULATE HIF; GENE; ALPHA	The von Hippel-Lindau ( VHL) gene product, pVHL, targets the alpha subunit of the hypoxia-inducible transcription factor ( HIF-alpha) for ubiquitin-dependent degradation. This tumor suppressor function is mediated by the alpha- and beta-domains responsible for assembling the pVHL E3 ubiquitin ligase complex and for recognizing the prolyl-hydroxylated HIF-alpha, respectively. The molecular basis for a large number of tumor-derived mutations can be attributed to alterations that directly compromise the ability of pVHL to assemble the E3 or to contact the substrate. Here we describe a new mechanism of oncogenic inactivation by VHL missense mutations that lie in the L1 and L7 linker regions distal to the HIF-alpha-binding pocket. Employing molecular dynamics simulations, we show that the tumorigenic L1 loop mutation of Ser(65) to Leu, deficient in promoting the degradation of HIF-alpha, disrupts the coordination of internal motions of the pVHL(.)HIF-1alpha complex. Furthermore, we demonstrate that in addition to S65L, five other tumor-derived VHL mutations located within the L1 loop are each defective in mediating proteolysis of HIF-2alpha. Moreover, dynamic organization of pVHL(.)HIF-1alpha recognition is focally centered on Gln(145) within the L7 loop, and its tumorigenic mutant Q145H abolishes almost all of the correlated dynamic motions. Intriguingly, Q145H, whereas defective in targeting cellular HIF-alpha for degradation, had an attenuated hydroxylation dependence in binding to HIF(.)1alpha in vitro. Taken together, our results suggest that specific association between pVHL and the hydroxylated HIF-alpha requires both the L1 and L7 loops to coordinate dynamic coupling among distant pVHL regions, whose mutational disruption inactivates VHL and is hence responsible for tumorigenesis.	CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pan, ZQ (corresponding author), CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.	zhen-qiang.pan@mssm.edu		Kentsis, Alex/0000-0002-8063-9191	NCI NIH HHS [CA095634, CA111515, CA063317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063317, R01CA095634, R01CA111515] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brauch H, 1999, JNCI-J NATL CANCER I, V91, P854, DOI 10.1093/jnci/91.10.854; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chillemi G, 2003, NUCLEIC ACIDS RES, V31, P1525, DOI 10.1093/nar/gkg242; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gallou C, 1999, HUM MUTAT, V13, P464, DOI 10.1002/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Karplus M, 2002, ACCOUNTS CHEM RES, V35, P321, DOI 10.1021/ar020082r; Klein TE, 1999, BIOPOLYMERS, V49, P167; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Leung Albert C, 2002, Expert Rev Anticancer Ther, V2, P673, DOI 10.1586/14737140.2.6.673; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Ma JP, 2000, J MOL BIOL, V302, P303, DOI 10.1006/jmbi.2000.4014; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Martin R, 1998, Hum Mutat, V12, P71, DOI 10.1002/(SICI)1098-1004(1998)12:1<71::AID-HUMU14>3.3.CO;2-1; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ohh Michael, 2003, Methods Mol Biol, V222, P167; Olschwang S, 1998, HUM MUTAT, V12, P424, DOI 10.1002/(SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.3.CO;2-8; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; Tai K, 2001, BIOPHYS J, V81, P715, DOI 10.1016/S0006-3495(01)75736-0; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; van der Harst E, 1998, INT J CANCER, V77, P337, DOI 10.1002/(SICI)1097-0215(19980729)77:3<337::AID-IJC5>3.3.CO;2-C; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	45	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7985	7996		10.1074/jbc.M413160200	http://dx.doi.org/10.1074/jbc.M413160200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611064	hybrid			2022-12-27	WOS:000227395700068
J	Muller, P; Ceskova, P; Vojtesek, B				Muller, P; Ceskova, P; Vojtesek, B			Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53 - Implications for cancer therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; P21(WAF1/CIP1) EXPRESSION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; MOLECULAR CHAPERONE; MDM2; GENE; MUTATIONS; ASSOCIATION	Several signaling pathways that monitor the dynamic state of the cell converge on the tumor suppressor p53. The ability of p53 to process these signals and exert a dynamic downstream response in the form of cell cycle arrest and/or apoptosis is crucial for preventing tumor development. This p53 function is abrogated by p53 gene mutations leading to alteration of protein conformation. Hsp90 has been implicated in regulating both wild-type and mutant p53 conformations, and Hsp90 antagonists are effective for the therapy of some human tumors. Using cell lines that contain human tumor-derived temperature-sensitive p53 mutants we show that Hsp90 is required for both stabilization and reactivation of mutated p53 at the permissive temperature. A temperature decrease to 32degreesC causes conversion to a protein conformation that is capable of inducing expression of MDM2, leading to reduction of reactivated p53 levels by negative feedback. Mutant reactivation is enhanced by simultaneous treatment with agents that stabilize the reactivated protein and is blocked by geldanamycin, a specific inhibitor of Hsp90 activity, indicating that Hsp90 antagonist therapy and therapies that act to reactivate mutant p53 will be incompatible. In contrast, Hsp90 is not required for maintaining wild-type p53 or for stabilizing wild-type p53 after treatment with chemotherapeutic agents, indicating that Hsp90 therapy might synergize with conventional therapies in patients with wild-type p53. Our data demonstrate the importance of the precise characterization of the interaction between p53 mutants and stress proteins, which may shed valuable information for fighting cancer via the p53 tumor suppressor pathway.	Masaryk Mem Canc Inst, Dept Expt Oncol, Brno 65653, Czech Republic	Masaryk Memorial Cancer Institute	Vojtesek, B (corresponding author), Masaryk Mem Canc Inst, Dept Expt Oncol, Zluty Kopec 7, Brno 65653, Czech Republic.	vojtesek@mou.cz	Muller, Petr/AAK-5014-2021; Muller, Petr/F-7762-2015	Muller, Petr/0000-0002-8404-4494; Muller, Petr/0000-0002-8404-4494				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARTEK J, 1991, ONCOGENE, V6, P1699; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Coates PJ, 2003, J PATHOL, V201, P377, DOI 10.1002/path.1456; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Fredersdorf S, 1996, AM J PATHOL, V148, P825; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hainaut P, 2002, NAT MED, V8, P21, DOI 10.1038/nm0102-21; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maki CG, 1996, CANCER RES, V56, P2649; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1987, ONCOGENE, V1, P453; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Vasilevskaya IA, 2003, CANCER RES, V63, P3241; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200; Zylicz M, 2001, IUBMB LIFE, V51, P283	60	50	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6682	6691		10.1074/jbc.M412767200	http://dx.doi.org/10.1074/jbc.M412767200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15613472	hybrid			2022-12-27	WOS:000227332700056
J	Uelhoff, A; Tatzelt, J; Aguzzi, A; Winklhofer, KF; Haass, C				Uelhoff, A; Tatzelt, J; Aguzzi, A; Winklhofer, KF; Haass, C			A pathogenic PrP mutation and Doppel interfere with polarized sorting of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PURKINJE-CELL DEGENERATION; BETA-PEPTIDE PRODUCTION; EXPERIMENTAL SCRAPIE; EPITHELIAL-CELLS; MDCK CELLS; IN-VIVO; MEMBRANE; MICE; ATAXIA	Several proteins linked to neurodegenerative diseases, such as the beta-amyloid precursor protein, amyloid beta-peptide, beta-secretase, and tau, undergo selective polarized sorting. We investigated polarized sorting of the mammalian prion protein (PrPC) and its homologue doppel (Dpl). In contrast to Dpl, which accumulates on the apical surface, PrPC is targeted selectively to the basolateral side in Madin-Darby canine kidney cells. An extensive deletion and domain swapping analysis revealed that the internal hydrophobic domain (HD) of PrP (amino acids 113-133) confers basolateral sorting in a dominant manner. PrP mutants lacking the HD are sorted apically, while Dpl chimeras containing the HD of PrP are directed to the basolateral membrane. Furthermore, a pathogenic PrP missense mutation within the HD leads to aberrant apical sorting of PrP as well.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	Max Planck Society; University of Zurich; University Zurich Hospital; University of Munich	Winklhofer, KF (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.	winklhof@biochem.mpg.de	Aguzzi, Adriano/A-3351-2008	Tatzelt, Jorg/0000-0001-5017-5528; Winklhofer, Konstanze/0000-0002-7256-8231; Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heske J, 2004, J BIOL CHEM, V279, P5435, DOI 10.1074/jbc.M309570200; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOSIK KS, 1991, J CELL SCI, P69; Li AM, 2000, AM J PATHOL, V157, P1447, DOI 10.1016/S0002-9440(10)64782-7; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Nishida N, 1999, LAB INVEST, V79, P689; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Sarnataro D, 2002, TRAFFIC, V3, P810, DOI 10.1034/j.1600-0854.2002.31106.x; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Tatzelt J, 1999, J NEUROPATH EXP NEUR, V58, P1244, DOI 10.1097/00005072-199912000-00005; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; Weissmann C, 1996, COLD SPRING HARB SYM, V61, P511; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Winklhofer KF, 2003, J BIOL CHEM, V278, P14961, DOI 10.1074/jbc.M209942200; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431	35	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5137	5140		10.1074/jbc.C400560200	http://dx.doi.org/10.1074/jbc.C400560200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15615717	hybrid, Green Accepted			2022-12-27	WOS:000227217100004
J	Calloni, G; Zoffoli, S; Stefani, M; Dobson, CM; Chiti, F				Calloni, G; Zoffoli, S; Stefani, M; Dobson, CM; Chiti, F			Investigating the effects of mutations on protein aggregation in the cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; MOLECULAR CHAPERONES; STABILITY; DEGRADATION; PROPENSITY; TOXICITY; INSIGHTS; PEPTIDE; CYTOSOL; CHARGE	The conversion of peptides and proteins into highly ordered and intractable aggregates is associated with a range of debilitating human diseases and represents a widespread problem in biotechnology. Protein engineering studies carried out in vitro have shown that mutations promote aggregation when they either destabilize the native state of a globular protein or accelerate the conversion of unfolded or partially folded conformations into oligomeric structures. We have extended such studies to investigate protein aggregation in vivo where a number of additional factors able to modify dramatically the aggregation behavior of proteins are present. We have expressed, in Escherichia coli cells, an E. coli protein domain, HypF-N. The results for a range of mutational variants indicate that although mutants with a conformational stability similar to that of the wild-type protein are soluble in the E. coli cytosol, variants with single point mutations predicted to destabilize the protein invariably aggregate after expression. We show, however, that aggregation of destabilized variants can be prevented by incorporating multiple mutations designed to reduce the intrinsic propensity of the polypeptide chain to aggregate; in the cases discussed here, this is achieved by an increase in the net charge of the protein. These results suggest that the principles being established to rationalize aggregation behavior in vitro have general validity for situations in vivo where aggregation has both biotechnological and medical relevance.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Cambridge; University of Florence	Dobson, CM (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cmd44@cam.ac.uk		STEFANI, MASSIMO/0000-0002-4490-1922; Calloni, Giulia/0000-0002-7216-929X				Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Calamai M, 2003, BIOCHEMISTRY-US, V42, P15078, DOI 10.1021/bi030135s; Calloni G, 2003, J MOL BIOL, V330, P577, DOI 10.1016/S0022-2836(03)00627-2; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Carrio MM, 2002, J BIOTECHNOL, V96, P3, DOI 10.1016/S0168-1656(02)00032-9; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 1999, NAT STRUCT BIOL, V6, P1005; Chiti F, 2002, P NATL ACAD SCI USA, V99, P16419, DOI 10.1073/pnas.212527999; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Chiti F, 2001, PROTEIN SCI, V10, P879, DOI 10.1110/ps.42401; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dougan DA, 2002, CELL MOL LIFE SCI, V59, P1607, DOI 10.1007/PL00012487; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Green NS, 2003, J AM CHEM SOC, V125, P13404, DOI 10.1021/ja030294z; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoffmann F, 2001, BIOTECHNOL BIOENG, V72, P315, DOI 10.1002/1097-0290(20010205)72:3<315::AID-BIT8>3.0.CO;2-G; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; KLEIN J, 1995, APPL ENVIRON MICROB, V61, P1220, DOI 10.1128/AEM.61.4.1220-1225.1995; Minton AP, 2000, CURR BIOL, V10, pR97, DOI 10.1016/S0960-9822(00)00301-8; Modesti A, 1995, PROTEIN EXPRES PURIF, V6, P799, DOI 10.1006/prep.1995.0011; Otzen DE, 2000, P NATL ACAD SCI USA, V97, P9907, DOI 10.1073/pnas.160086297; Quintas A, 2001, J BIOL CHEM, V276, P27207, DOI 10.1074/jbc.M101024200; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Relini A, 2004, J MOL BIOL, V338, P943, DOI 10.1016/j.jmb.2004.03.054; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Schlieker C, 2002, J BIOTECHNOL, V96, P13, DOI 10.1016/S0168-1656(02)00033-0; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Tjernberg L, 2002, J BIOL CHEM, V277, P43243, DOI 10.1074/jbc.M205570200; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Villegas V, 2000, PROTEIN SCI, V9, P1700, DOI 10.1110/ps.9.9.1700; Waldo GS, 2003, CURR OPIN CHEM BIOL, V7, P33, DOI 10.1016/S1367-5931(02)00017-0; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211	45	72	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10607	10613		10.1074/jbc.M412951200	http://dx.doi.org/10.1074/jbc.M412951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15611128	hybrid			2022-12-27	WOS:000227559600106
J	Chang, CC; Lin, DY; Fang, HI; Chen, RH; Shih, HM				Chang, CC; Lin, DY; Fang, HI; Chen, RH; Shih, HM			Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR SMAD4; FAS-BINDING-PROTEIN; SUMO-1 MODIFICATION; INDUCED APOPTOSIS; NUCLEAR; ACTIVATION; DOMAINS; PML; SIGNAL; COACTIVATORS	Daxx has been shown to function as an apoptosis regulator and transcriptional repressor via its interaction with various cytoplasmic and nuclear proteins. Here, we showed that Daxx interacts with Smad4 and represses its transcriptional activity via the C-terminal domain of Daxx. In vitro and in vivo interaction studies indicated that the binding of Smad4 to Daxx depends on Smad4 sumoylation. Substitution of Smad4 SUMO conjugation residue lysine 159, but not 113, to arginine not only disrupted Smad4-Daxx interaction but also relieved Daxx-elicited repression of Smad4 transcriptional activity. Furthermore, chromatin immunoprecipitation analyses revealed the recruitment of Daxx to an endogenous, Smad4-targeted promoter in a Lys(159) sumoylation-dependent manner. Finally, down-regulation of Daxx expression by RNA interference enhanced transforming growth factor beta-induced transcription of reporter and endogenous genes through a Smad4-dependent, but not K159R-Smad4-dependent, manner. Together, these results indicate that Daxx suppresses Smad4-mediated transcriptional activity by direct interaction with the sumoylated Smad4 and identify a novel role of Daxx in regulating transforming growth factor beta signaling.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 11529, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Life Sci, Natl Def Med Ctr, Taipei 11529, Taiwan; Natl Taiwan Univ, Coll Med, Div Mol & Genom Med, Natl Hlth Res Inst, Taipei 11529, Taiwan	National Taiwan University; National Defense Medical Center; National Taiwan University; National Health Research Institutes - Taiwan; National Taiwan University	Shih, HM (corresponding author), Acad Sinica, Inst Biomed Sci, Academia RD, 128,Sec 2, Taipei 11529, Taiwan.	hmshih@ibms.sinica.edu.tw	Shih, Hsiu-Ming/S-7023-2018					Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kim DW, 2003, MOL CELL BIOL, V23, P8704, DOI 10.1128/MCB.23.23.8704-8717.2003; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, CURR OPIN CELL BIOL, V12, P641, DOI 10.1016/S0955-0674(00)00144-7; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Long JY, 2004, BIOCHEM J, V379, P23, DOI 10.1042/BJ20031867; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 2001, J CELL SCI, V114, P4359; Obradovic D, 2004, MOL PHARMACOL, V65, P761, DOI 10.1124/mol.65.3.761; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Song JJ, 2003, J CELL BIOCHEM, V90, P304, DOI 10.1002/jcb.10619; Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	67	98	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10164	10173		10.1074/jbc.M409161200	http://dx.doi.org/10.1074/jbc.M409161200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637079	hybrid, Green Published			2022-12-27	WOS:000227559600053
J	Chen, ZH; Stokes, DL; Jones, LR				Chen, ZH; Stokes, DL; Jones, LR			Role of leucine 31 of phospholamban in structural and functional interactions with the Ca2+ pump of cardiac sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; INTERACTION SITE; CROSS-LINKING; CALCIUM-PUMP; CA2+-ATPASE; ATPASE; DOMAIN; INHIBITION; FORMS; THAPSIGARGIN	The ability of two loss-of-function mutants, L31A and L31C, of phospholamban (PLB) to bind to and inhibit the Ca2+ pump of cardiac sarcoplasmic reticulum (SERCA2a) was investigated using a molecular cross-linking approach. Leu(31) of PLB, located at the cytoplasmic membrane boundary, is a critical amino acid shown previously to be essential for Ca2+-ATPase inhibition. We observed that L31A or L31C mutations of PLB prevented the inhibition of Ca2+-ATPase activity and disabled the cross-linking of N27C and N30C of PLB to Lys(328) and Cys(318) of SERCA2a. Although L31C-PLB failed to cross-link to any Cys or Lys residue of wild-type SERCA2a, L31C did cross-link with high efficiency to T317C of SERCA2a with use of the homobifunctional sulfhydryl cross-linking reagent, 1,6-bismaleimidohexane. This places Leu(31) of PLB within 10 angstrom of Thr(317) of SERCA2a in the M4 helix. Thus, contrary to previous suggestions, PLB with loss-of-function mutations at Leu(31) retains the ability to bind to SERCA2a, despite losing inhibitory activity. Cross-linking of L31C-PLB to T317C-SERCA2a occurred only in the absence of Ca2+ and in the presence of nucleotide and was prevented by thapsigargin and by anti-PLB antibody, demonstrating for a fourth cross-linking pair that PLB interacts near M4 only when the Ca2+ pump is in the Ca2+-free, nucleotide-bound E2 conformation, but not in the E2 state inhibited by thapsigargin. L31I-PLB retained full functional and cross-linking activity, suggesting that a bulky hydrophobic residue at position 31 of PLB is essential for productive interaction with SERCA2a. A model for the three-dimensional structure of the interaction site is proposed.	Krannert Cardiovasc Res Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Indiana University System; Indiana University-Purdue University Indianapolis; New York University; New York University	Chen, ZH (corresponding author), Krannert Cardiovasc Res Inst, 1800 N Capitol Ave, Indianapolis, IN 46202 USA.	lrjones@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049428, R01HL049428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428] Funding Source: Medline; NIGMS NIH HHS [GM56960] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chen ZH, 2003, J BIOL CHEM, V278, P48348, DOI 10.1074/jbc.M309545200; Cornea RL, 2002, BIOPHYS J, V82, p527A; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; Haghighi K, 2004, BIOCHEM BIOPH RES CO, V322, P1214, DOI 10.1016/j.bbrc.2004.07.164; Hutter MC, 2002, CHEMBIOCHEM, V3, P1200, DOI 10.1002/1439-7633(20021202)3:12<1200::AID-CBIC1200>3.0.CO;2-H; INESI G, 1994, J MEMBRANE BIOL, V141, P1; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; Jones LR, 2002, J BIOL CHEM, V277, P28319, DOI 10.1074/jbc.M204085200; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Lamberth S, 2000, HELV CHIM ACTA, V83, P2141, DOI 10.1002/1522-2675(20000906)83:9<2141::AID-HLCA2141>3.0.CO;2-W; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SIMMERMAN HKB, 1989, BIOCHIM BIOPHYS ACTA, V997, P322, DOI 10.1016/0167-4838(89)90203-3; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; TATULIAN SA, 1995, BIOCHEMISTRY-US, V34, P4448, DOI 10.1021/bi00013a038; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WEGENER AD, 1986, J BIOL CHEM, V261, P5154	29	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10530	10539		10.1074/jbc.M414007200	http://dx.doi.org/10.1074/jbc.M414007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644311	hybrid			2022-12-27	WOS:000227559600097
J	Hoffmann, E; Thiefes, A; Buhrow, D; Dittrich-Breiholz, O; Schneider, H; Resch, K; Kracht, M				Hoffmann, E; Thiefes, A; Buhrow, D; Dittrich-Breiholz, O; Schneider, H; Resch, K; Kracht, M			MEK1-dependent delayed expression of Fos-related antigen-1 counteracts c-Fos and p65 NF-kappa B-mediated interleukin-8 transcription in response to cytokines or growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSACTIVATION DOMAIN; TUMOR-NECROSIS-FACTOR; IMMEDIATE-EARLY GENE; PROTEIN-KINASE; IN-VIVO; SIGNAL-TRANSDUCTION; INFLAMMATORY GENES; CELL-PROLIFERATION; DELTA-DOMAIN; CANCER CELLS	Binding sites for the dimeric transcription factor activator protein ( AP)-1 are found in numerous immunoregulatory and inflammatory genes. The precise mechanisms by which AP-1 activates or represses immune response genes and in particular the roles of individual AP-1 subunits in inflammatory responses are largely unknown. We report here that c-Fos and Fos-related antigen-1 ( Fra-1), two inducible components of AP-1, are recruited to the endogenous interleukin ( IL)-8 promoter in an IL-1 dependent manner. c-Fos activates IL-8 transcription and synergizes in this effect with p65 NF-kappaB. In contrast, Fra-1 strongly inhibits inducible IL-8 transcription. Fra-1 activation involves its stabilization, ubiquitination, and interaction with histone deacetylase-1. Blockade of MEK1 by PD98059 suppresses c-Fos and Fra-1 expression and, thus, affects two counteractive signals for IL-8 mRNA synthesis simultaneously. This disturbs the inducible recruitment of TATA box-binding protein and RNA polymerase II to the IL-8 promoter. Additional experiments reveal that, in conjunction with p65 NF-kappaB, the MEK1-ERK-dependent synthesis of c- Fos and Fra- 1 serves to adjust the overall expression level of IL-8 in response to two of its physiological inducers, IL-1 and epidermal growth factor. Relative to c-Fos, the delayed recruitment of Fra-1 to the IL-8 promoter provides an example how AP-1 subunits may dampen excessive chemokine synthesis.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany	Hannover Medical School	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kracht.Michael@MH-Hannover.DE		Kracht, Michael/0000-0002-8501-043X; Hoffmann-Lucke, Elke/0000-0002-2437-0140				ABATE C, 1991, ONCOGENE, V6, P2179; Acquaviva C, 2001, BIOCHIMIE, V83, P357, DOI 10.1016/S0300-9084(01)01243-3; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Bhattacharyya A, 2002, BIOCHEM J, V368, P121, DOI 10.1042/BJ20020555; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; Bruder JT, 1997, J VIROL, V71, P398, DOI 10.1128/JVI.71.1.398-404.1997; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Cook SJ, 1999, MOL CELL BIOL, V19, P330; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Freund A, 2004, ONCOGENE, V23, P6105, DOI 10.1038/sj.onc.1207815; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Grassl GA, 2003, CELL MICROBIOL, V5, P957, DOI 10.1046/j.1462-5822.2003.00339.x; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Holzberg D, 2003, J BIOL CHEM, V278, P40213, DOI 10.1074/jbc.M304058200; Hungness ES, 2000, SHOCK, V14, P386, DOI 10.1097/00024382-200014030-00025; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOVACS EJ, 1986, J IMMUNOL, V137, P3649; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; LIN JX, 1987, J BIOL CHEM, V262, P11908; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Schreiber M, 2000, DEVELOPMENT, V127, P4937; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Terasawa K, 2003, GENES CELLS, V8, P263, DOI 10.1046/j.1365-2443.2003.00631.x; Tkach V, 2003, ONCOGENE, V22, P5045, DOI 10.1038/sj.onc.1206570; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Treinies I, 1999, MOL CELL BIOL, V19, P321; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Ventura JJ, 2003, MOL CELL BIOL, V23, P2871, DOI 10.1128/MCB.23.8.2871-2882.2003; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Wenzel A, 2002, J NEUROCHEM, V80, P1089, DOI 10.1046/j.0022-3042.2002.00807.x; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; Wu GD, 1997, J BIOL CHEM, V272, P2396; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	59	98	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9706	9718		10.1074/jbc.M407071200	http://dx.doi.org/10.1074/jbc.M407071200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615716	hybrid			2022-12-27	WOS:000227453100128
J	de Pereda, JM; Wegener, KL; Santelli, E; Bate, N; Ginsberg, MH; Critchley, DR; Campbell, ID; Liddington, RC				de Pereda, JM; Wegener, KL; Santelli, E; Bate, N; Ginsberg, MH; Critchley, DR; Campbell, ID; Liddington, RC			Structural basis for phosphatidylinositol phosphate kinase type I gamma binding to Talin at focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-1-NMR SPECTRA; DOMAIN; SPECTROSCOPY; ENHANCEMENT; ACTIVATION; ASSIGNMENT; INTEGRINS; PROTEINS; PROGRAM; REGION	The cytoskeletal protein talin binds to a short C- terminal sequence in phosphatidylinositol phosphate kinase type I gamma ( PIPKI gamma), activating the enzyme and promoting the local production of phosphatidylinositol 4,5 bisphosphate, which regulates focal adhesion dynamics as well as clathrin- mediated endocytosis in neuronal cells. Here we show by crystallographic, NMR, and calorimetric analysis that the phosphotyrosine binding ( PTB)- like domain of talin engages the PIPKI gamma C terminus in a mode very similar to that of integrin binding. However, PIPKI gamma binds in the canonical PTB- peptide mode with an SPLH motif replacing the classic NPXY motif. The tighter packing of the SPLH motif against the hydrophobic core of talin may explain the stronger binding of PIPKI gamma. Two tyrosine residues flanking the SPLH motif ( Tyr- 644 and Tyr- 649) have been implicated in the regulation of talin binding. We show that phosphorylation at Tyr- 644, a Src phosphorylation site in vivo, has little effect on the binding mode or strength, which is consistent with modeling studies in which the phosphotyrosine makes surface- exposed salt bridges, and we suggest that its strong activating effect arises from the release of autoinhibitory restraints in the fulllength PIPKI gamma. Modeling studies suggest that phosphorylation of Tyr- 649 will likewise have little effect on talin binding, whereas phosphorylation of the SPLH serine is predicted to be strongly disruptive. Our data are consistent with the proposal that Src activity promotes a switch from integrin binding to PIPKI gamma binding that regulates focal adhesion turnover.	Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Oxford; University of Leicester; University of California System; University of California San Diego	Liddington, RC (corresponding author), Burnham Inst, Program Cell Adhes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org	de Pereda, Jose M/F-1733-2010; Wegener, Kate/E-5077-2010; de Pereda, Jose M/AAE-5226-2022	de Pereda, Jose M/0000-0002-8912-6739; Wegener, Kate/0000-0002-1562-6060; de Pereda, Jose M/0000-0002-8912-6739				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Liddington RC, 2003, CURR BIOL, V13, pR94, DOI 10.1016/S0960-9822(03)00035-6; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Roussel A, 1991, SILICON GRAPHICS GEO, P86; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TAPLEY P, 1989, ONCOGENE, V4, P325; Ulmer TS, 2003, BIOCHEMISTRY-US, V42, P8307, DOI 10.1021/bi034384s; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Xu D, 1997, PROTEIN ENG, V10, P999, DOI 10.1093/protein/10.9.999	33	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8381	8386		10.1074/jbc.M413180200	http://dx.doi.org/10.1074/jbc.M413180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623515	hybrid			2022-12-27	WOS:000227395700114
J	Liao, H; Bu, WY; Wang, TH; Ahmed, S; Xiao, ZC				Liao, H; Bu, WY; Wang, TH; Ahmed, S; Xiao, ZC			Tenascin-R plays a role in neuroprotection via its distinct domains that coordinate to modulate the microglia function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; JANUSIN; LOCALIZATION; J1-160/180; EVENTS	Microglia are one of the main cell types activated by brain injury. In the present study, we have investigated how domains of the extracellular matrix molecule tenascin-R (TN- R) modulate microglia function. We found that epidermal growth factor- like repeats inhibited adhesion and migration of microglia via a protein kinase A- dependent mechanism. In contrast, fibronectin 6 - 8 repeats promoted adhesion and migration of the primary microglia via a protein kinase C- dependent mechanism. Both domains of TN- R induced an up- regulation in the secretion of cytokines, such as chemokine- induced cytokine 3 and tumor neurosis factor alpha. Interestingly, epidermal growth factor- like repeats and fibronectin 6 - 8 induced a dramatic up- regulation in the secretion of brain- derived neurotrophic factorbeta transforming growth factor- beta and nerve growth factorbeta transforming growth factor- beta, respectively, and conditioned medium from activated microglia was able to promote neurite outgrowth of N1E- 115 cells and primary cortical neurons. These results suggest that TN- R plays a role in neuroprotection through distinct domains coordinating to modulate microglia function.	Singapore Gen Hosp, Neurobiol Lab, Dept Clin Res, Singapore 169609, Singapore; Ctr Mol Med, Singapore 117609, Singapore; Sichuan Univ, Coll Preclin & Forens Med, Dept Histol Embryol & Neurobiol, Chengdu 610065, Peoples R China; Inst Mol & Cell Biol, Singapore 117609, Singapore	Singapore General Hospital; Sichuan University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Xiao, ZC (corresponding author), Singapore Gen Hosp, Neurobiol Lab, Dept Clin Res, Block A,7 Hosp Dr, Singapore 169608, Singapore.	gcrxzc@sgh.com.sg	xiao, zhicheng/A-1529-2011	xiao, zhicheng/0000-0001-5172-762X				Angelov DN, 1998, J NEUROSCI, V18, P6218; BARTSCH U, 1993, GLIA, V9, P57, DOI 10.1002/glia.440090108; Collins L, 2003, J NEUROSCI METH, V125, P113, DOI 10.1016/S0165-0270(03)00042-6; Deryugina EI, 1996, J CELL SCI, V109, P643; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1986, J NEUROSCI, V6, P2163; HAMILTON SP, 1994, GLIA, V11, P326, DOI 10.1002/glia.440110405; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LOCHTER A, 1994, EUR J NEUROSCI, V6, P597, DOI 10.1111/j.1460-9568.1994.tb00304.x; Moore S, 1996, PROG NEUROBIOL, V48, P441, DOI 10.1016/0301-0082(95)00051-8; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x; Xiao ZC, 1997, J NEUROSCI RES, V49, P698, DOI 10.1002/(SICI)1097-4547(19970915)49:6<698::AID-JNR4>3.0.CO;2-2; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; Xiao ZC, 1997, J BIOL CHEM, V272, P32092, DOI 10.1074/jbc.272.51.32092; Xiao ZC, 1998, J NEUROSCI RES, V52, P390, DOI 10.1002/(SICI)1097-4547(19980515)52:4<390::AID-JNR3>3.3.CO;2-6	20	58	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8316	8323		10.1074/jbc.M412730200	http://dx.doi.org/10.1074/jbc.M412730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615725	hybrid			2022-12-27	WOS:000227395700106
J	Rose, JJ; Janvier, K; Chandrasekhar, S; Sekaly, RP; Bonifacino, JS; Venkatesano, S				Rose, JJ; Janvier, K; Chandrasekhar, S; Sekaly, RP; Bonifacino, JS; Venkatesano, S			CD4 down-regulation by HIV-1 and simian immunodeficiency virus (SIV) nef proteins involves both internalization and intracellular retention mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 ENVELOPE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; DILEUCINE MOTIF; SORTING PATHWAYS; CLATHRIN ADAPTER; BINDING SURFACE; VACCINIA VIRUS; COATED PITS; IN-VITRO; BETA-COP	Among the pleiotropic effects of Nef proteins of HIV and simian immunodeficiency virus ( SIV), down-modulation of cell surface expression of CD4 is a prominent phenotype. It has been presumed that Nef proteins accelerate endocytosis of CD4 by linking the receptor to the AP-2 clathrin adaptor. However, the related AP-1 and AP-3 adaptors have also been shown to interact with Nef, hinting at role( s) for these complexes in the intracellular retention of CD4. By using genetic inhibitors of endocytosis and small interfering RNA-induced knockdown of AP-2, we show that accelerated CD4 endocytosis is not a dominant mechanism of HIV-1( NL4-3 strain) Nef in epithelial cells, T lymphocyte cell lines, or peripheral blood lymphocytes. Furthermore, we show that both the CD4 recycling from the plasma membrane and the nascent CD4 in transit to the plasma membrane are susceptible to intracellular retention in HIV-1 Nef-expressing cells. In contrast, AP-2-mediated enhanced endocytosis constitutes the predominant mechanism for SIV ( MAC-239 strain) Nef-induced down-regulation of human CD4 in human cells.	NIAID, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Montreal, Montreal, PQ H3C 3J7, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universite de Montreal	Venkatesano, S (corresponding author), NIAID, Mol Biol Lab, NIH, Bldg 10,Rm 6A05, Bethesda, MD 20892 USA.	svls@nih.gov	Janvier, Katy/O-7780-2017	Janvier, Katy/0000-0002-3105-4736; Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000528, ZIAAI000528] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Benmerah A, 1999, J CELL SCI, V112, P1303; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; Bentham M, 2003, J GEN VIROL, V84, P2705, DOI 10.1099/vir.0.19274-0; Boehm M, 2002, GENE, V286, P175, DOI 10.1016/S0378-1119(02)00422-5; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BOUR S, 1991, J VIROL, V65, P6387, DOI 10.1128/JVI.65.12.6387-6396.1991; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Bresnahan PA, 1999, J IMMUNOL, V163, P2977; BRODER CC, 1993, J VIROL, V67, P913, DOI 10.1128/JVI.67.2.913-926.1993; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; GOLDING H, 1995, J VIROL, V69, P6140, DOI 10.1128/JVI.69.10.6140-6148.1995; Gratton S, 1996, J IMMUNOL, V157, P3305; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; HARRIS MPG, 1994, J MOL BIOL, V241, P136; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Janvier K, 2001, J VIROL, V75, P3971, DOI 10.1128/JVI.75.8.3971-3976.2001; Kim YH, 1999, VIROLOGY, V257, P208, DOI 10.1006/viro.1999.9642; KOENIG S, 1990, J IMMUNOL, V145, P127; Lock M, 1999, EMBO J, V18, P2722, DOI 10.1093/emboj/18.10.2722; MAITRA RK, 1991, VIROLOGY, V182, P522, DOI 10.1016/0042-6822(91)90593-Z; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; Mangasarian A, 1999, J VIROL, V73, P1964, DOI 10.1128/JVI.73.3.1964-1973.1999; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; Oldridge J, 1998, TRENDS CELL BIOL, V8, P302, DOI 10.1016/S0962-8924(98)01318-X; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Preusser A, 2002, BIOCHEM BIOPH RES CO, V292, P734, DOI 10.1006/bbrc.2002.6700; Preusser A, 2001, J VIROL, V75, P3960, DOI 10.1128/JVI.75.8.3960-3964.2001; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodman JS, 2000, J CELL SCI, V113, P183; Rossi F, 1996, VIROLOGY, V217, P397, DOI 10.1006/viro.1996.0130; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Venkatesan S, 2003, MOL BIOL CELL, V14, P3305, DOI 10.1091/mbc.e02-11-0714; VENKATESAN S, 1992, J VIROL, V66, P7469, DOI 10.1128/JVI.66.12.7469-7480.1992; Wei BL, 2003, CURR HIV RES, V1, P41, DOI 10.2174/1570162033352057; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; YUWEN H, 1993, VIROLOGY, V195, P732, DOI 10.1006/viro.1993.1424	62	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7413	7426		10.1074/jbc.M409420200	http://dx.doi.org/10.1074/jbc.M409420200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611114	hybrid			2022-12-27	WOS:000227395700002
J	Senger, T; Wichard, T; Kunze, S; Gobel, C; Lerchl, J; Pohnert, G; Feussner, I				Senger, T; Wichard, T; Kunze, S; Gobel, C; Lerchl, J; Pohnert, G; Feussner, I			A multifunctional lipoxygenase with fatty acid hydroperoxide cleaving activity from the moss Physcomitrella patens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSHROOMS PSALLIOTA-BISPORA; LINOLEIC-ACID; ALPHA,BETA,GAMMA,DELTA-UNSATURATED ALDEHYDES; POSITIONAL SPECIFICITY; PRIMARY DETERMINANT; CLEAVAGE; LYASE; PURIFICATION; 1-OCTEN-3-OL; PROTEIN	A complex mixture of fatty acid-derived aldehydes, ketones, and alcohols is released upon wounding of the moss Physcomitrella patens. To investigate the formation of these oxylipins at the molecular level we isolated a lipoxygenase from P. patens, which was identified in an EST library by sequence homology to lipoxygenases from plants. Sequence analysis of the cDNA showed that it exhibits a domain structure similar to that of type2 lipoxygenases from plants, harboring an N-terminal import signal for chloroplasts. The recombinant protein was identified as arachidonate 12-lipoxygenase and linoleate 13-lipoxygenase with a preference for arachidonic acid and eicosapentaenoic acid. In contrast to any other lipoxygenase cloned so far, this enzyme exhibited in addition an unusual high hydroperoxidase and also a fatty acid chain-cleaving lyase activity. Because of these unique features the pronounced formation of (2Z)-octen- 1-ol, 1-octen-3-ol, the dienal (5Z, 8Z, 10E)-12-oxo-dodecatrienoic acid and 12-keto eicosatetraenoic acid was observed when arachidonic acid was administered as substrate. 12-Hydroperoxy eicosatetraenoic acid was found to be only a minor product. Moreover, the P. patens LOX has a relaxed substrate tolerance accepting C-18-C-22 fatty acids giving rise to even more LOX-derived products. In contrast to other lipoxygenases a highly diverse product spectrum is formed by a single enzyme accounting for most of the observed oxylipins produced by the moss. This single enzyme might, in a fast and effective way, be involved in the formation of signal and/or defense molecules thus contributing to the broad resistance of mosses against pathogens.	Max Planck Inst Chem Okol, D-07745 Jena, Germany; IPK, D-06466 Gatersleben, Germany; Univ Gottingen, Albrecht von Haller Inst Pflanzenwissensch, D-37077 Gottingen, Germany; Plant Sci Sweden AB, S-26831 Svalov, Sweden	Max Planck Society; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; University of Gottingen	Pohnert, G (corresponding author), Max Planck Inst Chem Okol, Hans Knoll Str 8, D-07745 Jena, Germany.	Pohnert@ice.mpg.de	Feussner, Ivo/H-9320-2013; Wichard, Thomas/C-2794-2009; Wichard, Thomas/L-9861-2019; Pohnert, Georg/D-3721-2013	Feussner, Ivo/0000-0002-9888-7003; Wichard, Thomas/0000-0003-0061-4160; Wichard, Thomas/0000-0003-0061-4160; Pohnert, Georg/0000-0003-2351-6336				Adolph S, 2004, J EXP BIOL, V207, P2935, DOI 10.1242/jeb.01105; Adolph S, 2003, TETRAHEDRON, V59, P3003, DOI 10.1016/S0040-4020(03)00382-X; ANDRIANARISON RH, 1991, BIOCHEM BIOPH RES CO, V180, P1002, DOI 10.1016/S0006-291X(05)81165-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; DEMBITSKY VM, 1993, PROG LIPID RES, V32, P281, DOI 10.1016/0163-7827(93)90010-T; Drexler H, 2003, J PLANT PHYSIOL, V160, P779, DOI 10.1078/0176-1617-01025; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; Feussner I, 1998, FEBS LETT, V431, P433, DOI 10.1016/S0014-5793(98)00808-4; FEUSSNER I, 2000, ENZYMES LIPID MODIFI, P309; Firn RD, 2003, NAT PROD REP, V20, P382, DOI 10.1039/b208815k; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GERWICK WH, 1994, BBA-LIPID LIPID MET, V1211, P243, DOI 10.1016/0005-2760(94)90147-3; GLASGOW WC, 1986, J BIOL CHEM, V261, P200; Hornung E, 1999, P NATL ACAD SCI USA, V96, P4192, DOI 10.1073/pnas.96.7.4192; Ianora A, 2004, NATURE, V429, P403, DOI 10.1038/nature02526; Kenrick P, 1997, NATURE, V389, P33, DOI 10.1038/37918; Koljak R, 1997, SCIENCE, V277, P1994, DOI 10.1126/science.277.5334.1994; LEPAGE G, 1984, J LIPID RES, V25, P1391; Leverentz MK, 2002, PLANT PHYSIOL, V130, P273, DOI 10.1104/pp.000919; Matsui K, 2003, BIOSCI BIOTECH BIOCH, V67, P2280, DOI 10.1271/bbb.67.2280; Nishiyama T, 2003, P NATL ACAD SCI USA, V100, P8007, DOI 10.1073/pnas.0932694100; Noordermeer MA, 2001, CHEMBIOCHEM, V2, P494, DOI 10.1002/1439-7633(20010803)2:7/8<494::AID-CBIC494>3.0.CO;2-1; Nunez A, 2000, EUR J LIPID SCI TECH, V102, P181, DOI 10.1002/(SICI)1438-9312(200003)102:3<181::AID-EJLT181>3.0.CO;2-J; Pohnert G, 2002, NAT PROD REP, V19, P108, DOI 10.1039/a806888g; Pohnert G, 2000, ANGEW CHEM INT EDIT, V39, P4352, DOI 10.1002/1521-3773(20001201)39:23<4352::AID-ANIE4352>3.0.CO;2-U; PRIGGE S, 1996, BIOCHIMIE PARIS, V79, P629; SALCH YP, 1995, PLANT PHYSIOL, V108, P1211, DOI 10.1104/pp.108.3.1211; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; Vance RE, 2004, P NATL ACAD SCI USA, V101, P2135, DOI 10.1073/pnas.0307308101; Wichard T, 2005, J CHROMATOGR B, V814, P155, DOI 10.1016/j.jchromb.2004.10.021; Wichard T, 2005, ANGEW CHEM INT EDIT, V44, P158, DOI 10.1002/anie.200460686; WURZENBERGER M, 1986, LIPIDS, V21, P261, DOI 10.1007/BF02536408; WURZENBERGER M, 1984, BIOCHIM BIOPHYS ACTA, V795, P163, DOI 10.1016/0005-2760(84)90117-6; WURZENBERGER M, 1984, BIOCHIM BIOPHYS ACTA, V794, P18, DOI 10.1016/0005-2760(84)90292-3; WURZENBERGER M, 1982, Z LEBENSM UNTERS FOR, V175, P186, DOI 10.1007/BF01139769; Zank TK, 2002, PLANT J, V31, P255, DOI 10.1046/j.1365-313X.2002.01354.x	40	77	79	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7588	7596		10.1074/jbc.M411738200	http://dx.doi.org/10.1074/jbc.M411738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611050	hybrid			2022-12-27	WOS:000227395700021
J	Vlahopoulos, S; Zimmer, WE; Jenster, G; Belaguli, NS; Balk, SP; Brinkmann, AO; Lanz, RB; Zoumpourlis, VC; Schwartz, RJ				Vlahopoulos, S; Zimmer, WE; Jenster, G; Belaguli, NS; Balk, SP; Brinkmann, AO; Lanz, RB; Zoumpourlis, VC; Schwartz, RJ			Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; PROSTATE-SPECIFIC ANTIGEN; TRANSCRIPTIONAL ACTIVATION; SKELETAL-MUSCLE; PROTEIN-INTERACTION; BINDING PROTEIN; TINMAN HOMOLOG; TESTOSTERONE; ELEMENTS; SPECIFICITY	Androgen receptor (AR) induced precocious myogenesis in culture and myogenic specified gene activity. Increased levels of AR expression in replicating C2C12 myoblasts stimulated fusion into post-differentiated multinucleated myotubes and the appearance of skeletal alpha-actin transcripts, even in the absence of ligand. Furthermore, AR activated the skeletal alpha-actin promoter, which lacks GRE sites, in co-transfected C2C12 cells. AR co-activation of the skeletal alpha-actin promoter required co-expressed full-length serum response factor (SRF). In vitro, AR associated with SRF and was recruited by SRF to a alpha-actin promoter SRF binding site. Our data suggest that AR is capable of activating myogenic genes devoid of consensus AR binding sites via its recruitment by the myogenic enriched transcription factor, SRF.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Erasmus MC, Dept Urol, NL-3000 DR Rotterdam, Netherlands; Beth Israel Deaconess Med Ctr, Dept Med, Canc Biol Program, Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Erasmus MC, Dept Reprod & Dev, Rotterdam, Netherlands; Hellen Res Fdn, Inst Biol Res & Biotechnol, Unit Biomed Applicat, Athens, Greece	Baylor College of Medicine; University of South Alabama; Erasmus University Rotterdam; Erasmus MC; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Erasmus University Rotterdam; Erasmus MC; National Hellenic Research Foundation	Schwartz, RJ (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rschwartz@ibt.tamhsc.edu	Vlahopoulos, Spiros A/A-1186-2014; Vlahopoulos, Spiros/AAK-6362-2020	Vlahopoulos, Spiros A/0000-0001-6245-3863; Vlahopoulos, Spiros/0000-0001-6245-3863; Zimmer, Warren/0000-0002-0668-6096	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL49953, R01 HL50422] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; ALEN M, 1985, INT J SPORTS MED, V6, P24, DOI 10.1055/s-2008-1025808; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Basaria S, 2001, J CLIN ENDOCR METAB, V86, P5108, DOI 10.1210/jc.86.11.5108; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P407, DOI 10.1210/jc.82.2.407; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Evans NA, 2004, AM J SPORT MED, V32, P534, DOI 10.1177/0363546503262202; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, pE601, DOI 10.1152/ajpendo.00362.2001; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1986, MOL CELL ENDOCRINOL, V46, P1, DOI 10.1016/0303-7207(86)90064-X; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; Hakkinen K, 2001, J APPL PHYSIOL, V91, P569, DOI 10.1152/jappl.2001.91.2.569; Hakkinen K, 2000, J GERONTOL A-BIOL, V55, pB95, DOI 10.1093/gerona/55.2.b95; Hayes SA, 2001, CANCER RES, V61, P2112; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herbst KL, 2004, CURR OPIN CLIN NUTR, V7, P271, DOI 10.1097/00075197-200405000-00006; Huang ZQ, 2002, MOL ENDOCRINOL, V16, P924, DOI 10.1210/me.16.5.924; INOUE K, 1994, EUR J APPL PHYSIOL O, V69, P88, DOI 10.1007/BF00867933; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; JOUBERT Y, 1995, DEV BIOL, V169, P286, DOI 10.1006/dbio.1995.1144; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kim SW, 2001, ONCOGENE, V20, P6638, DOI 10.1038/sj.onc.1204695; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEADER DP, 1986, DNA-J MOLEC CELL BIO, V5, P235, DOI 10.1089/dna.1986.5.235; Lee DK, 2002, BIOCHEM BIOPH RES CO, V294, P408, DOI 10.1016/S0006-291X(02)00504-1; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MASTROGIACOMO I, 1982, ARCH ANDROLOGY, V9, P293, DOI 10.3109/01485018208990253; Mauras N, 1998, J CLIN ENDOCR METAB, V83, P1886, DOI 10.1210/jc.83.6.1886; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Reid J, 2002, J BIOL CHEM, V277, P41247, DOI 10.1074/jbc.M205220200; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SCHWARTZ RJ, 1980, BIOCHEMISTRY-US, V19, P2506, DOI 10.1021/bi00552a032; Shahidi NT, 2001, CLIN THER, V23, P1355, DOI 10.1016/S0149-2918(01)80114-4; Sheffield-Moore M, 2000, ANN MED, V32, P181, DOI 10.3109/07853890008998825; Sheffield-Moore M, 1999, J CLIN ENDOCR METAB, V84, P2705, DOI 10.1210/jc.84.8.2705; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; URBAN RJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE820, DOI 10.1152/ajpendo.1995.269.5.E820; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; ZHU H, 1994, J BIOL CHEM, V269, P3489	61	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7786	7792		10.1074/JBC.m413992200	http://dx.doi.org/10.1074/JBC.m413992200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623502	hybrid			2022-12-27	WOS:000227395700043
J	de Avalos, SV; Su, XF; Zhang, M; Okamoto, Y; Dowhan, W; Hannun, YA				de Avalos, SV; Su, XF; Zhang, M; Okamoto, Y; Dowhan, W; Hannun, YA			The phosphatidylglycerol/cardiolipin biosynthetic pathway is required for the activation of inositol phosphosphingolipid phospholipase C, Isc1p, during growth of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANIONIC PHOSPHOLIPIDS; CARDIOLIPIN SYNTHASE; RESPIRATORY-CHAIN; PEL1 GENE; CERAMIDE; STRESS; MITOCHONDRIA; OXIDASE; SPHINGOLIPIDS; PURIFICATION	Inositolsphingolipid phospholipase C (Isc1p) is the Saccharomyces cerevisiae member of the extended family of neutral sphingomyelinases that regulates the generation of bioactive ceramides. Recently, we reported that Isc1p is post-translationally activated in the post-diauxic phase of growth and that it localizes to mitochondria (Vaena de Avalos, S., Okamoto, Y., and Hannun, Y. A. (2004) J. Biol Chem. 279,11537-11545). In this study the in vivo mechanisms of activation and function of Isc1p were investigated. Deletion of ISC1 resulted in markedly lower growth in non-fermentable carbon sources. Interestingly, the growth defect of isc1Delta strains resembled that of pgs1Delta strains, lacking the committed step in the synthesis of phosphatidylglycerol (PG) and cardiolipin (CL), which were shown to activate Isc1p in vitro. Therefore, the role of Pgs1p in activation of Isc1p in vivo was investigated. The results showed that in the pgs1Delta strain, the growth-dependent activation of Isc1p was impaired as was the ISC1-dependent increase in the levels of phytoceramide during the post-diauxic phase, demonstrating that the activation of Isc1p in vivo is dependent on PGS1 and on the mitochondrial phospholipids PG/CL. Mechanistically, loss of Isc1p resulted in lower levels of mitochondrial cytochrome c oxidase subunits cox3p and cox4p, previously established targets of both PG and CL (Ostrander, D. B., Zhang, M., Mileykovskaya, E., Rho, M., and Dowhan, W. (2001) J. Biol. Chem. 276, 25262-25272), thus suggesting that Isc1p mediates at least some functions downstream of PG/CL. This study provides the first evidence for the mechanism of in vivo activation and function of Isc1p. A model with endogenous PG/CL as the in vivo activator of Isc1p is proposed.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Texas, Sch Med, Ctr Membrane Biol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA	Medical University of South Carolina; University of Texas System; University of Texas System	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu	Zhang, Mei/G-8690-2014; OKAMOTO, Yasuo/J-8438-2015		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825, GM55389] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITCH DA, 1990, BIOCHIM BIOPHYS ACTA, V1020, P34, DOI 10.1016/0005-2728(90)90090-Q; Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4; Bielawska A, 2000, METHOD ENZYMOL, V311, P518; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; de Avalos SV, 2004, J BIOL CHEM, V279, P11537, DOI 10.1074/jbc.M309586200; DEAVALOS SV, 2004, BIOACTIVE LIPIDS, P135; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; FOLCH J, 1957, J BIOL CHEM, V226, P497; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; Jazwinski SM, 2002, INT J BIOCHEM CELL B, V34, P1491, DOI 10.1016/S1357-2725(02)00044-4; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Okamoto Y, 2003, BIOCHEMISTRY-US, V42, P7855, DOI 10.1021/bi0341354; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Perry David K, 2003, Cancer Treat Res, V115, P345; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; SNEL MME, 1995, BIOCHEMISTRY-US, V34, P3605, DOI 10.1021/bi00011a015; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Stribinskis V, 2001, GENETICS, V158, P573; SUBIK J, 1974, FEBS LETT, V42, P309, DOI 10.1016/0014-5793(74)80753-2; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Voelker DR, 2000, BBA-MOL CELL BIOL L, V1486, P97, DOI 10.1016/S1388-1981(00)00051-2; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang M, 2003, J BIOL CHEM, V278, P35204, DOI 10.1074/jbc.M306729200; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	37	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7170	7177		10.1074/jbc.M411058200	http://dx.doi.org/10.1074/jbc.M411058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611094	hybrid			2022-12-27	WOS:000227332700108
J	Martemyanov, KA; Yoo, PJ; Skiba, NP; Arshavsky, VY				Martemyanov, KA; Yoo, PJ; Skiba, NP; Arshavsky, VY			R7BP, a novel neuronal protein interacting with RGS proteins of the R7 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACCELERATING PROTEIN; BETA-SUBUNIT; MEMBRANE ANCHOR; NERVOUS-SYSTEM; SIGNALING RGS; MICE LACKING; DOMAIN; R9AP; COMPLEX; PHOTORECEPTORS	The R7 subfamily of the regulators of G protein signaling (RGS) proteins is represented by four members broadly expressed in the mammalian nervous system. Here we report that in the brain all four R7 proteins form tight complexes with a previously unidentified protein, which we call the R7-binding protein or R7BP. We initially identified R7BP as a protein co-precipitating with the R7 protein, RGS9, from extracts obtained from the striatal region of the brain. We further showed that R7BP forms a tight complex with RGS9 in vitro and that this binding occurs via the N-terminal DEP domain of RGS9. R7BP is expressed throughout the entire central nervous system but not in any of the tested non-neuronal tissues. All four R7 RGS proteins co-precipitate with R7BP from brain extracts and recombinant R7 proteins bind recombinant R7BP with high efficiency. The closest homolog of R7BP is R9A.P which was previously found to interact with RGS9 in photoreceptors. Both R7BP and R9AP are related to the syntaxin subfamily of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins involved in vesicular trafficking and exocytosis. In photoreceptors R9AP regulates several critical properties of RGS9 including its intracellular targeting, stability and catalytic activity. This suggests that R7BP interactions with R7 proteins in the brain may also bear major functional significance.	Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Arshavsky, VY (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.	vadim_arshavsky@meei.harvard.edu			NATIONAL EYE INSTITUTE [R01EY012859] Funding Source: NIH RePORTER; NEI NIH HHS [EY-12859] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bouhamdan M, 2004, BBA-MOL CELL RES, V1691, P141, DOI 10.1016/j.bbamcr.2004.01.005; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen CK, 2003, P NATL ACAD SCI USA, V100, P6604, DOI 10.1073/pnas.0631825100; Gold SJ, 1997, J NEUROSCI, V17, P8024; Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Hunt RA, 2003, BIOCHEM BIOPH RES CO, V303, P594, DOI 10.1016/S0006-291X(03)00400-5; Jones MB, 2004, MOL INTERV, V4, P200, DOI 10.1124/mi.4.4.4; Keresztes G, 2004, J BIOL CHEM, V279, P1581, DOI 10.1074/jbc.C300456200; Keresztes G, 2003, MOL CELL NEUROSCI, V24, P687, DOI 10.1016/S1044-7431(03)00231-8; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Martemyanov KA, 2004, METHOD ENZYMOL, V390, P196; Martemyanov KA, 2003, J NEUROSCI, V23, P10175; Martemyanov KA, 2003, NEURON, V38, P857, DOI 10.1016/S0896-6273(03)00320-9; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Nishiguchi KM, 2004, NATURE, V427, P75, DOI 10.1038/nature02170; Rahman Z, 1999, J NEUROSCI, V19, P2016; Rahman Z, 2003, NEURON, V38, P941, DOI 10.1016/S0896-6273(03)00321-0; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100; Zhang D., 2000, J DESERT RES, V20, P59; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	29	121	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5133	5136		10.1074/jbc.C400596200	http://dx.doi.org/10.1074/jbc.C400596200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15632198	hybrid			2022-12-27	WOS:000227217100003
J	Palacios, VG; Robinson, LJ; Borysenko, CW; Lehmann, T; Kalla, SE; Blair, HC				Palacios, VG; Robinson, LJ; Borysenko, CW; Lehmann, T; Kalla, SE; Blair, HC			Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ALPHA; BONE MASS; EXPRESSION; GENISTEIN; BETA; ESTRADIOL; APOPTOSIS; OSTEOPROTEGERIN; INHIBITOR; PATHWAYS	We studied estrogen effects on osteoclastic differentiation using RAW264.7, a murine monocytic cell line. Differentiation, in response to RANKL and colony-stimulating factor 1, was evaluated while varying estrogen receptor (ER) stimulation by estradiol or nonsteroidal ER agonists was performed. The RAW264.7 cells were found to express ER alpha but not ER beta. In contrast to RANKL, which decreased ER alpha expression and induced osteoclast differentiation, 10 nM estradiol, 3 mu M genistein, or 3 mu M daidzein all increased ER alpha expression, stimulated cell proliferation, and decreased multinucleation, with the effects of estrogen >= daidzein > genistein. However, no estrogen agonist reduced RANKL stimulation of osteoclast differentiation markers or its down-regulation of ER alpha expression by more than similar to 50%. Genistein is also an Src kinase antagonist in vitro, but it did not decrease Src phosphorylation in RAW264.7 cells relative to other estrogen agonists. However, both phytoestrogens and estrogen inhibited RANKL-induced I kappa B degradation and NF-kappa B nuclear localization with the same relative potency as seen in proliferation and differentiation assays. This study demonstrates, for the first time, the direct effects of estrogen on osteoclast precursor differentiation and shows that, in addition to effecting osteoblasts, estrogen may protect bone by reducing osteoclast production. Genistein, which activates ERs selectively, inhibited osteoclastogenesis less effectively than the nonselective phytoestrogen daidzein, which effectively reproduced effects of estrogen.	Univ Pittsburgh, Dept Pathol & Cell Biol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Physiol, Pittsburgh, PA 15261 USA; Vet Affairs Med Ctr, Pittsburgh, PA 15243 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Blair, HC (corresponding author), Univ Pittsburgh, Dept Pathol & Cell Biol, 705 Scaife Hall, Pittsburgh, PA 15261 USA.	hcblair@imap.pitt.edu		Kalla, Sara/0000-0003-2437-5352	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012951] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47700] Funding Source: Medline; NIA NIH HHS [AG12951] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950-351X(98)80003-7; Barnes S, 2000, J NUTR, V130, p656S, DOI 10.1093/jn/130.3.656S; Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756-3282(02)00953-5; Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309; Braidman IP, 2001, J BONE MINER RES, V16, P214, DOI 10.1359/jbmr.2001.16.2.214; Brubaker KD, 1999, J BONE MINER RES, V14, P1861, DOI 10.1359/jbmr.1999.14.11.1861; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Cao LH, 2003, J CELL BIOCHEM, V89, P152, DOI 10.1002/jcb.10486; Cuzzocrea S, 2003, ENDOCRINOLOGY, V144, P1098, DOI 10.1210/en.2002-220597; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; FIORELLI G, 1995, P NATL ACAD SCI USA, V92, P2672, DOI 10.1073/pnas.92.7.2672; Fonseca D, 2004, BONE, V35, P489, DOI 10.1016/j.bone.2004.03.031; FOX MH, 1980, CYTOMETRY, V1, P71, DOI 10.1002/cyto.990010114; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gao YH, 1999, BIOL PHARM BULL, V22, P805, DOI 10.1248/bpb.22.805; Guo ZY, 2002, J BIOL CHEM, V277, P7044, DOI 10.1074/jbc.M109808200; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakamura I, 2003, ENDOCRINOLOGY, V144, P4739, DOI 10.1210/en.2003-0615; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oreffo ROC, 1999, HISTOCHEM CELL BIOL, V111, P125, DOI 10.1007/s004180050342; Ramalho AC, 2002, EUR CYTOKINE NETW, V13, P39; Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539; Rickard DJ, 1999, J CELL BIOCHEM, P123; Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S; Shevde NK, 1996, BLOOD, V87, P2683, DOI 10.1182/blood.V87.7.2683.bloodjournal8772683; Su SJ, 2000, CLIN CANCER RES, V6, P230; Tobe H, 1997, BIOSCI BIOTECH BIOCH, V61, P370, DOI 10.1271/bbb.61.370; Vegeto E, 2004, J STEROID BIOCHEM, V91, P59, DOI 10.1016/j.jsbmb.2004.02.004; Viereck V, 2002, J CELL BIOCHEM, V84, P725, DOI 10.1002/jcb.10087; Wersto RP, 2001, CYTOMETRY, V46, P296, DOI 10.1002/cyto.1171; Williams JP, 1998, AM J CLIN NUTR, V68, p1369S, DOI 10.1093/ajcn/68.6.1369S	36	103	109	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13720	13727		10.1074/jbc.M410995200	http://dx.doi.org/10.1074/jbc.M410995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15644335	hybrid			2022-12-27	WOS:000228095500067
J	Dodd, DA; Niederoest, B; Bloechlinger, S; Dupuis, L; Loeffler, JP; Schwab, ME				Dodd, DA; Niederoest, B; Bloechlinger, S; Dupuis, L; Loeffler, JP; Schwab, ME			Nogo-A, -B, and -C are found on the cell surface and interact together in many different cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYTOPIC MEMBRANE-PROTEIN; NEURITE OUTGROWTH; EXPRESSION; TOPOLOGY; TRAFFICKING; INHIBITOR; REGENERATION; REGULATOR; IDENTIFICATION; CALRETICULIN	Nogo-A, -B, and -C are generated from the Nogo/RTN-4 gene and share a highly conserved C-terminal domain. They lack an N-terminal signal sequence and are predominantly localized to the endoplasmic reticulum ( ER). We found the N terminus of endogenous Nogo-A exposed on the surface of fibroblasts, DRG neurons, and myoblasts. Surface-expressed Nogo-A was also present on presynaptic terminals of the neuromuscular junction and on DRG neurons in vivo. Surface biotinylations confirmed the presence of all Nogo isoforms on the surface. To search for proteins that interact with Nogo-A and suggest a function for the large intracellular pool of Nogo-A, immunoprecipitations were performed. Surprisingly, the most predominant proteins that interact with Nogo-A are Nogo-B and Nogo-C as seen with radiolabeled lysates and as confirmed by Western blotting in multiple cell lines. Nogo-A, -B, and -C share a 180-amino acid C-terminal domain with two highly conserved hydrophobic stretches that could form a channel or transporter in the ER and/or on the cell surface.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland; Univ Louis Pasteur Strasbourg 1, Fac Med, Lab Signalisat Mol & Neurodegenerescence, F-67085 Strasbourg, France	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Dodd, DA (corresponding author), Univ Zurich, Brain Res Inst, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	dodd@hifo.unizh.ch	Schwab, Martin E/B-6818-2016; Dupuis, Luc/A-6981-2012; LOEFFLER, Jean-Philippe/AAS-4401-2020					Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Chen MG, 1999, BIOCHEMISTRY-US, V38, P5471, DOI 10.1021/bi982153t; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Di Scala F, 2005, BIOCHEM J, V385, P125, DOI 10.1042/BJ20040458; Dupuis L, 2002, NEUROBIOL DIS, V10, P358, DOI 10.1006/nbdi.2002.0522; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; FURY M, 2002, SCI STKE PE, V123; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Huber AB, 2002, J NEUROSCI, V22, P3553; Hunt D, 2003, MOL CELL NEUROSCI, V24, P1083, DOI 10.1016/j.mcn.2003.09.002; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Kleizen B, 2000, EUR J CELL BIOL, V79, P544, DOI 10.1078/0171-9335-00078; Lambert C, 2001, J BIOL CHEM, V276, P22265, DOI 10.1074/jbc.M100956200; Levy D, 1996, Essays Biochem, V31, P49; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Lipscombe D, 2002, MOL NEUROBIOL, V26, P21, DOI 10.1385/MN:26:1:021; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Magnusson C, 2003, MOL CELL NEUROSCI, V22, P298, DOI 10.1016/S1044-7431(02)00036-2; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Moussa CEH, 2004, NEUROSCI LETT, V371, P239, DOI 10.1016/j.neulet.2004.09.004; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Oertle T, 2003, FASEB J, V17, P1238, DOI 10.1096/fj.02-1166hyp; Oertle T, 2003, J NEUROSCI, V23, P5393; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; OSTAPCHUK P, 1994, EMBO J, V13, P1048, DOI 10.1002/j.1460-2075.1994.tb06353.x; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Reiness CG, 2001, MOL CELL NEUROSCI, V17, P931, DOI 10.1006/mcne.2001.0985; Ren Z, 2003, J NEUROSCI, V23, P6608; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; SIPE DM, 1991, J BIOL CHEM, V266, P3469; Tozaki H, 2002, MOL BRAIN RES, V104, P111, DOI 10.1016/S0169-328X(02)00172-9; van der Haar ME, 1998, J NEUROSCI RES, V51, P371, DOI 10.1002/(SICI)1097-4547(19980201)51:3<371::AID-JNR10>3.0.CO;2-A; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Yamaga AK, 2002, J BIOL CHEM, V277, P33228, DOI 10.1074/jbc.M202304200; Zhang W, 2003, J BIOL CHEM, V278, P50128, DOI 10.1074/jbc.M309840200	51	129	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12494	12502		10.1074/jbc.M411827200	http://dx.doi.org/10.1074/jbc.M411827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15640160	hybrid			2022-12-27	WOS:000227922000053
J	Hwang, JI; Kim, HS; Lee, JR; Kim, E; Ryu, SH; Suh, PG				Hwang, JI; Kim, HS; Lee, JR; Kim, E; Ryu, SH; Suh, PG			The interaction of phospholipase C-beta 3 with Shank2 regulates mGluR-mediated calcium signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; POSTSYNAPTIC DENSITY; SYNAPTIC PROTEINS; INTRAMOLECULAR INTERACTION; PDZ DOMAINS; FAMILY; BRAIN; HOMER; EXPRESSION; COMPLEXES	Phospholipase C-beta isozymes that are activated by G protein-coupled receptors ( GPCR) and heterotrimeric G proteins carry a PSD-95/Dlg/ZO-1 (PDZ) domain binding motif at their C terminus. Through interactions with PDZ domains, this motif may endow the PLC-beta isozyme with specific roles in GPCR signaling events that occur in compartmentalized regions of the plasma membrane. In this study, we identified the interaction of PLC-beta 3 with Shank2, a PDZ domain-containing multimodular scaffold in the postsynaptic density (PSD). The C terminus of PLC-beta 3, but not other PLC-beta isotypes, specifically interacts with the PDZ domain of Shank2. Homer 1b, a Shank-interacting protein that is linked to group I metabotropic glutamate receptors and IP3 receptors, forms a multiple complex with Shank2 and PLC-beta 3. Importantly, microinjection of a synthetic peptide specifically mimicking the C terminus of PLC-beta 3 markedly reduces the mGluR-mediated intracellular calcium response. These results demonstrate that Shank2 brings PLC-beta 3 closer to Homer 1b and constitutes an efficient mGluR-coupled signaling pathway in the PSD region of neuronal synapses.	Pohang Univ Sci & Technol, POSTECH Biotech Ctr, Dept Life Sci, Div Mol & Life Sci, Pohang 790784, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Synaptogenesis, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Pohang University of Science & Technology (POSTECH); Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Suh, PG (corresponding author), Pohang Univ Sci & Technol, POSTECH Biotech Ctr, Dept Life Sci, Div Mol & Life Sci, Rm 143,San 31,Hyoja Dong, Pohang 790784, South Korea.	pgs@postech.ac.kr	Kim, Eunjoon/C-1566-2011; Suh, Pann-Ghill/F-3610-2010	Hwang, Jong-Ik/0000-0002-0729-1782; Ryu, Sung Ho/0000-0003-0913-3048				ABE T, 1992, J BIOL CHEM, V267, P13361; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Coward K, 2004, BIOCHEM BIOPH RES CO, V313, P894, DOI 10.1016/j.bbrc.2003.12.029; Delmas P, 2004, TRENDS NEUROSCI, V27, P41, DOI 10.1016/j.tins.2003.10.013; FLOR PJ, 1996, J NEUROCHEM, V15, P3970; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kreienkamp HJ, 2000, J BIOL CHEM, V275, P32387, DOI 10.1074/jbc.C000490200; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; Sala C, 2003, J NEUROSCI, V23, P6327; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Tadokoro S, 1999, P NATL ACAD SCI USA, V96, P13801, DOI 10.1073/pnas.96.24.13801; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; TANAKA O, 1994, NEUROSCI LETT, V182, P17, DOI 10.1016/0304-3940(94)90194-5; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; YOO SH, 1994, J BIOL CHEM, V269, P12001	35	65	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12467	12473		10.1074/jbc.M410740200	http://dx.doi.org/10.1074/jbc.M410740200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15632121	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000227922000050
J	Lingwood, C; Mylvaganam, M; Minhas, F; Binnington, B; Branch, DR; Pomes, R				Lingwood, C; Mylvaganam, M; Minhas, F; Binnington, B; Branch, DR; Pomes, R			The sulfogalactose moiety of sulfoglycosphingolipids serves as a mimic of tyrosine phosphate in many recognition processes - Prediction and demonstration of Src homology 2 domain/sulfogalactose binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARYLSULFATASE-A; CRYSTAL-STRUCTURE; HELICOBACTER-PYLORI; SIGNAL-TRANSDUCTION; PLATELET-ADHESION; GROWTH-RATE; L-SELECTIN; PROTEIN; SPECIFICITY; RECEPTOR	Multiple ligand co-recognition of 3'-sulfogalactosylceramide (SGC) and sulfotyrosine initiated the comparison of SGC and sulfotyrosine and, subsequently, phosphotyrosine (pY) binding. SGC is a receptor for ligands involved in cell adhesion/microbial pathology. pY forms a Src homology domain 2 recognition motif in intracellular signaling. Using hsp70, anti-SGC, and anti-pY antibodies, ligand binding is retained following phosphate/sulfate and tyrosine/galactose substitution in SGC and sulfate/phosphate exchange in pY. Remarkable lipid-dependent binding to phosphatidylethano-lamine-conjugated sulfotyrosine suggests "microenvironmental" modulation of sulfotyrosine-containing receptors, similar to glycosphingolipids. Based on an aryl substrate-bound co-crystal of arylsulfatase A, a sulfogalactose and phosphotyrosine esterase, modeling provides a solvation basis for co-recognition. c-Src/Src homology domain 2:SGC/phosphogalactosylceramide binding confirms our hypothesis, heralding a carbohydrate-based approach to regulation of phosphotyrosinemediated recognition.	Hosp Sick Children, Res Inst, Toronto, ON M4G 1X8, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Lab Med, Toronto, ON M5S 1A8, Canada; Canadian Blood Serv, Toronto, ON M5G 2M1, Canada; Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Canadian Blood Services; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Lingwood, C (corresponding author), Hosp Sick Children, Res Inst, Toronto, ON M4G 1X8, Canada.	cling@sickkids.ca						ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Azuma T, 2004, J INFECT DIS, V189, P820, DOI 10.1086/381782; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Berntson Z, 1998, J NEUROSCI RES, V52, P559, DOI 10.1002/(SICI)1097-4547(19980601)52:5<559::AID-JNR8>3.0.CO;2-B; BHAT S, 1993, AIDS RES HUM RETROV, V9, P175, DOI 10.1089/aid.1993.9.175; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Borthakur G, 2003, J THROMB HAEMOST, V1, P1288, DOI 10.1046/j.1538-7836.2003.00156.x; BOULANGER J, 1995, J CELL PHYSIOL, V165, P7, DOI 10.1002/jcp.1041650103; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chruszcz M, 2003, J INORG BIOCHEM, V96, P386, DOI 10.1016/S0162-0134(03)00176-4; Craven RJ, 2003, SURG ONCOL, V12, P39, DOI 10.1016/S0960-7404(03)00004-5; Cunto-Amesty G, 2001, Int Rev Immunol, V20, P157, DOI 10.3109/08830180109043032; DONELLADEANA A, 1991, BIOCHIM BIOPHYS ACTA, V1095, P75, DOI 10.1016/0167-4889(91)90046-Z; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FRISCH MJ, 1998, GAUSSIAN GAUSSIAN IN; Galustian C, 2002, IMMUNOLOGY, V105, P350, DOI 10.1046/j.1365-2567.2002.01369.x; Gieselmann V, 1998, J INHERIT METAB DIS, V21, P564, DOI 10.1023/A:1005471106088; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; Ha SN, 1988, CARBOHYD RES, V180, P207, DOI 10.1016/0008-6215(88)80078-8; Hartmann E, 1997, INFECT IMMUN, V65, P1729, DOI 10.1128/IAI.65.5.1729-1733.1997; Honke K, 2002, P NATL ACAD SCI USA, V99, P4227, DOI 10.1073/pnas.032068299; Huesca M, 1996, INFECT IMMUN, V64, P2643, DOI 10.1128/IAI.64.7.2643-2648.1996; JONES JA, 1986, BIOSCIENCE REP, V6, P265, DOI 10.1007/BF01115155; JONES JA, 1985, BIOSCIENCE REP, V5, P707, DOI 10.1007/BF01117004; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Konno A, 1996, INT IMMUNOL, V8, P1905, DOI 10.1093/intimm/8.12.1905; LINGWOOD C, 1981, CAN J BIOCHEM CELL B, V59, P556, DOI 10.1139/o81-077; Lingwood CA, 1996, GLYCOCONJUGATE J, V13, P495, DOI 10.1007/BF00731435; LINGWOOD CA, 1990, BIOL REPROD, V43, P694, DOI 10.1095/biolreprod43.4.694; LINGWOOD CA, 1999, TIGG, V11, P1; Lubman OY, 2003, J MOL BIOL, V328, P655, DOI 10.1016/S0022-2836(03)00344-9; Ma XZ, 2003, EXP HEMATOL, V31, P131, DOI 10.1016/S0301-472X(02)01025-1; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Mamelak D, 2001, J BIOL CHEM, V276, P449, DOI 10.1074/jbc.M006732200; Mamelak D, 2001, CARBOHYD RES, V335, P91, DOI 10.1016/S0008-6215(01)00209-9; Mamelak D, 2001, BIOCHEMISTRY-US, V40, P3572, DOI 10.1021/bi001643u; Mamelak D, 1997, GLYCOCONJUGATE J, V14, P715, DOI 10.1023/A:1018569417218; Merten M, 2001, CIRCULATION, V104, P2955, DOI 10.1161/hc4901.100383; Mitchell DJ, 2004, INFECT IMMUN, V72, P537, DOI 10.1128/IAI.72.1.537-545.2004; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; Morichika H, 1996, CANCER, V78, P43, DOI 10.1002/(SICI)1097-0142(19960701)78:1<43::AID-CNCR8>3.3.CO;2-2; Mylvaganam M., 2003, CARBOHYDRATE BASED D, P761; PALMA R, 2001, ACS SYM SER, V769, P112; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Phipps DJ, 1996, AIDS, V10, P1191, DOI 10.1097/00002030-199609000-00003; Rawadi G, 1996, INFECT IMMUN, V64, P637, DOI 10.1128/IAI.64.2.637-643.1996; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; Roy A B, 1979, Ciba Found Symp, P177; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Stoecker PW, 1998, ANAL BIOCHEM, V258, P103, DOI 10.1006/abio.1998.2577; STROBEL G, 1990, BIOCHEM INT, V20, P343; Sun JP, 2003, J BIOL CHEM, V278, P33392, DOI 10.1074/jbc.M304693200; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; URBAN JE, 1981, CAN J MICROBIOL, V27, P1283, DOI 10.1139/m81-197; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; Wang WQ, 2003, CURR TOP MED CHEM, V3, P739, DOI 10.2174/1568026033452302; WEERACHATYANUKU.W, 2001, MOL REPROD DEV, V9999, P1; Whetstone H, 2003, BIOCHEMISTRY-US, V42, P1611, DOI 10.1021/bi026735t; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446	67	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12542	12547		10.1074/jbc.M413724200	http://dx.doi.org/10.1074/jbc.M413724200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15634687	hybrid			2022-12-27	WOS:000227922000058
J	Watts, BA; George, T; Good, DW				Watts, BA; George, T; Good, DW			The basolateral NHE1 Na+/H+ exchanger regulates transepithelial HCO3- absorption through actin cytoskeleton remodeling in renal thick ascending limb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; APICAL MEMBRANE; BICARBONATE ABSORPTION; MOLECULAR PHYSIOLOGY; PRIMARY HYPERTENSION; PROXIMAL TUBULE; ION-TRANSPORT; H+ EXCHANGE; F-ACTIN; MICE	In the renal medullary thick ascending limb ( MTAL), inhibiting the basolateral NHE1 Na+/H+ exchanger with amiloride or nerve growth factor (NGF) results secondarily in inhibition of the apical NHE3 Na+/H+ exchanger, thereby decreasing transepithelial HCO3- absorption. MTALs from rats were studied by in vitro microperfusion to identify the mechanism underlying cross-talk between the two exchangers. The basolateral addition of 10 mu M amiloride or 0.7 nM NGF decreased HCO3- absorption by 27-32%. Jasplakinolide, which stabilizes F-actin, or latrunculin B, which disrupts F-actin, decreased basal HCO3- absorption by 30% and prevented the inhibition by amiloride or NGF. Jasplakinolide had no effect on HCO3- absorption in tubules bathed with amiloride or a Na+-free bath to inhibit NHE1. Jasplakinolide and latrunculin B did not prevent inhibition of HCO3- absorption by vasopressin or stimulation by hyposmolality, factors that regulate HCO3- absorption through primary effects on apical Na+/H+ exchange. Treatment of MTALs with amiloride or NGF for 15 min decreased polymerized actin with no change in total cell actin, as assessed both by fluorescence microscopy and by actin Triton X-100 solubility. Jasplakinolide prevented amiloride-induced actin remodeling. Vasopressin, which inhibits HCO3- absorption by an amount similar to that observed with amiloride and NGF but does not act via NHE1, did not affect cellular F-actin content. These results indicate that basolateral NHE1 regulates apical NHE3 and HCO3- absorption in the MTAL by controlling the organization of the actin cytoskeleton.	Univ Texas, Med Branch, Dept Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Good, DW (corresponding author), Univ Texas, Med Branch, Dept Med, 4-200 John Sealy Annex,301 Univ Blvd, Galveston, TX 77555 USA.	dgood@utmb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038217] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38217] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpern RJ, 2000, KIDNEY, P455; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BIEMESDERFER D, 1997, AM J PHYSIOL, V273, P289; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF83; BORENSZTEIN P, 1993, AM J PHYSIOL, V264, pF354, DOI 10.1152/ajprenal.1993.264.2.F354; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CHALUMEAU C, 2001, AM J PHYSIOL, V49, pF283; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Donowitz M, 2001, CURR TOP MEMBR, V50, P437; DRENCKHAHN D, 1993, RENAL PHYSIOL BIOCH, V16, P6; Frank AE, 2002, AM J PHYSIOL-RENAL, V282, pF1120, DOI 10.1152/ajprenal.00266.2001; Good DW, 2004, AM J PHYSIOL-RENAL, V287, pF1244, DOI 10.1152/ajprenal.00176.2004; Good DW, 1996, AM J PHYSIOL-RENAL, V270, pF691, DOI 10.1152/ajprenal.1996.270.4.F691; GOOD DW, 1993, SEMIN NEPHROL, V13, P225; GOOD DW, 1990, J CLIN INVEST, V85, P1006, DOI 10.1172/JCI114530; Good DW, 2000, AM J PHYSIOL-CELL PH, V279, pC1443, DOI 10.1152/ajpcell.2000.279.5.C1443; Good DW, 1995, P NATL ACAD SCI USA, V92, P12525, DOI 10.1073/pnas.92.26.12525; Goyal S, 2003, AM J PHYSIOL-RENAL, V284, pF467, DOI 10.1152/ajprenal.00352.2002; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Karmazyn M, 1999, CIRC RES, V85, P777, DOI 10.1161/01.RES.85.9.777; KRAPF R, 1991, J CLIN INVEST, V88, P783, DOI 10.1172/JCI115377; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; KUROO M, 1995, CIRC RES, V76, P148, DOI 10.1161/01.RES.76.1.148; Mills J W, 1994, Curr Opin Nephrol Hypertens, V3, P529, DOI 10.1097/00041552-199409000-00009; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlando RA, 2001, J AM SOC NEPHROL, V12, P1589, DOI 10.1681/ASN.V1281589; Orlov SN, 1999, AM J PHYSIOL-CELL PH, V276, pC511, DOI 10.1152/ajpcell.1999.276.3.C511; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Park K, 2001, J BIOL CHEM, V276, P27042, DOI 10.1074/jbc.M102901200; Peng Y, 2001, AM J PHYSIOL-RENAL, V280, pF34, DOI 10.1152/ajprenal.2001.280.1.F34; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SIFFERT W, 1995, HYPERTENSION, V26, P649, DOI 10.1161/01.HYP.26.4.649; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Szaszi K, 2001, J BIOL CHEM, V276, P40761, DOI 10.1074/jbc.M106724200; Szaszi K, 2000, CELL PHYSIOL BIOCHEM, V10, P265, DOI 10.1159/000016358; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wang T, 1999, AM J PHYSIOL-RENAL, V277, pF298, DOI 10.1152/ajprenal.1999.277.2.F298; Wang YG, 2003, CIRC RES, V93, P776, DOI 10.1161/01.RES.0000094746.24774.DC; Watts BA, 2002, AM J PHYSIOL-RENAL, V282, pF1056, DOI 10.1152/ajprenal.00133.2001; Watts BA, 1999, J CLIN INVEST, V104, P1593, DOI 10.1172/JCI7332; Watts BA, 1999, J BIOL CHEM, V274, P7841, DOI 10.1074/jbc.274.12.7841; Wei Y, 2002, AM J PHYSIOL-RENAL, V282, pF680, DOI 10.1152/ajprenal.00229.2001; Weinman EJ, 2001, KIDNEY INT, V60, P450, DOI 10.1046/j.1523-1755.2001.060002450.x; WU MS, 1994, J MEMBRANE BIOL, V142, P323	54	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11439	11447		10.1074/jbc.M410719200	http://dx.doi.org/10.1074/jbc.M410719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644322	hybrid			2022-12-27	WOS:000227761800067
J	Bremer, E; Samplonius, DF; van Genne, L; Dijkstra, MH; Kroesen, BJ; de Leij, LFMH; Helfrich, W				Bremer, E; Samplonius, DF; van Genne, L; Dijkstra, MH; Kroesen, BJ; de Leij, LFMH; Helfrich, W			Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv : sTRAIL fusion protein with specificity for human EGFR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; MONOCLONAL-ANTIBODY; PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA CELLS; HIGH-LEVEL; IN-VIVO; CASPASE-8; ZD1839; SENSITIVITY	Epidermal growth factor receptor (EGFR) signaling inhibition by monoclonal antibodies and EGFR-specific tyrosine kinase inhibitors has shown clinical efficacy in cancer by restoring susceptibility of tumor cells to therapeutic apoptosis induction. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer agent with tumor-selective apoptotic activity. Here we present a novel approach that combines EGFR-signaling inhibition with target cell-restricted apoptosis induction using a TRAIL fusion protein with engineered specificity for EGFR. This fusion protein, scFv425:sTRAIL, comprises the EGFR-blocking antibody fragment scFv425 genetically fused to soluble TRAIL (sTRAIL). Treatment with scFv425: sTRAIL resulted in the specific accretion to the cell surface of EGFR-positive cells only. EGFR-specific binding rapidly induced a dephosphorylation of EGFR and downstream mitogenic signaling, which was accompanied by cFLIP(L) down-regulation and Bad dephosphorylation. EGFR-specific binding converted soluble scFv425: sTRAIL into a membrane-bound form of TRAIL that cross-linked agonistic TRAIL receptors in a paracrine manner, resulting in potent apoptosis induction in a series of EGFR-positive tumor cell lines. Co-treatment of EGFR-positive tumor cells with the EGFR-tyrosine kinase inhibitor Iressa resulted in a potent synergistic pro-apoptotic effect, caused by the specific down-regulation of c-FLIPL. Furthermore, in mixed culture experiments binding of scFv425: sTRAIL to EGFR-positive target cells conveyed a potent apoptotic effect toward EGFR-negative bystander tumor cells. The favorable characteristics of scFv425: sTRAIL, alone and in combination with Iressa, as well as its potent anti-tumor bystander activity indicate its potential value for treatment of EGFR-expressing cancers.	Univ Groningen, Inst Drug Explorat, Univ Med Ctr Groningen, Dept Pathol & Lab Med,Sect Med Biol,Lab Tumor Imm, NL-9713 GZ Groningen, Netherlands	University of Groningen	Helfrich, W (corresponding author), Univ Groningen Hosp, Dept Pathol & Lab Med, Sect Med Biol, Lab Tumor Immunol, Bldg CMC VII,Rm T2-228,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	w.helfrich@med.rug.nl	Bremer, Edwin S/B-7508-2016	Bremer, Edwin S/0000-0002-0325-7376; Helfrich, Wijnand/0000-0001-7004-3995				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barker AJ, 2001, BIOORG MED CHEM LETT, V11, P1911, DOI 10.1016/S0960-894X(01)00344-4; Bremer E, 2004, NEOPLASIA, V6, P636, DOI 10.1593/neo.04229; Bremer E, 2004, INT J CANCER, V109, P281, DOI 10.1002/ijc.11702; Chan KC, 2002, CANCER RES, V62, P122; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; Gabler B, 1997, ANTICANCER RES, V17, P3157; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Herberman RB, 2002, SEMIN ONCOL, V29, P27, DOI 10.1053/sonc.2002.33079; Herbst RS, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.35644; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Jonsson G, 2003, ANTICANCER RES, V23, P1213; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kortt AA, 2001, BIOMOL ENG, V18, P95, DOI 10.1016/S1389-0344(01)00090-9; Leverkus M, 2000, CANCER RES, V60, P553; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Muller KM, 1998, FEBS LETT, V432, P45, DOI 10.1016/S0014-5793(98)00829-1; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Normanno N, 2003, J CELL PHYSIOL, V194, P13, DOI 10.1002/jcp.10194; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Osaki M, 2004, J CANCER RES CLIN, V130, P8, DOI 10.1007/s00432-003-0505-z; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Park SY, 2002, BIOCHEM BIOPH RES CO, V295, P515, DOI 10.1016/S0006-291X(02)00719-2; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Power BE, 2000, J IMMUNOL METHODS, V242, P193, DOI 10.1016/S0022-1759(00)00201-5; Raben D, 2002, SEMIN ONCOL, V29, P37, DOI 10.1053/sonc.2002.31521; RODECK U, 1987, J CELL BIOCHEM, V35, P315, DOI 10.1002/jcb.240350406; RODECK U, 1987, CANCER RES, V47, P3692; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Sedger LM, 1999, J IMMUNOL, V163, P920; Solomon B, 2003, INT J RADIAT ONCOL, V55, P713, DOI 10.1016/S0360-3016(02)04357-2; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	57	78	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10025	10033		10.1074/jbc.M413673200	http://dx.doi.org/10.1074/jbc.M413673200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644326	hybrid			2022-12-27	WOS:000227559600036
J	Groen, A; Lemeer, S; van der Wijk, T; Overvoorde, J; Heck, AJR; Ostman, A; Barford, D; Slijper, M; den Hertog, J				Groen, A; Lemeer, S; van der Wijk, T; Overvoorde, J; Heck, AJR; Ostman, A; Barford, D; Slijper, M; den Hertog, J			Differential oxidation of protein-tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM CATALYTIC DOMAINS; ACTIVE-SITE CYSTEINE; IN-VIVO; REVERSIBLE INACTIVATION; CRYSTAL-STRUCTURE; REDOX REGULATION; PTP-ALPHA; SUBSTRATE-SPECIFICITY; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE	Oxidation is emerging as an important regulatory mechanism of protein-tyrosine phosphatases (PTPs). Here we report that PTPs are differentially oxidized, and we provide evidence for the underlying mechanism. The membrane-proximal RPTP alpha-D1 was catalytically active but not readily oxidized as assessed by immunoprobing with an antibody that recognized oxidized catalytic site cysteines in PTPs (oxPTPs). In contrast, the membrane-distal RPTP alpha-D2, a poor PTP, was readily oxidized. Oxidized catalytic site cysteines in PTP immunoprobing and mass spectrometry demonstrated that mutation of two residues in the Tyr(P) loop and the WPD loop that reverse catalytic activity of RPTP alpha-D1 and RPTP alpha-D2 also reversed oxidizability, suggesting that oxidizability and catalytic activity are coupled. However, catalytically active PTP1B and LAR-D1 were readily oxidized. Oxidizability was strongly dependent on pH, indicating that the microenvironment of the catalytic cysteine has an important role. Crystal structures of PTP domains demonstrated that the orientation of the absolutely conserved PTP loop arginine correlates with oxidizability of PTPs, and consistently, RPTP alpha-D1, with a similar conformation as RPTP alpha-D1, was not readily oxidized. In conclusion, PTPs are differentially oxidized at physiological pH and H2O2 concentrations, and the PTP loop arginine is an important determinant for susceptibility to oxidation.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Utrecht, Dept Biomol Mass Spect, Bijvoet Ctr Biomol Res, NL-3584 CA Utrecht, Netherlands; Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Karolinska Inst, Canc Ctr Karolinska, Dept Pathol Oncol, SE-17176 Stockholm, Sweden; Inst Canc Res, Chester Beatty Labs, London SW3 6BJ, England	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University; Karolinska Institutet; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	hertog@niob.knaw.nl	Heck, Albert/D-7098-2011; Lemeer, Simone/I-4363-2016	Heck, Albert/0000-0002-2405-4404; 				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2002, J BIOL CHEM, V277, P47263, DOI 10.1074/jbc.M205810200; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; den Hertog J, 2005, ARCH BIOCHEM BIOPHYS, V434, P11, DOI 10.1016/j.abb.2004.05.024; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jackson MD, 2001, CHEM REV, V101, P2313, DOI 10.1021/cr000247e; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Meng TC, 2004, J BIOL CHEM, V279, P37716, DOI 10.1074/jbc.M404606200; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Persson C, 2005, METHODS, V35, P37, DOI 10.1016/j.ymeth.2004.07.006; Persson C, 2004, P NATL ACAD SCI USA, V101, P1886, DOI 10.1073/pnas.0304403101; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; Peters GH, 2004, BIOCHEMISTRY-US, V43, P8418, DOI 10.1021/bi0498757; Peters GH, 2003, BIOCHIMIE, V85, P527, DOI 10.1016/S0300-9084(03)00036-1; Peters GH, 2000, J BIOL CHEM, V275, P18201, DOI 10.1074/jbc.M910273199; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Sonnenburg ED, 2003, BIOCHEMISTRY-US, V42, P7904, DOI 10.1021/bi0340503; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Van der Sar AM, 1999, INT J DEV BIOL, V43, P785; van der Wijk T, 2004, J BIOL CHEM, V279, P44355, DOI 10.1074/jbc.M407483200; van der Wijk T, 2003, J BIOL CHEM, V278, P13968, DOI 10.1074/jbc.M300632200; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	44	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10298	10304		10.1074/jbc.M412424200	http://dx.doi.org/10.1074/jbc.M412424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15623519	hybrid			2022-12-27	WOS:000227559600069
J	Percherancier, Y; Berchiche, YA; Slight, I; Volkmer-Engert, R; Tamamura, H; Fujii, N; Bouvier, M; Heveker, N				Percherancier, Y; Berchiche, YA; Slight, I; Volkmer-Engert, R; Tamamura, H; Fujii, N; Bouvier, M; Heveker, N			Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; AGONIST-DEPENDENT DISSOCIATION; WEAK PARTIAL AGONISTS; CHEMOKINE RECEPTOR; LIVING CELLS; HIV-1 INFECTION; CONSTITUTIVE OLIGOMERIZATION; INDEPENDENT DIMERIZATION; QUANTITATIVE ASSESSMENT; DISEASE PROGRESSION	Homo- and heterodimerization have emerged as prominent features of G-protein- coupled receptors with possible impact on the regulation of their activity. Using a sensitive bioluminescence resonance energy transfer system, we investigated the formation of CXCR4 and CCR2 chemokine receptor dimers. We found that both receptors exist as constitutive homo- and heterodimers and that ligands induce conformational changes within the pre-formed dimers without promoting receptor dimer formation or disassembly. Ligands with different intrinsic efficacies yielded distinct bioluminescence resonance energy transfer modulations, indicating the stabilization of distinct receptor conformations. We also found that peptides derived from the transmembrane domains of CXCR4 inhibited activation of this receptor by blocking the ligand-induced conformational transitions of the dimer. Taken together, our data support a model in which chemokine receptor homo- and heterodimers form spontaneously and respond to ligand binding as units that undergo conformational changes involving both protomers even when only one of the two ligand binding sites is occupied.	Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Charite Univ Med, Dept Mol Lib, Inst Med Immunol, D-10117 Berlin, Germany; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan	Universite de Montreal; Universite de Montreal; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Kyoto University	Heveker, N (corresponding author), Hop St Justine, Ctr Rech, 6737,3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	nikolaus.heveker@recherche-ste-justine.qc.ca	Bouvier, Michel/H-2758-2014; Heveker, Nikolaus/G-5306-2012	Bouvier, Michel/0000-0003-1128-0100; Berchiche, Yamina/0000-0002-9559-9209; Volkmer, Rudolf/0000-0003-4710-1143; percherancier, yann/0000-0002-2410-5806				Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; AYOUB MA, 2004, MOL PHARM; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Berglund MM, 2003, J PHARMACOL EXP THER, V307, P1120, DOI 10.1124/jpet.103.055673; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Canals M, 2003, J BIOL CHEM, V278, P46741, DOI 10.1074/jbc.M306451200; Charo IF, 2003, MICROCIRCULATION, V10, P259, DOI 10.1038/sj.mn.7800191; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Couturier C, 2003, J BIOL CHEM, V278, P26604, DOI 10.1074/jbc.M302002200; Di Salvo J, 2000, EUR J PHARMACOL, V409, P143, DOI 10.1016/S0014-2999(00)00846-3; Dinger MC, 2003, J BIOL CHEM, V278, P10562, DOI 10.1074/jbc.M205747200; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Foxman EF, 1999, J CELL BIOL, V147, P577, DOI 10.1083/jcb.147.3.577; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Gazi L, 2003, EUR J BIOCHEM, V270, P3928, DOI 10.1046/j.1432-1033.2003.03773.x; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Grant M, 2004, J BIOL CHEM, V279, P36179, DOI 10.1074/jbc.M407310200; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Heveker N, 2001, MOL PHARMACOL, V59, P1418, DOI 10.1124/mol.59.6.1418; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Lapidot T, 2001, ANN NY ACAD SCI, V938, P83, DOI 10.1111/j.1749-6632.2001.tb03577.x; Latif R, 2002, J BIOL CHEM, V277, P45059, DOI 10.1074/jbc.M206693200; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 1999, NATURE, V400, P723, DOI 10.1038/23382; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rodriguez-Frade JM, 2004, EMBO J, V23, P66, DOI 10.1038/sj.emboj.7600020; Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P1897, DOI 10.1016/S0960-894X(01)00323-7; Tang JM, 2002, J VIROL, V76, P662, DOI 10.1128/JVI.76.2.662-672.2002; Tarasova NI, 1999, J BIOL CHEM, V274, P34911, DOI 10.1074/jbc.274.49.34911; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Toth PT, 2004, J PHARMACOL EXP THER, V310, P8, DOI 10.1124/jpet.103.064956; Trent JO, 2003, J BIOL CHEM, V278, P47136, DOI 10.1074/jbc.M307850200; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wurch T, 2001, FEBS LETT, V507, P109, DOI 10.1016/S0014-5793(01)02969-6; Yopp AC, 2004, J IMMUNOL, V173, P855, DOI 10.4049/jimmunol.173.2.855; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200	60	213	227	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9895	9903		10.1074/jbc.M411151200	http://dx.doi.org/10.1074/jbc.M411151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632118	hybrid			2022-12-27	WOS:000227559600020
J	Bancila, V; Cens, T; Monnier, D; Chanson, F; Faure, C; Dunant, Y; Bloc, A				Bancila, V; Cens, T; Monnier, D; Chanson, F; Faure, C; Dunant, Y; Bloc, A			Two SUR1-specific histidine residues mandatory for zinc-induced activation of the rat K-ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN2+ BINDING-SITE; SENSITIVE POTASSIUM CHANNELS; PULSATILE INSULIN-SECRETION; SULFONYLUREA RECEPTOR; HIPPOCAMPAL SLICES; GLUTAMATE-RECEPTOR; DIVALENT-CATIONS; SKELETAL-MUSCLE; PLASMA-INSULIN; IDENTIFICATION	Zinc at micromolar concentrations hyperpolarizes rat pancreatic beta-cells and brain nerve terminals by activating ATP-sensitive potassium channels (K-ATP). The molecular determinants of this effect were analyzed using insulinoma cell lines and cells transfected with either wild type or mutated K-ATP subunits. Zinc activated K-ATP in cells coexpressing rat Kir6.2 and SUR1 subunits, as in insulinoma cell lines. In contrast, zinc exerted an inhibitory action on SUR2A-containing cells. Therefore, SUR1 expression is required for the activating action of zinc, which also depended on extracellular pH and was blocked by diethyl pyrocarbonate, suggesting histidine involvement. The five SUR1-specific extracellular histidine residues were submitted to site-directed mutagenesis. Of them, two histidines (His-326 and His-332) were found to be critical for the activation of K-ATP by zinc, as confirmed by the double mutation H326A/H332A. In conclusion, zinc activates K-ATP by binding itself to extracellular His-326 and His-332 of the SUR1 subunit. Thereby zinc could exert a negative control on cell excitability and secretion process of pancreatic beta-and alpha-cells. In fact, we have recently shown that such a mechanism occurs in hippocampal mossy fibers, a brain region characterized, like the pancreas, by an important accumulation of zinc and a high density of SUR1-containing K-ATP.	CMU, Neurosci Fondamentales, CH-1211 Geneva 04, Switzerland; CNRS, CRBM, FRE 2593, F-34293 Montpellier 05, France; Synthelabo Rech, F-92504 Rueil Malmaison, France	University of Geneva; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Sanofi-Aventis; Sanofi France	Bloc, A (corresponding author), Univ Lausanne, Rue Bugnon 9, CH-1005 Lausanne, Switzerland.	Alain.Bloc@unil.ch	Cens, Thierry/M-3337-2017; Charlson, Fiona/R-8963-2019	Cens, Thierry/0000-0002-4109-2779; Charlson, Fiona/0000-0003-2876-5040				Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Bancila V, 2004, J NEUROCHEM, V90, P1243, DOI 10.1111/j.1471-4159.2004.02587.x; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bloc A, 2000, J PHYSIOL-LONDON, V529, P723, DOI 10.1111/j.1469-7793.2000.00723.x; Bokvist K, 1999, PFLUG ARCH EUR J PHY, V438, P428, DOI 10.1007/s004240051058; Bryan J, 2004, DIABETES, V53, pS104, DOI 10.2337/diabetes.53.suppl_3.S104; Choi YB, 1999, NEURON, V23, P171, DOI 10.1016/S0896-6273(00)80763-1; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Cole TB, 2000, EPILEPSY RES, V39, P153, DOI 10.1016/S0920-1211(99)00121-7; DREIXLER JC, 1994, MOL BRAIN RES, V22, P144, DOI 10.1016/0169-328X(94)90042-6; Fisher JL, 1998, J NEUROSCI, V18, P2944; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; Hernandez-Sanchez C, 2001, P NATL ACAD SCI USA, V98, P3549, DOI 10.1073/pnas.051012898; Heron-Milhavet L, 2004, MOL CELL NEUROSCI, V25, P585, DOI 10.1016/j.mcn.2003.10.012; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; Horenstein J, 1998, MOL PHARMACOL, V53, P870; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Karschin C, 1997, FEBS LETT, V401, P59, DOI 10.1016/S0014-5793(96)01438-X; Kristiansen LH, 2001, HISTOCHEM CELL BIOL, V115, P125, DOI 10.1007/s004180000241; Kurz LL, 1999, J BIOL CHEM, V274, P11687, DOI 10.1074/jbc.274.17.11687; KWOK WM, 1993, J GEN PHYSIOL, V102, P693, DOI 10.1085/jgp.102.4.693; Laedtke T, 2000, AM J PHYSIOL-ENDOC M, V279, pE520, DOI 10.1152/ajpendo.2000.279.3.E520; LANG DA, 1981, DIABETES, V30, P435, DOI 10.2337/diabetes.30.5.435; Li Y, 2001, J NEUROPHYSIOL, V86, P2597, DOI 10.1152/jn.2001.86.5.2597; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Mao CS, 1999, DIABETES, V48, P714, DOI 10.2337/diabetes.48.4.714; MATTHEWS DR, 1983, DIABETOLOGIA, V24, P231; MITCHELL CL, 1993, NEUROTOXICOL TERATOL, V15, P165, DOI 10.1016/0892-0362(93)90012-D; MOURRE C, 1989, BRAIN RES, V486, P159, DOI 10.1016/0006-8993(89)91288-2; NOEBELS JL, 1989, J NEUROGENET, V6, P53, DOI 10.3109/01677068909107100; Nyholm B, 2000, METABOLISM, V49, P896, DOI 10.1053/meta.2000.6737; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; Prost AL, 2004, J PHYSIOL-LONDON, V559, P157, DOI 10.1113/jphysiol.2004.065094; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; Sakura H, 1999, J PHYSIOL-LONDON, V521, P337, DOI 10.1111/j.1469-7793.1999.00337.x; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; WANG TL, 1995, J NEUROSCI, V15, P7684; Wooltorton JRA, 1997, J PHYSIOL-LONDON, V505, P633, DOI 10.1111/j.1469-7793.1997.633ba.x; Yamada K, 2001, SCIENCE, V292, P1543, DOI 10.1126/science.1059829; Yu SP, 1998, J NEUROSCI RES, V52, P612, DOI 10.1002/(SICI)1097-4547(19980601)52:5<612::AID-JNR13>3.0.CO;2-3; Zarkovic M, 1999, EUR J ENDOCRINOL, V141, P494, DOI 10.1530/eje.0.1410494	57	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8793	8799		10.1074/jbc.M413426200	http://dx.doi.org/10.1074/jbc.M413426200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15613469	hybrid			2022-12-27	WOS:000227453100022
J	Bodevin-Authelet, S; Kusche-Gullberg, M; Pummill, PE; DeAngelis, PL; Lindahl, U				Bodevin-Authelet, S; Kusche-Gullberg, M; Pummill, PE; DeAngelis, PL; Lindahl, U			Biosynthesis of hyaluronan - Direction of chain elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STREPTOCOCCUS-EQUISIMILIS; MOLECULAR DIRECTIONALITY; REDUCING END; SYNTHASE; POLYSACCHARIDE; GLYCOSYLTRANSFERASES; PYOGENES	Hyaluronan (HA), a functionally essential glycosaminoglycan in vertebrate tissues and a putative virulence factor in certain pathogenic bacteria, is an extended linear polymer composed of alternating units of glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). Uncertainty regarding the mechanism of HA biosynthesis has included the directionality of chain elongation, i.e. whether addition of monosaccharide units occurs at the reducing or non-reducing terminus of nascent chains. We have investigated this problem using yeast-derived recombinant HA synthases from Xenopus laevis (xlHAS1) and from Streptococcus pyogenes (spHAS). The enzymes were incubated with UDP-[H-3]GlcUA and UDP- [C-14]GlcNAc, under experimental conditions designed to yield HA chains with differentially labeled reducing-terminal and non-reducing terminal domains. Digestion of the products with a mixture of beta-glucuronidase and beta-N-acetylglucosaminidase exoenzymes resulted in truncation of the HA chain strictly from the non-reducing end and release of labeled monosaccharides. The change in H-3/C-14 ratio of the monosaccharide fraction, during the course of exoglycosidase digestion, was interpreted to indicate whether sugar units had been added at the reducing or non-reducing end. The results demonstrate that the vertebrate xlHAS1 and the bacterial spHAS extend HA in opposite directions. Chain elongation catalyzed by xlHAS1 occurs at the non-reducing end of the HA chain, whereas elongation catalyzed by spHAS occurs at the reducing end. The spHAS is the first glycosyltransferase that has been unanimously demonstrated to function at the reducing end of a growing glycosaminoglycan chain.	Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, SE-75123 Uppsala, Sweden; Hyalose LLC, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Uppsala University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Lindahl, U (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden.	Ulf.Lindahl@imbim.uu.se	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 2002, ANAT RECORD, V268, P317, DOI 10.1002/ar.10163; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; Hall CL, 1995, J NEURO-ONCOL, V26, P221, DOI 10.1007/BF01052625; Hoshi H, 2004, J BIOL CHEM, V279, P2341, DOI 10.1074/jbc.M305723200; Imai T, 2003, BIOCHEM J, V374, P755, DOI 10.1042/BJ20030145; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lidholt K, 1997, J BIOL CHEM, V272, P2682, DOI 10.1074/jbc.272.5.2682; LIDHOLT K, 1994, CARBOHYD RES, V255, P87, DOI 10.1016/S0008-6215(00)90972-8; LONGAS MO, 1981, BIOCHEM J, V197, P275, DOI 10.1042/bj1970275; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; Pummill PE, 2003, J BIOL CHEM, V278, P19808, DOI 10.1074/jbc.M301097200; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; ROBYT JF, 1974, ARCH BIOCHEM BIOPHYS, V165, P634, DOI 10.1016/0003-9861(74)90291-4; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 2002, GLYCOBIOLOGY, V12, P708; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; WARD JB, 1973, BIOCHEM J, V135, P721, DOI 10.1042/bj1350721	26	39	42	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8813	8818		10.1074/jbc.M412803200	http://dx.doi.org/10.1074/jbc.M412803200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623518	hybrid			2022-12-27	WOS:000227453100025
J	Sasaki, T; Shibasaki, T; Beguin, P; Nagashima, K; Miyazaki, M; Seino, S				Sasaki, T; Shibasaki, T; Beguin, P; Nagashima, K; Miyazaki, M; Seino, S			Direct inhibition of the interaction between alpha-interaction domain and beta-interaction domain of voltage-dependent Ca2+ channels by gem	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNELS; SUBUNIT INCREASES; RAD; GTPASE; DIHYDROPYRIDINE; EXPRESSION; SITES; RHO; TRANSLOCATION; MODULATION	The Ras-related small G-protein Gem regulates voltage-dependent Ca2+ channels (VDCCs) through interaction with the beta-subunit of the VDCC. This action of Gem is mediated by regulated alpha(1)-subunit expression at the plasma membrane. In the present study, we examined the mechanism of the inhibition of VDCC activity by Gem. The beta-interaction domain (BID) of the beta-subunit, which specifically interacts with the beta-interaction domain ( AID) of the alpha(1)-subunit, is shown to be essential for the interaction between Gem and beta-subunits. In addition, the AID peptide inhibited interaction between Gem and beta-subunits in a dose-dependent manner. GemS88N mutant, which has low binding affinity for guanine nucleotide, did not interact with beta-subunits, allowing alpha1-subunit expression at the plasma membrane. This inhibitory effect of wild-type Gem on VDCC activity was reduced in cells expressing GemS88N. The overexpression of wild- type Gem in pancreatic beta-cell line MIN6 cells suppressed Ca2+-triggered secretion, whereas overexpression of GemS88N induced Ca2+ -triggered secretion to control level. These results suggest that GTPase activity of Gem is required for the binding of Gem to BID that regulates VDCC activity through interaction with AID.	Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Epithelial Cell Biol Lab, Singapore 117609, Singapore; Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Kyoto 6068507, Japan; Chiba Univ, Grad Sch Med, Dept Gen Surg & Mol Embryol, Chiba 2608670, Japan	Kobe University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Kyoto University; Chiba University	Seino, S (corresponding author), Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan.	seino@med.kobe-u.ac.jp						Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; Ball SL, 2002, INVEST OPHTH VIS SCI, V43, P1595; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Gurnett CA, 1997, J BIOL CHEM, V272, P18508, DOI 10.1074/jbc.272.29.18508; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Herlitze S, 2003, J BIOENERG BIOMEMBR, V35, P621, DOI 10.1023/B:JOBB.0000008027.19384.c0; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; Kawaki J, 1999, DIABETES, V48, P2001, DOI 10.2337/diabetes.48.10.2001; Klussmann E, 2001, J BIOL CHEM, V276, P20451, DOI 10.1074/jbc.M010270200; Leone A, 2001, ONCOGENE, V20, P3217, DOI 10.1038/sj.onc.1204420; Maeda A, 2002, BIOCHEM BIOPH RES CO, V297, P1231, DOI 10.1016/S0006-291X(02)02342-2; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; Murata M, 2004, CIRC RES, V95, P398, DOI 10.1161/01.RES.0000138449.85324.c5; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Takahashi SX, 2004, P NATL ACAD SCI USA, V101, P7193, DOI 10.1073/pnas.0306665101; Tseng YH, 2001, CANCER RES, V61, P2071; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	46	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9308	9312		10.1074/jbc.M413773200	http://dx.doi.org/10.1074/jbc.M413773200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615719	hybrid			2022-12-27	WOS:000227453100082
J	Greenbaum, EA; Graves, CL; Mishizen-Eberz, AJ; Lupoli, MA; Lynch, DR; Englander, SW; Axelsen, PH; Giasson, BI				Greenbaum, EA; Graves, CL; Mishizen-Eberz, AJ; Lupoli, MA; Lynch, DR; Englander, SW; Axelsen, PH; Giasson, BI			The E46K mutation in alpha-synuclein increases amyloid fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL LEWY BODIES; BRAIN IRON ACCUMULATION; MULTIPLE SYSTEM ATROPHY; PURE AUTONOMIC FAILURE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; IN-VITRO; BODY DISEASE; NEURODEGENERATIVE DISEASES; NACP/ALPHA-SYNUCLEIN	The identification of a novel mutation (E46K) in one of the KTKEGV-type repeats in the amino-terminal region of alpha-synuclein suggests that this region and, more specifically, Glu residues in the repeats may be important in regulating the ability of alpha-synuclein to polymerize into amyloid fibrils. It was demonstrated that the E46K mutation increased the propensity of alpha-synuclein to fibrillize, but this effect was less than that of the A53T mutation. The substitution of Glu(46) for an Ala also increased the assembly of alpha-synuclein, but the polymers formed can have different ultrastructures, further indicating that this amino acid position has a significant effect on the assembly process. The effect of residue Glu(83) in the sixth repeat of alpha-synuclein, which lies closest to the amino acid stretch critical for filament assembly, was also studied. Mutation of Glu(83) to a Lys or Ala increased polymerization but perturbed some of the properties of mature amyloid. These results demonstrated that some of the Glu residues within the repeats can have significant effects on modulating the assembly of alpha-synuclein to form amyloid fibrils. The greater effect of the A53T mutation, even when compared with what may be predicted to be a more dramatic mutation such as E46K, underscores the importance of protein micro-environment in affecting protein structure. Moreover, the relative effects of the A53T and E46K mutations are consistent with the age of onset of disease. These findings support the notion that aberrant alpha-synuclein polymerization resulting in the formation of pathological inclusions can lead to disease.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Giasson, BI (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk,89A John Morgan Bldg, Philadelphia, PA 19104 USA.	giassonb@mail.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS045986, R01NS045986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020238, R56AG020238] Funding Source: NIH RePORTER; NIA NIH HHS [AG20238] Funding Source: Medline; NINDS NIH HHS [NS45986] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arai K, 2000, NEUROSCI LETT, V296, P171, DOI 10.1016/S0304-3940(00)01623-2; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Athanassiadou A, 1999, AM J HUM GENET, V65, P555, DOI 10.1086/302486; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Cabin DE, 2002, J NEUROSCI, V22, P8797; Choi W, 2004, FEBS LETT, V576, P363, DOI 10.1016/j.febslet.2004.09.038; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Crystal AS, 2003, J NEUROCHEM, V86, P1359, DOI 10.1046/j.1471-4159.2003.01949.x; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Duda JE, 2002, ACTA NEUROPATHOL, V104, P7, DOI 10.1007/s00401-002-0563-3; Duda JE, 2002, ANN NEUROL, V52, P205, DOI 10.1002/ana.10279; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Galvin JE, 2000, AM J PATHOL, V157, P361, DOI 10.1016/S0002-9440(10)64548-8; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Golbe LI, 1996, ANN NEUROL, V40, P767, DOI 10.1002/ana.410400513; Hamilton RL, 2000, BRAIN PATHOL, V10, P378; Haroutunian V, 2000, ARCH NEUROL-CHICAGO, V57, P1145, DOI 10.1001/archneur.57.8.1145; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hurtig HI, 2000, NEUROLOGY, V54, P1916, DOI 10.1212/WNL.54.10.1916; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kaufmann H, 2001, NEUROLOGY, V56, P980, DOI 10.1212/WNL.56.7.980; Kessler JC, 2003, BIOCHEMISTRY-US, V42, P672, DOI 10.1021/bi020429y; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; LENNOX G, 1989, J NEUROL NEUROSUR PS, V52, P1236, DOI 10.1136/jnnp.52.11.1236; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Markopoulou K, 1999, ANN NEUROL, V46, P374, DOI 10.1002/1531-8249(199909)46:3<374::AID-ANA13>3.0.CO;2-9; Mattila PM, 2000, ACTA NEUROPATHOL, V100, P285, DOI 10.1007/s004019900168; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Murray IVJ, 2003, BIOCHEMISTRY-US, V42, P8530, DOI 10.1021/bi027363r; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Papadimitriou A, 1999, NEUROLOGY, V52, P651, DOI 10.1212/WNL.52.3.651; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Saito Y, 2003, J NEUROPATH EXP NEUR, V62, P644, DOI 10.1093/jnen/62.6.644; Samuel W, 1996, J NEUROPATH EXP NEUR, V55, P44, DOI 10.1097/00005072-199601000-00005; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Silvestro L, 1999, BIOCHEMISTRY-US, V38, P113, DOI 10.1021/bi981289o; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Spira PJ, 2001, ANN NEUROL, V49, P313, DOI 10.1002/ana.67; Takeda A, 1998, AM J PATHOL, V152, P367; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Wakabayashi K, 1999, NEUROPATH APPL NEURO, V25, P363; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	67	285	289	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7800	7807		10.1074/jbc.M411638200	http://dx.doi.org/10.1074/jbc.M411638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632170	hybrid			2022-12-27	WOS:000227395700045
J	Hughes, TA; Brady, HJM				Hughes, TA; Brady, HJM			Expression of axin2 is regulated by the alternative 5 '-untranslated regions of its mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TRANSLATIONAL CONTROL; BETA-CATENIN; CANCER; PROTEIN; GENE; CARCINOMAS; PATHWAY; LEVEL; CELLS	Axin2 is a negative regulator of Wnt/beta-catenin signaling with roles in early development and tumor suppression. We find that axin2 expression is regulated at both transcriptional and translational levels. The gene allows transcription of mRNAs with three alternative 5'-untranslated regions, and these are differentially expressed in various human cell types. These untranslated regions can differentially determine protein expression from messages by influencing mRNA stability and translational efficiency. We identify short upstream reading frames and structural motifs that are responsible for modulation of mRNA translational efficiencies. We show that the proportions of axin2 message expressing each 5'-untranslated region influence the amount of Axin2 protein expressed within cells. We discuss this complex regulation in the context of the function of Axin2 as a tumor suppressor.	Inst Child Hlth, Camelia Botnar Labs, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England	University of London; University College London	Hughes, TA (corresponding author), Inst Child Hlth, Camelia Botnar Labs, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	t.hughes@ich.ucl.ac.uk	Hughes, Thomas/M-7063-2019; Hughes, Thomas A/O-8031-2015	Hughes, Thomas A/0000-0003-1169-3386; Brady, Hugh/0000-0002-3152-067X				Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Bar I, 2003, J BIOL CHEM, V278, P5802, DOI 10.1074/jbc.M207178200; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Davies WL, 2004, BIOCHEM BIOPH RES CO, V319, P410, DOI 10.1016/j.bbrc.2004.05.008; Davies WL, 2004, J BIOL CHEM, V279, P15877, DOI 10.1074/jbc.M313628200; de Moor CH, 2001, INT REV CYTOL, V203, P567; Dong X, 2001, CYTOGENET CELL GENET, V93, P26, DOI 10.1159/000056942; Frankton S, 2004, MOL ENDOCRINOL, V18, P1631, DOI 10.1210/me.2003-0346; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Grobe K, 2002, J BIOL CHEM, V277, P30699, DOI 10.1074/jbc.M111904200; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hernandez-Sanchez C, 2003, EMBO J, V22, P5582, DOI 10.1093/emboj/cdg515; Hernandez-Sanchez C, 2002, DIABETES, V51, P770, DOI 10.2337/diabetes.51.3.770; Hughes TA, 2005, EXP CELL RES, V303, P32, DOI 10.1016/j.yexcr.2004.09.014; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Landers JE, 1997, CANCER RES, V57, P3562; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Newton DC, 2003, J BIOL CHEM, V278, P636, DOI 10.1074/jbc.M209988200; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6; Phelan CM, 1998, CANCER RES, V58, P1004; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; Pontrelli L, 2004, BIOCHEMISTRY-US, V43, P6734, DOI 10.1021/bi049887s; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sobczak K, 2002, J BIOL CHEM, V277, P17349, DOI 10.1074/jbc.M109162200; Stoneley M, 2003, CURR MOL MED, V3, P597, DOI 10.2174/1566524033479474; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4	36	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8581	8588		10.1074/jbc.M410806200	http://dx.doi.org/10.1074/jbc.M410806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611123	hybrid			2022-12-27	WOS:000227395700134
J	Krishnegowda, G; Hajjar, AM; Zhu, JZ; Douglass, EJ; Uematsu, S; Akira, S; Woods, AS; Gowda, DC				Krishnegowda, G; Hajjar, AM; Zhu, JZ; Douglass, EJ; Uematsu, S; Akira, S; Woods, AS; Gowda, DC			Induction of proinflammatory responses in macrophages by the Glycosylphosphatidylinositols of Plasmodium falciparum - Cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; PROTEIN-KINASE-C; ERYTHROCYTIC STAGES; PARASITIC PROTOZOA; TRYPANOSOMA-CRUZI; CEREBRAL MALARIA; PHOSPHOLIPASE-D; NITRIC-OXIDE; ANCHORS; BIOSYNTHESIS	The glycosylphosphatidylinositol (GPI) anchors of Plasmodium falciparum have been proposed to be the major factors that contribute to malaria pathogenesis through their ability to induce proinflammatory responses. In this study we identified the receptors for P. falciparum GPI-induced cell signaling that leads to proinflammatory responses and studied the GPI structure-activity relationship. The data show that GPI signaling is mediated mainly through recognition by TLR2 and to a lesser extent by TLR4. The activity of sn-2-lyso-GPIs is comparable with that of the intact GPIs, whereas the activity of Man(3)-GPIs is about 80% that of the intact GPIs. The GPIs with three ( intact GPIs and Man3-GPIs) and two fatty acids (sn-2-lyso-GPIs) appear to differ considerably in the requirement of the auxiliary receptor, TLR1 or TLR6, for recognition by TLR2. The former are preferentially recognized by TLR2/TLR1, whereas the latter are favored by TLR2/TLR6. However, the signaling pathways initiated by all three GPI types are similar, involving the MyD88-dependent activation of extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 and NF-kappaB-signaling pathways. The signaling molecules of these pathways differentially contribute to the production of various cytokines and nitric oxide (Zhu, J., Krishnegowda, G., and Gowda, D. C. ( 2004) J. Biol. Chem. 280, 8617-8627). Our data also show that GPIs are degraded by the macrophage surface phospholipases predominantly into inactive species, indicating that the host can regulate GPI activity at least in part by this mechanism. These results imply that macrophage surface phospholipases play important roles in the GPI-induced innate immune responses and malaria pathogenesis.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Osaka Univ, Dept Host Def, Res Inst Microbial Dis, Osaka 5650871, Japan; NIDA, NIH, Baltimore, MD 21224 USA	University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Osaka University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Hajjar, AM (corresponding author), Univ Washington, Dept Immunol, Box 357650, Seattle, WA 98195 USA.	hajjar@u.washington.edu; gowda@psu.edu	Akira, Shizuo/C-3134-2009	GOWDA, KRISHNE/0000-0002-6042-0520; Hajjar, Adeline/0000-0002-4838-8070; Gowda, Channe/0000-0002-6860-5108	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041139] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69503, R01 HL069503] Funding Source: Medline; NIAID NIH HHS [R01 AI041139, AI41139] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi K, 2001, J IMMUNOL, V167, P5928, DOI 10.4049/jimmunol.167.10.5928; Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Almeida IC, 2001, J LEUKOCYTE BIOL, V70, P467; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; BAIRD JK, 1995, PARASITOL TODAY, V11, P105, DOI 10.1016/0169-4758(95)80167-7; Balmer P, 2000, PARASITE IMMUNOL, V22, P97, DOI 10.1046/j.1365-3024.2000.00281.x; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; BIRON CA, 1995, CURR OPIN IMMUNOL, V7, P485, DOI 10.1016/0952-7915(95)80093-X; Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; CLARK IA, 1987, J IMMUNOL, V139, P3493; DORSAM G, 1995, CLIN CHEM, V41, P862; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; GEROLD P, 1994, J BIOL CHEM, V269, P2597; GILLES HM, 1997, BRUCE CHAWATTS ESSEN, P1; Gowda DC, 2002, MICROBES INFECT, V4, P983, DOI 10.1016/S1286-4579(02)01619-2; GRAU GE, 1994, PARASITOL TODAY, V10, P408, DOI 10.1016/0169-4758(94)90236-4; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HOMMEL M, 1993, ANN TROP MED PARASIT, V87, P627, DOI 10.1080/00034983.1993.11812821; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; Kaufmann SHE, 2002, METHOD MICROBIOL, V32, P1; KWIATKOWSKI D, 1995, PARASITOL TODAY, V11, P206, DOI 10.1016/0169-4758(95)80079-4; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Milne KG, 1999, J BIOL CHEM, V274, P1465, DOI 10.1074/jbc.274.3.1465; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; Naik RS, 2000, J BIOL CHEM, V275, P24506, DOI 10.1074/jbc.M002151200; Naik RS, 2000, J EXP MED, V192, P1563, DOI 10.1084/jem.192.11.1563; O'Brien KD, 1999, CIRCULATION, V99, P2876, DOI 10.1161/01.CIR.99.22.2876; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; RILEY EM, 1994, MALARIA, P119; Ropert C, 2000, CURR OPIN MICROBIOL, V3, P395, DOI 10.1016/S1369-5274(00)00111-9; Ropert C, 2001, J IMMUNOL, V166, P3423, DOI 10.4049/jimmunol.166.5.3423; Rowe JA, 1998, MOL BIOCHEM PARASIT, V92, P177, DOI 10.1016/S0166-6851(97)00237-5; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Sakai H, 2004, J PHARM SCI-US, V93, P310, DOI 10.1002/jps.10525; Schofield L, 1996, J IMMUNOL, V156, P1886; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SCHOFIELD L, 1993, ANN TROP MED PARASIT, V87, P617, DOI 10.1080/00034983.1993.11812820; SHERMAN IW, 1998, MALARIA PARASITE BIO, P1; Smith T, 1999, T ROY SOC TROP MED H, V93, pS59; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311; Su Z, 2000, INFECT IMMUN, V68, P4399, DOI 10.1128/IAI.68.8.4399-4406.2000; SUZUKI T, 1982, P NATL ACAD SCI-BIOL, V79, P591, DOI 10.1073/pnas.79.2.591; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Tachado SD, 1996, J IMMUNOL, V156, P1897; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; Takeda K, 2004, J DERMATOL SCI, V34, P73, DOI 10.1016/j.jdermsci.2003.10.002; Takeda K, 2002, J ENDOTOXIN RES, V8, P459, DOI 10.1179/096805102125001073; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; vanderHeyde HC, 1997, EXP PARASITOL, V85, P206, DOI 10.1006/expr.1996.4132; Vijaykumar M, 2001, J BIOL CHEM, V276, P6909, DOI 10.1074/jbc.C100007200; WILLINGHAM MC, 1987, P NATL ACAD SCI USA, V84, P15916; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231; Zhu JZ, 2005, J BIOL CHEM, V280, P8617, DOI 10.1074/jbc.M413539200	63	376	390	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8606	8616		10.1074/jbc.M413541200	http://dx.doi.org/10.1074/jbc.M413541200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623512	Green Accepted, hybrid			2022-12-27	WOS:000227395700137
J	Sharma, GD; Ottino, P; Bazan, NG; Bazan, HEP				Sharma, GD; Ottino, P; Bazan, NG; Bazan, HEP			Epidermal and hepatocyte growth factors, but not keratinocyte growth factor, modulate protein kinase C alpha translocation to the plasma membrane through 15(S)-hydroxyeicosatetraenoic acid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; ACTIVATION; PROLIFERATION; KGF; HGF; LOCALIZATION; ENDOTHELIUM; METABOLITE; INDUCTION	Activation of protein kinase C (PKC) involves its recruitment to the membrane, where it interacts with its activator(s). We expressed PKCalpha fused to green fluorescent protein and examined its real time translocation to the plasma membrane in living human corneal epithelial cells. Upon 10 min of stimulation with epidermal and hepatocyte growth factors (EGF and HGF), PKCalpha translocated to the plasma membrane. Keratinocyte growth factor did not stimulate PKCalpha translocation up to 1 h after stimulation. Pretreatment with the 15-lipoxygenase metabolite, 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), followed by EGF or HGF, produced faster translocation of PKCalpha detectable at 2 min. However, the same concentration of 15(S)-HETE alone did not stimulate translocation. 15(S)-Hydroperoxyeicosatetraenoic acid and 5(S)-HETE did not affect growth factor-induced translocation of PKCalpha. PD153035, a specific inhibitor of tyrosine kinase activity of the EGF receptor, completely blocked PKCalpha translocation induced by EGF. PD98059, a specific MEK inhibitor, significantly inhibited EGF- and HGF- mediated PKCalpha translocation, which was reversed by addition of 15(S)-HETE. Phosphorylation of ERK1/2 by EGF was followed by phosphorylation of cytosolic phospholipase A(2) (cPLA(2)), and blocking ERK1/2 inhibited cPLA2 activation. Immunofluorescence demonstrated translocation of p-cPLA(2) to plasma and nuclear membranes as early as 2 min. This may further increase arachidonic acid release from membrane phospholipid pools and increase the intracellular pool of HETEs. In fact, in cells prelabeled with [H-3] arachidonic acid, EGF stimulated synthesis of 15(S)- HETE in the cytosolic fraction. 15(S)- HETE also reversed the effect of LOX inhibitor on EGF- mediated cell proliferation. Our results indicate that 15(S)- HETE is an intracellular second messenger that facilitates translocation of PKCalpha to the membrane and elucidate a mechanism that plays a regulatory role in cell proliferation crucial to corneal wound healing.	Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Ophthalmol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Sch Med, Neurosci Ctr Excellence, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Bazan, HEP (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Ophthalmol, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.	hbazan1@lsuhsc.edu	Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NATIONAL EYE INSTITUTE [R01EY006635, R01EY004928] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY04928, R01 EY06635] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alpert SE, 1999, AM J PHYSIOL-LUNG C, V277, pL457, DOI 10.1152/ajplung.1999.277.3.L457; BANDYOPADHYAY GK, 1988, J BIOL CHEM, V263, P7567; Chandrasekher G, 1998, EXP EYE RES, V67, P603, DOI 10.1006/exer.1998.0555; Chandrasekher G, 2002, INVEST OPHTH VIS SCI, V43, P1422; Chandrasekher G, 2001, EXP EYE RES, V73, P191, DOI 10.1006/exer.2001.1026; CHANG MS, 2004, INVESTIG OPHTHALMOL, V45; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; GRAEBER JE, 1990, PROSTAGLANDINS, V39, P665, DOI 10.1016/0090-6980(90)90026-R; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; HURST JS, 1994, EXP EYE RES, V59, P97, DOI 10.1006/exer.1994.1085; HURST JS, 1991, J BIOL CHEM, V266, P6726; Jackson RS, 2001, CORNEA, V20, P516, DOI 10.1097/00003226-200107000-00015; Jumblatt JE, 2002, CORNEA, V21, P818, DOI 10.1097/00003226-200211000-00018; Liang QW, 1998, INVEST OPHTH VIS SCI, V39, P1329; LIMINGA M, 1994, BBA-LIPID LIPID MET, V1210, P288, DOI 10.1016/0005-2760(94)90231-3; LIN NG, 1992, CURR EYE RES, V11, P899, DOI 10.3109/02713689209033487; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ottino P, 2003, EXP EYE RES, V76, P613, DOI 10.1016/S0014-4835(03)00003-4; Seth RK, 2001, INVEST OPHTH VIS SCI, V42, P3239; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Wagner S, 2000, EXP CELL RES, V258, P204, DOI 10.1006/excr.2000.4925; WILSON SE, 1994, EXP EYE RES, V59, P665, DOI 10.1006/exer.1994.1152; Wilson SE, 1999, INVEST OPHTH VIS SCI, V40, P2185; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Xu KP, 2002, INVEST OPHTH VIS SCI, V43, P3673; Zhou JZ, 2003, J BIOL CHEM, V278, P5388, DOI 10.1074/jbc.M209695200	29	39	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7917	7924		10.1074/jbc.M408852200	http://dx.doi.org/10.1074/jbc.M408852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15613483	hybrid			2022-12-27	WOS:000227395700060
J	Williams, KL; Zhang, YJ; Shkriabai, N; Karki, RG; Nicklaus, MC; Kotrikadze, N; Hess, S; Le Grice, SFJ; Craigie, R; Pathak, VK; Kvaratskhelia, M				Williams, KL; Zhang, YJ; Shkriabai, N; Karki, RG; Nicklaus, MC; Kotrikadze, N; Hess, S; Le Grice, SFJ; Craigie, R; Pathak, VK; Kvaratskhelia, M			Mass spectrometric analysis of the HIV-1 integrase-pyridoxal 5 '-phosphate complex reveals a new binding site for a nucleotide inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; DNA-BINDING; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; TERMINAL DOMAINS; STRAND TRANSFER; ACTIVE-SITE; IDENTIFICATION; CORE; ORGANIZATION	HIV-1 integrase (IN) is an important target for designing new antiviral therapies. Screening of potential inhibitors using recombinant IN-based assays has revealed a number of promising leads including nucleotide analogs such as pyridoxal 5'-phosphate (PLP). Certain PLP derivatives were shown to also exhibit antiviral activities in cell-based assays. To identify an inhibitory binding site of PLP to IN, we used the intrinsic chemical property of this compound to form a Schiff base with a primary amine in the protein at the nucleotide binding site. The amino acid affected was then revealed by mass spectrometric analysis of the proteolytic peptide fragments of IN. We found that an IC50 concentration (15 muM) of PLP modified a single IN residue, Lys(244), located in the C-terminal domain. In fact, we observed a correlation between interaction of PLP with Lys(244) and the compound's ability to impair formation of the IN(.)DNA complex. Site-directed mutagenesis studies confirmed an essential role of Lys(244) for catalytic activities of recombinant IN and viral replication. Molecular modeling revealed that Lys(244) together with several other DNA binding residues provides a plausible pocket for a nucleotide inhibitor-binding site. To our knowledge, this is the first report indicating that a small molecule inhibitor can impair IN activity through its binding to the protein C terminus. At the same time, our findings highlight the importance of structural analysis of the full-length protein.	Ohio State Univ, Coll Pharm, Hlth Sci Ctr, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Coll Pharm, Hlth Sci Ctr, Ctr Comprehens Canc, Columbus, OH 43210 USA; NCI Frederick, Lab Med Chem, Ft Detrick, MD 21702 USA; NCI Frederick, HIV Drug Resistance Program, Ft Detrick, MD 21702 USA; Tbilisi State Univ, Dept Cell & Mol Biol, GE-0128 Tbilisi, Georgia; NIDDK, NIH, Bethesda, MD 20892 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Ivane Javakhishvili Tbilisi State University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kvaratskhelia, M (corresponding author), Ohio State Univ, Coll Pharm, Hlth Sci Ctr, Ctr Retrovirus Res, 500 W 12th Ave, Columbus, OH 43210 USA.	kvaratskhelia.1@osu.edu	Nicklaus, Marc/N-4183-2014; Hess, Sonja/K-4842-2013	Hess, Sonja/0000-0002-5904-9816; Pathak, Vinay/0000-0003-2441-8412; Nicklaus, Marc/0000-0002-4775-7030	DIVISION OF BASIC SCIENCES - NCI [Z01BC010534] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010493, ZIABC010493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK070004, Z01DK036108] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brown P. O., 1997, P161; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; De Clercq E, 2001, CURR MED CHEM, V8, P1543, DOI 10.2174/0929867013371842; Drake RR, 1998, P NATL ACAD SCI USA, V95, P4170, DOI 10.1073/pnas.95.8.4170; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199; Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Krueger JK, 1999, BIOCHEMISTRY-US, V38, P10247, DOI 10.1021/bi990782c; LIPFORD JR, 1994, J ACQ IMMUN DEF SYND, V7, P1215; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Lundblad RL., 1995, TECHNIQUES PROTEIN M; Maroun RG, 1999, EUR J BIOCHEM, V260, P145, DOI 10.1046/j.1432-1327.1999.00130.x; Mazumder A, 1996, MOL PHARMACOL, V49, P621; Molteni V, 2001, ACTA CRYSTALLOGR D, V57, P536, DOI 10.1107/S0907444901001652; Morner A, 1999, J VIROL, V73, P2343; Nicklaus MC, 1997, J MED CHEM, V40, P920, DOI 10.1021/jm960596u; Pannecouque C, 2002, CURR BIOL, V12, P1169, DOI 10.1016/S0960-9822(02)00952-1; Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; Shkriabai N, 2004, P NATL ACAD SCI USA, V101, P6894, DOI 10.1073/pnas.0400873101; Stranix B.R., 2003, Patent No. [6,638,921, 6638921]; Svarovskaia ES, 2004, J VIROL, V78, P3210, DOI 10.1128/JVI.78.7.3210-3222.2004; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Yi JZ, 2002, J BIOL CHEM, V277, P12164, DOI 10.1074/jbc.M105072200; Zhang XC, 2001, BIOORGAN MED CHEM, V9, P1649, DOI 10.1016/S0968-0896(01)00075-X; Zhao L, 2003, BIOORG MED CHEM LETT, V13, P1175, DOI 10.1016/S0960-894X(03)00040-4	45	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7949	7955		10.1074/jbc.M413579200	http://dx.doi.org/10.1074/jbc.M413579200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615720	hybrid			2022-12-27	WOS:000227395700064
J	Yin, H; Chao, L; Chao, J				Yin, H; Chao, L; Chao, J			Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad(.)14-3-3 signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CARDIAC-HYPERTROPHY; CASPASE-3 ACTIVATION; 3-KINASE/AKT PATHWAY; CELL-SURVIVAL; GENE-TRANSFER; IN-VITRO; BAD; INFARCTION; HEART	Our previous study has shown that human tissue kallikrein protected against ischemia/reperfusion-induced myocardial injury. In the present study, we investigated the protective role of local kallikrein gene delivery in ischemia/reperfusion-induced cardiomyocyte apoptosis and its signaling mechanisms in promoting cardiomyocyte survival. Adenovirus carrying the human tissue kallikrein gene was delivered locally into the heart using a catheter-based technique. Expression and localization of recombinant human kallikrein in rat myocardium after gene transfer were determined immunohistochemically. Kallikrein gene delivery markedly reduced reperfusion-induced cardiomyocyte apoptosis identified by both in situ nick end-labeling and DNA fragmentation. Delivery of the kallikrein gene increased phosphorylation of Src, Akt, glycogen synthase kinase (GSK)-3beta, and Bad(Ser-136) but reduced caspase-3 activation in rat myocardium after reperfusion. The protective effect of kallikrein on apoptosis and its signaling mediators was blocked by icatibant and dominant-negative Akt, indicating a kinin B2 receptor-Akt-mediated event. Similarly, kinin or transduction of kallikrein in cultured cardiomyocytes promoted cell viability and attenuated apoptosis induced by hypoxia/reoxygenation. The effect of kallikrein on cardiomyocyte survival was blocked by dominant-negative Akt and a constitutively active mutant of GSK-3beta, but it was facilitated by constitutively active Akt, catalytically inactive GSK-3beta, lithium, and caspase-3 inhibitor. Moreover, kallikrein promoted Bad(.)14-3-3theta complex formation and inhibited Akt-GSK-3beta-dependent activation of caspase-3, whereas caspase-3 administration caused reduction of the Bad(.)14-3-3theta complex, indicating an interaction between Akt-GSK-caspase-3 and Akt-Bad(.)14-3-3 signaling pathways. In conclusion, kallikrein/kinin protects against cardiomyocyte apoptosis in vivo and in vitro via Akt-Bad(.)14-3-3 and Akt-GSK-3beta-caspase-3 signaling pathways.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Nanjing Med Univ, First Hosp, Dept Cardiol, Jiangsu 210029, Peoples R China	Medical University of South Carolina; Nanjing Medical University	Chao, J (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, BSB 733A,171 Ashley Ave, Charleston, SC 29425 USA.	chaoj@musc.edu			NHLBI NIH HHS [R01-HL9397] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agata J, 2002, HYPERTENSION, V40, P653, DOI 10.1161/01.HYP.0000036035.41122.99; Bae S, 2003, AM J PHYSIOL-HEART C, V285, pH983, DOI 10.1152/ajpheart.00005.2003; Bell RM, 2003, J MOL CELL CARDIOL, V35, P185, DOI 10.1016/S0022-2828(02)00310-3; Campbell DJ, 2001, AM J PHYSIOL-REG I, V281, pR1059, DOI 10.1152/ajpregu.2001.281.4.R1059; Chao J, 1998, HUM GENE THER, V9, P21, DOI 10.1089/hum.1998.9.1-21; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P9977, DOI 10.1073/pnas.161120198; Craig R, 2001, J BIOL CHEM, V276, P37621, DOI 10.1074/jbc.M103276200; Del Monte F, 2002, PHYSIOL GENOMICS, V9, P49, DOI 10.1152/physiolgenomics.00035.2001; Di Napoli P, 2003, AM HEART J, V146, P1105, DOI 10.1016/S0002-8703(03)00445-9; Dobrzynski E, 2002, AM J PHYSIOL-ENDOC M, V283, pE1291, DOI 10.1152/ajpendo.00147.2002; Federici M, 2001, FASEB J, V15, P22; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Kato K, 2003, AM J PHYSIOL-HEART C, V285, pH1506, DOI 10.1152/ajpheart.00270.2003; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Nebigil CG, 2003, FASEB J, V17, P1373, DOI 10.1096/fj.02-1122fje; Nozato T, 2001, J MOL CELL CARDIOL, V33, P1493, DOI 10.1006/jmcc.2001.1412; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004; Shimamura H, 2003, J AM SOC NEPHROL, V14, P1427, DOI 10.1097/01.ASN.0000066140.99610.32; Shinoda S, 2003, J NEUROCHEM, V86, P460, DOI 10.1046/j.1471-4159.2003.01860.x; Silva JA, 2000, FASEB J, V14, P1858; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; SUZUKI K, 2001, CIRCULATION S1, V104, P308; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Wang JM, 2000, BRAIN RES, V859, P381, DOI 10.1016/S0006-8993(00)02008-4; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Won J, 2003, J BIOL CHEM, V278, P19347, DOI 10.1074/jbc.M213098200; Xia CF, 2004, HYPERTENSION, V43, P452, DOI 10.1161/01.HYP.0000110905.29389.e5; Yang CC, 2003, J BIOL CHEM, V278, P25872, DOI 10.1074/jbc.M301744200; Yoshida H, 2000, HYPERTENSION, V35, P25, DOI 10.1161/01.HYP.35.1.25; Zhang HFM, 2003, J BIOL CHEM, V278, P33011, DOI 10.1074/jbc.M305352200; Zou YZ, 2003, CIRCULATION, V108, P3024, DOI 10.1161/01.CIR.0000101923.54751.77	38	93	105	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8022	8030		10.1074/jbc.M407179200	http://dx.doi.org/10.1074/jbc.M407179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611141	hybrid			2022-12-27	WOS:000227395700072
J	Anderson, JL; Frase, H; Michaelis, S; Hrycyna, CA				Anderson, JL; Frase, H; Michaelis, S; Hrycyna, CA			Purification, functional reconstitution, and characterization of the Saccharomyces cerevisiae isoprenylcysteine carboxylmethyltransferase Ste14p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; C-TERMINAL METHYLATION; A-FACTOR; P-GLYCOPROTEIN; K-RAS; YEAST; FARNESYL; FARNESYLTRANSFERASE; GENE	Numerous proteins, including Ras, contain a C-terminal CAAX motif that directs a series of three sequential post-translational modifications: isoprenylation of the cysteine residue, endoproteolysis of the three terminal amino acids and a-carboxyl methylesterification of the isoprenylated cysteine. This study focuses on the isoprenylcysteine carboxylmethyltransferase (Icmt) enzyme from Saccharomyces cerevisiae, Ste14p, the founding member of a homologous family of endoplasmic reticulum membrane proteins present in all eukaryotes. Ste14p, like all Icmts, has multiple membrane spanning domains, presenting a significant challenge to its purification in an active form. Here, we have detergent-solubilized, purified, and reconstituted enzymatically active His-tagged Ste14p from S. cerevisiae, thus providing conclusive proof that Ste14p is the sole component necessary for the carboxylmethylation of isoprenylated substrates. Among the extensive panel of detergents that was screened, optimal solubilization and retention of Ste14p activity occurred with n-dodecyl-beta-D-malto-side. The activity of Ste14p could be further optimized upon reconstitution into liposomes. Our expression and purification schemes generate milligram quantities of pure and active Ste14p, which is highly stable under many conditions. Using pure reconstituted Stel4p, we demonstrate quantitatively that Stel4p does not have a preference for the farnesyl or geranylgeranyl moieties in the model substrates N-acetyl-S-farnesyl-L-cysteine (AFC) and N-acetyl-S-geranylgeranyl-L-cysteine (AGGC) in vitro. In addition to catalyzing methylation of AFC, we also show that purified Ste14p methylates a known in vivo substrate, Ras2p. Evidence that metals ions are required for activity of Ste14p is also presented. These results pave the way for further characterization of pure Ste14p, as well as determination of its three-dimensional structure.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Johns Hopkins University	Hrycyna, CA (corresponding author), Purdue Univ, Dept Chem, 560 Oval Dr, W Lafayette, IN 47907 USA.	hrycyna@purdue.edu	Kelts, Jessica L./B-3946-2014	Kelts, Jessica L./0000-0002-1084-0498				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ambroziak P., 2001, ENZYMES, P155; Ambudkar SV, 1998, METHOD ENZYMOL, V292, P492; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Berkower C, 1996, J BIOL CHEM, V271, P22983, DOI 10.1074/jbc.271.38.22983; Buckner FS, 2002, BIOCHEM J, V367, P809, DOI 10.1042/BJ20020277; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Desrosiers RR, 1999, BIOCHEM BIOPH RES CO, V261, P790, DOI 10.1006/bbrc.1999.0936; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Fu HW, 1998, BIOCHEMISTRY-US, V37, P4465, DOI 10.1021/bi972511c; Hightower KE, 1999, CURR OPIN CHEM BIOL, V3, P176, DOI 10.1016/S1367-5931(99)80030-1; HITZEMAN RA, 1983, NUCLEIC ACIDS RES, V11, P2745, DOI 10.1093/nar/11.9.2745; HJELMELAND LM, 1990, METHOD ENZYMOL, V182, P253; HRYCYNA CA, 1993, PHARMACOL THERAPEUT, V59, P281, DOI 10.1016/0163-7258(93)90071-K; HRYCYNA CA, 1995, METHOD ENZYMOL, V250, P251; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Ketchum CJ, 2001, J BIOL CHEM, V276, P29007, DOI 10.1074/jbc.M100810200; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; OTA IM, 1989, J BIOL CHEM, V264, P12879; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Pei JM, 2001, TRENDS BIOCHEM SCI, V26, P275, DOI 10.1016/S0968-0004(01)01813-8; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; Richter P, 1997, ANALYST, V122, P1045, DOI 10.1039/a703379f; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Siemann S, 2002, BBA-GEN SUBJECTS, V1571, P190, DOI 10.1016/S0304-4165(02)00258-1; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; Tam A, 2001, J BIOL CHEM, V276, P46798, DOI 10.1074/jbc.M106150200; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Winter-Vann AM, 2003, P NATL ACAD SCI USA, V100, P6529, DOI 10.1073/pnas.1135239100; Yoo BC, 1998, EXP MOL MED, V30, P227, DOI 10.1038/emm.1998.33; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	47	37	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7336	7345		10.1074/jbc.M410292200	http://dx.doi.org/10.1074/jbc.M410292200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611058	hybrid			2022-12-27	WOS:000227332700126
J	Keren, N; Liberton, M; Pakrasi, HB				Keren, N; Liberton, M; Pakrasi, HB			Photochemical competence of assembled photosystem II core complex in cyanobacterial plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D1 PROTEIN; THYLAKOID MEMBRANES; SP PCC-6803; MECHANISM; MANGANESE; LIGHT; Q(A)	Cyanobacterial cells have two autonomous internal membrane systems, plasma membrane and thylakoid membrane. In these oxygenic photosynthetic organisms the assembly of the large membrane protein complex photosystem II (PSII) is an intricate process that requires the recruitment of numerous protein subunits and cofactors involved in excitation and electron transfer processes. Precise control of this assembly process is necessary because electron transfer reactions in partially assembled PSII can lead to oxidative damage and degradation of the protein complex. In this communication we demonstrate that the activation of PSII electron transfer reactions in the cyanobacterium Synechocystis sp. PCC 6803 takes place sequentially. In this organism partially assembled PSII complexes can be detected in the plasma membrane. We have determined that such PSII complexes can undergo light-induced charge separation and contain a functional electron acceptor side but not an assembled donor side. In contrast, PSII complexes in thylakoid membrane are fully assembled and capable of multiple turnovers. We conclude that PSII reaction center cores assembled in the plasma membrane are photochemically competent and can catalyze single turnovers. We propose that upon transfer of such PSII core complexes to the thylakoid membrane, additional proteins are incorporated followed by binding and activation of various donor side cofactors. Such a stepwise process protects cyanobacterial cells from potentially harmful consequences of performing water oxidation in a partially assembled PSII complex before it reaches its final destination in the thylakoid membrane.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Pakrasi, HB (corresponding author), Washington Univ, Dept Biol, St Louis, MO 63130 USA.	Pakrasi@wustl.edu		Keren, Nir/0000-0002-7356-8831				ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BABCOCK GT, 1975, BIOCHIM BIOPHYS ACTA, V396, P48, DOI 10.1016/0005-2728(75)90188-7; BISHOP NI, 1958, BIOCHIM BIOPHYS ACTA, V27, P205, DOI 10.1016/0006-3002(58)90313-5; Choquet Y, 2001, BIOCHEM SOC T, V29, P421, DOI 10.1042/BST0290421; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Goussias C, 2002, PHILOS T R SOC B, V357, P1369, DOI 10.1098/rstb.2002.1134; JOHNSON GN, 1995, BBA-BIOENERGETICS, V1229, P202, DOI 10.1016/0005-2728(95)00003-2; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; Keren N, 2002, BIOCHEMISTRY-US, V41, P15085, DOI 10.1021/bi026892s; KEREN N, 1998, MOL BIOL CHLOROPLAST, P569; KRIEGER A, 1995, BBA-BIOENERGETICS, V1229, P193, DOI 10.1016/0005-2728(95)00002-Z; LIND LK, 1993, J BIOL CHEM, V268, P1575; Norling B, 1998, FEBS LETT, V436, P189, DOI 10.1016/S0014-5793(98)01123-5; Roose JL, 2004, J BIOL CHEM, V279, P45417, DOI 10.1074/jbc.M408458200; Schreiber U, 1996, FEBS LETT, V397, P131, DOI 10.1016/S0014-5793(96)01176-3; SEIBERT M, 1988, PLANT PHYSIOL, V87, P303, DOI 10.1104/pp.87.2.303; Spence E, 2003, MOL MICROBIOL, V48, P1481, DOI 10.1046/j.1365-2958.2003.03519.x; Thornton LE, 2004, PLANT CELL, V16, P2164, DOI 10.1105/tpc.104.023515; vanWijk KJ, 1997, BIOCHEMISTRY-US, V36, P6178, DOI 10.1021/bi962921l; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898	22	36	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6548	6553		10.1074/jbc.M410218200	http://dx.doi.org/10.1074/jbc.M410218200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611096	hybrid			2022-12-27	WOS:000227332700038
J	Kurihara, I; Shibata, H; Kobayashi, S; Suda, N; Ikeda, Y; Yokota, K; Murai, A; Saito, I; Rainey, WE; Saruta, T				Kurihara, I; Shibata, H; Kobayashi, S; Suda, N; Ikeda, Y; Yokota, K; Murai, A; Saito, I; Rainey, WE; Saruta, T			Ubc9 and protein inhibitor of activated STAT 1 activate chicken ovalbumin upstream promoter-transcription factor I-mediated human CYP11B2 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-DEPENDENT TRANSCRIPTION; MODIFIER-1 SUMO-1 MODIFICATION; STEROIDOGENIC FACTOR-I; HUMAN ADRENAL-CORTEX; ANDROGEN RECEPTOR; ALDOSTERONE SYNTHASE; GLUCOCORTICOID RECEPTOR; COUP-TFI; INTERACTING PROTEIN-3; ADRENOCORTICAL TUMORS	Aldosterone synthase (CYP11B2) is involved in the final steps of aldosterone biosynthesis and expressed exclusively in the adrenal zona glomerulosa cells. Using an electrophoretic mobility shift assay, we demonstrate that COUP-TFI binds to the -129/-114 element (Ad5) of human CYP11B2 promoter. Transient transfection in H295R adrenal cells demonstrated that COUP-TFI enhanced CYP11B2 reporter activity. However, the reporter construct with mutated Ad5 sequences showed reduced basal and COUP-TFI-enhanced activity, suggesting that binding of COUP-TFI to Ad5 is important for CYP11B2 transactivation. To elucidate molecular mechanisms of COUP-TFI-mediated activity, we subsequently screened for COUP-TFI-interacting proteins from a human adrenal cDNA library using a yeast two-hybrid system and identified Ubc9 and PIAS1, which have small ubiquitin-related modifier-1 (SUMO-1) conjugase and ligase activities, respectively. The coimmuno-precipitation assays confirmed that COUP-TFI forms a complex with Ubc9 and PIAS1 in mammalian cells. Immunohistochemistry showed that Ubc9 and PIAS1 are markedly expressed in rat adrenal glomerulosa cells. Coexpression of Ubc9 and PIAS1 synergistically enhanced the COUP-TFI-mediated CYP11B2 reporter activity, indicating that both proteins function as coactivators of COUP-TFI. However, sumoylation-defective mutants, Ubc9 (C93S) and PIAS1 (C351S), continued to function as coactivators of COUP-TFI, indicating that sumoylation activity are separable from coactivator ability. In addition, chromatin immunoprecipitation assays demonstrated that ectopically expressed COUP-TFI, Ubc9, and PIAS1 were recruited to an endogenous CYP11B2 promoter. Moreover, reduction of Ubc9 or PIAS1 protein levels by small interfering RNA inhibited the CYP11B2 transactivation by COUP-TFI. Our data support a physiological role of Ubc9 and PIAS1 as transcriptional coactivators in COUP-TFI-mediated CYP11B2 transcription.	Keio Univ, Sch Med, Dept Internal Med, Tokyo 1608582, Japan; Keio Univ, Ctr Hlth, Shinjuku Ku, Tokyo 1608582, Japan; Yokohama City Univ, Grad Sch med, Dept Fine Morphol, Yokohama, Kanagawa 2360004, Japan; Univ Texas, SW Med Ctr, Div Reprod Endocrinol, Dallas, TX 75390 USA	Keio University; Keio University; Yokohama City University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shibata, H (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Tokyo 1608582, Japan.	hiro-405@cb3.so-net.ne.jp			NIDDK NIH HHS [DK043140] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043140, R01DK043140] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; Bassett MH, 2004, MOL CELL ENDOCRINOL, V217, P67, DOI 10.1016/j.mce.2003.10.011; Bassett MH, 2004, J BIOL CHEM, V279, P37622, DOI 10.1074/jbc.M405431200; Bassett MH, 2004, MOL ENDOCRINOL, V18, P279, DOI 10.1210/me.2003-0005; Bassett MH, 2002, J MOL ENDOCRINOL, V28, P125, DOI 10.1677/jme.0.0280125; Buholzer CF, 2005, MOL ENDOCRINOL, V19, P65, DOI 10.1210/me.2004-0061; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Chen WY, 2004, J BIOL CHEM, V279, P38730, DOI 10.1074/jbc.M405006200; Clyne CD, 1997, MOL ENDOCRINOL, V11, P638, DOI 10.1210/me.11.5.638; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kobayashi S, 2004, J MOL ENDOCRINOL, V32, P69, DOI 10.1677/jme.0.0320069; Komatsu T, 2004, MOL ENDOCRINOL, V18, P2451, DOI 10.1210/me.2004-0173; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lu LY, 2004, J CLIN ENDOCR METAB, V89, P4113, DOI 10.1210/jc.2004-0069; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nathan D, 2003, P NATL ACAD SCI USA, V100, P13118, DOI 10.1073/pnas.2436173100; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Pascual-Le Tallec L, 2003, MOL ENDOCRINOL, V17, P2529, DOI 10.1210/me.2003-0299; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pilon C, 1999, J CLIN ENDOCR METAB, V84, P4228, DOI 10.1210/jc.84.11.4228; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rainey WE, 1999, MOL CELL ENDOCRINOL, V151, P151, DOI 10.1016/S0303-7207(99)00051-9; SASANO H, 1995, J CLIN ENDOCR METAB, V80, P2378, DOI 10.1210/jc.80.8.2378; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shibata H, 2003, J STEROID BIOCHEM, V85, P449, DOI 10.1016/S0960-0760(03)00217-6; Shibata H, 2003, HORM RES, V59, P85, DOI 10.1159/000067830; Shibata H, 1998, ENDOCR RES, V24, P881, DOI 10.3109/07435809809032703; Shibata H, 2000, ENDOCR RES, V26, P1039, DOI 10.3109/07435800009048636; Shibata H, 2001, MOL GENET METAB, V74, P206, DOI 10.1006/mgme.2001.3231; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shibata H, 1998, J CLIN ENDOCR METAB, V83, P4520, DOI 10.1210/jc.83.12.4520; SHIBATA H, 1993, ACTA ENDOCRINOL-COP, V128, P235, DOI 10.1530/acta.0.1280235; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Takeda Y, 1999, J CLIN ENDOCR METAB, V84, P1633, DOI 10.1210/jc.84.5.1633; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Tirard M, 2004, J MOL ENDOCRINOL, V32, P825, DOI 10.1677/jme.0.0320825; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; VAL P, 2003, NUCL RECEPT, V1, P508; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	61	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6721	6730		10.1074/jbc.M411820200	http://dx.doi.org/10.1074/jbc.M411820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611122	hybrid			2022-12-27	WOS:000227332700061
J	Jeon, S; Kim, S; Kim, E; Lee, JE; Kim, SJ; Juhnn, YS; Kim, YS; Bae, CD; Park, J				Jeon, S; Kim, S; Kim, E; Lee, JE; Kim, SJ; Juhnn, YS; Kim, YS; Bae, CD; Park, J			Chloride conductance is required for the protein kinase A and Rac1-dependent phosphorylation of moesin at Thr-558 by KCl in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; RHO-ASSOCIATED KINASE; ERM PROTEINS; EZRIN/RADIXIN/MOESIN PROTEINS; DEPENDENT PHOSPHORYLATION; NEURITE OUTGROWTH; CULTURED NEURONS; CONE MORPHOLOGY; ACTIVATION; GTPASES	Moesin is a member of the ERM family, a family of cross-linkers between the plasma membrane and the actin cytoskeleton, which are known to be activated by phosphorylation. Previously, we reported the RhoA and Rho kinase-dependent phosphorylation of moesin at Thr-558 in hippocampal neuronal cells by glutamate. Here we studied the induction of moesin phosphorylation by KCl (60 mM) in PC12 cells. Moesin phosphorylation at Thr-558 was increased after 2 min of KCl treatment, peaked at 5 min, and returned to the basal level by 60 min. KCl also activated Rac1, but not RhoA, in PC12 cells, and KCl-induced moesin phosphorylation was suppressed in dominant negative Rac1 (N17 Rac1)-expressed cells. The inhibition of protein kinase A (PKA), known as an upstream kinase of Rac1, abolished Rac1 activation and moesin phosphorylation by KCl. Interestingly, the phosphorylation of moesin by KCl was independent of KCl-induced membrane depolarization and calcium influx but was dependent on KCl-induced chloride conductance. 60 mM KCl induced chloride conductance in PC12 cells, and pretreatment with Cl- channel blocker abolished Rac1 activation and moesin phosphorylation by KCl. These results suggest that the phosphorylation of moesin at Thr-558 in PC12 cells by KCl treatment is PKA- and Rac1-dependent and that KCl-induced chloride conductance is involved in the activation of this signaling system.	Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Samsung Biomed Res Inst, Suwon 440746, South Korea; Sungkyunkwan Univ, Sch Med, Dept Physiol, Samsung Biomed Res Inst, Suwon 440746, South Korea; Sungkyunkwan Univ, Sch Med, Ctr Neuronal Cell Excitabil Res, Suwon 440746, South Korea; Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Inst Human Behav Med, Seoul 110744, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Park, J (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Samsung Biomed Res Inst, Suwon 440746, South Korea.	jbpark@med.skku.ac.kr	Juhnn, Yong-Sung/J-2790-2012; Kim, Sung Joon/H-1825-2012	Kim, Sung-Joon/0000-0002-0289-121X				AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; BANKEN R, 2002, ELECTROCONVULSIVE TH; Beitner-Johnson D, 2002, CELL SIGNAL, V14, P133, DOI 10.1016/S0898-6568(01)00253-4; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Brauer M, 2003, AM J PHYSIOL-CELL PH, V285, pC22, DOI 10.1152/ajpcell.00289.2002; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gatto CL, 2003, J CELL BIOL, V162, P489, DOI 10.1083/jcb.200303039; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; Hansen TV, 2003, NEUROSCI LETT, V347, P57, DOI 10.1016/S0304-3940(03)00581-0; Hilborn MD, 1997, J NEUROSCI RES, V47, P16; Jeon S, 2002, J BIOL CHEM, V277, P16576, DOI 10.1074/jbc.M110380200; Kim SJ, 2004, EXP MOL MED, V36, P98, DOI 10.1038/emm.2004.14; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; NILIUS B, 1994, NEWS PHYSIOL SCI, V9, P105; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomikos GG, 2000, EUR NEUROPSYCHOPHARM, V10, P495, DOI 10.1016/S0924-977X(00)00122-X; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; O'Reilly N, 2002, BRAIN RES, V943, P245, DOI 10.1016/S0006-8993(02)02655-0; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Pende M, 1997, J NEUROSCI, V17, P1291; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Pokorska A, 2003, J NEUROCHEM, V84, P447, DOI 10.1046/j.1471-4159.2003.01504.x; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Steinert M, 1997, J PHYSIOL-LONDON, V500, P653, DOI 10.1113/jphysiol.1997.sp022050; Whittard JD, 2001, J CELL SCI, V114, P3265; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	45	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12181	12189		10.1074/jbc.M408253200	http://dx.doi.org/10.1074/jbc.M408253200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15634677	hybrid			2022-12-27	WOS:000227922000016
J	Shi, YJ; Sharma, A; Wu, H; Lichtenstein, A; Gera, J				Shi, YJ; Sharma, A; Wu, H; Lichtenstein, A; Gera, J			Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOPROTEIN-K PROTEIN; 5' UNTRANSLATED REGION; MESSENGER-RNA; MAMMALIAN TARGET; CELL-CYCLE; IN-VITRO; EXPRESSION; KINASE; INITIATION; BINDING	The macrolide antibiotic rapamycin inhibits the mammalian target of rapamycin protein (mTOR) kinase resulting in the global inhibition of cap-dependent protein synthesis, a blockade in ribosome component biosynthesis, and G(1) cell cycle arrest. G1 arrest may occur by inhibiting the protein synthesis of critical factors required for cell cycle progression. Hypersensitivity to mTOR inhibitors has been demonstrated in cells having elevated levels of AKT kinase activity, whereas cells containing quiescent AKT activity are relatively resistant. Our previous data suggest that low AKT activity induces resistance by allowing continued cap-independent protein synthesis of cyclin D1 and c-Myc proteins. In support of this notion, the current study demonstrates that the human cyclin D1 mRNA 5 similar to untranslated region contains an internal ribosome entry site (IRES) and that both this IRES and the c-myc IRES are negatively regulated by AKT activity. Furthermore, we show that cyclin D1 and c-myc IRES function is enhanced following exposure to rapamycin and requires both p38 MAPK and RAF/MEK/ERK signaling, as specific inhibitors of these pathways reduce IRES-mediated translation and protein levels under conditions of quiescent AKT activity. Thus, continued IRES-mediated translation initiation may permit cell cycle progression upon mTOR inactivation in cells in which AKT kinase activity is relatively low.	Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 91343 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 91343 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 91343 USA; Univ Calif Los Angeles, David Geffen Sch Med, Howard Hughes Med Inst, Los Angeles, CA 91343 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gera, J (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA.	gera@ucla.edu		Gera, Joseph/0000-0002-2908-6894	NATIONAL CANCER INSTITUTE [R01CA096920] Funding Source: NIH RePORTER; NCI NIH HHS [CA096920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Cai A, 1999, BIOCHEMISTRY-US, V38, P8538, DOI 10.1021/bi9830213; CARROLL R, 1993, ANAL BIOCHEM, V212, P17, DOI 10.1006/abio.1993.1284; CIGAN AM, 1987, GENE, V59, P1; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Figueroa C, 2003, ONCOGENE, V22, P5554, DOI 10.1038/sj.onc.1206496; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; JACOBSON AB, 1993, J MOL BIOL, V233, P261, DOI 10.1006/jmbi.1993.1504; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Niwa M, 2000, P NATL ACAD SCI USA, V97, P12396, DOI 10.1073/pnas.250476097; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Ostrowski J, 2001, P NATL ACAD SCI USA, V98, P9044, DOI 10.1073/pnas.161284098; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; Sekulic A, 2000, CANCER RES, V60, P3504; Sherr CJ, 2002, CELL CYCLE, V1, P36, DOI 10.4161/cc.1.1.106; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tranque P, 1998, P NATL ACAD SCI USA, V95, P12238, DOI 10.1073/pnas.95.21.12238; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhu Y, 2002, NEUROSCIENCE, V110, P191, DOI 10.1016/S0306-4522(01)00522-X; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	53	125	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10964	10973		10.1074/jbc.M407874200	http://dx.doi.org/10.1074/jbc.M407874200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15634685	hybrid			2022-12-27	WOS:000227761800012
J	Zheng, WP; Schwarzer, D; LeBeau, A; Weller, JL; Klein, DC; Cole, PA				Zheng, WP; Schwarzer, D; LeBeau, A; Weller, JL; Klein, DC; Cole, PA			Cellular stability of serotonin N-acetyltransferase conferred by phosphonodifluoromethylene alanine (Pfa) substitution for Ser-205	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSED PROTEIN LIGATION; TYROSINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; MELATONIN SYNTHESIS; CHEMICAL LIGATION; PHOSPHOSERINE; KINASE; INHIBITION; ENZYME; SEMISYNTHESIS	Large changes in the activity of serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) in the pineal gland control the rhythmic production of the timekeeping hormone melatonin. The activity of AANAT reflects changes in the amount and activation state of the AANAT protein, both of which increase at night. The molecular basis of this regulation is now becoming known, and recent data indicate that this involves phosphorylation- dependent binding to the 14-3-3 protein at two sites, one of which, Ser-205, is located several residues from the C terminus. In this study, we determined whether substitution of this residue with a non-hydrolyzable the phosphoserine/phosphothreonine mimetic would promote binding to the 14-3-3 protein and enhance cellular stability. To accomplish this, a C-terminal AANAT peptide containing the phosphonodifluoromethylene alanine at Ser-205 was synthesized and fused to bacterially expressed AANAT(30-199) using expressed protein ligation. The resulting semisynthetic protein has enhanced affinity for the expressed 14-3-3 protein and exhibits greater cellular stability in microinjection experiments, as compared with the unmodified AANAT. Enhanced 14-3-3 binding was also observed using humanized ovine AANAT, which has a different C-terminal sequence (Gly-Cys) than the ovine enzyme (Asp-Arg), indicating that that characteristic is not unique to the ovine enzyme. These studies provide the first evidence that substitution of Ser-205 with the stable phosphomimetic amino acid phosphonodifluoromethylene alanine enhances binding to 14-3-3 and the cellular stability of AANAT and are consistent with the view that Ser-205 phosphorylation plays a critical role in the regulation of AANAT activity and melatonin production.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; NICHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	pcole@jhmi.edu		Schwarzer, Dirk/0000-0002-7477-3319; Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000095, Z01HD000095] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arendt J., 1995, MELATONIN MAMMALIAN; Berkowitz DB, 1996, J ORG CHEM, V61, P4666, DOI 10.1021/jo9604752; Burke TR, 2001, BIOPOLYMERS, V60, P32, DOI 10.1002/1097-0282(2001)60:1<32::AID-BIP1002>3.0.CO;2-I; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Choi BH, 2004, J NEUROCHEM, V90, P442, DOI 10.1111/j.1471-4159.2004.02495.x; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Ferry G, 2002, CELL MOL LIFE SCI, V59, P1395, DOI 10.1007/s00018-002-8517-4; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ganguly S, 2005, P NATL ACAD SCI USA, V102, P1222, DOI 10.1073/pnas.0406871102; Ganguly S, 2001, P NATL ACAD SCI USA, V98, P8083, DOI 10.1073/pnas.141118798; GARNER P, 1991, ORG SYNTH, V70, P18; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; He S, 2003, P NATL ACAD SCI USA, V100, P12033, DOI 10.1073/pnas.2035256100; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; Klein DC, 2003, J NEUROENDOCRINOL, V15, P370, DOI 10.1046/j.1365-2826.2003.01000.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lu W, 2003, BIOCHEMISTRY-US, V42, P5461, DOI 10.1021/bi0340144; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; MINASCHEK G, 1989, EXP CELL RES, V183, P434, DOI 10.1016/0014-4827(89)90402-3; Modrof J, 2001, VIROLOGY, V287, P171, DOI 10.1006/viro.2001.1027; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Ottesen JJ, 2004, BIOCHEMISTRY-US, V43, P5698, DOI 10.1021/bi0498407; Pellois JP, 2004, J AM CHEM SOC, V126, P7170, DOI 10.1021/ja0499142; Scheibner KA, 2003, ANAL BIOCHEM, V317, P226, DOI 10.1016/S0003-2697(03)00087-3; Shen K, 2003, J AM CHEM SOC, V125, P16172, DOI 10.1021/ja0380401; Shogren-Knaak MA, 2003, J BIOL CHEM, V278, P15744, DOI 10.1074/jbc.M301445200; Wang DX, 2001, J AM CHEM SOC, V123, P8883, DOI 10.1021/ja010540b; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang ZS, 2003, J BIOL CHEM, V278, P4668, DOI 10.1074/jbc.M210028200; Zheng WP, 2003, NAT STRUCT BIOL, V10, P1054, DOI 10.1038/nsb1005; Zheng WP, 2002, CURR MED CHEM, V9, P1187, DOI 10.2174/0929867023370013	40	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10462	10467		10.1074/jbc.M412283200	http://dx.doi.org/10.1074/jbc.M412283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632116	hybrid			2022-12-27	WOS:000227559600088
J	Lee, W; Glaeser, H; Smith, LH; Roberts, RL; Moeckel, GW; Gervasini, G; Leake, BF; Kim, RB				Lee, W; Glaeser, H; Smith, LH; Roberts, RL; Moeckel, GW; Gervasini, G; Leake, BF; Kim, RB			Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2) - Implications for altered drug disposition and central nervous system drug entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATION; EXPRESSION; MEDIATE; FAMILY	Organic anion- transporting polypeptide 1A2 ( OATP1A2) is a drug uptake transporter known for broad substrate specificity, including many drugs in clinical use. Therefore, genetic variation in SLCO1A2 may have important implications to the disposition and tissue penetration of substrate drugs. In the present study, we demonstrate OATP1A2 protein expression in human brain capillary and renal distal nephron using immunohistochemistry. We also determined the extent of single nucleotide polymorphisms in SLCO1A2 upon analyses of ethnically defined genomic DNA samples ( n = 95 each for African-, Chinese-, European-, and Hispanic- Americans). We identified six nonsynonymous polymorphisms within the coding region of SLCO1A2 ( T38C ( I13T), A516C ( E172D), G559A ( A187T), A382T ( N128Y), A404T ( N135I), and C2003G ( T668S)), the allelic frequencies of which appeared to be ethnicity dependent. In vitro functional assessment revealed that the A516C and A404T variants had markedly reduced capacity for mediating the cellular uptake of OATP1A2 substrates, estrone 3-sulfate and two delta-opioid receptor agonists, deltorphin II, and [D-penicillamine2,5]enkephalin. On the other hand, the G559A and C2003G variants appeared to have substrate- dependent changes in transport activity. Cell surface biotinylation and immunofluorescence confocal microscopy suggested that altered plasma membrane expression of the transporter may contribute to reduced transport activity associated with the A516C, A404T, and C2003G variants. The A404T ( N135I) variant also showed a shift in the apparent molecular size, indicative of alterations in glycosylation status. Taken together, these data suggest that SLCO1A2 polymorphisms may be an important yet unrecognized contributor to interindividual variability in drug disposition and central nervous system entry of substrate drugs.	Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Univ Extremadura, Sch Med, Dept Pharmacol & Psychiat, Badajoz 06071, Spain	Vanderbilt University; Vanderbilt University; Vanderbilt University; Universidad de Extremadura	Kim, RB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, 572 RRB,23rd Ave & Pierce Ave, Nashville, TN 37232 USA.	richard.kim@vanderbilt.edu	Kim, Richard/D-6971-2011; Lee, Wooin/K-7789-2012; Gervasini, Guillermo/N-2198-2014	Kim, Richard/0000-0001-8148-1632; Lee, Wooin/0000-0001-7805-869X; Gervasini, Guillermo/0000-0002-0524-9767; Moeckel, Gilbert/0000-0002-6059-0837; Smith, Layton/0000-0003-2621-9740	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061374, R01GM054724, P01GM031304, R55GM054724] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00095] Funding Source: Medline; NHLBI NIH HHS [U01 HL65962] Funding Source: Medline; NIGMS NIH HHS [GM31304, GM54724, U01GM61374] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cai SY, 2002, AM J PHYSIOL-GASTR L, V282, pG702, DOI 10.1152/ajpgi.00458.2001; Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866; Eckhardt U, 1999, AM J PHYSIOL-GASTR L, V276, pG1037, DOI 10.1152/ajpgi.1999.276.4.G1037; Fricker G, 2004, PHARMACOLOGY, V70, P169, DOI 10.1159/000075545; Gao B, 2000, J PHARMACOL EXP THER, V294, P73; Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y; Hagenbuch B, 2002, NEWS PHYSIOL SCI, V17, P231, DOI 10.1152/nips.01402.2002; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kim RB, 2003, EUR J CLIN INVEST, V33, P1, DOI 10.1046/j.1365-2362.33.s2.5.x; Kim RB, 1999, J PHARMACOL EXP THER, V291, P1204; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; Mizuno N, 2003, PHARMACOL REV, V55, P425, DOI 10.1124/pr.55.3.1; Nozawa T, 2002, J PHARMACOL EXP THER, V302, P804, DOI 10.1124/jpet.302.2.804; Steckelbroeck S, 2004, J NEUROCHEM, V89, P403, DOI 10.1046/j.1471-4159.2004.02336.x; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Tirona RG, 2001, J BIOL CHEM, V276, P35669, DOI 10.1074/jbc.M103792200	16	283	291	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9610	9617		10.1074/jbc.M411092200	http://dx.doi.org/10.1074/jbc.M411092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632119	hybrid			2022-12-27	WOS:000227453100116
J	MacAulay, K; Blair, AS; Hajduch, E; Terashima, T; Baba, O; Sutherland, C; Hundal, HS				MacAulay, K; Blair, AS; Hajduch, E; Terashima, T; Baba, O; Sutherland, C; Hundal, HS			Constitutive activation of GSK3 down-regulates glycogen synthase abundance and glycogen deposition in rat skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE 3-BETA; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; INHIBITION; KINASE-3-BETA; PHOSPHORYLATION; INACTIVATION; EXPRESSION; MEMBRANE; LITHIUM	The effects of inhibition or constitutive activation of glycogen synthase kinase-3 (GSK3) on glycogen synthase (GS) activity, abundance, and glycogen deposition in L6 rat skeletal muscle cells were investigated. GS protein expression increased similar to5-fold during differentiation of L6 cells (comparing cells at the end of day 5 with those at the beginning of day 3). However, exposure of undifferentiated myoblasts (day 3) to 50 muM SB-415286, a GSK3 inhibitor, led to a significant elevation in GS protein that was not accompanied by changes in the abundance of GLUT4, another late differentiation marker. In contrast, stable expression of a constitutively active form of GSK3beta (GSK3(S9A)) led to a significant reduction (similar to80%) in GS protein that was antagonized by SB-415286. Inhibition of GSK3 or expression of the constitutively active GSK3S9A did not result in any detectable changes in GS mRNA abundance. However, the increase in GS protein in undifferentiated myoblasts or that seen following incubation of cells expressing GSK3S9A with GSK3 inhibitors was blocked by cycloheximide suggesting that GSK3 influences GS abundance possibly via control of mRNA translation. Consistent with the reduction in GS protein, cells expressing GSK3S9A were severely glycogen depleted as judged using a specific glycogen-staining antibody. Inhibiting GSK3 in wild-type or GSK3(S9A)-expressing cells using SB-415286 resulted in an attendant activation of GS, but not that of glucose transport. However, GS activation alone was insufficient for stimulating glycogen deposition. Only when muscle cells were incubated simultaneously with insulin and SB-415286 or with lithium (which stimulates GS and glucose transport) was an increase in glycogen accretion observed. Our findings suggest that GSK3 activity is an important determinant of GS protein expression and that while glycogen deposition in muscle cells is inherently dependent upon the activity/expression of GS, glucose transport is a key rate-determining step in this process.	Univ Dundee, Fac Life Sci, Sch Life Sci, Inst Med Sci,Div Mol Physiol, Dundee, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland; Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138549, Japan	University of Dundee; University of Dundee; Tokyo Medical & Dental University (TMDU)	Hundal, HS (corresponding author), Univ Dundee, Fac Life Sci, Sch Life Sci, Inst Med Sci,Div Mol Physiol, MSI-WTB Complex, Dundee, Scotland.	h.s.hundal@dundee.ac.uk	Hundal, Hari/A-8990-2008; Hajduch, Eric/B-7332-2008	Hundal, Hari/0000-0002-7621-4932; Hajduch, Eric/0000-0002-0125-7751; Sutherland, Calum/0000-0003-4398-7434				Azpiazu I, 2000, AM J PHYSIOL-ENDOC M, V278, pE234, DOI 10.1152/ajpendo.2000.278.2.E234; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Coghlan M.P., 2000, CHEM BIOL, V24, P1; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cohen Y, 1998, MED ONCOL, V15, P32, DOI 10.1007/BF02787342; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; Henriksen EJ, 2003, AM J PHYSIOL-ENDOC M, V284, pE892, DOI 10.1152/ajpendo.00346.2002; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; MacAulay K, 2003, EUR J BIOCHEM, V270, P3829, DOI 10.1046/j.1432-1033.2003.03777.x; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; Mukai F, 2002, J NEUROCHEM, V81, P1073, DOI 10.1046/j.1471-4159.2002.00918.x; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; Nikoulina SE, 2002, DIABETES, V51, P2190, DOI 10.2337/diabetes.51.7.2190; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; Pearce NJ, 2004, METABOLISM, V53, P1322, DOI 10.1016/j.metabol.2004.05.008; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Talbot SG, 2004, ANN SURG ONCOL, V11, P530, DOI 10.1245/ASO.2004.03.014; Tsygankova OM, 2004, J BIOL CHEM, V279, P5501, DOI 10.1074/jbc.M305824200; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2	40	54	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9509	9518		10.1074/jbc.M411648200	http://dx.doi.org/10.1074/jbc.M411648200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632169	hybrid			2022-12-27	WOS:000227453100105
J	Takanaga, H; Mackenzie, B; Suzuki, Y; Hediger, MA				Takanaga, H; Mackenzie, B; Suzuki, Y; Hediger, MA			Identification of mammalian proline transporter SIT1 ( SLC6A20) with characteristics of classical system imino	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; BRUSH-BORDER MEMBRANE; COMMON ELIMINATED REGION-1; FUNCTIONAL-CHARACTERIZATION; GENE FAMILY; GLUTAMATE TRANSPORTER; ORPHAN TRANSPORTER; MOLECULAR-CLONING; RAT-KIDNEY; VESICLES	Amino acid homeostasis depends on specific amino acid transport systems, many of which have been characterized at the molecular level. However, the classical System IMINO, defined as the Na+-dependent proline transport activity that escapes inhibition by alanine, had not been identified at the molecular level. We report here the functional characteristics and tissue distribution of Sodium/Imino-acid Transporter 1 (SIT1), which exhibits the properties of classical System IMINO. SIT1, the product of the slc6a20 gene, is a member of the SLC6 Na+- and Cl-- dependent neurotransmitter transporter family whose function has remained unknown. When expressed in Xenopus oocytes, rat SIT1 mediated the uptake of imino acids such as proline (K-0.5 similar to 0.2 mM) and pipecolate, as well as N-methylated amino acids (e. g. MeAIB, sarcosine). SIT1-mediated proline transport was pH-independent and insensitive to inhibition by alanine or lysine. Proline transport was Na+-dependent, Cl--stimulated, and voltage-dependent. Li+, but not H+, could substitute for Na+. Human SIT1 also functioned as a Na+-dependent proline transporter. Rat SIT1 mRNA was expressed in epithelial cells of duodenum, jejunum, ileum, stomach, cecum, colon, and kidney proximal tubule S 3 segments. SIT1 mRNA was also expressed in the choroid plexus, microglia, and meninges of the brain and in the ovary. Previous reports have documented the marked urinary hyperexcretion of proline in newborn rodents and man. We found that SIT1 was dramatically up-regulated in the kidneys of 3-day-old mice, accounting for the maturation of proline reabsorption in the mouse. The human slc6a20 gene coding SIT1 is an appropriate target for investigation of hereditary forms of iminoaciduria in man.	Harvard Univ, Brigham & Womens Hosp, Inst Med, Div Renal,Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hediger, MA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Inst Med, Div Renal,Dept Med, Rm 570,77 Ave Louis Pasteur, Boston, MA 02115 USA.	mhediger@rics.bwh.harvard.edu		Hediger, Matthias/0000-0003-1946-027X; SUZUKI, YOSHIRO/0000-0003-0010-1867; Mackenzie, Bryan/0000-0002-9661-8838				Anderson CMH, 2004, GASTROENTEROLOGY, V127, P1410, DOI 10.1053/j.gastro.2004.08.017; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Avissar NE, 2001, AM J PHYSIOL-CELL PH, V281, pC963, DOI 10.1152/ajpcell.2001.281.3.C963; BAERLOCHER KE, 1971, BIOCHIM BIOPHYS ACTA, V249, P353, DOI 10.1016/0005-2736(71)90114-3; Boll M, 2002, J BIOL CHEM, V277, P22966, DOI 10.1074/jbc.M200374200; Botzenhart E, 2002, KIDNEY INT, V62, P1136, DOI 10.1111/j.1523-1755.2002.kid552.x; BOYD CAR, 1981, J PHYSIOL-LONDON, V315, P9, DOI 10.1113/jphysiol.1981.sp013728; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; Farmer MK, 2000, GENOMICS, V70, P241, DOI 10.1006/geno.2000.6387; GOLDMANN DR, 1979, BIOCHEM J, V178, P253, DOI 10.1042/bj1780253; GOODMAN SI, 1967, J PEDIATR-US, V71, P246, DOI 10.1016/S0022-3476(67)80081-7; GOYER RA, 1968, AM J MED SCI, V256, P166, DOI 10.1097/00000441-196809000-00005; HAMMERMAN MR, 1977, J BIOL CHEM, V252, P591; Hatanaka T, 2002, BIOCHEM BIOPH RES CO, V291, P291, DOI 10.1006/bbrc.2002.6441; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kiss H, 2002, MAMM GENOME, V13, P646, DOI 10.1007/s00335-002-3037-y; Kiss H, 2001, GENOMICS, V73, P10, DOI 10.1006/geno.2000.6498; Kleta R, 2004, NAT GENET, V36, P999, DOI 10.1038/ng1405; LASLEY L, 1979, PEDIATR RES, V13, P65, DOI 10.1203/00006450-197901000-00014; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; Mackenzie B, 2003, J BIOL CHEM, V278, P23720, DOI 10.1074/jbc.M212718200; Mackenzie B., 1999, BIOMEMBRANE TRANSPOR, P327; MCANULTY RJ, 1987, COLLAGEN REL RES, V7, P93; MEDOW MS, 1986, P NATL ACAD SCI USA, V83, P7561, DOI 10.1073/pnas.83.19.7561; MUNCK BG, 1985, J MEMBRANE BIOL, V83, P15, DOI 10.1007/BF01868734; Munck LK, 1997, COMP BIOCHEM PHYS A, V118, P229, DOI 10.1016/S0300-9629(97)00072-8; Nash SR, 1998, RECEPTOR CHANNEL, V6, P113; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Romero MF, 1998, METHOD ENZYMOL, V296, P17; ROSS HJ, 1984, BRAIN RES, V295, P155, DOI 10.1016/0006-8993(84)90826-6; SCRIVER CR, 1982, PEDIATR RES, V16, P684, DOI 10.1203/00006450-198208000-00022; SCRIVER CR, 1961, NATURE, V192, P672, DOI 10.1038/192672a0; Seow HF, 2004, NAT GENET, V36, P1003, DOI 10.1038/ng1406; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; SMITH KE, 1995, FEBS LETT, V357, P86, DOI 10.1016/0014-5793(94)01328-X; STEVENS BR, 1985, J MEMBRANE BIOL, V87, P27, DOI 10.1007/BF01870696; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; Swarna M, 2004, BIOCHEM GENET, V42, P85, DOI 10.1023/B:BIGI.0000020464.05335.79; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Urdaneta E, 1998, J PHYSIOL BIOCHEM, V54, P155; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Wu GY, 1998, J NUTR, V128, P1249, DOI 10.1093/jn/128.8.1249; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200	50	106	110	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8974	8984		10.1074/jbc.M413027200	http://dx.doi.org/10.1074/jbc.M413027200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632147	hybrid			2022-12-27	WOS:000227453100044
J	Jakimowicz, P; Cheesman, MR; Bishai, WR; Chater, KF; Thomson, AJ; Buttner, MJ				Jakimowicz, P; Cheesman, MR; Bishai, WR; Chater, KF; Thomson, AJ; Buttner, MJ			Evidence that the Streptomyces developmental protein WhiD, a member of the WhiB family, binds a [4Fe-4S] cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COELICOLOR A3(2); ESCHERICHIA-COLI; BACILLUS-SUBTILIS; ENDONUCLEASE-III; COLONY MUTANTS; RNA-BINDING; SPORULATION; GENE; GROWTH; REGULATOR	WhiD is required for the late stages of sporulation in the Gram-positive bacterium Streptomyces coelicolor. WhiD is a member of the WhiB-like family of putative transcription factors that are present throughout the actinomycetes but absent from other organisms. This family of proteins has four near-invariant cysteines, suggesting that these residues might act as ligands for a metal cofactor. Overexpressed WhiD, purified from Escherichia coli, contained substoichiometric amounts of iron and had an absorption spectrum characteristic of a [2Fe-2S] cluster. After Fe-S cluster reconstitution under anaerobic conditions, WhiD contained similar to4 iron atoms/monomer and similar amounts of sulfide ion and gave an absorption spectrum characteristic of a [4Fe-4S] cluster. Reconstituted WhiD gave no electron paramagnetic resonance signal as prepared but, after reduction with dithionite, gave an electron paramagnetic resonance signal (g similar to2.06, 1.94) consistent with a one-electron reduction of a [4Fe-4S](2+) cluster to a [4Fe-4S](1+) state with electron spin of S = 1/2. The anaerobically reconstituted [4Fe-4S] cluster was oxygen sensitive. Upon exposure to air, absorption at 410 and 505 nm first increased and then showed a steady decrease with time until the protein was colorless in the near UV/visible region. These changes are consistent with an oxygen-induced change from a [4Fe-4S] to a [2Fe-2S] cluster, followed by complete loss of cluster from the protein. Each of the four conserved cysteine residues, Cys-23, -53, -56, and -62, was essential for WhiD function in vivo.	John Innes Inst, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Johns Hopkins Sch Med, Ctr TB Res, Dept Med, Baltimore, MD 21231 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia; Johns Hopkins University; Johns Hopkins Medicine	Jakimowicz, P (corresponding author), John Innes Inst, Dept Mol Microbiol, Coloney Lane, Norwich NR4 7UH, Norfolk, England.	Piotr.Jakimowicz@bbsrc.ac.uk		Buttner, Mark/0000-0002-3505-2981	NIAID NIH HHS [R01 AI 51668] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051668] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alen C, 1999, P NATL ACAD SCI USA, V96, P10412, DOI 10.1073/pnas.96.18.10412; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bentley SD, 2004, MOL MICROBIOL, V51, P1615, DOI 10.1111/j.1365-2958.2003.03949.x; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Brekasis D, 2003, EMBO J, V22, P4856, DOI 10.1093/emboj/cdg453; BRUMBY PE, 1965, J BIOL CHEM, V240, P2222; CHATER KF, 1972, J GEN MICROBIOL, V72, P9, DOI 10.1099/00221287-72-1-9; Crack J, 2004, J BIOL CHEM, V279, P9278, DOI 10.1074/jbc.M309878200; CRACK JC, 2003, THESIS U E ANGLIA NO; DAVIS NK, 1992, MOL GEN GENET, V232, P351, DOI 10.1007/BF00266237; Elliot MA, 2004, CURR OPIN MICROBIOL, V7, P594, DOI 10.1016/j.mib.2004.10.013; Flardh K, 1999, MICROBIOL-SGM, V145, P2229, DOI 10.1099/00221287-145-9-2229; Fromme JC, 2003, EMBO J, V22, P3461, DOI 10.1093/emboj/cdg311; FU WG, 1992, J BIOL CHEM, V267, P16135; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; Gomez JE, 2000, P NATL ACAD SCI USA, V97, P8554, DOI 10.1073/pnas.140225297; Hahn JS, 2000, J BIOL CHEM, V275, P38254, DOI 10.1074/jbc.M006079200; Hahn JS, 2000, J BACTERIOL, V182, P3767, DOI 10.1128/JB.182.13.3767-3774.2000; Hahn JS, 2002, J BACTERIOL, V184, P5214, DOI 10.1128/JB.184.19.5214-5222.2002; JANSSEN GR, 1993, GENE, V124, P133, DOI 10.1016/0378-1119(93)90774-W; Kieser T, 2000, PRACTICAL STREPTOMYC, P249; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; MCVITTIE A, 1974, J GEN MICROBIOL, V81, P291, DOI 10.1099/00221287-81-2-291; Molle V, 2000, J BACTERIOL, V182, P1286, DOI 10.1128/JB.182.5.1286-1295.2000; MORRIS RP, 2003, 13 NT S BIOL ACT MEL, P26; Nakano MM, 1998, ANNU REV MICROBIOL, V52, P165, DOI 10.1146/annurev.micro.52.1.165; ORMEJOHNSON WH, 1973, IRON SULFUR PROTEINS, V2, P194; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Paget MSB, 2001, MOL MICROBIOL, V39, P1036, DOI 10.1046/j.1365-2958.2001.02298.x; Soliveri JA, 2000, MICROBIOL-SGM, V146, P333, DOI 10.1099/00221287-146-2-333; STEPHENS PJ, 1978, BIOCHEM J, V27, P4770; Steyn AJC, 2002, P NATL ACAD SCI USA, V99, P3147, DOI 10.1073/pnas.052705399; SWEENEY WV, 1980, ANNU REV BIOCHEM, V49, P139, DOI 10.1146/annurev.bi.49.070180.001035; Tang Y, 1999, MICROBIOL-SGM, V145, P3069, DOI 10.1099/00221287-145-11-3069	36	88	91	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8309	8315		10.1074/jbc.M412622200	http://dx.doi.org/10.1074/jbc.M412622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615709	hybrid			2022-12-27	WOS:000227395700105
J	Kani, K; Warren, CM; Kaddis, CS; Loo, JA; Landgraf, R				Kani, K; Warren, CM; Kaddis, CS; Loo, JA; Landgraf, R			Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; NONCOVALENT PROTEIN COMPLEXES; EGF RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; CELL; ACTIVATION; BINDING; HER-2/NEU; ONCOGENE	ErbB receptors associate in a ligand-dependent or -independent manner, and overexpression of epidermal growth factor receptor (ErbB1) or ErbB2 results in ligand-independent activation. Ligand-independent activation is poorly understood, and dimerization alone is not sufficient for activation. ErbB receptors also form higher order oligomers, but the mechanism of oligomer formation and their contribution to signaling are not known. The kinase-deficient ErbB3 as well as its extracellular domains are particularly prone to ligand-independent oligomerization, and oligomers are destabilized by binding of the ligand heregulin. In contrast, ligand binding facilitates heterodimerization with ErbB2 and is expected to stabilize an extended conformation of the ErbB3 extracellular domain (ECD) in which the dimerization interface is exposed. In the absence of ligand, ErbB3 can adopt a closed conformation that is held together by an intramolecular tether. We used a constitutively extended form of the ErbB3-ECD to analyze the conformation of the ECD in oligomers and the mechanism of oligomer disruption by heregulin. The extended conformation of the ECD forms oligomers more readily, suggesting the crystallographically defined dimer interface is one of the interfaces involved in oligomerization. Heregulin destabilizes oligomeric complexes but not dimers, which are neither stabilized nor disrupted by ligand binding, indicating a distinct second interface in oligomers of ErbB3. Cross-linking and activation studies on membrane-embedded ErbB3/ErbB2 chimeras confirm this dual effect of heregulin. Most of the ErbB3-ECD on the cell surface is apparently kept in an open conformation through oligomerization, and the resulting oligomers adopt a conformation representing a state of reduced activity.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Landgraf, R (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA.	rlandgraf@mednet.ucla.edu		Kani, Kian/0000-0001-7774-265X	NCI NIH HHS [CA098881-01A1] Funding Source: Medline; NCRR NIH HHS [RR20004] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098881] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR020004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bacher G, 2001, J MASS SPECTROM, V36, P1038, DOI 10.1002/jms.208; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BERCHUCK A, 1990, CANCER RES, V50, P4087; Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; Berger MB, 2004, FEBS LETT, V569, P332, DOI 10.1016/j.febslet.2004.06.014; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; Era T, 2002, Methods Mol Biol, V185, P83; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Kaufman SL, 1998, ANAL BIOCHEM, V259, P195, DOI 10.1006/abio.1998.2644; Klein P, 2004, P NATL ACAD SCI USA, V101, P929, DOI 10.1073/pnas.0307285101; Landgraf R, 1998, BIOCHEMISTRY-US, V37, P3220, DOI 10.1021/bi972326z; Landgraf R, 2000, BIOCHEMISTRY-US, V39, P8503, DOI 10.1021/bi000953+; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Mattoon D, 2004, P NATL ACAD SCI USA, V101, P923, DOI 10.1073/pnas.0307286101; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Mouradian S, 1997, ANAL CHEM, V69, P919, DOI 10.1021/ac960785k; Nagy P, 1999, J CELL SCI, V112, P1733; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Rostom AA, 2000, P NATL ACAD SCI USA, V97, P5185, DOI 10.1073/pnas.97.10.5185; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sliwkowski MX, 2003, NAT STRUCT BIOL, V10, P158, DOI 10.1038/nsb0303-158; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Walker F, 2004, J BIOL CHEM, V279, P22387, DOI 10.1074/jbc.M401244200; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	36	43	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8238	8247		10.1074/jbc.M410944200	http://dx.doi.org/10.1074/jbc.M410944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611073	hybrid			2022-12-27	WOS:000227395700097
J	Liu, LR; Du, ZW; Zhao, HL; Liu, XL; Huang, XD; Shen, J; Ju, LM; Fang, FD; Zhang, JW				Liu, LR; Du, ZW; Zhao, HL; Liu, XL; Huang, XD; Shen, J; Ju, LM; Fang, FD; Zhang, JW			T to C substitution at-175 or-173 of the gamma-globin promoter affects GATA- and Oct-1 binding in vitro differently but can independently reproduce the hereditary persistence of fetal hemoglobin phenotype in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL REGULATION; TRANSCRIPTIONAL REPRESSION; GENE PROMOTER; HPFH; UPSTREAM; MUTATION; REGION; PROTEIN; EXPRESSION	The T to C substitution at position - 175 of the gamma-globin gene has been identified in some individuals with non-deletion hereditary persistence of fetal hemoglobin ( HPFH). In this study, the HPFH phenotype was reestablished in transgenic mice carrying the mu'LCRAgamma(-175)psibetadeltabeta construct, which contained a 3.1-kb mu'LCR cassette linked to a 29-kb fragment from the Agamma- to gamma-globin gene with the natural chromosome arrangement but with the - 175 mutation, which provided evidence for this single mutation as the cause of this form of HPFH. The HPFH phenotype was also reproduced in transgenic mice carrying the mu'LCRAgamma(-173)psibetadeltabeta construct, in which the - 175 T to C Agamma gene was substituted with the - 173 T to C Agamma gene. In vitro experiments proved that the - 175 mutation significantly reduced binding of Oct-1 but not GATA-1, whereas the - 173 mutation dramatically decreased binding of GATA-1 but not Oct-1. These results suggest that abrogation of either GATA-1 or Oct-1 binding to this promoter region may result in the HPFH phenotype. An in vivo footprinting assay revealed that either the - 175 mutation or the - 173 mutation significantly decreased overall protein binding to this promoter region in adult erythrocytes of transgenic mice. We hypothesize that a multiprotein complex containing GATA-1, Oct-1, and other protein factors may contribute to the formation of a repressive chromatin structure that silences gamma-globin gene expression in normal adult erythrocytes. Both the - 173 and - 175 T to C substitutions may disrupt the complex assembly and result in the reactivation of the gamma-globin gene in adult erythrocytes.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol, Beijing 100005, Peoples R China; Peking Union Med Coll, Beijing 100005, Peoples R China; Chinese Acad Med Sci, Inst Expt Anim, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhang, JW (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	junwu_zhang@pumc.edu.cn	Liu, Liren/AAX-8645-2021; Du, Zhanwen/H-9903-2016; liu, liren/ABH-6459-2020	Liu, Liren/0000-0001-7786-7874; liu, liren/0000-0001-7786-7874				BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; Cheng CK, 2002, ENDOCRINOLOGY, V143, P4693, DOI 10.1210/en.2002-220576; Cunningham JM, 1996, SEMIN HEMATOL, V33, P9; Delhase M, 1996, J BIOL CHEM, V271, P32349, DOI 10.1074/jbc.271.50.32349; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FINK PS, 1991, BIOTECHNIQUES, V10, P446; Forget BG, 1998, ANN NY ACAD SCI, V850, P38, DOI 10.1111/j.1749-6632.1998.tb10460.x; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; Hogan B, 1994, MANIPULATING MOUSE E; Kang SHL, 2002, NUCLEIC ACIDS RES, V30; Kim MK, 1996, MOL CELL BIOL, V16, P4366; Li QL, 2001, EMBO J, V20, P157, DOI 10.1093/emboj/20.1.157; LLOYD JA, 1989, NUCLEIC ACIDS RES, V17, P4339, DOI 10.1093/nar/17.11.4339; MAGIS W, 1995, BIOCHEM BIOPH RES CO, V214, P927, DOI 10.1006/bbrc.1995.2375; Malone CS, 2000, J IMMUNOL, V164, P2550, DOI 10.4049/jimmunol.164.5.2550; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P7783, DOI 10.1093/nar/16.16.7783; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; OTTOLENGHI S, 1988, BLOOD, V71, P815; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; RIXON MW, 1988, MOL CELL BIOL, V8, P713, DOI 10.1128/MCB.8.2.713; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; Stamatoyannopoulos G., 2001, MOL BASIS BLOOD DIS, Vthird, P135; STARCK J, 1994, BLOOD, V84, P1656; STOMING TA, 1989, BLOOD, V73, P329; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; SURREY S, 1988, BLOOD, V71, P807; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; ULRICH MJ, 1990, BLOOD, V75, P990; Wall RJ, 2000, ANIM BIOTECHNOL, V11, P19, DOI 10.1080/10495390009525944; Zhang JG, 1999, IEEE AERO EL SYS MAG, V14, P31, DOI 10.1109/62.756081	35	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7452	7459		10.1074/jbc.M411407200	http://dx.doi.org/10.1074/jbc.M411407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15613485	hybrid			2022-12-27	WOS:000227395700006
J	Lockhart, A; Ye, L; Judd, DB; Merritt, AT; Lowe, PN; Morgenstern, JL; Hong, GZ; Gee, AD; Brown, J				Lockhart, A; Ye, L; Judd, DB; Merritt, AT; Lowe, PN; Morgenstern, JL; Hong, GZ; Gee, AD; Brown, J			Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGO RED; IN-VITRO; BRAIN; PLAQUES; DERIVATIVES; PROTEIN; PROBES	Imaging the progression of Alzheimer's disease would greatly facilitate the discovery of therapeutics, and a wide range of ligands are currently under development for the detection of beta-amyloid peptide (Abeta)-containing plaques by using positron emission tomography. Here we report an in-depth characterization of the binding of seven previously described ligands to in vitro generated Abeta-(1 - 40) polymers. All of the compounds were derived from the benzothiazole compound thioflavin T and include 2-[4'-( methylamino) phenyl] benzothiazole and 2-(4'-dimethylamino-) phenyl-imidazo[1,2- a]-pyridine derivatives, 2-[4'-( dimethylamino) phenyl]-6-iodobenzothiazole and 2-[4'-(4"-methylpiperazin-1-yl)phenyl]-6- iodobenzothiazole, and a benzofuran compound (5-bromo-2-(4-dimethylaminophenyl) benzofuran). By using a range of fluorescent and radioligand binding assays, we find that these compounds display a more complex binding pattern than described previously and are consistent with three classes of binding sites on the Abeta fibrils. All of the compounds bound with very high affinity (low nM K-d) to a low capacity site (BS3) (1 ligand-binding site per similar to300 Abeta-(140) monomers) consistent with the previously recognized binding site for these compounds on the fibrils. However, the compounds also bound with high affinity (K-d similar to100 nM) to either one of two additional binding sites on the Abeta-(140) polymer. The properties of these sites, BS1 and BS2, suggest they are adjacent or partially overlapping and have a higher capacity than BS3, occurring every similar to35 or every similar to4 monomers of Abeta-(1 - 40)-peptide, respectively. Compounds appear to display selectivity for BS2 based on the presence of a halogen substitution ( 2-[4'-( dimethylamino) phenyl]-6-iodobenzothiazole,2-[4'-(4"-methylpiperazin-1-yl)phenyl]-6-iodobenzothiazole,and 5-bromo2-(4-dimethylaminophenyl) benzofuran) on their aromatic ring system. The presence of additional ligand-binding sites presents potential new targets for ligand development and may allow a more complete modeling of the current positron emission tomography data.	Addenbrookes Hosp, GlaxoSmithKline Res & Dev, Cambridge CB2 2GG, England; GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, High Throughput Chem, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, Mol Interact, Stevenage SG1 2NY, Herts, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; GlaxoSmithKline; University of Cambridge; GlaxoSmithKline; GlaxoSmithKline	Lockhart, A (corresponding author), Addenbrookes Hosp, GlaxoSmithKline, ACCI,Box 128,Hills Rd, Cambridge CB2 2GG, England.	andrew.2.lockhart@gsk.com		Gee, Antony/0000-0001-8389-9012				Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Agdeppa ED, 2003, NEUROSCIENCE, V117, P723, DOI 10.1016/S0306-4522(02)00907-7; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Gold G, 2001, J NEUROPATH EXP NEUR, V60, P946, DOI 10.1093/jnen/60.10.946; Hong GZ, 2003, FASEB J, V17, P1966, DOI 10.1096/fj.03-0181fje; KELENYL G, 1967, J HISTOCHEM CYTOCHEM, V15, P172; Klunk WE, 2002, J NEUROPATH EXP NEUR, V61, P797, DOI 10.1093/jnen/61.9.797; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klunk WE, 2001, LIFE SCI, V69, P1471, DOI 10.1016/S0024-3205(01)01232-2; Kung Hang F, 2003, Mol Imaging Biol, V5, P418, DOI 10.1016/j.mibio.2003.09.003; Kung HF, 2001, J AM CHEM SOC, V123, P12740, DOI 10.1021/ja0167147; Kung MP, 2002, BRAIN RES, V956, P202, DOI 10.1016/S0006-8993(02)03436-4; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Mathis CA, 2003, J MED CHEM, V46, P2740, DOI 10.1021/jm030026b; Mathis CA, 2002, BIOORG MED CHEM LETT, V12, P295, DOI 10.1016/S0960-894X(01)00734-X; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012; Nordberg A, 2004, LANCET NEUROL, V3, P519, DOI 10.1016/S1474-4422(04)00853-1; Ono M, 2002, NUCL MED BIOL, V29, P633, DOI 10.1016/S0969-8051(02)00326-8; Pope AJ, 1999, DRUG DISCOV TODAY, V4, P350, DOI 10.1016/S1359-6446(99)01340-9; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; Small GW, 2002, J MOL NEUROSCI, V19, P323; Styren SC, 2000, J HISTOCHEM CYTOCHEM, V48, P1223, DOI 10.1177/002215540004800906; Suemoto T, 2004, NEUROSCI RES, V48, P65, DOI 10.1016/j.neures.2003.09.005; Tolnay M, 2003, IUBMB LIFE, V55, P299, DOI 10.1080/1521654032000114348; VASSAR PS, 1959, ARCH PATHOL, V68, P487; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; Zhuang ZP, 2001, J MED CHEM, V44, P1905, DOI 10.1021/jm010045q	32	181	197	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7677	7684		10.1074/jbc.M412056200	http://dx.doi.org/10.1074/jbc.M412056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615711	hybrid			2022-12-27	WOS:000227395700031
J	Rifkin, DB				Rifkin, DB			Latent transforming growth factor-beta (TGF-beta) binding proteins: Orchestrators of TGF-beta availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							EXTRACELLULAR-MATRIX; COLORECTAL-CANCER; EMBRYONIC HEART; MARFAN-SYNDROME; ACTIVATION; LTBP-1; CELLS; IDENTIFICATION; EXPRESSION; TGF-BETA-1		NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University; New York University	Rifkin, DB (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1St Ave, New York, NY 10016 USA.	rifkid01@med.nyu.edu						Altmann CR, 2002, DEV BIOL, V248, P118, DOI 10.1006/dbio.2002.0716; Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Bashir MM, 1996, INT J BIOCHEM CELL B, V28, P531, DOI 10.1016/1357-2725(95)00167-0; Charbonneau Noe L, 2004, Birth Defects Res C Embryo Today, V72, P37, DOI 10.1002/bdrc.20000; Chen Y, 2003, J CELL PHYSIOL, V196, P319, DOI 10.1002/jcp.10296; Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706; Dabovic B, 2002, J CELL BIOL, V156, P227, DOI 10.1083/jcb.200111080; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; Gualandris A, 2000, MOL BIOL CELL, V11, P4295, DOI 10.1091/mbc.11.12.4295; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Hyytiainen M, 2003, J CELL BIOL, V163, P1363, DOI 10.1083/jcb.200309105; Hyytiainen M, 1998, J BIOL CHEM, V273, P20669, DOI 10.1074/jbc.273.32.20669; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Koli K, 2004, J CELL BIOL, V167, P123, DOI 10.1083/jcb.200403067; Koli K, 2001, MICROSC RES TECHNIQ, V52, P354, DOI 10.1002/1097-0029(20010215)52:4<354::AID-JEMT1020>3.0.CO;2-G; Koski C, 1999, J BIOL CHEM, V274, P32619, DOI 10.1074/jbc.274.46.32619; Lack J, 2003, J MOL BIOL, V334, P281, DOI 10.1016/j.jmb.2003.09.053; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; Mangasser-Stephan K, 1999, CELL TISSUE RES, V297, P363, DOI 10.1007/s004410051364; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOREN A, 1994, J BIOL CHEM, V269, P32469; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Nakajima Y, 1997, J CELL BIOL, V136, P193, DOI 10.1083/jcb.136.1.193; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Noguera I, 2003, GENE, V308, P31, DOI 10.1016/S0378-1119(03)00463-3; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; Penttinen C, 2002, J CELL SCI, V115, P3457; RUNYAN RB, 1992, MOL REPROD DEV, V32, P152, DOI 10.1002/mrd.1080320211; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; Shipley JM, 2000, MOL CELL BIOL, V20, P4879, DOI 10.1128/MCB.20.13.4879-4887.2000; Sterner-Kock A, 2002, GENE DEV, V16, P2264, DOI 10.1101/gad.229102; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Unsold C, 2001, J CELL SCI, V114, P187; Vehvilainen P, 2003, J BIOL CHEM, V278, P24705, DOI 10.1074/jbc.M212953200; Weiskirchen R, 2003, GENE, V308, P43, DOI 10.1016/S0378-1119(03)00464-5; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	50	327	339	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7409	7412		10.1074/jbc.R400029200	http://dx.doi.org/10.1074/jbc.R400029200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611103	hybrid			2022-12-27	WOS:000227395700001
J	Naiki, Y; Michelsent, KS; Zhang, WX; Chen, SA; Doherty, TM; Arditi, M				Naiki, Y; Michelsent, KS; Zhang, WX; Chen, SA; Doherty, TM; Arditi, M			Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; TGF-BETA; ACCELERATES ATHEROSCLEROSIS; DROSOPHILA EMBRYO; PLAQUE PHENOTYPE; INNATE IMMUNITY; MICE; TGF-BETA-1; PATHWAYS; CELLS	Transforming growth factor-beta1 (TGF-beta1) is a multifunctional, potent anti-inflammatory cytokine produced by many cell types that regulates cell proliferation, apoptosis, and immune responses. Toll-like receptors (TLRs) recognize various pathogen-associated molecular patterns and are therefore a pivotal component of the innate immune system. In this study we show that TGF-beta1 blocks the NF-KB activation and cytokine release that is stimulated by ligands for TLRs 2, 4, and 5. We further show that TGF-beta1 can specifically interfere with TLR2, -4, or -5 ligand-induced responses involving the adaptor molecule MyD88 (myeloid differentiation factor 88) but not the TRAM/TRIF signaling pathway by decreasing MyD88 protein levels in a dose- and time-dependent manner without altering its mRNA expression. The proteasome inhibitor epoxomicin abolished the MyD88 degradation induced by TGF-beta1. Furthermore, TGF-beta1 resulted in ubiquitination of MyD88 protein, suggesting that TGF-beta1 facilitates ubiquitination and proteasomal degradation of MyD88 and thereby attenuates MyD88-dependent signaling by decreasing cellular levels of MyD88 protein. These findings importantly contribute to our understanding of molecular mechanisms mediating anti-inflammatory modulation of immune responses by TGF-beta1.	Univ Calif Los Angeles, David Geffen Sch Med, Burns & Allen Res Inst, Cedars Sinai Med Ctr,Dept Pediat Infect Dis, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Burns & Allen Res Inst,Div Cardiol, Cedars Sinai Med Ctr,Atherosclerosis Res Ctr, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Arditi, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Burns & Allen Res Inst, Cedars Sinai Med Ctr,Dept Pediat Infect Dis, 8700 Beverly Blvd,Rm 4220, Los Angeles, CA 90048 USA.	moshe.arditi@cshs.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058128] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 66436] Funding Source: Medline; NIAID NIH HHS [AI 058128] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Araujo H, 2000, DEVELOPMENT, V127, P3631; BELLONE G, 1995, J IMMUNOL, V155, P1066; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Chen WJ, 2003, CYTOKINE GROWTH F R, V14, P85, DOI 10.1016/S1359-6101(03)00003-0; CHRIST M, 1994, J IMMUNOL, V153, P1936; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Doherty TM, 2004, J CLIN INVEST, V114, P1699, DOI 10.1172/JCI200423867; Fremond CM, 2004, J CLIN INVEST, V114, P1790, DOI 10.1172/JCI200421027; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gojova A, 2003, BLOOD, V102, P4052, DOI 10.1182/blood-2003-05-1729; Hansson G, 2004, ARTERIOSCL THROM VAS, V24, pE137, DOI 10.1161/01.ATV.0000130728.38755.09; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; McCartney-Francis N, 2004, J IMMUNOL, V172, P3814, DOI 10.4049/jimmunol.172.6.3814; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Michelsen KS, 2004, J IMMUNOL, V173, P5901, DOI 10.4049/jimmunol.173.10.5901; Miyazono K, 2004, ONCOGENE, V23, P4232, DOI 10.1038/sj.onc.1207131; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Netea MG, 2004, J LEUKOCYTE BIOL, V75, P749, DOI 10.1189/jlb.1103543; Olobo JO, 2001, SCAND J IMMUNOL, V53, P85, DOI 10.1046/j.1365-3083.2001.00844.x; Robertson AKL, 2003, J CLIN INVEST, V112, P1342, DOI 10.1172/JCI200318607; Roes J, 2003, P NATL ACAD SCI USA, V100, P7241, DOI 10.1073/pnas.0731875100; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Vento S, 2003, LANCET ONCOL, V4, P595, DOI 10.1016/S1470-2045(03)01218-X; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Xu XH, 2001, CIRCULATION, V104, P3103, DOI 10.1161/hc5001.100631; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	37	129	138	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5491	5495		10.1074/jbc.C400503200	http://dx.doi.org/10.1074/jbc.C400503200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15623538	hybrid			2022-12-27	WOS:000227217100047
J	Rodney, GG; Wilson, GM; Schneider, MF				Rodney, GG; Wilson, GM; Schneider, MF			A calmodulin binding domain of RyR increases activation of spontaneous Ca2+ sparks in frog skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM SPARKS; RYANODINE RECEPTOR; RELEASE CHANNEL; MODULATION; APOCALMODULIN; TERMINATION; INITIATION; REGION; SITE	The calmodulin C lobe binding region ( residues 3614 3643) on the sarcoplasmic reticulum Ca2+ release channel (RyR1) is thought to be a region of contact between subunits within RyR1 homotetramer Ca2+ release channels. To determine whether the 3614-3643 region is a regulatory site/interaction domain within RyR in muscle fibers, we have investigated the effect of a synthetic peptide corresponding to this region (R3614-3643) on Ca2+ sparks in frog skeletal muscle fibers. R3614-3643 (0.2-3.0 mu M) promoted the occurrence of Ca2+ sparks in a highly cooperative dose-dependent manner, with a half-maximal activation at 0.47 mu M and a maximal increase in frequency of similar to 5-fold. A peptide with a single amino acid substitution within R3614-3643 (L3624D) retained the ability to bind Ca2+-free calmodulin but did not increase Ca2+ spark frequency, suggesting that R3614-3643 does not modulate Ca2+ sparks by removal of endogenous calmodulin. Our data support a model in which the calmodulin binding domain of RyR1 modulates channel activity by at least two mechanisms: direct binding of calmodulin as well as interactions with other regions of RyR.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Fluroescence Spect, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Schneider, MF (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	mschneid@umaryland.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507; Rodney, George G/0000-0002-6968-1516	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023346, F32NS044636] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR08119] Funding Source: Medline; NIAMS NIH HHS [T32-AR07592] Funding Source: Medline; NINDS NIH HHS [R01-NS23346, F32-NS44636] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERS DM, 1994, METHOD CELL BIOL, V40, P3; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; Lacampagne A, 1998, J GEN PHYSIOL, V111, P207, DOI 10.1085/jgp.111.2.207; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; Rodney GG, 2004, FASEB J, V18, pA1289; Rodney GG, 2004, BIOPHYS J, V86, p223A; Rodney GG, 2003, BIOPHYS J, V85, P921, DOI 10.1016/S0006-3495(03)74531-7; Rodney GG, 2001, BIOCHEMISTRY-US, V40, P12430, DOI 10.1021/bi011078a; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Schneider MF, 1999, J GEN PHYSIOL, V113, P365, DOI 10.1085/jgp.113.3.365; Schneider MF, 2002, FRONT BIOSCI-LANDMRK, V7, pD1212, DOI 10.2741/schneide; Sencer S, 2001, J BIOL CHEM, V276, P38237; Shtifman A, 2000, BIOPHYS J, V79, P814, DOI 10.1016/S0006-3495(00)76338-7; Shtifman A, 2002, J GEN PHYSIOL, V119, P15, DOI 10.1085/jgp.119.1.15; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; TSUCHIYA T, 1988, BIOPHYS J, V53, P415, DOI 10.1016/S0006-3495(88)83118-7; Ward CW, 1998, BIOPHYS J, V74, pA269; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; Yamamoto T, 2000, J BIOL CHEM, V275, P11618, DOI 10.1074/jbc.275.16.11618; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200; Zhu XS, 2004, CELL CALCIUM, V35, P165, DOI 10.1016/j.ceca.2003.09.002	31	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11713	11722		10.1074/jbc.M408189200	http://dx.doi.org/10.1074/jbc.M408189200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15640144	hybrid			2022-12-27	WOS:000227761800100
J	Lieman, JH; Worley, LA; Harbour, JW				Lieman, JH; Worley, LA; Harbour, JW			Loss of Rb-E2F repression results in caspase-8-mediated apoptosis through inactivation of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE ENTRY; PROTEIN-TYROSINE PHOSPHATASES; TUMOR-SUPPRESSOR; CELL-DEATH; RETINOBLASTOMA PROTEIN; HUMAN BREAST; KAPPA-B; EXPRESSION; RB; ACTIVATION	Molecular hardwiring of the cell cycle to the apoptotic machinery is a critical tumor suppressor mechanism for eliminating hyperproliferative cells. Deregulation of the Rb-E2F repressor complex by genetic deletion or functional inhibition of Rb triggers apoptosis through both the intrinsic (caspase-9 mediated) and extrinsic (caspase-8 mediated) death pathways. Induction of the intrinsic pathway has been studied extensively and involves release of free E2F and direct transcriptional activation of E2F-responsive apoptotic genes such as ARF, APAF1, and CASP9. In contrast, the mechanisms leading to activation of the extrinsic pathway are less well understood. There is growing evidence that Rb-E2F perturbation induces the extrinsic pathway, at least in part, through derepression (as opposed to transactivation) of apoptotic genes. Here, we explore this possibility using cells in which Rb-E2F complexes are displaced from promoters without stimulating E2F transactivation. This derepression of Rb-E2F-regulated genes leads to apoptosis through inactivation of focal adhesion kinase and activation of caspase-8. These findings reveal a new mechanistic link between Rb-E2F and the extrinsic (caspase 8-mediated) apoptotic pathway.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Harbour, JW (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Box 8096,660 S Eucclid Ave, St Louis, MO 63110 USA.	harbour@wustl.edu	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809	NEI NIH HHS [EY13169] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013169] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Beviglia L, 2003, BIOCHEM J, V373, P201, DOI 10.1042/BJ20021846; Cance WG, 2000, CLIN CANCER RES, V6, P2417; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Cuncic C, 1999, BIOCHEM PHARMACOL, V58, P1859, DOI 10.1016/S0006-2952(99)00284-1; Dube N, 2004, CELL CYCLE, V3, P550; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Golubovskaya V, 2004, BBA-GENE STRUCT EXPR, V1678, P111, DOI 10.1016/j.bbaexp.2004.03.002; Guo Z, 2001, CANCER RES, V61, P8395; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hentze H, 2004, HEPATOLOGY, V39, P1311, DOI 10.1002/hep.20174; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Ilic D, 1997, J CELL SCI, V110, P401; Joshi SG, 2003, HISTOCHEM CELL BIOL, V119, P463, DOI 10.1007/s00418-003-0536-1; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Mortier E, 2001, CELL SIGNAL, V13, P901, DOI 10.1016/S0898-6568(01)00226-1; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tracey AS, 2000, J INORG BIOCHEM, V80, P11, DOI 10.1016/S0162-0134(00)00033-7; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200; Warabi M, 2000, EXP MOL PATHOL, V68, P187, DOI 10.1006/exmp.2000.2303; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	50	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10484	10490		10.1074/jbc.M409371200	http://dx.doi.org/10.1074/jbc.M409371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640164	hybrid			2022-12-27	WOS:000227559600091
J	Dam, TK; Oscarson, S; Roy, R; Das, SK; Page, D; Macaluso, F; Brewer, CF				Dam, TK; Oscarson, S; Roy, R; Das, SK; Page, D; Macaluso, F; Brewer, CF			Thermodynamic, kinetic, and electron microscopy studies of concanavalin A and Dioclea grandiflora lectin cross-linked with synthetic divalent carbohydrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED PRECIPITATION SYSTEMS; LOTUS-TETRAGONOLOBUS; NEGATIVE REGULATION; CORE TRIMANNOSIDE; T-CELLS; BINDING; GALECTIN-1; OLIGOSACCHARIDES; APOPTOSIS; LATTICES	The jack bean lectin concanavalin A (ConA) and the Dioclea grandiflora lectin (DGL) are highly homologous Man/Glc-specific members of the Diocleinae subtribe. Both lectins bind, cross-link, and precipitate with carbohydrates possessing multiple terminal nonreducing Man residues. The present study investigates the binding and cross-linking interactions of ConA and DGL with a series of synthetic divalent carbohydrates that possess spacer groups with increasing flexibility and length between terminal alpha-mannopyranoside residues. Isothermal titration microcalorimetry was used to determine the thermodynamics of binding of the two lectins to the divalent analogs, and kinetic light scattering and electron microscopy studies were used to characterize the cross-linking interactions of the lectins with the carbohydrates. The results demonstrated that divalent analogs with flexible spacer groups between the two terminal Man residues possess higher affinities for the two lectins as compared with those with inflexible spacer groups. Furthermore, despite their high degree of homology, ConA and DGL exhibit differences in their kinetics of cross-linking and precipitation with the divalent analogs. Electron microscopy shows the loss of organized cross-linked lattices of the two lectins with analogs possessing increased distance between the terminal Man residues. The loss of lattice patterns with the analogs is distinct for each lectin. These results have important implications for the interactions of lectins with multivalent carbohydrate receptors in biological systems.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Univ Stockholm, Dept Organ Chem, S-10691 Stockholm, Sweden; Univ Quebec, Montreal, PQ H3C 3P8, Canada	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stockholm University; University of Quebec; University of Quebec Montreal	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	brewer@aecom.yu.edu		Oscarson, Stefan/0000-0002-8273-4918	NATIONAL CANCER INSTITUTE [R01CA016054, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16054, P30 CA-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRAWAL BBL, 1967, BIOCHIM BIOPHYS ACTA, V147, P262, DOI 10.1016/0005-2795(67)90404-7; Ahmad N, 2004, J BIOL CHEM, V279, P10841, DOI 10.1074/jbc.M312834200; Akahani S, 1997, CANCER RES, V57, P5272; BHATTACHARYYA L, 1990, BIOCHEMISTRY-US, V29, P7523, DOI 10.1021/bi00484a022; BHATTACHARYYA L, 1988, BIOCHEMISTRY-US, V27, P8762, DOI 10.1021/bi00424a011; Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; BREWER CF, 1996, CHEMTRACTS BIOCH MOL, V6, P165; Cheng W, 1998, J BIOL CHEM, V273, P35016, DOI 10.1074/jbc.273.52.35016; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; Dam TK, 2000, J BIOL CHEM, V275, P16119, DOI 10.1074/jbc.M000670200; Dam TK, 2003, METHOD ENZYMOL, V362, P455; Dam TK, 2000, J BIOL CHEM, V275, P14223, DOI 10.1074/jbc.275.19.14223; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDMONDS BT, 1990, CELL MOTIL CYTOSKEL, V17, P106, DOI 10.1002/cm.970170206; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; Gupta D, 1996, EUR J BIOCHEM, V242, P320, DOI 10.1111/j.1432-1033.1996.0320r.x; Konstantinov KN, 1996, AM J PATHOL, V148, P25; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; MANDAL DK, 1992, BIOCHEMISTRY-US, V31, P12602, DOI 10.1021/bi00165a009; MOREIRA RA, 1983, PLANTA, V158, P63, DOI 10.1007/BF00395404; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Olsen LR, 1997, BIOCHEMISTRY-US, V36, P15073, DOI 10.1021/bi971828+; Pace KE, 1999, J IMMUNOL, V163, P3801; Page D, 1997, GLYCOCONJUGATE J, V14, P345, DOI 10.1023/A:1018522712250; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Roy R, 1999, PURE APPL CHEM, V71, P565, DOI 10.1351/pac199971040565; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SAHA SK, 1994, CARBOHYD RES, V254, P157; Varki A., 1999, ESSENTIALS GLYCOBIOL; Vespa GNR, 1999, J IMMUNOL, V162, P799; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	39	54	55	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8640	8646		10.1074/jbc.M412827200	http://dx.doi.org/10.1074/jbc.M412827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632152	hybrid			2022-12-27	WOS:000227453100004
J	Knodler, LA; Finlay, BB; Steele-Mortimer, O				Knodler, LA; Finlay, BB; Steele-Mortimer, O			The Salmonella effector protein SopB protects epithelial cells from apoptosis by sustained activation of Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROTYPE TYPHIMURIUM; MONOCYTE-DERIVED MACROPHAGES; III SECRETION SYSTEM; PATHOGENICITY ISLAND; HOST-CELL; SEROVAR TYPHIMURIUM; CULTURED MACROPHAGES; INFECTED MACROPHAGES; POLYAMINE DEPLETION; ACTIN CYTOSKELETON	Invasion of epithelial cells by Salmonella enterica is mediated by bacterial "effector" proteins that are delivered into the host cell by a type III secretion system. Although primarily known for their roles in actin rearrangements and membrane ruffling, translocated effectors also affect host cell processes that are not directly associated with invasion. Here, we show that SopB/SigD, an effector with phosphoinositide phosphatase activity, has anti-apoptotic activity in Salmonella-infected epithelial cells. Salmonella induced the sustained activation of Akt/protein kinase B, a pro-survival kinase, in a SopB-dependent manner. Failure to activate Akt resulted in increased levels of apoptosis after infection with a sopB deletion mutant (DeltasopB). Furthermore, cells infected with wild type bacteria, but not the DeltasopB strain, were protected from camptothecin-induced cleavage of caspase-3 and subsequent apoptosis. The antiapoptotic activity of SopB was dependent on its phosphatase activity, because a catalytically inactive mutant was unable to protect cells from the effects of camptothecin. Finally, small interfering RNA was used to demonstrate the essential role of Akt in SopB-mediated protection against apoptosis. These results provide new insights into the mechanisms of apoptosis and highlight how bacterial effectors can intercept signaling pathways to manipulate host responses.	NIAID, Rocky Mt Labs, Intracellular Parasites Lab, NIH, Hamilton, MT 59840 USA; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of British Columbia	Steele-Mortimer, O (corresponding author), NIAID, Rocky Mt Labs, Intracellular Parasites Lab, NIH, Hamilton, MT 59840 USA.	omortimer@niaid.nih.gov		Knodler, Leigh/0000-0002-3028-2198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000909, Z01AI000909] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramovitch RB, 2003, EMBO J, V22, P60, DOI 10.1093/emboj/cdg006; Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; Browne SH, 2002, INFECT IMMUN, V70, P7126, DOI 10.1128/IAI.70.12.7126-7135.2002; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; Cirillo DM, 1998, MOL MICROBIOL, V30, P175, DOI 10.1046/j.1365-2958.1998.01048.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Collier-Hyams LS, 2002, J IMMUNOL, V169, P2846, DOI 10.4049/jimmunol.169.6.2846; Deng WL, 2003, AM J PHYSIOL-GASTR L, V284, pG821, DOI 10.1152/ajpgi.00406.2002; Deng WL, 2002, GASTROENTEROLOGY, V123, P206, DOI 10.1053/gast.2002.34209; FIERER J, 1993, INFECT IMMUN, V61, P5231, DOI 10.1128/IAI.61.12.5231-5236.1993; Galan JE, 2000, METHOD ENZYMOL, V325, P496; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Galyov EE, 1997, MOL MICROBIOL, V25, P903, DOI 10.1111/j.1365-2958.1997.mmi525.x; Gibson EM, 2002, CANCER RES, V62, P488; Grossmann J, 2002, AM J GASTROENTEROL, V97, P1421, DOI 10.1016/S0002-9270(02)04143-6; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hernandez LD, 2004, SCIENCE, V304, P1805, DOI 10.1126/science.1098188; Hernandez LD, 2003, J CELL BIOL, V163, P1123, DOI 10.1083/jcb.200309161; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Hueffer K, 2004, CELL MICROBIOL, V6, P1019, DOI 10.1111/j.1462-5822.2004.00451.x; Jamir Y, 2004, PLANT J, V37, P554, DOI 10.1046/j.1365-313X.2003.01982.x; Jarvelainen HA, 2003, TRENDS CELL BIOL, V13, P204, DOI 10.1016/S0962-8924(03)00032-1; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; Kim JM, 1998, J CLIN INVEST, V102, P1815, DOI 10.1172/JCI2466; Knodler LA, 2002, MOL MICROBIOL, V43, P1089, DOI 10.1046/j.1365-2958.2002.02820.x; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; Kurita A, 2003, MICROB PATHOGENESIS, V35, P43, DOI 10.1016/S0882-4010(03)00066-4; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; LUK GD, 1990, BIOCHEM SOC T, V18, P1090, DOI 10.1042/bst0181090; Marcus SL, 2002, CELL MICROBIOL, V4, P435, DOI 10.1046/j.1462-5822.2002.00202.x; Marcus SL, 2001, FEBS LETT, V494, P201, DOI 10.1016/S0014-5793(01)02356-0; Monack DM, 2000, J EXP MED, V192, P249, DOI 10.1084/jem.192.2.249; Monack DM, 2001, MICROBES INFECT, V3, P1201, DOI 10.1016/S1286-4579(01)01480-0; Monack DM, 2001, CELL MICROBIOL, V3, P825, DOI 10.1046/j.1462-5822.2001.00162.x; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; Muller A, 2001, INT J MED MICROBIOL, V291, P197, DOI 10.1078/1438-4221-00125; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Paesold G, 2002, CELL MICROBIOL, V4, P771, DOI 10.1046/j.1462-5822.2002.00233.x; Perfettini JL, 2003, BIOCHIMIE, V85, P763, DOI 10.1016/j.biochi.2003.08.006; Ray RM, 2000, AM J PHYSIOL-CELL PH, V278, pC480, DOI 10.1152/ajpcell.2000.278.3.C480; Reis BP, 2003, VET MICROBIOL, V97, P269, DOI 10.1016/j.vetmic.2003.09.019; Santos RL, 2001, INFECT IMMUN, V69, P2293, DOI 10.1128/IAI.69.4.2293-2301.2001; SCHAUSER K, 2004, IN PRESS HISTOCHEM C; Steele-Mortimer O, 2000, J BIOL CHEM, V275, P37718, DOI 10.1074/jbc.M008187200; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Thomson BJ, 2001, INT J EXP PATHOL, V82, P65, DOI 10.1111/j.1365-2613.2001.iep195.x; Tsolis RM, 1999, INFECT IMMUN, V67, P4879, DOI 10.1128/IAI.67.9.4879-4885.1999; van der Velden AWM, 2003, J IMMUNOL, V171, P6742, DOI 10.4049/jimmunol.171.12.6742; van der Velden AWM, 2000, INFECT IMMUN, V68, P5702, DOI 10.1128/IAI.68.10.5702-5709.2000; Waterman SR, 2003, CELL MICROBIOL, V5, P501, DOI 10.1046/j.1462-5822.2003.00294.x; Watson PR, 2000, INFECT IMMUN, V68, P3744, DOI 10.1128/IAI.68.6.3744-3747.2000; Watson PR, 1998, INFECT IMMUN, V66, P1432, DOI 10.1128/IAI.66.4.1432-1438.1998; Zhang HFM, 2004, J BIOL CHEM, V279, P22539, DOI 10.1074/jbc.M314337200; Zhang SP, 2003, INFECT IMMUN, V71, P4795, DOI 10.1128/IAI.71.8.4795-4803.2003; Zhang SP, 2002, INFECT IMMUN, V70, P3843, DOI 10.1128/IAI.70.7.3843-3855.2002; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x; Zhou X, 2000, MICROBIOL IMMUNOL, V44, P987, DOI 10.1111/j.1348-0421.2000.tb02594.x; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	60	174	180	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9058	9064		10.1074/jbc.M412588200	http://dx.doi.org/10.1074/jbc.M412588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15642738	hybrid			2022-12-27	WOS:000227453100054
J	Pappan, KL; Pan, ZJ; Kwon, G; Marshall, CA; Coleman, T; Goldberg, IJ; McDaniel, ML; Semenkovich, CF				Pappan, KL; Pan, ZJ; Kwon, G; Marshall, CA; Coleman, T; Goldberg, IJ; McDaniel, ML; Semenkovich, CF			Pancreatic beta-cell lipoprotein lipase independently regulates islet glucose metabolism and normal insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULATING FATTY-ACIDS; RESISTANCE; GENE; OVEREXPRESSION; LIPOTOXICITY; LANGERHANS; IMPAIRMENT; SUBSTRATE; TRANSPORT; OXIDATION	Lipid and glucose metabolism are adversely affected by diabetes, a disease characterized by pancreatic beta-cell dysfunction. To clarify the role of lipids in insulin secretion, we generated mice with beta-cell-specific overexpression (betaLPL-TG) or inactivation (betaLPL-KO) of lipoprotein lipase (LPL), a physiologic provider of fatty acids. LPL enzyme activity and triglyceride content were increased in betaLPL-TG islets; decreased LPL enzyme activity in betaLPL-KO islets did not affect islet triglyceride content. Surprisingly, both betaLPL-TG and betaLPL-KO mice were strikingly hyperglycemic during glucose tolerance testing. Impaired glucose tolerance in betaLPL-KO mice was present at one month of age, whereas betaLPL-TG mice did not develop defective glucose homeostasis until approximately five months of age. Glucose-simulated insulin secretion was impaired in islets isolated from both mouse models. Glucose oxidation, critical for ATP production and triggering of insulin secretion mediated by the ATP-sensitive potassium (K-ATP) channel, was decreased in betaLPL-TG islets but increased in betaLPL-KO islets. Islet ATP content was not decreased in either model. Insulin secretion was defective in both betaLPL-TG and betaLPL-KO islets under conditions causing calcium-dependent insulin secretion independent of the K-ATP channel. These results show that beta-cell-derived LPL has two physiologically relevant effects in islets, the inverse regulation of glucose metabolism and the independent mediation of insulin secretion through effects distal to membrane depolarization.	Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol & Physiol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Columbia University	Semenkovich, CF (corresponding author), Washington Univ, Dept Med, Sch Med, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	csemenko@im.wustl.edu	Pappan, Kirk/AAV-5946-2021	Semenkovich, Clay/0000-0003-1163-1871; Pappan, Kirk/0000-0002-2341-8798	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045095, R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, R56DK006181, P30DK056341, R01DK006181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427, HL45095] Funding Source: Medline; NIDDK NIH HHS [DK06181, DK20579, DK56341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Augustus A, 2004, J BIOL CHEM, V279, P25050, DOI 10.1074/jbc.M401028200; Augustus AS, 2003, AM J PHYSIOL-ENDOC M, V284, pE331, DOI 10.1152/ajpendo.00298.2002; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Boucher A, 2004, J BIOL CHEM, V279, P27263, DOI 10.1074/jbc.M401167200; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CRESPIN SR, 1969, J CLIN INVEST, V48, P1934, DOI 10.1172/JCI106160; Cruz WS, 2001, J BIOL CHEM, V276, P12162, DOI 10.1074/jbc.M010707200; Dobbins RL, 1998, DIABETES, V47, P1613, DOI 10.2337/diabetes.47.10.1613; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; Goodarzi MO, 2004, DIABETES, V53, P214, DOI 10.2337/diabetes.53.1.214; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; HESS DT, 1992, J NEUROSCI, V12, P4634; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Liang Y, 1997, DIABETOLOGIA, V40, P1018, DOI 10.1007/s001250050783; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Liu YQ, 1999, DIABETES, V48, P1747, DOI 10.2337/diabetes.48.9.1747; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Ma L, 2004, P NATL ACAD SCI USA, V101, P9266, DOI 10.1073/pnas.0403201101; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MCDANIEL ML, 1974, DIABETOLOGIA, V10, P303; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; Mulder H, 2004, DIABETES, V53, P122, DOI 10.2337/diabetes.53.1.122; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Roduit R, 2004, DIABETES, V53, P1007, DOI 10.2337/diabetes.53.4.1007; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; Sambandam N, 1999, ARTERIOSCL THROM VAS, V19, P1526, DOI 10.1161/01.ATV.19.6.1526; Sato K, 1998, COMP BIOCHEM PHYS A, V119, P569, DOI 10.1016/S1095-6433(97)00468-6; Schlaepfer IR, 2003, J LIPID RES, V44, P1174, DOI 10.1194/jlr.M300003-JLR200; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; Tordjman K, 2002, J LIPID RES, V43, P936; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Warnotte C, 1999, MOL CELL ENDOCRINOL, V153, P147, DOI 10.1016/S0303-7207(99)00069-6; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Winzell MS, 2003, DIABETES, V52, P2057; Yaney GC, 2003, DIABETOLOGIA, V46, P1297, DOI 10.1007/s00125-003-1207-4; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042	49	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9023	9029		10.1074/jbc.M409706200	http://dx.doi.org/10.1074/jbc.M409706200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637076	hybrid			2022-12-27	WOS:000227453100049
J	Shishioh, N; Hong, YJ; Ohishi, K; Ashida, H; Maeda, Y; Kinoshita, T				Shishioh, N; Hong, YJ; Ohishi, K; Ashida, H; Maeda, Y; Kinoshita, T			GPI7 is the second partner of PIG-F and involved in modification of glycosylphosphatidylinositol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; ANCHOR BIOSYNTHESIS; TRANSFERRING PHOSPHOETHANOLAMINE; ALPHA-1,4-LINKED MANNOSE; MEMBRANE ANCHOR; CORE STRUCTURE; 3RD MANNOSE; YEAST; PROTEINS	Many eukaryotic cell surface proteins are anchored to the membrane via glycosylphosphatidylinositol (GPI). GPI is synthesized from phosphatidylinositol by stepwise reactions and attached en bloc to nascent proteins. In mammalian cells, the major GPI species transferred to proteins is termed H7. By attachment of an additional ethanolamine phosphate (EtNP) to the second mannose, H7 can be converted to H8, which acts as a minor type of protein-linked GPI and also exists as a free GPI on the cell surface. Yeast GPI7 is involved in the transfer of EtNP to the second mannose, but the corresponding mammalian enzyme has not yet been clarified. Here, we report that the human homolog of Gpi7p (hGPI7) forms a protein complex with PIG-F and is involved in the H7-to-H8 conversion. We knocked down hGPI7 by RNA interference and found that H7 accumulated with little production of H8. Immunoprecipitation experiments revealed that hGPI7 was associated with and stabilized by PIG-F, which is known to bind to and stabilize PIG-O, a protein homologous to hGPI7. PIG-O is a transferase that adds EtNP to the third mannose, rendering GPI capable of attaching to proteins. We further found that the overexpression of hGPI7 decreased the level of PIG-O and, therefore, decreased the level of EtNP transferred to the third mannose. Finally, we propose a mechanism for the regulation of GPI biosynthesis through competition between the two independent enzymes, PIG-O and hGPI7, for the common stabilizer, PIG-F.	Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, Suita, Osaka 5650871, Japan; Chonnam Natl Univ, Sch Med, Dept Microbiol, Genome Res Ctr Enteropathogen Bacteria, Kwangju 501746, South Korea; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Saitama 3320012, Japan	Osaka University; Chonnam National University; Japan Science & Technology Agency (JST)	Kinoshita, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Ashida, Hisashi/HCI-0293-2022; Kinoshita, Taroh/C-7353-2009	Ashida, Hisashi/0000-0001-5844-4075				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baumann NA, 2000, J BIOL CHEM, V275, P7378, DOI 10.1074/jbc.275.10.7378; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen R, 1996, P NATL ACAD SCI USA, V93, P2280, DOI 10.1073/pnas.93.6.2280; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Fujita M, 2004, J BIOL CHEM, V279, P51869, DOI 10.1074/jbc.M405232200; Galperin MY, 2001, PROTEINS, V45, P318, DOI 10.1002/prot.1152; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Hasuwa H, 2002, FEBS LETT, V532, P227, DOI 10.1016/S0014-5793(02)03680-3; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Imhof I, 2004, J BIOL CHEM, V279, P19614, DOI 10.1074/jbc.M401873200; Imhof I, 2000, GLYCOBIOLOGY, V10, P1271, DOI 10.1093/glycob/10.12.1271; INOUE N, 1993, J BIOL CHEM, V268, P6882; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 1996, GENOMICS, V34, P340, DOI 10.1006/geno.1996.0296; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; Richard M, 2002, MICROBIOL-SGM, V148, P2125, DOI 10.1099/00221287-148-7-2125; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; TAGUCHI R, 1994, BIOCHEMISTRY-US, V33, P1017, DOI 10.1021/bi00170a021; Taron CH, 2000, MOL BIOL CELL, V11, P1611, DOI 10.1091/mbc.11.5.1611; Tiede A, 1998, BIOCHEM J, V334, P609, DOI 10.1042/bj3340609; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; UEDA E, 1993, J BIOL CHEM, V268, P9998; Vainauskas S, 2004, J BIOL CHEM, V279, P6540, DOI 10.1074/jbc.M312191200; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; Watanabe R, 1999, BIOCHEM J, V339, P185, DOI 10.1042/0264-6021:3390185	38	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9728	9734		10.1074/jbc.M413755200	http://dx.doi.org/10.1074/jbc.M413755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632136	hybrid			2022-12-27	WOS:000227453100130
J	Tchougounova, E; Lundequist, A; Fajardo, I; Winberg, JO; Abrink, M; Pejler, G				Tchougounova, E; Lundequist, A; Fajardo, I; Winberg, JO; Abrink, M; Pejler, G			A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGELATINASE-A; IN-VIVO; 4-AMINOPHENYLMERCURIC ACETATE; MOLECULAR-BIOLOGY; TISSUE INHIBITOR; CARDIAC FIBROSIS; GELATINASE; ANGIOGENESIS; EXPRESSION; HEPARIN	Chymases, serine proteases exclusively expressed by mast cells, have been implicated in various pathological conditions. However, the basis for these activities is not known, i.e. the in vivo substrate(s) for mast cell chymase has not been identified. In this study we show that mice lacking the chymase mouse mast cell protease 4 (mMCP- 4) fail to process pro-matrix metalloprotease 9 (pro-MMP- 9) to its active form in vivo, whereas both the pro and active form of MMP-9 was found in tissues of wild type mice. Moreover, the processing of pro-MMP-2 into active enzyme was markedly defective in mMCP- 4 null animals. Histological analysis revealed an increase in collagen in the ear tissue of mMCP-4-deficient animals accompanied by increased ear thickness and a higher content of hydroxyproline. Furthermore, both lung and ear tissue from the knock-out animals showed a markedly increased staining for fibronectin. MMP-9 and MMP-2 are known to have a range of important activities, but the mechanisms for their activation in vivo have not been clarified previously. The present study thus indicates a key role for mast cell chymase in the regulation of pro-MMP-2 and -9 activities. Moreover, the results suggest an important role for mast cell chymase in regulating connective tissue homeostasis.	Swedish Univ Agr Sci, BMC, Dept Mol Biosci, S-75123 Uppsala, Sweden; Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway	Swedish University of Agricultural Sciences; UiT The Arctic University of Tromso	Pejler, G (corresponding author), Swedish Univ Agr Sci, BMC, Dept Mol Biosci, Box 575, S-75123 Uppsala, Sweden.	Gunnar.Pejler@bmc.uu.se	Åbrink, Magnus/AAK-8346-2020; Fajardo, Ignacio/L-2943-2014	Fajardo, Ignacio/0000-0001-6676-7579; Abrink, Magnus/0000-0002-1335-3927				Caughey GH, 2002, MOL IMMUNOL, V38, P1353, DOI 10.1016/S0161-5890(02)00087-1; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Galli SJ, 1997, J EXP MED, V186, P343, DOI 10.1084/jem.186.3.343; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kofford MW, 1997, J BIOL CHEM, V272, P7127, DOI 10.1074/jbc.272.11.7127; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Matsumoto T, 2003, CIRCULATION, V107, P2555, DOI 10.1161/01.CIR.0000074041.81728.79; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Muramatsu M, 2002, BRIT J PHARMACOL, V137, P554, DOI 10.1038/sj.bjp.0704893; Nagase H, 1997, BIOL CHEM, V378, P151; Norrby K, 2002, APMIS, V110, P355, DOI 10.1034/j.1600-0463.2002.100501.x; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takai S, 2003, J PHARMACOL EXP THER, V305, P17, DOI 10.1124/jpet.102.045179; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Tchougounova E, 2001, J BIOL CHEM, V276, P3772, DOI 10.1074/jbc.M008434200; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200	39	267	279	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9291	9296		10.1074/jbc.M410396200	http://dx.doi.org/10.1074/jbc.M410396200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615702	hybrid			2022-12-27	WOS:000227453100080
J	Yokoyama, N; Ischenko, I; Hayman, MJ; Miller, WT				Yokoyama, N; Ischenko, I; Hayman, MJ; Miller, WT			The C terminus of RON tyrosine kinase plays an autoinhibitory role	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; MULTIFUNCTIONAL DOCKING SITE; FACTOR SCATTER FACTOR; HGF RECEPTOR FAMILY; STRUCTURAL BASIS; CELL-TRANSFORMATION; CRYSTAL-STRUCTURE; GROWTH; MET; BINDING	RON is a receptor tyrosine kinase in the MET family. We have expressed and purified active RON using the Sf9/baculovirus system. The constructs used in this study comprise the kinase domain alone and the kinase domain plus the C-terminal region. The construct containing the kinase domain alone has a higher specific activity than the construct containing the kinase and C-terminal domains. Purified RON undergoes autophosphorylation, and the exogenous RON C terminus serves as a substrate. Peptides containing a dityrosine motif derived from the C-terminal tail inhibit RON in vitro or when delivered into intact cells, consistent with an autoinhibitory mechanism. Phenylalanine substitutions within these peptides increase the inhibitory potency. Moreover, introduction of these Phe residues into the dityrosine motif of the RON kinase leads to a decrease in kinase activity. Taken together, our data suggest a model in which the C-terminal tail of RON regulates kinase activity via an interaction with the kinase catalytic domain.	SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Sch Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NCI NIH HHS [CA 28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Atherton E., 1990, SOLID PHASE PEPTIDE; Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; Chiara F, 2004, J BIOL CHEM, V279, P19732, DOI 10.1074/jbc.M314070200; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; Danilkovitch-Miagkova A, 2003, CURR CANCER DRUG TAR, V3, P31, DOI 10.2174/1568009033333745; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FIXMAN ED, 1995, ONCOGENE, V10, P237; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; LONGATI P, 1994, ONCOGENE, V9, P49; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 2000, ONCOGENE, V19, P5208, DOI 10.1038/sj.onc.1203819; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Till JH, 2002, STRUCTURE, V10, P1187, DOI 10.1016/S0969-2126(02)00814-6; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Xiao ZQ, 2000, BIOCHEM BIOPH RES CO, V267, P669, DOI 10.1006/bbrc.1999.2011; Xu B, 1996, MOL CELL BIOCHEM, V158, P57; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	47	19	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8893	8900		10.1074/jbc.M412623200	http://dx.doi.org/10.1074/jbc.M412623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632155	hybrid			2022-12-27	WOS:000227453100034
J	Christensen, KE; Patel, H; Kuzmanov, U; Mejia, NR; MacKenzie, RE				Christensen, KE; Patel, H; Kuzmanov, U; Mejia, NR; MacKenzie, RE			Disruption of the Mthfd1 gene reveals a monofunctional 10-formyltetrahydrofolate synthetase in mammalian mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE-METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; DEPENDENT METHYLENETETRAHYDROFOLATE DEHYDROGENASE; 5,10-METHYLENETETRAHYDROFOLATE DEHYDROGENASE; C-1-TETRAHYDROFOLATE SYNTHASE; ENCODING MITOCHONDRIAL; TRIFUNCTIONAL ENZYME; MESSENGER-RNA; BINDING; SEQUENCE; PROTEIN	The Mthfd1 gene encoding the cytoplasmic methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase enzyme (DCS) was inactivated in embryonic stem cells. The null embryonic stem cells were used to generate spontaneously immortalized fibroblast cell lines that exhibit the expected purine auxotrophy. Elimination of these cytoplasmic activities allowed for the accurate assessment of similar activities encoded by other genes in these cells. A low level of 10-formyltetrahydrofolate synthetase was detected and was shown to be localized to mitochondria. However, NADP-dependent methylenetetrahydrofolate dehydrogenase activity was not detected. Northern blot analysis suggests that a recently identified mitochondrial DCS (Prasannan, P., Pike, S., Peng, K., Shane, B., and Appling, D. R. (2003) J. Biol. Chem. 278, 43178-43187) is responsible for the synthetase activity. The lack of NADP-dependent dehydrogenase activity suggests that this RNA may encode a monofunctional synthetase. Moreover, examination of the primary structure of this novel protein revealed mutations in key residues required for dehydrogenase and cyclohydrolase activities. This monofunctional synthetase completes the pathway for the production of formate from formyltetrahydrofolate in the mitochondria in our model of mammalian one-carbon folate metabolism in embryonic and transformed cells.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	MacKenzie, RE (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3A 2T5, Canada.	robert.mackenzie@mcgill.ca		Kuzmanov, Uros/0000-0002-3502-6986				Allaire M, 1998, STRUCTURE, V6, P173, DOI 10.1016/S0969-2126(98)00019-7; BARLOWE C K, 1988, Biofactors, V1, P171; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; GARROW TA, 1993, J BIOL CHEM, V268, P11910; HUM DW, 1988, J BIOL CHEM, V263, P15946; HUM DW, 1991, PROTEIN ENG, V4, P493, DOI 10.1093/protein/4.4.493; MacKenzie R E, 1984, FOLATES PTERINS CHEM, V1, P255; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; Monzingo AF, 2000, PROTEIN SCI, V9, P1374, DOI 10.1110/ps.9.7.1374; PASTERNACK LB, 1992, BIOCHEMISTRY-US, V31, P8713, DOI 10.1021/bi00152a005; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Patel H, 2003, J BIOL CHEM, V278, P19436, DOI 10.1074/jbc.M301718200; Patel H, 2002, ARCH BIOCHEM BIOPHYS, V403, P145, DOI 10.1016/S0003-9861(02)00203-5; Pawelek PD, 2000, BBA-PROTEIN STRUCT M, V1479, P59, DOI 10.1016/S0167-4838(00)00058-3; PELLETIER JN, 1995, BIOCHEMISTRY-US, V34, P12673, DOI 10.1021/bi00039a025; PERI KG, 1993, BIOCHIM BIOPHYS ACTA, V1171, P281, DOI 10.1016/0167-4781(93)90066-M; Prasannan P, 2003, J BIOL CHEM, V278, P43178, DOI 10.1074/jbc.M304319200; Rong YS, 1998, GENETICS, V150, P1551; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Schmidt A, 2000, BIOCHEMISTRY-US, V39, P6325, DOI 10.1021/bi992734y; SCRIMGEOUR KG, 1960, BIOCHEM BIOPH RES CO, V2, P230, DOI 10.1016/0006-291X(60)90019-X; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; Shen BW, 1999, PROTEIN SCI, V8, P1342, DOI 10.1110/ps.8.6.1342; STABEN C, 1986, J BIOL CHEM, V261, P4629; Sugiura T, 2004, BIOCHEM BIOPH RES CO, V315, P204, DOI 10.1016/j.bbrc.2004.01.035; TAN LUL, 1977, J BIOL CHEM, V252, P1117; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VILLAR E, 1985, J BIOL CHEM, V260, P2245; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022	32	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7597	7602		10.1074/jbc.M409380200	http://dx.doi.org/10.1074/jbc.M409380200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611115	hybrid			2022-12-27	WOS:000227395700022
J	Klinge, CM; Blankenship, KA; Risinger, KE; Bhatnagar, S; Noisin, EL; Sumanasekera, WK; Zhao, L; Brey, M; Keynton, RS				Klinge, CM; Blankenship, KA; Risinger, KE; Bhatnagar, S; Noisin, EL; Sumanasekera, WK; Zhao, L; Brey, M; Keynton, RS			Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RESPONSE ELEMENT SEQUENCE; RED WINE; POLYPHENOLIC COMPOUND; SELECTIVE LIGANDS; IN-VITRO; EXPRESSION; BINDING; PLASMA; CARDIOPROTECTION	Vascular endothelial cells ( EC) are an important target of estrogen action through both the classical genomic ( i.e. nuclear-initiated) activities of estrogen receptors alpha and beta ( ERalpha and ERbeta) and the rapid " nongenomic" ( i.e. membrane-initiated) activation of ER that stimulates intracellular phosphorylation pathways. We tested the hypothesis that the red wine polyphenol trans-resveratrol activates MAPK signaling via rapid ER activation in bovine aortic EC, human umbilical vein EC, and human microvascular EC. We report that bovine aortic EC, human umbilical vein EC, and human microvascular EC express ERalpha and ERbeta. We demonstrate that resveratrol and estradiol ( E-2) rapidly activated MAPK in a MEK-1, Src, matrix metalloproteinase, and epidermal growth factor receptor-dependent manner. Importantly, resveratrol activated MAPK and endothelial nitric-oxide synthase ( eNOS) at nM concentrations ( i.e. an order of magnitude less than that required for ER genomic activity) and concentrations possibly achieved transiently in serum following oral red wine consumption. Co-treatment with ER antagonists ICI 182,780 or 4-hydroxytamoxifen blocked resveratrol- or E-2-induced MAPK and eNOS activation, indicating ER dependence. We demonstrate for the first time that ERalpha-and ERbeta-selective agonists propylpyrazole triol and diarylpropionitrile, respectively, stimulate MAPK and eNOS activity. A red but not a white wine extract also activated MAPK, and activity was directly correlated with the resveratrol concentration. These data suggest that ER may play a role in the rapid effects of resveratrol in EC and that some of the atheroprotective effects of resveratrol may be mediated through rapid activation of ER signaling in EC.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Ctr Genet & Mol Med, Louisville, KY 40292 USA; Univ Louisville, Speed Sch Engn, Dept Mech Engn, Louisville, KY 40292 USA	University of Louisville; University of Louisville; University of Louisville	Klinge, CM (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.	carolyn.klinge@louisville.edu	Keynton, Robert S/G-6348-2011	Klinge, Carolyn/0000-0002-3358-4378	NIDDK NIH HHS [R01 DK 53220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson C, 2001, J ENDOCRINOL, V169, P241, DOI 10.1677/joe.0.1690241; Aziz MH, 2003, INT J ONCOL, V23, P17; Barletta F, 2004, MOL ENDOCRINOL, V18, P1096, DOI 10.1210/me.2003-0335; Bertelli A, 1998, DRUG EXP CLIN RES, V24, P133; Bertelli AAE, 1998, DRUG EXP CLIN RES, V24, P51; Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567; Bian Z, 2001, TRENDS CARDIOVAS MED, V11, P196, DOI 10.1016/S1050-1738(01)00102-5; Bitzan MM, 1998, J CLIN INVEST, V101, P372, DOI 10.1172/JCI522; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; Bruder JL, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-1; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Critchley HOD, 2001, J CLIN ENDOCR METAB, V86, P1370, DOI 10.1210/jc.86.3.1370; Das DK, 1999, DRUG EXP CLIN RES, V25, P115; El-Mowafy AM, 1999, FEBS LETT, V451, P63, DOI 10.1016/S0014-5793(99)00541-4; Evans MJ, 2002, ENDOCRINOLOGY, V143, P3785, DOI 10.1210/en.2002-220356; Figtree GA, 1999, CIRCULATION, V100, P1095, DOI 10.1161/01.CIR.100.10.1095; Flesch M, 1998, AM J PHYSIOL-HEART C, V275, pH1183, DOI 10.1152/ajpheart.1998.275.4.H1183; Fletcher SW, 2002, JAMA-J AM MED ASSOC, V288, P366, DOI 10.1001/jama.288.3.366; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fuqua SAW, 1999, CANCER RES, V59, P5425; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1; Gu XL, 1999, J AGR FOOD CHEM, V47, P3223, DOI 10.1021/jf981211e; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Herrington DM, 2003, PHARMACOGENOMICS, V4, P269, DOI 10.1517/phgs.4.3.269.22686; Hodgin JB, 2002, ENDOCRINOLOGY, V143, P4495, DOI 10.1210/en.2002-220844; Hsieh TC, 1999, CANCER RES, V59, P2596; Klinge CM, 1999, J STEROID BIOCHEM, V71, P1, DOI 10.1016/S0960-0760(99)00124-7; Klinge CM, 2003, J AGR FOOD CHEM, V51, P1850, DOI 10.1021/jf0259821; Klinge CM, 2001, MOL CELL ENDOCRINOL, V174, P151, DOI 10.1016/S0303-7207(01)00382-3; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kulakosky PC, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290137; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; Marier JF, 2002, J PHARMACOL EXP THER, V302, P369, DOI 10.1124/jpet.102.033340; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Olas B, 2002, THROMB RES, V107, P141, DOI 10.1016/S0049-3848(02)00273-6; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Rich RL, 2002, P NATL ACAD SCI USA, V99, P8562, DOI 10.1073/pnas.142288199; Ruf JC, 1999, DRUG EXP CLIN RES, V25, P125; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Sato M, 2002, ANN NY ACAD SCI, V957, P122, DOI 10.1111/j.1749-6632.2002.tb02911.x; Shih A, 2002, J CLIN ENDOCR METAB, V87, P1223, DOI 10.1210/jc.87.3.1223; Slater I, 1999, HUM EXP TOXICOL, V18, P625, DOI 10.1191/096032799678839464; Solomon CG, 2003, NEW ENGL J MED, V348, P579, DOI 10.1056/NEJMp030006; Stauffer SR, 2001, BIOORGAN MED CHEM, V9, P141, DOI 10.1016/S0968-0896(00)00228-5; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Stivala LA, 2001, J BIOL CHEM, V276, P22586, DOI 10.1074/jbc.M101846200; Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; Tredici G, 1999, DRUG EXP CLIN RES, V25, P99; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Wagner AH, 2001, FASEB J, V15, P2121, DOI 10.1096/fj.01-0123com; Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C; Watson CS, 2002, STEROIDS, V67, P429, DOI 10.1016/S0039-128X(01)00172-6; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	64	254	270	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7460	7468		10.1074/jbc.M411565200	http://dx.doi.org/10.1074/jbc.M411565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615701	hybrid			2022-12-27	WOS:000227395700007
J	Wei, JH; Chou, YF; Ou, YH; Yeh, YH; Tyan, SW; Sun, TP; Shen, CY; Shieh, SY				Wei, JH; Chou, YF; Ou, YH; Yeh, YH; Tyan, SW; Sun, TP; Shen, CY; Shieh, SY			TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUPLICATION GENE MPS1; PROTEIN-KINASE; CDS1 CHK2; SPINDLE CHECKPOINT; HUMAN P53; ATM; ACTIVATION; EXPRESSION; APOPTOSIS; OLIGOMERIZATION	CHK2/hCds1 plays important roles in the DNA damage-induced cell cycle checkpoint by phosphorylating several important targets, such as Cdc25 and p53. To obtain a better understanding of the CHK2 signaling pathway, we have carried out a yeast two-hybrid screen to search for potential CHK2-interacting proteins. Here, we report the identification of the mitotic checkpoint kinase, TTK/hMps1, as a novel CHK2-interacting protein. TTK/hMps1 directly phosphorylates CHK2 on Thr-68 in vitro. Expression of a TTK kinase-dead mutant, TTKD647A, interferes with the G(2)/M arrest induced by either ionizing radiation or UV light. Interestingly, induction of CHK2 Thr-68 phosphorylation and of several downstream events, such as cyclin B1 accumulation and Cdc2 Tyr-15 phosphorylation, is also affected. Furthermore, ablation of TTK expression using small interfering RNA results not only in reduced CHK2 Thr-68 phosphorylation, but also in impaired growth arrest. Our results are consistent with a model in which TTK functions upstream from CHK2 in response to DNA damage and suggest possible cross-talk between the spindle assembly checkpoint and the DNA damage checkpoint.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11490, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sec 2 Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Wei, Jen-Hsuan/AAG-2920-2021; Shieh, Sheau-Yann/N-9512-2018; Shen, CY/F-6271-2010	Wei, Jen-Hsuan/0000-0001-8958-6455; Shieh, Sheau-Yann/0000-0002-5351-4430; Ou, Yi-Hung/0000-0002-9909-7791				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bahassi El Mustapha, 2002, Oncogene, V21, P6633; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Castillo AR, 2002, J CELL BIOL, V156, P453, DOI 10.1083/jcb.200111025; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; He XW, 1998, J CELL SCI, V111, P1635; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; HOGG D, 1994, ONCOGENE, V9, P89; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LINDBERG RA, 1993, ONCOGENE, V8, P351; LIR ST, 2003, MOL BIOL CELL, V14, P1638; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; MILLS GB, 1992, J BIOL CHEM, V267, P16000; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHMANDT R, 1994, J IMMUNOL, V152, P96; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Winey M, 2002, ONCOGENE, V21, P6161, DOI 10.1038/sj.onc.1205712; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	66	76	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7748	7757		10.1074/jbc.M410152200	http://dx.doi.org/10.1074/jbc.M410152200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15618221	hybrid			2022-12-27	WOS:000227395700039
J	Besson, MT; Re, DB; Moulin, M; Birman, S				Besson, MT; Re, DB; Moulin, M; Birman, S			High affinity transport of taurine by the Drosophila aspartate transporter dEAAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; LONG-LASTING ENHANCEMENT; CULTURED ASTROCYTES; NERVOUS-SYSTEM; MUSHROOM BODIES; GLUTAMATE; EXPRESSION; BRAIN; IMMUNOREACTIVITY; CYSTEINE	Excitatory amino acid transporters (EAATs) are structurally related plasma membrane proteins known to mediate the Na+/K+-dependent uptake of the amino acids L-glutamate and DL-aspartate. In the nervous system, these proteins contribute to the clearance of glutamate from the synaptic cleft and maintain excitatory amino acid concentrations below excitotoxic levels. Two homologues exist in Drosophila melanogaster, dEAAT1 and dEAAT2, which are specifically expressed in the nervous tissue. We previously reported that dEAAT2 shows unique substrate discrimination as it mediates high affinity transport of aspartate but not glutamate. We now show that dEAAT2 can also transport the amino acid taurine with high affinity, a property that is not shared by two other transporters of the same family, Drosophila dEAAT1 and human hEAAT2. Taurine transport by dEAAT2 was efficiently blocked by an EAAT antagonist but not by inhibitors of the structurally unrelated mammalian taurine transporters. Taurine and aspartate are transported with similar K-m and relative efficacy and behave as mutually competitive inhibitors. dEAAT2 can mediate either net uptake or the heteroexchange of its two substrates, both being dependent on the presence of Na+ ions in the external medium. Interestingly, heteroexchange only occurs in one preferred substrate orientation, i.e. with taurine transported inwards and aspartate outwards, suggesting a mechanism of transinhibition of aspartate uptake by intracellular taurine. Therefore, dEAAT2 is actually an aspartate/taurine transporter. Further studies of this protein are expected to shed light on the role of taurine as a candidate neuromodulator and cell survival factor in the Drosophila nervous system.	Univ Mediterranee, Dev Biol Inst Marseille, CNRS, UMR 6545,Lab Genet & Physiol Dev, F-13288 Marseille 9, France; Univ Mediterranee, CNRS, UMR 6186, Lab Interact Cellulaires Neurodegenerescence & Ne, F-13402 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Birman, S (corresponding author), Univ Mediterranee, Dev Biol Inst Marseille, CNRS, UMR 6545,Lab Genet & Physiol Dev, Case 907, F-13288 Marseille 9, France.	birman@ibdm.univ-mrs.fr		Re, Diane/0000-0002-6842-6759				ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Bender AS, 2000, NEUROCHEM INT, V37, P269, DOI 10.1016/S0197-0186(00)00035-8; Besson MT, 2000, CURR BIOL, V10, P207, DOI 10.1016/S0960-9822(00)00339-0; Besson MT, 1999, FEBS LETT, V443, P97, DOI 10.1016/S0014-5793(98)01695-0; BICKER G, 1991, BRAIN RES, V560, P201, DOI 10.1016/0006-8993(91)91233-Q; Brand A, 1998, J NEUROCHEM, V71, P827; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; Chen YM, 2003, J NEUROCHEM, V84, P1332, DOI 10.1046/j.1471-4159.2003.01630.x; Chepkova AN, 2002, EUR J NEUROSCI, V16, P1523, DOI 10.1046/j.1460-9568.2002.02223.x; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Debernardi R, 1999, BRAIN RES, V850, P39, DOI 10.1016/S0006-8993(99)02022-3; del Olmo N, 2000, NEUROPHARMACOLOGY, V39, P40, DOI 10.1016/S0028-3908(99)00078-7; del Olmo N, 2000, BRAIN RES, V864, P298, DOI 10.1016/S0006-8993(00)02211-3; Dunlop J, 2001, J NEUROSCI RES, V66, P482, DOI 10.1002/jnr.1239; EICHMULLER S, 1995, J COMP NEUROL, V352, P297, DOI 10.1002/cne.903520211; El Idrissi A, 2004, NEUROCHEM RES, V29, P189, DOI 10.1023/B:NERE.0000010448.17740.6e; Hussy N, 2000, PROG NEUROBIOL, V62, P113, DOI 10.1016/S0301-0082(99)00071-4; HUXTABLE RJ, 1989, PROG NEUROBIOL, V32, P471, DOI 10.1016/0301-0082(89)90019-1; Jiang ZL, 2004, J NEUROPHYSIOL, V91, P248, DOI 10.1152/jn.00106.2003; Kanai Y, 2003, EUR J PHARMACOL, V479, P237, DOI 10.1016/j.ejphar.2003.08.073; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; Nassel DR, 1999, MICROSC RES TECHNIQ, V44, P121, DOI 10.1002/(SICI)1097-0029(19990115/01)44:2/3<121::AID-JEMT6>3.0.CO;2-F; NURNBERGER A, 1993, HISTOCHEMISTRY, V100, P285, DOI 10.1007/BF00270048; Oja SS, 1996, NEUROCHEM RES, V21, P161, DOI 10.1007/BF02529133; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PALL ML, 1971, BIOCHEM BIOPH RES CO, V42, P940, DOI 10.1016/0006-291X(71)90521-3; Pasantes-Morales H, 2002, NEUROCHEM RES, V27, P59, DOI 10.1023/A:1014850505400; Patel SA, 2004, NEUROPHARMACOLOGY, V46, P273, DOI 10.1016/j.neuropharm.2003.08.006; Pinilla J, 2001, CAN J PHYSIOL PHARM, V79, P1023, DOI 10.1139/cjpp-79-12-1023; Re DB, 2003, J NEUROCHEM, V85, P1159, DOI 10.1046/j.1471-4159.2003.01752.x; Rival T, 2004, CURR BIOL, V14, P599, DOI 10.1016/j.cub.2004.03.039; Roeder T, 1999, PROG NEUROBIOL, V59, P533, DOI 10.1016/S0301-0082(99)00016-7; Saransaari P, 2004, AMINO ACIDS, V26, P91, DOI 10.1007/s00726-003-0004-1; Saransaari P, 2000, AMINO ACIDS, V19, P509, DOI 10.1007/s007260070003; SCHAFER S, 1988, J COMP NEUROL, V268, P60, DOI 10.1002/cne.902680107; Schaffer SW, 2000, AMINO ACIDS, V18, P305, DOI 10.1007/PL00010320; Sergeeva OA, 2003, J PHYSIOL-LONDON, V550, P911, DOI 10.1113/jphysiol.2003.045864; Shanker G, 2001, J NEUROSCI RES, V66, P998, DOI 10.1002/jnr.10066; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; Sinakevitch I, 2001, J COMP NEUROL, V439, P352, DOI 10.1002/cne.1355; SMITH KE, 1992, MOL PHARMACOL, V42, P563; Soustelle L, 2002, DEV BIOL, V248, P294, DOI 10.1006/dbio.2002.0742; Stevenson PA, 1999, J COMP NEUROL, V404, P86, DOI 10.1002/(SICI)1096-9861(19990201)404:1<86::AID-CNE7>3.0.CO;2-8; Strausfeld NJ, 2003, MICROSC RES TECHNIQ, V62, P151, DOI 10.1002/jemt.10368; Trenkner E, 1990, Adv Exp Med Biol, V268, P239; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393	51	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6621	6626		10.1074/jbc.M412440200	http://dx.doi.org/10.1074/jbc.M412440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611131	hybrid			2022-12-27	WOS:000227332700047
J	Sandberg, MB; Bloksgaard, M; Duran-Sandoval, D; Duval, C; Staels, B; Mandrup, S				Sandberg, MB; Bloksgaard, M; Duran-Sandoval, D; Duval, C; Staels, B; Mandrup, S			The gene encoding Acyl-CoA-binding protein is subject to metabolic regulation by both sterol regulatory element-binding protein and peroxisome proliferator-activated receptor alpha in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; PPAR-ALPHA; ADIPOCYTE DIFFERENTIATION; LIGAND-BINDING; CULTURED-CELLS; INSULIN ACTION; INHIBITOR DBI; DESATURASE 1; EXPRESSION; LIVER	The acyl-CoA-binding protein (ACBP) is a 10-kDa intracellular lipid-binding protein that transports acyl-CoA esters. The protein is expressed in most cell types at low levels; however, expression is particularly high in cells with a high turnover of fatty acids. Here we confirm a previous observation that ACBP expression in rodent liver is down-regulated by fasting, and we show that insulin but not glucose is the inducer of ACBP expression in primary rat hepatocytes. In keeping with the regulation by insulin, we show that ACBP is a sterol regulatory element-binding protein 1c (SREBP-1c) target gene in hepatocytes. Members of the SREBP family activate the rat ACBP gene through binding sites for SREBP and the auxiliary factors Sp1 and nuclear factor Y in the proximal promoter. In addition, we show that ACBP is a peroxisome proliferator-activated receptor (PPAR) alpha target gene in cultured hepatocytes and is induced in the liver by fibrates in a PPARalpha-dependent manner. Thus, ACBP is a dual PPARalpha and SREBP-1c target gene in hepatocytes. Fasting leads to reduced activity of SREBP but increased activity of PPARalpha in hepatocytes, and in keeping with ACBP being a dual target gene, we show that ACBP expression is significantly lower in livers from PPARalpha knock-out mice than in livers from wild type mice. In conclusion, expression of ACBP in rodent hepatocytes is subject to dual metabolic regulation by PPARalpha and SREBP-1c, which may reflect the need for ACBP during lipogenic as well as lipo-oxidative conditions.	Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Univ Lille 2, Fac Pharm, F-59019 Lille, France; Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France	University of Southern Denmark; Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Mandrup, S (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.	s.mandrup@bmb.sdu.dk	Sandberg, Maria Boysen/AAE-6889-2019; Mandrup, Susanne/B-6693-2008; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Mandrup, Susanne/0000-0002-0961-5787				Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BHUIYAN J, 1995, METABOLISM, V44, P1185, DOI 10.1016/0026-0495(95)90013-6; BOVOLIN P, 1990, REGUL PEPTIDES, V29, P267, DOI 10.1016/0167-0115(90)90089-F; Brons-Poulsen J, 1998, MOL CELL PROBE, V12, P345, DOI 10.1006/mcpr.1998.0187; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Faergeman NJ, 1996, BIOCHEMISTRY-US, V35, P14118, DOI 10.1021/bi960545z; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; HANSEN HO, 1991, BIOCHEM J, V277, P341, DOI 10.1042/bj2770341; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Helledie T, 2000, J LIPID RES, V41, P1740; Helledie T, 2002, J BIOL CHEM, V277, P26821, DOI 10.1074/jbc.M111295200; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; KNUDSEN J, 1993, MOL CELL BIOCHEM, V123, P129, DOI 10.1007/BF01076484; Kragelund BB, 1999, BBA-MOL CELL BIOL L, V1441, P150, DOI 10.1016/S1388-1981(99)00151-1; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; MANDRUP S, 1992, J MOL BIOL, V228, P1011, DOI 10.1016/0022-2836(92)90888-Q; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Matsuzaka T, 2002, J LIPID RES, V43, P107; Medvedev AV, 2002, J BIOL CHEM, V277, P42639, DOI 10.1074/jbc.M208645200; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Patel DD, 2001, J LIPID RES, V42, P328; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SKORVE J, 1995, XENOBIOTICA, V25, P1181, DOI 10.3109/00498259509046675; STERCHELE PF, 1994, BIOCHEM PHARMACOL, V48, P955, DOI 10.1016/0006-2952(94)90366-2; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; Swinnen JV, 1998, J BIOL CHEM, V273, P19938, DOI 10.1074/jbc.273.32.19938; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Torra IP, 2000, ENDOCRINOLOGY, V141, P3799, DOI 10.1210/en.141.10.3799; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; WATERS KM, 1994, J BIOL CHEM, V269, P27773	52	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5258	5266		10.1074/jbc.M407515200	http://dx.doi.org/10.1074/jbc.M407515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15611101	hybrid			2022-12-27	WOS:000227217100020
J	Bertero, MG; Rothery, RA; Boroumand, N; Palak, M; Blasco, F; Ginet, N; Weiner, JH; Strynadka, NCJ				Bertero, MG; Rothery, RA; Boroumand, N; Palak, M; Blasco, F; Ginet, N; Weiner, JH; Strynadka, NCJ			Structural and biochemical characterization of a quinol binding site of Escherichia coli nitrate reductase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUMARATE REDUCTASE; HEME REDUCTION; MENAQUINOL; INHIBITORS; COORDINATION; GENERATION; MUTATIONS; MEMBRANE; SUBUNIT; CENTERS	The crystal structure of Escherichia coli nitrate reductase A (NarGHI) in complex with pentachlorophenol has been determined to 2.0 angstrom of resolution. We have shown that pentachlorophenol is a potent inhibitor of quinol: nitrate oxidoreductase activity and that it also perturbs the EPR spectrum of one of the hemes located in the membrane anchoring subunit ( NarI). This new structural information together with site-directed mutagenesis data, biochemical analyses, and molecular modeling provide the first molecular characterization of a quinol binding and oxidation site (Q-site) in NarGHI. A possible proton conduction pathway linked to electron transfer reactions has also been defined, providing fundamental atomic details of ubiquinol oxidation by NarGHI at the bacterial membrane.	Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada; Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; CNRS, Chim Bacterienne Lab, F-13402 Marseille, France; Commissariat Energie Atom Cadarache, LBC, UMR6191, F-13108 St Paul Les Durance, France	University of British Columbia; University of Alberta; Centre National de la Recherche Scientifique (CNRS); CEA	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca	Ginet, Nicolas/AEB-2370-2022	Boroumand, Nasim/0000-0002-3142-2762; Rothery, Richard/0000-0003-3265-1783; Bertero, Michela/0000-0002-2012-6706; Ginet, Nicolas/0000-0002-5544-4376				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Blasco F, 2001, CELL MOL LIFE SCI, V58, P179, DOI 10.1007/PL00000846; Brondijk THC, 2002, MOL MICROBIOL, V44, P245, DOI 10.1046/j.1365-2958.2002.02875.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; ENGEL PC, 1996, ENZYMOLOGY LABFAX, P100; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lancaster CRD, 2000, P NATL ACAD SCI USA, V97, P13051, DOI 10.1073/pnas.220425797; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magalon A, 1998, J BIOL CHEM, V273, P10851, DOI 10.1074/jbc.273.18.10851; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PASCAL MC, 1982, MOL GEN GENET, V188, P103, DOI 10.1007/BF00333001; RATHER RA, 1998, BIOCHEM J, V332, P35; RATHER RA, 2001, J MOL MICROB BIOTECH, V3, P273; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; Rothery RA, 2001, BIOCHEMISTRY-US, V40, P5260, DOI 10.1021/bi002393k; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; Rothery RA, 1999, BIOCHEMISTRY-US, V38, P12747, DOI 10.1021/bi990533o; Rothery RA, 1998, EUR J BIOCHEM, V254, P588, DOI 10.1046/j.1432-1327.1998.2540588.x; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; Zhao ZW, 2003, BIOCHEMISTRY-US, V42, P14225, DOI 10.1021/bi0350856; Zhao ZW, 2003, BIOCHEMISTRY-US, V42, P5403, DOI 10.1021/bi027221x	38	58	59	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14836	14843		10.1074/jbc.M410457200	http://dx.doi.org/10.1074/jbc.M410457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15615728	hybrid			2022-12-27	WOS:000228236800062
J	Johnson, RA; Shepard, EM; Scotto, KW				Johnson, RA; Shepard, EM; Scotto, KW			Differential regulation of MDR1 transcription by the p53 family members - Role of the DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN EXPRESSION; WILD-TYPE P53; BREAST-CANCER; MULTIDRUG-RESISTANCE; P53/P63/P73 FAMILY; SPONTANEOUS TUMORS; GENE-EXPRESSION; OVARIAN-CANCER; FEEDBACK LOOP; P63 ISOFORMS	Although the p53 family members share a similar structure and function, it has become clear that they differ with respect to their role in development and tumor progression. Because of the high degree of homology in their DNA binding domains (DBDs), it is not surprising that both p63 and p73 activate the majority of p53 target genes. However, recent studies have revealed some differences in a subset of the target genes affected, and the mechanism underlying this diversity has only recently come under investigation. Our laboratory has demonstrated previously that p53 represses transcription of the P-glycoprotein-encoding MDR1 gene via direct DNA binding through a novel p53 DNA-binding site (the HT site). By transient transfection analyses, we now show that p63 and p73 activate rather than repress MDR1 transcription, and they do so through an upstream promoter element (the alternative p63/p73 element (APE)) independent of the HT site. This activation is dependent on an intact DNA binding domain, because mutations within the p63DBD or p73DBD are sufficient to prevent APE-mediated activation. However, neither p63 nor p73 directly interact with the APE, suggesting an indirect mechanism of activation through this site. Most interestingly, when the p53DBD is replaced by the p63DBD, p53 is converted from a repressor working through the HT site to an activator working through the APE. Taken together, these data indicate that, despite considerable homology, the DBD of the p53 family members have unique properties and can differentially regulate gene targeting and transcriptional output by both DNA binding-dependent and -independent mechanisms.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08901 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA; Fox Chase Canc Ctr, Philadelphia, PA 19001 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Memorial Sloan Kettering Cancer Center; Cornell University; Fox Chase Cancer Center	Scotto, KW (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA.	scottoka@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA095792] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA95792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Baekelandt MM, 2000, ANTICANCER RES, V20, P1061; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; BRADLEY G, 1992, CANCER RES, V52, P5154; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Burger H, 2003, CLIN CANCER RES, V9, P827; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dominguez G, 2001, BREAST CANCER RES TR, V66, P183, DOI 10.1023/A:1010624717311; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Herranz M, 2000, LEUKEMIA, V14, P1325, DOI 10.1038/sj.leu.2401813; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Ishimoto O, 2002, CANCER RES, V62, P636; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; Levrero M, 2000, J CELL SCI, V113, P1661; LINN SC, 1995, ANN ONCOL, V6, P679, DOI 10.1093/oxfordjournals.annonc.a059284; Liu Y, 2000, CLIN CHEM LAB MED, V38, P877, DOI 10.1515/CCLM.2000.127; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Ruth AC, 2000, CANCER RES, V60, P2576; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2001, APOPTOSIS, V6, P447, DOI 10.1023/A:1012433522902; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Ueda Y, 2001, BIOCHEM J, V356, P859, DOI 10.1042/0264-6021:3560859; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	66	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13213	13219		10.1074/jbc.M414646200	http://dx.doi.org/10.1074/jbc.M414646200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15634666	hybrid			2022-12-27	WOS:000228095500004
J	Bouras, T; Fu, MF; Sauve, AA; Wang, F; Quong, AA; Perkins, ND; Hay, RT; Gu, W; Pestell, RG				Bouras, T; Fu, MF; Sauve, AA; Wang, F; Quong, AA; Perkins, ND; Hay, RT; Gu, W; Pestell, RG			SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; SUMO-1 MODIFICATION; PROTEIN SIR2; GENE; BINDING; P53; ACETYLTRANSFERASE; ACTIVATION; UBIQUITIN; CBP	The SIR2 family of nicotinamide adenosine dinucleotide (NAD)-dependent deacetylases modulates diverse biological functions in different species, including longevity, apoptosis, cell cycle exit, and cellular differentiation. SIRT1, the closest mammalian ortholog of the yeast SIR2 ( silent information regulator 2) gene, represses several transcription factors, including p53, NF kappa B and forkhead proteins. The p300 protein serves as a rate-limiting transcriptional cointegrator of diverse transcription factors either to activate or to repress transcription through modular subdomains. Herein, SIRT1 physically interacted with and repressed p300 transactivation, requiring the NAD-dependent deacetylase activity of SIRT1. SIRT1 repression involved the CRD1 transcriptional repression domain of p300. Two residues within the CRD1 domain (Lys-1020 and Lys-1024) were required for SIRT1 repression and served as substrates for SIRT1 deacetylation. These residues also serve as acceptor lysines for modification by the ubiquitin-like SUMO protein. The SUMO-specific protease SSP3 relieved SIRT1 repression of p300. SSP3 antagonism of SIRT1 required the SUMO-deconjugating function of SSP3. Thus, p300 serves as a deacetylase substrate for SIRT1 through a conserved SUMO consensus motif. Because p300 is a limiting transcriptional cofactor, deacetylation and repression of p300 by SIRT1 may serve an important integration point during metabolism and cellular differentiation.	Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Albert Einstein Coll Med, Lab Macromol Anal & Proteom, Bronx, NY 10461 USA; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD15 5EH, Scotland; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9TS, Fife, Scotland; Columbia Univ Coll Phys & Surg, Inst Transgenet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Georgetown University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Dundee; University of St Andrews; Columbia University; Columbia University	Pestell, RG (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Res Bldg Rm E501,3970 Reservoir Rd NW,Box 571468, Washington, DC 20057 USA.	pestell@georgetown.edu	Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024	NATIONAL CANCER INSTITUTE [R01CA093596, R01CA075503, R01CA070896, R01CA107382, P30CA051008, R01CA086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065220] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA51008-14, R01CA93596-01, R01CA86072, R01CA75503, R01CA70896, R01CA107382] Funding Source: Medline; NIDDK NIH HHS [R21 DK065220-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azuma N, 2000, HUM MOL GENET, V9, P363, DOI 10.1093/hmg/9.3.363; Bandyopadhyay D, 2002, CANCER RES, V62, P6231; BANERJEE AC, 1994, ONCOGENE, V9, P1733; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boutros PC, 2004, BIOCHEM BIOPH RES CO, V321, P707, DOI 10.1016/j.bbrc.2004.06.177; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Britanova O, 2002, GENOMICS, V80, P31, DOI 10.1006/geno.2002.6796; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodman RH, 2000, GENE DEV, V14, P1553; Gregory DJ, 2002, CELL CYCLE, V1, P343, DOI 10.4161/cc.1.5.153; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muraoka M, 1996, ONCOGENE, V12, P1565; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; RENN SC, 2004, BIOMED CENTRAL GENOM, V5, P1471; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2004, CURR MED CHEM, V11, P807, DOI 10.2174/0929867043455675; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smyth GK, 2004, STAT APPL GENETICS M; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verroust PJ, 2002, NEPHROL DIAL TRANSPL, V17, P1867, DOI 10.1093/ndt/17.11.1867; Wang C, 2004, METH MOL B, V241, P207; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; Xu LF, 2000, GENE DEV, V14, P585; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	73	259	273	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10264	10276		10.1074/jbc.M408748200	http://dx.doi.org/10.1074/jbc.M408748200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632193	hybrid			2022-12-27	WOS:000227559600065
J	Shin, JN; Seo, YW; Kim, M; Park, SY; Lee, MJ; Lee, BR; Oh, JW; Seol, DW; Kim, TH				Shin, JN; Seo, YW; Kim, M; Park, SY; Lee, MJ; Lee, BR; Oh, JW; Seol, DW; Kim, TH			Cisplatin inactivation of caspases inhibits death ligand-induced cell death in Vitro and fulminant liver damage in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; FAS LIGAND; ACTIVATION; MITOCHONDRIA; RESISTANCE; RECEPTORS; AGENTS; SENSITIZES; PROTEINS	Cisplatin is a platinum-containing chemotherapeutic drug that has been widely used to treat various human cancers. It acts by forming inter-and intracross-links of DNA, which is believed to be a major cause for its therapeutic efficacy. However, little attention has been paid to the effect of cisplatin on death ligand-induced cell death. Here we demonstrate that cisplatin inhibits death ligand-induced cell death in cell lines in a p53-independent manner. This inhibitory effect of cisplatin on cell death is direct, whereby cisplatin forms a complex with caspases leading to their inactivation. The cisplatin-caspase complex is reversed by the addition of reducing agent dithiothreitol, and caspase activity is regained. In addition, cisplatin shows a death-inhibition effect in in vivo animal models of fulminant liver damage induced by Fas activation and lipopolysaccharide-induced liver shock mediated by tumor necrosis factor-alpha. Together, we demonstrate that cisplatin inhibits cell death induced by death ligands in cell lines and in mice through caspase inactivation.	Chosun Univ, Sch Med, Dept Biochem, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Dept Anat, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Dept Pathol, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Med Sci & Engn Res Ctr Resistant Cells, Kwangju 501759, South Korea; Chonnam Natl Univ, Korea Basic Sci Inst, Gwang Ju Branch, Kwangju 500757, South Korea; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA	Chosun University; Chosun University; Chosun University; Chosun University; Chonnam National University; Korea Basic Science Institute (KBSI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kim, TH (corresponding author), Chosun Univ, Sch Med, Dept Biochem & Mol Biol, Rm 2205,2nd Floor New Med Bldg,375 Seosuk Dong, Kwangju 501759, South Korea.	thkim65@mail.chosun.ac.kr	Park, Sang-Youel/D-5966-2012	Park, Sang-Youel/0000-0003-0575-6045				Arizono Y, 2003, BRIT J CANCER, V88, P298, DOI 10.1038/sj.bjc.6600666; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Evdokiou A, 2002, INT J CANCER, V99, P491, DOI 10.1002/ijc.10376; Gong JG, 1999, NATURE, V399, P806; Ivanov AI, 1998, J BIOL CHEM, V273, P14721, DOI 10.1074/jbc.273.24.14721; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Seol DW, 2001, CANCER RES, V61, P1138; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wang XD, 2001, GENE DEV, V15, P2922; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yin XM, 2000, J MOL MED-JMM, V78, P203, DOI 10.1007/s001090000099; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zheng SJ, 2004, J CLIN INVEST, V113, P58, DOI 10.1172/JCI200419255	26	18	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10509	10515		10.1074/jbc.M413865200	http://dx.doi.org/10.1074/jbc.M413865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15634686	hybrid			2022-12-27	WOS:000227559600094
J	Srinivasan, M; Lu, DB; Eri, R; Brand, DD; Haque, A; Blum, JS				Srinivasan, M; Lu, DB; Eri, R; Brand, DD; Haque, A; Blum, JS			CD80 binding polyproline helical peptide inhibits T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; COLLAGEN-INDUCED ARTHRITIS; II HELIX; CRYSTAL-STRUCTURE; PROLINE RESIDUES; STRUCTURAL BASIS; SH3 DOMAIN; CD28; COMPLEX; MODEL	The critical role played by the CD28/CD152-CD80/CD86 costimulatory molecules in mediating T cell activation and suppression provides attractive targets for therapeutic strategies. CD28 and CD152 share a conserved polyproline motif in the ligand-binding region. Similar proline-rich regions in globular domains preferentially adopt a polyproline type II (PPII) helical conformation and are involved in transient protein-protein interactions. Interestingly, in the human CD80-CD152 complex, Pro102 of CD152 restricts the preceding proline to PPII helix in the binding orientation in relation to the shallow binding pocket of CD80. Peptide agents derived from binding sites of receptors that mimic the bioactive conformation have been shown to block receptor-ligand interactions. Contact preferences of the interface amino acids at the protein-protein interaction sites and the propensity of each residue to form PPII helix were integrated in the design of novel peptide agents referred to as CD80 competitive antagonist peptides. Structural and functional studies suggest potential therapeutic value for select CD80 competitive antagonist peptides.	Indiana Univ, Purdue Univ, Dept Oral Pathol, Sch Dent, Indianapolis, IN 46202 USA; Indiana Univ, Purdue Univ, Dept Microbiol, Indianapolis, IN 46202 USA; Indiana Univ, Purdue Univ, Dept Immunol, Indianapolis, IN 46202 USA; Univ Tennessee, Dept Med, Memphis, TN 38104 USA; Res Serv, Dept Vet Affairs, Memphis, TN 38104 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Srinivasan, M (corresponding author), Indiana Univ, Purdue Univ, Dept Oral Pathol, Sch Dent, 1121 W Michigan St, Indianapolis, IN 46202 USA.	mysriniv@iupui.edu	Eri, Rajaraman/AAM-3214-2020; Eri, Raj/AAD-1185-2020	Eri, Raj/0000-0003-1688-8043; Brand, David/0000-0002-9260-7963				ADZHUBEI AA, 1994, PROTEIN SCI, V3, P2395, DOI 10.1002/pro.5560031223; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Bahadur RP, 2004, J MOL BIOL, V336, P943, DOI 10.1016/j.jmb.2003.12.073; Bajorath J, 1997, J MOL GRAPH MODEL, V15, P135, DOI 10.1016/S1093-3263(97)00020-X; Bhattacharyya R, 2003, J MOL BIOL, V331, P925, DOI 10.1016/S0022-2836(03)00759-9; Brand DD, 2002, J IMMUNOL, V168, P490, DOI 10.4049/jimmunol.168.1.490; Chellgren BW, 2004, BIOCHEMISTRY-US, V43, P5864, DOI 10.1021/bi049922v; CHESTER A, 2004, DRUG DISCOVERY STRAT, V1, P23; Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X; COHEN NC, 1996, GUIDEBOOK MOL MODELI, V1, P1; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Creamer TP, 2002, ADV PROTEIN CHEM, V62, P263; Creamer TP, 1998, PROTEINS, V33, P218, DOI 10.1002/(SICI)1097-0134(19981101)33:2<218::AID-PROT6>3.0.CO;2-E; Erbe DV, 2002, J BIOL CHEM, V277, P7363, DOI 10.1074/jbc.M110162200; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Geourjon C, 2001, PROTEIN SCI, V10, P788, DOI 10.1110/ps.30001; Glaser F, 2001, PROTEINS, V43, P89, DOI 10.1002/1097-0134(20010501)43:2<89::AID-PROT1021>3.3.CO;2-8; Goronzy JJ, 2004, CURR OPIN RHEUMATOL, V16, P212, DOI 10.1097/00002281-200405000-00008; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Huang ZW, 1997, BIOPOLYMERS, V43, P367, DOI 10.1002/(SICI)1097-0282(1997)43:5<367::AID-BIP3>3.0.CO;2-T; Ikemizu S, 2000, IMMUNITY, V12, P51, DOI 10.1016/S1074-7613(00)80158-2; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kelly MA, 2001, BIOCHEMISTRY-US, V40, P14376, DOI 10.1021/bi011043a; KOEHLER KF, 1996, GUIDEBOOK MOL MODELI, V1, P281; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Metzler WJ, 1997, NAT STRUCT BIOL, V4, P527, DOI 10.1038/nsb0797-527; Moitessier N, 2004, J MED CHEM, V47, P4178, DOI 10.1021/jm0311386; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Ostrov DA, 2000, SCIENCE, V290, P816, DOI 10.1126/science.290.5492.816; Palma PN, 2000, PROTEINS, V39, P372, DOI 10.1002/(SICI)1097-0134(20000601)39:4<372::AID-PROT100>3.0.CO;2-Q; Park SH, 1997, PROTEIN SCI, V6, P1694, DOI 10.1002/pro.5560060809; Parrot I, 2002, J BIOL CHEM, V277, P45572, DOI 10.1074/jbc.M207606200; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; Shi ZS, 2002, ADV PROTEIN CHEM, V62, P163; Srinivasan M, 2002, J IMMUNOL, V169, P2180, DOI 10.4049/jimmunol.169.4.2180; Srinivasan M, 2001, J IMMUNOL, V167, P578, DOI 10.4049/jimmunol.167.1.578; SRINIVASAN M, 2005, IN PRESS CURR PROTEI, V6; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; Stapley BJ, 1999, PROTEIN SCI, V8, P587; Tellander AC, 2001, J AUTOIMMUN, V17, P39, DOI 10.1006/jaut.2001.0527; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VERWILGHEN J, 1994, J IMMUNOL, V153, P1378; Webb LMC, 1996, EUR J IMMUNOL, V26, P2320, DOI 10.1002/eji.1830261008; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Zhang XW, 2003, P NATL ACAD SCI USA, V100, P2586, DOI 10.1073/pnas.252771499	49	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10149	10155		10.1074/jbc.M409521200	http://dx.doi.org/10.1074/jbc.M409521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15598660	hybrid			2022-12-27	WOS:000227559600051
J	Yu, TS; Zeeman, SC; Thorneycroft, D; Fulton, DC; Dunstan, H; Lue, WL; Hegemann, B; Tung, SY; Umemoto, T; Chapple, A; Tsai, DL; Wang, SM; Smith, AM; Chen, J; Smith, SM				Yu, TS; Zeeman, SC; Thorneycroft, D; Fulton, DC; Dunstan, H; Lue, WL; Hegemann, B; Tung, SY; Umemoto, T; Chapple, A; Tsai, DL; Wang, SM; Smith, AM; Chen, J; Smith, SM			alpha-Amylase is not required for breakdown of transitory starch in Arabidopsis leaves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; DISPROPORTIONATING ENZYME; R1 PROTEIN; DEGRADATION; METABOLISM; MUTANT; LEADS; BIOSYNTHESIS; ENDOAMYLASE; INHIBITION	The Arabidopsis thaliana genome encodes three alpha-amylase-like proteins (AtAMY1, AtAMY2, and AtAMY3). Only AtAMY3 has a predicted N-terminal transit peptide for plastidial localization. AtAMY3 is an unusually large alpha-amylase (93.5 kDa) with the C-terminal half showing similarity to other known alpha-amylases. When expressed in Escherichia coli, both the whole AtAMY3 protein and the C-terminal half alone show alpha-amylase activity. We show that AtAMY3 is localized in chloroplasts. The starch-excess mutant of Arabidopsis sex4, previously shown to have reduced plastidial alpha-amylase activity, is deficient in AtAMY3 protein. Unexpectedly, T-DNA knock-out mutants of AtAMY3 have the same diurnal pattern of transitory starch metabolism as the wild type. These results show that AtAMY3 is not required for transitory starch breakdown and that the starch-excess phenotype of the sex4 mutant is not caused simply by deficiency of AtAMY3 protein. Knockout mutants in the predicted non-plastidial alpha-amylases AtAMY1 and AtAMY2 were also isolated, and these displayed normal starch breakdown in the dark as expected for extraplastidial amylases. Furthermore, all three AtAMY double knock-out mutant combinations and the triple knock-out degraded their leaf starch normally. We conclude that alpha-amylase is not necessary for transitory starch breakdown in Arabidopsis leaves.	Univ Edinburgh, Inst Mol Plant Sci, Edinburgh EH9 3JH, Midlothian, Scotland; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; John Innes Ctr Plant Sci Res, Dept Metab Biol, Norwich NR4 7UH, Norfolk, England; Natl Taiwan Univ, Dept Bot, Taipei 106, Taiwan	University of Edinburgh; Academia Sinica - Taiwan; University of Bern; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; National Taiwan University	Fulton, DC (corresponding author), Univ Edinburgh, Inst Mol Plant Sci, Mayfield Rd, Edinburgh EH9 3JH, Midlothian, Scotland.	daniel.fulton@ed.ac.uk	Hegemann, Björn/A-8761-2015; Smith, Steven M/G-7183-2015; Smith, Steven/HDM-9496-2022	Hegemann, Björn/0000-0002-1009-2952; Smith, Steven M/0000-0001-5661-9994; Zeeman, Samuel/0000-0002-2791-0915				BECK E, 1989, ANNU REV PLANT PHYS, V40, P95, DOI 10.1146/annurev.pp.40.060189.000523; Boyes DC, 2001, PLANT CELL, V13, P1499, DOI 10.1105/tpc.13.7.1499; CHEN MH, 1994, PLANT J, V6, P625, DOI 10.1046/j.1365-313X.1994.6050625.x; Chia T, 2004, PLANT J, V37, P853, DOI 10.1111/j.1365-313X.2003.02012.x; Critchley JH, 2001, PLANT J, V26, P89, DOI 10.1046/j.1365-313x.2001.01012.x; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; FINCHER GB, 1989, ANNU REV PLANT PHYS, V40, P305, DOI 10.1146/annurev.pp.40.060189.001513; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; HARGREAVES JA, 1988, PHYTOCHEMISTRY, V27, P1627, DOI 10.1016/0031-9422(88)80416-3; Harlow E., 1988, ANTIBODIES LAB MANUA; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Kakefuda G, 1997, PLANT PHYSIOL BIOCH, V35, P907; Kossmann J, 2000, CRIT REV PLANT SCI, V19, P171, DOI 10.1016/S0735-2689(00)80002-7; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; LI B, 1992, PLANT PHYSIOL, V98, P1277, DOI 10.1104/pp.98.4.1277; LIN TP, 1988, PLANT PHYSIOL, V86, P251, DOI 10.1104/pp.86.1.251; Lloyd JR, 2004, PLANT PHYSIOL, V134, P1347, DOI 10.1104/pp.103.038026; Lorberth R, 1998, NAT BIOTECHNOL, V16, P473, DOI 10.1038/nbt0598-473; Lu Y, 2004, PLANTA, V218, P466, DOI 10.1007/s00425-003-1127-z; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Niittyla T, 2004, SCIENCE, V303, P87, DOI 10.1126/science.1091811; OKITA TW, 1979, PLANT PHYSIOL, V64, P187, DOI 10.1104/pp.64.2.187; PREISS J, 1982, ANNU REV PLANT PHYS, V33, P431, DOI 10.1146/annurev.pp.33.060182.002243; Ritte G, 2002, P NATL ACAD SCI USA, V99, P7166, DOI 10.1073/pnas.062053099; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaffer R, 2001, PLANT CELL, V13, P113, DOI 10.1105/tpc.13.1.113; Scheidig A, 2002, PLANT J, V30, P581, DOI 10.1046/j.1365-313X.2002.01317.x; Smith SM, 2004, PLANT PHYSIOL, V136, P2687, DOI 10.1104/pp.104.044347; Stanley D, 2002, BIOLOGIA, V57, P137; STEUP M, 1983, PLANTA, V158, P428, DOI 10.1007/BF00397736; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Trethewey Richard N., 2000, VVolume 9, P205; WHITE CA, 1986, CARBOHYDRATE ANAL PR, P342; Yu TS, 2000, PLANT PHYSIOL, V123, P319, DOI 10.1104/pp.123.1.319; Yu TS, 2001, PLANT CELL, V13, P1907, DOI 10.1105/tpc.13.8.1907; Zeeman SC, 2004, NEW PHYTOL, V163, P247, DOI 10.1111/j.1469-8137.2004.01101.x; Zeeman SC, 2004, PLANT PHYSIOL, V135, P849, DOI 10.1104/pp.103.032631; Zeeman SC, 1998, PLANT J, V15, P357, DOI 10.1046/j.1365-313X.1998.00213.x; Zeeman SC, 1998, PLANT CELL, V10, P1699, DOI 10.1105/tpc.10.10.1699	39	123	135	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9773	9779		10.1074/jbc.M413638200	http://dx.doi.org/10.1074/jbc.M413638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637061	hybrid, Green Published			2022-12-27	WOS:000227559600005
J	Bao, XF; Mikami, T; Yamada, S; Faissner, A; Muramatsu, T; Sugahara, K				Bao, XF; Mikami, T; Yamada, S; Faissner, A; Muramatsu, T; Sugahara, K			Heparin-binding growth factor, pleiotrophin, mediates neuritogenic activity of embryonic pig brain-derived chondroitin sulfate/dermatan sulfate hybrid chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE HB-GAM; OUTGROWTH-PROMOTING ACTIVITY; PHOSPHATASE ZETA/RPTP-BETA; SPINAL-CORD-INJURY; NEURITE OUTGROWTH; DERMATAN SULFATE; NEUROTROPHIC FACTORS; HIPPOCAMPAL-NEURONS; MONOCLONAL-ANTIBODY; IDURONIC ACID	Chondroitin sulfate ( CS) and dermatan sulfate (DS) chains play roles in the central nervous system. Most notably, CS/ DS hybrid chains (E-CS/ DS) purified from embryonic pig brains bind growth factors and promote neurite outgrowth toward embryonic mouse hippocampal neurons in culture. However, the neuritogenic mechanism is not well understood. Here we showed that pleiotrophin ( PTN), a heparin-binding growth factor, produced mainly by glia cells, was the predominant binding partner for E-CS/DS in the membrane-associated protein fraction of neonatal rat brain. The CS/ DS chains were separated on a PTN column into unbound, low affinity, and high affinity fractions. The latter two fractions promoted outgrowth of dendrite- and axonlike neurites, respectively, whereas the unbound fraction showed no such activity. The activity of the low affinity fraction was abolished by an anti-PTN antibody or when glia cells were removed from the culture. In contrast, the high affinity fraction displayed activity under both these conditions. Hence, PTN mainly from glia cells mediated the activity of the low affinity but not the high affinity fraction. The anti-CS antibody 473HD neutralized the neuritogenic activities of both fractions. Interaction analysis indicated that the 473HD epitope and PTN-binding domains in the E-CS/DS chains largely overlap. The three affinity subfractions differed in disaccharide composition and the distribution of (L)-iduronic acid-containing disaccharides along the chains. Oversulfated disaccharides and nonconsecutive iduronic acid-containing units were the requirements for the E-CS/DS chains to bind PTN and to exhibit the neuritogenic activities. Thus, CS subpopulations with distinct structures in the mammalian brain play different roles in neuritogenesis through distinct molecular mechanisms, at least in part by regulating the functions of growth factors.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Ruhr Univ Bochum, Dept Mol Neurobiol, D-44801 Bochum, Germany; Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 4668550, Japan; JST, CREST, Kawaguchi, Saitama 3320012, Japan	Kobe Pharmaceutical University; Ruhr University Bochum; Nagoya University; Japan Science & Technology Agency (JST)	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BICKNESE AR, 1994, J NEUROSCI, V14, P3500; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Condic ML, 1999, J NEUROSCI, V19, P10036; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; DOU CL, 1994, J NEUROSCI, V14, P7616; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; Garwood J, 1999, J NEUROSCI, V19, P3888; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; ICHIJO H, 2003, CONNECT TISSUE, V35, P11; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; ITO Y, 2005, IN PRESS GLYCOBIOLOG; Jones LL, 2003, J NEUROSCI, V23, P9276; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; LAFONT F, 1992, DEVELOPMENT, V114, P17; Lauri SE, 1996, NEUROREPORT, V7, P1670, DOI 10.1097/00001756-199607080-00029; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Maeda N., 2003, CONNECT TISSUE, V35, P19; MCADAMS BD, 1995, J COMP NEUROL, V352, P594, DOI 10.1002/cne.903520408; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Muramatsu T, 2001, TRENDS GLYCOSCI GLYC, V13, P563, DOI 10.4052/tigg.13.563; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; OOHIRA A, 1986, J BIOL CHEM, V263, P10240; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SAITO H, 1968, J BIOL CHEM, V243, P1536; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Wilson MT, 2000, J COMP NEUROL, V424, P532, DOI 10.1002/1096-9861(20000828)424:3<532::AID-CNE10>3.0.CO;2-Z; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	56	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9180	9191		10.1074/jbc.M413423200	http://dx.doi.org/10.1074/jbc.M413423200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632143	hybrid			2022-12-27	WOS:000227453100067
J	Mori, T; O'Keefe, BR; Sowder, RC; Bringans, S; Gardella, R; Berg, S; Cochran, P; Turpin, JA; Buckheit, RW; McMahon, JB; Boyd, MR				Mori, T; O'Keefe, BR; Sowder, RC; Bringans, S; Gardella, R; Berg, S; Cochran, P; Turpin, JA; Buckheit, RW; McMahon, JB; Boyd, MR			Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYANOVIRIN-N BINDS; NATURAL-PRODUCTS; DC-SIGN; CULTURED CYANOBACTERIUM; ENVELOPE GLYCOPROTEIN; GP120; POTENT; SURFACE; INFECTIVITY	Griffithsin (GRFT), a novel anti-HIV protein, was isolated from an aqueous extract of the red alga Griffithsia sp. The 121-amino acid sequence of GRFT has been determined, and biologically active GRFT was subsequently produced by expression of a corresponding DNA sequence in Escherichia coli. Both native and recombinant GRFT displayed potent antiviral activity against laboratory strains and primary isolates of T- and M-tropic HIV-1 with EC50 values ranging from 0.043 to 0.63 nM. GRFT also aborted cell-to-cell fusion and transmission of HIV-1 infection at similar concentrations. High concentrations (e. g. 783 nM) of GRFT were not lethal to any tested host cell types. GRFT blocked CD4-dependent glycoprotein (gp) 120 binding to receptor-expressing cells and bound to viral coat glycoproteins (gp120, gp41, and gp160) in a glycosylation-dependent manner. GRFT preferentially inhibited gp120 binding of the monoclonal antibody (mAb) 2G12, which recognizes a carbohydrate-dependent motif, and the (mAb) 48d, which binds to CD4-induced epitope. In addition, GRFT moderately interfered with the binding of gp120 to sCD4. Further data showed that the binding of GRFT to soluble gp120 was inhibited by the monosaccharides glucose, mannose, and N-acetylglucosamine but not by galactose, xylose, fucose, N-acetylgalactosamine, or sialic acid-containing glycoproteins. Taken together these data suggest that GRFT is a new type of lectin that binds to various viral glycoproteins in a monosaccharide-dependent manner. GRFT could be a potential candidate microbicide to prevent the sexual transmission of HIV and AIDS.	NCI, Mol Targets Dev Program, Ctr Canc Res, Frederick, MD 21702 USA; SAIC Fredercik, Basic Res Program, Frederick, MD 21702 USA; SAIC Fredercik, AIDS Vaccine Program, Frederick, MD 21702 USA; So Res Inst, Retrovirus Res Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick	Mori, T (corresponding author), NCI, Mol Targets Dev Program, Ctr Canc Res, Bldg 562,Rm 201, Frederick, MD 21702 USA.	mori@ncifcrf.gov; okeefe@ncifcrf.gov		Bringans, Scott/0000-0003-4760-9377	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3; Beninati C, 2000, NAT BIOTECHNOL, V18, P1060, DOI 10.1038/80250; Bewley CA, 2004, J MOL BIOL, V339, P901, DOI 10.1016/j.jmb.2004.04.019; Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e; Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698; Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949, DOI 10.1124/mol.59.5.949; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; BOYD MR, 1988, AIDS ETIOLOGY DIAGNO, P305; BUCKHEIT RW, 1994, AIDS RES HUM RETROV, V10, P1497, DOI 10.1089/aid.1994.10.1497; BUCKHEIT RW, 1993, ANTIVIR RES, V21, P247, DOI 10.1016/0166-3542(93)90031-D; CARRA P. O., 1965, BIOCHEM J, V94, P171; Chang TLY, 2003, P NATL ACAD SCI USA, V100, P11672, DOI 10.1073/pnas.1934747100; Charan RD, 2000, J NAT PROD, V63, P1170, DOI 10.1021/np000039h; CLANTON DJ, 1992, J ACQ IMMUN DEF SYND, V5, P771; Cragg G. M., 2002, Ethnomedicine and drug discovery, P23; De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Esser MT, 1999, J VIROL, V73, P4360, DOI 10.1128/JVI.73.5.4360-4371.1999; Ganzon-Fortes ET, 1997, J APPL PHYCOL, V9, P525; Garber David A., 2003, AIDS Reviews, V5, P131; GARTNER S, 1990, TECHNIQUES HIV RES, P59; Giomarelli B, 2002, AIDS, V16, P1351, DOI 10.1097/00002030-200207050-00006; Gretz M. R., 1997, TECHNIQUES GLYCOBIOL, P613; GULAKOWSKI RJ, 1991, J VIROL METHODS, V33, P87, DOI 10.1016/0166-0934(91)90010-W; Haslin C, 2001, PLANTA MED, V67, P301, DOI 10.1055/s-2001-14330; Hill CM, 1996, NATURE, V382, P668, DOI 10.1038/382668a0; Hong PWP, 2002, J VIROL, V76, P12855, DOI 10.1128/JVI.76.24.12855-12865.2002; Kaixian Qian, 1993, Applied Biochemistry and Biotechnology, V43, P133, DOI 10.1007/BF02916437; Kruger C, 2002, NAT BIOTECHNOL, V20, P702, DOI 10.1038/nbt0702-702; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lee YK, 2002, MOL CELLS, V13, P12; Liao WR, 2003, J IND MICROBIOL BIOT, V30, P433, DOI 10.1007/s10295-003-0068-7; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MOORE JP, 1988, AIDS RES HUM RETROV, V4, P369, DOI 10.1089/aid.1988.4.369; Mori T, 1998, PROTEIN EXPRES PURIF, V12, P151, DOI 10.1006/prep.1997.0838; Mori T, 2001, ANTIMICROB AGENTS CH, V45, P664, DOI 10.1128/AAC.45.3.664-672.2001; *NIAID, 2004, FACT SHEET HIV INF W; O'Keefe BR, 2000, MOL PHARMACOL, V58, P982, DOI 10.1124/mol.58.5.982; O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003; O'Keefe BR, 2001, J NAT PROD, V64, P1373, DOI 10.1021/np0103362; PIOT P, 2001, AIDS S1, V15, P4; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Stratov I, 2004, CURR DRUG TARGETS, V5, P71, DOI 10.2174/1389450043490686; Tramont Edmund C, 2003, Expert Opin Emerg Drugs, V8, P37, DOI 10.1517/eoed.8.1.37.21033; *UN, 2004, REP GLOB AIDS EP; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004	50	530	551	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9345	9353		10.1074/jbc.M411122200	http://dx.doi.org/10.1074/jbc.M411122200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15613479	hybrid			2022-12-27	WOS:000227453100087
J	Stolt, PC; Chen, Y; Liu, PS; Bock, HH; Blacklow, SC; Herz, J				Stolt, PC; Chen, Y; Liu, PS; Bock, HH; Blacklow, SC; Herz, J			Phosphoinositide binding by the disabled-1 PTB domain is necessary for membrane localization and reelin signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; VLDL RECEPTOR; CLATHRIN; DAB1; IDENTIFICATION; GLYCOPROTEIN; INTERACTS; LIGAND	Disabled-1 (Dab1) is an essential adaptor protein that functions in the Reelin signaling pathway and is required for the regulation of neuronal migration during embryonic development. Dab1 interacts with NPXY motifs in the cytoplasmic tails of the lipoprotein receptors ApoER2 and very low density lipoprotein receptor through an amino- terminal phosphotyrosine binding (PTB) domain. Binding of Reelin to these receptors leads to tyrosine phosphorylation of Dab1 and the initiation of a signaling cascade that results in remodeling of the cytoskeleton. Structural and biochemical studies of the Dab1 PTB domain have demonstrated that this domain binds to both the NPXY peptide motif in the lipoprotein receptor tails as well as to the head group of phosphoinositide 4,5-P-2 through energetically independent mechanisms. Here we have investigated how phosphoinositide binding by the Dab1 PTB domain influences Reelin signal transduction. Our findings in cultured primary neurons that have been transduced with lentiviral constructs expressing mutant Dab1 forms reveal that phosphoinositide binding by the Dab1 PTB domain is necessary for proper membrane localization of Dab1 and for effective transduction of a Reelin signal.	Univ Freiburg, Zentrum Neurowissensch, D-79104 Freiburg, Germany; Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Freiburg; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bock, HH (corresponding author), Univ Freiburg, Zentrum Neurowissensch, Albertstr 23, D-79104 Freiburg, Germany.	hans.bock@zfn.uni-freiburg.de	Bock, Hans/AAF-2635-2021; Liu, Pingsheng/B-7124-2012	Stolt-Bergner, Peggy/0000-0002-5887-2915	NHLBI NIH HHS [HL61001, R37 HL063762, HL63762, HL20948] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL063762, R01HL061001, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Herrick TM, 2004, MOL BRAIN RES, V126, P121, DOI 10.1016/j.molbrainres.2004.03.022; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; May P, 2004, MOL CELL BIOL, V24, P8872, DOI 10.1128/MCB.24.20.8872-8883.2004; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Riddell DR, 2001, J LIPID RES, V42, P998; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sanada K, 2004, NEURON, V42, P197, DOI 10.1016/S0896-6273(04)00222-3; Stolt PC, 2004, BIOCHEMISTRY-US, V43, P10979, DOI 10.1021/bi049092l; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Strasser V, 2004, MOL CELL BIOL, V24, P1378, DOI 10.1128/MCB.24.3.1378-1386.2004; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	36	28	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9671	9677		10.1074/jbc.M413356200	http://dx.doi.org/10.1074/jbc.M413356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632144	hybrid			2022-12-27	WOS:000227453100124
J	Vilella, F; Herrero, E; Torres, J; de la Torre-Ruiz, MA				Vilella, F; Herrero, E; Torres, J; de la Torre-Ruiz, MA			Pkc1 and the upstream elements of the cell integrity pathway in Saccharomyces cerevisiae, Rom2 and Mtl1, are required for cellular responses to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE PATHWAY; ACTIN CYTOSKELETON; OSMOTIC-STRESS; WALL INTEGRITY; PROTEIN; YEAST; GROWTH; TRANSCRIPTION; MAINTENANCE; SENSOR	In this study we analyze the participation of the PKC1- MAPK cell integrity pathway in cellular responses to oxidative stress in Saccharomyces cerevisiae. Evidence is presented demonstrating that only Pkc1 and the upstream elements of the cell integrity pathway are essential for cell survival upon treatment with two oxidizing agents, diamide and hydrogen peroxide. Mtl1 is characterized for the first time as a cell-wall sensor of oxidative stress. We also show that the actin cytoskeleton is a cellular target for oxidative stress. Both diamide and hydrogen peroxide provoke a marked depolarization of the actin cytoskeleton, being Mtl1, Rom2 and Pkc1 functions all required to restore the correct actin organization. Diamide induces the formation of disulfide bonds in newly secreted cell-wall proteins. This mainly provokes structural changes in the cell outer layer, which activate the PKC1- MAPK pathway and hence the protein kinase Slt2. Our results led us to the conclusion that Pkc1 activity is required to overcome the effects of oxidative stress by: (i) enhancing the machinery required to repair the altered cell wall and (ii) restoring actin cytoskeleton polarity by promoting actin cable formation.	Univ Lleida, Dept Ciencies Med Basiques, Lleida 25198, Spain	Universitat de Lleida	de la Torre-Ruiz, MA (corresponding author), Univ Lleida, Dept Ciencies Med Basiques, Alcalde Rovira Roure 44, Lleida 25198, Spain.	madelatorre@cmb.udl.es	Vilella, Felipe/C-2970-2018; Torres-Rosell, Jordi/A-4213-2010; de la Torre, M Angeles/A-7357-2010; Herrero, Enrique/B-5592-2009	Torres-Rosell, Jordi/0000-0003-1308-6926; de la Torre, M Angeles/0000-0002-6111-1359; Herrero, Enrique/0000-0002-6763-111X; Vilella, Felipe/0000-0002-0039-9846				Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Alic N, 2003, J BIOL CHEM, V278, P41849, DOI 10.1074/jbc.M307760200; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Andrews PD, 2000, J CELL SCI, V113, P2685; Banan A, 2002, J PHARMACOL EXP THER, V301, P852, DOI 10.1124/jpet.301.3.852; Banuett F, 1998, MICROBIOL MOL BIOL R, V62, P249, DOI 10.1128/MMBR.62.2.249-274.1998; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; de la Torre-Ruiz MA, 2002, J BIOL CHEM, V277, P33468, DOI 10.1074/jbc.M203515200; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DENOBEL JG, 1990, YEAST, V6, P483, DOI 10.1002/yea.320060605; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dong YQ, 2003, J CELL BIOL, V161, P1081, DOI 10.1083/jcb.200212040; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Hasan R, 2002, MOL MICROBIOL, V45, P233, DOI 10.1046/j.1365-2958.2002.03011.x; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Holm A, 2003, BIOCHEM BIOPH RES CO, V302, P653, DOI 10.1016/S0006-291X(03)00231-6; Holm A, 2001, CELL MICROBIOL, V3, P439, DOI 10.1046/j.1462-5822.2001.00127.x; Kaiser C., 1994, METHODS YEAST GENETI; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Martin-Yken H, 2003, MOL MICROBIOL, V49, P23, DOI 10.1046/j.1365-2958.2003.03541.x; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Sekiya-Kawasaki M, 2002, GENETICS, V162, P663; Staleva L, 2004, MOL BIOL CELL, V15, P5574, DOI 10.1091/mbc.E04-02-0142; Toledano MB, 2003, TOP CURR GENET, V1, P241; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	42	114	116	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9149	9159		10.1074/jbc.M411062200	http://dx.doi.org/10.1074/jbc.M411062200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637049	hybrid, Green Published			2022-12-27	WOS:000227453100064
J	Amos, S; Martin, PM; Polar, GA; Parsons, SJ; Hussaini, IM				Amos, S; Martin, PM; Polar, GA; Parsons, SJ; Hussaini, IM			Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase C delta/c-Src pathways in glioblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MALIGNANT GLIOMAS; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; FAMILY KINASES; FACTOR-ALPHA; ACTIVATION; EXPRESSION; GENE; PROLIFERATION	Both the epidermal growth factor receptor (EGFR) and protein kinase C (PKC) play important roles in glioblastoma invasive growth; however, the interaction between the EGFR and PKC is not well characterized in glioblastomas. Treatment with EGF stimulated global phosphorylation of the EGFR at Tyr(845), Tyr(992), Tyr(1068), and Tyr(1045) in glioblastoma cell lines (U-1242 MG and U-87 MG). Interestingly, phorbol 12-myristate 13-acetate (PMA) stimulated phosphorylation of the EGFR only at Tyr1068 in the two glioblastoma cell lines. Phosphorylation of the EGFR at Tyr1068 was not detected in normal human astrocytes treated with the phorbol ester. PMA-induced phosphorylation of the EGFR at Tyr1068 was blocked by bisindolylmaleimide (BIM), a PKC inhibitor, and rottlerin, a PKCdelta-specific inhibitor. In contrast, Go 6976, an inhibitor of classical PKC isozymes, had no effect on PMA-induced EGFR phosphorylation. Furthermore, gene silencing with PKCdelta small interfering RNA (siRNA), siRNA against c-Src, and mutant c-Src( S12C/S48A) and treatment with a c-Src inhibitor (4-amino-5(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) abrogated PMA-induced EGFR phosphorylation at Tyr(1068). PMA induced serine/threonine phosphorylation of Src, which was blocked by both BIM and rottlerin. Inhibition of the EGFR with AG 1478 did not significantly alter PMA-induced EGFR Tyr(1068) phosphorylation, but completely blocked EGF-induced phosphorylation of the EGFR. The effects of PMA on MAPK phosphorylation and glioblastoma cell proliferation were reduced by BIM, rottlerin, the MEK inhibitor U0126, and PKCdelta and c-Src siRNAs. Taken together, our data demonstrate that PMA transactivates the EGFR and increases cell proliferation by activating the PKCdelta/c-Src pathway in glioblastomas.	Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Grad Program Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Amos, S (corresponding author), Univ Virginia, Hlth Syst, Dept Pathol, MR 5,Rm 3332,415 Lane Rd, Charlottesville, VA 22908 USA.	sa7h@virginia.edu		Amos, Samson/0000-0003-2780-2276	NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035122, R01NS035122] Funding Source: NIH RePORTER; NCI NIH HHS [CA90851, R01 CA090851] Funding Source: Medline; NINDS NIH HHS [NS35122, R29 NS035122, R01 NS035122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; BENZIL DL, 1992, CANCER RES, V52, P2951; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bostrom J, 1998, CANCER RES, V58, P29; Bredel M, 1997, ACTA NEUROCHIR, V139, P1000, DOI 10.1007/BF01411552; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cavenee WK, 2000, GLIOBLASTOMA, P29; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COCHET C, 1984, J BIOL CHEM, V259, P2553; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; Collins VP, 1998, CANCER SURV, V32, P37; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; COULDWELL WT, 1992, NEUROSURGERY, V31, P717; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; DETHLEFSEN SM, 1988, J CELL BIOCHEM, V69, P143; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Greco S, 2004, J CELL PHYSIOL, V201, P84, DOI 10.1002/jcp.20052; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Maasho K, 2004, J IMMUNOL METHODS, V284, P133, DOI 10.1016/j.jim.2003.10.010; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; Prados Michael D., 2000, Seminars in Oncology, V27, P1; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Saito S, 2002, J BIOL CHEM, V277, P44695, DOI 10.1074/jbc.M208332200; Samet JM, 2003, TOXICOL APPL PHARM, V191, P86, DOI 10.1016/S0041-008X(03)00219-9; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TODO T, 1991, NEUROSURGERY, V108, P11; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	70	94	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7729	7738		10.1074/jbc.M409056200	http://dx.doi.org/10.1074/jbc.M409056200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15618223	Green Accepted, hybrid			2022-12-27	WOS:000227395700037
J	Sekine, Y; Yamamoto, T; Yumioka, T; Sugiyama, K; Tsuji, S; Oritani, K; Shimoda, K; Minoguchi, M; Yoshimura, A; Matsuda, T				Sekine, Y; Yamamoto, T; Yumioka, T; Sugiyama, K; Tsuji, S; Oritani, K; Shimoda, K; Minoguchi, M; Yoshimura, A; Matsuda, T			Physical and functional interactions between STAP-2/BKS and STAT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CYTOKINE; RECEPTOR; PROLIFERATION; FAMILY; DIFFERENTIATION; ERYTHROPOIETIN	Signal-transducing adaptor protein family of proteins (STAPs), which currently contains two members, are proposed to be adaptor molecules because of their pleckstrin homology (PH) and Src-homology 2 (SH2)-like domains. STAP-1 has been shown to interact with STAT5 and the tyrosine kinase Tec. With regard to STAP-2/BKS functions, immunoprecipitation experiments and intracellular stainings revealed STAP-2/BKS binds STAT5 in several types of cells. Mutational studies revealed that the PH- and SH2-like domains of STAP-2/BKS interacted with the C-terminal region of STAT5. STAP-2/BKS and STAT5 were found to constitutively co-localize in the cytoplasm of resting cells, but STAP-2/BKS was found to dissociate upon STAT5 phosphorylation, suggesting a role in regulating signaling of STAT5. The physiological role of these interactions is not fully understood, but in studies of overexpression of STAP-2/BKS, cytokine-induced tyrosine phosphorylation and transcriptional activation of STAT5 was diminished. In addition, thymocytes from STAP-2/BKS-deficient mice showed the enhanced interleukin-2-dependent cell growth. Taken together, STAP-2/BKS is an additional modulator of STAT5-mediated signaling.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Kawanishi Pharma Res Inst, Nippon Boehringer Ingelheim Co Ltd, Kawanishi, Hyogo 6660193, Japan; Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Kyushu Univ, Fac Med, Dept Internal Med 1, Higashi Ku, Fukuoka 812, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Fukuoka 8128582, Japan	Hokkaido University; Boehringer Ingelheim; Osaka University; Kyushu University; Kyushu University	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Matsuda, Tadashi/A-3835-2012; Sekine, Yuichi/S-8813-2019; Yoshimura, Akihiko/K-5515-2013	Matsuda, Tadashi/0000-0002-3089-3757; Sekine, Yuichi/0000-0002-2861-603X; 				Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; IWAMURA T, 2003, BIOCHEM BIOPH RES CO, V282, P515; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kang JS, 2004, J IMMUNOL, V173, P2307, DOI 10.4049/jimmunol.173.4.2307; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Masuhara M, 2000, BIOCHEM BIOPH RES CO, V268, P697, DOI 10.1006/bbrc.2000.2223; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Muromoto R, 2003, FEBS LETT, V540, P223, DOI 10.1016/S0014-5793(03)00269-2; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Yamamoto T, 2003, BIOCHEM BIOPH RES CO, V306, P767, DOI 10.1016/S0006-291X(03)01042-8; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599	48	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8188	8196		10.1074/jbc.M411692200	http://dx.doi.org/10.1074/jbc.M411692200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611091	Green Published, hybrid			2022-12-27	WOS:000227395700092
J	Kobayashi, S; Bannister, ML; Gangopadhyay, JP; Hamada, T; Parness, J; Ikemoto, N				Kobayashi, S; Bannister, ML; Gangopadhyay, JP; Hamada, T; Parness, J; Ikemoto, N			Dantrolene stabilizes domain interactions within the ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CORE DISEASE; CA2+ RELEASE CHANNEL; MALIGNANT HYPERTHERMIA; SARCOPLASMIC-RETICULUM; INTERDOMAIN INTERACTION; CONFORMATIONAL-CHANGES; CALCIUM-RELEASE; BINDING-SITES; SKELETAL; MUTATIONS	Interdomain interactions between N-terminal and central domains serving as a "domain switch" are believed to be essential to the functional regulation of the skeletal muscle ryanodine receptor-1 Ca2+ channel. Mutational destabilization of the domain switch in malignant hyperthermia (MH), a genetic sensitivity to volatile anesthetics, causes functional instability of the channel. Dantrolene, a drug used to treat MH, binds to a region within this proposed domain switch. To explore its mechanism of action, the effect of dantrolene on MH-like channel activation by the synthetic domain peptide DP4 or anti-DP4 antibody was examined. A fluorescence probe, methylcoumarin acetate, was covalently attached to the domain switch using DP4 as a delivery vehicle. The magnitude of domain unzipping was determined from the accessibility of methylcoumarin acetate to a macromolecular fluorescence quencher. The Stern-Volmer quenching constant (K-Q) increased with the addition of DP4 or anti-DP4 antibody. This increase was reversed by dantrolene at both 37 and 22degreesC and was unaffected by calmodulin. [H-3]Ryanodine binding to the sarcoplasmic reticulum and activation of sarcoplasmic reticulum Ca2+ release, both measures of channel activation, were enhanced by DP4. These activities were inhibited by dantrolene at 37degreesC, yet required the presence of calmodulin at 22degreesC. These results suggest that the mechanism of action of dantrolene involves stabilization of domain-domain interactions within the domain switch, preventing domain unzipping-induced channel dysfunction. We suggest that temperature and calmodulin primarily affect the coupling between the domain switch and the downstream mechanism of regulation of Ca2+ channel opening rather than the domain switch itself.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia Pharmacol Pediat & Physiol & Biop, Piscataway, NJ 08854 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard Medical School	Ikemoto, N (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	ikemoto@bbri.org		Bannister, Mark/0000-0002-0865-5912	NHLBI NIH HHS [HL072841] Funding Source: Medline; NIAMS NIH HHS [AR045593, AR16922] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045593, R01AR016922] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Avila G, 2003, J GEN PHYSIOL, V121, P277, DOI 10.1085/jgp.200308791; BRITT BA, 1984, CAN ANAESTH SOC J, V31, P130, DOI 10.1007/BF03015252; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; Davis MR, 2003, NEUROMUSCULAR DISORD, V13, P151, DOI 10.1016/S0960-8966(02)00218-3; Dirksen RT, 2002, TRENDS CARDIOVAS MED, V12, P189, DOI 10.1016/S1050-1738(02)00163-9; Du GG, 2004, BIOCHEM J, V382, P557, DOI 10.1042/BJ20040580; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELLIS KO, 1973, J PHARM SCI, V62, P948, DOI 10.1002/jps.2600620619; FLEWELLEN EH, 1983, ANESTHESIOLOGY, V59, P275, DOI 10.1097/00000542-198310000-00002; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; GALLANT EM, 1982, NEUROSCI LETT, V28, P181, DOI 10.1016/0304-3940(82)90149-5; Galli L, 2002, CELL CALCIUM, V32, P143, DOI 10.1016/S0143-4160(02)00138-0; HAINAUT K, 1974, NATURE, V252, P728, DOI 10.1038/252728a0; HERBETTE L, 1982, ANNU REV PHARMACOL, V22, P413, DOI 10.1146/annurev.pa.22.040182.002213; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; INUI M, 1988, METHOD ENZYMOL, V157, P490; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; Kobayashi S, 2004, BIOCHEM J, V380, P561, DOI 10.1042/BJ20040112; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; LAMB GD, 1993, J MUSCLE RES CELL M, V14, P554, DOI 10.1007/BF00141551; Lamb GD, 2001, AM J PHYSIOL-CELL PH, V281, pC207, DOI 10.1152/ajpcell.2001.281.1.C207; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; Monnier N, 2003, HUM MOL GENET, V12, P1171, DOI 10.1093/hmg/ddg121; MORGAN KG, 1977, J PHARMACOL EXP THER, V201, P138; Nelson TE, 1996, ANESTHESIOLOGY, V84, P1368, DOI 10.1097/00000542-199606000-00013; OHNISHI ST, 1983, FEBS LETT, V161, P103; OHTA T, 1989, AM J PHYSIOL, V256, pC358, DOI 10.1152/ajpcell.1989.256.2.C358; OTHA T, 1990, EUR J PHARMACOL, V178, P11; Owen VJ, 1997, AM J PHYSIOL-CELL PH, V272, pC203, DOI 10.1152/ajpcell.1997.272.1.C203; Palnitkar SS, 1999, J MED CHEM, V42, P1872, DOI 10.1021/jm9805079; Palnitkar SS, 1997, BIOCHEM J, V326, P847, DOI 10.1042/bj3260847; PARNESS J, 1995, J BIOL CHEM, V270, P18465, DOI 10.1074/jbc.270.31.18465; Paul-Pletzer K, 2002, J BIOL CHEM, V277, P34918, DOI 10.1074/jbc.M205487200; Paul-Pletzer K, 2001, BIOCHEMISTRY-US, V40, P531, DOI 10.1021/bi001502s; Shtifman A, 2002, J GEN PHYSIOL, V119, P15, DOI 10.1085/jgp.119.1.15; Szentesi P, 2001, J GEN PHYSIOL, V118, P355, DOI 10.1085/jgp.118.4.355; Tammaro A, 2003, CLIN CHEM, V49, P761, DOI 10.1373/49.5.761; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; Yamamoto T, 2000, J BIOL CHEM, V275, P11618, DOI 10.1074/jbc.275.16.11618; Yamamoto T, 2002, BIOCHEMISTRY-US, V41, P1492, DOI 10.1021/bi015581z; Yang TZ, 2003, J BIOL CHEM, V278, P25722, DOI 10.1074/jbc.M302165200; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200; Zorzato F, 2003, HUM MOL GENET, V12, P379, DOI 10.1093/hmg/ddg032	46	97	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6580	6587		10.1074/jbc.M408375200	http://dx.doi.org/10.1074/jbc.M408375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611117	hybrid			2022-12-27	WOS:000227332700042
J	Naqvi, N; Liu, K; Graham, RM; Husain, A				Naqvi, N; Liu, K; Graham, RM; Husain, A			Molecular basis of exopeptidase activity in the C-terminal domain of human angiotensin I-converting enzyme - Insights into the origins of its exopeptidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P; HYDROLYSIS; BINDING; DEPENDENCE; CAPTOPRIL; ACE	Proteolytic processing is a primary means of biological control. Exopeptidases use terminal anchoring interactions to restrict cleavage at peptide substrate N or C termini. In contrast, internal peptide bond targeting by endopeptidases is through context-driven recognition. Angiotensin I-converting enzyme (ACE), a zinc metalloproteinase, has tandem duplicate catalytic domains, Nand C-terminal, each of which is a dual specificity enzyme with exo- and endocarboxypeptidase activities. The mechanisms by which ACE evolved from its endopeptidase ancestors as a dual specificity enzyme have not been defined. Based on kinetic studies of wild-type and mutant forms of the C-terminal catalytic domain of human ACE and of the ACE substrates angiotensin I, substance P, and bradykinin, as well as considerations of the ACE x-ray structure, we provide evidence that the acquisition of its exopeptidase activity is due to novel evolutionary specializations. These involve not only interactions between the S-2' subsite cognate for the C-terminal substrate P-2' side chain, acting in concert with carboxylate-docking interactions with Lys(1087) and Tyr(1096), but also electrostatic selection against a cationic C-terminal substrate carboxylate. With a blocked C terminus, substrate side chain interactions are dominant in cleavage site selection. In the evolution of obligate exopeptidases from endopeptidase ancestors, mutations that destroy context-driven peptide bond targeting are likely to have followed the acquisition of terminal docking interactions. Evolutionary intermediates between endopeptidases and obligate exopeptidases could therefore have been dual specificity proteinases like ACE.	Univ Alabama Birmingham, Ctr Heart Failure Res, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Biotechnol & Biomol Sci, Kensington, NSW 2033, Australia	University of Alabama System; University of Alabama Birmingham; Victor Chang Cardiac Research Institute; University of New South Wales Sydney	Husain, A (corresponding author), Univ Alabama Birmingham, Ctr Heart Failure Res, Dept Physiol & Biophys, Biomed Res Bldg 2,Rm 435,901 19th St S, Birmingham, AL 35294 USA.	ahusain@physiology.uab.edu	Husain, Ahsan/J-6861-2012	Husain, Ahsan/0000-0003-3426-3469				Acharya KR, 2003, NAT REV DRUG DISCOV, V2, P891, DOI 10.1038/nrd1227; AHN K, 2004, HDB PROTEOLYTIC ENZY, P429; CASCIERI MA, 1984, MOL PHARMACOL, V25, P287; CHEUNG HS, 1980, J BIOL CHEM, V255, P401; CORVOL P, 2004, HDB PROTEOLYTIC ENZY, P332; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Liu XF, 2001, J BIOL CHEM, V276, P33518, DOI 10.1074/jbc.M101495200; Natesh R, 2004, BIOCHEMISTRY-US, V43, P8718, DOI 10.1021/bi049480n; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; QUAY T, 1994, ARCH BIOCHEM BIOPHYS, V308, P133, DOI 10.1006/abbi.1994.1019; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; Skidgel RA, 2004, PEPTIDES, V25, P521, DOI 10.1016/j.peptides.2003.12.010; SKIDGEL RA, 1984, PEPTIDES, V5, P769, DOI 10.1016/0196-9781(84)90020-2; Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200; Turner AJ, 2004, HDB PROTEOLYTIC ENZY, P419; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; YOKOSAWA H, 1983, BIOCHEM BIOPH RES CO, V116, P735, DOI 10.1016/0006-291X(83)90586-7	18	17	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6669	6675		10.1074/jbc.M412638200	http://dx.doi.org/10.1074/jbc.M412638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15615692	hybrid			2022-12-27	WOS:000227332700054
J	Wustner, D				Wustner, D			Mathematical analysis of hepatic high density lipoprotein transport based on quantitative imaging data	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CLASS-B; PERFUSED-RAT-LIVER; PLASMA-MEMBRANE PROTEINS; POLYMERIC IGA RECEPTOR; CANINE KIDNEY-CELLS; HEPG2 CELLS; CANALICULAR MEMBRANE; LATE ENDOSOMES; NONVESICULAR TRANSPORT; SUBAPICAL COMPARTMENT	Hepatocytes internalize high density lipoprotein (HDL) at the basolateral membrane. Most HDL is recycled while some is shuttled to the canalicular membrane by transcytosis. Here, transport of HDL was analyzed by mathematical modeling based on measurements in polarized hepatic HepG2 cells. Recycling of HDL from basolateral sorting endosomes was modeled by applying the rapid equilibrium approach. Analytical expressions were derived, which describe in one model the transport of HDL to the subapical compartment/apical recycling compartment, the biliary canaliculus (BC), and to late endosomes and lysosomes (LE/LYS). Apical endocytosis of HDL predicted by the model was confirmed for rhodamine-dextran and fluorescent asialoorosomucoid, markers for LEALYS in living HepG2 cells. Budding of endocytic vesicles from the BC was directly observed by time lapse imaging of a fluorescent lipid probe. Based on fitted kinetic parameters and their covariance matrix a Monte Carlo simulation of HDL transport in hepatocytes was performed. The model was used to quantitatively assess release of HDL-associated free cholesterol by scavenger receptor BI. It is shown that only 6% of HDL-associated sterol reaches the BC as a constituent of the HDL particles, whereas the remaining sterol is rapidly released from HDL and shuttled to the BC by non-vesicular transport.	Max Delbruck Ctr Mol Med, Theoret Biophys Grp, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Wustner, D (corresponding author), Max Delbruck Ctr Mol Med, Theoret Biophys Grp, Robert Rossle Str 10, D-13125 Berlin, Germany.	da.wuestner@mdc-berlin.de	Eckhardt, Erik/G-1567-2010	Wustner, Daniel/0000-0003-4995-9709				BARR VA, 1995, J BIOL CHEM, V270, P27834, DOI 10.1074/jbc.270.46.27834; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BRANDT S, 1999, DATENANALYSE, P65; CIECHANOVER A, 1983, CELL, V32, P267, DOI 10.1016/0092-8674(83)90517-2; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CRAWFORD JM, 1995, J LIPID RES, V36, P2147; Crawford JM, 1996, SEMIN LIVER DIS, V16, P169, DOI 10.1055/s-2007-1007230; DANIELS CK, 1987, P SOC EXP BIOL MED, V186, P246; DELAMATRE JG, 1990, J LIPID RES, V31, P191; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; Gan YB, 2002, NAT CELL BIOL, V4, P605, DOI 10.1038/ncb827; Garcia A, 1996, BIOCHEMISTRY-US, V35, P13064, DOI 10.1021/bi952223l; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; Guendouzi K, 1998, BIOCHEMISTRY-US, V37, P14974, DOI 10.1021/bi9810508; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; HEINRICH P, 1996, REGULATION CELLULAR, P123; Ihrke G, 1998, J CELL BIOL, V141, P115, DOI 10.1083/jcb.141.1.115; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; KAMBOURIS AM, 1990, ARTERIOSCLEROSIS, V10, P582, DOI 10.1161/01.ATV.10.4.582; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; KLOPPEL TM, 1989, J CELL PHYSIOL, V138, P555, DOI 10.1002/jcp.1041380316; KLOPPEL TM, 1986, J CELL BIOCHEM, V32, P235, DOI 10.1002/jcb.240320310; KUIPERS F, 1997, SUBCELL BIOCH, V28, P1053; Leung SM, 2000, MOL BIOL CELL, V11, P2131, DOI 10.1091/mbc.11.6.2131; MOCKEL GM, 1995, AM J PHYSIOL-GASTR L, V269, pG73, DOI 10.1152/ajpgi.1995.269.1.G73; MOLOTKOVSKY JG, 1982, EUR J BIOCHEM, V122, P573; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; OSE L, 1980, BIOCHIM BIOPHYS ACTA, V620, P120, DOI 10.1016/0005-2760(80)90191-5; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PORTAL I, 1993, AM J PHYSIOL, V264, pG1052, DOI 10.1152/ajpgi.1993.264.6.G1052; PRESS WH, 1989, NUMERICAL RECIPES AR, P529; Rahner C, 2000, GASTROENTEROLOGY, V119, P1692, DOI 10.1053/gast.2000.20233; Rhainds D, 1999, EUR J BIOCHEM, V261, P227, DOI 10.1046/j.1432-1327.1999.00264.x; Robins SJ, 1997, J CLIN INVEST, V99, P380, DOI 10.1172/JCI119170; Robins SJ, 1999, HEPATOLOGY, V29, P1541, DOI 10.1002/hep.510290518; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Sai Y, 1999, J CELL SCI, V112, P4535; SCHARSCHMIDT BF, 1986, P NATL ACAD SCI USA, V83, P9488, DOI 10.1073/pnas.83.24.9488; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SCHIFF JM, 1986, HEPATOLOGY, V6, P837, DOI 10.1002/hep.1840060506; SCOTT LJ, 1992, J BIOL CHEM, V267, P6099; Secknus R, 1999, J GASTROEN HEPATOL, V14, P446, DOI 10.1046/j.1440-1746.1999.01881.x; Sehayek E, 2003, J LIPID RES, V44, P1605, DOI 10.1194/jlr.M200488-JLR200; SEWELL RB, 1983, J LIPID RES, V24, P391; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; SORMUNEN R, 1993, LAB INVEST, V68, P652; Sovic A, 2004, NEUROSCI LETT, V368, P11, DOI 10.1016/j.neulet.2004.04.097; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Tuma PL, 1999, J CELL BIOL, V145, P1089, DOI 10.1083/jcb.145.5.1089; Tuma PL, 2001, J CELL BIOL, V154, P1197, DOI 10.1083/jcb.200105138; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; Van Dyke Rebecca W, 2004, BMC Physiol, V4, P1, DOI 10.1186/1472-6793-4-1; van IJzendoorn SCD, 1998, J CELL BIOL, V142, P683, DOI 10.1083/jcb.142.3.683; Wakabayashi Y, 2004, MOL BIOL CELL, V15, P3485, DOI 10.1091/mbc.E03-10-0737; Weiss M, 2004, TRAFFIC, V5, P662, DOI 10.1111/j.1600-0854.2004.00215.x; WOLF DE, 1989, METHOD CELL BIOL, V30, P271; Wustner D, 2004, J LIPID RES, V45, P427, DOI 10.1194/jlr.M300440-JLR200; Wustner D, 2002, J BIOL CHEM, V277, P30325, DOI 10.1074/jbc.M202626200; Wustner D, 2001, TRAFFIC, V2, P277, DOI 10.1034/j.1600-0854.2001.9o135.x; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	69	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6766	6779		10.1074/jbc.M413238200	http://dx.doi.org/10.1074/jbc.M413238200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15613466	hybrid			2022-12-27	WOS:000227332700066
J	Meyers, M; Wagner, MW; Mazurek, A; Schmutte, C; Fishel, R; Boothman, DA				Meyers, M; Wagner, MW; Mazurek, A; Schmutte, C; Fishel, R; Boothman, DA			DNA mismatch repair-dependent response to fluoropyrimidine-generated damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; HUMAN EXONUCLEASE-I; MICROSATELLITE-INSTABILITY; COLORECTAL-CANCER; COLON-CANCER; ADJUVANT CHEMOTHERAPY; PHYSICAL INTERACTION; GENOMIC INSTABILITY; EXCISION-REPAIR; HUMAN BREAST	Previous studies from our laboratory indicated that expression of the MLH1 DNA mismatch repair (AMR) gene was necessary to restore cytotoxicity and an efficient G, arrest in HCT116 human colon cancer cells, as well as Mlhl(-/-) murine embryonic fibroblasts, after treatment with 5-fluoro-2'-deoxyuridine (FdUrd). Here, we show that an identical phenomenon occurred when expression of MSH2, the other major AMM gene, was restored in HEC59 human endometrial carcinoma cells or was present in adenovirus E1A-immortalized Msh(+/+) (compared with isogenic Msh2(-/-)) murine embryonic stem cells. Because NIAM status had little effect on cellular responses (i.e. G2 arrest and lethality) to the thymidylate synthase inhibitor, Tomudex, and a greater level of [H-3]FdUrd incorporation into DNA was found in MMR-deficient cells, we concluded that the differential FdUrd cytotoxicity between ADM-competent and MMR-deficient cells was mediated at the level of DNA incorporation. Analyses of ATPase activation suggested that the hMSH2-hMSH6 heterodimer only recognized FdUrd moieties (as the base 5-fluorouracil (FU) in DNA) when mispaired with guanine, but not paired with adenine. Furthermore, analyses of incorporated FdUrd using methyl-CpG-binding domain 4 glycosylase indicated that there was more misincorporated FU:Gua in the DNA of AUVIR-deficient HCT116 cells. Our data provide the first demonstration that MMR specifically detects FU:Gua (in the first round of DNA replication), signaling a sustained G, arrest and lethality.	Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Lab Mol Stress Responses, Cleveland, OH 44106 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, DNA Repair & Mol Carcinogenesis Program, Philadelphia, PA 19107 USA	Case Western Reserve University; Case Western Reserve University; Jefferson University	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, 3-531 Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.	david.boothman@case.edu	Boothman, David/Q-7776-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aebi S, 1996, CANCER RES, V56, P3087; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Berardini M, 2000, J BIOL CHEM, V275, P27851; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; BRANCH P, 1995, CANCER RES, V55, P2304; BRIGGLE TV, 1986, J CHROMATOGR, V381, P343, DOI 10.1016/S0378-4347(00)83600-2; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Caduff RF, 1996, AM J PATHOL, V148, P1671; Carethers JM, 1999, GASTROENTEROLOGY, V117, P123, DOI 10.1016/S0016-5085(99)70558-5; Carethers JM, 2004, GASTROENTEROLOGY, V126, P394, DOI 10.1053/j.gastro.2003.12.023; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Davis TW, 1998, CANCER RES, V58, P767; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drake JC, 1996, BIOCHEM PHARMACOL, V51, P1349, DOI 10.1016/0006-2952(96)00057-3; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FIELD JK, 1995, BRIT J CANCER, V71, P1065, DOI 10.1038/bjc.1995.205; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Glaab WE, 1998, CARCINOGENESIS, V19, P1931, DOI 10.1093/carcin/19.11.1931; Goel A, 2003, CANCER RES, V63, P1608; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; HAWN MT, 1995, CANCER RES, V55, P3721; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hungspreugs P., 2003, International Journal of Radiation Oncology Biology Physics, V57, pS143, DOI 10.1016/S0360-3016(03)00901-5; INGRAHAM HA, 1980, CANCER RES, V40, P998; JACKMAN AL, 1991, ADV EXP MED BIOL, V309, P19; KARRAN P, 1990, MUTAT RES, V236, P269, DOI 10.1016/0921-8777(90)90010-3; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 1999, CANCER RES, V59, P5068; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; KUFE DW, 1981, J BIOL CHEM, V256, P8885; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; Liu PF, 2002, CHEM RES TOXICOL, V15, P1001, DOI 10.1021/tx020030a; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; LOTHE RA, 1993, CANCER RES, V53, P5849; Lynch HT, 1998, ONCOLOGY-BASEL, V55, P103, DOI 10.1159/000011843; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; McLeod HL, 1999, BRIT J CANCER, V79, P191, DOI 10.1038/sj.bjc.6690033; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Meyers M, 2003, ONCOGENE, V22, P7376, DOI 10.1038/sj.onc.1206941; Meyers M, 2001, CANCER RES, V61, P5193; Meyers M, 1997, CANCER RES, V57, P206; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Orlandi L, 1999, BRIT J CANCER, V81, P252, DOI 10.1038/sj.bjc.6690685; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Reitmair AH, 1997, CANCER RES, V57, P3765; Renault B, 1996, HUM GENET, V98, P601, DOI 10.1007/s004390050267; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Umar A, 1997, CANCER RES, V57, P3949; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Wang WG, 2001, CANCER RES, V61, P5505; Watanabe M, 1996, INT J CANCER, V69, P394, DOI 10.1002/(SICI)1097-0215(19961021)69:5<394::AID-IJC7>3.3.CO;2-C; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Waters TR, 1997, BIOCHEMISTRY-US, V36, P2501, DOI 10.1021/bi9621573; WECKBECKER G, 1991, PHARMACOL THERAPEUT, V50, P367, DOI 10.1016/0163-7258(91)90051-M; YALOWICH JC, 1985, BIOCHEM PHARMACOL, V34, P2319, DOI 10.1016/0006-2952(85)90788-9; Yang GZ, 2004, CANCER CELL, V6, P139, DOI 10.1016/j.ccr.2004.06.024; Yin MB, 1999, EXP CELL RES, V247, P189, DOI 10.1006/excr.1998.4346	73	108	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5516	5526		10.1074/jbc.M412105200	http://dx.doi.org/10.1074/jbc.M412105200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15611052	hybrid			2022-12-27	WOS:000227217100051
J	Sohn, D; Schulze-Osthoff, K; Janicke, RU				Sohn, D; Schulze-Osthoff, K; Janicke, RU			Caspase-8 can be activated by interchain proteolysis without receptor-triggered dimerization during drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED-PROXIMITY MODEL; DEATH DOMAIN PROTEIN; CYTOCHROME-C; MEDIATED APOPTOSIS; OCCURS DOWNSTREAM; CELLS; CLEAVAGE; MECHANISM; CD95; FRAGMENTATION	Proteases of the caspase family are thought to be activated by proteolytic processing of their inactive zymogens. However, although proteolytic cleavage is sufficient for executioner caspases, a different mechanism has been recently proposed for initiator caspases, such as caspase-8, which are believed to be activated by proximity-induced dimerization. According to this model, dimerization rather than proteolytic processing is considered as the critical event for caspase-8 activation. Such a mechanism would suggest that in the absence of a dimerization platform such as the death-inducing signaling complex, caspase-8 proteolytic cleavage would result in an inactive enzyme. As several studies have described caspase-8 cleavage during mitochondrial apoptosis, we now investigated whether caspase-8 becomes indeed catalytically active in this pathway. Using an in vivo affinity labeling approach, we demonstrate that caspase-8 is activated in etoposide-treated cells in vivo in the absence of the receptor-induced death-inducing signaling complex formation. Furthermore, we show that both caspase-3 and -6 are required for the efficient activation of caspase-8. Our data therefore indicate that interchain cleavage of caspase-8 in the mitochondrial pathway is sufficient to produce an active enzyme even in the absence of receptor-driven procaspase-8 dimerization.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Sohn, D (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chang DW, 2003, J BIOL CHEM, V278, P16466, DOI 10.1074/jbc.C300089200; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fischer B, 2003, BIOCHEM BIOPH RES CO, V306, P516, DOI 10.1016/S0006-291X(03)01004-0; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jones DT, 2001, BLOOD, V98, P2800, DOI 10.1182/blood.V98.9.2800; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Milner AE, 2002, CELL DEATH DIFFER, V9, P287, DOI 10.1038/sj/cdd/4400945; Murphy BM, 2004, J BIOL CHEM, V279, P36916, DOI 10.1074/jbc.M402039200; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nie Z, 2002, CELL DEATH DIFFER, V9, P1172, DOI 10.1038/sj.cdd.4401094; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	48	85	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5267	5273		10.1074/jbc.M408585200	http://dx.doi.org/10.1074/jbc.M408585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15611097	hybrid			2022-12-27	WOS:000227217100021
J	Cao, J; Rehemtulla, A; Pavlaki, M; Kozarekar, P; Chiarelli, C				Cao, J; Rehemtulla, A; Pavlaki, M; Kozarekar, P; Chiarelli, C			Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 MATRIX-METALLOPROTEINASE; PROPROTEIN CONVERTASES FURIN; TISSUE INHIBITOR; CELL-SURFACE; INTRACELLULAR TRAFFICKING; PROCESSING ENZYMES; TUMOR PROGRESSION; GENE-EXPRESSION; IV COLLAGENASE; PRO-GELATINASE	Proprotein convertases play an important role in tumorigenesis and invasiveness. Here, we report that a dibasic amino acid convertase, furin, directly cleaves proMMP-2 within the trans-Golgi network leading to an inactive form of matrix metalloproteinase- 2 (MMP-2). Co-transfection of COS-1 cells with both proMMP-2 and furin cDNAs resulted in the cleavage of the N-terminal propeptide of proMMP-2. The molecular mass of cleaved MMP-2 (63 kDa), detected in both cell lysates and conditioned medium, is between the intermediate and fully activated forms of MMP- 2 induced by membrane type 1-MMP. Furin-cleaved MMP- 2 does not possess proteolytic activity as examined in a cell-free assay. Treatment of transfected cells with a furin inhibitor resulted in a dose-dependent inhibition of proMMP- 2 cleavage; recombinant tissue inhibitor of metalloproteinase- 2, which binds to the active site of membrane type 1-MMP, had no inhibitory effect. Site-directed mutagenesis of amino acids in the furin consensus recognition motif of proMMP- 2((RKPR72)-K-69 down arrow) prevented propeptide cleavage, thereby identifying the scissile bond and characterizing the basic amino acids required for cleavage. Other experimental observations were consistent with intracellular furin cleavage of proMMP- 2 in the trans-Golgi network. The furin cleavage site in other proMMPs was examined. MMP- 3, which contains the RXXR furin consensus sequence, was cleaved in furin co-transfected cells, whereas MMP- 1, which lacks an RXXR consensus sequence, was not cleaved. In conclusion, we report the novel observation that furin can directly cleave the RXXR amino acid sequence in the propeptide domain of proMMP- 2 leading to inactivation of the enzyme.	SUNY Stony Brook, Sch Med, Dept Med, Stony Brook, NY 11794 USA; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Dept Res, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Cao, J (corresponding author), SUNY Stony Brook, Sch Med, Dept Med, Rm 004, Stony Brook, NY 11794 USA.	jian.cao@sunysb.edu						Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Bassi DE, 2000, MOL CARCINOGEN, V28, P63, DOI 10.1002/1098-2744(200006)28:2<63::AID-MC1>3.3.CO;2-3; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; Cao J, 2004, J BIOL CHEM, V279, P14129, DOI 10.1074/jbc.M312120200; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Gu F, 2001, CELL MOL LIFE SCI, V58, P1067, DOI 10.1007/PL00000922; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LOWENSTEIN PR, 1994, EUR J NEUROSCI, V6, P1453, DOI 10.1111/j.1460-9568.1994.tb01007.x; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nagase H, 1997, BIOL CHEM, V378, P151; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Paquette B, 2003, J STEROID BIOCHEM, V87, P65, DOI 10.1016/S0960-0760(03)00386-8; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; REHEMTULLA A, 1992, BLOOD, V79, P2349; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VISCHER UM, 1994, BLOOD, V83, P3536; WALKER JA, 1994, J VIROL, V68, P1213, DOI 10.1128/JVI.68.2.1213-1218.1994; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; Xue ML, 2004, EXP CELL RES, V299, P119, DOI 10.1016/j.yexcr.2004.05.015; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	50	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10974	10980		10.1074/jbc.M412370200	http://dx.doi.org/10.1074/jbc.M412370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15637056	hybrid			2022-12-27	WOS:000227761800013
J	Wajih, N; Sane, DC; Hutson, SM; Wallin, R				Wajih, N; Sane, DC; Hutson, SM; Wallin, R			Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity - Evidence for a functional CXXC redox center in the system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPOXIDE REDUCTASE; FACTOR-IX; 2,3-EPOXIDE REDUCTASE; WARFARIN RESISTANCE; IN-VITRO; LIVER; RAT; PURIFICATION; INHIBITION; PROTEINS	The vitamin K-dependent gamma-arboxylation system in the endoplasmic reticulum membrane responsible for gamma- carboxyglutamic acid modification of vitamin K-dependent proteins includes gamma-carboxylase and vitamin K 2,3-epoxide reductase (VKOR). An understanding of the mechanism by which this system works at the molecular level has been hampered by the difficulty of identifying VKOR involved in warfarin sensitive reduction of vitamin K 2,3-epoxide to reduced vitamin K1H2, the gamma-carboxylase cofactor. Identification and cloning of VKORC1, a proposed subunit of a larger VKOR enzyme complex, have provided opportunities for new experimental approaches aimed at understanding the vitamin K-dependent gamma-carboxylation system. In this work we have engineered stably transfected baby hamster kidney cells containing gamma-carboxylase and VKORC1 cDNA constructs, respectively, and stably double transfected cells with the gamma-carboxylase and the VKORC1 cDNA constructs in a bicistronic vector. All engineered cells showed increased activities of the enzymes encoded by the cDNAs. However increased activity of the gamma- carboxylation system, where VKOR provides the reduced vitamin K1H2 cofactor, was measured only in cells transfected with VKORC1 and the double transfected cells. The results show that VKOR is the rate-limiting step in the gamma-carboxylation system and demonstrate successful engineering of cells containing a recombinant vitamin K-dependent gamma-carboxylation system with enhanced capacity for gamma-carboxyglutamic acid modification. The proposed thioredoxin-like (CXXC135)-C-132 redox center in VKORC1 was tested by expressing the VKORC1 mutants Cys(132)/Ser and Cys(135)/Ser in BHK cells. Both of the expressed mutant proteins were inactive supporting the existence of a CXXC redox center in VKOR.	Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	Wallin, R (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA.	rwallin@wfubmc.edu	Wajih, Nadeem/GMW-6625-2022		NHLBI NIH HHS [HL06933] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Begent LA, 2001, J PHARM PHARMACOL, V53, P481, DOI 10.1211/0022357011775776; CAIN D, 1998, J BIOL CHEM, V273, P4982; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; FASCO MJ, 1983, BIOCHEMISTRY-US, V22, P5655, DOI 10.1021/bi00293a031; Fregin A, 2002, BLOOD, V100, P3229, DOI 10.1182/blood-2002-03-0698; Funakoshi H, 2002, J NEUROSCI RES, V68, P150, DOI 10.1002/jnr.10211; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Goodstadt L, 2004, TRENDS BIOCHEM SCI, V29, P289, DOI 10.1016/j.tibs.2004.04.004; Hallgren KW, 2002, BIOCHEMISTRY-US, V41, P15045, DOI 10.1021/bi026016e; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HE XH, 1995, J HISTOCHEM CYTOCHEM, V43, P85, DOI 10.1177/43.1.7822769; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; LEE JJ, 1984, BIOCHEMISTRY-US, V23, P2246, DOI 10.1021/bi00305a024; Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254; MUKHARJI I, 1985, P NATL ACAD SCI USA, V82, P2713, DOI 10.1073/pnas.82.9.2713; Nolte I, 2000, BBA-PROTEIN STRUCT M, V1543, P123, DOI 10.1016/S0167-4838(00)00188-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Roth DA, 2001, BLOOD, V98, P3600, DOI 10.1182/blood.V98.13.3600; SADOWSKI JA, 1976, J BIOL CHEM, V251, P2770; SILVERMAN RB, 1989, J MED CHEM, V32, P2138, DOI 10.1021/jm00129a019; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; Suttie J. W., 1978, Handbook of lipid research. Volume 2. The fat-soluble vitamins, P211; SUTTIE JW, 1987, P NATL ACAD SCI USA, V84, P634, DOI 10.1073/pnas.84.3.634; Tishler M, 1940, J AM CHEM SOC, V62, P2866, DOI 10.1021/ja01867a066; Wajih N, 2004, J BIOL CHEM, V279, P43052, DOI 10.1074/jbc.M407180200; Wajih N, 2004, J BIOL CHEM, V279, P25276, DOI 10.1074/jbc.M401645200; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; Wallin R, 2004, TRENDS MOL MED, V10, P299, DOI 10.1016/j.molmed.2004.05.003; WALLIN R, 1984, P NATL ACAD SCI-BIOL, V81, P4095, DOI 10.1073/pnas.81.13.4095; WALLIN R, 1987, INT J BIOCHEM, V19, P1063, DOI 10.1016/0020-711X(87)90307-7; Wallin R, 2001, FASEB J, V15, P2542, DOI 10.1096/fj.01-0337fje; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	40	63	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10540	10547		10.1074/jbc.M413982200	http://dx.doi.org/10.1074/jbc.M413982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640149	hybrid			2022-12-27	WOS:000227559600098
J	Yanagawa, T; Funasaka, T; Tsutsumi, S; Raz, T; Tanaka, N; Raz, A				Yanagawa, T; Funasaka, T; Tsutsumi, S; Raz, T; Tanaka, N; Raz, A			Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSPHEROCYTIC HEMOLYTIC-ANEMIA; TUMOR AUTOCRINE MOTILITY; CRYSTAL-STRUCTURE; PHOSPHOHEXOSE ISOMERASE; GLUCOSEPHOSPHATE ISOMERASE; CANCER-CELLS; GLUCOSE-6-PHOSPHATE ISOMERASE; ALLOSTERIC PROPERTIES; FACTOR NEUROLEUKIN; GLYCOLYTIC ENZYME	Phosphoglucose isomerase (PGI; EC 5.3.1.9) is a cytosolic housekeeping enzyme of the sugar metabolism pathways that plays a key role in both glycolysis and gluconeogenesis. PGI is a multifunctional dimeric protein that extracellularly acts as a cytokine with properties that include autocrine motility factor (AMF)-eliciting mitogenic, motogenic, and differentiation functions, and PGI has been implicated in tumor progression and metastasis. Little is known of the biochemical regulation of PGI/AMF activities, although it is known that human PGI/AMF is phosphorylated at Ser(185) by protein kinase CK2 ( CK2); however, the physiological significance of this phosphorylation is unknown. Thus, by site-directed mutagenesis, we substituted Ser185 with aspartic acid (S185D) or glutamic acid (S185E), which introduces a negative charge and conformational changes that mimic phosphorylation. A Ser-to-Ala mutant protein (S185A) was generated to abolish phosphorylation. Biochemical analyses revealed that the phosphorylation mutant proteins of PGI exhibited decreased enzymatic activity, whereas the S185A mutant PGI protein retained full enzymatic activity. PGI phosphorylation by CK2 also led to down-regulation of enzymatic activity. Furthermore, CK2 knockdown by RNA interference was associated with up-regulation of cellular PGI enzymatic activity. The three recombinant mutant proteins exhibited indistinguishable cytokine activity and receptor-binding affinities compared with the wild-type protein. In both in vitro and in vivo assays, the wild-type and S185A mutant proteins underwent active species dimerization, whereas both the S185D and S185E mutant proteins also formed tetramers. These results demonstrate that phosphorylation affects the allosteric kinetic properties of the enzyme, resulting in a less active form of PGI, whereas non-phosphorylated protein species retain cytokine activity. The process by which phosphorylation modulates the enzymatic activity of PGI thus has an important implication for the understanding of the biological regulation of this key glucose metabolism-regulating enzyme.	Karmanos Canc Inst, Tumor Progress & Metastasis Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Gunma Univ, Grad Sch Med, Dept Orthoped Surg, Maebashi, Gumma 3718511, Japan; Gunma Univ, Grad Sch Med, Dept Gen Surg Sci Surg 1, Maebashi, Gumma 3718511, Japan; Showa Univ, Sch Pharmaceut Sci, Tokyo 1428555, Japan	Barbara Ann Karmanos Cancer Institute; Wayne State University; Gunma University; Gunma University; Showa University	Raz, A (corresponding author), Karmanos Canc Inst, Tumor Progress & Metastasis Program, 110 E Warren Ave, Detroit, MI 48201 USA.	raza@karmanos.org		Tanaka, Nobutada/0000-0001-5365-4698	NATIONAL CANCER INSTITUTE [R01CA051714] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51714] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHTBUEHLER G, 1977, CELL, V12, P333, DOI 10.1016/0092-8674(77)90109-X; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; BAUMANN M, 1988, CANCER RES, V48, P7018; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P402, DOI 10.1006/bcmd.1997.0157; BLAIR JB, 1982, J BIOL CHEM, V257, P7595; Cai GZ, 1997, BIOPHYS CHEM, V64, P199, DOI 10.1016/S0301-4622(96)02232-6; Cao MJ, 2000, BIOCHEM BIOPH RES CO, V272, P485, DOI 10.1006/bbrc.2000.2803; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; Chou CC, 2000, J BIOL CHEM, V275, P23154, DOI 10.1074/jbc.M002017200; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; FILELLA X, 1991, TUMOR BIOL, V12, P360, DOI 10.1159/000217737; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Funasaka T, 2002, INT J CANCER, V101, P217, DOI 10.1002/ijc.10617; Funasaka T, 2002, BIOCHEM BIOPH RES CO, V293, P192, DOI 10.1016/S0006-291X(02)00202-4; Funasaka T, 2001, BIOCHEM BIOPH RES CO, V285, P118, DOI 10.1006/bbrc.2001.5135; Gracy R W, 1975, Methods Enzymol, V41, P392; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; Haga A, 2000, BBA-PROTEIN STRUCT M, V1480, P235, DOI 10.1016/S0167-4838(00)00075-3; HARRISON RA, 1974, ANAL BIOCHEM, V61, P500, DOI 10.1016/0003-2697(74)90417-5; HOFER HW, 1985, BIOCHEM BIOPH RES CO, V129, P892, DOI 10.1016/0006-291X(85)91975-8; Jeffery CJ, 2000, BIOCHEMISTRY-US, V39, P955, DOI 10.1021/bi991604m; JOHANSSON T, 1985, BIOCHEM BIOPH RES CO, V133, P608, DOI 10.1016/0006-291X(85)90948-9; Kao HW, 2002, MOL BIOL EVOL, V19, P367, DOI 10.1093/oxfordjournals.molbev.a004092; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; Lim ACB, 2004, J BIOL CHEM, V279, P4433, DOI 10.1074/jbc.M310563200; LIOTTA LA, 1974, CANCER RES, V34, P997; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; MERKLE S, 1993, BLOOD, V81, P206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NETTELBLAD FA, 1987, FEBS LETT, V214, P249, DOI 10.1016/0014-5793(87)80064-9; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; REISS N, 1986, BIOCHEM J, V239, P691, DOI 10.1042/bj2390691; REPESH LA, 1989, INVAS METAST, V9, P192; ROSE ZB, 1976, J BIOL CHEM, V251, P4817; SAKAKIBARA R, 1983, J BIOL CHEM, V258, P8656; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHROTER W, 1985, EUR J PEDIATR, V144, P301, DOI 10.1007/BF00441768; Signarvic RS, 2003, J MOL BIOL, V334, P1, DOI 10.1016/j.jmb.2003.09.041; SILLETTI S, 1991, CANCER RES, V51, P3507; Smalheiser NR, 1996, MOL BIOL CELL, V7, P1003, DOI 10.1091/mbc.7.7.1003; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P5412, DOI 10.1073/pnas.96.10.5412; Tanaka N, 2002, J MOL BIOL, V318, P985, DOI 10.1016/S0022-2836(02)00186-9; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watanabe H, 1996, CANCER RES, V56, P2960; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; Yakirevich E, 2000, BIOL REPROD, V62, P1016, DOI 10.1095/biolreprod62.4.1016; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867	50	26	29	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10419	10426		10.1074/jbc.M409457200	http://dx.doi.org/10.1074/jbc.M409457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637053	hybrid			2022-12-27	WOS:000227559600083
J	Denis, FM; Benecke, A; Di Gioia, Y; Touw, IP; Cayre, YE; Lutz, PG				Denis, FM; Benecke, A; Di Gioia, Y; Touw, IP; Cayre, YE; Lutz, PG			PRAM-1 potentiates arsenic trioxide-induced JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HEMATOPOIETIC PROGENITOR KINASE; LYMPHOCYTE ANTIGEN RECEPTORS; CASPASE-MEDIATED CLEAVAGE; ACTIN-BINDING PROTEIN-1; N-TERMINAL KINASE; RETINOIC ACID; ADAPTER PROTEIN; RAR-ALPHA; HISTONE DEACETYLASE	The promyelocytic leukemia RARalpha target gene encoding an adaptor molecule-1 (PRAM-1) is involved in a signaling pathway induced by retinoic acid in acute promyelocytic leukemia (APL) cells. To better understand the function of PRAM-1, we have undertaken the identification of its partners through a yeast two-hybrid screen. Here, we show that the proline-rich domain of PRAM-1 interacted with the Src homology 3 (SH3) domain of hematopoietic progenitor kinase 1 (HPK-1)-interacting protein of 55 kDa (HIP-55, also called SH3P7 and Abp1) known to stimulate the activity of HPK-1 and c-Jun N-terminal kinase (JNK). Overexpression of PRAM-1 in the NB4 APL cell line increased arsenic trioxide-induced JNK activation through a caspase 3-like-dependent activity. Dissociation of the SH3 domain from the rest of the HIP-55 protein was observed in the NB4 APL cell line treated with arsenic trioxide due to specific cleavage by caspase 3-like enzymes. The cleavage of HIP-55 correlated with the induction of PRAM-1 mRNA and protein expression. Taken together, our results suggest that the caspase 3-cleaved SH3 domain of HIP-55 is likely involved in PRAM-1-mediated JNK activation upon arsenic trioxide-induced differentiation of NB4 cells.	Hop Robert Debre, INSERM, U417, F-75935 Paris 19, France; Inst Hautes Etud Sci, F-91440 Bures Sur Yvette, France; Erasmus Med Ctr, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Thomas Jefferson Univ, Dept Microbiol Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Univ La Sapienza II, I-00161 Rome, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; Erasmus University Rotterdam; Erasmus MC; Jefferson University; Sapienza University Rome	Lutz, PG (corresponding author), Univ Paris 05, Dept Biol Cellulaire, Inst Cochin Genet Mol, INSERM,U567,CNRS,UMR 8104, 22 Rue Mechain, F-75014 Paris, France.	lutz@cochin.inserm.fr	Benecke, Arndt G./T-1079-2019; Lutz, Pierre/B-8822-2009	Lutz, Pierre/0000-0003-0590-9101				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen GQ, 1996, BLOOD, V88, P1052; Chen YR, 2001, BIOCHEM BIOPH RES CO, V288, P981, DOI 10.1006/bbrc.2001.5862; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Collins SJ, 1998, BLOOD, V91, P2631, DOI 10.1182/blood.V91.8.2631.2631_2631_2633; daSilva AJ, 1997, J IMMUNOL, V158, P2007; Ensenat D, 1999, J BIOL CHEM, V274, P33945, DOI 10.1074/jbc.274.48.33945; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; Geng LP, 2001, P NATL ACAD SCI USA, V98, P11527, DOI 10.1073/pnas.191378198; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Griffiths EK, 2001, SCIENCE, V293, P2260, DOI 10.1126/science.1063397; GRIFFITHS EK, 2002, SCI STKE; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Han J, 2003, J BIOL CHEM, V278, P52195, DOI 10.1074/jbc.M305026200; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; LANOTTE M, 1991, BLOOD, V77, P1080; Larbolette O, 1999, MOL CELL BIOL, V19, P1539; Le Bras S, 2004, J BIOL CHEM, V279, P15550, DOI 10.1074/jbc.M312659200; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Lutz PG, 2001, BLOOD, V97, P2449, DOI 10.1182/blood.V97.8.2449; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mise-Omata S, 2003, BIOCHEM BIOPH RES CO, V301, P704, DOI 10.1016/S0006-291X(02)02972-8; Moog-Lutz C, 2003, BLOOD, V102, P3371, DOI 10.1182/blood-2002-11-3462; Moog-Lutz C, 2001, J BIOL CHEM, V276, P22375, DOI 10.1074/jbc.M011683200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P726, DOI 10.1006/bbrc.2001.5416; Peterson EJ, 2003, IMMUNOL REV, V192, P113, DOI 10.1034/j.1600-065X.2003.00026.x; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; ROWLEY JD, 1977, LANCET, V1, P549; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887	46	8	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9043	9048		10.1074/jbc.M413564200	http://dx.doi.org/10.1074/jbc.M413564200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637062	hybrid			2022-12-27	WOS:000227453100052
J	Graves, PR; Winkfield, KM; Haystead, TAJ				Graves, PR; Winkfield, KM; Haystead, TAJ			Regulation of zipper-interacting protein kinase activity in vitro and in vivo by multisite phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN PHOSPHATASE; SMOOTH-MUSCLE; LIGHT-CHAIN; DAP-KINASE; CRYSTAL-STRUCTURE; SERINE/THREONINE KINASE; APOPTOTIC ACTIVITY; INSULIN-RECEPTOR; TYROSINE KINASE; MAP KINASE	Zipper-interacting protein kinase ( ZIPK) is a widely expressed serine/threonine kinase implicated in cell death and smooth muscle contractility, but its mechanism of regulation is unknown. We have identified six phosphorylation sites in ZIPK that regulate both its enzyme activity and localization, including Thr(180), Thr(225), Thr(265), Thr(299), Thr(306), and Ser(311). Mutational analysis showed that phosphorylation of Thr(180) in the kinase activation T-loop, Thr(225) in the substrate-binding groove, and Thr(265) in kinase subdomain X is essential for full ZIPK autophosphorylation and activity toward exogenous substrates. Abrogation of phosphorylation of Thr(299), Thr(306), and Ser(311) had little effect on enzyme activity, but mutation of Thr(299) and Thr(300) to alanine resulted in redistribution of ZIPK from the cytosol to the nucleus. Mutation of Thr(299) alone to alanine caused ZIPK to assume a diffuse cellular localization, whereas T299D redistributed the enzyme to the cytoplasm. C-terminal truncations of ZIPK at amino acid 273 or 342 or mutation of the leucine zipper motif increased ZIPK activity toward exogenous substrates by severalfold, suggesting a phosphorylation-independent autoinhibitory role for the C-terminal domain. Additionally, mutation of the leucine zipper reduced the ability of ZIPK to oligomerize and also caused ZIPK to relocalize from the cytoplasm to the nucleus in vivo. Together, our findings show that ZIPK is positively regulated by phosphorylation within its kinase domain and that it contains an inhibitory C-terminal domain that controls enzyme activity, localization, and oligomerization.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Haystead, TAJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27710 USA.	hayst001@mc.duke.edu			NHLBI NIH HHS [HL19242-28] Funding Source: Medline; NIDDK NIH HHS [DK52378-08] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bialik S, 2004, CELL DEATH DIFFER, V11, P631, DOI 10.1038/sj.cdd.4401386; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Diskin R, 2004, J BIOL CHEM, V279, P47040, DOI 10.1074/jbc.M404595200; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hartshorne DJ, 2004, J BIOL CHEM, V279, P37211, DOI 10.1074/jbc.R400018200; Hoelz A, 2003, MOL CELL, V11, P1241, DOI 10.1016/S1097-2765(03)00171-0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Karim SM, 2004, CIRC RES, V95, P612, DOI 10.1161/01.RES.0000142736.39359.58; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kogel D, 2003, EUR J CANCER, V39, P249, DOI 10.1016/S0959-8049(02)00477-X; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Komatsu S, 2004, J CELL BIOL, V165, P243, DOI 10.1083/jcb.200309056; Lontay B, 2004, J COMP NEUROL, V478, P72, DOI 10.1002/cne.20273; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; Mackey AJ, 2003, NUCLEIC ACIDS RES, V31, P3859, DOI 10.1093/nar/gkg513; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Murata-Hori M, 2001, ONCOGENE, V20, P8175, DOI 10.1038/sj.onc.1205055; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Shani G, 2004, MOL CELL BIOL, V24, P8611, DOI 10.1128/MCB.24.19.8611-8626.2004; Shani G, 2001, EMBO J, V20, P1099, DOI 10.1093/emboj/20.5.1099; Shohat G, 2002, BBA-PROTEINS PROTEOM, V1600, P45, DOI 10.1016/S1570-9639(02)00443-0; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7	35	64	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9363	9374		10.1074/jbc.M412538200	http://dx.doi.org/10.1074/jbc.M412538200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611134	hybrid			2022-12-27	WOS:000227453100089
J	Sato, K; Sakai, E; Veith, PD; Shoji, M; Kikuchi, Y; Yukitake, H; Ohara, N; Naito, M; Okamoto, K; Reynolds, EC; Nakayama, K				Sato, K; Sakai, E; Veith, PD; Shoji, M; Kikuchi, Y; Yukitake, H; Ohara, N; Naito, M; Okamoto, K; Reynolds, EC; Nakayama, K			Identification of a new membrane-associated protein that influences transport/maturation of gingipains and adhesins of Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; CYSTEINE PROTEINASE; ARG-GINGIPAIN; BIOCHEMICAL-CHARACTERIZATION; INSERTION MUTAGENESIS; VIRULENCE FACTORS; ESCHERICHIA-COLI; ENCODING GENES; MUTANTS; AUTOTRANSPORTER	The dual membrane envelopes of Gram-negative bacteria provide two barriers of unlike nature that regulate the transport of molecules into and out of organisms. Organisms have developed several systems for transport across the inner and outer membranes. The Gram-negative periodontopathogenic bacterium Porphyromonas gingivalis produces proteinase and adhesin complexes, gingipains/adhesins, on the cell surface and in the extracellular milieu as one of the major virulence factors. Gingipains and/or adhesins are encoded by kgp, rgpA, rgpB, and hagA on the chromosome. In this study, we isolated a P. gingivalis mutant (porT), which showed very weak activities of gingipains in the cell lysates and culture supernatants. Subcellular fractionation and immunoblot analysis demonstrated that precursor forms of gingipains and adhesins were accumulated in the periplasmic space of the porT mutant cells. Peptide mass fingerprinting and N-terminal amino acid sequencing of the precursor proteins and the kgp'-'rgpB chimera gene product in the porT mutant indicated that these proteins lacked the signal peptide regions, consistent with their accumulation in the periplasm. The PorT protein seemed to be membrane-associated and exposed to the periplasmic space, as revealed by subcellular fractionation and immunoblot analysis using anti-PorT antiserum. These results suggest that the membrane-associated protein PorT is essential for transport of the kgp, rgpA, rgpB, and hagA gene products across the outer membrane from the periplasm to the cell surface, where they are processed and matured.	Nagasaki Univ, Grad Sch Biomed Sci, Div Microbiol & Oral Infect, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Div Oral Mol Pharmacol, Dept Dev & Reconstruct Med, Nagasaki 8528588, Japan; Univ Melbourne, Sch Dent Sci, Cooperat Res Ctr Oral Hlth Sci, Melbourne, Vic 3010, Australia	Nagasaki University; Nagasaki University; University of Melbourne	Nakayama, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Div Microbiol & Oral Infect, Nagasaki 8528588, Japan.	knak@net.nagasaki-u.ac.jp	Shoji, Mikio/J-8283-2018; OHARA, Naoya/B-2481-2011	Shoji, Mikio/0000-0002-7605-4721; Reynolds, Eric/0000-0002-6618-4856; sakai, eiko/0000-0002-6776-6540; Veith, Paul/0000-0002-7344-1662; KIKUCHI, YUICHIRO/0000-0001-7232-837X; NAITO, Mariko/0000-0003-0769-7747				Abaibou H, 2001, INFECT IMMUN, V69, P325, DOI 10.1128/IAI.69.1.325-335.2001; Armitage G C, 1996, Ann Periodontol, V1, P37, DOI 10.1902/annals.1996.1.1.37; Bhogal PS, 1997, MICROBIOL-SGM, V143, P2485, DOI 10.1099/00221287-143-7-2485; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Chen T, 2000, MICROB PATHOGENESIS, V28, P235, DOI 10.1006/mpat.1999.0338; CHRISTERSSON LA, 1992, J PERIODONTOL, V63, P418, DOI 10.1902/jop.1992.63.5.418; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Curtis MA, 1999, J PERIODONTAL RES, V34, P464, DOI 10.1111/j.1600-0765.1999.tb02282.x; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; Economou A, 1999, TRENDS MICROBIOL, V7, P315, DOI 10.1016/S0966-842X(99)01555-3; FELDHAUS MJ, 1991, J BACTERIOL, V173, P4540, DOI 10.1128/JB.173.14.4540-4543.1991; GENCO CA, 1995, INFECT IMMUN, V63, P2459; Henderson IR, 2001, INFECT IMMUN, V69, P1231, DOI 10.1128/IAI.69.3.1231-1243.2001; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; Holt SC, 1999, PERIODONTOL 2000, V20, P168, DOI 10.1111/j.1600-0757.1999.tb00162.x; Hu NT, 1998, MICROBIOL-SGM, V144, P1479, DOI 10.1099/00221287-144-6-1479; Irfan U M, 2001, J Int Acad Periodontol, V3, P14; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; Kamaguchi A, 2003, MICROBIOL-SGM, V149, P1257, DOI 10.1099/mic.0.25997-0; Konninger UW, 1999, MOL MICROBIOL, V32, P1212, DOI 10.1046/j.1365-2958.1999.01433.x; LAWSON DA, 1992, INFECT IMMUN, V60, P1524, DOI 10.1128/IAI.60.4.1524-1529.1992; Lewis JP, 1999, J BACTERIOL, V181, P4905, DOI 10.1128/JB.181.16.4905-4913.1999; Loveless BJ, 1997, MOL MEMBR BIOL, V14, P113, DOI 10.3109/09687689709048171; Maurer J, 1999, J BACTERIOL, V181, P7014, DOI 10.1128/JB.181.22.7014-7020.1999; Mikolajczyk-Pawlinska J, 1998, BIOL CHEM, V379, P205, DOI 10.1515/bchm.1998.379.2.205; Milner P, 1996, FEMS MICROBIOL LETT, V140, P125, DOI 10.1016/0378-1097(96)00159-0; Mol O, 2001, J MOL MICROB BIOTECH, V3, P135; Mol O, 1996, FEMS MICROBIOL REV, V19, P25, DOI 10.1016/0168-6445(96)00022-8; Mortz E, 2001, PROTEOMICS, V1, P1359, DOI 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q; Murakami Y, 2002, EUR J ORAL SCI, V110, P157, DOI 10.1034/j.1600-0722.2002.11171.x; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; Okamoto K, 1998, J BIOL CHEM, V273, P21225, DOI 10.1074/jbc.273.33.21225; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; Oliver RC, 1998, J PERIODONTOL, V69, P269, DOI 10.1902/jop.1998.69.2.269; Papadopoulos S, 1999, STAND MAG, V1, P110; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; PIKE R, 1994, J BIOL CHEM, V269, P406; Potempa J, 2000, PERIODONTOL 2000, V24, P153, DOI 10.1034/j.1600-0757.2000.2240108.x; Rangarajan M, 1997, BIOCHEM J, V323, P701, DOI 10.1042/bj3230701; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355; Saier MH, 2000, MICROBIOL-SGM, V146, P1775, DOI 10.1099/00221287-146-8-1775; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAH HN, 1989, FEMS MICROBIOL LETT, V61, P213, DOI 10.1016/0378-1097(89)90199-7; Shi Y, 1999, J BIOL CHEM, V274, P17955, DOI 10.1074/jbc.274.25.17955; Shoji M, 2004, MOL MICROBIOL, V52, P1513, DOI 10.1111/j.1365-2958.2004.04105.x; Shoji M, 2002, MICROBIOL-SGM, V148, P1183, DOI 10.1099/00221287-148-4-1183; Simpson W, 1999, INFECT IMMUN, V67, P5012, DOI 10.1128/IAI.67.10.5012-5020.1999; Slakeski N, 1998, MICROBIOL-UK, V144, P1583, DOI 10.1099/00221287-144-6-1583; Smalley JW, 1998, BIOCHEM J, V331, P681, DOI 10.1042/bj3310681; SMALLEY JW, 1988, ARCH ORAL BIOL, V33, P323, DOI 10.1016/0003-9969(88)90065-9; VALENT QA, 1995, MOL MICROBIOL, V16, P1243, DOI 10.1111/j.1365-2958.1995.tb02346.x; Veith PD, 2002, BIOCHEM J, V363, P105, DOI 10.1042/0264-6021:3630105; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Yen MR, 2002, BBA-BIOMEMBRANES, V1562, P6, DOI 10.1016/S0005-2736(02)00359-0	56	105	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8668	8677		10.1074/jbc.M413544200	http://dx.doi.org/10.1074/jbc.M413544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634642	hybrid			2022-12-27	WOS:000227453100008
J	Solbak, AI; Richardson, TH; McCann, RT; Kline, KA; Bartnek, F; Tomlinson, G; Tan, XQ; Parra-Gessert, L; Frey, GJ; Podar, M; Luginbuhl, P; Gray, KA; Mathur, EJ; Robertson, DE; Burk, MJ; Hazlewood, GP; Short, JM; Kerovuo, J				Solbak, AI; Richardson, TH; McCann, RT; Kline, KA; Bartnek, F; Tomlinson, G; Tan, XQ; Parra-Gessert, L; Frey, GJ; Podar, M; Luginbuhl, P; Gray, KA; Mathur, EJ; Robertson, DE; Burk, MJ; Hazlewood, GP; Short, JM; Kerovuo, J			Discovery of pectin-degrading enzymes and directed evolution of a novel pectate lyase for processing cotton fabric	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CELLULOSE; FAMILY; GENE; CLASSIFICATION; PERFORMANCE; HYDROLASES; STABILITY; DOMAINS; DISPLAY	There is a growing need in the textile industry for more economical and environmentally responsible approaches to improve the scouring process as part of the pretreatment of cotton fabric. Enzymatic methods using pectin-degrading enzymes are potentially valuable candidates in this effort because they could reduce the amount of toxic alkaline chemicals currently used. Using high throughput screening of complex environmental DNA libraries more than 40 novel microbial pectate lyases were discovered, and their enzymatic properties were characterized. Several candidate enzymes were found that possessed pH optima and specific activities on pectic material in cotton fibers compatible with their use in the scouring process. However, none exhibited the desired temperature characteristics. Therefore, a candidate enzyme was selected for evolution. Using Gene Site Saturation Mutagenesis(TM) technology, 36 single site mutants exhibiting improved thermotolerance were produced. A combinatorial library derived from the 12 best performing single site mutants was then generated by using Gene Reassembly(TM) technology. Nineteen variants with further improved thermotolerance were produced. These variants were tested for both improved thermotolerance and performance in the bioscouring application. The best performing variant (CO14) contained eight mutations and had a melting temperature 16 degreesC higher than the wild type enzyme while retaining the same specific activity at 50 degreesC. Optimal temperature of the evolved enzyme was 70 degreesC, which is 20 degreesC higher than the wild type. Scouring results obtained with the evolved enzyme were significantly better than the results obtained with chemical scouring, making it possible to replace the conventional and environmentally harmful chemical scouring process.	Diversa Corp, San Diego, CA 92121 USA		Kerovuo, J (corresponding author), Diversa Corp, San Diego, CA 92121 USA.	jkerovuo@diversa.com	Podar, Mircea/B-7299-2012	Podar, Mircea/0000-0003-2776-0205				Batra S. K., 1985, Handbook of fiber science and technology, V4, P727; Bolam DN, 2004, J BIOL CHEM, V279, P22953, DOI 10.1074/jbc.M313317200; Brown IE, 2001, BIOCHEM J, V355, P155, DOI 10.1042/0264-6021:3550155; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Chakravarty S, 2002, BIOCHEMISTRY-US, V41, P8152, DOI 10.1021/bi025523t; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; Coutinho PM, 1999, ROY SOC CH, P3; Garrett JB, 2004, APPL ENVIRON MICROB, V70, P3041, DOI 10.1128/AEM.70.5.3041-3046.2004; GHANGAS GS, 1989, J BACTERIOL, V171, P2963, DOI 10.1128/jb.171.6.2963-2969.1989; Gray KA, 2003, ADV APPL MICROBIOL, V52, P1, DOI 10.1016/S0065-2164(03)01001-3; Gray KA, 2001, ADV SYNTH CATAL, V343, P607, DOI 10.1002/1615-4169(200108)343:6/7<607::AID-ADSC607>3.0.CO;2-M; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Kataeva IA, 2002, APPL ENVIRON MICROB, V68, P4292, DOI 10.1128/AEM.68.9.4292-4300.2002; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; Kobayashi T, 2003, WORLD J MICROB BIOT, V19, P269, DOI 10.1023/A:1023698007103; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kretz KA, 2004, METHOD ENZYMOL, V388, P3; McKie VA, 2001, BIOCHEM J, V355, P167, DOI 10.1042/0264-6021:3550167; Palackal N, 2004, PROTEIN SCI, V13, P494, DOI 10.1110/ps.03333504; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; Richardson TH, 2002, J BIOL CHEM, V277, P26501, DOI 10.1074/jbc.M203183200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seagull R. W., 2000, Journal of Cotton Science, V4, P97; Short J. M., 2001, [No title captured], Patent No. [US6171820, 6171820]; Short J. M., 2001, US Patent, Patent No. 6174673; Short JM, 1997, NAT BIOTECHNOL, V15, P1322, DOI 10.1038/nbt1297-1322; SHORT JM, 1999, Patent No. 5939250; SHORT JM, 1999, Patent No. 5958672; SHORT JM, 2001, Patent No. 6280926; SHORT JM, 2003, Patent No. 6537776; Slater K., 2003, ENV IMPACT TEXTILES; Snead M A, 1997, Methods Mol Biol, V69, P53	33	90	103	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9431	9438		10.1074/jbc.M411838200	http://dx.doi.org/10.1074/jbc.M411838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15618218	hybrid			2022-12-27	WOS:000227453100096
J	Wong, KS; Sharma, A; Awasthi, S; Matlock, EF; Rogers, L; Van Lint, C; Skiest, DJ; Burns, DK; Harrod, R				Wong, KS; Sharma, A; Awasthi, S; Matlock, EF; Rogers, L; Van Lint, C; Skiest, DJ; Burns, DK; Harrod, R			HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin signaling through CREB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NERVE GROWTH-FACTOR; AIDS DEMENTIA COMPLEX; NECROSIS-FACTOR-ALPHA; ADENOVIRAL ONCOPROTEIN E1A; HUMAN FETAL ASTROCYTES; VPR INDUCES APOPTOSIS; D-ASPARTATE RECEPTORS; NUCLEAR-PROTEIN CBP; SYMPATHETIC NEURONS	The human immunodeficiency virus type-1 (HIV-1) infects microglia, macrophages, and astrocytes in the central nervous system (CNS) and may cause severe neurological diseases, such as AIDS-related dementias or progressive encephalopathies, as a result of CNS inflammation and neurotrophin signaling defects associated with expression of viral antigens and HIV-1 replication in the brain. The HIV Tat protein can be endocytosed by surrounding uninfected cells; interacts with transcriptional coactivators/acetyltransferases, p300/CREB-binding protein, and p300/CREB-binding protein-associated factor (PCAF); and induces neuronal apoptosis. Since nerve growth factor (NGF) receptor and brain-derived neurotrophic factor receptor signaling through CREB requires p300 and PCAF histone acetyltransferases, we sought to determine whether HIV-1 Tat coactivator interactions interfere with neurotrophin receptor signaling in neuronal cells. Here, we demonstrate that Tat-coactivator interactions inhibit NGF- and brain-derived neurotrophic factor-responsive CRE trans-activation and neurotrophin protection against apoptosis in PC12 and IMR-32 neuroblastoma cells. Purified recombinant Tat or Tat-derived synthetic peptides, spanning p300- and PCAF-binding sequences, inhibit histone H3/H4 acetylation in vitro. A Tat mutant, Tat(K28A/K50A), defective for binding p300 and PCAF, neither repressed NGF- responsive CRE transactivation nor inhibited histone acetylation. HIV-1 Tat interacts in PCAF complexes in post-mortem CNS tissues from donor neuro-AIDS patients, as determined by fluorescence resonance energy transfer immunoconfocal microscopy. Importantly, these findings suggest that HIV-1 Tat-coactivator interactions may contribute to neurotrophin signaling impairments and neuronal apoptosis associated with HIV-1 infections of the CNS.	So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA; Free Univ Brussels, Inst Biol & Med Mol, Serv Chim Biol, Mol Virol Lab, B-6041 Gosselies, Belgium; Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Div Neuropathol, Dallas, TX 75235 USA	Southern Methodist University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Harrod, R (corresponding author), So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA.	rharrod@mail.smu.edu		Mauldin, Kasuen/0000-0001-9220-8033				Abraham S, 2003, VIROLOGY, V309, P196, DOI 10.1016/S0042-6822(03)00112-0; Albright AV, 1996, VIROLOGY, V217, P211, DOI 10.1006/viro.1996.0108; Bergonzini V, 2004, ONCOGENE, V23, P7701, DOI 10.1038/sj.onc.1207828; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bonwetsch R, 1999, J NEUROVIROL, V5, P685, DOI 10.3109/13550289909021297; Boven LA, 1999, J NEUROIMMUNOL, V97, P154, DOI 10.1016/S0165-5728(99)00044-2; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; BURNS DK, 1992, J CHILD NEUROL, V7, P332, DOI 10.1177/088307389200700402; BURNS DK, 1991, ARCH PATHOL LAB MED, V115, P1112; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chauhan A, 2003, J BIOL CHEM, V278, P13512, DOI 10.1074/jbc.M209381200; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; *CTR DIS CONTR, 1992, HIV AIDS SURV REP; Cunningham AL, 1997, J LEUKOCYTE BIOL, V62, P117, DOI 10.1002/jlb.62.1.117; CUPP C, 1993, ONCOGENE, V8, P2231; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; Dore GJ, 1999, AIDS, V13, P1249, DOI 10.1097/00002030-199907090-00015; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; ENSOLI F, 1994, VIROLOGY, V200, P668, DOI 10.1006/viro.1994.1230; ENSOLI F, 1995, VIROLOGY, V210, P221, DOI 10.1006/viro.1995.1336; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Galey D, 2003, J NEUROVIROL, V9, P358, DOI 10.1080/13550280390201119; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Garaci E, 1999, P NATL ACAD SCI USA, V96, P14013, DOI 10.1073/pnas.96.24.14013; Garaci E, 2003, P NATL ACAD SCI USA, V100, P8927, DOI 10.1073/pnas.1332627100; GARTNER S, 1986, JAMA-J AM MED ASSOC, V256, P2365, DOI 10.1001/jama.256.17.2365; Gendelman H.E., 1997, DEFENSE BRAIN, P290; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang H, 1999, MOL CELL BIOL, V19, P8136; *JOINT UN NAT PROG, 2001, HIV AIDS CHIN TIT PE; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; Kaehlcke K, 2003, MOL CELL, V12, P167, DOI 10.1016/S1097-2765(03)00245-4; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kruman II, 1999, AM J PATHOL, V155, P39, DOI 10.1016/S0002-9440(10)65096-1; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; Li XC, 2000, P NATL ACAD SCI USA, V97, P8584, DOI 10.1073/pnas.140222497; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; LOVE S, 2002, GREENFIELDS NEUROPAT, P50; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; McArthur JC, 2003, J NEUROVIROL, V9, P205, DOI 10.1080/13550280390194109; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500; Miura Y, 2003, P NATL ACAD SCI USA, V100, P2777, DOI 10.1073/pnas.2628048100; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; NATH A, 1995, J NEUROPATH EXP NEUR, V54, P320, DOI 10.1097/00005072-199505000-00005; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; Niikura M, 1996, ONCOGENE, V13, P313; Patel CA, 2002, J NEUROVIROL, V8, P86, DOI 10.1080/13550280290049552; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; Perry SW, 1998, J BIOL CHEM, V273, P17660, DOI 10.1074/jbc.273.28.17660; Persidsky Y, 1997, J NEUROVIROL, V3, P401, DOI 10.3109/13550289709031186; Prendergast MA, 2002, BRAIN RES, V954, P300, DOI 10.1016/S0006-8993(02)03360-7; Ramirez SH, 2001, J NEUROCHEM, V78, P874, DOI 10.1046/j.1471-4159.2001.00467.x; Rappaport J, 1999, J LEUKOCYTE BIOL, V65, P458, DOI 10.1002/jlb.65.4.458; Recio JA, 1997, J BIOL CHEM, V272, P26807, DOI 10.1074/jbc.272.43.26807; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Sacktor N, 2001, NEUROLOGY, V56, P257, DOI 10.1212/WNL.56.2.257; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; SHARPLESS N, 1992, VIROLOGY, V191, P813, DOI 10.1016/0042-6822(92)90257-P; Shi B, 1998, J NEUROVIROL, V4, P281, DOI 10.3109/13550289809114529; Simpson DM, 1996, MED CLIN N AM, V80, P1363, DOI 10.1016/S0025-7125(05)70494-6; Skiest DJ, 2002, CLIN INFECT DIS, V34, P103, DOI 10.1086/324350; Song L, 2003, J NEUROVIROL, V9, P399, DOI 10.1080/13550280390201704; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; *UN NAT DEV PROGR, 2001, HIV AIDS; Wildemann B, 2001, MOL MED, V7, P193, DOI 10.1007/BF03401953; Wong DS, 2004, J BIOL CHEM, V279, P55667, DOI 10.1074/jbc.M408174200; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshioka M, 1995, ADV NEUROIMMUNOL, V5, P335, DOI 10.1016/0960-5428(95)00012-Q; Zauli G, 2001, FASEB J, V15, P483, DOI 10.1096/fj.00-0354com	95	36	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9390	9399		10.1074/jbc.M408643200	http://dx.doi.org/10.1074/jbc.M408643200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611041	hybrid			2022-12-27	WOS:000227453100091
J	Bean, RR; Verhamme, IM; Bock, PE				Bean, RR; Verhamme, IM; Bock, PE			Role of the streptokinase alpha-domain in the interactions of streptokinase with plasminogen and plasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; BLOOD-COAGULATION PROTEINASES; AMINO-ACID-SEQUENCE; HUMAN-FACTOR V; ACTIVE-SITE; FLUORESCENCE PROBES; CONFORMATIONAL ACTIVATION; MACROMOLECULAR SUBSTRATE; MEDIATED ACTIVATION; CIRCULAR-DICHROISM	The role of the streptokinase ( SK) alpha-domain in plasminogen ( Pg) and plasmin ( Pm) interactions was investigated in quantitative binding studies employing active site fluorescein-labeled [ Glu] Pg, [ Lys] Pg, and [ Lys] Pm, and the SK truncation mutants, SK-( 55 - 414), SK-( 70 414), and SK-( 152 - 414). Lysine binding site ( LBS)-dependent and - independent binding were resolved from the effects of the lysine analog, 6-aminohexanoic acid. The mutants bound indistinguishably, consistent with unfolding of the alpha-domain on deletion of SK-( 1 - 54). The affinity of SK for [ Glu] Pg was LBS-independent, and although [ Lys] Pg affinity was enhanced 13-fold by LBS interactions, the LBS-independent free energy contributions were indistinguishable. alpha-Domain truncation reduced the affinity of SK for [ Glu] Pg 2-7-fold and [ Lys] Pg less than or equal to 2-fold, but surprisingly, rendered both interactions near totally LBS-dependent. The LBS-independent affinity of SK for [ Lys] Pm, 3000-fold higher compared with [ Lys] Pg, was reduced dramatically by alpha-domain truncation. Thermodynamic analysis demonstrates that the SK alpha-domain contributes substantially to affinity for all Pg/Pm species solely through LBS-independent interactions, and that the higher affinity of SK for [ Lys] Pm compared with [ Lys] Pg involves all three SK domains. The residual affinity of the SK betagamma-fragment for all Pg/Pm species was increased by an enhanced contribution to complex stability from LBS-dependent interactions or free energy coupling between LBS-dependent and - independent interactions. Redistribution of the free energy contributions accompanying alpha-domain truncation demonstrates the interdependence of SK domains in stabilizing the SK- Pg/Pm complexes. The flexible segments connecting the SK alpha, beta, and gamma domains allow their rearrangement into a distinctly different bound conformation accompanying loss of the constraint imposed by interactions of the alpha-domain.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu			NHLBI NIH HHS [R01 HL056181, R01 HL056181-11, HL56181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; Boxrud PD, 2004, J BIOL CHEM, V279, P36633, DOI 10.1074/jbc.M405264200; Boxrud PD, 2004, J BIOL CHEM, V279, P36642, DOI 10.1074/jbc.M405265200; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; BROCKWAY WJ, 1974, BIOCHEMISTRY-US, V13, P2063, DOI 10.1021/bi00707a010; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; Chaudhary A, 1999, PROTEIN SCI, V8, P2791; CHIBBER BAK, 1986, J BIOL CHEM, V261, P5289; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; ConejeroLara F, 1996, PROTEIN SCI, V5, P2583, DOI 10.1002/pro.5560051221; DAMASCHUN G, 1992, EUR BIOPHYS J BIOPHY, V20, P355; Dhar J, 2002, J BIOL CHEM, V277, P13257, DOI 10.1074/jbc.M108422200; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Fay WP, 1998, THROMB HAEMOSTASIS, V79, P985; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Kim DM, 2000, THROMB RES, V99, P93, DOI 10.1016/S0049-3848(00)00225-5; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; Liu L, 2000, J BIOL CHEM, V275, P37686, DOI 10.1074/jbc.M003963200; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; MCCLINTOCK DK, 1974, BIOCHEMISTRY-US, V13, P5334, DOI 10.1021/bi00723a013; Mundada LV, 2003, J BIOL CHEM, V278, P24421, DOI 10.1074/jbc.M301825200; NIEUWENHUIZEN W, 1989, THROMB HAEMOSTASIS, V61, P208; Parrado J, 1996, PROTEIN SCI, V5, P693; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; Sazonova IY, 2004, J BIOL CHEM, V279, P24994, DOI 10.1074/jbc.M400253200; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SIEFRING GE, 1976, J BIOL CHEM, V251, P3913; SJOHOLM I, 1973, EUR J BIOCHEM, V39, P471, DOI 10.1111/j.1432-1033.1973.tb03146.x; Sundram V, 2003, J BIOL CHEM, V278, P30569, DOI 10.1074/jbc.M303799200; TAYLOR FB, 1968, BIOCHEMISTRY-US, V7, P232, DOI 10.1021/bi00841a028; Terzyan S, 2004, PROTEINS, V56, P277, DOI 10.1002/prot.20070; VIOLAND BN, 1976, J BIOL CHEM, V251, P3906; Wakeham N, 2002, PROTEIN ENG, V15, P753, DOI 10.1093/protein/15.9.753; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110	49	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7504	7510		10.1074/jbc.M411637200	http://dx.doi.org/10.1074/jbc.M411637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623524	hybrid, Green Accepted			2022-12-27	WOS:000227395700012
J	Feng, L; Sheppard, K; Tumbula-Hansen, D; Soll, D				Feng, L; Sheppard, K; Tumbula-Hansen, D; Soll, D			Gln-tRNA(Gln) formation from Glu-tRNA(Gln) requires cooperation of an asparaginase and a Glu-tRNA(Gln) kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; CRYSTAL-STRUCTURE; CATALYTIC TRIAD; GLUTAMINE; AMIDOTRANSFERASE; MECHANISM; ENZYMES; PROTEIN; ACID	Gln-tRNA(Gln) is synthesized from Glu-tRNA(Gln) in most microorganisms by a tRNA-dependent amidotransferase in a reaction requiring ATP and an amide donor such as glutamine. GatDE is a heterodimeric amidotransferase that is ubiquitous in Archaea. GatD resembles bacterial asparaginases and is expected to function in amide donor hydrolysis. We show here that Methanothermobacter thermautotrophicus GatD acts as a glutaminase but only in the presence of both Glu-tRNA(Gln) and the other subunit, GatE. The fact that only Glu-tRNA(Gln) but not tRNA(Gln) could activate the glutaminase activity of GatD suggests that glutamine hydrolysis is coupled tightly to transamidation. M. thermautotrophicus GatDE enzymes that were mutated in GatD at each of the four critical asparaginase-active site residues lost the ability to hydrolyze glutamine and were unable to convert Glu-tRNA(Gln) to Gln-tRNA(Gln) when glutamine was the amide donor. However, ammonium chloride rescued the activities of these mutants, suggesting that the integrity of the ATPase and the transferase activities in the mutant GatDE enzymes was maintained. In addition, pyroglutamyl-tRNA(Gln) accumulated during the reaction catalyzed by the glutaminase-deficient mutants or by GatE alone. The pyroglutamyl-tRNA is most likely a cyclized by-product derived from gamma-phosphoryl-Glu-tRNA(Gln), the proposed high energy intermediate in Glu-tRNA(Gln) transamidation. That GatE alone could form the intermediate indicates that GatE is a Glu-tRNA(Gln) kinase. The activation of Glu-tRNA(Gln) via gamma-phosphorylation bears a similarity to the mechanism used by glutamine synthetase, which may point to an ancient link between glutamine synthesized for metabolism and translation.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu		Hansen, Debra T./0000-0003-4395-8297				Aghaiypour K, 2001, BIOCHEMISTRY-US, V40, P5655, DOI 10.1021/bi0029595; Carlson BA, 2004, P NATL ACAD SCI USA, V101, P12848, DOI 10.1073/pnas.0402636101; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Feng L, 2002, EXTREMOPHILES, V6, P167, DOI 10.1007/s007920100245; FENG L, 2004, AMINOACYL TRNA SYNTH, P314; Harpel MR, 2002, BIOCHEMISTRY-US, V41, P6398, DOI 10.1021/bi012126u; Horiuchi KY, 2001, BIOCHEMISTRY-US, V40, P6450, DOI 10.1021/bi002599l; Ibba M, 2000, TRENDS BIOCHEM SCI, V25, P311, DOI 10.1016/S0968-0004(00)01600-5; KRISHNASWAMY PR, 1962, J BIOL CHEM, V237, P2932; Labahn J, 2002, J MOL BIOL, V322, P1053, DOI 10.1016/S0022-2836(02)00886-0; Nishimura A, 2001, BIOSCI BIOTECH BIOCH, V65, P477, DOI 10.1271/bbb.65.477; Ortlund E, 2000, BIOCHEMISTRY-US, V39, P1199, DOI 10.1021/bi991797d; Palm GJ, 1996, FEBS LETT, V390, P211, DOI 10.1016/0014-5793(96)00660-6; Shin S, 2002, EMBO J, V21, P2509, DOI 10.1093/emboj/21.11.2509; SWAIN AL, 1993, P NATL ACAD SCI USA, V90, P1474, DOI 10.1073/pnas.90.4.1474; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; WILCOX M, 1969, EUR J BIOCHEM, V11, P405, DOI 10.1111/j.1432-1033.1969.tb00788.x; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	21	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8150	8155		10.1074/jbc.M411098200	http://dx.doi.org/10.1074/jbc.M411098200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611111	hybrid			2022-12-27	WOS:000227395700087
J	Lin, CG; Chen, CC; Leu, SJ; Grzeszkiewicz, TM; Lau, LF				Lin, CG; Chen, CC; Leu, SJ; Grzeszkiewicz, TM; Lau, LF			Integrin-dependent functions of the angiogenic inducer NOV (CCN3) - Implication in wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; HUMAN SKIN FIBROBLASTS; VASCULAR ENDOTHELIAL-CELLS; C-TERMINAL DOMAIN; SULFATE PROTEOGLYCAN; BINDING-SITE; CYR61 GENE; IN-VIVO; EXPRESSION	The novel angiogenic inducer CCN3 ( NOV, nephroblastoma overexpressed) is a matricellular protein of the CCN family, which also includes CCN1 (CYR61), CCN2 (CTGF), CCN4 (WISP-1), CCN5 (WISP-2), and CCN6 (WISP-3). CCN3 is broadly expressed in derivatives of all three germ layers during mammalian development, and its deranged expression is associated with vascular injury and a broad range of tumors. We have shown that CCN3 promotes proangiogenic activities in vascular endothelial cells through integrin receptors and induces neovascularization in vivo (Lin, C. G., Leu, S. J., Chen, N., Tebeau, C. M., Lin, S. X., Yeung, C. Y., and Lau, L. F. (2003) J. Biol. Chem. 278, 24200-24208). In this study, we show that CCN3 is highly expressed in granulation tissue of cutaneous wounds 5-7 days after injury and is capable of inducing responses in primary fibroblasts consistent with wound healing. Purified CCN3 supports primary skin fibroblast adhesion through integrins alpha(5)beta(1) and alpha(6)beta(1) and induces fibroblast chemotaxis through integrin alpha(v)beta(5). We show that CCN3 is a novel ligand of alpha(v)beta(5) in a solid phase binding assay. Although not mitogenic on its own, CCN3 also enhances basic fibroblast growth factor-induced DNA synthesis. Furthermore, CCN3 up-regulates MMP-1 and PAI-1 expression but interacts with TGF-beta1 in an antagonistic or synergistic manner to regulate the expression of specific genes. These findings, together with its angiogenic activity, support a role for CCN3 in cutaneous wound healing in skin fibroblasts and establish its matricellular mode of action through integrin receptors.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 9000 S Ashland Ave, Chicago, IL 60607 USA.	lflau@uic.edu		Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [R01 CA046565, R01 CA046565-16, CA80080, CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1994, CURRENT PROTOCOSL MO; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Chevalier G, 1998, AM J PATHOL, V152, P1563; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Ellis PD, 2003, J VASC RES, V40, P234, DOI 10.1159/000071887; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; Fataccioli V, 2002, HUM GENE THER, V13, P1461, DOI 10.1089/10430340260185094; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Hirasaki S, 2001, HEPATOL RES, V19, P294, DOI 10.1016/S1386-6346(00)00101-7; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Inkinen K, 2003, CONNECT TISSUE RES, V44, P19, DOI 10.1080/03008200390151918; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kocialkowski S, 2001, ANAT EMBRYOL, V203, P417, DOI 10.1007/s004290100177; Lafont J, 2002, J BIOL CHEM, V277, P41220, DOI 10.1074/jbc.M204405200; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; Leu SJ, 2004, J BIOL CHEM, V279, P44177, DOI 10.1074/jbc.M407850200; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Li CL, 2002, J CLIN PATHOL-MOL PA, V55, P250, DOI 10.1136/mp.55.4.250; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; Lombet Alain, 2003, Cell Commun Signal, V1, P1, DOI 10.1186/1478-811X-1-1; MacDonald HR, 2001, TRENDS IMMUNOL, V22, P155; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Natarajan D, 2000, DEV DYNAM, V219, P417, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1058>3.0.CO;2-2; Noszczyk BH, 2002, EXP DERMATOL, V11, P311, DOI 10.1034/j.1600-0625.2002.110404.x; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Scholz G, 1996, MOL CELL BIOL, V16, P481; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Su BY, 2001, J CLIN PATHOL-MOL PA, V54, P184, DOI 10.1136/mp.54.3.184; Takigawa M, 2003, DRUG NEWS PERSPECT, V16, P11, DOI 10.1358/dnp.2003.16.1.829302; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Yu CY, 2003, J PATHOL, V201, P609, DOI 10.1002/path.1468	65	95	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8229	8237		10.1074/jbc.M404903200	http://dx.doi.org/10.1074/jbc.M404903200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611078	hybrid			2022-12-27	WOS:000227395700096
J	White, KA; Yore, MM; Deng, DX; Spinella, MJ				White, KA; Yore, MM; Deng, DX; Spinella, MJ			Limiting effects of RIP140 in estrogen signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RETINOIC ACID RECEPTOR; HUMAN EMBRYONAL CARCINOMA; INTERACTING PROTEIN 140; NUCLEAR RECEPTOR; MOLECULAR-MECHANISMS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; COREPRESSOR RIP140; NEGATIVE-FEEDBACK	The receptor interacting protein 140 (RIP140) belongs to a unique subclass of nuclear receptor coregulators with the ability to bind and repress the action of a number of agonist-bound hormone receptors. We have previously demonstrated that all-trans-retinoic acid (RA) induction of RIP140 constitutes a rate-limiting step in the regulation of retinoid receptor signaling. Here we demonstrate that RIP140 is also a limiting regulator of estrogen receptor signaling. Overexpression of RIP140 dose dependently inhibits estrogen-dependent reporter activity in human breast cancer cells. Furthermore, small interfering RNA to RIP140 enhances estrogen-dependent signaling. Our previous studies indicate that RIP140 is a direct target of RA. We report here that RA can abrogate estrogen-mediated cell cycle re-entry. In addition, RA treatment of estrogen-dependent breast cancer cells opposes estrogen receptor-dependent reporter activity, implying that a proportion of RA effects are anti-estrogenic. We provide evidence for a role for RIP140 in mediating anti-estrogenic effects of RA. RIP140 small interfering RNA blocks RA-mediated repression of estrogen receptor activity and provides a growth advantage to estrogen-dependent cells. Together these data implicate a regulatory role for RIP140 in mediating anti-estrogenic effects of RA in estrogen-dependent breast cancer cells and suggest that acute regulation of coregulator expression may be a general mechanism to integrate diverse hormone signals.	Dartmouth Med Coll, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Med Coll, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NCI NIH HHS [R01 CA104312, R01-CA104312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bischoff ED, 1998, CANCER RES, V58, P479; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Christian M, 2004, J BIOL CHEM, V279, P15645, DOI 10.1074/jbc.M313906200; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; DEMIRPENCE E, 1994, CANCER RES, V54, P1458; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1992, CANCER RES, V52, P3938; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Gottardis MM, 1996, BREAST CANCER RES TR, V38, P85, DOI 10.1007/BF01803787; Graham JD, 2000, STEROIDS, V65, P579, DOI 10.1016/S0039-128X(00)00116-1; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Kerley JS, 2001, BIOCHEM BIOPH RES CO, V285, P969, DOI 10.1006/bbrc.2001.5274; KURIE JM, 1993, DIFFERENTIATION, V54, P123; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Moon Richard C., 1994, P573; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Niles RM, 2000, NUTRITION, V16, P1084, DOI 10.1016/S0899-9007(00)00436-6; Okamoto K, 2000, CANCER CHEMOTH PHARM, V46, P128, DOI 10.1007/s002800000125; Peters GA, 1999, MOL ENDOCRINOL, V13, P286, DOI 10.1210/me.13.2.286; Prakash P, 2000, NUTR REV, V58, P170, DOI 10.1111/j.1753-4887.2000.tb01856.x; Rishi AK, 1996, CANCER RES, V56, P5246; Rosenauer A, 1998, CANCER RES, V58, P5110; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; Schneider SM, 2000, CANCER RES, V60, P5479; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, INVAS METAST, V14, P329; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Sporn MB, 2002, NAT REV CANCER, V2, P537, DOI 10.1038/nrc844; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Suh N, 2002, CLIN CANCER RES, V8, P3270; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Wan YH, 2002, MOL ENDOCRINOL, V16, P1204, DOI 10.1210/me.16.6.1204; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; White JH, 2004, VITAM HORM, V68, P123; White KA, 2003, J BIOL CHEM, V278, P43889, DOI 10.1074/jbc.C300374200; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/mend.15.4.0624; Zujewski J, 2002, ENVIRON MOL MUTAGEN, V39, P264, DOI 10.1002/em.10054	68	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7829	7835		10.1074/jbc.M412707200	http://dx.doi.org/10.1074/jbc.M412707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632153	hybrid			2022-12-27	WOS:000227395700049
J	Humphries, AD; Streimann, IC; Stojanovski, D; Johnston, AJ; Yano, M; Hoogenraad, NJ; Ryan, MT				Humphries, AD; Streimann, IC; Stojanovski, D; Johnston, AJ; Yano, M; Hoogenraad, NJ; Ryan, MT			Dissection of the mitochondrial import and assembly pathway for human Tom40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; PROTEIN IMPORT; PREPROTEIN TRANSLOCASE; FUNCTIONAL-ANALYSIS; INTERMEMBRANE SPACE; RECEPTOR COMPLEX; ADP/ATP CARRIER; BIOGENESIS; CHANNEL; PORE	Tom40 is the channel-forming subunit of the translocase of the mitochondrial outer membrane ( TOM complex), essential for protein import into mitochondria. Tom40 is synthesized in the cytosol and contains information for its mitochondrial targeting and assembly. A number of stable import intermediates have been identified for Tom40 precursors in fungi, the first being an association with the sorting and assembly machinery (SAM) of the outer membrane. By examining the import pathway of human Tom40, we have been able to elucidate additional features in its import. We identify that Hsp90 is involved in delivery of the Tom40 precursor to mitochondria in an ATP-dependent manner. The precursor then forms its first stable intermediate with the outer face of the TOM complex before its membrane integration and assembly. Deletion of an evolutionary conserved region within Tom40 disrupts the TOM complex intermediate and causes it to stall at a new complex in the intermembrane space that we identify to be the mammalian SAM. Unlike its fungal counterparts, the human Tom40 precursor is not found stably arrested at a SAM intermediate. Nevertheless, we show that Tom40 assembly is reduced in mitochondria depleted of human Sam50. These findings are discussed in context with current models from fungal studies.	La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia; Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8600811, Japan	La Trobe University; Kumamoto University	Hoogenraad, NJ (corresponding author), La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia.	N.Hoogenraad@latrobe.edu.au; M.Ryan@latrobe.edu.au	Ryan, Michael/X-2152-2019; Hoogenraad, Nicholas J/C-7505-2011; Ryan, Michael T/C-6673-2011	Ryan, Michael/0000-0003-2586-8829; Ryan, Michael T/0000-0003-2586-8829; Stojanovski, Diana/0000-0002-0199-3222; Johnston, Amelia/0000-0003-4289-3516				Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Armstrong LC, 1999, J CELL BIOCHEM, V74, P11, DOI 10.1002/(SICI)1097-4644(19990701)74:1<11::AID-JCB2>3.0.CO;2-V; Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; Bagos PG, 2004, NUCLEIC ACIDS RES, V32, pW400, DOI 10.1093/nar/gkh417; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Esaki M, 2003, NAT STRUCT BIOL, V10, P988, DOI 10.1038/nsb1008; Frohlich KU, 2000, FEBS LETT, V473, P6, DOI 10.1016/S0014-5793(00)01474-5; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; Harlow E., 1999, USING ANTIBODIES LAB; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KEIL P, 1993, J BIOL CHEM, V268, P19177; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Meisinger C, 2004, DEV CELL, V7, P61, DOI 10.1016/j.devcel.2004.06.003; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Milenkovic D, 2004, J BIOL CHEM, V279, P22781, DOI 10.1074/jbc.C400120200; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; PERALTA D, 1993, EUR J BIOCHEM, V211, P881, DOI 10.1111/j.1432-1033.1993.tb17621.x; Pfanner N, 2004, NAT STRUCT MOL BIOL, V11, P1044, DOI 10.1038/nsmb852; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Ryan MT, 2004, CURR BIOL, V14, pR207, DOI 10.1016/j.cub.2004.02.024; Ryan MT, 2002, ADV PROTEIN CHEM, V59, P223; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Simpson RJ, 2003, PROTEINS PROTEOMICS; SMITH MG, 1995, MOL BIOL CELL, V6, P1381, DOI 10.1091/mbc.6.10.1381; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Suzuki H, 2004, J BIOL CHEM, V279, P50619, DOI 10.1074/jbc.M408604200; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Waizenegger T, 2004, EMBO REP, V5, P704, DOI 10.1038/sj.embor.7400183; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200; Yano M, 2000, MOL CELL BIOL, V20, P7205, DOI 10.1128/MCB.20.19.7205-7213.2000; Yano M, 1998, J BIOL CHEM, V273, P26844, DOI 10.1074/jbc.273.41.26844; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	62	142	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11535	11543		10.1074/jbc.M413816200	http://dx.doi.org/10.1074/jbc.M413816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644312	hybrid			2022-12-27	WOS:000227761800079
J	Arinze, IJ; Kawai, Y				Arinze, IJ; Kawai, Y			Transcriptional activation of the human G alpha(i2) gene promoter through nuclear factor-kappa B and antioxidant response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; EMBRYONAL CARCINOMA-CELLS; PROTEIN-KINASE; ALPHA-SUBUNIT; MEGAKARYOCYTIC DIFFERENTIATION; K562 CELLS; PROTOONCOGENE TRANSCRIPTION; LOCALIZATION SEQUENCE; OXIDATIVE STRESS; RETINOIC ACID	Very little is known regarding molecular mechanism(s) underlying transcriptional regulation of any G-protein gene despite the importance of G-protein expression in modulating cellular processes. Here we show that phorbol myristate acetate (PMA) and tert-butylhydroquinone (tBHQ), which induce oxidative stress in cells, up-regulate transcription of G alpha(i2) in K562 cells. Redox-sensing chemicals abrogated this transcriptional effect. A dominant negative I-kappa B double mutant (S32A/S36A) suppressed PMA-induced transcription by 54-62%, suggesting involvement of nuclear factor-kappa B (NF-kappa B). SN50, a cell-permeable peptide that inhibits nuclear import of stress-responsive transcription factors (such as NF-kappa B), inhibited PMA- and tBHQ-induced transcription. Deletion of an NF-kappa B-binding motif that maps at +10/+19 in the promoter resulted in 55-60% suppression of PMA- induced transcription, and 81% suppression of tBHQ-induced transcription. Mutation of an antioxidant response element ( ARE) that maps at -84/-76 in the promoter resulted in 51 and 86% decrease in PMA- and tBHQ-induced transcription, respectively. In electrophoretic mobility shift assays, this element formed complexes with the transcription factors NF-E2p45 and Nrf2 that are prototypic for binding to the ARE, as well as with c-Fos, which can also interact with the ARE. Chromatin immunoprecipitation analysis demonstrated recruitment of these transcription factors to the promoter. Exogenously transfected Nrf2 transactivated the G alpha(i2) gene promoter; the cytoskeleton-associated protein, Keap1, abrogated this effect. Taken together, the present studies reveal that transcription factors that bind NF-kappa B and/or antioxidant response elements play an activating role in the transcription of the human G alpha(i2) gene.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA	Meharry Medical College	Arinze, IJ (corresponding author), Meharry Med Coll, Dept Biochem, 1005 David B Todd Jr,Blvd, Nashville, TN 37208 USA.	iarinze@mmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008037] Funding Source: NIH RePORTER; NIGMS NIH HHS [S06-GM08037-32] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 2004, HDB CELL SIGNALING, P99; Arinze IJ, 2003, J BIOL CHEM, V278, P17785, DOI 10.1074/jbc.M209430200; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Datta R, 2000, J BIOL CHEM, V275, P41000, DOI 10.1074/jbc.M009322200; Davis MG, 2000, BIOCHEM J, V346, P455, DOI 10.1042/0264-6021:3460455; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Eschenhagen T, 1996, BASIC RES CARDIOL, V91, P41, DOI 10.1007/BF00795361; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 2002, SIGNAL TRANSDUCTION, P208; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; ITO K, 1997, BIOCHEM BIOPH RES CO, V236, P313; ITO K, 1995, MOL CELL BIOL, V15, P4184; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Kang CD, 1996, BIOCHEM BIOPH RES CO, V221, P95, DOI 10.1006/bbrc.1996.0551; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; Li JJ, 1997, CANCER RES, V57, P3569; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishida M, 2002, J BIOL CHEM, V277, P9036, DOI 10.1074/jbc.M107392200; Papaiahgari S, 2004, J BIOL CHEM, V279, P42302, DOI 10.1074/jbc.M408275200; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SHETH B, 1991, BIOCHEM J, V275, P809, DOI 10.1042/bj2750809; Song XS, 2001, J BIOL CHEM, V276, P34651, DOI 10.1074/jbc.M105894200; SOZERI O, 1992, ONCOGENE, V7, P2259; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEINSTEIN LS, 1990, MOL ENDOCRINOL, V4, P958, DOI 10.1210/mend-4-7-958; Werry TD, 2003, BIOCHEM J, V374, P281, DOI 10.1042/BJ20030312; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	64	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9786	9795		10.1074/jbc.M414006200	http://dx.doi.org/10.1074/jbc.M414006200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640523	hybrid			2022-12-27	WOS:000227559600007
J	van Baal, J; de Widt, J; Divecha, N; van Blitterswijk, WJ				van Baal, J; de Widt, J; Divecha, N; van Blitterswijk, WJ			Translocation of diacylglycerol kinase theta from cytosol to plasma membrane in response to activation of G protein-coupled receptors and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAINS; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; PLECKSTRIN HOMOLOGY DOMAIN; PROMOTING PHORBOL ESTERS; PHOSPHATIDIC-ACID; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; IN-VITRO; ALPHA; CELLS	Diacylglycerol kinase (DGK) phosphorylates the second messenger diacylglycerol (DAG) to phosphatidic acid. We previously identified DGK theta as one of nine mammalian DGK isoforms and reported on its regulation by interaction with RhoA and by translocation to the plasma membrane in response to noradrenaline. Here, we have investigated how the localization of DGK theta, fused to green fluorescent protein, is controlled upon activation of G protein-coupled receptors in A431 cells. Extracellular ATP, bradykinin, or thrombin induced DGK theta translocation from the cytoplasm to the plasma membrane within 2-6 min. This translocation, independent of DGK activity, was preceded by protein kinase C (PKC) translocation and was blocked by PKC inhibitors. Conversely, activation of PKC by 12-O-tetra-decanoylphorbol-13-acetate induced DGK theta translocation. Membrane-permeable DAG ( dioctanoylglycerol) also induced DGK theta translocation but in a PKC (stauro-sporin)-independent fashion. Mutations in the cysteine-rich domains of DGK theta abrogated its hormone- and DAG-induced translocation, suggesting that these domains are essential for DAG binding and DGK theta recruitment to the membrane. We show that DGK theta interacts selectively with and is phosphorylated by PKC epsilon and -eta and that peptide agonist-induced selective activation of PKC epsilon directly leads to DGK theta translocation. Our data are consistent with the concept that hormone- induced PKC activation regulates the intracellular localization of DGK theta, which may be important in the negative regulation of PKC epsilon and/or PKC eta activity.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Divecha, N (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	n.divecha@nki.nl; w.v.blitterswijk@nki.nl		divecha, nullin/0000-0001-9695-6039				Abramovici H, 2003, MOL BIOL CELL, V14, P4499, DOI 10.1091/mbc.E03-03-0190; AHMED S, 1993, J BIOL CHEM, V268, P10709; Baldanzi G, 2004, ONCOGENE, V23, P4828, DOI 10.1038/sj.onc.1207633; Bregoli L, 2001, J BIOL CHEM, V276, P23288, DOI 10.1074/jbc.M101501200; Burrell HE, 2003, J INVEST DERMATOL, V120, P440, DOI 10.1046/j.1523-1747.2003.12050.x; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; de Turco EBR, 2001, P NATL ACAD SCI USA, V98, P4740, DOI 10.1073/pnas.081536298; Diaz-Flores E, 2003, J BIOL CHEM, V278, P29208, DOI 10.1074/jbc.M303165200; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Ho A, 2001, CANCER RES, V61, P474; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; Houssa B, 1997, J BIOL CHEM, V272, P10422; Houssa B, 1998, BIOCHEM J, V331, P677; HUANG NN, 1991, J CELL PHYSIOL, V146, P483, DOI 10.1002/jcp.1041460320; Imai S, 2004, BIOCHEM J, V382, P957, DOI 10.1042/BJ20040681; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; Jones DR, 2000, FEBS LETT, V476, P160, DOI 10.1016/S0014-5793(00)01702-6; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; Kanda N, 2002, J INVEST DERMATOL, V119, P1080, DOI 10.1046/j.1523-1747.2002.19510.x; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Los AP, 2004, BBA-MOL CELL BIOL L, V1636, P169, DOI 10.1016/j.bbalip.2003.11.008; Luo B, 2004, CELL SIGNAL, V16, P891, DOI 10.1016/j.cellsig.2004.01.010; Luo B, 2003, J CELL BIOL, V160, P929, DOI 10.1083/jcb.200208120; Luo B, 2003, J BIOL CHEM, V278, P39542, DOI 10.1074/jbc.M307153200; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; Musashi M, 2000, INT J HEMATOL, V72, P12; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Oshevski S, 1999, BIOCHEM BIOPH RES CO, V263, P603, DOI 10.1006/bbrc.1999.1425; Raghu P, 2000, NEURON, V26, P169, DOI 10.1016/S0896-6273(00)81147-2; Ralevic V, 1998, PHARMACOL REV, V50, P413; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Shindo M, 2003, J BIOL CHEM, V278, P18448, DOI 10.1074/jbc.M300400200; Shindo M, 2001, BIOCHEM BIOPH RES CO, V289, P451, DOI 10.1006/bbrc.2001.5935; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Topham MK, 2002, THROMB HAEMOSTASIS, V88, P912; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Torres B, 2002, J BIOL CHEM, V277, P7761, DOI 10.1074/jbc.M110352200; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANDERBEND RL, 1994, J BIOL CHEM, V269, P4098; Walker AJ, 2001, BIOCHEM J, V353, P129, DOI 10.1042/bj3530129; Watters DJ, 1999, BIOCHEM PHARMACOL, V58, P383, DOI 10.1016/S0006-2952(99)00063-5; Xiao GQ, 2001, AM J PHYSIOL-CELL PH, V281, pC1477, DOI 10.1152/ajpcell.2001.281.5.C1477	58	57	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9870	9878		10.1074/jbc.M409301200	http://dx.doi.org/10.1074/jbc.M409301200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632189	hybrid			2022-12-27	WOS:000227559600017
J	Zhou, H; Kramer, RH				Zhou, H; Kramer, RH			Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ADHESION; RHO-GTPASES; ALPHA-6-BETA-4 INTEGRIN; INTRAHEPATIC METASTASIS; MEMBRANE PROTRUSION; ACTIN ORGANIZATION; LAMELLAE FORMATION; FOCAL ADHESIONS; MIGRATION; RAC	Integrin-ligand binding regulates tumor cell motility and invasion. Cell migration also involves the Rho GTPases that control the interplay between adhesion receptors and the cytoskeleton. We evaluated how specific extracellular matrix ligands modulate Rho GTPases and control motility of human squamous cell carcinoma cells. On laminin-5 substrates, the epithelial cells rapidly spread and migrated, but on type I collagen the cells spread slowly and showed reduced motility. We found that RhoA activity was suppressed in cells attached to laminin-5 through the alpha 3 integrin receptor. In contrast, RhoA was strongly activated in cells bound to type I collagen and this was mediated by the alpha 2 integrin. Inhibiting the RhoA pathway by expression of a dominant- negative RhoA mutant or by directly inhibiting ROCK, reduced focal adhesion formation and enhanced cell migration on type I collagen. Cdc42 and Rac and their downstream target PAK1 were activated following adhesion to laminin-5. PAK1 activation induced by laminin-5 was suppressed by expression of a dominant- negative Cdc42. Moreover, constitutively active PAK1 stimulated migration on collagen I substrates. Our results indicate that in squamous epithelial cells, collagen-alpha 2 beta 1 integrin binding activates RhoA, slowing cell locomotion, whereas laminin-5 alpha 3 beta 1 integrin interaction inhibits RhoA and activates PAK1, stimulating cell migration. The data demonstrate that specific ligand- integrin pairs regulate cell motility differentially by selectively modulating activities of Rho GTPases and their effectors.	Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA.	rkramer@itsa.ucsf.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011436, P01DE013904, T32DE007204] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11436, 5T32DE007204, DE13904] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bourne HR, 2002, NATURE, V419, P21, DOI 10.1038/419021a; Choma DP, 2004, J CELL SCI, V117, P3947, DOI 10.1242/jcs.01251; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Fujiwara H, 2004, EXP CELL RES, V292, P67, DOI 10.1016/j.yexcr.2003.08.010; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ho WC, 1997, MOL BIOL CELL, V8, P1863, DOI 10.1091/mbc.8.10.1863; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; ILLC D, 1995, NATURE, V377, P539; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kawano K, 2001, EXP CELL RES, V262, P180, DOI 10.1006/excr.2000.5083; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; LANGHOFER M, 1993, J CELL SCI, V105, P753; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Moyano JV, 2003, MOL BIOL CELL, V14, P3699, DOI 10.1091/mbc.E02-10-0667; Nakajima M, 2003, CANCER CHEMOTH PHARM, V52, P319, DOI 10.1007/s00280-003-0641-9; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nguyen BP, 2001, J BIOL CHEM, V276, P43860, DOI 10.1074/jbc.M103404200; Nishimura Y, 2003, PATHOL ONCOL RES, V9, P83, DOI 10.1007/BF03033750; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Olivo C, 2000, ONCOGENE, V19, P1428, DOI 10.1038/sj.onc.1203440; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Palecek SP, 1999, ANN BIOMED ENG, V27, P219, DOI 10.1114/1.176; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; Plopper GE, 1998, BREAST CANCER RES TR, V51, P57, DOI 10.1023/A:1006086218174; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Takamura M, 2001, HEPATOLOGY, V33, P577, DOI 10.1053/jhep.2001.22652; Wakatsuki T, 2003, J CELL SCI, V116, P1617, DOI 10.1242/jcs.00340; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yao CC, 1996, J BIOL CHEM, V271, P25598, DOI 10.1074/jbc.271.41.25598; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	76	85	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10624	10635		10.1074/jbc.M411900200	http://dx.doi.org/10.1074/jbc.M411900200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15611088	hybrid			2022-12-27	WOS:000227559600108
J	Du, M; Reid, SA; Jayaraman, V				Du, M; Reid, SA; Jayaraman, V			Conformational changes in the ligand-binding domain of a functional ionotropic glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTOR; CRYSTAL-STRUCTURES; ION CHANNELS; CORE; ACTIVATION; DESENSITIZATION	Fluorescence resonance energy transfer was used to determine the structural changes in the extracellular ligand-binding segment in a functional glutamate receptor that contains the ligand-binding, transmembrane, and C-terminal segments. These studies indicate that the structural changes previously reported for the isolated ligand-binding domain due to the binding of partial and full agonists are also observed in this functional receptor, thus validating the detailed structure-function relationships that have been previously developed based on the structure of the isolated ligand-binding domain. Additionally, these studies provide the first evidence that there are no significant changes in the extent of cleft closure between the activated and desensitized states of the glutamate bound form of the receptor consistent with the previous functional investigations, which suggest that desensitization is mediated primarily by changes in the interactions between subunits composing the receptor.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Marquette Univ, Dept Chem, Milwaukee, WI 53201 USA	University of Texas System; University of Texas Health Science Center Houston; Marquette University	Jayaraman, V (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, MSB 4-106,6341 Fannin, Houston, TX 77030 USA.	vasanthi.jayaraman@uth.tmc.edu	Reid, Scott/J-6491-2016	Reid, Scott/0000-0001-9916-7414				Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; Cheng Q, 2004, J BIOL CHEM, V279, P26346, DOI 10.1074/jbc.M403111200; Deming D, 2003, J BIOL CHEM, V278, P17589, DOI 10.1074/jbc.C300105200; Gouaux E, 2004, J PHYSIOL-LONDON, V554, P249, DOI 10.1113/jphysiol.2003.054320; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Horning MS, 2004, NEURON, V41, P379, DOI 10.1016/S0896-6273(04)00018-2; Jayaraman V, 2000, BIOCHEMISTRY-US, V39, P8693, DOI 10.1021/bi000892f; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Madden DR, 2002, CURR OPIN DRUG DI DE, V5, P741; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Madden DR, 2001, J BIOL CHEM, V276, P37821; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; McFeeters RL, 2004, FASEB J, V18, P428, DOI 10.1096/fj.03-0873rev; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a	21	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8633	8636		10.1074/jbc.C400590200	http://dx.doi.org/10.1074/jbc.C400590200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632199	hybrid			2022-12-27	WOS:000227453100002
J	Kaul-Ghanekar, R; Majumdar, S; Jalota, A; Gulati, N; Dubey, N; Saha, B; Chattopadhyay, S				Kaul-Ghanekar, R; Majumdar, S; Jalota, A; Gulati, N; Dubey, N; Saha, B; Chattopadhyay, S			Abnormal V(D)J recombination of T cell receptor beta locus in SMAR1 transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX ATTACHMENT REGIONS; TCR-BETA; BINDING-PROTEIN; GENE REARRANGEMENT; ALPHA-ENHANCER; RAG PROTEINS; TRANSCRIPTION; SATB1; ACCESSIBILITY; CHROMATIN	Scaffold/matrix-associated region-1-binding protein (SMAR1) specifically interacts with the MARbeta sequence, which is located 400-bp upstream of the murine TCRbeta enhancer and is highly expressed during the DP stage of thymocyte development. To further analyze the functions of SMAR1, transgenic mice were generated that express SMAR1 in a tissue-independent manner. SMAR1-overexpressing mice exhibit severely altered frequency of the T cells expressing commonly used Vbetas (Vbeta5.1/5.2 and Vbeta8.1/ 8.2/8.3). The rearrangements of Vbeta5.1/5.2, Vbeta8.1/8.2/8.3 loci are also reduced in SMAR1 transgenic mice. The T cells in SMAR1 transgenic mice exhibit a mild perturbation at the early DN stage. SMAR1 transgenic mice exhibit hypercellular lymph nodes and spleen accompanied with prominent architectural defects in these organs. These results indicate that SMAR1 plays an important role in the regulation of T cell development as well as V(D)J recombination besides maintaining the architecture of the lymphoid organs.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India; Natl Inst Immunol, New Delhi 100067, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Chattopadhyay, S (corresponding author), Natl Ctr Cell Sci, Pune Univ Campus, Pune 411007, Maharashtra, India.	samit@nccs.res.in	Dubey, Nitin/I-2232-2019	Dubey, Nitin/0000-0003-2635-9217; Majumdar, Subeer/0000-0003-1724-7483				ALVAREZ JD, 1995, J IMMUNOL, V155, P1191; Alvarez JD, 2000, GENE DEV, V14, P521; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bories JC, 1996, P NATL ACAD SCI USA, V93, P7871, DOI 10.1073/pnas.93.15.7871; Brown ML, 2002, P NATL ACAD SCI USA, V99, P4532, DOI 10.1073/pnas.072495299; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; Chattopadhyay S, 2000, GENOMICS, V68, P93, DOI 10.1006/geno.2000.6279; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chattopadhyay S, 1998, J IMMUNOL, V160, P1256; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GODFREY DI, 1994, J IMMUNOL, V152, P4783; Goebel P, 2002, J IMMUNOL, V169, P2477, DOI 10.4049/jimmunol.169.5.2477; Goulet B, 2002, CANCER RES, V62, P6625; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; HOOD L, 1995, ANN NY ACAD SCI, V758, P390, DOI 10.1111/j.1749-6632.1995.tb24844.x; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kaul R, 2003, INT J CANCER, V103, P606, DOI 10.1002/ijc.10881; Kaul-Ghanekar R, 2004, NUCLEIC ACIDS RES, V32, P4862, DOI 10.1093/nar/gkh807; KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j; Krangel MS, 2003, NAT IMMUNOL, V4, P624, DOI 10.1038/ni0703-624; LANSFORD R, 1996, MOL IMMUNOL, P1; LAUZURICA P, 1994, J EXP MED, V179, P1913, DOI 10.1084/jem.179.6.1913; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Okada A, 1994, Semin Immunol, V6, P185, DOI 10.1006/smim.1994.1024; Rampalli S, 2003, NUCLEIC ACIDS RES, V31, P3248, DOI 10.1093/nar/gkg410; Schlissel M S, 1997, Semin Immunol, V9, P161, DOI 10.1006/smim.1997.0066; Schlissel MS, 2003, NAT REV IMMUNOL, V3, P890, DOI 10.1038/nri1225; Sikes ML, 1998, J IMMUNOL, V161, P1399; Sleckman BP, 1997, IMMUNITY, V7, P505, DOI 10.1016/S1074-7613(00)80372-6; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Whitehurst CE, 2000, IMMUNITY, V13, P703, DOI 10.1016/S1074-7613(00)00069-8; Whitehurst CE, 1999, IMMUNITY, V10, P313, DOI 10.1016/S1074-7613(00)80031-X; Wolfer A, 2002, IMMUNITY, V16, P869, DOI 10.1016/S1074-7613(02)00330-8; Zhong XP, 1999, P NATL ACAD SCI USA, V96, P11970, DOI 10.1073/pnas.96.21.11970; ZONG RT, 1995, J BIOL CHEM, V270, P24010, DOI 10.1074/jbc.270.41.24010	49	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9450	9459		10.1074/jbc.M412206200	http://dx.doi.org/10.1074/jbc.M412206200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623522	hybrid			2022-12-27	WOS:000227453100098
J	Rubin, C; Zwang, Y; Vaisman, N; Ron, D; Yarden, Y				Rubin, C; Zwang, Y; Vaisman, N; Ron, D; Yarden, Y			Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of sprouty-2 inhibition of different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SERUM RESPONSE ELEMENT; C-CBL; ERK ACTIVATION; RING FINGER; MAP KINASE; FGF; ANTAGONIST; EXPRESSION; PROTEINS	Sprouty proteins are evolutionarily conserved negative feedback regulators of multiple receptor tyrosine kinases. Mammalian versions of these proteins differentially regulate signaling induced by the fibroblast and the epidermal growth factors (FGF and EGF, respectively). Herein we show that, although both growth factors elevate expression of Sprouty-2, FGF- and not EGF-induced activation of the Erk/MAPK pathway is inhibited by Sprouty-2. Attenuation of FGF- signaling is accompanied by the induction of Sprouty-2 phosphorylation on the amino-terminal as well as carboxyl-terminal tyrosine residues, which are less effectively modified upon EGF treatment. Mutagenesis of carboxyl-terminal tyrosines, especially a newly identified phosphorylation site, tyrosine 227, impaired the inhibitory activity of Sprouty-2. These results attribute a novel role for carboxyl-terminal tyrosine residues and yet unidentified phosphotyrosine-binding proteins in the differential regulation of Sprouty-2 activity.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Sigma Aldrich Israel Ltd, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel	Weizmann Institute of Science; Merck KGaA; MilliporeSigma; Technion Israel Institute of Technology	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	YARDEN, YOSEF/K-1467-2012		NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hanafusa H, 2004, J BIOL CHEM, V279, P22992, DOI 10.1074/jbc.M312498200; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kramer S, 1999, DEVELOPMENT, V126, P2515; Leeksma OC, 2002, EUR J BIOCHEM, V269, P2546, DOI 10.1046/j.1432-1033.2002.02921.x; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Mason JM, 2004, MOL BIOL CELL, V15, P2176, DOI 10.1091/mbc.E03-07-0503; Minowada G, 1999, DEVELOPMENT, V126, P4465; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhang SB, 2001, MECH DEVELOP, V109, P367, DOI 10.1016/S0925-4773(01)00526-3	41	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9735	9744		10.1074/jbc.M408308200	http://dx.doi.org/10.1074/jbc.M408308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637081	hybrid			2022-12-27	WOS:000227453100131
J	Sanchez-Barbero, F; Strassner, J; Garcia-Canero, R; Steinhilber, W; Casals, C				Sanchez-Barbero, F; Strassner, J; Garcia-Canero, R; Steinhilber, W; Casals, C			Role of the degree of oligomerization in the structure and function of human surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING PROPERTIES; COLLAGEN TRIPLE-HELIX; INNATE IMMUNE-SYSTEM; N-TERMINAL DOMAINS; PULMONARY COLLECTINS; SELF-AGGREGATION; LUNG; LIPOPOLYSACCHARIDE; FORM; CD14	The role of the degree of oligomerization in the structure and function of human surfactant protein A (SP-A) was investigated using a human SP-A1 mutant (SP-A1(DeltaAVC,C6S)),,expressed in mammalian cells, resulting from site-directed substitution of serine for Cys(6) and substitution of a functional signal peptide for the cysteine-containing SP-A signal sequence. This Cys(6) mutant lacked the NH2-terminal Ala(-3)-Val(-2)-Cys(-1)(DeltaAVC) extension present in some SP-A1 isoforms. (SP-A1(DeltaAVC,C6S)) was assembled exclusively as trimers as detected by electron microscopy and size exclusion chromatography. Trimeric SP-A1(DeltaAVC,C6S) was compared with supratrimeric SP-A1, which is structurally and functionally comparable to the octadecameric protein isolated from human lung lavages. SP-A1(DeltaAVC,C6S) showed reduced thermal stability of the collagen domain, studied by circular dichroism, and increased susceptibility to trypsin degradation. The T-m was 32.7 degreesC for SP-A1(DeltaAVC,C6S) and 44.5 degreesC for SP-A1. Although SP-A1(DeltaAVC,C6S) was capable of binding to calcium, rough lipopolysaccharide, and phospholipid vesicles, this mutant was unable to induce rough lipopolysaccharide and phospholipid vesicle aggregation, to enhance the interfacial adsorption of SP-B/SP-C-surfactant membranes, and to undergo self-association in the presence of Ca2+. On the other hand, the lack of supratrimeric assembly hardly affected the ability of SP-A1(DeltaAVC,C6S) to inhibit the production of tumor necrosis factor-alpha by macrophage-like U937 cells stimulated with either smooth or rough lipopolysaccharide. We conclude that supratrimeric assembly of human SP-A is essential for collagen triple helix stability at physiological temperatures, protection against proteases, protein self-association, and SP-A-induced ligand aggregation. The supratrimeric assembly is not essential for the binding of SP-A to ligands and anti-inflammatory effects of SP-A.	Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Hosp Puerta Hierro, Dept Expt Biochem, Madrid 28035, Spain; ALTANA Pharma AG, Dept Biotechnol, D-78467 Constance, Germany	Complutense University of Madrid; Hospital Puerta de Hierro-Majadahonda; Altana	Casals, C (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.	ccasalsc@bio.ucm.es	Casals, Cristina/H-4658-2015	Casals, Cristina/0000-0003-2696-0918				BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; Canadas O, 2004, BIOCHEMISTRY-US, V43, P9926, DOI 10.1021/bi036227z; CASALS C, 1989, BIOCHIM BIOPHYS ACTA, V1003, P201, DOI 10.1016/0005-2760(89)90256-7; CASALS C, 1993, BIOCHEM J, V296, P585, DOI 10.1042/bj2960585; Casals C, 2001, PEDIATR PATHOL MOL M, V20, P249, DOI 10.1080/152279501750412216; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; ELHALWAGI BM, 1997, BIOCHEMISTRY-US, V36, P7015; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Floros J, 1998, BBA-MOL BASIS DIS, V1408, P312, DOI 10.1016/S0925-4439(98)00077-5; Garcia-Verdugo I, 2003, BIOCHEMISTRY-US, V42, P9532, DOI 10.1021/bi0347196; Garcia-Verdugo I, 2002, BIOCHEMISTRY-US, V41, P14041, DOI 10.1021/bi026540l; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; HAAS C, 1991, EUR J BIOCHEM, V197, P799; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; Hickling TP, 1998, MOL MED, V4, P266, DOI 10.1007/BF03401923; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; Ikegami M, 2001, J BIOL CHEM, V276, P38542, DOI 10.1074/jbc.M102054200; Kitchens RL, 1998, J IMMUNOL, V160, P1920; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3; McCormack FX, 2003, J BIOL CHEM, V278, P36250, DOI 10.1074/jbc.M303086200; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1998, BBA-MOL BASIS DIS, V1408, P109, DOI 10.1016/S0925-4439(98)00062-3; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; Palaniyar N, 1998, BIOCHEM BIOPH RES CO, V250, P131, DOI 10.1006/bbrc.1998.9284; Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200; Palaniyar N, 2000, BIOCHEMISTRY-US, V39, P6310, DOI 10.1021/bi992793b; Ridsdale RA, 1999, BBA-MOL BASIS DIS, V1453, P23, DOI 10.1016/S0925-4439(98)00057-X; Ruano MLF, 1998, J BIOL CHEM, V273, P15183, DOI 10.1074/jbc.273.24.15183; Ruano MLF, 2000, BIOCHEMISTRY-US, V39, P6529, DOI 10.1021/bi000188z; Ruano MLF, 1996, BIOCHEM J, V313, P683, DOI 10.1042/bj3130683; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; SKELLY RR, 1979, INFECT IMMUN, V23, P287, DOI 10.1128/IAI.23.2.287-293.1979; Stamme C, 2002, AM J RESP CELL MOL, V27, P353, DOI 10.1165/rcmb.4812; TAKAYAMA K, 1994, J BIOL CHEM, V269, P2241; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TUNER MW, 2003, MOL IMMUNOL, V40, P423; van de Wetering JK, 2004, EUR J BIOCHEM, V271, P1229, DOI 10.1111/j.1432-1033.2004.04040.x; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wang GR, 2004, BIOCHEMISTRY-US, V43, P4227, DOI 10.1021/bi036023i; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590; Worthman LAD, 2000, BIOPHYS J, V79, P2657, DOI 10.1016/S0006-3495(00)76504-0; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	55	48	48	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7659	7670		10.1074/jbc.M410266200	http://dx.doi.org/10.1074/jbc.M410266200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615713	hybrid			2022-12-27	WOS:000227395700029
J	Sarkar, A; Caamano, S; Fernandez, JM				Sarkar, A; Caamano, S; Fernandez, JM			The elasticity of individual titin PEVK exons measured by single molecule atomic force microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIANT PROTEIN TITIN; ISOFORM EXPRESSION; PASSIVE STIFFNESS; MUSCLE-STIFFNESS; SPRING ELEMENTS; SKELETAL-MUSCLE; STRIATED-MUSCLE; CARDIAC TITIN; DIVERSITY; MECHANICS	The I-band region of the giant muscle protein titin contains a large domain enriched for the amino acids proline, glutamate, valine, and lysine and is denoted the PEVK domain. The PEVK domain of titin encodes a random coil shown to be an important factor in the passive elasticity of titin. Muscle-specific splicing of 116 PEVK exons encodes this domain. It has been proposed that proline contents determine the elasticity of the PEVK polypeptide, where the individual exons code for "flexibility cassettes." To test this hypothesis, we have measured the elasticity of three distinct polypeptides encoded by individual PEVK exons (161, 120 and 184) that varied greatly in their proline contents (7, 14, and 37% respectively) and total PEVK contents (55, 70, and 87%). We used single molecule atomic force microscopy techniques to measure the persistence length, p, of the engineered PEVK proteins. Surprisingly, all three exons 161, 120, and 184 coded for proteins with similar values of persistence length, p = 0.92 0.38, 0.89 0.42, and 0.98 0.4 nm, respectively. We conclude that the PEVK exons encode polypeptides of similar elastic properties, unrelated to their total PEVK contents. Hence, alternative splicing solely adjusts the length of the PEVK domain of titin.	Columbia Univ, Dept Biol Sci, Fairchild Ctr 1011A, New York, NY 10027 USA; Mayo Clin, Coll Med, Dept Neurol Surg, Rochester, MN 55905 USA	Columbia University; Mayo Clinic	Fernandez, JM (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild Ctr 1011A, 1212 Amsterdam Ave,MC 2449, New York, NY 10027 USA.	jfernandez@columbia.edu						Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P11288, DOI 10.1073/pnas.96.20.11288; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Freiburg A, 2000, CIRC RES, V86, P1114; FURST DO, 1995, J MOL CELL CARDIOL, V27, P951, DOI 10.1016/0022-2828(95)90064-0; Granzier H, 2002, J PHYSIOL-LONDON, V541, P335, DOI 10.1113/jphysiol.2001.014381; Granzier HL, 2004, CIRC RES, V94, P284, DOI 10.1161/01.RES.0000117769.88862.F8; Improta S, 1998, J MOL BIOL, V284, P761, DOI 10.1006/jmbi.1998.2028; Labeit D, 2003, P NATL ACAD SCI USA, V100, P13716, DOI 10.1073/pnas.2235652100; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Lahmers S, 2004, CIRC RES, V94, P505, DOI 10.1161/01.RES.0000115522.52554.86; Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697; Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00938; Li HB, 2001, P NATL ACAD SCI USA, V98, P10682, DOI 10.1073/pnas.191189098; Linke WA, 1998, P NATL ACAD SCI USA, V95, P8052, DOI 10.1073/pnas.95.14.8052; Linke WA, 2000, HISTOL HISTOPATHOL, V15, P799, DOI 10.14670/HH-15.799; Nelson P, 1999, P NATL ACAD SCI USA, V96, P14342, DOI 10.1073/pnas.96.25.14342; Oberhauser AF, 1999, NAT STRUCT BIOL, V6, P1025; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; SCHIMMEL PR, 1967, P NATL ACAD SCI USA, V58, P52, DOI 10.1073/pnas.58.1.52; Schlierf M, 2004, P NATL ACAD SCI USA, V101, P7299, DOI 10.1073/pnas.0400033101; Trombitas K, 2000, BIOPHYS J, V79, P3226, DOI 10.1016/S0006-3495(00)76555-6; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; WANG K, 1991, P NATL ACAD SCI USA, V88, P7101, DOI 10.1073/pnas.88.16.7101; Watanabe K, 2002, J BIOL CHEM, V277, P11549, DOI 10.1074/jbc.M200356200; Wu YM, 2002, CIRCULATION, V106, P1384, DOI 10.1161/01.CIR.0000029804.61510.02	26	45	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6261	6264		10.1074/jbc.C400573200	http://dx.doi.org/10.1074/jbc.C400573200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15632200	hybrid			2022-12-27	WOS:000227332700004
J	Venkatraman, G; Gomes, AV; Kerrick, WGL; Potter, JD				Venkatraman, G; Gomes, AV; Kerrick, WGL; Potter, JD			Characterization of troponin T dilated cardiomyopathy mutations in the fetal troponin isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CARDIAC-MUSCLE CONTRACTION; THIN FILAMENT REGULATION; CA2+ SENSITIVITY; SKELETAL-MUSCLE; HUMAN HEART; DEVELOPMENTAL EXPRESSION; FUNCTIONAL CONSEQUENCES; FORCE DEVELOPMENT; PH SENSITIVITY	The major goal of this study was to elucidate how troponin T (TnT) dilated cardiomyopathy (DCM) mutations in fetal TnT and fetal troponin affect the functional properties of the fetal heart that lead to infantile cardiomyopathy. The DCM mutations R141W and Delta K210 were created in the TnT1 isoform, the primary isoform of cardiac TnT in the embryonic heart. In addition to a different TnT isoform, a different troponin I (TnI) isoform, slow skeletal TnI (ssTnI), is the dominant isoform in the embryonic heart. In skinned fiber studies, TnT1-wild-type (WT)-treated fibers reconstituted with cardiac TnI.troponin C (TnC) or ssTnI.TnC significantly increased Ca2+ sensitivity of force development when compared with TnT3-WT-treated fibers at both pH 7.0 and pH 6.5. Porcine cardiac fibers treated with TnT1 that contained the DCM mutations (R141W and Delta K210), when reconstituted with either cardiac TnI.TnC or ssTnI.TnC, significantly decreased Ca2+ sensitivity of force development compared with TnT1-WT at both pH values. The R141W mutation, which showed no significant change in the Ca2+ sensitivity of force development in the TnT3 isoform, caused a significant decrease in the TnT1 isoform. The Delta K210 mutation caused a greater decrease in Ca2+ sensitivity and maximal isometric force development compared with the R141W mutation in both the fetal and adult TnT isoforms. When complexed with cardiac TnI.TnC or ssTnI.TnC, both TnT1 DCM mutations strongly decreased maximal actomyosin ATPase activity as compared with TnT1-WT. Our results suggest that a decrease in maximal actomyosin ATPase activity in conjunction with decreased Ca2+ sensitivity of force development may cause a severe DCM phenotype in infants with the mutations.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33101 USA	University of Miami; University of Miami	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu	Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NHLBI NIH HHS [HL67415, HL42325] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042325, R37HL042325, R01HL067415] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; BHAVSAR PK, 1991, FEBS LETT, V292, P5, DOI 10.1016/0014-5793(91)80820-S; Bodor GS, 1997, CIRCULATION, V96, P1495, DOI 10.1161/01.CIR.96.5.1495; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; COOPER TA, 1984, SCIENCE, V226, P979, DOI 10.1126/science.6095446; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gomes AV, 2004, J BIOL CHEM, V279, P49579, DOI 10.1074/jbc.M407340200; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; Harada K, 2004, J BIOL CHEM, V279, P14488, DOI 10.1074/jbc.M309355200; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; HUNKELER NM, 1991, CIRC RES, V69, P1409, DOI 10.1161/01.RES.69.5.1409; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; Li DX, 2001, CIRCULATION, V104, P2188, DOI 10.1161/hc4301.098285; Lu QW, 2003, J MOL CELL CARDIOL, V35, P1421, DOI 10.1016/j.yjmcc.2003.09.003; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MCAULIFFE JJ, 1991, PEDIATR RES, V29, P580, DOI 10.1203/00006450-199106010-00012; Moore DD, 1995, GLOB MOB SURV; Morimoto S, 2000, BIOCHEM BIOPH RES CO, V267, P912, DOI 10.1006/bbrc.1999.2068; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; Morimoto S, 1999, BIOCHEM BIOPH RES CO, V261, P79, DOI 10.1006/bbrc.1999.1000; Morimoto Sachio, 2002, Fukuoka Igaku Zasshi, V93, P1; MURAKAMI U, 1976, J BIOCHEM, V80, P611, DOI 10.1093/oxfordjournals.jbchem.a131316; Murphy RT, 2004, LANCET, V363, P371, DOI 10.1016/S0140-6736(04)15468-8; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; PAN BS, 1992, J BIOL CHEM, V267, P23052; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; Solaro RJ, 1996, J MOL CELL CARDIOL, V28, P217; SOLARO RJ, 1986, CIRC RES, V58, P721, DOI 10.1161/01.RES.58.5.721; STRZELECKAGOLASZEWSKA H, 1975, EUR J BIOCHEM, V55, P221, DOI 10.1111/j.1432-1033.1975.tb02154.x; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; Venkatraman G, 2003, J BIOL CHEM, V278, P41670, DOI 10.1074/jbc.M302148200; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Wolska BM, 2001, J PHYSIOL-LONDON, V536, P863, DOI 10.1111/j.1469-7793.2001.00863.x	44	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17584	17592		10.1074/jbc.M409337200	http://dx.doi.org/10.1074/jbc.M409337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15623536	hybrid			2022-12-27	WOS:000228807200004
J	Lin, DB; Takemoto, DJ				Lin, DB; Takemoto, DJ			Oxidative activation of protein kinase C gamma through the C1 domain - Effects on gap junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHORBOL-BINDING DOMAIN; LENS EPITHELIAL-CELLS; HYDROGEN-PEROXIDE; PKC-GAMMA; INTERCELLULAR COMMUNICATION; TYROSINE PHOSPHORYLATION; STRESS; IDENTIFICATION; MECHANISMS	The accumulation of reactive oxygen species (ROS, for example H2O2) is linked to several chronic pathologies, including cancer and cardiovascular and neurodegenerative diseases (Gate, L., Paul, J., Ba, G. N., Tew, K. D., and Tapiero, H. (1999) Biomed. Pharmacother. 53, 169 180). Protein kinase C (PKC) gamma is a unique isoform of PKC that is found in neuronal cells and eye tissues. This isoform is activated by ROS such as H2O2. Mutations (H101Y, G118D, S119P, and G128D) in the PKC gamma Cys-rich C1B domain caused a form of dominant non-episodic cerebellar ataxia in humans (Chen, D.-H., Brkanac, Z., Verlinde, C. L. M. J., Tan, X.-J., Bylenok, L., Nochli, D., Matsushita, M., Lipe, H., Wolff, J., Fernandez, M., Cimino, P. J., Bird, T. D., and Raskind, W. H. (2003) Am. J. Hum. Genet. 72, 839-849; van de Warrenburg, B. P. C., Verbeek, D. S., Piersma, S. J., Hennekam, F. A. M., Pearson, P. L., Knoers, N. V. A. M., Kremer, H. P. H., and Sinke, R. J. (2003) Neurology 61, 1760-1765). This could be due to a failure of the mutant PKC gamma proteins to be activated by ROS and to subsequently inhibit gap junctions. The purpose of this study was to demonstrate the cellular mechanism of activation of PKC gamma by H2O2 and the resultant effects on gap junction activity. H2O2 stimulated PKC gamma enzyme activity independently of elevations in cellular diacylglycerol, the natural PKC activator. Okadaic acid, a phosphatase inhibitor, did not affect H2O2-stimulated PKC gamma activity, indicating that dephosphorylation was not involved. The reductant, dithiothreitol, abolished the effects of H2O2, suggesting a direct oxidation of PKC gamma at the Cys-rich C1 domain. H2O2 induced the C1 domain of PKC gamma to translocate to plasma membranes, whereas the C2 domain did not. Direct effects of H2O2 on PKC gamma were demonstrated using two-dimensional SDS-PAGE. Results demonstrated that PKC gamma formed disulfide bonds in response to H2O2. H2O2-activated PKC gamma was targeted into caveolin-1- and connexin 43-containing lipid rafts, and the PKC gamma phosphorylated the connexin 43 gap junction proteins on Ser-368. This resulted in disassembly of connexin 43 gap junction plaques and decreased gap junction activity. Results suggested that H2O2 caused oxidation of the C1 domain, activation of the PKC gamma, and inhibition of gap junctions. This inhibition of gap junctions could provide a protection to cells against oxidative stress.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Takemoto, DJ (corresponding author), Kansas State Univ, Dept Biochem, 103 Willard Hall, Manhattan, KS 66506 USA.	dtak@ksu.edu		Lin, Dingbo/0000-0002-7441-8210	NATIONAL EYE INSTITUTE [R01EY013421] Funding Source: NIH RePORTER; NEI NIH HHS [EY13421] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Aronowski J, 2000, J CEREBR BLOOD F MET, V20, P343, DOI 10.1097/00004647-200002000-00016; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; CARDELL M, 1993, J NEUROCHEM, V61, P1308, DOI 10.1111/j.1471-4159.1993.tb13623.x; Chen DH, 2003, AM J HUM GENET, V72, P839, DOI 10.1086/373883; Chen KCW, 2004, EXP EYE RES, V78, P1057, DOI 10.1016/j.exer.2004.02.004; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Cho JH, 2002, CARCINOGENESIS, V23, P1163, DOI 10.1093/carcin/23.7.1163; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; Garcia L, 2002, FEBS LETT, V523, P90, DOI 10.1016/S0014-5793(02)02950-2; Gate L, 1999, BIOMED PHARMACOTHER, V53, P169, DOI 10.1016/S0753-3322(99)80086-9; Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200; Hering H, 2003, J NEUROSCI, V23, P3262; Hoffmann JH, 2004, EMBO J, V23, P160, DOI 10.1038/sj.emboj.7600016; Hossain MZ, 1999, J CELL PHYSIOL, V179, P87, DOI 10.1002/(SICI)1097-4652(199904)179:1<87::AID-JCP11>3.0.CO;2-K; Huang RP, 1999, CARCINOGENESIS, V20, P485, DOI 10.1093/carcin/20.3.485; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; KOLB H, 1993, VISUAL NEUROSCI, V10, P341, DOI 10.1017/S0952523800003734; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lewis S, 2001, MOL VIS, V7, P164; Lin D, 2004, MOL VIS, V10, P688; Lin DB, 2003, INVEST OPHTH VIS SCI, V44, P5259, DOI 10.1167/iovs.03-0296; Lin DB, 2003, INVEST OPHTH VIS SCI, V44, P1160, DOI 10.1167/iovs.02-0737; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; MAO JR, 1995, BRAIN RES, V677, P257, DOI 10.1016/0006-8993(95)00161-I; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Milton NGN, 2004, DRUG AGING, V21, P81, DOI 10.2165/00002512-200421020-00002; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nguyen TA, 2003, EXP EYE RES, V76, P565, DOI 10.1016/S0014-4835(03)00049-6; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohsawa M, 2001, EUR J PHARMACOL, V429, P157, DOI 10.1016/S0014-2999(01)01317-6; Pawelczyk T, 2000, MOL CELL BIOCHEM, V209, P69, DOI 10.1023/A:1007063331593; Rouach N, 2004, GLIA, V45, P28, DOI 10.1002/glia.10300; Saleh SM, 2000, EXP EYE RES, V71, P99, DOI 10.1006/exer.2000.0847; Saleh SM, 2001, MOL VIS, V7, P240; Shamloo M, 1999, NEUROREPORT, V10, P931, DOI 10.1097/00001756-199904060-00007; Shaw AR, 2003, CURR OPIN MOL THER, V5, P294; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; Stevanin G, 2004, ARCH NEUROL-CHICAGO, V61, P1242, DOI 10.1001/archneur.61.8.1242; Stone JR, 2004, ARCH BIOCHEM BIOPHYS, V422, P119, DOI 10.1016/j.abb.2003.12.029; Todt I, 2001, J MEMBRANE BIOL, V181, P107, DOI 10.1007/s00232001-0014-4; van de Warrenburg BPC, 2003, NEUROLOGY, V61, P1760, DOI 10.1212/01.WNL.0000098883.79421.73; VOET D, 2004, BIOCH BIOMOLECULES M, V1; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wagner LM, 2002, MOL VIS, V8, P59; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yamamoto T, 2000, BIOCHEM BIOPH RES CO, V273, P960, DOI 10.1006/bbrc.2000.3048; Zhou JZ, 2003, J BIOL CHEM, V278, P5388, DOI 10.1074/jbc.M209695200	59	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13682	13693		10.1074/jbc.M407762200	http://dx.doi.org/10.1074/jbc.M407762200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15642736	hybrid, Green Submitted			2022-12-27	WOS:000228095500063
J	Vantler, M; Caglayan, E; Zimmermann, WH; Baumer, AT; Rosenkranz, S				Vantler, M; Caglayan, E; Zimmermann, WH; Baumer, AT; Rosenkranz, S			Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells - Only phosphatidylinositol 3 '-kinase is important	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-SUBUNIT; PROTEIN-KINASE-C; BCL-2 PHOSPHORYLATION; OXIDATIVE STRESS; SURVIVAL PATHWAY; MATRIX ADHESION; DEATH; RAS; AKT; ACTIVATION	Peptide growth factors contribute to the pathogenesis of cardiovascular diseases by inducing a variety of cellular responses including anti- apoptotic effects. Several of the signaling molecules that are activated by growth factor receptors such as Src family kinases ( Src), phosphatidylinositol 3 '- kinase ( PI3K), phospholipase C gamma ( PLC gamma), Ras, and SHP- 2 were shown to mediate survival signals. We systematically investigated the relative contribution of each signaling molecule for growth factor-dependent cell survival in vascular smooth muscle cells ( VSMC). Our approach was the use of mutated platelet-derived growth factor ( PDGF) beta- receptors ( beta PDGFR) in which the tyrosine residues required for binding of each signaling molecule were individually mutated to phenylalanine. To bypass endogenous PDGFR in VSMC we used chimeric receptors ( ChiRs), containing the extracellular domain of the macrophage colony- stimulating factor ( M- CSF) receptor and the cytoplasmic domain of the wild type ( WT) or mutated beta PDGFR. Selective activation of the ChiR- WT with M- CSF significantly reduced apoptosis to the same extent as PDGF- BB in non- transfected cells. Deletion of the binding site for PI3K, but not for Src, RasGAP, SHP- 2, or PLC gamma, completely abolished the anti- apoptotic effect. Consistently, a ChiR mutant that only binds PI3K was fully able to mediate cell survival as efficiently as the ChiR- WT. Furthermore, the PDGF- dependent anti- apoptotic effect in non- transfected cells was completely abolished by the PI3K inhibitor wortmannin, whereas inhibitors of Src, PLC gamma, ERK, or p38 MAP kinase had no effect. The exploration of downstream signaling events revealed that PDGF- BB activates the anti- apoptotic Akt signaling pathway in a PI3K- dependent manner. Moreover, Akt phosphorylates and thus inactivates the pro- apoptotic proteins BAD and Forkhead transcription factors ( FKHR, FKHRL1). We conclude that growth factor- dependent cell survival in VSMC is mediated only by activation of the PI3K/ Akt pathway, whereas all other receptor- associated signaling molecules do not play a significant role.	Univ Cologne, Innere Med Klin 3, D-50924 Cologne, Germany; Univ Cologne, CMMC, D-50924 Cologne, Germany; Univ Hamburg, Hosp Eppendorf, Inst Expt & Klin Pharmakol, D-20246 Hamburg, Germany	University of Cologne; University of Cologne; University of Hamburg	Rosenkranz, S (corresponding author), Univ Cologne, Innere Med Klin 3, Kerpener Str 62, D-50924 Cologne, Germany.	Stephan.Rosenkranz@medizin.uni-koeln.de	Zimmermann, Wolfram-Hubertus H/I-6838-2012; Caglayan, Evren/ABB-8674-2020	Zimmermann, Wolfram-Hubertus H/0000-0003-1190-4040; 				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Bai XC, 2002, BIOCHEM J, V363, P395, DOI 10.1042/0264-6021:3630395; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Chattopadhyay A, 2002, J CELL SCI, V115, P2233; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GENG YJ, 1995, AM J PATHOL, V147, P251; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Godar DE, 1999, J INVEST DERM SYMP P, V4, P17, DOI 10.1038/sj.jidsp.5640175; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jung F, 2000, CARDIOVASC RES, V48, P148, DOI 10.1016/S0008-6363(00)00152-8; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; STONEMAN VE, 2004, CLIN SCI, V1, P1; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	42	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14168	14176		10.1074/jbc.M413310200	http://dx.doi.org/10.1074/jbc.M413310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15640155	hybrid			2022-12-27	WOS:000228095500120
J	Bandyopadhyay, BC; Swaim, WD; Liu, XB; Redman, RS; Patterson, RL; Ambudkar, IS				Bandyopadhyay, BC; Swaim, WD; Liu, XB; Redman, RS; Patterson, RL; Ambudkar, IS			Apical localization of a functional TRPC3/TRPC6-Ca2+-signaling complex in polarized epithelial cells - Role in apical Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR POTENTIAL CHANNELS; SIGNALING COMPLEX; TRPC3 CHANNELS; PROTEIN; ENTRY; TRISPHOSPHATE; ORGANIZATION; ACTIVATION; EXPRESSION; SECRETION	Receptor-coupled [Ca2+](i) increase is initiated in the apical region of epithelial cells and has been associated with apically localized Ca2+-signaling proteins. However, localization of Ca2+ channels that are regulated by such Ca2+-signaling events has not yet been established. This study examines the localization of TRPC channels in polarized epithelial cells and demonstrates a role for TRPC3 in apical Ca2+ uptake. Endogenously and exogenously expressed TRPC3 was localized apically in polarized Madin-Darby canine kidney cells (MDCK) and salivary gland epithelial cells. In contrast, TRPC1 was localized basolaterally, whereas TRPC6 was detected in both locations. Localization of G alpha(q/11), inositol 1,4,5-trisphosphate receptor-3, and phospholipase C beta 1 and -beta 2 was also predominantly apical. TRPC3 co-immunoprecipitated with endogenous TRPC6, phospholipase C beta s, G alpha(q/11), inositol 1,4,5-trisphosphate receptor-3, and syntaxin 3 but not with TRPC1. Furthermore, 1-oleoyl-2-acetyl-sn-glycerol (OAG)-stimulated apical Ca-45(2+) uptake was higher in TRPC3-MDCK cells compared with control (MDCK) cells. Bradykinin-stimulated apical Ca-45(2+) uptake and transepithelial Ca-45(2+) flux were also higher in TRPC3-expressing cells. Consistent with this, OAG induced [Ca2+](i) increase in the apical, but not basal, region of TRPC3-MDCK cells that was blocked by EGTA addition to the apical medium. Most importantly, (i) TRPC3 was detected in the apical region of rat submandibular gland ducts, whereas TRPC6 was present in apical as well as basolateral regions of ducts and acini; and (ii) OAG stimulated Ca2+ influx into dispersed ductal cells. These data demonstrate functional localization of TRPC3/TRPC6 channels in the apical region of polarized epithelial cells. In salivary gland ducts this could contribute to the regulation of salivary [Ca2+] and secretion.	NIDCR, Gene Therapy & Therapeut Branch, Secretory Physiol Sect, NIH, Bethesda, MD 20892 USA; Dept Vet Affairs Med Ctr, Oral Pathol Res Lab, Washington, DC 20422 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ambudkar, IS (corresponding author), NIDCR, Gene Therapy & Therapeut Branch, Secretory Physiol Sect, NIH, Bldg 10,Rm N-113, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov	Bandyopadhyay, Bidhan/AAC-6828-2022	Bandyopadhyay, Bidhan/0000-0003-2364-8945	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Beech DJ, 2003, CELL CALCIUM, V33, P433, DOI 10.1016/S0143-4160(03)00054-X; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bird GSJ, 1998, EUR J MORPHOL, V36, P153; Bootman MD, 2001, J CELL SCI, V114, P2213; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Grases F, 2003, CLIN CHIM ACTA, V334, P131, DOI 10.1016/S0009-8981(03)00227-4; He XJ, 1998, PFLUG ARCH EUR J PHY, V435, P375, DOI 10.1007/s004240050526; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 2002, ADV EXP MED BIOL, V506, P175; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; LEE MG, 1997, J BIOL CHEM, V27; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; LOPEZBURILLO S, 1988, BIOCHIM BIOPHYS ACTA, V939, P335, DOI 10.1016/0005-2736(88)90078-8; Luo X, 1999, AM J PHYSIOL-CELL PH, V277, pC205, DOI 10.1152/ajpcell.1999.277.2.C205; Mandon B, 1997, AM J PHYSIOL-RENAL, V273, pF718, DOI 10.1152/ajprenal.1997.273.5.F718; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MONTELL C, 2001, SCIENCE STKE; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Muallem S, 1999, CELL CALCIUM, V26, P173, DOI 10.1054/ceca.1999.0077; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nijenhuis T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8; Nilius B, 2003, ENDOTHELIUM-J ENDOTH, V10, P5, DOI 10.1080/10623320303356; Petersen OH, 2003, CELL CALCIUM, V33, P337, DOI 10.1016/S0143-4160(03)00047-2; Petersen OH, 2000, J KOREAN MED SCI, V15, pS44, DOI 10.3346/jkms.2000.15.S.S44; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; SIMMONS NL, 1992, J PHYSIOL-LONDON, V447, P1; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246	41	77	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12908	12916		10.1074/jbc.M410013200	http://dx.doi.org/10.1074/jbc.M410013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15623527	hybrid			2022-12-27	WOS:000227922000100
J	Carver, TE; Bordeau, B; Cummings, MD; Petrella, EC; Pucci, MJ; Zawadzke, LE; Dougherty, BA; Tredup, JA; Bryson, JW; Yanchunas, J; Doyle, ML; Witmer, MR; Nelen, MI; DesJarlais, RL; Jaeger, EP; Devine, H; Asel, ED; Springer, BA; Bone, R; Salemme, FR; Todd, MJ				Carver, TE; Bordeau, B; Cummings, MD; Petrella, EC; Pucci, MJ; Zawadzke, LE; Dougherty, BA; Tredup, JA; Bryson, JW; Yanchunas, J; Doyle, ML; Witmer, MR; Nelen, MI; DesJarlais, RL; Jaeger, EP; Devine, H; Asel, ED; Springer, BA; Bone, R; Salemme, FR; Todd, MJ			Decrypting the biochemical function of an essential gene from Streptococcus pneumoniae using ThermoFluor (R) technology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID; AMINOTRANSFERASE; ENZYME	The protein product of an essential gene of unknown function from Streptococcus pneumoniae was expressed and purified for screening in the ThermoFluor (R) affinity screening assay. This assay can detect ligand binding to proteins of unknown function. The recombinant protein was found to be in a dimeric, native-like folded state and to unfold cooperatively. ThermoFluor was used to screen the protein against a library of 3000 compounds that were specifically selected to provide information about possible biological functions. The results of this screen identified pyridoxal phosphate and pyridoxamine phosphate as equilibrium binding ligands (K-d similar to 50 pM, K-d similar to 2.5 mu M, respectively), consistent with an enzymatic cofactor function. Several nucleotides and nucleotide sugars were also identified as ligands of this protein. Sequence comparison with two enzymes of known structure but relatively low overall sequence homology established that several key residues directly involved in pyridoxal phosphate binding were strictly conserved. Screening a collection of generic drugs and natural products identified the antifungal compound canescin A as an irreversible covalent modifier of the enzyme. Our investigation of this protein indicates that its probable biological role is that of a nucleoside diphospho-keto-sugar aminotransferase, although the preferred keto-sugar substrate remains unknown. These experiments demonstrate the utility of a generic affinity-based ligand binding technology in decrypting possible biological functions of a protein, an approach that is both independent of and complementary to existing genomic and proteomic technologies.	Johnson & Johnson Pharmaceut Res & Dev LLC, Exton, PA 19341 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA	Johnson & Johnson; Johnson & Johnson USA; Bristol-Myers Squibb; Bristol-Myers Squibb	Todd, MJ (corresponding author), Johnson & Johnson Pharmaceut Res & Dev LLC, 665 Stockton Dr, Exton, PA 19341 USA.	Mcumming@prdus.jnj.com; Mtodd3@prdus.jnj.com		Doyle, Michael/0000-0003-4569-6315				Adam GC, 2002, MOL CELL PROTEOMICS, V1, P781, DOI 10.1074/mcp.R200006-MCP200; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Angawi RF, 2003, J NAT PROD, V66, P1259, DOI 10.1021/np0301285; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; Chan Pan F., 2002, Current Drug Targets - Infectious Disorders, V2, P291, DOI 10.2174/1568005023342227; CHOI SY, 1992, BIOFACTORS, V3, P191; Doyle ML, 2003, J BIOL CHEM, V278, P9426, DOI 10.1074/jbc.M209220200; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; INOUE Y, 1989, J BIOL CHEM, V264, P9673; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; Kim CG, 1998, J BIOL CHEM, V273, P6030, DOI 10.1074/jbc.273.11.6030; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; MacBeath G, 1999, J AM CHEM SOC, V121, P7967, DOI 10.1021/ja991083q; MATULIS D, 2005, IN PRESS BIOCH; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; PATTE JC, 1980, MOL GEN GENET, V179, P319, DOI 10.1007/BF00425459; Percudani R, 2003, EMBO REP, V4, P850, DOI 10.1038/sj.embor.embor914; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; Smith C, 2004, NATURE, V428, P225, DOI 10.1038/428225a; Smith HE, 1999, FEMS MICROBIOL LETT, V178, P265, DOI 10.1111/j.1574-6968.1999.tb08686.x; Strausberg RL, 2003, SCIENCE, V300, P294, DOI 10.1126/science.1083395; Thanassi JA, 2002, NUCLEIC ACIDS RES, V30, P3152, DOI 10.1093/nar/gkf418; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; TONEY MD, 1993, BIOCHEMISTRY-US, V32, P1471, DOI 10.1021/bi00057a010; Williams C, 2000, CURR OPIN BIOTECH, V11, P42, DOI 10.1016/S0958-1669(99)00053-1; Yakunin AF, 2004, CURR OPIN CHEM BIOL, V8, P42, DOI 10.1016/j.cbpa.2003.12.003	31	52	56	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11704	11712		10.1074/jbc.M413278200	http://dx.doi.org/10.1074/jbc.M413278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15634672	hybrid			2022-12-27	WOS:000227761800099
J	Chatterjee, A; Mridula, P; Mishra, RK; Mittal, R; Hosur, RV				Chatterjee, A; Mridula, P; Mishra, RK; Mittal, R; Hosur, RV			Folding regulates autoprocessing of HIV-1 protease precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-MAGNETIC-RESONANCE; NMR CHEMICAL-SHIFTS; GAG-POL POLYPROTEIN; TRANSFRAME PROTEIN; TYPE-1 PROTEASE; DYNAMIC CHARACTERIZATION; RETROVIRAL PROTEASES; VIRAL INFECTIVITY; UNFOLDED PROTEINS	Autoprocessing of HIV-1 protease ( PR) precursors is a crucial step in the generation of the mature protease. Very little is known regarding the molecular mechanism and regulation of this important process in the viral life cycle. In this context we report here the first and complete residue level investigations on the structural and folding characteristics of the 17-kDa precursor TFR-PR-C-nn ( 161 residues) of HIV-1 protease. The precursor shows autoprocessing activity indicating that the solution has a certain population of the folded active dimer. Removal of the 5-residue extension, C-nn at the C-terminal of PR enhanced the activity to some extent. However, NMR structural characterization of the precursor containing a mutation, D25N in the PR at pH 5.2 and 32 degrees C under different conditions of partial and complete denaturation by urea, indicate that the precursor has a high tendency to be unfolded. The major population in the ensemble displays some weak folding propensities in both the TFR and the PR regions, and many of these in the PR region are the non-native type. As both D25N mutant and wild-type PR are known to fold efficiently to the same native dimeric form, we infer that TFR cleavage enables removal of the non-native type of preferences in the PR domain to cause constructive folding of the protein. These results indicate that intrinsic structural and folding preferences in the precursor would have important regulatory roles in the autoprocessing reaction and generation of the mature enzyme.	Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India; Tata Inst Fundamental Res, Dept Sci Biol, Bombay 400005, Maharashtra, India	Tata Institute of Fundamental Research (TIFR); Tata Institute of Fundamental Research (TIFR)	Hosur, RV (corresponding author), Tata Inst Fundamental Res, Dept Chem Sci, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.	hosur@tifr.res.in	Mishra, Ram/ABA-6071-2020; Mishra, Ram/AAJ-1538-2020	Mishra, Ram/0000-0002-9528-0476; 				Beissinger M, 1996, EUR J BIOCHEM, V237, P383, DOI 10.1111/j.1432-1033.1996.0383k.x; Bhavesh NS, 2003, J BIOL CHEM, V278, P19980, DOI 10.1074/jbc.M301615200; Bhavesh NS, 2001, BIOCHEMISTRY-US, V40, P14727, DOI 10.1021/bi015683p; BURSTEIN H, 1992, J VIROL, V66, P1781, DOI 10.1128/JVI.66.3.1781-1785.1992; CANDOTTI D, 1994, CR ACAD SCI III-VIE, V317, P183; DARKE PL, 1989, J BIOL CHEM, V264, P2307; Dautin N, 2003, J VIROL, V77, P8216, DOI 10.1128/JVI.77.15.8216-8226.2003; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; Dyson HJ, 2002, ADV PROTEIN CHEM, V62, P311; Dyson HJ, 2001, METHOD ENZYMOL, V339, P258; Eliezer D, 2000, BIOCHEMISTRY-US, V39, P2894, DOI 10.1021/bi992545f; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; FESIK SW, 1990, Q REV BIOPHYS, V23, P97, DOI 10.1017/S0033583500005515; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200; Juneja J, 2003, CURR SCI INDIA, V84, P157; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARACOSTAS V, 1993, VIROLOGY, V193, P661, DOI 10.1006/viro.1993.1174; KAY J, 1990, BIOCHIM BIOPHYS ACTA, V1048, P1, DOI 10.1016/0167-4781(90)90015-T; Kazmirski SL, 2001, P NATL ACAD SCI USA, V98, P4349, DOI 10.1073/pnas.071054398; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; LEGRICE SFJ, 1988, EMBO J, V7, P2547, DOI 10.1002/j.1460-2075.1988.tb03103.x; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; Louis JM, 2003, J BIOL CHEM, V278, P6085, DOI 10.1074/jbc.M209726200; Louis JM, 1999, NAT STRUCT BIOL, V6, P868; Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Panchal SC, 2001, J BIOMOL NMR, V20, P135, DOI 10.1023/A:1011239023422; Panchal SC, 2000, CURR SCI INDIA, V79, P1684; PARTIN K, 1991, P NATL ACAD SCI USA, V88, P4776, DOI 10.1073/pnas.88.11.4776; Paulus C, 1999, J BIOL CHEM, V274, P21539, DOI 10.1074/jbc.274.31.21539; Penkett CJ, 1997, J MOL BIOL, V274, P152, DOI 10.1006/jmbi.1997.1369; Pettit SC, 2004, J VIROL, V78, P8477, DOI 10.1128/JVI.78.16.8477-8485.2004; Pillai B, 2001, PROTEINS, V43, P57, DOI 10.1002/1097-0134(20010401)43:1<57::AID-PROT1017>3.0.CO;2-D; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; ROSE JR, 1995, J VIROL, V69, P2751; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; Schwarzinger S, 2002, BIOCHEMISTRY-US, V41, P12681, DOI 10.1021/bi020381o; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; Shortle DR, 1996, CURR OPIN STRUC BIOL, V6, P24, DOI 10.1016/S0959-440X(96)80091-1; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P166; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i	57	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11369	11378		10.1074/jbc.M412603200	http://dx.doi.org/10.1074/jbc.M412603200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15632156	hybrid			2022-12-27	WOS:000227761800059
J	Comayras, R; Jungas, C; Lavergne, J				Comayras, R; Jungas, C; Lavergne, J			Functional consequences of the organization of the photosynthetic apparatus in Rhodobacter sphaeroides - II. A study of PufX(-) membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CYTOCHROME BC(1) COMPLEX; ELECTRON-TRANSFER; CORE COMPLEX; RHODOSPIRILLUM-RUBRUM; RHODOPSEUDOMONAS-SPHAEROIDES; SUPRAMOLECULAR ORGANIZATION; ALPHA-POLYPEPTIDE; NATIVE MEMBRANES; REACTION CENTERS	In the bacterium R. sphaeroides, the polypeptide PufX is indispensable for photosynthetic growth. Its deletion is known to have important consequences on the organization of the photosynthetic apparatus. In the wildtype strain, complexes between the reaction center (RC) and the antenna (light-harvesting complex 1 (LH1)) are associated in dimers, and LH1 does not fully encircle the RC. In the absence of PufX, the complexes become monomeric, and the LH1 ring closes around the RC. We analyzed the functional consequences of PufX deletion. Some effects can be ascribed to the monomerization of the RC(.)LH1 complexes: the number of RCs that share a common antenna for excitation transfer or a common quinone pool become smaller. We examined the kinetic effects of the closed LH1 ring on quinone turnover: diffusion across LH1 entails a delay of similar to 1 ms, and the barrier appears to be located directly against the quinone-binding (secondary quinone acceptor (Q(B))) pocket. The diffusion of ubiquinol from the RC to the cytochrome bc(1) complex is similar to 2-fold slower in the mutant, suggesting an increased distance between the two complexes. The properties of the Q(B) pocket (binding of inhibitors, stabilization of Q(B)(-), and rate of Q(B)-H-2 formation) appear to be modified in the mutant. Another specificity of PufX(-) is the accumulation of closed centers in the Q(A)(-) (where Q(A) is the primary quinone acceptor) state as the secondary acceptor pool becomes reduced, which is probably the origin of photosynthetic incompetence. We suggest that this is related to the Q(B) pocket alterations. The malfunction of the reaction center is probably due to a faulty association with LH1 that is prevented in the PufX- containing structure.	CEA Cadarache, Dept Ecophysiol Vegetale & Microbiol, UMR 6191, CNRS Commissariat Energie Atom Aix Marseille 2, F-13108 St Paul Les Durance, France	CEA	Lavergne, J (corresponding author), CEA Cadarache, Dept Ecophysiol Vegetale & Microbiol, UMR 6191, CNRS Commissariat Energie Atom Aix Marseille 2, F-13108 St Paul Les Durance, France.	jerome.lavergne@cea.fr						Bahatyrova S, 2004, NATURE, V430, P1058, DOI 10.1038/nature02823; BARZ WP, 1995, BIOCHEMISTRY-US, V34, P15248, DOI 10.1021/bi00046a033; BARZ WP, 1995, BIOCHEMISTRY-US, V34, P15235, DOI 10.1021/bi00046a032; COMAYRAS F, 2005, PHOTOSYNTHESIS FUNDA; Comayras R, 2005, J BIOL CHEM, V280, P11203, DOI 10.1074/jbc.M412088200; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; DUTTON PL, 1972, EUR J BIOCHEM, V30, P495, DOI 10.1111/j.1432-1033.1972.tb02121.x; Fotiadis D, 2004, J BIOL CHEM, V279, P2063, DOI 10.1074/jbc.M310382200; Francia F, 1999, BIOCHEMISTRY-US, V38, P6834, DOI 10.1021/bi982891h; Francia F, 2004, BIOCHEMISTRY-US, V43, P14199, DOI 10.1021/bi048629s; Francia F, 2002, EUR J BIOCHEM, V269, P1877, DOI 10.1046/j.1432-1033.2002.02834.x; GINET N, PHOTOSYNTHESIS FUNDA; Guergova-Kuras M, 1999, PROTEIN EXPRES PURIF, V15, P370, DOI 10.1006/prep.1998.1018; Jamieson SJ, 2002, EMBO J, V21, P3927, DOI 10.1093/emboj/cdf410; JOLIOT A, 1964, CR HEBD ACAD SCI, V258, P4622; Joliot P, 1997, BBA-BIOENERGETICS, V1318, P374, DOI 10.1016/S0005-2728(96)00114-4; JOLIOT P, 2005, IN PRESS BIOCH BIOPH; Jungas C, 1999, EMBO J, V18, P534, DOI 10.1093/emboj/18.3.534; Kramer H, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P89; Lavergen J, 1999, BIOCHEMISTRY-US, V38, P4542, DOI 10.1021/bi9827621; LAVERGNE J, 1995, BIOPHYS J, V68, P2474, DOI 10.1016/S0006-3495(95)80429-7; Lavergne J, 1996, PHOTOSYNTH RES, V48, P127, DOI 10.1007/BF00041003; MCGLYNN P, 1994, FEBS LETT, V349, P349, DOI 10.1016/0014-5793(94)00701-2; McGlynn P, 1996, J BIOL CHEM, V271, P3285, DOI 10.1074/jbc.271.6.3285; PAILLOTIN G, 1972, J THEOR BIOL, V36, P223, DOI 10.1016/0022-5193(72)90094-X; Pugh RJ, 1998, BBA-BIOENERGETICS, V1366, P301, DOI 10.1016/S0005-2728(98)00131-5; Recchia PA, 1998, BIOCHEMISTRY-US, V37, P11055, DOI 10.1021/bi980657l; Roszak AW, 2003, SCIENCE, V302, P1969, DOI 10.1126/science.1088892; ROTT MA, 1993, J BACTERIOL, V175, P358, DOI 10.1128/JB.175.2.358-366.1993; RUTHERFORD AW, 1980, FEBS LETT, V110, P257, DOI 10.1016/0014-5793(80)80086-X; Scheuring S, 2004, J BIOL CHEM, V279, P3620, DOI 10.1074/jbc.M310050200; Scheuring S, 2004, P NATL ACAD SCI USA, V101, P11293, DOI 10.1073/pnas.0404350101; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; Siebert CA, 2004, EMBO J, V23, P690, DOI 10.1038/sj.emboj.7600092; Tiede DM, 1996, BIOCHEMISTRY-US, V35, P10763, DOI 10.1021/bi9605907; Vermeglio A, 2002, BBA-BIOENERGETICS, V1555, P60, DOI 10.1016/S0005-2728(02)00255-4; VERMEGLIO A, 1982, FUNCTION QUINONES EN, P169; WRAIGHT CA, 1979, BIOCHIM BIOPHYS ACTA, V548, P309, DOI 10.1016/0005-2728(79)90138-5	38	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11214	11223		10.1074/jbc.M412089200	http://dx.doi.org/10.1074/jbc.M412089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15632163	hybrid			2022-12-27	WOS:000227761800042
J	Kobayashi, H; Tanaka, N; Asao, H; Miura, S; Kyuuma, M; Semura, K; Ishii, N; Sugamura, K				Kobayashi, H; Tanaka, N; Asao, H; Miura, S; Kyuuma, M; Semura, K; Ishii, N; Sugamura, K			Hrs, a mammalian master molecule in vesicular transport and protein sorting, suppresses the degradation of ESCRT proteins signal transducing adaptor molecule 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ZINC-FINGER DOMAIN; E VPS PROTEINS; EARLY ENDOSOMES; UBIQUITINATED PROTEINS; JANUS KINASES; FACTOR BRN-2; CELL-GROWTH; CLATHRIN; BINDING	The degradation and sorting of cytoplasmic and cell-surface proteins are crucial steps in the control of cellular functions. We previously identified three mammalian Vps (vacuolar protein sorting) proteins, Hrs (hepatocyte growth factor-regulated tyrosine kinase substrate) and signal transducing adaptor molecule (STAM) 1 and -2, which are tyrosine-phosphorylated upon cytokine/ growth factor stimulation. Hrs and the STAMs each contain a ubiquitin-interacting motif and through formation of a complex are involved in the vesicle transport of early endosomes. To explore the mechanism and cellular function of this complex in mammalian cells, we established an Hrs-defective fibroblastoid cell line (hrs(-/-)); embryos with this genotype died in utero. In the hrs(-/-) cells only trace amounts of STAM1 and STAM2 were detected. Introduction of wild-type Hrs or an Hrs mutant with an intact STAM binding domain (Hrs-dFYVE) fully restored STAM1 and STAM2 expression, whereas mutants with no STAM binding ability (Hrs-dC2, Hrs-dM) failed to express the STAMs. This regulated control of STAM expression by Hrs was independent of transcription. Interestingly, STAM1 degradation was mediated by proteasomes and was partially dependent on the ubiquitin-interacting motif of STAM1. Revertant Hrs expression in hrs(-/-) cells not only led to the accumulation of ubiquitinated proteins, including intracytoplasmic vesicles, but also restored STAM1 levels in early endosomes and eliminated the enlarged endosome phenotype caused by the absence of Hrs. These results suggest that Hrs is a master molecule that controls in part the degradation of STAM1 and the accumulation of ubiquitinated proteins.	Tohoku Univ, Grad Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808575, Japan; Yamagata Univ, Sch Med, Dept Immunol, Yamagata 9909585, Japan; Toho Univ, Sch Med, Dept Urol 1, Ota Ku, Tokyo 1438541, Japan	Tohoku University; Tohoku University; Yamagata University	Tanaka, N (corresponding author), Tohoku Univ, Grad Sch Med, Dept Microbiol & Immunol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	n-tanaka@mail.tains.tohoku.ac.jp						Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Hansen K, 1997, FEBS LETT, V409, P195, DOI 10.1016/S0014-5793(97)00495-X; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Mizuno E, 2004, J BIOCHEM, V135, P385, DOI 10.1093/jb/mvh046; Mizuno E, 2003, MOL BIOL CELL, V14, P3675, DOI 10.1091/mbc.E02-12-0823; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Onodera J, 2004, J BIOL CHEM, V279, P16071, DOI 10.1074/jbc.M312706200; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Tanaka N, 2002, EMBO REP, V3, P785, DOI 10.1093/embo-reports/kvf153; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Yamada M, 2002, MOL CELL BIOL, V22, P8648, DOI 10.1128/MCB.22.24.8648-8658.2002; Yamada M, 2001, MOL CELL BIOL, V21, P3807, DOI 10.1128/MCB.21.11.3807-3819.2001; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	44	39	42	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10468	10477		10.1074/jbc.M409969200	http://dx.doi.org/10.1074/jbc.M409969200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640163	hybrid			2022-12-27	WOS:000227559600089
J	Rayner, BS; Wu, BJ; Raftery, M; Stocker, R; Witting, PK				Rayner, BS; Wu, BJ; Raftery, M; Stocker, R; Witting, PK			Human S-nitroso oxymyoglobin is a store of vasoactive nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NO-CENTER-DOT; HUMAN MYOGLOBIN; ALPHA-TOCOPHEROL; HUMAN PLASMA; HEME IRON; OXYGEN; TRANSNITROSATION; IDENTIFICATION; HEMOGLOBIN; CYSTEINE	Nitric oxide ((NO)-N-center dot) regulates vascular function, and myoglobin (Mb) is a heme protein present in skeletal, cardiac, and smooth muscle, where it facilitates O-2 transfer. Human ferric Mb binds (NO)-N-center dot to yield nitrosylheme and S-nitroso (S-NO) Mb (Witting, P. K., Douglas, D. J., and Mauk, A. G. (2001) J. Biol. Chem. 276, 3991 3998). Here we show that human ferrous oxy-myoglobin (oxyMb) oxidizes (NO)-N-center dot, with a second order rate constant k = 2.8 +/- 0.1 x 10(7) M-1 (.)s(-1) as determined by stopped-flow spectroscopy. Mixtures containing oxyMb and S-nitrosoglutathione or S-nitrosocysteine added at 1.5- 2 moles of S-nitrosothiol/mol oxyMb yielded S-NO oxyMb through trans-nitrosation equilibria as confirmed with mass spectrometry. Rate constants for the equilibrium reactions were k(forward) = 110 +/- 3 and k(reverse) = 16 +/- 3 M(-1.)s(-1) for S- nitrosoglutathione and k(forward) = 293 +/- 5 and k(reverse) = 20 +/- 2 M(-1.)s(-1) for S- nitrosocysteine. Incubation of S- NO oxyMb with Cu2+ ions stimulated (NO)-N-center dot release as measured with a (NO)-N-center dot electrode. Similarly, Cu2+ released (NO)-N-center dot from Mb immunoprecipitated from cultured human vascular smooth muscle cells (VSMCs) that were pre-treated with diethylaminenonoate. No (NO)-N-center dot release was observed from VSMCs treated with vehicle alone or immunoprecipitates obtained from porcine aortic endothelial cells with and without diethylaminenonoate treatment. Importantly, pre-constricted aortic rings relaxed in the presence of S- NO oxyMb in a cyclic GMP-dependent process. These data indicate that human oxyMb rapidly oxidizes (NO)-N-center dot and that biologically relevant S- nitrosothiols can trans-(S)nitrosate human oxyMb. Furthermore, S-NO oxyMb can be isolated from cultured human VSMCs exposed to an exogenous (NO)-N-center dot donor at physiologic concentration. The potential biologic implications of S-NO oxyMb acting as a source of (NO)-N-center dot are discussed.	Concord Repatriat Gen Hosp, ANZAC Res Inst, Vasc Biol Grp, Concord, NSW 2139, Australia; Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Univ New S Wales, Biomed Mass Spectrometry Unit, Sydney, NSW 2052, Australia	Concord Repatriation General Hospital; University of Sydney; ANZAC Research Institute; University of New South Wales Sydney; University of New South Wales Sydney	Witting, PK (corresponding author), Concord Repatriat Gen Hosp, ANZAC Res Inst, Vasc Biol Grp, Hosp Rd, Concord, NSW 2139, Australia.	pwitting@anzac.edu.au	Stocker, Roland/AAV-4489-2021; Witting, Paul/ABD-2053-2020; Ekanayake, Kanchana/P-8817-2016; Research Institute, ANZAC/CAE-9030-2022; Witting, Paul/L-9786-2019	Witting, Paul/0000-0003-2237-7004; Wu, Ben/0000-0003-2826-4190				AlSadoni HH, 1997, BRIT J PHARMACOL, V121, P1047, DOI 10.1038/sj.bjp.0701218; Andriambeloson E, 2002, REDOX REP, V7, P131, DOI 10.1179/135100002125000361; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Brookes PS, 2003, J BIOL CHEM, V278, P31603, DOI 10.1074/jbc.M211784200; Brovkovych V, 1999, J PHARMACEUT BIOMED, V19, P135, DOI 10.1016/S0731-7085(98)00090-9; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; BRUNORI M, 2001, TRENDS BIOCHEM SCI, V26, P290; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; COLONNA G, 1982, BIOCHEMISTRY-US, V21, P212, DOI 10.1021/bi00531a002; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Enoki Y, 1998, COMP BIOCHEM PHYS B, V120, P183, DOI 10.1016/S0305-0491(98)10007-X; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Fujita S, 1998, CARDIOVASC RES, V38, P655, DOI 10.1016/S0008-6363(98)00051-0; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HAGLER L, 1979, J BIOL CHEM, V254, P6505; He GW, 2001, CIRCULATION, V104, pI344; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Hogg N, 1999, ANAL BIOCHEM, V272, P257, DOI 10.1006/abio.1999.4199; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; Hunter CL, 1997, BIOCHEMISTRY-US, V36, P1018, DOI 10.1021/bi961993+; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; Janero DR, 2004, P NATL ACAD SCI USA, V101, P16958, DOI 10.1073/pnas.0406075101; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Joshi MS, 2001, NITRIC OXIDE-BIOL CH, V5, P561, DOI 10.1006/niox.2001.0369; Jourd'heuil D, 2000, FREE RADICAL BIO MED, V28, P409, DOI 10.1016/S0891-5849(99)00257-9; JURGENS KD, 1994, P NATL ACAD SCI USA, V91, P3829, DOI 10.1073/pnas.91.9.3829; Kalyanaraman B, 1996, METHODS ENZYMOL, V268, P168; KATZ IR, 1984, J BIOL CHEM, V259, P7504; KEANEY JF, 1994, J CLIN INVEST, V93, P844, DOI 10.1172/JCI117039; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LUI X, 2004, AM J PHYSIOL-HEART C, V2874, pH2421; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; Muller B, 1996, BRIT J PHARMACOL, V119, P1281, DOI 10.1111/j.1476-5381.1996.tb16034.x; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; Papadopoulos S, 2001, P NATL ACAD SCI USA, V98, P5904, DOI 10.1073/pnas.101109798; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Qiu Y, 1998, J BIOL CHEM, V273, P23426, DOI 10.1074/jbc.273.36.23426; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Spencer NY, 2000, J BIOL CHEM, V275, P36562, DOI 10.1074/jbc.M005347200; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Tsikas D, 2002, J CHROMATOGR B, V772, P335, DOI 10.1016/S1570-0232(02)00121-6; Vanin AF, 2004, NITRIC OXIDE-BIOL CH, V10, P60, DOI 10.1016/j.niox.2004.02.005; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; Witting PK, 2002, BIOCHEMISTRY-US, V41, P11495, DOI 10.1021/bi025835w; Witting PK, 2001, J BIOL CHEM, V276, P3991, DOI 10.1074/jbc.M005758200; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhang H, 1996, ANAL BIOCHEM, V237, P141, DOI 10.1006/abio.1996.0212; Zhang J, 2001, AM J PHYSIOL-HEART C, V280, pH1318; Zhang Y, 2002, FREE RADICAL BIO MED, V32, P1212, DOI 10.1016/S0891-5849(02)00829-8; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	66	33	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9985	9993		10.1074/jbc.M410564200	http://dx.doi.org/10.1074/jbc.M410564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644316	hybrid			2022-12-27	WOS:000227559600031
J	Yun, H; Lee, M; Kim, SS; Ha, J				Yun, H; Lee, M; Kim, SS; Ha, J			RETRACTED: Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma (Retracted article. See vol. 293, pg. 18014, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							HYPOXIA-INDUCIBLE FACTOR-1; GENE-EXPRESSION; OXIDATIVE STRESS; O-2 HOMEOSTASIS; LKB1; CELLS; STABILIZATION; IDENTIFICATION; TRANSCRIPTION; HYPOGLYCEMIA	The induction of proangiogenic cytokines such as vascular endothelial growth factor (VEGF) is a critical feature of tumor angiogenesis. In the present study, we examined the mechanisms of VEGF gene expression induced by glucose deprivation in cancer cells, a role of AMP-activated protein kinase (AMPK) in the process, and the signal transduction pathway. AMPK functions as an energy sensor to provide metabolic adaptation under ATP-depleting conditions such as hypoxia and nutritional deprivation. Here, we show that glucose deprivation leads to a significant increase in the mRNA level of VEGF, GLUT1, and PFKFB3 genes in several cancer cells via a hypoxia-inducible factor-1-independent mechanism, and we demonstrate an essential role of AMPK in these gene expressions. Our data suggest that VEGF mRNA induction by glucose deprivation is due to an increase in mRNA stability, and the AMPK activity is necessary and sufficient to confer the stability to VEGF mRNA. We further show that reactive oxygen species is involved in glucose deprivation-induced AMPK activity in DU145 human prostate carcinomas, and c-Jun aminoterminal kinase acts as an upstream component in AMPK activation cascades under these conditions. LKB1, which was recently identified as a direct upstream kinase of AMPK, was not detected in DU145 cells. In conclusion, our results demonstrate a novel and major role of AMPK in the post-transcriptional regulation of VEGF, further implying its potential role in tumor angiogenesis.	Kyung Hee Univ, Coll Med, Dept Biochem & Mol Biol, Med Res Ctr Bioreact React Oxygen Species, Seoul 130701, South Korea	Kyung Hee University	Ha, J (corresponding author), Kyung Hee Univ, Coll Med, Dept Biochem & Mol Biol, Med Res Ctr Bioreact React Oxygen Species, Hoegi Dong 1, Seoul 130701, South Korea.	hajh@khu.ac.kr	Kim, Sung Soo/S-2540-2017	Kim, Sung Soo/0000-0002-6817-7668				Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; Berra E, 2000, CANCER METAST REV, V19, P139, DOI 10.1023/A:1026506011458; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; HA J, 1994, J BIOL CHEM, V269, P22162; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Levy AP, 1998, TRENDS CARDIOVAS MED, V8, P246, DOI 10.1016/S1050-1738(98)00020-6; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Onesto C, 2004, J BIOL CHEM, V279, P34217, DOI 10.1074/jbc.M400219200; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Singh P, 2004, MOL CELL BIOCHEM, V260, P153, DOI 10.1023/B:MCBI.0000026067.08356.13; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	41	125	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9963	9972		10.1074/jbc.M412994200	http://dx.doi.org/10.1074/jbc.M412994200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640157	hybrid			2022-12-27	WOS:000227559600028
J	Cole, NB; Murphy, DD; Lebowitz, J; Di Noto, L; Levine, RL; Nussbaum, RL				Cole, NB; Murphy, DD; Lebowitz, J; Di Noto, L; Levine, RL; Nussbaum, RL			Metal-catalyzed oxidation of alpha-synuclein - Helping to define the relationship between oligomers, protofibrils, and filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MULTIPLE SYSTEM ATROPHY; ATOMIC-FORCE MICROSCOPY; AMINO-ACID-RESIDUES; PARKINSONS-DISEASE; LEWY BODIES; IN-VITRO; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; CROSS-LINKING; INHIBITS FIBRILLATION	Oxidative stress is implicated in a number of neuro-degenerative diseases and is associated with the selective loss of dopaminergic neurons of the substantia nigra in Parkinson's disease. The role of alpha-synuclein as a potential target of intracellular oxidants has been demonstrated by the identification of posttranslational modifications of synuclein within intracellular aggregates that accumulate in Parkinson's disease brains, as well as the ability of a number of oxidative insults to induce synuclein oligomerization. The relationship between these relatively small soluble oligomers, potentially neurotoxic synuclein protofibrils, and synuclein filaments remains unclear. We have found that metal-catalyzed oxidation of alpha-synuclein inhibited formation of synuclein filaments with a concomitant accumulation of beta sheet-rich oligomers that may represent synuclein protofibrils. Similar results with a number of oxidative and enzymatic treatments suggest that the covalent association of synuclein into higher molecular mass oligomers/ protofibrils represents an alternate pathway from filament formation and renders synuclein less prone to proteasomal degradation.	NHGRI, NIH, Genet Dis Res Branch, Bethesda, MD 20892 USA; NINDS, NIH, Div Extramural Activities, Bethesda, MD 20892 USA; NIH, Off Res Serv, Div Bioengn & Phys Sci, Bethesda, MD 20892 USA; NHLBI, NIH, Biochem Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cole, NB (corresponding author), NHGRI, NIH, Genet Dis Res Branch, 49 Convent Dr,Rm 4B67, Bethesda, MD 20892 USA.	ncole@mail.nih.gov	Levine, Rodney L/D-9885-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000225, ZIAHL000225] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000117] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD011081] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Adler A J, 1973, Methods Enzymol, V27, P675; ARMSTRONG D, 1982, EXP EYE RES, V35, P157, DOI 10.1016/S0014-4835(82)80063-8; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; Baba M, 1998, AM J PATHOL, V152, P879; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BIRCKBICHLER PJ, 1981, P NATL ACAD SCI-BIOL, V78, P5005, DOI 10.1073/pnas.78.8.5005; Campbell BCV, 2000, NEUROBIOL DIS, V7, P192, DOI 10.1006/nbdi.2000.0286; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2000, ANN NY ACAD SCI, V920, P42; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Duda JE, 2000, J NEUROPATH EXP NEUR, V59, P830, DOI 10.1093/jnen/59.9.830; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ferrington DA, 2004, FEBS LETT, V578, P217, DOI 10.1016/j.febslet.2004.11.003; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Girotti A W, 1985, J Free Radic Biol Med, V1, P87; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Held KD, 1996, RADIAT RES, V145, P542, DOI 10.2307/3579272; Hokenson MJ, 2004, BIOCHEMISTRY-US, V43, P4621, DOI 10.1021/bi049979h; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; JENSEN PH, 1995, BIOCHEM J, V310, P91, DOI 10.1042/bj3100091; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KEHRER JP, 1994, FREE RADICAL BIO MED, V17, P65, DOI 10.1016/0891-5849(94)90008-6; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; KIM K, 1985, J BIOL CHEM, V260, P5394; Kim TD, 2002, BIOCHEMISTRY-US, V41, P13782, DOI 10.1021/bi026284c; Kowall NW, 2000, NEUROREPORT, V11, P211, DOI 10.1097/00001756-200001170-00041; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MINOTTI G, 1987, CHEM PHYS LIPIDS, V44, P191, DOI 10.1016/0009-3084(87)90050-8; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Netto LES, 1996, ARCH BIOCHEM BIOPHYS, V333, P233, DOI 10.1006/abbi.1996.0386; Nichols MR, 2002, BIOCHEMISTRY-US, V41, P6115, DOI 10.1021/bi015985r; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Park SM, 2002, J BIOL CHEM, V277, P28512, DOI 10.1074/jbc.M111971200; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Requena JR, 2003, AMINO ACIDS, V25, P221, DOI 10.1007/s00726-003-0012-1; Requena JR, 2001, FREE RADICAL BIO MED, V30, P141, DOI 10.1016/S0891-5849(00)00430-5; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; SPEAR N, 1994, ARCH BIOCHEM BIOPHYS, V312, P198, DOI 10.1006/abbi.1994.1299; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Thiruchelvam M, 2000, BRAIN RES, V873, P225, DOI 10.1016/S0006-8993(00)02496-3; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Welch KD, 2002, FREE RADICAL BIO MED, V32, P577, DOI 10.1016/S0891-5849(02)00760-8; WINTERBOURN CC, 1979, BIOCHEM J, V182, P625, DOI 10.1042/bj1820625; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200; Yamin G, 2003, J BIOL CHEM, V278, P27630, DOI 10.1074/jbc.M303302200; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	103	109	113	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9678	9690		10.1074/jbc.M409946200	http://dx.doi.org/10.1074/jbc.M409946200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615715	hybrid, Green Submitted			2022-12-27	WOS:000227453100125
J	Matsuura, K; Yoshioka, S; Tosha, T; Hori, H; Ishimori, K; Kitagawa, T; Morishima, I; Kagawa, N; Waterman, MR				Matsuura, K; Yoshioka, S; Tosha, T; Hori, H; Ishimori, K; Kitagawa, T; Morishima, I; Kagawa, N; Waterman, MR			Structural diversities of active site in clinical azole-bound forms between sterol 14 alpha-demethylases ( CYP51s) from human and Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDA-ALBICANS CYP51; LANOSTEROL 14-ALPHA-METHYL DEMETHYLASE; RESONANCE RAMAN; CYTOCHROME P450BM3; ESCHERICHIA-COLI; 14-ALPHA-STEROL DEMETHYLASE; DIFFERENTIAL INHIBITION; CATALYTIC-PROPERTIES; CRYSTAL-STRUCTURE; EXPRESSION	To gain insights into the molecular basis of the design for the selective azole anti-fungals, we compared the binding properties of azole-based inhibitors for cytochrome P450 sterol 14alpha-demethylase (CYP51) from human (HuCYP51) and Mycobacterium tuberculosis (MtCYP51). Spectroscopic titration of azoles to the CYP51s revealed that HuCYP51 has higher affinity for ketoconazole (KET), an azole derivative that has long lipophilic groups, than MtCYP51, but the affinity for fluconazole (FLU), which is a member of the anti-fungal armamentarium, was lower in HuCYP51. The affinity for 4-phenylimidazole (4-PhIm) to MtCYP51 was quite low compared with that to HuCYP51. In the resonance Raman spectra for HuCYP51, the FLU binding induced only minor spectral changes, whereas the prominent high frequency shift of the bending mode of the heme vinyl group was detected in the KET- or 4-PhIm-bound forms. On the other hand, the bending mode of the heme propionate group for the FLU-bound form of MtCYP51 was shifted to high frequency as found for the KET- bound form, but that for 4-PhIm was shifted to low frequency. The EPR spectra for 4-PhIm-bound MtCYP51 and FLU-bound HuCYP51 gave multiple g values, showing heterogeneous binding of the azoles, whereas the single g(x) and g(z) values were observed for other azole-bound forms. Together with the alignment of the amino acid sequence, these spectroscopic differences suggest that the region between the B' and C helices, particularly the hydrophobicity of the C helix, in CYP51s plays primary roles in determining strength of interactions with azoles; this differentiates the binding specificity of azoles to CYP51s.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan	Kyoto University; Vanderbilt University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Osaka University	Ishimori, K (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan.	koichiro@scl.kyoto-u.ac.jp	Tosha, Takehiko/AAR-2404-2020; Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021; MATSUURA, Koji/B-2419-2011; Matsuura, Koji/AAU-9111-2021	Tosha, Takehiko/0000-0002-8971-0759; Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; 	NIGMS NIH HHS [GM67871, GM37942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R01GM067871, R37GM037942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937; Bellamine A, 2004, J LIPID RES, V45, P2000, DOI 10.1194/jlr.M400239-JLR200; Berka V, 1998, BIOCHEMISTRY-US, V37, P6136, DOI 10.1021/bi980133l; Cabello-Hurtado F, 1999, EUR J BIOCHEM, V262, P435, DOI 10.1046/j.1432-1327.1999.00376.x; Chen ZC, 2003, BIOCHEMISTRY-US, V42, P2542, DOI 10.1021/bi027206s; Chen ZC, 2004, BIOCHEMISTRY-US, V43, P1798, DOI 10.1021/bi034920g; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; Debeljak N, 2003, ARCH BIOCHEM BIOPHYS, V409, P159, DOI 10.1016/S0003-9861(02)00418-6; Deng TJ, 1999, BIOCHEMISTRY-US, V38, P13699, DOI 10.1021/bi991287j; DiDomenico B, 1999, CURR OPIN MICROBIOL, V2, P509, DOI 10.1016/S1369-5274(99)00009-0; DIJMAGHANIAN S, 2004, CHIRALITY, V16, P79; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; FISCHER RT, 1989, J LIPID RES, V30, P1621; Georgopapadakou NH, 1998, CURR OPIN MICROBIOL, V1, P547, DOI 10.1016/S1369-5274(98)80087-8; Guardiola-Diaz HM, 2001, BIOCHEM PHARMACOL, V61, P1463, DOI 10.1016/S0006-2952(01)00571-8; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; Ji HT, 2003, J MED CHEM, V46, P474, DOI 10.1021/jm020362c; Ji HT, 2000, J MED CHEM, V43, P2493, DOI 10.1021/jm990589g; Kapetanaki S, 2003, BIOCHEMISTRY-US, V42, P3835, DOI 10.1021/bi026992y; Lamb D, 1999, DRUG RESIST UPDATE, V2, P390, DOI 10.1054/drup.1999.0112; Lamb DC, 1998, FEBS LETT, V425, P263, DOI 10.1016/S0014-5793(98)00247-6; Lamb DC, 1999, YEAST, V15, P755, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;755::AID-YEA417&gt;3.0.CO;2-8; Lamb DC, 1997, FEMS MICROBIOL LETT, V149, P25, DOI 10.1111/j.1574-6968.1997.tb10303.x; Lamb DC, 2000, CHEM-BIOL INTERACT, V125, P165, DOI 10.1016/S0009-2797(99)00169-6; Lamb DC, 1997, J BIOL CHEM, V272, P5682, DOI 10.1074/jbc.272.9.5682; Lepesheva GI, 2003, BIOCHEMISTRY-US, V42, P9091, DOI 10.1021/bi034663f; Lepesheva GI, 2004, BIOCHEMISTRY-US, V43, P10789, DOI 10.1021/bi048967t; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; McLean KJ, 2002, MICROBIOL-SGM, V148, P2937, DOI 10.1099/00221287-148-10-2937; McLean KJ, 2002, J INORG BIOCHEM, V91, P527, DOI 10.1016/S0162-0134(02)00479-8; Munro AW, 2003, BIOCHEM SOC T, V31, P625, DOI 10.1042/BST0310625; Noble MA, 1998, BIOCHEMISTRY-US, V37, P15799, DOI 10.1021/bi980462d; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Podust LM, 2001, J INORG BIOCHEM, V87, P227, DOI 10.1016/S0162-0134(01)00388-9; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; SAGARA Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P272, DOI 10.1006/abbi.1993.1349; Sheehan DJ, 1999, CLIN MICROBIOL REV, V12, P40, DOI 10.1128/CMR.12.1.40; Smith SJ, 2003, BIOPOLYMERS, V70, P620, DOI 10.1002/bip.10502; Solomons T. W. G., 1996, ORGANIC CHEM; Souter A, 2000, J CHEM TECHNOL BIOT, V75, P933, DOI 10.1002/1097-4660(200010)75:10<933::AID-JCTB301>3.0.CO;2-C; Tanaka T, 2004, CHEM PHARM BULL, V52, P830, DOI 10.1248/cpb.52.830; TRZASKOS JM, 1984, J BIOL CHEM, V259, P3402; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; Uchida T, 2004, J BIOL CHEM, V279, P53613, DOI 10.1074/jbc.M409719200; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Yoshida Y, 2000, BIOCHEM BIOPH RES CO, V273, P799, DOI 10.1006/bbrc.2000.3030; Zarn Jurg A., 2003, Environmental Health Perspectives, V111, P255	51	36	38	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9088	9096		10.1074/jbc.M413042200	http://dx.doi.org/10.1074/jbc.M413042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611056	hybrid			2022-12-27	WOS:000227453100058
J	Moreau, B; Straube, S; Fisher, RJ; Putney, JW; Parekh, AB				Moreau, B; Straube, S; Fisher, RJ; Putney, JW; Parekh, AB			Ca2+-calmodulin-dependent facilitation and Ca2+ inactivation of Ca2+ release-activated Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURRENT I-CRAC; CALCIUM-DEPENDENT INACTIVATION; FEEDBACK INHIBITION; INFLUX; CALMODULIN; DEPLETION; MECHANISM; STORES; ENTRY; DISSOCIATION	In non-excitable cells, one major route for Ca2+ influx is through store-operated Ca2+ channels in the plasma membrane. These channels are activated by the emptying of intracellular Ca2+ stores, and in some cell types store-operated influx occurs through Ca2+ release-activated Ca2+ (CRAC) channels. Here, we report that intracellular Ca2+ modulates CRAC channel activity through both positive and negative feedback steps in RBL-1 cells. Under conditions in which cytoplasmic Ca2+ concentration can fluctuate freely, we find that store-operated Ca2+ entry is impaired either following overexpression of a dominant negative calmodulin mutant or following whole-cell dialysis with a calmodulin inhibitory peptide. The peptide had no inhibitory effect when intracellular Ca2+ was buffered strongly at low levels. Hence, Ca2+-calmodulin is not required for the activation of CRAC channels per se but is an important regulator under physiological conditions. We also find that the plasma membrane Ca2+ ATPase is the dominant Ca2+ efflux pathway in these cells. Although the activity of the Ca2+ pump is regulated by calmodulin, the store-operated Ca2+ entry is more sensitive to inhibition by the calmodulin mutant than by Ca2+ extrusion. Hence, these two plasmalemmal Ca2+ transport systems may differ in their sensitivities to endogenous calmodulin. Following the activation of Ca2+ entry, the rise in intracellular Ca2+ subsequently feeds back to further inhibit Ca2+ influx. This slow inactivation can be activated by a relatively brief Ca2+ influx (30-60 s); it reverses slowly and is not altered by overexpression of the calmodulin mutant. Hence, the same messenger, intracellular Ca2+, can both facilitate and inactivate Ca2+ entry through store-operated CRAC channels and through different mechanisms.	Univ Oxford, Dept Physiol, Lab Cellular & Mol Signalling, Oxford OX1 3PT, England	University of Oxford	Parekh, AB (corresponding author), NIEHS, Calcium Regulat Sect, Dept Hlth & Human Serv, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	anant.parekh@physiol.ox.ac.uk	Straube, Sebastian/E-1937-2016; Putney, James W/F-7247-2019	Straube, Sebastian/0000-0001-7862-0398; Putney, James W/0000-0002-3379-4789	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER; Medical Research Council [G0200218] Funding Source: Medline; MRC [G0200218] Funding Source: UKRI	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Cao YM, 1998, FEBS LETT, V424, P33, DOI 10.1016/S0014-5793(98)00133-1; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Csordas G, 2003, J BIOL CHEM, V278, P42273, DOI 10.1074/jbc.M305248200; Fierro L, 2000, J PHYSIOL-LONDON, V522, P247, DOI 10.1111/j.1469-7793.2000.t01-1-00247.x; Fierro L, 1999, J MEMBRANE BIOL, V168, P9, DOI 10.1007/s002329900493; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1994, J BIOL CHEM, V269, P31525; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Glitsch MD, 2002, J PHYSIOL-LONDON, V539, P93, DOI 10.1113/jphysiol.2001.012826; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; KWAN CY, 1990, J BIOL CHEM, V265, P678; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Louzao MC, 1996, J BIOL CHEM, V271, P14807, DOI 10.1074/jbc.271.25.14807; Machaca K, 2003, J BIOL CHEM, V278, P33730, DOI 10.1074/jbc.M305023200; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; TAYLOR CW, 1995, J MEMBRANE BIOL, V145, P109; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Vaca L, 1996, FEBS LETT, V390, P289, DOI 10.1016/0014-5793(96)00675-8; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597	42	29	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8776	8783		10.1074/jbc.M409619200	http://dx.doi.org/10.1074/jbc.M409619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611075	hybrid			2022-12-27	WOS:000227453100020
J	Nolan, Y; Maher, FO; Martin, DS; Clarke, RM; Brady, MT; Bolton, AE; Mills, KHG; Lynch, MA				Nolan, Y; Maher, FO; Martin, DS; Clarke, RM; Brady, MT; Bolton, AE; Mills, KHG; Lynch, MA			Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ACTIVATED PROTEIN-KINASES; RAT HIPPOCAMPUS; RECEPTOR ANTAGONIST; CELL-DEATH; IL-4; CYTOKINE; EXPRESSION; IMPAIRMENT; MECHANISMS	It is well documented that long term potentiation (LTP) is impaired in the hippocampus of the aged animal. Among the changes that contribute to this impairment is an increase in hippocampal concentration of the pro-inflammatory cytokine interleukin-1beta (IL-1beta), and increased IL-1beta-induced signaling. In this study we investigated the possibility that these changes were a consequence of decreased concentration of the anti-inflammatory cytokine, IL-4, and decreased IL-4-stimulated signaling. We report that functional IL-4 receptors are expressed on granule cells of the dentate gyrus and that receptor activation results in phosphorylation of JAK1 and STAT6. Hippocampal IL-4 concentration was decreased with age, and this was accompanied by a decrease in phosphorylation of JAK1 and STAT6. The evidence indicates that IL-4 modulates expression of IL-1beta mRNA and protein and that it attenuates IL-1beta-induced impairment of LTP and phosphorylation of JNK and c-Jun. We argued that, if a decrease in hippocampal IL-4 concentration significantly contributed to the age-related impairment in LTP, then restoration of IL-4 should restore LTP. To test this, we treated rats with VP015(phospholipid microparticles-incorporating phosphatidylserine), which increases IL-4 concentration in hippocampus. The data indicate that the VP015-induced increase in IL-4 concentration in hippocampus of aged rats and lipopolysaccharide (LPS)-treated rats was accompanied by a reversal of the age-related and LPS-induced impairment in LTP in perforant path granule cell synapses. We propose that interplay between pro-inflammatory and anti-inflammatory responses impact significantly on synaptic function in the hippocampus of the aged rat.	Trinity Coll Dublin, Inst Neurosci, Dept Physiol, Dublin 2, Ireland; Trinity Coll Dublin, Dept Biochem, Immune Regulat Res Grp, Dublin 2, Ireland; Vasogen Ireland Ltd, Shannon, Ireland	Trinity College Dublin; Trinity College Dublin	Lynch, MA (corresponding author), Trinity Coll Dublin, Inst Neurosci, Dept Physiol, Dublin 2, Ireland.	lynchma@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222; Nolan, Yvonne/0000-0003-2426-234X; Lynch, Marina/0000-0002-4631-0499				Bluthe RM, 2002, NEUROPSYCHOPHARMACOL, V26, P86, DOI 10.1016/S0893-133X(01)00305-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brodie C, 1998, J NEUROIMMUNOL, V81, P20, DOI 10.1016/S0165-5728(97)00154-9; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Crepaldi L, 2002, INT IMMUNOL, V14, P1145, DOI 10.1093/intimm/dxf079; HAAN EA, 1981, J NEUROCHEM, V37, P243, DOI 10.1111/j.1471-4159.1981.tb05315.x; Hauss-Wegrzyniak B, 1999, NEUROBIOL AGING, V20, P305, DOI 10.1016/S0197-4580(99)00028-7; Lynch AM, 2004, J NEUROCHEM, V88, P635, DOI 10.1046/j.1471-4159.2003.02157.x; Lynch AM, 2002, EUR J NEUROSCI, V15, P1779, DOI 10.1046/j.1460-9568.2002.02012.x; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Mendoza-Fernandez V, 2000, BRAIN RES, V885, P14, DOI 10.1016/S0006-8993(00)02877-8; Minogue AM, 2003, J BIOL CHEM, V278, P27971, DOI 10.1074/jbc.M302530200; Molina-Holgado E, 2001, EUR J NEUROSCI, V13, P493, DOI 10.1046/j.0953-816x.2000.01412.x; Murray CA, 1998, J NEUROSCI, V18, P2974; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nolan Y, 2004, J NEUROIMMUNOL, V151, P12, DOI 10.1016/j.jneuroim.2004.02.001; Nolan Y, 2003, EXP NEUROL, V184, P794, DOI 10.1016/S0014-4886(03)00301-7; Nolan Y, 2002, NEUROIMMUNOMODULAT, V10, P40, DOI 10.1159/000064413; NOLAN YM, 2002, SOC NEUR ABSTR; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; Shaw KN, 2001, BEHAV BRAIN RES, V124, P47, DOI 10.1016/S0166-4328(01)00232-7; Smith P, 2001, EUR J IMMUNOL, V31, P1495, DOI 10.1002/1521-4141(200105)31:5&lt;1495::AID-IMMU1495&gt;3.0.CO;2-8; Szczepanik AM, 2001, J NEUROIMMUNOL, V113, P49, DOI 10.1016/S0165-5728(00)00404-5; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200	26	165	177	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9354	9362		10.1074/jbc.M412170200	http://dx.doi.org/10.1074/jbc.M412170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615726	hybrid, Green Published			2022-12-27	WOS:000227453100088
J	Cohen, LA; Guan, JL				Cohen, LA; Guan, JL			Residues within the first subdomain of the FERM-like domain in focal adhesion kinase are important in its regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY KINASES; SIGNAL-TRANSDUCTION; TERMINAL DOMAIN; N-TERMINI; INTEGRIN; BINDING; FAK; PHOSPHORYLATION; LOCALIZATION; AUTOPHOSPHORYLATION	We have previously described regulation of focal adhesion kinase (FAK) by its amino-terminal FERM-like domain through an autoinhibitory interaction with its kinase domain (Cooper, L. A., Shen, T. L., and Guan, J. L. (2003) Mol. Cell. Biol. 23, 8030-8041). Here we show that the first two subdomains of the FERM-like domain are independently capable of inhibiting phosphorylation of FAK in trans. We characterized several point mutations within the first subdomain of the FERM-like domain and find that mutation of Lys-38 to alanine results in a FAK mutant that is strongly hyperphosphorylated when expressed in mammalian cells, and promotes increased phosphorylation of the FAK substrate paxillin. A second mutation of Lys-78 to alanine results in a FAK mutant that is underphosphorylated, but can be activated by extracellular matrix stimuli. Like deletion of the amino terminus itself the K38A mutation is phosphorylated in suspension. The Delta375 truncation mutant of FAK is strongly phosphorylated both when Tyr-397 is mutated to phenylalanine, and in the presence of the Src inhibitor, PP2, suggesting that removal of the amino terminus can render FAK Src independent. This is in contrast to the K38A mutant that is not phosphorylated in the Y397F background, and which shows decreased phosphorylation in the presence of the Src inhibitor PP2, suggesting that regulation of FAK by Src is a secondary step in its activation. The K38A mutation weakens the interaction between the amino terminus of FAK and its own kinase domain, and disrupts the ability of the amino terminus to inhibit the phosphorylation of FAK in trans. The K38A mutation of FAK also increases the ability of FAK to promote cell cycle progression and cell migration, suggesting that hyperphosphorylation of this mutant can positively affect FAK function in cells. Together, these data strongly suggest a role for the first FAK subdomain of the FERM domain in its normal regulation and function in the cell.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	jg19@cornell.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Bretscher A, 1997, J CELL SCI, V110, P3011; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Dunty JM, 2004, MOL CELL BIOL, V24, P5353, DOI 10.1128/MCB.24.12.5353-5368.2004; Dunty JM, 2002, J BIOL CHEM, V277, P45644, DOI 10.1074/jbc.M201779200; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; Hamada K, 2001, ACTA CRYSTALLOGR D, V57, P891, DOI 10.1107/S0907444901005716; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Ilic D, 1997, J CELL SCI, V110, P401; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Smith WJ, 2003, J BIOL CHEM, V278, P4949, DOI 10.1074/jbc.M210601200; Toutant M, 2002, MOL CELL BIOL, V22, P7731, DOI 10.1128/MCB.22.22.7731-7743.2002; Zhao J H, 2000, Prog Mol Subcell Biol, V25, P37; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	32	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8197	8207		10.1074/jbc.M412021200	http://dx.doi.org/10.1074/jbc.M412021200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611137	hybrid			2022-12-27	WOS:000227395700093
J	Zhu, JZ; Krishnegowda, G; Gowda, DC				Zhu, JZ; Krishnegowda, G; Gowda, DC			Induction of proinflammatory responses in macrophages by the Glycosylphosphatidylinositols of Plasmodium falciparum - The requirement of extracellular signal-regulated kinase, p38, c-Jun N-terminal kinase and NF-kappa B pathways for the expression of proinflammatory cytokines and nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASES; VASCULAR ENDOTHELIAL-CELLS; TNF-ALPHA; MAP KINASE; CEREBRAL MALARIA; IL-12 PRODUCTION; SYNTHASE; ANCHORS; INNATE	The glycosylphosphatidylinositol (GPI) anchors of Plasmodium falciparum have been proposed to be the major factors that contribute to malaria pathogenesis by eliciting the production of proinflammatory cytokines and nitric oxide by the host innate immune system. In this study we demonstrate that the parasite GPIs can effectively induce the production of TNF-alpha at 5-20 nM concentrations in interferon-gamma-primed monocytes and macrophages. The potency of the parasite GPIs activity is physiologically relevant to their ability to contribute to severe malaria pathogenesis. More importantly, we investigated the requirement of the extracellular signal-regulated kinase (ERK)-, c-Jun N-terminal kinase (JNK)-, p38-, and NF-kappaB-signaling pathways that are activated in response to P. falciparum GPIs through toll-like receptor-mediated recognition (Krishnegowda, G., Hajjar, A. M., Zhu J. Z., Douglass, E. J., Uematsu, S., Akira, S., Wood, A. S., and Gowda, D. C. ( 2005) J. Biol. Chem. 280, 8606 - 8616) for the proinflammatory responses by macrophages. The data conclusively show that the production of TNF-alpha, interleukin (IL)-12, IL-6, and nitric oxide by macrophages stimulated with parasite GPIs is critically dependent on the NF-kappaB and JNK pathways. NF-kappaB1 is essential for IL-6 and IL-12 production but not for TNF-alpha and nitric oxide, whereas NF-kappaB/c-Rel appears to be important for all four proinflammatory mediators. JNK1 and JNK2 are functionally redundant for the expression of TNF-alpha, IL-6, and nitric oxide, whereas JNK2 but not JNK1 is essential for IL-12 production. The ERK signaling pathway is not involved in TNF-alpha and nitric oxide production, but, interestingly, negatively regulates the expression of IL-6 and IL-12. Furthermore, p38 is critical for the production of IL-6 and IL-12 but is only marginally required for the production of TNF-alpha and nitric oxide. Thus, our data define the differential requirement of the downstream signaling molecules for the production of key proinflammatory cytokines and nitric oxide by macrophages in response to P. falciparum GPI stimuli. The data have important implications for the development of therapeutics for malaria treatment.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Gowda, DC (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA.	gowda@psu.edu		Gowda, Channe/0000-0002-6860-5108; GOWDA, KRISHNE/0000-0002-6042-0520	NIAID NIH HHS [R01 AI041139, AI41139] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041139] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; Almeida IC, 2001, J LEUKOCYTE BIOL, V70, P467; Amarante-Paffaro A, 2004, REPRODUCTION, V128, P207, DOI 10.1530/rep.1.00214; Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Caivano M, 1998, FEBS LETT, V429, P249, DOI 10.1016/S0014-5793(98)00578-X; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Chan ED, 1999, J IMMUNOL, V162, P415; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clark IA, 2003, PHARMACOL THERAPEUT, V99, P221, DOI 10.1016/S0163-7258(03)00060-3; COT S, 1994, J INFECT DIS, V169, P1417, DOI 10.1093/infdis/169.6.1417; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Feng GJ, 1999, J IMMUNOL, V163, P6403; Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011; GRAU GE, 1994, PARASITOL TODAY, V10, P408, DOI 10.1016/0169-4758(94)90236-4; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; Hale KK, 1999, J IMMUNOL, V162, P4246; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HOMMEL M, 1993, ANN TROP MED PARASIT, V87, P627, DOI 10.1080/00034983.1993.11812821; Hua LWL, 2002, J NEUROIMMUNOL, V126, P180, DOI 10.1016/S0165-5728(02)00055-3; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; KARUNAWEERA ND, 1992, P NATL ACAD SCI USA, V89, P3200, DOI 10.1073/pnas.89.8.3200; Kaufmann SHE, 2002, METHOD MICROBIOL, V32, P1; Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Mackintosh CL, 2004, TRENDS PARASITOL, V20, P597, DOI 10.1016/j.pt.2004.09.006; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; MILLER RA, 1994, CURRENT PROTOCOL IMM, V1; Naik RS, 2000, J EXP MED, V192, P1563, DOI 10.1084/jem.192.11.1563; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; NUSSLER AK, 1994, J INFECT DIS, V169, P1418, DOI 10.1093/infdis/169.6.1418; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; Ropert C, 2000, CURR OPIN MICROBIOL, V3, P395, DOI 10.1016/S1369-5274(00)00111-9; Ropert C, 2001, J IMMUNOL, V166, P3423, DOI 10.4049/jimmunol.166.5.3423; Schofield L, 1996, J IMMUNOL, V156, P1886; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHERMAN IW, 1998, MALARIA PARASITE BIO, P1; Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tachado SD, 1996, J IMMUNOL, V156, P1897; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; Takeda K, 2004, J DERMATOL SCI, V34, P73, DOI 10.1016/j.jdermsci.2003.10.002; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Vijaykumar M, 2001, J BIOL CHEM, V276, P6909, DOI 10.1074/jbc.C100007200; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	63	123	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8617	8627		10.1074/jbc.M413539200	http://dx.doi.org/10.1074/jbc.M413539200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611045	Green Accepted, hybrid			2022-12-27	WOS:000227395700138
J	Hepp, G; Puri, N; Hohenstein, AC; Crawford, GL; Whiteheart, SW; Roche, PA				Hepp, G; Puri, N; Hohenstein, AC; Crawford, GL; Whiteheart, SW; Roche, PA			Phosphorylation of SNAP-23 regulates exocytosis from mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SYNAPTOSOME-ASSOCIATED PROTEIN; ACTIVATED HUMAN PLATELETS; SNARE-COMPLEX; GRANULE EXOCYTOSIS; MEMBRANE-FUSION; SYNTAXIN 4; DIFFERENTIAL PHOSPHORYLATION; NEUROTRANSMITTER RELEASE; POSSIBLE INVOLVEMENT	Regulated exocytosis is a process in which a physiological trigger initiates the translocation, docking, and fusion of secretory granules with the plasma membrane. A class of proteins termed SNAREs (including SNAP-23, syntaxins, and VAMPs) are known regulators of secretory granule/plasma membrane fusion events. We have investigated the molecular mechanisms of regulated exocytosis in mast cells and find that SNAP-23 is phosphorylated when rat basophilic leukemia mast cells are triggered to degranulate. The kinetics of SNAP-23 phosphorylation mirror the kinetics of exocytosis. We have identified amino acid residues Ser(95) and Ser(120) as the major phosphorylation sites in SNAP-23 in rodent mast cells. Quantitative analysis revealed that similar to10% of SNAP-23 was phosphorylated when mast cell degranulation was induced. These same residues were phosphorylated when mouse platelet degranulation was induced with thrombin, demonstrating that phosphorylation of SNAP-23 Ser(95) and Ser(120) is not restricted to mast cells. Although triggering exocytosis did not alter the absolute amount of SNAP-23 bound to SNAREs, after stimulation essentially all of the SNAP-23 bound to the plasma membrane SNARE syntaxin 4 and the vesicle SNARE VAMP-2 was phosphorylated. Regulated exocytosis studies revealed that overexpression of SNAP-23 phosphorylation mutants inhibited exocytosis from rat basophilic leukemia mast cells, demonstrating that phosphorylation of SNAP-23 on Ser(120) and Ser(95) modulates regulated exocytosis by mast cells.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Roche, PA (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B36, Bethesda, MD 20892 USA.	paul.roche@nih.gov		Whiteheart, Sidney/0000-0001-5577-0473; Roche, Paul/0000-0002-8949-9172; HEPP, regine/0000-0002-7683-7451				Anderson HA, 1998, J IMMUNOL, V160, P4850; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Fujita H, 1998, BIOCHEM J, V329, P527, DOI 10.1042/bj3290527; Genoud S, 1999, J NEUROCHEM, V72, P1699, DOI 10.1046/j.1471-4159.1999.721699.x; Gonelle-Gispert C, 2002, BIOCHEM J, V368, P223, DOI 10.1042/BJ20020896; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hepp R, 2002, FEBS LETT, V532, P52, DOI 10.1016/S0014-5793(02)03629-3; Hibi T, 2000, BIOCHEM BIOPH RES CO, V271, P36, DOI 10.1006/bbrc.2000.2591; Iwasaki S, 2000, J BIOCHEM-TOKYO, V128, P407, DOI 10.1093/oxfordjournals.jbchem.a022768; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kataoka M, 2000, J NEUROCHEM, V74, P2058, DOI 10.1046/j.1471-4159.2000.0742058.x; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Klenchin VA, 2000, BIOCHIMIE, V82, P399, DOI 10.1016/S0300-9084(00)00208-X; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Littleton JT, 2001, P NATL ACAD SCI USA, V98, P12233, DOI 10.1073/pnas.221450198; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; Marti-Verdeaux S, 2003, J CELL SCI, V116, P325, DOI 10.1242/jcs.00216; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Polgar J, 2003, J BIOL CHEM, V278, P44369, DOI 10.1074/jbc.M307864200; Pombo I, 2001, J BIOL CHEM, V276, P42893, DOI 10.1074/jbc.M103527200; Puri N, 2003, J IMMUNOL, V171, P5345, DOI 10.4049/jimmunol.171.10.5345; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; RIVERA J, 1997, PROTEIN KINASE C, P133; Rutledge Tara W, 2004, Methods Mol Biol, V272, P109; Schraw TD, 2003, BLOOD, V102, P1716, DOI 10.1182/blood-2003-01-0331; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; St-Denis JF, 1999, BIOCHEM J, V338, P709, DOI 10.1042/0264-6021:3380709; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vaidyanathan VV, 2001, J BIOL CHEM, V276, P25101, DOI 10.1074/jbc.M103536200; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu NJ, 2004, J BIOL CHEM, V279, P40601, DOI 10.1074/jbc.M406896200	42	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6610	6620		10.1074/jbc.M412126200	http://dx.doi.org/10.1074/jbc.M412126200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611044	hybrid			2022-12-27	WOS:000227332700046
J	Yokoyama, H; Matsui, I				Yokoyama, H; Matsui, I			A novel thermostable membrane protease forming an operon with a stomatin homolog from the hyperthermophilic archaebacterium Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC ACTIVITY; SUBSTRATE RECOGNITION; SERINE PEPTIDASES; AAA PROTEASES; PROTEINS; PREDICTION; FAMILIES; DOMAIN; IDENTIFICATION; MITOCHONDRIA	Membrane-bound proteases play several important roles in protein quality control and regulation. In the genome of the hyperthermophilic archaebacterium Pyrococcus horikoshii, the open reading frames PH1510 and PH1511 are homologous to the genes nfed ((n) under bar odulation (f) under bar ormation (e) under bar fficiency (D) under bar) and stomatin, respectively, and probably form an operon. The nfed proteins are putative membrane proteins, and the N-terminal region shows homology to C1pP-type serine proteases. Stomatin is one of the major integral membrane proteins of human erythrocytes, and its absence is associated with the hemolytic anemia known as hereditary stomatocytosis. Thus, the N-terminal region of PH1510 (1510-N, residues 16-236) was expressed and purified. From activity staining and SDS-PAGE analysis using fluorescein isothiocyanate-casein, 1510-N was identified as a thermostable endo-type protease. From site-directed mu. tagenesis, the conserved Ser-97 and Lys-138 are involved in proteolysis and, therefore, PH1510 is probably a serine protease with a catalytic Ser-Lys dyad. The sites of cleavage by 1510-N are rich in hydrophobic residues. The site P1 (position -1 relative to the cleavage site) is mainly leucine. P4 and P4' are mainly hydrophobic residues. Interestingly, the 1510-N protease cleaves the C-terminal hydrophobic region of PH1511. From this result and the probability of an operon, PH1510 probably functions in cooperation with PH1511. It is hypothesized that the cleavage of the stomatin-homolog PH1511 by the PH1510 protease causes an ion channel to open.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan.	matsui@aist.go.jp		Yokoyama, Hideshi/0000-0002-3137-2793				ANDREWS AT, 1985, J CHROMATOGR, V348, P177, DOI 10.1016/S0021-9673(01)92451-3; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P3149, DOI 10.1021/bi992709s; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; Bolhuis A, 1999, J BIOL CHEM, V274, P24585, DOI 10.1074/jbc.274.35.24585; Ermolaeva MD, 2001, NUCLEIC ACIDS RES, V29, P1216, DOI 10.1093/nar/29.5.1216; FIAT AM, 1989, MOL CELL BIOCHEM, V87, P5, DOI 10.1007/BF00421079; Fukui T, 2002, J BACTERIOL, V184, P3689, DOI 10.1128/JB.184.13.3689-3698.2002; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Green JB, 2004, BLOOD CELL MOL DIS, V32, P411, DOI 10.1016/j.bcmd.2004.01.016; Higashibata H, 2003, J BIOL CHEM, V278, P15983, DOI 10.1074/jbc.M207748200; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Jansen T, 2003, FEMS MICROBIOL LETT, V228, P121, DOI 10.1016/S0378-1097(03)00744-4; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Keiler KC, 1996, J BIOL CHEM, V271, P2589, DOI 10.1074/jbc.271.5.2589; Kihara A, 1996, EMBO J, V15, P6122, DOI 10.1002/j.1460-2075.1996.tb01000.x; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Langer T, 2001, BIOCHEM SOC T, V29, P431, DOI 10.1042/BST0290431; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; Rajaram S, 1999, GENETICS, V153, P1673; Rawlings ND, 1999, NUCLEIC ACIDS RES, V27, P325, DOI 10.1093/nar/27.1.325; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; SOTO MJ, 1994, MOL PLANT MICROBE IN, V7, P703, DOI 10.1094/MPMI-7-0703; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187	31	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6588	6594		10.1074/jbc.M411748200	http://dx.doi.org/10.1074/jbc.M411748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611110	hybrid			2022-12-27	WOS:000227332700043
J	Vogel, C; Kienitz, A; Muller, R; Bastians, H				Vogel, C; Kienitz, A; Muller, R; Bastians, H			The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG CANCERS; FREQUENT IMPAIRMENT; ASSEMBLY CHECKPOINT; DNA-DAMAGE; CELL-CYCLE; CYTOTOXICITY; INHIBITOR; APOPTOSIS; UCN-01; P53	A novel strategy in cancer therapy is the induction of mitotic cell death by the pharmacological abrogation of cell cycle checkpoints. UCN-01 is such a compound that overrides the G(2) cell cycle arrest induced by DNA damage and forces cells into a deleterious mitosis. The molecular pathways leading to mitotic cell death are largely unknown although recent evidence indicates that mitotic cell death represents a special case of apoptosis. Here, we demonstrate that the mitotic spindle checkpoint is activated upon chemotherapeutic treatment with topoisomerase II poisons and UCN-01. Cells that are forced to enter mitosis in the presence of topoisomerase inhibition arrest transiently in a prometaphase like state. By using a novel pharmacological inhibitor of the spindle checkpoint and spindle checkpoint-deficient cells we show that the spindle checkpoint function is required for the mitotic arrest and, most importantly, for efficient induction of mitotic cell death. Thus, our results demonstrate that the mitotic spindle checkpoint is an important determinant for the outcome of a chemotherapy based on the induction of mitotic cell death. Its frequent inactivation in human cancer might contribute to the observed resistance of tumor cells to these chemotherapeutic drugs.	Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35037 Marburg, Germany	Philipps University Marburg	Bastians, H (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res IMT, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	bastians@imt.uni-marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kohn EA, 2003, CANCER RES, V63, P31; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Masuda A, 2003, AM J PATHOL, V163, P1109, DOI 10.1016/S0002-9440(10)63470-0; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Saeki A, 2002, CANCER-AM CANCER SOC, V94, P2047, DOI 10.1002/cncr.10448; Shao RG, 1997, CANCER RES, V57, P4029; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Wang XH, 2002, CANCER RES, V62, P1662; Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6	22	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4025	4028		10.1074/jbc.C400545200	http://dx.doi.org/10.1074/jbc.C400545200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15611124	hybrid			2022-12-27	WOS:000227096600006
J	Cohen, P; Yang, GQ; Yu, XX; Soukas, AA; Wolfish, CS; Friedman, JM; Li, C				Cohen, P; Yang, GQ; Yu, XX; Soukas, AA; Wolfish, CS; Friedman, JM; Li, C			Induction of leptin receptor expression in the liver by leptin and food deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE-1; DB/DB MICE; IN-VITRO; DEFICIENCY; OBESITY; MODULATION; GENE; ACTIVATION; GENERATION; MUTATION	Leptin resistance is a common feature of obesity and the metabolic syndrome. However, the regulated expression of the leptin receptor (Ob-R) has not been studied in detail. Expression profiling of liver mRNA in leptin-treated wild-type mice revealed a marked increase in leptin receptor mRNA levels, which had not previously been described. This was confirmed by isoform-specific real-time PCR, which showed a > 25-fold increase in the mRNAs encoding the short forms (Ob-Ra, Ob-Rc) and a > 10-fold increase in the mRNA encoding the long (Ob-Rb) form of the leptin receptor in liver. In parallel, we also observed induction of plasma-soluble leptin receptor (SLR) protein by leptin administration, pair feeding, and short term food restriction. However, induction of SLR by leptin is abolished in mice with selective deletion of Ob-R from liver using Cre-LoxP technology. These data suggest that the liver is a major source of Ob-R mRNA expression under conditions of negative energy balance. Membrane-bound Ob-R is then shed into the circulation as SLR. Our study thus reveals an unexpected role of the liver in modulating total circulating leptin levels and possibly its biological activity.	Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, C (corresponding author), Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA.	Cai.Li@UTSouthwestern.edu	Abrams, William R/A-5782-2008		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060137] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60137] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105; Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cohen P, 2004, J NUTR, V134, p2455S, DOI 10.1093/jn/134.9.2455S; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Cohen Paul, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P271, DOI 10.2174/1568008033340117; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Ge HF, 2002, J BIOL CHEM, V277, P45898, DOI 10.1074/jbc.M205825200; Gibson WT, 2004, J CLIN ENDOCR METAB, V89, P4821, DOI 10.1210/jc.2004-0376; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Kowalski TJ, 2001, DIABETES, V50, P425, DOI 10.2337/diabetes.50.2.425; Landt M, 2000, CLIN CHEM, V46, P379; Lee GH, 1997, MAMM GENOME, V8, P445, DOI 10.1007/s003359900466; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Li C, 1998, J BIOL CHEM, V273, P10078, DOI 10.1074/jbc.273.16.10078; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; Mazerbourg S, 2004, GROWTH HORM IGF RES, V14, P71, DOI 10.1016/j.ghir.2003.10.002; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; Soukas A, 2000, GENE DEV, V14, P963; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; van Dielen FMH, 2002, J CLIN ENDOCR METAB, V87, P1708, DOI 10.1210/jc.87.4.1708; Yang GQ, 2004, MOL ENDOCRINOL, V18, P1354, DOI 10.1210/me.2004-0027; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	68	75	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10034	10039		10.1074/jbc.M413684200	http://dx.doi.org/10.1074/jbc.M413684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644325	hybrid			2022-12-27	WOS:000227559600037
J	Koropatkin, NM; Cleland, WW; Holden, HM				Koropatkin, NM; Cleland, WW; Holden, HM			Kinetic and structural analysis of alpha-D-glucose-1-phosphate cytidylyltransferase from Salmonella typhi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE; ESCHERICHIA-COLI; GENE; PYROPHOSPHORYLASE; PURIFICATION; MECHANISM	Tyvelose is a 3,6-dideoxyhexose found in the O-antigen of the surface lipopolysaccharides of some pathogenic bacteria. It is synthesized via a complex biochemical pathway that is initiated by the formation of CDP-D-glucose. The production of this ligand is catalyzed by the enzyme glucose-1-phosphate cytidylyltransferase, which utilizes alpha-D-glucose 1-phosphate and MgCTP as substrates. Previous x-ray crystallographic investigations have demonstrated that the Salmonella typhi enzyme complexed with the product CDP-glucose is a fully integrated hexamer displaying 32 point group symmetry. The binding pocket for CDP-glucose is shared between two subunits. Here we describe both a detailed kinetic analysis of the cytidylyltransferase and a structural investigation of the enzyme complexed with MgCTP. These data demonstrate that the reaction catalyzed by the cytidylyltransferase proceeds via a sequential rather than a Bi Bi ping-pong mechanism as was previously reported. Additionally, the enzyme utilizes both CTP and UTP equally well as substrates. The structure of the enzyme with bound MgCTP reveals that the binding pocket for the nucleotide is contained within one subunit rather than shared between two. Key side chains involved in nucleotide binding include Thr(14), Arg(15), Lys(25), and Arg(111). In the previous structure of the enzyme complexed with CDP-glucose, those residues defined by Thr(14) to Ile(21) were disordered. The kinetic and x-ray crystallographic data presented here support a mechanism for this enzyme that is similar to that reported for the glucose-1-phosphate thymidylyltransferases.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cleland, WW (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NIDDK NIH HHS [DK47814] Funding Source: Medline; NIGMS NIH HHS [GM18938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R01DK047814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018938, R37GM018938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; Beyer S, 1998, EUR J BIOCHEM, V258, P1059, DOI 10.1046/j.1432-1327.1998.2581059.x; Cleland W W, 1979, Methods Enzymol, V63, P103; GINSBURG V, 1962, BIOCHEM BIOPH RES CO, V7, P1, DOI 10.1016/0006-291X(62)90132-8; He XMM, 2002, ANNU REV BIOCHEM, V71, P701, DOI 10.1146/annurev.biochem.71.110601.135339; KIMATA K, 1966, J BIOL CHEM, V241, P1099; Koropatkin NM, 2004, J BIOL CHEM, V279, P44023, DOI 10.1074/jbc.M407755200; LINDQVIST L, 1994, J BIOL CHEM, V269, P122; MAYER RM, 1965, J BIOL CHEM, V240, P1900; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; NIKAIDO H, 1966, J BIOL CHEM, V241, P1376; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROUSSEL A, 1998, SILICON GRAPHICS GEO, P77; RUBENSTE.PA, 1974, J BIOL CHEM, V249, P3789; Samuel G, 2003, CARBOHYD RES, V338, P2503, DOI 10.1016/j.carres.2003.07.009; THORSON JS, 1994, J BACTERIOL, V176, P1840, DOI 10.1128/jb.176.7.1840-1849.1994; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Zuccotti S, 2001, J MOL BIOL, V313, P831, DOI 10.1006/jmbi.2001.5073	18	24	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10774	10780		10.1074/jbc.M414111200	http://dx.doi.org/10.1074/jbc.M414111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15634670	hybrid			2022-12-27	WOS:000227559600124
J	Pillinger, MH; Marjanovic, N; Kim, SY; Scher, JU; Izmirly, P; Tolani, S; Dinsell, V; Lee, YC; Blaser, MJ; Abramson, SB				Pillinger, MH; Marjanovic, N; Kim, SY; Scher, JU; Izmirly, P; Tolani, S; Dinsell, V; Lee, YC; Blaser, MJ; Abramson, SB			Matrix metalloproteinase secretion by gastric epithelial cells is regulated by E prostaglandins and MAPKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; HELICOBACTER-PYLORI; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; IN-VITRO; SYNOVIAL FIBROBLASTS; GELATINASE-A; PEPTIC-ULCER; P38	Because matrix metalloproteinases ( MMPs) play roles in inflammatory tissue injury, we asked whether MMP secretion by gastric epithelial cells may contribute to gastric injury in response to signals involved in Helicobacter pylori-induced inflammation and/or cyclooxygenase inhibition. Tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and epidermal growth factor (EGF) stimulated gastric cell MMP-1 secretion, indicating that MMP-1 secretion occurs in inflammatory as well as noninflammatory situations. MMP-1 secretion required activation of the MAPK Erk and subsequent protein synthesis but was down-regulated by the alternate MAPK, p38. In contrast, secretion of MMP-13 was stimulated by TNF-alpha/IL-1 beta but not EGF and was Erk-independent and mediated by p38. MMP-13 secretion was more rapid (peak, 6 h) than MMP-1 (peak >= 30 h) and only partly depended on protein synthesis, suggesting initial release of a pre-existing MMP-13 pool. Therefore, MMP-1 and MMP-13 secretion are differentially regulated by MAPKs. MMP-1 secretion was regulated by E prostaglandins (PGEs) in an Erk-dependent manner. PGEs enhanced Erk activation and MMP-1 secretion in response to EGF but inhibited Erk and MMP-1 when TNF-alpha and IL-1 beta were the stimuli, indicating that the effects of PGEs on gastric cell responses are context-dependent. These data show that secretion of MMPs is differentially regulated by MAPKs and suggest mechanisms through which H. pylori infection and/or cyclooxygenase inhibition may induce epithelial cell signaling to contribute to gastric ulcerogenesis.	New York Harbor Healthcare Syst, Dept Med, Med Serv, New York, NY 10010 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; Hosp Joint Dis & Med Ctr, Dept Rheumatol, New York, NY 10003 USA; Chungbuk Natl Univ, Coll Med, Dept Microbiol, Cheongju 361763, South Korea	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Chungbuk National University	Pillinger, MH (corresponding author), New York Harbor Healthcare Syst, Dept Med, Med Serv, 423 E 23rd St,New York Campus Vet Adm, New York, NY 10010 USA.	michael.pillinger@med.nyu.edu		Dinsell, Victoria/0000-0002-5067-3698; Abramson, Steven/0000-0002-0668-6344; Lee, Yong Chan/0000-0001-8800-6906	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR47206-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM63270] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Atkinson SJ, 2001, FEBS LETT, V491, P222, DOI 10.1016/S0014-5793(01)02204-9; Bebb JR, 2003, GUT, V52, P1408, DOI 10.1136/gut.52.10.1408; Bergin PJ, 2004, HELICOBACTER, V9, P201, DOI 10.1111/j.1083-4389.2004.00232.x; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; Bode W, 2003, BIOCHEM SOC SYMP, V70, P1; Bou-Gharios G, 2004, CELL PROLIFERAT, V37, P207, DOI 10.1111/j.1365-2184.2004.00306.x; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Breyer RM, 2001, MOL PHARMACOL, V59, P1357, DOI 10.1124/mol.59.6.1357; Chan F K, 1997, Gastrointest Endosc Clin N Am, V7, P671; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; CRAWFORD JM, 1999, ROBBINS PATHOLOGIC B, P793; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cunnane G, 2001, ARTHRITIS RHEUM-US, V44, P1744, DOI 10.1002/1529-0131(200108)44:8<1744::AID-ART309>3.0.CO;2-K; Cunnane Gaye, 1998, Archivum Immunologiae et Therapiae Experimentalis, V46, P1; DIBATTISTA JA, 1995, J RHEUMATOL, V22, P123; DIBATTISTA JA, 1994, LAB INVEST, V71, P270; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; ElZimaity HMT, 1996, HUM PATHOL, V27, P1348, DOI 10.1016/S0046-8177(96)90349-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ford AC, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003840.pub4; Foster ML, 2000, DRUG NEWS PERSPECT, V13, P488; Garcia-Gonzalez MA, 2003, CLIN EXP IMMUNOL, V134, P525, DOI 10.1111/j.1365-2249.2003.02325.x; Garcia-Gonzalez MA, 2001, CLIN EXP IMMUNOL, V125, P368, DOI 10.1046/j.1365-2249.2001.01593.x; GEORGESCU HI, 1988, IN VITRO CELL DEV B, V24, P1015; GILLESSEN A, 1993, SCAND J GASTROENTERO, V28, P688, DOI 10.3109/00365529309098273; Gooz M, 2003, GUT, V52, P1250, DOI 10.1136/gut.52.9.1250; Gooz M, 2001, AM J PHYSIOL-GASTR L, V281, pG823, DOI 10.1152/ajpgi.2001.281.3.G823; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hatae N, 2002, J BIOCHEM, V131, P781, DOI 10.1093/oxfordjournals.jbchem.a003165; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; JOHANSSON C, 1982, SCAND J GASTROENTERO, V17, P21; Johansson N, 2000, J CELL SCI, V113, P227; Kobayashi N, 2001, J PHYSIOL PHARMACOL, V52, P195; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lanas A, 2001, GENES IMMUN, V2, P415, DOI 10.1038/sj.gene.6363798; Langman MJS, 2003, FUND CLIN PHARMACOL, V17, P393, DOI 10.1046/j.1472-8206.2003.00179.x; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; Liverton NJ, 1999, J MED CHEM, V42, P2180, DOI 10.1021/jm9805236; Manthey CL, 1998, J LEUKOCYTE BIOL, V64, P409, DOI 10.1002/jlb.64.3.409; Martel-Pelletier J, 2001, BEST PRACT RES CL RH, V15, P805, DOI 10.1053/berh.2001.0195; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; McLay IM, 2001, BIOORGAN MED CHEM, V9, P537, DOI 10.1016/S0968-0896(00)00331-X; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nomura H, 1996, INT J CANCER, V69, P9, DOI 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peek RM, 1995, LAB INVEST, V73, P760; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; PILLINGER MH, 1995, ADV PROSTAG THROMB L, V23, P311; Pillinger MH, 2003, J IMMUNOL, V171, P6080, DOI 10.4049/jimmunol.171.11.6080; Pillinger MH, 1997, ANN NY ACAD SCI, V832, P1, DOI 10.1111/j.1749-6632.1997.tb46232.x; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; REUANEN N, 1998, J BIOL CHEM, V273, P5137; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; SALVATORI R, 1992, ENDOCRINOLOGY, V131, P21, DOI 10.1210/en.131.1.21; SELVA E, 1993, J BIOL CHEM, V268, P2250; Shahin M, 2001, MICROSC RES TECHNIQ, V53, P396, DOI 10.1002/jemt.1108; Slomiany BL, 2001, J PHYSIOL PHARMACOL, V52, P185; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Suzuki K, 1997, J BONE MINER RES, V12, P561, DOI 10.1359/jbmr.1997.12.4.561; Takahashi S, 1999, J PHARMACOL EXP THER, V291, P634; Troost Esther, 2003, Can J Gastroenterol, V17 Suppl B, p8B; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Vincenti MP, 1998, BIOCHEM J, V331, P341, DOI 10.1042/bj3310341; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; Woodgett JR, 1996, CANCER SURV, V27, P127; Wroblewski LE, 2003, J CELL SCI, V116, P3017, DOI 10.1242/jcs.00518; Yamanishi Y, 2001, RHEUM DIS CLIN N AM, V27, P355, DOI 10.1016/S0889-857X(05)70206-4; Yokoyama T, 2000, ALIMENT PHARM THERAP, V14, P193, DOI 10.1046/j.1365-2036.2000.014s1193.x; Zambon CF, 2002, CYTOKINE, V18, P242, DOI 10.1006/cyto.2002.0891; ZURIER RB, 1977, ARTHRITIS RHEUM, V20, P1449, DOI 10.1002/art.1780200802; ZURIER RB, 1977, ARTHRITIS RHEUM, V20, P723, DOI 10.1002/art.1780200213; ZURIER RB, 1971, NATURE, V234, P304, DOI 10.1038/234304a0	82	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9973	9979		10.1074/jbc.M413522200	http://dx.doi.org/10.1074/jbc.M413522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640153	hybrid			2022-12-27	WOS:000227559600029
J	Yadav, VK; Lakshmi, G; Medhamurthy, R				Yadav, VK; Lakshmi, G; Medhamurthy, R			Prostaglandin F-2 alpha-mediated activation of apoptotic signaling cascades in the corpus luteum during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; PROTEIN-KINASE-C; DNA FRAGMENTATION; CASPASE INHIBITORS; EGG EXTRACTS; CELL-DEATH; LIFE-SPAN; IN-VITRO; PROSTAGLANDIN-F2-ALPHA; RAT	Prostaglandin F-2 alpha (PGF(2 alpha)) acting via a G protein-coupled receptor has been shown to induce apoptosis in the corpus luteum of many species. Studies were carried out to characterize changes in the apoptotic signaling cascade(s) culminating in luteal tissue apoptosis during PGF(2 alpha)-induced luteolysis in the bovine species in which initiation of apoptosis was demonstrable at 18 h after exogenous PGF(2 alpha) treatment. An analysis of intrinsic arm of apoptotic signaling cascade elements revealed that PGF(2 alpha) injection triggered increased ratio of Bax to Bcl-2 in the luteal tissue as early as 4 h posttreatment that remained elevated until 18 h. This increase was associated with the elevation in the active caspase-9 and -3 protein levels and activity (p < 0.05) at 4-12 h, but a spurt in the activity was seen only at 18 h posttreatment that could not be accounted for by the changes in the Bax/Bcl-2 ratio or changes in translocation of Bax to mitochondria. Examination of luteal tissue for FasL/Fas death receptor cascade revealed increased expression of FasL and Fas at 18 h accompanied by a significant (p < 0.05) induction in the caspase-8 activity and truncated Bid levels. Furthermore, intrabursal administration of specific caspase inhibitors, downstream to the extrinsic and intrinsic apoptotic signaling cascades, in a pseudopregnant rat model revealed a greater importance of extrinsic apoptotic signaling cascade in mediating luteal tissue apoptosis during PGF(2 alpha) treatment. The DNase responsible for PGF(2 alpha)-induced apoptotic DNA fragmentation was found to be Ca2+/Mg2+-dependent, temperature-sensitive DNase, and optimally active at neutral pH conditions. This putative DNase was inhibited by the recombinant inhibitor of caspase-activated DNase, and immunodepletion of caspase-activated DNase from luteal lysates abolished the observed DNA fragmentation activity. Together, these data demonstrate for the first time temporal and spatial changes in the apoptotic signaling cascades during PGF(2 alpha)-induced apoptosis in the corpus luteum.	Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Medhamurthy, R (corresponding author), Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India.	rmm@mrdg.iisc.ernet.in	medhamurthy, rudraiah/A-9067-2009; yadav, VIJAY k/Q-2540-2016	yadav, VIJAY k/0000-0003-2345-2846				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bacci ML, 1996, DOMEST ANIM ENDOCRIN, V13, P361, DOI 10.1016/0739-7240(96)00049-5; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Bjurulf E, 1998, BIOL REPROD, V59, P17, DOI 10.1095/biolreprod59.1.17; BOONE DL, 1995, BIOL REPROD, V53, P1057, DOI 10.1095/biolreprod53.5.1057; Carambula Silvia F, 2003, Reprod Biol Endocrinol, V1, P15, DOI 10.1186/1477-7827-1-15; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fauvel H, 2001, AM J PHYSIOL-HEART C, V280, pH1608, DOI 10.1152/ajpheart.2001.280.4.H1608; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Johnson CR, 2004, APOPTOSIS, V9, P423, DOI 10.1023/B:APPT.0000031457.90890.13; JUENGEL JL, 1993, ENDOCRINOLOGY, V132, P249, DOI 10.1210/en.132.1.249; Lara HE, 2000, ENDOCRINOLOGY, V141, P1059, DOI 10.1210/en.141.3.1059; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Matousek M, 2001, MOL HUM REPROD, V7, P35, DOI 10.1093/molehr/7.1.35; McCormack JT, 1998, BIOL REPROD, V58, P255, DOI 10.1095/biolreprod58.1.255; McCracken JA, 1999, PHYSIOL REV, V79, P263, DOI 10.1152/physrev.1999.79.2.263; MCGUIRE WJ, 1994, BIOL REPROD, V51, P800, DOI 10.1095/biolreprod51.4.800; MCLEAN MP, 1995, ENDOCRINOLOGY, V136, P4963, DOI 10.1210/en.136.11.4963; Methot N, 2004, J EXP MED, V199, P199, DOI 10.1084/jem.20031791; MOGIL RJ, 1994, J IMMUNOL, V152, P1674; Motta AB, 1999, MOL HUM REPROD, V5, P1011, DOI 10.1093/molehr/5.11.1011; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Niswender GD, 2000, PHYSIOL REV, V80, P1, DOI 10.1152/physrev.2000.80.1.1; NISWENDER GD, 1994, PHYSL REPROD, V2, P781; Pharriss B B, 1972, Recent Prog Horm Res, V28, P51; Prigent-Tessier A, 1999, J BIOL CHEM, V274, P37982, DOI 10.1074/jbc.274.53.37982; Quirk SM, 2000, BIOL REPROD, V63, P49, DOI 10.1095/biolreprod63.1.49; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; Rueda BR, 1997, BIOL REPROD, V56, P186, DOI 10.1095/biolreprod56.1.186; RUEDA BR, 1995, BIOL REPROD, V52, P305, DOI 10.1095/biolreprod52.2.305; Rueda BR, 1999, BIOL REPROD, V60, P1087, DOI 10.1095/biolreprod60.5.1087; Rueda BR, 2000, MOL CELL ENDOCRINOL, V164, P59, DOI 10.1016/S0303-7207(00)00235-5; Stocco CO, 2000, J BIOL CHEM, V275, P37202, DOI 10.1074/jbc.M006016200; Suter J, 2001, BIOL REPROD, V64, P1481, DOI 10.1095/biolreprod64.5.1481; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Taniguchi H, 2002, BIOL REPROD, V66, P754, DOI 10.1095/biolreprod66.3.754; Terranova PF, 1997, DOMEST ANIM ENDOCRIN, V14, P1, DOI 10.1016/S0739-7240(96)00094-X; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Urbano A, 1998, J BIOL CHEM, V273, P34820, DOI 10.1074/jbc.273.52.34820; Wang ZY, 2003, J PHARMACOL SCI, V92, P19, DOI 10.1254/jphs.92.19; WILTBANK MC, 1990, BIOL REPROD, V42, P239, DOI 10.1095/biolreprod42.2.239; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yadav VK, 2004, MOL HUM REPROD, V10, P629, DOI 10.1093/molehr/gah089; Yadav VK, 2002, BIOL REPROD, V67, P752, DOI 10.1095/biolreprod.102.004077; ZELEZNIK AJ, 1989, ENDOCRINOLOGY, V125, P2218, DOI 10.1210/endo-125-4-2218	61	59	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10357	10367		10.1074/jbc.M409596200	http://dx.doi.org/10.1074/jbc.M409596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15623530	hybrid			2022-12-27	WOS:000227559600076
J	Broderick, KE; Singh, V; Zhuang, SH; Kambo, A; Chen, JC; Sharma, VS; Pilz, RB; Boss, GR				Broderick, KE; Singh, V; Zhuang, SH; Kambo, A; Chen, JC; Sharma, VS; Pilz, RB; Boss, GR			Nitric oxide scavenging by the cobalamin precursor cobinamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECREASED PURINE SYNTHESIS; DEPENDENT PROTEIN-KINASE; METHYLMALONYL-COA MUTASE; AMINO-ACID STARVATION; GENE-EXPRESSION; SELECTIVE-INHIBITION; METHIONINE SYNTHASE; INTRINSIC-FACTOR; SEPTIC SHOCK; ANALOGS	Nitric oxide (NO) is an important signaling molecule, and a number of NO synthesis inhibitors and scavengers have been developed to allow study of NO functions and to reduce excess NO levels in disease states. We showed previously that cobinamide, a cobalamin (vitamin B-12) precursor, binds NO with high affinity, and we now evaluated the potential of cobinamide as a NO scavenger in biologic systems. We found that cobinamide reversed NO-stimulated fluid secretion in Drosophila Malpighian tubules, both when applied in the form of a NO donor and when produced intracellularly by nitricoxide synthase. Moreover, feeding flies cobinamide markedly attenuated subsequent NO-induced increases in tubular fluid secretion. Cobinamide was taken up efficiently by cultured rodent cells and prevented NO-induced phosphorylation of the vasodilator-stimulated phosphoprotein VASP both when NO was provided to the cells and when NO was generated intracellularly. Cobinamide appeared to act via scavenging NO because it reduced nitrite and nitrate concentrations in both the fly and mammalian cell systems, and it did not interfere with cGMP-induced phosphorylation of VASP. In rodent and human cells, cobinamide exhibited toxicity at concentrations greater than or equal to 50 muM with toxicity completely prevented by providing equimolar amounts of cobalamin. Combining cobalamin with cobinamide had no effect on the ability of cobinamide to scavenge NO. Cobinamide did not inhibit the in vitro activity of either of the two mammalian cobalamin-dependent enzymes, methionine synthase or methylmalonyl-coenzyme A mutase; however, it did inhibit the in vivo activities of the enzymes in the absence, but not presence, of cobalamin, suggesting that cobinamide toxicity was secondary to interference with cobalamin metabolism. As part of these studies, we developed a facile method for producing and purifying cobinamide. We conclude that cobinamide is an effective intra- and extracellular NO scavenger whose modest toxicity can be eliminated by cobalamin.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gboss@ucsd.edu		Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R01CA090932, T32CA081211] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA90932, 5T32 CA81211] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN DA, 1983, J CHEM SOC DALTON, P217, DOI 10.1039/dt9830000217; BOSS GR, 1984, J BIOL CHEM, V259, P2936; BOSS GR, 1982, J BIOL CHEM, V257, P4242; BRAUN S R, 1970, Journal of Experimental Medicine, V131, P443, DOI 10.1084/jem.131.3.443; Broderick KE, 2003, AM J PHYSIOL-CELL PH, V285, pC1207, DOI 10.1152/ajpcell.00123.2003; Chen YC, 2003, MOL CELL BIOL, V23, P4066, DOI 10.1128/MCB.23.12.4066-4082.2003; Chowdhury S, 1999, BIOCHEMISTRY-US, V38, P15287, DOI 10.1021/bi9914762; CLANCY RM, 1995, P SOC EXP BIOL MED, V210, P93; Cobb JP, 1999, CRIT CARE MED, V27, P855, DOI 10.1097/00003246-199905000-00002; Danishpajooh IO, 2001, J BIOL CHEM, V276, P27296, DOI 10.1074/jbc.M104043200; Dow JAT, 2003, PHYSIOL REV, V83, P687, DOI 10.1152/physrev.00035.2002; El Mabrouk M, 2000, LIFE SCI, V67, P1613, DOI 10.1016/S0024-3205(00)00744-X; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; ELKHOLTY S, 1991, GASTROENTEROLOGY, V101, P1399, DOI 10.1016/0016-5085(91)90094-2; Fedosov SN, 1995, BIOCHEMISTRY-US, V34, P16082, DOI 10.1021/bi00049a023; Fedosov SN, 2002, J BIOL CHEM, V277, P9989, DOI 10.1074/jbc.M111399200; FORD SH, 1991, J CHROMATOGR, V536, P185, DOI 10.1016/S0021-9673(01)89248-7; FORD SH, 1991, J INORG BIOCHEM, V41, P235, DOI 10.1016/0162-0134(91)80015-A; FORSYTH JC, 1993, J TOXICOL-CLIN TOXIC, V31, P277, DOI 10.3109/15563659309000395; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GREENBERG SS, 1995, J PHARMACOL EXP THER, V273, P257; Gudi T, 1996, J BIOL CHEM, V271, P4597; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; HALL A H, 1987, Journal of Emergency Medicine, V5, P115, DOI 10.1016/0736-4679(87)90074-6; Hallemeesch MM, 2002, CLIN NUTR, V21, P111, DOI 10.1054/clnu.2001.0513; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HAYWARD GC, 1965, J CHEM SOC, P6485, DOI 10.1039/jr9650006485; Heneka MT, 1997, J CLIN INVEST, V99, P47, DOI 10.1172/JCI119132; Holscher C, 1997, TRENDS NEUROSCI, V20, P298, DOI 10.1016/S0166-2236(97)01065-5; HOTCHKISS RS, 1992, LANCET, V339, P434, DOI 10.1016/0140-6736(92)90127-O; Ichinose F, 2003, AM J PHYSIOL-HEART C, V285, pH2524, DOI 10.1152/ajpheart.00530.2003; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; IGNARRO L, 1995, ADV PHARMACOL, V45, P105; KANAZAWA S, 1986, P SOC EXP BIOL MED, V183, P333; KIKUCHI M, 1989, CLIN CHIM ACTA, V184, P307, DOI 10.1016/0009-8981(89)90064-8; Kim HW, 2002, SHOCK, V17, P423, DOI 10.1097/00024382-200205000-00014; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; KOLHOUSE JF, 1991, J BIOL CHEM, V266, P23010; KOLHOUSE JF, 1978, NEW ENGL J MED, V299, P785, DOI 10.1056/NEJM197810122991501; KOLHOUSE JF, 1977, J CLIN INVEST, V60, P1381, DOI 10.1172/JCI108899; Komeno M, 2004, J VET MED SCI, V66, P53, DOI 10.1292/jvms.66.53; KONDO H, 1980, P NATL ACAD SCI-BIOL, V77, P817, DOI 10.1073/pnas.77.2.817; KONDO H, 1992, INT J HEMATOL, V56, P167; KONDO H, 1982, J CLIN INVEST, V70, P889, DOI 10.1172/JCI110685; Liaudet L, 1998, J INFECT DIS, V177, P127, DOI 10.1086/513813; LloydJones DM, 1996, ANNU REV MED, V47, P365; Menezes J, 1999, AM J PHYSIOL-GASTR L, V277, pG144, DOI 10.1152/ajpgi.1999.277.1.G144; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Morin MJ, 1998, CRIT CARE MED, V26, P1258, DOI 10.1097/00003246-199807000-00031; Nadler EP, 2001, AM J PHYSIOL-GASTR L, V281, pG173, DOI 10.1152/ajpgi.2001.281.1.G173; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nedvetsky PI, 2002, P NATL ACAD SCI USA, V99, P16510, DOI 10.1073/pnas.262701999; O'Kane CJ, 2003, SEMIN CELL DEV BIOL, V14, P3, DOI 10.1016/S1084-9521(02)00162-3; Oltean S, 2003, J BIOL CHEM, V278, P20778, DOI 10.1074/jbc.M300845200; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; Poon BY, 2003, CIRCULATION, V108, P1107, DOI 10.1161/01.CIR.0000086321.04702.AC; PRATT JM, 1972, INORGANIC CHEM VITAM, P144; Price S, 2003, EUR J PHARMACOL, V472, P111, DOI 10.1016/S0014-2999(03)01826-0; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Riedel B, 1999, BIOCHEM J, V341, P133, DOI 10.1042/0264-6021:3410133; Saavedra-Molina A, 2003, AMINO ACIDS, V24, P95, DOI 10.1007/s00726-002-0331-7; Shah V, 2004, GASTROENTEROLOGY, V126, P903, DOI 10.1053/j.gastro.2003.11.046; Sharma VS, 2003, BIOCHEMISTRY-US, V42, P8900, DOI 10.1021/bi034469t; SHULTZ PJ, 1992, J CLIN INVEST, V90, P1718, DOI 10.1172/JCI116045; SPAIN DA, 1994, J TRAUMA, V36, P720, DOI 10.1097/00005373-199405000-00021; STABLER SP, 1991, J CLIN INVEST, V87, P1422, DOI 10.1172/JCI115148; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; Tickoo S, 2002, CURR OPIN PHARMACOL, V2, P555, DOI 10.1016/S1471-4892(02)00206-0; Tribl B, 2004, AM J PHYSIOL-HEART C, V286, pH340, DOI 10.1152/ajpheart.00234.2003; Vincent JL, 2000, AM J RESP CRIT CARE, V161, P1781, DOI 10.1164/ajrccm.161.6.9812004; Weinberg JB, 1998, BIOCHEM BIOPH RES CO, V246, P393, DOI 10.1006/bbrc.1998.8629; WEISSBACH H, 1963, J BIOL CHEM, V238, P3318; WILLARD HF, 1976, HUM GENET, V34, P277, DOI 10.1007/BF00295291; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; ZERBE NF, 1993, CRIT CARE MED, V21, P465, DOI 10.1097/00003246-199303000-00027; Zhuang SH, 2004, J BIOL CHEM, V279, P10397, DOI 10.1074/jbc.M313048200	78	54	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8678	8685		10.1074/jbc.M410498200	http://dx.doi.org/10.1074/jbc.M410498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632180	hybrid			2022-12-27	WOS:000227453100009
J	Jesch, SA; Zhao, X; Wells, MT; Henry, SA				Jesch, SA; Zhao, X; Wells, MT; Henry, SA			Genome-wide analysis reveals inositol, not choline, as the major effector of Ino2p-Ino4p and unfolded protein response target gene expression in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHETIC-ENZYMES; SACCHAROMYCES-CEREVISIAE ENCODES; ENDOPLASMIC-RETICULUM; INOSITOL-1-PHOSPHATE SYNTHASE; PHOSPHATIDYLSERINE SYNTHASE; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTIONAL ACTIVATION; MICROARRAY EXPERIMENTS; TRANSMEMBRANE PROTEIN; REGULATORY ELEMENTS	In the yeast Saccharomyces cerevisiae, the transcription of many genes encoding enzymes of phospholipid biosynthesis are repressed in cells grown in the presence of the phospholipid precursors inositol and choline. A genome-wide approach using cDNA microarray technology was used to profile the changes in the expression of all genes in yeast that respond to the exogenous presence of inositol and choline. We report that the global response to inositol is completely distinct from the effect of choline. Whereas the effect of inositol on gene expression was primarily repressing, the effect of choline on gene expression was activating. Moreover, the combination of inositol and choline increased the number of repressed genes compared with inositol alone and enhanced the repression levels of a subset of genes that responded to inositol. In all, 110 genes were repressed in the presence of inositol and choline. Two distinct sets of genes exhibited differential expression in response to inositol or the combination of inositol and choline in wild-type cells. One set of genes contained the UAS(INO) sequence and were bound by Ino2p and Ino4p. Many of these genes were also negatively regulated by OPI1, suggesting a common regulatory mechanism for Ino2p, Ino4p, and Opi1p. Another nonoverlapping set of genes was coregulated by the unfolded protein response pathway, an ER- localized stress response pathway, but was not dependent on OPI1 and did not show further repression when choline was present together with inositol. These results suggest that inositol is the major effector of target gene expression, whereas choline plays a minor role.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Henry, SA (corresponding author), 260 Roberts Hall, Ithaca, NY 14853 USA.	sah42@cornell.edu	Henry, Susan/K-5464-2014		NIGMS NIH HHS [GM19629, R37 GM019629, R01 GM019629, F32 GM019629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almaguer C, 2004, J BIOL CHEM, V279, P31937, DOI 10.1074/jbc.M403648200; Almaguer C, 2003, EUKARYOT CELL, V2, P729, DOI 10.1128/EC.2.4.729-736.2003; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; Bedalov A, 2003, MOL CELL BIOL, V23, P7044, DOI 10.1128/MCB.23.19.7044-7054.2003; Boeke J.D., 1991, MOL CELLULAR BIOL YE, V1, P193; Brachmann CB, 1998, YEAST, V14, P115; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 2004, BIOCHEM CELL BIOL, V82, P62, DOI 10.1139/o03-064; Chang HJ, 2004, GENETICS, V168, P1899, DOI 10.1534/genetics.104.032961; Chang HJ, 2002, GENETICS, V162, P29; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Curcio MJ, 1999, TRENDS GENET, V15, P43, DOI 10.1016/S0168-9525(98)01643-6; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Dudoit S, 2002, STAT SINICA, V12, P111; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Graves JA, 2000, GENETICS, V154, P1485; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; Griac P, 1997, J BACTERIOL, V179, P5843, DOI 10.1128/jb.179.18.5843-5848.1997; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1994, J BIOCHEM-TOKYO, V115, P131, DOI 10.1093/oxfordjournals.jbchem.a124287; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; KODAKI T, 1991, J BIOCHEM-TOKYO, V109, P276; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LAI K, 1994, J BIOL CHEM, V269, P2245; LAMPING E, 1994, GENETICS, V137, P55; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Muller O, 2003, J CELL SCI, V116, P1107, DOI 10.1242/jcs.00328; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Papa FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Santiago TC, 2003, J BIOL CHEM, V278, P38723, DOI 10.1074/jbc.M303008200; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; Schwank S, 1997, CURR GENET, V31, P462, DOI 10.1007/s002940050231; Shen HF, 1997, J BIOL CHEM, V272, P11215; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; SWEDE MJ, 1992, METHOD ENZYMOL, V209, P21; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; Wang XJ, 2003, BIOINFORMATICS, V19, P1341, DOI 10.1093/bioinformatics/btg154; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	82	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9106	9118		10.1074/jbc.M411770200	http://dx.doi.org/10.1074/jbc.M411770200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611057	hybrid, Green Accepted			2022-12-27	WOS:000227453100060
J	Puertollano, R				Puertollano, R			Interactions of Tom1L1 with the multivesicular body sorting machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ASSOCIATION; UBIQUITIN-BINDING; GAMMA-ADAPTIN; EGF RECEPTOR; VHS DOMAIN; HUMAN GGA1; PROTEIN; COMPLEX; HRS; TSG101	Tom1L1 ( Tom1-like1) and related proteins Tom1 ((T) under bar arget (o) under barf (M) under bar yb1) and Tom1L2 ( Tom1- like2) constitute a new protein family characterized by the presence of a VHS ((V) under bar ps27p/ (H) under bar rs/(S) under bar tam) domain in the N- terminal portion followed by a GAT ((G) under bar GA (a) under bar nd (T) under bar om) domain. Recently it was demonstrated that the GAT domain of both Tom1 and Tom1L1 binds ubiquitin, suggesting that these proteins might participate in the sorting of ubiquitinated proteins into multivesicular bodies ( MVBs). Here we report a novel interaction between Tom1L1 and members of the MVB sorting machinery. Specifically, we found that the VHS domain of Tom1L1 interacts with Hrs ( (H) under bar epatocyte growth factor-(r) under bar egulated tyrosine kinase (s) under bar ubstrate), whereas a PTAP motif, located between the VHS and GAT domain of Tom1L1, is responsible for binding to TSG101 ((t) under bar umor (s) under bar usceptibility gene 101). Myc epitopetagged Tom1L1 showed a cytosolic distribution but was recruited to endosomes following Hrs expression. In addition, Tom1L1 possesses several tyrosine motifs at the C-terminal region that mediate interactions with members of the Src family kinases and other signaling proteins such as Grb2 and p85. We showed that a fraction of Fyn kinase localizes at endosomes and that this distribution becomes more evident after epidermal growth factor internalization. Moreover, expression of a constitutive active form of Fyn also promoted the recruitment of Tom1L1 to enlarged endosomes. Taken together, we propose that Tom1L1 could act as an intermediary between signaling and degradative pathways.	NHLBI, Lab Cell Signaling, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Puertollano, R (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 50,Rm 3537, Rockville, MD 20852 USA.	puertolr@mail.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000140, ZIAHL000140] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2002, EUR J BIOCHEM, V269, P3881, DOI 10.1046/j.1432-1033.2002.03046.x; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gillooly DJ, 2003, HISTOCHEM CELL BIOL, V120, P445, DOI 10.1007/s00418-003-0591-7; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Katoh Y, 2004, J BIOL CHEM, V279, P24435, DOI 10.1074/jbc.M400059200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Mattera R, 2004, J BIOL CHEM, V279, P31409, DOI 10.1074/jbc.M402183200; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Misra S, 2000, BIOCHEMISTRY-US, V39, P11282, DOI 10.1021/bi0013546; Ponting CP, 1997, J MOL MED-JMM, V75, P467; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2001, J CELL SCI, V114, P2255; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Seto ES, 2002, GENE DEV, V16, P1314, DOI 10.1101/gad.989602; Seykora JT, 2002, J BIOL CHEM, V277, P2812, DOI 10.1074/jbc.M106813200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; SORKIN A, 1991, J BIOL CHEM, V266, P23453; Suer S, 2003, P NATL ACAD SCI USA, V100, P4451, DOI 10.1073/pnas.0831133100; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Yamakami M, 2004, BIOL PHARM BULL, V27, P564, DOI 10.1248/bpb.27.564; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; Zhu GY, 2003, BIOCHEMISTRY-US, V42, P6392, DOI 10.1021/bi034334n; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	62	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9258	9264		10.1074/jbc.M412481200	http://dx.doi.org/10.1074/jbc.M412481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611048	hybrid			2022-12-27	WOS:000227453100076
J	Ulmer, TS; Bax, A; Cole, NB; Nussbaum, RL				Ulmer, TS; Bax, A; Cole, NB; Nussbaum, RL			Structure and dynamics of micelle-bound human alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDIMENSIONAL NMR EXPERIMENTS; MODEL-FREE APPROACH; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; DIPOLAR COUPLINGS; CHEMICAL-SHIFTS; STRUCTURE REFINEMENT; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; LEWY BODIES	Misfolding of the protein alpha-synuclein (aS), which associates with presynaptic vesicles, has been implicated in the molecular chain of events leading to Parkinson's disease. Here, the structure and dynamics of micelle- bound aS are reported. Val(3)-Val(37) and Lys(45)Thr(92) form curved alpha-helices, connected by a well ordered, extended linker in an unexpected anti-parallel arrangement, followed by another short extended region (Gly(93)-Lys(97)), overlapping the recently identified chaperone- mediated autophagy recognition motif and a highly mobile tail (Asp(98)-Ala(140)). Helix curvature is significantly less than predicted based on the native micelle shape, indicating a deformation of the micelle by aS. Structural and dynamic parameters show a reduced helical content for Ala(30)-Val37. A dynamic variation in interhelical distance on the microsecond timescale is complemented by enhanced sub-nanosecond timescale dynamics, particularly in the remarkably glycine-rich segments of the helices. These unusually rich dynamics may serve to mitigate the effect of aS binding on membrane fluidity. The well ordered conformation of the helix- helix connector indicates a defined interaction with lipidic surfaces, suggesting that, when bound to larger diameter synaptic vesicles, it can act as a switch between this structure and a previously proposed uninterrupted helix.	NHGRI, Lab Chem Phys, NIDDK, NIH, Bethesda, MD 20892 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Ulmer, TS (corresponding author), NHGRI, Lab Chem Phys, NIDDK, NIH, Bethesda, MD 20892 USA.	tobias.ulmer@nih.gov			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029020] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson CAF, 2002, STRUCTURE, V10, P175, DOI 10.1016/S0969-2126(02)00700-1; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bansal M, 2000, J BIOMOL STRUCT DYN, V17, P811, DOI 10.1080/07391102.2000.10506570; Bertini I, 2001, METHOD ENZYMOL, V339, P314, DOI 10.1016/S0076-6879(01)39320-5; Bruce CD, 2002, J PHYS CHEM B, V106, P3788, DOI 10.1021/jp013616z; Bussell R, 2003, J MOL BIOL, V329, P763, DOI 10.1016/S0022-2836(03)00520-5; Case DA, 1998, CURR OPIN STRUC BIOL, V8, P624, DOI 10.1016/S0959-440X(98)80155-3; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Delaglio F, 2000, J AM CHEM SOC, V122, P2142, DOI 10.1021/ja993603n; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Dev KK, 2003, NEUROPHARMACOLOGY, V45, P14, DOI 10.1016/S0028-3908(03)00140-0; Donaldson LW, 2001, J AM CHEM SOC, V123, P9843, DOI 10.1021/ja011241p; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fernandez CO, 2004, EMBO J, V23, P2039, DOI 10.1038/sj.emboj.7600211; Garg G, 2004, PRAMANA-J PHYS, V63, P351, DOI 10.1007/BF02704997; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; Iwahara J, 2004, J AM CHEM SOC, V126, P5879, DOI 10.1021/ja031580d; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jaroniec CP, 2004, J BIOMOL NMR, V30, P181, DOI 10.1023/B:JNMR.0000048946.71249.2f; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo E, 2004, EUR J BIOCHEM, V271, P3180, DOI 10.1111/j.1432-1033.2004.04250.x; Kahle PJ, 2002, J NEUROCHEM, V82, P449, DOI 10.1046/j.1471-4159.2002.01020.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kumar S, 1998, BIOPHYS J, V75, P1935, DOI 10.1016/S0006-3495(98)77634-9; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Louhivuori M, 2004, J BIOMOL NMR, V29, P517, DOI 10.1023/B:JNMR.0000034347.01925.ad; Meiler J, 2001, J AM CHEM SOC, V123, P6098, DOI 10.1021/ja010002z; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nuscher B, 2004, J BIOL CHEM, V279, P21966, DOI 10.1074/jbc.M401076200; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Oldfield E, 2002, ANNU REV PHYS CHEM, V53, P349, DOI 10.1146/annurev.physchem.53.082201.124235; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; REHAGE H, 1991, MOL PHYS, V74, P933, DOI 10.1080/00268979100102721; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Sharon R, 2003, J BIOL CHEM, V278, P49874, DOI 10.1074/jbc.M309127200; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; SKLENAR V, 1995, J MAGN RESON SER A, V114, P132, DOI 10.1006/jmra.1995.1119; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y; Tycko R, 2000, J AM CHEM SOC, V122, P9340, DOI 10.1021/ja002133q; Ulmer TS, 2003, J AM CHEM SOC, V125, P9179, DOI 10.1021/ja0350684; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9; Zhu G, 2000, J MAGN RESON, V143, P423, DOI 10.1006/jmre.2000.2022	70	655	661	4	186	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9595	9603		10.1074/jbc.M411805200	http://dx.doi.org/10.1074/jbc.M411805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615727	hybrid			2022-12-27	WOS:000227453100114
J	Lee, EO; Kang, JL; Chong, YH				Lee, EO; Kang, JL; Chong, YH			The amyloid-beta peptide suppresses transforming growth factor-beta 1-induced matrix metalloproteinase-2 production via Smad7 expression in human monocytic THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; DIRECT BINDING; PLASMA-LEVELS; RECEPTORS-I; MATRIX-METALLOPROTEINASE-9; GROWTH-FACTOR-BETA-1; TGF-BETA-1	Accumulation of the amyloid-beta(Abeta) peptide in the brain is a crucial factor in the development of Alzheimer disease. Expression of transforming growth factor-beta1 (TGF-beta1), an immunosuppressive cytokine, has been associated in vivo with Abeta accumulation in transgenic mice and recently with Abeta clearance by activated microglia, suggesting its deleterious and beneficial effects in neuronal cells. In this study, we demonstrated that TGF-beta1 stimulated the production of matrix metalloproteinase-2 (MMP-2) in a time- and dose-dependent manner in a human monocytic THP-1 cell line. Notably, we found that Abeta1 - 42 consistently inhibited the TGF-beta1-induced production of MMP-2, the endogenous gene containing Smad response elements, whereas the reverse peptide, Abeta42 - 1, evidenced little effect. Additionally, Abeta1 - 42 reduced TGF-beta1-induced increase in plasminogen activator inhibitor-1 (PAI-1). This inhibitory effect of Abeta1 - 42 was also seen in human astroglial T98G cell line. Furthermore, Abeta1 - 42 significantly induced the expression of Smad7, which appears in turn to mediate the Abeta suppression of the TGF-beta1-induced MMP-2 production. Indeed, Smad7 overexpression mimicked the inhibitory effect of Abeta1 - 42 on TGF-beta1-induced MMP-2 production. Importantly, Abeta1 - 42 markedly suppressed the transactivation of the transfected reporter construct, p3TP-Lux, which contains TGF-beta1-inducible Smad response elements. This was concomitant with a decreased MMP-2 production in TGF-beta1-treated cells. Inhibition of cellular Smad7 levels via the small interference RNA method significantly ameliorated the Abeta1 - 42-mediated suppression of TGF-beta1-inducible transcription reporter activity, thereby restoring MMP-2 induction, whereas Smad7 transfection down-regulated TGF-beta1-inducible transcription reporter activity. Collectively, these data suggest that Abeta1 - 42 may play an important role in the negative regulation of TGF-beta1-induced MMP-2 production via Smad7 expression.	Ewha Womans Univ, Coll Med, Dept Microbiol, Div Mol Biol & Neurosci,Ewha Med Res Inst, Seoul 158710, South Korea; Ewha Womans Univ, Coll Med, Dept Physiol, Div Mol Biol & Neurosci,Ewha Med Res Inst, Seoul 158710, South Korea	Ewha Womans University; Ewha Womans University	Chong, YH (corresponding author), Ewha Womans Univ, Coll Med, Dept Microbiol, Div Mol Biol & Neurosci,Ewha Med Res Inst, 911-1,Mok 6 Dong, Seoul 158710, South Korea.	younghae@ewha.ac.kr						Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; Backstrom JR, 1996, J NEUROSCI, V16, P7910; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Chong YH, 2003, MOL PHARMACOL, V63, P690, DOI 10.1124/mol.63.3.690; Chong YH, 2001, J BIOL CHEM, V276, P23511, DOI 10.1074/jbc.M009466200; Cordoliani-Mackowiak MA, 2003, ARCH NEUROL-CHICAGO, V60, P585, DOI 10.1001/archneur.60.4.585; Dai CS, 2003, J BIOL CHEM, V278, P12537, DOI 10.1074/jbc.M300777200; De Servi B, 2002, EXP GERONTOL, V37, P813, DOI 10.1016/S0531-5565(02)00018-9; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dhandapani KM, 2003, CELL BIOCHEM BIOPHYS, V39, P13, DOI 10.1385/CBB:39:1:13; Docagne F, 2002, MOL CELL NEUROSCI, V21, P634, DOI 10.1006/mcne.2002.1206; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Gabriel C, 2002, FASEB J, V16, P277, DOI 10.1096/fj.02-0403fje; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Grammas P, 2002, AM J PATHOL, V160, P1583, DOI 10.1016/S0002-9440(10)61105-4; Greene RM, 2003, J CELL PHYSIOL, V197, P261, DOI 10.1002/jcp.10355; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Harris-White ME, 1998, J NEUROSCI, V18, P10366; Helbecque N, 2003, NEUROSCI LETT, V350, P181, DOI 10.1016/S0304-3940(03)00905-4; Huang SS, 1998, J BIOL CHEM, V273, P27640, DOI 10.1074/jbc.273.42.27640; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jung SS, 2003, J NEUROCHEM, V85, P1208, DOI 10.1046/j.1471-4159.2003.01745.x; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lanzrein AS, 1998, ALZ DIS ASSOC DIS, V12, P215, DOI 10.1097/00002093-199809000-00016; Lee EO, 2004, J NEUROIMMUNOL, V155, P21, DOI 10.1016/j.jneuroim.2004.05.012; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lippa CF, 1998, NEUROBIOL AGING, V19, P527, DOI 10.1016/S0197-4580(98)00089-X; Lorenzl S, 2003, NEUROCHEM INT, V43, P191, DOI 10.1016/S0197-0186(03)00004-4; Luedecking EK, 2000, HUM GENET, V106, P565, DOI 10.1007/s004390050026; Mazur-Kolecka B, 2003, NEUROBIOL AGING, V24, P355, DOI 10.1016/S0197-4580(02)00095-7; Melchor JP, 2003, J NEUROSCI, V23, P8867; Mousseau DD, 2003, J BIOL CHEM, V278, P38715, DOI 10.1074/jbc.M304080200; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2002, TRENDS MOL MED, V8, P361, DOI 10.1016/S1471-4914(02)02376-6; Perini G, 2002, J EXP MED, V195, P907, DOI 10.1084/jem.20011797; Ren RF, 1997, MOL BRAIN RES, V48, P315, DOI 10.1016/S0169-328X(97)00108-3; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shek FWT, 2002, AM J PATHOL, V160, P1787, DOI 10.1016/S0002-9440(10)61125-X; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Soeda S, 2004, NEUROREPORT, V15, P855, DOI 10.1097/00001756-200404090-00024; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stawowy P, 2004, CARDIOVASC RES, V63, P87, DOI 10.1016/j.cardiores.2004.03.010; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tenner AJ, 2001, NEUROBIOL AGING, V22, P849, DOI 10.1016/S0197-4580(01)00301-3; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vaday GG, 2001, J LEUKOCYTE BIOL, V69, P613; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321	62	38	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7845	7853		10.1074/jbc.M409101200	http://dx.doi.org/10.1074/jbc.M409101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632190	hybrid			2022-12-27	WOS:000227395700051
J	Nakamura, Y; Awai, K; Masuda, T; Yoshioka, Y; Takamiya, K; Ohta, H				Nakamura, Y; Awai, K; Masuda, T; Yoshioka, Y; Takamiya, K; Ohta, H			A novel phosphatidylcholine-hydrolyzing phospholipase C induced by phosphate starvation in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE GENES; DIGALACTOSYLDIACYLGLYCEROL SYNTHASE; PLASMA; CELLS; GROWTH; PURIFICATION; PROTEINS; TISSUES; STRESS; DGD2	During phosphate starvation, it is known that phospholipids are degraded, and conversely, a nonphosphorus galactolipid digalactosyldiacylglycerol accumulates in the root plasma membrane of plants. We report a novel phospholipase C that hydrolyzes phosphatidylcholine and is greatly induced in response to phosphate deprivation in Arabidopsis. Since phosphatidylcholine-hydrolyzing activity by phospholipase C was highly upregulated in phosphate-deprived plants, gene expression of some phospholipase C was expected to be induced during phosphate starvation. Based on amino acid sequence similarity to a bacterial phosphatidylcholine-hydrolyzing phospholipase C, six putative phospholipase Cs were identified in the Arabidopsis genome, one of which, NPC4, showed significant transcriptional activation upon phosphate limitation. Molecular cloning and functional expression of NPC4 confirmed that the NPC4 gene encoded a functional phosphatidylcholine-hydrolyzing phospholipase C that did not require Ca2+ for its activity. Subcellular localization analysis showed that NPC4 protein was highly enriched in the plasma membrane. Analyses of transferred DNA-tagged npc4 mutants revealed that disruption of NPC4 severely reduces the phosphatidylcholine-hydrolyzing phospholipase C activity in response to phosphate starvation. These results suggest that NPC4 plays an important role in the supply of both inorganic phosphate and diacylglycerol from membrane-localized phospholipids that would be used for phosphate supplementation and the replacement of polar lipids in the root plasma membrane during phosphate deprivation.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Kanagawa 2268501, Japan; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Nagoya Univ, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Tokyo Institute of Technology; Michigan State University; Nagoya University	Ohta, H (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259-B-14 Nagatsuta Cho, Kanagawa 2268501, Japan.	hohta@bio.titech.ac.jp	Nakamura, Yuki/AAY-2551-2021; Masuda, Tatsuru/E-7942-2013; Awai, Koichiro/B-5119-2010; Ohta, Hiroyuki/B-1840-2014	Nakamura, Yuki/0000-0003-2897-4301; Masuda, Tatsuru/0000-0002-1585-5832; Awai, Koichiro/0000-0002-1731-7499; Ohta, Hiroyuki/0000-0002-1068-3242				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; [Anonymous], METHODS CHLOROPLAST; Awai K, 2001, P NATL ACAD SCI USA, V98, P10960, DOI 10.1073/pnas.181331498; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHRASTIL J, 1987, J AGR FOOD CHEM, V35, P624, DOI 10.1021/jf00076a045; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hirayama T, 1997, PLANT MOL BIOL, V34, P175, DOI 10.1023/A:1005885230896; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; Johansen KA, 1996, INFECT IMMUN, V64, P3259, DOI 10.1128/IAI.64.8.3259-3266.1996; Jouhet J, 2003, FEBS LETT, V544, P63, DOI 10.1016/S0014-5793(03)00477-0; Joyard J, 1998, LIPIDS PHOTOSYNTHESI, P21, DOI DOI 10.1007/0-306-48087-5_; KATES M, 1955, CAN J BIOCHEM PHYS, V33, P575, DOI 10.1139/y55-072; Kawaguchi J, 2001, J BONE MINER RES, V16, P260, DOI 10.1359/jbmr.2001.16.2.260; Kelly AA, 2003, PLANT CELL, V15, P2694, DOI 10.1105/tpc.016675; Kelly AA, 2002, J BIOL CHEM, V277, P1166, DOI 10.1074/jbc.M110066200; Kobayashi K, 2004, PLANT PHYSIOL, V134, P640, DOI 10.1104/pp.103.032656; LARSSON C, 1987, METHOD ENZYMOL, V148, P558; Laxalt AM, 2002, CURR OPIN PLANT BIOL, V5, P332, DOI 10.1016/S1369-5266(02)00268-6; LYNCH J, 1995, PLANT PHYSIOL, V109, P7, DOI 10.1104/pp.109.1.7; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nakamura Y, 2003, LIPIDS, V38, P1107, DOI 10.1007/s11745-006-1166-x; Ohshima Y, 2001, PLANT CELL PHYSIOL, V42, P1119, DOI 10.1093/pcp/pce141; Qin CB, 2002, PLANT PHYSIOL, V128, P1057, DOI 10.1104/pp.010928; Raghothama KG, 1999, ANNU REV PLANT PHYS, V50, P665, DOI 10.1146/annurev.arplant.50.1.665; ROUETMAYER MA, 1995, LIPIDS, V30, P739, DOI 10.1007/BF02537801; Schaller GE, 1995, METHOD CELL BIOL, V50, P129, DOI 10.1016/S0091-679X(08)61027-4; Scherer GFE, 2002, BIOCHEM BIOPH RES CO, V293, P766, DOI 10.1016/S0006-291X(02)00292-9; STRAUSS H, 1976, LIPIDS, V11, P442, DOI 10.1007/BF02532834; Titball RW, 1998, J APPL MICROBIOL, V84, p127S; Wang XM, 2004, CURR OPIN PLANT BIOL, V7, P329, DOI 10.1016/j.pbi.2004.03.012; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; Wang XM, 2001, ANNU REV PLANT PHYS, V52, P211, DOI 10.1146/annurev.arplant.52.1.211; Yamaryo Y, 2003, PLANT CELL PHYSIOL, V44, P844, DOI 10.1093/pcp/pcg110; YANG SF, 1967, J BIOL CHEM, V242, P477; YOTSUSHIMA K, 1992, BIOSCI BIOTECH BIOCH, V56, P1247, DOI 10.1271/bbb.56.1247; YOTSUSHIMA K, 1993, PLANT PHYSIOL, V102, P165, DOI 10.1104/pp.102.1.165	42	183	207	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7469	7476		10.1074/jbc.M408799200	http://dx.doi.org/10.1074/jbc.M408799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15618226	hybrid			2022-12-27	WOS:000227395700008
J	Deb-Rinker, P; Ly, D; Jezierski, A; Sikorska, M; Walker, PR				Deb-Rinker, P; Ly, D; Jezierski, A; Sikorska, M; Walker, PR			Sequential DNA methylation of the Nanog and Oct-4 upstream regions in human NT2 cells during neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; PLURIPOTENCY SUSTAINING FACTOR; GENE-EXPRESSION; ES CELLS; EC CELLS; IN-VIVO; MOUSE; TERATOCARCINOMA; IDENTIFICATION; CLONING	Human NT2 cells, which differentiate into neurons and astrocytes, initially express and then permanently down-regulate Nanog and Oct-4 (POU51F1). We investigated the relationship between the expression of these genes and the methylation state of their 5-flanking regions. Gene expression and DNA methylation were assayed with quantitative polymerase chain reaction and bisulfite genomic sequencing, respectively. Retinoic acid-induced differentiation of NT2 cells to neurons is accompanied by a sequential decrease in the expression of both genes, paralleled by sequential epigenetic modification of their upstream regions. This is the first report demonstrating changes in DNA methylation in the promoter regions of Nanog and Oct-4 in a human cell line.	Natl Res Council Canada, Inst Biol Sci, Neurobiol Program, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Deb-Rinker, P (corresponding author), Natl Res Council Canada, Inst Biol Sci, Neurobiol Program, Bldg M-54,1200 Montreal Rd, Ottawa, ON K1A 0R6, Canada.	Paromita.Deb-Rinker@nrc.gc.ca						BENSHUSHAN E, 1993, MOL CELL BIOL, V13, P891, DOI 10.1128/MCB.13.2.891; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Cavaleri F, 2003, CELL, V113, P551, DOI 10.1016/S0092-8674(03)00394-5; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dey A, 1997, METHODS, V11, P197, DOI 10.1006/meth.1996.0406; Fuhrmann G, 1999, CELL MOL BIOL, V45, P717; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hart AH, 2004, DEV DYNAM, V230, P187, DOI 10.1002/dvdy.20034; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Minucci S, 1996, EMBO J, V15, P888, DOI 10.1002/j.1460-2075.1996.tb00423.x; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Nordhoff V, 2001, MAMM GENOME, V12, P309, DOI 10.1007/s003350010279; Pan GJ, 2003, CELL RES, V13, P499, DOI 10.1038/sj.cr.7290193; ROSFJORD E, 1994, BIOCHEM BIOPH RES CO, V203, P1795, DOI 10.1006/bbrc.1994.2395; Schoorlemmer J, 1995, MOL BIOL REP, V21, P129, DOI 10.1007/BF00997235; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Tsuji-Takayama K, 2004, BIOCHEM BIOPH RES CO, V323, P86, DOI 10.1016/j.bbrc.2004.08.052; WALKER PR, 2005, IN PRESS CELL CYCLE; Zhang ZJ, 2004, J NEUROCHEM, V88, P1424, DOI 10.1046/j.1471-4159.2003.02275.x	26	149	165	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6257	6260		10.1074/jbc.C400479200	http://dx.doi.org/10.1074/jbc.C400479200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15615706	hybrid			2022-12-27	WOS:000227332700003
J	Fujimura, T; Solorzano, A; Esteban, R				Fujimura, T; Solorzano, A; Esteban, R			Native replication intermediates of the yeast 20 S RNA virus have a single-stranded RNA backbone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIPARTITE 3'-CIS-ACTING SIGNAL; 23 S RNA; SACCHAROMYCES-CEREVISIAE; RIBONUCLEOPROTEIN COMPLEX; IN-VIVO; 20S RNA; POLYMERASE; FORM; IDENTIFICATION; ENCAPSIDATION	20 S RNA virus is a positive strand RNA virus found in Saccharomyces cerevisiae. The viral genome (2.5 kb) only encodes its RNA polymerase (p91) and forms a ribonucleoprotein complex with p91 in vivo. A lysate prepared from 20 S RNA-induced cells showed an RNA polymerase activity that synthesized the positive strands of viral genome. When in vitro products, after phenol extraction, were analyzed in a time course, radioactive nucleotides were first incorporated into double-stranded RNA (dsRNA) intermediates and then chased out to the final single-stranded RNA products. The positive and negative strands in these dsRNA intermediates were non-covalently associated, and the release of the positive strand products from the intermediates required a net RNA synthesis. We found, however, that these dsRNA intermediates were an artifact caused by phenol extraction. Native replication intermediates had a single-stranded RNA backbone as judged by RNase sensitivity experiments, and they migrated distinctly from a dsRNA form in non-denaturing gels. Upon completion of RNA synthesis, positive strand RNA products as well as negative strand templates were released from replication intermediates. These results indicate that the native replication intermediates consist of a positive strand of less than unit length and a negative strand template loosely associated, probably through the RNA polymerase p91. Therefore, W, a dsRNA form of 20 S RNA that accumulates in yeast cells grown at 37 degreesC, is not an intermediate in the 20 S RNA replication cycle, but a by-product.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Fujimura, T (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Avda Campo Charro S-N, Salamanca 37007, Spain.	tfujimura@usal.es	Esteban, Rosa/K-4356-2014; Fujimura, Tsutomu/K-5807-2014	Esteban, Rosa/0000-0001-6804-7209; Fujimura, Tsutomu/0000-0002-9457-6769; Solorzano, Alicia/0000-0003-0072-3463				BALTIMORE D, 1968, J MOL BIOL, V32, P359, DOI 10.1016/0022-2836(68)90015-6; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; DOBKIN C, 1979, BIOCHEMISTRY-US, V18, P2038, DOI 10.1021/bi00577a030; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; Esteban R, 2003, P NATL ACAD SCI USA, V100, P2568, DOI 10.1073/pnas.0530167100; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; Fujimura T, 2004, J BIOL CHEM, V279, P44219, DOI 10.1074/jbc.M408530200; Fujimura T, 2004, J BIOL CHEM, V279, P13215, DOI 10.1074/jbc.M313797200; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; GarciaCuellar MP, 1997, RNA, V3, P27; GARCIACUELLAR MP, 1996, THESIS U SALAMANCA; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; Kamen R., 1975, RNA PHAGES, P203; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; MEYER J, 1978, VIROLOGY, V85, P445, DOI 10.1016/0042-6822(78)90451-8; NOVAK JE, 1991, J VIROL, V65, P3384, DOI 10.1128/JVI.65.6.3384-3387.1991; RICHARDS OC, 1984, J MOL BIOL, V173, P325, DOI 10.1016/0022-2836(84)90124-4; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P20363, DOI 10.1074/jbc.273.32.20363; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4; Solorzano A, 2000, J BIOL CHEM, V275, P26428, DOI 10.1074/jbc.M002281200; SPIEGELMAN S, 1968, COLD SPRING HARB SYM, V33, P101, DOI 10.1101/SQB.1968.033.01.015; WEISSMANN C, 1968, COLD SPRING HARB SYM, V33, P83, DOI 10.1101/SQB.1968.033.01.014; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 2000, VIRUS TAXONOMY, P651; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905	30	11	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7398	7406		10.1074/jbc.M412048200	http://dx.doi.org/10.1074/jbc.M412048200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611054	hybrid			2022-12-27	WOS:000227332700132
J	Hayashi, M; Yagi, M; Nito, K; Kamada, T; Nishimura, M				Hayashi, M; Yagi, M; Nito, K; Kamada, T; Nishimura, M			Differential contribution of two peroxisomal protein receptors to the maintenance of peroxisomal functions in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE ORGANELLE FORMATION; TARGETING SIGNAL TYPE-1; DOUBLE-STRANDED-RNA; LONGER ISOFORM; PTS1 RECEPTOR; GENE; IMPORT; MICROBODIES; EXPRESSION; MUTANT	Peroxisomes in higher plant cells are known to differentiate in function depending on the cell type. Because of the functional differentiation, plant peroxisomes are subdivided into several classes, such as glyoxysomes and leaf peroxisomes. These peroxisomal functions are maintained by import of newly synthesized proteins containing one of two peroxisomal targeting signals known as PTS1 and PTS2. These targeting signals are known to be recognized by the cytosolic receptors, Pex5p and Pex7p, respectively. To demonstrate the contribution of Pex5p and Pex7p to the maintenance of peroxisomal functions in plants, double-stranded RNA constructs were introduced into the genome of Arabidopsis thaliana. Expression of the PEX5 and PEX7 genes was efficiently reduced by the double-stranded RNA-mediated interference in the transgenic Arabidopsis. The Pex5p-deficient Arabidopsis showed reduced activities for both glyoxysomal and leaf peroxisomal functions. An identical phenotype was observed in a transgenic Arabidopsis overexpressing functionally defective Pex5p. In contrast, the Pex7p-deficient Arabidopsis showed reduced activity for glyoxysomal function but not for leaf peroxisomal function. Analyses of peroxisomal protein import in the transgenic Arabidopsis revealed that Pex5p was involved in import of both PTS1-containing proteins and PTS2-containing proteins, whereas Pex7p contributed to the import of only PTS2-containing proteins. Overall, the results indicated that Pex5p and Pex7p play different roles in the maintenance of glyoxysomal and leaf peroxisomal functions in plants.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Hayashi, M (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.	makoto@nibb.ac.jp		Nishimura, Mikio/0000-0001-7960-9721				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEEVERS H, 1979, ANNU REV PLANT PHYS, V30, P159, DOI 10.1146/annurev.pp.30.060179.001111; BEEVERS H, 1982, ANN NY ACAD SCI, V386, P243, DOI 10.1111/j.1749-6632.1982.tb21420.x; Brickner DG, 1998, PLANT PHYSIOL, V116, P309, DOI 10.1104/pp.116.1.309; Brites P, 2003, HUM MOL GENET, V12, P2255, DOI 10.1093/hmg/ddg236; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Charlton W, 2002, PLANT PEROXISOMES, P385; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; FRANKLIN LA, 1992, PLANTA, V186, P399, DOI 10.1007/BF00195321; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; Hayashi M, 1996, PLANT J, V10, P225, DOI 10.1046/j.1365-313X.1996.10020225.x; Hayashi M, 1997, PLANT CELL PHYSIOL, V38, P759, DOI 10.1093/oxfordjournals.pcp.a029233; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; Hayashi M, 2000, J PLANT RES, V113, P103, DOI 10.1007/PL00013888; Hayashi M, 2000, CELL BIOCHEM BIOPHYS, V32, P295, DOI 10.1385/CBB:32:1-3:295; Hayashi M, 2000, EMBO J, V19, P5701, DOI 10.1093/emboj/19.21.5701; Hu JP, 2002, SCIENCE, V297, P405, DOI 10.1126/science.1073633; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; James P, 1996, GENETICS, V144, P1425; Kamada T, 2003, PLANT CELL PHYSIOL, V44, P1275, DOI 10.1093/pcp/pcg173; KATO A, 1995, PLANT MOL BIOL, V27, P377, DOI 10.1007/BF00020191; Kato A, 1996, PLANT MOL BIOL, V31, P843, DOI 10.1007/BF00019471; Klein ATJ, 2001, J BIOL CHEM, V276, P15034, DOI 10.1074/jbc.M010776200; KRAUSE GH, 1988, PHYSIOL PLANTARUM, V74, P566, DOI 10.1111/j.1399-3054.1988.tb02020.x; Kunau WH, 1998, CURR OPIN MICROBIOL, V1, P232, DOI 10.1016/S1369-5274(98)80016-7; Levin JZ, 2000, PLANT MOL BIOL, V44, P759, DOI 10.1023/A:1026584607941; Lin Y, 1999, SCIENCE, V284, P328, DOI 10.1126/science.284.5412.328; Mano S, 2002, PLANT CELL PHYSIOL, V43, P331, DOI 10.1093/pcp/pcf037; Matsumura T, 2000, J BIOL CHEM, V275, P21715, DOI 10.1074/jbc.M000721200; Motley AM, 2000, EMBO REP, V1, P40, DOI 10.1093/embo-reports/kvd010; Mullen RT, 2002, PLANT PEROXISOMES, P339; Mullen RT, 2001, TRENDS PLANT SCI, V6, P256, DOI 10.1016/S1360-1385(01)01951-3; Nishimura M, 1996, CELL STRUCT FUNCT, V21, P387, DOI 10.1247/csf.21.387; Nito K, 2002, PLANT CELL PHYSIOL, V43, P355, DOI 10.1093/pcp/pcf057; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; QUIST G, 1992, PLANTA, V186, P450; Schumann U, 2003, P NATL ACAD SCI USA, V100, P9626, DOI 10.1073/pnas.1633697100; Smith NA, 2000, NATURE, V407, P319, DOI 10.1038/35030305; Sparkes IA, 2003, PLANT PHYSIOL, V133, P1809, DOI 10.1104/pp.103.031252; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; TOLBERT NE, 1982, ANN NY ACAD SCI, V386, P254, DOI 10.1111/j.1749-6632.1982.tb21421.x; Trelease RN, 1996, PROTOPLASMA, V195, P156, DOI 10.1007/BF01279194; Wimmer C, 1998, PLANT J, V16, P453, DOI 10.1046/j.1365-313x.1998.00320.x; Zolman BK, 2004, P NATL ACAD SCI USA, V101, P1786, DOI 10.1073/pnas.0304368101; Zolman BK, 2000, GENETICS, V156, P1323	47	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14829	14835		10.1074/jbc.M411005200	http://dx.doi.org/10.1074/jbc.M411005200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15637057	hybrid			2022-12-27	WOS:000228236800061
J	Szabo, I; Bock, J; Jekle, A; Soddemann, M; Adams, C; Lang, F; Zoratti, M; Gulbins, E				Szabo, I; Bock, J; Jekle, A; Soddemann, M; Adams, C; Lang, F; Zoratti, M; Gulbins, E			A novel potassium channel in lymphocyte mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; T-LYMPHOCYTES; KV1.3; MEMBRANE; TRANSPORT; PROTEIN; SUBUNIT; CELL; PURIFICATION; CALCIUM	The margatoxin-sensitive Kv1.3 is the major potassium channel in the plasma membrane of T lymphocytes. Electron microscopy, patch clamp, and immunological studies identified the potassium channel Kv1.3, thought to be localized exclusively in the cell membrane, in the inner mitochondrial membrane of T lymphocytes. Patch clamp of mitoplasts and mitochondrial membrane potential measurements disclose the functional expression of a mitochondrial margatoxin-sensitive potassium channel. To identify unambiguously the mitochondrial localization of Kv1.3, we employed a genetic model and stably transfected CTLL-2 cells, which are genetically deficient for this channel, with Kv1.3. Mitochondria isolated from Kv1.3-reconstituted CTLL-2 expressed the channel protein and displayed an activity, which was identical to that observed in Jurkat mitochondria, whereas mitochondria of mock-transfected cells lacked a channel with the characteristics of Kv1.3. Our data provide the first molecular identification of a mitochondrial potassium conductance.	Univ Padua, Dept Biol, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Essen Gesamthsch, Dept Mol Biol, D-45122 Essen, Germany; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Duisburg Essen; Eberhard Karls University of Tubingen	Szabo, I (corresponding author), Univ Padua, Dept Biol, Viale G Colombo 3, I-35121 Padua, Italy.	ildi@civ.bio.unipd.it	Szabo, Ildiko/AAW-5972-2021; Padova, Ildiko/K-5344-2016; Gulbins, Erich/L-6989-2014	Szabo, Ildiko/0000-0002-3637-3947; Gulbins, Erich/0000-0002-3117-1342; Jekle, Andreas/0000-0001-9416-2622				Bahring R, 2004, MOL MEMBR BIOL, V21, P19, DOI 10.1080/09687680310001597749; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; BEDNAREK MA, 1994, BIOCHEM BIOPH RES CO, V198, P619, DOI 10.1006/bbrc.1994.1090; Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Beutner G, 2001, J BIOL CHEM, V276, P21482, DOI 10.1074/jbc.M101486200; Bock J, 2002, BIOCHEM BIOPH RES CO, V295, P526, DOI 10.1016/S0006-291X(02)00695-2; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; CAHALAN MD, 1985, J PHYSIOL-LONDON, V358, P197, DOI 10.1113/jphysiol.1985.sp015548; Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; Dahlem YA, 2004, BBA-BIOENERGETICS, V1656, P46, DOI 10.1016/j.bbabio.2004.01.003; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; DIWAN JJ, 1988, BIOCHEM BIOPH RES CO, V153, P224, DOI 10.1016/S0006-291X(88)81212-9; Dreyer I, 2001, FEBS LETT, V505, P233, DOI 10.1016/S0014-5793(01)02832-0; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P1, DOI 10.1016/S0005-2728(03)00109-9; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grunnet M, 2003, BBA-BIOMEMBRANES, V1616, P85, DOI 10.1016/S0005-2736(03)00198-6; Grunnet M, 2003, BIOPHYS J, V85, P1525, DOI 10.1016/S0006-3495(03)74585-8; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Hajdu P, 2003, PFLUG ARCH EUR J PHY, V445, P674, DOI 10.1007/s00424-002-0974-y; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; KIMMICH GA, 1967, BIOCHIM BIOPHYS ACTA, V131, P413, DOI 10.1016/0005-2728(67)90001-1; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Koni PA, 2003, J BIOL CHEM, V278, P39443, DOI 10.1074/jbc.M304879200; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Kunkele KP, 1998, J BIOL CHEM, V273, P31032, DOI 10.1074/jbc.273.47.31032; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; Liu YG, 1999, ANN NY ACAD SCI, V874, P27, DOI 10.1111/j.1749-6632.1999.tb09222.x; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Minners J, 2003, CARDIOVASC RES, V59, P1, DOI 10.1016/S0008-6363(03)00337-7; Mourre C, 1999, J PHARMACOL EXP THER, V291, P943; NICOLLI A, 1991, J BIOL CHEM, V266, P9465; O'Rourke B, 2000, J PHYSIOL-LONDON, V529, P23, DOI 10.1111/j.1469-7793.2000.00023.x; O'Rourke B, 2004, CIRC RES, V94, P420, DOI 10.1161/01.RES.0000117583.66950.43; PAHAPILL PA, 1992, J PHYSIOL-LONDON, V445, P407, DOI 10.1113/jphysiol.1992.sp018931; PALIWAL R, 1992, BIOCHEMISTRY-US, V31, P2223, DOI 10.1021/bi00123a003; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rezaul K, 2005, MOL CELL PROTEOMICS, V4, P169, DOI 10.1074/mcp.M400115-MCP200; Schilling T, 2000, AM J PHYSIOL-CELL PH, V279, pC1123, DOI 10.1152/ajpcell.2000.279.4.C1123; Siemen D, 1999, BIOCHEM BIOPH RES CO, V257, P549, DOI 10.1006/bbrc.1999.0496; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; Spencer RH, 1997, J BIOL CHEM, V272, P2389; Suh KS, 2004, J BIOL CHEM, V279, P4632, DOI 10.1074/jbc.M311632200; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Szewczyk A, 1993, Pol J Pharmacol, V45, P437; Szewczyk A, 1996, J BIOENERG BIOMEMBR, V28, P147, DOI 10.1007/BF02110645; Tanaka N, 2004, MOL GENET GENOMICS, V271, P566, DOI 10.1007/s00438-004-1002-z; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Teisseyre A, 2002, CELL MOL BIOL LETT, V7, P1095; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Watanabe I, 2003, J PHYSIOL-LONDON, V550, P51, DOI 10.1113/jphysiol.2003.040337; Xu JC, 2003, HUM MOL GENET, V12, P551, DOI 10.1093/hmg/ddg049; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360; Yao XQ, 1996, J CLIN INVEST, V97, P2525, DOI 10.1172/JCI118700; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	65	165	173	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12790	12798		10.1074/jbc.M413548200	http://dx.doi.org/10.1074/jbc.M413548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15632141	hybrid			2022-12-27	WOS:000227922000087
J	Smith, JJ; Alphy, S; Seibert, AL; Blumenthal, KM				Smith, JJ; Alphy, S; Seibert, AL; Blumenthal, KM			Differential phospholipid binding by site 3 and site 4 toxins - Implications for structural variability between voltage-sensitive sodium channel domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; SEA-ANEMONE TOXIN; SCORPION TOXIN; MOLECULAR DETERMINANTS; RECEPTOR-SITES; MOVEMENT; SURFACE; LOOP; LOCALIZATION; INHIBITION	It has been shown recently that polypeptide toxins that modulate the gating properties of voltage- sensitive cation channels are able to bind to phospholipid membranes, leading to the suggestion that these toxins are able to access a channel- binding site that remains membranerestricted ( Lee, S.- Y., and MacKinnon, R. ( 2004) Nature 430, 232 - 235). We therefore examined the ability of anthopleurin B ( ApB), a sea anemone toxin that selectively modifies inactivation kinetics of Na(V)1. x channels, and ProTx- II, a spider toxin that modifies activation kinetics of the same channels, to bind to liposomes. Whereas ProTx- II can be quantitatively depleted from solution upon incubation with phosphatidylcholine/ phosphatidylserine liposomes, ApB displays no discernible phospholipid binding activity. We therefore examined the activities of structurally unrelated site 3 and site 4 toxins derived from Leiurus and Centruroides venoms, respectively, in the same assay. Like ApB, the site 3 toxin LqqV shows no lipid binding activity, whereas the site 4 toxin Centruroides toxin II, like ProTx- II, is completely bound. We conclude that toxins that modify inactivation kinetics via binding to NaV1. x site 3 lack the ability to bind phospholipids, whereas site 4 toxins, which modify activation, have this activity. This inherent difference suggests that the conformation of domain II more closely resembles that of the K(V)AP channel than does the conformation of domain IV.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Blumenthal, KM (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 3435 Main St, Buffalo, NY 14214 USA.	kblumen@buffalo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060582] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-60582] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Benzinger GR, 1998, J BIOL CHEM, V273, P80, DOI 10.1074/jbc.273.1.80; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Deschenes I, 1998, J MEMBRANE BIOL, V164, P25, DOI 10.1007/s002329900390; DiasKadambi BL, 1996, J BIOL CHEM, V271, P9422, DOI 10.1074/jbc.271.16.9422; DiasKadambi BL, 1996, J BIOL CHEM, V271, P23828, DOI 10.1074/jbc.271.39.23828; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; JAIMOVICH E, 1982, P NATL ACAD SCI-BIOL, V79, P3896, DOI 10.1073/pnas.79.12.3896; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9; Kraus RL, 2002, BIOPHYS J, V82, p85A; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Lee SY, 2004, NATURE, V430, P232, DOI 10.1038/nature02632; Li-Smerin Y, 1998, P NATL ACAD SCI USA, V95, P8585, DOI 10.1073/pnas.95.15.8585; Li-Smerin Y, 2000, J GEN PHYSIOL, V115, P673, DOI 10.1085/jgp.115.6.673; Middleton RE, 2002, BIOCHEMISTRY-US, V41, P14734, DOI 10.1021/bi026546a; Moscho A, 1996, P NATL ACAD SCI USA, V93, P11443, DOI 10.1073/pnas.93.21.11443; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; RAY R, 1978, J BIOL CHEM, V253, P7307; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Seibert AL, 2003, BIOCHEMISTRY-US, V42, P14515, DOI 10.1021/bi035291d; SHEETS MF, 1995, J GEN PHYSIOL, V106, P617, DOI 10.1085/jgp.106.4.617; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; Wang JM, 2004, J GEN PHYSIOL, V123, P455, DOI 10.1085/jgp.200309005; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	34	62	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11127	11133		10.1074/jbc.M412552200	http://dx.doi.org/10.1074/jbc.M412552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15632158	hybrid			2022-12-27	WOS:000227761800032
J	Swarts, HGP; Koenderink, JB; Willems, PHGM; Krieger, E; De Pont, JJHHM				Swarts, HGP; Koenderink, JB; Willems, PHGM; Krieger, E; De Pont, JJHHM			Asn(792) participates in the hydrogen bond network around the K+-binding pocket of gastric H,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-BINDING; SARCOPLASMIC-RETICULUM; COMPETITIVE INHIBITOR; STRUCTURAL-CHANGES; CALCIUM-PUMP; H+,K+-ATPASE; NA+,K+-ATPASE; CONFORMATION; MUTATION; ATPASE	Asn(792) present in M5 of gastric H, K-ATPase is highly conserved within the P-type ATPase family. A direct role in K+ binding was postulated for Na, K-ATPase but was not found in a recent model for gastric H, K-ATPase (Koenderink, J. B., Swarts, H. G. P., Willems, P. H. G. M., Krieger, E., and De Pont, J. J. H. H. M. (2004) J. Biol. Chem. 279, 16417-16424). Therefore, its role in K+ binding and E-1/E-2 conformational equilibrium in gastric H, K-ATPase was studied by site-directed mutagenesis and expression in Sf9 cells. N792Q and N792A, but not N792D and N792E, had a markedly reduced K+ affinity in both the ATPase and dephosphorylation reactions. In addition, N792A shifted the conformational equilibrium to the E-1 form. In double mutants, the effect of N792A on K+ sensitivity was overruled by either E820Q (K+-independent activity) or E343D ( no dephosphorylation activity). Models were made for the mutants based on the E-2 structure of Ca2+-ATPase. In the wild-type model the acid amide group of Asn(792) has hydrogen bridges to Lys(791), Ala(339), and Val(341). Comparison of the effects of the various mutants suggests that the hydrogen bridge between the carbonyl oxygen of Asn792 and the amino group of Lys(791) is essential for the K+ sensitivity and the E-2 preference of wild-type enzyme. Moreover, there was a high positive correlation (r = 0.98) between the in silico calculated energy difference of the E-2 form ( mutants versus wild type) and the experimentally measured IC50 values for vanadate, which reflects the direction of the E-2<-> E-1 conformational equilibrium. These data strongly support the validity of the model in which Asn(792) participates in the hydrogen bond network around the K+-binding pocket.	Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Bioinformat, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.dePont@ncmls.ru.nl	Willems, P.H.G.M./L-4759-2015; Koenderink, Jan/N-3578-2014	Willems, P.H.G.M./0000-0002-0915-1599; 				Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; Jorgensen PL, 2003, ANN NY ACAD SCI, V986, P22, DOI 10.1111/j.1749-6632.2003.tb07135.x; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koenderink JB, 2004, J BIOL CHEM, V279, P16417, DOI 10.1074/jbc.M400020200; Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MENDLEIN J, 1990, J BIOL CHEM, V265, P5030; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Swarts HGP, 1999, MOL PHARMACOL, V55, P541; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Swarts HGP, 2001, J BIOL CHEM, V276, P36909, DOI 10.1074/jbc.M103945200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vagin O, 2002, BIOCHEMISTRY-US, V41, P12755, DOI 10.1021/bi025921w; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; Wang GL, 2003, BIOINFORMATICS, V19, P1589, DOI 10.1093/bioinformatics/btg224	25	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11488	11494		10.1074/jbc.M412321200	http://dx.doi.org/10.1074/jbc.M412321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644331	hybrid, Green Published			2022-12-27	WOS:000227761800073
J	Guan, HC; Hou, SH; Ricciardi, RP				Guan, HC; Hou, SH; Ricciardi, RP			DNA binding of repressor nuclear factor-kappa B p50/p50 depends on phosphorylation of Ser(337) by the protein kinase A catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CLASS-I ENHANCER; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-MECHANISMS; P65 SUBUNIT; RHEUMATOID-ARTHRITIS; 12-TRANSFORMED CELLS; P50; TRANSACTIVATION; EXPRESSION	The NF-kappa B p50/p50 homodimer is mainly associated with transcriptional repression. Previously, we demonstrated that phosphorylation of NF-kappa B p50 Ser(337) is critical for DNA binding. Here, we report that p50 Ser(337) is constitutively phosphorylated by the protein kinase A catalytic subunit (PKAc) in three different cell types, which may account for the constant binding of p50/p50 to DNA in unstimulated cells. This was demonstrated first by showing that treatment of cells with PKAc-specific inhibitors blocked p50/p50 DNA binding. Second, phosphorylation of p50 by PKAc was prevented by substitution of Ser337 to alanine. Third, both p50 and PKAc proteins as well as kinase activity that phosphorylates p50 were found to co-fractionate following gel filtration chromatography. Finally, PKAc and p50 were shown to be able to reciprocally co-immunoprecipitate one another, and their physical association was blocked by a PKA catalytic site inhibitory peptide. This indicates that phosphorylation of p50 Ser337 involves direct contact with the PKAc catalytic center. In contrast to the dramatic elevation of nuclear p50/p65 heterodimers induced by tumor necrosis factor alpha, DNA binding of p50/p50 homodimers was not greatly altered. Taken together, these findings reveal for the first time that there is a direct interaction between PKAc and p50 that accounts for constitutive phosphorylation of p50 Ser(337) and the existence of DNA bound p50/p50 in the nuclei of most resting cells. This mechanism of DNA binding by p50/p50 following phosphorylation of Ser337 by PKAc may represent an important means for maintaining stable negative regulation of NF-kappa B gene expression in the absence of extracellular stimulation.	Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ricciardi, RP (corresponding author), Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA.	ricciardi@biochem.dental.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER; NCI NIH HHS [CA29797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365-2249.2004.02342.x; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Griffioen G, 2002, CURR GENET, V41, P199, DOI 10.1007/s00294-002-0308-9; Grundstrom S, 2004, J BIOL CHEM, V279, P8460, DOI 10.1074/jbc.M312398200; Guan HC, 2003, VIROLOGY, V309, P114, DOI 10.1016/S0042-6822(02)00135-6; He B, 2003, EUR J BIOCHEM, V270, P2174, DOI 10.1046/j.1432-1033.2003.03574.x; Hou SH, 2003, J BIOL CHEM, V278, P45994, DOI 10.1074/jbc.M307971200; Hou SH, 2002, J VIROL, V76, P3212, DOI 10.1128/JVI.76.7.3212-3220.2002; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; LI CCH, 1994, J BIOL CHEM, V269, P30089; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liu XH, 1996, MOL CELL BIOL, V16, P398; Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Thornburg NJ, 2003, CANCER RES, V63, P8293; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	41	79	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9957	9962		10.1074/jbc.M412180200	http://dx.doi.org/10.1074/jbc.M412180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642694	hybrid			2022-12-27	WOS:000227559600027
J	Zhu, ZL; Liang, Z; Zhang, TY; Zhu, ZQ; Xu, WH; Teng, MK; Niu, LW				Zhu, ZL; Liang, Z; Zhang, TY; Zhu, ZQ; Xu, WH; Teng, MK; Niu, LW			Crystal structures and amidolytic activities of two glycosylated snake venom serine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTORTRIX-CONTORTRIX VENOM; PLASMINOGEN-ACTIVATOR; TRIMERESURUS-STEJNEGERI; CARBOHYDRATE STRUCTURE; MOLECULAR-CLONING; ACUTUS VENOM; C ACTIVATOR; THROMBIN; COMPLEX; PROTEASE	We deduced that Agkistrodon actus venom serine proteinases I and II, previously isolated from the venom of A. acutus (Zhu, Z., Gong, P., Teng, M., and Niu, L. ( 2003) Acta Crystallogr. Sect. D Biol. Crystallogr. 59, 547-550), are encoded by two almost identical genes, with only the single substitution Asp for Asn at residue 62. Amidolytic assays indicated that they possess slightly different enzymatic properties. Crystal structures of A. actus venom serine proteinases I and II were determined at resolution of 2.0 and 2.1 angstrom with the identification of trisaccharide (NAG(301)-FUC302-NAG(303)) and monosaccharide (NAG(301)) residues in them, respectively. The substrate binding sites S3 of the two proteinases appear much shallower than that of Trimeresurus stejnegeri venom plasminogen activator despite the overall structural similarity. Based on structural analysis, we showed that these Asn(35)-linked oligosaccharides collide spatially with some inhibitors, such as soybean trypsin inhibitor, and would therefore hinder their inhibitory binding. Difference of the carbohydrates in both the proteinases might also lead to their altered catalytic activities.	Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Hefei 230026, Anhui, Peoples R China; Chinese Acad Sci, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; Chinese Acad Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; Chinese Academy of Sciences	Teng, MK (corresponding author), Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.	lwniu@ustc.edu.cn	Zhu, Zhiqiang/J-6210-2016					BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; Braud S, 2000, J BIOL CHEM, V275, P1823, DOI 10.1074/jbc.275.3.1823; Braud S, 2000, BIOCHIMIE, V82, P851, DOI 10.1016/S0300-9084(00)01178-0; Braud S, 2002, BIOCHEMISTRY-US, V41, P8478, DOI 10.1021/bi016069g; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L, PYMOL MOL GRAPHICS S; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; Gempeler-Messina PM, 2001, HAEMOSTASIS, V31, P266; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Henriques ES, 2004, PROTEIN SCI, V13, P2355, DOI 10.1110/ps.04746804; ITOH N, 1987, J BIOL CHEM, V262, P3132; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISIEL W, 1987, J BIOL CHEM, V262, P12607; LOCHNIT G, 1995, EUR J BIOCHEM, V228, P805, DOI 10.1111/j.1432-1033.1995.tb20326.x; Matsui T, 2000, BBA-PROTEIN STRUCT M, V1477, P146, DOI 10.1016/S0167-4838(99)00268-X; MCMULLEN BA, 1989, BIOCHEMISTRY-US, V28, P674, DOI 10.1021/bi00428a039; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Parry MAA, 1998, STRUCT FOLD DES, V6, P1195, DOI 10.1016/S0969-2126(98)00119-1; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; STUBBS MT, 1995, FEBS LETT, V375, P103, DOI 10.1016/0014-5793(95)01190-P; Wang YM, 2001, BIOCHEM J, V354, P161, DOI 10.1042/0264-6021:3540161; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246; Zhang Y, 1997, J BIOL CHEM, V272, P20531, DOI 10.1074/jbc.272.33.20531; Zhu ZL, 2003, ACTA CRYSTALLOGR D, V59, P547, DOI 10.1107/S0907444902023375	26	48	52	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10524	10529		10.1074/jbc.M412900200	http://dx.doi.org/10.1074/jbc.M412900200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632114	hybrid			2022-12-27	WOS:000227559600096
J	Kim, J; Hamamoto, S; Ravazzola, M; Orci, L; Schekman, R				Kim, J; Hamamoto, S; Ravazzola, M; Orci, L; Schekman, R			Uncoupled packaging of amyloid precursor protein and presenilin 1 into coat protein complex II vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE; COPII VESICLES; MEMBRANE-PROTEINS; CARGO SELECTION; TRANSPORT; ER; SEC24P; TRAFFICKING; COMPONENT; DYNAMICS	Mutant forms of presenilin (PS) 1 and 2 and amyloid precursor protein (APP) lead to familial Alzheimer's disease. Several reports indicate that PS may modulate APP export from the endoplasmic reticulum (ER). To develop a test of this possibility, we reconstituted the capture of APP and PS1 in COPII (coat protein complex II) vesicles formed from ER membranes in permeabilized cultured cells. The recombinant forms of mammalian COPII proteins were active in a reaction that measures coat subunit assembly and coated vesicle budding on chemically defined synthetic liposomes. However, the recombinant COPII proteins were not active in cargo capture and vesicle budding from microsomal membranes. In contrast, rat liver cytosol was active in stimulating the sorting and packaging of APP, PS1, and p58 (an itinerant ER to Golgi marker protein) into transport vesicles from donor ER membranes. Budding was stimulated in dilute cytosol by the addition of recombinant COPII proteins. Fractionation of the cytosol suggested one or more additional proteins other than the COPII subunits may be essential for cargo selection or vesicle formation from the mammalian ER membrane. The recombinant Sec24C specifically recognized the APP C-terminal region for packaging. Titration of Sarla distinguished the packaging requirements of APP and PS1. Furthermore, APP packaging was not affected by deletion of PS1 or PS1 and 2, suggesting APP and PS1 trafficking from the ER are normally uncoupled.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Geneva, Sch Med, Dept Cellular Physiol & Metab, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	schekman@berkeley.edu	Kim, Jinoh/AAF-9178-2020	Kim, Jinoh/0000-0003-2841-147X				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Antonny B, 2003, EMBO REP, V4, P419, DOI 10.1038/sj.embor.embor812; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Aridor M, 2000, J BIOL CHEM, V275, P35673, DOI 10.1074/jbc.C000449200; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; Dudognon P, 2004, FEBS LETT, V561, P44, DOI 10.1016/S0014-5793(04)00109-7; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; Espenshade PJ, 2002, P NATL ACAD SCI USA, V99, P11694, DOI 10.1073/pnas.182412799; Farmaki T, 1999, J CELL SCI, V112, P589; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; Futai E, 2004, EMBO J, V23, P4146, DOI 10.1038/sj.emboj.7600428; Gusarova V, 2003, J BIOL CHEM, V278, P48051, DOI 10.1074/jbc.M306898200; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Klumperman J, 1998, J CELL SCI, V111, P3411; Lederkremer GZ, 2001, P NATL ACAD SCI USA, V98, P10704, DOI 10.1073/pnas.191359398; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Matsuoka K, 2000, METHODS, V20, P417, DOI 10.1006/meth.2000.0955; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nufer O, 2002, J CELL SCI, V115, P619; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; Pathre P, 2003, EMBO J, V22, P4059, DOI 10.1093/emboj/cdg390; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; SHARROCKS AD, 1994, GENE, V138, P105, DOI 10.1016/0378-1119(94)90789-7; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Supek F, 2002, J CELL BIOL, V158, P1029, DOI 10.1083/jcb.200207053; Tang BL, 1999, BIOCHEM BIOPH RES CO, V258, P679, DOI 10.1006/bbrc.1999.0574; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Ying M, 2000, J CELL SCI, V113, P3623; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	54	76	77	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7758	7768		10.1074/jbc.M411091200	http://dx.doi.org/10.1074/jbc.M411091200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623526	hybrid			2022-12-27	WOS:000227395700040
J	Qin, HJ; Carr, HS; Wu, XC; Muallem, D; Tran, NH; Frost, JA				Qin, HJ; Carr, HS; Wu, XC; Muallem, D; Tran, NH; Frost, JA			Characterization of the biochemical and transforming properties of the neuroepithelial transforming protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; VAV PROTOONCOGENE PRODUCT; TUMOR-SUPPRESSOR PROTEIN; RHO-GTPASES; TYROSINE PHOSPHORYLATION; DBL; FAMILY; ACTIVATION; TIAM1	Rho family small G proteins are key regulators of cytoskeletal organization and oncogenic transformation whose activation is controlled by a family of proteins known as guanine nucleotide exchange factors (GEFs). In this work we have characterized the structural and biological determinants for cytoskeletal regulation and cell transformation by the neuroepithelioma transforming gene 1 (NET1), which is a GEF specific for RhoA, but not Cdc42 or Rac1. Previously it was shown that the biological activity and nuclear localization of NET1 is controlled by its amino terminus. Here we demonstrate that the amino terminus of NET1 does not function as cis-acting autoinhibitory domain, nor does it affect the ability of full-length NET1 to stimulate actin stress fiber formation. We also show that the nuclear localization of NET1 is controlled by two separate domains within its amino terminus, only one of which contains the previously identified NLS sequences. Importantly, we find that the ability of NET1 to stimulate actin stress fiber formation does not correlate with its transforming activity, because NET1 proteins that potently stimulate stress fiber formation do not transform cells. Furthermore, the presence of a potential PDZ binding site in the C terminus of NET1 is critical to its ability to transform cells, but is not required for enzymatic activity or for effects on the actin cytoskeleton. Thus, these data highlight a divergence between the ability of NET1 to stimulate cytoskeletal reorganization and to transform cells, and implicate the interaction with PDZ domain-containing proteins as critical to NET1-dependent transformation.	Univ Texas, Hlth Sci Ctr, Dept Intergrav Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Frost, JA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Intergrav Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	jeffrey.a.frost@uth.tmc.edu		Frost, Jeffrey/0000-0001-9722-1536				Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chan AML, 1996, ONCOGENE, V12, P1259; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harris BZ, 2001, J CELL SCI, V114, P3219; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kristelly R, 2004, J BIOL CHEM, V279, P47352, DOI 10.1074/jbc.M406056200; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Solski PA, 2000, METHOD ENZYMOL, V325, P425; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wherlock M, 2002, J CELL SCI, V115, P239; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhang MJ, 2003, ACCOUNTS CHEM RES, V36, P530, DOI 10.1021/ar020210b; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	39	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7603	7613		10.1074/jbc.M412141200	http://dx.doi.org/10.1074/jbc.M412141200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611121	hybrid			2022-12-27	WOS:000227395700023
J	Sala, F; Mulet, J; Sala, S; Gerber, S; Criado, M				Sala, F; Mulet, J; Sala, S; Gerber, S; Criado, M			Charged amino acids of the N-terminal domain are involved in coupling binding and Gating in alpha 7 nicotinic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNATURE DISULFIDE LOOP; ACETYLCHOLINE-RECEPTOR; GLYCINE RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; GABA(A) RECEPTOR; LIGAND-BINDING; M2-M3 LOOP; SUBUNIT; ACTIVATION	Binding of agonists to nicotinic acetylcholine receptors generates a sequence of conformational changes resulting in channel opening. Previously, we have shown that the aspartate residue Asp-266 at the M2-M3 linker of the alpha7 nicotinic receptor is involved in connecting binding and gating. High resolution structural data suggest that this region could interact with the so-called loops 2 and 7 of the extracellular N-terminal region. In this case, certain charged amino acids present in these loops could integrate together with Asp-266 and other amino acids, a mechanism involved in channel activation. To test this hypothesis, all charged residues in these loops, Asp-42, Asp-44, Glu-45, Lys-46, Asp-128, Arg-130, and Asp-135, were substituted with other amino acids, and expression levels and electrophysiological responses of mutant receptors were determined. Mutants at positions Glu-45, Lys-46, and Asp-135 exhibited poor or null functional responses to different nicotinic agonists regardless of significant membrane expression, whereas D128A showed a gain of function effect. Because the double reverse charge mutant K46D/D266K did not restore receptor function, a gating mechanism controlled by the pairwise electrostatic interaction between these residues is not likely. Rather, a network of interactions formed by residues Lys-46, Asp-128, Asp135, Asp-266, and possibly others appears to link agonist binding to channel gating.	Univ Miguel Hernandez, Consejo Super Invest Cientificas, Inst Neurociencias, Alicante 03550, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Criado, M (corresponding author), Univ Miguel Hernandez, Consejo Super Invest Cientificas, Inst Neurociencias, Apdo 18, Alicante 03550, Spain.	Criado@umh.es	Mulet, Jose/K-6538-2014; Criado, Manuel/K-5109-2014; Sala, Salvador/L-7104-2014	Mulet, Jose/0000-0001-7506-4875; Criado, Manuel/0000-0002-3953-0346; Sala, Salvador/0000-0002-5607-0097; Sala, Francisco/0000-0002-2080-7683				Absalom NL, 2004, EXP PHYSIOL, V89, P145, DOI 10.1113/expphysiol.2003.026815; Absalom NL, 2003, J BIOL CHEM, V278, P50151, DOI 10.1074/jbc.M305357200; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; Chakrapani S, 2003, J GEN PHYSIOL, V122, P521, DOI 10.1085/jgp.200308885; Chakrapani S, 2004, J GEN PHYSIOL, V123, P341, DOI 10.1085/jgp.200309004; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; GARCIAGUZMAN M, 1994, BIOCHEMISTRY-US, V33, P15198, DOI 10.1021/bi00254a031; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Herrgard S, 2000, BIOCHEMISTRY-US, V39, P2921, DOI 10.1021/bi9916980; Hogg RC, 2003, REV PHYSIOL BIOCH P, V147, P1, DOI 10.1007/s10254-003-0005-1; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUSAMA T, 1994, NEUROREPORT, V5, P1209, DOI 10.1097/00001756-199406020-00012; Lee DL, 2003, PROTEIN SCI, V12, P1395, DOI 10.1110/ps.0241403; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lindstrom JM, 2003, ANN NY ACAD SCI, V998, P41, DOI 10.1196/annals.1254.007; LYNCH JW, 1995, J BIOL CHEM, V270, P12799; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Nakamura H, 1996, Q REV BIOPHYS, V29, P1, DOI 10.1017/S0033583500005746; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; Rovira JC, 1999, PFLUG ARCH EUR J PHY, V439, P86, DOI 10.1007/s004240051131; Sala F, 2002, BRIT J PHARMACOL, V136, P183, DOI 10.1038/sj.bjp.0704699; Schofield CM, 2004, BIOCHEMISTRY-US, V43, P10058, DOI 10.1021/bi036159g; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9	30	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6642	6647		10.1074/jbc.M411048200	http://dx.doi.org/10.1074/jbc.M411048200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611071	hybrid			2022-12-27	WOS:000227332700050
J	Voigt, P; Brock, C; Nurnberg, B; Schaefer, M				Voigt, P; Brock, C; Nurnberg, B; Schaefer, M			Assigning functional domains within the p101 regulatory subunit of phosphoinositide 3-kinase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; CELL-ACTIVATION; LIVING CELLS; 3-KINASE; KINASE; RECEPTOR; ROLES; PI3K-GAMMA; PROTEINS; BINDING	Phosphoinositide 3-Kinase (PI3K) gamma is a lipid kinase that is regulated by G-protein-coupled receptors. It plays a crucial role in inflammatory and allergic processes. Activation of PI3Kgamma is primarily mediated by Gbetagamma subunits. The regulatory p101 subunit of PI3Kgamma binds to Gbetagamma and, thereby, recruits the catalytic p110gamma subunit to the plasma membrane. Despite its crucial role in the activation of PI3Kgamma, the structural organization of p101 is still largely elusive. Employing fluorescence resonance energy transfer measurements, coimmunoprecipitation and colocalization studies with p101 deletion mutants, we show here that distinct regions within the p101 primary structure are responsible for interaction with p110gamma and Gbetagamma. The p110gamma binding site is confined to the N terminus, whereas binding to Gbetagamma is mediated by a C-terminal domain of p101. These domains appear to be highly conserved among various species ranging from Xenopus to men. In addition to establishing a domain structure for p101, our results point to the existence of a previously unknown, p101-related regulatory subunit for PI3Kgamma.	Univ Med Berlin, Charite, Inst Pharmakol, D-14195 Berlin, Germany; Klinikum Univ Dusseldorf, Inst Biochem & Mol Biol 2, D-40225 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Schaefer, M (corresponding author), Univ Med Berlin, Charite, Inst Pharmakol, Campus Benjamin Franklin Thielallee 67-73, D-14195 Berlin, Germany.	schae@zedat.fu-berlin.de		Voigt, Philipp/0000-0003-4366-0490; Nurnberg, Bernd/0000-0002-5995-6555				Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Simonsen A, 2001, NAT CELL BIOL, V3, pE179, DOI 10.1038/35087112; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	25	54	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5121	5127		10.1074/jbc.M413104200	http://dx.doi.org/10.1074/jbc.M413104200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15611065	hybrid			2022-12-27	WOS:000227096600134
J	Dummler, BA; Hauge, C; Silber, J; Yntema, HG; Kruse, LS; Kofoed, B; Hemmings, BA; Alessi, DR; Frodin, M				Dummler, BA; Hauge, C; Silber, J; Yntema, HG; Kruse, LS; Kofoed, B; Hemmings, BA; Alessi, DR; Frodin, M			Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; PROTEIN-KINASE; DOCKING SITE; MAP KINASE; IN-VIVO; OOCYTE MATURATION; AGC KINASES; C-JUN; PHOSPHORYLATION; MITOGEN	The 90-kDa ribosomal S6 kinases (RSK1-3) are important mediators of growth factor stimulation of cellular proliferation, survival, and differentiation and are activated via coordinated phosphorylation by ERK and 3-phosphoinositide-dependent protein kinase-1 (PDK1). Here we performed the functional characterization of a predicted new human RSK homologue, RSK4. We showed that RSK4 is a predominantly cytosolic protein with very low expression and several characteristics of the RSK family kinases, including the presence of two functional kinase domains and a C-terminal docking site for ERK. Surprisingly, however, in all cell types analyzed, endogenous RSK4 was maximally (constitutively) activated under serum-starved conditions where other RSKs are inactive due to their requirement for growth factor stimulation. Constitutive activation appeared to result from constitutive phosphorylation of Ser(232), Ser(372), and Ser(389), and the low basal ERK activity in serum-starved cells appeared to be sufficient for induction of similar to 50% of the constitutive RSK4 activity. Finally experiments in mouse embryonic stem cells with targeted deletion of the PDK1 gene suggested that PDK1 was not required for phosphorylation of Ser232, a key regulatory site in the activation loop of the N-terminal kinase domain, that in other RSKs is phosphorylated by PDK1. The unusual regulation and growth factor-independent kinase activity indicate that RSK4 is functionally distinct from other RSKs and may help explain recent findings suggesting that RSK4 can participate in non-growth factor signaling as for instance p53-induced growth arrest.	Biotech Res & Innovat Ctr, Kinase Signalling Lab, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Glostrup Hosp, Dept Clin Biochem, DK-2600 Glostrup, Denmark; Univ Med Ctr St Raboud, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Friedrich Miescher Inst, CH-4558 Basel, Switzerland; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Copenhagen; Radboud University Nijmegen; Friedrich Miescher Institute for Biomedical Research; University of Dundee	Frodin, M (corresponding author), Biotech Res & Innovat Ctr, Kinase Signalling Lab, Fruebjergvej 3, DK-2100 Copenhagen, Denmark.	morten.frodin@bric.dk	Yntema, H.G./L-4771-2015	Frodin, Morten/0000-0003-3691-9820; Alessi, Dario/0000-0002-2140-9185	MRC [MC_U127015387] Funding Source: UKRI; Medical Research Council [MC_U127015387] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; El-Haschimi K, 2003, DIABETES, V52, P1340, DOI 10.2337/diabetes.52.6.1340; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Gross SD, 2001, J BIOL CHEM, V276, P46099, DOI 10.1074/jbc.C100496200; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kohn M, 2003, GENE EXPR PATTERNS, V3, P173, DOI 10.1016/S1567-133X(03)00004-8; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; MYERS MG, 1991, J BIOL CHEM, V266, P10616; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Schwab MS, 2001, CURR BIOL, V11, P141, DOI 10.1016/S0960-9822(01)00045-8; SCHWEIZER A, 1993, J CELL SCI, V104, P685; Silverman E, 2004, MOL CELL BIOL, V24, P10573, DOI 10.1128/MCB.24.24.10573-10583.2004; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tomas-Zuber M, 2001, J BIOL CHEM, V276, P5892, DOI 10.1074/jbc.M005822200; Tomas-Zuber M, 2000, J BIOL CHEM, V275, P23549, DOI 10.1074/jbc.M002586200; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	55	85	93	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13304	13314		10.1074/jbc.M408194200	http://dx.doi.org/10.1074/jbc.M408194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15632195	Green Published, hybrid			2022-12-27	WOS:000228095500016
J	Hong, HJ; Hutchings, MI; Hill, LM; Buttner, MJ				Hong, HJ; Hutchings, MI; Hill, LM; Buttner, MJ			The role of the novel Fem protein VanK in vancomycin resistance in Streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; INTERPEPTIDE BRIDGE; GENE; BIOSYNTHESIS; ANTIBIOTICS; PRECURSOR; INACTIVATION; SYSTEM; WALLS; STEP	The non-pathogenic, non-glycopeptide- producing actinomycete Streptomyces coelicolor carries a cluster of seven genes ( vanSRJKHAX) that confers inducible, high level resistance to vancomycin. The vanK gene has no counterpart in previously characterized vancomycin resistance clusters, yet vanK is required for vancomycin resistance in S. coelicolor. VanK belongs to the Fem family of enzymes, which add the branch amino acid( s) to the stem pentapeptide of peptidoglycan precursors. Upon exposure to vancomycin, the VanRS two- component system switches on expression of all seven van genes, and the VanHAX enzymes reprogram the cell wall such that precursors terminate D-Ala-D-lactate ( Lac) rather than D-AlaD- Ala, thus conferring resistance to vancomycin, which only binds D- Ala- D- Ala- containing precursors. Here we provide biochemical and genetic evidence that VanK is required for vancomycin resistance because the constitutively expressed FemX enzyme, encoded elsewhere on the chromosome, cannot recognize D- Lac-containing precursors as a substrate, whereas VanK can. Consistent with this view, D- Lac-containing precursors carrying the Gly branch are present in the wild type transiently exposed to vancomycin but are undetectable in a vanK mutant treated in the same way. Further, femX null mutants are viable in the presence of vancomycin but die in its absence. Because only VanK can recognize D- Lac-containing precursors, vancomycin- induced expression of VanHAX in a vanK mutant is lethal, and so vanK is required for vancomycin resistance.	John Innes Inst, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; John Innes Inst, Dept Metab Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Hong, HJ (corresponding author), John Innes Inst, Dept Mol Microbiol, Coloney Lane, Norwich NR4 7UH, Norfolk, England.	Hong@bbsrc.ac.uk	Hutchings, Matt/D-1923-2009	Hutchings, Matt/0000-0001-6628-5940; Buttner, Mark/0000-0002-3505-2981				BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BIBB MJ, 1994, MOL MICROBIOL, V14, P533, DOI 10.1111/j.1365-2958.1994.tb02187.x; BillotKlein D, 1996, J BACTERIOL, V178, P4696, DOI 10.1128/jb.178.15.4696-4703.1996; Bouhss A, 2002, J BIOL CHEM, V277, P45935, DOI 10.1074/jbc.M207449200; Bugg T.D.H., 1999, COMPREHENSIVE NATURA, P241; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Ehlert K, 1997, J BACTERIOL, V179, P7573, DOI 10.1128/jb.179.23.7573-7576.1997; Gregory MA, 2003, J BACTERIOL, V185, P5320, DOI 10.1128/JB.185.17.5320-5323.2003; Gust B, 2003, P NATL ACAD SCI USA, V100, P1541, DOI 10.1073/pnas.0337542100; Healy VL, 2000, CHEM BIOL, V7, pR109, DOI 10.1016/S1074-5521(00)00116-2; Hegde SS, 2001, J BIOL CHEM, V276, P6998, DOI 10.1074/jbc.M008591200; Hegde SS, 2003, J BIOL CHEM, V278, P22861, DOI 10.1074/jbc.M301565200; HENZE U, 1993, J BACTERIOL, V175, P1612, DOI 10.1128/JB.175.6.1612-1620.1993; Hong HJ, 2004, MOL MICROBIOL, V52, P1107, DOI 10.1111/j.1365-2958.2004.04032.x; Hong HJ, 2002, MOL MICROBIOL, V44, P1199, DOI 10.1046/j.1365-2958.2002.02960.x; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; LEYHBOUILLE M, 1970, BIOCHEMISTRY-US, V9, P2944, DOI 10.1021/bi00817a002; Paget MSB, 1999, J BACTERIOL, V181, P204, DOI 10.1128/JB.181.1.204-211.1999; Pearson H, 2002, NATURE, V418, P469, DOI 10.1038/418469b; Pootoolal J, 2002, P NATL ACAD SCI USA, V99, P8962, DOI 10.1073/pnas.102285099; Pootoolal J, 2002, ANNU REV PHARMACOL, V42, P381, DOI 10.1146/annurev.pharmtox.42.091601.142813; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; Rohrer S, 2003, ANTIMICROB AGENTS CH, V47, P837, DOI 10.1128/AAC.47.3.837-846.2003; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schneider T, 2004, MOL MICROBIOL, V53, P675, DOI 10.1111/j.1365-2958.2004.04149.x; Serina S, 2004, FEMS MICROBIOL LETT, V240, P69, DOI 10.1016/j.femsle.2004.09.017; Severin A, 2004, J BIOL CHEM, V279, P3398, DOI 10.1074/jbc.M309593200; Tenover FC, 2004, ANTIMICROB AGENTS CH, V48, P275, DOI 10.1128/AAC.48.1.275-280.2004; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Walsh CT, 1996, CHEM BIOL, V3, P21, DOI 10.1016/S1074-5521(96)90079-4; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; WILLIAMS DH, 1983, J AM CHEM SOC, V105, P1332, DOI 10.1021/ja00343a043; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C	40	117	118	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13055	13061		10.1074/jbc.M413801200	http://dx.doi.org/10.1074/jbc.M413801200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15632111	hybrid			2022-12-27	WOS:000227922000116
J	Zhu, XY; Jiang, JH; Shen, HL; Wang, HZ; Zong, HL; Li, ZJ; Yang, YZ; Niu, ZY; Liu, WC; Chen, XN; Hu, Y; Gu, JX				Zhu, XY; Jiang, JH; Shen, HL; Wang, HZ; Zong, HL; Li, ZJ; Yang, YZ; Niu, ZY; Liu, WC; Chen, XN; Hu, Y; Gu, JX			Elevated beta 1,4-galactosyltransferase I in highly metastatic human lung cancer cells - Identification of E1AF as important transcription activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SURFACE GALACTOSYLTRANSFERASE; MATRIX-METALLOPROTEINASE; CARCINOMA-CELLS; SIGNALING PATHWAY; BREAST-CANCER; EXPRESSION; PEA3; GROWTH; INVASION	The elevated levels of beta 1,4-galactosyltransferase I ( GalT I; EC 2.4.1.38) are detected in highly metastatic lung cancer PGBE1 cells compared with its less metastatic partner PGLH7 cells. Decreasing the GalT I surface expression by small interfering RNA or interfering with the surface of GalT I function by mutation inhibited cell adhesion on laminin, the invasive potential in vitro, and tyrosine phosphorylation of focal adhesion kinase. The mechanism by which GalT I activity is up-regulated in highly metastatic cells remains unclear. To investigate the regulation of GalT I expression, we cloned the 5'-region flanking the transcription start point of the GalT I gene (-1653 to -52). Cotransfection of the GalT I promoter/luciferase reporter and the Ets family protein E1AF expression plasmid increased the luciferase reporter activity in a dose-dependent manner. By deletion and mutation analyses, we identified an Ets-binding site between nucleotides -205 and -200 in the GalT I promoter that was critical for responsiveness to E1AF. It was identified that E1AF could bind to and activate the GalT I promoter by electrophoretic mobility shift assay in PGLH7 cells and COS1 cells. A stronger affinity of E1AF for DNA has contributed to the elevated expression of GalT I in PGBE1 cells. Stable transfection of the E1AF expression plasmid resulted in increased GalT I expression in PGLH7 cells, and stable transfectants migrated faster than control cells. Meanwhile, the content of the beta 1,4- Gal branch on the cell surface was increased in stably transfected PGLH7 cells. GalT I expression can also be induced by epidermal growth factor and dominant active Ras, JNK1, and ERK1. These data suggest an essential role for E1AF in the activation of the human GalT I gene in highly metastatic lung cancer cells.	Fudan Univ, Shanghai Med Coll, Gene Res Ctr, State Key Lab Genet Engn, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Coll, Med Ctr, Dept Mol Virol, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Gu, JX (corresponding author), Fudan Univ, Shanghai Med Coll, Gene Res Ctr, State Key Lab Genet Engn, Shanghai 200032, Peoples R China.	jxgu@shmu.edu.cn	Zong, Hongliang/F-9366-2013; liu, weicheng/D-4173-2013; Wang, Hanzhou/G-9814-2012	Zong, Hongliang/0000-0002-5855-5733; Wang, Hanzhou/0000-0002-0493-827X				ALBINI A, 1987, CANCER RES, V47, P3239; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; APPEDDU PA, 1994, P NATL ACAD SCI USA, V91, P2095, DOI 10.1073/pnas.91.6.2095; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bieche I, 2004, CARCINOGENESIS, V25, P405, DOI 10.1093/carcin/bgh024; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Dall'Olio F, 2001, GLYCOCONJUGATE J, V18, P841, DOI 10.1023/A:1022288022969; Davidson B, 2004, CLIN EXP METASTAS, V21, P191, DOI 10.1023/B:CLIN.0000037703.37275.35; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; ECKSTEIN DJ, 1989, J CELL BIOL, V108, P2507, DOI 10.1083/jcb.108.6.2507; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; Furukawa K, 1999, BBA-GEN SUBJECTS, V1473, P54, DOI 10.1016/S0304-4165(99)00169-5; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Habelhah H, 1999, ONCOGENE, V18, P1771, DOI 10.1038/sj.onc.1202465; HAGAN RCO, 1996, ONCOGENE, V13, P1323; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; HAUKE C, 1993, J NEUROSCI METH, V50, P273, DOI 10.1016/0165-0270(93)90034-O; Hida K, 1997, AM J PATHOL, V150, P2125; HINTON DA, 1995, EXP CELL RES, V219, P640, DOI 10.1006/excr.1995.1274; Hiroumi H, 2001, INT J CANCER, V93, P786, DOI 10.1002/ijc.1410; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Iguchi A, 2000, BIOCHEM BIOPH RES CO, V279, P166, DOI 10.1006/bbrc.2000.3925; Ji SY, 2003, MOL CELL BIOCHEM, V252, P9, DOI 10.1023/A:1025594510011; Johnson FM, 1999, J CELL SCI, V112, P2785; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAILLET CM, 1994, J CELL SCI, V107, P1713; Narimatsu H, 1998, Tanpakushitsu Kakusan Koso, V43, P2394; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; PASSANITI A, 1990, CANCER RES, V50, P7261; PAULUS W, 1994, J NEUROSURG, V80, P515, DOI 10.3171/jns.1994.80.3.0515; PENNO MB, 1989, P NATL ACAD SCI USA, V86, P6057, DOI 10.1073/pnas.86.16.6057; PURUSHOTHAM KR, 1992, BIOCHEM J, V284, P767, DOI 10.1042/bj2840767; SAO T, 2004, J BIOL CHEM, V279, P39574; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shibakura M, 2003, INT J CANCER, V103, P380, DOI 10.1002/ijc.10842; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; Shur BD, 1993, CURR OPIN CELL BIOL, V5, P854, DOI 10.1016/0955-0674(93)90035-O; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Taguchi K, 1997, JPN J CANCER RES, V88, P394, DOI 10.1111/j.1349-7006.1997.tb00395.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wassler MJ, 2000, J CELL SCI, V113, P237; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; WU AM, 1988, CARBOHYD RES, V178, P243, DOI 10.1016/0008-6215(88)80116-2; Yamashita H, 2003, ONCOL REP, V10, P1857; YOUAKIM A, 1994, P NATL ACAD SCI USA, V91, P10913, DOI 10.1073/pnas.91.23.10913; Zhang S, 2003, MOL CELL BIOCHEM, V243, P81, DOI 10.1023/A:1021683324548; ZHU WY, 1995, CHINESE J PATHOL, V24, P136	57	72	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12503	12516		10.1074/jbc.M413631200	http://dx.doi.org/10.1074/jbc.M413631200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15611127	hybrid			2022-12-27	WOS:000227922000054
J	Janowiak, BE; Griffith, OW				Janowiak, BE; Griffith, OW			Glutathione synthesis in Streptococcus agalactiae - One protein accounts for gamma-glutamylcysteine synthetase and glutathione synthetase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE-CYSTEINE LIGASE; STATE ANALOG INHIBITORS; ESCHERICHIA-COLI-B; D-ALANINE LIGASE; RAT-KIDNEY; BUTHIONINE SULFOXIMINE; KINETIC MECHANISM; S-TRANSFERASE; DDLA GENE; PURIFICATION	gamma-Glutamylcysteine synthetase (gamma-GCS) and glutathione synthetase (GS), distinct enzymes that together account for glutathione (GSH) synthesis, have been isolated and characterized from several Gram-negative prokaryotes and from numerous eukaryotes including mammals, amphibians, plants, yeast, and protozoa. Glutathione synthesis is relatively uncommon among the Gram-positive bacteria, and, to date, neither the genes nor the proteins involved have been identified. In the present report, we show that crude extracts of Streptococcus agalactiae catalyze the gamma-GCS and GS reactions and can synthesize GSH from its constituent amino acids. The putative gene for S. agalactiae gamma-GCS was identified and cloned, and the corresponding protein was expressed and purified. Surprisingly, it was found that the isolated enzyme catalyzes both the ATP-dependent synthesis of L-gamma-glutamyl-L-cysteine from L-glutamate and L-cysteine and the ATP-dependent synthesis of GSH from L-gamma-glutamyl-L-cysteine and glycine. This novel bifunctional enzyme, referred to as gamma-GCS-GS, has been characterized in terms of catalytic activity, substrate specificity, and inhibition by GSH, cystamine, and transition state analog sulfoximines. The N-terminal 518 amino acids of gamma-GCS-GS (total M-r 85,000) show 32% identity and 43% similarity with E. coli gamma-GCS (M-r 58,000), but the C-terminal putative GS domain (remaining 202 amino acids) of gamma-GCS-GS shows no significant homology with known GS sequences. The C terminus (360 amino acids) is, however, homologous to D-Ala, D-Ala ligase (24% identity; 38% similarity), an enzyme having the same protein fold as known GS proteins. These results are discussed in terms of the evolution of GSH synthesis and the possible occurrence of a similar bifunctional GSH synthesis enzyme in other bacterial species.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Griffith, OW (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	griffith@mcw.edu		Janowiak, Blythe/0000-0001-8103-2474				Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; ARCA P, 1990, FEBS LETT, V263, P77, DOI 10.1016/0014-5793(90)80709-R; BOUTER S, 1988, BIOCHEM PHARMACOL, V37, P577, DOI 10.1016/0006-2952(88)90128-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; Brenot A, 2004, INFECT IMMUN, V72, P408, DOI 10.1128/IAI.72.1.408-413.2004; BROWN CM, 1972, J APPL CHEM BIOTECHN, V22, P363, DOI 10.1002/jctb.5020220307; Bubert A, 1997, J CLIN MICROBIOL, V35, P179, DOI 10.1128/JCM.35.1.179-183.1997; CAMPBELL EB, 1991, ANAL BIOCHEM, V194, P268, DOI 10.1016/0003-2697(91)90229-M; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Copley SD, 2002, GENOME BIOL, V3; DAUB E, 1988, BIOCHEMISTRY-US, V27, P3701, DOI 10.1021/bi00410a027; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; Frankenberg L, 2002, J BACTERIOL, V184, P6351, DOI 10.1128/JB.184.22.6351-6356.2002; Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; GRIFFITH OW, 1977, BIOCHEM BIOPH RES CO, V79, P919, DOI 10.1016/0006-291X(77)91198-6; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P268, DOI 10.1073/pnas.76.1.268; GRIFFITH OW, 1981, J BIOL CHEM, V256, P4900; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Gushima H, 1983, J Appl Biochem, V5, P210; Hibi T, 2004, P NATL ACAD SCI USA, V101, P15052, DOI 10.1073/pnas.0403277101; Hiratake J, 2002, BIOSCI BIOTECH BIOCH, V66, P1500, DOI 10.1271/bbb.66.1500; HUANG CS, 1993, J BIOL CHEM, V268, P20578; IIZUKA M, 1989, J BACTERIOL, V171, P6039, DOI 10.1128/jb.171.11.6039-6042.1989; Inoue Y, 1998, BBA-GENE STRUCT EXPR, V1395, P315, DOI 10.1016/S0167-4781(97)00199-1; INOUE Y, 1993, APPL MICROBIOL BIOT, V38, P473; Jez JM, 2004, J BIOL CHEM, V279, P33463, DOI 10.1074/jbc.M405127200; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; King KY, 2000, J BACTERIOL, V182, P5290, DOI 10.1128/JB.182.19.5290-5299.2000; LEBO RV, 1978, J BIOL CHEM, V253, P2615; MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1985, METHOD ENZYMOL, V113, P445; Misra I, 1998, PROTEIN EXPRES PURIF, V13, P268, DOI 10.1006/prep.1998.0897; MOOZ ED, 1967, BIOCHEMISTRY-US, V6, P1722, DOI 10.1021/bi00858a022; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Njalsson R, 2001, BIOCHEM BIOPH RES CO, V289, P80, DOI 10.1006/bbrc.2001.5961; OPPENHEIMER L, 1979, J BIOL CHEM, V254, P5184; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Phlippen N, 2003, J BIOL CHEM, V278, P40152, DOI 10.1074/jbc.M303102200; RUOFF KL, 1990, EUR J CLIN MICROBIOL, V9, P75, DOI 10.1007/BF01963630; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; Sherrill C, 1998, J BACTERIOL, V180, P1454, DOI 10.1128/JB.180.6.1454-1459.1998; STRUMEYER D, 1962, BIOCHEM PREP, V9, P52; TELLELIN H, 2002, P NATL ACAD SCI USA, V99, P12391; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tokutake N, 1998, BIOORGAN MED CHEM, V6, P1935, DOI 10.1016/S0968-0896(98)00142-4; Tu ZH, 1998, BIOCHEM J, V336, P675, DOI 10.1042/bj3360675; Vuilleumier S, 1997, J BACTERIOL, V179, P1431, DOI 10.1128/jb.179.5.1431-1441.1997; WILLETT NP, 1966, J BACTERIOL, V91, P2245, DOI 10.1128/JB.91.6.2245-2250.1966; ZAWADZKE LE, 1991, BIOCHEMISTRY-US, V30, P1673, DOI 10.1021/bi00220a033	58	87	103	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11829	11839		10.1074/jbc.M414326200	http://dx.doi.org/10.1074/jbc.M414326200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15642737	hybrid			2022-12-27	WOS:000227761800112
J	Mazzocca, A; Sciammetta, SC; Carloni, V; Cosmi, L; Annunziato, F; Harada, T; Abrignani, S; Pinzani, M				Mazzocca, A; Sciammetta, SC; Carloni, V; Cosmi, L; Annunziato, F; Harada, T; Abrignani, S; Pinzani, M			Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE 1; PHOSPHATIDYLINOSITOL 4-KINASE; SIGNAL-TRANSDUCTION; MMP2 ACTIVATION; GENE-EXPRESSION; GROWTH-FACTOR; HUMAN LIVERS; TRANSCRIPTION; SUPERFAMILY; GELATINASE	The hepatitis C virus (HCV) envelope E2 glycoprotein is a key molecule regulating the interaction of HCV with cell surface proteins. E2 binds the major extracellular loop of human CD81, a tetraspanin expressed on various cell types including hepatocytes and B lymphocytes. Regardless, information on the biological functions originating from this interaction are largely unknown. Since human hepatic stellate cells (HSC) express high levels of CD81 at the cell surface, we investigated the E2/CD81 interaction in human HSC and the possible effects arising from this interaction. Matrix metalloproteinase-2 (MMP-2; gelatinase A), a major enzyme involved in the degradation of normal hepatic extracellular matrix, was up-regulated following the interaction between E2 and CD81. In particular, by employing zymography and Western blot, we observed that E2 binding to CD81 induces a time-dependent increase in the synthesis and activity of MMP-2. This effect was abolished by preincubating HSC with an anti-CD81 neutralizing antibody. Similar effects were detected in NIH3T3 mouse fibroblasts transfected with human CD81 with identical time course features. In addition, E2/CD81 interaction in human HSC induced the up-regulation of MMP-2 by increasing activator protein-2/DNA binding activity via ERK/MAPK phosphorylation. Finally, suppression of CD81 by RNA interference in human HSC abolished the described effects of E2 on these cells, indicating that CD81 is essential for the activation of the signaling pathway leading to the up-regulation of MMP-2. These results suggest that HSC may represent a potential target for HCV. The interaction of HCV envelope with CD81 on the surface of human HSC induces an increased expression of MMP-2. Increased degradation of the normal hepatic extracellular matrix in areas where HCV is concentrated may favor inflammatory infiltration and further parenchymal damage.	Univ Florence, Dipartimento Med Interna, Ctr Ric Trasferimento & Alta Formaz, MCIDNENT, I-50134 Florence, Italy; Chiron Vaccines Res Ctr, I-53100 Siena, Italy	University of Florence; Novartis	Mazzocca, A (corresponding author), Univ Florence, Dipartimento Med Interna, Ctr Ric Trasferimento & Alta Formaz, MCIDNENT, 85 Vilae Morgagni, I-50134 Florence, Italy.	a.mazzocca@dmi.unifi.it	Annunziato, Francesco/C-1155-2013	Annunziato, Francesco/0000-0001-8798-7589; Abrignani, Sergio/0000-0002-0794-3285; MAZZOCCA, Antonio/0000-0003-0940-7352				Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; ARTHUR MJP, 1992, BIOCHEM J, V287, P701, DOI 10.1042/bj2870701; Bataller R, 2004, GASTROENTEROLOGY, V126, P529, DOI 10.1053/j.gastro.2003.11.018; Benyon RC, 1996, GASTROENTEROLOGY, V110, P821, DOI 10.1053/gast.1996.v110.pm8608892; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Carloni V, 2004, ONCOGENE, V23, P1566, DOI 10.1038/sj.onc.1207287; CASINI A, 1993, GASTROENTEROLOGY, V105, P245, DOI 10.1016/0016-5085(93)90033-9; Cassiman D, 2002, J HEPATOL, V37, P527, DOI 10.1016/S0168-8278(02)00263-5; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Flint M, 2000, REV MED VIROL, V10, P101, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;101::AID-RMV268&gt;3.0.CO;2-W; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; Guccione M, 2002, AM J PHYSIOL-RENAL, V282, pF164, DOI 10.1152/ajprenal.0318.2000; Han YP, 2001, J CELL SCI, V114, P131; Heile JM, 2000, J VIROL, V74, P6885, DOI 10.1128/JVI.74.15.6885-6892.2000; Johnston JB, 2000, J VIROL, V74, P7211, DOI 10.1128/JVI.74.16.7211-7220.2000; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Kovalenko OV, 2004, BIOCHEM J, V15, P407; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Marra F, 2002, FRONT BIOSCI, V7, pD1899, DOI 10.2741/marra; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Mazzocca A, 2002, J HEPATOL, V37, P322, DOI 10.1016/S0168-8278(02)00175-7; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pinzani M, 1996, AM J PATHOL, V148, P785; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Takahara T, 1997, HEPATOLOGY, V26, P1521; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Theret N, 1997, AM J PATHOL, V150, P51; Theret N, 1998, AM J PATHOL, V153, P945, DOI 10.1016/S0002-9440(10)65636-2; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	44	100	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11329	11339		10.1074/jbc.M410161200	http://dx.doi.org/10.1074/jbc.M410161200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15611113	hybrid			2022-12-27	WOS:000227761800054
J	Chai, SC; Jerkins, AA; Banik, JJ; Shalev, I; Pinkham, JL; Uden, PC; Maroney, MJ				Chai, SC; Jerkins, AA; Banik, JJ; Shalev, I; Pinkham, JL; Uden, PC; Maroney, MJ			Heterologous expression, purification, and characterization of recombinant rat cysteine dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CELL-LINES; LIQUID-CHROMATOGRAPHY; LIVER; TAURINE; OXIDASE; OXYGENASE; SYSTEM; CYSTEINESULFINATE; METABOLISM; ACTIVATION	Cysteine dioxygenase (CDO, EC 1.13.11.20) catalyzes the oxidation of cysteine to cysteine sulfinic acid, which is the first major step in cysteine catabolism in mammalian tissues. Rat liver CDO was cloned and expressed in Escherichia coli as a 26.8-kDa N-terminal fusion protein bearing a polyhistidine tag. Purification by immobilized metal affinity chromatography yielded homogeneous protein, which was catalytically active even in the absence of the secondary protein-A, which has been reported to be essential for activity in partially purified native preparations. As compared with those existing purification protocols for native CDO, the milder conditions used in the isolation of the recombinant CDO allowed a more controlled study of the properties and activity of CDO, clarifying conflicting findings in the literature. Apo-protein was inactive in catalysis and was only activated by iron. Metal analysis of purified recombinant protein indicated that only 10% of the protein contained iron and that the iron was loosely bound to the protein. Kinetic studies showed that the recombinant enzyme displayed a Km value of 2.5 +/- 0.4 mM at pH 7.5 and 37 degrees C. The enzyme was shown to be specific for L-cysteine oxidation, whereas homocysteine inhibited CDO activity.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA; Univ Arizona, Nutr Sci Program, Tucson, AZ 85721 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Arizona; University of Arizona	Maroney, MJ (corresponding author), Univ Massachusetts, Dept Chem, Lederle Grad Res Tower,Rm 701,701 N Pleasant St, Amherst, MA 01003 USA.	mmaroney@chem.umass.edu		Chai, Sergio/0000-0002-8257-8599; Maroney, Michael/0000-0002-5598-3038	NIDDK NIH HHS [R03-DK-50933] Funding Source: Medline; NIGMS NIH HHS [T32 GM008515, T32 GM08515] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK050933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008515] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGLEY PJ, 1995, ANAL BIOCHEM, V227, P40, DOI 10.1006/abio.1995.1250; De Marco C, 1966, Boll Soc Ital Biol Sper, V42, P94; EMERY P, 1992, ANN RHEUM DIS, V51, P318, DOI 10.1136/ard.51.3.318; EWETZ L, 1966, BIOCHIM BIOPHYS ACTA, V128, P296, DOI 10.1016/0926-6593(66)90176-7; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366; HOSOKAWA Y, 1990, BIOCHEM BIOPH RES CO, V168, P473, DOI 10.1016/0006-291X(90)92345-Z; Huxtable RJ, 2000, ADV EXP MED BIOL, V483, P1; Kamisaki Y, 1996, ADV EXP MED BIOL, V403, P445; KUMAR V, 1983, BIOCHEMISTRY-US, V22, P762, DOI 10.1021/bi00273a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN S, 1986, ANAL CHEM, V58, P1602, DOI 10.1021/ac00121a004; LOMBARDINI JB, 1969, PHYSIOL CHEM PHYS M, V1, P1; LOMBARDINI JB, 1969, J BIOL CHEM, V244, P1172; Mampel J, 1999, MICROBIOL-UK, V145, P3255, DOI 10.1099/00221287-145-11-3255; McCaddon A, 2003, BIOL PSYCHIAT, V53, P254, DOI 10.1016/S0006-3223(02)01451-8; McKay DB, 2003, J BACTERIOL, V185, P2944, DOI 10.1128/JB.185.9.2944-2951.2003; OLNEY JW, 1990, SCIENCE, V248, P596, DOI 10.1126/science.2185543; Parsons RB, 1998, J HEPATOL, V29, P595, DOI 10.1016/S0168-8278(98)80155-4; Parsons RB, 1998, NEUROTOXICOLOGY, V19, P599; PEAN AR, 1995, J NEUROL SCI, V129, P107, DOI 10.1016/0022-510X(95)00078-G; PERRY TL, 1985, ANN NEUROL, V18, P482, DOI 10.1002/ana.410180411; Pierno S, 1996, ADV EXP MED BIOL, V403, P249; Riegert U, 1999, J BACTERIOL, V181, P4812, DOI 10.1128/JB.181.16.4812-4817.1999; SAKAKIBARA S, 1976, BIOCHIM BIOPHYS ACTA, V422, P273, DOI 10.1016/0005-2744(76)90138-8; SAKAKIBARA S, 1973, BIOCHEM BIOPH RES CO, V52, P1093, DOI 10.1016/0006-291X(73)91050-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saransaari P, 1996, ADV EXP MED BIOL, V403, P481; Satoh H, 1996, ADV EXP MED BIOL, V403, P285; Shen XM, 1997, CHEM RES TOXICOL, V10, P147, DOI 10.1021/tx960145c; SORBO B, 1965, BIOCHEM BIOPH RES CO, V18, P359, DOI 10.1016/0006-291X(65)90714-X; WEINSTEIN CL, 1988, J BIOL CHEM, V263, P16568; Wilkinson LJ, 2002, TOXICOL IN VITRO, V16, P481, DOI 10.1016/S0887-2333(02)00031-0; YAMAGUCHI K, 1971, BIOCHIM BIOPHYS ACTA, V237, P502, DOI 10.1016/0304-4165(71)90270-4; YAMAGUCHI K, 1978, J BIOCHEM-TOKYO, V83, P479, DOI 10.1093/oxfordjournals.jbchem.a131935; YAMAGUCHI K, 1987, METHOD ENZYMOL, V143, P395; Yamaguchi K., 1980, NATURAL SULFUR COMPO, P175	36	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9865	9869		10.1074/jbc.M413733200	http://dx.doi.org/10.1074/jbc.M413733200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15623508	hybrid			2022-12-27	WOS:000227559600016
J	Murray, RZ; Wylie, FG; Khromykh, T; Hume, DA; Stow, JL				Murray, RZ; Wylie, FG; Khromykh, T; Hume, DA; Stow, JL			Syntaxin 6 and Vti1b form a novel SNARE complex, which is up-regulated in activated macrophages to facilitate exocytosis of tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; MEMBRANE-FUSION; PROTEIN; RECEPTORS; LOCALIZATION; VESICLES; DOMAINS; SYSTEM; CELLS; VAMP7	A key function of activated macrophages is to secrete proinflammatory cytokines such as TNF alpha; however, the intracellular pathway and machinery responsible for cytokine trafficking and secretion is largely undefined. Here we show that individual SNARE proteins involved in vesicle docking and fusion are regulated at both gene and protein expression upon stimulation with the bacterial cell wall component lipopolysaccharide. Focusing on two intracellular SNARE proteins, Vti1b and syntaxin 6 (Stx6), we show that they are up-regulated in conjunction with increasing cytokine secretion in activated macrophages and that their levels are selectively titrated to accommodate the volume and timing of post-Golgi cytokine trafficking. In macrophages, Vti1b and syntaxin 6 are localized on intracellular membranes and are present on isolated Golgi membranes and on Golgi-derived TNF alpha vesicles budded in vitro. By immunoprecipitation, we find that Vti1b and syntaxin 6 interact to form a novel intracellular Q-SNARE complex. Functional studies using overexpression of full-length and truncated proteins show that both Vti1b and syntaxin 6 function and have rate-limiting roles in TNF alpha trafficking and secretion. This study shows how macrophages have uniquely adapted a novel Golgi-associated SNARE complex to accommodate their requirement for increased cytokine secretion.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Special Res Ctr Funct & Appl Genom, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Cooperat Res cTr Chron Inflammatory Dis, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland; University of Queensland	Stow, JL (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j-stow@imb.uq.edu.au	Khromykh, Tatiana/D-3952-2017; Hume, David A/C-7695-2013; Stow, Jennifer L/I-4723-2013; Murray, Rachael/J-1370-2012	Khromykh, Tatiana/0000-0001-6629-6885; Stow, Jennifer L/0000-0002-5409-9101; Murray, Rachael/0000-0002-4935-7794; Hume, David/0000-0002-2615-1478				Anderson P, 2004, J LEUKOCYTE BIOL, V76, P42, DOI 10.1189/jlb.1103536; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chidambaram S, 2004, J BIOL CHEM, V279, P4175, DOI 10.1074/jbc.M308667200; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Hackam DJ, 1996, J IMMUNOL, V156, P4377; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; Hirst J, 2004, MOL BIOL CELL, V15, P5593, DOI 10.1091/mbc.E04-06-0468; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Logan MR, 2002, J ALLERGY CLIN IMMUN, V109, P299, DOI 10.1067/mai.2002.121453; Pagan JK, 2003, CURR BIOL, V13, P156, DOI 10.1016/S0960-9822(03)00006-X; Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Prekeris R, 2000, EUR J CELL BIOL, V79, P771, DOI 10.1078/0171-9335-00109; Pryor PR, 2004, EMBO REP, V5, P590, DOI 10.1038/sj.embor.7400150; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; Rothman JE, 2002, NAT MED, V8, P1059, DOI 10.1038/nm770; Rowland JE, 2005, MOL CELL BIOL, V25, P66, DOI 10.1128/MCB.25.1.66-77.2005; Shurety W, 2001, LAB INVEST, V81, P107, DOI 10.1038/labinvest.3780216; Shurety W, 2000, J INTERF CYTOK RES, V20, P427, DOI 10.1089/107999000312379; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Wade N, 2001, J BIOL CHEM, V276, P19820, DOI 10.1074/jbc.M010838200; Ward DM, 2000, MOL BIOL CELL, V11, P2327, DOI 10.1091/mbc.11.7.2327; Wendler F, 2001, TRAFFIC, V2, P606, DOI 10.1034/j.1600-0854.2001.20903.x; Wylie FG, 2003, TRAFFIC, V4, P175, DOI 10.1034/j.1600-0854.2003.00106.x	31	119	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10478	10483		10.1074/jbc.M414420200	http://dx.doi.org/10.1074/jbc.M414420200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640147	Green Published, hybrid			2022-12-27	WOS:000227559600090
J	Tapp, H; Al-Naggar, IM; Yarmola, EG; Harrison, A; Shaw, G; Edison, AS; Bubb, MR				Tapp, H; Al-Naggar, IM; Yarmola, EG; Harrison, A; Shaw, G; Edison, AS; Bubb, MR			MARCKS is a natively unfolded protein with an inaccessible actin-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-KINASE SUBSTRATE; FILAMENT CROSS-LINKING; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CRYSTAL-STRUCTURE; F-ACTIN; MYOBLAST MIGRATION; EFFECTOR PEPTIDE; BOVINE BRAIN; PHOSPHORYLATION; CALPAIN	Myristoylated alanine-rich C kinase substrate (MARCKS) is an unfolded protein that contains well characterized actin-binding sites within the phosphorylation site domain (PSD), yet paradoxically, we now find that intact MARCKS does not bind to actin. Intact MARCKS also does not bind as well to calmodulin as does the PSD alone. Myristoylation at the N terminus alters how calmodulin binds to MARCKS, implying that, despite its unfolded state, the distant N terminus influences binding events at the PSD. We show that the free PSD binds with site specificity to MARCKS, suggesting that long-range intramolecular interactions within MARCKS are also possible. Because of the unusual primary sequence of MARCKS with an overall isoelectric point of 4.2 yet a very basic PSD (overall charge of +13), we speculated that ionic interactions between oppositely charged domains of MARCKS were responsible for long-range interactions within MARCKS that sterically influence binding events at the PSD and that explain the observed differences between properties of the PSD and MARCKS. Consistent with this hypothesis, chemical modifications of MARCKS that neutralize negatively charged residues outside of the PSD allow the PSD to bind to actin and increase the affinity of MARCKS for calmodulin. Similarly, both myristoylation of MARCKS and cleavage of MARCKS by calpain are shown to increase the availability of the PSD so as to activate its actin-binding activity. Because abundant evidence supports the conclusion that MARCKS is an important protein in regulating actin dynamics, our data imply that post-translational modifications of MARCKS are necessary and sufficient to regulate actin-binding activity.	Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Malcom Randall Vet Affairs Med Ctr, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Bubb, MR (corresponding author), Univ Florida, Coll Med, Dept Med, POB 100221, Gainesville, FL 32610 USA.	bubbmr@medicine.ufl.edu	, Gerry/X-2377-2019	Edison, Arthur/0000-0002-5686-2350				ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Braun T, 2000, BIOCHIMIE, V82, P705, DOI 10.1016/S0300-9084(00)01154-8; Bubb MR, 2002, J BIOL CHEM, V277, P20999, DOI 10.1074/jbc.M201371200; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; CHAO D, 1994, BIOCHEM CELL BIOL, V72, P391, DOI 10.1139/o94-052; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; Dedieu S, 2003, BIOL CELL, V95, P615, DOI 10.1016/j.biolcel.2003.09.005; Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014; Domanska-Janik K, 1998, ACTA NEUROBIOL EXP, V58, P247; Dulong S, 2004, BIOCHEM J, V382, P1015, DOI 10.1042/BJ20040347; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Iioka H, 2004, J CELL BIOL, V164, P169, DOI 10.1083/jcb.200310027; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; KASTURI R, 1993, J BIOL CHEM, V268, P7958; KIM JY, 1994, J BIOL CHEM, V269, P28214; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lee KK, 2002, PROTEIN SCI, V11, P1004, DOI 10.1110/ps.4700102; Lu D, 1998, J CELL BIOL, V142, P217, DOI 10.1083/jcb.142.1.217; MANENTI S, 1993, J BIOL CHEM, V268, P6878; Manenti S, 1999, BIOCHEM J, V340, P775, DOI 10.1042/0264-6021:3400775; MANENTI S, 1995, BIOCHEM SOC T, V23, P561, DOI 10.1042/bst0230561; Matsubara M, 2004, EMBO J, V23, P712, DOI 10.1038/sj.emboj.7600093; Matsubara M, 2003, J BIOL CHEM, V278, P48898, DOI 10.1074/jbc.M305488200; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Muller U, 1997, BRAIN RES, V757, P24, DOI 10.1016/S0006-8993(96)01435-7; Neltner BS, 2000, CELL SIGNAL, V12, P71, DOI 10.1016/S0898-6568(99)00065-0; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; Sechi AS, 2000, J CELL SCI, V113, P3685; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Song JC, 1999, AM J PHYSIOL-CELL PH, V277, pC1239, DOI 10.1152/ajpcell.1999.277.6.C1239; Spizz G, 2001, J BIOL CHEM, V276, P32264, DOI 10.1074/jbc.M103960200; Sundaram M, 2004, BIOCHEM CELL BIOL, V82, P191, DOI 10.1139/o03-087; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Vergeres G, 1998, BIOCHEM J, V330, P5, DOI 10.1042/bj3300005; Victor KG, 2001, BIOPHYS J, V81, P2241, DOI 10.1016/S0006-3495(01)75871-7; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; Wohnsland F, 2000, J STRUCT BIOL, V131, P217, DOI 10.1006/jsbi.2000.4299; Wohnsland F, 2000, BIOPHYS CHEM, V85, P169, DOI 10.1016/S0301-4622(00)00113-7; Wohnsland F, 2000, J BIOL CHEM, V275, P20873, DOI 10.1074/jbc.M910298199; Yamauchi E, 2003, NAT STRUCT BIOL, V10, P226, DOI 10.1038/nsb900; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200	56	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9946	9956		10.1074/jbc.M414614200	http://dx.doi.org/10.1074/jbc.M414614200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640140	hybrid			2022-12-27	WOS:000227559600026
J	Watanabe, S; Kodaki, T; Makino, K				Watanabe, S; Kodaki, T; Makino, K			Complete reversal of coenzyme specificity of xylitol dehydrogenase and increase of thermostability by the introduction of structural zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MEDIUM-CHAIN DEHYDROGENASES/REDUCTASES; YEAST PICHIA-STIPITIS; ALCOHOL-DEHYDROGENASE; COFACTOR SPECIFICITY; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SORBITOL DEHYDROGENASE; ISOCITRATE DEHYDROGENASE; SULFOLOBUS-SOLFATARICUS	Pichia stipitis NAD(+)-dependent xylitol dehydrogenase (XDH), a medium-chain dehydrogenase/reductase, is one of the key enzymes in ethanol fermentation from xylose. For the construction of an efficient biomass-ethanol conversion system, we focused on the two areas of XDH, 1) change of coenzyme specificity from NAD(+) to NADP(+) and 2) thermostabilization by introducing an additional zinc atom. Site-directed mutagenesis was used to examine the roles of Asp(207), Ile(208), Phe(209), and Asn(211) in the discrimination between NAD(+) and NADP(+). Single mutants (D207A, I208R, F209S, and N211R) improved 5 similar to 48-fold in catalytic efficiency (k(cat)/K-m) with NADP(+) compared with the wild type but retained substantial activity with NAD(+). The double mutants (D207A/I208R and D207A/F209S) improved by 3 orders of magnitude in k(cat)/K-m with NADP(+), but they still preferred NAD(+) to NADP(+). The triple mutant (D207A/I208R/F209S) and quadruple mutant (D207A/I208R/F209S/N211R) showed more than 4500-fold higher values in k(cat)/K-m with NADP(+) than the wild-type enzyme, reaching values comparable with k(cat)/K-m with NAD(+) of the wild-type enzyme. Because most NADP(+)-dependent XDH mutants constructed in this study decreased the thermostability compared with the wild-type enzyme, we attempted to improve the thermostability of XDH mutants by the introduction of an additional zinc atom. The introduction of three cysteine residues in wild-type XDH gave an additional zinc-binding site and improved the thermostability. The introduction of this mutation in D207A/I208R/F209S and D207A/I208R/F209S/N211R mutants increased the thermostability and further increased the catalytic activity with NADP(+).	Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Kyoto Univ, Int Innovat Ctr, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Agcy, JST, CREST, Uji, Kyoto 6110011, Japan	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST)	Makino, K (corresponding author), Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan.	kmak@iae.kyoto-u.ac.jp						AMMENDOLA S, 1992, BIOCHEMISTRY-US, V31, P12514, DOI 10.1021/bi00164a031; BAKER PJ, 1992, J MOL BIOL, V228, P662, DOI 10.1016/0022-2836(92)90848-E; Banfield MJ, 2001, J MOL BIOL, V306, P239, DOI 10.1006/jmbi.2000.4381; Banta S, 2002, BIOCHEMISTRY-US, V41, P6226, DOI 10.1021/bi015987b; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; Chen RD, 1996, P NATL ACAD SCI USA, V93, P12171, DOI 10.1073/pnas.93.22.12171; CHEN Z, 1991, EUR J BIOCHEM, V202, P263, DOI 10.1111/j.1432-1033.1991.tb16371.x; Cho H, 2003, ARCH BIOCHEM BIOPHYS, V419, P139, DOI 10.1016/j.abb.2003.09.019; Danielson UH, 1999, BIOCHEMISTRY-US, V38, P9254, DOI 10.1021/bi9903300; EKLUND H, 1985, BIOCHEMISTRY-US, V24, P8005, DOI 10.1021/bi00348a025; Esposito L, 2002, J MOL BIOL, V318, P463, DOI 10.1016/S0022-2836(02)00088-8; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Galkin A, 1997, PROTEIN ENG, V10, P687, DOI 10.1093/protein/10.6.687; GRIMSHAW CE, 1992, J BIOL CHEM, V267, P15334; Guy JE, 2003, J MOL BIOL, V331, P1041, DOI 10.1016/S0022-2836(03)00857-X; Holmberg N, 1999, PROTEIN ENG, V12, P851, DOI 10.1093/protein/12.10.851; Huang YW, 2001, MOL ENDOCRINOL, V15, P2010, DOI 10.1210/me.15.11.2010; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; Ingram LO, 1998, BIOTECHNOL BIOENG, V58, P204, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<204::AID-BIT13>3.0.CO;2-C; Jeffries TW, 2004, APPL MICROBIOL BIOT, V63, P495, DOI 10.1007/s00253-003-1450-0; JELOKOVA J, 1994, EUR J BIOCHEM, V225, P1015, DOI 10.1111/j.1432-1033.1994.1015b.x; Johansson K, 2001, CHEM-BIOL INTERACT, V130, P351, DOI 10.1016/S0009-2797(00)00260-X; Korkhin Y, 1998, J MOL BIOL, V278, P967, DOI 10.1006/jmbi.1998.1750; KOTTER P, 1990, CURR GENET, V18, P493, DOI 10.1007/BF00327019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUVERGEAT V, 1995, BIOCHEMISTRY-US, V34, P12426, DOI 10.1021/bi00038a041; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lunzer R, 1998, BIOCHEM J, V336, P91, DOI 10.1042/bj3360091; MAGONET E, 1992, BIOCHEM J, V287, P361, DOI 10.1042/bj2870361; Marini I, 1997, ARCH BIOCHEM BIOPHYS, V340, P383, DOI 10.1006/abbi.1997.9882; METZGER MH, 1995, EUR J BIOCHEM, V228, P50, DOI 10.1111/j.1432-1033.1995.tb20227.x; NG K, 1992, J BIOL CHEM, V267, P24989; NISHIYAMA M, 1993, J BIOL CHEM, V268, P4656; Nordling E, 2002, EUR J BIOCHEM, V269, P4267, DOI 10.1046/j.1432-1033.2002.03114.x; Ostergaard S, 2000, MICROBIOL MOL BIOL R, V64, P34, DOI 10.1128/MMBR.64.1.34-50.2000; Pauly TA, 2003, STRUCTURE, V11, P1071, DOI 10.1016/S0969-2126(03)00167-9; Penning TM, 2001, CHEM REV, V101, P3027, DOI 10.1021/cr000049n; Riveros-Rosas H, 2003, EUR J BIOCHEM, V270, P3309, DOI 10.1046/j.1432-1033.2003.03704.x; RIZZI M, 1989, J FERMENT BIOENG, V67, P20, DOI 10.1016/0922-338X(89)90080-9; Rosell A, 2003, J BIOL CHEM, V278, P40573, DOI 10.1074/jbc.M307384200; Rosell A, 2003, J MOL BIOL, V330, P75, DOI 10.1016/S0022-2836(03)00431-5; Schepens I, 2000, J BIOL CHEM, V275, P20996, DOI 10.1074/jbc.M002066200; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Serov AE, 2002, BIOCHEM J, V367, P841, DOI 10.1042/BJ20020379; Steen IH, 2002, ARCH MICROBIOL, V178, P297, DOI 10.1007/s00203-002-0439-x; Svensson S, 2000, J MOL BIOL, V302, P441, DOI 10.1006/jmbi.2000.4039; Walfridsson M, 1997, APPL MICROBIOL BIOT, V48, P218, DOI 10.1007/s002530051041; Walfridsson M, 1996, APPL ENVIRON MICROB, V62, P4648, DOI 10.1128/AEM.62.12.4648-4651.1996; Wang H, 2000, BIOCHEMISTRY-US, V39, P7813, DOI 10.1021/bi0003745; Wang JC, 1999, BIOSCI BIOTECH BIOCH, V63, P2216, DOI 10.1271/bbb.63.2216; Wiegert T, 1997, J BIOL CHEM, V272, P13126, DOI 10.1074/jbc.272.20.13126; Wolfe GR, 1999, INSECT BIOCHEM MOLEC, V29, P113, DOI 10.1016/S0965-1748(98)00114-3; Woodyer R, 2003, BIOCHEMISTRY-US, V42, P11604, DOI 10.1021/bi035018b; Yang ZN, 1997, J MOL BIOL, V265, P330, DOI 10.1006/jmbi.1996.0731; Zaldivar J, 2001, APPL MICROBIOL BIOT, V56, P17, DOI 10.1007/s002530100624; Zhang L, 1999, BIOCHEMISTRY-US, V38, P11440, DOI 10.1021/bi991101g	57	141	161	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10340	10349		10.1074/jbc.M409443200	http://dx.doi.org/10.1074/jbc.M409443200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15623532	hybrid			2022-12-27	WOS:000227559600074
J	Yamano, K; Ishikawa, D; Esaki, M; Endo, T				Yamano, K; Ishikawa, D; Esaki, M; Endo, T			The phosphate carrier has an ability to be sorted to either the TIM22 pathway or the TIM23 pathway for its import into yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWIN-PORE TRANSLOCASE; INTERMEMBRANE SPACE; PROTEIN TRANSLOCATION; ADP/ATP CARRIER; OUTER-MEMBRANE; COMPLEX	Most mitochondrial proteins are synthesized in the cytosol, imported into mitochondria via the TOM40 ( translocase of the mitochondrial outer membrane 40) complex, and follow several distinct sorting pathways to reach their destination submitochondrial compartments. Phosphate carrier (PiC) is an inner membrane protein with 6 transmembrane segments (TM1-TM6) and requires, after translocation across the outer membrane, the Tim9-Tim10 complex and the TIM22 complex to be inserted into the inner membrane. Here we analyzed an in vitro import of fusion proteins between various PiC segments and mouse dihydrofolate reductase. The fusion protein without TM1 and TM2 was translocated across the outer membrane but was not inserted into the inner membrane. The fusion proteins without TM1-TM4 were not inserted into the inner membrane but instead translocated across the inner membrane. Functional defects of Tim50 of the TIM23 complex caused either by depletion of the protein or the addition of anti-Tim50 antibodies blocked translocation of the fusion proteins without TM1-TM4 across the inner membrane, suggesting that lack of TM1-TM4 led to switch of its sorting pathway from the TIM22 pathway to the TIM23 pathway. PiC thus appears to have a latent signal for sorting to the TIM23 pathway, which is exposed by reduced interactions with the Tim9-Tim10 complex and maintenance of the import competence.	Nagoya Univ, Dept Chem, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, JST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University; Japan Science & Technology Agency (JST); Nagoya University; Japan Science & Technology Agency (JST); Nagoya University	Endo, T (corresponding author), Nagoya Univ, Dept Chem, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	endo@biochem.chem.nagoya-u.ac.jp	Esaki, Masatoshi/ABS-6645-2022; Esaki, Masatoshi/L-6591-2017					Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Chacinska A, 2004, EMBO J, V23, P3735, DOI 10.1038/sj.emboj.7600389; Curran SP, 2004, J BIOL CHEM, V279, P43744, DOI 10.1074/jbc.M404878200; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; DAUM G, 1982, J BIOL CHEM, V257, P3028; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Esaki M, 1999, P NATL ACAD SCI USA, V96, P11770, DOI 10.1073/pnas.96.21.11770; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; Naoe M, 2004, J BIOL CHEM, V279, P47815, DOI 10.1074/jbc.M410272200; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Pfanner N, 2004, NAT STRUCT MOL BIOL, V11, P1044, DOI 10.1038/nsmb852; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; SIRRENBERG C, 1997, J BIOL CHEM, V272, P29663; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	20	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10011	10017		10.1074/jbc.M413264200	http://dx.doi.org/10.1074/jbc.M413264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644337	hybrid			2022-12-27	WOS:000227559600034
J	Carrigan, PE; Riggs, DL; Chinkers, M; Smith, DF				Carrigan, PE; Riggs, DL; Chinkers, M; Smith, DF			Functional comparison of human and Drosophila hop reveals novel role in steroid receptor maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE HSP70/HSC70; TETRATRICOPEPTIDE REPEAT DOMAIN; IN-VITRO PHOSPHORYLATION; CELL-CYCLE KINASES; PROGESTERONE-RECEPTOR; SACCHAROMYCES-CEREVISIAE; ATPASE ACTIVITY; CO-CHAPERONES; HSP90 ATPASE	Hsp70/Hsp90 organizing protein (Hop) coordinates Hsp70 and Hsp90 interactions during assembly of steroid receptor complexes. Hop is composed of three tetratricopeptide repeat (TPR) domains (TPR1, TPR2a, and TPR2b) and two DP repeat domains (DP1 and DP2); Hsp70 interacts directly with TPR1 and Hsp90 with TPR2a, but the function of other domains is less clear. Human Hop and the Saccharomyces cerevisiae ortholog Sti1p, which share a common domain arrangement, are functionally interchangeable in a yeast growth assay and in supporting the efficient maturation of glucocorticoid receptor (GR) function. To gain a better understanding of Hop structure/function relationships, we have extended comparisons to the Hop ortholog from Drosophila melanogaster (dHop), which lacks DP1. Although dHop binds Hsp70 and Hsp90 and can rescue the growth defect in yeast lacking Sti1p, dHop failed to support GR function in yeast, which suggests a novel role for Hop in GR maturation that goes beyond Hsp binding. Chimeric Hop constructs combining human and Drosophila domains demonstrate that the C-terminal domain DP2 is critical for this previously unrecognized role in steroid receptor function.	Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA; Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA	Mayo Clinic; Mayo Clinic Phoenix; University of South Alabama	Smith, DF (corresponding author), Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Johnson Res Bldg,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	smith.david26@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044923] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK44923] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Carrigan PE, 2004, J BIOL CHEM, V279, P16185, DOI 10.1074/jbc.M314130200; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Dornan J, 2003, CURR TOP MED CHEM, V3, P1392, DOI 10.2174/1568026033451899; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Longshaw VM, 2000, BIOL CHEM, V381, P1133, DOI 10.1515/BC.2000.139; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nelson GM, 2003, CELL STRESS CHAPERON, V8, P125, DOI 10.1379/1466-1268(2003)008<0125:COTCDR>2.0.CO;2; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SULLIVAN WP, 1985, BIOCHEMISTRY-US, V24, P4214, DOI 10.1021/bi00336a060; Vilardell J, 1997, MOL CELL BIOL, V17, P1959, DOI 10.1128/MCB.17.4.1959; Ward BK, 2002, J BIOL CHEM, V277, P40799, DOI 10.1074/jbc.M207097200; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200	38	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8906	8911		10.1074/jbc.M414245200	http://dx.doi.org/10.1074/jbc.M414245200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632128	hybrid			2022-12-27	WOS:000227453100036
J	Grishko, VI; Rachek, LI; Spitz, DR; Wilson, GL; LeDoux, SP				Grishko, VI; Rachek, LI; Spitz, DR; Wilson, GL; LeDoux, SP			Contribution of mitochondrial DNA repair to cell resistance from oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 8-OXOGUANINE GLYCOSYLASE; ISCHEMIA-REPERFUSION; CATALASE ACTIVITY; MESSENGER-RNA; UP-REGULATION; EXPRESSION; DAMAGE; HOGG1; ENDONUCLEASE; MOUSE	Numerous studies have revealed that a part of the cellular response to chronic oxidative stress involves increased antioxidant capacity. However, another defense mechanism that has received less attention is DNA repair. Because of the important homeostatic role of mitochondria and the exquisite sensitivity of mitochondrial DNA (mtDNA) to oxidative damage, we hypothesized that mtDNA repair plays an important role in the protection against oxidative stress. To test this hypothesis mtDNA damage and repair was evaluated in normal HA1 Chinese hamster fibroblasts and oxidative stress-resistant variants isolated following chronic exposure to H2O2 or 95% O-2. Reactive oxygen species were generated enzymatically using xanthine oxidase and hypoxanthine. When treated with xanthine oxidase reduced levels of initial mtDNA damage and enhanced mtDNA repair were observed in the cells from the oxidative stress-resistant variants, relative to the parental cell line. This enhanced mtDNA repair correlated with an increase in mitochondrial apurinic/apyrimidinic endonuclease activity in both H2O2- and O-2-resistant HA1 variants. This is the first report showing enhanced mtDNA repair in the cellular response to chronic oxidative stress. These results provide further evidence for the crucial role that mtDNA repair pathways play in protecting cells against the deleterious effects of reactive oxygen species.	Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Orthoped, Mobile, AL 36688 USA; Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	University of South Alabama; University of South Alabama; University of Iowa	LeDoux, SP (corresponding author), Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA.	sledoux@usouthal.edu		Spitz, Douglas/0000-0002-1254-8765	NATIONAL CANCER INSTITUTE [R01CA100045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019602] Funding Source: NIH RePORTER; NCI NIH HHS [CA100045] Funding Source: Medline; NIA NIH HHS [AG19602] Funding Source: Medline; NIEHS NIH HHS [ES05865, ES03456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230; FRIEDBERG EC, 1994, DNA REPAIR, P135; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; Frossi B, 2002, J CELL PHYSIOL, V193, P180, DOI 10.1002/jcp.10159; GROMBACHER T, 1996, CARCINOGENESIS, V17, P2336; Hodges NJ, 2002, CARCINOGENESIS, V23, P55, DOI 10.1093/carcin/23.1.55; Hunt CR, 1998, CANCER RES, V58, P3986; Kim HN, 2001, CARCINOGENESIS, V22, P265, DOI 10.1093/carcin/22.2.265; LeDoux SP, 1999, MUTAT RES-DNA REPAIR, V434, P149, DOI 10.1016/S0921-8777(99)00026-9; Lee MR, 2004, J BIOL CHEM, V279, P9857, DOI 10.1074/jbc.M311132200; Lin LH, 2000, J NEUROCHEM, V74, P1098; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; Pritsos CA, 1997, ONCOL RES, V9, P333; Rachek LI, 2002, J BIOL CHEM, V277, P44932, DOI 10.1074/jbc.M208770200; Rachek LI, 2004, NUCLEIC ACIDS RES, V32, P3240, DOI 10.1093/nar/gkh648; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Rusyn I, 2004, CANCER RES, V64, P1050, DOI 10.1158/0008-5472.CAN-03-3027; Scheffler IE, 2001, MITOCHONDRION, V1, P3, DOI 10.1016/S1567-7249(00)00002-7; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; SPITZ DR, 1988, RADIAT RES, V114, P114, DOI 10.2307/3577149; SPITZ DR, 1992, ARCH BIOCHEM BIOPHYS, V292, P221, DOI 10.1016/0003-9861(92)90071-4; Stuart JA, 2004, NUCLEIC ACIDS RES, V32, P2181, DOI 10.1093/nar/gkh533; SULLIVAN SJ, 1992, AM J PHYSIOL, V262, pL748, DOI 10.1152/ajplung.1992.262.6.L748; Tsurudome Y, 1999, CARCINOGENESIS, V20, P1573, DOI 10.1093/carcin/20.8.1573; Tsuruya K, 2003, DNA REPAIR, V2, P211, DOI 10.1016/S1568-7864(02)00214-8; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	32	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8901	8905		10.1074/jbc.M413022200	http://dx.doi.org/10.1074/jbc.M413022200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632148	hybrid			2022-12-27	WOS:000227453100035
J	Liu, YH; Yerushalmi, GM; Grigera, PR; Parsons, JT				Liu, YH; Yerushalmi, GM; Grigera, PR; Parsons, JT			Mislocalization or reduced expression of arf GTPase-activating protein ASAP1 inhibits cell spreading and migration by influencing Arf1 GTPase cycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; FOCAL ADHESION KINASE; BINDING-PROTEIN; ACTIN CYTOSKELETON; TYROSINE PHOSPHORYLATION; PAXILLIN RECRUITMENT; PLASMA-MEMBRANE; GOLGI MEMBRANES; F-ACTIN; COMPLEX	ADP-ribosylation factor (Arf) family of small GTP-binding proteins plays a central role in membrane trafficking and cytoskeletal remodeling. ASAP1 (Arf-GAP containing SH3, ankyrin repeats, and PH domain) is a phospholipid-dependent Arf GTPase-activating protein (Arf-GAP) that binds to protein-tyrosine kinases Src and focal adhesion kinase. Using affinity chromatography and mass spectrometry (MS), we identified the adaptor protein CD2-associated protein (CD2AP) as a candidate binding partner of ASAP1. Both co-immunoprecipitation and GST pull-down experiments confirmed that CD2AP stably interacts with ASAP1 through its N-terminal SH3 domains. Using a mislocalization strategy, we show that sequestration of endogenous ASAP1 to mitochondria with a CD2AP SH3-mito fusion protein (the three N-terminal SH3 domains of CD2AP fused to Listeria monocytogenes ActA mitochondria-targeting sequence) inhibited REF52 cell spreading and migration in response to fibronectin stimulation. Using an alternative strategy we show that suppressing ASAP1 expression with small interfering RNA duplexes also significantly retarded cell spreading and inhibited cell migration. Furthermore, abrogation of ASAP1 function using either small interfering RNAs or mislocalization approaches caused an increase of GTP loading on Arf1 and loss of paxillin from adhesions. These results taken together with our previous observations that overexpression of ASAP1 inhibits cell spreading and alters paxillin localization to adhesions (Liu, Y., Loijens, J. C., Martin, K. H., Karginov, A. V., and Parsons, J. T. (2002) Mol. Biol. Cell. 13, 2147 - 2156) suggest that the recruitment of certain adhesion components such as paxillin requires dynamic GTP/GDP turnover of Arf1 GTPase.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel	University of Virginia; University of Virginia; Tel Aviv University; Sackler Faculty of Medicine	Parsons, JT (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, Box 800734, Charlottesville, VA 22908 USA.	jtp@virginia.edu			NCI NIH HHS [CA40042, CA29243, CA80606] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA029243, R01CA080606, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Lehtonen S, 2002, AM J PHYSIOL-RENAL, V283, pF734, DOI 10.1152/ajprenal.00312.2001; Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02-01-0018; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Slack JK, 1999, J BIOL CHEM, V274, P27177, DOI 10.1074/jbc.274.38.27177; Song J, 1998, J CELL SCI, V111, P2257; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Weed SA, 1998, J CELL SCI, V111, P2433; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	45	53	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8884	8892		10.1074/jbc.M412200200	http://dx.doi.org/10.1074/jbc.M412200200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632162	hybrid			2022-12-27	WOS:000227453100033
J	Zhong, L; Tan, Y; Zhou, A; Yu, QM; Zhou, JH				Zhong, L; Tan, Y; Zhou, A; Yu, QM; Zhou, JH			RING finger ubiquitin-protein isopeptide ligase Nrdp1/FLRF regulates parkin stability and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; ENCODING ALPHA-SYNUCLEIN; DISEASE GENE-PRODUCT; LEWY BODIES; 2 PARTS; MUTATIONS; FAMILIES; DEGRADATION; DROSOPHILA; DEMENTIA	Parkin is a ubiquitin-protein isopeptide ligase. It has been suggested that loss of function in parkin causes accumulation and aggregation of its substrates, leading to death of dopaminergic neurons in Parkinson disease. Using the yeast two-hybrid screen, we isolated a RING finger protein that interacted with the N terminus of parkin in a Drosophila cDNA library. Interaction between human parkin and the mammalian RING finger protein homologue Nrdp1/FLRF, a ubiquitin-protein isopeptide ligase that ubiquitinates ErbB3 and ErbB4, was validated by in vitro binding assay, co-immunoprecipitation, and immunofluorescence co-localization. Significantly, pulse-chase experiments showed that co-transfection of Nrdp1 and parkin reduced the half-life of parkin from 5 to 2.5 h. Consistent with these findings, we further observed that degradation of CDCrel-1, a parkin substrate, was facilitated by overexpression of parkin protein. However, co-transfection of Nrdp1 with parkin reversed the effects of parkin on CDCrel-1 degradation. We conclude that Nrdp1 is a parkin modifier that accelerates degradation of parkin, resulting in a reduction of parkin activity.	Univ Massachusetts, Sch Med, Dept Med, Program Neurosci, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Zhou, JH (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Program Neurosci, 364 Plantat St,LRB 325, Worcester, MA 01605 USA.	jianhua.zhou@umassmed.edu						Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Abdullah JM, 2001, BLOOD CELL MOL DIS, V27, P320, DOI 10.1006/bcmd.2001.0390; Athanassiadou A, 1999, AM J HUM GENET, V65, P555, DOI 10.1086/302486; Baba M, 1998, AM J PATHOL, V152, P879; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bonifati V, 2001, J NEUROL NEUROSUR PS, V71, P531, DOI 10.1136/jnnp.71.4.531; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Dickson DW, 2001, CURR OPIN NEUROL, V14, P423, DOI 10.1097/00019052-200108000-00001; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Gai WP, 1995, BRAIN, V118, P1447, DOI 10.1093/brain/118.6.1447; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Hattori N, 1998, BIOCHEM BIOPH RES CO, V249, P754, DOI 10.1006/bbrc.1998.9134; Huynh DP, 2003, HUM MOL GENET, V12, P2587, DOI 10.1093/hmg/ddg269; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Leroy E, 1998, HUM GENET, V103, P424, DOI 10.1007/s004390050845; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lucking CB, 1998, LANCET, V352, P1355, DOI 10.1016/S0140-6736(05)60746-5; Matsumine H, 1998, GENOMICS, V49, P143, DOI 10.1006/geno.1997.5196; Matsumine H, 1997, AM J HUM GENET, V60, P588; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Ren Y, 2003, J NEUROSCI, V23, P3316; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Takeda A, 1998, AM J PATHOL, V152, P367; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	44	43	46	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9425	9430		10.1074/jbc.M408955200	http://dx.doi.org/10.1074/jbc.M408955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632191	hybrid			2022-12-27	WOS:000227453100095
J	Voisset, C; Callens, N; Blanchard, E; Dubuisson, J; Vu-Dac, N				Voisset, C; Callens, N; Blanchard, E; Dubuisson, J; Vu-Dac, N			High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; DC-SIGN; CELL ENTRY; SR-BI; RECOMBINANT VACCINIA; CANDIDATE RECEPTOR; CHOLESTEROL EFFLUX; LIPID TRANSPORT; APOA-I; BINDING	The scavenger receptor class B type I (SR-BI) has recently been shown to interact with hepatitis C virus (HCV) envelope glycoprotein E2, suggesting that it might be involved at some step of HCV entry into host cells. However, due to the absence of a cell culture system to efficiently amplify HCV, it is not clear how SR-BI contributes to HCV entry. Here, we sought to determine how high density lipoproteins (HDLs), the natural ligand of SR-BI, affect HCV entry. By using the recently described infectious HCV pseudotyped particles (HCVpps) that display functional E1E2 glycoprotein complexes, we showed that HDLs are able to markedly enhance HCVpp entry. We did not find any evidence of HDL association with HCVpps, suggesting that HCVpps do not enter into target cells using HDL as a carrier to bind to its receptor. Interestingly, lipid-free apoA-I and apoA-II, the major HDL apolipoproteins, were unable to enhance HCVpp infectivity. In addition, drugs inhibiting HDL cholesteryl transfer (block lipid transport (BLT)-2 and BLT-4) reduced HDL enhancement of HCVpp entry, suggesting a role for lipid transfer in facilitating HCVpp entry. Importantly, silencing of SR-BI expression in target cells by RNA interference markedly reduced HDL-mediated enhancement of HCVpp entry. Finally, enhancement of HCVpp entry was also suppressed when the SR-BI binding region on HCV glycoprotein E2 was deleted. Altogether, these data indicate that HDL-mediated enhancement of HCVpp entry involves a complex interplay between SR-BI, HDL, and HCV envelope glycoproteins, and they highlight the active role of HDLs in HCV entry.	CNRS, UPR 2511, Unite Hepatite C, Inst Biol Lille, F-59021 Lille, France; Inst Pasteur, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Dubuisson, J (corresponding author), CNRS, UPR 2511, Unite Hepatite C, Inst Biol Lille, 1 Rue Calmette,BP447, F-59021 Lille, France.	jean.dubuisson@ibl.fr	Eckhardt, Erik/G-1567-2010; Voisset, Cecile/AAK-1636-2020; callens, nathalie/P-2256-2016; Dubuisson, Jean/E-6813-2016	callens, nathalie/0000-0002-7508-6596; Voisset, Cecile/0000-0001-7505-1927; Dubuisson, Jean/0000-0003-1626-7693				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; CALVO D, 1993, J BIOL CHEM, V268, P18929; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; Connelly MA, 2003, J BIOL CHEM, V278, P25773, DOI 10.1074/jbc.M302820200; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P14067, DOI 10.1073/pnas.0405695101; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; de Beer MC, 2001, J LIPID RES, V42, P309; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100; Hatch F T, 1968, Adv Lipid Res, V6, P1; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Lavillette D, 2005, HEPATOLOGY, V41, P265, DOI 10.1002/hep.20542; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Lund-Katz S, 2003, FRONT BIOSCI-LANDMRK, V8, pD1044, DOI 10.2741/1077; MAJOR ME, 2001, FIELDS VIROLOGY, P1127; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nieland TJF, 2002, P NATL ACAD SCI USA, V99, P15422, DOI 10.1073/pnas.222421399; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Saunier B, 2003, J VIROL, V77, P546, DOI 10.1128/JVI.77.1.546-559.2003; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Temel RE, 2002, J BIOL CHEM, V277, P26565, DOI 10.1074/jbc.M203014200; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Triyatni M, 2002, J VIROL, V76, P9335, DOI 10.1128/JVI.76.18.9335-9344.2002; Voisset C, 2004, BIOL CELL, V96, P413, DOI 10.1016/j.biolcel.2004.03.008; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004	47	196	209	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7793	7799		10.1074/jbc.M411600200	http://dx.doi.org/10.1074/jbc.M411600200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632171	hybrid			2022-12-27	WOS:000227395700044
J	Yagishita, N; Ohneda, K; Amano, T; Yamasaki, S; Sugiura, A; Tsuchimochi, K; Shin, H; Kawahara, K; Ohneda, O; Ohta, T; Tanaka, S; Yamamoto, M; Maruyama, I; Nishioka, K; Fukamizu, A; Nakajima, T				Yagishita, N; Ohneda, K; Amano, T; Yamasaki, S; Sugiura, A; Tsuchimochi, K; Shin, H; Kawahara, K; Ohneda, O; Ohta, T; Tanaka, S; Yamamoto, M; Maruyama, I; Nishioka, K; Fukamizu, A; Nakajima, T			Essential role of synoviolin in embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; MOTILITY FACTOR-RECEPTOR; E3 UBIQUITIN LIGASE; CELL-DEATH; HUMAN HRD1; APOPTOSIS; GATA-1; PARKIN	We recently reported the importance of Synoviolin in quality control of proteins through the endoplasmic reticulum (ER)-associated degradation (ERAD) system and its involvement in the pathogenesis of arthropathy through its anti-apoptotic effect. For further understanding of the role of Synoviolin in vivo, we generated in this study synoviolin-deficient (syno(-/-)0 mice by gene-targeted disruption. Strikingly, all fetuses lacking syno died in utero around embryonic day 13.5, although Hrd1p, a yeast orthologue of Synoviolin, is non-essential for survival. Histologically, hypocellularity and aberrant apoptosis were noted in the syno(-/-) fetal liver. Moreover, definitive erythropoiesis was affected in noncell autonomous manner in syno(-/-) embryos, causing death in utero. Cultured embryonic fibroblasts derived from syno(-/-) mice were more susceptible to endoplasmic reticulum stress-induced apoptosis than those from syno(+/+) mice, but the susceptibility was rescued by overexpression of synoviolin. Our findings emphasized the indispensable role of the Synoviolin in embryogenesis.	St Marianna Univ, Sch Med, Inst Med Sci, Dept Genome Sci,Miyamae Ku, Kawasaki, Kanagawa 2168512, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan; Kagoshima Univ, Fac Med, Lab Mol Med, Kagoshima 8908520, Japan; Kagoshima Univ, Fac Med, Dept Dermatol, Kagoshima 8908520, Japan; St Marianna Univ, Sch Med, Dept Surg, Kawasaki, Kanagawa 2168512, Japan; St Marianna Univ, Sch Med, Lab Surg Oncol, Kawasaki, Kanagawa 2168512, Japan; Univ Tokyo, Dept Orthopaed Surg, Tokyo 1130033, Japan	Saint Marianna University; University of Tsukuba; University of Tsukuba; University of Tsukuba; Kagoshima University; Kagoshima University; Saint Marianna University; Saint Marianna University; University of Tokyo	Nakajima, T (corresponding author), St Marianna Univ, Sch Med, Inst Med Sci, Dept Genome Sci,Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168512, Japan.	nakashit@marianna-u.ac.jp	fukamizu, akiyoshi/J-5350-2012; Yamamoto, Masayuki/A-4873-2010; Tanaka, Sakae/Y-3061-2019; Ohneda, Kinuko/AAC-8822-2019	fukamizu, akiyoshi/0000-0002-8786-6020; Yamamoto, Masayuki/0000-0002-9073-9436; Tanaka, Sakae/0000-0001-9210-9414; Ohta, Tomohiko/0000-0002-9700-7342				ALTER BP, 1982, HEMOGLOBIN, V6, P517, DOI 10.3109/03630268209083764; Amano T, 2003, GENE DEV, V17, P2436, DOI 10.1101/gad.1096603; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Cernanec J, 2002, ARTHRITIS RHEUM-US, V46, P968, DOI 10.1002/art.10213; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; GLOBEL GA, 1998, P NATL ACAD SCI USA, V95, P2061; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Kaneko M, 2002, FEBS LETT, V532, P147, DOI 10.1016/S0014-5793(02)03660-8; Kawahara K, 1999, BIOCHEM BIOPH RES CO, V266, P417, DOI 10.1006/bbrc.1999.1812; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; MCCARTY DJ, 1989, ARTHRITIS ALLIED CON; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Nadav E, 2003, BIOCHEM BIOPH RES CO, V303, P91, DOI 10.1016/S0006-291X(03)00279-1; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Ohneda K, 2002, ACTA HAEMATOL-BASEL, V108, P237, DOI 10.1159/000065660; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Reimold AM, 2000, GENE DEV, V14, P152; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; RUSSELL ES, 1974, ANN NY ACAD SCI, V241, P25, DOI 10.1111/j.1749-6632.1974.tb21864.x; Scott BB, 2002, J RHEUMATOL, V29, P230; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shimizu K, 1999, FEBS LETT, V456, P295, DOI 10.1016/S0014-5793(99)00966-7; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; ZON LI, 1995, BLOOD, V86, P2876	45	68	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7909	7916		10.1074/jbc.M410863200	http://dx.doi.org/10.1074/jbc.M410863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611074	hybrid			2022-12-27	WOS:000227395700059
J	Riondino, S; Lotti, LV; Cutini, L; Pulcinelli, FM				Riondino, S; Lotti, LV; Cutini, L; Pulcinelli, FM			Collagen-induced platelet shape change is not affected by positive feedback pathway inhibitors and cAMP-elevating agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-2; GLYCOPROTEIN-VI; CYCLIC-AMP; SIGNAL-TRANSDUCTION; FREE CALCIUM; ACTIVATION; MYOSIN; AGGREGATION	Shape change is the earliest response of platelets to stimuli; it is mainly dependent upon Ca2+/calmodulin interaction subsequent to Ca2+ mobilization and is mediated by myosin light chain kinase (MLCK) activation. It has been recently suggested that collagen itself is not able to elicit platelet shape change in the absence of ADP and thromboxane A(2) costimulation but is capable of inducing MLCK activation. Since we hypothesize that the morphological changes of the few platelets that adhere to collagen might not be revealed by turbidimetry, the aim of this study was to assess platelet shape change using transmission electron microscopy, in the absence of the amplificatory feedback pathways of ADP and thromboxane A2. Our results demonstrated that only the platelets in contact with insoluble collagen fibers underwent a typical shape change, whereas those further away remained quiescent. Moreover, since cAMP enhances Ca2+ mobilization in response to collagen, in the present study, we also investigated whether cAMP is involved in the inhibition of collagen-induced platelet shape change and MLC phosphorylation. Platelets were thus treated with iloprost (28 nm) prior to stimulation. Electron microscopy studies demonstrated that iloprost did not modify collagen-induced shape change, whereas immunoblotting studies showed a slight inhibition of MLC phosphorylation in the presence of enhanced cAMP levels. We can thus conclude that collagen is able to cause platelet shape change through activation of Ca2+/calmodulin-dependent MLCK, without the involvement of amplificatory pathways. Enhanced cytosolic cAMP levels do not inhibit collagen-induced platelet shape change but exert a weak inhibitory action on MLCK.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy	Sapienza University Rome	Riondino, S (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy.	silvia.riondino@uniromal.it	Riondino, Silvia/AAV-7126-2020	Riondino, Silvia/0000-0002-2965-402X; Pulcinelli, Fabio M./0000-0003-2595-396X				Aster RH, 1964, J CLIN INVEST, V43, P834; Atkinson BT, 2001, EUR J BIOCHEM, V268, P5242, DOI 10.1046/j.0014-2956.2001.02448.x; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; CONTI MA, 1981, J BIOL CHEM, V256, P3178; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; DANIEL JL, 1992, METHOD ENZYMOL, V215, P78; FEINSTEIN MB, 1983, BIOCHEM BIOPH RES CO, V113, P598, DOI 10.1016/0006-291X(83)91768-0; FOX JEB, 1993, ADV EXP MED BIOL, V344, P175; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIDAKA H, 1981, MOL PHARMACOL, V20, P571; Israels SJ, 1996, PRACT APPROACH SER, P279; Jarvis GE, 2002, BRIT J PHARMACOL, V137, P107, DOI 10.1038/sj.bjp.0704834; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kunicki TJ, 2001, CIRCULATION, V104, P1451, DOI 10.1161/circ.104.13.1451; LEVIN RM, 1979, J PHARMACOL EXP THER, V208, P454; Mangin P, 2004, J THROMB HAEMOST, V2, P969, DOI 10.1111/j.1538-7836.2004.00722.x; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; NISHIKAWA M, 1992, CELL SIGNAL, V4, P453, DOI 10.1016/0898-6568(92)90039-B; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Quinton TM, 2002, BLOOD, V99, P3228, DOI 10.1182/blood.V99.9.3228; Riondino S, 2002, EUR J BIOCHEM, V269, P5878, DOI 10.1046/j.1432-1033.2002.03305.x; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH JB, 1993, BIOCHEM BIOPH RES CO, V191, P695, DOI 10.1006/bbrc.1993.1273; SMITH JB, 1992, BIOCHEM J, V283, P889, DOI 10.1042/bj2830889; Wilde JI, 2000, PLATELETS, V11, P286; YAMANISHI J, 1983, THROMB RES, V32, P183, DOI 10.1016/0049-3848(83)90029-4	29	14	16	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6504	6510		10.1074/jbc.M407854200	http://dx.doi.org/10.1074/jbc.M407854200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15598663	hybrid			2022-12-27	WOS:000227332700033
J	Mullner, H; Deutsch, G; Leitner, E; Ingolic, E; Daum, G				Mullner, H; Deutsch, G; Leitner, E; Ingolic, E; Daum, G			YEH2/YLR020c encodes a novel steryl ester hydrolase of the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; LIPID PARTICLES; LIPOPROTEIN METABOLISM; HYDROLYSIS; MEMBRANE; STEROLS; ENZYMES; TRANSLOCATION; PURIFICATION; MITOCHONDRIA	Previous work from our laboratory (Zinser, E., Paltauf, F., and Daum, G. (1993) J. Bacteriol. 175, 2853-2858) demonstrated steryl ester hydrolase activity in the plasma membrane of the yeast Saccharomyces cerevisiae. Here, we show that the gene product of YEH2/YLR020c, which is homologous to several known mammalian steryl ester hydrolases, is the enzyme catalyzing this reaction. Deletion of yeast YEH2 led to complete loss of plasma membrane steryl ester hydrolase activity whereas overexpression of the gene resulted in a significant elevation of the activity. Purification of enzymatically active Yeh2p close to homogeneity unambiguously identified this protein as a steryl ester hydrolase and thus as the first enzyme of this kind characterized in S. cerevisiae. In addition to evidence obtained in vitro experiments in vivo contributed to the characterization of this novel enzyme. Sterol analysis of yeh2 Delta unveiled a slightly elevated level of zymosterol suggesting that the esterified form of this sterol precursor is a preferred substrate of Yeh2p. However, in strains bearing hybrid proteins with strongly enhanced Yeh2p activity decreased levels of all steryl esters were observed. Thus, it appears that Yeh2p activity is not restricted to distinct steryl esters but rather has broad substrate specificity. The fact that in a yeh2 Delta deletion strain bulk steryl ester mobilization occurred at a similar rate as in wild type suggested that Yeh2p is not the only steryl ester hydrolase but that other enzymes with overlapping function exist in the yeast.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria; Graz Univ Technol, Inst Food Chem & Food Technol, A-8010 Graz, Austria; Graz Univ Technol, Res Inst Electron Microscopy, A-8010 Graz, Austria	Graz University of Technology; Graz University of Technology; Graz University of Technology	Daum, G (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at	Leitner, Erich/AAG-8826-2021	Leitner, Erich/0000-0003-2520-2111				Athenstaedt K, 2003, J BIOL CHEM, V278, P23317, DOI 10.1074/jbc.M302577200; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; Buhman KF, 2000, BBA-MOL CELL BIOL L, V1529, P142, DOI 10.1016/S1388-1981(00)00144-X; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAUM G, 1982, J BIOL CHEM, V257, P3028; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fowler S.D., 1984, P329; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Koffel R, 2005, MOL CELL BIOL, V25, P1655, DOI 10.1128/MCB.25.5.1655-1668.2005; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; LEBER R, 1995, BBA-BIOMEMBRANES, V1234, P119, DOI 10.1016/0005-2736(94)00270-Y; LEE FT, 1988, BIOCHIM BIOPHYS ACTA, V963, P258, DOI 10.1016/0005-2760(88)90289-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LORENZ RT, 1986, J BACTERIOL, V167, P981, DOI 10.1128/jb.167.3.981-985.1986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Morimoto C, 2001, J LIPID RES, V42, P120; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Peelman F, 2000, CURR OPIN LIPIDOL, V11, P155, DOI 10.1097/00041433-200004000-00008; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; Quail M A, 1996, Methods Mol Biol, V53, P123; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SMITH SJ, 1993, YEAST, V9, P1177, DOI 10.1002/yea.320091104; Smith SJ, 1997, BBA-LIPID LIPID MET, V1345, P71, DOI 10.1016/S0005-2760(96)00165-8; Sonnhammer E., 1998, P 6 INT C INT SYST M; Sorger D, 2004, J BIOL CHEM, V279, P31190, DOI 10.1074/jbc.M403251200; TAKETANI S, 1978, BIOCHIM BIOPHYS ACTA, V525, P87, DOI 10.1016/0005-2744(78)90202-4; TULLER G, 1995, FEBS LETT, V372, P29, DOI 10.1016/0014-5793(95)00950-E; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; Wei SH, 1997, J BIOL CHEM, V272, P14159, DOI 10.1074/jbc.272.22.14159; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993; Zweytick D, 2000, EUR J BIOCHEM, V267, P1075, DOI 10.1046/j.1432-1327.2000.01103.x; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	50	47	49	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13321	13328		10.1074/jbc.M409914200	http://dx.doi.org/10.1074/jbc.M409914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15632184	hybrid			2022-12-27	WOS:000228095500018
J	LIn, XN; Varnai, P; Csordas, G; Balla, A; Nagai, T; Miyawaki, A; Balla, T; Hajnoczky, G				LIn, XN; Varnai, P; Csordas, G; Balla, A; Nagai, T; Miyawaki, A; Balla, T; Hajnoczky, G			Control of calcium signal propagation to the mitochondria by inositol 1,4,5-trisphosphate-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTICALLY INACTIVE PROTEIN; PLECKSTRIN HOMOLOGY DOMAIN; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MEMBRANE LOCALIZATION; RYANODINE RECEPTORS; CA2+; OSCILLATIONS; ACTIVATION; BINDING	Cytosolic Ca2+ ([Ca2+](c)) signals triggered by many agonists are established through the inositol 1,4,5-trisphosphate (IP3) messenger pathway. This pathway is believed to use Ca2+-dependent local interactions among IP3 receptors (IP3R) and other Ca2+ channels leading to coordinated Ca2+ release from the endoplasmic reticulum throughout the cell and coupling Ca2+ entry and mitochondrial Ca2+ uptake to Ca2+ release. To evaluate the role of IP3 in the local control mechanisms that support the propagation of [Ca2+](c) waves, storeoperated Ca2+ entry, and mitochondrial Ca2+ uptake, we used two IP3-binding proteins (IP3BP): 1) the PH domain of the phospholipase C-like protein, p130 (p130PH); and 2) the ligand-binding domain of the human type-IIP3R (IP3R224-605). As expected, p130PH-GFP and GFP-IP3R224-605 behave as effective mobile cytosolic IP3 buffers. In COS-7 cells, the expression of IP3BPs had no effect on store-operated Ca2+ entry. However, the IP3-linked [Ca2+] c signal appeared as a regenerative wave and IP3BPs slowed down the wave propagation. Most importantly, IP3BPs largely inhibited the mitochondrial [Ca2+] signal and decreased the relationship between the [Ca2+](c) and mitochondrial [Ca2+] signals, indicating disconnection of the mitochondria from the [Ca2+](c) signal. These data suggest that IP3 elevations are important to regulate the local interactions among IP3Rs during propagation of [Ca2+](c) waves and that the IP3-dependent synchronization of Ca2+ release events is crucial for the coupling between Ca2+ release and mitochondrial Ca2+ uptake.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; RIKEN, Brain Sci Inst, Adv Technol Dev Ctr, Lab Cell Funct & Dynam, Wako, Saitama 3510198, Japan	Jefferson University; Semmelweis University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); RIKEN	Hajnoczky, G (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 253 JAH, Philadelphia, PA 19107 USA.	Gyorgy.Hajnoczky@jefferson.edu	Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235; Balla, Andras/0000-0002-6450-2793; Csordas, Gyorgy/0000-0003-3156-1460; Balla, Tamas/0000-0002-9077-3335; Nagai, Takeharu/0000-0003-2650-9895	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bolsover S, 2001, BIOCHEM J, V356, P345, DOI 10.1042/0264-6021:3560345; Callamaras N, 1998, J PHYSIOL-LONDON, V509, P81, DOI 10.1111/j.1469-7793.1998.081bo.x; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Csordas G, 2001, CELL CALCIUM, V29, P249, DOI 10.1054/ceca.2000.0191; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Kanematsu T, 2002, EMBO J, V21, P1004, DOI 10.1093/emboj/21.5.1004; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; Lee SB, 2004, J BIOL CHEM, V279, P24362, DOI 10.1074/jbc.M312772200; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; Ma HT, 2003, BIOCHEM J, V376, P667, DOI 10.1042/BJ20031345; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Putney JW, 2001, J CELL SCI, V114, P2223; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 2004, SCIENCE STKE; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Takeuchi H, 2000, BIOCHEM J, V349, P357, DOI 10.1042/0264-6021:3490357; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Wagner J, 2004, CELL CALCIUM, V35, P433, DOI 10.1016/j.ceca.2003.10.009; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Young KW, 2003, J BIOL CHEM, V278, P20753, DOI 10.1074/jbc.M211555200	49	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12820	12832		10.1074/jbc.M411591200	http://dx.doi.org/10.1074/jbc.M411591200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15644334	hybrid			2022-12-27	WOS:000227922000090
J	Berkmen, M; Boyd, D; Beckwith, J				Berkmen, M; Boyd, D; Beckwith, J			The nonconsecutive disulfide bond of Escherichia coli phytase (AppA) renders it dependent on the protein-disulfide isomerase, DsbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; ACID-PHOSPHATASE; ENDOPLASMIC-RETICULUM; PERIPLASMIC PROTEIN; CHAPERONE ACTIVITY; CRYSTAL-STRUCTURES; LIGHT-CHAINS; GENE; OXIDOREDUCTASES; IDENTIFICATION	The formation of protein disulfide bonds in the Escherichia coli periplasm by the enzyme DsbA is an inaccurate process. Many eukaryotic proteins with nonconsecutive disulfide bonds expressed in E. coli require an additional protein for proper folding, the disulfide bond isomerase DsbC. Here we report studies on a native E. coli periplasmic acid phosphatase, phytase ( AppA), which contains three consecutive and one nonconsecutive disulfide bonds. We show that AppA requires DsbC for its folding. However, the activity of an AppA mutant lacking its nonconsecutive disulfide bond is DsbC-independent. An AppA homolog, Agp, a periplasmic acid phosphatase with similar structure, lacks the nonconsecutive disulfide bond but has the three consecutive disulfide bonds found in AppA. The consecutively disulfide-bonded Agp is not dependent on DsbC but is rendered dependent by engineering into it the conserved nonconsecutive disulfide bond of AppA. Taken together, these results provide support for the proposal that proteins with nonconsecutive disulfide bonds require DsbC for full activity and that disulfide bonds are formed predominantly during translocation across the cytoplasmic membrane.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Beckwith, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	jbeckwith@hms.harvard.edu		Berkmen, Mehmet/0000-0002-9579-9745	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055090] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55090] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BERGMAN LW, 1979, J SUPRAMOL STR CELL, V11, P9, DOI 10.1002/jss.400110103; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BOQUET PL, 1987, J BACTERIOL, V169, P1663, DOI 10.1128/jb.169.4.1663-1669.1987; Braun P, 2001, J BIOL CHEM, V276, P26030, DOI 10.1074/jbc.M007122200; Chang JY, 2004, BIOCHEMISTRY-US, V43, P4522, DOI 10.1021/bi0360354; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Cottrill MA, 2002, CAN J MICROBIOL, V48, P801, DOI 10.1139/W02-076; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DASSA E, 1982, J BIOL CHEM, V257, P6669; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DELORENZ.F, 1966, J BIOL CHEM, V241, P1562; Elksne L E, 1996, J Bacteriol, V178, P4306; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Garrett JB, 2004, APPL ENVIRON MICROB, V70, P3041, DOI 10.1128/AEM.70.5.3041-3046.2004; Golovan S, 2000, CAN J MICROBIOL, V46, P59, DOI 10.1139/cjm-46-1-59; GREINER R, 1993, ARCH BIOCHEM BIOPHYS, V303, P107, DOI 10.1006/abbi.1993.1261; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hiniker A, 2004, J BIOL CHEM, V279, P12967, DOI 10.1074/jbc.M311391200; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee DC, 2003, J BIOL CHEM, V278, P31412, DOI 10.1074/jbc.M213154200; Lim D, 2000, NAT STRUCT BIOL, V7, P108; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Miksch G, 2002, APPL MICROBIOL BIOT, V59, P685, DOI 10.1007/s00253-002-1071-z; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rodriguez E, 2000, ARCH BIOCHEM BIOPHYS, V382, P105, DOI 10.1006/abbi.2000.2021; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; Sone M, 1997, J BIOL CHEM, V272, P10349; TOUATI E, 1986, MOL GEN GENET, V202, P257, DOI 10.1007/BF00331647	42	101	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11387	11394		10.1074/jbc.M411774200	http://dx.doi.org/10.1074/jbc.M411774200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15642731	hybrid			2022-12-27	WOS:000227761800061
J	Kolberg, M; Logan, DT; Bleifuss, G; Potsch, S; Sjoberg, BM; Graslund, A; Lubitz, W; Lassmann, GN; Lendzian, F				Kolberg, M; Logan, DT; Bleifuss, G; Potsch, S; Sjoberg, BM; Graslund, A; Lubitz, W; Lassmann, GN; Lendzian, F			A new tyrosyl radical on Phe(208) as ligand to the diiron center in Escherichia coli ribonucleotide reductase, mutant R2-Y122H - Combined X-ray diffraction and EPR/ENDOR studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; NUCLEAR DOUBLE-RESONANCE; HIGH-FIELD EPR; IRON-OXYGEN RECONSTITUTION; METHANE MONOOXYGENASE; PROTEIN R2; CRYSTAL-STRUCTURE; RADICAL-DIIRON(III) COFACTOR; 3-DIMENSIONAL STRUCTURE; PARAMAGNETIC-RESONANCE	The R2 protein subunit of class I ribonucleotide reductase (RNR) belongs to a structurally related family of oxygen bridged diiron proteins. In wild-type R2 of Escherichia coli, reductive cleavage of molecular oxygen by the diferrous iron center generates a radical on a nearby tyrosine residue (Tyr122), which is essential for the enzymatic activity of RNR, converting ribonucleotides into deoxyribonucleotides. In this work, we characterize the mutant E. coli protein R2-Y122H, where the radical site is substituted with a histidine residue. The x-ray structure verifies the mutation. R2-Y122H contains a novel stable paramagnetic center which we name H, and which we have previously proposed to be a diferric iron center with a strongly coupled radical, (FeFeR)-Fe-III-R-III . Here we report a detailed characterization of center H, using H-1/H-2-N-14/N-15- and Fe-57-ENDOR in comparison with the (FeFeIV)-Fe-III intermediate X observed in the iron reconstitution reaction of R2. Specific deuterium labeling of phenylalanine residues reveals that the radical results from a phenylalanine. As Phe(208) is the only phenylalanine in the ligand sphere of the iron site, and generation of a phenyl radical requires a very high oxidation potential, we propose that in Y122H residue Phe(208) is hydroxylated, as observed earlier in another mutant (R2-Y122F/E238A), and further oxidized to a phenoxyl radical, which is coordinated to Fe1. This work demonstrates that small structural changes can redirect the reactivity of the diiron site, leading to oxygenation of a hydrocarbon, as observed in the structurally similar methane monoxygenase, and beyond, to formation of a stable iron-coordinated radical.	Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Stockholm Univ, Dept Mol Biol & Funct Genom, S-10691 Stockholm, Sweden; Lund Univ, Dept Mol Biophys, S-22100 Lund, Sweden; Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Tech Univ Berlin, Inst Chem, Max Volmer Lab, D-10623 Berlin, Germany; Max Planck Inst Bioanorgan Chem, D-45470 Mulheim, Germany	Stockholm University; Stockholm University; Lund University; University of Oslo; Technical University of Berlin; Max Planck Society	Graslund, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	astrid@dbb.su.se	Logan, Derek T/A-1114-2011; Kolberg, Matthias/AAY-3478-2021; Kolberg, Matthias/G-2784-2011; Logan, Derek/O-2497-2019	Logan, Derek T/0000-0002-0098-8560; Kolberg, Matthias/0000-0001-8288-5364; Logan, Derek/0000-0002-0098-8560; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; Andersson K. K., 1995, ADV INORG CHEM, V43, P359; [Anonymous], 1990, ELECT PARAMAGNETIC R, DOI DOI 10.1007/978-3-642-74599-7; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; ATTA M, 1994, J AM CHEM SOC, V116, P6429, DOI 10.1021/ja00093a051; Baik MH, 2003, CHEM REV, V103, P2385, DOI 10.1021/cr950244f; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin J, 2001, J AM CHEM SOC, V123, P7017, DOI 10.1021/ja002114g; BENDER CJ, 1994, J BIOL CHEM, V269, P15993; Bleifuss G, 2001, BIOCHEMISTRY-US, V40, P15362, DOI 10.1021/bi010707d; BLINC R, 1974, CHEM PHYS LETT, V28, P158, DOI 10.1016/0009-2614(74)80041-2; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BRABEC V, 1980, BIOPHYS CHEM, V12, P159, DOI 10.1016/0301-4622(80)80048-2; Burdi D, 1996, J AM CHEM SOC, V118, P281, DOI 10.1021/ja952651e; Burdi D, 1998, J AM CHEM SOC, V120, P12910, DOI 10.1021/ja9824270; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Coremans JWA, 1996, J AM CHEM SOC, V118, P12141, DOI 10.1021/ja962076u; DAVIES ER, 1974, PHYS LETT A, VA 47, P1, DOI 10.1016/0375-9601(74)90078-4; DAVYDOV R, 1994, J AM CHEM SOC, V116, P11120, DOI 10.1021/ja00103a029; DeRose VJ, 1996, J AM CHEM SOC, V118, P121, DOI 10.1021/ja951108v; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Ehrenberg A, 2001, BIOSYSTEMS, V62, P9, DOI 10.1016/S0303-2647(01)00133-2; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FESSENDEN RW, 1963, J CHEM PHYS, V39, P2147, DOI 10.1063/1.1701415; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gunther MR, 2002, J BIOL CHEM, V277, P9160, DOI 10.1074/jbc.M107342200; HENDRICH MP, 1992, J BIOL CHEM, V267, P261; Hoganson CW, 1996, J AM CHEM SOC, V118, P4672, DOI 10.1021/ja953979a; Hogbom M, 2004, SCIENCE, V305, P245, DOI 10.1126/science.1098419; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; KABSCH W, 2001, INT TABLES CRYSALLOG; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; Kinter M, 2000, PROTEIN SEQUENCING I, P160; Kolberg M, 2000, J AM CHEM SOC, V122, P9856, DOI 10.1021/ja0005892; Kolberg M, 2004, BBA-PROTEINS PROTEOM, V1699, P1, DOI 10.1016/j.bbapap.2004.02.007; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lassmann G, 2000, J PHYS CHEM A, V104, P9144, DOI 10.1021/jp001437w; Lassmann G, 1999, J PHYS CHEM A, V103, P1283, DOI 10.1021/jp9843454; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; Lendzian F, 1996, BER BUNSEN PHYS CHEM, V100, P2036, DOI 10.1002/bbpc.19961001219; LIPPARD J, 1994, ANNU REV MICROBIOL, V48, P371; Liu A, 1998, BIOCHEM BIOPH RES CO, V246, P740, DOI 10.1006/bbrc.1998.8701; LIU A, 2000, INTERACTION IRON PRO; Logan DT, 1998, BIOCHEMISTRY-US, V37, P10798, DOI 10.1021/bi9806403; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; LUBITZ W, 1996, ADV PHOTOSYNTHESIS B, P255; MAGLIOZZO RS, 1993, BIOCHEMISTRY-US, V32, P8446, DOI 10.1021/bi00084a009; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Potsch S, 1999, J BIOL CHEM, V274, P17696, DOI 10.1074/jbc.274.25.17696; RAVI N, 1994, J AM CHEM SOC, V116, P8007, DOI 10.1021/ja00097a007; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; Roshick C, 2000, J BIOL CHEM, V275, P38111, DOI 10.1074/jbc.M006367200; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SCHOLES CP, 1982, J AM CHEM SOC, V104, P2724, DOI 10.1021/ja00374a007; SCHWEIGER A, 1991, ANGEW CHEM INT EDIT, V30, P265, DOI 10.1002/anie.199102651; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; Snodin MD, 1999, CHEM-EUR J, V5, P2554, DOI 10.1002/(SICI)1521-3765(19990903)5:9<2554::AID-CHEM2554>3.3.CO;2-8; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; STESMANS A, 1989, REV SCI INSTRUM, V60, P2949, DOI 10.1063/1.1140633; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; Thelander L, 1978, Methods Enzymol, V51, P227; Torrent M, 2002, J COMPUT CHEM, V23, P59, DOI 10.1002/jcc.1157; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Valentine AM, 1998, J AM CHEM SOC, V120, P2190, DOI 10.1021/ja974169x; Veselov A, 1996, INORG CHEM, V35, P3702, DOI 10.1021/ic951544i; Willems JP, 1997, J AM CHEM SOC, V119, P9816, DOI 10.1021/ja9709942; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZWEYGART W, 1994, J MAGN RESON SER A, V109, P172, DOI 10.1006/jmra.1994.1151	84	12	13	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11233	11246		10.1074/jbc.M414634200	http://dx.doi.org/10.1074/jbc.M414634200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15634667	hybrid			2022-12-27	WOS:000227761800044
J	Humphries, JD; Schofield, NR; Mostafavi-Pour, Z; Green, LJ; Garratt, AN; Mould, AP; Humphries, MJ				Humphries, JD; Schofield, NR; Mostafavi-Pour, Z; Green, LJ; Garratt, AN; Mould, AP; Humphries, MJ			Dual functionality of the anti-beta 1 integrin antibody, 12G10, exemplifies agonistic signalling from the ligand binding pocket of integrin adhesion receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CONFORMATIONAL-CHANGES; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; MOLECULAR-BASIS; ACTIVATION; BETA-1; SITES; RECOGNITION	Although integrins are known to mediate connections between extracellular adhesion molecules and the intracellular actin cytoskeleton, the mechanisms that are responsible for coupling ligand binding to intracellular signaling, for generating diversity in signaling, and for determining the efficacy of integrin signaling in response to ligand engagement are largely unknown. By characterizing the class of anti-integrin monoclonal antibodies (mAbs) that stimulate integrin activation and ligand binding, we have identified integrin-ligand-mAb complexes that exhibit differential signaling properties. Specifically, addition of 12G10 mAb to cells adhering via integrin alpha 4 beta 1 was found to trigger disruption of the actin cytoskeleton and prevent cell attachment and spreading, whereas mAb addition to cells adhering via alpha 5 beta 1 stimulated all of these processes. In contrast, soluble ligand binding to either alpha 4 beta 1 or alpha 5 beta 1 was augmented or unaffected by 12G10. The regions of the integrin responsible for differential signaling were then mapped using chimeras. Surprisingly, a chimeric alpha 5 integrin containing the beta-propeller domain from the ligand binding pocket of alpha 4 exhibited the same signaling properties as the full-length alpha 4 integrin, whereas exchanging or removing cytoplasmic domains had no effect. Thus the mAb 12G10 demonstrates dual functionality, inhibiting cell adhesion and spreading while augmenting soluble ligand binding, via a mechanism that is determined by the extracellular beta-propeller domain of the associating alpha-subunit. These findings therefore demonstrate a direct and variable agonistic link between the ligand binding pocket of integrins and the cell interior that is independent of the alpha cytoplasmic domains. We propose that either ligand-specific transmembrane conformational changes or ligand-specific differences in the kinetics of transmembrane domain separation underlie integrin agonism.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Humphries, MJ (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	martin.humphries@man.ac.uk	Humphries, Jonathan D./AAE-7760-2022; Mostafavi-Pour, Zohreh/T-5588-2018; Garratt, Alistair/AAG-2715-2021; Garratt, Alistair N/D-9893-2013	Humphries, Jonathan D./0000-0002-8953-7079; Mostafavi-Pour, Zohreh/0000-0002-3779-177X; Garratt, Alistair N/0000-0001-9631-3041; Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228	Wellcome Trust [074941] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barton SJ, 2004, BIOCHEM J, V380, P401, DOI 10.1042/BJ20031973; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Humphries MJ, 2000, TRENDS PHARMACOL SCI, V21, P29, DOI 10.1016/S0165-6147(99)01410-8; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Mannion BA, 1996, J IMMUNOL, V157, P2039; Miao H, 2002, J CELL SCI, V115, P2199; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Newham P, 1998, J IMMUNOL, V160, P4508; Newham P, 1997, J BIOL CHEM, V272, P19429, DOI 10.1074/jbc.272.31.19429; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pujades C, 1997, MOL BIOL CELL, V8, P2647, DOI 10.1091/mbc.8.12.2647; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Tsuchida J, 1997, FEBS LETT, V416, P212, DOI 10.1016/S0014-5793(97)01206-4; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Whittard JD, 2001, J CELL SCI, V114, P3265; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	47	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10234	10243		10.1074/jbc.M411102200	http://dx.doi.org/10.1074/jbc.M411102200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632175	Green Accepted, hybrid			2022-12-27	WOS:000227559600062
J	Morrison, MD; Reiley, W; Zhang, MY; Sun, SC				Morrison, MD; Reiley, W; Zhang, MY; Sun, SC			An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappa B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B2 P100; CD40; SURVIVAL; KINASE; EXPRESSION; GENE; PROTEINS; SYSTEM; LIGAND; IKK	BAFF receptor (BAFFR) is a member of the TNF receptor ( TNFR) superfamily that regulates the survival and maturation of B cells. BAFFR exerts its signaling function by inducing activation of NF-kappa B, although the underlying mechanism has not been well defined. By using a chimeric BAFFR, we show that BAFFR preferentially induces the noncanonical NF-kappa B signaling pathway. This specific function of BAFFR is mediated by a sequence motif, PVPAT, which is homologous to the TRAF-binding site (PVQET) present in CD40, a TNFR known to induce both the canonical and noncanonical NF-kappa B pathways. Mutation of this putative TRAF-binding motif within BAFFR abolishes its interaction with TRAF3 as well as its ability to induce noncanonical NF-kappa B. Interestingly, modification of the PVPAT sequence to the typical TRAF-binding sequence, PVQET, is sufficient to render the BAFFR capable of inducing strong canonical NF-kappa B signaling. Further, this functional acquisition of the modified BAFFR is associated with its stronger and more rapid association with TRAF3. These findings suggest that the PVPAT sequence of BAFFR not only functions as a key signaling motif of BAFFR but also determines its signaling specificity in the induction of the noncanonical NF-kappa B pathway.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA094922, T32CA060395] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA60395-09, CA94922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; D'Souza BN, 2004, J VIROL, V78, P1800, DOI 10.1128/JVI.78.4.1800-1816.2004; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HAMANO T, 1982, J IMMUNOL, V129, P1403; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; Hostager BS, 2002, J IMMUNOL, V168, P3318, DOI 10.4049/jimmunol.168.7.3318; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Mackay F, 2004, CURR OPIN PHARMACOL, V4, P347, DOI 10.1016/j.coph.2004.02.009; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Manning E, 2002, EUR J IMMUNOL, V32, P39, DOI 10.1002/1521-4141(200201)32:1<39::AID-IMMU39>3.0.CO;2-Y; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Patke A, 2004, CURR OPIN IMMUNOL, V16, P251, DOI 10.1016/j.coi.2004.01.007; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Shulga-Morskaya S, 2004, J IMMUNOL, V173, P2331, DOI 10.4049/jimmunol.173.4.2331; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Trescol-Biemont MC, 2004, BIOCHIMIE, V86, P287, DOI 10.1016/j.biochi.2004.04.001; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xu LG, 2002, J IMMUNOL, V169, P6883, DOI 10.4049/jimmunol.169.12.6883; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101	42	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10018	10024		10.1074/jbc.M413634200	http://dx.doi.org/10.1074/jbc.M413634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644327	hybrid			2022-12-27	WOS:000227559600035
J	Xin, MG; Deng, XM				Xin, MG; Deng, XM			Nicotine inactivation of the proapoptotic function of Bax through phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG-CANCER; BCL-2 FAMILY-MEMBERS; INDUCED APOPTOSIS; MITOCHONDRIA; PROTEIN; UBIQUITINATION; TRANSLOCATION; DEGRADATION; SURVIVAL; SMOKING	Nicotine-induced cell survival is associated with chemoresistance of human lung cancer cells, but our understanding of the intracellular mechanism(s) is fragmentary. Bax is a major proapoptotic member of the Bcl2 family and a molecule required for apoptotic cell death. Growth factor (i.e. granulocyte-macrophage colony-stimulating factor)-induced phosphorylation of Bax has been reported to negatively regulate its proapoptotic function. Because Bax is ubiquitously expressed in both small cell lung cancer and non-small cell lung cancer cells, nicotine may mimic growth factor( s) to regulate the activity of Bax. We found that nicotine potently induces Bax phosphorylation at Ser-184, which results in abrogation of the proapoptotic activity of Bax and increased cell survival. AKT, a known physiological Bax kinase, is activated by nicotine, co-localizes with Bax in the cytoplasm, and can directly phosphorylate Bax in vitro. Treatment of cells with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or specific depletion of AKT expression by RNA interference can block both nicotine-induced Bax phosphorylation and cell survival. Importantly, nicotine-induced Bax phosphorylation potently blocks stress-induced translocation of Bax from cytosol to mitochondria, impairs Bax insertion into mitochondrial membranes, and reduces the half-life of Bax protein (i.e. from 9-12 h to < 6 h). Because knockdown of Bax expression by gene silencing results in prolonged cell survival following treatment with cisplatin in the absence or presence of nicotine, Bax may be an essential component in the nicotine survival signaling pathway. Thus, nicotine-induced survival and chemoresistance of human lung cancer cells may occur in a novel mechanism involving activation of PI3K/AKT that directly phosphorylates and inactivates the proapoptotic function of Bax.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu	高, 雨莉/HGU-8187-2022					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; *AM CANC SOC, 2003, CANC FACTS FIG, P13; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Dresler CM, 2003, LUNG CANCER-J IASLC, V39, P119, DOI 10.1016/S0169-5002(02)00455-5; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Eldering E, 2004, EUR J IMMUNOL, V34, P1950, DOI 10.1002/eji.200324817; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Groeger AM, 2001, ANTICANCER RES, V21, P3627; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Maki CG, 1996, CANCER RES, V56, P2649; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; OLTVAI ZN, 1993, CELL, V74, P619; PARK PG, 1995, CANCER RES, V55, P3504; Perissin L, 1996, ANTICANCER RES, V16, P3409; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	47	182	210	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10781	10789		10.1074/jbc.M500084200	http://dx.doi.org/10.1074/jbc.M500084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642728	hybrid			2022-12-27	WOS:000227559600125
J	Clemons, NJ; Buzzard, K; Steel, R; Anderson, RL				Clemons, NJ; Buzzard, K; Steel, R; Anderson, RL			Hsp72 inhibits Fas-mediated apoptosis upstream of the mitochondria in type II cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CYTOCHROME-C RELEASE; STRESS-INDUCED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; HLA-DR MOLECULES; JURKAT T-CELLS; BREAST-CANCER; TUMOR-CELLS; DIFFERENTIAL EXPRESSION	Heat shock protein 72 (Hsp72) inhibits apoptosis induced by some stresses that trigger the intrinsic apoptosis pathway. However, with the exception of TNFalpha-induced apoptosis, a role for Hsp72 in modulating the extrinsic pathway of apoptosis has not been clearly established. In this study, it was demonstrated that Hsp72 could inhibit Fas-mediated apoptosis of type II CCRF-CEM cells, but not type I SW480 or CH1 cells. Similar results were obtained when Fas ligand or an agonistic Fas antibody initiated the Fas apoptosis pathway. In CCRF-CEM cells, Hsp72 inhibited mitochondrial membrane depolarization and cytochrome c release but did not alter surface Fas expression or processing of caspase-8 and Bid, indicating that Hsp72 acts upstream of the mitochondria to inhibit Fas-mediated apoptosis. Thus, the ability of Hsp72 to inhibit Fas-mediated apoptosis is limited to type II cells where involvement of the intrinsic pathway is required for efficient effector caspase activation.	Peter MacCallum Canc Ctr, Canc Biol Lab, Melbourne, Vic 3002, Australia	Peter Maccallum Cancer Center	Anderson, RL (corresponding author), Peter MacCallum Canc Ctr, Canc Biol Lab, Locked Bag 1,Beckett St, Melbourne, Vic 8006, Australia.	robin.anderson@petermac.org	Clemons, Nicholas/AAN-6516-2020; Anderson, Robin/K-6966-2019; Anderson, Robin/I-2306-2013; Anderson, Robin/S-1005-2017	Clemons, Nicholas/0000-0001-9283-9978; Anderson, Robin/0000-0002-6841-7422; /0000-0002-0423-6120	NCI NIH HHS [CA81421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Athanassiadou P, 1998, EUR J CANCER PREV, V7, P225, DOI 10.1097/00008469-199806000-00007; Bratton SB, 2003, CELL DEATH DIFFER, V10, P4, DOI 10.1038/sj.cdd.4401176; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; CHANT ID, 1995, BRIT J HAEMATOL, V90, P163, DOI 10.1111/j.1365-2141.1995.tb03395.x; CIOCCA DR, 1992, CANCER RES, V52, P3648; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Conroy SE, 1996, BRIT J CANCER, V74, P717, DOI 10.1038/bjc.1996.427; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Creagh EM, 1999, IMMUNOLOGY, V97, P36; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FULLER KJ, 1994, EUR J CANCER, V30A, P1884, DOI 10.1016/0959-8049(94)00362-9; FUQUA SAW, 1994, BREAST CANCER RES TR, V32, P67, DOI 10.1007/BF00666207; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermisson M, 2000, ONCOGENE, V19, P2338, DOI 10.1038/sj.onc.1203554; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kaur J, 1995, INT J CANCER, V63, P774, DOI 10.1002/ijc.2910630604; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Krammer P H, 1999, Adv Immunol, V71, P163; LAZARIS AC, 1995, DIS COLON RECTUM, V38, P739, DOI 10.1007/BF02048033; Lazaris AC, 1997, BREAST CANCER RES TR, V43, P43, DOI 10.1023/A:1005706110275; LAZARIS AC, 1995, VIRCHOWS ARCH, V426, P461; Lee HO, 2003, CYTOKINE GROWTH F R, V14, P325, DOI 10.1016/S1359-6101(03)00028-5; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Liu FF, 1996, INT J HYPERTHER, V12, P301, DOI 10.3109/02656739609022517; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Nanbu K, 1998, CANCER DETECT PREV, V22, P549, DOI 10.1046/j.1525-1500.1998.00069.x; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Ozoren N, 2002, EXP CELL RES, V281, P175, DOI 10.1006/excr.2002.5660; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Ralhan R, 1995, CLIN CANCER RES, V1, P1217; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tran SEF, 2003, CELL DEATH DIFFER, V10, P1137, DOI 10.1038/sj.cdd.4401278; Tsuchiya D, 2003, J CEREBR BLOOD F MET, V23, P718, DOI 10.1097/01.WCB.0000054756.97390.F7; van Loo G, 2003, CYTOKINE, V22, P62, DOI 10.1016/S1043-4666(03)00111-X; Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang XD, 2001, GENE DEV, V15, P2922; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	80	41	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9005	9012		10.1074/jbc.M414165200	http://dx.doi.org/10.1074/jbc.M414165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632129	hybrid			2022-12-27	WOS:000227453100047
J	Faour, WH; Alaaeddine, N; Mancini, A; He, QW; Jovanovic, D; Di Battista, JA				Faour, WH; Alaaeddine, N; Mancini, A; He, QW; Jovanovic, D; Di Battista, JA			Early growth response factor-1 mediates prostaglandin E-2-dependent transcriptional suppression of cytokine-induced tumor necrosis factor-alpha gene expression in human macrophages and rheumatoid arthritis-affected synovial fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PROSTANOID RECEPTORS; MESSENGER-RNA; BINDING-PROTEIN; TNF-ALPHA; EGR-1; PROMOTER; ELEMENT; SP1; E-2	Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic pro-inflammatory cytokine that modulates a broad range of inflammatory and immunological processes. We have investigated the potential immunomodulatory properties of prostaglandin E-2 (PGE(2)) by examining the molecular mechanism by which the eicosanoid suppresses T-cell-derived interleukin-17 (IL-17)-induced TNF-alpha mRNA expression and protein synthesis in human macrophages and rheumatoid arthritis-affected synovial fibroblasts. Initial studies confirmed that PGE2 induces egr-1 mRNA expression and protein synthesis by restricted SAPK2/p38 MAPK-dependent activating transcription factor-2 (ATF-2) dimer transactivation of the egr-1 promoter as judged by studies using wild-type (WT) and deletion mutant egr-1 promoter constructs, Northern and Western blotting, and standard and supershift electrophoretic mobility shift analyses. Using human leukemic monocytic THP-1 cells stably transfected with WT and dominant-negative mutant expression constructs of Egr-1, cotransfected or not with a WT pTNF-615SVOCAT construct, we observed that PGE2 inhibition of IL-17-stimulated TNF-alpha mRNA expression and promoter activity was dependent on Egr-1 expression, as mutants of Egr-1, alone or in combination, markedly abrogated any inhibitory effect of PGE2. Standard and supershift electrophoretic mobility shift analysis, signaling "decoy" overexpression studies, and pTNF-615SVOCAT promoter assays using WT and mutant promoter constructs revealed that IL-17-up-regulated promoter activity was largely dependent on ATF-2/c-Jun transactivation. PGE(2) suppression of IL-17-inducedATF-2/c-Jun transactivation and DNA binding was dependent on Egr-1-mediated inhibition of induced c-Jun expression. We suggest that egr-1 is an immediate-early PGE(2) target gene that may be a key regulatory factor in mediating eicosanoid control of genes involved in the immune and inflammatory responses.	McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1A1, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 8M5, Canada; Univ Balamand, Dept Pharmacol, Tripoli 9616, Lebanon	McGill University; McGill University; University of Ottawa; University Balamand	Di Battista, JA (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth Sci, Div Clin Immunol & Rheumatol, Rm M11-22,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	john.dibattista@mcgill.ca	faour, wissam/J-3419-2019	faour, wissam/0000-0002-0746-3687				AGARWAL, 1995, HUMAN CYTOKINES THEI; Austin SC, 1999, PROSTAG OTH LIPID M, V58, P231, DOI 10.1016/S0090-6980(99)00041-6; Burg ND, 2001, CLIN IMMUNOL, V99, P7, DOI 10.1006/clim.2001.5007; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DEGROOP TP, 1991, NUCLEIC ACIDS RES, V19, P775; Di Battista JA, 1999, OSTEOARTHR CARTILAGE, V7, P395, DOI 10.1053/joca.1998.0222; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Fang MA, 1996, PROSTAG LEUKOTR ESS, V54, P109, DOI 10.1016/S0952-3278(96)90067-8; FAOUR W, 2000, OSTEOARTHRITIS CAR S, V8, pS10; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Harriman G, 1999, ANN RHEUM DIS, V58, P61; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hasunuma T, 1998, SPRINGER SEMIN IMMUN, V20, P41, DOI 10.1007/BF00831998; He W, 2002, J RHEUMATOL, V29, P546; HU QW, 2001, OSTEOARTHRITIS CAR S, V9, pS9; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; Lanoix J, 1998, ONCOGENE, V17, P2495, DOI 10.1038/sj.onc.1202166; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LOTZ M, 1997, ARTHRITIS ALLIED CON, P439; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McCarthy TL, 1996, J BIOL CHEM, V271, P6666, DOI 10.1074/jbc.271.12.6666; MORIN N, 1999, OSTEOARTHR CARTILAGE, V7, pS21; Muzio M, 2000, BIOCHEM SOC T, V28, P563, DOI 10.1042/bst0280563; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Russell DL, 2003, MOL ENDOCRINOL, V17, P520, DOI 10.1210/me.2002-0066; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Smith W.L.B.P., 1991, BIOCH LIPIDS LIPOPRO, P297, DOI [10.1016/S0167-7306(08)60338-5, DOI 10.1016/S0167-7306(08)60338-5]; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; SVETLOV S, 1993, BIOCHIM BIOPHYS ACTA, V1177, P75, DOI 10.1016/0167-4889(93)90160-Q; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; TRABANDT A, 1992, RHEUMATOL INT, V12, P53, DOI 10.1007/BF00300977; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286	53	38	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9536	9546		10.1074/jbc.M414067200	http://dx.doi.org/10.1074/jbc.M414067200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15640148	hybrid			2022-12-27	WOS:000227453100108
J	Hamimes, S; Arakawa, H; Stasiak, AZ; Kierzek, AM; Hirano, S; Yang, YG; Takata, M; Stasiak, A; Buerstedde, JM; Van Dyck, E				Hamimes, S; Arakawa, H; Stasiak, AZ; Kierzek, AM; Hirano, S; Yang, YG; Takata, M; Stasiak, A; Buerstedde, JM; Van Dyck, E			RDM1, a novel RNA recognition motif (RRM)-containing protein involved in the cell response to cisplatin in vertebrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; STRAND BREAK REPAIR; DNA-DAMAGE RECOGNITION; HUMAN MISMATCH REPAIR; HUMAN RAD52 PROTEIN; HOMOLOGOUS RECOMBINATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GENE CONVERSION; DUPLEX DNA	A variety of cellular proteins has the ability to recognize DNA lesions induced by the anti-cancer drug cisplatin, with diverse consequences on their repair and on the therapeutic effectiveness of this drug. We report a novel gene involved in the cell response to cisplatin in vertebrates. The RDM1 gene ( for (R) under barA (D) under bar 52 (M) under bar otif 1) was identified while searching databases for sequences showing similarities to RAD52, a protein involved in homologous recombination and DNA double-strand break repair. Ablation of RDM1 in the chicken B cell line DT40 led to a more than 3-fold increase in sensitivity to cisplatin. However, RDM1(-/-) cells were not hypersensitive to DNA damages caused by ionizing radiation, UV irradiation, or the alkylating agent methylmethane sulfonate. The RDM1 protein displays a nucleic acid binding domain of the RNA recognition motif (RRM) type. By using gel-shift assays and electron microscopy, we show that purified, recombinant chicken RDM1 protein interacts with single-stranded DNA as well as double-stranded DNA, on which it assembles filament-like structures. Notably, RDM1 recognizes DNA distortions induced by cisplatin-DNA adducts in vitro. Finally, human RDM1 transcripts are abundant in the testis, suggesting a possible role during spermatogenesis.	Int Agcy Res Canc, F-69732 Lyon, France; GSF, Inst Mol Radiobiol, D-85764 Neuherberg, Germany; Univ Lausanne, Lab Anal Ultrastruct, CH-1015 Lausanne, Switzerland; Univ Surrey, SBMS, Guildford GU2 7XH, Surrey, England; Kawasaki Med Sch, Kurashiki, Okayama 7010192, Japan; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	World Health Organization; International Agency for Research on Cancer (IARC); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Lausanne; University of Surrey; Kawasaki Medical School; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Van Dyck, E (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69732 Lyon, France.	Vandyck@iarc.fr	Yang, Yungui/ABF-2507-2021; Stasiak, Andrzej/E-5551-2010	Stasiak, Andrzej/0000-0002-0398-1989; Kierzek, Andrzej/0000-0002-2605-9057; Van Dyck, Eric/0000-0001-8614-2402; Takata, Minoru/0000-0002-4926-3675				Abdrakhmanov I, 2000, GENOME RES, V10, P2062, DOI 10.1101/gr.10.12.2062; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arakawa H, 2004, DEV DYNAM, V229, P458, DOI 10.1002/dvdy.10495; Arakawa H, 2001, BMC Biotechnol, V1, P7, DOI 10.1186/1472-6750-1-7; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bessho T, 2003, J BIOL CHEM, V278, P5250, DOI 10.1074/jbc.M212323200; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; Birger Y, 2003, EMBO J, V22, P1665, DOI 10.1093/emboj/cdg142; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Davies NP, 2000, NUCLEIC ACIDS RES, V28, P2954, DOI 10.1093/nar/28.15.2954; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Green CM, 2003, EMBO J, V22, P5163, DOI 10.1093/emboj/cdg478; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hara R, 2003, MOL CELL BIOL, V23, P4121, DOI 10.1128/MCB.23.12.4121-4125.2003; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Lan L, 2004, DNA REPAIR, V3, P135, DOI 10.1016/j.dnarep.2003.10.005; Lindahl T, 2001, PROG NUCLEIC ACID RE, V68, pXVII; Lloyd JA, 2005, J MOL BIOL, V345, P239, DOI 10.1016/j.jmb.2004.10.065; Massey A, 2003, DNA REPAIR, V2, P73, DOI 10.1016/S1568-7864(02)00187-8; Masters JRW, 2003, NAT REV CANCER, V3, P517, DOI 10.1038/nrc1120; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Mortensen UH, 2002, GENETICS, V161, P549; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Muller B, 1994, Methods Mol Biol, V30, P413; Parsons CA, 2000, EMBO J, V19, P4175, DOI 10.1093/emboj/19.15.4175; PRASHER DC, 1983, J BIOL CHEM, V258, P6340; PROBA K, 1995, GENE, V159, P203, DOI 10.1016/0378-1119(95)00018-2; Ranatunga W, 2001, J BIOL CHEM, V276, P15876, DOI 10.1074/jbc.M011747200; Reardon JT, 2003, GENE DEV, V17, P2539, DOI 10.1101/gad.1131003; RESNICK MA, 1969, GENETICS, V62, P519; Rhoades AR, 2004, MOL CELL BIOL, V24, P3907, DOI 10.1128/MCB.24.9.3907-3917.2004; Selvakumaran M, 2003, CANCER RES, V63, P1311; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; SOGO JM, 1987, ELECTRON MICROS, P61; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Thoma BS, 2003, MOL CARCINOGEN, V38, P1, DOI 10.1002/mc.10143; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; van den Bosch M, 2002, BIOL CHEM, V383, P873; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Van Dyck E, 2001, EMBO REP, V2, P905, DOI 10.1093/embo-reports/kve201; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wang D, 2003, BIOCHEMISTRY-US, V42, P6747, DOI 10.1021/bi034264k; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; West SC, 2000, COLD SPRING HARB SYM, V65, P315, DOI 10.1101/sqb.2000.65.315; Wong B, 2002, BIOCHEMISTRY-US, V41, P5404, DOI 10.1021/bi012077l; Wood RD, 2000, COLD SPRING HARB SYM, V65, P173, DOI 10.1101/sqb.2000.65.173; Wozniak K, 2002, ACTA BIOCHIM POL, V49, P583; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h	79	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9225	9235		10.1074/jbc.M412874200	http://dx.doi.org/10.1074/jbc.M412874200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611051	hybrid			2022-12-27	WOS:000227453100072
J	Sliskovic, I; Raturi, A; Mutus, B				Sliskovic, I; Raturi, A; Mutus, B			Characterization of the S-denitrosation activity of protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; NITROSOTHIOLS; MECHANISM; STATE; 2,3-DIAMINONAPTHALENE; TRANSNITROSATION; ISOMERIZATION; RIBONUCLEASE; GLUTATHIONE; REDUCTION	S-Nitrosoglutathione (GSNO) denitrosation activity of recombinant human protein disulfide isomerase (PDI) has been kinetically characterized by monitoring the loss of the S-NO absorbance, using a NO electrode, and with the aid of the fluorogenic NOx probe 2,3-diaminonaphthalene. The initial rates of denitrosation as a function of [GSNO] displayed hyperbolic behavior irrespective of the method used to monitor denitrosation. The Km values estimated for GSNO were 65 +/- 5 muM and 40 +/- 10 muM for the loss in the S-NO bond and NO production (NO electrode or 2,3- diaminonaphthalene), respectively. Hemoglobin assay provided additional evidence that the final product of PDI-dependent GSNO denitrosation was NO. A catalytic mechanism, involving a nitroxyl disulfide intermediate stabilized by imidazole (His(160) a-domain or His(589) a'-domain), which after undergoing a one-electron oxidation decomposes to yield NO plus dithiyl radical, has been proposed. Evidence for the formation of thiyl/dithiyl radicals during PDI-catalyzed denitrosation was obtained with 4-((9-acridinecarbonyl)-amino)2,2,6,6- tetramethylpiperidine-1-oxyl. Evidence has also been obtained showing that in a NO- and O-2-rich environment, PDI can form N2O3 in its hydrophobic domains. This "NO-charged PDI" can perform intra- and intermolecular S-nitrosation reactions similar to that proposed for serum albumin. Interestingly, reduced PDI was able to denitrosate S-nitrosated PDI (PDI-SNO) resulting in the release of NO. PDI-SNO, once formed, is stable at room temperature in the absence of reducing agent over the period of 2 h. It has been established that PDI is continuously secreted from cells that are net producers of NO- like endothelial cells. The present demonstration that PDI can be S-nitrosated and that PDI-SNO can be denitrosated by PDI suggests that this enzyme could be intimately involved in the transport of intracellular NO equivalents to the cell surface as well as the previous demonstration of PDI in the transfer of S-nitrosothiolbound NO to the cytosol.	Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada	University of Windsor	Mutus, B (corresponding author), Univ Windsor, Dept Chem & Biochem, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	mutusb@uwindsor.ca						ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P7982, DOI 10.1021/ja00312a031; Borisenko GG, 2004, J AM CHEM SOC, V126, P9221, DOI 10.1021/ja0495157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN K, 1995, BRIT J HAEMATOL, V90, P425, DOI 10.1111/j.1365-2141.1995.tb05169.x; Collet JF, 2002, J BIOL CHEM, V277, P26886, DOI 10.1074/jbc.M203028200; Essex DW, 1999, BIOCHEMISTRY-US, V38, P10398, DOI 10.1021/bi990694s; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Goss SPA, 1999, FREE RADICAL RES, V31, P597, DOI 10.1080/10715769900301171; GREY WR, 1997, PROTEIN STRUCTURE, P165; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Houk KN, 2003, J AM CHEM SOC, V125, P6972, DOI 10.1021/ja029655l; Jourd'heuil D, 2000, FREE RADICAL BIO MED, V28, P409, DOI 10.1016/S0891-5849(99)00257-9; Kleinhenz DJ, 2003, FREE RADICAL BIO MED, V34, P856, DOI 10.1016/S0891-5849(02)01438-7; Lahav J, 2000, FEBS LETT, V475, P89, DOI 10.1016/S0014-5793(00)01630-6; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; Narindrasorasak S, 2003, BIOCHEM BIOPH RES CO, V311, P405, DOI 10.1016/j.bbrc.2003.09.226; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Noble DR, 2001, J CHEM SOC PERK T 2, P13, DOI 10.1039/b008112o; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6; Pfeiffer S, 1998, ANAL BIOCHEM, V258, P68, DOI 10.1006/abio.1998.2562; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Primm TP, 2001, J BIOL CHEM, V276, P281, DOI 10.1074/jbc.M007670200; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; Raturi A, 2004, ANAL BIOCHEM, V326, P281, DOI 10.1016/j.ab.2003.12.015; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; ROOT P, 2004, BIOCHEM J, V382, P1; Schwaller M, 2003, J BIOL CHEM, V278, P7154, DOI 10.1074/jbc.M211036200; Sideraki V, 2000, BIOCHEMISTRY-US, V39, P1180, DOI 10.1021/bi992246q; Solovyov A, 2004, PROTEIN SCI, V13, P1902, DOI 10.1110/ps.04716104; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Williams DLH, 1996, METHOD ENZYMOL, V268, P299; Wink DA, 1999, METHOD ENZYMOL, V301, P201; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhang XJ, 2000, ELECTROANAL, V12, P425, DOI 10.1002/(SICI)1521-4109(20000401)12:6<425::AID-ELAN425>3.3.CO;2-Y; Zheng J, 2001, J BIOL CHEM, V276, P15747, DOI 10.1074/jbc.M011444200	45	128	132	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8733	8741		10.1074/jbc.M408080200	http://dx.doi.org/10.1074/jbc.M408080200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611098	hybrid			2022-12-27	WOS:000227453100015
J	Tom-Yew, SAL; Cui, DT; Bekker, EG; Murphy, MEP				Tom-Yew, SAL; Cui, DT; Bekker, EG; Murphy, MEP			Anion-independent iron coordination by the Campylobacter jejuni ferric binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTIC ANION; TRANSPORT; ACQUISITION; METABOLISM; HOMOLOGY; REVEALS; PROGRAM; IDIA	Campylobacter jejuni, the leading cause of human gastroenteritis, expresses a ferric binding protein ( cFbpA) that in many pathogenic bacteria functions to acquire iron as part of their virulence repertoire. Recombinant cFbpA is isolated with ferric iron bound from Escherichia coli. The crystal structure of cFbpA reveals unprecedented iron coordination by only five protein ligands. The histidine and one tyrosine are derived from the N-terminal domain, whereas the three remaining tyrosine ligands are from the C-terminal domain. Surprisingly, a synergistic anion present in all other characterized ferric transport proteins is not observed in the cFbpA iron-binding site, suggesting a novel role for this protein in iron uptake. Furthermore, cFbpA is shown to bind iron with high affinity similar to Neisserial FbpA and exhibits an unusual preference for ferrous iron ( oxidized subsequently to the ferric form) or ferric iron chelated by oxalate. Sequence and structure analyses reveal that cFbpA is a member of a new class of ferric binding proteins that includes homologs from invasive and intracellular bacteria as well as cyanobacteria. Overall, six classes are defined based on clustering within the tree and by their putative iron coordination. The absence of a synergistic anion in the iron coordination sphere of cFbpA also suggests an alternative model of evolution for FbpA homologs involving an early iron-binding ancestor instead of a requirement for a preexisting anion-binding ancestor.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Murphy, MEP (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	michael.murphy@ubc.ca	Murphy, Michael/R-6805-2017	Murphy, Michael/0000-0003-2589-0014				ADHIKARI P, 1995, J BIOL CHEM, V270, P25142, DOI 10.1074/jbc.270.42.25142; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGERER A, 1992, J BACTERIOL, V174, P1378, DOI 10.1128/jb.174.4.1378-1387.1992; [Anonymous], 2002, PHOTOSYNTHETICA; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; Bekker EG, 2004, BIOCHEMISTRY-US, V43, P9195, DOI 10.1021/bi036143q; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; Dhungana S, 2003, P NATL ACAD SCI USA, V100, P3659, DOI 10.1073/pnas.0536897100; FIELD LH, 1986, INFECT IMMUN, V54, P126, DOI 10.1128/IAI.54.1.126-132.1986; GORBACH SL, 1999, MECH MICROBIAL DIS, P215; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katoh H, 2001, PLANT CELL PHYSIOL, V42, P823, DOI 10.1093/pcp/pce106; Katoh H, 2001, J BACTERIOL, V183, P2779, DOI 10.1128/JB.183.9.2779-2784.2001; Konkel ME, 1999, MOL MICROBIOL, V32, P691, DOI 10.1046/j.1365-2958.1999.01376.x; Kopecko DJ, 2001, TRENDS MICROBIOL, V9, P389, DOI 10.1016/S0966-842X(01)02107-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michel KP, 2004, PHYSIOL PLANTARUM, V120, P36, DOI 10.1111/j.0031-9317.2004.0229.x; Mietzner TA, 1998, CURR TOP MICROBIOL, V225, P113; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'Brien DK, 2000, CELL MICROBIOL, V2, P505, DOI 10.1046/j.1462-5822.2000.00074.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Palyada K, 2004, J BACTERIOL, V186, P4714, DOI 10.1128/JB.186.14.4714-4729.2004; PARK SF, 1995, J BACTERIOL, V177, P2259, DOI 10.1128/jb.177.9.2259-2264.1995; PATCH MG, 1981, INORG CHIM ACTA, V56, P71; Raphael BH, 2003, CAN J MICROBIOL, V49, P727, DOI 10.1139/W03-086; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Richardson PT, 1995, MICROBIOL-SGM, V141, P3181, DOI 10.1099/13500872-141-12-3181; Rock J. D., 2001, IJMM International Journal of Medical Microbiology, V291, P125; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; SCHRYVERS AB, 1999, MOL MICROBIOL, V32, P117; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shouldice SR, 2004, J BACTERIOL, V186, P3903, DOI 10.1128/JB.186.12.3903-3910.2004; Shouldice SR, 2003, J BIOL CHEM, V278, P41093, DOI 10.1074/jbc.M306821200; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Tolle J, 2002, MICROBIOL-SGM, V148, P3293, DOI 10.1099/00221287-148-10-3293; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Vliet AHM, 2002, FEMS MICROBIOL REV, V26, P173, DOI 10.1111/j.1574-6976.2002.tb00609.x; Wooldridge KG, 1997, TRENDS MICROBIOL, V5, P96, DOI 10.1016/S0966-842X(97)01004-4	49	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9283	9290		10.1074/jbc.M412479200	http://dx.doi.org/10.1074/jbc.M412479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15613474	hybrid			2022-12-27	WOS:000227453100079
J	Anderson, KM; Ashida, H; Maskos, K; Dell, A; Li, SC; Li, YT				Anderson, KM; Ashida, H; Maskos, K; Dell, A; Li, SC; Li, YT			A clostridial endo-beta-galactosidase that cleaves both blood group A and B glycotopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; REDUCING SUGARS; GROUP ANTIGENS; GAS-GANGRENE; PERFRINGENS; NEURAMINIDASE; PURIFICATION; VIRULENCE; OLIGOSACCHARIDES; CHROMATOGRAPHY	We have isolated an endo-beta-galactosidase designated E-ABase from Clostridium perfringens ATCC 10543 capable of liberating both the A trisaccharide (A-Tri; GalNalpha1-->3(Fucalpha1-->2)Gal) and B trisaccharide (B-Tri; Galalpha1-->3( Fucalpha1-->2)Gal) from glycoconjugates containing blood group A and B glycotopes, respectively. We have subsequently cloned the gene (eabC) that encodes E-ABase from this organism. This gene was found to be identical to the CPE0329 gene of C. perfringens strain 13, whose product was labeled as a hypothetical protein (Shimizu, T., Ohtani, K., Hirakawa, H., Ohshima, K., Yamashita, A., Shiba, T., Ogasawara, N., Hattori, M., Kuhara, S., and Hayashi, H. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 996 - 1001). Since the amino acid sequence of E-ABase does not bear detectable similarity to any of the 97 existing families of glycoside hydrolases, we have proposed to assign this unusual enzyme to a new family, GH98. We also expressed eabC in Escherichia coli BL21(DE3) and obtained 27 mg of fully active recombinant E-ABase from 1 liter of culture. Recombinant E-ABase not only destroyed the blood group A and B antigenicity of human type A and B erythrocytes, but also released A-Tri and B-Tri from blood group A (+)- and B+-containing glycoconjugates. The structures of A-Tri and B-Tri liberated from A(+) porcine gastric mucin and B+ human ovarian cyst glycoprotein were established by NMR spectroscopy. The unique specificity of E-ABase should make it useful for studying the structure and function of blood group A- and B-containing glycoconjugates as well as for identifying other glycosidases belonging to the new GH98 family.	Tulane Univ, Sch Med, Ctr Hlth Sci, Dept Biochem, New Orleans, LA 70112 USA; Tulane Univ, Coordinated Instrumentat Facil, New Orleans, LA 70118 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England	Tulane University; Tulane University; Imperial College London	Li, YT (corresponding author), Tulane Univ, Sch Med, Ctr Hlth Sci, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.	yli1@tulane.edu		Ashida, Hisashi/0000-0001-5844-4075	NHLBI NIH HHS [5F31 HL068296-03] Funding Source: Medline; NINDS NIH HHS [NS09626] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F31HL068296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson K, 2000, ANAL BIOCHEM, V287, P337, DOI 10.1006/abio.2000.4829; ANGYAL SJ, 1969, ANGEW CHEM INT EDIT, V8, P157, DOI 10.1002/anie.196901571; ANGYAL SJ, 1991, ADV CARBOHYD CHEM BI, V49, P19, DOI 10.1016/S0065-2318(08)60180-8; ANGYAL SJ, 1984, ADV CARBOHYD CHEM BI, V42, P15, DOI 10.1016/S0065-2318(08)60122-5; ANGYAL SJ, 1979, CARBOHYD RES, V77, P37, DOI 10.1016/S0008-6215(00)83791-X; Ashida H, 2002, BIOCHEMISTRY-US, V41, P2388, DOI 10.1021/bi011940e; Ashida H, 2001, J BIOL CHEM, V276, P28226, DOI 10.1074/jbc.M103589200; Ausubel FM, 1991, CURRENT PROTOCOLS MO; AWAD MM, 1995, MOL MICROBIOL, V15, P191, DOI 10.1111/j.1365-2958.1995.tb02234.x; Azurmendi HF, 2002, CARBOHYD RES, V337, P905, DOI 10.1016/S0008-6215(02)00070-8; BOYLE MDP, 1976, J IMMUNOL, V116, P661; CASSIDY JT, 1965, J BIOL CHEM, V240, P3501; Cassidy JT, 1966, METHODS ENZYMOL, V8, P680; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P29; CHIEN SF, 1975, BIOCHEM BIOPH RES CO, V65, P683, DOI 10.1016/S0006-291X(75)80200-2; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; CORFIELD T, 1992, GLYCOBIOLOGY, V2, P509, DOI 10.1093/glycob/2.6.509; DEN H, 1975, J CHROMATOGR, V111, P217, DOI 10.1016/S0021-9673(01)80167-9; FRASER AG, 1978, J MED MICROBIOL, V11, P269, DOI 10.1099/00222615-11-3-269; GERWIG GJ, 1989, J BIOL CHEM, V264, P1027; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HATTON MWC, 1973, BIOCHIM BIOPHYS ACTA, V327, P114, DOI 10.1016/0005-2744(73)90108-3; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOSKINS LC, 1995, TRANSFUSION, V35, P813, DOI 10.1046/j.1537-2995.1995.351096026361.x; KRAEMER PM, 1968, BIOCHIM BIOPHYS ACTA, V167, P205, DOI 10.1016/0005-2744(68)90296-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng L, 1998, GENE, V222, P187, DOI 10.1016/S0378-1119(98)00496-X; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; NIILO L, 1980, CAN VET J, V21, P141; Ogawa H, 2000, J BIOL CHEM, V275, P19368, DOI 10.1074/jbc.M001888200; Petit L, 1999, TRENDS MICROBIOL, V7, P104, DOI 10.1016/S0966-842X(98)01430-9; ROOD JI, 1991, MICROBIOL REV, V55, P621, DOI 10.1128/MMBR.55.4.621-648.1991; Rood JI, 1998, ANNU REV MICROBIOL, V52, P333, DOI 10.1146/annurev.micro.52.1.333; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; SMITH LDS, 1979, REV INFECT DIS, V1, P254; Sterne M, 1981, Br Vet J, V137, P443; Stevens DL, 2002, CLIN INFECT DIS, V35, pS93, DOI 10.1086/341928; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P271, DOI 10.1007/BF01047847; TAKASAKI S, 1976, J BIOL CHEM, V251, P3603; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; TRAMS EG, 1976, J NEUROCHEM, V27, P1035, DOI 10.1111/j.1471-4159.1976.tb00305.x; Zhu YP, 2001, J ORG CHEM, V66, P6244, DOI 10.1021/jo010541m	45	39	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7720	7728		10.1074/jbc.M414099200	http://dx.doi.org/10.1074/jbc.M414099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15618227	hybrid			2022-12-27	WOS:000227395700036
J	Bollen, YJM; Nabuurs, SM; van Berkel, WJH; van Mierlo, CPM				Bollen, YJM; Nabuurs, SM; van Berkel, WJH; van Mierlo, CPM			Last in, first out	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS FLAVODOXIN; AZOTOBACTER-VINELANDII APOFLAVODOXIN; MONONUCLEOTIDE COFACTOR BINDING; VULGARIS FLAVODOXIN; ANALOG BINDING; KINETICS; PROTEIN; THERMODYNAMICS; RECONSTITUTION; INTERMEDIATE	Although many proteins require the binding of a ligand to be functional, the role of ligand binding during folding is scarcely investigated. Here, we have reported the influence of the flavin mononucleotide (FMN) cofactor on the global stability and folding kinetics of Azotobacter vinelandii holoflavodoxin. Earlier studies have revealed that A. vinelandii apoflavodoxin kinetically folds according to the four-state mechanism: I-1 double left right arrow unfolded apoflavodoxin double left right arrow I-2 double left right arrow native apoflavodoxin. I-1 is an off-pathway molten globule-like intermediate that populates during denaturant-induced equilibrium unfolding; I-2 is a high energy on-pathway folding intermediate that never populates to a significant extent. Here, we have presented extensive denaturant-induced equilibrium unfolding data of holoflavodoxin, holoflavodoxin with excess FMN, and apoflavodoxin as well as kinetic folding and unfolding data of holoflavodoxin. All folding data are excellently described by a five-state mechanism: I-1 + FMN double left right arrow unfolded apoflavodoxin + FMN double left right arrow I-2 + FMN double left right arrow native apoflavodoxin + FMN double left right arrow holoflavodoxin. The last step in flavodoxin folding is thus the binding of FMN to native apoflavodoxin. I-1, I-2, and unfolded apoflavodoxin do not interact to a significant extent with FMN. The autonomous formation of native apoflavodoxin is essential during holoflavodoxin folding. Excess FMN does not accelerate holoflavodoxin folding, and FMN does not act as a nucleation site for folding. The stability of holoflavodoxin is so high that even under strongly denaturing conditions FMN needs to be released first before global unfolding of the protein can occur.	Wageningen Univ, Biochem Lab, Dept Agrotechnol & Food Sci, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	van Mierlo, CPM (corresponding author), Wageningen Univ, Biochem Lab, Dept Agrotechnol & Food Sci, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	carlo.vanmierlo@wur.nl	van Berkel, Willem J.H./O-2431-2014; vanMierlo, Carlo p/B-4491-2016	van Berkel, Willem J.H./0000-0002-6551-2782; vanMierlo, Carlo p/0000-0002-5358-8392; Bollen, Yves/0000-0001-6251-3360				Apiyo D, 2002, PROTEIN SCI, V11, P1129, DOI 10.1110/ps.3840102; Apiyo D, 2000, BBA-PROTEIN STRUCT M, V1479, P214, DOI 10.1016/S0167-4838(00)00032-7; Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; BALDWIN RL, 1996, FOLD DES, V1, P1; BARMAN BG, 1972, BIOCHEMISTRY-US, V11, P4746, DOI 10.1021/bi00775a018; Bertini I, 1997, BIOCHEMISTRY-US, V36, P9332, DOI 10.1021/bi970810w; Bieri O, 1999, BIOCHEMISTRY-US, V38, P12460, DOI 10.1021/bi9909703; Bollen YJM, 2004, BIOCHEMISTRY-US, V43, P10475, DOI 10.1021/bi049545m; BOLLEN YJM, 2005, IN PRESS BIOPHYS CHE; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P338; EDMONDSON DE, 1971, BIOCHEMISTRY-US, V10, P124; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Hefti MH, 2003, EUR J BIOCHEM, V270, P4227, DOI 10.1046/j.1432-1033.2003.03802.x; KLUGKIST J, 1986, EUR J BIOCHEM, V155, P33, DOI 10.1111/j.1432-1033.1986.tb09455.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; Mayhew S G, 1980, Methods Enzymol, V66, P217; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; Murray TA, 2003, BIOCHEMISTRY-US, V42, P2317, DOI 10.1021/bi026968k; Murray TA, 2003, BIOCHEMISTRY-US, V42, P2307, DOI 10.1021/bi026967s; Nuallain BO, 2002, EUR J BIOCHEM, V269, P212, DOI 10.1046/j.0014-2956.2002.02637.x; PRESS WH, 1992, NUMERICAL RECIPES AR, P517; Pueyo JJ, 1996, BIOCHEM J, V313, P855, DOI 10.1042/bj3130855; Robinson CR, 1997, BIOCHEMISTRY-US, V36, P16141, DOI 10.1021/bi971470h; Steensma E, 1998, PROTEIN SCI, V7, P306; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; Thorneley RNF, 1994, FLAVINS AND FLAVOPROTEINS 1993, P343; van Mierlo CPM, 1999, J MOL CATAL B-ENZYM, V7, P147, DOI 10.1016/S1381-1177(99)00037-5; Van Mierlo CPM, 2000, PROTEIN SCI, V9, P145; Van Mierlo CPM, 1998, PROTEIN SCI, V7, P2331, DOI 10.1002/pro.5560071110; VANBERKEL WJH, 1991, EUR J BIOCHEM, V197, P769	31	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7836	7844		10.1074/jbc.M412871200	http://dx.doi.org/10.1074/jbc.M412871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632150	Green Published, hybrid			2022-12-27	WOS:000227395700050
J	Ehirchiou, D; Xiong, YM; Li, Y; Brew, S; Zhang, L				Ehirchiou, D; Xiong, YM; Li, Y; Brew, S; Zhang, L			Dual function for a unique site within the beta I-2 domain of integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INTERCELLULAR-ADHESION MOLECULE-1; CD11B A-DOMAIN; I-DOMAIN; MAC-1 CD11B/CD18; BINDING-SITE; CONFORMATIONAL-CHANGES; BETA(2) SUBUNIT; INSERTED DOMAIN; DISULFIDE BONDS	Integrin activation has been postulated to occur in part via conformational changes in the I domain of the beta subunit ( the beta I domain), especially near the F-alpha(7) loop, in response to " inside- out" signaling. However, direct evidence for a role of the F-alpha(7) loop in ligand binding and activity modulation is still lacking. Here, we report our finding that the F- alpha(7) loop ( residues 344 - 358) within the beta(2)I domain has dual functions in ligand binding by alpha(M)beta(2). On the one hand, it supports intercellular adhesion molecule 1 (ICAM- 1) binding to alpha(M)beta(2) directly as part of a recognition interface formed by five noncontiguous segments ( Pro(192) - Glu(197), Asn(213) - Glu(220), Leu(225) - Leu(230), Ser(324) - Thr(329), and Glu(344) - Asp(348)) on the apex of the beta(2)I domain. On the other hand, it controls the open and closed conformation of the alpha(M)beta(2) receptor, thereby indirectly affecting alpha(M)beta(2) binding to other ligands. Switching the five constituent sequences of the ICAM- 1- binding site within the beta(2)I domain to their beta 1 counterparts destroyed ICAM- 1 binding but had no effect on the gross conformations of the receptor. Of the five ICAM- 1 bindingdefective mutants, four had normal or even stronger interaction with Fg and C3bi, as reported in our previous study. Synthetic peptides derived from the identified site inhibited alpha(M)beta(2)- ICAM- 1 interaction and supported direct binding to ICAM- 1. Most importantly, perturbation of the F- alpha7 loop caused conformational changes within the beta(2)I domain, which was further propagated to other regions of alpha(M)beta(2). Altogether, our data demonstrate that inside- out signaling could modulate ligand binding directly by changing the ligand- binding pocket per se and/ or indirectly by inducing multiple conformational changes within the receptor.	Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Biochem, Rockville, MD 20855 USA		Zhang, L (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20855 USA.	ZHANGL@USA.REDCROSS.ORG			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061589, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL61589-01, P01 HL054710, R01 HL061589] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; Binnerts ME, 1996, J BIOL CHEM, V271, P9962, DOI 10.1074/jbc.271.17.9962; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; LI Z, 1989, J PROTEIN CHEM, V8, P471, DOI 10.1007/BF01026431; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; McCleverty CJ, 2003, BIOCHEM J, V372, P121, DOI 10.1042/BJ20021273; MOYLE M, 1994, J BIOL CHEM, V269, P10008; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROSS GD, 1985, J IMMUNOL, V134, P3307; Shimaoka M, 2002, P NATL ACAD SCI USA, V99, P16737, DOI 10.1073/pnas.252633099; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; UGAROVA T, 1995, THROMB HAEMOSTASIS, V74, P253; Woska JR, 1996, J IMMUNOL, V156, P4680; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2002, J BIOL CHEM, V277, P46639, DOI 10.1074/jbc.M207971200; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	41	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8324	8331		10.1074/jbc.M413525200	http://dx.doi.org/10.1074/jbc.M413525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615722	hybrid			2022-12-27	WOS:000227395700107
J	Hong, S; Choi, I; Woo, JM; Oh, J; Kim, T; Choi, E; Kim, TW; Jung, YK; Kim, DH; Sun, CH; Yi, GS; Eddy, EM; Cho, CH				Hong, S; Choi, I; Woo, JM; Oh, J; Kim, T; Choi, E; Kim, TW; Jung, YK; Kim, DH; Sun, CH; Yi, GS; Eddy, EM; Cho, CH			Identification and integrative analysis of 28 novel genes specifically expressed and developmentally regulated in murine spermatogenic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE GERM-CELLS; MOUSE SPERMATOGENESIS; MALE-INFERTILITY; FERTILIN-BETA; MICE LACKING; MUTANT MICE; SPERM; TESTIS; PROTEIN; MEIOSIS	Mammalian spermatogenesis is a highly ordered process that occurs in mitotic, meiotic, and postmeiotic phases. The unique mechanisms responsible for this tightly regulated developmental process suggest the presence of an intrinsic genetic program composed of spermatogenic cell-specific genes. In this study, we analyzed the mouse round spermatid UniGene library currently containing 2124 gene-oriented transcript clusters, predicting that 467 of them are testis-specific genes, and systematically identified 28 novel genes with evident testis-specific expression by in silico and in vitro approaches. We analyzed these genes by Northern blot hybridization and cDNA cloning, demonstrating the presence of additional transcript sequences in five genes and multiple transcript isoforms in six genes. Genomic analysis revealed lack of human orthologues for 10 genes, implying a relationship between these genes and male reproduction unique to mouse. We found that all of the novel genes are expressed in developmentally regulated and stage-specific patterns, suggesting that they are primary regulators of male germ cell development. Using computational bioinformatics tools, we found that 20 gene products are potentially involved in various processes during spermatogenesis or fertilization. Taken together, we predict that over 20% of the genes from the round spermatid library are testis-specific, have discovered the 28 authentic, novel genes with probable spermatogenic cell-specific expression by the integrative approach, and provide new and thorough information about the novel genes by various in vitro and in silico analyses. Thus, the study establishes on a comprehensive scale a new basis for studies to uncover molecular mechanisms underlying the reproductive process.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Informat & Commun Univ, Sch Engn, Taejon 305714, South Korea; NIEHS, Gamete Biol Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	Gwangju Institute of Science & Technology (GIST); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cho, CH (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	choch@gist.ac.kr	Kim, Taewan/M-5867-2013; Yi, Gwan-Su/A-7896-2011; Choi, Inchul/AAF-6264-2021	Kim, Taewan/0000-0002-7202-009X; Yi, Gwan-Su/0000-0003-0012-6546; Choi, Inchul/0000-0001-5011-2658; Jung, Yong-Keun/0000-0002-9686-3120	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES070076, Z01ES070076] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Almstrup K, 2004, BIOL REPROD, V70, P1751, DOI 10.1095/biolreprod.103.026575; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Brener E, 2003, BIOL REPROD, V68, P837, DOI 10.1095/biolreprod.102.009233; ChenMoses A, 1997, CELL GROWTH DIFFER, V8, P711; Cho C, 2001, NAT GENET, V28, P82, DOI 10.1038/ng0501-82; Cho C, 2003, BIOL REPROD, V69, P211, DOI 10.1095/biolreprod.102.015115; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Choi IC, 2004, GENOMICS, V83, P636, DOI 10.1016/j.ygeno.2003.10.001; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Eddy EM, 1995, REPROD FERT DEVELOP, V7, P695, DOI 10.1071/RD9950695; Eddy EM, 2002, RECENT PROG HORM RES, V57, P103, DOI 10.1210/rp.57.1.103; Eddy EM, 1998, SEMIN CELL DEV BIOL, V9, P451, DOI 10.1006/scdb.1998.0201; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; Ellis PJI, 2004, MOL HUM REPROD, V10, P271, DOI 10.1093/molehr/gah043; FITZGERALD J, 1994, DNA CELL BIOL, V13, P531, DOI 10.1089/dna.1994.13.531; Fujii T, 2002, EMBO REP, V3, P367, DOI 10.1093/embo-reports/kvf073; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Groth D, 2004, NUCLEIC ACIDS RES, V32, pW313, DOI 10.1093/nar/gkh406; Guo R, 2004, MOL REPROD DEV, V67, P264, DOI 10.1002/mrd.20026; Hurst S, 1998, MOL REPROD DEV, V49, P81, DOI 10.1002/(SICI)1098-2795(199801)49:1&lt;81::AID-MRD9&gt;3.0.CO;2-K; Khetchoumian K, 2004, J BIOL CHEM, V279, P48329, DOI 10.1074/jbc.M404779200; KLEENE KC, 1990, DEV BIOL, V137, P395, DOI 10.1016/0012-1606(90)90263-I; Kotaja N, 2004, P NATL ACAD SCI USA, V101, P10620, DOI 10.1073/pnas.0401947101; LI SSL, 1989, BIOL REPROD, V40, P173, DOI 10.1095/biolreprod40.1.173; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; MORALES CR, 1994, BIOL REPROD, V50, P309, DOI 10.1095/biolreprod50.2.309; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rossi P, 2004, GENE EXPR PATTERNS, V4, P267, DOI 10.1016/j.modgep.2003.11.003; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Shirley CR, 2004, BIOL REPROD, V71, P1220, DOI 10.1095/biolreprod.104.029363; Toshima J, 1998, BIOCHEM BIOPH RES CO, V249, P107, DOI 10.1006/bbrc.1998.9099; Vidal F, 2001, J CELL SCI, V114, P435; vonBulow M, 1997, EXP CELL RES, V233, P216, DOI 10.1006/excr.1997.3564; Wang H, 2002, MOL CELL BIOL, V22, P8478, DOI 10.1128/MCB.22.24.8478-8490.2002; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683; Zhao M, 2001, MOL CELL BIOL, V21, P7243, DOI 10.1128/MCB.21.21.7243-7255.2001; Zhu DH, 1997, DEVELOPMENT, V124, P3007	43	49	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7685	7693		10.1074/jbc.M412444200	http://dx.doi.org/10.1074/jbc.M412444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15613475	hybrid			2022-12-27	WOS:000227395700032
J	Ikeda, R; Yoshida, K; Tsukahara, S; Sakamoto, Y; Tanaka, H; Furukawa, K; Inoue, I				Ikeda, R; Yoshida, K; Tsukahara, S; Sakamoto, Y; Tanaka, H; Furukawa, K; Inoue, I			The promyelotic leukemia zinc finger promotes osteoblastic differentiation of human mesenchymal stem cells as an upstream regulator of CBFA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTERIOR LONGITUDINAL LIGAMENT; BONE MORPHOGENETIC PROTEIN-2; PLZF-RAR-ALPHA; NEGATIVE REGULATION; GENE-EXPRESSION; MESSENGER-RNA; STROMAL CELLS; OSSIFICATION; SPINE; C2C12	Ossification of the posterior longitudinal ligament of the spine (OPLL) is the leading cause of myelopathy in Japan and is diagnosed by ectopic bone formation in the paravertebral ligament. OPLL is a systemic high bone mass disease with a strong genetic background. To detect genes relevant to the pathogenesis of OPLL, we performed a cDNA microarray analysis of systematic gene expression profiles during the osteoblastic differentiation of ligament cells from OPLL patients ( OPLL cells), patients with a disorder called ossification of yellow ligament (OYL), and non-OPLL controls together with human mesenchymal stem cells (hMSCs) after stimulating them with osteogenic differentiation medium ( OS). Twenty-four genes were up-regulated during osteoblastic differentiation in OPLL cells. Zinc finger protein 145 (promyelotic leukemia zinc finger or PLZF) was one of the highly expressed genes during osteoblastic differentiation in all the cells examined. We investigated the roles of PLZF in the regulation of osteoblastic differentiation of hMSCs and C2C12 cells. Small interfering RNA-mediated gene silencing of PLZF resulted in a reduction in the expression of osteoblast-specific genes such as the alkaline phosphatase, collagen 1A1 (Col1a1), Runx2/core-binding factor 1 (Cbfa1), and osteocalcin genes, even in the presence of OS in hMSCs. The expression of PLZF was unaffected by the addition of bone morphogenetic protein 2 (BMP-2), and the expression of BMP-2 was not affected by PLZF in hMSCs. In C2C12 cells, overexpression of PLZF increased the expression of Cbfa1 and Col1a1; on the other hand, the overexpression of CBFA1 did not affect the expression of Plzf. These findings indicate that PLZF plays important roles in early osteoblastic differentiation as an upstream regulator of CBFA1 and thereby might participate in promoting the ossification of spinal ligament cells in OPLL patients.	Univ Tokyo, Div Genet Diag, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; Yamaguchi Univ, Dept Orthoped Surg, Sch Med, Ube, Yamaguchi 7558505, Japan; Hirosaki Univ, Sch Med, Dept Pharmacol, Hirosaki, Aomori 0368562, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	University of Tokyo; Yamaguchi University; Hirosaki University; Japan Science & Technology Agency (JST)	Inoue, I (corresponding author), Univ Tokyo, Div Genet Diag, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ituro@ims-u-tokyo.ac.jp						Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Furushima K, 2002, J BONE MINER RES, V17, P128, DOI 10.1359/jbmr.2002.17.1.128; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; HARRIS SE, 1994, J BONE MINER RES, V9, P389; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Koga H, 1998, AM J HUM GENET, V62, P1460, DOI 10.1086/301868; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Maeda S, 2001, J BONE MINER RES, V16, P948, DOI 10.1359/jbmr.2001.16.5.948; Matsunaga S., 1997, OSSIFICATION POSTERI, P11; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756-3282(02)00826-8; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100; Reddi AH, 1997, NAT MED, V3, P837, DOI 10.1038/nm0897-837; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Schecroun N, 2003, BONE, V32, P252, DOI 10.1016/S8756-3282(02)00970-5; Shen ZJ, 2002, J BIOL CHEM, V277, P29840, DOI 10.1074/jbc.M203157200; Tanaka T, 2003, AM J HUM GENET, V73, P812, DOI 10.1086/378593; TENENBAUM HC, 1985, ENDOCRINOLOGY, V117, P2211, DOI 10.1210/endo-117-5-2211; TERAYAMA K, 1989, SPINE, V14, P1184, DOI 10.1097/00007632-198911000-00009; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamauchi T, 1999, J BONE MINER METAB, V17, P296, DOI 10.1007/s007740050098; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	42	74	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8523	8530		10.1074/jbc.M409442200	http://dx.doi.org/10.1074/jbc.M409442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623533	hybrid			2022-12-27	WOS:000227395700129
J	Jameson, EE; Roof, RA; Whorton, MR; Mosberg, HI; Sunahara, RK; Neubig, RR; Kennedy, RT				Jameson, EE; Roof, RA; Whorton, MR; Mosberg, HI; Sunahara, RK; Neubig, RR; Kennedy, RT			Real-time detection of basal and stimulated G protein GTPase activity using fluorescent GTP analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION INHIBITOR; LOW-AFFINITY INTERACTIONS; HETEROTRIMERIC G-PROTEIN; ESCHERICHIA-COLI; ALPHA-SUBUNITS; CAPILLARY-ELECTROPHORESIS; GUANINE-NUCLEOTIDES; ACTIVATING PROTEINS; BINDING; RAS	Hydrolysis of fluorescent GTP analogues BODIPY(R) FL guanosine 5'-O-( thiotriphosphate) (BGTPgammaS) and BODIPY(R) FL GTP (BGTP) by Ggamma(i1) and Galpha(o) was characterized using on-line capillary electrophoresis laser-induced fluorescence assays in order that changes in substrate, substrate-enzyme complex, and product could be monitored separately. Apparent k(cat) values (Vmax/[E]) and Km values were determined from steady-state assays for each substrate-protein pair. When BGTP was the substrate, maximum turnover numbers for Galpha(o) and Galpha(i1) were 8.3 +/- 1 x 10(-3) and 3.0 +/- 0.2 x 10(-2) s(-1), respectively, and Km values were 120 +/- 60 and 940 +/- 160 nM. Assays with BGTPgammaS yielded maximum turnover numbers of 1.6 +/- 0.1 x 10(-4) and 5.5 +/- 0.3 x 10(-4) s(-1) for Galpha(o) and Galpha(i1); Km values were 14 +/- 8 and 87 +/- 22 nM. Acceleration of Galpha GTPase activity by regulators of G protein signaling (RGS) was demonstrated in both steady-state and pseudo-single-turnover assay formats with BGTP. Nanomolar RGS increased the rate of enzyme product formation (BODIPY(R) FL GDP (BGDP)) by 117 - 213% under steady-state conditions and accelerated the rate of G protein-BGTP complex decay by 199 - 778% in pseudo-single-turnover assays. Stimulation of GTPase activity by RGS proteins was inhibited 38 - 81% by 40 muM YJ34, a previously reported peptide RGS inhibitor. Taken together, these results illustrate that Galpha subunits utilize BGTP as a substrate similarly to GTP, making BGTP a useful fluorescent indicator of G protein activity. The unexpected levels of BGTPgammaS hydrolysis detected suggest that caution should be used when interpreting data from fluorescence assays with this probe.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kennedy, RT (corresponding author), Univ Michigan, Dept Chem, 930 N Univ, Ann Arbor, MI 48109 USA.	rtkenn@umich.edu	Kennedy, Robert/G-9095-2016; Sunahara, Roger/AAJ-8667-2020	Kennedy, Robert/0000-0003-2447-7471; Neubig, Richard/0000-0003-0501-0008	NIDA NIH HHS [DA03910] Funding Source: Medline; NIGMS NIH HHS [GM39561, GM068603] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003910] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; German I, 2000, J CHROMATOGR B, V742, P353, DOI 10.1016/S0378-4347(00)00180-8; Gille A, 2003, LIFE SCI, V74, P271, DOI 10.1016/j.lfs.2003.09.014; Gille A, 2003, N-S ARCH PHARMACOL, V368, P210, DOI 10.1007/s00210-003-0783-7; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hooker TF, 1997, ANAL CHEM, V69, P4134, DOI 10.1021/ac970342w; Jameson EE, 2003, ANAL CHEM, V75, P4297, DOI 10.1021/ac0342976; Jin Y, 2004, J PEPT RES, V63, P141, DOI 10.1111/j.1399-3011.2003.00114.x; Kimple RJ, 2004, BIOCHEM J, V378, P801, DOI 10.1042/BJ20031686; Kimple RJ, 2003, COMB CHEM HIGH T SCR, V6, P399; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Korlach J, 2004, P NATL ACAD SCI USA, V101, P2800, DOI 10.1073/pnas.0308579100; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LINDER ME, 1990, J BIOL CHEM, V265, P8243; McEwen DP, 2001, ANAL BIOCHEM, V291, P109, DOI 10.1006/abio.2001.5011; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; Murakoshi H, 2004, P NATL ACAD SCI USA, V101, P7317, DOI 10.1073/pnas.0401354101; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; Paduch M, 2001, ACTA BIOCHIM POL, V48, P829; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Remmers AE, 1996, J BIOL CHEM, V271, P4791; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Sermon BA, 1998, J BIOL CHEM, V273, P9480, DOI 10.1074/jbc.273.16.9480; Shackman JG, 2004, J CHROMATOGR A, V1040, P273, DOI 10.1016/j.chroma.2004.04.004; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sullivan SM, 2000, J BACTERIOL, V182, P3460, DOI 10.1128/JB.182.12.3460-3466.2000; Tao L, 1996, ANAL CHEM, V68, P3899, DOI 10.1021/ac960560+; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Wu SK, 1998, J BIOL CHEM, V273, P26931, DOI 10.1074/jbc.273.41.26931; Zera EM, 1996, J BIOL CHEM, V271, P12925, DOI 10.1074/jbc.271.22.12925	43	36	44	4	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7712	7719		10.1074/jbc.M413810200	http://dx.doi.org/10.1074/jbc.M413810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15613467	hybrid			2022-12-27	WOS:000227395700035
J	Kudoh, A; Fujita, M; Zhang, LM; Shirata, N; Daikoku, T; Sugaya, Y; Isomura, H; Nishiyama, Y; Tsurumi, T				Kudoh, A; Fujita, M; Zhang, LM; Shirata, N; Daikoku, T; Sugaya, Y; Isomura, H; Nishiyama, Y; Tsurumi, T			Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; NIJMEGEN BREAKAGE SYNDROME; DEPENDENT KINASE-ACTIVITY; MRE11 COMPLEX; INDUCED PHOSPHORYLATION; CYCLE PROGRESSION; HISTONE H2AX; IN-VIVO; PROTEIN; ACTIVATION	When exposed to genotoxic stress, eukaryotic cells demonstrate a DNA damage response with delay or arrest of cell-cycle progression, providing time for DNA repair. Induction of the Epstein-Barr virus (EBV) lytic program elicited a cellular DNA damage response, with activation of the ataxia telangiectasia-mutated (ATM) signal transduction pathway. Activation of the ATM-Rad3-related (ATR) replication checkpoint pathway, in contrast, was minimal. The DNA damage sensor Mre11-Rad50-Nbs1 (MRN) complex and phosphorylated ATM were recruited and retained in viral replication compartments, recognizing newly synthesized viral DNAs as abnormal DNA structures. Phosphorylated p53 also became concentrated in replication compartments and physically interacted with viral BZLF1 protein. Despite the activation of ATM checkpoint signaling, p53-downstream signaling was blocked, with rather high S-phase CDK activity associated with progression of lytic infection. Therefore, although host cells activate ATM checkpoint signaling with response to the lytic viral DNA synthesis, the virus can skillfully evade this host checkpoint security system and actively promote an S-phase-like environment advantageous for viral lytic replication.	Aichi Canc Ctr Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Natl Canc Ctr, Div Virol, Chuo Ku, Tokyo 1040045, Japan; Nagoya Univ, Grad Sch Med, Dept Virol, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; National Cancer Center - Japan; Nagoya University	Tsurumi, T (corresponding author), Aichi Canc Ctr Res Inst, Div Virol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ttsurumi@aichi-cc.jp	zhang, lumin/R-3456-2016	Fujita, Masatoshi/0000-0001-6617-2452				Ahn JY, 2000, CANCER RES, V60, P5934; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FIXMAN ED, 1995, J VIROL, V69, P2998, DOI 10.1128/JVI.69.5.2998-3006.1995; FLEMINGTON EK, 1991, J VIROL, V65, P7073, DOI 10.1128/JVI.65.12.7073-7077.1991; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Krauer KG, 2004, ONCOGENE, V23, P1342, DOI 10.1038/sj.onc.1207253; Kudoh A, 2004, J VIROL, V78, P104, DOI 10.1128/JVI.78.1.104-115.2004; Kudoh A, 2003, J VIROL, V77, P851, DOI 10.1128/JVI.77.2.851-861.2003; Lin WC, 2001, GENE DEV, V15, P1833; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mauser A, 2002, J VIROL, V76, P12543, DOI 10.1128/JVI.76.24.12543-12552.2002; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; NEVINS JR, 1992, SCIENCE, V258, P424; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Swenson JJ, 1999, J VIROL, V73, P6540, DOI 10.1128/JVI.73.8.6540-6550.1999; TAKAGI S, 1991, VIROLOGY, V185, P309, DOI 10.1016/0042-6822(91)90778-A; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tsurumi T, 2001, CURR TOP MICROBIOL, V258, P65; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; WESTPHAL CH, 1997, CURR BIOL, V7, P789; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	50	146	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8156	8163		10.1074/jbc.M411405200	http://dx.doi.org/10.1074/jbc.M411405200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611093	hybrid			2022-12-27	WOS:000227395700088
J	Osada, Y; Hashimoto, T; Nishimura, A; Matsuo, Y; Wakabayashi, T; Iwatsubo, T				Osada, Y; Hashimoto, T; Nishimura, A; Matsuo, Y; Wakabayashi, T; Iwatsubo, T			CLAC binds to amyloid beta peptides through the positively charged amino acid cluster within the collagenous domain 1 and inhibits formation of amyloid fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; SENILE PLAQUES; XIII COLLAGEN; ALZHEIMERS-DISEASE; PROTEIN; PATHOGENESIS; PRECURSOR; A-BETA-40; TERMINUS; BRAINS	CLAC ( collagenous Alzheimer amyloid plaque component) is a proteolytic fragment derived from a novel membrane-bound collagen, CLAC-P/collagen type XXV, that deposits in senile plaques associated with amyloid beta peptides (Abeta) in the brains of patients with Alzheimer's disease. We previously showed that CLAC binds to the fibrillized form of Abeta in vitro, although the mechanism and the subdomains that mediate interaction of CLAC with Abeta as well as the effect of binding of CLAC on amyloid fibril formation remain unknown. Here we show that the collagenous domain 1 of CLAC, which is rich in positively charged amino acid residues, mediates its interaction with Abeta and that this binding is mediated by an electrostatic interaction and requires formation of the triple helix structure of CLAC. The soluble form of CLAC purified from the media of cells transfected with CLAC-P inhibited fibrillization of Abeta in vitro, especially in its elongation phase. These results suggest the anti-amyloidogenic roles of CLAC in the pathophysiology of Alzheimer's disease.	Univ Tokyo, Dept Neuropathol & Neurosci, Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Iwatsubo, T (corresponding author), Univ Tokyo, Dept Neuropathol & Neurosci, Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	iwatsubo@mol.f.u-tokyo.ac.jp	Hashimoto, Tadafumi/A-7723-2013; Wakabayashi, Tomoko/GSD-1544-2022	Hashimoto, Tadafumi/0000-0001-5442-4800				Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; DOI T, 1993, J BIOL CHEM, V268, P2126; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ElKhoury J, 1996, NATURE, V382, P716; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JIANG HX, 1994, J IMMUNOL, V152, P5050; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KELLER KM, 1986, BIOCHIM BIOPHYS ACTA, V882, P1, DOI 10.1016/0304-4165(86)90047-4; Kowa H, 2004, NEUROBIOL AGING, V25, pS163, DOI 10.1016/S0197-4580(04)80548-7; Kowa H, 2004, AM J PATHOL, V165, P273, DOI 10.1016/S0002-9440(10)63295-6; Latvanlehto A, 2003, J BIOL CHEM, V278, P37590, DOI 10.1074/jbc.M305974200; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; Mizuno K, 1996, J BIOCHEM-TOKYO, V120, P934; Naiki H, 1997, BIOCHEMISTRY-US, V36, P6243, DOI 10.1021/bi9624705; Naiki H, 1996, LAB INVEST, V74, P374; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Snellman A, 2000, J BIOL CHEM, V275, P8936, DOI 10.1074/jbc.275.12.8936; Soderberg L, 2005, J BIOL CHEM, V280, P1007, DOI 10.1074/jbc.M403628200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200	33	44	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8596	8605		10.1074/jbc.M413340200	http://dx.doi.org/10.1074/jbc.M413340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615705	hybrid			2022-12-27	WOS:000227395700136
J	Villa, F; Deak, M; Bloomberg, GB; Alessi, DR; van Aalten, DMF				Villa, F; Deak, M; Bloomberg, GB; Alessi, DR; van Aalten, DMF			Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer - Evidence for a second phosphotyrosine substrate recognition pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; ALPHA; 1B; DOMAIN; IDENTIFICATION; SPECIFICITY; ACTIVATION; MECHANISM; KINASES; COMPLEX	Protein-tyrosine phosphatase-L1 (PTPL1, also known as FAP-1, PTP1E, PTP-BAS, and PTPN13) is mutated in a significant number of colorectal tumors and may play a role in down-regulating signaling responses mediated by phosphatidylinositol 3-kinase, although the precise substrates are as yet unknown. In this study, we describe a 1.8 Angstrom resolution crystal structure of a fully active fragment of PTPL1 encompassing the catalytic domain. PTPL1 adopts the standard PTP fold, albeit with an unusually positioned additional N-terminal helix, and shows an ordered phosphate in the active site. Interestingly, a positively charged pocket is located near the PTPL1 catalytic site, reminiscent of the second phosphotyrosine binding site in PTP1B, which is required to dephosphorylate peptides containing two adjacent phosphotyrosine residues (as occurs for example in the activated insulin receptor). We demonstrate that PTPL1, like PTP1B, interacts with and dephosphorylates a bis-phosphorylated insulin receptor peptide more efficiently than monophosphorylated peptides, indicating that PTPL1 may down-regulate the phosphatidylinositol 3-kinase pathway, by dephosphorylating insulin or growth factor receptors that contain tandem phosphotyrosines. The structure also reveals that four out of five PTPL1 mutations found in colorectal cancers are located on solvent-exposed regions remote from the active site, consistent with these mutants being normally active. In contrast, the fifth mutation, which changes Met-2307 to Thr, is close to the active site cysteine and decreases activity significantly. Our studies provide the first molecular description of the PTPL1 catalytic domain and give new insight into the function of PTPL1.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit,MSI,WTB, Dundee DD1 5EH, Scotland; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Dundee; University of Dundee; University of Bristol	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk	villa, fabrizio/G-5757-2012	van Aalten, Daan/0000-0002-1499-6908; Alessi, Dario/0000-0002-2140-9185				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bompard G, 2003, J CELL SCI, V116, P2519, DOI 10.1242/jcs.00448; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ciccarelli FD, 2003, TRENDS BIOCHEM SCI, V28, P349, DOI 10.1016/S0968-0004(03)00116-6; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Dickinson RJ, 2002, BIOCHEM J, V364, P145, DOI 10.1042/bj3640145; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Iversen LF, 2002, J BIOL CHEM, V277, P19982, DOI 10.1074/jbc.M200567200; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kimber WA, 2003, BIOCHEM J, V376, P525, DOI 10.1042/BJ20031154; LINDQVIST Y, 1994, EUR J BIOCHEM, V221, P139, DOI 10.1111/j.1432-1033.1994.tb18722.x; Nakai Y, 2000, EUR J BIOCHEM, V267, P7170, DOI 10.1046/j.1432-1327.2000.01818.x; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Peters GH, 2004, BIOCHEMISTRY-US, V43, P8418, DOI 10.1021/bi0498757; Peters GH, 2000, J BIOL CHEM, V275, P18201, DOI 10.1074/jbc.M910273199; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Yokote K, 1996, J BIOL CHEM, V271, P5101; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	38	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8180	8187		10.1074/jbc.M412211200	http://dx.doi.org/10.1074/jbc.M412211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611135	hybrid			2022-12-27	WOS:000227395700091
J	Yasukawa, T; Tokunaga, E; Ota, H; Sugita, H; Martyn, JAJ; Kaneki, M				Yasukawa, T; Tokunaga, E; Ota, H; Sugita, H; Martyn, JAJ; Kaneki, M			S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; GLUCOSE-TRANSPORT; SIGNAL-TRANSDUCTION; NITROSATIVE STRESS; MICE LACKING; ACTIVATION; CELLS; GENE	Inducible nitric-oxide synthase ( iNOS) has been implicated in many human diseases including insulin resistance. However, how iNOS causes or exacerbates insulin resistance remains largely unknown. Protein S-nitrosylation is now recognized as a prototype of a redox-dependent, cGMP-independent signaling component that mediates a variety of actions of nitric oxide ( NO). Here we describe the mechanism of inactivation of Akt/protein kinase B ( PKB) in NO donor-treated cells and diabetic ( db/db) mice. NO donors induced S-nitrosylation and inactivation of Akt/PKB in vitro and in intact cells. The inhibitory effects of NO donor were independent of phosphatidylinositol 3-kinase and cGMP. In contrast, the concomitant presence of oxidative stress accelerated S-nitrosylation and inactivation of Akt/PKB. In vitro denitrosylation with reducing agent reactivated recombinant and cellular Akt/PKB from NO donortreated cells. Mutated Akt1/PKBalpha( C224S), in which cysteine 224 was substituted by serine, was resistant to NO donor-induced S-nitrosylation and inactivation, indicating that cysteine 224 is a major S-nitrosylation acceptor site. In addition, S-nitrosylation of Akt/PKB was increased in skeletal muscle of diabetic ( db/db) mice compared with wild-type mice. These data suggest that S-nitrosylation-mediated inactivation may contribute to the pathogenesis of iNOS- and/or oxidative stress-involved insulin resistance.	Harvard Univ, Sch Med, Shriners Hosp Children, Massachusetts Gen Hosp,Dept Anesthesia & Crit Car, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kaneki, M (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, 149 13th St,Rm 6604, Charlestown, MA 02129 USA.	mkaneki@helix.mgh.harvard.edu			NIDDK NIH HHS [R01DK058127] Funding Source: Medline; NIGMS NIH HHS [R01GM055082, R01 GM055082, R01GM061411, GM21700, R01GM031569] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055082, P50GM021700, R01GM031569, R01GM061411] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARON AD, 1995, AM J PHYSIOL-ENDOC M, V269, pE709, DOI 10.1152/ajpendo.1995.269.4.E709; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; Butler R, 1998, CLIN SCI, V94, P175, DOI 10.1042/cs0940175; Carvalho E, 2000, DIABETOLOGIA, V43, P1107, DOI 10.1007/s001250051501; Carvalho E, 2000, MOL CELL BIOCHEM, V206, P7, DOI 10.1023/A:1007009723616; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cook S, 2004, DIABETES, V53, P2067, DOI 10.2337/diabetes.53.8.2067; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Drew B, 2002, ANN NY ACAD SCI, V959, P66, DOI 10.1111/j.1749-6632.2002.tb02084.x; Duplain H, 2001, CIRCULATION, V104, P342, DOI 10.1161/01.CIR.104.3.342; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Gunnett CA, 2003, STROKE, V34, P2970, DOI 10.1161/01.STR.0000099123.55171.3F; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hirose M, 2000, AM J PHYSIOL-ENDOC M, V279, pE1235, DOI 10.1152/ajpendo.2000.279.6.E1235; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Kaneki M, 1999, MOL CELL BIOL, V19, P461; Kapur S, 1997, DIABETES, V46, P1691, DOI 10.2337/diabetes.46.11.1691; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; KUO PC, 1995, ANN SURG, V221, P220, DOI 10.1097/00000658-199503000-00003; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Liberatore GT, 1999, NAT MED, V5, P1403; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; Mannick JB, 2002, ARCH BIOCHEM BIOPHYS, V408, P1, DOI 10.1016/S0003-9861(02)00490-3; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MCGEHEE RE, 1993, MOL ENDOCRINOL, V7, P551, DOI 10.1210/me.7.4.551; Montagnani M, 2002, J BIOL CHEM, V277, P1794, DOI 10.1074/jbc.M103728200; Nadler ST, 2001, AM J PHYSIOL-ENDOC M, V281, pE1249, DOI 10.1152/ajpendo.2001.281.6.E1249; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Park JH, 2002, J BIOL CHEM, V277, P47073, DOI 10.1074/jbc.M207053200; Patel RP, 2000, CARDIOVASC RES, V47, P465, DOI 10.1016/S0008-6363(00)00086-9; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; Sennlaub F, 2002, J NEUROSCI, V22, P3987, DOI 10.1523/JNEUROSCI.22-10-03987.2002; Shankar RR, 2000, DIABETES, V49, P684, DOI 10.2337/diabetes.49.5.684; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Song XM, 1999, AM J PHYSIOL-REG I, V277, pR1690, DOI 10.1152/ajpregu.1999.277.6.R1690; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; SUGITA H, 2002, AM J PHYSIOL, V282, pC386; SWISLOCKI A, 1995, AM J HYPERTENS, V8, P1009, DOI 10.1016/0895-7061(95)00161-1; Uddin S, 1997, BLOOD, V90, P2574; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wink DA, 2000, SEMIN PERINATOL, V24, P20, DOI 10.1016/S0146-0005(00)80049-X; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	60	201	209	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7511	7518		10.1074/jbc.M411871200	http://dx.doi.org/10.1074/jbc.M411871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632167	hybrid			2022-12-27	WOS:000227395700013
J	Maxwell, MA; Cleasby, ME; Harding, A; Stark, A; Cooney, GJ; Muscat, GEO				Maxwell, MA; Cleasby, ME; Harding, A; Stark, A; Cooney, GJ; Muscat, GEO			Nur77 regulates lipolysis in skeletal muscle cells - Evidence for cross-talk between the beta-adrenergic and an orphan nuclear hormone receptor pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIET-INDUCED THERMOGENESIS; FATTY-ACID; UNCOUPLING PROTEIN-3; MEDIATES TRANSACTIVATION; INSULIN-RESISTANCE; LIPID-METABOLISM; ADIPOSE-TISSUE; MESSENGER-RNA; UP-REGULATION; MICE	Skeletal muscle is a major mass peripheral tissue that accounts for similar to 40% of total body weight and 50% of energy expenditure and is a primary site of glucose disposal and fatty acid oxidation. Consequently, muscle has a significant role in insulin sensitivity, obesity, and the blood-lipid profile. Excessive caloric intake is sensed by the brain and induces beta-adrenergic receptor (beta-AR)- mediated adaptive thermogenesis. beta-AR null mice develop severe obesity on a high fat diet. However, the target gene(s), target tissues(s), and molecular mechanism involved remain obscure. We observed that 30 - 60 min of beta-AR agonist ( isoprenaline) treatment of C2C12 skeletal muscle cells strikingly activated (> 100-fold) the expression of the mRNA encoding the nuclear hormone receptor, Nur77. In contrast, the expression of other nuclear receptors that regulate lipid and carbohydrate metabolism was not induced. Stable transfection of Nur77-specific small interfering RNAs (siNur77) into skeletal muscle cells repressed endogenous Nur77 mRNA expression. Moreover, we observed attenuation of gene and protein expression associated with the regulation of energy expenditure and lipid homeostasis, for example AMP-activated protein kinase gamma 3, UCP3, CD36,adiponectin receptor 2, GLUT4, and caveolin-3. Attenuation of Nur77 expression resulted in decreased lipolysis. Finally, in concordance with the cell culture model, injection and electrotransfer of siNur77 into mouse tibialis cranialis muscle resulted in the repression of UCP3 mRNA expression. This study demonstrates regulatory cross-talk between the nuclear hormone receptor and beta-AR signaling pathways. Moreover, it suggests Nur77 modulates the expression of genes that are key regulators of skeletal muscle lipid and energy homeostasis. In conclusion, we speculate that Nur77 agonists would stimulate lipolysis and increase energy expenditure in skeletal muscle and suggest selective activators of Nur77 may have therapeutic utility in the treatment of obesity.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Div Mol Genet & Dev, St Lucia, Qld 4072, Australia; Univ Queensland, Div Mol Cell Biol, St Lucia, Qld 4072, Australia; Garvan Inst Med Res, Diabet & Obes Res Program, Darlinghurst, NSW 2010, Australia	University of Queensland; University of Queensland; University of Queensland; Garvan Institute of Medical Research	Muscat, GEO (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	g.muscat@imb.uq.edu.au	Harding, Angus/B-4120-2012; Muscat, George/A-6401-2017	Muscat, George/0000-0002-5829-5695				Arashiro R, 2003, PEDIATR INT, V45, P135, DOI 10.1046/j.1442-200X.2003.01685.x; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Barnes BR, 2004, J BIOL CHEM, V279, P38441, DOI 10.1074/jbc.M405533200; BING GY, 1991, MOL BRAIN RES, V11, P43, DOI 10.1016/0169-328X(91)90019-T; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Clapham JC, 2001, BIOCHEM BIOPH RES CO, V287, P1058, DOI 10.1006/bbrc.2001.5698; Collins S, 2004, MOL ENDOCRINOL, V18, P2123, DOI 10.1210/me.2004-0193; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Dulloo AG, 2001, BIOCHEM SOC T, V29, P785, DOI 10.1042/BST0290785; Ellsworth DL, 2002, INT J OBESITY, V26, P928, DOI 10.1038/sj.ijo.0802020; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Grimaldi PA, 1997, PROSTAG LEUKOTR ESS, V57, P71, DOI 10.1016/S0952-3278(97)90495-6; Hailstones D, 1998, J LIPID RES, V39, P369; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Heron-Milhavet L, 2004, ENDOCRINOLOGY, V145, P4667, DOI 10.1210/en.2003-1543; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Holst D, 2003, EXP CELL RES, V288, P168, DOI 10.1016/S0014-4827(03)00179-4; Holst D, 2003, BBA-MOL CELL BIOL L, V1633, P43, DOI 10.1016/S1388-1981(03)00071-4; Kim OY, 2004, INT J OBESITY, V28, P434, DOI 10.1038/sj.ijo.0802562; Lau P, 2004, J BIOL CHEM, V279, P36828, DOI 10.1074/jbc.M404927200; Lepretre Frederic, 2004, Hum Mutat, V24, P104, DOI 10.1002/humu.9256; LIM RW, 1995, BIOCHEM J, V308, P785, DOI 10.1042/bj3080785; Lowell BB, 2003, J BIOL CHEM, V278, P29385, DOI 10.1074/jbc.R300011200; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Ma XW, 2004, HUM MOL GENET, V13, P2197, DOI 10.1093/hmg/ddh233; Mahlapuu M, 2004, AM J PHYSIOL-ENDOC M, V286, pE194, DOI 10.1152/ajpendo.00147.2003; Martinez JA, 2003, J NUTR, V133, P2549, DOI 10.1093/jn/133.8.2549; Matsushita H, 2003, MATURITAS, V45, P39, DOI 10.1016/S0378-5122(03)00088-4; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V283, P785, DOI 10.1006/bbrc.2001.4848; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200; Okabe T, 1998, J ENDOCRINOL, V156, P169, DOI 10.1677/joe.0.1560169; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Ramakrishnan SN, 2005, J BIOL CHEM, V280, P8651, DOI 10.1074/jbc.M413949200; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Rosmond R, 2003, INT J OBESITY, V27, P1141, DOI 10.1038/sj.ijo.0802397; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; Shiwaku K, 2003, INT J OBESITY, V27, P1028, DOI 10.1038/sj.ijo.0802375; Song KH, 2002, ENDOCRINOLOGY, V143, P2208, DOI 10.1210/en.143.6.2208; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V258, P187, DOI 10.1006/bbrc.1999.0617; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wang S, 2002, ANN NY ACAD SCI, V967, P112; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yu HY, 2004, AM J PHYSIOL-CELL PH, V286, pC283, DOI 10.1152/ajpcell.00319.2003; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	60	135	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12573	12584		10.1074/jbc.M409580200	http://dx.doi.org/10.1074/jbc.M409580200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15640143	hybrid			2022-12-27	WOS:000227922000062
J	Bezy, O; Elabd, C; Cochet, O; Petersen, RK; Kristiansen, K; Dani, C; Ailhaud, R; Amri, EZ				Bezy, O; Elabd, C; Cochet, O; Petersen, RK; Kristiansen, K; Dani, C; Ailhaud, R; Amri, EZ			Delta-interacting protein A, a new inhibitory partner of CCAAT/enhancer-binding protein beta, implicated in adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CLONAL EXPANSION; GENE-EXPRESSION; C/EBP-BETA; LEUCINE-ZIPPER; ACTIVATION; PHOSPHORYLATION; TRANSCRIPTION; ORGANIZATION; GENERATION; ISOFORMS	CCAAT/enhancer-binding protein beta (C/EBP beta) is expressed early during the adipocyte differentiation program and plays an important role in this process. In an attempt to identify novel proteins that interact with C/EBP beta, we performed a yeast two-hybrid screen with a preadipocyte cDNA library and identified a new co-regulator, delta-interacting protein A (DIPA). DIPA mRNA is expressed during adipocyte differentiation of clonal cell lines. DIPA interacts with C/EBP beta and -delta proteins in intact cells and inhibits their transcriptional activity but not that of C/EBP alpha. Stable overexpression of DIPA in preadipocytes partially inhibits adipocyte differentiation, whereas its gene silencing enhances this process. DIPA and C/EBP beta co-localize in the nucleus, and overexpression of DIPA in preadipocytes results in a partial inhibition of the mitotic clonal expansion which is critical for differentiation. Thus, DIPA is a novel partner of C/EBP beta that down-regulates early events of adipogenesis.	Fac Sci, Inst Signaling Dev Biol & Canc Res, Ctr Biochim, UMR 6543 CNRS, F-06108 Nice, France; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	University of Southern Denmark	Amri, EZ (corresponding author), Fac Sci, Inst Signaling Dev Biol & Canc Res, Ctr Biochim, UMR 6543 CNRS, Parc Valrose, F-06108 Nice, France.	amri@unice.fr	Kristiansen, Karsten/J-5148-2014; DANI, Christian/G-3639-2014	Kristiansen, Karsten/0000-0002-6024-0917; DANI, Christian/0000-0003-3228-0230; amri, Ez-Zoubir/0000-0001-8426-5396; Bezy, Olivier/0000-0003-4367-5043				Abderrahim-Ferkoune A, 2003, J LIPID RES, V44, P994, DOI 10.1194/jlr.M200382-JLR200; Abderrahim-Ferkoune A, 2004, EXP CELL RES, V293, P219, DOI 10.1016/j.yexcr.2003.10.020; AMRI EZ, 1991, J LIPID RES, V32, P1449; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Elberg G, 2000, J BIOL CHEM, V275, P27815; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kubo Y, 2000, IN VITRO CELL DEV-AN, V36, P38; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Massiera F, 2003, J LIPID RES, V44, P271, DOI 10.1194/jlr.M200346-JLR200; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tong Q, 2001, Rev Endocr Metab Disord, V2, P349, DOI 10.1023/A:1011863414321; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Welm AL, 1999, MOL CELL BIOL, V19, P1695; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	42	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11432	11438		10.1074/jbc.M411741200	http://dx.doi.org/10.1074/jbc.M411741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644333	hybrid			2022-12-27	WOS:000227761800066
J	Morty, RE; Pelle, R; Vadasz, I; Uzcanga, GL; Seeger, W; Bubis, J				Morty, RE; Pelle, R; Vadasz, I; Uzcanga, GL; Seeger, W; Bubis, J			Oligopeptidase B from Trypanosoma evansi - A parasite peptidase that inactivates atrial natriuretic factor in the bloodstream of infected hosts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUCEI-BRUCEI; SERINE OLIGOPEPTIDASES; PROLYL OLIGOPEPTIDASE; AFRICAN TRYPANOSOMES; RAT; CRUZI; PURIFICATION; PROTEINASE; SPECIFICITY; CONGOLENSE	Serine oligopeptidases of trypanosomatids are emerging as important virulence factors and therapeutic targets in trypanosome infections. We report here the isolation and characterization of oligopeptidase B ( OpdB) and its corresponding gene from Trypanosoma evansi, a pathogen of significant veterinary importance. The T. evansi opdB gene was present as a single copy per haploid genome containing an open reading frame of 2148 bp encoding a protein of 80.664 kDa. Purified OpdB hydrolyzed substrates with basic residues in P-1 ( k(cat)/ Km for carbobenzyloxy-(L)-arginyl-(L)-arginyl-7-amido-4-methylcoumarin, 337s(-1.)mu M-1) and exhibited potent arginyl carboxypeptidase activity ( kcat/ Km for Val-Lys-Arg down arrow Arg-OH, 231 s(-1.)mM(-1)). While not secreted, T. evansi released OpdB into the plasma of infected hosts where it retained catalytic activity. Plasma OpdB levels correlated with blood parasitemia. In vitro, OpdB cleaved the peptide hormone atrial natriuretic factor (ANF) at four sites: Arg(3)down arrow Arg(4), Arg(4)down arrow Ser(5), Arg(11)down arrow Ile(12), and Arg(27)down arrow Tyr(28), thereby abrogating smooth muscle relaxant and prohypotensive properties of ANF. Circulating plasma ANF levels in T. evansi-infected rats were depressed from 130 to 8 pg(.)ml(-1), and plasma ANF levels inversely correlated with plasma OpdB activity. The in vitro half-life of ANF in rat plasma was reduced 300-fold in plasma from T. evansi-infected rodents, which contains high levels of OpdB activity. Addition of OpdB inhibitors to cell-free plasma from infected rodents significantly abrogated this ANF hydrolysis. Furthermore the in vivo ANF half-life was reduced 5-fold in T. evansi-infected rats. Thus, we propose a role for OpdB in peptide hormone dysregulation in trypanosomiasis, specifically in generating the depressed plasma levels of ANF in mammals infected with T. evansi.	Univ Giessen, Ctr Med, Dept Internal Med, D-35392 Giessen, Germany; Int Livestock Res Inst, Nairobi, Kenya; Univ Simon Bolivar, Dept Biol Celular, Caracas 1081A, Venezuela	Justus Liebig University Giessen; CGIAR; International Livestock Research Institute (ILRI); Simon Bolivar University	Morty, RE (corresponding author), Univ Giessen, Ctr Med, Dept Internal Med, Aulweg 123,Raum 6-11, D-35392 Giessen, Germany.	rory.morty@innere.med.uni-giessen.giessen.de	Vadasz, Istvan/AAO-8288-2021	Uzcanga, Graciela Lucia/0000-0003-1680-2086; Vadasz, Istvan/0000-0003-1370-9783; Bubis, Jose/0000-0002-8839-6745; Seeger, Werner/0000-0003-1946-0894				ABEBE G, 1993, ACTA ENDOCRINOL-COP, V129, P75, DOI 10.1530/acta.0.1290075; Aiyar A, 2000, Methods Mol Biol, V132, P221; ANOSA V O, 1976, Tropical Animal Health and Production, V8, P14, DOI 10.1007/BF02383360; Biswas D, 2001, EXP PARASITOL, V99, P148, DOI 10.1006/expr.2001.4664; BOREHAM PFL, 1976, BRIT J PHARMACOL, V58, P137, DOI 10.1111/j.1476-5381.1976.tb07702.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brun R, 1998, VET PARASITOL, V79, P95, DOI 10.1016/S0304-4017(98)00146-0; Burleigh BA, 1997, J CELL BIOL, V136, P609, DOI 10.1083/jcb.136.3.609; CONDRA CL, 1988, J CLIN INVEST, V81, P1348, DOI 10.1172/JCI113462; DEBOLD AJ, 1982, P SOC EXP BIOL MED, V170, P133; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; Desquesnes M, 1996, Rev Elev Med Vet Pays Trop, V49, P322; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Goossens B, 1998, VET PARASITOL, V79, P283, DOI 10.1016/S0304-4017(98)00171-X; GRAB DJ, 1987, J CELL BIOL, V105, P737, DOI 10.1083/jcb.105.2.737; Grellier P, 2001, J BIOL CHEM, V276, P47078, DOI 10.1074/jbc.M106017200; GROS C, 1990, EUR J PHARMACOL, V179, P45, DOI 10.1016/0014-2999(90)90400-Z; HARRIS P, 1987, BRIT HEART J, V58, P190; Hemerly JP, 2003, BIOCHEM J, V373, P933, DOI 10.1042/BJ20030342; Hermanson G. T., 1992, IMMOBILIZED AFFINITY; HEUMANN D, 1989, MOL BIOCHEM PARASIT, V33, P67, DOI 10.1016/0166-6851(89)90043-1; Hoare C, 1972, TRYPANOSOMES MAMMALS; HUBLART M, 1990, ACTA TROP, V47, P177, DOI 10.1016/0001-706X(90)90024-T; Jaffe CL, 2003, PARASITOL RES, V91, P229, DOI 10.1007/s00436-003-0960-0; LONSDALEECCLES JD, 1995, BIOCHEM J, V305, P549, DOI 10.1042/bj3050549; LUBBESMEYER HJ, 1988, AM J PHYSIOL, V254, pR567, DOI 10.1152/ajpregu.1988.254.4.R567; Maack T, 1996, KIDNEY INT, V49, P1732, DOI 10.1038/ki.1996.257; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Mackey ZB, 2004, J BIOL CHEM, V279, P48426, DOI 10.1074/jbc.M402470200; Maugeri DA, 2004, FEMS MICROBIOL LETT, V234, P117, DOI 10.1016/j.femsle.2004.03.018; MISONO KS, 1984, BIOCHEM BIOPH RES CO, V123, P444, DOI 10.1016/0006-291X(84)90250-X; MORRISON WI, 1981, AM J PATHOL, V102, P168; Morty RE, 1999, J BIOL CHEM, V274, P26149, DOI 10.1074/jbc.274.37.26149; Morty RE, 1999, MOL BIOCHEM PARASIT, V102, P145, DOI 10.1016/S0166-6851(99)00097-3; Morty RE, 2002, J BACTERIOL, V184, P3329, DOI 10.1128/JB.184.12.3329-3337.2002; Morty RE, 2001, INFECT IMMUN, V69, P2757, DOI 10.1128/IAI.69.4.2757-2761.2001; MURTHY KK, 1988, BIOCHEM J, V250, P665, DOI 10.1042/bj2500665; NDUNGU JM, 1991, J SMALL ANIM PRACT, V32, P579, DOI 10.1111/j.1748-5827.1991.tb00891.x; NDUNGU JM, 1992, PARASITOL RES, V78, P553, DOI 10.1007/BF00936451; Okenu DMN, 1999, PARASITOL RES, V85, P424, DOI 10.1007/s004360050571; OLINS GM, 1987, BIOCHIM BIOPHYS ACTA, V901, P97, DOI 10.1016/0005-2736(87)90260-4; PELLE R, 1993, MOL BIOCHEM PARASIT, V59, P277, DOI 10.1016/0166-6851(93)90225-M; Rao MR, 1998, DRUG CHEM TOXICOL, V21, P27, DOI 10.3109/01480549809017848; SANTANA JM, 1992, BIOCHEM BIOPH RES CO, V187, P1466, DOI 10.1016/0006-291X(92)90467-Y; Santana JM, 1997, BIOCHEM J, V325, P129, DOI 10.1042/bj3250129; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Simonsen U, 1999, J PHYSIOL-LONDON, V516, P271, DOI 10.1111/j.1469-7793.1999.271aa.x; SOUDAN B, 1993, EXP CLIN ENDOCRINOL, V101, P166, DOI 10.1055/s-0029-1211225; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; SUGIMOTO K, 1992, AGENT ACTION SUPPL, V38, P376; SUGIYAMA M, 1984, BIOCHEM BIOPH RES CO, V123, P338, DOI 10.1016/0006-291X(84)90418-2; TETAERT D, 1993, INT J PEPT PROT RES, V41, P147; THIBAULT G, 1985, BIOCHEM BIOPH RES CO, V130, P981, DOI 10.1016/0006-291X(85)91711-5; THIBAULT G, 1984, BIOCHEM BIOPH RES CO, V125, P938, DOI 10.1016/0006-291X(84)91374-3; TIZARD I, 1978, MICROBIOL REV, V42, P661, DOI 10.1128/MMBR.42.4.664-681.1978; Troeberg L, 1999, EXP PARASITOL, V91, P349, DOI 10.1006/expr.1998.4386; Troeberg L, 1996, EUR J BIOCHEM, V238, P728, DOI 10.1111/j.1432-1033.1996.0728w.x; Wise W C, 1989, Prog Clin Biol Res, V299, P243; Yamaguchi K, 2000, SHOCK, V14, P535, DOI 10.1097/00024382-200014050-00007	61	55	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10925	10937		10.1074/jbc.M410066200	http://dx.doi.org/10.1074/jbc.M410066200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644339	hybrid			2022-12-27	WOS:000227761800008
J	Ownby, K; Xu, HM; White, RH				Ownby, K; Xu, HM; White, RH			A Methanocaldococcus jannaschii archaeal signature gene encodes for a 5-formaminoimidazole-4-carboxamide-1 beta-D-ribofuranosyl 5 '-monophosphate synthetase - A new enzyme in purine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMATE-UTILIZING METHANOGEN; METHANOCOCCUS-JANNASCHII; ESCHERICHIA-COLI; FORMYL PHOSPHATE; COENZYME-M; FORMYLTETRAHYDROFOLATE SYNTHETASE; METHANOBACTERIUM-FORMICICUM; TRANSFORMYLASE; DEHYDROGENASE; PURIFICATION	We have identified and characterized a new member of the ATP-grasp enzyme family that catalyzes the ATP- and formate-dependent formylation of 5-aminoimidazole-4-carboxamide-1- -1-beta-D-ribofuranosyl 5'-monophosphate (AICAR) to 5-formaminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5'-monophosphate (FAICAR) in the absence of folates. The enzyme, which we designate as PurP, is the product of the Methanocaldococcus jannaschii purP gene (MJ0136), which is a signature gene for Archaea. As is characteristic of reactions catalyzed by this family of enzymes, the other products of the reaction, ADP and P-i, were produced stoichiometrically with the amount of ATP, formate, and AICAR used. Formyl phosphate was found to substitute for ATP and formate in the reaction, yet the methylene analog, phosphonoacetaldehyde, was not an inhibitor or substrate for the reaction. The enzyme, along with PurO, which catalyzes the cyclization of FAICAR to inosine 5'-monophosphate, catalyzes the same overall transformation in purine biosynthesis as is accomplished by PurH in bacteria and eukaryotes. No homology exists between PurH and either PurO or PurP. H-1 NMR and gas chromatography-mass spectrometry analysis of an M. jannaschii cell extract showed the presence of free formate that can be used by the enzyme for purine biosynthesis. This formate arises by the reduction of CO2 with hydrogen; this was demonstrated by incorporating C-13 into the formate when M. jannaschii cell extracts were incubated with (HCO3-)-C-13 and hydrogen gas. The presence of this signature gene in all of the Archaea indicates the presence of a purine biosynthetic pathway proceeding in the absence of folate coenzymes.	Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	White, RH (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem, 103 Engel Hall 0308, Blacksburg, VA 24061 USA.	rhwhite@vt.edu						BARON SF, 1989, J BACTERIOL, V171, P3846, DOI 10.1128/jb.171.7.3846-3853.1989; BARON SF, 1989, J BACTERIOL, V171, P3854, DOI 10.1128/jb.171.7.3854-3859.1989; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; EGUCHI SY, 1985, APPL MICROBIOL BIOT, V22, P148; FLAKS JG, 1957, J BIOL CHEM, V229, P603; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gill MS, 1997, J ORG CHEM, V62, P7351, DOI 10.1021/jo970904b; Gladyshev VN, 1996, J BIOL CHEM, V271, P8095, DOI 10.1074/jbc.271.14.8095; Graham DE, 2000, P NATL ACAD SCI USA, V97, P3304, DOI 10.1073/pnas.050564797; Graupner M, 2000, J BACTERIOL, V182, P3688, DOI 10.1128/JB.182.13.3688-3692.2000; Graupner M, 2002, J BACTERIOL, V184, P1471, DOI 10.1128/JB.184.5.1471-1473.2002; Graupner M, 2001, BIOCHEMISTRY-US, V40, P10859, DOI 10.1021/bi0107703; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; GUNSALUS RP, 1978, BIOCHEMISTRY-US, V17, P2374, DOI 10.1021/bi00605a019; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; HUTTEN TJ, 1981, J BACTERIOL, V145, P27, DOI 10.1128/JB.145.1.27-34.1981; JONES JB, 1979, ARCH BIOCHEM BIOPHYS, V195, P255, DOI 10.1016/0003-9861(79)90351-5; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Kage S, 2004, J CHROMATOGR B, V805, P113, DOI 10.1016/j.jchromb.2004.02.029; Kappock TJ, 2000, CURR OPIN CHEM BIOL, V4, P567, DOI 10.1016/S1367-5931(00)00133-2; Koike H, 1999, P JPN ACAD B-PHYS, V75, P263, DOI 10.2183/pjab.75.263; Koonin EV, 1998, CURR OPIN STRUC BIOL, V8, P355, DOI 10.1016/S0959-440X(98)80070-5; Kunkel A, 1998, EUR J BIOCHEM, V252, P467, DOI 10.1046/j.1432-1327.1998.2520467.x; Li H, 2003, BIOCHEMISTRY-US, V42, P9771, DOI 10.1021/bi034779b; Li H, 2003, J BIOL CHEM, V278, P11100, DOI 10.1074/jbc.M212460200; LOVLEY DR, 1984, APPL ENVIRON MICROB, V48, P81, DOI 10.1128/AEM.48.1.81-87.1984; Maden BEH, 2000, BIOCHEM J, V350, P609, DOI 10.1042/0264-6021:3500609; Makarova KS, 1999, GENOME RES, V9, P608; MAROLEWSKI A, 1994, BIOCHEMISTRY-US, V33, P2531, DOI 10.1021/bi00175a023; Marolewski AE, 1997, BIOCHEMISTRY-US, V36, P6709, DOI 10.1021/bi962961p; MEJILLANO MR, 1989, BIOCHEMISTRY-US, V28, P5136, DOI 10.1021/bi00438a034; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; NISHIO N, 1983, J FERMENT TECHNOL, V61, P557; PHAM DN, 1993, BIOCHEMISTRY-US, V32, P13725, DOI 10.1021/bi00212a043; Pomper BK, 2002, FEBS LETT, V523, P133, DOI 10.1016/S0014-5793(02)02962-9; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; SELKOV E, 1997, GENE, V197, P11; SMITH MR, 1983, J BACTERIOL, V156, P516, DOI 10.1128/JB.156.2.516-523.1983; SMITHERS GW, 1987, BIOCHEMISTRY-US, V26, P3943, DOI 10.1021/bi00387a030; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; STEWART V, 1988, MICROBIOL REV, V52, P190, DOI 10.1128/MMBR.52.2.190-232.1988; White RH, 2004, BIOCHEMISTRY-US, V43, P7618, DOI 10.1021/bi0495127; White RH, 1997, J BACTERIOL, V179, P3374, DOI 10.1128/jb.179.10.3374-3377.1997	44	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10881	10887		10.1074/jbc.M413937200	http://dx.doi.org/10.1074/jbc.M413937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15623504	hybrid			2022-12-27	WOS:000227761800003
J	Archer-Lahlou, E; Escrieut, C; Clerc, P; Martinez, J; Moroder, L; Logsdon, C; Kopin, A; Seva, C; Dufresne, M; Pradayrol, L; Maigret, B; Fourmy, D				Archer-Lahlou, E; Escrieut, C; Clerc, P; Martinez, J; Moroder, L; Logsdon, C; Kopin, A; Seva, C; Dufresne, M; Pradayrol, L; Maigret, B; Fourmy, D			Molecular mechanism underlying partial and full agonism mediated by the human cholecystokinin-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; BINDING SITES; CONFORMATIONAL-CHANGES; ENZYME-SECRETION; ACTIVATION; BETA(2)-ADRENOCEPTOR; INTERACTS; RHODOPSIN; ANALOGS	The cholecystokinin-1 receptor (CCK1R) is a G protein-coupled receptor ( GPCR) that regulates important physiological functions. As for other GPCRs, the molecular basis of full and partial agonism is still far from clearly understood. In the present report, using both laboratory experiments and molecular modeling approaches, we have investigated the partial agonism mechanism of JMV 180, on the human CCK1R. We first showed that efficacy of the CCK1R to activate phospholipase C is dependent on the correct orientation of the C-terminal end of peptidic ligands toward residue Phe(330) of helix VI. We have previously reported that a single mutation of Met(121) ( helix III) markedly reduced the receptor-mediated inositol phosphate production upon stimulation by CCK. Computational simulations predicted that residue 121 affected orientation of the C-terminal end of CCK, thus suggesting that the molecular complex with a reduced inositol phosphate production observed with the mutated CCK1R resembles that resulting from binding of JMV 180 to the WT-CCK1R. Pharmacological, biochemical, and functional characterizations of the two receptor ligand complexes with decreased abilities to signal were carried out in different cell types. We found that they presented the same features, such as total dependence of inositol phosphate production to G alpha(q) expression, single affinity of binding sites, insensitivity of binding to non-hydrolyzable GTP, absence of GTP gamma[S-35] binding following agonist stimulation, similarity of dose-response curves for amylase secretion, and incapacity to induce acute pancreatitis in pancreatic acini. We concluded that helices VI and III of the CCK1R are functionally linked through the CCK1R agonist binding site and that positioning of the C-terminal ends of peptidic agonists toward Phe(330) of helix VI is responsible for extent of phospholipase C activation through G alpha(q) coupling. Given the potential therapeutic interest of partial agonists such as JMV 180, our structural data will serve for target structure-based design of new CCK1R ligands.	CHU Rangueil, INSERM, U531, F-31059 Toulouse, France; CNRS, UMR 5810, F-34093 Montpellier, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Res Ctr, Dept Med & Mol Pharmacol, Boston, MA 02111 USA; Univ Henri Poincare, CNRS, F-54506 Vandoeuvre Les Nancy, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Max Planck Society; University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Fourmy, D (corresponding author), CHU Rangueil, INSERM, U531, Bat L3,TSA 50032, F-31059 Toulouse, France.	Daniel.Fourmy@toulouse.inserm.fr	Martinez, Jean/R-9421-2019; Fourmy, Daniel/AAE-3703-2019; SEVA, Catherine/O-9166-2014; Dufresne, Marlène/M-6332-2014	Martinez, Jean/0000-0002-9267-4621; Fourmy, Daniel/0000-0001-9910-4827; SEVA, Catherine/0000-0002-4265-7372; Moroder, Luis/0000-0001-9570-5713				Archer-Lahlou E, 2005, J MED CHEM, V48, P180, DOI 10.1021/jm049886y; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Clark RB, 1999, TRENDS PHARMACOL SCI, V20, P279, DOI 10.1016/S0165-6147(99)01351-6; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Escrieut C, 2002, J BIOL CHEM, V277, P7546, DOI 10.1074/jbc.M108563200; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FONG TM, 1994, MED RES REV, V14, P387, DOI 10.1002/med.2610140402; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; Fourmy D, 2002, PHARMACOL TOXICOL, V91, P313, DOI 10.1034/j.1600-0773.2002.910608.x; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gershengorn MC, 2001, ENDOCRINOLOGY, V142, P2, DOI 10.1210/en.142.1.2; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Gigoux V, 1999, PROTEIN SCI, V8, P2347; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Ji BA, 2000, J BIOL CHEM, V275, P19115, DOI 10.1074/jbc.M001685200; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MARTINEZ J, 1986, J MED CHEM, V29, P2201, DOI 10.1021/jm00161a012; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; Noble F, 1999, PHARMACOL REV, V51, P745; Pommier B, 2003, J NEUROCHEM, V85, P454, DOI 10.1046/j.1471-4159.2003.01690.x; Poosti R, 2000, MOL PHARMACOL, V58, P1381, DOI 10.1124/mol.58.6.1381; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SALUJA AK, 1989, P NATL ACAD SCI USA, V86, P8968, DOI 10.1073/pnas.86.22.8968; Schwartz TW, 1996, TRENDS PHARMACOL SCI, V17, P213, DOI 10.1016/0165-6147(96)10017-1; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Weiss JM, 1996, J THEOR BIOL, V181, P381, DOI 10.1006/jtbi.1996.0139; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701; Yu PR, 1998, AM J PHYSIOL-GASTR L, V275, pG203, DOI 10.1152/ajpgi.1998.275.2.G203; YULE DI, 1993, AM J PHYSIOL, V265, pG999, DOI 10.1152/ajpgi.1993.265.5.G999	46	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10664	10674		10.1074/jbc.M409451200	http://dx.doi.org/10.1074/jbc.M409451200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632187	hybrid			2022-12-27	WOS:000227559600112
J	Panchal, RG; Halverson, KM; Ribot, W; Lane, D; Kenny, T; Abshire, TG; Ezzell, JW; Hoover, TA; Powell, B; Little, S; Kasianowicz, JJ; Bavari, S				Panchal, RG; Halverson, KM; Ribot, W; Lane, D; Kenny, T; Abshire, TG; Ezzell, JW; Hoover, TA; Powell, B; Little, S; Kasianowicz, JJ; Bavari, S			Purified Bacillus anthracis lethal toxin complex formed in Vitro and during infection exhibits functional and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTIVE ANTIGEN COMPONENT; PROTEIN-KINASE KINASE; PLANAR LIPID-BILAYERS; PROTEOLYTIC INACTIVATION; MAMMALIAN-CELLS; FACTOR CLEAVES; EDEMA FACTOR; N-TERMINUS; MEMBRANE; CHANNEL	Anthrax protective antigen (PA, 83 kDa), a pore-forming protein, upon protease activation to 63 kDa (PA(63)), translocates lethal factor (LF) and edema factor (EF) from endosomes into the cytosol of the cell. The relatively small size of the heptameric PA(63) pore (similar to 12 angstrom) raises questions as to how large molecules such as LF and EF can move through the pore. In addition, the reported high binding affinity between PA and EF/LF suggests that EF/LF may not dissociate but remain complexed with activated PA(63). In this study, we found that purified (PA(63))(7)-LF complex exhibited biological and functional activities similar to the free LF. Purified LF complexed with PA(63) heptamer was able to cleave both a synthetic peptide substrate and endogenous mitogen-activated protein kinase kinase substrates and kill susceptible macrophage cells. Electrophysiological studies of the complex showed strong rectification of the ionic current at positive voltages, an effect similar to that observed if LF is added to the channels formed by heptameric PA(63) pore. Complexes of (PA(63))(7)-LF found in the plasma of infected animals showed functional activity. Identifying active complex in the blood of infected animals has important implications for therapeutic design, especially those directed against PA and LF. Our studies suggest that the individual toxin components and the complex must be considered as critical targets for anthrax therapeutics.	USAMRIID, Frederick, MD 21702 USA; NCI SAIC Frederick, NIH, Dev Therapeut Program, Target Struct Based Drug Discovery Grp, Frederick, MD 21702 USA; NIST, Gaithersburg, MD 20899 USA	United States Army Medical Research Institute of Infectious Diseases; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institute of Standards & Technology (NIST) - USA	Panchal, RG (corresponding author), USAMRIID, 1425 Porter St, Frederick, MD 21702 USA.	rekha.panchal@amedd.army.mil; sina.bavari@amedd.army.mil	Bavari, Sina/L-3642-2019; Panchal, Rekha/None	Bavari, Sina/0000-0001-8424-5635; Ribot, Wilson/0000-0002-9691-4004; Panchal, Rekha/0000-0001-8621-9078				Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072; Agrawal A, 2003, NATURE, V424, P329, DOI 10.1038/nature01794; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P905, DOI 10.1085/jgp.96.5.905; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Di Marzio EA, 2003, J CHEM PHYS, V119, P6378, DOI 10.1063/1.1603725; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Duesbery NS, 1999, CELL MOL LIFE SCI, V55, P1599, DOI 10.1007/s000180050399; Duesbery NS, 1999, J APPL MICROBIOL, V87, P289, DOI 10.1046/j.1365-2672.1999.00892.x; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; Erwin JL, 2001, INFECT IMMUN, V69, P1175, DOI 10.1128/IAI.69.2.1175-1177.2001; EZZELL JW, 1992, J GEN MICROBIOL, V138, P543, DOI 10.1099/00221287-138-3-543; FINKELSTEIN A, 1994, TOXICOLOGY, V87, P29, DOI 10.1016/0300-483X(94)90153-8; KASIANOWICZ JJ, 1995, BIOPHYS J, V69, P94, DOI 10.1016/S0006-3495(95)79879-4; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LITTLE SF, 1988, INFECT IMMUN, V56, P1807, DOI 10.1128/IAI.56.7.1807-1813.1988; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Nguyen TL, 2004, J BIOMOL STRUCT DYN, V22, P253, DOI 10.1080/07391102.2004.10531226; Panchal RG, 2004, NAT STRUCT MOL BIOL, V11, P67, DOI 10.1038/nsmb711; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Pellizzari R, 2000, INT J MED MICROBIOL, V290, P421; Popov SG, 2002, FEBS LETT, V527, P211, DOI 10.1016/S0014-5793(02)03228-3; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Singh Y, 1999, INFECT IMMUN, V67, P1853; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Zhang S, 2004, BIOPHYS J, V87, P3842, DOI 10.1529/biophysj.104.050864; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	37	47	49	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10834	10839		10.1074/jbc.M412210200	http://dx.doi.org/10.1074/jbc.M412210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644338	hybrid			2022-12-27	WOS:000227559600131
J	Stark, GR				Stark, GR			My life in science, not the restaurant business	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Biographical-Item									Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA.	starkg@ccf.org							0	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9753	9760		10.1074/jbc.X400011200	http://dx.doi.org/10.1074/jbc.X400011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632125	hybrid			2022-12-27	WOS:000227559600001
J	Yang, CS; Yu, CC; Chuang, HC; Chang, CW; Chang, GD; Yao, TP; Chen, HW				Yang, CS; Yu, CC; Chuang, HC; Chang, CW; Chang, GD; Yao, TP; Chen, HW			FBW2 targets GCMa to the ubiquitin-proteasome degradation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; DNA-BINDING; C-MYC; PROTEIN STABILITY; BETA-CATENIN; CELLS; DROSOPHILA; LIGASE; SKP2; EXPRESSION	The GCM proteins GCMa/1 and GCMb/2 are novel zinc-containing transcription factors critical for glial cell differentiation in fly and for placental as well as parathyroid gland development in mouse. Previous pulse-chase experiments have demonstrated differential protein stabilities of GCM proteins with half-lives from similar to 30 min to 2 h (Tuerk, E. E., Schreiber, J., and Wegner, M. (2000) J. Biol. Chem. 275, 4774-4782). However, little is known about the machinery that controls GCM protein degradation. Here, we report the identification of an SCF complex as the GCM ubiquitin-protein isopeptide ligase (E3) that regulates human GCMa (hGCMa) degradation. We found that SKP1 and CUL1, two key components of the SCF complex, associate with hGCMa in vivo. We further identify the human F-box protein FBW2 (hFBW2) as the substrate recognition subunit in the SCF E3 complex for hGCMa. We show that hFBW2 interacts with hGCMa in a phosphorylation-dependent manner and promotes hGCMa ubiquitination. Supporting a critical role for hFBW2 in hGCMa degradation, knockdown of hFBW2 expression by RNA interference leads to a reduction in hGCMa ubiquitination and a concomitant increase in hGCMa protein stability. Our study identifies the SCFhFBW2 E3 complex as the key machinery that targets hGCMa to the ubiquitin-proteasome degradation system.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 106, Taiwan; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Academia Sinica - Taiwan; National Taiwan University; Duke University	Chen, HW (corresponding author), Acad Sinica, Inst Biol Chem, Rm 609,128 Acad Rd,Sect 2, Taipei 115, Taiwan.	hwchen@gate.sinica.edu.tw	Chang, Ching-Wen/N-7867-2018	Chang, Ching-Wen/0000-0002-5693-3809				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Alfonso TB, 2002, DEV BIOL, V248, P369, DOI 10.1006/dbio.2002.0740; Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Basyuk E, 1999, DEV DYNAM, V214, P303, DOI 10.1002/(SICI)1097-0177(199904)214:4<303::AID-AJA3>3.3.CO;2-2; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen CP, 2004, PLACENTA, V25, P413, DOI 10.1016/j.placenta.2003.10.014; Cohen SX, 2003, EMBO J, V22, P1835, DOI 10.1093/emboj/cdg182; Gunther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kammerer M, 2001, EMBO J, V20, P4664, DOI 10.1093/emboj/20.17.4664; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Schreiber J, 1998, NUCLEIC ACIDS RES, V26, P2337, DOI 10.1093/nar/26.10.2337; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tuerk EE, 2000, J BIOL CHEM, V275, P4774, DOI 10.1074/jbc.275.7.4774; Van de Bor V, 2002, CURR OPIN GENET DEV, V12, P465, DOI 10.1016/S0959-437X(02)00327-1; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamada K, 1999, J BIOL CHEM, V274, P32279, DOI 10.1074/jbc.274.45.32279; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200	40	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10083	10090		10.1074/jbc.M413986200	http://dx.doi.org/10.1074/jbc.M413986200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640526	hybrid, Green Published			2022-12-27	WOS:000227559600043
J	Zhong, HL; Takeda, A; Nazari, R; Shio, H; Blobel, G; Yaseen, NR				Zhong, HL; Takeda, A; Nazari, R; Shio, H; Blobel, G; Yaseen, NR			Carrier-independent nuclear import of the transcription factor PU.1 via RanGTP-stimulated binding to Nup153	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; PORE COMPLEX PROTEIN; PUTATIVE ONCOGENE; BETA-CATENIN; C/EBP-BETA; PHOSPHORYLATION; NUCLEOPORIN; EXPORT; TRANSLOCATION; LOCALIZATION	PU.1 is a transcription factor of the Ets family with important functions in hematopoietic cell differentiation. Using green fluorescent protein-PU.1 fusions, we show that the Ets DNA binding domain of PU.1 is necessary and sufficient for its nuclear localization. Fluorescence and ultrastructural nuclear import assays showed that PU.1 nuclear import requires energy but not soluble carriers. PU.1 interacted directly with two nucleoporins, Nup62 and Nup153. The binding of PU.1 to Nup153, but not to Nup62, increased dramatically in the presence of RanGMPPNP, indicating the formation of a PU.1 (.) RanGTP (.) Nup153 complex. The Ets domain accounted for the bulk of the interaction of PU.1 with Nup153 and RanGMPPNP. Because Nup62 is located close to the midplane of the nuclear pore complex whereas Nup153 is at its nuclear side, these findings suggest a model whereby RanGTP propels PU.1 toward the nuclear side of the nuclear pore complex by increasing its affinity for Nup153. This notion was confirmed by ultrastructural studies using gold-labeled PU.1 in permeabilized cells.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Bioimaging Resource Ctr, New York, NY 10021 USA	Northwestern University; Feinberg School of Medicine; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	Yaseen, NR (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	n-yaseen@northwestern.edu		Yaseen, Nabeel/0000-0001-6902-5116	NCI NIH HHS [CA 93873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA093873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Anderson MK, 1999, DEVELOPMENT, V126, P3131; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Bibak N, 2004, ANAL BIOCHEM, V333, P57, DOI 10.1016/j.ab.2004.06.017; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Dahl R, 2003, BLOOD CELL MOL DIS, V31, P229, DOI 10.1016/S1079-9796(03)00152-9; Dimaano C, 2001, J BIOL CHEM, V276, P45349, DOI 10.1074/jbc.M102592200; Dohner K, 2003, BLOOD, V102, P3850, DOI 10.1182/blood-2003-08-2654; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fahrenkrog B, 2002, J STRUCT BIOL, V140, P254, DOI 10.1016/S1047-8477(02)00524-5; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fontoura BMA, 2000, J BIOL CHEM, V275, P31289, DOI 10.1074/jbc.M004651200; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gustin KE, 2002, J VIROL, V76, P8787, DOI 10.1128/JVI.76.17.8787-8796.2002; Gustin KE, 2001, EMBO J, V20, P240, DOI 10.1093/emboj/20.1.240; Iida H, 2000, INT J HEMATOL, V71, P153; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Joo M, 2004, J BIOL CHEM, V279, P6658, DOI 10.1074/jbc.M306267200; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kose S, 1999, FEBS LETT, V463, P327, DOI 10.1016/S0014-5793(99)01641-5; Kuersten S, 2002, MOL CELL BIOL, V22, P5708, DOI 10.1128/MCB.22.16.5708-5720.2002; Lamandin C, 2002, BLOOD, V100, P4680, DOI 10.1182/blood-2002-08-2563; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Lloberas J, 1999, IMMUNOL TODAY, V20, P184, DOI 10.1016/S0167-5699(99)01442-5; Lodie TA, 1997, J IMMUNOL, V158, P1848; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Mazzi P, 2004, J IMMUNOL, V172, P4941, DOI 10.4049/jimmunol.172.8.4941; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Mizuki M, 2003, BLOOD, V101, P3164, DOI 10.1182/blood-2002-06-1677; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Panopoulos AD, 2002, J BIOL CHEM, V277, P19001, DOI 10.1074/jbc.M112271200; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RAY D, 1990, ONCOGENE, V5, P663; Ribbeck K, 2002, EMBO J, V21, P2664, DOI 10.1093/emboj/21.11.2664; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Rieske P, 2001, J BIOL CHEM, V276, P8460, DOI 10.1074/jbc.M007482200; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Suh EK, 2003, EXP CELL RES, V290, P447, DOI 10.1016/S0014-4827(03)00370-7; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Warren LA, 2003, CURR OPIN IMMUNOL, V15, P166, DOI 10.1016/S0952-7915(03)00011-6; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978	72	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10675	10682		10.1074/jbc.M412878200	http://dx.doi.org/10.1074/jbc.M412878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632149	hybrid			2022-12-27	WOS:000227559600113
J	Ghatak, S; Misra, S; Toole, BP				Ghatak, S; Misra, S; Toole, BP			Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; LIPID RAFTS; CD44 INTERACTION; SOLUBLE CD44; SURFACE CD44; TUMOR-CELLS; IN-VIVO; ACTIVATION; EMMPRIN; PROTEIN	Hyaluronan is enriched in many types of human cancers, and manipulations of hyaluronan expression or interactions have a major influence on tumor progression in animal models. Increased ErbB2 activity is characteristic of several cancers and is responsible for many aspects of malignant cell behavior in these cancers. In this study we show that constitutively high levels of active, i.e. autophosphorylated, ErbB2 in HCT116 colon carcinoma cells and TA3/St mammary carcinoma cells are dependent on endogenous hyaluronan-CD44 interaction. Dependence on hyaluronan-CD44 interaction was demonstrated by the administration of hyaluronan oligomers, experimentally induced expression of soluble CD44, and small interfering RNA knockdown of CD44 expression. On the other hand, increasing hyaluronan production by overexpression of hyaluronan synthase 2 or emmprin causes elevated ErbB2 phosphorylation in MCF-7 mammary carcinoma cells, which normally exhibit low levels of ErbB2 activity. Furthermore, in HCT116 and TA3/St cells, inhibition of endogenous hyaluronan-CD44 interaction causes disassembly of a constitutive, lipid raft-associated, signaling complex containing phosphorylated ErbB2, CD44, ezrin, phosphoinositide 3-kinase, and the chaperone molecules, Hsp90 and cdc37. Stimulation of hyaluronan production in MCF-7 cells induces assembly of this complex. We conclude that hyaluronan regulates ErbB2 activity and its interactions with other signaling factors in carcinoma cells.	Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	Medical University of South Carolina	Toole, BP (corresponding author), Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA.	ghatak@musc.edu; toolebp@musc.edu			NCI NIH HHS [CA79866, CA73839] Funding Source: Medline; NCRR NIH HHS [RR-17698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073839, R01CA079866] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017698] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BISWAS C, 1995, CANCER RES, V55, P434; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Chen JS, 2003, DRUG RESIST UPDATE, V6, P129, DOI 10.1016/S1368-7646(03)00040-2; Citri A, 2004, CELL CYCLE, V3, P51; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Hommelgaard AM, 2004, MOL BIOL CELL, V15, P1557, DOI 10.1091/mbc.E03-08-0596; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Lesley J, 2000, J BIOL CHEM, V275, P26967; Li RS, 2001, J CELL PHYSIOL, V186, P371, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8; Luke HJ, 1999, BIOCHEM J, V343, P71, DOI 10.1042/0264-6021:3430071; Marieb EA, 2004, CANCER RES, V64, P1229, DOI 10.1158/0008-5472.CAN-03-2832; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Nagy P, 2002, J CELL SCI, V115, P4251, DOI 10.1242/jcs.00118; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tsatas D, 2002, J CLIN NEUROSCI, V9, P282, DOI 10.1054/jocn.2001.1063; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Ward JA, 2003, AM J PATHOL, V162, P1403, DOI 10.1016/S0002-9440(10)64273-3; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yu Q, 1996, J BIOL CHEM, V271, P20603, DOI 10.1074/jbc.271.34.20603; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zeng CX, 1998, INT J CANCER, V77, P396; Zhou BP, 2003, SEMIN ONCOL, V30, P38, DOI 10.1053/j.seminoncol.2003.08.006; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	43	184	199	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8875	8883		10.1074/jbc.M410882200	http://dx.doi.org/10.1074/jbc.M410882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632176	hybrid			2022-12-27	WOS:000227453100032
J	Gong, X; Yu, L; Xia, D; Yu, CA				Gong, X; Yu, L; Xia, D; Yu, CA			Evidence for electron equilibrium between the two hemes b(L) in the dimeric cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; IRON-SULFUR PROTEIN; RHODOBACTER-SPHAEROIDES; SUPEROXIDE FORMATION; CRYSTAL-STRUCTURE; Q(O) SITE; Q-CYCLE; CHEMILUMINESCENCE; INHIBITION; GENERATION	Structural analysis of the dimeric mitochondrial cytochrome bc(1) complex suggests that electron transfer between inter-monomer hemes b(L)-b(L) may occur during bc(1) catalysis. Such electron transfer may be facilitated by the aromatic pairs present between the two b(L) hemes in the two symmetry-related monomers. To test this hypothesis, R. sphaeroides mutants expressing His(6)- tagged bc1 complexes with mutations at three aromatic residues (Phe-195, Tyr-199, and Phe-203), located between two bL hemes, were generated and characterized. All three mutants grew photosynthetically at a rate comparable to that of wild-type cells. The bc(1) complexes prepared from mutants F195A, Y199A, and F203A have, respectively, 78%, 100%, and 100% of ubiquinol-cytochrome c reductase activity found in the wild- type complex. Replacing the Phe-195 of cytochrome b with Tyr, His, or Trp results in mutant complexes ( F195Y, F195H, or F195W) having the same ubiquinol-cytochrome c reductase activity as the wild- type. These results indicate that the aromatic group at position195 of cytochrome b is involved in electron transfer reactions of the bc1 complex. The rate of superoxide anion ( O-2.) generation, measured by the chemiluminescence of 2-methyl-6-( pmethoxyphenyl)3,7- dihydroimidazo[ 1,2-alpha] pyrazin-3-one hydrochloride- O2. adduct during oxidation of ubiquinol, is 3 times higher in the F195A complex than in the wild- type or mutant complexes Y199A or F203A. This supports the idea that the interruption of electron transfer between the two bL hemes enhances electron leakage to oxygen and thus decreases the ubiquinol-cytochrome c reductase activity.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; NIH, Cell Biol Lab, Ctr Canc Inst, Bethesda, MD 20892 USA	Oklahoma State University System; Oklahoma State University - Stillwater; National Institutes of Health (NIH) - USA	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okstate.edu			NATIONAL CANCER INSTITUTE [Z01BC010319, ZIABC010319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki S, 2002, MED MYCOL, V40, P13, DOI 10.1080/mmy.40.1.13.19; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DENICOLA A, 1995, FREE RADICAL BIO MED, V19, P11, DOI 10.1016/0891-5849(94)00239-G; Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kambayashi Yasuhiro, 2003, J Toxicol Sci, V28, P139, DOI 10.2131/jts.28.139; KISHIMOTO W, 1995, PANCREAS, V11, P122, DOI 10.1097/00006676-199508000-00002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; Midorikawa J, 2001, JPN CIRC J, V65, P207, DOI 10.1253/jcj.65.207; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; NAKANO M, 1990, METHOD ENZYMOL, V186, P585; NAKANO M, 1990, METHOD ENZYMOL, V186, P227; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; Osyczka A, 2004, NATURE, V427, P607, DOI 10.1038/nature02242; Soriano GM, 1999, J BIOENERG BIOMEMBR, V31, P201, DOI 10.1023/A:1005463527752; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tso SC, 2000, J BIOL CHEM, V275, P15287, DOI 10.1074/jbc.M907367199; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; UEHARA K, 1993, FEBS LETT, V335, P167, DOI 10.1016/0014-5793(93)80722-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2004, BIOCHEMISTRY-US, V43, P1488, DOI 10.1021/bi035378z; Xiao KH, 2001, J BIOL CHEM, V276, P46125, DOI 10.1074/jbc.M107436200; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	40	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9251	9257		10.1074/jbc.M409994200	http://dx.doi.org/10.1074/jbc.M409994200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615714	hybrid			2022-12-27	WOS:000227453100075
J	Or, E; Boyd, D; Gon, P; Beckwith, J; Rapoport, T				Or, E; Boyd, D; Gon, P; Beckwith, J; Rapoport, T			The bacterial ATPase SecA functions as a monomer in protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; SIGNAL SEQUENCE; PRECURSOR PROTEINS; TERMINAL REGION; BINDING; RECOGNITION; NUCLEOTIDE; DOMAINS; SECYEG	The ATPase SecA drives the post-translational translocation of proteins through the SecY channel in the bacterial inner membrane. SecA is a dimer that can dissociate into monomers under certain conditions. To address the functional importance of the monomeric state, we generated an Escherichia coli SecA mutant that is almost completely monomeric (> 99%), consistent with predictions from the crystal structure of Bacillus subtilis SecA. In vitro, the monomeric derivative retained significant activity in various assays, and in vivo, it sustained 85% of the growth rate of wild type cells and reduced the accumulation of precursor proteins in the cytoplasm. Disulfide cross-linking in intact cells showed that mutant SecA is monomeric and that even its parental dimeric form is dissociated. Our results suggest that SecA functions as a monomer during protein translocation in vivo.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Rapoport, T (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.	tom_rapoport@hms.harvard.edu	GON, Stephanie/O-8324-2016	GON, Stephanie/0000-0002-1513-5018	NIGMS NIH HHS [GM05286, GM41883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; Bu ZM, 2003, J MOL BIOL, V332, P23, DOI 10.1016/S0022-2836(03)00840-4; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; Dempsey BR, 2002, J MOL BIOL, V315, P831, DOI 10.1006/jmbi.2001.5279; Ding HY, 2003, BIOCHEMISTRY-US, V42, P13468, DOI 10.1021/bi035099b; Doyle SM, 2000, BIOCHEMISTRY-US, V39, P11667, DOI 10.1021/bi000299y; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Driessen AJM, 2001, TRENDS MICROBIOL, V9, P193, DOI 10.1016/S0966-842X(01)01980-1; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; Etchegaray JP, 1999, J BIOL CHEM, V274, P10079, DOI 10.1074/jbc.274.15.10079; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Katzen F, 2002, METHOD ENZYMOL, V348, P54, DOI 10.1016/S0076-6879(02)48626-0; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Osborne AR, 2004, P NATL ACAD SCI USA, V101, P10937, DOI 10.1073/pnas.0401742101; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Ritz D, 2001, SCIENCE, V294, P158, DOI 10.1126/science.1063143; ROLLO EE, 1988, J BACTERIOL, V170, P3281, DOI 10.1128/jb.170.7.3281-3282.1988; SHINKAI A, 1990, BIOCHEM BIOPH RES CO, V172, P1217, DOI 10.1016/0006-291X(90)91578-G; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	51	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9097	9105		10.1074/jbc.M413947200	http://dx.doi.org/10.1074/jbc.M413947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15618215	hybrid			2022-12-27	WOS:000227453100059
J	Cassanova, N; O'Brien, KM; Stahl, BT; McClure, T; Poyton, RO				Cassanova, N; O'Brien, KM; Stahl, BT; McClure, T; Poyton, RO			Yeast flavohemoglobin, a nitric oxide oxidoreductase, is located in both the cytosol and the mitochondrial matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; S-NITROSOHEMOGLOBIN; NITROSATIVE STRESS; PROTEIN; EXPRESSION; OXYGEN; GENE; SUBUNIT	Yeast flavohemoglobin, YHb, encoded by the nuclear gene YHB1, has been implicated in both the oxidative and nitrosative stress responses in Saccharomyces cerevisiae. Previous studies have shown that the expression of YHB1 is optimal under normoxic or hyperoxic conditions, yet respiring yeast cells have low levels of reduced YHb pigment as detected by carbon monoxide (CO) photolysis difference spectroscopy of glucose-reduced cells. Here, we have addressed this apparent discrepancy by determining the intracellular location of the YHb protein and analyzing the relationships between respiration, YHb level, and intracellular location. We have found that although intact respiration-proficient cells lack a YHb CO spectral signature, cell extracts from these cells have both a YHb CO spectral signature and nitric oxide (NO) consuming activity. This suggests either that YHb cannot be reduced in vivo or that YHb heme is maintained in an oxidized state in respiring cells. By using an anti-YHb antibody and CO difference spectroscopy and by measuring NO consumption, we have found that YHb localizes to two distinct intracellular compartments in respiring cells, the mitochondrial matrix and the cytosol. Moreover, we have found that the distribution of YHb between these two compartments is affected by the presence or absence of oxygen and by the mitochondrial genome. The findings suggest that YHb functions in oxidative stress indirectly by consuming NO, which inhibits mitochondrial respiration and leads to enhanced production of reactive oxygen species, and that cells can regulate intracellular distribution of YHb in accordance with this function.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Poyton, RO (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	Poyton@spot.colorado.edu			NIGMS NIH HHS [GM30228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agorio A, 2003, J BIOL CHEM, V278, P12920, DOI 10.1074/jbc.M209266200; ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; Boveris A, 2000, ANN NY ACAD SCI, V899, P121; Bradbury MW, 2000, BIOCHEM J, V345, P423, DOI 10.1042/0264-6021:3450423; Buisson N, 1998, J BIOL CHEM, V273, P9527, DOI 10.1074/jbc.273.16.9527; Burke PV, 1998, J EXP BIOL, V201, P1163; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Cadenas E, 2000, FREE RADICAL RES, V33, P747, DOI 10.1080/10715760000301271; CHURCH C, 2004, J BIOL CHEM, DOI DOI 10.1074/JBC.M410726200; CRAMM R, 1994, J BIOL CHEM, V269, P7349; Dagsgaard C, 2001, J BIOL CHEM, V276, P7593, DOI 10.1074/jbc.M009180200; Dirmeier R, 2002, J BIOL CHEM, V277, P34773, DOI 10.1074/jbc.M203902200; Domitrovic T, 2003, FEMS YEAST RES, V3, P341, DOI 10.1016/S1567-1356(03)00039-4; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Forsha D, 2001, BIOCHEM SOC T, V29, P436, DOI 10.1042/BST0290436; Foster MW, 2004, J BIOL CHEM, V279, P25891, DOI 10.1074/jbc.M313853200; Frey AD, 2000, APPL ENVIRON MICROB, V66, P98, DOI 10.1128/AEM.66.1.98-104.2000; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Hardison R, 1998, J EXP BIOL, V201, P1099; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jin C, 2003, J BIOL CHEM, V278, P14698, DOI 10.1074/jbc.M300593200; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutsenko S, 1998, P NATL ACAD SCI USA, V95, P6004, DOI 10.1073/pnas.95.11.6004; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; MOK TCK, 1969, BIOCHIM BIOPHYS ACTA, V172, P438, DOI 10.1016/0005-2728(69)90140-6; Mueller JC, 2004, MITOCHONDRION, V3, P315, DOI 10.1016/j.mito.2004.02.002; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; O'Brien KM, 2004, J BIOL CHEM, V279, P51817, DOI 10.1074/jbc.M405958200; Petrova VY, 2004, BIOCHEM J, V380, P393, DOI 10.1042/BJ20040042; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POYTON RO, 1975, J BIOL CHEM, V250, P762; Poyton RO, 2004, METHOD ENZYMOL, V381, P644; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; RIGGS AF, 1991, AM ZOOL, V31, P535; Schild L, 2003, FASEB J, V17, P2194, DOI 10.1096/fj.02-1170com; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VELOURS J, 1977, ARCH BIOCHEM BIOPHYS, V182, P295, DOI 10.1016/0003-9861(77)90310-1; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; WU M, 1987, J BIOL CHEM, V262, P12275; YCAS M, 1956, EXP CELL RES, V11, P1; Zhao XJ, 1996, J BIOL CHEM, V271, P25131, DOI 10.1074/jbc.271.41.25131; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	60	67	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7645	7653		10.1074/jbc.M411478200	http://dx.doi.org/10.1074/jbc.M411478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611069	hybrid			2022-12-27	WOS:000227395700027
J	Li, W; Hertzberg, EL; Spray, DC				Li, W; Hertzberg, EL; Spray, DC			Regulation of connexin43-protein binding in astrocytes in response to chemical ischemia/hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; C-SRC; INTERCELLULAR COMMUNICATION; PHOSPHORYLATION STATE; CELL-DEATH; RAT-BRAIN; IN-VIVO; CONNEXIN-43; MOUSE; PHOSPHATASE	Connexin-protein interactions are believed to be critical for the regulation of gap junctional intercellular communication and for the function of gap junctions formed by these complexes. We have primarily used immunoprecipitation strategies to investigate whether connexin43 binds to selected signaling and cytoskeletal proteins and whether connexin43-protein binding is altered in cultured astrocytes exposed to chemical ischemia/hypoxia, a treatment that resembles ischemia in vivo. Chemical ischemia/hypoxia induced marked dephosphorylation of connexin43, which was accompanied by increased association of connexin43 with c-Src, ERK1/2, and mitogen-activated protein kinase phosphatase-1 and by decreased association between connexin43 and beta-actin. Moreover, we found that endogenous c-Src in normal astrocytes exists primarily in the Triton X-100-soluble membrane fraction, distinct from the Triton-insoluble fraction, which contains gap junctions. After chemical ischemia/hypoxia, c-Src appeared in the Triton-insoluble fraction and was co-immunoprecipitated with connexin43, suggesting that chemical ischemia/hypoxia induced translocation of c-Src to the Triton-insoluble fraction and association with connexin43. Furthermore, the "dephosphorylated" form of connexin43 was immunoprecipitated by a phosphotyrosine antibody, suggesting tyrosine phosphorylation of connexin43 by c-Src. In addition, the association between connexin43 and c-Src was blocked by inhibition of connexin43 dephosphorylation, suggesting that the interaction between connexin43 and c-Src can be regulated by alterations in the phosphorylation state of connexin43. These results identify new binding partners for connexin43 and demonstrate that interactions between connexin43 and protein kinases and phosphatases are dynamically altered as a consequence of connexin43 phosphorylation.	Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Spray, DC (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, 1410 Pelham Pkwy, Bronx, NY 10461 USA.	spray@aecom.yu.edu		Li, Wei/0000-0002-7941-7022; Spray, David/0000-0001-8368-5073	NINDS NIH HHS [NS41282] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cotrina ML, 1998, J NEUROSCI, V18, P2520; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; Cruciani V, 1999, EXP CELL RES, V252, P449, DOI 10.1006/excr.1999.4650; Cusato K, 2003, J NEUROSCI, V23, P6413; Duffy HS, 2004, CIRC RES, V94, P215, DOI 10.1161/01.RES.0000113924.06926.11; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Hertzberg EL, 2000, METHODS, V20, P129, DOI 10.1006/meth.1999.0931; HOSSAIN MZ, 1994, J NEUROCHEM, V62, P2394; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kawahara N, 2004, J CEREBR BLOOD F MET, V24, P212, DOI 10.1097/01.WCB.0000106012.33322.A2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Li WEI, 2000, EUR J NEUROSCI, V12, P2644, DOI 10.1046/j.1460-9568.2000.00162.x; Li WEI, 2000, NEUROSCIENCE, V97, P113, DOI 10.1016/S0306-4522(00)00032-4; Li WEI, 1998, EUR J NEUROSCI, V10, P2444, DOI 10.1046/j.1460-9568.1998.00253.x; Li WEI, 2002, DEVELOPMENT, V129, P2031; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loo LWM, 1999, MOL CARCINOGEN, V25, P187, DOI 10.1002/(SICI)1098-2744(199907)25:3<187::AID-MC5>3.3.CO;2-F; Mikalsen SO, 1998, J BIOL CHEM, V273, P10036, DOI 10.1074/jbc.273.16.10036; Moorby CD, 2000, MOL CARCINOGEN, V28, P23, DOI 10.1002/(SICI)1098-2744(200005)28:1<23::AID-MC4>3.0.CO;2-J; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; Nagy JI, 2000, EUR J NEUROSCI, V12, P4567, DOI 10.1046/j.1460-9568.2000.01331.x; Nakase T, 2004, AM J PATHOL, V164, P2067, DOI 10.1016/S0002-9440(10)63765-0; Naruse K, 1998, FEBS LETT, V441, P111, DOI 10.1016/S0014-5793(98)01528-2; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Theiss C, 2002, EXP CELL RES, V281, P197, DOI 10.1006/excr.2002.5652; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Warn-Cramer BJ, 2004, BBA-BIOMEMBRANES, V1662, P81, DOI 10.1016/j.bbamem.2003.10.018; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Wu Y, 2000, BBA-MOL CELL RES, V1497, P27, DOI 10.1016/S0167-4889(00)00043-4; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047	41	60	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7941	7948		10.1074/jbc.M410548200	http://dx.doi.org/10.1074/jbc.M410548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15618229	hybrid			2022-12-27	WOS:000227395700063
J	Motoyama, M; Yamazaki, S; Eto-Kimura, A; Takeshige, K; Muta, T				Motoyama, M; Yamazaki, S; Eto-Kimura, A; Takeshige, K; Muta, T			Positive and negative regulation of nuclear factor-kappa B-mediated transcription by I kappa B-xi, an inducible nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOPROTEIN BCL-3; ADAPTIVE IMMUNITY; MAMMALIAN-CELLS; GENE-EXPRESSION; ESSENTIAL ROLES; ALPHA; ACTIVATION; RECEPTOR; PATHWAY; ZETA	IkappaB-zeta is an inducible nuclear protein that interacts with nuclear factor-kappaB ( NF-kappaB) via its carboxyl-terminal ankyrin-repeats. Previous studies using an NF-kappaB reporter have shown that IkappaB-zeta inhibits the activity of NF-kappaB. In the present study, we dissected the amino-terminal region of IkappaB-zeta, which shows no homology to any other proteins. Indirect immunofluorescence studies demonstrated the presence of a bipartite nuclear localization signal spanning amino acids 163 - 178. Using GAL4 fusion proteins, we found that internal fragments containing amino acids 329 - 402 possessed intrinsic transcriptional activation activity. Interestingly, the activity was not detected in GAL4 fusion proteins of the full-length IkappaB-zeta. On the other hand, the GAL4-dependent transcriptional activity was generated by co-expression of the GAL4-NF-kappaB p50 subunit fusion protein and the full-length IkappaB-zeta, neither of which exhibited the activity on their own. A new splicing variant, IkappaB-zeta( D), with a deletion of amino acids 236 - 429, was found to lack transactivation activity. Forced expression of IkappaB-zeta, but not IkappaB-zeta( D), augmented interleukin-6 production, indicating the functional significance of the transactivation activity. In contrast, tumor necrosis factor-alpha production was inhibited by expression of IkappaB-zeta, highlighting the dual functions of this molecule. These results indicate that IkappaB-zeta harbors latent transcriptional activation activity, and that the activity is expressed upon interaction with the NF-kappaB p50 subunit. In addition to the inhibitory activity on NF-kappaB-mediated transcription, the transcriptional activation activity of IkappaB-zeta should be crucial for the regulation of inflammation.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan	Kyushu University	Muta, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan.	tmuta@mailserver.med.kyushu-u.ac.jp						Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Eto A, 2003, BIOCHEM BIOPH RES CO, V301, P495, DOI 10.1016/S0006-291X(02)03082-6; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; NAGAHARI K, 1980, GENE, V10, P137; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shiina T, 2001, IMMUNOGENETICS, V53, P649, DOI 10.1007/s00251-001-0376-x; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TANABE O, 1988, J IMMUNOL, V141, P3875; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200	48	112	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7444	7451		10.1074/jbc.M412738200	http://dx.doi.org/10.1074/jbc.M412738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15618216	hybrid			2022-12-27	WOS:000227395700005
J	Yang, JH; Ishimori, K; O'Brian, MR				Yang, JH; Ishimori, K; O'Brian, MR			Two heme binding sites are involved in the regulated degradation of the bacterial iron response regulator (Irr) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRADYRHIZOBIUM-JAPONICUM; SALMONELLA-TYPHIMURIUM; DEPENDENT DEGRADATION; TRANSCRIPTION FACTOR; OXYGEN SENSOR; N-TERMINUS; BIOSYNTHESIS; MUTANT; BACH1; IDENTIFICATION	The iron response regulator (Irr) protein from Bradyrhizobium japonicum is a conditionally stable protein that degrades in response to cellular iron availability. This turnover is heme-dependent, and rapid degradation involves heme binding to a heme regulatory motif (HRM) of Irr. Here, we show that Irr confers iron-dependent instability on glutathione S-transferase (GST) when fused to it. Analysis of Irr-GST derivatives with C-terminal truncations of Irr implicated a second region necessary for degradation, other than the HRM, and showed that the HRM was not sufficient to confer instability on GST. The HRM-defective mutant IrrC29A degraded in the presence of iron but much more slowly than the wild-type protein. This slow turnover was heme-dependent, as discerned by the stability of Irr in a heme-defective mutant strain. Whereas the HRM of purified recombinant Irr binds ferric ( oxidized) heme, a second site that binds ferrous ( reduced) heme was identified based on spectral analysis of truncation and substitution mutants. A mutant in which histidines 117 - 119 were changed to alanines severely diminished ferrous, but not ferric, heme binding. Introduction of these substitutions in an Irr-GST fusion stabilized the protein in vivo in the presence of iron. We conclude that normal iron-dependent Irr degradation involves two heme binding sites and that both redox states of heme are required for rapid turnover.	SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Kyoto University	O'Brian, MR (corresponding author), SUNY Buffalo, Dept Biochem, 140 Farber Hall, Buffalo, NY 14214 USA.	mrobrian@buffalo.edu	Ishimori, Koichiro/AAQ-4434-2021; Ishimori, Koichiro/S-1247-2016	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-067966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFT RL, 1984, J BIOL CHEM, V259, P301; Bourdon E, 2003, BLOOD CELL MOL DIS, V31, P247, DOI 10.1016/S1079-9796(03)00161-X; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHAUHAN S, 1995, J BIOL CHEM, V270, P19823, DOI 10.1074/jbc.270.34.19823; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; FRUSTACI JM, 1991, J BACTERIOL, V173, P1145, DOI 10.1128/jb.173.3.1145-1150.1991; Goessling LS, 1998, J BIOL CHEM, V273, P12555, DOI 10.1074/jbc.273.20.12555; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; GUERINOT ML, 1986, P NATL ACAD SCI USA, V83, P1837, DOI 10.1073/pnas.83.6.1837; Hach A, 2000, J BIOL CHEM, V275, P248, DOI 10.1074/jbc.275.1.248; Hamza I, 1998, J BIOL CHEM, V273, P21669, DOI 10.1074/jbc.273.34.21669; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Kurokawa H, 2004, J BIOL CHEM, V279, P20186, DOI 10.1074/jbc.M314199200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; Lee HC, 2003, MOL CELL BIOL, V23, P5857, DOI 10.1128/MCB.23.16.5857-5866.2003; Letoffe S, 2001, MOL MICROBIOL, V41, P439, DOI 10.1046/j.1365-2958.2001.02530.x; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; Nakajima O, 1999, EMBO J, V18, P6282, DOI 10.1093/emboj/18.22.6282; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Panek H, 2002, MICROBIOL-SGM, V148, P2273, DOI 10.1099/00221287-148-8-2273; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Qi ZH, 1999, P NATL ACAD SCI USA, V96, P13056, DOI 10.1073/pnas.96.23.13056; Qi ZH, 2002, MOL CELL, V9, P155, DOI 10.1016/S1097-2765(01)00431-2; Rafie-Kolpin M, 2000, J BIOL CHEM, V275, P5171, DOI 10.1074/jbc.275.7.5171; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Suzuki H, 2004, EMBO J, V23, P2544, DOI 10.1038/sj.emboj.7600248; Wang LY, 1999, J BACTERIOL, V181, P6033, DOI 10.1128/JB.181.19.6033-6041.1999; Wang LY, 1999, J BACTERIOL, V181, P1211, DOI 10.1128/JB.181.4.1211-1219.1999; Wexler M, 2003, MICROBIOL-SGM, V149, P1357, DOI 10.1099/mic.0.26130-0; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952	35	74	75	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7671	7676		10.1074/jbc.M411664200	http://dx.doi.org/10.1074/jbc.M411664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15613477	hybrid			2022-12-27	WOS:000227395700030
J	Karlgren, S; Pettersson, N; Nordlander, B; Mathai, JC; Brodsky, JL; Zeidel, ML; Bill, RM; Hohmann, S				Karlgren, S; Pettersson, N; Nordlander, B; Mathai, JC; Brodsky, JL; Zeidel, ML; Bill, RM; Hohmann, S			Conditional osmotic stress in yeast - A system to study transport through aquaglyceroporins and osmostress signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GLYCEROL HOG PATHWAY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; WATER-STRESS; SECRETORY VESICLES; RESPONSE PATHWAY; PLASMA-MEMBRANE; DISTINCT ROLES; 2 ISOENZYMES	The accumulation and transport of solutes are hallmarks of osmoadaptation. In this study we have employed the inability of the Saccharomyces cerevisiae gpd1Delta gpd2Delta mutant both to produce glycerol and to adapt to high osmolarity to study solute transport through aquaglyceroporins and the control of osmostress-induced signaling. High levels of different polyols, including glycerol, inhibited growth of the gpd1Delta gpd2Delta mutant. This growth inhibition was suppressed by expression of the hyperactive allele Fps1-Delta1 of the osmogated yeast aquaglyceroporin, Fps1. The degree of suppression correlated with the relative rate of transport of the different polyols tested. Transport studies in secretory vesicles confirmed that Fps1-Delta1 transports polyols at increased rates compared with wild type Fps1. Importantly, wild type Fps1 and Fps1-Delta1 showed similarly low permeability for water. The growth defect on polyols in the gpd1Delta gpd2Delta mutant was also suppressed by expression of a heterologous aquaglyceroporin, rat AQP9. We surmised that this suppression was due to polyol influx, causing the cells to passively adapt to the stress. Indeed, when aquaglyceroporin-expressing gpd1Delta gpd2Delta mutants were treated with glycerol, xylitol, or sorbitol, the osmosensing HOG pathway was activated, and the period of activation correlated with the apparent rate of polyol uptake. This observation supports the notion that deactivation of the HOG pathway is closely coupled to osmotic adaptation. Taken together, our "conditional" osmotic stress system facilitates studies on aquaglyceroporin function and reveals features of the osmosensing and signaling system.	Univ Gothenburg, Dept Cell & Mol Biol, S-40530 Gothenburg, Sweden; Univ Pittsburgh, Lab Epithelial Cell Biol, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Gothenburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hohmann, S (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol, Box 462, S-40530 Gothenburg, Sweden.	hohmann@gmm.gu.se	Hohmann, Stefan/K-9895-2013; Bill, Roslyn M/D-4554-2012	Hohmann, Stefan/0000-0002-0809-1985; Bill, Roslyn M/0000-0003-1331-0852				ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Bill RM, 2001, J BIOL CHEM, V276, P36543, DOI 10.1074/jbc.M105045200; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Brown A D, 1978, Adv Microb Physiol, V17, P181, DOI 10.1016/S0065-2911(08)60058-2; Coury LA, 1999, METHOD ENZYMOL, V306, P169; Coury LA, 1998, AM J PHYSIOL-RENAL, V274, pF34, DOI 10.1152/ajprenal.1998.274.1.F34; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; Dihazi H, 2004, J BIOL CHEM, V279, P23961, DOI 10.1074/jbc.M312974200; Duchesne L, 2001, KIDNEY INT, V60, P422, DOI 10.1046/j.1523-1755.2001.060002422.x; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; HOHMANN S, 2001, AQUAPORINS; Holst B, 2000, MOL MICROBIOL, V37, P108, DOI 10.1046/j.1365-2958.2000.01968.x; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Karlgren S, 2004, EUR J BIOCHEM, V271, P771, DOI 10.1111/j.1432-1033.2004.03980.x; Klebl F, 2003, FEBS LETT, V547, P69, DOI 10.1016/S0014-5793(03)00671-9; Krallish I, 1997, APPL MICROBIOL BIOT, V47, P447, DOI 10.1007/s002530050954; Krantz M, 2004, EUKARYOT CELL, V3, P1381, DOI 10.1128/EC.3.6.1381-1390.2004; Labbe S, 1999, METHOD ENZYMOL, V306, P145; Lages F, 1999, MICROBIOL-UK, V145, P2577, DOI 10.1099/00221287-145-9-2577; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; Liu ZJ, 2002, P NATL ACAD SCI USA, V99, P6053, DOI 10.1073/pnas.092131899; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAUREL C, 1994, J BIOL CHEM, V269, P11869; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; O'Rourke SM, 2002, TRENDS GENET, V18, P405, DOI 10.1016/S0168-9525(02)02723-3; Oliveira R, 2003, BBA-BIOMEMBRANES, V1613, P57, DOI 10.1016/S0005-2736(03)00138-X; Pahlman AK, 2001, J BIOL CHEM, V276, P3555, DOI 10.1074/jbc.M007164200; Reiser V, 2003, J CELL BIOL, V161, P1035, DOI 10.1083/jcb.200301099; Sanders OI, 1997, J BACTERIOL, V179, P3365, DOI 10.1128/jb.179.10.3365-3367.1997; Shen B, 1999, PLANT PHYSIOL, V121, P45, DOI 10.1104/pp.121.1.45; Sherman F., 1983, METHODS YEAST GENETI; Siderius M, 2000, MOL MICROBIOL, V36, P1381, DOI 10.1046/j.1365-2958.2000.01955.x; Tamas MJ, 2001, CURR GENET, V40, P2, DOI 10.1007/s002940100234; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; Tamas MJ, 2003, J BIOL CHEM, V278, P6337, DOI 10.1074/jbc.M209792200; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Warringer J, 2003, YEAST, V20, P53, DOI 10.1002/yea.931; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	50	32	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7186	7193		10.1074/jbc.M413210200	http://dx.doi.org/10.1074/jbc.M413210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611083	Green Accepted, hybrid			2022-12-27	WOS:000227332700110
J	Naggi, A; Casu, B; Perez, M; Torri, G; Cassinelli, G; Penco, S; Pisano, C; Giannini, G; Ishai-Michaeli, R; Vlodavsky, I				Naggi, A; Casu, B; Perez, M; Torri, G; Cassinelli, G; Penco, S; Pisano, C; Giannini, G; Ishai-Michaeli, R; Vlodavsky, I			Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; TUMOR-METASTASIS; EXTRACELLULAR-MATRIX; HEPATOCELLULAR-CARCINOMA; MAMMALIAN HEPARANASE; MEDIATED DEGRADATION; SULFATE; EXPRESSION; ANGIOGENESIS; ANTICOAGULANT	Heparanase is an endo-beta-glucuronidase that cleaves heparan sulfate (HS) chains of heparan sulfate proteoglycans on cell surfaces and in the extracellular matrix (ECM). Heparanase, overexpressed by most cancer cells, facilitates extravasation of blood-borne tumor cells and causes release of growth factors sequestered by HS chains, thus accelerating tumor growth and metastasis. Inhibition of heparanase with HS mimics is a promising target for a novel strategy in cancer therapy. In this study, in vitro inhibition of recombinant heparanase was determined for heparin derivatives differing in degrees of 2-O- and 6-O- sulfation, N-acetylation, and glycol splitting of nonsulfated uronic acid residues. The contemporaneous presence of sulfate groups at O-2 of IdoA and at O-6 of GlcN was found to be non-essential for effective inhibition of heparanase activity provided that one of the two positions retains a high degree of sulfation. N-Desulfation/N-acetylation involved a marked decrease in the inhibitory activity for degrees of N-acetylation higher than 50%, suggesting that at least one NSO3 group per disaccharide unit is involved in interaction with the enzyme. On the other hand, glycol splitting of preexisting or of both preexisting and chemically generated nonsulfated uronic acids dramatically increased the heparanase-inhibiting activity irrespective of the degree of N-acetylation. Indeed N-acetylated heparins in their glycol-split forms inhibited heparanase as effectively as the corresponding N-sulfated derivatives. Whereas heparin and N-acetylheparins containing unmodified D-glucuronic acid residues inhibited heparanase by acting, at least in part, as substrates, their glycol-split derivatives were no more susceptible to cleavage by heparanase. Glycol-split N-acetylheparins did not release basic fibroblast growth factor from ECM and failed to stimulate its mitogenic activity. The combination of high inhibition of heparanase and low release/potentiation of ECM-bound growth factor indicates that N-acetylated, glycol-split heparins are potential antiangiogenic and antimetastatic agents that are more effective than their counterparts with unmodified backbones.	G Ronzoni Inst Chem & Biochem Res, I-20133 Milan, Italy; Sigma Tau Res Dept, I-00040 Pomezia, Rome, Italy; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel; Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Casu, B (corresponding author), G Ronzoni Inst Chem & Biochem Res, Via G Colombo 81, I-20133 Milan, Italy.	casu@ronzoni.it		Torri, Giangiacomo/0000-0002-2077-1203; pisano, claudio/0000-0001-8624-2980				Altinbas M, 2004, J THROMB HAEMOST, V2, P1266, DOI 10.1111/j.1538-7836.2004.00871.x; BARNER M, 1987, BLOOD, V70, P551; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bertini S, 2005, BIOMACROMOLECULES, V6, P168, DOI 10.1021/bm049693s; Casu B, 1996, ARZNEIMITTEL-FORSCH, V46, P472; Casu B, 2004, J MED CHEM, V47, P838, DOI 10.1021/jm030893g; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Casu B, 2002, BIOCHEMISTRY-US, V41, P10519, DOI 10.1021/bi020118n; CASU B, 1986, ARZNEIMITTEL-FORSCH, V36-1, P637; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; CASU B, 1990, NEW TRENDS HAEMOSTAS, P2; CIFONELL.JA, 1968, CARBOHYD RES, V8, P233, DOI 10.1016/S0008-6215(00)80159-7; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; HRICOVINI M, 2003, 12 EUR CARB S GREN F; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Katz A, 2002, ISRAEL MED ASSOC J, V4, P996; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koliopanos A, 2001, CANCER RES, V61, P4655; KORRAMIAN BA, 1987, IND POLYSACCHARIDES, P339; Kwan CP, 2001, J BIOL CHEM, V276, P23421, DOI 10.1074/jbc.M010786200; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724; Levidiotis V, 2001, KIDNEY INT, V60, P1287, DOI 10.1046/j.1523-1755.2001.00934.x; LEVVY GA, 1959, BIOCHEM J, V73, P127, DOI 10.1042/bj0730127; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Lindahl U, 2000, GLYCOCONJUGATE J, V17, P597, DOI 10.1023/A:1011030711317; Linhardt RJ, 2003, J MED CHEM, V46, P2551, DOI 10.1021/jm030176m; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; MULLOY B, 1993, BIOCHEM J, V293, P840; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Parish CR, 1999, CANCER RES, V59, P3433; PARISH CR, 1987, INT J CANCER, V40, P511, DOI 10.1002/ijc.2910400414; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; PIANI S, 1993, J CARBOHYD CHEM, V12, P507, DOI 10.1080/07328309308019404; Pisano C, 2005, GLYCOBIOLOGY, V15, p1C, DOI 10.1093/glycob/cwi007; REJ RN, 1990, CARBOHYD RES, V200, P437, DOI 10.1016/0008-6215(90)84209-D; Sandback-Pikas D., 1998, J BIOL CHEM, V273, P18770; Sato T, 2004, J SURG ONCOL, V87, P174, DOI 10.1002/jso.20097; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 2003, PATHOPHYSIOL HAEMO T, V33, P59, DOI 10.1159/000073296; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; Xiao Y, 2003, HEPATOL RES, V26, P192, DOI 10.1016/S1386-6346(03)00107-4; Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com	66	191	210	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12103	12113		10.1074/jbc.M414217200	http://dx.doi.org/10.1074/jbc.M414217200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15647251	hybrid			2022-12-27	WOS:000227922000007
J	Iwai, M; Tateishi, Y; Hattori, M; Mizutani, A; Nakamura, T; Futatsugi, A; Inoue, T; Furuichi, T; Michikawa, T; Mikoshiba, K				Iwai, M; Tateishi, Y; Hattori, M; Mizutani, A; Nakamura, T; Futatsugi, A; Inoue, T; Furuichi, T; Michikawa, T; Mikoshiba, K			Molecular cloning of mouse type 2 and type 3 inositol 1,4,5-trisphosphate receptors and identification of a novel type 2 receptor splice variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; CA2+ RELEASE SITES; XENOPUS OOCYTES; FUNCTIONAL-CHARACTERIZATION; TRISPHOSPHATE RECEPTOR; MONOCLONAL-ANTIBODIES; PHOSPHOLIPASE-C; INSP3 RECEPTOR; MESSENGER-RNA; SMOOTH-MUSCLE	We isolated cDNAs encoding type 2 and type 3 inositol 1,4,5-trisphosphate (IP3) receptors (IP(3)R2 and IP(3)R3, respectively) from mouse lung and found a novel alternative splicing segment, SIm2, at 176-208 of IP3R2. The long form (IP(3)R2 SIm2+) was dominant, but the short form (IP(3)R2 SIm2-) was detected in all tissues examined. IP(3)R2 SIm2- has neither IP3 binding activity nor Ca2+ releasing activity. In addition to its reticular distribution, IP(3)R2 SIm2+ is present in the form of clusters in the endoplasmic reticulum of resting COS-7 cells, and after ATP or Ca2+ ionophore stimulation, most of the IP(3)R2 SIm2+ is in clusters. IP(3)R3 is localized uniformly on the endoplasmic reticulum of resting cells and forms clusters after ATP or Ca2+ ionophore stimulation. IP(3)R2 SIm2- does not form clusters in either resting or stimulated cells. IP3 binding-deficient site-directed mutants of IP(3)R2 SIm2+ and IP(3)R3 fail to form clusters, indicating that IP3 binding is involved in the cluster formation by these isoforms. Coexpression of IP(3)R2 SIm2+ prevents stimulus-induced IP3R clustering, suggesting that IP(3)R2 SIm2- functions as a negative coordinator of stimulus-induced IP3R clustering. Expression of IP(3)R2 SIm2- in CHO-K1 cells significantly reduced ATP-induced Ca2+ entry, but not Ca2+ release, suggesting that the novel splice variant of IP(3)R2 specifically influences the dynamics of the sustained phase of Ca2+ signals.	Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Dept Basic Med Sci,Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, Calcium Oscillat Project, Int Cooperat Res Project, Tokyo 1080071, Japan; RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, NTT IMSUT, Dept Basic Med Sci,Div Neural Signal Informat, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST); RIKEN; RIKEN; University of Tokyo	Michikawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Dept Basic Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	takamich@ims.u-tokyo.ac.jp	Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Furuichi, Teiichi/B-5086-2014; Mizutani, Akihiro/GPS-4809-2022; Hattori, Mitsuharu/F-3859-2010	Inoue, Takafumi/0000-0002-2728-0060; Furuichi, Teiichi/0000-0002-9676-1888; Mizutani, Akihiro/0000-0003-4155-802X; Hattori, Mitsuharu/0000-0002-0503-4969				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Baylis HA, 1999, J MOL BIOL, V294, P467, DOI 10.1006/jmbi.1999.3229; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Callamaras N, 2000, EMBO J, V19, P3608, DOI 10.1093/emboj/19.14.3608; Callamaras N, 1999, J GEN PHYSIOL, V113, P199, DOI 10.1085/jgp.113.2.199; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Futatsugi A, 1998, BIOCHEM J, V334, P559, DOI 10.1042/bj3340559; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haak LL, 2001, J NEUROSCI, V21, P3860, DOI 10.1523/JNEUROSCI.21-11-03860.2001; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; Hattori M, 2004, J BIOL CHEM, V279, P11967, DOI 10.1074/jbc.M311456200; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Iwasaki H, 2002, J BIOL CHEM, V277, P2763, DOI 10.1074/jbc.M108839200; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; Marchant JS, 2001, EMBO J, V20, P65, DOI 10.1093/emboj/20.1.65; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Munger SD, 2000, J BIOL CHEM, V275, P20450, DOI 10.1074/jbc.M001989200; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Natsume T, 1999, BIOCHEM BIOPH RES CO, V260, P527, DOI 10.1006/bbrc.1999.0905; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Nerou EP, 2001, BIOCHEM J, V355, P59, DOI 10.1042/bj3550059; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NUCIFORA FC, 1995, MOL BRAIN RES, V32, P291, DOI 10.1016/0169-328X(95)00089-B; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; PENNER R, 2004, SCI STKE; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; Segel IH, 1993, ENZYME KINETICS BEHA, P346; SHARP AH, 1993, J NEUROSCI, V13, P3051; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; Sun XP, 1998, J PHYSIOL-LONDON, V509, P67, DOI 10.1111/j.1469-7793.1998.067bo.x; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Tovey SC, 2001, J CELL SCI, V114, P3979; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Wilson BS, 1998, MOL BIOL CELL, V9, P1465, DOI 10.1091/mbc.9.6.1465; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	73	91	94	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10305	10317		10.1074/jbc.M413824200	http://dx.doi.org/10.1074/jbc.M413824200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632133	hybrid			2022-12-27	WOS:000227559600070
J	Shimoi, W; Ezawa, I; Nakamoto, K; Uesaki, S; Gabreski, G; Aridor, M; Yamamoto, A; Nagahama, M; Tagaya, M; Tani, K				Shimoi, W; Ezawa, I; Nakamoto, K; Uesaki, S; Gabreski, G; Aridor, M; Yamamoto, A; Nagahama, M; Tagaya, M; Tani, K			p125 is localized in endoplasmic reticulum exit sites and involved in their organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SEC23P-INTERACTING PROTEIN; PREFERRING PHOSPHOLIPASE A(1); DE-NOVO FORMATION; GOLGI TRANSPORT; SHOOT GRAVITROPISM; CARGO SELECTION; COPII VESICLES; ER; EXPORT; IDENTIFICATION	Transport vesicles coated with the COPII complex, which is assembled from Sar1p, Sec23p-Sec24p, and Sec13p-Sec31p, are involved in protein export from the endoplasmic reticulum (ER). We previously identified and characterized a novel Sec23p-interacting protein, p125, that is only expressed in mammals and exhibits sequence homology with phosphatidic acid-preferring phospholipase A(1) (PA-PLA(1)). In this study, we examined the localization and function of p125 in detail. By using immunofluorescence and electron microscopy, we found that p125 is principally localized in ER exit sites where COPII-coated vesicles are produced. Analyses of chimeric proteins comprising p125 and two other members of the mammalian PA-PLA(1) family (PA-PLA(1) and KIAA0725p) showed that, for localization to ER exit sites, the p125-specific N-terminal region is critical, and the putative lipase domain is interchangeable with KIAA0725p but not with PA-PLA(1). RNA interference-mediated depletion of p125 affected the organization of ER exit sites. The structure of the cis-Golgi compartment was also substantially disturbed, whereas the medial-Golgi was not. Protein export from the ER occurred without a significant delay in p125-depleted cells. Our study suggests that p125 is a mammalian-specific component of ER exit sites and participates in the organization of this compartment.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Nagahama Inst Biosci & Technol, Dept Cell Biol, Shiga 5260829, Japan	Tokyo University of Pharmacy & Life Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tani, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan.	tani@ls.toyaku.ac.jp			NIDDK NIH HHS [R01 DK062318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062318] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Aridor M, 2000, J BIOL CHEM, V275, P35673, DOI 10.1074/jbc.C000449200; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 2002, CURR OPIN CELL BIOL, V14, P417, DOI 10.1016/S0955-0674(02)00348-4; Bevis BJ, 2002, NAT CELL BIOL, V4, P750, DOI 10.1038/ncb852; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Garcia-Mata R, 2003, MOL BIOL CELL, V14, P2250, DOI 10.1091/mbc.E02-11-0730; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Han MH, 2001, J BIOL CHEM, V276, P27698, DOI 10.1074/jbc.M101983200; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; HIGGS HN, 1994, P NATL ACAD SCI USA, V91, P9574, DOI 10.1073/pnas.91.20.9574; Hong WJ, 1998, J CELL SCI, V111, P2831; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kato T, 2002, PLANT CELL, V14, P33, DOI 10.1105/tpc.010215; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kondylis V, 2003, J CELL BIOL, V162, P185, DOI 10.1083/jcb.200301136; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mizoguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P144, DOI 10.1006/bbrc.2000.3846; Morita MT, 2002, PLANT CELL, V14, P47, DOI 10.1105/tpc.010216; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Nagahama M, 2002, J CELL SCI, V115, P4483, DOI 10.1242/jcs.00093; Nakajima K, 2002, J BIOL CHEM, V277, P11329, DOI 10.1074/jbc.M111092200; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; Pathre P, 2003, EMBO J, V22, P4059, DOI 10.1093/emboj/cdg390; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, 1995, METHOD ENZYMOL, V257, P49; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Shima DT, 1999, CURR BIOL, V9, P821, DOI 10.1016/S0960-9822(99)80365-0; Stephens DJ, 2000, J CELL SCI, V113, P2177; Stephens DJ, 2003, EMBO REP, V4, P210, DOI 10.1038/sj.embor.embor736; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; Tang BL, 2000, J BIOL CHEM, V275, P13597, DOI 10.1074/jbc.275.18.13597; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	47	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10141	10148		10.1074/jbc.M409673200	http://dx.doi.org/10.1074/jbc.M409673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15623529	hybrid			2022-12-27	WOS:000227559600050
J	Ko, YG; Nishino, K; Hattori, N; Arai, Y; Tanaka, S; Shiota, K				Ko, YG; Nishino, K; Hattori, N; Arai, Y; Tanaka, S; Shiota, K			Stage-by-stage change in DNA methylation status of Dnmt1 locus during mouse early development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; HUMAN CANCER-CELLS; HISTONE DEACETYLASE COMPLEX; DE-NOVO METHYLATION; GENE-EXPRESSION; PREIMPLANTATION DEVELOPMENT; TRANSCRIPTIONAL REPRESSOR; MAINTENANCE METHYLATION; CPG METHYLATION; GERM-LINE	Methylation of DNA is involved in tissue- specific gene control, and establishment of DNA methylation pattern in the genome is thought to be essential for embryonic development. Three isoforms of Dnmt1 ( DNA methyltransferase 1) transcripts, Dnmt1s, Dnmt1o, and Dnmt1p, are produced by alternative usage of multiple first exons. Dnmt1s is expressed in somatic cells. Dnmt1p is found only in pachytene spermatocytes, whereas Dnmt1o is specific to oocytes and preimplantation embryos. Here we determined that there is a tissuedependent differentially methylated region ( T- DMR) in the 5' region of Dnmt1o but not in that of the Dnmt1s/1p. The methylation status of the Dnmt1o T- DMR was distinctively different in the oocyte from that in the sperm and adult somatic tissues and changed at each stage from fertilization to blastocyst stage, suggesting that active methylation and demethylation occur during preimplantation development. The T-DMR was highly methylated in somatic cells and embryonic stem cells. Analysis using Dnmt-deficient embryonic stem cell lines revealed that Dnmt1, Dnmt3a, and Dnmt3b are each partially responsible for maintenance of methylation of Dnmt1o T- DMR. In particular, there are compensatory and cooperative roles between Dnmt3a and Dnmt3b. Thus, the regulatory region of Dnmt1o, but not of Dnmt1s/1p, appeared to be a target of DNA methylation. The present study also suggested that the DNA methylation status of the gene region dynamically changes during embryogenesis independently of the change in the bulk DNA methylation status.	Univ Tokyo, Dept Anim Resource Sci, Lab Cellular Biochem, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Shiota, K (corresponding author), Univ Tokyo, Dept Anim Resource Sci, Lab Cellular Biochem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ashiota@mail.ecc.u-tokyo.ac.jp		Hattori, Naoko/0000-0002-0901-4869; Tanaka, Satoshi/0000-0002-4745-550X				Aoki F, 1997, DEV BIOL, V181, P296, DOI 10.1006/dbio.1996.8466; Aoki F, 2003, MOL REPROD DEV, V64, P270, DOI 10.1002/mrd.10227; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cardoso MC, 1999, J CELL BIOL, V147, P25, DOI 10.1083/jcb.147.1.25; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Cho JH, 2001, ENDOCRINOLOGY, V142, P3389, DOI 10.1210/en.142.8.3389; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Doherty AS, 2002, DEV BIOL, V242, P255, DOI 10.1006/dbio.2001.0534; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; Hata K, 2002, DEVELOPMENT, V129, P1983; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; Hattori N, 2004, GENOME RES, V14, P1733, DOI 10.1101/gr.2431504; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KAWASE E, 1994, INT J DEV BIOL, V38, P385; Kimura H, 1998, BIOCHEM BIOPH RES CO, V253, P495, DOI 10.1006/bbrc.1998.9802; Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406; Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Mertineit C, 1998, DEVELOPMENT, V125, P889; MONK M, 1987, DEVELOPMENT, V99, P371; NAGY A, 2003, MANIPULATING MOUSE E, P186; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nishino K, 2004, J BIOL CHEM, V279, P22306, DOI 10.1074/jbc.M309513200; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	54	71	78	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9627	9634		10.1074/jbc.M413822200	http://dx.doi.org/10.1074/jbc.M413822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634679	hybrid			2022-12-27	WOS:000227453100118
J	Krasel, C; Bunemann, MB; Lorenz, K; Lohse, MJ				Krasel, C; Bunemann, MB; Lorenz, K; Lohse, MJ			beta-arrestin binding to the beta(2)-adrenergic receptor requires both receptor phosphorylation and receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; LIVING CELLS; KINASE; DESENSITIZATION; ENDOCYTOSIS; MICE; SEQUESTRATION; COMPLEXES	Homologous desensitization of beta(2)-adrenergic receptors has been shown to be mediated by phosphorylation of the agonist-stimulated receptor by G-protein-coupled receptor kinase 2 (GRK2) followed by binding of beta-arrestins to the phosphorylated receptor. Binding of beta-arrestin to the receptor is a prerequisite for subsequent receptor desensitization, internalization via clathrin-coated pits, and the initiation of alternative signaling pathways. In this study we have investigated the interactions between receptors and beta-arrestin2 in living cells using fluorescence resonance energy transfer. We show that (a) the initial kinetics of beta-arrestin2 binding to the receptor is limited by the kinetics of GRK2-mediated receptor phosphorylation; (b) repeated stimulation leads to the accumulation of GRK2-phosphorylated receptor, which can bind beta-arrestin2 very rapidly; and (c) the interaction of beta-arrestin2 with the receptor depends on the activation of the receptor by agonist because agonist withdrawal leads to swift dissociation of the receptor-beta-arrestin2 complex. This fast agonist-controlled association and dissociation of beta-arrestins from prephosphorylated receptors should permit rapid control of receptor sensitivity in repeatedly stimulated cells such as neurons.	Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany		Lohse, MJ (corresponding author), Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012; Krasel, Cornelius/AAH-7074-2019; Lorenz, Kristina/F-3522-2016	Lohse, Martin J/0000-0002-0599-3510; Krasel, Cornelius/0000-0001-8309-8696; Lorenz, Kristina/0000-0002-5747-2207				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Charest PG, 2003, J BIOL CHEM, V278, P41541, DOI 10.1074/jbc.M306589200; CONTRERAS ML, 1986, J PHARMACOL EXP THER, V239, P136; Del Carmine R, 2004, MOL PHARMACOL, V66, P356, DOI 10.1124/mol.66.2.356; Del Carmine R, 2002, BRIT J PHARMACOL, V135, P1715, DOI 10.1038/sj.bjp.0704622; Devanathan S, 2004, BIOCHEMISTRY-US, V43, P3280, DOI 10.1021/bi035825a; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Eidne KA, 2002, TRENDS ENDOCRIN MET, V13, P415, DOI 10.1016/S1043-2760(02)00669-0; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Gainetdinov RR, 2003, NEURON, V38, P291, DOI 10.1016/S0896-6273(03)00192-2; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hasbi A, 2004, MOL ENDOCRINOL, V18, P1277, DOI 10.1210/me.2003-0440; Hoffmann C, 2004, N-S ARCH PHARMACOL, V369, P151, DOI 10.1007/s00210-003-0860-y; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kim YM, 2002, J BIOL CHEM, V277, P16837, DOI 10.1074/jbc.M201379200; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 2002, BIOCHEMISTRY-US, V41, P10692, DOI 10.1021/bi025705n; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McLean AJ, 2000, BRIT J PHARMACOL, V130, P1825, DOI 10.1038/sj.bjp.0703506; MUELLER H, 1988, MOL PHARMACOL, V34, P347; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; STICKLE D, 1991, BIOCHEM PHARMACOL, V42, P1069, DOI 10.1016/0006-2952(91)90290-L; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vrecl M, 2004, J BIOMOL SCREEN, V9, P322, DOI 10.1177/1087057104263212; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	50	131	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9528	9535		10.1074/jbc.M413078200	http://dx.doi.org/10.1074/jbc.M413078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634674	hybrid			2022-12-27	WOS:000227453100107
J	Moller, M; Botti, H; Batthyany, C; Rubbo, H; Radi, R; Denicola, A				Moller, M; Botti, H; Batthyany, C; Rubbo, H; Radi, R; Denicola, A			Direct measurement of nitric oxide and oxygen partitioning into liposomes and low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED LIPID DERIVATIVES; ORGANIC PEROXYL RADICALS; BILAYER-MEMBRANES; ALPHA-TOCOPHEROL; NITROGEN-DIOXIDE; AQUEOUS-SOLUTION; N-ALKANES; DIFFUSION; OXIDATION; PEROXIDATION	Nitric oxide ((NO)-N-.) has been proposed to play a relevant role in modulating oxidative reactions in lipophilic media like biomembranes and lipoproteins. Two factors that will regulate (NO)-N-. reactivity in the lipid milieu are its diffusion and solubility, but there is no data concerning the actual diffusion (D) and partition coefficients (K-P) of (NO)-N-. in biologically relevant hydrophobic phases. Herein, a "equilibrium-shift" method was designed to directly determine the (NO)-N-. and O-2 partition coefficients in liposomes and low density lipoprotein (LDL) relative to water. It was found that (NO)-N-. partitions 4.4- and 3.4-fold in liposomes and LDL, respectively, whereas O-2 behaves similarly with values of 3.9 and 2.9, respectively. In addition, actual diffusion coefficients in these hydrophobic phases were determined using fluorescence quenching and found that (NO)-N-. diffuses similar to2 times slower than O-2 in the core of LDL and 12 times slower than in buffer (D-NO(LDL) = 3.9 x 10(-6) cm(2) s(-1), D-O2(LDL) = 7.0 x 10(-6) cm(2) s(-1), D-NO(buffer) = D-O2(buffer) = 4.5 x 10(-5) cm(2) s(-1)). The influence of (NO)-N-. and O-2 partitioning and diffusion in membranes and lipoproteins on (NO)-N-. reaction with lipid radicals and auto-oxidation is discussed. Particularly, the 3-4- fold increase in O-2 and (NO)-N-. concentration within biological hydrophobic phases provides quantitative support for the idea of an accelerated auto-oxidation of (NO)-N-. in lipid-containing structures, turning them into sites of enhanced local production of oxidant and nitrosating species.	Univ Republica, Lab Fisicoquim Biol, Fac Ciencias, Montevideo 11400, Uruguay; Univ Republica, Dept Bioquim, Fac Med, Montevideo 11400, Uruguay; Univ Republica, Ctr Free Rad & Biomed Res, Montevideo 11400, Uruguay	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay	Denicola, A (corresponding author), Univ Republica, Lab Fisicoquim Biol, Fac Ciencias, Igua 4225, Montevideo 11400, Uruguay.	denicola@fcien.edu.uy	Batthyany, Carlos I./A-6478-2009	Moller, Matias N./0000-0002-3486-8217; Batthyany, Carlos/0000-0002-0627-1982; Denicola, Ana/0000-0002-5181-9708; Rubbo, Homero/0000-0002-7897-6551	FOGARTY INTERNATIONAL CENTER [R03TW001493] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW001493] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Balazy M, 2001, J PHARMACOL EXP THER, V299, P611; Batthyany C, 2000, ARCH BIOCHEM BIOPHYS, V384, P335, DOI 10.1006/abbi.2000.2102; BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; Botti H, 2004, FREE RADICAL BIO MED, V36, P152, DOI 10.1016/j.freeradbiomed.2003.10.006; Brookes PS, 2003, J BIOL CHEM, V278, P31603, DOI 10.1074/jbc.M211784200; Byun J, 1999, FEBS LETT, V455, P243, DOI 10.1016/S0014-5793(99)00893-5; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; COGAN U, 1973, BIOCHEMISTRY-US, V12, P521, DOI 10.1021/bi00727a026; Coles B, 2002, CIRC RES, V91, P375, DOI 10.1161/01.RES.0000032114.68919.EF; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Denicola A, 2002, J BIOL CHEM, V277, P932, DOI 10.1074/jbc.M106589200; DEYOUNG LR, 1990, J PHYS CHEM-US, V94, P801, DOI 10.1021/j100365a054; Dzikovski BG, 2003, BIOPHYS J, V85, P1005, DOI 10.1016/S0006-3495(03)74539-1; EVANS DF, 1981, J CHEM PHYS, V74, P1298, DOI 10.1063/1.441190; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Goldstein S, 2004, J PHYS CHEM A, V108, P1719, DOI 10.1021/jp037431z; Goss SPA, 1997, J BIOL CHEM, V272, P21647, DOI 10.1074/jbc.272.34.21647; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Han P, 1996, J PHYS CHEM-US, V100, P5597, DOI 10.1021/jp952903y; HARE F, 1979, BIOCHIM BIOPHYS ACTA, V555, P388, DOI 10.1016/0005-2736(79)90393-6; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; Kelley EE, 1999, ARCH BIOCHEM BIOPHYS, V370, P97, DOI 10.1006/abbi.1999.1386; Kowert BA, 1999, J PHYS CHEM A, V103, P779, DOI 10.1021/jp984025k; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; LAKOWICZ JR, 1977, BIOCHIM BIOPHYS ACTA, V471, P401, DOI 10.1016/0005-2736(77)90045-1; Lide D.R., 1998, CRC HDB CHEM PHYS; LIEB WR, 1986, J MEMBRANE BIOL, V92, P111, DOI 10.1007/BF01870701; LISSI EA, 1989, J BIOENERG BIOMEMBR, V21, P375, DOI 10.1007/BF00762728; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MARQUSEE JA, 1986, J CHEM PHYS, V85, P434, DOI 10.1063/1.451621; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; Orlova EV, 1999, P NATL ACAD SCI USA, V96, P8420, DOI 10.1073/pnas.96.15.8420; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; POWER GG, 1970, J APPL PHYSIOL, V29, P145, DOI 10.1152/jappl.1970.29.2.145; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; Rubbo H, 2002, METHOD ENZYMOL, V359, P200; Rubbo H, 1996, METHOD ENZYMOL, V269, P385; SALERNO JC, 1996, NITRIC OXIDE PRINCIP, P83; SHAW AW, 1977, J CHEM SOC FARADAY T, V8, P1239; SHINITZKY M, 1974, J BIOL CHEM, V249, P2652; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; SMOTKIN ES, 1991, BIOCHIM BIOPHYS ACTA, V1061, P33, DOI 10.1016/0005-2736(91)90265-A; Subczynski WK, 1996, FREE RADICAL RES, V24, P343, DOI 10.3109/10715769609088032; Subczynski WK, 1998, BIOCHEMISTRY-US, V37, P3156, DOI 10.1021/bi972148+; Teerlink T, 2004, J LIPID RES, V45, P954, DOI 10.1194/jlr.M300521-JLR200; WINDREM DA, 1980, BIOCHIM BIOPHYS ACTA, V600, P655, DOI 10.1016/0005-2736(80)90469-1; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2; Zhang H, 2003, J BIOL CHEM, V278, P8969, DOI 10.1074/jbc.M211561200	55	113	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8850	8854		10.1074/jbc.M413699200	http://dx.doi.org/10.1074/jbc.M413699200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632138	hybrid			2022-12-27	WOS:000227453100029
J	Ramos-Castaneda, J; Park, YN; Liu, M; Hauser, K; Rudolph, H; Shull, GE; Jonkman, MF; Mori, K; Ikeda, S; Ogawa, H; Arvan, P				Ramos-Castaneda, J; Park, YN; Liu, M; Hauser, K; Rudolph, H; Shull, GE; Jonkman, MF; Mori, K; Ikeda, S; Ogawa, H; Arvan, P			Deficiency of ATP2C1, a golgi ion pump, induces secretory pathway defects in endoplasmic reticulum ( ER)-associated degradation and sensitivity to ER stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; HAILEY-HAILEY-DISEASE; SACCHAROMYCES-CEREVISIAE; QUALITY-CONTROL; CA2+; YEAST; MUTATIONS; CALCIUM; CELLS; PMR1	Relatively few clues have been uncovered to elucidate the cell biological role(s) of mammalian ATP2C1 encoding an inwardly directed secretory pathway Ca2+/Mn2+ pump that is ubiquitously expressed. Deficiency of ATP2C1 results in a human disease ( Hailey-Hailey), which primarily affects keratinocytes. ATP2C1-encoded protein is detected in the Golgi complex in a calcium-dependent manner. A small interfering RNA causes knockdown of ATP2C1 expression, resulting in defects in both post-translational processing of wild-type thyroglobulin ( a secretory glycoprotein) as well as endoplasmic reticulum-associated protein degradation of mutant thyroglobulin, whereas degradation of a nonglycosylated misfolded secretory protein substrate appears unaffected. Knockdown of ATP2C1 is not associated with elevated steady state levels of ER chaperone proteins, nor does it block cellular activation of either the PERK, ATF6, or Ire1/XBP1 portions of the ER stress response. However, deficiency of ATP2C1 renders cells hypersensitive to ER stress. These data point to the important contributions of the Golgi-localized ATP2C1 protein in homeostatic maintenance throughout the secretory pathway.	Univ Michigan, Med Ctr, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA; Ctr Invest Enfermedades Infecciosas, Cuernavaca 62508, Morelos, Mexico; Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Groningen Hosp, Dept Dermatol, NL-9700 RB Groningen, Netherlands; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068304, Japan; Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 1138421, Japan	University of Michigan System; University of Michigan; University of Stuttgart; University System of Ohio; University of Cincinnati; University of Groningen; Kyoto University; Juntendo University	Arvan, P (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol Diabet & Metab, 5560 MSRB2,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu	Ramos-Castañeda, jose/V-6678-2019; Mori, Kazutoshi/K-6106-2015; Mori, Kazutoshi/AAW-5449-2020; Longo, Kenneth A/A-5631-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280, R01DK040344, R29DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040344-19, R01 DK048280, DK40344, DK48280, R01 DK048280-12A2, R01 DK040344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Behne MJ, 2003, J INVEST DERMATOL, V121, P688, DOI 10.1046/j.1523-1747.2003.12528.x; Bernards M, 2000, J INVEST DERMATOL, V114, P1058, DOI 10.1046/j.1523-1747.2000.00960-2.x; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Cronin SR, 2002, J CELL BIOL, V157, P1017, DOI 10.1083/jcb.200203052; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fairclough RJ, 2003, J BIOL CHEM, V278, P24721, DOI 10.1074/jbc.M300509200; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu M, 2003, J BIOL CHEM, V278, P14798, DOI 10.1074/jbc.M212070200; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; Mengesdorf T, 2001, BIOCHEM J, V356, P805, DOI 10.1042/0264-6021:3560805; Mitchell KJ, 2004, DIABETES, V53, P393, DOI 10.2337/diabetes.53.2.393; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Okorokov LA, 1998, FEMS MICROBIOL LETT, V162, P83, DOI 10.1111/j.1574-6968.1998.tb12982.x; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Reinhardt TA, 2004, AM J PHYSIOL-CELL PH, V286, pC164, DOI 10.1152/ajpcell.00065.2003; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Timmons L, 2002, MOL CELL, V10, P435, DOI 10.1016/S1097-2765(02)00657-3; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Ton VK, 2002, J BIOL CHEM, V277, P6422, DOI 10.1074/jbc.M110612200; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Van Baelen K, 2003, BIOCHEM BIOPH RES CO, V306, P430, DOI 10.1016/S0006-291X(03)00977-X; Varadi A, 2002, DIABETES, V51, pS190, DOI 10.2337/diabetes.51.2007.S190; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Vashist S, 2002, MOL BIOL CELL, V13, P3955, DOI 10.1091/mbc.02-06-0090; WITSELL DL, 1990, J BIOL CHEM, V265, P15731; Wootton LL, 2004, BBA-BIOMEMBRANES, V1664, P189, DOI 10.1016/j.bbamem.2004.05.009; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245	51	44	46	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9467	9473		10.1074/jbc.M413243200	http://dx.doi.org/10.1074/jbc.M413243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623514	Green Accepted, hybrid			2022-12-27	WOS:000227453100100
J	Salnikova, AB; Kryndushkin, DS; Smirnov, VN; Kushnirov, VV; Ter-Avanesyan, MD				Salnikova, AB; Kryndushkin, DS; Smirnov, VN; Kushnirov, VV; Ter-Avanesyan, MD			Nonsense suppression in yeast cells overproducing Sup35 (eRF3) is caused by its non-heritable amyloids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO APPEARANCE; SACCHAROMYCES-CEREVISIAE; PSI+ PRION; PROTEIN; AGGREGATION; GENE; PROPAGATION; REPLICATION; MAINTENANCE; DETERMINANT	The [PSI+] prion determinant of Saccharomyces cerevisiae causes nonsense suppressor phenotype due to a reduced function of the translation termination factor Sup35 (eRF3) polymerized into amyloid fibrils. Prion state of the Rnq1 protein, [PIN+], is required for the [PSI+] de novo generation but not propagation. Yeast [psi(-)] [PIN+] cells overproducing Sup35 can exhibit nonsense suppression without generation of a stable [PSI+]. Here, we show that in such cells, most of Sup35 represents amyloid polymers, although the remaining Sup35 monomer is sufficient for normal translation termination. The presence of these polymers strictly depends on [PIN+], suggesting that their maintenance relies on efficient generation de novo rather than inheritance. Sup35 polymers contain Rnq1, confirming a hypothesis that Rnq1 polymers seed Sup35 polymerization. About 10% of cells overproducing Sup35 form colonies on medium selective for suppression, which suggests that the proportion of Sup35 monomers to polymers varies between cells of transformants, allowing selection of cells deficient for soluble Sup35. A hybrid Sup35 with the N-terminal domain replaced for 66 glutamine residues also polymerizes and can cause nonsense suppression when overproduced. The described polymers of these proteins differ from the [PSI+] polymers by poor heritability and very high frequency of the de novo appearance, thus being more similar to amyloids than to prions.	Cardiol Res Ctr, Inst Expt Cardiol, Moscow 121552, Russia	National Medical Research Center of Cardiology	Ter-Avanesyan, MD (corresponding author), Cardiol Res Ctr, Inst Expt Cardiol, 3rd Cherepkovskaya St 15A, Moscow 121552, Russia.	mdter@cardio.ru	Vitaly, Kushnirov/AAU-6003-2021	Kushnirov, Vitaly/0000-0003-0316-0766				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley ME, 2004, MOL MICROBIOL, V51, P1649, DOI 10.1111/j.1365-2958.2003.03955.x; CHERNOFF YO, 1992, YEAST, V8, P489, DOI 10.1002/yea.320080702; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; DAGKESAMANSKAYA AR, 1991, GENETICS, V128, P513; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Derkatch IL, 1997, GENETICS, V147, P507; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Meriin AB, 2003, MOL CELL BIOL, V23, P7554, DOI 10.1128/MCB.23.21.7554-7565.2003; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; ROSE MD, 1990, METHODS YEAST GENETI, P184; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; TUITE MF, 1981, GENETICS, V98, P691; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	25	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8808	8812		10.1074/jbc.M410150200	http://dx.doi.org/10.1074/jbc.M410150200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15618222	hybrid			2022-12-27	WOS:000227453100024
J	Tautz, L; Bruckner, S; Sareth, S; Alonso, A; Bogetz, J; Bottini, N; Pellecchia, M; Mustelin, T				Tautz, L; Bruckner, S; Sareth, S; Alonso, A; Bogetz, J; Bottini, N; Pellecchia, M; Mustelin, T			Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; VIRULENCE DETERMINANT; RESPIRATORY BURST; PROTEIN; YOPH; ENTEROCOLITICA; PSEUDOTUBERCULOSIS; PLASMID; PESTIS; PHOSPHORYLATION	To avoid detection and targeting by the immune system, the plague-causing bacterium Yersinia pestis uses a type III secretion system to deliver a set of inhibitory proteins into the cytoplasm of immune cells. One of these proteins is an exceptionally active tyrosine phosphatase termed YopH, which paralyzes lymphocytes and macrophages by dephosphorylating critical tyrosine kinases and signal transduction molecules. Because Y. pestis strains lacking YopH are avirulent, we set out to develop small molecule inhibitors for YopH. We used a novel and cost-effective approach, in which leads from a chemical library screening were analyzed and computationally docked into the crystal structure of YopH. This resulted in the identification of a series of novel YopH inhibitors with nanomolar K-i values, as well as the structural basis for inhibition. Our inhibitors lack the polar phosphate-mimicking moiety of rationally designed tyrosine phosphatase inhibitors, and they readily entered live cells and rescued them from YopH-induced tyrosine dephosphorylation, signaling paralysis, and cell death. These inhibitors may become useful for treating the lethal infection by Y. pestis.	Burnham Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Mustelin, T (corresponding author), Burnham Inst, Infect & Inflammatory Dis Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Bogetz, Jori F./U-2258-2019; Alonso, Andrés/L-7523-2014; Pellecchia, Maurizio/Y-7072-2018; Ingegnoli, Francesca/B-6226-2017; Tautz, Lutz/M-9989-2014	Alonso, Andrés/0000-0001-8674-9378; Mustelin, Tomas/0000-0001-5912-8840; Ingegnoli, Francesca/0000-0002-6727-1273; Tautz, Lutz/0000-0002-4075-6238	NIAID NIH HHS [AI55789, AI53114] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055789, R21AI053114] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aepfelbacher M, 1999, BIOL CHEM, V380, P795, DOI 10.1515/BC.1999.099; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Alonso A, 2004, J BIOL CHEM, V279, P4922, DOI 10.1074/jbc.M308978200; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Andersson K, 1996, MOL MICROBIOL, V20, P1057, DOI 10.1111/j.1365-2958.1996.tb02546.x; Autenrieth IB, 1996, J MED MICROBIOL, V44, P285, DOI 10.1099/00222615-44-4-285; AUTENRIETH IB, 1993, INFECT IMMUN, V61, P2585, DOI 10.1128/IAI.61.6.2585-2595.1993; AUTENRIETH IB, 1993, IMMUNOBIOLOGY, V187, P1; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Black DS, 1998, MOL MICROBIOL, V29, P1263, DOI 10.1046/j.1365-2958.1998.01014.x; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; Cheng LW, 2000, J BACTERIOL, V182, P3183, DOI 10.1128/JB.182.11.3183-3190.2000; CHRISTIE A B, 1982, Ecology of Disease, V1, P111; Cleri D J, 1997, Semin Respir Infect, V12, P12; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; DeVinney R, 2000, TRENDS MICROBIOL, V8, P29, DOI 10.1016/S0966-842X(99)01657-1; Ernst JD, 2000, CELL MICROBIOL, V2, P379, DOI 10.1046/j.1462-5822.2000.00075.x; Evdokimov AG, 2001, ACTA CRYSTALLOGR D, V57, P793, DOI 10.1107/S0907444901004875; FRIESEN HG, 1995, MRC COMMUNIQUE, V21, P2; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; GREEN SP, 1995, J LEUKOCYTE BIOL, V57, P972, DOI 10.1002/jlb.57.6.972; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Guiyoule A, 2001, EMERG INFECT DIS, V7, P43, DOI 10.3201/eid0701.010106; HARTLAND EL, 1994, INFECT IMMUN, V62, P4445, DOI 10.1128/IAI.62.10.4445-4453.1994; Hawley RJ, 2001, ANNU REV MICROBIOL, V55, P235, DOI 10.1146/annurev.micro.55.1.235; Hinnebusch BJ, 1997, J MOL MED, V75, P645, DOI 10.1007/s001090050148; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Liang FB, 2003, J BIOL CHEM, V278, P41734, DOI 10.1074/jbc.M307152200; McGovern TW, 1999, ARCH DERMATOL, V135, P311, DOI 10.1001/archderm.135.3.311; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; Montagna LG, 2001, J BIOL CHEM, V276, P5005, DOI 10.1074/jbc.M009045200; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; Ruckdeschel K, 1996, INFECT IMMUN, V64, P724, DOI 10.1128/IAI.64.3.724-733.1996; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Sauvonnet N, 2002, MOL MICROBIOL, V45, P805, DOI 10.1046/j.1365-2958.2002.03053.x; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; STRALEY SC, 1986, INFECT IMMUN, V51, P445, DOI 10.1128/IAI.51.2.445-454.1986; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Titball RW, 1998, BRIT MED BULL, V54, P625, DOI 10.1093/oxfordjournals.bmb.a011715; Titball RW, 2001, VACCINE, V19, P4175, DOI 10.1016/S0264-410X(01)00163-3; Yao T, 1999, J EXP MED, V190, P1343, DOI 10.1084/jem.190.9.1343	51	58	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9400	9408		10.1074/jbc.M413122200	http://dx.doi.org/10.1074/jbc.M413122200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615724	hybrid			2022-12-27	WOS:000227453100092
J	Meier, S; Neupert, W; Herrmann, JM				Meier, S; Neupert, W; Herrmann, JM			Conserved N-terminal negative charges in the Tim17 subunit of the TIM23 translocase play a critical role in the import of preproteins into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; INNER MEMBRANE; SACCHAROMYCES-CEREVISIAE; PRESEQUENCE TRANSLOCASE; YEAST; COMPLEX; MOTOR; COMPONENT; CHANNEL; BINDING	The TIM23 complex of the mitochondrial inner membrane mediates the import of preproteins that contain positively charged targeting signals. This translocase consists of the two phylogenetically related membrane-embedded subunits Tim17 and Tim23 to which four largely hydrophilic subunits, Tim50, Tim44, Tim16, and Tim14, are attached. Whereas in vitro reconstitution experiments have suggested a pore-forming capacity of recombinant Tim23, virtually nothing is known about the properties and function of Tim17. We employed a combined genetic and biochemical approach to address the function of Tim17 in preprotein translocation. Tim17 exposes an N-terminal hydrophilic stretch into the intermembrane space. Truncation of the first 11 amino acid residues of this stretch did not affect the stability or integrity of TIM23 subunits but strongly impaired the import of preproteins. Moreover, expression of the truncated Tim17 variant led to a dominant negative effect on the mitochondrial membrane potential. By an alanine-scanning approach we identified two conserved negative charges in the N terminus of Tim17 as critical for Tim17 function. The replacement of these positions by positively charged residues results in a strong growth defect, which can be cured by reverting two conserved positive charges into aspartate residues between transmembrane domains two and three of Tim17. On the basis of these observations we propose that charged residues in Tim17 are critical for the preprotein-induced gating of the TIM23 translocase.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Herrmann, JM (corresponding author), Univ Munich, Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	hannes.herrmann@bio.med.uni-muenchen.de						Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Brachmann CB, 1998, YEAST, V14, P115; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; GARTNER F, 1995, J BIOL CHEM, V270, P3788; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; GLASER SM, 1990, MOL CELL BIOL, V10, P1873, DOI 10.1128/MCB.10.5.1873; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Herrmann JM, 2001, METHOD CELL BIOL, V65, P217, DOI 10.1016/S0091-679X(01)65013-1; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Sambrook J, 1989, MOL CLONING; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; SIKORSKI RS, 1989, GENETICS, V122, P19; Szyrach G, 2003, EMBO J, V22, P6448, DOI 10.1093/emboj/cdg623; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	37	59	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7777	7785		10.1074/jbc.M412158200	http://dx.doi.org/10.1074/jbc.M412158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15618217	hybrid			2022-12-27	WOS:000227395700042
J	Barbato, JC; Huang, QQ; Hossaint, MM; Bond, M; Jin, JP				Barbato, JC; Huang, QQ; Hossaint, MM; Bond, M; Jin, JP			Proteolytic N-terminal truncation of cardiac troponin I enhances ventricular diastolic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WORKING MOUSE HEART; OXYGEN-CONSUMPTION; FLUID SHIFTS; PRESSURE; PHOSPHORYLATION; TIME; PROTEINS; PEPTIDE; CALCIUM; DOMAIN	Besides the core structure conserved in all troponin I isoforms, cardiac troponin I (cTnI) has an N-terminal extension that contains phosphorylation sites for protein kinase A under beta-adrenergic regulation. A restricted cleavage of this N-terminal regulatory domain occurs in normal cardiac muscle and is up-regulated during hemodynamic adaptation (Z.-B. Yu, L.-F. Zhang, and J.-P. Jin (2001) J. Biol. Chem. 276, 15753-15760). In the present study, we developed transgenic mice overexpressing the N-terminal truncated cTnI (cTnI-ND) in the heart to examine its biochemical and physiological significance. Ca2+-activated actomyosin ATPase activity showed that cTnI-ND myofibrils had lower affinity for Ca2+ than controls, similar to the effect of isoproterenol treatment. In vivo and isolated working heart experiments revealed that cTnI-ND hearts had a significantly faster rate of relaxation and lower left ventricular end diastolic pressure compared with controls. The higher baseline relaxation rate of cTnI-ND hearts was at a level similar to that of wild type mouse hearts under beta-adrenergic stimulation. The decrease in cardiac output due to lowered preload was significantly smaller for cTnI-ND hearts compared with controls. These findings indicate that removal of the N-terminal extension of cTnI via restricted proteolysis enhances cardiac function by increasing the rate of myocardial relaxation and lowering left ventricular end diastolic pressure to facilitate ventricular filling, thus resulting in better utilization of the Frank-Starling mechanism.	Northwestern Univ, Feinberg Sch Med, Sect Mol Cardiol, Evanston, IL 60201 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Northwestern University; Feinberg School of Medicine; Case Western Reserve University; University System of Maryland; University of Maryland Baltimore	Jin, JP (corresponding author), Northwestern Univ, Feinberg Sch Med, Sect Mol Cardiol, Evanston, IL 60201 USA.	jpjin@northwestern.edu	Jin, Jian-Ping/AAD-1149-2020	Jin, JP/0000-0001-9932-1063	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056256, T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016613] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56256, T32-HL07653] Funding Source: Medline; NIAMS NIH HHS [AR-048816] Funding Source: Medline; NIA NIH HHS [AG-16613] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barbato JC, 2002, HYPERTENSION, V40, P130, DOI 10.1161/01.HYP.0000025879.29822.24; Biesiadecki BJ, 2004, J BIOL CHEM, V279, P13825, DOI 10.1074/jbc.M314225200; Biesiadecki BJ, 2002, J BIOL CHEM, V277, P18459, DOI 10.1074/jbc.M200788200; BRAZIER J, 1974, CIRCULATION, V49, P968, DOI 10.1161/01.CIR.49.5.968; BUCKBERG GD, 1972, CIRC RES, V30, P67, DOI 10.1161/01.RES.30.1.67; BUNGO MW, 1987, J APPL PHYSIOL, V62, P278, DOI 10.1152/jappl.1987.62.1.278; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; Chemla D, 2000, AM J PHYSIOL-HEART C, V279, pH122, DOI 10.1152/ajpheart.2000.279.1.H122; Convertino V, 1992, J Fla Med Assoc, V79, P517; Convertino VA, 1997, AM J PHYSIOL-REG I, V273, pR93, DOI 10.1152/ajpregu.1997.273.1.R93; CONVERTINO VA, 1994, AM J PHYSIOL, V266, pR1962, DOI 10.1152/ajpregu.1994.266.6.R1962; DUNCAN HW, 1987, BASIC RES CARDIOL, V82, P226, DOI 10.1007/BF01906853; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FERRO G, 1995, CIRCULATION, V92, P342, DOI 10.1161/01.CIR.92.3.342; Fiske CH, 1925, J BIOL CHEM, V66, P375; GAFFNEY FA, 1985, AM J CARDIOL, V56, P634, DOI 10.1016/0002-9149(85)91025-2; Gauthier NS, 1998, J MOL CELL CARDIOL, V30, P453, DOI 10.1006/jmcc.1997.0610; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GOTO Y, 1990, CIRC RES, V66, P999, DOI 10.1161/01.RES.66.4.999; GUO XD, 1994, J BIOL CHEM, V269, P15210; GUYTON AC, 1973, AM HEART J, V86, P431, DOI 10.1016/0002-8703(73)90132-4; HISANO R, 1987, CIRC RES, V61, P318, DOI 10.1161/01.RES.61.3.318; HOFFMAN JIE, 1978, AM J CARDIOL, V41, P327, DOI 10.1016/0002-9149(78)90174-1; Hope SA, 2002, AM J PHYSIOL-HEART C, V283, pH1150, DOI 10.1152/ajpheart.00216.2002; Huang QQ, 1999, J PHYSIOL-LONDON, V520, P231, DOI 10.1111/j.1469-7793.1999.00231.x; Jin JP, 2001, BIOCHEMISTRY-US, V40, P2623, DOI 10.1021/bi002423j; Jin JP, 1996, GENE, V168, P217, DOI 10.1016/0378-1119(95)00803-9; Jin JP, 1996, BIOCHEM BIOPH RES CO, V225, P883, DOI 10.1006/bbrc.1996.1267; Karpe Dixon J., 2001, STAT METHODS HLTH CA, P371; Kass DA, 1996, CIRCULATION, V93, P1533, DOI 10.1161/01.CIR.93.8.1533; Khairallah M, 2004, AM J PHYSIOL-HEART C, V286, pH1461, DOI 10.1152/ajpheart.00942.2003; Layland J, 2004, J PHYSIOL-LONDON, V556, P835, DOI 10.1113/jphysiol.2004.061176; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; McDonough JL, 1999, CIRC RES, V84, P9; MOORE TP, 1987, AVIAT SPACE ENVIR MD, V58, pA91; Mullan BA, 2002, HYPERTENSION, V40, P804, DOI 10.1161/01.HYP.0000039961.13718.00; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; NEELY JR, 1967, AM J PHYSIOL, V212, P804; ORourke MF, 1996, J HYPERTENS, V14, pS147; PARAZYNSKI SE, 1991, J APPL PHYSIOL, V71, P2469, DOI 10.1152/jappl.1991.71.6.2469; Perhonen MA, 2001, J APPL PHYSIOL, V91, P645, DOI 10.1152/jappl.2001.91.2.645; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; Sangha DS, 2001, J APPL PHYSIOL, V91, P789, DOI 10.1152/jappl.2001.91.2.789; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; SOLARO RJ, 1980, EUR HEART J SUPPL, V1, P21; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; TOMASELLI CM, 1987, AVIAT SPACE ENVIR MD, V58, P3; Ward DG, 2002, J BIOL CHEM, V277, P41795, DOI 10.1074/jbc.M206744200; Wu LL, 2001, AM J PHYSIOL-REG I, V281, pR408, DOI 10.1152/ajpregu.2001.281.2.R408; Yu ZB, 2001, J BIOL CHEM, V276, P15753, DOI 10.1074/jbc.M011048200; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773	56	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6602	6609		10.1074/jbc.M408525200	http://dx.doi.org/10.1074/jbc.M408525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611140	hybrid			2022-12-27	WOS:000227332700045
J	Cho, KN; Choi, JY; Kim, CH; Baek, SJ; Chung, KC; Moon, UY; Kim, RS; Lee, WJ; Koo, JS; Yoon, JH				Cho, KN; Choi, JY; Kim, CH; Baek, SJ; Chung, KC; Moon, UY; Kim, RS; Lee, WJ; Koo, JS; Yoon, JH			Prostaglandin E-2 induces MUC8 gene expression via a mechanism involving ERK MAPK/RSK1/cAMP response element binding protein activation in human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GENOMIC ORGANIZATION; INTERLEUKIN-1-BETA; SEQUENCE; KINASE; MUC5AC; PHOSPHORYLATION; DIFFERENTIATION; RECEPTORS; REVEALS	MUC8 gene expression is overexpressed in nasal polyp epithelium and is also increased by treatment with inflammatory mediators in nasal epithelial cells. These data suggest that MUC8 may be one of important mucin genes expressed in human airway. However, the mechanisms of various inflammatory mediator-induced MUC8 gene expression in normal nasal epithelial cells remain unclear. We examined the mechanism by which prostaglandin E-2 (PGE2), an arachidonic acid metabolite, increases MUC8 gene expression levels. Here, we show that ERK mitogen-activated protein kinase is essential for PGE2-induced MUC8 gene expression in normal human nasal epithelial cells and that p90 ribosomal S 6 protein kinase 1 (RSK1) mediates the PGE2-induced phosphorylation of cAMP-response element binding protein. Our results also indicate that cAMP-response element at the -803 region of the MUC8 promoter is an important site of PGE2-induced MUC8 gene expression. In conclusion, this study gives insights into the molecular mechanism of PGE2-induced MUC8 gene expression in human airway epithelial cells.	Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Airway Mucus Inst, Seoul 120752, South Korea; Yonsei Univ, Coll Med, BK21 Project Med Sci, Seoul 120752, South Korea; Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Texas System; UTMD Anderson Cancer Center; Yonsei University; Ewha Womans University	Yoon, JH (corresponding author), Yonsei Univ, Coll Med, Dept Otorhinolaryngol, 134 Shinchon Dong, Seoul 120752, South Korea.	jhyoon@yumc.yonsei.ac.kr	Yoon, Joo-Heon/E-5781-2016; Koo, J Peter/AAE-6700-2019; Kim, Chang-Hoon/D-7205-2016	Kim, Chang-Hoon/0000-0003-1238-6396; Yoon, Joo-Heon/0000-0003-2404-7156; Baek, Seung/0000-0001-7866-7778				Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Boiti C, 2001, J ENDOCRINOL, V168, P141, DOI 10.1677/joe.0.1680141; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; BUKHAVE K, 1980, GASTROENTEROLOGY, V78, P32; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen Y, 2004, AM J RESP CELL MOL, V30, P155, DOI 10.1165/rcmb.2003-0103OC; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gray T, 2004, MOL PHARMACOL, V66, P337, DOI 10.1124/mol.66.2.337; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; GUM JR, 1994, J BIOL CHEM, V269, P2440; Higuchi T, 2004, J BIOL CHEM, V279, P1968, DOI 10.1074/jbc.M304558200; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Keates AC, 1997, BIOCHEM J, V324, P295, DOI 10.1042/bj3240295; KIM CH, 2005, IN PRESS ACTA OTOLAR; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Kim YD, 2002, MOL PHARMACOL, V62, P1112, DOI 10.1124/mol.62.5.1112; Kimura M, 2001, ENDOCRINOLOGY, V142, P4428, DOI 10.1210/en.142.10.4428; Lapensee L, 1997, FERTIL STERIL, V68, P702, DOI 10.1016/S0015-0282(97)00317-8; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Plath KES, 2003, CLIN EXP ALLERGY, V33, P342, DOI 10.1046/j.1365-2222.2003.01610.x; Roberts ML, 1998, BIOCHEM BIOPH RES CO, V251, P166, DOI 10.1006/bbrc.1998.9434; Seong JK, 2002, ACTA OTO-LARYNGOL, V122, P401, DOI 10.1080/00016480260000094; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SHANKAR V, 1994, BIOCHEM J, V300, P295, DOI 10.1042/bj3000295; Shimamoto C, 2005, AM J PHYSIOL-GASTR L, V288, pG39, DOI 10.1152/ajpgi.00060.2004; Song KS, 2003, J BIOL CHEM, V278, P34890, DOI 10.1074/jbc.M303911200; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; SPICER AP, 1991, J BIOL CHEM, V266, P15099; van de Bovenkamp JHB, 1998, BIOCHEM BIOPH RES CO, V245, P853, DOI 10.1006/bbrc.1998.8535; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; VanKlinken BJW, 1997, BIOCHEM BIOPH RES CO, V238, P143, DOI 10.1006/bbrc.1997.7258; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yoon JH, 2002, DIFFERENTIATION, V70, P77, DOI 10.1046/j.1432-0436.2002.700202.x; Yoon JH, 2000, ANN OTO RHINOL LARYN, V109, P594, DOI 10.1177/000348940010900612	42	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6676	6681		10.1074/jbc.M412722200	http://dx.doi.org/10.1074/jbc.M412722200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15615708	hybrid			2022-12-27	WOS:000227332700055
J	Sturm, B; Bistrich, U; Schranzhofer, M; Sarsero, JP; Rauen, U; Scheiber-Mojdehkar, B; de Groot, H; Ioannou, P; Petrat, F				Sturm, B; Bistrich, U; Schranzhofer, M; Sarsero, JP; Rauen, U; Scheiber-Mojdehkar, B; de Groot, H; Ioannou, P; Petrat, F			Friedreich's ataxia, no changes in mitochondrial labile iron in human lymphoblasts and fibroblasts - A decrease in antioxidative capacity?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; TRANSFERRIN RECEPTOR; CHELATABLE IRON; RESPONSIVE ELEMENT; YEAST FRATAXIN; MESSENGER-RNA; TRANSLATIONAL REGULATION; PERMEABILITY TRANSITION; ACONITASE ACTIVITY; LIVING CELLS	Friedreich's ataxia (FRDA) is caused by low expression of frataxin, a small mitochondrial protein. Studies with both yeast and mammals have suggested that decreased frataxin levels lead to elevated intramitochondrial concentrations of labile (chelatable) iron, and consequently to oxidative mitochondrial damage. Here, we used the mitochondrion-selective fluorescent iron indicator/chelator rhodamine B-[(1,10-phenanthrolin-5-yl)aminocarbonyl]benzylester (RPA) to determine the mitochondrial chelatable iron of FRDA patient lymphoblast and fibroblast cell lines, in comparison with age- and sex-matched control cells. No alteration in the concentration of mitochondrial chelatable iron could be observed in patient cells, despite strongly decreased frataxin levels. Uptake studies with 55 Fe-transferrin and iron loading with ferric ammonium citrate revealed no significant differences in transferrin receptor density and iron responsive protein/iron regulatory element binding activity between patients and controls. However, sensitivity to H2O2 was significantly increased in patient cells, and H2O2 toxicity could be completely inhibited by the ubiquitously distributing iron chelator 2,2'-dipyridyl, but not by the mitochondrion-selective chelator RPA. Our data strongly suggest that frataxin deficiency does not affect the mitochondrial labile iron pool or other parameters of cellular iron metabolism and suggest a decreased antioxidative defense against extramitochondrial iron-derived radicals in patient cells. These results challenge current concepts favoring the use of mitochondrion-specific iron chelators and antioxidants to treat FRDA.	Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, D-45122 Essen, Germany; Med Univ Vienna, Dept Med Chem, A-1090 Vienna, Austria; Vienna Bioctr, Max F Ferutz Labs, Inst Med Biochem, Div Mol Biol, A-1030 Vienna, Austria; Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Res Grp, Parkville, Vic 3052, Australia	University of Duisburg Essen; Medical University of Vienna; Vienna Biocenter (VBC); Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Petrat, F (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.	frank.petrat@uni-essen.de	Rauen, Ursula/N-2137-2014; Sarsero, Joseph/D-1881-2011	Scheiber-Mojdehkar, Barbara/0000-0002-4114-9413; Sturm, Brigitte/0000-0002-2493-4874				Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; ALBERTS B, 1994, MOL BIOL CELL, P657; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BATES GW, 1975, J BIOL CHEM, V250, P2177; Becker EM, 2002, BLOOD, V99, P3813, DOI 10.1182/blood.V99.10.3813; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Campanella A, 2004, HUM MOL GENET, V13, P2279, DOI 10.1093/hmg/ddh232; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Delatycki MB, 1999, ANN NEUROL, V45, P673, DOI 10.1002/1531-8249(199905)45:5<673::AID-ANA20>3.3.CO;2-H; Dhungana S, 2004, BIOCHEMISTRY-US, V43, P205, DOI 10.1021/bi0353631; Feelders RA, 1999, CLIN CHEM LAB MED, V37, P1, DOI 10.1515/CCLM.1999.001; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; GUO B, 1994, J BIOL CHEM, V269, P24252; HALLIWELL B, 1999, FREE RADICAL BIO MED, P132; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; Jiralerspong S, 2001, FEBS LETT, V509, P101, DOI 10.1016/S0014-5793(01)03140-4; Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Konijn AM, 1999, BLOOD, V94, P2128, DOI 10.1182/blood.V94.6.2128.418k20_2128_2134; Lamarche J., 1993, HDB CEREBELLAR DIS, P453; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Levi S, 2004, INT J BIOCHEM CELL B, V36, P1887, DOI 10.1016/j.biocel.2003.10.020; Lomonosova EE, 1998, FREE RADICAL BIO MED, V25, P493, DOI 10.1016/S0891-5849(98)00080-X; Mascotti DP, 1996, PROG NUCLEIC ACID RE, V55, P121, DOI 10.1016/S0079-6603(08)60191-9; Mateo I, 2004, ACTA NEUROL SCAND, V109, P75, DOI 10.1034/j.1600-0404.2003.00190.x; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Petrat F, 2002, BIOCHEM J, V362, P137, DOI 10.1042/0264-6021:3620137; Petrat F, 2002, BIOL CHEM, V383, P489, DOI 10.1515/BC.2002.051; Petrat F, 2001, BIOCHEM J, V356, P61, DOI 10.1042/0264-6021:3560061; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Ponka P, 1997, BLOOD, V89, P1; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Rauen U, 2004, J HEPATOL, V40, P607, DOI 10.1016/j.jhep.2003.12.021; Rauen U, 2003, FREE RADICAL BIO MED, V35, P1664, DOI 10.1016/j.freeradbiomed.2003.09.018; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Rotig A, 2002, TRENDS MOL MED, V8, P221, DOI 10.1016/S1471-4914(02)02330-4; Scarano V, 2001, NEUROLOGY, V57, P159, DOI 10.1212/WNL.57.1.159; Sitte K, 2002, CLIN GENET, V62, P250, DOI 10.1034/j.1399-0004.2002.620312.x; Smith R. M., 1990, CRITICAL STABILITY C, V2, P251; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Sugrue MM, 2001, BIOL SIGNAL RECEPT, V10, P176; Tan G, 2001, HUM MOL GENET, V10, P2099, DOI 10.1093/hmg/10.19.2099; Tan GL, 2003, HUM MOL GENET, V12, P1699, DOI 10.1093/hmg/ddg187; Tozzi G, 2002, ARCH DIS CHILD, V86, P376, DOI 10.1136/adc.86.5.376; Voncken M, 2004, NEUROGENETICS, V5, P1, DOI 10.1007/s10048-003-0170-z; Waldvogel D, 1999, ANN NEUROL, V46, P123, DOI 10.1002/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; Wilson RB, 2000, ANN NEUROL, V47, P659, DOI 10.1002/1531-8249(200005)47:5<659::AID-ANA17>3.3.CO;2-K; Wong A, 2000, ANTIOXID REDOX SIGN, V2, P461, DOI 10.1089/15230860050192233	61	59	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6701	6708		10.1074/jbc.M408717200	http://dx.doi.org/10.1074/jbc.M408717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15615730	hybrid			2022-12-27	WOS:000227332700058
J	Carlson, BA; Xu, XM; Gladyshev, VN; Hatfield, DL				Carlson, BA; Xu, XM; Gladyshev, VN; Hatfield, DL			Selective rescue of selenoprotein expression in mice lacking a highly specialized methyl group in selenocysteine tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED DISRUPTION; SELENIUM DEFICIENCY; MESSENGER-RNAS; KNOCKOUT MICE; GPX2 GENES; MOUSE; CANCER; TRANSLATION; PROTEIN; TRSP	Selenocysteine (Sec) is the 21st amino acid in the genetic code. Its tRNA is variably methylated on the 2'-0hydroxyl site of the ribosyl moiety at position 34 (Um34). Herein, we identified a role of Um34 in regulating the expression of some, but not all, selenoproteins. A strain of knock-out transgenic mice was generated, wherein the Sec tRNA gene was replaced with either wild type or mutant Sec tRNA transgenes. The mutant transgene yielded a tRNA that lacked two base modifications, Nisopentenyladenosine at position 37 (i(6) A37) and Um34. Several selenoproteins, including glutathione peroxidases 1 and 3, SeIR, and SelT, were not detected in mice rescued with the mutant transgene, whereas other selenoproteins, including thioredoxin reductases 1 and 3 and glutathione peroxidase 4, were expressed in normal or reduced levels. Northern blot analysis suggested that other selenoproteins (e.g. SeIW) were also poorly expressed. This novel regulation of protein expression occurred at the level of translation and manifested a tissue-specific pattern. The available data suggest that the Um34 modification has greater influence than the VA37 modification in regulating the expression of various mammalian selenoproteins and Um34 is required for synthesis of several members of this protein class. Many proteins that were poorly rescued appear to be involved in responses to stress, and their expression is also highly dependent on selenium in the diet. Furthermore, their mRNA levels are regulated by selenium and are subject to nonsense-mediated decay. Overall, this study described a novel mechanism of regulation of protein expression by tRNA modification that is in turn regulated by levels of the trace element, selenium.	NCI, Canc Res Ctr, Lab Canc Prevent, Mol Biol Selnium Sect,NIH, Bethesda, MD 20892 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System; University of Nebraska Lincoln	Hatfield, DL (corresponding author), NCI, Canc Res Ctr, Lab Canc Prevent, Mol Biol Selnium Sect,NIH, Bldg 37,Rm 6032A, Bethesda, MD 20892 USA.	hatfield@dc37a.nci.nih.gov	Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013	Gladyshev, Vadim/0000-0002-0372-7016	NATIONAL CANCER INSTITUTE [ZIABC005317, Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM061603] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behne D, 1998, ANALYST, V123, P871, DOI 10.1039/a708699g; BEIER H, 1984, EMBO J, V3, P1091, DOI 10.1002/j.1460-2075.1984.tb01934.x; Bock A, 2001, SELENIUM: ITS MOLECULAR BIOLOGY AND ROLE IN HUMAN HEALTH, P7; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Carlson BA, 1999, VIROLOGY, V255, P2, DOI 10.1006/viro.1998.9569; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; Cheng WH, 2003, FREE RADICAL BIO MED, V34, P918, DOI 10.1016/S0891-5849(03)00021-2; Chittum HS, 1997, BIOCHEMISTRY-US, V36, P8634, DOI 10.1021/bi970608t; Chittum HS, 1997, BBA-MOL CELL RES, V1359, P25, DOI 10.1016/S0167-4889(97)00092-X; Chu FF, 2004, CANCER RES, V64, P962, DOI 10.1158/0008-5472.CAN-03-2272; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; DIAMOND AM, 1993, J BIOL CHEM, V268, P14215; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Esworthy RS, 2001, AM J PHYSIOL-GASTR L, V281, pG848, DOI 10.1152/ajpgi.2001.281.3.G848; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; Gladyshev VN, 1999, P NATL ACAD SCI USA, V96, P835, DOI 10.1073/pnas.96.3.835; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; HILL KE, 1992, BIOCHEM BIOPH RES CO, V185, P260, DOI 10.1016/S0006-291X(05)80984-2; Hu YJ, 2003, CANCER RES, V63, P3347; Hu YJ, 2001, CANCER RES, V61, P2307; Jameson RR, 2004, RNA, V10, P1142, DOI 10.1261/rna.7370104; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; Kim LK, 2000, RNA, V6, P1306, DOI 10.1017/S1355838200000388; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2000, J BIOL CHEM, V275, P35540, DOI 10.1074/jbc.M004014200; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; Lei XG, 2001, BIOFACTORS, V14, P93, DOI 10.1002/biof.5520140113; MEIER F, 1985, EMBO J, V4, P823, DOI 10.1002/j.1460-2075.1985.tb03704.x; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Ratnasinghe D, 2000, CANCER RES, V60, P6381; Schneider MJ, 2001, MOL ENDOCRINOL, V15, P2137, DOI 10.1210/me.15.12.2137; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Weiss SL, 1998, RNA, V4, P816, DOI 10.1017/S1355838298971990; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Yeung CH, 2000, BIOL REPROD, V63, P612, DOI 10.1095/biolreprod63.2.612	45	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5542	5548		10.1074/jbc.M411725200	http://dx.doi.org/10.1074/jbc.M411725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15611090	hybrid, Green Published			2022-12-27	WOS:000227217100054
J	Wandall, HH; Pizette, S; Pedersen, JW; Eichert, H; Levery, SB; Mandel, U; Cohen, SM; Clausen, H				Wandall, HH; Pizette, S; Pedersen, JW; Eichert, H; Levery, SB; Mandel, U; Cohen, SM; Clausen, H			Egghead and brainiac are essential for glycosphingolipid biosynthesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EGF RECEPTOR; DROSOPHILA-MELANOGASTER; UDP-GLCNAC; 3 MEMBERS; EXPRESSION; FAMILY; ALPHA; DIFFERENTIATION; ENCODES	The Drosophila genes, brainiac and egghead, encode glycosyltransferases predicted to act sequentially in early steps of glycosphingolipid biosynthesis, and both genes are required for development in Drosophila. egghead encodes a beta4-mannosyltransferase, and brainiac encodes a beta3-N-acetylglucosaminyltransferase predicted by in vitro analysis to control synthesis of the glycosphingolipid core structure, GlcNAcbeta1-3Manbeta14Glcbeta1-Cer, found widely in invertebrates but not vertebrates. In this report we present direct in vivo evidence for this hypothesis. egghead and brainiac mutants lack elongated glycosphingolipids and exhibit accumulation of the truncated precursor glycosphingolipids. Furthermore, we demonstrate that despite fundamental differences in the core structure of mammalian and Drosophila glycosphingolipids, the Drosophila egghead mutant can be rescued by introduction of the mammalian lactosylceramide glycosphingolipid biosynthetic pathway (Galbeta1-4Glcbeta1-Cer) using a human beta4-galactosyltransferase (beta4Gal-T6) transgene. Conversely, introduction of egghead in vertebrate cells (Chinese hamster ovary) resulted in near complete blockage of biosynthesis of glycosphingolipids and accumulation of Manbeta1-4GIcbeta1-Cer. The study demonstrates that glycosphingolipids are essential for development of complex organisms and suggests that the function of the Drosophila glycosphingolipids in development does not depend on the core structure.	European Mol Biol Lab, Dev Biol Unit, D-69117 Heidelberg, Germany; Univ Copenhagen, Fac Hlth Sci, DK-2200 Copenhagen N, Denmark; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA	European Molecular Biology Laboratory (EMBL); University of Copenhagen; University System Of New Hampshire; University of New Hampshire	Cohen, SM (corresponding author), European Mol Biol Lab, Dev Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Stephen.Cohen@embl-heidelberg.de	Cohen, Stephen M/G-9930-2011; clausen, henrik/AAD-8016-2021	Cohen, Stephen M/0000-0003-2858-9163; Wandall, Hans H./0000-0003-0240-9232; Mandel, Ulla/0000-0001-7012-9836; Clausen, Henrik/0000-0002-0915-5055				Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Bennion B, 2003, J LIPID RES, V44, P2073, DOI 10.1194/jlr.M300184-JLR200; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DE SB, 1999, NATURE, V398, P518; FENDERSON BA, 1986, J CELL BIOL, V103, pA225; GOODE S, 1992, DEVELOPMENT, V116, P177; Goode S, 1996, DEVELOPMENT, V122, P3863; Goode S, 1996, DEV BIOL, V178, P35, DOI 10.1006/dbio.1996.0196; Griffitts JS, 2003, J BIOL CHEM, V278, P45594, DOI 10.1074/jbc.M308142200; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; KOGANEYA AK, 2004, J BIOL CHEM, V279, P35995; Kudo T, 2002, J BIOL CHEM, V277, P47724, DOI 10.1074/jbc.M205839200; Mandel U, 1999, GLYCOBIOLOGY, V9, P43, DOI 10.1093/glycob/9.1.43; Meuillet EJ, 2000, EXP CELL RES, V256, P74, DOI 10.1006/excr.1999.4509; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Muller R, 2002, J BIOL CHEM, V277, P32417, DOI 10.1074/jbc.C200381200; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Rebbaa A, 1996, GLYCOBIOLOGY, V6, P399, DOI 10.1093/glycob/6.4.399; Rubsam R, 1998, MECH DEVELOP, V72, P131, DOI 10.1016/S0925-4773(98)00023-9; Schwientek T, 2002, J BIOL CHEM, V277, P32421, DOI 10.1074/jbc.M206213200; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Urban S, 2002, EMBO J, V21, P4277, DOI 10.1093/emboj/cdf434; Wandall HH, 2003, J BIOL CHEM, V278, P1411, DOI 10.1074/jbc.C200619200; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	31	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4858	4863		10.1074/jbc.C400571200	http://dx.doi.org/10.1074/jbc.C400571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15611100	hybrid			2022-12-27	WOS:000227096600105
J	Saksena, S; Gill, RK; Tyagi, S; Alrefai, WA; Sarwar, Z; Ramaswamy, K; Dudeja, PK				Saksena, S; Gill, RK; Tyagi, S; Alrefai, WA; Sarwar, Z; Ramaswamy, K; Dudeja, PK			Involvement of c-Src and protein kinase C delta in the inhibition of Cl-/OH- exchange activity in Caco-2 cells by serotonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT DISTAL COLON; TYROSINE PHOSPHORYLATION; ELECTROLYTE TRANSPORT; RECEPTOR SUBTYPES; 5-HT4 RECEPTOR; CHOLERA-TOXIN; ILEAL MUCOSA; NITRIC-OXIDE; INTESTINAL SECRETAGOGUE; SECRETORY RESPONSE	Serotonin (5-hydroxytryptamine (5-HT)) is an important neurotransmitter and intercellular messenger regulating various gastrointestinal functions, including electrolyte transport. To date, however, no information is available with respect to its effects on the human intestinal apical anion exchanger Cl-/OH- (HCO3-). The present studies were therefore undertaken to examine the direct effects of serotonin on OH- gradient-driven 4,4 '-diisothiocyanato-stilbene-2,2 '-disulfonic acid-sensitive Cl-36(-) uptake utilizing the post-confluent transformed human intestinal epithelial cell line Caco-2. Our results demonstrate that serotonin inhibits Cl-/OH- exchange activity in Caco-2 cells via both tyrosine kinase and Ca2+-independent protein kinase C delta-mediated pathways involving either 5-HT3 or 5-HT4 receptor subtype. The data consistent with our inference are as follows. (i) The short term treatment of cells with 5-HT (0.1 mu M) for 15-60 min significantly decreased C-/OH- exchange (50-70%, p < 0.05). (ii) The specific agonists for 5-HT3, m-chlorophenylbiguanide, and 5-HT4, 3-(4-allylpiperazin-1-yl)-2-quinoxaline chloronitrile, mimicked the effects of serotonin. (iii) Tropisetron dual inhibitor for both the 5-HT3/4 receptor subtypes significantly blocked the inhibition, whereas specific 5-HT3 (Y-25130) or 5-HT4 receptor (RS39604) antagonist failed to block the inhibitory effects of 5-HT. (iv) The Ca2+ chelator 1,2-bis(2-aminophenoxy) ethane-N,N,N ',N '- tetraacetic acid tetra( acetoxymethyl ester) had no effect on the serotonin-induced inhibition. (v) The specific protein kinase C (PKC) inhibitors chelerythrine chloride or calphostin C completely blocked the inhibition by 5-HT. (vi) The specific inhibitor for PKC delta, rottlerin, significantly blocked the inhibition by 5-HT. (vii) The specific tyrosine kinase inhibitor, herbimycin, or Src family kinase inhibitor, PP1, abolished the 5-HT-mediated inhibition of Cl-/OH- exchange activity. (viii) 5-HT stimulated tyrosine phosphorylation of c-Src kinase and PKC delta.	Univ Illinois, Med Res Serv, Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA; Univ Illinois, Dept Med, Sect Digest Dis & Nutr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Dudeja, PK (corresponding author), Univ Illinois, Med Res Serv, Jesse Brown Vet Affairs Med Ctr, 600-151,820 S Damen Ave, Chicago, IL 60612 USA.	pkdudeja@uic.edu			NIDDK NIH HHS [DK 67990, DK 33349, DK 68324, DK62221, DK54016] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054016, R01DK068324, R01DK067990, R01DK033349] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alcalde AI, 2000, EUR J PHARMACOL, V403, P9, DOI 10.1016/S0014-2999(00)00484-2; BEUBLER E, 1990, GASTROENTEROLOGY, V99, P83, DOI 10.1016/0016-5085(90)91233-V; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOCKAERT J, 1992, TRENDS PHARMACOL SCI, V13, P141, DOI 10.1016/0165-6147(92)90051-7; BOLTON JE, 1977, J MEMBRANE BIOL, V35, P159, DOI 10.1007/BF01869947; BONHAUS DW, 1993, J NEUROCHEM, V61, P1927, DOI 10.1111/j.1471-4159.1993.tb09835.x; Borman RA, 1997, ANN NY ACAD SCI, V812, P224, DOI 10.1111/j.1749-6632.1997.tb48183.x; BORMAN RA, 1993, BRIT J PHARMACOL, V110, P927, DOI 10.1111/j.1476-5381.1993.tb13901.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHHEIT KH, 1989, N-S ARCH PHARMACOL, V339, P704; BUDHOO MR, 1994, J SURG RES, V57, P44, DOI 10.1006/jsre.1994.1107; BURLEIGH DE, 1993, EUR J PHARMACOL, V241, P125, DOI 10.1016/0014-2999(93)90943-C; CHALLACOMBE DN, 1977, GUT, V18, P882, DOI 10.1136/gut.18.11.882; COOKE HJ, 1986, GASTROENTEROLOGY, V90, P1057, DOI 10.1016/0016-5085(86)90889-9; COOKE HJ, 1991, AM J PHYSIOL, V261, pG833, DOI 10.1152/ajpgi.1991.261.5.G833; COOKE HJ, 1985, EUR J PHARMACOL, V111, P329, DOI 10.1016/0014-2999(85)90639-9; COX DA, 1995, J PHARMACOL EXP THER, V272, P143; de Bruijn K M, 1992, Drugs, V43 Suppl 3, P11; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DONOWITZ M, 1980, AM J PHYSIOL, V239, pG463, DOI 10.1152/ajpgi.1980.239.6.G463; DONOWITZ M, 1975, AM J DIG DIS, V20, P1115, DOI 10.1007/BF01070754; DONOWITZ M, 1977, AM J PHYSIOL, V232, pE85, DOI 10.1152/ajpendo.1977.232.1.E85; EKLUND S, 1987, ACTA PHYSIOL SCAND, V129, P115, DOI 10.1111/j.1748-1716.1987.tb08046.x; GAGINELLA TS, 1983, J PHYSIOL-LONDON, V335, P101, DOI 10.1113/jphysiol.1983.sp014522; GERSHON MD, 1985, EXPERIENTIA, V41, P863, DOI 10.1007/BF01970002; GERSHON MD, 1981, GASTROENTEROLOGY, V80, P1571; Gill RK, 2002, AM J PHYSIOL-GASTR L, V283, pG747, DOI 10.1152/ajpgi.00294.2001; GILL RK, 2005, IN PRESS GASTROENTER; HANSEN MB, 1995, PHARMACOL TOXICOL, V77, P3; Hansen MB, 1997, COMP BIOCHEM PHYS A, V118, P283, DOI 10.1016/S0300-9629(97)00085-6; HARDCASTLE J, 1981, J PHYSIOL-LONDON, V320, P41, DOI 10.1113/jphysiol.1981.sp013933; HEGDE SS, 1995, BRIT J PHARMACOL, V115, P1087, DOI 10.1111/j.1476-5381.1995.tb15922.x; HOYER D, 1991, J RECEPTOR RES, V11, P197, DOI 10.3109/10799899109066399; HOYER D, 1994, PHARMACOL REV, V46, P157; JAFFE BM, 1986, J PHARMACOL EXP THER, V238, P536; KELLUM JM, 1994, AM J PHYSIOL, V267, P357; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; KYOSOLA K, 1977, SCAND J GASTROENTERO, V12, P363; LEYSEN J, 1984, NEUROPHARMACOLOGY, V23, P247, DOI 10.1016/0028-3908(84)90066-2; MORIARTY KJ, 1987, GUT, V28, P844, DOI 10.1136/gut.28.7.844; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; OHNO S, 1994, J BIOL CHEM, V269, P17495; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; OLSNES S, 1987, BIOCHEMISTRY-US, V26, P2778, DOI 10.1021/bi00384a019; RACKE K, 1991, PHARMACOL RES, V23, P13, DOI 10.1016/S1043-6618(05)80101-X; Saksena S, 2003, GASTROENTEROLOGY, V124, pA143, DOI 10.1016/S0016-5085(03)80707-2; Saksena S, 2002, AM J PHYSIOL-GASTR L, V283, pG626, DOI 10.1152/ajpgi.00395.2001; Saksena S, 2002, AM J PHYSIOL-CELL PH, V283, pC1492, DOI 10.1152/ajpcell.00473.2001; Salvador MT, 1997, LIFE SCI, V61, P309, DOI 10.1016/S0024-3205(97)00387-1; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; SCHULTZ BD, 1988, FASEB J, V2, pA1722; SIRIWARDENA AK, 1993, J SURG RES, V55, P55, DOI 10.1006/jsre.1993.1108; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Stoner MC, 2000, SURGERY, V128, P240, DOI 10.1067/msy.2000.107608; SUNDARAM U, 1991, P NATL ACAD SCI USA, V88, P6249, DOI 10.1073/pnas.88.14.6249; THOMPSON JH, 1971, RES COMMUN CHEM PATH, V2, P687; ZIMMERMAN TW, 1984, GASTROENTEROLOGY, V86, P310; ZINNER MJ, 1986, GASTROENTEROLOGY, V90, P515, DOI 10.1016/0016-5085(86)91102-9	59	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11859	11868		10.1074/jbc.M411553200	http://dx.doi.org/10.1074/jbc.M411553200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15637072	hybrid			2022-12-27	WOS:000227761800115
J	Corradetti, MN; Inoki, K; Guan, KL				Corradetti, MN; Inoki, K; Guan, KL			The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS COMPLEX; TUMOR-SUPPRESSOR GENE; CELL-GROWTH; KINASE; MTOR; TSC2; DROSOPHILA; RHEB; HYPOXIA; S6K	The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays an essential role in cell growth control. mTOR stimulates cell growth by phosphorylating p70 ribosomal S6 kinase (S6K) and eukaryote initiation factor 4E-binding protein 1 (4EBP1). The mTOR pathway is regulated by a wide variety of cellular signals, including mitogenic growth factors, nutrients, cellular energy levels, and stress conditions. Recent studies have proposed several mechanisms to explain how mTOR is regulated by growth factors and cellular energy levels. However, little is known as to how mTOR is regulated by stress conditions. We observed that two stress-induced proteins, RTP801/Redd1 and RTP801L/Redd2, potently inhibit signaling through mTOR. Our data support that RTP801 and RTP801L work downstream of AKT and upstream of TSC2 to inhibit mTOR functions. These results add a new dimension to mTOR pathway regulation and provide a possible molecular mechanism of how cellular stress conditions may regulate mTOR function.	Univ Michigan, Inst Life Sci, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Inst Life Sci, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	Guan, Kun-Liang/ADK-7088-2022; INOKI, KEN/A-1202-2007		NICHD NIH HHS [5-T32-HD075005] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD075005] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lee MJ, 2004, MOL CELL BIOL, V24, P3918, DOI 10.1128/MCB.24.9.3918-3927.2004; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Monfar M, 1996, MOL ENDOCRINOL, V10, P1107, DOI 10.1210/me.10.9.1107; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shah OJ, 2002, J BIOL CHEM, V277, P2525, DOI 10.1074/jbc.M105935200; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Stewart MJ, 1996, P NATL ACAD SCI USA, V93, P10791, DOI 10.1073/pnas.93.20.10791; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Worby C A, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.95.pl1; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	37	189	214	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9769	9772		10.1074/jbc.C400557200	http://dx.doi.org/10.1074/jbc.C400557200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632201	hybrid			2022-12-27	WOS:000227559600004
J	Hiesberger, T; Shao, XL; Gourley, E; Reimann, A; Pontoglio, M; Igarashi, P				Hiesberger, T; Shao, XL; Gourley, E; Reimann, A; Pontoglio, M; Igarashi, P			Role of the hepatocyte nuclear factor-1 beta (HNF-1 beta) C-terminal domain in Pkhd1 (ARPKD) gene transcription and renal cystogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; HNF1 HOMEOPROTEIN FAMILY; EPITHELIAL-CELLS; DNA-BINDING; FACTOR-I; PROTEIN; EXPRESSION; MUTATION; DIMERIZATION; PROMOTER	Hepatocyte nuclear factor-1 beta (HNF-1 beta) is a homeodomain-containing transcription factor that regulates tissue-specific gene expression in the kidney and other epithelial organs. Mutations of HNF-1 beta produce congenital cystic abnormalities of the kidney, and previous studies showed that HNF-1 beta regulates the expression of the autosomal recessive polycystic kidney disease (ARPKD) gene, Pkhd1. Here we show that the C-terminal region of HNF-1 beta contains an activation domain that is functional when fused to a heterologous DNA-binding domain. An HNF-1 beta deletion mutant lacking the C-terminal domain interacts with wild-type HNF-1 beta, binds DNA, and functions as a dominant-negative inhibitor of a chromosomally integrated Pkhd1 promoter. The activation of the Pkhd1 promoter by wild-type HNF-1 beta is stimulated by sodium butyrate or coactivators CREB (cAMP-response element)-binding protein (CBP) and P/CAF. The interaction with CBP and P/CAF requires the C-terminal domain. Expression of an HNF-1 beta C-terminal deletion mutant in transgenic mice produces renal cysts, increased cell proliferation, and dilatation of the ureter similar to mice with kidney-specific inactivation of HNF-1 beta. Pkhd1 expression is inhibited in cystic collecting ducts but not in non-cystic proximal tubules, despite transgene expression in this nephron segment. We conclude that the C-terminal domain of HNF-1 beta is required for the activation of the Pkhd1 promoter. Deletion mutants lacking the C-terminal domain function as dominant-negative mutants, possibly by preventing the recruitment of histone acetylases to the promoter. Cyst formation correlates with inhibition of Pkhd1 expression, which argues that mutations of HNF-1 beta produce kidney cysts by down-regulating the ARPKD gene, Pkhd1. Expression of HNF-1 beta in proximal tubules may protect against cystogenesis.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Nephrol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Basic Sci, Dallas, TX 75390 USA; Inst Pasteur, CNRS URA 1644, Unit Gene Express & Dis, F-75014 Paris, France	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Hiesberger, T (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Hiesberger@UTSouthwestern.edu		Igarashi, Peter/0000-0001-8698-1185	NIDDK NIH HHS [P50 DK-57328, R01-DK-42921, R01 DK042921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042921, P50DK057328] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; Bai Y, 2002, AM J PHYSIOL-RENAL, V283, pF839, DOI 10.1152/ajprenal.00128.2002; Barbacci E, 1999, DEVELOPMENT, V126, P4795; Barbacci E, 2004, HUM MOL GENET, V13, P3139, DOI 10.1093/hmg/ddh338; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; Bingham C, 2003, KIDNEY INT, V63, P1645, DOI 10.1046/j.1523-1755.2003.00903.x; Bingham C, 2000, KIDNEY INT, V57, P898, DOI 10.1046/j.1523-1755.2000.057003898.x; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; Cheret C, 2002, J MOL BIOL, V322, P929, DOI 10.1016/S0022-2836(02)00816-1; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; Coffinier C, 1999, DEVELOPMENT, V126, P4785; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Gresh L, 2004, EMBO J, V23, P1657, DOI 10.1038/sj.emboj.7600160; Hiesberger T, 2004, J CLIN INVEST, V113, P814, DOI 10.1172/JCI200420083; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; LAZZARO D, 1992, DEVELOPMENT, V114, P469; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; Onuchic LF, 2002, AM J HUM GENET, V70, P1305, DOI 10.1086/340448; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; Pontoglio M, 2000, J AM SOC NEPHROL, V11, pS140; Pontoglio M, 2000, EMBO REP, V1, P359, DOI 10.1093/embo-reports/kvd071; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Quaggin SE, 1998, MECH DEVELOP, V71, P37, DOI 10.1016/S0925-4773(97)00201-3; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; RINGEISEN F, 1993, J BIOL CHEM, V268, P25706; Shao XL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016443.50138.CD; Shelton JM, 2000, J LIPID RES, V41, P532; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; Wild W, 2000, P NATL ACAD SCI USA, V97, P4695, DOI 10.1073/pnas.080010897; WOODS AE, 1996, LAB HISTOPATHOLOGY C, V1; WOODS AE, 1996, LAB HISTOPATHOLOGY C, V2; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	36	63	67	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10578	10586		10.1074/jbc.M414121200	http://dx.doi.org/10.1074/jbc.M414121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647252	hybrid			2022-12-27	WOS:000227559600103
J	Park, JB; Levine, M				Park, JB; Levine, M			Cloning, sequencing, and characterization of alternatively spliced glutaredoxin 1 cDNA and its genomic gene - Chromosomal localization, mRNA stability, and origin of pseudogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN DONOR SYSTEM; THIOLTRANSFERASE GLUTAREDOXIN; S-THIOLATION; PROTEASE; PURIFICATION; ACTIVATION; EXPRESSION; PROTEINS; CYSTEINE; CELLS	Alternatively spliced human glutaredoxin (Grx1(as)) cDNA was isolated from a neutrophil cDNA library, using a P-32-labeled human glutaredoxin (Grx1) cDNA probe under non-stringent conditions. The sequence of Grx1as cDNA indicated that the open reading frame of the gene was identical to the open reading frame of the previously reported first human glutaredoxin ( Grx1) cDNA, but the 3'- untranslated region of Grx1as was not homologous to Grx1 cDNA. Northern blot and RT-PCR analyses showed Grx1as mRNA was expressed in normal human neutrophils and transformed cells including U937, HL-60, THP, and Jurkat cells. Cloning and sequencing of the genomic gene corresponding to Grx1as cDNA showed that two different glutaredoxin cDNAs ( Grx1as and Grx1) were generated from the same genomic gene via alternative splicing. Origination of Grx1as and Grx1 from the same gene was confirmed by chromosomal localization of the Grx1as gene to chromosome 5q13, the same location where the Grx1 gene was localized previously. During screening of the Grx1(as) genomic gene, two additional glutaredoxin pseudogenes were also isolated. Surprisingly, these pseudogenes contained 3'-untranslated regions that were nearly identical to the 3'-untranslated regions of Grx1(as), not Grx1, cDNA. Because 3'-untranslated regions may be important in stabilizing mRNAs, the effect of the two 3'-untranslated regions of Grx1 and Grx1(as) on mRNA stability was investigated using luciferase reporter vectors with the 3'-untranslated regions. Luciferase activity was 2.6-fold greater in cells transfected with the reporter vector containing the 3'-untranslated region of Grx1as cDNA compared with the 3'-untranslated region of Grx1 cDNA. These data indicate that Grx1as cDNA is an alternatively spliced human Grx1 cDNA and that the Grx1(as) 3'-untranslated region may have a role in stabilizing mRNA.	NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; USDA ARS, Beltsville Human Nutr Res Ctr, Phytonutrients Lab, Beltsville, MD 20770 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Agriculture (USDA)	Levine, M (corresponding author), NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Rm 4D52,MSC 1372, Bethesda, MD 20892 USA.	markL@mail.nih.gov			NIDDK NIH HHS [Z01 DK 54506] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054506] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; FERNANDO MR, 1994, BBA-GENE STRUCT EXPR, V1218, P229, DOI 10.1016/0167-4781(94)90019-1; GRASSER FA, 1992, ONCOGENE, V7, P1005; GRIERSON AW, 1994, J GEN VIROL, V75, P2761, DOI 10.1099/0022-1317-75-10-2761; HOLMGREN A, 1978, J BIOL CHEM, V253, P7424; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; LUNDSTROMLJUNG J, 1995, J BIOL CHEM, V270, P7822, DOI 10.1074/jbc.270.14.7822; LUTHMAN M, 1979, P NATL ACAD SCI USA, V76, P2158, DOI 10.1073/pnas.76.5.2158; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Padilla CA, 1996, GENOMICS, V32, P455, DOI 10.1006/geno.1996.0141; Park JB, 1997, GENE, V197, P189, DOI 10.1016/S0378-1119(97)00262-X; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; RACKER E, 1955, J BIOL CHEM, V217, P867; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; STEVENSON HC, 1981, SCAND J IMMUNOL, V14, P243, DOI 10.1111/j.1365-3083.1981.tb00561.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WELLS WW, 1990, J BIOL CHEM, V265, P15361; YANG YF, 1989, GENE, V83, P339, DOI 10.1016/0378-1119(89)90120-0	30	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10427	10434		10.1074/jbc.M412450200	http://dx.doi.org/10.1074/jbc.M412450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637068	hybrid			2022-12-27	WOS:000227559600084
J	Farah, CA; Liazoghli, D; Perreault, S; Desjardins, M; Guimont, A; Anton, A; Lauzon, M; Kreibich, G; Paiement, J; Leclerc, N				Farah, CA; Liazoghli, D; Perreault, S; Desjardins, M; Guimont, A; Anton, A; Lauzon, M; Kreibich, G; Paiement, J; Leclerc, N			Interaction of microtubule-associated protein-2 and p63 - A new link between microtubules and rough endoplasmic reticulum membranes in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CEREBELLAR MACRONEURONS; TAU-ANTISENSE OLIGONUCLEOTIDES; RAT-BRAIN MITOCHONDRIA; HIPPOCAMPAL-NEURONS; PROJECTION DOMAINS; NEURITE FORMATION; ACTIN-BINDING; RIBOPHORIN-I; SF9 CELLS; MAP2	Neurons are polarized cells presenting two distinct compartments, dendrites and an axon. Dendrites can be distinguished from the axon by the presence of rough endoplasmic reticulum ( RER). The mechanism by which the structure and distribution of the RER is maintained in these cells is poorly understood. In the present study, we investigated the role of the dendritic microtubule-associated protein-2 (MAP2) in the RER membrane positioning by comparing their distribution in brain subcellular fractions and in primary hippocampal cells and by examining the MAP2-microtubule interaction with RER membranes in vitro. Subcellular fractionation of rat brain revealed a high MAP2 content in a subfraction enriched with the endoplasmic reticulum markers ribophorin and p63. Electron microscope morphometry confirmed the enrichment of this subfraction with RER membranes. In cultured hippocampal neurons, MAP2 and p63 were found to concomitantly compartmentalize to the dendritic processes during neuronal differentiation. Protein blot overlays using purified MAP2c protein revealed its interaction with p63, and immunoprecipitation experiments performed in HeLa cells showed that this interaction involves the projection domain of MAP2. In an in vitro reconstitution assay, MAP2-containing microtubules were observed to bind to RER membranes in contrast to microtubules containing tau, the axonal MAP. This binding of MAP2c microtubules was reduced when an anti-p63 antibody was added to the assay. The present results suggest that MAP2 is involved in the association of RER membranes with microtubules and thereby could participate in the differential distribution of RER membranes within a neuron.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Universite de Montreal; New York University	Leclerc, N (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	nicole.leclerc@umontreal.ca						Aihara Y, 2001, J NEUROSCI RES, V65, P236, DOI 10.1002/jnr.1147; Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Al-Bassam J, 2002, J CELL BIOL, V157, P1187, DOI 10.1083/jcb.200201048; ALLAN V, 1994, J CELL SCI, V107, P1885; Bannai H, 2004, J CELL SCI, V117, P163, DOI 10.1242/jcs.00854; BARTLETT WP, 1984, J NEUROSCI, V4, P1954; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; BAUDHUIN P, 1967, J CELL BIOL, V32, P181, DOI 10.1083/jcb.32.1.181; Belanger D, 2002, J CELL SCI, V115, P1523; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BLOOM GS, 1983, J CELL BIOL, V96, P1523, DOI 10.1083/jcb.96.6.1523; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; CORREAS I, 1990, BIOCHEM J, V269, P61, DOI 10.1042/bj2690061; Cunningham CC, 1997, J CELL BIOL, V136, P845, DOI 10.1083/jcb.136.4.845; De Zeeuw CI, 1997, NEURON, V19, P1187, DOI 10.1016/S0896-6273(00)80411-0; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; DOMINGUEZ JM, 1991, EXP CELL RES, V192, P137, DOI 10.1016/0014-4827(91)90168-T; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; Farah CA, 2003, J NEUROCHEM, V84, P77, DOI 10.1046/j.1471-4159.2003.01505.x; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Felgner H, 1997, J CELL BIOL, V138, P1067, DOI 10.1083/jcb.138.5.1067; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Goslin K., 1991, CULTURING NERVE CELL, P251; Harada A, 1998, J CELL BIOL, V141, P51, DOI 10.1083/jcb.141.1.51; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; HEIMANN R, 1985, J BIOL CHEM, V260, P2160; HERNANDEZ MA, 1986, EUR J BIOCHEM, V154, P41, DOI 10.1111/j.1432-1033.1986.tb09356.x; Hillman D., 1988, INTRINSIC DETERMINAN, P83; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; JANCSIK V, 1989, CELL MOTIL CYTOSKEL, V14, P372, DOI 10.1002/cm.970140307; JUNG D, 1993, CELL MOTIL CYTOSKEL, V24, P245, DOI 10.1002/cm.970240405; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; Kempf M, 1996, J NEUROSCI, V16, P5583; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; Lane JD, 1999, MOL BIOL CELL, V10, P1909, DOI 10.1091/mbc.10.6.1909; Lavoie C, 1996, J CELL SCI, V109, P1415; Le Bot N, 1998, J CELL BIOL, V143, P1559, DOI 10.1083/jcb.143.6.1559; Leclerc N, 1996, MOL BIOL CELL, V7, P443, DOI 10.1091/mbc.7.3.443; LECLERC N, 1993, P NATL ACAD SCI USA, V90, P6223, DOI 10.1073/pnas.90.13.6223; LETERRIER JF, 1982, J CELL BIOL, V95, P982, DOI 10.1083/jcb.95.3.982; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LINDEN M, 1989, BIOCHEM J, V261, P167, DOI 10.1042/bj2610167; Lu M, 2001, MOL BIOL CELL, V12, P171, DOI 10.1091/mbc.12.1.171; LUDIN B, 1993, HIPPOCAMPUS, V3, P61; Matanis T, 2002, NAT CELL BIOL, V4, P986, DOI 10.1038/ncb891; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; PAIEMENT J, 1981, J CELL BIOL, V91, pA329; Peters A., 1991, FINE STRUCTURE NERVO; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RAJASEKARAN AK, 1995, NUCLEIC ACIDS RES, V23, P313, DOI 10.1093/nar/23.3.313; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; SATTILARO RF, 1986, BIOCHEMISTRY-US, V25, P2003, DOI 10.1021/bi00356a025; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SHARMA N, 1994, CELL MOTIL CYTOSKEL, V27, P234, DOI 10.1002/cm.970270305; TERASAKI M, 1994, CELL MOTIL CYTOSKEL, V29, P291, DOI 10.1002/cm.970290402; TERASAKI M, 1990, CELL MOTIL CYTOSKEL, V15, P71, DOI 10.1002/cm.970150203; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Torre ER, 1996, J NEUROSCI, V16, P5967; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; Watson P, 2005, NAT CELL BIOL, V7, P48, DOI 10.1038/ncb1206	76	39	40	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9439	9449		10.1074/jbc.M412304200	http://dx.doi.org/10.1074/jbc.M412304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623521	hybrid			2022-12-27	WOS:000227453100097
J	Haas, IG; Frank, M; Veron, N; Kemler, R				Haas, IG; Frank, M; Veron, N; Kemler, R			Presenilin-dependent processing and nuclear function of gamma-protocadherins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; EMBRYONIC STEM-CELLS; SECRETASE ACTIVITY; CADHERIN; NOTCH; PROTEOLYSIS; DIVERSITY; CLEAVAGE; NEURONS	The recently described protocadherin gene clusters encode cadherin-related proteins, which are highly expressed in the vertebrate nervous system. Here, we report biochemical studies addressing proteolytic processing of gamma-protocadherins. These type-I transmembrane proteins are cleaved by a metalloproteinase in vivo, generating a soluble extracellular fragment and a carboxyl-terminal fragment associated with the cellular membrane. In addition, we show that the carboxyl-terminal fragment is a substrate for further cleavage mediated by presenilin. Consequently, accumulation of the fragment is found when gamma-secretase is inactivated either by the specific presenilin- inhibitor L685,458 or in double mutant murine embryonic fibroblasts lacking both presenilin genes. The gamma-secretase- generated carboxyl-terminal fragment is largely unstable but accumulates when proteasomal degradation is inhibited. Interestingly, the proteolytic fragment generated by gamma-secretase can localize to the nucleus. This is the first report providing experimental evidence for a cell surface receptor signaling function of protocadherins regulated by proteolytic events.	Max Planck Inst Immunobiol, Dept Mol Embryol, D-79108 Freiburg, Germany	Max Planck Society	Haas, IG (corresponding author), Max Planck Inst Immunobiol, Dept Mol Embryol, Stubeweg 51, D-79108 Freiburg, Germany.	haasi@immunbio.mpg.de						Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Angst BD, 2001, J CELL SCI, V114, P625; Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; DE SB, 1999, NATURE, V398, P518; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Finley MFA, 1996, J NEUROSCI, V16, P1056; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Heyers D, 2003, J COMP NEUROL, V460, P155, DOI 10.1002/cne.10631; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; KESSLER SW, 1975, J IMMUNOL, V115, P1617; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kotani M, 2002, J NEUROSCI RES, V67, P595, DOI 10.1002/jnr.10150; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Phillips GR, 2003, J NEUROSCI, V23, P5096; Redies C, 2000, PROG NEUROBIOL, V61, P611, DOI 10.1016/S0301-0082(99)00070-2; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Serafini T, 1999, CELL, V98, P133, DOI 10.1016/S0092-8674(00)81008-9; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Vanhalst K, 2001, FEBS LETT, V495, P120, DOI 10.1016/S0014-5793(01)02372-9; Wang XZ, 2002, NEURON, V36, P843, DOI 10.1016/S0896-6273(02)01090-5; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y	40	111	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9313	9319		10.1074/jbc.M412909200	http://dx.doi.org/10.1074/jbc.M412909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611067	hybrid			2022-12-27	WOS:000227453100083
J	Jozic, D; Bourenkov, G; Lim, NH; Visse, R; Nagase, H; Bode, W; Maskos, K				Jozic, D; Bourenkov, G; Lim, NH; Visse, R; Nagase, H; Bode, W; Maskos, K			X-ray structure of human proMMP-1 - New insights into procollagenase activation and collagen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; MATRIX METALLOPROTEINASES; TISSUE INHIBITORS; FIBROBLAST COLLAGENASE; SUBSTRATE-SPECIFICITY; BONE-RESORPTION; HELPING HAND; MATRIX-METALLOPROTEINASE-2; PROGELATINASE; RECOGNITION	Vertebrate collagenases, members of the matrix metalloproteinase (MMP) family, initiate interstitial fibrillar collagen breakdown. It is essential in many biological processes, and unbalanced collagenolysis is associated with diseases such as arthritis, cancer, atherosclerosis, aneurysm, and fibrosis. These metalloproteinases are secreted from the cell as inactive precursors, procollagenases (proMMPs). To gain insights into the structural basis of their activation mechanisms and collagen binding, we have crystallized recombinant human proMMP-1 and determined its structure to 2.2 Angstrom resolution. The catalytic metalloproteinase domain and the C-terminal hemopexin (Hpx) domain show the classical MMP-fold, but the structure has revealed new features in surface loops and domain interaction. The prodomain is formed by a three- helix bundle and gives insight into the stepwise activation mechanism of proMMP-1. The prodomain interacts with the Hpx domain, which affects the position of the Hpx domain relative to the catalytic domain. This interaction results in a "closed" configuration of proMMP-1 in contrast to the "open" configuration observed previously for the structure of active MMP-1. This is the first evidence of mobility of the Hpx domain in relation to the catalytic domain, providing an important clue toward the understanding of the collagenase-collagen interaction and subsequent collagenolysis.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, London W6 8LH, England; Deutsch Elektron Synchrotron, AG Prot Dynam, Max Planck Gesellsch, Arb Grp Strakturelle Mol Biol, D-22603 Hamburg, Germany	Max Planck Society; Imperial College London; University of Oxford; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Nagase, H (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.	h.nagase@imperial.ac.uk; maskos@biochem.mpg.de	Lim, Ngee Han/B-4226-2011; Bourenkov, Gleb P/C-7794-2017	Bourenkov, Gleb P/0000-0002-2617-5920; Lim, Ngee Han/0000-0002-8520-7857				ALLAN JA, 1991, J CELL SCI, V99, P789; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Bode W, 2003, BIOL CHEM, V384, P863, DOI 10.1515/BC.2003.097; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURK D, 1992, THESIS TU MUNICH GER; Cha HJ, 2002, J MOL BIOL, V320, P1065, DOI 10.1016/S0022-2836(02)00558-2; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; Delaisse JM, 2000, CLIN CHIM ACTA, V291, P223, DOI 10.1016/S0009-8981(99)00230-2; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; Elkins PA, 2002, ACTA CRYSTALLOGR D, V58, P1182, DOI 10.1107/S0907444902007849; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; GROSS J, 1962, P NATL ACAD SCI USA, V48, P1014, DOI 10.1073/pnas.48.6.1014; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nagase H, 1997, BIOL CHEM, V378, P151; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Pilcher BK, 1999, ANN NY ACAD SCI, V878, P12, DOI 10.1111/j.1749-6632.1999.tb07671.x; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WELGUS HG, 1984, COLLAGEN REL RES, V4, P377; Woessner JF, 1998, BIOL EXTRAC, P1; WOESSNER JF, 1980, COLLAGENASE NORMAL P, P223; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	48	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9578	9585		10.1074/jbc.M411084200	http://dx.doi.org/10.1074/jbc.M411084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611040	hybrid			2022-12-27	WOS:000227453100112
J	Kessler, PS; Parsons, M				Kessler, PS; Parsons, M			Probing the role of compartmentation of glycolysis in procyclic form Trypanosoma brucei RNA interference studies of PEX14, hexokinase, and phosphofructokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GLYCOSOMES; ENZYMES; PEROXISOMES; INHIBITION; METABOLISM; GENERATION; MICROBODY; KINETICS; LIBRARY	Trypanosoma brucei and related organisms contain an organelle evolutionarily related to peroxisomes that sequesters glycolysis, among other pathways. We have shown previously that disruption of protein import into this organelle, the glycosome, can be accomplished through RNA interference (RNAi)-mediated knockdown of the peroxin PEX14. Decreased PEX14 in turn leads to cell death, which, at least in the procyclic stage, can be triggered by the presence of glucose. Here we show that fructose, which is taken up and metabolized by procyclic form T. brucei, and glycerol, which interfaces with the glycosomal glycolytic pathway, are also toxic during PEX14 RNAi. Earlier computer modeling studies predicted that glycolysis would be toxic to T. brucei in the absence of glycosomal compartmentation because of the intrinsic lack of feedback regulation of the parasite hexokinase and phosphofructokinase. To further test this hypothesis, we performed double RNAi, targeting hexokinase and PEX14. Knockdown of hexokinase rescued PEX14 knockdown cells from glucose toxicity, even though glycosomal proteins continue to be mislocalized to the cytosol. Knockdown of phosphofructokinase was benign in the absence of glucose but toxic in the presence of glucose. When PEX14 and phosphofructokinase mRNAs were jointly targeted for RNAi, glycerol remained toxic to the parasites. Taken together, these data indicate that the glycosome provides significant, but not complete, protection of trypanosomes from the dangerous design of glycolysis.	Seattle Biomed Res Inst, Seattle, WA 98109 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Pathobiol, Seattle, WA 98195 USA	Center for Infectious Disease Research; University of Washington; University of Washington Seattle	Parsons, M (corresponding author), Seattle Biomed Res Inst, 307 Westlake Ave N STE 500, Seattle, WA 98109 USA.	marilyn.parsons@sbri.org		Parsons, Marilyn/0000-0003-3994-8096	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022635] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI22635] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bakker BM, 1997, J BIOL CHEM, V272, P3207, DOI 10.1074/jbc.272.6.3207; Bakker BM, 2000, P NATL ACAD SCI USA, V97, P2087, DOI 10.1073/pnas.030539197; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; de Walque S, 1999, MOL BIOCHEM PARASIT, V104, P107, DOI 10.1016/S0166-6851(99)00144-9; Drew ME, 2003, J BIOL CHEM, V278, P46596, DOI 10.1074/jbc.M309320200; EISENTHAL R, 1989, BIOCHIM BIOPHYS ACTA, V985, P81, DOI 10.1016/0005-2736(89)90107-7; Flaspohler JA, 1997, MOL CELL BIOL, V17, P1093, DOI 10.1128/MCB.17.3.1093; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; Guerra-Giraidez C, 2002, J CELL SCI, V115, P2651; Hua Q, 2003, J BACTERIOL, V185, P7053, DOI 10.1128/JB.185.24.7053-7067.2003; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; MICHELOTTI EF, 1987, J BIOL CHEM, V262, P927; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; NWAGWU M, 1982, ACTA TROP, V39, P61; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; Park JH, 2001, J CELL SCI, V114, P173; PARKER HL, 1995, MOL BIOCHEM PARASIT, V69, P269, DOI 10.1016/0166-6851(94)00208-5; Parsons M, 2004, MOL MICROBIOL, V53, P717, DOI 10.1111/j.1365-2958.2004.04203.x; Pearson TW, 2000, MOL BIOCHEM PARASIT, V111, P333, DOI 10.1016/S0166-6851(00)00327-3; Plewes KA, 2003, INFECT IMMUN, V71, P5910, DOI 10.1128/IAI.71.10.5910-5920.2003; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; Teusink B, 1998, TRENDS BIOCHEM SCI, V23, P162, DOI 10.1016/S0968-0004(98)01205-5; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zufferey R, 2003, J BIOL CHEM, V278, P44708, DOI 10.1074/jbc.M308063200	32	40	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9030	9036		10.1074/jbc.M412033200	http://dx.doi.org/10.1074/jbc.M412033200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637070	hybrid			2022-12-27	WOS:000227453100050
J	Kim, TS; Maeda, A; Maeda, T; Heinlein, C; Kedishvili, N; Palczewski, K; Nelson, PS				Kim, TS; Maeda, A; Maeda, T; Heinlein, C; Kedishvili, N; Palczewski, K; Nelson, PS			Delayed dark adaptation in 11-cis-retinol dehydrogenase-deficient mice - A role of RDH11 in visual processes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN DEHYDROGENASE/REDUCTASE; RETINALDEHYDE-BINDING PROTEIN; CONE-ROD DYSTROPHY; ALL-TRANS-RETINOL; RECESSIVE RETINITIS-PIGMENTOSA; LEBER CONGENITAL AMAUROSIS; FUNDUS-ALBIPUNCTATUS; STARGARDTS-DISEASE; VERTEBRATE RETINA; KNOCKOUT MICE	The oxidation of 11-cis-retinol to 11-cis-retinal in the retinal pigment epithelium (RPE) represents the final step in a metabolic cycle that culminates in visual pigment regeneration. Retinol dehydrogenase 5 (RDH5) is responsible for a majority of the 11-cis-RDH activity in the RPE, but the formation of 11-cis-retinal in rdh5(-/-) mice suggests another enzyme(s) is present. We have previously shown that RDH11 is also highly expressed in RPE cells and has dual specificity for both cis- and trans-retinoid substrates. To investigate the role of RDH11 in the retinoid cycle, we generated rdh11(-/-) and rdh5(-/-) rdh11(-/-) mice and examined their electrophysiological responses to various intensities of illumination and during dark adaptation. Retinoid profiles of dark-adapted rdh11(-/-) mice did not show significant differences compared with wild-type mice, whereas an accumulation of cis-esters was detected in rdh5(-/-) and rdh5(-/-) rdh11(-/-) mice. Following light stimulation, 73% more cis-retinyl esters were stored in rdh5(-/-) rdh11(-/-) mice compared with rdh5(-/-) mice. Single-flash ERGs of rdh11(-/-) showed normal responses under dark- and light-adapted conditions, but exhibited delayed dark adaptation following high bleaching levels. Double knockout mice also had normal ERG responses in dark- and light-adapted conditions, but had a further delay in dark adaptation relative to either rdh11(-/-) or rdh5(-/-) mice. Taken together, these results suggest that RDH11 has a measurable role in regenerating the visual pigment by complementing RDH5 as an 11-cis-RDH in RPE cells, and indicate that an additional unidentified enzyme(s) oxidizes 11- cis- retinol or that an alternative pathway contributes to the retinoid cycle.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu		Kedishvili, Natalia/0000-0001-6917-4891	NCI NIH HHS [CA85859, P01 CA085859] Funding Source: Medline; NEI NIH HHS [R01 EY008061, EY08061] Funding Source: Medline; NIAAA NIH HHS [R01 AA012153] Funding Source: Medline; NIDDK NIH HHS [R01 DK065204, DK65204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA085859] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012153] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Allikmets Rando, 2004, Ophthalmic Genet, V25, P67, DOI 10.1080/13816810490514261; Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Belyaeva OV, 2003, BIOCHEMISTRY-US, V42, P14838, DOI 10.1021/bi035288u; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Driessen C, 2003, VISION RES, V43, P3075, DOI 10.1016/S0042-6989(03)00483-8; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Duester G, 2001, CHEM-BIOL INTERACT, V130, P469, DOI 10.1016/S0009-2797(00)00292-1; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Howes KA, 2002, EMBO J, V21, P1545, DOI 10.1093/emboj/21.7.1545; Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Kasus-Jacobi A, 2003, J BIOL CHEM, V278, P32380, DOI 10.1074/jbc.M304969200; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Kelsell RE, 1998, HUM MOL GENET, V7, P1179, DOI 10.1093/hmg/7.7.1179; Lin BY, 2001, CANCER RES, V61, P1611; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; Martras S, 2004, EUR J BIOCHEM, V271, P1660, DOI 10.1111/j.1432-1033.2004.04058.x; Mata NL, 1998, BBA-LIPID LIPID MET, V1394, P16, DOI 10.1016/S0005-2760(98)00078-2; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; MATSCHINSKY FM, 1968, J NEUROCHEM, V15, P643, DOI 10.1111/j.1471-4159.1968.tb08963.x; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Moore S, 2002, GENE, V293, P149, DOI 10.1016/S0378-1119(02)00718-7; Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P3925; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Perrault I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Shang EY, 2002, J LIPID RES, V43, P590; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wu BX, 2002, INVEST OPHTH VIS SCI, V43, P3365; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; Zhang M, 2001, J BIOL CHEM, V276, P44083, DOI 10.1074/jbc.M105748200; Zhuang R, 2002, BIOCHEMISTRY-US, V41, P3477, DOI 10.1021/bi0119316	60	84	86	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8694	8704		10.1074/jbc.M413172200	http://dx.doi.org/10.1074/jbc.M413172200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634683	Green Accepted, hybrid			2022-12-27	WOS:000227453100011
J	Uemura, T; Tachihara, K; Tomitori, H; Kashiwagi, K; Igarashi, K				Uemura, T; Tachihara, K; Tomitori, H; Kashiwagi, K; Igarashi, K			Characteristics of the polyamine transporter TPO1 and regulation of its activity and cellular localization by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES SPERMINE UPTAKE; PROTEIN-KINASE; VACUOLAR MEMBRANE; YEAST; GENE; PUTRESCINE; RESISTANCE; MUTANTS; CLONING; IDENTIFICATION	The subcellular localization of the polyamine transporter TPO1 of Saccharomyces cerevisiae was determined by sucrose gradient centrifugation and indirect immunofluorescence microscopy. When expressed from a multi- copy vector, TPO1 was located mainly on the plasma membrane, but with some localization on the vacuolar membrane. Polyamine transport by TPO1 was dependent on pH. Uptake of spermidine and spermine occurred at alkaline pH (pH 8.0), whereas inhibition of spermidine uptake, but not spermine uptake, was observed at acidic pH (pH 5.0). This suggests that TPO1 catalyzes polyamine excretion at acidic pH, similar to the PotE transporter in Escherichia coli. Paraquat, a polyamine analogue, was excreted by TPO1 at a rate comparable with the excretion of spermidine (deduced from the inhibition of spermidine uptake) at pH 5.0. However, excretion of preloaded radiolabeled spermidine and spermine was not observed in intact cells, suggesting that preloaded spermidine (or spermine) exists mainly as spermidine (or spermine)-ribosome complex in cells. The transport activity of TPO1 was enhanced through phosphorylation at Ser(19) by protein kinase C and at Thr(52) by casein kinase 1. Sorting of TPO1 from the endoplasmic reticulum to the plasma membrane was enhanced through phosphorylation at Ser(342) by cAMP-dependent protein kinases 1 and 2.	Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan	Chiba University	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187				Albertsen M, 2003, J BIOL CHEM, V278, P12820, DOI 10.1074/jbc.M210715200; ANDRE B, 1993, MOL GEN GENET, V237, P17; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; Desmoucelles C, 2002, J BIOL CHEM, V277, P27036, DOI 10.1074/jbc.M111433200; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAISER C, 1994, METHODS YEAST GENETI, P141; KAKINUMA Y, 1995, BIOCHEM BIOPH RES CO, V216, P985, DOI 10.1006/bbrc.1995.2717; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; MARUYAMA T, 1994, BBA-BIOMEMBRANES, V1194, P289, DOI 10.1016/0005-2736(94)90311-5; Matta MAD, 2001, GENE, V272, P111, DOI 10.1016/S0378-1119(01)00558-3; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; Nozaki T, 1996, BIOCHEM BIOPH RES CO, V228, P452, DOI 10.1006/bbrc.1996.1681; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Robertson LS, 2000, P NATL ACAD SCI USA, V97, P5984, DOI 10.1073/pnas.100113397; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sorin A, 1997, J BIOL CHEM, V272, P9895; Teixeira MC, 2002, BIOCHEM BIOPH RES CO, V292, P530, DOI 10.1006/bbrc.2002.6691; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; Uemura T, 2004, BIOCHEM BIOPH RES CO, V315, P1082, DOI 10.1016/j.bbrc.2004.01.162; WATANABE S, 1991, J BIOL CHEM, V266, P20803	38	64	68	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9646	9652		10.1074/jbc.M410274200	http://dx.doi.org/10.1074/jbc.M410274200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637075	hybrid			2022-12-27	WOS:000227453100121
J	Jarvis, TC; Beaudry, AA; Bullard, JM; Janjic, N; McHenry, CS				Jarvis, TC; Beaudry, AA; Bullard, JM; Janjic, N; McHenry, CS			Reconstitution of a minimal DNA replicase from Pseudomonas aeruginosa and stimulation by non-cognate auxiliary factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; CLAMP-LOADER COMPLEX; ESCHERICHIA-COLI; BETA-SUBUNIT; BINDING-PROTEIN; EPSILON-SUBUNIT; GAMMA-SUBUNIT; PROCESSIVE ELONGATION; CYSTIC-FIBROSIS; THETA SUBUNIT	DNA polymerase III holoenzyme is responsible for chromosomal replication in bacteria. The components and functions of Escherichia coli DNA polymerase III holoenzyme have been studied extensively. Here, we report the reconstitution of replicase activity by essential components of DNA polymerase holoenzyme from the pathogen Pseudomonas aeruginosa. We have expressed and purified the processivity factor (beta), single-stranded DNA-binding protein, a complex containing the polymerase (alpha) and exonuclease (epsilon) subunits, and the essential components of the DnaX complex (tau(3)deltadelta'). Efficient primer elongation requires the presence of alphaepsilon, beta, and tau(3)deltadelta'. Pseudomonas aeruginosa alphaepsilon can substitute completely for E. coli polymerase III in E. coli holoenzyme reconstitution assays. Pseudomonas beta and tau(3)deltadelta' exhibit a 10- fold lower activity relative to their E. coli counterparts in E. coli holoenzyme reconstitution assays. Although the Pseudomonas counterpart to the E. coli psi subunit was not apparent in sequence similarity searches, addition of purified E. coli chi and psi ( components of the DnaX complex) increases the apparent specific activity of the Pseudomonas tau(3)deltadelta' complex similar to10-fold and enables the reconstituted enzyme to function better under physiological salt conditions.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Replidyne Inc, Louisville, CO 80027 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,B-121, Denver, CO 80262 USA.	mchenry@uchsc.edu			NIGMS NIH HHS [1-R43-GM64854-01, R01-GM060273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060273, R43GM064854] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; Blinkova A, 1997, J BACTERIOL, V179, P4438, DOI 10.1128/jb.179.13.4438-4442.1997; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CARTER JR, 1992, J BACTERIOL, V174, P7013, DOI 10.1128/JB.174.21.7013-7025.1992; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; Caspi R, 2000, J BIOL CHEM, V275, P18454, DOI 10.1074/jbc.M000552200; CRUTE JJ, 1983, J BIOL CHEM, V258, P1344; Cull M., 1990, METHOD ENZYMOL, V12, P147; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DREISEIKELMANN B, 1987, NUCLEIC ACIDS RES, V15, P385, DOI 10.1093/nar/15.2.385; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; Genschel J, 1996, GENE, V182, P137, DOI 10.1016/S0378-1119(96)00535-5; Giamarellou H, 2001, MED CLIN N AM, V85, P19, DOI 10.1016/S0025-7125(05)70303-5; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; GRIMWOOD K, 1992, J PAEDIATR CHILD H, V28, P4, DOI 10.1111/j.1440-1754.1992.tb02609.x; Gulbis JM, 2004, EUR J BIOCHEM, V271, P439, DOI 10.1046/j.1432-1033.2003.03944.x; HENSON JM, 1979, GENETICS, V92, P1041; HORIUCHI T, 1978, MOL GEN GENET, V163, P277, DOI 10.1007/BF00271956; HURWITZ J, 1974, P NATL ACAD SCI USA, V71, P6, DOI 10.1073/pnas.71.1.6; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; Keniry MA, 2000, PROTEIN SCI, V9, P721; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LEE SH, 1991, J BIOL CHEM, V266, P594; MAKI S, 1988, J BIOL CHEM, V263, P6555; Maschmeyer G, 2000, EUR J CLIN MICROBIOL, V19, P915, DOI 10.1007/s100960000410; McHenry CS, 2003, MOL MICROBIOL, V49, P1157, DOI 10.1046/j.1365-2958.2003.03645.x; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; NOUER SA, 2002, 42 INT C ANT AG CHEM; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Perrino FW, 1999, BIOCHEMISTRY-US, V38, P16001, DOI 10.1021/bi991429+; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; Roussel P, 2003, ADV EXP MED BIOL, V535, P17; SAHM DF, 2002, 42 INT C ANT AG CHEM; SAKAKIBARA Y, 1980, MOL GEN GENET, V178, P541, DOI 10.1007/BF00337859; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Seville M, 1996, BIOTECHNIQUES, V21, P664; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; Song MS, 2001, J BIOL CHEM, V276, P35165, DOI 10.1074/jbc.M100389200; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Viguera E, 2003, MOL MICROBIOL, V50, P193, DOI 10.1046/j.1365-2958.2003.03658.x; Witte G, 2003, NUCLEIC ACIDS RES, V31, P4434, DOI 10.1093/nar/gkg498; XIAO H, 1993, J BIOL CHEM, V268, P11779; YEE TW, 1990, P NATL ACAD SCI USA, V87, P1278, DOI 10.1073/pnas.87.4.1278	58	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7890	7900		10.1074/jbc.M412263200	http://dx.doi.org/10.1074/jbc.M412263200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611049	Green Published, hybrid			2022-12-27	WOS:000227395700057
J	Kellenberger, S; Gautschi, I; Pfister, Y; Schild, L				Kellenberger, S; Gautschi, I; Pfister, Y; Schild, L			Intracellular thiol-mediated modulation of epithelial sodium channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; PSEUDOHYPOALDOSTERONISM TYPE-1; AMILORIDE BLOCK; ION PERMEATION; ALPHA-SUBUNIT; PORE REGION; ENAC; CONDUCTANCE; IDENTIFICATION; MUTATIONS	The epithelial sodium channel ENaC is physiologically important in the kidney for the regulation of the extracellular fluid volume, and in the lungs for the maintenance of the appropriate airway surface liquid volume that lines the pulmonary epithelium. Besides the regulation of ENaC by hormones, intracellular factors such as Na+ ions, pH, or Ca2+ are responsible for fast adaptive responses of ENaC activity to changes in the intracellular milieu. In this study, we show that ENaC is rapidly and reversibly inhibited by internal sulfhydryl-reactive molecules such as methanethiosulfonate derivatives of different sizes, the metal cations Cd2+ and Zn2+, or copper(II) phenanthroline, a mild oxidizing agent that promotes the formation of disulfide bonds. At the single channel level, these agents applied intracellularly induce the appearance of long channel closures, suggesting an effect on ENaC gating. The intracellular reducing agent dithiothreitol fully reverses the rundown of ENaC activity in inside-out patches. Our observations suggest that changes in intracellular redox potential modulate ENaC activity and may regulate ENaC-mediated Na+ transport in epithelia. Finally, substitution experiments reveal that multiple cysteine residues in the amino and carboxyl termini of ENaC subunits are responsible for this thiol-mediated inhibition of ENaC.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Schild, L (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Laurent.Schild@unil.ch		Kellenberger, Stephan/0000-0003-1755-6198				Abriel H, 1999, J PHYSIOL-LONDON, V516, P31, DOI 10.1111/j.1469-7793.1999.031aa.x; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Broillet MC, 1997, NEURON, V18, P951, DOI 10.1016/S0896-6273(00)80334-7; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Cotten JF, 1997, J BIOL CHEM, V272, P25617, DOI 10.1074/jbc.272.41.25617; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Firsov D, 1999, J BIOL CHEM, V274, P2743, DOI 10.1074/jbc.274.5.2743; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Harrington MA, 1999, J BIOL CHEM, V274, P27536, DOI 10.1074/jbc.274.39.27536; Harrington MA, 2002, BIOPHYS J, V82, P1278, DOI 10.1016/S0006-3495(02)75484-2; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Kellenberger S, 2003, MOL PHARMACOL, V64, P848, DOI 10.1124/mol.64.4.848; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lipton SA, 2002, TRENDS NEUROSCI, V25, P474, DOI 10.1016/S0166-2236(02)02245-2; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Neale EJ, 2003, J BIOL CHEM, V278, P29079, DOI 10.1074/jbc.M301991200/6493; Poet M, 2001, EMBO J, V20, P5595, DOI 10.1093/emboj/20.20.5595; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; STUTTS MJ, 1994, J BIOL CHEM, V269, P8667; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; VERREY F, 2001, KIDNEY, P1441	31	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7739	7747		10.1074/jbc.M409955200	http://dx.doi.org/10.1074/jbc.M409955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623528	hybrid			2022-12-27	WOS:000227395700038
J	Kiely, PA; Leahy, M; O'Gorman, D; O'Connor, R				Kiely, PA; Leahy, M; O'Gorman, D; O'Connor, R			RACK1-mediated integration of adhesion and insulin-like growth factor I (IGF-I) signaling and cell migration are defective in cells expressing an IGF-I receptor mutated at tyrosines 1250 and 1251	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SRC FAMILY KINASES; BETA-SUBUNIT; EXTRACELLULAR-MATRIX; INTERACTING PROTEIN; PHOSPHATASE SHP-2; CYCLE PROGRESSION; FOCAL ADHESIONS; AKT ACTIVATION; BREAST-CANCER	The scaffolding protein receptor for activated C kinase (RACK1) has been proposed to mediate the integration of insulin-like growth factor I receptor (IGF-IR) and adhesion signaling. Here we investigated the mechanism of this integration of signaling, by using an IGF-IR mutant (Y1250F/Y1251F) that is deficient in anti-apoptotic and transforming function. RACK1 was found to associate with the IGF-IR only in adherent cells and did not associate with the IGF-IR in nonadherent cells, lymphocytic cells, or cells expressing the Y1250F/Y1251F mutant. In R-cells transiently expressing the Y1250F/Y1251F mutant RACK1 became constitutively associated with beta1 integrin and did not associate with Shc, Src, or Shp2. This was accompanied by the loss of formation of a complex containing the IGF-IR, RACK1, and beta1 integrin; loss of migratory capacity; enhanced Src and FAK activity; enhanced Akt phosphorylation; and decreased p38 mitogen-activated protein kinase activity. Shc was not phosphorylated in response to IGF-IR in cells expressing the Y1250F/Y1251F mutant and remained associated with protein phosphatase 2A. Similar alterations in signaling were observed in cells that were stimulated with IGF-IR in nonadherent cultures. Our data suggest that disruption of RACK1 scaffolding function in cells expressing the Y1250F/Y1251F mutant results in the loss of adhesion signals that are necessary to regulate Akt activity and to promote turnover of focal adhesions and cell migration.	Natl Univ Ireland Univ Coll Cork, Dept Biochem, Cell Biol Lab, Cork, Ireland	University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Cell Biol Lab, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422				Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Blakesley VA, 1998, J BIOL CHEM, V273, P18411, DOI 10.1074/jbc.273.29.18411; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hongo A, 1996, ONCOGENE, V12, P1231; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Leahy M, 2004, J BIOL CHEM, V279, P18306, DOI 10.1074/jbc.M309234200; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Li XW, 2003, J BIOL CHEM, V278, P41646, DOI 10.1074/jbc.M306274200; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Maile LA, 2002, ENDOCRINOLOGY, V143, P4259, DOI 10.1210/en.2002-220395; Maloney EK, 2003, CANCER RES, V63, P5073; Manes S, 1999, MOL CELL BIOL, V19, P3125; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Miller LD, 2004, ONCOGENE, V23, P5682, DOI 10.1038/sj.onc.1207735; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Resnicoff M, 1998, INT J MOL MED, V1, P883; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tai YT, 2003, CANCER RES, V63, P5850; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	48	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7624	7633		10.1074/jbc.M412889200	http://dx.doi.org/10.1074/jbc.M412889200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611085	hybrid			2022-12-27	WOS:000227395700025
J	Nichols, JD; Rajagopalan, KV				Nichols, JD; Rajagopalan, KV			In vitro molybdenum ligation to molybdopterin using purified components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MOEA; COFACTOR BIOSYNTHESIS; CRYSTAL-STRUCTURE; CONVERTING FACTOR; SULFITE OXIDASE; GENE-PRODUCT; PRECURSOR-Z; PROTEIN; TUNGSTEN; MOLYBDATE	We have previously shown that Escherichia coli MoeA and MogA are required in vivo for the final step of molybdenum cofactor biosynthesis, the addition of the molybdenum atom to the dithiolene of molybdopterin. MoeA was also shown to facilitate the addition of molybdenum in an assay using crude extracts from E. coli moeA(-) cells. The experiments detailed in this report utilized an in vitro assay for MoeA-mediated molybdenum ligation to de novo synthesized molybdopterin using only purified components and monitoring the reconstitution of human aposulfite oxidase. In this assay, maximum activation was achieved by delaying the addition of aposulfite oxidase to allow for adequate molybdenum coordination to occur. Tungsten, which substitutes for molybdenum in hyperthermophilic organisms, could also be ligated to molybdopterin using this system, though not as efficiently as molybdenum. Addition of thiol compounds to the assay inhibited activity. Addition of MogA also inhibited the reaction. However, in the presence of ATP and magnesium, addition of MogA to the assay increased the level of aposulfite oxidase reconstitution beyond that observed with MoeA alone. This effect was not observed in the absence of MoeA. The results presented here demonstrate that MoeA is responsible for mediating molybdenum ligation to molybdopterin, whereas MogA stimulates this activity in an ATP-dependent manner.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raj@biochem.duke.edu			NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LA, 1997, EUR J BIOCHEM, V246, P119, DOI 10.1111/j.1432-1033.1997.00119.x; Buc J, 1999, MOL MICROBIOL, V32, P159, DOI 10.1046/j.1365-2958.1999.01340.x; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hagedoorn PL, 2003, FEBS LETT, V555, P606, DOI 10.1016/S0014-5793(03)01359-0; Hanzelmann P, 2004, J BIOL CHEM, V279, P34721, DOI 10.1074/jbc.M313398200; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; Hille R, 2002, TRENDS BIOCHEM SCI, V27, P360, DOI 10.1016/S0968-0004(02)02107-2; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; Johnson MK, 1996, CHEM REV, V96, P2817, DOI 10.1021/cr950063d; JONES HP, 1977, J BIOL CHEM, V252, P4988; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Nichols J, 2002, J BIOL CHEM, V277, P24995, DOI 10.1074/jbc.M203238200; Pilato R. S., 1999, BIOINORGANIC CATALYS, P81; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; Sandu C, 2002, ARCH MICROBIOL, V178, P465, DOI 10.1007/s00203-002-0474-7; SCHMITZ RA, 1992, FEBS LETT, V309, P78, DOI 10.1016/0014-5793(92)80743-Z; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Temple CA, 2000, J BIOL CHEM, V275, P40202, DOI 10.1074/jbc.M007407200; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3	35	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7817	7822		10.1074/jbc.M413783200	http://dx.doi.org/10.1074/jbc.M413783200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632135	hybrid			2022-12-27	WOS:000227395700047
J	Runyan, CE; Schnaper, HW; Poncelet, AC				Runyan, CE; Schnaper, HW; Poncelet, AC			The role of internalization in transforming growth factor beta 1-induced Smad2 association with smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-I EXPRESSION; MEDIATED ENDOCYTOSIS; EARLY ENDOSOMES; FYVE DOMAIN; MEMBRANE	Recent data investigating the role of the Smad anchor for receptor activation ( SARA) in TGF-beta signaling have suggested that it has a crucial function in both aiding the recruitment of Smad to the TGF-beta receptor, and ensuring appropriate subcellular localization of the activated receptor-bound complex. The FYVE domain in SARA directs its localization to early endosomal compartments where it can interact with both the TGF-beta receptors and Smads. However, the necessity of endocytosis in the TGF-beta response remains controversial. We sought to examine the role of internalization in TGF-beta/Smad signaling in human kidney mesangial cells. Using co-immunoprecipitation studies, we show that endogenous Smad2 interacts with SARA after TGF-beta1 stimulation. Inhibition of clathrin-mediated internalization only slightly affects TGF-beta1-stimulated association between SARA and Smad2, Smad2 phosphorylation, or Smad2 interaction with Smad4. However, endocytosis inhibition decreases TGF-beta1-induced Smad2 nuclear translocation and thus abrogates Smad2-dependent transcriptional responses. The TGF-beta1-stimulated association between SARA and Smad2 peaks at 30 min followed by separation of the complex components. However, under conditions of inhibited endocytosis, Smad2 remains bound to SARA for at least 6 h without a significant decline in associated levels. This lack of complex dissociation correlates with a lack of Smad2 nuclear accumulation and reduction of Smad2-dependent ARE-Luc reporter activity. Our data therefore suggest that endocytosis plays a critical role in TGF-beta signaling in mesangial cells, and that internalization enhances the dissociation of Smad2 from the TGF-beta receptor-SARA complex, allowing Smad2 to accumulate in the nucleus and modulate target gene transcription.	Northwestern Univ, Feinberg Sch Med, Dept Pediat, WARD, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Runyan, CE (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, WARD, 12-110,303 E Chicago Ave, Chicago, IL 60611 USA.	c-runyan@northwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049362, K01DK064074] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK49362, KO1-DK64074-01, R01 DK049362] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Goto D, 2001, BIOCHEM BIOPH RES CO, V281, P1100, DOI 10.1006/bbrc.2001.4489; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hu Y, 2002, J CELL SCI, V115, P4755, DOI 10.1242/jcs.00177; ISHISAKI A, 1997, EMBO J, V16, P5353; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mitchell H, 2004, MOL BIOL CELL, V15, P4166, DOI 10.1091/mbc.E04-03-0245; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; QIN BY, 2002, GENE DEV, V16, P1867; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Schnaper HW, 1996, J CELL SCI, V109, P2521; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; Zhou YL, 2004, MOL ENDOCRINOL, V18, P1818, DOI 10.1210/me.2004-0079	31	92	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8300	8308		10.1074/jbc.M407939200	http://dx.doi.org/10.1074/jbc.M407939200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15613484	hybrid			2022-12-27	WOS:000227395700104
J	Jarvinen, A; Grigorenko, N; Khomutov, AR; Hyvonen, MT; Uimari, A; Vepsalainen, J; Sinervirta, R; Keinanen, TA; Vujcic, S; Alhonen, L; Porter, CW; Jannet, J				Jarvinen, A; Grigorenko, N; Khomutov, AR; Hyvonen, MT; Uimari, A; Vepsalainen, J; Sinervirta, R; Keinanen, TA; Vujcic, S; Alhonen, L; Porter, CW; Jannet, J			Metabolic stability of alpha-methylated polyamine derivatives and their use as substitutes for the natural polyamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; ACUTE-PANCREATITIS; TRANSGENIC RATS; OXIDASE; SPERMINE; CELLS; DECARBOXYLASE; REGENERATION; PURIFICATION; SENSITIVITY	Metabolically stable polyamine derivatives may serve as useful surrogates for the natural polyamines in studies aimed to elucidate the functions of individual polyamines. Here we studied the metabolic stability of a-methylspermidine, alpha-methylspermine, and bis-alpha-methylspermine, which all have been reported to fulfill many of the putative physiological functions of the natural polyamines. In vivo studies were performed with the transgenic rats overexpressing spermidine/spermine N-1-acetyltransferase. alpha-Methylspermidine effectively accumulated in the liver and did not appear to undergo any further metabolism. On the other hand, alpha-methylspermine was readily converted to alpha-methylspermidine and spermidine; similarly, bis-alpha-methylspermine was converted to alpha-methylspermidine to some extent, both conversions being inhibited by the polyamine oxidase inhibitor N-1,N-2-bis(2,3-butadienyl)-1,4-butanediamine. Furthermore, we used recombinant polyamine oxidase, spermidine/spermine N-1-acetyltransferase, and the recently discovered spermine oxidase in the kinetic studies. In vitro studies confirmed that methylation did not protect spermine analogs from degradation, whereas the spermidine analog was stable. Both alpha-methylspermidine and bis-alpha-methylspermine overcame the proliferative block of early liver regeneration in transgenic rats and reversed the cytostasis induced by an inhibition of ornithine decarboxylase in cultured fetal fibroblasts.	Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 117984, Russia; Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	University of Eastern Finland; University of Eastern Finland; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Roswell Park Cancer Institute	Jannet, J (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, POB 1627, FIN-70211 Kuopio, Finland.	Janne@uku.fi	Keinänen, Tuomo/AAC-5630-2019; Khomutov, Alex/G-2128-2015	Khomutov, Alex/0000-0001-6833-7855				Alhonen L, 2000, P NATL ACAD SCI USA, V97, P8290, DOI 10.1073/pnas.140122097; Alhonen L, 2002, BIOCHEM J, V362, P149, DOI 10.1042/0264-6021:3620149; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; BOLKENIUS FN, 1985, BIOCHIM BIOPHYS ACTA, V838, P69, DOI 10.1016/0304-4165(85)90251-X; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; Grigorenko NA, 2004, RUSS J BIOORG CHEM+, V30, P396, DOI 10.1023/B:RUBI.0000037268.98349.ce; GRIGORENKO NA, 2005, IN PRESS BIORGAN KHI, V31; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; HOLTTA E, 1983, METHOD ENZYMOL, V94, P306; HYVONEN T, 1992, J CHROMATOGR-BIOMED, V574, P17, DOI 10.1016/0378-4347(92)80093-6; JANNE J, 1971, J BIOL CHEM, V246, P1725; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; KUMAZAWA T, 1990, ANAL BIOCHEM, V188, P105, DOI 10.1016/0003-2697(90)90535-H; LAKANEN JR, 1992, J MED CHEM, V35, P724, DOI 10.1021/jm00082a013; Mackintosh CA, 2000, BIOCHEM J, V351, P439, DOI 10.1042/0264-6021:3510439; Niiranen K, 2002, J BIOL CHEM, V277, P25323, DOI 10.1074/jbc.M203599200; Rasanen TL, 2002, J BIOL CHEM, V277, P39867, DOI 10.1074/jbc.M205967200; Varnado BL, 2000, BIOORG CHEM, V28, P395, DOI 10.1006/bioo.2000.1195; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wang YL, 2001, CANCER RES, V61, P5370; Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3	22	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6595	6601		10.1074/jbc.M412788200	http://dx.doi.org/10.1074/jbc.M412788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611107	hybrid, Green Published			2022-12-27	WOS:000227332700044
J	Brickley, K; Smith, MJ; Beck, M; Stephenson, FA				Brickley, K; Smith, MJ; Beck, M; Stephenson, FA			GRIF-1 and OIP106, members of a novel gene family of coiled-coil domain proteins - Association in vivo and in vitro with kinesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-GLCNAC TRANSFERASE; HUNTINGTIN; MITOCHONDRIA; TRANSPORT; RECEPTOR; NEURONS; CLONING; IDENTIFICATION; TRAFFICKING; P150(GLUED)	gamma-Aminobutyric acidA receptor-interacting factor (GRIF-1) is a 913-amino acid protein proposed to function as a GABA(A) receptor beta(2) subunit-interacting, trafficking protein. GRIF-1 shares similar to 44% amino acid sequence identity with O-linked N-acetylglucosamine transferase interacting protein 106, OIP106. Both proteins contain predicted coiled-coil domains and probably constitute a novel gene family. The Drosophila orthologue of this family of proteins may be Milton. Milton shares similar to 44% amino acid homology with GRIF-1. Milton is proposed to function in kinesin-mediated transport of mitochondria to nerve terminals. We report here that GRIF-1 and OIP106 also associate with kinesin and mitochondria. Following expression in human embryonic kidney 293 cells, both GRIF-1 and OIP106 were shown by co-immunoprecipitation to be specifically associated with an endogenous kinesin heavy chain species of 115 kDa and exogenous KIF5C. Association of GRIF-1 with kinesin was also evident in native brain and heart tissue. In the brain, anti-GRIF-1-(8-633) antibodies specifically co-immunoprecipitated two kinesin-immunoreactive species with molecular masses of 118 and 115 kDa, and in the heart, one kinesin-immunoreactive species, 115 kDa, was immunoprecipitated. Further studies revealed that GRIF-1 was predominantly associated with KIF5A in the brain and with KIF5B in both the heart and in HEK 293 cells. Yeast two-hybrid interaction assays and immunoprecipitations showed that GRIF-1 associated directly with KIF5C with the GRIF-1/KIF5C interaction domain localized to GRIF-1-(124-283). These results further support a role for GRIF-1 and OIP106 in protein and/or organelle transport in excitable cells in a manner analogous to glutamate receptor-interacting-protein 1, in the motor-dependent transport of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate glutamate excitatory neurotransmitter receptors to dendrites.	Univ London, Dept Pharmaceut & Biol Chem, Sch Pharm, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Stephenson, FA (corresponding author), Univ London, Dept Pharmaceut & Biol Chem, Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.	anne.stephenson@ulsop.ac.uk	Smith, Miriam/J-4001-2015	Smith, Miriam/0000-0002-3184-0817				Akhtar S, 2002, J BIOL CHEM, V277, P16376, DOI 10.1074/jbc.M109698200; Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Cole RN, 2001, J NEUROCHEM, V79, P1080, DOI 10.1046/j.1471-4159.2001.00655.x; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gorska-Andrzejak J, 2003, J COMP NEUROL, V463, P372, DOI 10.1002/cne.10750; Guillaud L, 2003, J NEUROSCI, V23, P131; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Kanai Y, 2000, J NEUROSCI, V20, P6374, DOI 10.1523/JNEUROSCI.20-17-06374.2000; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; Li YK, 2002, J BIOL CHEM, V277, P28212, DOI 10.1074/jbc.M111612200; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Marcora E, 2003, P NATL ACAD SCI USA, V100, P9578, DOI 10.1073/pnas.1133382100; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; SMITH M, 2003, 5693 SOC NEUR; STEPHENSON FA, 1991, MOL NEUROBIOL, P183; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; Tang R, 2003, ELECTRON LETT, V39, P195, DOI 10.1049/el:20030141; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8	27	132	148	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14723	14732		10.1074/jbc.M409095200	http://dx.doi.org/10.1074/jbc.M409095200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15644324	hybrid			2022-12-27	WOS:000228236800049
J	Broaddus, VC; Dansen, TB; Abayasiriwardana, KS; Wilson, SM; Finch, AJ; Swigart, LB; Hunt, AE; Evan, GI				Broaddus, VC; Dansen, TB; Abayasiriwardana, KS; Wilson, SM; Finch, AJ; Swigart, LB; Hunt, AE; Evan, GI			Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FADD-DEPENDENT APOPTOSIS; CYTOCHROME-C RELEASE; DEATH RECEPTOR 5; IN-VITRO; BAX; CHEMOTHERAPY; MITOCHONDRIA; ACTIVATION; CELLS; CASPASE-8	The death ligand, TRAIL ( tumor necrosis factor-related apoptosis-inducing ligand), has shown great promise for inducing apoptosis selectively in tumors. Although many tumor cells are resistant to TRAIL-induced apoptosis alone, they can often be sensitized by co-treatment with DNA-damaging agents such as etoposide. However, the molecular mechanism underlying this therapeutically important synergy is unknown. We explored the mechanism mediating TRAIL-DNA damage apoptotic synergy in human mesothelioma cells, a tumor type particularly refractory to existing therapies. We show that Bid, a cytoplasmic Bcl-2 homology domain 3-containing protein activated by caspase 8 in response to TRAIL ligation, is essential for TRAIL-etoposide apo-ptotic synergy and, furthermore, that exposure to DNA damage primes cells to induction of apoptosis by otherwise sublethal levels of activated Bid. Finally, we show that the extensive caspase 8 cleavage seen during TRAIL-etoposide synergy is a consequence and not a cause of the apoptotic cascade activated downstream of Bid. These data indicate that TRAIL-etoposide apoptotic synergy arises because DNA damage increases the inherent sensitivity of cells to levels of TRAIL-activated Bid that would otherwise be insufficient for apoptosis. Such studies indicate how the adroit combination of differing proapoptotic and sublethal signals can provide an effective strategy for treating refractory tumors.	Univ Calif San Francisco, San Francisco Gen Hosp, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, Ctr Comprehens Canc, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Broaddus, VC (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, Box 0854, San Francisco, CA 94143 USA.	sfcourt@itsa.ucsf.edu		Finch, Andrew/0000-0002-8065-4623; Dansen, Tobias/0000-0001-5259-8815	NATIONAL CANCER INSTITUTE [R01CA095671, R01CA098018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008985] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA098018-01, R01CA95671] Funding Source: Medline; NIEHS NIH HHS [R01ES08985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Broaddus VC, 1996, J CLIN INVEST, V98, P2050, DOI 10.1172/JCI119010; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu WH, 2001, AM J RESP CELL MOL, V25, P111, DOI 10.1165/ajrcmb.25.1.4472; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Nagane M, 2000, CANCER RES, V60, P847; Pataer A, 2001, J THORAC CARDIOV SUR, V121, P61, DOI 10.1067/mtc.2001.111419; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 2002, J MOL MED-JMM, V80, P137, DOI 10.1007/s00109-001-0293-3; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shi J, 2003, CURR MOL MED, V3, P727, DOI 10.2174/1566524033479401; Singh TR, 2003, CANCER RES, V63, P5390; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Song JH, 2003, CLIN CANCER RES, V9, P4255; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Van Valen F, 2003, INT J CANCER, V107, P929, DOI 10.1002/ijc.11503; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Vogelzang NJ, 2002, SEMIN ONCOL, V29, P35, DOI 10.1053/sonc.2002.37469; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu XX, 2002, INT J ONCOL, V20, P949	47	46	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12486	12493		10.1074/jbc.M408190200	http://dx.doi.org/10.1074/jbc.M408190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15615731	hybrid			2022-12-27	WOS:000227922000052
J	Lutz, S; Freichel-Blomquist, A; Yang, Y; Rumenapp, U; Jakobs, KH; Schmidt, M; Wieland, T				Lutz, S; Freichel-Blomquist, A; Yang, Y; Rumenapp, U; Jakobs, KH; Schmidt, M; Wieland, T			The guanine nucleotide exchange factor p63RhoGEF, a specific link between G(q/11)-coupled receptor signaling and RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; LEUKEMIA-ASSOCIATED RHO; SERUM RESPONSE FACTOR; PHOSPHOLIPASE-C; ACTIVATION; INVOLVEMENT; GTPASES; FAMILY; GENE	The monomeric GTPase RhoA, which is a key regulator of numerous cellular processes, is activated by a variety of G protein-coupled receptors, through either G(12) or Gq family proteins. Here we report that p63RhoGEF, a recently identified RhoA-specific guanine nucleotide exchange factor, enhances the Rho-dependent gene transcription induced by agonist-stimulated G(q/11)- coupled receptors ( M-3-cholinoceptor, histamine H-1 receptor) or GTPase-deficient mutants of G alpha(q) and G(alpha 11). We further demonstrate that active G(alpha q) or G(alpha 11), but not G(alpha 12) or G(alpha 13), strongly enhances p63RhoGEF- induced RhoA activation by direct protein-protein interaction with p63RhoGEF at its C-terminal half. Moreover, the activation of p63RhoGEF by G(alpha q/11) occurs independently of and in competition to the activation of the canonical G(alpha q/11) effector phospholipase C beta. Therefore, our results elucidate a new signaling pathway by which G(q/11)- coupled receptors specifically induce Rho signaling through a direct interaction of activated G(alpha q/11) subunits with p63RhoGEF.	Heidelberg Univ, Fak Klin Med Mannheim, Inst Pharmakol & Toxikol, D-68169 Mannheim, Germany; Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany	Ruprecht Karls University Heidelberg; University of Duisburg Essen	Wieland, T (corresponding author), Heidelberg Univ, Fak Klin Med Mannheim, Inst Pharmakol & Toxikol, Maybachstr 14-16, D-68169 Mannheim, Germany.	thomas.wieland@urz.uni-heidelberg.de	Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Anger T, 2004, J BIOL CHEM, V279, P3906, DOI 10.1074/jbc.M309496200; Bakker RA, 2000, EUR J PHARMACOL, V387, pR5, DOI 10.1016/S0014-2999(99)00803-1; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; DAVIS PD, 1992, J MED CHEM, V35, P177, DOI 10.1021/jm00079a024; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; Lutz S, 2004, N-S ARCH PHARMACOL, V369, P540, DOI 10.1007/s00210-004-0926-5; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1; Rumenapp U, 2002, BIOCHEM J, V366, P721, DOI 10.1042/BJ20020654; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Souchet M, 2002, J CELL SCI, V115, P629; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031	33	151	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11134	11139		10.1074/jbc.M411322200	http://dx.doi.org/10.1074/jbc.M411322200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15632174	hybrid			2022-12-27	WOS:000227761800033
J	Giannattasio, M; Lazzaro, F; Plevani, P; Falconi, MM				Giannattasio, M; Lazzaro, F; Plevani, P; Falconi, MM			The DNA damage checkpoint response requires histone H2B ubiquitination by Rad6-Bre1 and H3 methylation by Dot1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; CELL-CYCLE CHECKPOINTS; BUDDING YEAST RAD9; SACCHAROMYCES-CEREVISIAE; MEC1-DEPENDENT PHOSPHORYLATION; H2AX PHOSPHORYLATION; CONJUGATING ACTIVITY; REPAIR; PROTEIN; RECRUITMENT	The cellular response to DNA lesions entails the recruitment of several checkpoint and repair factors to damaged DNA, and chromatin modifications may play a role in this process. Here we show that in Saccharomyces cerevisiae epigenetic modification of histones is required for checkpoint activity in response to a variety of genotoxic stresses. We demonstrate that ubiquitination of histone H2B on lysine 123 by the Rad6-Bre1 complex, is necessary for activation of Rad53 kinase and cell cycle arrest. We found a similar requirement for Dot1-dependent methylation of histone H3. Loss of H3-Lys(79) methylation does not affect Mec1 activation, whereas it renders cells checkpoint-defective by preventing phosphorylation of Rad9. Such results suggest that histone modifications may have a role in checkpoint function by modulating the interactions of Rad9 with chromatin and active Mec1 kinase.	Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy	University of Milan	Plevani, P (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy.	paolo.plevani@unimi.it; marco.muzifalconi@unimi.it	Lazzaro, Federico/J-3585-2013; Muzi-Falconi, Marco/A-6035-2012; Giannattasio, Michele/M-8318-2019	Lazzaro, Federico/0000-0001-6415-2925; Muzi-Falconi, Marco/0000-0001-7046-6090; Giannattasio, Michele/0000-0001-7099-5718; PLEVANI, PAOLO/0000-0003-1869-2626	Telethon [GGP030406] Funding Source: Medline	Telethon(Fondazione Telethon)		BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Corda Y, 1999, NAT GENET, V21, P204, DOI 10.1038/5991; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Du LL, 2003, MOL CELL BIOL, V23, P6150, DOI 10.1128/MCB.23.17.6150-6158.2003; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; FALCONI MM, 1993, P NATL ACAD SCI USA, V90, P10519, DOI 10.1073/pnas.90.22.10519; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fernandez-Capetillo O, 2003, CELL CYCLE, V2, P426, DOI 10.4161/cc.2.5.509; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Koundrioukoff S, 2004, DNA REPAIR, V3, P969, DOI 10.1016/j.dnarep.2004.03.010; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Longhese MP, 1996, MOL CELL BIOL, V16, P3235; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; Naiki T, 2004, MOL CELL BIOL, V24, P3277, DOI 10.1128/MCB.24.8.3277-3285.2004; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; Osley MA, 2004, BBA-GENE STRUCT EXPR, V1677, P74, DOI 10.1016/j.bbaexp.2003.10.013; Paciotti V, 2000, GENE DEV, V14, P2046; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X	56	219	233	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9879	9886		10.1074/jbc.M414453200	http://dx.doi.org/10.1074/jbc.M414453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632126	hybrid			2022-12-27	WOS:000227559600018
J	Li, ZY; Kitchen, JL; Boeneman, K; Anand, P; Crooke, E				Li, ZY; Kitchen, JL; Boeneman, K; Anand, P; Crooke, E			Restoration of growth to acidic phospholipid-deficient cells by DnaA(L366K) is independent of its capacity for nucleotide binding and exchange and requires DnaA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI CHROMOSOMAL ORIGIN; IN-VITRO REPLICATION; ESCHERICHIA-COLI; INITIATOR PROTEIN; COMPLEX; DOMAIN; CYCLE; OLIGOMERIZATION; HDA	In the absence of adequate levels of cellular acidic phospholipids, Escherichia coli remain viable but are arrested for growth. Expression of a DnaA protein that contains a single amino acid substitution in the membrane-binding domain, DnaA(L366K), in concert with expression of wild-type DnaA protein, restores growth. DnaA protein has high affinity for ATP and ADP, and in vitro lipid bilayers that are fluid and contain acidic phospholipids reactivate inert ADP-DnaA by promoting an exchange of ATP for ADP. Here, nucleotide and lipid interactions and replication activity of purified DnaA(L366K) were examined to gain insight into the mechanism of how it restores growth to cells lacking acidic phospholipids. DnaA(L366K) behaved like wildtype DnaA with respect to nucleotide binding affinities and hydrolysis properties, specificity of acidic phospholipids for nucleotide release, and origin binding. Yet, DnaA(L366K) was feeble at initiating replication from oriC unless augmented with a limiting quantity of wildtype DnaA, reflecting the in vivo requirement that both wild-type and a mutant form of DnaA must be expressed and act together to restore growth to acidic phospholipid deficient cells.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Program Tumor Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Crooke, E (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	crooke@georgetown.edu	Gemmill, Kelly/G-2167-2012		NCI NIH HHS [T32CA009686] Funding Source: Medline; NIGMS NIH HHS [R01GM49700, R01 GM049700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049700] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; Blaesing F, 2000, MOL MICROBIOL, V36, P557, DOI 10.1046/j.1365-2958.2000.01881.x; Camara JE, 2003, J BACTERIOL, V185, P3244, DOI 10.1128/JB.185.10.3244-3248.2003; Carr KM, 2001, J BIOL CHEM, V276, P44919, DOI 10.1074/jbc.M107463200; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; Cassler MR, 1999, NUCLEIC ACIDS RES, V27, P4570, DOI 10.1093/nar/27.23.4570; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; Crooke E, 1995, METHOD ENZYMOL, V262, P500; CROOKE E, 1992, J BIOL CHEM, V267, P16779; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; HWANG DS, 1990, J BIOL CHEM, V265, P19244; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Ichihashi N, 2003, J BIOL CHEM, V278, P28778, DOI 10.1074/jbc.M212202200; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; Kim PD, 2003, J BACTERIOL, V185, P1817, DOI 10.1128/JB.185.6.1817-1824.2003; Kitchen JL, 1999, BIOCHEMISTRY-US, V38, P6213, DOI 10.1021/bi982733q; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; Li ZY, 1999, PROTEIN EXPRES PURIF, V17, P41, DOI 10.1006/prep.1999.1094; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; Ryan VT, 2004, MOL MICROBIOL, V51, P1347, DOI 10.1046/j.1365-2958.2003.03906.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Simmons LA, 2003, MOL MICROBIOL, V49, P849, DOI 10.1046/j.1365-2958.2003.03603.x; SLATER S, 1993, J BACTERIOL, V175, P4260, DOI 10.1128/JB.175.13.4260-4262.1993; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; Zheng WD, 2001, EMBO J, V20, P1164, DOI 10.1093/emboj/20.5.1164	41	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9796	9801		10.1074/jbc.M413923200	http://dx.doi.org/10.1074/jbc.M413923200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642730	hybrid			2022-12-27	WOS:000227559600008
J	Oesterreicher, S; Blum, WF; Schmidt, B; Braulke, T; Kubler, B				Oesterreicher, S; Blum, WF; Schmidt, B; Braulke, T; Kubler, B			Interaction of insulin-like growth factor II (IGF-II) with multiple plasma proteins - High affinity binding of plasminogen to IGF-II and IGF-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYSIS; PREGNANCY; RECEPTOR; IGFBP-3; SERUM; IDENTIFICATION; TRANSFERRIN; INHIBITOR; FRAGMENTS; COMPLEX	In the circulation, most of the insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases are bound in high molecular mass complexes of >= 150 kDa. To investigate molecular interactions between proteins involved in IGF(.)IGFBP complexes, Cohn fraction IV of human plasma was subjected to IGF-II affinity chromatography followed by reversed-phase high pressure liquid chromatography and analysis of bound proteins. Mass spectrometry and Western blotting revealed the presence of IGFBP-3, IGFBP-5, transferrin, plasminogen, prekallikrein, antithrombin III, and the soluble IGF-II/mannose 6-phosphate receptor in the eluate. Furthermore, an IGFBP-3 protease cleaving also IGFBP-2 but not IGFBP-4 was co-purified from the IGF-II column. Inhibitor studies and IGFBP-3 zymography have demonstrated that the 92-kDa IGFBP-3 protease belongs to the class of serine-dependent proteases. IGF-II ligand blotting and surface plasmon resonance spectrometry have been used to identify plasminogen as a novel high affinity IGF-II-binding protein capable of binding to IGFBP-3 with 50-fold higher affinity than transferrin. In combination with transferrin, the overall binding constant of plasminogen/transferrin for IGF-II was reduced 7-fold. Size exclusion chromatography of the IGF-II matrix eluate revealed that transferrin, plasminogen, and the IGFBP-3 protease are present in different high molecular mass complexes of >= 440 kDa. The present data indicate that IGFs, low and high affinity IGFBPs, several IGFBP-associated proteins, and IGFBP proteases can interact, which may result in the formation of binary, ternary, and higher molecular weight complexes capable of modulating IGF binding properties and the stability of IGFBPs.	Univ Hamburg, Childrens Hosp, Dept Biochem, Hosp Eppendorf, D-20246 Hamburg, Germany; Eli Lilly & Co, D-61350 Bad Homburg, Germany; Univ Childrens Hosp, D-35392 Giessen, Germany; Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Eli Lilly; Lilly Deutschland GmbH; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen	Braulke, T (corresponding author), Univ Hamburg, Childrens Hosp, Dept Biochem, Hosp Eppendorf, Martinistr 52, D-20246 Hamburg, Germany.	braulke@uke.uni-hamburg.de	Braulke, Thomas/AAV-9121-2020; Kuebler, Bernd/K-2823-2017	Braulke, Thomas/0000-0002-2336-8532; Kuebler, Bernd/0000-0002-4472-871X				BAXTER RC, 1989, J BIOL CHEM, V264, P11843; Baxter RC, 2002, J CLIN ENDOCR METAB, V87, P271, DOI 10.1210/jc.87.1.271; BLUM WF, 1990, J CLIN ENDOCR METAB, V70, P1292, DOI 10.1210/jcem-70-5-1292; Booth BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE465, DOI 10.1152/ajpendo.1996.271.3.E465; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Byun DW, 2001, J CLIN ENDOCR METAB, V86, P847, DOI 10.1210/jc.86.2.847; Campbell PG, 1999, J BIOL CHEM, V274, P30215, DOI 10.1074/jbc.274.42.30215; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; Campbell PG, 1998, AM J PHYSIOL-ENDOC M, V275, pE321, DOI 10.1152/ajpendo.1998.275.2.E321; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE996, DOI 10.1152/ajpendo.1997.273.5.E996; Collen D, 2001, Hematology Am Soc Hematol Educ Program, P1; Durham SK, 1999, HORM METAB RES, V31, P216, DOI 10.1055/s-2007-978722; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; Kricker JA, 2003, ENDOCRINOLOGY, V144, P2807, DOI 10.1210/en.2002-221086; Kubler B, 2002, FEBS LETT, V518, P124, DOI 10.1016/S0014-5793(02)02673-X; Kubler B, 1998, ENDOCRINOLOGY, V139, P1556, DOI 10.1210/en.139.4.1556; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Maile LA, 1999, GROWTH HORM IGF RES, V9, P85, DOI 10.1054/ghir.1999.0096; Maile LA, 1998, ENDOCRINOLOGY, V139, P4772, DOI 10.1210/en.139.12.4772; Maile LA, 2000, GROWTH HORM IGF RES, V10, P71, DOI 10.1054/ghir.2000.0142; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; PARKER KC, 1983, BIOCHEMISTRY-US, V22, P1145, DOI 10.1021/bi00274a024; Renne T, 2002, J BIOL CHEM, V277, P4892, DOI 10.1074/jbc.M105221200; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; Standker L, 2000, BIOCHEMISTRY-US, V39, P5082, DOI 10.1021/bi992513s; Storch S, 2001, FEBS LETT, V509, P395, DOI 10.1016/S0014-5793(01)03204-5; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; Upton Z, 1999, ENDOCRINOLOGY, V140, P2928, DOI 10.1210/en.140.6.2928; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; Xu Y, 1998, J CLIN ENDOCR METAB, V83, P437, DOI 10.1210/jc.83.2.437; ZAPF J, 1981, J CLIN INVEST, V68, P1321, DOI 10.1172/JCI110379; Zwad O, 2002, FEBS LETT, V510, P211, DOI 10.1016/S0014-5793(01)03267-7	40	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9994	10000		10.1074/jbc.M411754200	http://dx.doi.org/10.1074/jbc.M411754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642732	hybrid			2022-12-27	WOS:000227559600032
J	Barnes, N; Tsivkovskii, R; Tsivkovskaia, N; Lutsenko, S				Barnes, N; Tsivkovskii, R; Tsivkovskaia, N; Lutsenko, S			The copper-transporting ATPases, Menkes and Wilson disease proteins, have distinct roles in adult and developing cerebellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; GENE-EXPRESSION; MESSENGER-RNA; MACULAR MOUSE; MOTTLED GENE; CERULOPLASMIN; DISORDER; ATP7B; MODEL; CNS	Copper is essential for brain metabolism, serving as a cofactor to superoxide dismutase, dopamine-beta hydroxylase, amyloid precursor protein, ceruloplasmin, and other proteins required for normal brain function. The copper- transporting ATPases ATP7A and ATP7B play a central role in distribution of copper in the central nervous system; genetic mutations in ATP7A and ATP7B lead to severe neurodegenerative disorders, Menkes disease and Wilson disease, respectively. Although both ATP7A and ATP7B are required, their specific roles and regulation in the brain remain poorly understood. Using high- resolution imaging and functional assays, we demonstrate that ATP7A and ATP7B show cell-specific distribution in adult cerebellum, have distinct enzymatic characteristics, and are regulated differently during development. ATP7B is continuously expressed in Purkinje neurons (PN) where it delivers copper to the ferroxidase ceruloplasmin. ATP7A is a faster copper transporter than Wilson disease protein as evidenced by faster rates of catalytic reactions. The expression of ATP7A switches during development from PN to Bergmann glia, the cells supporting PN function in adult brain. Inactivation of ATP7B (Wilson disease protein) by gene knock- out induces a striking shift in the expression of the ATP7B target protein, ceruloplasmin, from PN to Bergmann glia, where ATP7A (Menkes disease protein) is present. The induced cell- specific change in expression restores copper delivery to ceruloplasmin via ATP7A. Overall, the results provide evidence for distinct functions of ATP7A and ATP7B in the cerebellum and illustrate a tight link between copper homeostasis in PN and Bergmann glia.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	lutsenko@ohsu.edu			NIGMS NIH HHS [P01-GM067166-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; BEARN AG, 1960, ANN HUM GENET, V24, P33; Buiakova OI, 1999, HUM MOL GENET, V8, P1665, DOI 10.1093/hmg/8.9.1665; FRIEDEN E, 1986, CLIN PHYSIOL BIOCH, V4, P11; Furuya S, 2000, P NATL ACAD SCI USA, V97, P11528, DOI 10.1073/pnas.200364497; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Iwase T, 1996, ACTA NEUROPATHOL, V91, P482, DOI 10.1007/s004010050455; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; Kuo YM, 1997, HUM MOL GENET, V6, P1043, DOI 10.1093/hmg/6.7.1043; MENKES JH, 1962, PEDIATRICS, V29, P764; Millhauser GL, 2004, ACCOUNTS CHEM RES, V37, P79, DOI 10.1021/ar0301678; Miyajima H, 2003, NEUROPATHOLOGY, V23, P345, DOI 10.1046/j.1440-1789.2003.00521.x; Mothe AJ, 2000, MOL BRAIN RES, V76, P73, DOI 10.1016/S0169-328X(99)00336-8; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Murata Y, 1998, J INHERIT METAB DIS, V21, P199, DOI 10.1023/A:1005383114315; Murata Y, 1997, PEDIATR RES, V42, P436, DOI 10.1203/00006450-199710000-00003; Patel BN, 2002, J NEUROSCI, V22, P6578; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Prodan CI, 2002, NEUROLOGY, V59, P1453, DOI 10.1001/archneur.59.9.1453; Prohaska JR, 2004, J NUTR, V134, P1003, DOI 10.1093/jn/134.5.1003; REICHENBACH A, 1995, J BRAIN RES, V36, P509; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHEINBERG IH, 1952, SCIENCE, V116, P484, DOI 10.1126/science.116.3018.484; STEVENSON TC, 2003, J BIOL CHEM, V278, P12278; Sutherland ML, 1996, J NEUROSCI, V16, P2191; Terada K, 1998, J BIOL CHEM, V273, P1815, DOI 10.1074/jbc.273.3.1815; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200	30	136	137	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9640	9645		10.1074/jbc.M413840200	http://dx.doi.org/10.1074/jbc.M413840200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634671	hybrid			2022-12-27	WOS:000227453100120
J	Dyer, JL; Liu, Y; de la Huerga, IP; Taylor, CW				Dyer, JL; Liu, Y; de la Huerga, IP; Taylor, CW			Long lasting inhibition of adenylyl cyclase selectively mediated by inositol 1,4,5-trisphosphate-evoked calcium release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; SMOOTH-MUSCLE-CELLS; DEPENDENT PROTEIN-KINASE; C6-2B GLIOMA-CELLS; ARGININE-VASOPRESSIN; INTRACELLULAR CA2+; NONEXCITABLE CELLS; ANCHORING PROTEIN; PLASMA-MEMBRANE; SKELETAL-MUSCLE	In A7r5 smooth muscle cells, vasopressin stimulates release of Ca2+ from intracellular stores and Ca2+ entry, and it inhibits adenylyl cyclase (AC) activity. Inhibition of AC is prevented by inhibition of phospholipase C or when the increase in cytosolic [Ca2+] is prevented by the Ca2+ buffer, BAPTA. It is unaffected by pertussis toxin, inhibition of protein kinase C, or L-type Ca2+ channels or by removal of extracellular Ca2+. The independence of extracellular Ca2+ occurs despite inhibition of AC by vasopressin persisting for at least 15 min, whereas the cytosolic [Ca2+] returns to its basal level within 1-2 min in Ca2+- free medium. Although capacitative Ca2+ entry (CCE), activated by emptying stores with thapsigargin, inhibits AC, Ca2+ entry via CCE or L-type Ca2+ channels activated by vasopressin is ineffective. Temporally separating vasopressin-evoked Ca2+ release from the assessment of AC activity revealed that the transient Ca2+ signal resulting from Ca2+ mobilization causes a long lasting inhibition of AC. By contrast, inhibition of AC by thapsigargin-evoked CCE reverses rapidly after removal of extracellular Ca2+. Inhibition of AC by vasopressin is prevented by inhibition of Ca2+-calmodulin-dependent protein kinase II. We conclude that persistent inhibition of AC (probably AC-3) by vasopressin is mediated by inositol trisphosphate-evoked Ca2+ release causing activation of Ca2+-calmodulin-dependent protein kinase II. Our results establish that an important interaction between two ubiquitous signaling pathways is tuned selectively to Ca2+ release via inositol trisphosphate receptors and that the interaction transduces a transient Ca2+ signal into a long lasting inhibition of AC.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Taylor, CW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	cwt1000@cam.ac.uk	Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044				Abdel-Latif AA, 2001, EXP BIOL MED, V226, P153, DOI 10.1177/153537020122600302; Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Antoni FA, 2000, FRONT NEUROENDOCRIN, V21, P103, DOI 10.1006/frne.1999.0193; ANTONI FA, 1995, J BIOL CHEM, V270, P28055; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Bruce JIE, 2003, CELL CALCIUM, V34, P431, DOI 10.1016/S0143-4160(03)00150-7; BYRON KL, 1993, J BIOL CHEM, V268, P6945; Byron KL, 1996, CIRC RES, V78, P813, DOI 10.1161/01.RES.78.5.813; Byron KL, 2002, J BIOL CHEM, V277, P7298, DOI 10.1074/jbc.M104726200; CARAMELO C, 1991, AM J PHYSIOL, V260, pF46, DOI 10.1152/ajprenal.1991.260.1.F46; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Colbran RJ, 2004, BIOCHEM J, V378, P1, DOI 10.1042/BJ20031547; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Cooper DMF, 1998, J BIOL CHEM, V273, P27703, DOI 10.1074/jbc.273.42.27703; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Fagan KA, 2000, J BIOL CHEM, V275, P40187, DOI 10.1074/jbc.M006606200; FARNDALE RW, 1992, CELL SIGNALLING PRAC, P75; Guldemeester A, 1999, AM J PHYSIOL-LUNG C, V276, pL1010, DOI 10.1152/ajplung.1999.276.6.L1010; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; HO MKC, 1992, SIGNAL TRANSDUCTION, P223; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; Ishikawa Y, 2000, MOL CELL ENDOCRINOL, V162, P107, DOI 10.1016/S0303-7207(00)00210-0; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; MANNING M, 1981, J MED CHEM, V24, P701, DOI 10.1021/jm00138a012; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Matovcik LM, 1996, J HISTOCHEM CYTOCHEM, V44, P1243, DOI 10.1177/44.11.8918899; Moneer Z, 2003, BIOCHEM J, V370, P439, DOI 10.1042/BJ20021104; Moneer Z, 2002, BIOCHEM J, V362, P13, DOI 10.1042/0264-6021:3620013; Mons N, 1998, LIFE SCI, V62, P1647, DOI 10.1016/S0024-3205(98)00122-2; Nori A, 2003, BIOCHEM J, V370, P873, DOI 10.1042/BJ20021624; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Smith KE, 2002, J BIOL CHEM, V277, P6025, DOI 10.1074/jbc.M109615200; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; THIBONNIER M, 1991, ENDOCRINOLOGY, V129, P2845, DOI 10.1210/endo-129-6-2845; Webb JG, 2001, AM J PHYSIOL-HEART C, V281, pH1545, DOI 10.1152/ajpheart.2001.281.4.H1545; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Werry TD, 2003, BIOCHEM J, V374, P281, DOI 10.1042/BJ20030312; Wong MPM, 2000, BRIT J PHARMACOL, V130, P1021, DOI 10.1038/sj.bjp.0703411; Wong ST, 2001, J BIOL CHEM, V276, P34206, DOI 10.1074/jbc.M103923200; Woodrum DA, 2001, MOL CELL ENDOCRINOL, V177, P135, DOI 10.1016/S0303-7207(01)00407-5; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YU HJ, 1993, MOL PHARMACOL, V44, P689; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; Zhang JH, 1997, AM J PHYSIOL-HEART C, V273, pH971, DOI 10.1152/ajpheart.1997.273.2.H971	58	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8936	8944		10.1074/jbc.M410045200	http://dx.doi.org/10.1074/jbc.M410045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632122	hybrid			2022-12-27	WOS:000227453100040
J	Estruch, F; Hodge, CA; Rodriguez-Navarro, S; Cole, CN				Estruch, F; Hodge, CA; Rodriguez-Navarro, S; Cole, CN			Physical and genetic interactions link the yeast protein Zds1p with mRNA nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAD-BOX PROTEINS; CYTOPLASMIC FIBRILS; CAPPING ENZYME; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; NUCLEOPORIN; HELICASES; REQUIRES	Eukaryotic gene expression requires the export of mRNA from the nucleus to the cytoplasm. The DEAD box protein Dbp5p is an essential export factor conserved from yeast to man. A fraction of Dbp5p forms a complex with nucleoporins of the cytoplasmic filaments of the nuclear pore complex. Gfd1p was identified originally as a multicopy suppressor of the rat8-2 ts allele of DBP5. Here we reported that Dbp5p and Gfd1p interact with Zds1p, a protein previously identified as a multicopy suppressor in several yeast genetic screens. By using the two-hybrid system, we showed that Zds1p interacts in vivo with both Gfd1p and Dbp5p. In vitro binding experiments revealed that Gfd1p and Dbp5p bind directly to the C-terminal part of Zds1p. In addition, ZDS1 interacted genetically with mutant alleles of genes encoding key factors in mRNA export, including DBP5 and MEX67. Furthermore, deletion of ZDS1 or of both ZDS1 and the closely related ZDS2 exacerbated the poly(A)(+) export defects shown by dbp5-2 and mex67-5 mutants. We proposed that Zds1p associates with the complex formed by Dbp5p, Gfd1p, and nucleoporins at the cytosolic fibrils of the nuclear pore complex and is required for optimal mRNA export.	Univ Valencia, Fac Biol, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Genet, Hanover, NH 03755 USA	University of Valencia; Dartmouth College; Dartmouth College	Estruch, F (corresponding author), Univ Valencia, Fac Biol, Dept Bioquim & Biol Mol, Dr Moliner 50, E-46100 Burjassot, Spain.	francisco.estruch@uv.es	Rodríguez-Navarro, Susana/B-5182-2014; Cole, Charles/GRR-1551-2022	Rodríguez-Navarro, Susana/0000-0001-7472-3111; 				Bandhakavi S, 2003, FEBS LETT, V554, P295, DOI 10.1016/S0014-5793(03)01165-7; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; Bi EF, 1996, MOL CELL BIOL, V16, P5264; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cole CN, 2002, METHOD ENZYMOL, V351, P568; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Del Priore V, 1997, J CELL SCI, V110, P2987; Dimaano C, 2004, MOL CELL BIOL, V24, P3069, DOI 10.1128/MCB.24.8.3069-3076.2004; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; Estruch F, 2003, MOL BIOL CELL, V14, P1664, DOI 10.1091/mbc.E02-09-0602; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Fresco LD, 1996, RNA, V2, P584; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goldstein AL, 1996, MOL BIOL CELL, V7, P917, DOI 10.1091/mbc.7.6.917; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; Griffioen G, 2001, MOL CELL BIOL, V21, P511, DOI 10.1128/MCB.21.2.511-523.2001; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Hurwitz ME, 1998, P NATL ACAD SCI USA, V95, P11241, DOI 10.1073/pnas.95.19.11241; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; James P, 1996, GENETICS, V144, P1425; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Kikuma T, 2004, J BIOL CHEM, V279, P20692, DOI 10.1074/jbc.M400231200; Lei EP, 2003, MOL BIOL CELL, V14, P836, DOI 10.1091/mbc.E02-08-0520; Linder P, 2003, BIOL CELL, V95, P157, DOI 10.1016/S0248-4900(03)00032-7; Linder P, 2000, NAT STRUCT BIOL, V7, P97, DOI 10.1038/72464; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Roy N, 1999, CHROMOSOMA, V108, P146, DOI 10.1007/s004120050364; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Schroeder SC, 2004, MOL CELL, V13, P377, DOI 10.1016/S1097-2765(04)00007-3; Schwer B, 1998, NUCLEIC ACIDS RES, V26, P803, DOI 10.1093/nar/26.3.803; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Suntharalingam M, 2004, J BIOL CHEM, V279, P35384, DOI 10.1074/jbc.M402044200; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zhao J, 2002, EMBO J, V21, P1177, DOI 10.1093/emboj/21.5.1177	54	12	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9691	9697		10.1074/jbc.M413025200	http://dx.doi.org/10.1074/jbc.M413025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15619606	hybrid			2022-12-27	WOS:000227453100126
J	Swarnakar, S; Ganguly, K; Kundu, P; Banerjee, A; Maity, P; Sharma, AV				Swarnakar, S; Ganguly, K; Kundu, P; Banerjee, A; Maity, P; Sharma, AV			Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROESOPHAGEAL-REFLUX DISEASE; EXTRACELLULAR-MATRIX; LIPID-PEROXIDATION; MUCOSAL INJURY; KAPPA-B; CELLS; OMEPRAZOLE; MATRIX-METALLOPROTEINASE-9; COLLAGENASE	Matrix metalloproteinases (MMPs) are suggested to play a critical role in extracellular matrix degradation and remodeling during inflammation and wound healing processes. However, the role of MMPs in indomethacin-induced gastric ulcer and its healing process are not clearly understood. This study is aimed at determining the regulation of MMP-9 and -2 activities in indomethacin-induced acute gastric ulceration and healing. Indomethacin-ulcerated stomach extracts exhibit significant up-regulation of pro-MMP-9 (92 kDa) activity and moderate reduction of MMP-2 activity, which strongly correlate with indomethacin dose and severity of ulcer. The anti-inflammatory and antioxidant properties of curcumin, an active component of turmeric, suggest that curcumin may exert antiulcer activity through scavenging reactive oxygen species, by regulating MMP activity, or both. To test these possibilities, the effect of curcumin in indomethacin-induced gastric ulcer is examined by biochemical and histological methods. The results show that curcumin exhibits potent antiulcer activity in acute ulcer in rat model by preventing glutathione depletion, lipid peroxidation, and protein oxidation. Denudation of epithelial cells during damage of gastric lumen is reversed by curcumin through re-epithelialization. Furthermore, both oral and intraperitoneal administration of curcumin blocks gastric ulceration in a dose-dependent manner. It accelerates the healing process and protects gastric ulcer through attenuation of MMP-9 activity and amelioration of MMP-2 activity. Omeprazole, an established antiulcer drug does not inhibit MMP-9 while protecting indomethacin-induced gastric ulcer. We conclude that antiulcer activity of curcumin is primarily attributed to MMP-9 inhibition, one of the major pathways of ulcer healing.	Indian Inst Chem Biol, Dept Physiol, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Swarnakar, S (corresponding author), Indian Inst Chem Biol, Dept Physiol, 4 Raja Sc Mullick Rd, Kolkata 700032, W Bengal, India.	snehasiktas@hotmail.com	Ganguly, Krishnendu/D-7869-2012; Maity, Pallab/L-3896-2017	Maity, Pallab/0000-0001-9769-3533; Kundu, Parag/0000-0002-8684-7530; GANGULY, KRISHNENDU/0000-0002-9905-4724				Baragi VM, 1997, SCAND J GASTROENTERO, V32, P419, DOI 10.3109/00365529709025075; Biswas K, 2003, J BIOL CHEM, V278, P10993, DOI 10.1074/jbc.M210328200; BROZOZWSKI T, 2001, MICROSC RES TECHNIQ, V43, P343; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ERNST H, 1995, SCAND J GASTROENTERO, V30, P847, DOI 10.3109/00365529509101590; Fujii Y, 2000, P SOC EXP BIOL MED, V224, P102, DOI 10.1046/j.1525-1373.2000.22407.x; Hozumi A, 2001, AM J PHYSIOL-LUNG C, V281, pL1444, DOI 10.1152/ajplung.2001.281.6.L1444; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; ITO A, 1995, FEBS LETT, V360, P75, DOI 10.1016/0014-5793(95)00085-N; Jaruga E, 1998, FEBS LETT, V433, P287, DOI 10.1016/S0014-5793(98)00919-3; Jones MK, 1999, NAT MED, V5, P1418; Klinkenberg-Knol EC, 2000, GASTROENTEROLOGY, V118, P661, DOI 10.1016/S0016-5085(00)70135-1; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Langtry HD, 1998, DRUGS, V56, P447, DOI 10.2165/00003495-199856030-00012; Lempinen M, 2000, EUR SURG RES, V32, P169, DOI 10.1159/000008759; Magid R, 2003, J BIOL CHEM, V278, P32994, DOI 10.1074/jbc.M304799200; MCIAREN J, 2000, MOL HUM REPORD, V6, P1033; Menges M, 2000, Z GASTROENTEROL, V38, P887, DOI 10.1055/s-2000-10300; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; Miralles M, 1999, J VASC SURG, V29, P884, DOI 10.1016/S0741-5214(99)70216-8; Miura T, 2002, BIOCHEM PHARMACOL, V63, P2069, DOI 10.1016/S0006-2952(02)00995-4; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Morise Z, 1998, AM J PHYSIOL-GASTR L, V274, pG246, DOI 10.1152/ajpgi.1998.274.2.G246; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Parks WC, 1998, BIOL EXTRAC, P263; Piedagnel R, 1999, J BIOL CHEM, V274, P1614, DOI 10.1074/jbc.274.3.1614; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; SaarialhoKere UK, 1996, AM J PATHOL, V148, P519; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Shahin M, 2001, MICROSC RES TECHNIQ, V53, P396, DOI 10.1002/jemt.1108; Slomiany BL, 1997, SCAND J GASTROENTERO, V32, P638, DOI 10.3109/00365529708996511; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Surh YJ, 2002, FOOD CHEM TOXICOL, V40, P1091, DOI 10.1016/S0278-6915(02)00037-6; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; TYGAT GN, 2001, EUR J GASTROEN HEPAT, V1, pS29; Wallace John L., 2001, American Journal of Medicine, V110, p19S, DOI 10.1016/S0002-9343(00)00631-8; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; YOSHIKAWA T, 1993, GUT, V34, P732, DOI 10.1136/gut.34.6.732	41	176	182	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9409	9415		10.1074/jbc.M413398200	http://dx.doi.org/10.1074/jbc.M413398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615723	hybrid			2022-12-27	WOS:000227453100093
J	Barnes, WG; Reiter, E; Violin, JD; Ren, XR; Milligan, G; Lefkowitz, RJ				Barnes, WG; Reiter, E; Violin, JD; Ren, XR; Milligan, G; Lefkowitz, RJ			beta-arrestin 1 and G(alpha q/11) coordinately activate RhoA and stress fiber formation following receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CONTRACTION; PROTEIN-COUPLED RECEPTORS; ANGIOTENSIN-II; BETA-ARRESTIN; CLATHRIN ADAPTER; RHO/RHO-KINASE; INVOLVEMENT; G-ALPHA(Q); DESENSITIZATION; MECHANISMS	beta-Arrestins were initially shown, in conjunction with G protein-coupled receptor kinases, to be involved in the desensitization and internalization of activated seven-transmembrane receptors. Recently, beta-arrestin 2 has been shown to act as a signal mediator in mitogen-activated protein kinase cascades and to play a positive regulatory role in chemotaxis. We now show that beta-arrestin 1 is required to activate the small GTPase RhoA leading to the re-organization of stress fibers following the activation of the angiotensin II type 1A receptor. This angiotensin II type 1A receptor-directed RhoA activation and stress fiber formation also require the activation of the heterotrimeric G protein G(alphaq/11). Whereas neither beta-arrestin 1 nor G(alphaq/11) activation alone is sufficient to robustly activate RhoA, the concurrent recruitment of beta-arrestin 1 and activation of G(alphaq/11) leads to full activation of RhoA and to the subsequent formation of stress fibers.	Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Biochem, Durham, NC USA; Duke Univ, Ctr Med, Dept Med, Durham, NC USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	Howard Hughes Medical Institute; Duke University; Duke University; University of Glasgow	Lefkowitz, RJ (corresponding author), Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021; Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	NHLBI NIH HHS [HL 70631, HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070631, R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dutt P, 2002, FEBS LETT, V531, P565, DOI 10.1016/S0014-5793(02)03625-6; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gaborik Z, 2003, ENDOCRINOLOGY, V144, P2220, DOI 10.1210/en.2002-0135; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; Hisaoka T, 2001, CARDIOVASC RES, V49, P319, DOI 10.1016/S0008-6363(00)00279-0; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kim S, 2000, PHARMACOL REV, V52, P11; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kuwahara M, 2002, EUR J PHARMACOL, V436, P15, DOI 10.1016/S0014-2999(01)01591-6; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Matrougui K, 2001, ARTERIOSCL THROM VAS, V21, P1288, DOI 10.1161/hq0801.093653; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Nakamura A, 2003, J VASC RES, V40, P244, DOI 10.1159/000071888; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Postma M, 2004, EMBO REP, V5, P35, DOI 10.1038/sj.embor.7400051; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Rattan S, 2003, EXP BIOL MED, V228, P972, DOI 10.1177/153537020322800814; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ryan MJ, 2004, HYPERTENSION, V43, P1074, DOI 10.1161/01.HYP.0000123074.89717.3d; Sadoshima J, 1998, CIRC RES, V82, P1352, DOI 10.1161/01.RES.82.12.1352; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Slice LW, 2003, J CELL PHYSIOL, V194, P127, DOI 10.1002/jcp.10195; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Touyz RM, 2000, PHARMACOL REV, V52, P639; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100	51	151	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8041	8050		10.1074/jbc.M412924200	http://dx.doi.org/10.1074/jbc.M412924200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611106	hybrid			2022-12-27	WOS:000227395700074
J	Goodson, ML; Jonas, BA; Privalsky, ML				Goodson, ML; Jonas, BA; Privalsky, ML			Alternative mRNA splicing of SMRT creates functional diversity by generating corepressor Isoforms with different affinities for different nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTORS; RETINOIC-ACID-RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; LIGAND-BINDING DOMAIN; MOBILITY-SHIFT ASSAY; REV-ERBA-ALPHA; COUP-TF II; N-COR; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION	Many eukaryotic transcription factors are bimodal in their regulatory properties and can both repress and activate expression of their target genes. These divergent transcriptional properties are conferred through recruitment of auxiliary proteins, denoted coactivators and corepressors. Repression plays a particularly critical role in the functions of the nuclear receptors, a large family of ligand-regulated transcription factors involved in metazoan development, differentiation, reproduction, and homeostasis. The SMRT corepressor interacts directly with nuclear receptors and serves, in turn, as a platform for the assembly of a larger corepressor complex. We report here that SMRT is expressed in cells by alternative mRNA splicing to yield two distinct variants or isoforms. We designate these isoforms SMRTalpha and SMRTtau and demonstrate that these isoforms have significantly different affinities for different nuclear receptors. These isoforms are evolutionarily conserved and are expressed in a tissue-specific manner. Our results suggest that differential mRNA splicing serves to customize corepressor function in different cells, allowing the transcriptional properties of nuclear receptors to be adapted to different contexts.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Jonas, Brian/AAS-3639-2020; Goodson, Michael L/G-4175-2010	Jonas, Brian/0000-0002-4921-5809; Goodson, Michael/0000-0002-3464-490X	NIDDK NIH HHS [5F32DK062654-02, DK53538, R01 DK053528, R01 DK053528-03] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528, R03DK053538, F32DK062654] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bailey P, 1998, NUCLEIC ACIDS RES, V26, P5501, DOI 10.1093/nar/26.23.5501; Bailey PJ, 1997, J STEROID BIOCHEM, V63, P165, DOI 10.1016/S0960-0760(97)00079-4; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Carlberg C, 2004, J STEROID BIOCHEM, V89-90, P227, DOI 10.1016/j.jsbmb.2004.03.112; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chatterjee VKK, 2001, BIOCHEM SOC T, V29, P227, DOI 10.1042/bst0290227; CHATTERJEE VKK, 1992, CANCER SURV, V14, P147; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Farboud B, 2003, MOL CELL BIOL, V23, P2844, DOI 10.1128/MCB.23.8.2844-2858.2003; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Glass CK, 2000, GENE DEV, V14, P121; Gronemeyer H, 2001, CELL MOL BIOL LETT, V6, P3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guenther MG, 2000, GENE DEV, V14, P1048; Hauksdottir H, 2003, MOL ENDOCRINOL, V17, P373, DOI 10.1210/me.2002-0340; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huber BR, 2003, MOL ENDOCRINOL, V17, P107, DOI 10.1210/me.2002-0097; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Keightley MC, 1998, MOL CELL ENDOCRINOL, V137, P1, DOI 10.1016/S0303-7207(97)00236-0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Koide T, 2001, GENE DEV, V15, P2111, DOI 10.1101/gad.908801; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Makowski A, 2003, MOL ENDOCRINOL, V17, P273, DOI 10.1210/me.2002-0310; Malartre M, 2004, NUCLEIC ACIDS RES, V32, P4676, DOI 10.1093/nar/gkh786; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Matsushita A, 2000, J ENDOCRINOL, V167, P493, DOI 10.1677/joe.0.1670493; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Privalsky ML, 2000, MOL CELL ENDOCRINOL, V159, P109, DOI 10.1016/S0303-7207(99)00201-4; Sachs LM, 2002, MOL CELL BIOL, V22, P8527, DOI 10.1128/MCB.22.24.8527-8538.2002; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; Segalla S, 2003, MOL CELL BIOL, V23, P8795, DOI 10.1128/MCB.23.23.8795-8808.2003; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Tomita A, 2004, MOL CELL BIOL, V24, P3337, DOI 10.1128/MCB.24.8.3337-3346.2004; Tomita A, 2003, J BIOL CHEM, V278, P30788, DOI 10.1074/jbc.M303309200; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Whitfield GK, 1999, J CELL BIOCHEM, P110; Wong C, 2000, BIOTECHNIQUES, V28, P426, DOI 10.2144/00283bm07; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Yang ZH, 2001, MOL ENDOCRINOL, V15, P1170, DOI 10.1210/me.15.7.1170; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; ZHANG XK, 1991, NEW BIOL, V3, P169	90	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7493	7503		10.1074/jbc.M411514200	http://dx.doi.org/10.1074/jbc.M411514200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632172	hybrid, Green Accepted			2022-12-27	WOS:000227395700011
J	Wernick, NLB; Haucke, V; Simister, NE				Wernick, NLB; Haucke, V; Simister, NE			Recognition of the tryptophan-based endocytosis signal in the neonatal Fc receptor by the mu subunit of adaptor protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIUM-CHAIN SUBUNIT; FACTOR-II RECEPTOR; SORTING SIGNALS; MAMMARY-GLAND; IMMUNOGLOBULIN-G; HUMAN PLACENTA; TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; IGG TRANSPORT; BIDIRECTIONAL TRANSCYTOSIS	Endocytosis of membrane proteins is typically mediated by signals present in their cytoplasmic domains. These signals usually contain an essential tyrosine or pair of leucine residues. Both tyrosine- and dileucine-based endocytosis signals are recognized by the adaptor complex AP-2. The best understood of these interactions occurs between the tyrosine-based motif, YXXPhi, and the mu2 subunit of AP-2. We recently reported a tryptophan-based endocytosis signal, WLSL, contained within the cytoplasmic domain of the neonatal Fc receptor. This signal resembles YXXPhi. We have investigated the mechanism by which the tryptophan-based signal is recognized. Both interaction assays in vitro and endocytosis assays in vivo show that mu2 binds the tryptophan-based signal. Furthermore, the WLSL sequence binds the same site as YXXPhi. Unlike the WXXF motif, contained in stonin 2 and other endocytic proteins, WLSL does not bind the a subunit of AP-2. These observations reveal a functional similarity between the tryptophan-based endocytosis signal and the YXXPhi motif, and an unexpected versatility of mu2 function.	Brandeis Univ, Rosenstiel Ctr Basic Biomed Sci, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany	Brandeis University; Brandeis University; Free University of Berlin	Simister, NE (corresponding author), Brandeis Univ, Rosenstiel Ctr Basic Biomed Sci, MS 029, Waltham, MA 02254 USA.	simister@brandeis.edu		Haucke, Volker/0000-0003-3119-6993	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027691] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27691] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adamski FM, 2000, MOL IMMUNOL, V37, P435, DOI 10.1016/S0161-5890(00)00065-1; AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Banbury AN, 2003, J BIOL CHEM, V278, P12022, DOI 10.1074/jbc.M211966200; BERRYMAN M, 1995, J CELL SCI, V108, P2347; BLUMBERG RS, 1995, J CLIN INVEST, V95, P2397, DOI 10.1172/JCI117934; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Borvak J, 1998, INT IMMUNOL, V10, P1289, DOI 10.1093/intimm/10.9.1289; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Cianga P, 1999, EUR J IMMUNOL, V29, P2515, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2515::AID-IMMU2515&gt;3.0.CO;2-D; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Crump CM, 1998, J BIOL CHEM, V273, P28073, DOI 10.1074/jbc.273.43.28073; Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968; Ellinger I, 1999, EUR J IMMUNOL, V29, P733, DOI 10.1002/(SICI)1521-4141(199903)29:03<733::AID-IMMU733>3.0.CO;2-C; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; Gafencu A, 2003, PLACENTA, V24, P664, DOI 10.1016/S0143-4004(03)00041-9; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Haymann JP, 2000, J AM SOC NEPHROL, V11, P632, DOI 10.1681/ASN.V114632; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Israel EJ, 1997, IMMUNOLOGY, V92, P69, DOI 10.1046/j.1365-2567.1997.00326.x; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JADOT M, 1992, J BIOL CHEM, V267, P11069; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jha A, 2004, J BIOL CHEM, V279, P2281, DOI 10.1074/jbc.M305644200; JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kacskovics I, 2000, J IMMUNOL, V164, P1889, DOI 10.4049/jimmunol.164.4.1889; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kobayashi N, 2002, AM J PHYSIOL-RENAL, V282, pF358, DOI 10.1152/ajprenal.0164.2001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kristoffersen EK, 1996, EUR J IMMUNOL, V26, P1668, DOI 10.1002/eji.1830260741; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leach JL, 1996, J IMMUNOL, V157, P3317; LEACH L, 1991, HISTOCHEM J, V23, P444, DOI 10.1007/BF01041374; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Mayer B, 2002, VET IMMUNOL IMMUNOP, V87, P327, DOI 10.1016/S0165-2427(02)00059-4; Mayer B, 2002, IMMUNOLOGY, V107, P288, DOI 10.1046/j.1365-2567.2002.01514.x; McCarthy KM, 2000, J CELL SCI, V113, P1277; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Nordeng TW, 1999, J BIOL CHEM, V274, P21139, DOI 10.1074/jbc.274.30.21139; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Praetor A, 2002, J MOL BIOL, V321, P277, DOI 10.1016/S0022-2836(02)00626-5; RAGHAVAN M, 1995, P NATL ACAD SCI USA, V92, P11200, DOI 10.1073/pnas.92.24.11200; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Roopenian DC, 2003, J IMMUNOL, V170, P3528, DOI 10.4049/jimmunol.170.7.3528; Schnulle PM, 2003, VET IMMUNOL IMMUNOP, V91, P227, DOI 10.1016/S0165-2427(02)00294-5; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400; Stefaner I, 1999, J BIOL CHEM, V274, P8998, DOI 10.1074/jbc.274.13.8998; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Walther K, 2004, P NATL ACAD SCI USA, V101, P964, DOI 10.1073/pnas.0307862100; Ward ES, 2003, INT IMMUNOL, V15, P187, DOI 10.1093/intimm/dxg018; Wu Z, 2001, J BIOL CHEM, V276, P5240, DOI 10.1074/jbc.M006684200	77	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7309	7316		10.1074/jbc.M410752200	http://dx.doi.org/10.1074/jbc.M410752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15598658	hybrid			2022-12-27	WOS:000227332700123
J	Kresge, N; Simoni, RD; Hill, RL				Kresge, N; Simoni, RD; Hill, RL			Succeeding in science despite the odds; Studying metabolism with NMR by Mildred Cohn (Reprinted from J Biol Chem, vol 201, pg 735, 1953 and J Biol Chem, vol 237, pg 176-181, 1962)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Reprint							MAGNETIC-RESONANCE SPECTRA; TRIPHOSPHATE							Kresge, Nicole/0000-0003-1551-6627				COHN M, 1962, J BIOL CHEM, V237, P176; Cohn M, 2003, SCIENTIST, V17, P15; COHN M, 1953, J BIOL CHEM, V201, P735; COHN M, 1960, J BIOL CHEM, V235, P3250; Cori CF, 1928, J BIOL CHEM, V79, P321; CORI GERTY T., 1938, JOUR BIOL CHEM, V124, P543; Cori GT, 1939, J BIOL CHEM, V127, P771; Cori GT, 1943, J BIOL CHEM, V151, P31; Du Vigneaud V, 1941, J BIOL CHEM, V140, P625; Green AA, 1943, J BIOL CHEM, V151, P21; WASSERMAN E, 2000, DOOR DREAM CONVERSAT, P43	11	0	0	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52							e12					2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15615732				2022-12-27	WOS:000225793600130
J	Wilson, DK; Cerna, D; Chew, E				Wilson, DK; Cerna, D; Chew, E			The 1.1-angstrom structure of the spindle checkpoint protein Bub3p reveals functional regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD-REPEAT PROTEIN; CRYSTAL-STRUCTURE; ASSEMBLY CHECKPOINT; GENES; PHOSPHORYLATION; ASSOCIATION; COMPONENT; RESIDUES; INSIGHTS; ENCODES	Bub3p is a protein that mediates the spindle checkpoint, a signaling pathway that ensures correct chromosome segregation in organisms ranging from yeast to mammals. It is known to function by co-localizing at least two other proteins, Mad3p and the protein kinase Bub1p, to the kinetochore of chromosomes that are not properly attached to mitotic spindles, ultimately resulting in cell cycle arrest. Prior sequence analysis suggested that Bub3p was composed of three or four WD repeats (also known as WD40 and beta-transducin repeats), short sequence motifs appearing in clusters of 4-16 found in many hundreds of eukaryotic proteins that fold into four-stranded blade-like sheets. We have determined the crystal structure of Bub3p from Saccharomyces cerevisiae at 1.1 angstrom and a crystallographic R-factor of 15.3%, revealing seven authentic repeats. In light of this, it appears that many of these repeats therefore remain hidden in sequences of other proteins. Analysis of random and site-directed mutants identifies the surface of Bub3p involved in checkpoint function through binding of Bub1p and Mad3p. Sequence alignments indicate that these surfaces are mostly conserved across Bub3 proteins from diverse species. A structural comparison with other proteins containing WD repeats suggests that these folds may bind partner proteins using similar surface areas on the top and sides of the propeller. The sequences composing these regions are the most divergent within the repeat across all WD repeat proteins and could potentially be modulated to provide specificity in partner protein binding without perturbation of the core structure.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Wilson, DK (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	dave@alanine.ucdavis.edu			NIGMS NIH HHS [GM59810, GM66135, GM17891] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066135, F31GM017891, R01GM059810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Colosimo A, 1999, BIOTECHNIQUES, V26, P870, DOI 10.2144/99265bm15; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Grabsch H, 2003, J PATHOL, V200, P16, DOI 10.1002/path.1324; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Harlow E., 1988, LAB MANUAL; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Hisbergues M, 2001, PROTEIN SCI, V10, P293, DOI 10.1110/ps.22701; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Larsen NA, 2004, J MOL BIOL, V344, P885, DOI 10.1016/j.jmb.2004.09.094; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Madrona AY, 2004, PROTEIN SCI, V13, P1557, DOI 10.1110/ps.04704704; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mohri K, 2004, J BIOL CHEM, V279, P31697, DOI 10.1074/jbc.M403351200; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pickles LM, 2002, STRUCTURE, V10, P751, DOI 10.1016/S0969-2126(02)00768-2; Puig O, 1998, YEAST, V14, P1139; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Seeley TW, 1999, BIOCHEM BIOPH RES CO, V257, P589, DOI 10.1006/bbrc.1999.0514; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; van Nocker S, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-50; Voegtli WC, 2003, J BIOL CHEM, V278, P34373, DOI 10.1074/jbc.M302773200; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	46	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13944	13951		10.1074/jbc.M412919200	http://dx.doi.org/10.1074/jbc.M412919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15644329	hybrid			2022-12-27	WOS:000228095500096
J	Alikhani, M; Alikhani, ZB; Graves, DT				Alikhani, M; Alikhani, ZB; Graves, DT			FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FORKHEAD TRANSCRIPTION FACTORS; CELL-DEATH; CASPASE-8 ACTIVATION; FACTOR-ALPHA; IN-VIVO; INDUCTION; PROTEIN; PROLIFERATION; SUPERFAMILY	Tumor necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory and pro-apoptotic mediator that plays an important role in several normal and disease processes. TNF-induced cell death is one of the principal mechanisms by which cells are removed. Although TNF-mediated apoptosis has been the subject of intense investigation, the transcriptional mechanisms through which it promotes apoptosis are not well understood and, paradoxically, the archetypal TNF-induced nuclear factor NF kappa B is anti-apoptotic. To identify a potential master transcriptional regulator of apoptosis, we examined an array of TNF-alpha-activated transcription factors. Forkhead box class-O 1 (FOXO1) was strongly activated, which was confirmed in vitro and in vivo by electrophoretic mobility shift assay. The central importance of FOXO1 was established in experiments with small inhibitory RNA (siRNA) that specifically silenced FOXO1. When FOXO1 was silenced, fibroblast apoptosis was reduced 76%. Other siRNAs that partially inhibited FOXO1 expression were proportionately effective in reducing apoptosis. Transcriptional profiling was then carried out in conjunction with siRNA to establish mechanisms by which FOXO1 modulated apoptosis. In the absence of FOXO1, TNF-alpha failed to up-regulate a large number of pro-apoptotic gene families including ligands, receptors, adapter molecules, mitochondrial proteins, and caspases. siRNA silencing also blocked down-regulation of anti-apoptotic genes. These results indicate that TNF induces activation of the FOXO1 transcription factor, which acts as a master switch to control apoptosis.	Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Boston University	Graves, DT (corresponding author), Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, 700 Albany St W-202 D, Boston, MA 02118 USA.	dgraves@bu.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007559] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01DE07559] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alikhani M, 2004, J DENT RES, V83, P671, DOI 10.1177/154405910408300903; Alikhani M, 2004, J CELL PHYSIOL, V201, P341, DOI 10.1002/jcp.20067; Alikhani MI, 2003, J BIOL CHEM, V278, P52901, DOI 10.1074/jbc.M307638200; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beutler BA, 1999, J RHEUMATOL, V26, P16; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Engel D, 2004, AM J PHYSIOL-HEART C, V287, pH1303, DOI 10.1152/ajpheart.00053.2004; Faraco PR, 1999, BIOCHEM BIOPH RES CO, V261, P385, DOI 10.1006/bbrc.1999.1042; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Graves DT, 2001, J DENT RES, V80, P1875, DOI 10.1177/00220345010800100301; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; LASTER SM, 1988, J IMMUNOL, V141, P2629; Leenders H, 2000, EUR J IMMUNOL, V30, P2980, DOI 10.1002/1521-4141(200010)30:10<2980::AID-IMMU2980>3.0.CO;2-9; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Piguet PF, 1999, LAB INVEST, V79, P495; ROBAYE B, 1991, AM J PATHOL, V138, P447; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685	43	97	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12096	12102		10.1074/jbc.M412171200	http://dx.doi.org/10.1074/jbc.M412171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15632117	hybrid			2022-12-27	WOS:000227922000006
J	Perbandt, M; Hoppener, J; Betzel, C; Walter, RD; Liebau, E				Perbandt, M; Hoppener, J; Betzel, C; Walter, RD; Liebau, E			Structure of the major cytosolic glutathione S-transferase from the parasitic nematode Onchocerca volvulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; HUMAN PLACENTA; BIOCHEMICAL-CHARACTERIZATION; 3-DIMENSIONAL STRUCTURE; MULTIPLE TREATMENTS; CRYSTAL-STRUCTURE; SUPERGENE FAMILY; ENDEMIC FOCI; PI; DRUG	Onchocerciasis is a debilitating parasitic disease caused by the filarial worm Onchocerca volvulus. Similar to other helminth parasites, O. volvulus is capable of evading the host's immune responses by a variety of defense mechanisms, including the detoxification activities of the glutathione S-transferases (GSTs). Additionally, in response to drug treatment, helminth GSTs are highly up-regulated, making them tempting targets both for chemotherapy and for vaccine development. We analyzed the three-dimensional x-ray structure of the major cytosolic GST from O. volvulus ( Ov-GST2) in complex with its natural substrate glutathione and its competitive inhibitor S-hexylglutathione at 1.5 and 1.8 angstrom resolution, respectively. From the perspective of the biochemical classification, the Ov-GST2 seems to be related to pi-class GSTs. However, in comparison to other pi-class GSTs, in particular to the host's counterpart, the Ov-GST2 reveals significant and unusual differences in the sequence and overall structure. Major differences can be found in helix alpha-2, an important region for substrate recognition. Moreover, the binding site for the electrophilic co-substrate is spatially increased and more solvent-accessible. These structural alterations are responsible for different substrate specificities and will form the basis of parasite-specific structure-based drug design investigations.	Univ Hamburg, Inst Biochem & Foodchem, Dept Biochem & Mol Biol, D-20146 Hamburg, Germany; Bernhard Nocht Inst Trop Med, Dept Biochem, D-20359 Hamburg, Germany	University of Hamburg; Bernhard Nocht Institut fur Tropenmedizin	Perbandt, M (corresponding author), Univ Hamburg, Inst Biochem & Foodchem, Dept Biochem & Mol Biol, Martin Luther King Pl 6, D-20146 Hamburg, Germany.	Perbandt@chemie.uni-hamburg.de	Betzel, Christian/G-8105-2018; Perbandt, Markus/K-7603-2018	Betzel, Christian/0000-0002-3879-5019; 				Alka, 2004, VET PARASITOL, V121, P277, DOI 10.1016/j.vetpar.2004.03.007; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Awadzi K, 2004, ANN TROP MED PARASIT, V98, P231, DOI 10.1179/000349804225003253; Awadzi K, 2004, ANN TROP MED PARASIT, V98, P359, DOI 10.1179/000349804225003442; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROPHY PM, 1993, PARASITOL TODAY, V9, P128, DOI 10.1016/0169-4758(93)90173-D; Brophy PM, 2000, BIOORG MED CHEM LETT, V10, P979, DOI 10.1016/S0960-894X(00)00142-6; BROPHY PM, 1995, INT J PARASITOL, V25, P641, DOI 10.1016/0020-7519(94)00151-D; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; Coles BF, 2003, BIOFACTORS, V17, P115, DOI 10.1002/biof.5520170112; CUPP EW, 1992, PARASITOL TODAY, V8, P212, DOI 10.1016/0169-4758(92)90267-6; DIRR H, 1994, J MOL BIOL, V243, P72, DOI 10.1006/jmbi.1994.1631; DIRR HW, 1991, EUR J BIOCHEM, V196, P693, DOI 10.1111/j.1432-1033.1991.tb15867.x; Fritz-Wolf K, 2003, P NATL ACAD SCI USA, V100, P13821, DOI 10.1073/pnas.2333763100; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; Harder A, 2002, PARASITOL RES, V88, P591, DOI 10.1007/s00436-001-0589-9; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hoppner J, 2004, ACTA CRYSTALLOGR D, V60, P1496, DOI 10.1107/S090744490401460X; Johnson KA, 2003, BIOCHEMISTRY-US, V42, P10084, DOI 10.1021/bi034449r; KAWALEK JC, 1984, INT J PARASITOL, V14, P173, DOI 10.1016/0020-7519(84)90045-6; Kilili KG, 2004, J BIOL CHEM, V279, P24540, DOI 10.1074/jbc.M309882200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liebau E, 1996, MOL BIOCHEM PARASIT, V80, P27, DOI 10.1016/0166-6851(96)02660-6; Liebau E, 1997, BIOCHEM J, V324, P659, DOI 10.1042/bj3240659; Lo B.M., 1997, BIOCHEMISTRY-US, V36, P6207; Manevich Y, 2004, P NATL ACAD SCI USA, V101, P3780, DOI 10.1073/pnas.0400181101; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; Molyneux DH, 2003, TRENDS PARASITOL, V19, P516, DOI 10.1016/j.pt.2003.09.004; Mortensen LL, 2003, J AM VET MED ASSOC, V223, P495, DOI 10.2460/javma.2003.223.495; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Oakley AJ, 1998, BIOCHEMISTRY-US, V37, P9912, DOI 10.1021/bi980323w; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perbandt M, 2004, J BIOL CHEM, V279, P1336, DOI 10.1074/jbc.M309663200; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Prade L, 1997, STRUCTURE, V5, P1287, DOI 10.1016/S0969-2126(97)00281-5; Ralat LA, 2004, J BIOL CHEM, V279, P50204, DOI 10.1074/jbc.M407445200; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RICCI G, 1991, J BIOL CHEM, V266, P21409; Rossjohn J, 1997, J MOL BIOL, V273, P857, DOI 10.1006/jmbi.1997.1338; ROUSSELL A, 1991, SILICON GRAPHICS DIR; Salinas AE, 1999, CURR MED CHEM, V6, P279; Sangster N, 1996, PARASITOLOGY, V113, pS201, DOI 10.1017/S0031182000077982; SCHAFFER J, 1988, J BIOL CHEM, V263, P17405; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; Sommer A, 2003, INFECT IMMUN, V71, P3603, DOI 10.1128/IAI.71.6.3603-3606.2003; Sommer A, 2001, INFECT IMMUN, V69, P7718, DOI 10.1128/IAI.69.12.7718-7728.2001; Stella L, 1998, J BIOL CHEM, V273, P23267, DOI 10.1074/jbc.273.36.23267; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; Townsend Danyelle, 2003, Am J Pharmacogenomics, V3, P157, DOI 10.2165/00129785-200303030-00002; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; Van Rossum AJ, 2004, INFECT IMMUN, V72, P2780, DOI 10.1128/IAI.72.5.2780-2790.2004; VANDEWAA EA, 1993, ARCH BIOCHEM BIOPHYS, V303, P15, DOI 10.1006/abbi.1993.1249; Vega MC, 1998, J BIOL CHEM, V273, P2844, DOI 10.1074/jbc.273.5.2844; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILCE MCJ, 1994, J MOL BIOL, V236, P1407, DOI 10.1016/0022-2836(94)90067-1; Wildenburg G, 1998, EXP PARASITOL, V88, P34, DOI 10.1006/expr.1998.4189	69	24	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12630	12636		10.1074/jbc.M413551200	http://dx.doi.org/10.1074/jbc.M413551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15640152	hybrid			2022-12-27	WOS:000227922000068
J	Savolainen, K; Bhaumik, P; Schmitz, W; Kotti, TJ; Conzelmann, E; Wierenga, RK; Hiltunen, JK				Savolainen, K; Bhaumik, P; Schmitz, W; Kotti, TJ; Conzelmann, E; Wierenga, RK; Hiltunen, JK			alpha-methylacyl-CoA racemase from Mycobacterium tuberculosis - Mutational and structural characterization of the active site and the fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI YFDW; X-RAY-DIFFRACTION; 2-METHYLACYL-COA RACEMASE; CRYSTAL-STRUCTURE; BETA-OXIDATION; GENE-PRODUCT; ACID; FAMILY; MITOCHONDRIAL; PURIFICATION	alpha-Methylacyl-CoA racemase (Amacr) catalyzes the racemization of alpha-methyl-branched CoA esters. Sequence comparisons have shown that this enzyme is a member of the family III CoA transferases. The mammalian Amacr is involved in bile acid synthesis and branched-chain fatty acid degradation. In human, mutated variants of Amacr have been shown to be associated with disease states. Amino acid sequence alignment of Amacrs and its homologues from various species revealed 26 conserved protic residues, assumed to be potential candidates as catalytic residues. Amacr from Mycobacterium tuberculosis (MCR) was taken as a representative of the racemases. To determine their importance for efficient catalysis, each of these 26 protic residues of MCR was mutated into an alanine, respectively, and the mutated variants were overexpressed in Escherichia coli. It was found that four variants (R91A, H126A, D156A, and E241A) were properly folded but had much decreased catalytic efficiency. Apparently, Arg(91), His(126), Asp(156), and Glu(241) are important catalytic residues of MCR. The importance of these residues for catalysis can be rationalized by the 1.8 angstrom resolution crystal structure of MCR, which shows that the catalytic site is at the interface between the large and small domain of two different subunits of the dimeric enzyme. This crystal structure is the first structure of a complete enzyme of the bile acid synthesis pathway. It shows that MCR has unique structural features, not seen in the structures of the sequence related formyl-CoA transferases, suggesting that the family III CoA transferases can be subdivided in at least two classes, being racemases and CoA transferases.	Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Wurzburg, Theodor Boveri Inst Biowissensch, Biozentrum, D-97074 Wurzburg, Germany	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Wurzburg	Hiltunen, JK (corresponding author), Univ Oulu, Bioctr Oulu, POB 3000, FIN-90014 Oulu, Finland.	kalervo.hiltunen@oulu.fi		Hiltunen, Kalervo/0000-0002-3073-9602; Savolainen, Kalle/0000-0002-1244-7200				Amery L, 2000, J LIPID RES, V41, P1752; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bhaumik P, 2003, ACTA CRYSTALLOGR D, V59, P353, DOI 10.1107/S0907444902020735; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; *DEL SCI, 1998, PYMOL MAN; Ferdinandusse S, 2000, J LIPID RES, V41, P1890; Ferdinandusse S, 2000, NAT GENET, V24, P188, DOI 10.1038/72861; Gogos A, 2004, ACTA CRYSTALLOGR D, V60, P507, DOI 10.1107/S0907444904000034; Gruez A, 2003, J BIOL CHEM, V278, P34582, DOI 10.1074/jbc.C300282200; Hasson MS, 1998, P NATL ACAD SCI USA, V95, P10396, DOI 10.1073/pnas.95.18.10396; Heider J, 2001, FEBS LETT, V509, P345, DOI 10.1016/S0014-5793(01)03178-7; Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; Jelakovic S, 2003, J MOL BIOL, V326, P127, DOI 10.1016/S0022-2836(02)01374-8; Jiang Z, 2003, CANCER DETECT PREV, V27, P422, DOI 10.1016/j.cdp.2003.07.003; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jonsson S, 2004, J BIOL CHEM, V279, P36003, DOI 10.1074/jbc.M404873200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Klenchin VA, 2004, BIOCHEMISTRY-US, V43, P10370, DOI 10.1021/bi049197o; Kotti TJ, 2000, J BIOL CHEM, V275, P20887, DOI 10.1074/jbc.M002067200; Kumar-Sinha C, 2004, AM J PATHOL, V164, P787, DOI 10.1016/S0002-9440(10)63167-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu LJ, 2002, J MOL BIOL, V319, P479, DOI 10.1016/S0022-2836(02)00296-6; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mobitz H, 2004, BIOCHEMISTRY-US, V43, P9685, DOI 10.1021/bi049580t; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen JI, 1996, BIOCHEM BIOPH RES CO, V224, P37, DOI 10.1006/bbrc.1996.0981; Ricagno S, 2003, EMBO J, V22, P3210, DOI 10.1093/emboj/cdg333; Rouhi AM, 1999, CHEM ENG NEWS, V77, P52, DOI 10.1021/cen-v077n020.p052; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Sakai Y, 2004, J BACTERIOL, V186, P7214, DOI 10.1128/JB.186.21.7214-7220.2004; Savolainen K, 2004, HUM MOL GENET, V13, P955, DOI 10.1093/hmg/ddh107; SCHMITZ W, 1994, EUR J BIOCHEM, V222, P313, DOI 10.1111/j.1432-1033.1994.tb18870.x; Schmitz W, 1997, EUR J BIOCHEM, V244, P434, DOI 10.1111/j.1432-1033.1997.00434.x; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; Schulz JM, 2004, J BIOL CHEM, V279, P32796, DOI 10.1074/jbc.M405005200; Setchell KDR, 2003, GASTROENTEROLOGY, V124, P217, DOI 10.1053/gast.2003.50017; SNIDER DE, 1994, TUBERCULOSIS PATHOGE, P2; Takahashi M, 2003, ONCOGENE, V22, P6810, DOI 10.1038/sj.onc.1206869; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Van Veldhoven PP, 2001, EUR J CLIN INVEST, V31, P714, DOI 10.1046/j.1365-2362.2001.00877.x; WHITE WB, 1988, J BACTERIOL, V170, P4555, DOI 10.1128/jb.170.10.4555-4561.1988	47	36	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12611	12620		10.1074/jbc.M409704200	http://dx.doi.org/10.1074/jbc.M409704200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15632186	hybrid			2022-12-27	WOS:000227922000066
J	Wang, T; Hu, YC; Dong, SZ; Fan, M; Tamae, D; Ozeki, M; Gao, Q; Gius, D; Li, JJ				Wang, T; Hu, YC; Dong, SZ; Fan, M; Tamae, D; Ozeki, M; Gao, Q; Gius, D; Li, JJ			Co-activation of ERK, NF-kappa B, and GADD45 beta in response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; SUPEROXIDE-DISMUTASE GENE; FREE-RADICAL SCAVENGERS; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTORS; STRESS RESPONSES; INHIBITOR PD98059; INDUCED APOPTOSIS; GENOTOXIC STRESS; FAMILY PROTEINS	NF-kappa B has been well documented to play a critical role in signaling cell stress reactions. The extracellular signal-regulated kinase (ERK) regulates cell proliferation and survival. GADD45 beta is a primary cell cycle element responsive to NF-kappa B activation in anti-apoptotic responses. The present study provides evidence demonstrating that NK-kappa B, ERK and GADD45 beta are co-activated by ionizing radiation (IR) in a pattern of mutually dependence to increase cell survival. Stress conditions generated in human breast cancer MCF-7 cells by the administration of a single exposure of 5 Gy IR resulted in the activation of ERK but not p38 or JNK, along with an enhancement of the NF-kappa B transactivation and GADD45 beta expression. Overexpression of dominant negative Erk (DN-Erk) or pre-exposure to ERK inhibitor PD98059 inhibited NF-kappa B. Transfection of dominant negative mutant I kappa B that blocks NF-kappa B nuclear translocation, inhibited ERK activity and GADD45 beta expression and increased cell radiosensitivity. Interaction of p65 and ERK was visualized in living MCF-7 cells by bimolecular fluorescence complementation analysis. Antisense inhibition of GADD45 beta strikingly blocked IR-induced NF-kappa B and ERK but not p38 and JNK. Overall, these results demonstrate a possibility that NF-kappa B, ERK, and GADD45 beta are able to coordinate in a loop-like signaling network to defend cells against the cytotoxicity induced by ionizing radiation.	Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, W Lafayette, IN 47907 USA; Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Duarte, CA 91010 USA; Bio Rad Labs Inc, Life Sci Grp, San Ramon, CA 94583 USA; NCI, Ctr Canc Res, Radiat Oncol Sci Program, Mol Radiat Oncol,NIH, Bethesda, MD 20892 USA; Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; City of Hope; Beckman Research Institute of City of Hope; City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Purdue University System; Purdue University; Purdue University West Lafayette Campus	Li, JJ (corresponding author), Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, 1279 Civil Engn Blvd,550 Stadium Mall Dr, W Lafayette, IN 47907 USA.	jjli@purdue.edu		Li, Jian Jian/0000-0003-3694-9675	NCI NIH HHS [R01 CA101990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010544, R01CA101990] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Ajenjo N, 2004, J BIOL CHEM, V279, P32813, DOI 10.1074/jbc.M313656200; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 2001, RADIAT RES, V156, P657, DOI 10.1667/0033-7587(2001)156[0657:IOGEAA]2.0.CO;2; Anders M, 2003, CANCER RES, V63, P2088; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Bebien M, 2003, ONCOGENE, V22, P1836, DOI 10.1038/sj.onc.1206334; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bradbury CM, 2001, CANCER RES, V61, P7689; Chen XF, 2002, CANCER RES, V62, P1213; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; Chung HK, 2003, J BIOL CHEM, V278, P28079, DOI 10.1074/jbc.M212835200; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Duffey DC, 1999, CANCER RES, V59, P3468; Fornace AJ, 1999, GENE EXPRESSION, V7, P387; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Granville DJ, 2000, BLOOD, V95, P256; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Hara T, 1998, BIOCHEM BIOPH RES CO, V244, P41, DOI 10.1006/bbrc.1998.8210; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hassan KA, 2002, CANCER RES, V62, P6414; He HC, 1999, CELL GROWTH DIFFER, V10, P307; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kataoka Y, 2002, INT J RADIAT ONCOL, V53, P180, DOI 10.1016/S0360-3016(01)02820-6; Kiningham KK, 1997, CANCER RES, V57, P5265; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li ZK, 2001, RADIAT RES, V155, P543, DOI 10.1667/0033-7587(2001)155[0543:EGAIMH]2.0.CO;2; Li ZK, 2001, FREE RADICAL BIO MED, V30, P260, DOI 10.1016/S0891-5849(00)00468-8; Liang K, 2003, MOL CANCER THER, V2, P1113; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Meier KE, 1998, CELL SIGNAL, V10, P415, DOI 10.1016/S0898-6568(97)00140-X; MOODIE SA, 1995, ONCOGENE, V11, P447; Murley JS, 2001, FREE RADICAL BIO MED, V30, P1426, DOI 10.1016/S0891-5849(01)00554-8; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shonai T, 2002, CELL DEATH DIFFER, V9, P963, DOI 10.1038/sj.cdd.4401050; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; Sreekumar A, 2001, CANCER RES, V61, P7585; Suzuki K, 2001, CANCER RES, V61, P5396; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Xia LQ, 2004, CANCER RES, V64, P221, DOI 10.1158/0008-5472.CAN-03-0969; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhao WL, 2001, CANCER RES, V61, P5537	72	62	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12593	12601		10.1074/jbc.M410982200	http://dx.doi.org/10.1074/jbc.M410982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15642734	hybrid, Green Accepted			2022-12-27	WOS:000227922000064
J	Gumpricht, E; Dahl, R; Devereaux, MW; Sokol, RJ				Gumpricht, E; Dahl, R; Devereaux, MW; Sokol, RJ			Licorice compounds glycyrrhizin and 18 beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION; INDUCED APOPTOSIS; HEPATIC MITOCHONDRIA; CELL-DEATH; IN-VITRO; URSODEOXYCHOLIC ACID; DEPENDENT MANNER; LIVER-INJURY; GROWTH	The accumulation of hydrophobic bile acids results in cholestatic liver injury by increasing oxidative stress, mitochondrial dysfunction, and activation of cell signaling pathways. Licorice root and its constituents have been utilized as antihepatotoxic agents. The purpose of this study was to evaluate the potential modulation by a primary component of licorice root, glycyrrhizin (GL), and its metabolite, 18 beta-glycyrrhetinic acid (GA), in a hepatocyte model of cholestatic liver injury. Preincubation of fresh rat hepatocyte suspensions with GL or GA reduced glycochenodeoxycholic acid (GCDC)-dependent reactive oxygen species generation, with GA more potent than GL. Interestingly, GL and GA had opposing effects toward GCDC-induced cytotoxicity; GA prevented both necrosis and apoptosis, whereas GL enhanced apoptosis. GCDC promoted activation of caspase 10, caspase 3, and PARP; all were inhibited by GA but not GL. Induction of apoptosis by GCDC was also associated with activation of JNK, which was prevented by GA. Activation of caspase 9 and dissipation of mitochondrial membrane potential were prevented by GA but not GL. In liver mitochondrial studies, GL and GA were both potent inhibitors of the mitochondrial permeability transition, reactive oxygen species generation, and cytochrome c release at submicromolar concentrations. Results from this study suggest that GL exhibits proapoptotic properties, whereas GA is a potent inhibitor of bile acid-induced apoptosis and necrosis in a manner consistent with its antioxidative effect.	Childrens Hosp, Pediat Liver Ctr, Denver, CO 80218 USA; Univ Colorado, Sch Med, Sect Pediat Gastroenterol Hepatol & Nutr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Sch Med, Pediat Gen Clin Res Ctr, Denver, CO 80262 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sokol, RJ (corresponding author), Childrens Hosp, Pediat Liver Ctr, Box B290,1056 E 19th Ave, Denver, CO 80218 USA.	Sokol.Ronald@tchden.org		Gumpricht, Eric/0000-0001-6034-3484	NIDDK NIH HHS [R01 DK-38446] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038446] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAO T, 1991, BIOCHEM PHARMACOL, V41, P1025; Armanini D, 2002, EXP CLIN ENDOCR DIAB, V110, P257, DOI 10.1055/s-2002-34587; Aso Y., 1977, IGAKUNO AYUMI, V102, P562; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Chan HT, 2003, TOXICOLOGY, V188, P211, DOI 10.1016/S0300-483X(03)00087-8; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chieco P, 1997, HISTOCHEM J, V29, P875, DOI 10.1023/A:1026446008712; DEGROOT G, 1988, J CHROMATOGR, V456, P71, DOI 10.1016/0021-9673(86)80007-3; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; GREIM H, 1973, BIOCHEM MED METAB B, V8, P280, DOI 10.1016/0006-2944(73)90032-X; Gumpricht E, 2004, PEDIATR RES, V55, P814, DOI 10.1203/01.PDR.0000117845.23762.6B; Gumpricht E, 2002, J BIOL CHEM, V277, P25823, DOI 10.1074/jbc.M112305200; Gumpricht E, 2000, TOXICOL APPL PHARM, V164, P102, DOI 10.1006/taap.2000.8894; HATTORI M, 1988, CHEM PHARM BULL, V33, P210; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; ISHIDA S, 1993, BIOL PHARM BULL, V16, P293; Jeong HG, 2002, PHARMACOL RES, V46, P221, DOI 10.1016/S1043-6618(02)00121-4; Jones SA, 2004, EXP CELL RES, V292, P29, DOI 10.1016/j.yexcr.2003.08.005; Kinjo J, 2003, BIOL PHARM BULL, V26, P1357, DOI 10.1248/bpb.26.1357; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Krutovskikh VA, 2002, ONCOGENE, V21, P1989, DOI 10.1038/sj.onc.1205187; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Kyriakis John M, 2004, Methods Mol Biol, V250, P61; Li MK, 2004, SEMIN LIVER DIS, V24, P21; NAGAI T, 1991, ARCH ENVIRON CON TOX, V20, P432, DOI 10.1007/BF01064416; NOSE M, 1994, PLANTA MED, V60, P136, DOI 10.1055/s-2006-959435; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; Powell AA, 2001, BIOCHEM J, V356, P481, DOI 10.1042/0264-6021:3560481; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Rodrigues CMP, 1998, MOL MED, V4, P165, DOI 10.1007/BF03401914; Rodrigues CMP, 1999, CELL DEATH DIFFER, V6, P842, DOI 10.1038/sj.cdd.4400560; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Schoemaker MH, 2004, HEPATOLOGY, V39, P1563, DOI 10.1002/hep.20246; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; Shah GM, 1995, ANAL BIOCHEM, V232, P251, DOI 10.1006/abio.1995.0016; Shivaram KN, 1998, FREE RADICAL BIO MED, V25, P480, DOI 10.1016/S0891-5849(98)00077-X; Sokol RJ, 1998, GASTROENTEROLOGY, V114, P164, DOI 10.1016/S0016-5085(98)70644-4; Sokol RJ, 2003, J PEDIATR GASTR NUTR, V37, P4, DOI 10.1097/00005176-200307000-00003; SOKOL RJ, 1995, GASTROENTEROLOGY, V109, P1249, DOI 10.1016/0016-5085(95)90585-5; Sokol RJ, 2001, PEDIATR RES, V49, P519, DOI 10.1203/00006450-200104000-00014; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Takeda S, 1996, J PHARM PHARMACOL, V48, P902, DOI 10.1111/j.2042-7158.1996.tb05998.x; Tanahashi T, 2002, J STEROID BIOCHEM, V80, P441, DOI 10.1016/S0960-0760(02)00033-X; van Rossum TGJ, 1999, CLIN THER, V21, P2080, DOI 10.1016/S0149-2918(00)87239-2; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Webster CRL, 2001, HEPATOLOGY, V33, P608, DOI 10.1053/jhep.2001.22756; YAMAMURA Y, 1992, J PHARM SCI, V81, P1042, DOI 10.1002/jps.2600811018; Yerushalmi B, 2001, HEPATOLOGY, V33, P616, DOI 10.1053/jhep.2001.22702; Yoshikawa M, 1999, BIOL PHARM BULL, V22, P951, DOI 10.1248/bpb.22.951	54	112	122	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10556	10563		10.1074/jbc.M411673200	http://dx.doi.org/10.1074/jbc.M411673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642733	hybrid			2022-12-27	WOS:000227559600100
J	Perron, AL; Sarret, P; Gendron, L; Stroh, T; Beaudet, A				Perron, AL; Sarret, P; Gendron, L; Stroh, T; Beaudet, A			Identification and functional characterization of a 5-transmembrane domain variant isoform of the NTS2 neurotensin receptor in rat central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICE VARIANT; ANTIPSYCHOTIC-DRUGS; BINDING-PROPERTIES; STABLE EXPRESSION; MOLECULAR-CLONING; MICRO-INJECTION; CELLS; MECHANISMS; INTERNALIZATION; NEURONS	The present study demonstrated that alternative splicing of the rat nts2 receptor gene generates a 5-transmembrane domain variant isoform (vNTS2) that is co-expressed with the full-length NTS2 receptor throughout the brain and spinal cord, as evidenced by reverse transcription-PCR. The vNTS2 polypeptide is 281 amino acids in length, which is 135 amino acids shorter than the full-length isoform. Immunohistochemical and radioligand binding studies revealed that the HA-tagged recombinant vNTS2 receptor is poorly targeted to plasma membranes in transfected COS-7 cells. Binding studies also showed that the truncated receptor displayed a 5000-fold lower affinity for neurotensin (NT) than its full-length counterpart (IC50 of 10 mu M and 2 nM, respectively). Yet NT binding induced efficient internalization of receptor-ligand complexes in vNTS2-transfected cells. Furthermore, it produced a rapid (< 5 min) activation of the mitogen-activated protein kinases (ERK1/2) pathway, indicating functional coupling of the variant receptor. This activation is sustained (> 1 h) and is also produced by the NTS2 agonist levocabastine. Western blotting experiments suggested that vNTS2 is not expressed in monomeric form in the rat central nervous system. However, it does appear to form a variety of multimeric complexes, including homodimers and heterodimers, with the full-length NTS2. Indeed, co-immunoprecipitation studies in dually transfected cells demonstrated that the two receptor isoforms can form stable associations. Taken together, the present results indicated that the rat vNTS2 is a functional receptor that may play a role in NT signaling in mammalian central nervous system.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Beaudet, A (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Rm 896,3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.beaudet@mcgill.ca		Sarret, Philippe/0000-0002-7627-701X; Gendron, Louis/0000-0002-2058-8863				AMAR S, 1985, BIOCHEM BIOPH RES CO, V129, P117, DOI 10.1016/0006-291X(85)91411-1; Barroso S, 2000, J BIOL CHEM, V275, P328, DOI 10.1074/jbc.275.1.328; Binder EB, 2001, BIOL PSYCHIAT, V50, P856, DOI 10.1016/S0006-3223(01)01211-2; Botto JM, 1997, FEBS LETT, V400, P211, DOI 10.1016/S0014-5793(96)01391-9; Botto JM, 1997, NEUROSCI LETT, V223, P193, DOI 10.1016/S0304-3940(97)13437-1; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BOZOU JC, 1989, BIOCHEM BIOPH RES CO, V161, P1144, DOI 10.1016/0006-291X(89)91361-2; Canton H, 1996, MOL PHARMACOL, V50, P799; Cape EG, 2000, J NEUROSCI, V20, P8452, DOI 10.1523/JNEUROSCI.20-22-08452.2000; CHABRY J, 1994, J NEUROCHEM, V63, P19; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Furnham N, 2004, PROTEINS, V54, P596, DOI 10.1002/prot.10568; Gendron L, 2004, MOL PHARMACOL, V66, P1421, DOI 10.1124/mol.104.002303; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Hermans E, 1998, PHARMACOL THERAPEUT, V79, P89, DOI 10.1016/S0163-7258(98)00009-6; HERMANS E, 1992, MOL BRAIN RES, V15, P332, DOI 10.1016/0169-328X(92)90126-V; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; KALIVAS PW, 1982, BRAIN RES, V243, P279, DOI 10.1016/0006-8993(82)90251-7; Kilpartick GJ, 1999, TRENDS PHARMACOL SCI, V20, P294, DOI 10.1016/S0165-6147(99)01355-3; KINKEAD B, 1994, J CLIN PSYCHIAT, V55, P30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN GE, 1980, PEPTIDES, V1, P333, DOI 10.1016/0196-9781(80)90011-X; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Minneman K P, 2001, Mol Interv, V1, P108; Miyata I, 1999, BIOCHEM BIOPH RES CO, V256, P692, DOI 10.1006/bbrc.1999.0392; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; Motomura T, 1998, METABOLISM, V47, P804, DOI 10.1016/S0026-0495(98)90116-0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Nambi P, 2000, J PHARMACOL EXP THER, V292, P247; NEMEROFF CB, 1979, P NATL ACAD SCI USA, V76, P5368, DOI 10.1073/pnas.76.10.5368; NISHIMATSU S, 1994, BBA-GENE STRUCT EXPR, V1218, P401, DOI 10.1016/0167-4781(94)90193-7; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; PoinotChazel G, 1996, BIOCHEM J, V320, P145, DOI 10.1042/bj3200145; Rekasi Z, 2000, P NATL ACAD SCI USA, V97, P10561, DOI 10.1073/pnas.180313297; Richard F, 2001, MOL PHARMACOL, V60, P1392, DOI 10.1124/mol.60.6.1392; RIOUX F, 1981, EUR J PHARMACOL, V69, P241, DOI 10.1016/0014-2999(81)90469-6; Sarret P, 2003, J COMP NEUROL, V461, P520, DOI 10.1002/cne.10718; Sarrett P, 2002, J BIOL CHEM, V277, P36233, DOI 10.1074/jbc.M202586200; SCHMAUSS C, 1993, P NATL ACAD SCI USA, V90, P8942, DOI 10.1073/pnas.90.19.8942; SNIJDERS R, 1982, NEUROPHARMACOLOGY, V21, P465; St-Gelais F, 2004, J NEUROSCI, V24, P2566, DOI 10.1523/JNEUROSCI.5376-03.2004; Sun YJ, 2001, MOL BRAIN RES, V95, P167, DOI 10.1016/S0169-328X(01)00220-0; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; WATSON MA, 1992, J NEUROCHEM, V59, P1967, DOI 10.1111/j.1471-4159.1992.tb11035.x; YAMADA M, 1993, EUR J PHARM-MOLEC PH, V244, P99, DOI 10.1016/0922-4106(93)90064-G; Zhang YF, 1998, BRIT J CANCER, V78, P1141, DOI 10.1038/bjc.1998.643	50	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10219	10227		10.1074/jbc.M410557200	http://dx.doi.org/10.1074/jbc.M410557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637074	hybrid			2022-12-27	WOS:000227559600060
J	Richardson, DK; Kashyap, S; Bajaj, M; Cusi, K; Mandarino, SJ; Finlayson, J; DeFronzo, RA; Jenkinson, CP; Mandarino, LJ				Richardson, DK; Kashyap, S; Bajaj, M; Cusi, K; Mandarino, SJ; Finlayson, J; DeFronzo, RA; Jenkinson, CP; Mandarino, LJ			Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; FREE FATTY-ACIDS; INSULIN-RESISTANCE; GLUCOSE-METABOLISM; COLLAGEN-SYNTHESIS; MAP KINASE; DYSFUNCTION; DENSITY; OBESE; ATHEROSCLEROSIS	The association between elevated plasma free fatty acid (FFA) concentrations and insulin resistance is well known. Although the cause and effect relationship between FFAs and insulin resistance is complex, plasma FFA is negatively correlated with the expression of peroxisome proliferator activated receptor-gamma cofactor-1 (PGC-1) and nuclear encoded mitochondrial genes. To test whether this association is causal, we infused a triglyceride emulsion (or saline as control) into healthy subjects to increase plasma FFA for 48 h followed by muscle biopsies, microarray analysis, quantitative real time PCR, and immunoblots. Lipid infusion increased plasma FFA concentration from 0.48 +/- 0.02 to 1.73 +/- 0.43 mM and decreased insulin-stimulated glucose disposal from 8.82 +/- 0.69 to 6.67 +/- 0.66 mg/ kg center dot min, both with p < 0.05. PGC-1 mRNA, along with mRNAs for a number of nuclear encoded mitochondrial genes, were reduced by lipid infusion (p < 0.05). Microarray analysis also revealed that lipid infusion caused a significant overexpression of extracellular matrix genes and connective tissue growth factor. Quantitative reverse transcription PCR showed that the mRNA expression of collagens and multiple extracellular matrix genes was higher after the lipid infusion (p < 0.05). Immunoblot analysis revealed that lipid infusion also increased the expression of collagens and the connective tissue growth factor protein. These data suggest that an experimental increase in FFAs decreases the expression of PGC-1 and nuclear encoded mitochondrial genes and also increases the expression of extracellular matrix genes in a manner reminiscent of inflammation.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Diabet, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Mandarino, LJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Diabet, 7703 Floyd Curl Dr,MC 7886, San Antonio, TX 78229 USA.	mandarino@uthscsa.edu	Coletta, Dawn/G-6382-2016; Bajaj, Mandeep/B-6060-2009	Kashyap, Sangeeta/0000-0002-7489-6650; Coletta, Dawn/0000-0001-5819-5152	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047936, R01DK066483, R56DK024092, R01DK079195, R01DK024092] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-01346] Funding Source: Medline; NIDDK NIH HHS [DK66483, DK24092, R01 DK079195, DK47936] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BONORA E, 1993, DIABETES, V42, P764, DOI 10.2337/diabetes.42.5.764; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; CAMPBELL PJ, 1994, AM J PHYSIOL, V266, pE600, DOI 10.1152/ajpendo.1994.266.4.E600; Candido R, 2002, CIRCULATION, V106, P246, DOI 10.1161/01.CIR.0000021122.63813.32; COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864; Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Fernandez-Real JM, 1999, DIABETOLOGIA, V42, P1367, DOI 10.1007/s001250051451; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Goodpaster Bret H, 2002, Curr Diab Rep, V2, P216, DOI 10.1007/s11892-002-0086-2; Gore-Hyer E, 2003, ARTHRITIS RHEUM-US, V48, P798, DOI 10.1002/art.10953; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hojlund K, 2003, J BIOL CHEM, V278, P10436, DOI 10.1074/jbc.M212881200; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Kashyap S, 2003, DIABETES, V52, P2461, DOI 10.2337/diabetes.52.10.2461; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; KELLEY DE, 1991, AM J CLIN NUTR, V54, P509, DOI 10.1093/ajcn/54.3.509; KELLEY DE, 1990, J CLIN INVEST, V86, P1999, DOI 10.1172/JCI114935; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Kurikawa N, 2003, BRIT J PHARMACOL, V139, P1085, DOI 10.1038/sj.bjp.0705339; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Ohnishi H, 1998, J MOL CELL CARDIOL, V30, P2411, DOI 10.1006/jmcc.1998.0799; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; REYNISDOTTIR S, 1994, J CLIN INVEST, V93, P2590, DOI 10.1172/JCI117271; Ruperez M, 2003, AM J PATHOL, V163, P1937, DOI 10.1016/S0002-9440(10)63552-3; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; THIEBAUD D, 1982, METABOLISM, V31, P1128, DOI 10.1016/0026-0495(82)90163-9; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang SN, 2001, KIDNEY INT, V60, P96, DOI 10.1046/j.1523-1755.2001.00776.x; Welle S, 2003, PHYSIOL GENOMICS, V14, P149, DOI 10.1152/physiolgenomics.00049.2003; Yang X, 2002, DIABETOLOGIA, V45, P1584, DOI 10.1007/s00125-002-0905-7; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	45	190	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10290	10297		10.1074/jbc.M408985200	http://dx.doi.org/10.1074/jbc.M408985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15598661	hybrid			2022-12-27	WOS:000227559600068
J	Tackett, AJ; Chen, YF; Cameron, CE; Raney, KD				Tackett, AJ; Chen, YF; Cameron, CE; Raney, KD			Multiple full-length NS3 molecules are required for optimal unwinding of oligonucleotide DNA in Vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI UVRD; NONSTRUCTURAL PROTEINS; SUBGENOMIC REPLICONS; OLIGOMERIC STRUCTURE; HEXAMERIC HELICASES; ACTIVE MECHANISM; PCRA HELICASE; STEP-SIZE	NS3 ( nonstructural protein 3) from the hepatitis C virus is a 3' -> 5' helicase classified in helicase superfamily 2. The optimally active form of this helicase remains uncertain. We have used unwinding assays in the presence of a protein trap to investigate the first cycle of unwinding by full-length NS3. When the enzyme was in excess of the substrate, NS3 (500 nM) unwound > 80% of a DNA substrate containing a 15-nucleotide overhang and a 30-bp duplex (45:30-mer; 1 nM). This result indicated that the active form of NS3 that was bound to the DNA prior to initiation of the reaction was capable of processive DNA unwinding. Unwinding with varying ratios of NS3 to 45:30-mer allowed us to investigate the active form of NS3 during the first unwinding cycle. When the substrate concentration slightly exceeded that of the enzyme, little or no unwinding was observed, indicating that if a monomeric form of the protein is active, then it exhibits very low processivity. Binding of NS3 to the 45:30-mer was measured by electrophoretic mobility shift assays, resulting in K-D = 2.7 +/- 0.4 nM. Binding to individual regions of the substrate was investigated by measuring the K-D for a 15-mer oligonucleotide as well as a 30-mer duplex. NS3 bound tightly to the 15-mer (K-D = 1.3 +/- 0.2 nM) and, surprisingly, fairly tightly to the double-stranded 30-mer (K-D = 11.3 +/- 1.3 nM). However, NS3 was not able to rapidly unwind a blunt-end duplex. Thus, under conditions of optimal unwinding, the 45:30-mer is initially saturated with the enzyme, including the duplex region. The unwinding data are discussed in terms of a model whereby multiple molecules of NS3 bound to the single-stranded DNA portion of the substrate are required for optimal unwinding.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Arkansas System; University of Arkansas Medical Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Raney, KD (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham St,Mail Slot 516, Little Rock, AR 72205 USA.	raneykevind@uams.edu			NCRR NIH HHS [P20 RR15569] Funding Source: Medline; NIAID NIH HHS [AI47350] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047350] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahnert P, 2000, EMBO J, V19, P3418, DOI 10.1093/emboj/19.13.3418; Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bujalowski W, 2003, TRENDS BIOCHEM SCI, V28, P116, DOI 10.1016/S0968-0004(03)00034-3; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Byrd AK, 2004, NAT STRUCT MOL BIOL, V11, P531, DOI 10.1038/nsmb774; Carroll SS, 1996, METHOD ENZYMOL, V275, P365; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Galletto R, 2004, J MOL BIOL, V343, P83, DOI 10.1016/j.jmb.2004.07.055; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Lam AMI, 2003, J VIROL, V77, P3950, DOI 10.1128/JVI.77.7.3950-3961.2003; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Levin MK, 2003, J BIOL CHEM, V278, P23311, DOI 10.1074/jbc.M301283200; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; Maluf NK, 2003, J MOL BIOL, V325, P889, DOI 10.1016/S0022-2836(02)01276-7; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Mottola G, 2002, VIROLOGY, V293, P31, DOI 10.1006/viro.2001.1229; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Neddermann P, 1997, BIOL CHEM, V378, P469; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; PATEL SS, 1993, J BIOL CHEM, V268, P10668; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Preugschat F, 2000, BIOCHEMISTRY-US, V39, P5174, DOI 10.1021/bi9923860; Sali DL, 1998, BIOCHEMISTRY-US, V37, P3392, DOI 10.1021/bi972010r; Schwartz M, 2004, P NATL ACAD SCI USA, V101, P11263, DOI 10.1073/pnas.0404157101; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Tackett AJ, 2001, NUCLEIC ACIDS RES, V29, P565, DOI 10.1093/nar/29.2.565; Tackett AJ, 2001, BIOCHEMISTRY-US, V40, P543, DOI 10.1021/bi002122+; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3	45	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10797	10806		10.1074/jbc.M407971200	http://dx.doi.org/10.1074/jbc.M407971200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15634684	hybrid, Green Published			2022-12-27	WOS:000227559600127
J	Takeuchi, H; Mizuno, T; Zhang, GQ; Wang, JY; Kawanokuchi, J; Kuno, R; Suzumura, A				Takeuchi, H; Mizuno, T; Zhang, GQ; Wang, JY; Kawanokuchi, J; Kuno, R; Suzumura, A			Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ANTIGEN-PRESENTING CELLS; NITRIC-OXIDE; MORPHOLOGICAL-CHANGES; RECEPTOR ACTIVATION; DENDRITE MORPHOLOGY; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; GLUTAMATE; DEGENERATION	Recent studies suggest that excitotoxicity may contribute to neuronal damage in neurodegenerative diseases including Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Activated microglia have been observed around degenerative neurons in these diseases, and they are thought to act as effector cells in the degeneration of neural cells in the central nervous system. Neuritic beading, focal bead-like swellings in the dendrites and axons, is a neuropathological sign in epilepsy, trauma, ischemia, aging, and neurodegenerative diseases. Previous reports showed that neuritic beading is induced by various stimuli including glutamate or nitric oxide and is a neuronal response to harmful stimuli. However, the precise physiologic significance of neuritic beading is unclear. We provide evidence that neuritic beading induced by activated microglia is a feature of neuronal cell dysfunction toward neuronal death, and the neurotoxicity of activated microglia is mediated through N-methyl-D-aspartate (NMDA) receptor signaling. Neuritic beading occurred concordant with a rapid drop in intracellular ATP levels and preceded neuronal death. The actual neurite beads consisted of collapsed cytoskeletal proteins and motor proteins arising from impaired neuronal transport secondary to cellular energy loss. The drop in intracellular ATP levels was because of the inhibition of mitochondrial respiratory chain complex IV activity downstream of NMDA receptor signaling. Blockage of NMDA receptors nearly completely abrogated mitochondrial dysfunction and neurotoxicity. Thus, neuritic beading induced by activated microglia occurs through NMDA receptor signaling and represents neuronal cell dysfunction preceding neuronal death. Blockage of NMDA receptors may be an effective therapeutic approach for neurodegenerative diseases.	Nagoya Univ, Dept Neuroimmunol, Environm Med Res Inst, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Takeuchi, H (corresponding author), Nagoya Univ, Dept Neuroimmunol, Environm Med Res Inst, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	htake@riem.nagoya-u.ac.jp		Takeuchi, Hideyuki/0000-0001-5912-7581				Bal-Price A, 2001, J NEUROSCI, V21, P6480; Banno M, 2005, NEUROPHARMACOLOGY, V48, P283, DOI 10.1016/j.neuropharm.2004.10.002; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; DELISLE MB, 1984, J NEUROL SCI, V63, P241, DOI 10.1016/0022-510X(84)90199-0; Dickson TC, 1999, EXP NEUROL, V156, P100, DOI 10.1006/exnr.1998.7010; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faddis BT, 1997, J NEUROSCI, V17, P951; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.3.CO;2-#; Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; Goel S, 2003, NEUROPATHOLOGY, V23, P262, DOI 10.1046/j.1440-1789.2003.00510.x; Hasbani MJ, 2001, J NEUROSCI, V21, P2393, DOI 10.1523/JNEUROSCI.21-07-02393.2001; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hiruma H, 2003, J NEUROSCI, V23, P8967; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057; Ikegaya Y, 2001, J CELL SCI, V114, P4083; Kawanokuchi J, 2004, NEUROPHARMACOLOGY, V46, P734, DOI 10.1016/j.neuropharm.2003.11.007; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kipnis J, 2004, P NATL ACAD SCI USA, V101, P14663, DOI 10.1073/pnas.0404842101; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Koutsilieri E, 2002, PARKINSONISM RELAT D, V8, P401, DOI 10.1016/S1353-8020(02)00021-4; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Mattila PM, 1999, ACTA NEUROPATHOL, V98, P157, DOI 10.1007/s004010051064; McGeer PL, 2002, MUSCLE NERVE, V26, P459, DOI 10.1002/mus.10191; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; Mizuno T, 2004, NEUROPHARMACOLOGY, V46, P404, DOI 10.1016/j.neuropharm.2003.09.009; MIZUNO T, 1994, BRAIN RES, V656, P141, DOI 10.1016/0006-8993(94)91375-7; Mungrue IN, 2004, J CELL SCI, V117, P2627, DOI 10.1242/jcs.01187; Nelson PT, 2002, ANN MED, V34, P491, DOI 10.1080/078538902321117698; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Ohno K, 2003, J PHARMACOL EXP THER, V306, P66, DOI 10.1124/jpet.103.049973; Oliva AA, 2002, J NEUROSCI, V22, P8052; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Overly CC, 1996, J CELL SCI, V109, P971; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Pavlidis M, 2003, INVEST OPHTH VIS SCI, V44, P5196, DOI 10.1167/iovs.03-0614; Rego AC, 2000, NEUROCHEM INT, V36, P159, DOI 10.1016/S0197-0186(99)00107-2; Roediger B, 2003, NEUROBIOL DIS, V13, P222, DOI 10.1016/S0969-9961(03)00038-X; Saito Y, 2003, J NEUROPATH EXP NEUR, V62, P644, DOI 10.1093/jnen/62.6.644; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schwab JM, 2004, CELL DEATH DIFFER, V11, P1245, DOI 10.1038/sj.cdd.4401487; Schwartz M, 2003, TRENDS NEUROSCI, V26, P297, DOI 10.1016/S0166-2236(03)00126-7; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Suzumura A, 1996, BRAIN RES, V713, P192, DOI 10.1016/0006-8993(95)01535-3; SUZUMURA A, 1987, J NEUROIMMUNOL, V15, P263, DOI 10.1016/0165-5728(87)90121-4; Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R; Takahashi T, 1997, ACTA NEUROPATHOL, V94, P294, DOI 10.1007/s004010050707; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Turner MR, 2004, NEUROBIOL DIS, V15, P601, DOI 10.1016/j.nbd.2003.12.012; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Zhao WH, 2004, J NEUROPATH EXP NEUR, V63, P964, DOI 10.1093/jnen/63.9.964; Zhu B, 2003, AM J PATHOL, V162, P1639, DOI 10.1016/S0002-9440(10)64298-8; Zietlow R, 1999, EUR J NEUROSCI, V11, P1657, DOI 10.1046/j.1460-9568.1999.00583.x	62	218	229	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10444	10454		10.1074/jbc.M413863200	http://dx.doi.org/10.1074/jbc.M413863200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640150	hybrid			2022-12-27	WOS:000227559600086
J	Jakopitsch, C; Wanasinghe, A; Jantschko, W; Furtmuller, PG; Obinger, C				Jakopitsch, C; Wanasinghe, A; Jantschko, W; Furtmuller, PG; Obinger, C			Kinetics of interconversion of ferrous enzymes, compound II and compound III, of wild-type Synechocystis catalase-peroxidase and Y249F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL CAVITY MUTATIONS; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; KATG; LACTOPEROXIDASE; OXYGEN; DECOMPOSITION; BINDING	With the exception of catalase-peroxidases, heme peroxidases show no significant ability to oxidize hydrogen peroxide and are trapped and inactivated in the compound III form by H2O2 in the absence of one-electron donors. Interestingly, some KatG variants, which lost the catalatic activity, form compound III easily. Here, we compared the kinetics of interconversion of ferrous enzymes, compound II and compound III of wild-type Synechocystis KatG, the variant Y249F, and horseradish peroxidase (HRP). It is shown that dioxygen binding to ferrous KatG and Y249F is reversible and monophasic with apparent bimolecular rate constants of (1.2 +/- 0.3) x 10(5) M-1 s(-1) and (1.6 +/- 0.2) x 10(5) M-1 s(-1) (pH 7, 25 degreesC), similar to HRP. The dissociation constants (K-D) of the ferrous-dioxygen were calculated to be 84 muM (wild-type KatG) and 129 muM (Y249F), higher than that in HRP (1.9 muM). Ferrous Y249F and HRP can also heterolytically cleave hydrogen peroxide, forming water and an oxo-ferryl-type compound II at similar rates ((2.4 +/- 0.3) x 10(5) M-1 s(-1) and (1.6 +/- 0.2) x 10(5) M-1 s(-1) (pH 7, 25 degreesC)). Significant differences were observed in the H2O2-mediated conversion of compound II to compound III as well as in the spectral features of compound II. When compared with HRP and other heme peroxidases, in Y249F, this reaction is significantly faster ((1.2 +/- 0.2) x 10(4) M-1 s(-1))). Ferrous wild-type KatG was also rapidly converted by hydrogen peroxide in a two-phasic reaction via compound II to compound III (approximate to2.0 x 10(5) M-1 s(-1)), the latter being also efficiently transformed to ferric KatG. These findings are discussed with respect to a proposed mechanism for the catalatic activity.	Univ Nat Resources & App Life Sci, Dept Chem, Div Biochem, Met Prot Res Grp,BOKU, A-1190 Vienna, Austria		Obinger, C (corresponding author), Univ Nat Resources & App Life Sci, Dept Chem, Div Biochem, Met Prot Res Grp,BOKU, Muthgasse 18, A-1190 Vienna, Austria.	christian.obinger@boku.ac.at	Furtmüller, Paul G./Y-5819-2018; Obinger, Christian/AAV-3173-2021	Furtmüller, Paul G./0000-0002-1199-2469; Jakopitsch, Christa/0000-0002-5855-2057; Obinger, Christian/0000-0002-7133-3430				ADEDIRAN SA, 1989, EUR J BIOCHEM, V186, P571, DOI 10.1111/j.1432-1033.1989.tb15246.x; Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; CAI DY, 1992, J BIOL CHEM, V267, P11149; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Dunford H. B., 1999, HEME PEROXIDASES; Ghiladi RA, 2004, J AM CHEM SOC, V126, P4772, DOI 10.1021/ja031728t; HU SH, 1991, J AM CHEM SOC, V113, P7189, DOI 10.1021/ja00019a015; Jakopitsch C, 2003, FEBS LETT, V552, P135, DOI 10.1016/S0014-5793(03)00901-3; Jakopitsch C, 1999, BIOL CHEM, V380, P1087, DOI 10.1515/BC.1999.135; Jakopitsch C, 2004, J BIOL CHEM, V279, P46082, DOI 10.1074/jbc.M408399200; Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200; Jantschko W, 2005, ARCH BIOCHEM BIOPHYS, V434, P51, DOI 10.1016/j.abb.2004.10.014; Jantschko W, 2004, ARCH BIOCHEM BIOPHYS, V426, P91, DOI 10.1016/j.abb.2004.03.019; Jantschko W, 2003, BIOCHEM BIOPH RES CO, V312, P292, DOI 10.1016/j.bbrc.2003.10.117; KOHLER H, 1988, ARCH BIOCHEM BIOPHYS, V264, P438, DOI 10.1016/0003-9861(88)90309-8; LARDINOIS OM, 1995, FREE RADICAL RES, V22, P251, DOI 10.3109/10715769509147544; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Nicholls P, 2001, ADV INORG CHEM, V51, P51; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P389; Santoni E, 2004, BIOCHEMISTRY-US, V43, P5792, DOI 10.1021/bi035835b; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Wada K, 2002, ACTA CRYSTALLOGR D, V58, P157, DOI 10.1107/S0907444901017735; WOOD PM, 1988, BIOCHEM J, V253, P287, DOI 10.1042/bj2530287; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200	28	38	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9037	9042		10.1074/jbc.M413317200	http://dx.doi.org/10.1074/jbc.M413317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637065	hybrid			2022-12-27	WOS:000227453100051
J	Yang, WJ; Yang, DD; Na, SQ; Sandusky, GE; Zhang, Q; Zhao, GS				Yang, WJ; Yang, DD; Na, SQ; Sandusky, GE; Zhang, Q; Zhao, GS			Dicer is required for embryonic angiogenesis during mouse development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; DOUBLE-STRANDED-RNA; TYROSINE KINASE TIE; INTERFERENCE; RECEPTOR; EXPRESSION; GENES; IDENTIFICATION; MECHANISMS; MICRORNAS	Dicer is a multi-domain protein responsible for the generation of short interfering RNAs (siRNAs) from long double-stranded RNAs during RNA interference. It is also involved in the maturation of microRNAs, some of which are transcriptional regulators of developmental timing in nematodes. To assess the role of Dicer in mammals, we generated Dicer(ex)1/2 mice with a deletion of the amino acid sequences corresponding to the first and second exons of the dicer gene via homologous recombination. We found that Dicer(ex1/2) homozygous embryos displayed a retarded phenotype and died between days 12.5 and 14.5 of gestation. Thus, these results show that dicer(ex1/2) is severely hypomorphic and that Dicer is essential for normal mouse development. Interestingly, we also found that blood vessel formation/maintenance in dicer(ex1/2) embryos and yolk sacs were severely compromised, suggesting a possible role for Dicer in angiogenesis. This finding is consistent with the altered expression of vegf, flt1, kdr, and tie1 in the mutant embryos. Taken together, the results of this study indicate that Dicer exerts its function on mouse embryonic angiogenesis probably through its role in the processing of microRNAs that regulate the expression levels of some critical angiogenic regulators in the cell.	Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Zhao, GS (corresponding author), Lilly Corp Ctr, DC 0424, Indianapolis, IN 46285 USA.	Zhao_Genshi@lilly.com						ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BERSNSTEIN E, 2003, NAT GENET, V35, P213; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grosshans H, 2002, J CELL BIOL, V156, P17, DOI 10.1083/jcb.200111033; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kontos CD, 2002, MOL CELL BIOL, V22, P1704, DOI 10.1128/MCB.22.6.1704-1713.2002; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Partanen J, 1996, DEVELOPMENT, V122, P3013; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Plasterk RHA, 2000, CURR OPIN GENET DEV, V10, P562, DOI 10.1016/S0959-437X(00)00128-3; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang W, 1999, DEV DYNAM, V215, P108, DOI 10.1002/(SICI)1097-0177(199906)215:2<108::AID-DVDY3>3.3.CO;2-9; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582	37	416	463	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9330	9335		10.1074/jbc.M413394200	http://dx.doi.org/10.1074/jbc.M413394200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15613470	hybrid			2022-12-27	WOS:000227453100085
J	Antal, M; Bordeau, V; Douchin, V; Felden, B				Antal, M; Bordeau, V; Douchin, V; Felden, B			A small bacterial RNA regulates a putative ABC transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; MESSENGER-RNA; ENCODING GENES; HFQ; BINDING; PROTEIN; EXPRESSION; ROLES	A small noncoding bacterial ribonucleic acid of 62-64 nucleotides, RydC, was identified in the genomes of Escherichia coli, Salmonella, and Shigella. In vivo, RydC binds to the RNA-binding protein Hfq, and it is unstable when Hfq is absent. Mobility assays reveal that complex formation between RydC and Hfq is specific, with an apparent binding constant of similar to300 nM. Sequence alignments combined with structural probing demonstrate that RydC folds as a pseudoknot. Hfq binds the loops crossing the deep and shallow grooves of the pseudoknotted RNA and reorganizes its overall conformation. An interaction with a polycistronic mRNA, yejABEF, which encodes a putative ABC transporter, was detected by affinity purification of immobilized RNA-Hfq complexes. In vivo, the yejABEF operon is expressed on minimal medium. Remarkably, its expression is reduced when RydC is absent, and the operon is degraded when RydC expression is stimulated. This observation correlates with the growth defects associated with a stimulation of its expression in vivo, generating a thermosensitive phenotype that affects growth on minimal media supplemented with glycerol, maltose, or ribose. We conclude that RydC regulates the yejABEF-encoded ABC permease at the mRNA level. This small RNA may contribute to optimal adaptation of some Enterobacteria to environmental conditions.	Univ Rennes 1, UPRES Jeune Equipe 2311, Espri Inserm, F-35043 Rennes, France; Univ Paris 11, Ctr Sci Orsay, CNRS, UMR 8621,Inst Genet & Microbiol, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Felden, B (corresponding author), Univ Rennes 1, UPRES Jeune Equipe 2311, Espri Inserm, 2 Ave Prof Leon Bernard, F-35043 Rennes, France.	bfelden@univ-rennes1.fr	Bordeau, Valérie/L-1992-2015; felden, brice/L-4825-2015	BORDEAU, VALERIE/0000-0003-1137-1053; Sensen, Maria/0000-0003-4256-371X				Argaman L, 2001, CURR BIOL, V11, P941, DOI 10.1016/S0960-9822(01)00270-6; Bohn C, 2004, MOL MICROBIOL, V52, P427, DOI 10.1111/j.1365-2958.2004.03985.x; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Chen S, 2004, J BACTERIOL, V186, P6689, DOI 10.1128/JB.186.20.6689-6697.2004; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Draper DE, 1996, TRENDS BIOCHEM SCI, V21, P145; Felden B, 1997, RNA, V3, P89; Geissmann TA, 2004, EMBO J, V23, P396, DOI 10.1038/sj.emboj.7600058; Hershberg R, 2003, NUCLEIC ACIDS RES, V31, P1813, DOI 10.1093/nar/gkg297; HIGGINS CF, 1983, J BACTERIOL, V155, P1434, DOI 10.1128/JB.155.3.1434-1438.1983; Masse E, 2003, CURR OPIN MICROBIOL, V6, P120, DOI 10.1016/S1369-5274(03)00027-4; Moll I, 2003, RNA, V9, P1308, DOI 10.1261/rna.5850703; Monnet V, 2003, CELL MOL LIFE SCI, V60, P2100, DOI 10.1007/s00018-003-3054-3; Opdyke JA, 2004, J BACTERIOL, V186, P6698, DOI 10.1128/JB.186.20.6698-6705.2004; Pichon C, 2003, BIOINFORMATICS, V19, P1707, DOI 10.1093/bioinformatics/btg235; Saurin W, 1999, J MOL EVOL, V48, P22, DOI 10.1007/PL00006442; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; Storz G, 2004, CURR OPIN MICROBIOL, V7, P140, DOI 10.1016/j.mib.2004.02.015; Tsui HCT, 1997, J BACTERIOL, V179, P7476, DOI 10.1128/jb.179.23.7476-7487.1997; Urbanowski ML, 2000, MOL MICROBIOL, V37, P856, DOI 10.1046/j.1365-2958.2000.02051.x; Vecerek B, 2003, MOL MICROBIOL, V50, P897, DOI 10.1046/j.1365-2958.2003.03727.x; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang AX, 2003, MOL MICROBIOL, V50, P1111, DOI 10.1046/j.1365-2958.2003.03734.x; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3	24	79	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7901	7908		10.1074/jbc.M413071200	http://dx.doi.org/10.1074/jbc.M413071200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15618228	hybrid			2022-12-27	WOS:000227395700058
J	Gravel, SP; Servant, MJ				Gravel, SP; Servant, MJ			Roles of an I kappa B kinase-related pathway in human cytomegalovirus-infected vascular smooth muscle cells - A molecular link in pathogen-induced proatherosclerotic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-3; DOUBLE-STRANDED-RNA; GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION; SIGNALING PATHWAYS; VIRAL-INFECTION; GLYCOPROTEIN-B; IKK-EPSILON; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTOR	Viral and bacterial pathogens have long been suspected to affect atherogenesis directly. However, mechanisms linking innate immunity to chronic inflammatory diseases such as atherosclerosis are still poorly defined. Here we show that infection of primary human aortic smooth muscle cells ( HAOSMC) with human cytomegalovirus ( HCMV) leads to activation of the novel IkappaB kinase ( IKK)-related kinase, Tank-binding kinase-1 ( TBK1), a major effector of the cellular innate immune response. We demonstrate that part of the HCMV inflammatory response is most likely mediated via this novel kinase because the canonical IKK complex was only poorly activated upon infection of HAOSMC. An increase in TBK1 phosphotransferase activity led to a strong activation of the interferon regulatory factor ( IRF)-3 transcription factor as measured by its C-terminal phosphorylation, dimerization, and DNA binding activity. In addition to TBK1, HAOSMC also express another IKK-related kinase isoform, IKK, albeit at a lower level. Nevertheless, both isoforms were required for full activation of IRF-3 by HCMV. The transcripts of proatherosclerotic genes Ccl5 ( encoding for the chemokine RANTES ( regulated upon activation, normal T cell expressed and secreted)) and Cxcl10 ( encoding for the chemokine IP-10 ( interferon-gamma-inducible protein 10)) were induced in an IRF-3-dependent manner after HCMV infection of smooth muscle cells. In addition, cytokine arrays analysis showed that RANTES and IP-10 were the predominant chemokines present in the supernatant of HCMV-infected HAOSMC. Activation of the TBK1/IRF-3 pathway was independent of epidermal growth factor receptor and pertussis toxin-sensitive G protein-coupled receptor activation. Our results thus add additional molecular clues to a possible role of HCMV as a modulator of atherogenesis through the induction of a proinflammatory response that is, in part, dependent of an IKK-related kinase pathway.	Univ Montreal, Fac Pharm, Stn Ctr Ville Montreal, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Servant, MJ (corresponding author), Univ Montreal, Fac Pharm, Stn Ctr Ville Montreal, POB 6128, Montreal, PQ H3C 3J7, Canada.	marc.servant@umontreal.ca		Gravel, Simon-Pierre/0000-0001-8411-8054				Abate DA, 2004, J VIROL, V78, P10995, DOI 10.1128/JVI.78.20.10995-11006.2004; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Arkonac B, 1997, J HEART LUNG TRANSPL, V16, P1035; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Boehme KW, 2004, J VIROL, V78, P1202, DOI 10.1128/JVI.78.3.1202-1211.2004; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Boyle KA, 1999, MOL CELL BIOL, V19, P3607; Browne EP, 2003, P NATL ACAD SCI USA, V100, P11439, DOI 10.1073/pnas.1534570100; Burnett MS, 2004, CIRCULATION, V109, P893, DOI 10.1161/01.CIR.0000112585.47513.45; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Carlquist JF, 1999, J INFECT DIS, V179, P1094, DOI 10.1086/314734; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Compton T, 2004, TRENDS CELL BIOL, V14, P5, DOI 10.1016/j.tcb.2003.10.009; Compton T, 2003, J VIROL, V77, P4588, DOI 10.1128/JVI.77.8.4588-4596.2003; Dasu MRK, 2003, BURNS, V29, P527, DOI 10.1016/S0305-4179(03)00154-2; Dhaunsi GS, 2003, J BIOMED SCI, V10, P505, DOI 10.1159/000072377; Epstein SE, 2002, CIRC RES, V90, P2, DOI 10.1161/res.90.1.2; Ewald JA, 2003, EXP CELL RES, V282, P121, DOI 10.1016/S0014-4827(02)00014-9; Feire AL, 2004, P NATL ACAD SCI USA, V101, P15470, DOI 10.1073/pnas.0406821101; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Giasson E, 1997, J BIOL CHEM, V272, P26879, DOI 10.1074/jbc.272.43.26879; Gutermann A, 2002, CURR TOP MICROBIOL, V269, P1; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Johnson RA, 2000, J VIROL, V74, P1158, DOI 10.1128/JVI.74.3.1158-1167.2000; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kawamura A, 2003, CIRC J, V67, P851, DOI 10.1253/circj.67.851; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Kuvin JT, 1999, AM HEART J, V137, P216, DOI 10.1053/hj.1999.v137.92261; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; McGettrick AF, 2004, MOL IMMUNOL, V41, P577, DOI 10.1016/j.molimm.2004.04.006; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Mogensen TH, 2001, MICROBIOL MOL BIOL R, V65, P131, DOI 10.1128/MMBR.65.1.131-150.2001; Murphy EA, 2000, J VIROL, V74, P7108, DOI 10.1128/JVI.74.15.7108-7118.2000; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; NIEMINEN MS, 1993, EUR HEART J, V14, P12; Nomura F, 2000, GENES CELLS, V5, P191; Pampou SY, 2000, VIRCHOWS ARCH, V436, P539, DOI 10.1007/s004289900173; Parissis JT, 2002, J INTERF CYTOK RES, V22, P223, DOI 10.1089/107999002753536194; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Preston CM, 2001, J VIROL, V75, P8909, DOI 10.1128/JVI.75.19.8909-8916.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Servant MJ, 2002, BIOCHEM PHARMACOL, V64, P985, DOI 10.1016/S0006-2952(02)01165-6; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Setsuda J, 1999, AM J PATHOL, V155, P257, DOI 10.1016/S0002-9440(10)65119-X; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shibutani T, 1997, J CLIN INVEST, V100, P2054, DOI 10.1172/JCI119738; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Simmen KA, 2001, P NATL ACAD SCI USA, V98, P7140, DOI 10.1073/pnas.121177598; Speir E, 1998, CIRC RES, V83, P210, DOI 10.1161/01.RES.83.2.210; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Streblow DN, 2001, J NUTR, V131, p2798S, DOI 10.1093/jn/131.10.2798S; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Veillard NR, 2004, CIRC RES, V94, P253, DOI 10.1161/01.RES.0000109793.17591.4E; VOIDIN L, 2002, AM J PHYSIOL, V283, pC446; von Hundelshausen P, 2001, CIRCULATION, V103, P1772, DOI 10.1161/01.CIR.103.13.1772; Wang JM, 1998, INT J CLIN LAB RES, V28, P83, DOI 10.1007/s005990050024; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Wang XK, 1996, J BIOL CHEM, V271, P24286, DOI 10.1074/jbc.271.39.24286; Yun JJ, 2001, TRANSPLANTATION, V71, P1649, DOI 10.1097/00007890-200106150-00026; Zhou YF, 1999, BIOCHEM BIOPH RES CO, V256, P608, DOI 10.1006/bbrc.1999.0387; Zhou YF, 1996, J CLIN INVEST, V98, P2129, DOI 10.1172/JCI119019; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	80	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7477	7486		10.1074/jbc.M410392200	http://dx.doi.org/10.1074/jbc.M410392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15619605	hybrid			2022-12-27	WOS:000227395700009
J	Pain, D; Chirn, GW; Strassel, C; Kemp, DM				Pain, D; Chirn, GW; Strassel, C; Kemp, DM			Multiple retropseudogenes from pluripotent cell-specific gene expression indicates a potential signature for novel gene identification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; L1 RETROTRANSPOSITION; NANOG; TERATOCARCINOMA; OCT-4	Oct4, Nanog, and Stella are transcription factors specifically expressed in embryonic stem (ES) cells and germ lineage cells that impart critical functions in the maintenance of pluripotency. Here, we report the excessive frequency and apparent selectivity of retrotransposition of ES cell-specific genes. Six highly homologous pseudogenes for Oct4, 10 for Nanog, and 16 for Stella were identified by nucleotide BLAST (basic local alignment sequence tool) searches against the respective gene mRNA transcripts. Of 15 non-ES cell-specific transcription factor genes, only one had a single pseudogene hit in our screen, emphasizing the apparent selectivity. We present a hypothesis whereby retrotransposition of ES or germ cell-specific genes may reflect an innate predisposition. This is based on the increased probability of germ-line transmission when retrotransposition occurs at a very early stage of development within cells known to contribute to the germ cell lineage. The parental genes for Nanog, Stella, and another embryonic gene, GDF3 are all located on chromosome 12p13 of the human genome, and on chromosome 6 in mouse. Here, we identified an Oct4 pseudogene at the same respective loci in both human and mouse genomes, suggesting functional relevance and indicative of epigenetic regulation. We tested whether the apparent susceptibility for ES cell-specific gene retrotransposition may be extrapolated to a more unified phenomenon, such that a bioinformatic approach may represent a potentially novel strategy for identification of genes with embryonic cell-specific functionality. A preliminary investigation indeed revealed a single gene, previously demonstrated to be responsible for multiple retropseudo-genes via germ cell-specific expression in Xenopus.	Novartis Inst Biomed Res, Diabet & Metab Dis Area, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA USA; IKN, Cambridge, MA USA	Novartis; Massachusetts Institute of Technology (MIT)	Kemp, DM (corresponding author), Novartis Inst Biomed Res, Diabet & Metab Dis Area, 100 Technol Sq, Cambridge, MA 02139 USA.	Daniel.kemp@pharma.novartis.com						ABDALLAH B, 1991, P NATL ACAD SCI USA, V88, P9277, DOI 10.1073/pnas.88.20.9277; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Caricasole AAD, 1998, ONCOGENE, V16, P95, DOI 10.1038/sj.onc.1201515; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; Devor EJ, 2003, HUM BIOL, V75, P661, DOI 10.1353/hub.2003.0075; Geijsen N, 2004, NATURE, V427, P148, DOI 10.1038/nature02247; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; Lund A, 1996, GENOMICS, V36, P359, DOI 10.1006/geno.1996.0475; MADSEN HO, 1990, NUCLEIC ACIDS RES, V18, P1513, DOI 10.1093/nar/18.6.1513; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Payer B, 2003, CURR BIOL, V13, P2110, DOI 10.1016/j.cub.2003.11.026; Pochampally RR, 2004, BLOOD, V103, P1647, DOI 10.1182/blood-2003-06-1967; Prak ETL, 2003, P NATL ACAD SCI USA, V100, P1832, DOI 10.1073/pnas.0337627100	17	100	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6265	6268		10.1074/jbc.C400587200	http://dx.doi.org/10.1074/jbc.C400587200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15640145	hybrid			2022-12-27	WOS:000227332700005
J	Senokuchi, T; Matsumura, T; Sakai, M; Yano, M; Taguchi, T; Matsuo, T; Sonoda, K; Kukidome, D; Imoto, K; Nishikawa, T; Kim-Mitsuyama, S; Takuwa, Y; Araki, E				Senokuchi, T; Matsumura, T; Sakai, M; Yano, M; Taguchi, T; Matsuo, T; Sonoda, K; Kukidome, D; Imoto, K; Nishikawa, T; Kim-Mitsuyama, S; Takuwa, Y; Araki, E			Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small g protein-p38 ALAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; COLONY-STIMULATING FACTOR; COENZYME-A REDUCTASE; HUMAN ENDOTHELIAL-CELLS; PIGS IN-VIVO; PROTEIN-KINASE; GM-CSF; PLAQUE STABILITY; DNA-SYNTHESIS; FOAM CELLS	Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) ameliorate atherosclerotic diseases. Macrophages play an important role in the development and subsequent stability of atherosclerotic plaques. We reported previously that oxidized low density lipoprotein (Ox-LDL) induced macrophage proliferation through the secretion of granulocyte/macrophage colony-stimulating factor (GM-CSF) and the consequent activation of p38 MAPK. The present study was designed to elucidate the mechanism of the inhibitory effect of statins on macrophage proliferation. Mouse peritoneal macrophages were used in our study. Cerivastatin and simvastatin each inhibited Ox-LDL-induced [H-3]thymidine incorporation into macrophages. Statins did not inhibit Ox-LDL-induced GM-CSF production, but inhibited GM-CSF-induced p38 MAPK activation. Farnesyl transferase inhibitor and geranylgeranyl transferase inhibitor inhibited GM-CSF-induced macrophage proliferation, and farnesyl pyrophosphate and geranylgeranyl pyrophosphate prevented the effect of statins. GM-CSF-induced p38 MAPK phosphorylation was also inhibited by farnesyl transferase inhibitor or geranylgeranyl transferase inhibitor, and farnesyl pyrophosphate and geranylgeranyl pyrophosphate prevented the suppression of GM-CSF-induced p38 MAPK phosphorylation by statins. Furthermore, we found that statin significantly inhibited the membrane translocation of the small G protein family members Ras and Rho. GM-CSF-induced p38 MAPK activation and macrophage proliferation was partially inhibited by overexpression of dominant negative Ras and completely by that of RhoA. In conclusion, statins inhibited GM-CSF-induced Ras- or RhoA-p38 MAPK signal cascades, thereby suppressing Ox-LDL-induced macrophage proliferation. The significant inhibition of macrophage proliferation by statins may also explain, at least in part, their anti-atherogenic action.	Kumamoto Univ, Grad Sch Med Sci, Dept Metab Med, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Pharmacol & Mol Therapeut, Kumamoto 8608556, Japan; Kanazawa Univ, Grad Sch Med, Dept Physiol, Kanazawa, Ishikawa 9208640, Japan	Kumamoto University; Kumamoto University; Kanazawa University	Matsumura, T (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Metab Med, 1-1-1 Honjo, Kumamoto 8608556, Japan.	takeshim@gpo.kumamoto-u.ac.jp						Aikawa M, 2001, CIRCULATION, V103, P276; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; Bea F, 2002, ARTERIOSCL THROM VAS, V22, P1832, DOI 10.1161/01.ATV.0000036081.01231.16; Bendriss-Vermare N, 2001, J CLIN INVEST, V107, P835, DOI 10.1172/JCI11734; Biwa T, 1998, J BIOL CHEM, V273, P28305, DOI 10.1074/jbc.273.43.28305; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHODAKEWITZ JA, 1988, J IMMUNOL, V140, P832; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Deguchi J, 1999, CIRC RES, V85, P565, DOI 10.1161/01.RES.85.7.565; Essig M, 1998, CIRC RES, V83, P683, DOI 10.1161/01.RES.83.7.683; Eto M, 2002, CIRCULATION, V105, P1756, DOI 10.1161/01.CIR.0000015465.73933.3B; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Guijarro C, 1998, CIRC RES, V83, P490, DOI 10.1161/01.RES.83.5.490; HAKAMATA H, 1994, ARTERIOSCLER THROMB, V14, P1860, DOI 10.1161/01.ATV.14.11.1860; Hamilton JA, 1999, ARTERIOSCL THROM VAS, V19, P98, DOI 10.1161/01.ATV.19.1.98; IRANI K, 1994, BIOCHEM BIOPH RES CO, V202, P1252, DOI 10.1006/bbrc.1994.2065; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Koh KK, 2000, CARDIOVASC RES, V47, P648, DOI 10.1016/S0008-6363(00)00146-2; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Libby P, 2002, NAT MED, V8, P1257, DOI 10.1038/nm1102-1257; Mallat Z, 2003, CIRC RES, V93, P884, DOI 10.1161/01.RES.0000099062.55042.9A; Martens JS, 1998, J BIOL CHEM, V273, P4915, DOI 10.1074/jbc.273.9.4915; Matsumura T, 1997, ARTERIOSCL THROM VAS, V17, P3013, DOI 10.1161/01.ATV.17.11.3013; Matsuo T, 2004, BIOCHEM BIOPH RES CO, V314, P817, DOI 10.1016/j.bbrc.2003.12.161; Miyata K, 2000, ARTERIOSCL THROM VAS, V20, P2351, DOI 10.1161/01.ATV.20.11.2351; MORENO PR, 1994, CIRCULATION, V90, P775, DOI 10.1161/01.CIR.90.2.775; Morishige K, 2001, ARTERIOSCL THROM VAS, V21, P548, DOI 10.1161/01.ATV.21.4.548; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; Rabbani R, 1999, CARDIOVASC RES, V41, P402, DOI 10.1016/S0008-6363(98)00279-X; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sakai M, 1997, ATHEROSCLEROSIS, V133, P51, DOI 10.1016/S0021-9150(97)00118-4; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; Schaefer CA, 2004, VASC PHARMACOL, V41, P67, DOI 10.1016/j.vph.2004.05.002; Senokuchi T, 2004, ATHEROSCLEROSIS, V176, P233, DOI 10.1016/j.atherosclerosis.2004.05.019; SPAGNOLI LG, 1991, ATHEROSCLEROSIS, V88, P87, DOI 10.1016/0021-9150(91)90260-A; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; Wassmann S, 2001, MOL PHARMACOL, V59, P646, DOI 10.1124/mol.59.3.646; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2	46	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6627	6633		10.1074/jbc.M412531200	http://dx.doi.org/10.1074/jbc.M412531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611087	hybrid			2022-12-27	WOS:000227332700048
J	Shostak, Y; Yamamoto, KR				Shostak, Y; Yamamoto, KR			Overlapping but separable determinants of DNA binding and nuclear localization map to the C-terminal end of the Caenorhabditis elegans DAF-12 DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-RECEPTOR; HORMONE-RECEPTOR; TRANSCRIPTIONAL-ACTIVATION; DEVELOPMENTAL AGE; ANDROGEN RECEPTOR; FINGER; EXTENSION; ESTROGEN; SIGNALS; PROTEIN	Proteins are commonly viewed as modular assemblies of functional domains. We analyzed a loss-of-function mutation in the Caenorhabditis elegans intracellular receptor DAF-12, a conservative substitution of an arginine to a lysine at position 197 (R197K). Arg(197) resides in region similar to a nuclear localization signal, just downstream of the receptor minimal zinc finger DNA binding domain (DBD) core. We found that the R197K, but not mutations of neighboring arginine or lysine residues, dramatically reduced DAF-12 transcriptional regulatory activity in a yeast reporter assay. This reduction in regulatory activity correlated with greatly decreased DNA binding affinity in vitro, suggesting a role for the DAF-12 DBD C-terminal region (dbdC), and specifically for Arg(197), in DNA binding. Remarkably, three basic residues immediately contiguous with Arg(197) played little role in DNA binding and rather affected nuclear localization; in contrast, Arg(197) itself was dispensable for nuclear localization. Thus, DAF-12 dbdC harbors overlapping but separable determinants of DNA binding and nuclear localization in a single small region.	Univ Calif San Francisco, Program Biochem & Mol Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yamamoto, KR (corresponding author), Univ Calif San Francisco, Program Biochem & Mol Biol, San Francisco, CA 94143 USA.	yamamoto@cgl.ucsf.edu						Antebi A, 2000, GENE DEV, V14, P1512; Antebi A, 1998, DEVELOPMENT, V125, P1191; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gems D, 1998, GENETICS, V150, P129; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; Hsieh JC, 1999, BIOCHEMISTRY-US, V38, P16347, DOI 10.1021/bi9916574; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jagath JR, 1998, BIOCHEMISTRY-US, V37, P15408, DOI 10.1021/bi981523a; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; LACASSE EC, 1993, ENDOCRINOLOGY, V132, P1017, DOI 10.1210/en.132.3.1017; LARSEN PL, 1995, GENETICS, V139, P1567; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; Melvin VS, 2002, J BIOL CHEM, V277, P25115, DOI 10.1074/jbc.M110400200; Munster AK, 2002, J BIOL CHEM, V277, P19688, DOI 10.1074/jbc.M201093200; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Poukka H, 2000, J CELL SCI, V113, P2991; Rastinejad F, 2000, EMBO J, V19, P1045, DOI 10.1093/emboj/19.5.1045; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Rastinejad Fraydoon, 1998, P105; REMEROWSKI ML, 1991, BIOCHEMISTRY-US, V30, P11620, DOI 10.1021/bi00114a003; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Shostak Y, 2004, GENE DEV, V18, P2529, DOI 10.1101/gad.1218504; Siddiqui AA, 2000, PARASITOL RES, V86, P24, DOI 10.1007/PL00008502; SIKORSKI RS, 1989, GENETICS, V122, P19; Snow MI, 2000, BBA-GENE STRUCT EXPR, V1494, P104, DOI 10.1016/S0167-4781(00)00224-4; Verrijdt G, 2002, BIOCHEM J, V361, P97, DOI 10.1042/0264-6021:3610097; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457; [No title captured]	44	4	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6554	6560		10.1074/jbc.M412928200	http://dx.doi.org/10.1074/jbc.M412928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611047	hybrid			2022-12-27	WOS:000227332700039
J	Wahl-Schott, C; Baumann, L; Zong, XG; Biel, M				Wahl-Schott, C; Baumann, L; Zong, XG; Biel, M			An arginine residue in the pore region is a key determinant of chloride dependence in cardiac pacemaker channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CATION CURRENT; RABBIT SINOATRIAL NODE; DOMINANT-NEGATIVE SUPPRESSION; THALAMIC RELAY NEURONS; CURRENT I-F; HCN CHANNELS; TYROSINE KINASE; MOLECULAR-BASIS; CELLS; INHIBITION	The modulation of ion channel activity by extracellular ions plays a central role in the control of heart function. Here, we show that the sinoatrial pacemaker current I-f is strongly affected by the extracellular Cl- concentration. We investigated the molecular basis of the Cl- dependence in heterologously expressed hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that represent the molecular correlate of I-f. Currents carried by the two cardiac HCN channel isoforms (HCN2 and HCN4) showed the same strong Cl- dependence as the sinoatrial I-f and decreased to about 10% in the absence of external Cl-. In contrast, the neuronal HCN1 current was reduced to only 50% under the same conditions. Depletion of Cl- did not affect the voltage dependence of activation or the ion selectivity of the channels, indicating that the reduction of I-f was caused by a decrease of channel conductance. A series of chimeras between HCN1 and HCN2 was constructed to identify the structural determinants underlying the different Cl- dependence of HCN1 and HCN2. Exchange of the ion-conducting pore region was sufficient to switch the Cl- dependence from HCN1- to HCN2-type and vice versa. Replacement of a single alanine residue in the pore of HCN1 (Ala-352) by an arginine residue present in HCN2 at equivalent position (Arg-405) induced HCN2-type chloride sensitivity in HCN1. Our data indicate that Arg-405 is a key component of a domain that allosterically couples Cl- binding with channel activation.	Univ Munich, Dept Pharm Pharmakol Nat Wissensch, D-81377 Munich, Germany	University of Munich	Biel, M (corresponding author), Univ Munich, Dept Pharm, Zentrum Pharmaforsch, Butenandtstr 7-13, D-81377 Munich, Germany.	mbiel@cup.uni-muenchen.de	Wahl-Schott, Christian A/J-2623-2015; Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052				Accili EA, 1997, J PHYSIOL-LONDON, V500, P643, DOI 10.1113/jphysiol.1997.sp022049; Adrogue HJ, 1998, NEW ENGL J MED, V338, P107, DOI 10.1056/NEJM199801083380207; Altomare C, 2003, J PHYSIOL-LONDON, V549, P347, DOI 10.1113/jphysiol.2002.027698; Azene EM, 2003, J PHYSIOL-LONDON, V547, P349, DOI 10.1113/jphysiol.2003.039768; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Baruscotti M, 2004, ANN NY ACAD SCI, V1015, P111, DOI 10.1196/annals.1302.009; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; CHANG F, 1991, J PHYSIOL-LONDON, V440, P367, DOI 10.1113/jphysiol.1991.sp018713; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Decher N, 2003, PFLUG ARCH EUR J PHY, V446, P633, DOI 10.1007/s00424-003-1127-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Er F, 2003, CIRCULATION, V107, P485, DOI 10.1161/01.CIR.0000045672.32920.CB; FRACE AM, 1992, J PHYSIOL-LONDON, V453, P307, DOI 10.1113/jphysiol.1992.sp019230; Galla JH, 2000, J AM SOC NEPHROL, V11, P369, DOI 10.1681/ASN.V112369; Gravante B, 2004, J BIOL CHEM, V279, P43847, DOI 10.1074/jbc.M401598200; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Kimura K, 2004, GENES CELLS, V9, P631, DOI 10.1111/j.1356-9597.2004.00752.x; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Mangoni ME, 2001, CARDIOVASC RES, V52, P51, DOI 10.1016/S0008-6363(01)00370-4; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; Mingin GC, 1999, J UROLOGY, V162, P1122, DOI 10.1016/S0022-5347(01)68092-3; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Munsch T, 1999, J PHYSIOL-LONDON, V519, P493, DOI 10.1111/j.1469-7793.1999.0493m.x; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Nolan MF, 2003, CELL, V115, P551, DOI 10.1016/S0092-8674(03)00884-5; Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Peco-Antic A, 2000, PEDIATR NEPHROL, V15, P286, DOI 10.1007/s004670000419; Qu JH, 2004, J BIOL CHEM, V279, P43497, DOI 10.1074/jbc.M405018200; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Roncaglia P, 2002, BIOPHYS J, V83, P1953, DOI 10.1016/S0006-3495(02)73957-X; Santonastaso P, 1998, INT J EAT DISORDER, V24, P439, DOI 10.1002/(SICI)1098-108X(199812)24:4<439::AID-EAT12>3.0.CO;2-4; Schram G, 2002, CIRC RES, V90, P939, DOI 10.1161/01.RES.0000018627.89528.6F; Schulze-Bahr E, 2003, J CLIN INVEST, V111, P1537, DOI 10.1172/JCI200316387; Shibata S, 1999, BRIT J PHARMACOL, V128, P1284, DOI 10.1038/sj.bjp.0702903; Stieber J, 2004, TRENDS CARDIOVAS MED, V14, P23, DOI 10.1016/j.tcm.2003.09.006; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Ueda K, 2004, J BIOL CHEM, V279, P27194, DOI 10.1074/jbc.M311953200; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Vargas G, 2002, J MEMBRANE BIOL, V188, P115, DOI 10.1007/s00232-001-0178-y; Wu JY, 1997, PFLUG ARCH EUR J PHY, V434, P509, DOI 10.1007/s004240050430; Wu JY, 2000, BBA-BIOMEMBRANES, V1463, P15, DOI 10.1016/S0005-2736(99)00233-3; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Yu HG, 2004, PFLUG ARCH EUR J PHY, V447, P392, DOI 10.1007/s00424-003-1204-y; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009; Zong XG, 2001, J BIOL CHEM, V276, P6313, DOI 10.1074/jbc.M010326200	49	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13694	13700		10.1074/jbc.M413197200	http://dx.doi.org/10.1074/jbc.M413197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15644313	hybrid			2022-12-27	WOS:000228095500064
J	Ballicora, MA; Dubay, JR; Devillers, CH; Preiss, J				Ballicora, MA; Dubay, JR; Devillers, CH; Preiss, J			Resurrecting the ancestral enzymatic role of a modulatory subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; SITE-DIRECTED MUTAGENESIS; POTATO-TUBER; ESCHERICHIA-COLI; AGROBACTERIUM-TUMEFACIENS; BACTERIAL GLYCOGEN; REGULATORY ENZYME; CRYSTAL-STRUCTURE; EXPRESSION; CLONING	In the post-genomic era, functional prediction of genes is largely based on sequence similarity searches, but sometimes the homologues bear different roles because of evolutionary adaptations. For instance, the existence of enzyme and non-enzyme homologues poses a difficult case for function prediction and the extent of this phenomenon is just starting to be surveyed. Different evolutionary paths are theoretically possible for the loss or acquisition of enzyme function. Here we studied the ancestral role of a model non-catalytic modulatory subunit. With a rational approach, we "resurrected" enzymatic activity from that subunit to experimentally prove that it derived from a catalytic ancestor. We show that this protein (L subunit ADP-glucose pyrophosphorylase) evolved to have a regulatory role, losing catalytic residues more than 130 million years ago, but preserving, possibly as a by-product, the substrate site architecture. Inactivation of catalytic subunits could be the consequence of a general evolutionary strategy to explore new regulatory roles in hetero-oligomers.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Preiss, J (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	preiss@msu.edu		Ballicora, Miguel/0000-0002-5324-0724				Aravind L, 1998, CURR BIOL, V8, pR111, DOI 10.1016/S0960-9822(98)70982-0; Ballicora MA, 1998, PLANT PHYSIOL, V118, P265, DOI 10.1104/pp.118.1.265; Ballicora MA, 2004, PHOTOSYNTH RES, V79, P1, DOI 10.1023/B:PRES.0000011916.67519.58; Ballicora MA, 2002, BIOCHEMISTRY-US, V41, P9431, DOI 10.1021/bi025793b; Ballicora MA, 2003, MICROBIOL MOL BIOL R, V67, P213, DOI 10.1128/MMBR.67.2.213-225.2003; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Bremer K, 2000, P NATL ACAD SCI USA, V97, P4707, DOI 10.1073/pnas.080421597; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; CHARNG YY, 1992, PLANT MOL BIOL, V20, P37, DOI 10.1007/BF00029147; Choi JH, 2000, BIOINFORMATICS, V16, P1056, DOI 10.1093/bioinformatics/16.11.1056; Doan DNP, 1999, PLANT PHYSIOL, V121, P965, DOI 10.1104/pp.121.3.965; Frueauf JB, 2003, PLANT J, V33, P503, DOI 10.1046/j.1365-313X.2003.01643.x; Frueauf JB, 2001, J BIOL CHEM, V276, P46319, DOI 10.1074/jbc.M107408200; Fu YB, 1998, PLANT PHYSIOL, V117, P989, DOI 10.1104/pp.117.3.989; Gerlt JA, 2000, GENOME BIOL, V1; Gomez-Casati DF, 2001, BIOCHEMISTRY-US, V40, P10169, DOI 10.1021/bi002615e; Gould SJ, 1997, P NATL ACAD SCI USA, V94, P10750, DOI 10.1073/pnas.94.20.10750; Grishin NV, 2001, J MOL BIOL, V307, P31, DOI 10.1006/jmbi.2000.4486; Hannah LC, 2001, PLANT PHYSIOL, V127, P173, DOI 10.1104/pp.127.1.173; HAUGEN TH, 1979, J BIOL CHEM, V254, P127; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; Igarashi RY, 2000, ARCH BIOCHEM BIOPHYS, V376, P47, DOI 10.1006/abbi.1999.1689; IGLESIAS AA, 1993, J BIOL CHEM, V268, P1081; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JIN X, 2005, IN PRESS EMBO J; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KRIEGER E, 2003, STRUCTURAL BIOINFORM, P509; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MEYER CR, 1993, ARCH BIOCHEM BIOPHYS, V302, P64, DOI 10.1006/abbi.1993.1181; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; OKITA TW, 1990, PLANT PHYSIOL, V93, P785, DOI 10.1104/pp.93.2.785; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pedro CN, 2003, J BIOL CHEM, V278, P28508, DOI 10.1074/jbc.M304280200; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; Pils B, 2004, J MOL BIOL, V340, P399, DOI 10.1016/j.jmb.2004.04.063; Press W. H., 1988, NUMERICAL RECIPES C, P656; Richard SB, 2001, NAT STRUCT BIOL, V8, P641, DOI 10.1038/89691; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 2000, METH MOL B, V143, P97; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Sivaraman J, 2002, J BIOL CHEM, V277, P44214, DOI 10.1074/jbc.M206932200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; Takata H, 1997, J BACTERIOL, V179, P4689, DOI 10.1128/jb.179.15.4689-4698.1997; Thornton JW, 2004, NAT REV GENET, V5, P366, DOI 10.1038/nrg1324; Todd AE, 2002, STRUCTURE, V10, P1435, DOI 10.1016/S0969-2126(02)00861-4; Uttaro AD, 1998, ARCH BIOCHEM BIOPHYS, V357, P13, DOI 10.1006/abbi.1998.0786; Wang SM, 1998, PLANT J, V13, P63, DOI 10.1046/j.1365-313X.1998.00009.x; Yep A, 2004, ANAL BIOCHEM, V324, P52, DOI 10.1016/j.ab.2003.09.024	56	45	47	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10189	10195		10.1074/jbc.M413540200	http://dx.doi.org/10.1074/jbc.M413540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632142	hybrid			2022-12-27	WOS:000227559600056
J	Heiska, L; Carpen, O				Heiska, L; Carpen, O			Src phosphorylates ezrin at tyrosine 477 and induces a phosphospecific association between ezrin and a Kelch-repeat protein family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; MICROVILLAR CORE PROTEIN; EPIDERMAL-GROWTH-FACTOR; PLASMA-MEMBRANE; DROSOPHILA KELCH; CELL-ADHESION; CROSS-LINKING; ERM PROTEINS; HUMAN GENES; IN-VITRO	Ezrin, a linker between plasma membrane and actin cytoskeleton possesses morphogenic properties and can promote dissemination of tumor cells. Ezrin is phosphorylated on tyrosine, but a detailed picture of the signaling pathways involved in this modification is lacking. The transforming tyrosine kinase Src has various cytoskeletal substrates and is involved in regulation of cellular adhesion. We studied the role of Src in tyrosine phosphorylation of ezrin in adherent cells. We show that ezrin is phosphorylated in human embryonic kidney 293 cells in a Src family-dependent way. In SYF cells lacking Src, Yes, and Fyn, ezrin was not tyrosine-phosphorylated but reintroduction of wild-type Src followed by Src activation or introduction of active Src restored phosphorylation. Mapping of the Src-catalyzed tyrosine in vitro and in vivo by site-directed mutagenesis demonstrated Tyr(477) as the primary target residue. We generated a pTyr(477)-phosphospecific antibody, which confirmed that Tyr(477) becomes phosphorylated in cells in a Src-dependent manner. Tyr(477) phosphorylation did not affect ezrin head-to-tail association or phosphorylation of ezrin on threonine 566, indicating that the function of Tyr(477) phosphorylation is not related to the intramolecular regulation of ezrin. A modified yeast two-hybrid screen in which ezrin bait was phosphorylated by Src identified a novel interaction with a kelch-repeat protein family member, KBTBD2 (Kelch-repeat and BTB/POZ domain containing 2). The Src dependence of the interaction was further verified by affinity precipitation assays. Identification of a functional interplay with Src opens novel avenues for further characterization of the biological activities of ezrin.	Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; Turku Univ Hosp, FIN-20520 Turku, Finland; Univ Helsinki, Biomedicum Helsinki, Dept Pathol, Neurosci Program, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, FIN-00014 Helsinki, Finland	University of Turku; University of Turku; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Carpen, O (corresponding author), Univ Turku, Dept Pathol, Kiinamyllkatu 10, FIN-20520 Turku, Finland.	ocarpen@utu.fi						Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Adams JC, 1998, EMBO J, V17, P4964, DOI 10.1093/emboj/17.17.4964; Akisawa N, 1999, BIOCHEM BIOPH RES CO, V258, P395, DOI 10.1006/bbrc.1999.0653; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Autero M, 2003, FEBS LETT, V535, P82, DOI 10.1016/S0014-5793(02)03861-9; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Chen Y, 2002, J BIOL CHEM, V277, P30495, DOI 10.1074/jbc.M202076200; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Elliott BE, 2004, J CELL BIOCHEM, V92, P16, DOI 10.1002/jcb.20033; FAZIOLI F, 1993, ONCOGENE, V8, P1335; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Geiger KD, 2000, AM J PATHOL, V157, P1785, DOI 10.1016/S0002-9440(10)64816-X; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Hoeflich KP, 2003, BIOCHEMISTRY-US, V42, P11634, DOI 10.1021/bi0350497; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; ILMONEN S, 2004, IN PRESS MOD PATHOL; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Keegan K, 1996, ONCOGENE, V12, P1537; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Kumar N, 2004, J BIOL CHEM, V279, P24915, DOI 10.1074/jbc.C400110200; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nestl A, 2001, CANCER RES, V61, P1569; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Ronty M, 2004, FEBS LETT, V566, P30, DOI 10.1061/j.febslet.2004.04.006; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Sasagawa K, 2002, J BIOL CHEM, V277, P44140, DOI 10.1074/jbc.M202596200; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tomar A, 2004, MOL BIOL CELL, V15, P4807, DOI 10.1091/mbc.E04-05-0431; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VanHouten JN, 2001, ONCOGENE, V20, P5366, DOI 10.1038/sj.onc.1204701; Velichkova M, 2002, CELL MOTIL CYTOSKEL, V51, P147, DOI 10.1002/cm.10025; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; Wang L, 2002, BIOCHEM BIOPH RES CO, V293, P1426, DOI 10.1016/S0006-291X(02)00398-4; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Wick W, 2001, J NEUROSCI, V21, P3360, DOI 10.1523/JNEUROSCI.21-10-03360.2001; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAO X, 1993, AM J PHYSIOL, V265, P36; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhai LW, 2001, J BIOL CHEM, V276, P36163, DOI 10.1074/jbc.C100418200; Zhang ZY, 2004, MOL BIOL CELL, V15, P4234, DOI 10.1091/mbc.E04-03-0264	77	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10244	10252		10.1074/jbc.M411353200	http://dx.doi.org/10.1074/jbc.M411353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15623525	hybrid			2022-12-27	WOS:000227559600063
J	Politis, EG; Roth, AF; Davis, NG				Politis, EG; Roth, AF; Davis, NG			Transmembrane topology of the protein palmitoyl transferase Akr1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; PLASMA-MEMBRANE; FACTOR RECEPTOR; YEAST; LOCALIZATION; DOMAIN; GLYCOSYLATION; UBIQUITINATION	The two recently identified protein acyl transferases (PATs), Akr1p and Erf2p/Erf4p, point toward the DHHC protein family as a likely PAT family. The DHHC protein family, defined by the novel, zinc finger-like DHHC cysteine-rich domain (DHHC-CRD), is a diverse collection of polytopic membrane proteins extending through all eukaryotes. To define the PAT domains that are oriented to the cytoplasm and are thus available to effect the cytoplasmically limited palmitoyl modification, we have determined the transmembrane topology of the yeast PAT Akr1p. Portions of the yeast protein invertase (Suc2p) were inserted in-frame at 10 different hydrophilic sites within the Akr1 polypeptide. Three of the Akr1-Suc2-Akr1 insertion proteins were found to be extensively glycosylated, indicating that the invertase segment inserted at these Akr1p sites is luminally oriented. The remaining seven insertion proteins were not glycosylated, consistent with a cytoplasmic orientation for these sites. The results support a model in which the Akr1 polypeptide crosses the bilayer six times with the bulk of its hydrophilic domains disposed toward the cytoplasm. Cytoplasmic domains include both the relatively large, ankyrin repeat-containing N-terminal domain and the DHHC-CRD, which maps to a cytosolic loop segment. Functionality of the different Akr1-Suc2-Akr1 proteins also was examined. Insertions at only 4 of the 10 sites were found to disrupt Akr1p function. Interestingly, these four sites all map cytoplasmically, suggesting key roles for these cytoplasmic domains in Akr1 PAT function. Finally, extrapolating from the Akr1p topology, topology models are proposed for other DHHC protein family members.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Davis, NG (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, Elliman Bldg,Rm 1224,421 E Canfield, Detroit, MI 48201 USA.	ndavis@genetics.wayne.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65525] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; CLARK KL, 1988, COLD SPRING HARB SYM, V53, P611, DOI 10.1101/SQB.1988.053.01.070; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leventis R, 1997, BIOCHEMISTRY-US, V36, P5546, DOI 10.1021/bi963029h; Li BJ, 2002, J BIOL CHEM, V277, P28870, DOI 10.1074/jbc.M202388200; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; REDDY VA, 1988, J BIOL CHEM, V263, P6978; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; SIKORSKI RS, 1989, GENETICS, V122, P19; Singaraja RR, 2002, HUM MOL GENET, V11, P2815, DOI 10.1093/hmg/11.23.2815; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Sun BM, 2004, MOL BIOL CELL, V15, P1397, DOI 10.1091/mbc.E03-09-0682; Uemura T, 2002, BIOCHEM BIOPH RES CO, V296, P492, DOI 10.1016/S0006-291X(02)00900-2; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	27	67	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10156	10163		10.1074/jbc.M411946200	http://dx.doi.org/10.1074/jbc.M411946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632165	hybrid			2022-12-27	WOS:000227559600052
J	Saeki, N; Tokuo, H; Ikebe, M				Saeki, N; Tokuo, H; Ikebe, M			BIG1 is a binding partner of myosin IXb and regulates its Rho-GTPase activating protein activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE PROTEIN; ADP-RIBOSYLATION FACTOR-1; ARF; CLONING; DOMAIN; FAMILY	Myosin IXb, a member of the myosin superfamily, is a molecular motor that possesses a GTPase activating protein ( GAP) for Rho. Through the yeast two-hybrid screening using the tail domain of myosin IXb as bait we found BIG1, a guanine nucleotide exchange factor for ADP-ribosylation factor (Arf1), as a potential binding partner for myosin IXb. The interaction between myosin IXb and BIG1 was demonstrated by co-immunoprecipitation of endogenous myosin IXb and BIG1 with anti-BIG1 antibodies in normal rat kidney cells. Using the isolated proteins, it was demonstrated that myosin IXb and BIG1 directly bind to each other. Various truncation mutants of the myosin IXb tail domain were produced, and it was revealed that the binding region of myosin IXb to BIG1 is the zinc finger/GAP domain. Interestingly, the GAP activity of myosin IXb was significantly inhibited by the addition of BIG1 with IC50 of 0.06 mu M. The RhoA binding to myosin IXb was inhibited by the addition of BIG1 with the concentration similar to the inhibition of the GAP activity. Likewise, RhoA inhibited the BIG1 binding of myosin IXb. These results suggest that BIG1 and RhoA compete with each other for the binding to myosin IXb, thus resulting in the inhibition of the GAP activity by BIG1. The present study identified BIG1, the Arf guanine nucleotide exchange factor, as a new binding partner for myosin IXb, which inhibited the GAP activity of myosin IXb. The findings raise a concept that the myosin transports the signaling molecule as a cargo that functions as a regulator for the myosin molecule.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu		Tokuo, Hiroshi/0000-0002-7614-7805	NCI NIH HHS [SC006103] Funding Source: Medline; NIAMS NIH HHS [AR41653, AR048898] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR048898] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Camera P, 2003, NAT CELL BIOL, V5, P1071, DOI 10.1038/ncb1064; Chieregatti E, 1998, J CELL SCI, V111, P3597; Gorman SW, 1999, GENOMICS, V59, P150, DOI 10.1006/geno.1999.5867; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Li HW, 2003, P NATL ACAD SCI USA, V100, P1627, DOI 10.1073/pnas.0337678100; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Martin ME, 2000, J BIOL CHEM, V275, P19050, DOI 10.1074/jbc.275.25.19050; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Post PL, 2002, J BIOL CHEM, V277, P11679, DOI 10.1074/jbc.M111173200; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567	24	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10128	10134		10.1074/jbc.M413415200	http://dx.doi.org/10.1074/jbc.M413415200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644318	hybrid			2022-12-27	WOS:000227559600048
J	Schattenberg, JRM; Wang, YJ; Singh, R; Rigoli, RM; Czaja, MJ				Schattenberg, JRM; Wang, YJ; Singh, R; Rigoli, RM; Czaja, MJ			Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION SENSITIZES HEPATOCYTES; NONALCOHOLIC FATTY LIVER; RECEPTOR SUBSTRATE-1; MICE LACKING; CYTOCHROME-P450 2E1; PHOSPHOENOLPYRUVATE CARBOXYKINASE; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; OXIDATIVE STRESS; CELL-DEATH	Insulin resistance and increased cytochrome P450 2E1 (CYP2E1) expression are both associated with and mechanistically implicated in the development of nonalcoholic fatty liver disease. Although currently viewed as distinct factors, insulin resistance and CYP2E1 expression may be interrelated through the ability of CYP2E1-induced oxidant stress to impair hepatic insulin signaling. To test this possibility, the effects of in vitro and in vivo CYP2E1 overexpression on hepatocyte insulin signaling were examined. CYP2E1 overexpression in a hepatocyte cell line decreased tyrosine phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2 in response to insulin. CYP2E1 overexpression was also associated with increased inhibitory serine 307 and 636/639 IRS-1 phosphorylation. In parallel, the effects of insulin on Akt activation, glycogen synthase kinase 3, and FoxO1a phosphorylation, and glucose secretion were all significantly decreased in CYP2E1 over-expressing cells. This inhibition of insulin signaling by CYP2E1 overexpression was partially c-Jun N-terminal kinase dependent. In the methionine- and choline-deficient diet mouse model of steatohepatitis with CYP2E1 overexpression, insulin-induced IRS-1, IRS-2, and Akt phosphorylation were similarly decreased. These findings indicate that increased hepatocyte CYP2E1 expression and the presence of steatohepatitis result in the down-regulation of insulin signaling, potentially contributing to the insulin resistance associated with nonalcoholic fatty liver disease.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Czaja, MJ (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	czaja@aecom.yu.edu	Schattenberg, Jörn M./C-1301-2013	Schattenberg, Jörn M./0000-0002-4224-4703	NIDDK NIH HHS [DK61498, DK41296, R01 DK061498] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK061498] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Altomonte J, 2003, AM J PHYSIOL-ENDOC M, V285, pE718, DOI 10.1152/ajpendo.00156.2003; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; BEALE EG, 1985, J BIOL CHEM, V260, P748; Boden G, 2001, AM J PHYSIOL-ENDOC M, V280, pE23, DOI 10.1152/ajpendo.2001.280.1.E23; Chitturi S, 2002, HEPATOLOGY, V35, P373, DOI 10.1053/jhep.2002.30692; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CZAJA MJ, 1991, J CELL PHYSIOL, V147, P434, DOI 10.1002/jcp.1041470308; Diehl AM, 2004, GUT, V53, P923, DOI 10.1136/gut.2003.037309; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hirashima Y, 2003, J ENDOCRINOL, V179, P253, DOI 10.1677/joe.0.1790253; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Jones BE, 2002, ANTIOXID REDOX SIGN, V4, P701, DOI 10.1089/152308602760598846; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Lawlor MA, 2001, J CELL SCI, V114, P2903; Le HT, 2004, BIOCHEM BIOPH RES CO, V314, P321, DOI 10.1016/j.bbrc.2003.12.087; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; Liu HL, 2002, AM J PHYSIOL-GASTR L, V282, pG257, DOI 10.1152/ajpgi.00304.2001; Liu HL, 2002, HEPATOLOGY, V35, P772, DOI 10.1053/jhep.2002.32534; Liu HL, 2000, J BIOL CHEM, V275, P40155, DOI 10.1074/jbc.M001565200; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; MEIER UT, 1992, CELL, V70, P127; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakatani Y, 2004, J BIOL CHEM, V279, P45803, DOI 10.1074/jbc.M406963200; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; Ono H, 2003, DIABETES, V52, P2905, DOI 10.2337/diabetes.52.12.2905; Pagano G, 2002, HEPATOLOGY, V35, P367, DOI 10.1053/jhep.2002.30690; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rinella ME, 2004, J HEPATOL, V40, P47, DOI 10.1016/j.jhep.2003.09.020; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Schattenberg JM, 2004, HEPATOLOGY, V39, P444, DOI 10.1002/hep.20067; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; Tirosh A, 2001, BIOCHEM J, V355, P757, DOI 10.1042/bj3550757; Valverde AM, 2003, DIABETES, V52, P2239, DOI 10.2337/diabetes.52.9.2239; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang ZQ, 2003, BRIT J CLIN PHARMACO, V55, P77, DOI 10.1046/j.1365-2125.2003.01731.x; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yahagi N, 2004, J BIOL CHEM, V279, P20571, DOI 10.1074/jbc.M400884200; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200	62	148	158	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9887	9894		10.1074/jbc.M410310200	http://dx.doi.org/10.1074/jbc.M410310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632182	hybrid			2022-12-27	WOS:000227559600019
J	Bomberger, JM; Parameswaran, N; Hall, CS; Aiyar, N; Spielman, WS				Bomberger, JM; Parameswaran, N; Hall, CS; Aiyar, N; Spielman, WS			Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLMALEIMIDE-SENSITIVE FACTOR; PLASMA ADRENOMEDULLIN LEVELS; RENAL DAMAGE; CARDIAC-HYPERTROPHY; BINDING; EXPRESSION; INTERNALIZATION; COMPLEX; SYSTEM	RAMPs (1-3) are single transmembrane accessory proteins crucial for plasma membrane expression, which also determine receptor phenotype of various G-protein-coupled receptors. For example, adrenomedullin receptors are comprised of RAMP2 or RAMP3 ( AM1R and AM2R, respectively) and calcitonin receptor-like receptor ( CRLR), while a CRLR heterodimer with RAMP1 yields a calcitonin gene-related peptide receptor. The major aim of this study was to determine the role of RAMPs in receptor trafficking. We hypothesized that a PDZ type I domain present in the C terminus of RAMP3, but not in RAMP1 or RAMP2, leads to protein-protein interactions that determine receptor trafficking. Employing adenylate cyclase assays, radioligand binding, and immunofluorescence microscopy, we observed that in HEK293 cells the CRLR-RAMP complex undergoes agonist-stimulated desensitization and internalization and fails to resensitize (i.e. degradation of the receptor complex). Co-expression of N-ethylmaleimide- sensitive factor ( NSF) with the CRLR- RAMP3 complex, but not CRLR- RAMP1 or CRLR- RAMP2 complex, altered receptor trafficking to a recycling pathway. Mutational analysis of RAMP3, by deletion and point mutations, indicated that the PDZ motif of RAMP3 interacts with NSF to cause the change in trafficking. The role of RAMP3 and NSF in AM2R recycling was confirmed in rat mesangial cells, where RNA interference with RAMP3 and pharmacological inhibition of NSF both resulted in a lack of receptor resensitization/ recycling after agonist-stimulated desensitization. These findings provide the first functional difference between the AM1R and AM2R at the level of post-endocytic receptor trafficking. These results indicate a novel function for RAMP3 in the poste-endocytic sorting of the AM-R and suggest a broader regulatory role for RAMPs in receptor trafficking.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; GlaxoSmithKline, Dept Vasc Biol, King Of Prussia, PA 19406 USA	Michigan State University; GlaxoSmithKline	Spielman, WS (corresponding author), Michigan State Univ, Dept Physiol, 2201 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	spielman@msu.edu	Parameswaran, Narayanan/V-1969-2019	Parameswaran, Narayanan/0000-0002-8894-5564				Aiyar N, 2002, BIOCHEM PHARMACOL, V63, P1949, DOI 10.1016/S0006-2952(02)00990-5; AIYAR N, 1987, MOL PHARMACOL, V31, P180; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Chao J, 1997, Hypertens Res, V20, P269, DOI 10.1291/hypres.20.269; Choksi T, 2002, BRIT J PHARMACOL, V136, P784, DOI 10.1038/sj.bjp.0704761; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Cueille C, 2002, BIOCHEM BIOPH RES CO, V294, P340, DOI 10.1016/S0006-291X(02)00487-4; Dobrzynski E, 2002, AM J PHYSIOL-ENDOC M, V283, pE1291, DOI 10.1152/ajpendo.00147.2002; Dobrzynski E, 2000, HYPERTENSION, V36, P995, DOI 10.1161/01.HYP.36.6.995; Garcia-Unzueta MT, 1998, DIABETES CARE, V21, P999, DOI 10.2337/diacare.21.6.999; Hilaire S, 2001, J BIOL CHEM, V276, P42182, DOI 10.1074/jbc.M107323200; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; Kubo A, 1998, NEPHRON, V80, P227, DOI 10.1159/000045172; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Nakamura T, 1998, ENDOCR J, V45, P241, DOI 10.1507/endocrj.45.241; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089; Neuwald AF, 1999, STRUCTURE, V7, pR19, DOI 10.1016/S0969-2126(99)80015-X; Nishikimi T, 2003, HYPERTENSION, V41, P512, DOI 10.1161/01.HYP.0000053447.64213.C4; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Nowak W, 2002, AM J PHYSIOL-CELL PH, V282, pC1322, DOI 10.1152/ajpcell.00561.2001; Parameswaran N, 2000, EUR J PHARMACOL, V407, P205, DOI 10.1016/S0014-2999(00)00656-7; Roh J, 2004, J BIOL CHEM, V279, P7264, DOI 10.1074/jbc.M305332200; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Tadokoro K, 2003, REGUL PEPTIDES, V112, P71, DOI 10.1016/s0167-0115(03)00024-7; Wang C, 2001, AM J PHYSIOL-RENAL, V280, pF964, DOI 10.1152/ajprenal.2001.280.6.F964; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200; Zhang JJ, 2000, HUM GENE THER, V11, P1817, DOI 10.1089/10430340050129440	33	94	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9297	9307		10.1074/jbc.M413786200	http://dx.doi.org/10.1074/jbc.M413786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15613468	hybrid			2022-12-27	WOS:000227453100081
J	Hashimoto, Y; Hosaka, H; Oinuma, K; Goda, M; Higashibata, H; Kobayashi, M				Hashimoto, Y; Hosaka, H; Oinuma, K; Goda, M; Higashibata, H; Kobayashi, M			Nitrile pathway involving Acyl-CoA synthetase - Overall metabolic gene organization and purification and characterization of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-CHLORORAPHIS B23; RHODOCOCCUS-RHODOCHROUS J1; FATTY-ACID DEGRADATION; TRIPLE BOND SYNTHESIS; COENZYME-A SYNTHETASE; ESCHERICHIA-COLI; ALDOXIME DEHYDRATASE; MOLECULAR CHARACTERIZATION; ISONITRILE HYDRATASE; REACTION-PRODUCT	Two open reading frames (nhpS and acsA) were identified immediately downstream of the previously described Pseudomonas chlororaphis B23 nitrile hydratase (NHase) gene cluster ( encoding aldoxime dehydratase, amidase, the two NHase subunits, and an uncharacterized protein). The amino acid sequence deduced from acsA shows similarity to that of acyl-CoA synthetase (AcsA). The acsA gene product expressed in Escherichia coli showed acyl-CoA synthetase activity toward butyric acid and CoA as substrates, with butyryl-CoA being synthesized. From the E. coli transformant, AcsA was purified to homogeneity and characterized. The quality of the recombinant protein was verified by the NH2-terminal amino acid sequence and the results of matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The apparent Km values for butyric acid, CoA, and ATP were 0.32 +/- 0.04, 0.37 +/- 0.02, and 0.22 +/- 0.02 mM, respectively. AcsA was shown to be a short-chain acyl-CoA synthetase, according to the catalytic efficiencies (k(cat)/K-m) for various acids. The substrate specificity of AcsA was similar to those of aldoxime dehydratase, NHase, and amidase, the genes of which coexist in the same orientation in the gene cluster. P. chlororaphis B23 grew when cultured in a medium containing butyraldoxime as the sole carbon and nitrogen source. The activities of aldoxime dehydratase, NHase, and amidase were detected together with that of acyl-CoA synthetase under the culture conditions used. Moreover, on culture in a medium containing butyric acid as the sole carbon source, acyl-CoA synthetase activity was also detected. Together with the adjacent locations of the aldoxime dehydratase, NHase, amidase, and acyl-CoA synthetase genes, these findings suggest that the four enzymes are sequentially correlated with one another in vivo to utilize butyraldoxime as a carbon and nitrogen source. This is the first report of an overall "nitrile pathway" (aldoxime-->nitrile-->amide-->acid-->acyl-CoA) comprising these enzymes.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba	Kobayashi, M (corresponding author), Univ Tsukuba, Inst Appl Biochem, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.			HIGASHIBATA, Hiroki/0000-0001-7416-5316				ASANO Y, 1980, AGR BIOL CHEM TOKYO, V44, P2251, DOI 10.1080/00021369.1980.10864311; BARTLING D, 1994, P NATL ACAD SCI USA, V91, P6021, DOI 10.1073/pnas.91.13.6021; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; BLACK PN, 1992, J BIOL CHEM, V267, P25513; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; CISKANIK LM, 1995, APPL ENVIRON MICROB, V61, P998, DOI 10.1128/AEM.61.3.998-1003.1995; CLARK D, 1981, J BACTERIOL, V148, P521, DOI 10.1128/JB.148.2.521-526.1981; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Endo I, 1999, TRENDS BIOTECHNOL, V17, P244, DOI 10.1016/S0167-7799(99)01303-7; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fukatsu H, 2004, P NATL ACAD SCI USA, V101, P13726, DOI 10.1073/pnas.0405082101; Goda M, 2002, J BIOL CHEM, V277, P45860, DOI 10.1074/jbc.M208571200; Goda M, 2001, J BIOL CHEM, V276, P23480, DOI 10.1074/jbc.M007856200; Hann EC, 1999, BIOORGAN MED CHEM, V7, P2239, DOI 10.1016/S0968-0896(99)00157-1; Hansen CH, 2001, J BIOL CHEM, V276, P24790, DOI 10.1074/jbc.M102637200; Hansen CH, 2001, J BIOL CHEM, V276, P11078, DOI 10.1074/jbc.M010123200; Herai S, 2004, P NATL ACAD SCI USA, V101, P14031, DOI 10.1073/pnas.0406058101; Hull AK, 2000, P NATL ACAD SCI USA, V97, P2379, DOI 10.1073/pnas.040569997; KAMEDA K, 1985, BIOCHIM BIOPHYS ACTA, V840, P29, DOI 10.1016/0304-4165(85)90158-8; Kasuya F, 1996, BIOCHEM PHARMACOL, V51, P805, DOI 10.1016/0006-2952(95)02399-2; Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9; KOBAYASHI M, 1995, P NATL ACAD SCI USA, V92, P714, DOI 10.1073/pnas.92.3.714; Kobayashi M, 2000, CURR OPIN CHEM BIOL, V4, P95, DOI 10.1016/S1367-5931(99)00058-7; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, BIOCHEMISTRY-US, V31, P9000, DOI 10.1021/bi00152a042; KOBAYASHI M, 1992, J BIOL CHEM, V267, P20746; Kobayashi M, 1998, NAT BIOTECHNOL, V16, P733, DOI 10.1038/nbt0898-733; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOBAYASHI M, 1994, FEMS MICROBIOL LETT, V120, P217, DOI 10.1016/0378-1097(94)90474-X; Komeda H, 1996, P NATL ACAD SCI USA, V93, P4267, DOI 10.1073/pnas.93.9.4267; Komeda H, 1996, J BIOL CHEM, V271, P15796, DOI 10.1074/jbc.271.26.15796; Komeda H, 1996, P NATL ACAD SCI USA, V93, P10572, DOI 10.1073/pnas.93.20.10572; Konishi K, 2004, J BIOL CHEM, V279, P47619, DOI 10.1074/jbc.M407223200; KUMARI S, 1995, J BACTERIOL, V177, P2878, DOI 10.1128/jb.177.10.2878-2886.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MARTINEZBLANCO H, 1992, J BIOL CHEM, V267, P5474; NAGASAWA T, 1987, EUR J BIOCHEM, V162, P691, DOI 10.1111/j.1432-1033.1987.tb10692.x; NAGASAWA T, 1989, EXPERIENTIA, V45, P1066, DOI 10.1007/BF01950160; NISHIYAMA M, 1991, J BACTERIOL, V173, P2465, DOI 10.1128/jb.173.8.2465-2472.1991; Normanly J, 1997, PLANT CELL, V9, P1781, DOI 10.1105/tpc.9.10.1781; Oinuma KI, 2003, J BIOL CHEM, V278, P29600, DOI 10.1074/jbc.M211832200; Oinuma KI, 2004, FEBS LETT, V568, P44, DOI 10.1016/j.febslet.2004.05.008; Olivera ER, 2001, MOL MICROBIOL, V39, P863, DOI 10.1046/j.1365-2958.2001.02296.x; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PAULI G, 1974, J BACTERIOL, V117, P1178, DOI 10.1128/JB.117.3.1178-1183.1974; Pekarsky Y, 1998, P NATL ACAD SCI USA, V95, P8744, DOI 10.1073/pnas.95.15.8744; Popescu VC, 2001, BIOCHEMISTRY-US, V40, P7984, DOI 10.1021/bi010198f; Reintanz B, 2001, PLANT CELL, V13, P351, DOI 10.1105/tpc.13.2.351; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SHIMIZU S, 1981, BIOCHEM BIOPH RES CO, V103, P1231, DOI 10.1016/0006-291X(81)90254-0; Yamada H, 2001, CHEM REC, V1, P152; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	58	35	37	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8660	8667		10.1074/jbc.M405686200	http://dx.doi.org/10.1074/jbc.M405686200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632196	hybrid			2022-12-27	WOS:000227453100007
J	Khundmiri, SJ; Dean, WL; McLeish, KR; Lederer, ED				Khundmiri, SJ; Dean, WL; McLeish, KR; Lederer, ED			Parathyroid hormone-mediated regulation of Na+-K+-ATPase requires ERK-dependent translocation of protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPOSSUM KIDNEY-CELLS; PROXIMAL TUBULE; ANGIOTENSIN-II; SIGNALING PATHWAYS; EPITHELIAL-CELLS; PKC ISOFORMS; MUSCLE-CELLS; ACTIVATION; DELTA; PHOSPHORYLATION	Parathyroid hormone (PTH) inhibits Na+-K+-ATPase activity by serine phosphorylation of the alpha(1) subunit through protein kinase C (PKC)- and extracellular signal-regulated kinase (ERK)-dependent pathways. Based on previous studies we postulated that PTH regulates sodium pump activity through isoform-specific PKC-dependent activation of ERK. In the present work utilizing opossum kidney cells, a model of renal proximal tubule, PTH stimulated membrane translocation of PKCalpha by 102 +/- 16% and PKC betaI by 41 +/- 7% but had no effect on PKCbetaII and PKCzeta. Both PKCalpha and PKCbetaI phosphorylated the Na+-K+-ATPase alpha(1) subunit in vitro. PTH increased the activity of PKCalpha but not PKCbetaI. Coimmuno-precipitation assays demonstrated that treatment with PTH enhanced the association between Na+-K+-ATPase alpha(1) subunit and PKCalpha, whereas the association between Na+-K+-ATPase alpha(1) subunit and PKCbetaI remained unchanged. A PKCalpha inhibitory peptide blocked PTH-stimulated serine phosphorylation of the Na+-K+ ATPase alpha(1) subunit and inhibition of Na+-K+-ATPase activity. Pharmacologic inhibition of MEK-1 blocked PTH-stimulated translocation of PKCalpha, whereas transfection of constitutively active MEK-1 cDNA induced translocation of PKCalpha and increased phosphorylation of the Na+-K+-ATPase alpha(1) subunit. In contrast, PTH-stimulated ERK activation was not inhibited by pretreatment with the PKCalpha inhibitory peptide. Inhibition of PKCalpha expression by siRNA did not inhibit PTH-mediated ERK activation but significantly reduced PTH-mediated phosphorylation of the Na+-K+-ATPase alpha(1) subunit. Pharmacologic inhibition of phosphoinositide 3-kinase blocked PTH-stimulated ERK activation, translocation of PKCalpha, and phosphorylation of the Na+-K+-ATPase alpha(1) subunit. We conclude that PTH stimulates Na+-K+-ATPase phosphorylation and decreases the activity of Na+-K+-ATPase by ERK-dependent activation of PKCalpha.	Univ Louisville, Kidney Dis Program, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Khundmiri, SJ (corresponding author), Univ Louisville, Kidney Dis Program, 570 S Preston St, Louisville, KY 40202 USA.	syed.khundmiri@louisville.edu	McLeish, Kenneth R./B-9819-2013	McLeish, Kenneth R./0000-0002-7816-3286; Khundmiri, Syed/0000-0002-0364-0412	NIDDK NIH HHS [DK62389] Funding Source: Medline; BLRD VA [I01 BX000610] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062389] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Al-Khalili L, 2004, J BIOL CHEM, V279, P25211, DOI 10.1074/jbc.M402152200; Aristimuno PC, 1997, AM J PHYSIOL-RENAL, V272, pF624, DOI 10.1152/ajprenal.1997.272.5.F624; Boesch DM, 2001, AM J PHYSIOL-REG I, V281, pR861, DOI 10.1152/ajpregu.2001.281.3.R861; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; Budu CE, 2002, BRIT J PHARMACOL, V137, P1380, DOI 10.1038/sj.bjp.0704962; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; Clarke H, 2000, KIDNEY INT, V58, P1004, DOI 10.1046/j.1523-1755.2000.00258.x; Coulson R, 1996, AM J PHYSIOL-RENAL, V270, pF263, DOI 10.1152/ajprenal.1996.270.2.F263; Disatnik MH, 2002, J CELL SCI, V115, P2151; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HIRD RB, 1995, CIRCULATION, V92, P433, DOI 10.1161/01.CIR.92.9.433; Hussain T, 2003, EXP BIOL MED, V228, P134, DOI 10.1177/153537020322800202; Isenovic ER, 2004, ENDOCRINOLOGY, V145, P1151, DOI 10.1210/en.2003-0100; KARIM Z, 1995, AM J PHYSIOL-CELL PH, V269, pC134, DOI 10.1152/ajpcell.1995.269.1.C134; Khundmiri SJ, 2004, J BIOL CHEM, V279, P17418, DOI 10.1074/jbc.M311715200; Khundmiri SJ, 2002, AM J PHYSIOL-RENAL, V282, pF512, DOI 10.1152/ajprenal.00111.2000; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lederer ED, 1998, J AM SOC NEPHROL, V9, P975; Lederer ED, 2003, J AM SOC NEPHROL, V14, P1711, DOI 10.1097/01.ASN.0000072744.67971.21; Liang MY, 1999, AM J PHYSIOL-RENAL, V277, pF859, DOI 10.1152/ajprenal.1999.277.6.F859; Mendez CF, 2003, J BIOL CHEM, V278, P44753, DOI 10.1074/jbc.M308664200; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okafor MC, 2002, INVEST OPHTH VIS SCI, V43, P790; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; Ridge KM, 2002, MOL BIOL CELL, V13, P1381, DOI 10.1091/mbc.01-07-0323; ROTEM R, 1990, P NATL ACAD SCI USA, V87, P7305, DOI 10.1073/pnas.87.18.7305; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Tran CM, 1996, BIOCHEMISTRY-US, V35, P47, DOI 10.1021/bi951238g; Wang XD, 1996, J INVEST MED, V44, P566; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711	39	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8705	8713		10.1074/jbc.M408606200	http://dx.doi.org/10.1074/jbc.M408606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637080	hybrid			2022-12-27	WOS:000227453100012
J	Piret, JP; Minet, E; Cosse, JP; Ninane, N; Debacq, C; Raes, M; Michiels, C				Piret, JP; Minet, E; Cosse, JP; Ninane, N; Debacq, C; Raes, M; Michiels, C			Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-CANCER CELLS; MCL-1 EXPRESSION; FACTOR 1-ALPHA; ANTIAPOPTOTIC ACTION; SIGNALING PATHWAY; UTERINE CERVIX; BCL-2 FAMILY; TUMOR-GROWTH; HIF-ALPHA; FACTOR-1-ALPHA	Increased levels of Mcl-1 (myeloid cell factor-1) have been reported in several cancers, suggesting an important role played by Mcl-1 in cancer cell survival. Mcl-1 is an anti-apoptotic protein shown to delay or block apoptosis. In this work, using semiquantitative immunofluorescence, real-time PCR, and RNase protection assay, an increase in Mcl-1 expression was detected in hepatoma HepG2 cells incubated under hypoxia or in the presence of cobalt chloride. Through analysis of the Mcl-1 promoter sequence, a putative HIF-1 (hypoxia-inducible factor-1) binding site was identified. A Mcl-1 promoter fragment containing this hypoxia-responsive element was able to bind HIF-1 in vitro. It also induced hypoxia-dependent transcription of a luciferase reporter gene, which was suppressed by anti-HIF-1alpha short interfering RNA. Finally, overexpression of Mcl-1 protected HepG2 cells against apoptosis induced by tertbutyl hydroperoxide as shown by inhibition of caspase-3 activation and DNA fragmentation. All these data suggest a potential anti-apoptotic role of HIF-1 that could protect cells against apoptosis under hypoxia by overexpression of the Mcl-1 protein.	Univ Namur, Lab Biochem & Cellular Biol, B-5000 Namur, Belgium; FUSAGx, B-5030 Gembloux, Belgium	University of Namur	Michiels, C (corresponding author), Univ Namur, Lab Biochem & Cellular Biol, 61 Rue Bruxelles, B-5000 Namur, Belgium.	carine.michiels@fundp.ac.be						Akakura N, 2001, CANCER RES, V61, P6548; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Brown JM, 1999, CANCER RES, V59, P5863; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Feldser D, 1999, CANCER RES, V59, P3915; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Hockel M, 1996, CANCER RES, V56, P4509; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V148, P1567; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Leuenroth SJ, 2000, SURGERY, V128, P171, DOI 10.1067/msy.2000.107609; Leuenroth SJ, 2000, J LEUKOCYTE BIOL, V68, P158; Lin ZW, 2000, AM J PHYSIOL-ENDOC M, V278, pE958, DOI 10.1152/ajpendo.2000.278.5.E958; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rofstad EK, 2000, BRIT J CANCER, V83, P354, DOI 10.1054/bjoc.2000.1266; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Sowter HM, 2001, CANCER RES, V61, P6669; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang XN, 1997, EXP CELL RES, V235, P210, DOI 10.1006/excr.1997.3667; Yu EZ, 2004, LAB INVEST, V84, P553, DOI 10.1038/labinvest.3700071; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	58	109	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9336	9344		10.1074/jbc.M411858200	http://dx.doi.org/10.1074/jbc.M411858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611089	hybrid			2022-12-27	WOS:000227453100086
J	Guo, HB; Lee, I; Bryan, BT; Pierce, M				Guo, HB; Lee, I; Bryan, BT; Pierce, M			Deletion of mouse embryo fibroblast N-acetylglucosaminyltransferase V stimulates alpha 5 beta 1 integrin expression mediated by the protein kinase C signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE-PHOSPHATASE SHP-2; CELL-CELL ADHESION; FIBRONECTIN RECEPTOR; EPITHELIAL-CELLS; LIGAND-BINDING; LUNG METASTASIS; GENE PROMOTER; E-CADHERIN; MIGRATION	An N- linked glycan often increased during oncogenic transformation contains beta( 1,6)- linked GlcNAc, synthesized by the N- acetylglucosaminyltransferase V ( GnTV). The progression of polyoma middle T- antigen oncoproteininduced mammary carcinomas in GnT- V null mice was significantly retarded compared with that observed in wild- type mice. The matrix adhesion of mouse embryonic fibroblasts ( MEF) from GnT- V null and wildtype mice was investigated to understand the mechanism by which deletion of GnT- V could retard tumor progression. GnT- V null MEF displayed enhanced adhesion to and spreading on fibronectin- coated plates with concomitant inhibition of cell migration. GnT- V null MEF also showed increased focal adhesion kinase tyrosine phosphorylation, consistent with decreased cell motility on fibronectin- coated plates. Expression of GnT- V cDNA in the null MEF reversed these abnormal characteristics, indicating the direct involvement of N- glycosylation events in these phenotypic changes. The alpha5beta1 fibronectin receptors exhibited increased clustering on the null MEF cell surfaces, consistent with previous studies that observed less integrin clustering in cells overexpressing GnT- V. Most surprisingly, GnT- V null MEF displayed increased expression levels of both alpha5 and beta1 subunits in lysates and on the cell surface. Increased alpha5beta1 expression in the null MEF was because of increased alpha5beta1 transcript levels that declined after re- expression of GnT- V cDNA, confirming that increased alpha5beta1 expression in null MEF was because of changes in GnT- V expression. The increased null MEF transcripts were shown to be caused at least in part by increased integrin promoter activity. Moreover, increased alpha5beta1 integrin transcripts in GnT- V null MEF were not due to a differential response to fibronectin; rather, they appeared to be mediated by activation of a protein kinase C signaling pathway. These results demonstrate that deletion of MEF GnT- V resulted in enhanced integrin clustering and activation of alpha5beta1 transcription by protein kinase C signaling, which in turn up- regulated levels of cell surface alpha5beta1 fibronectin receptors that resulted in increased matrix adhesion and inhibition of migration.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Pierce, M (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.	hawkeye@uga.edu		Lee, Intaek/0000-0003-1084-674X; Bryan, Beau/0000-0002-6595-4134				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BROCKHAUSEN I, 1988, BIOCHIMIE, V70, P1521, DOI 10.1016/0300-9084(88)90289-1; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; Granovsky M, 2000, NAT MED, V6, P306; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guo HB, 2003, J BIOL CHEM, V278, P52412, DOI 10.1074/jbc.M308837200; Guo HB, 2000, GLYCOCONJUGATE J, V17, P315, DOI 10.1023/A:1007177806496; Guo HB, 2002, CANCER RES, V62, P6837; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HUANG S, 1994, J CELL PHYSIOL, V161, P470, DOI 10.1002/jcp.1041610310; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Inamori K, 2003, J BIOL CHEM, V278, P43102, DOI 10.1074/jbc.M308255200; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Kaneko M, 2003, FEBS LETT, V554, P515, DOI 10.1016/S0014-5793(03)01234-1; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Larouche K, 2000, J BIOL CHEM, V275, P39182, DOI 10.1074/jbc.M002945200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Manes S, 1999, MOL CELL BIOL, V19, P3125; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MURAKAMI J, 1992, J LAB CLIN MED, V120, P86; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Pierce M, 1997, GLYCOCONJUGATE J, V14, P623, DOI 10.1023/A:1018592627696; Rajagopal S, 1997, J CELL PHYSIOL, V170, P138, DOI 10.1002/(SICI)1097-4652(199702)170:2<138::AID-JCP5>3.0.CO;2-P; Roman J, 2004, AM J PHYSIOL-LUNG C, V287, pL239, DOI 10.1152/ajplung.00244.2003; Rosfjord EC, 1999, EXP CELL RES, V248, P260, DOI 10.1006/excr.1998.4390; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; Schaller MD, 2004, J CELL BIOL, V166, P157, DOI 10.1083/jcb.200406151; Schirner M, 1998, CLIN EXP METASTAS, V16, P427; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Sieg DJ, 1999, J CELL SCI, V112, P2677; Tanaka Y, 2002, J BIOL CHEM, V277, P21446, DOI 10.1074/jbc.M202238200; Tani N, 2003, BRIT J CANCER, V88, P327, DOI 10.1038/sj.bjc.6600710; Yamamoto H, 2000, CANCER RES, V60, P134; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zamir E, 2001, J CELL SCI, V114, P3583; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049	64	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8332	8342		10.1074/jbc.M413532200	http://dx.doi.org/10.1074/jbc.M413532200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615721	hybrid			2022-12-27	WOS:000227395700108
J	Leung-Theung-Long, S; Roulet, E; Clerc, P; Escrieut, C; Marchal-Victorion, S; Ritz-Laser, B; Philippe, J; Pradayrol, L; Seva, C; Fourmy, D; Dufresne, M				Leung-Theung-Long, S; Roulet, E; Clerc, P; Escrieut, C; Marchal-Victorion, S; Ritz-Laser, B; Philippe, J; Pradayrol, L; Seva, C; Fourmy, D; Dufresne, M			Essential interaction of Egr-1 at an islet-specific response element for basal and gastrin-dependent glucagon gene transactivation in pancreatic alpha-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; DNA-BINDING SPECIFICITY; TYROSINE PHOSPHORYLATION; EXPRESSION; RECEPTOR; INSULIN; HYPOGLYCEMIA; ASSOCIATION; ACTIVATION; SECRETION	The peptide hormone gastrin is secreted from G cells of the gastric antrum and is the main inducer of gastric acid secretion via activation of its receptor the cholecystokinin 2 (CCK2) receptor. Both gastrin and CCK2 receptors are also transiently detected in the fetal pancreas and believed to exert growth/differentiation effects during endocrine pancreatic development. We demonstrated previously that whereas gastrin expression is extinguished in adult pancreas, CCK2 receptors are present in human glucagon-producing cells where their activation stimulates glucagon secretion. Based on these findings, we investigate in the present study whether gastrin regulates glucagon gene expression. To this aim, the CCK2 receptor was stably expressed into a glucagon-producing pancreatic islet cell line, and a glucagon-reporter fusion gene was transiently transfected in this new cellular model. We report that gastrin stimulates glucagon gene expression in glucagon-producing pancreatic cells. By using progressively 5'-increased sequences of the glucagon gene, gastrin responsiveness was located within the minimal promoter. Moreover, we clearly identified early growth response protein 1 (Egr-1) as an essential transcription factor interacting with the islet cell-specific G4 element. Egr-1 was shown to be essential for basal and gastrin-dependent glucagon gene transactivation. Furthermore, our results demonstrate that the MEK1/ERK1/2 pathway couples the CCK2 receptor to nuclearization and DNA binding of Egr-1. In conclusion, our data provide new information concerning the transcriptional regulation of the glucagon gene. Moreover they open new working hypothesis with reference to a potential role of gastrin in glucagon-producing pancreatic cells.	Hosp Rangueil, IFR31, INSERM, U531, F-31059 Toulouse, France; Univ Hosp, Diabet Unit, CH-1211 Geneva 14, Switzerland	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Geneva	Dufresne, M (corresponding author), INSERM, U531, Inst Louis Bugnard, IFR31, F-31432 Toulouse 4, France.	dufresne@toulouse.inserm.fr	SEVA, Catherine/O-9166-2014; Fourmy, Daniel/AAE-3703-2019; Dufresne, Marlène/M-6332-2014	SEVA, Catherine/0000-0002-4265-7372; Fourmy, Daniel/0000-0001-9910-4827; LEUNG-THEUNG-LONG, Stephane/0000-0001-5590-9666				BARDRAM L, 1990, P NATL ACAD SCI USA, V87, P298, DOI 10.1073/pnas.87.1.298; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; Boushey RP, 2003, GASTROENTEROLOGY, V125, P1164, DOI 10.1016/S0016-5085(03)01195-8; BRAND SJ, 1984, NATURE, V309, P456, DOI 10.1038/309456a0; CAO XM, 1993, J BIOL CHEM, V268, P16949; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Dehez S, 2002, CELL GROWTH DIFFER, V13, P375; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; Dumonteil E, 1998, ENDOCRINOLOGY, V139, P4540, DOI 10.1210/en.139.11.4540; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Le Bras S, 1998, DIABETES, V47, P1236, DOI 10.2337/diabetes.47.8.1236; Marco E, 2003, J MOL BIOL, V328, P9, DOI 10.1016/S0022-2836(03)00243-2; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; Prasadan K, 2002, DIABETES, V51, P3229, DOI 10.2337/diabetes.51.11.3229; Raychowdhury R, 2002, MOL ENDOCRINOL, V16, P2802, DOI 10.1210/me.2001-0292; Saillan-Barreau C, 1999, DIABETES, V48, P2015, DOI 10.2337/diabetes.48.10.2015; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Taborsky GJ, 1998, DIABETES, V47, P995, DOI 10.2337/diabetes.47.7.995; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178	26	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7976	7984		10.1074/jbc.M407485200	http://dx.doi.org/10.1074/jbc.M407485200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611055	hybrid			2022-12-27	WOS:000227395700067
J	Lux, A; Beil, C; Majety, M; Barron, S; Gallione, CJ; Kuhn, HM; Berg, JN; Kioschis, P; Marchuk, DA; Hafner, M				Lux, A; Beil, C; Majety, M; Barron, S; Gallione, CJ; Kuhn, HM; Berg, JN; Kioschis, P; Marchuk, DA; Hafner, M			Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; ENDOTHELIAL-CELLS; I RECEPTORS; SIGNAL-TRANSDUCTION; IMPRINTED GENE; ENDOGLIN; IDENTIFICATION; ANGIOGENESIS; ACTIVATION; MOUSE	Mutations in activin receptor-like kinase 1 (ALK1), a transforming growth factor (TGF)-beta type I receptor, lead to the vascular disorder hereditary hemorrhagic telangiectasia caused by abnormal vascular remodeling. The underlying molecular cause of this disease is not well understood. Identifying binding partners for ALK1 will help to understand its cellular function. Using the two-hybrid system, we identified an ALK1-binding protein encoded by an ancient retroviral/retrotransposon element integrated as a single copy gene known as PEG10 on human chromosome 7q21. PEG10 contains two overlapping reading frames from which two proteins, PEG10-RF1 and PEG10-RF1/2, are translated by a typical retroviral -1 ribosomal frameshift mechanism. Reverse transcription-PCR and Northern blot analysis showed a broad range of PEG10 expression in different tissues and cell types, i.e. human placenta, brain, kidney, endothelial cells, lymphoblasts, and HepG2 and HEK293 cells. However, endogenous PEG10-RF1 and PEG10-RF1/2 proteins were only detected in HepG2 and HEK293 cells. PEG10-RF1, which is the major PEG10 protein product, represents a gag-like protein, and PEG10-RF1/2 represents a gag-pol-like protein. PEG10-RF1 also interacts with different members of TGF-beta superfamily type I and II receptors. PEG10-RF1 binding to ALK1 is mediated by a 200-amino acid domain with no recognized motif. PEG10-RF1 inhibits ALK1 as well as ALK5 signaling. Co-expression of ALK1 and PEG10-RF1 in different cell types induced morphological changes reminiscent of neuronal cells or sprouting cells. This is the first report of a human retroviral-like protein interacting with members of the TGF-beta receptor family.	Univ Hosp Mannheim, D-68163 Mannheim, Germany; Univ Appl Sci Mannheim, Inst Mol Biol & Cell Culture Technol, D-68163 Mannheim, Germany; Univ Dundee, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Ruprecht Karls University Heidelberg; University of Mannheim; University of Dundee; Duke University	Lux, A (corresponding author), Univ Hosp Mannheim, D-68163 Mannheim, Germany.	a.lux@fh-mannheim.de		Marchuk, Douglas/0000-0002-3110-6671	NHLBI NIH HHS [HL49171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Berg JN, 1997, AM J HUM GENET, V61, P60, DOI 10.1086/513903; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Bowzard JB, 1998, J VIROL, V72, P9034, DOI 10.1128/JVI.72.11.9034-9044.1998; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Dunn BM, 2002, GENOME BIOL, V3; Dunn BM, 2002, ESSAYS BIOCHEM, V38, P113, DOI 10.1042/bse0380113; ENGELBERGKULKA H, 1994, MOL MICROBIOL, V11, P3, DOI 10.1111/j.1365-2958.1994.tb00283.x; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; Garamszegi N, 2001, MOL BIOL CELL, V12, P2881, DOI 10.1091/mbc.12.9.2881; GARDNER MB, 1991, TRENDS GENET, V7, P22, DOI 10.1016/0168-9525(91)90017-K; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; HATANAKA M, 1989, J CELL BIOCHEM, V40, P15, DOI 10.1002/jcb.240400103; James P, 1996, GENETICS, V144, P1425; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Klaus Daniel J., 1998, Human Mutation, V12, P137, DOI 10.1002/(SICI)1098-1004(1998)12:2<137::AID-HUMU15>3.0.CO;2-M; Lamouille S, 2002, BLOOD, V100, P4495, DOI 10.1182/blood.V100.13.4495; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; LIMJOCO TI, 1993, J VIROL, V67, P4163, DOI 10.1128/JVI.67.7.4163-4168.1993; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Mo JY, 2002, J BIOL CHEM, V277, P50788, DOI 10.1074/jbc.M210376200; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Okabe H, 2003, CANCER RES, V63, P3043; Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Poon DTK, 1998, J VIROL, V72, P1983, DOI 10.1128/JVI.72.3.1983-1993.1998; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; Shigemoto K, 2001, NUCLEIC ACIDS RES, V29, P4079, DOI 10.1093/nar/29.19.4079; Tang SJ, 1998, DEVELOPMENT, V125, P1877; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528; VOGT VM, 1975, J MOL BIOL, V96, P471, DOI 10.1016/0022-2836(75)90174-6; Volff JN, 2001, MOL BIOL EVOL, V18, P266, DOI 10.1093/oxfordjournals.molbev.a003801; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhang DY, 2004, HEPATOLOGY, V39, P954, DOI 10.1002/hep.20135	54	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8482	8493		10.1074/jbc.M409197200	http://dx.doi.org/10.1074/jbc.M409197200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611116	hybrid			2022-12-27	WOS:000227395700125
J	Michiue, H; Tomizawa, K; Wei, FY; Matsushita, M; Lu, YF; Ichikawa, T; Tamiya, T; Date, I; Matsui, H				Michiue, H; Tomizawa, K; Wei, FY; Matsushita, M; Lu, YF; Ichikawa, T; Tamiya, T; Date, I; Matsui, H			The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PERMEABLE PEPTIDES; ARGININE-RICH PEPTIDES; IN-VIVO; EXOGENOUS WT-P53; CELLULAR UPTAKE; CELLS; TAT; ENDOCYTOSIS; DELIVERY; THERAPY	Protein transduction therapy is a newly developing method that allows proteins, peptides, and biologically active compounds to penetrate across the plasma membrane by being fused with cell-penetrating peptides such as polyarginine. Polyarginine-fused p53 protein penetrates across the plasma membrane of cancer cells and inhibits the growth of the cells. However, the protein is often entrapped inside macropinosomes in the cytoplasm. Therefore, high dose concentrations of the protein are needed for it to function effectively. To overcome this problem, in the present study, polyarginine-fused p53 was linked with the NH2-terminal domain of influenza virus hemagglutinin-2 subunit (HA2), which is a pH-dependent fusogenic peptide that induces the lysis of membranes at low pH levels. The protein was capable of efficiently translocating into the nucleus of glioma cells and induced p21(WAF1) transcriptional activity more effectively than did polyarginine-fused p53 protein. Moreover, low concentrations of the protein significantly inhibited the growth of cancer cells. These results suggest that protein transduction therapy using polyarginine and HA2 may be useful as a method for cancer therapy.	Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama 7008558, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Neurol Surg, Okayama 7008558, Japan; Kagawa Univ, Fac Med, Dept Neurol Surg, Kagawa 7610793, Japan; Japan Sci & Technol Corp, Prot Therapy, New Techynol Venture Oriented Res & Dev, Okayama 7008558, Japan	Okayama University; Okayama University; Kagawa University; Japan Science & Technology Agency (JST)	Tomizawa, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Physiol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	tomikt@md.okayama-u.ac.jp	MICHIUE, Hiroyuki/B-2320-2011; Wei, Fan-Yan/AAD-8461-2021; Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627; Wei, Fan-Yan/0000-0002-4843-724X				D'Orazi G, 2000, J GENE MED, V2, P11; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Hsu CH, 2002, J BIOL CHEM, V277, P22725, DOI 10.1074/jbc.M200089200; Marutani M, 1999, CANCER RES, V59, P4765; Matsui H, 2003, CURR PROTEIN PEPT SC, V4, P151, DOI 10.2174/1389203033487270; Matsushita M, 2001, J NEUROSCI, V21, P6000, DOI 10.1523/JNEUROSCI.21-16-06000.2001; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Scardigli R, 1997, GENE THER, V4, P1371, DOI 10.1038/sj.gt.3300530; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Skehel JJ, 2001, BIOCHEM SOC T, V29, P623, DOI 10.1042/BST0290623; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Takenobu T, 2002, MOL CANCER THER, V1, P1043; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Zender L, 2002, CANCER GENE THER, V9, P489, DOI 10.1038/sj.cgt.7700465; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155	26	115	133	4	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8285	8289		10.1074/jbc.M412430200	http://dx.doi.org/10.1074/jbc.M412430200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611109	hybrid, Green Submitted			2022-12-27	WOS:000227395700102
J	Hodgson, MC; Astapova, I; Cheng, S; Lee, LJ; Verhoeven, MC; Choi, E; Balk, SP; Hollenberg, AN				Hodgson, MC; Astapova, I; Cheng, S; Lee, LJ; Verhoeven, MC; Choi, E; Balk, SP; Hollenberg, AN			The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PROSTATE-CANCER; LIGAND-BINDING DOMAIN; HORMONE-RECEPTORS; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; STRUCTURAL BASIS; COACTIVATOR; SMRT; GENE; COMPLEXES	The androgen receptor (AR) activates target gene expression in the presence of agonist ligands via the recruitment of transcriptional coactivators, but recent work shows that overexpression of the nuclear corepressors NCoR and SMRT attenuates this agonist-mediated AR activation. Here we demonstrate using NCoR siRNA and chromatin immunoprecipitation that endogenous NCoR is recruited to and represses the dihydrotestosterone (DHT)-liganded AR. Furthermore this study shows that NCoR and coactivators compete for AR in the presence of DHT. AR antagonists such as bicalutamide that are currently in use for prostate cancer treatment can also mediate NCoR recruitment, but mifepristone (RU486) at nanomolar concentrations is unique in its ability to markedly enhance the AR-NCoR interaction. The RU486-liganded AR interacted with a C-terminal fragment of NCoR, and this interaction was mediated by the two most C-terminal nuclear receptor interacting domains (RIDs) present in NCoR. Significantly, in addition to the AR ligand binding domain, the AR N terminus was also required for this interaction. Mutagenesis studies demonstrate that the N-terminal surface of the AR-mediating NCoR recruitment was distinct from tau5 and from the FXXLF motif that mediates agonist-induced N-C-terminal interaction. Taken together these data demonstrate that NCoR is a physiological regulator of the AR and reveal a new mechanism for AR antagonism that may be exploited for the development of more potent AR antagonists.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Balk, SP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.	sbalk@bidmc.harvard.edu; thollenb@bidmc.harvard.edu		Hodgson, Myles/0000-0002-0194-1254	NIDDK NIH HHS [DK61047, DK56123] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061047, R56DK056123, R01DK056123] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Berrevoets CA, 2004, BIOCHEM J, V379, P731, DOI 10.1042/BJ20031456; Berrevoets CA, 2002, MOL CELL ENDOCRINOL, V198, P97, DOI 10.1016/S0303-7207(02)00373-8; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cadepond F, 1997, ANNU REV MED, V48, P129; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cheng ST, 2002, MOL ENDOCRINOL, V16, P1492, DOI 10.1210/me.16.7.1492; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Dotzlaw H, 2003, MOL CELL ENDOCRINOL, V213, P79, DOI 10.1016/j.mce.2003.10.036; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao TS, 1996, J STEROID BIOCHEM, V59, P9, DOI 10.1016/S0960-0760(96)00097-0; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2000, GENE DEV, V14, P1048; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Joyce R, 1998, J UROLOGY, V159, P149, DOI 10.1016/S0022-5347(01)64039-4; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Liao GQ, 2003, J BIOL CHEM, V278, P5052, DOI 10.1074/jbc.M206374200; Liu Z, 2002, P NATL ACAD SCI USA, V99, P7940, DOI 10.1073/pnas.122225699; Makowski A, 2003, MOL ENDOCRINOL, V17, P273, DOI 10.1210/me.2002-0310; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Song LN, 2004, MOL ENDOCRINOL, V18, P70, DOI 10.1210/me.2003-0189; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang Q, 2004, MOL ENDOCRINOL, V18, P1376, DOI 10.1210/me.2003-0421; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Webb Paul, 2003, Nucl Recept, V1, P4, DOI 10.1186/1478-1336-1-4; WONG CI, 1993, J BIOL CHEM, V268, P19004; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a	55	117	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6511	6519		10.1074/jbc.M408972200	http://dx.doi.org/10.1074/jbc.M408972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15598662	hybrid			2022-12-27	WOS:000227332700034
J	Miyake, Y; Mizuno, T; Yanagi, K; Hanaoka, F				Miyake, Y; Mizuno, T; Yanagi, K; Hanaoka, F			Novel splicing variant of mouse Orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; EUKARYOTIC DNA-REPLICATION; ALPHA-PRIMASE COMPLEX; CELL-CYCLE; POLYMERASE ALPHA; LARGE SUBUNIT; IN-VIVO; PROTEIN; YEAST; ARCHITECTURE	DNA replication is controlled by the stepwise assembly of the pre-replicative complex and the replication apparatus. Loading of the origin recognition complex (ORC) onto the chromatin is a prerequisite for the assembly of the pre-replicative complex. To define the physiological functions of the mammalian ORC, we cloned ORC subunit cDNAs from mouse NIH3T3 cells and found novel variant forms of Orc1, Orc2, and Orc3 each derived from alternative RNA splicing. The variant form of Orc1, Orc1B, lacks 35 amino acid residues in exon 5; the variant of Orc2, Orc2B, lacks 48 amino acid residues in exon 2. In the Orc3 variant, Orc3B, only 1 amino acid residue is deleted in exon 15. Reverse transcription-PCR analysis showed that the full-length Orc1-3 subunits, Orc1A, Orc2A, and Orc3A, as well as Orc2B and Orc3B, were widely expressed in various mouse cell lines and mouse tissues. In contrast, Orc1B was only expressed in the thymus and at an early embryonic stage. Overexpression of these Orc subunits in cultured cells revealed that Orc1A, Orc2A, Orc3A, Orc2B, and Orc3B are localized in the nucleus, whereas Orc1B remains exclusively in the cytoplasm. Moreover, fusion of the 35 amino acids spliced fragment from mOrc1A with beta-galactosidase resulted in its translocation into the nucleus. When Orc1B is expressed transiently, its degradation occurs in a proteasome-independent manner, whereas Orc1A is rapidly degraded by the ubiquitin-proteasome pathway. Taken together, we conclude that mouse Orc1, Orc2, and Orc3 each exist in two alternative-splicing variants and that naturally occurring Orc1B lacks a functional domain that is essential for nuclear translocation and proteasome-dependent degradation.	Japan Sci & Technol Corp, CREST, Wako, Saitama 3510198, Japan; RIKEN, Cellular Physiol Lab, Discovery Res Inst, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); RIKEN; Osaka University	Hanaoka, F (corresponding author), Japan Sci & Technol Corp, CREST, Wako, Saitama 3510198, Japan.	fhanaoka@fbs.osaka-u.ac.jp	Miyake, Yasuyuki/AAS-1504-2021	Miyake, Yasuyuki/0000-0001-6250-0260				Aladjem MI, 2004, EMBO REP, V5, P686, DOI 10.1038/sj.embor.7400185; Araki M, 2003, EMBO J, V22, P6115, DOI 10.1093/emboj/cdg573; Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bose ME, 2004, MOL CELL BIOL, V24, P774, DOI 10.1128/MCB.24.2.774-786.2004; Burich R, 2003, CURR GENET, V44, P195, DOI 10.1007/s00294-003-0443-y; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; DePamphilis ML, 2003, GENE, V310, P1, DOI 10.1016/S0378-1119(03)00546-8; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Hart EA, 2002, CURR GENET, V41, P342, DOI 10.1007/s00294-002-0316-9; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Jiang JJ, 2003, J BIOCHEM, V133, P423, DOI 10.1093/jb/mvg055; Kneissl M, 2003, J MOL BIOL, V327, P111, DOI 10.1016/S0022-2836(03)00079-2; Laman H, 2001, EXP CELL RES, V271, P230, DOI 10.1006/excr.2001.5360; Li CJ, 2004, MOL CELL BIOL, V24, P5875, DOI 10.1128/MCB.24.13.5875-5886.2004; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Mizuno T, 1999, MOL CELL BIOL, V19, P7886; Mizuno T, 1998, MOL CELL BIOL, V18, P3552, DOI 10.1128/MCB.18.6.3552; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; Ohta S, 2003, J BIOL CHEM, V278, P41535, DOI 10.1074/jbc.M307535200; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Wen F, 2004, TRENDS GENET, V20, P232, DOI 10.1016/j.tig.2004.03.005; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200	41	8	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12643	12652		10.1074/jbc.M413280200	http://dx.doi.org/10.1074/jbc.M413280200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15634681	hybrid			2022-12-27	WOS:000227922000070
J	Roscoe, W; Veitch, GIL; Gong, XQ; Pellegrino, E; Bai, D; McLachlan, E; Shao, Q; Kidder, GM; Laird, DW				Roscoe, W; Veitch, GIL; Gong, XQ; Pellegrino, E; Bai, D; McLachlan, E; Shao, Q; Kidder, GM; Laird, DW			Oculodentodigital dysplasia-causing connexin43 mutants are non-functional and exhibit dominant effects on wild-type connexin43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; MARIE-TOOTH-DISEASE; LIVE MAMMALIAN-CELLS; X-LINKED FORM; MEMBRANE CHANNELS; INTERCELLULAR COMMUNICATION; HEARING-LOSS; TUMOR CELLS; RAT-HEART; MUTATIONS	Oculodentodigital dysplasia, a rare condition displaying congenital craniofacial deformities and limb abnormalities, has been associated with over 20 known human connexin43 (Cx43) mutations. The localization of two of these mutants, G21R and G138R, was examined in Cx43-positive normal rat kidney cells (NRK) and Cx43-negative gap junctional intercellular communication-deficient HeLa cells. Green fluorescent protein-tagged and untagged Cx43 G21R and G138R mutants were transported to the plasma membrane and formed punctate structures reminiscent of gap junction plaques in both NRK and HeLa cells. Further localization studies revealed no significant trafficking defects as subpopulations of Cx43 mutants were found in both the Golgi apparatus and lysosomes, not unlike wild-type Cx43. Dual patch clamp functional analysis of the mutants expressed in gap junctional intercellular communication-deficient N2A cells revealed that neither G21R nor G138R formed functional gap junction channels, although they successfully reached cell-cell interfaces between cell pairs. Importantly, when either mutant was expressed in NRK cells, dye coupling experiments revealed that both mutants inhibited endogenous Cx43 function. These studies suggest that, although patients suffering from oculodentodigital dysplasia possess one wild-type Cx43 allele, it is likely that Cx43-mediated gap junctional intercellular communication is reduced below 50% because of a dominant-negative effect of mutant Cx43 on wild-type Cx43.	Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Dent Sci Bldg,Rm 00077, London, ON N6A 5C1, Canada.	dale.laird@fmd.uwo.ca	Bai, Donglin/ABB-9924-2021; Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015; Bai, Donglin/A-5799-2008	Bai, Donglin/0000-0003-1112-6947; Laird, Dale W/0000-0002-4568-3285; Bai, Donglin/0000-0003-1112-6947				Abrams CK, 2001, BRAIN RES, V900, P9, DOI 10.1016/S0006-8993(00)03327-8; Alexander DB, 2003, CURR MED CHEM, V10, P2045, DOI 10.2174/0929867033456927; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Boyadjiev SA, 1999, GENOMICS, V58, P34, DOI 10.1006/geno.1999.5814; Bukauskas FF, 2000, P NATL ACAD SCI USA, V97, P2556, DOI 10.1073/pnas.050588497; Castro CHM, 2003, CELL COMMUN ADHES, V10, P445, DOI 10.1080/15419060390267700; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Falk MM, 2000, EUR J CELL BIOL, V79, P564, DOI 10.1078/0171-9335-00080; Falk MM, 1998, J BIOL CHEM, V273, P7856, DOI 10.1074/jbc.273.14.7856; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; Feldman PA, 1997, J MEMBRANE BIOL, V155, P275, DOI 10.1007/s002329900180; Gladwin A, 1997, HUM MOL GENET, V6, P123, DOI 10.1093/hmg/6.1.123; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Jorgensen NR, 2003, J BIOL CHEM, V278, P4082, DOI 10.1074/jbc.M205880200; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laird DW, 2001, METH MOL B, V154, P135; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LAIRD DW, 1990, J CELL SCI, V97, P109; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931; Li WEI, 2002, DEVELOPMENT, V129, P2031; Loddenkemper T, 2002, J NEUROL, V249, P584, DOI 10.1007/s004150200068; Martin PEM, 2000, J NEUROCHEM, V74, P711, DOI 10.1046/j.1471-4159.2000.740711.x; Marziano NK, 2003, HUM MOL GENET, V12, P805, DOI 10.1093/hmg/ddg076; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; NAUS CCG, 1993, EXP CELL RES, V206, P72, DOI 10.1006/excr.1993.1122; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; Pal JD, 2000, AM J PHYSIOL-CELL PH, V279, pC596, DOI 10.1152/ajpcell.2000.279.3.C596; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Qin H, 2003, J BIOL CHEM, V278, P30005, DOI 10.1074/jbc.M300614200; Rabionet R, 2000, HUM MUTAT, V16, P190, DOI 10.1002/1098-1004(200009)16:3<190::AID-HUMU2>3.3.CO;2-9; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Ressot C, 2000, BRAIN RES REV, V32, P192, DOI 10.1016/S0165-0173(99)00081-8; Richardson RR, 2004, J MED GENET, V41, P60, DOI 10.1136/jmg.2003.012005; Rouan F, 2001, J CELL SCI, V114, P2105; Rouan F, 2003, EXP DERMATOL, V12, P191, DOI 10.1034/j.1600-0625.2003.120210.x; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Seki A, 2004, CIRC RES, V95, P22, DOI 10.1161/01.RES.0000140737.62245.c5; SEKI AC, 2004, HEART RHYTHM, V1, P1; Sohl G, 2003, CELL COMMUN ADHES, V10, P173, DOI 10.1080/15419060390262877; Srinivas M, 1999, J PHYSIOL-LONDON, V517, P673, DOI 10.1111/j.1469-7793.1999.0673s.x; Steel KP, 1998, NAT GENET, V20, P319, DOI 10.1038/3781; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; Thonnissen E, 2002, HUM GENET, V111, P190, DOI 10.1007/s00439-002-0750-2; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Waldo KL, 1999, DEV BIOL, V208, P307, DOI 10.1006/dbio.1999.9219; Wang HL, 2003, J NEUROCHEM, V84, P735, DOI 10.1046/j.1471-4159.2003.01555.x; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076	54	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11458	11466		10.1074/jbc.M409564200	http://dx.doi.org/10.1074/jbc.M409564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644317	hybrid			2022-12-27	WOS:000227761800069
J	Papo, N; Shai, Y				Papo, N; Shai, Y			A molecular mechanism for lipopolysaccharide protection of gram-negative bacteria from antimicrobial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PHOSPHOLIPID-MEMBRANES; INFRARED-SPECTROSCOPY; MODEL MEMBRANES; INNATE IMMUNITY; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; BINDING-KINETICS; DODECYL-SULFATE; OUTER-MEMBRANE	Cationic antimicrobial peptides serve as the first chemical barrier between all organisms and microbes. One of their main targets is the cytoplasmic membrane of the microorganisms. However, it is not yet clear why some peptides are active against one particular bacterial strain but not against others. Recent studies have suggested that the lipopolysaccharide (LPS) outer membrane is the first protective layer that actually controls peptide binding and insertion into Gram-negative bacteria. In order to shed light on these interactions, we synthesized and investigated a 12-mer amphipathic alpha-helical antimicrobial peptide (K5L7) and its diastereomer (4D-K5L7) (containing four D-amino acids). Interestingly, although both peptides strongly bind LPS bilayers and depolarize bacterial cytoplasmic membranes, only the diastereomer kills Gram-negative bacteria. Attenuated total reflectance Fourier transform infrared, CD, and surface plasmon resonance spectroscopies revealed that only the diastereomer penetrates the LPS layer. In contrast, K5L7 binds cooperatively to the polysaccharide chain and the outer phosphate groups. As a result, the self-associated K5L7 is unable to traverse through the tightly packed LPS molecules, revealed by epifluorescence studies with LPS giant unilamellar vesicles. The difference in the peptides' modes of binding is further demonstrated by the ability of the diastereomer to induce LPS miscellization, as shown by transmission electron microscopy. In addition to increasing our understanding of the molecular basis of the protection of bacteria by LPS, this study presents a potential strategy to overcome resistance by LPS, and it should help in the design of antimicrobial peptides for future therapeutic purposes.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Papo, Niv/R-3946-2017					Albrecht MT, 2002, RESPIR RES, V3, DOI 10.1186/rr167; Andra J, 2004, ANTIMICROB AGENTS CH, V48, P1593, DOI 10.1128/AAC.48.5.1593-1599.2004; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BLONDELLE SE, 1995, BIOPHYS J, V68, P351, DOI 10.1016/S0006-3495(95)80194-3; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Brandenburg K, 1997, BBA-BIOMEMBRANES, V1329, P183, DOI 10.1016/S0005-2736(97)00109-0; Chaby R, 1999, DRUG DISCOV TODAY, V4, P209, DOI 10.1016/S1359-6446(99)01336-7; Chapple DS, 2004, ANTIMICROB AGENTS CH, V48, P2190, DOI 10.1128/AAC.48.6.2190-2198.2004; DASILVA A, 2003, BIOCHIM BIOPHYS ACTA, V7, P1; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Ding L, 2003, BIOCHEMISTRY-US, V42, P12251, DOI 10.1021/bi035130+; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P923, DOI 10.1002/bip.360230509; Epand R, 2003, BIOPOLYMERS, V71, P2, DOI 10.1002/bip.10372; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; Farnaud S, 2004, FEMS MICROBIOL LETT, V233, P193, DOI 10.1016/j.femsle.2004.01.039; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Gutsmann T, 2000, J MEMBRANE BIOL, V176, P223, DOI 10.1007/s002320001092; Hancock REW, 2002, FEMS MICROBIOL LETT, V206, P143, DOI 10.1016/S0378-1097(01)00480-3; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Harrick N.J., 1967, INTERNAL REFLECTION; HIRAKURA Y, 2002, BIOCHIM BIOPHYS ACTA, V3, P1; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Mangoni ML, 2000, PEPTIDES, V21, P1673, DOI 10.1016/S0196-9781(00)00316-8; Mangoni ML, 2000, EUR J BIOCHEM, V267, P1447, DOI 10.1046/j.1432-1327.2000.01143.x; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P12553, DOI 10.1021/bi00039a009; Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Meng FG, 2001, BIOCHIMIE, V83, P953, DOI 10.1016/S0300-9084(01)01340-2; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Moscho A, 1996, P NATL ACAD SCI USA, V93, P11443, DOI 10.1073/pnas.93.21.11443; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Oren Z, 2000, BIOCHEMISTRY-US, V39, P6103, DOI 10.1021/bi992408i; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Papo N, 2003, PEPTIDES, V24, P1693, DOI 10.1016/j.peptides.2003.09.013; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; Papo N, 2002, J BIOL CHEM, V277, P33913, DOI 10.1074/jbc.M204928200; PLESIAT P, 1992, MOL MICROBIOL, V6, P1323, DOI 10.1111/j.1365-2958.1992.tb00853.x; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; Snyder S, 1999, BIOCHEMISTRY-US, V38, P10758, DOI 10.1021/bi990867d; Stark M, 2002, ANTIMICROB AGENTS CH, V46, P3585, DOI 10.1128/AAC.46.11.3585-3590.2002; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Tack BF, 2002, EUR J BIOCHEM, V269, P1181, DOI 10.1046/j.0014-2956.2002.02751.x; Tatulian SA, 1997, J MOL BIOL, V268, P809, DOI 10.1006/jmbi.1997.1014; Thomas CJ, 1999, J BIOL CHEM, V274, P29624, DOI 10.1074/jbc.274.42.29624; Tossi A, 2000, BIOPOLYMERS, V55, P4; Tsubery H, 2000, BIOCHEMISTRY-US, V39, P11837, DOI 10.1021/bi000386q; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; VONTSCHARNER V, 1981, BIOPHYS J, V36, P409, DOI 10.1016/S0006-3495(81)84740-6; WEIS RM, 1991, CHEM PHYS LIPIDS, V57, P227, DOI 10.1016/0009-3084(91)90078-P; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P15297, DOI 10.1021/bi001774v; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29; YANAGIDA N, 1986, J BACTERIOL, V166, P937, DOI 10.1128/jb.166.3.937-944.1986; Zanetti M, 2002, CURR PHARM DESIGN, V8, P779, DOI 10.2174/1381612023395457; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LJ, 2000, BIOCHEMISTRY-US, V39, P14504, DOI 10.1021/bi0011173; Zhang LJ, 1999, BIOCHEMISTRY-US, V38, P8102, DOI 10.1021/bi9904104	85	203	210	4	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10378	10387		10.1074/jbc.M412865200	http://dx.doi.org/10.1074/jbc.M412865200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632151	hybrid			2022-12-27	WOS:000227559600078
J	Thimm, J; Mechler, A; Lin, H; Rhee, S; Lal, R				Thimm, J; Mechler, A; Lin, H; Rhee, S; Lal, R			Calcium-dependent open/closed conformations and interfacial energy maps of reconstituted hemichannels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; ATOMIC-FORCE MICROSCOPY; PHASE-SHIFT; SURFACE; DISSIPATION; CONNEXIN43; PERMEABILITY; CONDUCTANCE; MEMBRANE; PROTEIN	Using an atomic force microscope, we have studied three-dimensional molecular topography and calcium-sensitive conformational changes of individual hemichannels. Full-length (non-truncated) Cx43 hemichannels (connexons), when reconstituted in lipid bilayer, appear as randomly distributed individual particles and clusters. They show a lack of preferential orientation of insertion into lipid membrane; in a single bilayer, connexons with protrusion of either the extracellular face or the large non-truncated cytoplasmic face are observed. Extracellular domains of these undocked hemichannels are structurally different from hemichannels in the docked gap junctional plaques examined after their exposure by force dissection or chemical dissection. Calcium induced a reversible change in the extracellular pore diameter. Hemichannels imaged in a physiological buffer with 1.8 mM Ca+2 had the pore diameter of similar to 1.8 nm, consistent with the closed channel conformation. Reducing Ca+2 concentration to similar to 1.4, 1, and 0 mM, which changes hemichannels from the closed to open conformation, increased the pore diameter to similar to 2.5 nm for similar to 27, 74, and 100% of hemichannels, respectively. Thus, open/close probability of the hemichannel appears to be [Ca2+]-dependent. Computational analysis of the atomic force microscopy phase mode imaging reveals a significantly higher interfacial energy for open hemichannels that results from the interactions between the atomic force microscope probe and the hydrophobic domains. Thus, hydrophobic extracellular domains of connexins regulate calcium-dependent conformational changes.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Yeungnam Univ, Dept Biochem, Kyongsan 712749, South Korea	University of California System; University of California Santa Barbara; Yeungnam University	Lal, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.	lal@lifesci.ucsb.edu	Mechler, Adam/C-5777-2009; Thimm, Julian/D-1214-2009	Mechler, Adam/0000-0002-6428-6760; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056290] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM056290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams CK, 2002, P NATL ACAD SCI USA, V99, P3980, DOI 10.1073/pnas.261713499; ADAMSON AW, 1997, PHYSL CHEM SURFACES; Bar G, 2000, SURF SCI, V444, pL11, DOI 10.1016/S0039-6028(99)00975-9; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Burnham NA, 1997, NANOTECHNOLOGY, V8, P67, DOI 10.1088/0957-4484/8/2/004; Cao FL, 1998, J CELL SCI, V111, P31; Cleveland JP, 1998, APPL PHYS LETT, V72, P2613, DOI 10.1063/1.121434; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Cotrina ML, 1998, J NEUROSCI, V18, P2520; Crescenzi O, 2002, EUR J BIOCHEM, V269, P5642, DOI 10.1046/j.1432-1033.2002.03271.x; Czajkowsky DM, 1998, ULTRAMICROSCOPY, V74, P1, DOI 10.1016/S0304-3991(98)00024-2; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; Ebihara L, 1996, BIOPHYS J, V71, P742, DOI 10.1016/S0006-3495(96)79273-1; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FIREK L, 1995, J MOL CELL CARDIOL, V27, P1633, DOI 10.1016/S0022-2828(95)90623-1; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; GANTHIER M, 2001, PHYS REV LETT, V85, P5348; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; Hulser DF, 1997, EXP CELL RES, V233, P240, DOI 10.1006/excr.1997.3568; Israelachvili JN, 1985, INTERMOLECULAR SURFA; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Kokavecz J, 2003, APPL SURF SCI, V210, P123, DOI 10.1016/S0169-4332(02)01491-5; LAIRD DW, 1990, J CELL SCI, V97, P109; LAL R, 1994, AM J PHYSIOL, V266, pC1, DOI 10.1152/ajpcell.1994.266.1.C1; LAL R, 1995, AM J PHYSIOL-CELL PH, V268, pC968, DOI 10.1152/ajpcell.1995.268.4.C968; Lal R, 2001, MICROSC RES TECHNIQ, V52, P273, DOI 10.1002/1097-0029(20010201)52:3<273::AID-JEMT1013>3.0.CO;2-M; LAL R, 1992, CIRC RES, V71, P737, DOI 10.1161/01.RES.71.3.737; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; MANJUNATH CK, 1984, AM J PHYSIOL, V246, pH865, DOI 10.1152/ajpheart.1984.246.6.H865; MANJUNATH CK, 1986, J MEMBRANE BIOL, V90, P43, DOI 10.1007/BF01869685; Mechler A, 2003, APPL PHYS LETT, V82, P3740, DOI 10.1063/1.1577392; Mechler A, 2001, MAT SCI ENG C-BIO S, V15, P29, DOI 10.1016/S0928-4931(01)00211-9; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Schneider SW, 1998, PFLUG ARCH EUR J PHY, V435, P362, DOI 10.1007/s004240050524; Sosinsky G, 2000, CURR TOP MEMBR, V49, P1; Tamayo J, 1998, APPL PHYS LETT, V73, P2926, DOI 10.1063/1.122632; Thimm J, 2002, BIOPHYS J, V82, p513A; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; UNWIN PNT, 1983, J CELL BIOL, V97, P1459, DOI 10.1083/jcb.97.5.1459; Valiunas V, 2002, CIRC RES, V91, P104, DOI 10.1161/01.RES.0000025638.24255.AA; Vila AO, 2001, COLLOID SURFACE A, V189, P1, DOI 10.1016/S0927-7757(01)00604-5; WEISENHORN AL, 1992, PHYS REV B, V45, P11226, DOI 10.1103/PhysRevB.45.11226; WRIGLEY NG, 1984, BIOPHYS J, V45, P201, DOI 10.1016/S0006-3495(84)84148-X; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	57	138	142	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10646	10654		10.1074/jbc.M412749200	http://dx.doi.org/10.1074/jbc.M412749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15615707	hybrid			2022-12-27	WOS:000227559600110
J	Garzon, J; Rodriguez-Munoz, M; Lopez-Fando, A; Sanchez-Blazquez, P				Garzon, J; Rodriguez-Munoz, M; Lopez-Fando, A; Sanchez-Blazquez, P			Activation of mu-opioid receptors transfers control of G alpha subunits to the regulator of G-protein signaling RGS9-2 - Role in receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; MORPHINE-TOLERANCE; ANTISENSE OLIGODEOXYNUCLEOTIDES; SUPRASPINAL ANALGESIA; HEK-293 CELLS; MOUSE-BRAIN; AGONIST; KINASE; PHOSPHORYLATION; MICE	In mouse periaqueductal gray matter (PAG) membranes, the mu-opioid receptor (MOR) coprecipitated the alpha-subunits of the G(i/o/z/q/11) proteins, the Gbeta(1/2) subunits, and the regulator of G-protein signaling RGS9-2 and its partner protein Gbeta(5). RGS7 and RGS11 present in this neural structure showed no association with MOR. In vivo intracerebroventricular injection of morphine did not alter MOR immunoreactivity, but 30 min and 3 h after administration, the coprecipitation of Galpha subunits with MORs was reduced by up to 50%. Furthermore, the association between Galpha subunits and RGS9-2 proteins was increased. Twenty-four hours after receiving intracerebroventricular morphine, the Galpha subunits left the RGS9-2 proteins and re-associated with the MORs. However, doses of the opioid able to induce tolerance promoted the stable transfer of Galpha subunits to the RGS9-2 control. This was accompanied by Ser phosphorylation of RGS9-2 proteins, which increased their coprecipitation with 14-3-3 proteins. In the PAG membranes of morphine-desensitized mice, the capacity of the opioid to stimulate G-protein-related guanosine 5'-O-(3-[S-35] thiotriphosphate) binding as well as low K-m GTPase activity was attenuated. The in vivo knockdown of RGS9-2 expression prevented morphine from altering the association between MORs and G-proteins, and tolerance did not develop. In PAG membranes from RGS9- 2 knockdown mice, morphine showed full capacity to activate G-proteins. Thus, the tolerance that develops following an adequate dose of morphine is caused by the stabilization and retention of MOR-activated Galpha subunits by RGS9- 2 proteins. This multistep process is initiated by the morphine-induced transfer of MOR-associated Galpha subunits to the RGS9- 2 proteins, followed by Ser phosphorylation of the latter and their binding to 14-3-3 proteins. This regulatory mechanism probably precedes the loss of MORs from the cell membrane, which has been observed with other opioid agonists.	CSIC, Inst Cajal, Dept Neuropharmacol, E-28002 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Garzon, J (corresponding author), CSIC, Inst Cajal, Dept Neuropharmacol, Avd Dr Arce 37, E-28002 Madrid, Spain.	jgarzon@cajal.csic.es		Rodriguez-Munoz, Maria/0000-0001-6611-8050; Garzon, Javier/0000-0002-0053-258X; Sanchez Blazquez, Pilar/0000-0002-7211-4504				Anger T, 2004, J BIOL CHEM, V279, P3906, DOI 10.1074/jbc.M309496200; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Balasubramanian N, 2001, BIOCHEMISTRY-US, V40, P12619, DOI 10.1021/bi015624b; Benzing T, 2000, J BIOL CHEM, V275, P28167; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bernstein MA, 1997, DRUG ALCOHOL DEPEN, V44, P41, DOI 10.1016/S0376-8716(96)01320-8; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Buzas B, 1996, NEUROREPORT, V7, P1505, DOI 10.1097/00001756-199606170-00013; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chalecka-Franaszek E, 2000, J NEUROCHEM, V74, P1068, DOI 10.1046/j.1471-4159.2000.0741068.x; Chavkin C, 2001, MOL PHARMACOL, V60, P20, DOI 10.1124/mol.60.1.20; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; Fischer T, 2003, P NATL ACAD SCI USA, V100, P8270, DOI 10.1073/pnas.1432965100; Garzon J, 1997, EUR J NEUROSCI, V9, P1194, DOI 10.1111/j.1460-9568.1997.tb01474.x; GARZON J, 1995, MOL PHARMACOL, V47, P738; Garzon J, 2003, NEUROPSYCHOPHARMACOL, V28, P1983, DOI 10.1038/sj.npp.1300263; Garzon J, 2002, NEUROPHARMACOLOGY, V42, P813, DOI 10.1016/S0028-3908(02)00027-8; Garzon J, 2001, NEUROPHARMACOLOGY, V40, P560, DOI 10.1016/S0028-3908(00)00198-2; Garzon J, 2001, EUR J NEUROSCI, V13, P801, DOI 10.1046/j.0953-816x.2000.01444.x; Garzon J, 2000, METHOD ENZYMOL, V314, P3; GEORGOUSSI Z, 1995, BIOCHEM J, V306, P71, DOI 10.1042/bj3060071; Granneman JG, 1998, MOL PHARMACOL, V54, P687; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Hendry IA, 2000, BRAIN RES, V870, P10, DOI 10.1016/S0006-8993(00)02387-8; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; HUIDOBRO F, 1976, J PHARMACOL EXP THER, V198, P318; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LIUCHEN LY, 1993, MOL PHARMACOL, V44, P749; Lopez-Fando A, 2005, NEUROPSYCHOPHARMACOL, V30, P99, DOI 10.1038/sj.npp.1300515; Mao H, 2004, J BIOL CHEM, V279, P26314, DOI 10.1074/jbc.M401800200; Martemyanov KA, 2003, NEURON, V38, P857, DOI 10.1016/S0896-6273(03)00320-9; McLaughlin JP, 2004, J BIOL CHEM, V279, P1810, DOI 10.1074/jbc.M305796200; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Sanchez-Blazquez P, 1998, J PHARMACOL EXP THER, V285, P820; Sanchez-Blazquez P, 2003, NEUROPHARMACOLOGY, V45, P82, DOI 10.1016/S0028-3908(03)00149-7; Sanchez-Blazquez P, 2001, BRAIN RES BULL, V54, P229, DOI 10.1016/S0361-9230(00)00448-2; SanchezBlazquez P, 1995, J PHARMACOL EXP THER, V275, P1590; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Sim-Selley LJ, 2000, J NEUROSCI, V20, P4555, DOI 10.1523/JNEUROSCI.20-12-04555.2000; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Smith FL, 2002, BRAIN RES, V958, P28, DOI 10.1016/S0006-8993(02)03394-2; Sowa ME, 2000, P NATL ACAD SCI USA, V97, P1483, DOI 10.1073/pnas.030409597; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trapaidze N, 2000, MOL BRAIN RES, V76, P220, DOI 10.1016/S0169-328X(00)00002-4; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WERLING LL, 1989, P NATL ACAD SCI USA, V86, P6393, DOI 10.1073/pnas.86.16.6393; WISE A, 1995, J BIOL CHEM, V270, P17196, DOI 10.1074/jbc.270.29.17196; YAKSH TL, 1976, BRAIN RES, V114, P83, DOI 10.1016/0006-8993(76)91009-X; Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang D., 2000, J DESERT RES, V20, P59; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	64	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8951	8960		10.1074/jbc.M407005200	http://dx.doi.org/10.1074/jbc.M407005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632124	hybrid			2022-12-27	WOS:000227453100042
J	Santa-Marta, M; da Silva, FA; Fonseca, AM; Goncalves, J				Santa-Marta, M; da Silva, FA; Fonseca, AM; Goncalves, J			HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRION INFECTIVITY FACTOR; ANTIVIRAL ACTIVITY; ANTIBODY DIVERSIFICATION; ESCHERICHIA-COLI; DNA DEAMINATION; HUMAN APOBEC3G; SOR GENE; TYPE-1; AID	The human apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G), also known as CEM-15, is a host-cell factor involved in innate resistance to retroviral infection. HIV-1 viral infectivity factor (Vif) protein was shown to protect the virus from APOBEC3G-mediated viral cDNA hypermutation. The mechanism proposed for protection of the virus by HIV-1 Vif is mediated by APOBEC3G degradation through ubiquitination and the proteasomal pathway. Here we show that in Escherichia coli the APOBEC3G-induced cytidine deamination is inhibited by expression of Vif without depletion of deaminase. Moreover, inhibition of deaminase-mediated bacterial hypermutation is dependent on a single amino acid substitution D128K that renders APOBEC3G resistant to Vif inhibition. This single amino acid was elegantly proven by other authors to determine species-specific sensitivity. Our results show that in bacteria this single amino acid substitution controls Vif-dependent blocking of APOBEC3G that is dependent on a strong protein interaction. The C-terminal region of Vif is responsible for this strong protein-protein interaction. In conclusion, our experiments suggest a complement to the model of Vif-induced degradation of APOBEC3G by bringing to relevance that deaminase inhibition can also result from a direct interaction with Vif protein.	Univ Lisbon, Fac Farm, Ctr Patogenese Mol, Unidade Retrovirus & Infeccoes Assoc, P-1649019 Lisbon, Portugal	Universidade de Lisboa	Goncalves, J (corresponding author), Univ Lisbon, Fac Farm, Ctr Patogenese Mol, Unidade Retrovirus & Infeccoes Assoc, Av Forcas Armadas, P-1649019 Lisbon, Portugal.	joao.goncalves@ff.ul.pt	Goncalves, Joao/B-2013-2008; Silva, Frederico Aires/ABD-9602-2021; iMed.ULisboa, M2B/B-5277-2014; Santa-Marta, Mariana/L-2407-2013	Goncalves, Joao/0000-0002-1245-3715; Silva, Frederico Aires/0000-0002-3821-419X; iMed.ULisboa, M2B/0000-0002-1245-3715; Santa-Marta, Mariana/0000-0002-0243-4158				Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; Beletskii A, 1996, P NATL ACAD SCI USA, V93, P13919, DOI 10.1073/pnas.93.24.13919; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; BORMAN AM, 1995, J VIROL, V69, P2058, DOI 10.1128/JVI.69.4.2058-2067.1995; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; Cascalho M, 2004, J IMMUNOL, V172, P6513, DOI 10.4049/jimmunol.172.11.6513; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; da Silva FA, 2004, J MOL BIOL, V340, P525, DOI 10.1016/j.jmb.2004.04.062; FAN LJ, 1992, VIROLOGY, V190, P19, DOI 10.1016/0042-6822(92)91188-Z; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; Goff SP, 2003, CELL, V114, P281, DOI 10.1016/S0092-8674(03)00602-0; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Goncalves Joao, 2004, Retrovirology, V1, P28, DOI 10.1186/1742-4690-1-28; Harris RS, 2003, NAT IMMUNOL, V4, P641, DOI 10.1038/ni0703-641; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kao Sandra, 2004, Retrovirology, V1, P27, DOI 10.1186/1742-4690-1-27; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Li JL, 2004, J CELL BIOCHEM, V92, P560, DOI 10.1002/jcb.20082; Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004; MA XY, 1994, J VIROL, V68, P1714, DOI 10.1128/JVI.68.3.1714-1720.1994; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Mehta A, 2002, RNA, V8, P69, DOI 10.1017/S1355838202015649; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Phillips GJ, 2000, BIOTECHNIQUES, V28, P400, DOI 10.2144/00283bm02; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wichroski MJ, 2005, J BIOL CHEM, V280, P8387, DOI 10.1074/jbc.M408048200; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	50	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8765	8775		10.1074/jbc.M409309200	http://dx.doi.org/10.1074/jbc.M409309200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611076	hybrid			2022-12-27	WOS:000227453100019
J	Edelman, AM; Kim, WY; Higgins, D; Goldstein, EG; Oberdoerster, M; Sigurdson, W				Edelman, AM; Kim, WY; Higgins, D; Goldstein, EG; Oberdoerster, M; Sigurdson, W			Doublecortin kinase-2, a novel doublecortin-related protein kinase associated with terminal segments of axons and dendrites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCORTICAL LAMINAR HETEROTOPIA; MICROTUBULE-ASSOCIATED PROTEIN; NEURONAL MIGRATION; DOMAIN-STRUCTURE; GENE; BRAIN; PHOSPHORYLATION; EXPRESSION; MUTATIONS; KIAA0369	The microtubule (MT)-associated DCX protein plays an essential role in the development of the mammalian cerebral cortex. We report on the identification of a protein kinase, doublecortin kinase-2 (DCK2), with a domain ( DC) highly homologous to DCX. DCK2 has MT binding activity associated with its DC domain and protein kinase activity mediated by a kinase domain, organized in a structure in which the two domains are functionally independent. Overexpression of DCK2 stabilizes the MT cytoskeleton against cold-induced depolymerization. Autophosphorylation of DCK2 strongly reduces its affinity for MTs. DCK2 and DCX mRNAs are nervous system-specific and are expressed during the period of cerebrocortical lamination. DCX is down-regulated postnatally, whereas DCK2 persists in abundance into adulthood, suggesting that the DC sequence has previously unrecognized functions in the mature nervous system. In sympathetic neurons, DCK2 is localized to the cell body and to the terminal segments of axons and dendrites. DCK2 may represent a phosphorylation-dependent switch for the reversible control of MT dynamics in the vicinity of neuronal growth cones.	SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Edelman, AM (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA.	aedelman@acsu.buffalo.edu						Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; Burgess HA, 2002, J BIOL CHEM, V277, P17696, DOI 10.1074/jbc.M111981200; Burgess HA, 2001, J BIOL CHEM, V276, P36397, DOI 10.1074/jbc.M105153200; Burgess HA, 1999, J NEUROSCI RES, V58, P567, DOI 10.1002/(SICI)1097-4547(19991115)58:4<567::AID-JNR9>3.3.CO;2-K; Burgess HA, 2000, MOL CELL NEUROSCI, V16, P529, DOI 10.1006/mcne.2000.0891; Corbo JC, 2002, J NEUROSCI, V22, P7548; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; des Portes V, 1998, HUM MOL GENET, V7, P1063, DOI 10.1093/hmg/7.7.1063; des Portes V, 1998, CELL, V92, P51; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Engels BM, 2004, MOL BRAIN RES, V120, P103, DOI 10.1016/j.molbrainres.2003.10.006; Feng YY, 2001, NAT REV NEUROSCI, V2, P408, DOI 10.1038/35077559; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gleeson JG, 1999, ANN NEUROL, V45, P146, DOI 10.1002/1531-8249(199902)45:2<146::AID-ANA3>3.0.CO;2-N; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Gonczy P, 2001, DEV CELL, V1, P363, DOI 10.1016/S1534-5807(01)00046-6; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Halpain Shelley, 2002, Trends in Cell Biology, V12, P455, DOI 10.1016/S0962-8924(02)02359-0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Higgins D., 1991, CULTURING NERVE CELL, P177; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Kim MH, 2003, NAT STRUCT BIOL, V10, P324, DOI 10.1038/nsb918; KINGSTON RE, 1996, CURR PROTOCOLS MOL B, V36; Kruidering M, 2001, J BIOL CHEM, V276, P38417, DOI 10.1074/jbc.M103471200; LEIN P, 1995, NEURON, V15, P597, DOI 10.1016/0896-6273(95)90148-5; Lin PT, 2000, J NEUROSCI, V20, P9152; Mandell JW, 1996, PERSPECT DEV NEUROBI, V4, P125; Matsumoto N, 1999, GENOMICS, V56, P179, DOI 10.1006/geno.1998.5673; MIZGUCHI M, 1999, AM J PATHOL, V155, P1713; Omori Y, 1998, J HUM GENET, V43, P169, DOI 10.1007/s100380050063; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; Rieder C.L., 1990, International Review of Cytology, V122, P153, DOI 10.1016/S0074-7696(08)61208-5; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sapir T, 2000, HUM MOL GENET, V9, P703, DOI 10.1093/hmg/9.5.703; Schaar BT, 2004, NEURON, V41, P203, DOI 10.1016/S0896-6273(03)00843-2; Shang LM, 2003, BIOCHEMISTRY-US, V42, P2185, DOI 10.1021/bi026913i; Sheetz MP, 1998, PROG NEUROBIOL, V55, P577, DOI 10.1016/S0301-0082(98)00021-5; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; Sossey-Alaoui K, 1999, GENOMICS, V56, P121, DOI 10.1006/geno.1998.5718; Sossey-Alaoui K, 1998, HUM MOL GENET, V7, P1327, DOI 10.1093/hmg/7.8.1327; Tanaka T, 2004, NEURON, V41, P215, DOI 10.1016/S0896-6273(03)00852-3; Taylor KR, 2000, J BIOL CHEM, V275, P34442, DOI 10.1074/jbc.M007078200; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Vaillant AR, 2002, NEURON, V34, P985, DOI 10.1016/S0896-6273(02)00717-1; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104; Vreugdenhil E, 2001, MOL BRAIN RES, V94, P67, DOI 10.1016/S0169-328X(01)00213-3; Washbourne P, 2002, NAT NEUROSCI, V5, P751, DOI 10.1038/nn883; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417	51	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8531	8543		10.1074/jbc.M411027200	http://dx.doi.org/10.1074/jbc.M411027200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611072	hybrid			2022-12-27	WOS:000227395700130
J	Fernandez, JP; McMaster, CR				Fernandez, JP; McMaster, CR			Nte1p-mediated deacylation of phosphatidylcholine functionally interacts with Sec14p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; PHOSPHATIDYLINOSITOL TRANSFER PROTEINS; OXYSTEROL BINDING-PROTEIN; PHOSPHOLIPASE-D ACTIVITY; YEAST GOLGI-COMPLEX; SACCHAROMYCES-CEREVISIAE; VESICLE TRAFFICKING; PHOSPHATIDIC-ACID; LIPID-METABOLISM; CELL-GROWTH	Deciphering the function of the essential yeast Sec14p protein has revealed a regulatory interface between cargo secretion from Golgi and lipid homeostasis. Abrogation of the CDP-choline (CDP-Cho) pathway for phosphatidylcholine ( PC) synthesis allows for life in the absence of the otherwise essential Sec14p. Nte1p, the product of open reading frame YML059c, is an integral membrane phospholipase against CDP-Cho-derived PC producing intracellular glycerophosphocholine (GPCho) and free fatty acids. We monitored Nte1p activity through in vivo PC turnover measurements and observed that intracellular GPCho accumulation is decreased in a sec14(ts) strain shifted to 37 degreesC in 10 mM choline (Cho)-containing medium compared with a Sec14p-proficient strain. Overexpression of two Sec14p homologs Sfh2p and Sfh4p in sec14ts cells restored secretion and growth at the restrictive temperature but did not restore GPCho accumulation. Instead, newly synthesized PC was degraded by phospholipase D (Spo14p). Similar analysis performed in a sec14Delta background confirmed these observations. These results imply that the ability of Sfh2p and Sfh4p to restore secretion and growth is not through a shared function with Sec14p in the regulation of PC turnover via Nte1p. Furthermore, our analyses revealed a profound alteration of PC metabolism triggered by the absence of Sec14p: Nte1p unresponsiveness, Spo14p activation, and deregulation of Pct1p. Sfh2p- and Sfh4p-overexpressing cells coped with the absence of Sec14p by controlling the rate of phosphocholine formation, limiting the amount of Cho available for this reaction, and actively excreting Cho from the cell. Increased Sfh4p also significantly reduced the uptake of exogenous Cho. Beyond the new PC metabolic control features we ascribe to Sfh2p and Sfh4p we also describe a second role for Sec14p in mediating PC homeostasis. Sec14p acts as a positive regulator of Nte1p-mediated PC deacylation with the functional consequence of increased Nte1p activity increasing the permissive temperature for the growth of sec14ts cells.	Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, 5849 Univ Ave,Rm C-302, Halifax, NS B3H 4H7, Canada.	Christopher.mcmaster@dal.ca		McMaster, Christopher/0000-0003-0822-5776				AMES BN, 1960, J BIOL CHEM, V235, P769; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; Fyrst H, 1999, BIOCHEMISTRY-US, V38, P5864, DOI 10.1021/bi9824590; Henneberry AL, 2001, MOL BIOL CELL, V12, P511, DOI 10.1091/mbc.12.3.511; Holic R, 2004, EUR J BIOCHEM, V271, P4401, DOI 10.1111/j.1432-1033.2004.04377.x; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; Howe AG, 2001, BBA-MOL CELL BIOL L, V1534, P65, DOI 10.1016/S1388-1981(01)00181-0; Kaiser C., 1994, METHODS YEAST GENETI; LEE KS, 1994, J BIOL CHEM, V269, P19725; Li XM, 2000, MOL BIOL CELL, V11, P1989, DOI 10.1091/mbc.11.6.1989; Li XM, 2002, J CELL BIOL, V157, P63, DOI 10.1083/jcb.200201037; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; McMaster CR, 2004, TOP CURR GENET, V6, P5; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Rivas MP, 1999, MOL BIOL CELL, V10, P2235, DOI 10.1091/mbc.10.7.2235; Routt SM, 2004, BIOCHEM CELL BIOL, V82, P254, DOI 10.1139/o03-089; Rudge SA, 1999, BBA-MOL CELL BIOL L, V1439, P167, DOI 10.1016/S1388-1981(99)00092-X; Schnabl M, 2003, EUR J BIOCHEM, V270, P3133, DOI 10.1046/j.1432-1033.2003.03688.x; Sciorra VA, 2002, J CELL BIOL, V159, P1039, DOI 10.1083/jcb.200205056; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; Warnick G R, 1986, Methods Enzymol, V129, P101; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Xie ZH, 2001, MOL BIOL CELL, V12, P1117, DOI 10.1091/mbc.12.4.1117; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200	33	40	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8544	8552		10.1074/jbc.M413999200	http://dx.doi.org/10.1074/jbc.M413999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611060	hybrid			2022-12-27	WOS:000227395700131
J	Ray, S; Gao, C; Wyatt, K; Fariss, RN; Bundek, A; Zelenka, P; Wistow, G				Ray, S; Gao, C; Wyatt, K; Fariss, RN; Bundek, A; Zelenka, P; Wistow, G			Platelet-derived growth factor D, tissue-specific expression in the eye, and a key role in control of lens epithelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATED LIGAND; PDGF-BETA-RECEPTOR; DIFFERENTIATION; ALPHA; ORIENTATION; NEIBANK; PROJECT; BIOLOGY	Platelet-derived growth factor D (PDGF-D), also known as Iris-expressed growth factor, is a member of the PDGF/vascular endothelial growth factor family. The expression of PDGF-D in the eye is tissue-specific. In the anterior segment, it is localized to iris and ciliary body, whereas in the retina, PDGF-D is restricted to the outer plexiform layer. PDGF-D is present in aqueous humor but is not detectable in mature lens or in mouse lens-derived alphaTN4-1 cells. However, it is expressed in rabbit lens-derived N/N1003A cells. N/N1003A cell-conditioned medium stimulates proliferation in rat lens explants, and this is blocked by immunodepletion of PDGF-D. Immunopurified PDGF-D also stimulates cell proliferation in rat lens explants and in NIH 3T3 cells. In organ culture of rat eye anterior segments, anti-PDGF-D strongly inhibits lens epithelial cell proliferation. This finding suggests a major in vivo role for PDGF-D in the mechanisms of coordinated growth of eye tissues. Intervention in the PDGF-D pathway in the eye, perhaps by antibody or blocking peptide, could be useful in the treatment of certain cataracts, including post-operative secondary cataract.	NEI, NIH, Sect Mol Struct & Funct Genom, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Wistow, G (corresponding author), NEI, NIH, Sect Mol Struct & Funct Genom, Bldg 7,Rm 201, Bethesda, MD 20892 USA.	graeme@helix.nih.gov	Fariss, Robert/ABI-1771-2020	Fariss, Robert/0000-0003-3227-7170	NATIONAL EYE INSTITUTE [Z01EY000238, Z01EY000433, ZIAEY000238, ZIAEY000433] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLS GL, 1967, VERTEBRATE EYE ITS A; Apte RS, 1998, J IMMUNOL, V160, P5693; Beebe DC, 2000, DEV BIOL, V220, P424, DOI 10.1006/dbio.2000.9638; BEEBE DC, 1986, T OPHTHAL SOC UK, V105, P123; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475; Chamberlain CG, 1989, GROWTH FACTORS, V1, P125, DOI 10.3109/08977198909029122; Chaum E, 2003, J CELL BIOCHEM, V88, P57, DOI 10.1002/jcb.10354; COULOMBRE A J, 1975, International Ophthalmology Clinics, V15, P7, DOI 10.1097/00004397-197501510-00003; COULOMBRE JL, 1963, SCIENCE, V142, P1489, DOI 10.1126/science.142.3598.1489; COULOMBRE JL, 1969, INVEST OPHTH VISUAL, V8, P251; DARWIN CR, 1860, AUTOBIOGRAPHY C DARW; DAWKINS R, 1994, NATURE, V368, P690, DOI 10.1038/368690a0; ESHAGIAN J, 1982, T OPHTHAL SOC UK, V102, P364; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Glasser A, 2001, INT OPHTHALMOL CLIN, V41, P1, DOI 10.1097/00004397-200104000-00003; Hamada T, 2001, BIOCHEM BIOPH RES CO, V280, P733, DOI 10.1006/bbrc.2000.4187; Harding JJ, 1984, EYE B, V1b, P207; HYATT GA, 1993, DEVELOPMENT, V117, P701; ISHIZAKI Y, 1993, J CELL BIOL, V121, P899, DOI 10.1083/jcb.121.4.899; Jeffery WR, 2001, DEV BIOL, V231, P1, DOI 10.1006/dbio.2000.0121; KAPPELHOF JP, 1992, ACTA OPHTHALMOL, V70, P13; Kok A, 2002, GROWTH FACTORS, V20, P27, DOI 10.1080/08977190290022202; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li H, 2003, ONCOGENE, V22, P1501, DOI 10.1038/sj.onc.1206223; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Li XR, 2003, CYTOKINE GROWTH F R, V14, P91, DOI 10.1016/S1359-6101(02)00090-4; Maidment JM, 2004, INVEST OPHTH VIS SCI, V45, P1427, DOI 10.1167/iovs.03-1187; McAvoy JW, 1999, EYE, V13, P425, DOI 10.1038/eye.1999.117; NILSSON DE, 1994, P ROY SOC B-BIOL SCI, V256, P53, DOI 10.1098/rspb.1994.0048; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; POTTS JD, 1994, INVEST OPHTH VIS SCI, V35, P3413; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; REDDAN JR, 1983, INVEST OPHTH VIS SCI, V24, P409; Reneker LW, 1996, DEV BIOL, V180, P554, DOI 10.1006/dbio.1996.0328; Shui YB, 2003, INVEST OPHTH VIS SCI, V44, P3911, DOI 10.1167/iovs.02-1226; Tsai YJ, 2000, BBA-GENE STRUCT EXPR, V1492, P196, DOI 10.1016/S0167-4781(00)00066-X; WESTERMARK B, 1990, CIBA F SYMP, V150, P6; Wistow G, 2002, MOL VIS, V8, P185; Wistow G, 2002, MOL VIS, V8, P161; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052	42	28	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8494	8502		10.1074/jbc.M413570200	http://dx.doi.org/10.1074/jbc.M413570200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611105	hybrid			2022-12-27	WOS:000227395700126
J	Klaus, SMJ; Wegkamp, A; Sybesma, W; Hugenholtz, J; Gregory, JF; Hanson, AD				Klaus, SMJ; Wegkamp, A; Sybesma, W; Hugenholtz, J; Gregory, JF; Hanson, AD			A nudix enzyme removes pyrophosphate from dihydroneopterin triphosphate in the folate synthesis pathway of bacteria and plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED GENE-EXPRESSION; P-AMINOBENZOATE BRANCH; GTP CYCLOHYDROLASE-I; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; FOLIC-ACID; COENZYME-A; BIOSYNTHESIS; MUTT; CLONING	Removal of pyrophosphate from dihydroneopterin triphosphate (DHNTP) is the second step in the pterin branch of the folate synthesis pathway. There has been controversy over whether this reaction requires a specific pyrophosphohydrolase or is a metal ion-dependent chemical process. The genome of Lactococcus lactis has a multicistronic folate synthesis operon that includes an open reading frame (ylgG) specifying a putative Nudix hydrolase. Because many Nudix enzymes are pyrophosphohydrolases, YlgG was expressed in Escherichia coli and characterized. The recombinant protein showed high DHNTP pyrophosphohydrolase activity with a K. value of 2 mum, had no detectable activity against deoxynucleoside triphosphates or other typical Nudix hydrolase substrates, required a physiological level (similar to1 mm) of Mg2+, and was active as a monomer. Essentially no reaction occurred without enzyme at I mm Mg2+. Inactivation of ylgG in L. lactis resulted in DHNTP accumulation and folate depletion, confirming that YlgG functions in folate biosynthesis. We therefore propose that ylgG be redesignated as folQ. The closest Arabidopsis homolog of YlgG (encoded by Nudix gene At1g68760) was expressed in E. coli and shown to have Mg2+-dependent DHNTP pyrophosphohydrolase activity. This protein (AtNUDT1) was reported previously to have NADH pyrophosphatase activity in the presence of 5 mm Mn2+ (Dobrzanska, M., Szurmak, B., Wyslouch-Cieszynska, A., and Kraszewska, E. (2002) J. Biol. Chem. 277, 50482-50486). However, we found that this activity is negligible at physiological levels of Mn2+ and that, with 1 mM Mg2+, AtNUDT1 prefers DHNTP and (deoxy) nucleoside triphosphates.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; NIZO Food Res, Wageningen Ctr Food Sci, Dept Flavor Nutr & Nat Ingredients, NL-6710 BA Ede, Netherlands; Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; NIZO Food Research; State University System of Florida; University of Florida	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	adha@mail.ifas.ufl.edu		Gregory, Jesse/0000-0002-9976-2085				Abdelraheim SR, 2003, BIOCHEM J, V374, P329, DOI 10.1042/BJ20030441; Basset G, 2002, P NATL ACAD SCI USA, V99, P12489, DOI 10.1073/pnas.192278499; Basset GJC, 2004, PLANT J, V40, P453, DOI 10.1111/j.1365-313X.2004.02231.x; Basset GJC, 2004, P NATL ACAD SCI USA, V101, P1496, DOI 10.1073/pnas.0308331100; Bermingham A, 2002, BIOESSAYS, V24, P637, DOI 10.1002/bies.10114; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Bracher A, 1998, J BIOL CHEM, V273, P28132, DOI 10.1074/jbc.273.43.28132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Cartwright JL, 2000, J BIOL CHEM, V275, P32925, DOI 10.1074/jbc.M005015200; CHANG CF, 1986, J BACTERIOL, V167, P935, DOI 10.1128/jb.167.3.935-939.1986; CHUNG HJ, 2002, BIOCHIM BIOPHYS ACTA, V1524, P183; de la Garza RD, 2004, P NATL ACAD SCI USA, V101, P13720, DOI 10.1073/pnas.0404208101; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; DESAIZIEU A, 1995, BIOCHEM J, V306, P371, DOI 10.1042/bj3060371; DEVOS WM, 1989, GENE, V85, P169, DOI 10.1016/0378-1119(89)90477-0; DEVRIES FWT, 1975, ANN BOTANY, V39, P77; Dobrzanska M, 2002, J BIOL CHEM, V277, P50482, DOI 10.1074/jbc.M205207200; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fernandez RF, 2004, APPL ENVIRON MICROB, V70, P121, DOI 10.1128/AEM.70.1.121-128.2004; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; GANGOLA P, 1987, J BIOL CHEM, V262, P12570; Goyer A, 2004, PLANT PHYSIOL, V135, P103, DOI 10.1104/pp.103.038430; Green J. C., 1996, ESCHERICHIA COLI SAL, P665; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; HORNE DW, 1988, CLIN CHEM, V34, P2357; Hossain T, 2004, P NATL ACAD SCI USA, V101, P5158, DOI 10.1073/pnas.0401342101; Igamberdiev AU, 2001, BIOCHEM J, V360, P225, DOI 10.1042/0264-6021:3600225; Kang LW, 2003, J BACTERIOL, V185, P4110, DOI 10.1128/JB.185.14.4110-4118.2003; Kehres DG, 2003, FEMS MICROBIOL REV, V27, P263, DOI 10.1016/S0168-6445(03)00052-4; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; Mildvan AS, 1999, ADV ENZYMOL RAMB, V73, P183, DOI 10.1002/9780470123195.ch6; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; OTTO R, 1983, FEMS MICROBIOL LETT, V16, P69, DOI 10.1111/j.1574-6968.1983.tb00261.x; PLOWMAN J, 1974, J BIOL CHEM, V249, P5559; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; ROTTLANDER E, 1970, MOL GEN GENET, V108, P47, DOI 10.1007/BF00343184; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Scott J, 2000, J SCI FOOD AGR, V80, P795, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;795::AID-JSFA599&gt;3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000515)80:7<795::AID-JSFA599>3.0.CO;2-K]; Stralsjo LM, 2003, J AGR FOOD CHEM, V51, P128, DOI 10.1021/jf020699n; SUZUKI Y, 1974, J BIOL CHEM, V249, P2405; Swarbrick JD, 2000, J MOL BIOL, V302, P1165, DOI 10.1006/jmbi.2000.4085; Sybesma W, 2003, APPL ENVIRON MICROB, V69, P3069, DOI 10.1128/AEM.69.6.3069-3076.2003; Sybesma W, 2001, BIOTECHNIQUES, V31, P466, DOI 10.2144/01313bm02; Tassotto ML, 2002, J BIOL CHEM, V277, P15807, DOI 10.1074/jbc.M200965200; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Werner-Felmayer G, 2002, CURR DRUG METAB, V3, P159, DOI 10.2174/1389200024605073; Xu WL, 2000, BIOCHEM BIOPH RES CO, V273, P753, DOI 10.1006/bbrc.2000.2999; Xu WL, 2003, FASEB J, V17, pA574; Xu WL, 2003, J BIOL CHEM, V278, P37492, DOI 10.1074/jbc.M307639200; Xu WL, 2001, MOL MICROBIOL, V39, P286, DOI 10.1046/j.1365-2958.2001.02267.x; Yang TB, 2003, TRENDS PLANT SCI, V8, P505, DOI 10.1016/j.tplants.2003.09.004	57	82	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5274	5280		10.1074/jbc.M413759200	http://dx.doi.org/10.1074/jbc.M413759200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15611104	hybrid			2022-12-27	WOS:000227217100022
J	Moriguchi, M; Hissong, BD; Gadina, M; Yamaoka, K; Tiffany, HL; Murphy, PM; Candotti, F; O'Shea, JJ				Moriguchi, M; Hissong, BD; Gadina, M; Yamaoka, K; Tiffany, HL; Murphy, PM; Candotti, F; O'Shea, JJ			CXCL12 signaling is independent of Jak2 and Jak3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; RECEPTOR DIMERIZATION; MICE LACKING; LYMPHOID DEVELOPMENT; FERM DOMAIN; ACTIVATION; CHEMOKINES; STATS; LYMPHOPOIESIS; MUTATIONS	Janus kinases (Jaks) are a small family of cytoplasmic tyrosine kinases, critical for signaling by Type I and II cytokine receptors. The importance of Jaks in signaling by these receptors has been firmly established by analysis of mutant cell lines, the generation of Jak knock-out mice, and the identification of patients with Jak3 mutations. While a number of other ligands that do not bind Type I and II cytokine receptors have also been reported to activate Jaks, the requirement for Jaks in signaling by these receptors is less clear. Chemokines for example, which bind seven transmembrane receptors, have been reported to activate Jaks, and principally through the use of pharmacological inhibitors, it has been argued that Jaks are essential for chemokine signaling. In the present study, we focused on CXCR4, which binds the chemokine CXCL12 or stromal cell-derived factor-1, a chemokine that has been reported to activate Jak2 and Jak3. We found that the lack of Jak3 had no effect on CXCL12 signaling or chemotaxis nor did overexpression of wild-type versions of the kinase. Similarly, overexpression of wild-type or catalytically inactive Jak2 or "knocking-down" Jak2 expression using siRNA also had no effect. We also found that in primary lymphocytes, CXCL12 did not induce appreciable phosphorylation of any of the Jaks compared with cytokines for which these kinases are required. Additionally, little or no Stat ( signal transducer and activator of transcription) phosphorylation was detected. Thus, we conclude that in contrast to previous reports, Jaks, especially Jak3, are unlikely to play an essential role in chemokine signaling.	NIAMS, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	O'Shea, JJ (corresponding author), NIAMS, Mol Immunol & Inflammat Branch, NIH, Bldg 10,Rm 9N262,10 Ctr Dr, Bethesda, MD 20892 USA.	osheajo@mail.nih.gov	Gadina, Massimo/R-4195-2019	Candotti, Fabio/0000-0001-6399-6042	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000615, ZIAAI000615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ansel KM, 2001, CURR OPIN IMMUNOL, V13, P172, DOI 10.1016/S0952-7915(00)00201-6; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Biswas SK, 2002, INT IMMUNOPHARMACOL, V2, P1095, DOI 10.1016/S1567-5769(02)00055-3; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Changelian PS, 2003, SCIENCE, V302, P875, DOI 10.1126/science.1087061; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hilkens CMU, 2001, FEBS LETT, V505, P87, DOI 10.1016/S0014-5793(01)02783-1; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; Kijowski J, 2001, STEM CELLS, V19, P453, DOI 10.1634/stemcells.19-5-453; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; Masters J, 2001, J BIOL CHEM, V276, P48371, DOI 10.1074/jbc.M108019200; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Soldevila G, 2004, IMMUNOLOGY, V112, P191, DOI 10.1111/j.1365-2567.2004.01863.x; Stein JV, 2003, BLOOD, V101, P38, DOI 10.1182/blood-2002-03-0841; THELEN M, 2001, SCI STKE, pPE34; Thomis DC, 1997, CURR OPIN IMMUNOL, V9, P541, DOI 10.1016/S0952-7915(97)80108-2; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342; Zhou YJ, 1997, P NATL ACAD SCI USA, V94, P13850, DOI 10.1073/pnas.94.25.13850; Zhou YJ, 2000, MOL CELL BIOL, V20, P4371, DOI 10.1128/MCB.20.12.4371-4380.2000; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	46	34	36	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17408	17414		10.1074/jbc.M414219200	http://dx.doi.org/10.1074/jbc.M414219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15611059	hybrid			2022-12-27	WOS:000228615500106
J	Kim, JI; Lee, CJ; Jin, MS; Lee, CH; Paik, SG; Lee, H; Lee, JO				Kim, JI; Lee, CJ; Jin, MS; Lee, CH; Paik, SG; Lee, H; Lee, JO			Crystal structure of CD14 and its implications for lipopolysaccharide signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PEPTIDOGLYCAN; RECEPTOR; RECOGNITION; BINDING; ENDOTOXIN; LPS; IDENTIFICATION; ACTIVATION; PROTEIN; MICE	Lipopolysaccharide, the endotoxin of Gram-negative bacteria, induces extensive immune responses that can lead to fatal septic shock syndrome. The core receptors recognizing lipopolysaccharide are CD14, TLR4, and MD-2. CD14 binds to lipopolysaccharide and presents it to the TLR4/MD-2 complex, which initiates intracellular signaling. In addition to lipopolysaccharide, CD14 is capable of recognizing a few other microbial and cellular products. Here, we present the first crystal structure of CD14 to 2.5 angstrom resolution. A large hydrophobic pocket was found on the NH2-terminal side of the horseshoe-like structure. Previously identified regions involved in lipopolysaccharide binding map to the rim and bottom of the pocket indicating that the pocket is the main component of the lipopolysaccharide-binding site. Mutations that interfere with lipopolysaccharide signaling but not with lipopolysaccharide binding are also clustered in a separate area near the pocket. Ligand diversity of CD14 could be explained by the generous size of the pocket, the considerable flexibility of the rim of the pocket, and the multiplicity of grooves available for ligand binding.	Chungnam Natl Univ, Inst Biotechnol, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Chungnam Natl Univ, Dept Biol, Sch Biosci & Biotechnol, Taejon 305701, South Korea	Chungnam National University; Korea Advanced Institute of Science & Technology (KAIST); Korea University; Chungnam National University	Lee, H (corresponding author), Chungnam Natl Univ, Inst Biotechnol, Taejon 305701, South Korea.	hlee@cnu.ac.kr; jieoh.lee@kaist.ac.kr	Lee, Jie-Oh/C-1581-2011; Lee, Jie-Oh/AAG-4302-2020	Lee, Jie-Oh/0000-0001-6519-6049				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cunningham MD, 2000, J IMMUNOL, V164, P3255, DOI 10.4049/jimmunol.164.6.3255; Dziarski R, 2000, INFECT IMMUN, V68, P5254, DOI 10.1128/IAI.68.9.5254-5260.2000; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Gregory CD, 1999, APOPTOSIS, V4, P11, DOI 10.1023/A:1009673914340; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoshino K, 1999, J IMMUNOL, V162, P3749; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; JUAN TSC, 1995, J BIOL CHEM, V270, P17237, DOI 10.1074/jbc.270.29.17237; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leturcq DJ, 1996, J CLIN INVEST, V98, P1533, DOI 10.1172/JCI118945; MCGINLEY MD, 1995, J BIOL CHEM, V270, P5213, DOI 10.1074/jbc.270.10.5213; Miyake K, 2003, INT IMMUNOPHARMACOL, V3, P119, DOI 10.1016/S1567-5769(02)00258-8; Muroi M, 2002, J BIOL CHEM, V277, P42372, DOI 10.1074/jbc.M205966200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shapiro RA, 1997, INFECT IMMUN, V65, P293, DOI 10.1128/IAI.65.1.293-297.1997; Stelter F, 1997, EUR J BIOCHEM, V243, P100, DOI 10.1111/j.1432-1033.1997.00100.x; Stelter F, 1998, PROG CLIN BIOL RES, V397, P301; Stelter F, 1999, J IMMUNOL, V163, P6035; Sugiyama T, 2001, J IMMUNOL, V166, P826, DOI 10.4049/jimmunol.166.2.826; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361	39	183	196	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11347	11351		10.1074/jbc.M414607200	http://dx.doi.org/10.1074/jbc.M414607200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644310	hybrid			2022-12-27	WOS:000227761800056
J	Boyer-Guittaut, M; Birsoy, K; Potel, C; Elliott, G; Jaffray, E; Desterro, JM; Hay, RT; Oelgeschlager, T				Boyer-Guittaut, M; Birsoy, K; Potel, C; Elliott, G; Jaffray, E; Desterro, JM; Hay, RT; Oelgeschlager, T			SUMO-1 modification of human transcription factor (TF) IID complex subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; BOX-BINDING; HISTONE FOLD; TAF(II)250; UBIQUITIN; YEAST; ACTIVATION	The TFIID complex is composed of the TATA-binding protein (TBP) and TBP-associated factors (TAFs) and is the only component of the general RNA polymerase II (RNAP II) transcription machinery with intrinsic sequence-specific DNA-binding activity. Binding of transcription factor (TF) IID to the core promoter region of protein-coding genes is a key event in RNAP II transcription activation and is the first and rate-limiting step of transcription initiation complex assembly. Intense research efforts in the past have established that TFIID promoter-binding activity as well as the function of TFIID-promoter complexes is tightly regulated through dynamic TFIID interactions with positive- and negative-acting transcription regulatory proteins. However, very little is known about the role of post-translational modifications in the regulation of TFIID. Here we show that the human TFIID subunits hsTAF5 and hsTAF12 are modified by the small ubiquitin-related modifier SUMO-1 in vitro and in human cells. We identify Lys-14 in hsTAF5 and Lys-19 in hsTAF12 as the primary SUMO-1 acceptor sites and show that SUMO conjugation has no detectable effect on nuclear import or intranuclear distribution of hsTAF5 and hsTAF12. Finally, we demonstrate that purified human TFIID complex can be SUMO-1-modified in vitro at both hsTAF5 and hsTAF12. We find that SUMO-1 conjugation at hsTAF5 interferes with binding of TFIID to promoter DNA, whereas modification of hsTAF12 has no detectable effect on TFIID promoter-binding activity. Our observations suggest that reversible SUMO modification at hsTAF5 contributes to the dynamic regulation of TFIID promoter-binding activity in human cells.	Marie Curie Res Inst, Transcript Lab, Oxted RH8 0TL, Surrey, England; Marie Curie Res Inst, Virus Assembly Lab, Oxted RH8 0TL, Surrey, England; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland	University of St Andrews	Oelgeschlager, T (corresponding author), Marie Curie Res Inst, Transcript Lab, Oxted RH8 0TL, Surrey, England.	t.oelgeschlager@mcri.ac.uk	Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019; Guittaut, Michael/ABE-4274-2021	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024; Guittaut, Michael/0000-0001-9540-5593; Oelgeschlager, Thomas/0000-0002-4086-719X; Desterro, Joana/0000-0002-6359-7233				Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; Matsuzaki K, 2003, BIOCHEM BIOPH RES CO, V306, P32, DOI 10.1016/S0006-291X(03)00910-0; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Panse VG, 2004, J BIOL CHEM, V279, P41346, DOI 10.1074/jbc.M407950200; Pereira LA, 2003, GENE, V315, P1, DOI 10.1016/S0378-1119(03)00714-5; Perletti L, 2001, BMC Mol Biol, V2, P4, DOI 10.1186/1471-2199-2-4; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Pointud JC, 2003, J CELL SCI, V116, P1847, DOI 10.1242/jcs.00391; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Sawa C, 2004, MOL CELL BIOL, V24, P4734, DOI 10.1128/MCB.24.11.4734-4742.2004; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wassarman DA, 2001, J CELL SCI, V114, P2895; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	52	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9937	9945		10.1074/jbc.M414149200	http://dx.doi.org/10.1074/jbc.M414149200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637059	hybrid			2022-12-27	WOS:000227559600025
J	Jeong, SJ; Pise-Masison, CA; Radonovich, MF; Park, HU; Brady, JN				Jeong, SJ; Pise-Masison, CA; Radonovich, MF; Park, HU; Brady, JN			A novel NF-kappa B pathway involving IKK beta and p65/Re1A ser-536 phosphorylation results in p53 inhibition in the absence of 1NF-kappa B transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; NECROSIS-FACTOR-ALPHA; TYPE-1 TAX PROTEIN; P65 SUBUNIT; GENE-EXPRESSION; KINASE-ALPHA; DEPENDENT TRANSCRIPTION; ADAPTER FUNCTION; ACTIVATION; RELA/P65	Nuclear factor kappa B (NF-kappa B) plays an important role in regulating cellular transformation and apoptosis. The human T-cell lymphotropic virus type I protein, Tax, which is critical for viral transformation, modulates the transcription of several cellular genes through activation of NF-kappa B. We have demonstrated previously that Tax inhibits p53 activity through the p65/RelA subunit of NF-kappa B. We now present evidence that suggests that the upstream kinase IKK beta plays an important role in Tax-induced p53 inhibition through phosphorylation of p65/RelA at Ser-536. First, mouse embryo fibroblast (MEF) IKK beta-/- cells did not support Tax-mediated p53 inhibition, whereas MEFs lacking IKK alpha allowed Tax inhibition of p53. Second, transfection of IKK beta wild type (WT), but not a kinase-dead mutant, into IKK beta-/- cells rescued p53 inhibition by Tax. Third, the IKK beta-specific inhibitor SC-514 decreased the ability of Tax to inhibit p53. Fourth, we show that phosphorylation of p65/RelA at Ser-536 is important for Tax inhibition of p53 using MEF p65/RelA-/- cells transfected with p65/RelA WT or mutant plasmids. Moreover, Tax induced p65/RelA Ser536 phosphorylation in WT or IKK alpha-/- cells but failed to induce the phosphorylation of p65/RelA Ser-536 in IKK beta-/- cells, suggesting a link between IKK beta and p65/RelA phosphorylation. Consistent with this observation, blocking IKK beta kinase activity by SC-514 decreases the phosphorylation of p65/RelA at Ser-536 in the presence of Tax in human T-cell lymphotropic virus type I-transformed cells. Finally, the ability of Tax to inhibit p53 is distinguished from the NF-kappa B transcription activation pathway. Our work, therefore, describes a novel Tax-NF-kappa B p65/RelA pathway that functions to inhibit p53 but does not require NF-kappa B transcription activity.	NCI, Tumor Virus Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brady, JN (corresponding author), NCI, Tumor Virus Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005254, Z01BC005691, Z01BC005254, ZIABC005691] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GESSAIN A, 1985, LANCET, V2, P407; Gregory D, 2004, J VIROL, V78, P13582, DOI 10.1128/JVI.78.24.13582-13590.2004; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; IJICHI S, 1990, ANN RHEUM DIS, V49, P718, DOI 10.1136/ard.49.9.718; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAGRENADE L, 1990, LANCET, V336, P1345; Lee HY, 1998, J BIOL CHEM, V273, P7066, DOI 10.1074/jbc.273.12.7066; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; OSAME M, 1986, LANCET, V1, P1031; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; SASAKI K, 1989, BRIT J OPHTHALMOL, V73, P812, DOI 10.1136/bjo.73.10.812; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	63	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10326	10332		10.1074/jbc.M412643200	http://dx.doi.org/10.1074/jbc.M412643200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15611068	hybrid			2022-12-27	WOS:000227559600072
J	Chantret, I; Dancourt, J; Barbat, A; Moore, SEH				Chantret, I; Dancourt, J; Barbat, A; Moore, SEH			Two proteins homologous to the N- and C-terminal domains of the bacterial glycosyltransferase Murg are required for the second step of dolichyl-linked oligosaccharide synthesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACETYLGLUCOSAMINE TRANSFERASE; PEPTIDOGLYCAN BIOSYNTHESIS; GLYCOPROTEINS; MEMBRANE; SOLUBILIZATION; GENE; ACETYLGLUCOSAMINYLPYROPHOSPHORYLDOLICHOL; GLYCOSYLATION; GLUCOSIDASE	Two highly conserved eukaryotic gene products of unknown function showing homology to glycosyltransferases involved in the second steps of bacterial peptidoglycan (Murg) and capsular polysaccharide ( Cps14f/ Cps14g) biosynthesis have been identified in silico. The amino acid sequence of the eukaryotic protein that is homologous to the lipid acceptor- and membrane-associating N-terminal domain of Murg and the Cps14f beta4-galactosyltransferase enhancer protein is predicted to possess a cleavable signal peptide and transmembrane helices. The other eukaryotic protein is predicted to possess neither transmembrane regions nor a signal peptide but is homologous to the UDP-sugar binding C-terminal domain of Murg and the Cps14g beta4-galactosyltransferase. Both the eukaryotic proteins are encoded by essential genes in Saccharomyces cerevisiae, and down-regulation of either causes growth retardation, reduced N-glycosylation of carboxypeptidase Y, and accumulation of dolichyl-PP-GlcNAc. In vitro studies demonstrate that these proteins are required for transfer of [H-3]GlcNAc from UDP-[H-3]GlcNAc onto dolichyl-PP-GlcNAc. To conclude, two gene products showing homology to bacterial glycosyltransferases are required for the second step in dolichyl-PP-oligosaccharide biosynthesis.	INSERM, U504, F-94807 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Moore, SEH (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier,Batiment INSERM, F-94807 Villejuif, France.	moore@vjf.inserm.fr	Moore, Stuart/AAF-3920-2021; CHANTRET, Isabelle/AAF-7134-2021; Dancourt, Julia/U-1533-2017	Moore, Stuart/0000-0002-1020-2242; CHANTRET, Isabelle/0000-0002-0896-1274; Dancourt, Julia/0000-0002-6237-1566				Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; Barbosa MDFS, 2002, ANAL BIOCHEM, V306, P17, DOI 10.1006/abio.2001.5691; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bejar CM, 2004, FEBS LETT, V573, P99, DOI 10.1016/j.febslet.2004.07.060; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Crouvoisier M, 1999, FEBS LETT, V449, P289, DOI 10.1016/S0014-5793(99)00412-3; Dal Nogare AR, 1998, GLYCOBIOLOGY, V8, P625, DOI 10.1093/glycob/8.6.625; FISHER D, 2000, PAC S BIOC HAW, P119; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Ha S., 2001, Current Drug Targets - Infectious Disorders, V1, P201, DOI 10.2174/1568005014606116; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; HANOVER JA, 1981, ARCH BIOCHEM BIOPHYS, V211, P1, DOI 10.1016/0003-9861(81)90423-9; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEIFETZ A, 1977, J BIOL CHEM, V252, P3057; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Jaeken J, 2004, J Inherit Metab Dis, V27, P423, DOI 10.1023/B:BOLI.0000031221.44647.9e; KEAN EL, 1983, BIOCHIM BIOPHYS ACTA, V750, P268, DOI 10.1016/0005-2760(83)90028-0; KEAN EL, 1991, J BIOL CHEM, V266, P942; Kean EL, 1999, J BIOL CHEM, V274, P34072, DOI 10.1074/jbc.274.48.34072; Kolkman MAB, 1997, J BIOL CHEM, V272, P19502, DOI 10.1074/jbc.272.31.19502; LEHLE L, 1976, FEBS LETT, V71, P167, DOI 10.1016/0014-5793(76)80922-2; MENGINLECREULX D, 1990, NUCLEIC ACIDS RES, V18, P2810, DOI 10.1093/nar/18.9.2810; MENGINLECREULX D, 1991, J BACTERIOL, V173, P4625, DOI 10.1128/jb.173.15.4625-4636.1991; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; SPIRO RG, 1979, J BIOL CHEM, V254, P7659; TAKATSUKI A, 1971, J ANTIBIOT, V24, P215, DOI 10.7164/antibiotics.24.215; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Videira P, 2001, BIOCHEM J, V358, P457, DOI 10.1042/0264-6021:3580457	31	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9236	9242		10.1074/jbc.M413941200	http://dx.doi.org/10.1074/jbc.M413941200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615718	hybrid			2022-12-27	WOS:000227453100073
J	Hu, XJ; Haney, N; Kropp, D; Kabore, AF; Johnston, JB; Gibson, SB				Hu, XJ; Haney, N; Kropp, D; Kabore, AF; Johnston, JB; Gibson, SB			Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELLS; GROWTH-FACTORS; KAPPA-B; OVARIAN; SURVIVAL; LYSOPHOSPHOLIPIDS; EXPRESSION; CHLORAMBUCIL; FIBROBLASTS; REQUIREMENT	Lysophosphatidic acid (LPA) protects epithelial and fibroblast cell lines from apoptosis. In B-cells, LPA acts as a growth factor promoting cell proliferation. Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD19+/CD5+ B-lymphocytes primarily through a block in apoptosis. The mechanisms underlying this defect are not fully understood. We investigated whether LPA could be a survival factor in CLL cells. Herein, we demonstrate that LPA protects B-cell lines BJAB and I-83 and primary CLL cells but not normal B-cells from fludarabine- and etoposide-induced apoptosis. Furthermore, LPA prevented spontaneous apoptosis in primary CLL cells. The LPA(1) expression was found to be increased in primary CLL cells compared with normal B-cells correlating with LPA prevention of apoptosis. Treatment of primary CLL cells with the LPA receptor antagonist, diacylglycerol pyrophosphate, reverses the protective effect of LPA against apoptosis, and down-regulation of the LPA(1) by siRNA blocked LPA-mediated protection against spontaneous apoptosis in primary CLL cells. The protective effect of LPA was inhibited by blocking activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. These results indicate that LPA is a survival factor in B-cell lines and primary CLL cells but not normal B-cells. Thus, drugs targeting the LPA receptors might be an effective therapy against B-cell-derived malignancies such as CLL.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Pediat, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada	University of Manitoba; University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	gibsonsb@cc.umanitoba.ca		Gibson, Spencer/0000-0003-0119-732X				Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Bannerji R, 2000, CURR OPIN ONCOL, V12, P22, DOI 10.1097/00001622-200001000-00004; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; BEGLEITER A, 1995, LEUKEMIA, V9, P1875; Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Burger JA, 2000, BLOOD, V96, P2655; BUTTURINI A, 1988, LEUKEMIA RES, V12, P89, DOI 10.1016/S0145-2126(98)80013-1; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; DEN GW, 2003, AM J PHYSIOL, V284, pG8221; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Gibson EM, 2002, CANCER RES, V62, P488; Goetzl EJ, 2000, ANN NY ACAD SCI, V905, P177; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hernandez M, 2000, J NEUROCHEM, V75, P1575, DOI 10.1046/j.1471-4159.2000.0751575.x; JOHNSTON JB, 2003, WINTROBES CLIN HEMAT, P2429; Jones DT, 2003, BLOOD, V101, P3174, DOI 10.1182/blood-2002-07-2143; Kang YC, 2004, CELL DEATH DIFFER, V11, P1287, DOI 10.1038/sj.cdd.4401489; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Lee YK, 2004, BLOOD, V104, P788, DOI 10.1182/blood-2003-08-2763; Mainou-Fowler T, 2001, LEUKEMIA LYMPHOMA, V42, P689, DOI 10.3109/10428190109099331; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Palmetshofer A, 1999, THROMB HAEMOSTASIS, V82, P1532; Pangalis GA, 2002, HEMATOL ONCOL, V20, P103, DOI 10.1002/hon.696; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Rother E, 2003, CIRCULATION, V108, P741, DOI 10.1161/01.CIR.0000083715.37658.C4; Rubio I, 2003, BIOCHEM J, V376, P571, DOI 10.1042/BJ20031410; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Sasagawa T, 1999, LIPIDS, V34, P17, DOI 10.1007/s11745-999-332-5; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Shida D, 2003, CANCER RES, V63, P1706; Swarthout JT, 2000, CELL MOL LIFE SCI, V57, P1978, DOI 10.1007/PL00000678; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Wickremasinghe RG, 2001, BRIT J HAEMATOL, V114, P608, DOI 10.1046/j.1365-2141.2001.02978.x; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X	42	49	50	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9498	9508		10.1074/jbc.M410455200	http://dx.doi.org/10.1074/jbc.M410455200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15618220	hybrid			2022-12-27	WOS:000227453100104
J	Lee, JE; Kim, K; Sacchettini, JC; Smith, CV; Safe, S				Lee, JE; Kim, K; Sacchettini, JC; Smith, CV; Safe, S			DRIP150 coactivation of estrogen receptor alpha in ZR-75 breast cancer cells is independent of LXXLL motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; ER-ALPHA; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; DEPENDENT TRANSCRIPTION; COFACTOR COMPLEX; BINDING PROTEIN; DNA-BINDING; TRAP220; INTERACTS	Vitamin D receptor-interacting protein 150 (DRIP150) has been identified as part of mediator-like complexes that enhance transcriptional activation of the estrogen receptor (ER) and other nuclear receptors (NRs). DRIP150 coactivates ligand-dependent ERalpha-mediated transactivation in ZR-75 and MDA-MB-231 breast cancer cells transfected with a (luciferase) reporter construct (pERE3) regulated by three tandem estrogen-responsive elements. Coactivation of ERalpha by DRIP150 in ZR-75 cells was activation function 2-dependent and required an intact helix 12 that typically interacts with LXXLL motifs (NR box) in p160 steroid receptor coactivators. DRIP150 contains C- and N-terminal NR boxes (amino acids 1182-1186 and 69-73, respectively), and deletion analysis of DRIP150 showed that regions containing these sequences were not necessary for coactivation of ERalpha. Analysis of multiple DRIP150 deletion mutants identified a 23-amino-acid sequence (789-811) required for coactivation activity. Analysis of the protein crystal structure data base identified two regions at amino acids 789-794 and 795-804, which resembled alpha-helical motifs in Lanuginosa lipase/histamine N-methyltransferase and hepatocyte nuclear factor 1, respectively. By using a squelching assay and specific amino acid point mutations within each alpha-helix, the NIFSEVRVYN (795-804) region was identified as the critical sequence required for the activity of DRIP150. These results demonstrate that coactivation of ERalpha by DRIP150 in ZR-75 cells is NR box-independent and requires a novel sequence with putative alpha-helical structure.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU,Vet Res Bldg 409, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu		Kim, Kyounghyun/0000-0002-7240-2768	NCI NIH HHS [CA104116] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P15071, DOI 10.1021/bi0013905; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Horton JR, 2001, STRUCTURE, V9, P837, DOI 10.1016/S0969-2126(01)00643-8; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Margeat E, 2001, J MOL BIOL, V306, P433, DOI 10.1006/jmbi.2000.4418; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nilsson S, 2002, CRIT REV BIOCHEM MOL, V37, P1, DOI 10.1080/10409230290771438; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Saville B, 2002, J BIOL CHEM, V277, P2485, DOI 10.1074/jbc.M109021200; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Taatjes DJ, 2004, MOL CELL, V14, P675, DOI 10.1016/j.molcel.2004.05.014; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Warnmark A, 2002, J BIOL CHEM, V277, P21862, DOI 10.1074/jbc.M200764200; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Wu Q, 2004, J BIOL CHEM, V279, P53602, DOI 10.1074/jbc.M409778200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	56	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8819	8830		10.1074/jbc.M413184200	http://dx.doi.org/10.1074/jbc.M413184200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15625066	hybrid			2022-12-27	WOS:000227453100026
J	Linsdell, P				Linsdell, P			Location of a common inhibitor binding site in the cytoplasmic vestibule of the cystic fibrosis transmembrane conductance regulator chloride channel pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL-CHANNEL; MOLECULAR DETERMINANTS; ANION-BINDING; DIRECT BLOCK; CELL-LINE; CFTR; GLIBENCLAMIDE; PERMEABILITY; SELECTIVITY; ACID	Chloride transport by the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is inhibited by a broad range of organic anions that enter the channel pore from its cytoplasmic end, physically occluding the Cl- permeation pathway. These open channel blocker molecules are presumed to bind within a relatively wide pore inner vestibule that shows little discrimination between different large anions. The present study uses patch clamp recording to identify a pore-lining lysine residue, Lys-95, that acts to attract large blocker molecules into this inner vestibule. Mutations that remove the fixed positive charge associated with this amino acid residue dramatically weaken the blocking effects of five structurally unrelated open channel blockers (glibenclamide, 4,4'-dinitrostilbene-2,2'-disulfonic acid, lonidamine, 5-nitro-2-(3-phenylpropylamino) benzoic acid, and taurolithocholate-3-sulfate) when applied to the cytoplasmic face of the membrane. Mutagenesis of Lys-95 also induced amino acid side chain charge-dependent rectification of the macroscopic current-voltage relationship, consistent with the fixed positive charge on this residue normally acting to attract Cl- ions from the intracellular solution into the pore. These results identify Lys-95 as playing an important role in attracting permeant anions into the channel pore inner vestibule, probably by an electrostatic mechanism. This same electrostatic attraction mechanism also acts to attract larger anionic molecules into the relatively wide inner vestibule, where these substances bind to block Cl- permeation. Thus, structurally diverse open channel blockers of CFTR appear to share a common molecular mechanism of action that involves interaction with a positively charged amino acid side chain located in the inner vestibule of the pore.	Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS B3H 1X5, Canada	Dalhousie University	Linsdell, P (corresponding author), Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS B3H 1X5, Canada.	paul.linsdell@dal.ca		Linsdell, Paul/0000-0001-6257-6273				Bachmann A, 1999, N-S ARCH PHARMACOL, V360, P473, DOI 10.1007/s002109900096; Cai Z, 1999, BRIT J PHARMACOL, V128, P108, DOI 10.1038/sj.bjp.0702748; CAI Z, 2003, VIRTUAL REPOSITORY C; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; Ge N, 2004, J BIOL CHEM, V279, P55283, DOI 10.1074/jbc.M411935200; Gong XD, 2004, ARCH BIOCHEM BIOPHYS, V426, P78, DOI 10.1016/j.abb.2004.03.033; Gong XD, 2003, J GEN PHYSIOL, V122, P673, DOI 10.1085/jgp.200308889; Gong XD, 2003, J PHYSIOL-LONDON, V549, P375, DOI 10.1113/jphysiol.2002.038216; Gong XD, 2003, J PHYSIOL-LONDON, V549, P387, DOI 10.1113/jphysiol.2002.038232; Gong XD, 2002, J PHYSIOL-LONDON, V540, P39, DOI 10.1113/jphysiol.2001.013235; Gong XD, 2002, BRIT J PHARMACOL, V137, P928, DOI 10.1038/sj.bjp.0704932; Gupta J, 2003, MOL MEMBR BIOL, V20, P45, DOI 10.1080/0968031000045824; Gupta J, 2002, PFLUG ARCH EUR J PHY, V443, P739, DOI 10.1007/s00424-001-0762-0; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kidd JF, 2004, CURR TOP DEV BIOL, V60, P215; Linsdell P, 2000, CAN J PHYSIOL PHARM, V78, P490, DOI 10.1139/cjpp-78-6-490; Linsdell P, 2000, BIOPHYS J, V78, P2973, DOI 10.1016/S0006-3495(00)76836-6; Linsdell P, 1999, BRIT J PHARMACOL, V126, P1471, DOI 10.1038/sj.bjp.0702458; Linsdell P, 2002, J PHYSIOL-LONDON, V540, P29, DOI 10.1113/jphysiol.2001.013234; Linsdell P, 1998, J GEN PHYSIOL, V111, P601, DOI 10.1085/jgp.111.4.601; Linsdell P, 2001, EUR J PHARMACOL, V411, P255, DOI 10.1016/S0014-2999(00)00928-6; Linsdell P, 2001, J PHYSIOL-LONDON, V531, P51, DOI 10.1111/j.1469-7793.2001.0051j.x; Linsdell P, 1996, J PHYSIOL-LONDON, V496, P687, DOI 10.1113/jphysiol.1996.sp021719; Mansoura MK, 1998, BIOPHYS J, V74, P1320, DOI 10.1016/S0006-3495(98)77845-2; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; Mikhailov MV, 2001, FEBS LETT, V499, P154, DOI 10.1016/S0014-5793(01)02538-8; RIODAN JR, 1989, SCIENCE, V245, P1066; Rosenberg MF, 2004, J BIOL CHEM, V279, P39051, DOI 10.1074/jbc.M407434200; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; Schultz BD, 1999, PHYSL REV S, V79, P109; Scott-ward TS, 2004, MOL MEMBR BIOL, V21, P27, DOI 10.1080/09687680310001597758; Sheppard DN, 2004, J GEN PHYSIOL, V124, P109, DOI 10.1085/JGP.200409135; Sheppard DN, 1997, J PHYSIOL-LONDON, V503, P333, DOI 10.1111/j.1469-7793.1997.333bh.x; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Smith SS, 2001, J GEN PHYSIOL, V118, P407, DOI 10.1085/jgp.118.4.407; Smith SS, 1999, J GEN PHYSIOL, V114, P799, DOI 10.1085/jgp.114.6.799; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Walsh KB, 1999, BRIT J PHARMACOL, V127, P369, DOI 10.1038/sj.bjp.0702562; Zhang ZR, 2004, J MEMBRANE BIOL, V199, P15, DOI 10.1007/s00232-004-0672-0; Zhang ZR, 2000, J MEMBRANE BIOL, V175, P35, DOI 10.1007/s002320001053; Zhou Z, 2002, J GEN PHYSIOL, V120, P647, DOI 10.1085/jgp.20028685	42	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8945	8950		10.1074/jbc.M414354200	http://dx.doi.org/10.1074/jbc.M414354200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634668	hybrid			2022-12-27	WOS:000227453100041
J	Morbitzer, M; Herget, T				Morbitzer, M; Herget, T			Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; NEURAL DIFFERENTIATION; GENE-EXPRESSION; PROTEIN; SELENOCYSTEINE; REPLICATION; TRANSLATION; ADENOVIRUS; RIBAVIRIN; SELENIUM	There is great medical need to develop novel therapies for treatment of human hepatitis C virus (HCV). By gene expression analysis of three HCV-subgenomic RNA replicon cell lines, we identified cellular proteins whose expression is affected by the presence of HCV and therefore may serve as drug targets. Data from cDNA array filter hybridization, as well as from Northern and Western blotting, revealed that the gastrointestinal-glutathione peroxidase (GI-GPx) was drastically down-regulated (up to 20-fold) in all replicon cell lines tested. Concomitantly, total cellular glutathione peroxidase activity was drastically reduced, which rendered these human liver cells more susceptible toward oxidative stress. Interferon alpha caused down-regulation of the HCV-replicon followed by recovery of GI-GPx expression to nearly normal levels. Furthermore, expression of GI-GPx in replicon cells by gene transduction caused down-regulation of HCV RNA in a dose-dependent manner. Moreover, activating the endogenous gene coding for GI-GPx by all-trans-retinoic acid ( RA) was sufficient to cause down-regulation of the HCV replicon. A small interfering RNA duplex abrogated GI-GPx up-regulation by RA and concomitantly suppression of HCV. The RA effect was dependent on the presence of sodium selenite, was reversible, and was independent of RNA-activated protein kinase. Taken together, these results show that HCV inhibits the expression of GI-GPx in replicon cells to promote its intracellular propagation. Modulation of GI-GPx activity may open new avenues of treatment for HCV patients.	AXXIMA Pharmaceut AG, D-81377 Munich, Germany		Herget, T (corresponding author), Merck KGaA, Frankfurter Str 250, D-64293 Darmstadt, Germany.	thomas.herget@merck.de						Bartenschlager R, 2002, NAT REV DRUG DISCOV, V1, P911, DOI 10.1038/nrd942; Bodenheimer HC, 1997, HEPATOLOGY, V26, P473, DOI 10.1002/hep.510260231; Brigelius-Flohe R, 1995, BIOFACTORS, V5, P125; Brigelius-Flohe R, 2003, BIOFACTORS, V17, P93, DOI 10.1002/biof.5520170110; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Bureau C, 2001, J BIOL CHEM, V276, P23077, DOI 10.1074/jbc.M100698200; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Cheng WH, 1998, J NUTR, V128, P1070, DOI 10.1093/jn/128.7.1070; CHU FF, 1993, J BIOL CHEM, V268, P2571; Chu FF, 1999, J NUTR, V129, P1846, DOI 10.1093/jn/129.10.1846; CHU FF, 1995, ARCH BIOCHEM BIOPHYS, V323, P288, DOI 10.1006/abbi.1995.9962; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Cotten M, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng128; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; EVANS MD, 1997, ADV MOL CEL, V20, P25; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; FARRINGTON JA, 1973, BIOCHIM BIOPHYS ACTA, V314, P372, DOI 10.1016/0005-2728(73)90121-7; Florian S, 2001, FREE RADICAL RES, V35, P655, DOI 10.1080/10715760100301181; Forns X, 1999, TRENDS MICROBIOL, V7, P402, DOI 10.1016/S0966-842X(99)01590-5; Gladyshev V. N., 1999, Recent Research Developments in Biochemistry, V1, P145; Glotzer JB, 2001, J VIROL, V75, P2421, DOI 10.1128/JVI.75.5.2421-2434.2001; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Hardy MP, 2002, BIOCHEM J, V365, P355, DOI 10.1042/BJ20020105; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; Herget T, 1998, J NEUROCHEM, V70, P47; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; Kelner MJ, 2000, GENE, V248, P109, DOI 10.1016/S0378-1119(00)00137-2; KLEBL BM, 2005, IN PRESS ANTIVIR CHE; Koul A, 2004, NAT REV MICROBIOL, V2, P189, DOI 10.1038/nrmicro840; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Lanford RE, 2001, J VIROL, V75, P8074, DOI 10.1128/JVI.75.17.8074-8081.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Malins DC, 1996, P NATL ACAD SCI USA, V93, P2557, DOI 10.1073/pnas.93.6.2557; Miyamoto Y, 2003, BIOL CHEM, V384, P567, DOI 10.1515/BC.2003.064; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4; Qadri I, 2004, BIOCHEM J, V378, P919, DOI 10.1042/BJ20031587; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Samuel CE, 2004, NAT BIOTECHNOL, V22, P280, DOI 10.1038/nbt0304-280; Takigawa Y, 2004, MICROBIOL IMMUNOL, V48, P591, DOI 10.1111/j.1348-0421.2004.tb03556.x; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Valgimigli M, 2002, FREE RADICAL RES, V36, P939, DOI 10.1080/107156021000006653; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003; Williams B.R., 2001, SCI STKE, V2001, pre2; Wilson JA, 2003, P NATL ACAD SCI USA, V100, P2783, DOI 10.1073/pnas.252758799; Zhou SF, 2003, VIROLOGY, V310, P333, DOI 10.1016/S0042-6822(03)00152-1; 2002, Patent No. 02066022	59	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8831	8841		10.1074/jbc.M413730200	http://dx.doi.org/10.1074/jbc.M413730200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623509	hybrid			2022-12-27	WOS:000227453100027
J	Portevin, D; D'Auria, LD; Montrozier, H; Houssin, C; Stella, A; Laneelle, MA; Bardou, F; Guilhot, C; Daffe, M				Portevin, D; D'Auria, LD; Montrozier, H; Houssin, C; Stella, A; Laneelle, MA; Bardou, F; Guilhot, C; Daffe, M			The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth - Identification of the carboxylation product and determination of the acyl-CoA carboxylase components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; PERMEABILITY BARRIER; BIOSYNTHESIS; TUBERCULOSIS; VIRULENCE; ENVELOPE; PROTEIN; MUTANT; INHA; INACTIVATION	Mycolic acids are major and specific long-chain fatty acids of the cell envelope of several important human pathogens such as Mycobacterium tuberculosis, M. leprae, and Corynebacterium diphtheriae. Their biosynthesis is essential for mycobacterial growth and represents an attractive target for developing new antituberculous drugs. We have previously shown that the pks13 gene encodes condensase, the enzyme that performs the final condensation step of mycolic acid biosynthesis and is flanked by two genes, fadD32 and accD4. To determine the functions of the gene products we generated two mutants of C. glutamicum with an insertion/deletion within either fadD32 or accD4. The two mutant strains were deficient in mycolic acid production and exhibited the colony morphology that typifies the mycolate-less mutants of corynebacteria. Application of multiple analytical approaches to the analysis of the mutants demonstrated the accumulation of a tetradecylmalonic acid in the DeltafadD32::km mutant and its absence from the DeltaaccD4::km strain. The parental corynebacterial phenotype was restored upon the transfer of the wild-type fadD32 and accD4 genes in the mutants. These data demonstrated that both FadD32 and AccD4-containing acyl-CoA carboxylase are required for the production of mycolic acids. They also prove that the proteins catalyze, respectively, the activation of one fatty acid substrate and the carboxylation of the other substrate, solving the long-debated question of the mechanism involved in the condensation reaction. We used comparative genomics and applied a combination of molecular biology and proteomic technologies to the analysis of proteins that co-immunoprecipitated with AccD4. This resulted in the identification of AccA3 and AccD5 as subunits of the acyl-CoA carboxylase. Finally, we used conditionally replicative plasmids to show that both the fadD32 and accD4 genes are essential for the survival of M. smegmatis. Thus, in addition to Pks13, FadD32 and AccD4 are promising targets for the development of new antimicrobial drugs against pathogenic species of mycobacteria and related microorganisms.	CNRS, Dept Mecanismes Mol Infect Mycobacteriennes, F-31077 Toulouse, France; CNRS, Plateforme Prot IPBS, CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Toulouse 3, UMR 5089, F-31077 Toulouse, France; CNRS, Lab Biotechnol Microorganismes Interet Ind, Inst Genet & Microbiol, F-91405 Orsay, France; Univ Paris 11, UMR 8621, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Guilhot, C (corresponding author), CNRS, Dept Mecanismes Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse, France.	guilhot@ipbs.fr; daffe@ipbs.fr	Portevin, Damien/ABB-4546-2021	Portevin, Damien/0000-0003-2949-9557; Sousa, Celia R/0000-0001-8988-3724				ADAMS R, 1941, ORG SYNTH, V1, P250; ARNSTADT KI, 1975, EUR J BIOCHEM, V55, P561, DOI 10.1111/j.1432-1033.1975.tb02193.x; Asselineau C, 2002, PROG LIPID RES, V41, P501, DOI 10.1016/S0163-7827(02)00008-5; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Brosius J, 1988, Biotechnology, V10, P205; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COLLINS MD, 1982, J GEN MICROBIOL, V128, P129; COLLINS MD, 1988, FEMS MICROBIOL LETT, V49, P349; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; Dusch N, 1999, APPL ENVIRON MICROB, V65, P1530; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; Gao LY, 2003, MOL MICROBIOL, V49, P1547, DOI 10.1046/j.1365-2958.2003.03667.x; GASTAMBIDEODIER M, 1960, BIOCHEM Z, V333, P285; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; GUILHOT C, 1992, FEMS MICROBIOL LETT, V98, P181; Jager W, 1996, ARCH MICROBIOL, V166, P76, DOI 10.1007/s002030050359; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; KUNDU M, 1991, J GEN MICROBIOL, V137, P2197, DOI 10.1099/00221287-137-9-2197; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Le Dantec C, 2001, J BACTERIOL, V183, P2157, DOI 10.1128/JB.183.7.2157-2164.2001; Lee RE, 1997, BBA-LIPID LIPID MET, V1346, P275, DOI 10.1016/S0005-2760(97)00051-9; Liu J, 1999, P NATL ACAD SCI USA, V96, P4011, DOI 10.1073/pnas.96.7.4011; Marrakchi H, 2000, MICROBIOL-UK, V146, P289, DOI 10.1099/00221287-146-2-289; Mdluli K, 1998, MOL MICROBIOL, V27, P1223, DOI 10.1046/j.1365-2958.1998.00774.x; Mills JA, 2004, J BIOL CHEM, V279, P43540, DOI 10.1074/jbc.M407782200; Minnikin D. E., 1980, MICROBIOLOGICAL CLAS, P189; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Parish T, 1998, METH MOL B, V101, P77, DOI 10.1385/0-89603-471-2:77; Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x; PEYRET JL, 1993, MOL MICROBIOL, V9, P97, DOI 10.1111/j.1365-2958.1993.tb01672.x; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; REYES O, 1991, GENE, V107, P61, DOI 10.1016/0378-1119(91)90297-O; SHIMAKATA T, 1984, ARCH BIOCHEM BIOPHYS, V229, P329, DOI 10.1016/0003-9861(84)90159-0; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; WALKER RW, 1973, BIOCHIM BIOPHYS ACTA, V326, P52, DOI 10.1016/0005-2760(73)90027-1; Wang L, 2000, J BIOL CHEM, V275, P7224, DOI 10.1074/jbc.275.10.7224; *WHO, 2000, WHO IUATLD GLOB PROJ; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469	51	129	137	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8862	8874		10.1074/jbc.M408578200	http://dx.doi.org/10.1074/jbc.M408578200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632194	hybrid			2022-12-27	WOS:000227453100031
J	Proweller, A; Pear, WS; Parmacek, MS				Proweller, A; Pear, WS; Parmacek, MS			Notch signaling represses myocardin-induced smooth muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR CHF1/HEY2; CARDIAC GENE-EXPRESSION; IN-VIVO; VASCULAR DEVELOPMENT; EMBRYONIC LETHALITY; NEOINTIMA FORMATION; ARTERIAL INJURY; CARG ELEMENTS; GROWTH-FACTOR	Notch signaling is essential for vascular patterning and response of the vasculature to injury and growth factor stimulation. Despite these findings, the molecular basis of Notch signaling in the vasculature is poorly understood. Here we report that activation of Notch signaling mediated through members of the HRT family of basic helix-loop-helix transcription factors represses smooth muscle cell (SMC) differentiation and expression of genes encoding smooth muscle cell contractile markers. Activation of Notch receptors by Jagged1 or forced expression of the constitutively active Notch1 intracellular domain in C3H10T1/2 fibroblasts inhibited myocardin-dependent transcription of SMC-restricted genes and activity of multiple SMC-restricted transcriptional regulatory elements. Consistent with these findings, forced expression of HRT2 inhibited myocardin-induced expression of SMC-restricted genes and activity of SMC-restricted transcriptional regulatory elements. Moreover, forced expression of HRT2 repressed transcription of multiple SMC-restricted transcriptional regulatory elements in A10 SMCs. The repressive function of HRT2 was not mediated via the capacity of HRT2 to bind SMC CArG elements or by disruption of myocardin-SRF protein complexes. Structure-function analyses of HRT2 indicated that repression required the basic DNA binding domain and additional C-terminal sequence. Taken together, these results demonstrate that Notch signaling represses myocardin-dependent SMC transcription. These data are consistent with a model wherein Notch signaling represses SMC differentiation and maintenance of the contractile SMC phenotype.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Parmacek, MS (corresponding author), Univ Penn, Dept Med, 9123 Founders Pavil,3400 Spruce St, Philadelphia, PA 19104 USA.	Michael.parmacek@uphs.upenn.edu		Parmacek, Michael/0000-0003-1449-4665	NCI NIH HHS [P01 CA93615] Funding Source: Medline; NHLBI NIH HHS [P01 HL075380, T32 HL0783, R01 HL56915, K08 HL079072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA093615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL079072, R01HL056915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; BochatonPiallat ML, 1996, ARTERIOSCL THROM VAS, V16, P815, DOI 10.1161/01.ATV.16.6.815; Campos AH, 2002, CIRC RES, V91, P999, DOI 10.1161/01.RES.0000044944.99984.25; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004; Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Iso T, 2003, ARTERIOSCL THROM VAS, V23, P543, DOI 10.1161/01.ATV.0000060892.81529.8F; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kamath BM, 2004, CIRCULATION, V109, P1354, DOI 10.1161/01.CIR.0000121361.01862.A4; Kathiriya IS, 2004, J BIOL CHEM, V279, P54937, DOI 10.1074/jbc.M409879200; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; MAJESKY MW, 1994, TEX HEART I J, V21, P78; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9; Rao RS, 1997, CARDIOVASC RES, V36, P118, DOI 10.1016/S0008-6363(97)00156-9; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Ross DA, 2004, EXP CELL RES, V296, P173, DOI 10.1016/j.yexcr.2004.02.003; Sakata Y, 2004, ARTERIOSCL THROM VAS, V24, P2069, DOI 10.1161/01.ATV.0000143936.77094.a4; Sakata Y, 2002, P NATL ACAD SCI USA, V99, P16197, DOI 10.1073/pnas.252648999; Shanahan CM, 1997, ARTERIOSCL THROM VAS, V17, P2437, DOI 10.1161/01.ATV.17.11.2437; Shanahan CM, 1998, ARTERIOSCL THROM VAS, V18, P333, DOI 10.1161/01.ATV.18.3.333; Strobeck M, 2001, J BIOL CHEM, V276, P16418, DOI 10.1074/jbc.M100631200; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Wamhoff BR, 2004, CIRC RES, V95, P981, DOI 10.1161/01.RES.0000147961.09840.fb; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang DZ, 2004, CURR OPIN GENET DEV, V14, P558, DOI 10.1016/j.gde.2004.08.003; Wang WL, 2003, BIOCHEM BIOPH RES CO, V308, P596, DOI 10.1016/S0006-291X(03)01453-0; Wang WL, 2002, J BIOL CHEM, V277, P23165, DOI 10.1074/jbc.M201409200; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	62	97	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8994	9004		10.1074/jbc.M413316200	http://dx.doi.org/10.1074/jbc.M413316200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634680	hybrid			2022-12-27	WOS:000227453100046
J	Wei, CC; Wang, ZQ; Durra, D; Hemann, C; Hille, R; Garcin, ED; Getzoff, ED; Stuehr, DJ				Wei, CC; Wang, ZQ; Durra, D; Hemann, C; Hille, R; Garcin, ED; Getzoff, ED; Stuehr, DJ			The three nitric-oxide synthases differ in their kinetics of tetrahydrobiopterin radical formation, heme-dioxy reduction, and arginine hydroxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-TURNOVER CONDITIONS; STOPPED-FLOW SPECTROSCOPY; NO COMPLEX-FORMATION; ELECTRON-TRANSFER; ENDOTHELIAL-CELLS; BINDING-KINETICS; OXYGEN-BINDING; CATALYSIS; DOMAIN; PTERIN	The nitric-oxide synthases (NOSs) make nitric oxide and citrulline from L-arginine. How the bound cofactor (6R)-tetrahydrobiopterin (H4B) participates in Arg hydroxylation is a topic of interest. We demonstrated previously that H4B radical formation in the inducible NOS oxygenase domain (iNOSoxy) is kinetically coupled to the disappearance of a heme-dioxy intermediate and to Arg hydroxylation. Here we report single turnover studies that determine and compare the kinetics of these transitions in Arg hydroxylation reactions catalyzed by the oxygenase domains of endothelial and neuronal NOSs (eNOSoxy and nNOSoxy). There was a buildup of a heme-dioxy intermediate in eNOSoxy and nNOSoxy followed by a monophasic transition to ferric enzyme during the reaction. The rate of heme-dioxy decay matched the rates of H4B radical formation and Arg hydroxylation in both enzymes. The rates of H4B radical formation differed such that nNOSoxy (18 s(-1)) > iNOSoxy (11 s(-1)) > eNOSoxy (6 s(-1)), whereas the lifetimes of the resulting H4B radical followed an opposite rank order. 5MeH(4)B supported a three-fold faster radical formation and greater radical stability relative to H4B in both eNOSoxy and nNOSoxy. Our results indicate the following: (i) the three NOSs share a common mechanism, whereby H4B transfers an electron to the heme-dioxy intermediate. This step enables Arg hydroxylation and is rate-limiting for all subsequent steps in the hydroxylation reaction. (ii) A direct correlation exists between pterin radical stability and the speed of its formation in the three NOSs. (iii) Uncoupled NO synthesis often seen for eNOS at low H4B concentrations may be caused by the slow formation and poor stability of its H4B radical.	Cleveland Clin Fdn, Dept Immunol NB3, Lerner Res Inst, Cleveland, OH 44195 USA; Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Cleveland Clinic Foundation; Scripps Research Institute; University System of Ohio; Ohio State University	Wei, CC (corresponding author), Cleveland Clin Fdn, Dept Immunol NB3, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	weic@ccf.org; stuehrd@ccf.org	Garcin, Elsa D/C-1556-2013	Garcin, Elsa D/0000-0003-0501-8421; Wei, Chin-Chuan/0000-0001-6453-9409; Hemann, Craig/0000-0002-7380-4072	NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058481] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL58883] Funding Source: Medline; NIGMS NIH HHS [GM58481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Bec N, 2000, J INORG BIOCHEM, V81, P207, DOI 10.1016/S0162-0134(00)00104-5; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berka V, 2004, BIOCHEMISTRY-US, V43, P13137, DOI 10.1021/bi049026j; Berka V, 2004, J BIOL CHEM, V279, P32243, DOI 10.1074/jbc.M404044200; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Du M, 2003, J BIOL CHEM, V278, P6002, DOI 10.1074/jbc.M209606200; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Groves JT, 2000, CURR OPIN CHEM BIOL, V4, P687, DOI 10.1016/S1367-5931(00)00146-0; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; Iwanaga T, 1999, BIOCHEMISTRY-US, V38, P16629, DOI 10.1021/bi991277i; KLATT P, 1994, J BIOL CHEM, V269, P13861; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Marchal S, 2004, J BIOL CHEM, V279, P19824, DOI 10.1074/jbc.M313587200; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Rosenfeld RJ, 2002, BIOCHEMISTRY-US, V41, P13915, DOI 10.1021/bi026313j; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Rusche KM, 2001, J BIOL CHEM, V276, P421, DOI 10.1074/jbc.M006860200; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Wang ZQ, 2001, BIOCHEMISTRY-US, V40, P12819, DOI 10.1021/bi011182s; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; Wei CC, 2002, METHOD ENZYMOL, V354, P320; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143	46	41	42	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8929	8935		10.1074/jbc.M409737200	http://dx.doi.org/10.1074/jbc.M409737200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632185	hybrid			2022-12-27	WOS:000227453100039
J	Barnes, AP; Livera, G; Huang, PB; Sun, CW; O'Neal, WK; Conti, M; Stutts, MJ; Milgram, SL				Barnes, AP; Livera, G; Huang, PB; Sun, CW; O'Neal, WK; Conti, M; Stutts, MJ; Milgram, SL			Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA(2) ADRENERGIC-RECEPTOR; ACTIVATED PROTEIN-KINASE; CL-SECRETION; RAT-BRAIN; CELLS; CFTR; PHOSPHORYLATION; EXPRESSION; IDENTIFICATION	We demonstrated previously that Calu-3 airway epithelial cells sense adenosine on their luminal surface through adenosine A2B receptors coupled to adenylyl cyclase. Occupancy of these receptors leads to activation of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel through protein kinase A (PKA) anchored at the apical membrane. Because luminal A2B receptor activation does not raise total cellular cAMP levels, we hypothesized that activation of phosphodiesterases (PDEs) confines cAMP generated by apical A2B receptors to a microdomain that includes the CFTR channel. Using reverse transcription-PCR, Western blotting, and activity measurements, PDE4D was identified as the major PDE species in airway epithelia. Consistent with these results, inhibitors of PDE4, but not PDE3, selectively abolished the lateral confinement of cAMP signaling in apical membrane patches during cell-attached recordings. Furthermore, stimulation of the CFTR in excised apical patches by rolipram and RS25344 indicated that PDE4 is localized in close proximity to the CFTR channel. Indeed, immunohistochemistry of human airway sections revealed that PDE4D is localized in the apical domain of the cell. PDE4 was activated after luminal adenosine exposure in a PKA-dependent manner. Because PDE4 activity is positively regulated by PKA, our results support a model whereby the PDE diffusion barrier is proportional to the degree of receptor stimulation. These findings underscore the concept that subcellular localization of individual PDE isozymes is an important mechanism for confining cAMP signaling to functional domains within cells.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res, Chapel Hill, NC 27599 USA; Univ N Carolina, Treatment Ctr, Chapel Hill, NC 27599 USA; Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Stanford University	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Campus Box 7090, Chapel Hill, NC 27599 USA.	milg@med.unc.edu	LIVERA, Gabriel/F-5740-2019; Huang, Pingbo/I-1127-2019	LIVERA, Gabriel/0000-0001-8436-4730; Huang, Pingbo/0000-0002-4560-8760; Barnes, Anthony/0000-0002-4598-9591	NHLBI NIH HHS [HL34322, HL60280] Funding Source: Medline; NICHD NIH HHS [5T32HD40127-02, HD20788] Funding Source: Medline; NIDDK NIH HHS [KO1 DK02777-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD040127] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060280, P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002777] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Cobb BR, 2003, AM J RESP CELL MOL, V29, P410, DOI 10.1165/rcmb.2002-0247OC; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Cui X, 2002, EUR J PHARMACOL, V451, P295, DOI 10.1016/S0014-2999(02)02294-X; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Fuhrmann M, 1999, AM J RESP CELL MOL, V20, P292, DOI 10.1165/ajrcmb.20.2.3140; Gadsby DC, 1999, ADV SEC MESS PHOSPH, V33, P79; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; Jurevicius J, 2003, J PHYSIOL-LONDON, V551, P239, DOI 10.1113/jphysiol.2003.045211; Kelley TJ, 1997, P NATL ACAD SCI USA, V94, P2604, DOI 10.1073/pnas.94.6.2604; KELLEY TJ, 1995, AM J RESP CELL MOL, V13, P657, DOI 10.1165/ajrcmb.13.6.7576703; Kreda SM, 2000, NAT BIOTECHNOL, V18, P635, DOI 10.1038/76479; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; KREDA SM, 2004, PEDIATR PULM, V38, P199; Kultgen PL, 2002, MOL BIOL CELL, V13, P4156, DOI 10.1091/mbc.E02-07-0391; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Mehats C, 2003, FASEB J, V17, P1831, DOI 10.1096/fj.03-0274com; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; O'Grady SM, 2002, J MEMBRANE BIOL, V185, P137, DOI 10.1007/s00232-001-0120-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Randak C, 2003, CELL, V115, P837, DOI 10.1016/S0092-8674(03)00983-8; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; SETTE C, 1994, J BIOL CHEM, V269, P9245; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Singh Ashvani K, 2002, Methods Mol Med, V70, P129; Smith SN, 1999, AM J RESP CELL MOL, V20, P129, DOI 10.1165/ajrcmb.20.1.3278; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; STUTTS MJ, 1995, AM J PHYSIOL-CELL PH, V268, pC425, DOI 10.1152/ajpcell.1995.268.2.C425; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Wright LC, 1998, AM J PHYSIOL-LUNG C, V275, pL694, DOI 10.1152/ajplung.1998.275.4.L694; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	45	85	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7997	8003		10.1074/jbc.M407521200	http://dx.doi.org/10.1074/jbc.M407521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611099	Green Published, hybrid			2022-12-27	WOS:000227395700069
J	Braun, DC; Garfield, SH; Blumberg, PM				Braun, DC; Garfield, SH; Blumberg, PM			Analysis by fluorescence resonance energy transfer of the interaction between ligands and protein kinase C delta in the intact cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPROMOTING 12-DEOXYPHORBOL 13-ESTERS; PHORBOL 12-MYRISTATE 13-ACETATE; CD-1 MOUSE SKIN; DOWN-REGULATION; BRYOSTATIN 1; GLUTAMINE-SYNTHETASE; LIVING CELLS; GLIAL-CELLS; IN-VIVO; PHOSPHORYLATION	The role of the protein kinase C (PKC) family of serine/threonine kinases in cellular differentiation, proliferation, apoptosis, and other responses makes them attractive therapeutic targets. The activation of PKCs by ligands in vivo varies depending upon cell type; therefore, methods are needed to screen the potency of PKCs in this context. Here we describe a genetically encoded chimera of native PKCdelta fused to yellow- and cyan-shifted green fluorescent protein, which can be expressed in mammalian cells. This chimeric protein kinase, CY-PKCdelta, retains native or near-native activity in the several biological and biochemical parameters that we tested. Binding assays showed that CY-PKCdelta and native human PKCdelta have similar binding affinity for phorbol 12,13-dibutyrate. Analysis of translocation by Western blotting and confocal microscopy showed that CY-PKCdelta, translocates from the cytosol to the membrane upon treatment with ligand, that the translocation has similar dose dependence as that of endogenous PKCdelta, and that the pattern of translocation is indistinguishable from that of the green fluorescent protein-PKCdelta fusion well characterized from earlier studies. Treatment with phorbol ester of cells expressing CY-PKCdelta resulted in a dose-dependent increase in FRET that could be visualized in situ by confocal microscopy or measured fluorometrically. By using this construct, we were able to measure the kinetics and potencies of 12 known PKC ligands, with respect to CY-PKCdelta, in the intact cell. The CY-PKCdelta chimera and the in vivo assays described here therefore show potential for high throughput screening of prospective PKCdelta ligands within the context of cell type.	NCI, NIH, Lab Expt Carcinogenesis, Bethesda, MD 20892 USA; Gallaudet Univ, Dept Biol, Washington, DC 20002 USA; Cellular Carcinogenesis & Tumor Promot Lab, Washington, DC 20002 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blumberg, PM (corresponding author), NCI, NIH, Lab Expt Carcinogenesis, Bldg 37,Rm 4048,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005270, Z01BC005270] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Bocklandt S, 2003, ANTIVIR RES, V59, P89, DOI 10.1016/S0166-3542(03)00034-2; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Brodie C, 1998, MOL BRAIN RES, V56, P108, DOI 10.1016/S0169-328X(98)00035-7; Calleja V, 2003, BIOCHEM J, V372, P33, DOI 10.1042/BJ20030358; Clamp A, 2002, ANTI-CANCER DRUG, V13, P673, DOI 10.1097/00001813-200208000-00001; DOKAS LA, 1990, BRAIN RES BULL, V24, P321, DOI 10.1016/0361-9230(90)90086-F; Graham DL, 2001, ANAL BIOCHEM, V296, P208, DOI 10.1006/abio.2001.5306; GUSTAFSON KR, 1992, J MED CHEM, V35, P1978, DOI 10.1021/jm00089a006; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Hurley JH, 1997, PROTEIN SCI, V6, P477; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Kedei N, 2004, CANCER RES, V64, P3243, DOI 10.1158/0008-5472.CAN-03-3403; KUBINYI H, 1976, ARZNEIMITTEL-FORSCH, V26, P1991; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P133; Lewin Nancy E, 2003, Methods Mol Biol, V233, P129; Lorenzo PS, 1997, J BIOL CHEM, V272, P33338, DOI 10.1074/jbc.272.52.33338; Lorenzo PS, 1999, CANCER RES, V59, P6137; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mochly-Rosen D, 2000, SEMIN IMMUNOL, V12, P55, DOI 10.1006/smim.2000.0207; Murphy TV, 1999, EUR J PHARMACOL, V381, P77, DOI 10.1016/S0014-2999(99)00540-3; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Neininger A, 2001, EMBO REP, V2, P703, DOI 10.1093/embo-reports/kve157; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Ogbourne SM, 2004, CANCER RES, V64, P2833, DOI 10.1158/0008-5472.CAN-03-2837; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Sambrook J., 2001, MOL CLONING LAB MANU; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1993, CANCER RES, V53, P2507; SZALLASI Z, 1992, CARCINOGENESIS, V13, P2161, DOI 10.1093/carcin/13.11.2161; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Truong K, 2001, NAT STRUCT BIOL, V8, P1069, DOI 10.1038/nsb728; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wan QJ, 2000, J BIOL CHEM, V275, P12136, DOI 10.1074/jbc.275.16.12136; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233	41	35	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8164	8171		10.1074/jbc.M413896200	http://dx.doi.org/10.1074/jbc.M413896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611119	hybrid			2022-12-27	WOS:000227395700089
J	Gonen, R; Beach, D; Ainey, C; Yablonski, D				Gonen, R; Beach, D; Ainey, C; Yablonski, D			T cell receptor-induced activation of phospholipase C-gamma 1 depends on a sequence-independent function of the P-I region of SLP-76	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE RESIDUES; ANTIGEN RECEPTOR; MOLECULAR-CLONING; LAT; PHOSPHORYLATION; REQUIREMENT; PLC-GAMMA-1; DOMAINS; LOCALIZATION; STIMULATION	SLP- 76 forms part of a hematopoietic- specific adaptor protein complex, and is absolutely required for T cell development and activation. T cell receptor ( TCR)- induced activation of phospholipase C- gamma1 ( PLC- gamma1) depends on three features of SLP- 76: the N- terminal tyrosine phosphorylation sites, the Gads- binding site, and an intervening sequence, denoted the P- I region, which binds to the SH3 domain of PLC- gamma1 ( SH3(PLC)) via a low affinity interaction. Despite extensive research, the mechanism whereby SLP- 76 regulates PLC- gamma1 remains uncertain. In this study, we uncover and explore an apparent paradox: whereas the P- I region as a whole is essential for TCRinduced activation of PLC- gamma1 and nuclear factor of activated T cells ( NFAT), no particular part of this region is absolutely required. To better understand the contribution of the P- I region to PLC- gamma1 activation, we mapped the PLC- gamma1- binding site within the region, and created a SLP- 76 mutant that fails to bind SH3PLC, but is fully functional, mediating TCR- induced phosphorylation of PLC- gamma1 at tyrosine 783, calcium flux, and nuclear factor of activated T cells activation. Unexpectedly, full functionality of this mutant was maintained even under less than optimal stimulation conditions, such as a low concentration of the anti- TCR antibody. Another SLP- 76 mutant, in which the P- I region was scrambled to abolish any sequencedependent protein- binding motifs, also retained significant functionality. Our results demonstrate that SLP- 76 need not interact with SH3(PLC) to activate PLC- gamma1, and further suggest that the P- I region of SLP- 76 serves a structural role that is sequence- independent and is not directly related to protein- protein interactions.	Technion Israel Inst Technol, Rappaport Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Yablonski, D (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, POB 9649,Bat Galim, IL-31096 Haifa, Israel.	debya@tx.technion.ac.il		Yablonski, Deborah/0000-0003-2979-0440; Blecher, Ronnie/0000-0003-2847-1149				Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Ebinu JO, 2000, BLOOD, V95, P3199; Fang N, 1996, J IMMUNOL, V157, P3769; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Houtman JCD, 2004, BIOCHEMISTRY-US, V43, P4170, DOI 10.1021/bi0357311; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; Kettner A, 2003, MOL CELL BIOL, V23, P2395, DOI 10.1128/MCB.23.7.2395-2406.2003; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kumar L, 2002, P NATL ACAD SCI USA, V99, P884, DOI 10.1073/pnas.022619199; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; Newbrough SA, 2003, IMMUNITY, V19, P759; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sambrook J., 2001, MOL CLONING LAB MANU; Sanzenbacher R, 1999, J IMMUNOL, V163, P3143; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Singer AL, 2004, J BIOL CHEM, V279, P15481, DOI 10.1074/jbc.M313339200; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stoica B, 1998, J IMMUNOL, V160, P1059; Tvorogov D, 2002, EXP CELL RES, V277, P86, DOI 10.1006/excr.2002.5545; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WU J, 1995, MOL CELL BIOL, V15, P4337; Yablonski D, 2001, ADV IMMUNOL, V79, P93, DOI 10.1016/S0065-2776(01)79003-7; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8364	8370		10.1074/jbc.M409437200	http://dx.doi.org/10.1074/jbc.M409437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623534	hybrid			2022-12-27	WOS:000227395700112
J	Kragt, A; Brouwer, TV; van den Berg, M; Distel, B				Kragt, A; Brouwer, TV; van den Berg, M; Distel, B			The Saccharomyces cerevisiae peroxisomal import receptor Pex5p is monoubiquitinated in wild type cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; MEMBRANE-PROTEIN PEX13P; PTS1 RECEPTOR; ENDOPLASMIC-RETICULUM; HANSENULA-POLYMORPHA; PICHIA-PASTORIS; SH3 DOMAIN; BIOGENESIS; MATRIX; INTERACTS	Pex5p is a mobile receptor for peroxisomal targeting signal type I-containing proteins that cycles between the cytoplasm and the peroxisome. Here we show that Pex5p is a stable protein that is monoubiquitinated in wild type cells. By making use of mutants defective in vacuolar or proteasomal degradation we demonstrate that monoubiquitinated Pex5p is not a breakdown intermediate of either system. Monoubiquitinated Pex5p is localized to peroxisomes, and ubiquitination requires the presence of functional docking and RING finger complexes, which suggests that it is a late event in peroxisomal matrix protein import. In pex1, pex4, pex6, pex15, and pex22 mutants, all of which are blocked in the terminal steps of peroxisomal matrix protein import, polyubiquitinated forms of Pex5p accumulate, ubiquitination being dependent on the ubiquitin-conjugating enzyme Ubc4p. However, Ubc4p is not required for Pex5p ubiquitination in wild type cells, and cells lacking Ubc4p are not affected in peroxisome biogenesis. These results indicate that Pex5p monoubiquitination in wild type cells serves to regulate rather than to degrade Pex5p, which is supported by the observed stability of Pex5p. We propose that Pex5p monoubiquitination in wild type cells is required for the recycling of Pex5p from the peroxisome, whereas Ubc4p-mediated polyubiquitination of Pex5p in mutants blocked in the terminal steps of peroxisomal matrix protein import may function as a disposal mechanism for Pex5p when it gets stuck in the import pathway.	Acad Med Ctr, Dept Biochem Med, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Distel, B (corresponding author), Acad Med Ctr, Dept Biochem Med, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.distel@amc.uva.nl						Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Amerik AY, 1997, EMBO J, V16, P4826; Birschmann I, 2003, MOL BIOL CELL, V14, P2226, DOI 10.1091/mbc.E02-11-0752; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; DEJONGE W, 2003, THESIS U UTRECHT UTR; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Eckert JH, 2003, J CELL SCI, V116, P3623, DOI 10.1242/jcs.00678; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; GUELMAN R, 2002, BONE, V30, P23; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson MA, 2001, YEAST, V18, P621, DOI 10.1002/yea.711; JONES EW, 1977, GENETICS, V85, P23; Kiel JAKW, 2005, J BIOL CHEM, V280, P1921, DOI 10.1074/jbc.M403632200; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; Komori M, 1999, FEBS LETT, V457, P397, DOI 10.1016/S0014-5793(99)01087-X; Kunau WH, 2001, CURR BIOL, V11, pR659, DOI 10.1016/S0960-9822(01)00386-4; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Platta H, 2004, BIOCHEM J, V384, P37, DOI 10.1042/BJ20040572; Purdue PE, 2001, J BIOL CHEM, V276, P47684, DOI 10.1074/jbc.M106823200; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	53	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7867	7874		10.1074/jbc.M413553200	http://dx.doi.org/10.1074/jbc.M413553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632140	hybrid			2022-12-27	WOS:000227395700054
J	Prakash, R; Krejci, L; Van Komen, S; Schurer, KA; Kramer, W; Sung, P				Prakash, R; Krejci, L; Van Komen, S; Schurer, KA; Kramer, W; Sung, P			Saccharomyces cerevisiae MPH1 gene, required for homologous recombination-mediated mutation avoidance, encodes a 3 ' to 5 ' DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENTS; RAD51 RECOMBINASE; DNA-DAMAGE; YEAST; SRS2; PROTEINS; MUTANTS; REPAIR; MPH1	The MPH1 (mutator pHenotype 1) gene of Saccharomyces cerevisiae was identified on the basis of elevated spontaneous mutation rates of haploid cells deleted for this gene. Further studies showed that MPH1 functions to channel DNA lesions into an error-free DNA repair pathway. The Mph1 protein contains the seven conserved motifs of the superfamily 2 (SF2) family of nucleic acid unwinding enzymes. Genetic analyses have found epistasis of the mph1 deletion with mutations in the RAD52 gene group that mediates homologous recombination and DNA repair by homologous recombination. To begin dissecting the biochemical functions of the MPH1-encoded product, we have expressed it in yeast cells and purified it to near homogeneity. We show that Mph1 has a robust ATPase function that requires single-stranded DNA for activation. Consistent with its homology to members of the SF2 helicase family, we find a DNA helicase activity in Mph1. We present data to demonstrate that the Mph1 DNA helicase activity is fueled by ATP hydrolysis and has a 3' to 5' polarity with respect to the DNA strand on which this protein translocates. The DNA helicase activity of Mph1 is enhanced by the heterotrimeric single-stranded DNA binding protein replication protein A. These results, thus, establish Mph1 as an ATP-dependent DNA helicase, and the availability of purified Mph1 should facilitate efforts at deciphering the role of this protein in homologous recombination and mutation avoidance.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Gottingen, Inst Genet & Microbiol, Dept Mol Genet & Preparat Mol Biol, D-37077 Gottingen, Germany	Yale University; University of Gottingen	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,C130 Sterling Hall Med, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu	Krejci, Lumir/B-7842-2009	Krejci, Lumir/0000-0002-4732-1405	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES07061] Funding Source: Medline; NIGMS NIH HHS [R01GM57814] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Aylon Y, 2004, MUTAT RES-REV MUTAT, V566, P231, DOI 10.1016/j.mrrev.2003.10.001; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; EINBERGER H, 1990, J VIROL, V64, P4274, DOI 10.1128/JVI.64.9.4274-4280.1990; Entian KD, 1999, MOL GEN GENET, V262, P683, DOI 10.1007/PL00013817; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; PALLADINO F, 1992, GENETICS, V132, P23; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RONG L, 1991, GENETICS, V127, P75; Scheller J, 2000, GENETICS, V155, P1069; Schurer KA, 2004, GENETICS, V166, P1673, DOI 10.1534/genetics.166.4.1673; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Van Komen S, 2003, J BIOL CHEM, V278, P44331, DOI 10.1074/jbc.M307256200; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7	21	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7854	7860		10.1074/jbc.M413898200	http://dx.doi.org/10.1074/jbc.M413898200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15634678	hybrid			2022-12-27	WOS:000227395700052
J	Sun, MH; Andreassi, JL; Liu, SQ; Pinto, R; Triccas, JA; Leyh, TS				Sun, MH; Andreassi, JL; Liu, SQ; Pinto, R; Triccas, JA; Leyh, TS			The trifunctional sulfate-activating complex (SAC) of Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-PHOSPHOSULFATE KINASE; ATP SULFURYLASE-GTPASE; PHOSPHORYLATED ENZYME INTERMEDIATE; PENICILLIUM-CHRYSOGENUM; ADENOSINE-5'-PHOSPHOSULFATE KINASE; CHLAMYDOMONAS-REINHARDII; ADENYLYLSULFATE KINASE; CONFORMATIONAL-CHANGE; PURIFICATION; HYDROLYSIS	The sulfate activation pathway is essential for the assimilation of sulfate and, in many bacteria, is comprised of three reactions: the synthesis of adenosine 5'-phosphosulfate (APS), the hydrolysis of GTP, and the 3'-phosphorylation of APS to produce 3'-phosphoadenosine 5'-phosphosulfate ( PAPS), whose sulfuryl group is reduced or transferred to other metabolites. The entire sulfate activation pathway is organized into a single complex in Mycobacterium tuberculosis. Although present in many bacteria, these tripartite complexes have not been studied in detail. Initial rate characterization of the mycobacterial system reveals that it is poised for extremely efficient throughput: at saturating ATP, PAPS synthesis is 5800 times more efficient than APS synthesis. The APS kinase domain of the complex does not appear to form the covalent E (.) P intermediate observed in the closely related APS kinase from Escherichia coli. The stoichiometry of GTP hydrolysis and APS synthesis is 1:1, and the APS synthesis reaction is driven 1.1 x 10(6)-fold further during GTP hydrolysis; the system harnesses the full chemical potential of the hydrolysis reaction to the synthesis of APS. A key energy-coupling step in the mechanism is a ligand-induced isomerization that enhances the affinity of GTP and commits APS synthesis and GTP hydrolysis to the completion of the catalytic cycle. Ligand-induced increases in guanine nucleotide affinity observed in the mycobacterial system suggest that it too undergoes the energy-coupling isomerization.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Centenary Inst Canc Med & Cell Biol, Mycobacterial Res Grp, Newtown, NSW 2042, Australia	Yeshiva University; Albert Einstein College of Medicine; University of Sydney; Centenary Institute	Leyh, TS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	leyh@aecom.yu.edu	Triccas, Jamie/AAD-7629-2020	Triccas, James/0000-0003-3730-2339	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054469] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54469] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Britton Warwick J., 1994, Trends in Microbiology, V2, P284, DOI 10.1016/0966-842X(94)90005-1; Buchmeier NA, 2003, MOL MICROBIOL, V47, P1723, DOI 10.1046/j.1365-2958.2003.03416.x; Cleland W W, 1979, Methods Enzymol, V63, P103; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; GOREN MB, 1976, P NATL ACAD SCI USA, V73, P2510, DOI 10.1073/pnas.73.7.2510; GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P116, DOI 10.1016/0005-2760(70)90067-6; HOMMES FA, 1987, BIOCHIM BIOPHYS ACTA, V924, P270, DOI 10.1016/0304-4165(87)90022-5; Jencks W. P., 1976, HDB BIOCH MOL BIOL, V1, P296; JENDER HG, 1984, ARCH MICROBIOL, V138, P9, DOI 10.1007/BF00425399; KANNO N, 1990, BOT MAR, V33, P369, DOI 10.1515/botm.1990.33.4.369; Kochi A, 2001, B WORLD HEALTH ORGAN, V79, P71; Lansdon EB, 2002, BIOCHEMISTRY-US, V41, P13672, DOI 10.1021/bi026556b; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LIU CX, 1994, BIOCHEMISTRY-US, V33, P7309, DOI 10.1021/bi00189a036; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; MIDDLEBROOK G, 1959, P NATL ACAD SCI USA, V45, P1801, DOI 10.1073/pnas.45.12.1801; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; Nunn P, 2001, SCAND J INFECT DIS, V33, P329, DOI 10.1080/003655401750173887; PABST MJ, 1988, J IMMUNOL, V140, P634; Pinto R, 2004, MICROBIOL-SGM, V150, P1681, DOI 10.1099/mic.0.26894-0; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; ROBBINS PW, 1958, J BIOL CHEM, V233, P686; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SATISHCHANDRAN C, 1989, J BIOL CHEM, V264, P15012; Satishchandran C, 2000, ARCH BIOCHEM BIOPHYS, V378, P210, DOI 10.1006/abbi.2000.1841; SCHWENN JD, 1981, PHYTOCHEMISTRY, V20, P601, DOI 10.1016/0031-9422(81)85141-2; SCHWENN JD, 1984, FEBS LETT, V170, P76, DOI 10.1016/0014-5793(84)81372-1; Spiegelberg BD, 1999, J BIOL CHEM, V274, P13619, DOI 10.1074/jbc.274.19.13619; Sprinzl M, 2000, BIOL CHEM, V381, P367, DOI 10.1515/BC.2000.049; STORER AC, 1974, BIOCHEM J, V141, P205, DOI 10.1042/bj1410205; Triccas JA, 1999, MICROBIOL-SGM, V145, P2923, DOI 10.1099/00221287-145-10-2923; Triccas JA, 2000, IMMUNOL CELL BIOL, V78, P311, DOI 10.1046/j.1440-1711.2000.00934.x; WANG RX, 1995, BIOCHEMISTRY-US, V34, P490, DOI 10.1021/bi00002a013; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wei J, 1998, BIOCHEMISTRY-US, V37, P17163, DOI 10.1021/bi9817461; Wei J, 1999, BIOCHEMISTRY-US, V38, P6311, DOI 10.1021/bi990216h; Wei J, 2000, BIOCHEMISTRY-US, V39, P4704, DOI 10.1021/bi992210y; Wei J, 2002, BIOCHEMISTRY-US, V41, P8493, DOI 10.1021/bi025953j	42	23	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7861	7866		10.1074/jbc.M409613200	http://dx.doi.org/10.1074/jbc.M409613200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615729	hybrid			2022-12-27	WOS:000227395700053
J	Mahata, B; Bhattacharyya, SN; Mukherjee, S; Adhya, S				Mahata, B; Bhattacharyya, SN; Mukherjee, S; Adhya, S			Correction of translational defects in patient-derived mutant mitochondria by complex-mediated import of a cytoplasmic tRNA*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA MITOCHONDRIA; TRYPANOSOMA-BRUCEI; INNER MEMBRANE; MERRF-SYNDROME; NUCLEAR-DNA; MUTATIONS; AMINOACYLATION; SYNTHETASE; RECEPTORS; TRNA(LYS)	A variety of clinical disorders result from mutations in mitochondrial tRNA genes, leading to translational defects. We show here that a protein complex from the kinetoplastid protozoon Leishmania induces specific, ATP-dependent import of human cytoplasmic tRNA(1)(Lys) into human mitochondria in vitro. The imported tRNA undergoes efficient aminoacylation within the organelle and supports organellar protein synthesis. Moreover, translation in mitochondria from patients with myclonic epilepsy with ragged red fibers (MERRF) and Kearns-Sayre syndrome (KSS), containing mutant tRNA(Lys) genes, is stimulated to near-wild-type levels and the formation of aberrant polypeptides suppressed by complex-mediated import. These results suggest a novel way to introduce RNAs for the modulation of mitochondrial gene expression.	Indian Inst Chem Biol, Genet Engn Lab, Kolkata 7000032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, 4 Raja SC Mullick Rd, Kolkata 7000032, W Bengal, India.	sadhya@iicb.res.in	MUKHERJEE, SAIKAT/ABF-1050-2021	Mahata, Bidesh/0000-0002-4506-0184				Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; Bhattacharyya SN, 2004, J BIOL CHEM, V279, P11259, DOI 10.1074/jbc.C300540200; Bhattacharyya SN, 2003, MOL CELL BIOL, V23, P5217, DOI 10.1128/MCB.23.15.5217-5224.2003; Bhattacharyya SN, 2002, MOL CELL BIOL, V22, P4372, DOI 10.1128/MCB.22.12.4372-4382.2002; Bhattacharyya SN, 2000, MOL CELL BIOL, V20, P7410, DOI 10.1128/MCB.20.19.7410-7417.2000; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; Delage L, 2003, PLANT J, V34, P623, DOI 10.1046/j.1365-313X.2003.01752.x; Enriquez J A, 1996, Methods Enzymol, V264, P183, DOI 10.1016/S0076-6879(96)64019-1; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Goswami S, 2003, NUCLEIC ACIDS RES, V31, P5552, DOI 10.1093/nar/gkg773; HANCOCK K, 1990, J BIOL CHEM, V265, P19203; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101; Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931; Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; MERRICK WC, 1983, METHOD ENZYMOL, V101, P606; MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561; Mukherjee S, 1999, J BIOL CHEM, V274, P31249, DOI 10.1074/jbc.274.44.31249; Schneider A, 2000, TRENDS CELL BIOL, V10, P509, DOI 10.1016/S0962-8924(00)01854-7; SCHNEIDER A, 1994, MOL CELL BIOL, V14, P2317, DOI 10.1128/MCB.14.4.2317; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; Sobreira C, 1999, BIOCHEM BIOPH RES CO, V266, P179, DOI 10.1006/bbrc.1999.1758; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x; Tolkunova E, 2000, J BIOL CHEM, V275, P35063, DOI 10.1074/jbc.M006265200; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	28	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5141	5144		10.1074/jbc.C400572200	http://dx.doi.org/10.1074/jbc.C400572200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15619607	hybrid			2022-12-27	WOS:000227217100005
J	Yin, LH; Bennani-Baiti, N; Powell, CT				Yin, LH; Bennani-Baiti, N; Powell, CT			Phorbol ester-induced apoptosis of C4-2 cells requires both a unique and a redundant protein kinase C signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; N-TERMINAL KINASE; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; EPITHELIAL-CELLS; LNCAP MODEL; ACTIVATION; ANDROGEN; ALPHA; PKC; EXPRESSION	Phorbol 12-myristate 13-acetate (PMA) potently induces apoptosis of LNCaP human prostate cancer cells. Here, we show that C4-2 cells, androgen-hypersensitive derivatives of LNCaP cells, also are sensitive to PMA-induced apoptosis. Previous reports have implicated activation of protein kinase C (PKC) isozymes alpha and delta in PMA-induced LNCaP apoptosis using overexpression, pharmacological inhibitors, and dominant-negative constructs, but have left unresolved if other isozymes are involved, if there are separate requirements for individual PKC isozymes, or if there is redundancy. We have resolved these questions in C4-2 cells using stable expression of short hairpin RNAs to knock down expression of specific PKC isozymes individually and in pairs. Partial knockdown of PKCdelta inhibited PMA-induced C4-2 cell death almost completely, whereas near-complete knockdown of PKCalpha had no effect. Knockdown of PKCepsilon alone had no effect, but simultaneous knockdown of both PKCalpha and PKCepsilon in C4-2 cells that continued to express normal levels of PKCdelta inhibited PMA-induced apoptosis. Thus, our data indicate that there is an absolute requirement for PKCdelta in PMA-induced C4-2 apoptosis but that the functions of PKCalpha and PKCepsilon in apoptosis induction are redundant, such that either one (but not both) is required. Investigation of PMA-induced events required for LNCaP and C4-2 apoptosis revealed that p38 activation is dependent on PKCdelta, whereas induction of retinoblastoma protein hypophosphorylation requires both PKC signaling pathways and is downstream of p38 activation in the PKCdelta pathway.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Powell, CT (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, ND50,9500 Euclid Ave, Cleveland, OH 44195 USA.	powellt@ccf.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047650] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK/CA47650] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONIDACINO JS, 2002, CURRENT PROTOCOLS CE; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chen MW, 2002, ONCOGENE, V21, P7861, DOI 10.1038/sj.onc.1205991; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garzotto M, 1998, CANCER RES, V58, P2260; Gregory CW, 2001, CANCER RES, V61, P2892; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Kominsky SL, 2000, CANCER RES, V60, P3904; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sumitomo M, 2000, CANCER RES, V60, P6590; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; THALMANN GN, 1994, CANCER RES, V54, P2577; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; Wu DQ, 2002, CANCER RES, V62, P2423; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; YOUNG CYF, 1994, ONCOL RES, V6, P203; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	29	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5533	5541		10.1074/jbc.M405266200	http://dx.doi.org/10.1074/jbc.M405266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15611126	hybrid			2022-12-27	WOS:000227217100053
J	Gerber, M; Tenney, K; Conaway, JW; Conaway, RC; Eissenberg, JC; Shilatifard, A				Gerber, M; Tenney, K; Conaway, JW; Conaway, RC; Eissenberg, JC; Shilatifard, A			Regulation of heat shock gene expression by RNA polymerase II elongation factor, elongin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-SIII; IN-VIVO; DROSOPHILA-MELANOGASTER; IDENTIFICATION; COMPLEX; PROMOTER; SPT6; END	The elongation stage of transcription by RNA polymerase II (Pol II) has emerged as an essential regulated step. Elongin A (EloA) is the largest subunit of the Elongin complex that can increase the catalytic rate of mRNA synthesis by Pol II. We recently demonstrated that the Elongin A homologue, in Drosophila, dEloA, is essential and has properties consistent with those of a Pol II elongation factor in vivo. The goal of this study was to test whether dEloA is required for heat shock gene transcription, since heat shock gene expression is thought to be controlled at the level of Pol II elongation. Here, we demonstrate that dEloA is rapidly recruited to heat shock loci with Pol II in response to heat shock. Furthermore, through the use of RNA interference in vivo, we show that dEloA is required for the proper expression of one of these genes, HSP70, and that its requirement for heat shock gene expression is exerted after the initiation of transcription at heat shock loci. Our data represent the first demonstration of an essential role for an RNA polymerase II elongation factor in the regulation of heat shock gene expression in an animal model.	St Louis Univ, Hlth Sci Ctr, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; St Louis Univ, Ctr Canc, St Louis, MO 63104 USA	Saint Louis University; Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; Saint Louis University	Shilatifard, A (corresponding author), St Louis Univ, Hlth Sci Ctr, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.	shilatia@slu.edu		Conaway, Joan/0000-0002-2786-0663	NCI NIH HHS [1R01CA089455] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089455] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Aso T, 2000, J BIOL CHEM, V275, P6546, DOI 10.1074/jbc.275.9.6546; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CONAWAY JW, 1993, CELL MOL BIOL RES, V39, P323; Gerber M, 2004, MOL CELL BIOL, V24, P9911, DOI 10.1128/MCB.24.22.9911-9919.2004; Gerber M, 2001, EMBO J, V20, P6104, DOI 10.1093/emboj/20.21.6104; GREENLEAF A L, 1978, Chromosoma (Berlin), V65, P127, DOI 10.1007/BF00329465; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Lis JT, 2000, GENE DEV, V14, P792; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Yamazaki K, 2002, J BIOL CHEM, V277, P26444, DOI 10.1074/jbc.M202859200; Yamazaki K, 2003, J BIOL CHEM, V278, P13585, DOI 10.1074/jbc.C300047200	17	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4017	4020		10.1074/jbc.C400487200	http://dx.doi.org/10.1074/jbc.C400487200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15611125	hybrid			2022-12-27	WOS:000227096600004
J	Hasne, MP; Ullman, B				Hasne, MP; Ullman, B			Identification and characterization of a polyamine permease from the protozoan parasite Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; TRYPANOSOMA-BRUCEI-BRUCEI; ORNITHINE-DECARBOXYLASE; ESCHERICHIA-COLI; DONOVANI PROMASTIGOTES; TRANSPORT PROTEIN; SPERMIDINE TRANSPORT; AMINO-ACIDS; PUTRESCINE; GENE	The proteins that mediate polyamine translocation into eukaryotic cells have not been identified at the molecular level. To define the polyamine transport pathways in eukaryotic cells we have cloned a gene, LmPOT1, that encodes a polyamine transporter from the protozoan pathogen, Leishmania major. Sequence analysis of LmPOT1 predicted an unusual 803-residue polytopic protein with 9 - 12 transmembrane domains. Expression of LmPOT1 cRNA in Xenopus laevis oocytes revealed LmPOT1 to be a high affinity transporter for both putrescine and spermidine, whereas expression of LmPOT1 in Trypanosoma brucei stimulated putrescine uptake that was sensitive to inhibition by pentamidine and proton ionophores. Immunoblot analysis established that LmPOT1 was expressed predominantly in the insect vector form of L. major, and immunofluorescence demonstrated that LmPOT1 was localized predominantly to the parasite plasma membrane. To our knowledge this is the first molecular identification and characterization of a cell surface polyamine transporter in eukaryotic cells.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	ullmanb@ohsu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI041622, R01AI041622] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41622] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Bacchi CJ, 2002, MINI-REV MED CHEM, V2, P553, DOI 10.2174/1389557023405549; BACCHI CJ, 1992, ANTIMICROB AGENTS CH, V36, P2736, DOI 10.1128/AAC.36.12.2736; Balcar VJ, 2002, BIOL PHARM BULL, V25, P291, DOI 10.1248/bpb.25.291; Basselin M, 2000, MOL BIOCHEM PARASIT, V109, P37, DOI 10.1016/S0166-6851(00)00234-6; Basselin M, 2002, ANTIMICROB AGENTS CH, V46, P3731, DOI 10.1128/AAC.46.12.3731-3738.2002; Basselin M, 1996, BIOCHEM J, V315, P631, DOI 10.1042/bj3150631; BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; Burchmore RJS, 2001, INT J PARASITOL, V31, P1311, DOI 10.1016/S0020-7519(01)00259-4; CHANG KP, 1980, SCIENCE, V209, P1240, DOI 10.1126/science.7403880; Colman A., 1984, TRANSCRIPTION TRANSL, P49; DAVIS RH, 1988, ARCH BIOCHEM BIOPHYS, V267, P479, DOI 10.1016/0003-9861(88)90054-9; de Koning HP, 2001, MOL PHARMACOL, V59, P586; GAWELTHOMPSON K, 1988, J CELL PHYSIOL, V136, P237, DOI 10.1002/jcp.1041360205; GILLIN FD, 1984, J PROTOZOOL, V31, P161, DOI 10.1111/j.1550-7408.1984.tb04308.x; GLASER TA, 1992, MOL BIOCHEM PARASIT, V51, P9, DOI 10.1016/0166-6851(92)90195-P; Hasne MP, 2000, MOL BIOCHEM PARASIT, V111, P299, DOI 10.1016/S0166-6851(00)00321-2; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HUNTER KJ, 1994, EUR J BIOCHEM, V226, P1019, DOI 10.1111/j.1432-1033.1994.t01-1-01019.x; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; Kanai Y, 2003, EUR J PHARMACOL, V479, P237, DOI 10.1016/j.ejphar.2003.08.073; Kandpal M, 1997, LIFE SCI, V60, P1793, DOI 10.1016/S0024-3205(97)00139-2; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KAUR K, 1986, J PROTOZOOL, V33, P518, DOI 10.1111/j.1550-7408.1986.tb05654.x; KHAN NA, 1990, PATHOBIOLOGY, V58, P172, DOI 10.1159/000163579; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; MCCANN PP, 1981, MED BIOL, V59, P434; Minchin RF, 2004, INT J BIOCHEM CELL B, V36, P271, DOI 10.1016/S1357-2725(03)00245-0; Okuda T, 2003, NEUROCHEM RES, V28, P483, DOI 10.1023/A:1022809003997; POULIN R, 1995, J BIOL CHEM, V270, P1695, DOI 10.1074/jbc.270.4.1695; Roberts SC, 2002, J BIOL CHEM, V277, P5902, DOI 10.1074/jbc.M110118200; Roberts SC, 2001, MOL BIOCHEM PARASIT, V115, P217, DOI 10.1016/S0166-6851(01)00293-6; Rost B, 1996, METHOD ENZYMOL, V266, P525; Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stein A, 2003, J BIOL CHEM, V278, P35127, DOI 10.1074/jbc.M306188200; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VANVOORHIS WC, 1990, DRUGS, V40, P176, DOI 10.2165/00003495-199040020-00002; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887	52	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15188	15194		10.1074/jbc.M411331200	http://dx.doi.org/10.1074/jbc.M411331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15632173	hybrid			2022-12-27	WOS:000228236800103
J	Ishikita, H; Knapp, EW				Ishikita, H; Knapp, EW			Energetics of proton transfer pathways in reaction centers from Rhodobacter sphaeroides - The Glu-H173 activated mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL REACTION CENTERS; PHOTOSYNTHETIC REACTION-CENTER; SECONDARY QUINONE Q(B); ELECTRON-TRANSFER; PHOTOSYSTEM-II; 2ND-SITE MUTATION; CRYSTAL-STRUCTURE; REDOX POTENTIALS; BINDING-SITES; H-SUBUNIT	Electron transfer between the primary and secondary quinones (Q(A), Q(B)) in the bacterial photosynthetic reaction center (bRC) is coupled with proton uptake at QB. The protons are conducted from the cytoplasmic side, probably with the participation of two water channels. Mutations of titratable residues like Asp-L213 to Asn ( inhibited mutant) or the double mutant Glu-L212 to Ala/Asp-L213 to Ala inhibit these electron transfer-coupled proton uptake events. The inhibition of the proton transfer ( PT) process in the single mutant can be restored by a second mutation of Arg-M233 to Cys or Arg-H177 to His ( revertant mutant). These revertant mutants shed light on the location of the main proton transfer pathway of wild type bRC. In contrast to the wild type and inhibited mutant bRC, the revertant mutant bRC showed notable proton uptake at Glu-H173 upon formation of the Q(B)(-) state. In all of these mutants, the pK(a) of Asp-M17 decreased by 1.4-2.4 units with respect to the wild type bRC, whereas a significant pK(a) upshift of up to 5.8 units was observed at Glu-H122, Asp-H170, Glu-H173, and Glu-H230 in the revertant mutants. These residues belonging to the main PT pathway are arranged along water channel P1 localized mainly in subunit H. bRC possesses subunit H, which has no counterpart in photosystem II. Thus, bRC may possess alternative PT pathways involving water channels in subunit H, which becomes active in case the main PT pathway is blocked.	Free Univ Berlin, Inst Chem, D-14195 Berlin, Germany	Free University of Berlin	Knapp, EW (corresponding author), Free Univ Berlin, Inst Chem, Takustr 6, D-14195 Berlin, Germany.	knapp@chemie.fu-berlin.de	Knapp, Ernst-Walter/E-4493-2010; Ishikita, Hiroshi/G-9864-2018; Knapp, Ernst-Walter/AAH-6720-2021	Knapp, Ernst-Walter/0000-0002-2858-0460; Ishikita, Hiroshi/0000-0002-5849-8150; Knapp, Ernst-Walter/0000-0002-2858-0460				Abresch EC, 1998, PHOTOSYNTH RES, V55, P119, DOI 10.1023/A:1006047519260; Adelroth P, 2001, BIOCHEMISTRY-US, V40, P14538, DOI 10.1021/bi011585s; Alexov EG, 1999, BIOCHEMISTRY-US, V38, P8253, DOI 10.1021/bi982700a; ARATA H, 1981, BIOCHIM BIOPHYS ACTA, V638, P201, DOI 10.1016/0005-2728(81)90228-0; ARATA H, 1983, BIOCHIM BIOPHYS ACTA, V726, P394; Axelrod HL, 2000, P NATL ACAD SCI USA, V97, P1542, DOI 10.1073/pnas.97.4.1542; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; de Wijn R, 2001, BIOCHEMISTRY-US, V40, P11912, DOI 10.1021/bi010852r; DEBUS RJ, 1985, BIOCHEMISTRY-US, V24, P2488, DOI 10.1021/bi00331a015; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Gerencser L, 2002, BIOCHEMISTRY-US, V41, P9132, DOI 10.1021/bi0256633; Gerencser L, 2001, BIOCHEMISTRY-US, V40, P1850, DOI 10.1021/bi0021636; Grafton AK, 1999, J PHYS CHEM B, V103, P5380, DOI 10.1021/jp9901139; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; Gunner MR, 2004, STRUCTURE, V12, P518, DOI 10.1016/j.str.2004.03.013; HANSON DK, 1992, PHOTOSYNTH RES, V32, P147, DOI 10.1007/BF00035949; HANSON DK, 1992, BIOCHIM BIOPHYS ACTA, V1102, P260, DOI 10.1016/0005-2728(92)90108-E; HANSON DK, 1993, P NATL ACAD SCI USA, V90, P8929, DOI 10.1073/pnas.90.19.8929; HINERWADEL R, 1995, BIOCHEMISTRY-US, V34, P2832; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Ishikita H, 2005, J AM CHEM SOC, V127, P1963, DOI 10.1021/ja045058i; Ishikita H, 2005, FEBS LETT, V579, P712, DOI 10.1016/j.febslet.2004.12.049; Ishikita H, 2004, J AM CHEM SOC, V126, P8059, DOI 10.1021/ja038092q; Ishikita H, 2003, J BIOL CHEM, V278, P52002, DOI 10.1074/jbc.M306434200; Ishikita H, 2003, BIOCHEMISTRY-US, V42, P3882, DOI 10.1021/bi026781t; MAROTI P, 1994, P NATL ACAD SCI USA, V91, P5617, DOI 10.1073/pnas.91.12.5617; MAROTI P, 1995, NAT STRUCT BIOL, V2, P1057, DOI 10.1038/nsb1295-1057; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P329, DOI 10.1016/0005-2728(88)90092-8; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; NABEDRYK E, 1995, BIOCHEMISTRY-US, V34, P14722, DOI 10.1021/bi00045a013; Nabedryk E, 1998, BIOCHEMISTRY-US, V37, P14457, DOI 10.1021/bi981139d; Nabedryk E, 2001, BIOCHEMISTRY-US, V40, P13826, DOI 10.1021/bi011423w; Paddock ML, 2003, FEBS LETT, V555, P45, DOI 10.1016/S0014-5793(03)01149-9; Paddock ML, 2003, BIOCHEMISTRY-US, V42, P9626, DOI 10.1021/bi0346648; Paddock ML, 1998, PHOTOSYNTH RES, V55, P281, DOI 10.1023/A:1005953615604; Paddock ML, 1999, P NATL ACAD SCI USA, V96, P6183, DOI 10.1073/pnas.96.11.6183; PADDOCK ML, 1989, P NATL ACAD SCI USA, V86, P6602, DOI 10.1073/pnas.86.17.6602; Paddock ML, 2001, BIOCHEMISTRY-US, V40, P6893, DOI 10.1021/bi010280a; PRINCE RC, 1976, ARCH BIOCHEM BIOPHYS, V172, P329, DOI 10.1016/0003-9861(76)90084-9; Rabenstein B, 1998, BIOCHEMISTRY-US, V37, P2488, DOI 10.1021/bi971921y; Rabenstein B, 1998, EUR BIOPHYS J BIOPHY, V27, P626, DOI 10.1007/s002490050174; Rabenstein B, 2000, BIOCHEMISTRY-US, V39, P10487, DOI 10.1021/bi000413c; RABENSTEIN B, 2004, BIOENERGETICS, P71; RONGEY SH, 1993, P NATL ACAD SCI USA, V90, P1325, DOI 10.1073/pnas.90.4.1325; SHIPTON CA, 1990, Z NATURFORSCH C, V45, P388; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Takahashi E, 1996, P NATL ACAD SCI USA, V93, P2640, DOI 10.1073/pnas.93.7.2640; TAKAHASHI E, 1990, BIOCHIM BIOPHYS ACTA, V1020, P107, DOI 10.1016/0005-2728(90)90100-I; Ullmann GM, 1999, EUR BIOPHYS J BIOPHY, V28, P533, DOI 10.1007/s002490050236; Utschig LM, 1998, BIOCHEMISTRY-US, V37, P8278, DOI 10.1021/bi980395n; Voigt P, 2003, J BIOL CHEM, V278, P51993, DOI 10.1074/jbc.M307560200; Warshel A, 1997, J BIOL INORG CHEM, V2, P143, DOI 10.1007/s007750050119; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; Xu Q, 2004, STRUCTURE, V12, P703, DOI 10.1016/j.str.2004.03.001	58	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12446	12450		10.1074/jbc.M413531200	http://dx.doi.org/10.1074/jbc.M413531200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15637063	hybrid			2022-12-27	WOS:000227922000047
J	Hache, G; Liddament, MT; Harris, RS				Hache, G; Liddament, MT; Harris, RS			The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EDITING ENZYME APOBEC3G; VIRUS-LIKE PARTICLES; ANTIVIRAL ACTIVITY; HIV-1 VIRIONS; VIF PROTEIN; IN-VIVO; DEGRADATION; GAG; EVOLUTION; IMMUNITY	The human proteins APOBEC3F and APOBEC3G restrict retroviral infection by deaminating cytosine residues in the first cDNA strand of a replicating virus. These proteins have two putative deaminase domains, and it is unclear whether one or both catalyze deamination, unlike their homologs, AID and APOBEC1, which are well characterized single domain deaminases. Here, we show that only the C-terminal cytosine deaminase domain of APOBEC3F and -3G governs retroviral hypermutation. A chimeric protein with the N-terminal cytosine deaminase domain from APOBEC3G and the C-terminal cytosine deaminase domain from APOBEC3F elicited a dinucleotide hypermutation preference nearly indistinguishable from that of APOBEC3F. This 5'-T (C) under bar -> T (T) under bar mutational specificity was confirmed in a heterologous Escherichia coli-based mutation assay, in which the 5'-C (C) under bar -> C (T) under bar dinucleotide hypermutation preference of APOBEC3G also mapped to the C-terminal deaminase domain. An N-terminal APOBEC3G deletion mutant displayed a preference indistinguishable from that of the full-length protein, and replacing the C-terminal deaminase domain of APOBEC3F with AID resulted in an AID-like mutational signature. Together, these data indicate that only the C-terminal domain of APOBEC3F and -3G dictates the retroviral minus strand 5'-T (C) under bar and 5'-C (C) under bar dinucleotide hypermutation preferences, respectively, leaving the N-terminal domain to perform other aspects of retroviral restriction.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Harris, RS (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.	rsh@umn.edu		Liddament, Mark/0000-0002-8130-3972				Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Douaisi M, 2004, BIOCHEM BIOPH RES CO, V321, P566, DOI 10.1016/j.bbrc.2004.07.005; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Li JL, 2004, J CELL BIOCHEM, V92, P560, DOI 10.1002/jcb.20082; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang JZ, 2004, HUM MOL GENET, V13, P1785, DOI 10.1093/hmg/ddh183; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	33	148	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10920	10924		10.1074/jbc.M500382200	http://dx.doi.org/10.1074/jbc.M500382200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647250	hybrid			2022-12-27	WOS:000227761800007
J	Neagoe, PE; Lemieux, C; Sirois, MG				Neagoe, PE; Lemieux, C; Sirois, MG			Vascular endothelial growth factor(VEGF)-A(165)-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and-2 heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); CELL PAF SYNTHESIS; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; NITRIC-OXIDE; HUMAN-LYMPHOCYTES; TYROSINE KINASE; P42/44 MAPK; CROSS-TALK; SYNTHASE	We previously reported that vascular endothelial growth factor (VEGF)-A(165) inflammatory effect is mediated by acute platelet-activating factor synthesis from endothelial cells upon the activation of VEGF receptor-2 (VEGFR-2) and its coreceptor, neuropilin-1 (NRP-1). In addition, VEGF-A(165) promotes the release of other endothelial mediators including nitric oxide and prostacyclin (PGI(2)). However, it is unknown whether VEGF-A(165) is mediating PGI2 synthesis through VEGF receptor-1 (VEGFR-1) and/or VEGF receptor-2 (VEGFR-2) activation and whether the coreceptor NRP-1 potentiates VEGF-A(165) activity. In this study, PGI2 synthesis in bovine aortic endothelial cells (BAEC) was assessed by quantifying its stable metabolite (6- keto prostaglandin F-1 alpha, 6- keto PGF(1 alpha)) by enzyme-linked immunosorbent assay. Treatment of BAEC with VEGF analogs, VEGF-A(165) (VEGFR-1, VEGFR-2 and NRP-1 agonist) and VEGF-A(121) ( VEGFR-1 and VEGFR-2 agonist) ( up to 10(-9) M), increased PGI2 synthesis by 70- and 40-fold within 15 min. Treatment with VEGFR-1 ( placental growth factor and VEGF-B) or VEGFR-2 (VEGF-C) agonist did not increase PGI2 synthesis. The combination of VEGFR-1 and VEGFR-2 agonists did not increase PGI2 release. Pretreatment with a VEGFR-2 inhibitor abrogated PGI2 release mediated by VEGF-A(165) and VEGF-A(121), and pretreatment of BAEC with antisense oligomers targeting VEGFR-1 or VEGFR-2 mRNA reduced PGI2 synthesis mediated by VEGF-A(165) and VEGF-A(121) up to 79%. In summary, our data demonstrate that the activation of VEGFR-1 and VEGFR-2 heterodimer (VEGFR-1/R-2) is essential for PGI2 synthesis mediated by VEGF-A(165) and VEGF-A(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 homodimers with corresponding agonists. In addition, the binding of VEGF-A(165) to NRP-1 potentiates its capacity to promote PGI(2) synthesis.	Univ Montreal, Montreal Heart Inst, Dept Pharmacol, Res Ctr, Montreal, PQ H1T 1C8, Canada	Universite de Montreal	Sirois, MG (corresponding author), Univ Montreal, Montreal Heart Inst, Dept Pharmacol, Res Ctr, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada.	martin.sirois@icm-mhi.org						ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Arbiser JL, 2000, AM J PATHOL, V156, P1469, DOI 10.1016/S0002-9440(10)65015-8; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P197, DOI 10.1038/sj.bjp.0704215; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Bian K, 2001, FREE RADICAL BIO MED, V31, P421, DOI 10.1016/S0891-5849(01)00600-1; Bryant CE, 1998, LIFE SCI, V62, P2195, DOI 10.1016/S0024-3205(98)00197-0; BUNTING S, 1983, BRIT MED BULL, V39, P271, DOI 10.1093/oxfordjournals.bmb.a071832; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEWITT DL, 1983, J CLIN INVEST, V72, P1882, DOI 10.1172/JCI111151; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; Hink U, 2003, J AM COLL CARDIOL, V42, P1826, DOI 10.1016/j.jacc.2003.07.009; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Huang K, 2001, INT J BIOCHEM CELL B, V33, P315, DOI 10.1016/S1357-2725(01)00019-X; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MARCUS AJ, 1978, J BIOL CHEM, V253, P7138; Martinez-Gonzalez J, 2004, ATHEROSCLEROSIS, V174, P305, DOI 10.1016/j.atherosclerosis.2004.01.037; Merhi-Soussi F, 2003, BRIT J PHARMACOL, V139, P321, DOI 10.1038/sj.bjp.0705253; Merhi-Soussi F, 2000, J LEUKOCYTE BIOL, V68, P881; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Norata GD, 2004, ARTERIOSCL THROM VAS, V24, P871, DOI 10.1161/01.ATV.zhq0504.1403; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rebsamen MC, 2003, J MOL CELL CARDIOL, V35, P81, DOI 10.1016/S0022-2828(02)00281-X; Rollin S, 2004, BLOOD, V103, P3789, DOI 10.1182/blood-2003-07-2272; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7; Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SPISNI E, 1992, PROSTAG LEUKOTR ESS, V47, P111, DOI 10.1016/0952-3278(92)90146-A; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; van Rossum GSAT, 2001, J BIOL CHEM, V276, P28976, DOI 10.1074/jbc.M101361200; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699	54	98	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9904	9912		10.1074/jbc.M412017200	http://dx.doi.org/10.1074/jbc.M412017200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637071	hybrid			2022-12-27	WOS:000227559600021
J	Nelson, ME; Finazzi, G; Wang, QJ; Middleton-Zarka, KA; Whitmarsh, J; Kallas, T				Nelson, ME; Finazzi, G; Wang, QJ; Middleton-Zarka, KA; Whitmarsh, J; Kallas, T			Cytochrome b(6) arginine 214 of Synechococcus sp PCC 7002, a key residue for quinone-reductase site function and turnover of the cytochrome bf complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; B(6)F COMPLEX; BC(1) COMPLEX; CHLAMYDOMONAS-REINHARDTII; INHIBITOR BINDING; B/F COMPLEX; OXYGENIC PHOTOSYNTHESIS; PROTON TRANSFERS; DOMAIN MOVEMENT	Quinone-reductase (Q(i)) domains of cyanobacterial/ chloroplast cytochrome bf and bacterial/mitochondrial bc complexes differ markedly, and the cytochrome bf Q(i) site mechanism remains largely enigmatic. To investigate the bf Q(i) domain, we constructed the mutation R214H, which substitutes histidine for a conserved arginine in the cytochrome b(6) polypeptide of the cyanobacterium Synechococcus sp. SPCC 7002. At high light intensity, the R214H mutant grew similar to 2.5-fold more slowly than the wild type. Slower growth arose from correspondingly slower overall turnover of the bf complex. Specifically, as shown in single flash turnover experiments of cytochrome b6 reduction and oxidation, the R214H mutation partially blocked electron transfer to the Qi site, mimicking the effect of the Q(i) site inhibitor 2-N-4-hydroxyquinoline-N-oxide. The kinetics of cytochrome b6 oxidation were largely unaffected by hydrogen-deuterium exchange in the mutant but were slowed considerably in the wild type. This suggests that although protonation events influenced the kinetics of cytochrome b(6) oxidation at the Q(i) site in the wild type, electron flow limited this reaction in the R214H mutant. Redox titration of membranes revealed midpoint potentials ( E-m,E- 7) of the two b hemes similar to those in the wild type. Our data define cytochrome b(6) Arg(214) as a key residue for Q(i) site catalysis and turnover of the cytochrome bf complex. In the recent cytochrome bf structures, Arg(214) lies near the Q(i) pocket and the newly discovered c(i) or x heme. We propose a model for Q(i) site function and a role for Arg214 in plastoquinone binding.	Univ Wisconsin, Dept Biol & Microbiol, Oshkosh, WI 54901 USA; Inst Biol Physicochim, CNRS UPR 1261, F-75005 Paris, France; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA	University of Wisconsin System; Centre National de la Recherche Scientifique (CNRS); University of Illinois System; University of Illinois Urbana-Champaign	Kallas, T (corresponding author), Univ Wisconsin, Dept Biol & Microbiol, Oshkosh, WI 54901 USA.	kallas@uwosh.edu		Wang, Qingjun/0000-0002-1959-4107				ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; BACIOU L, 1995, BIOCHEMISTRY-US, V34, P7967, DOI 10.1021/bi00025a001; Barbagallo RP, 2000, J BIOL CHEM, V275, P26121, DOI 10.1074/jbc.M002299200; Baymann F, 2001, BIOCHEMISTRY-US, V40, P10570, DOI 10.1021/bi010194a; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Breyton C, 2000, BBA-BIOENERGETICS, V1459, P467, DOI 10.1016/S0005-2728(00)00185-7; Breyton C, 2000, J BIOL CHEM, V275, P13195, DOI 10.1074/jbc.275.18.13195; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; Cramer WA, 2004, BIOCHEMISTRY-US, V43, P5921, DOI 10.1021/bi049444o; CRAMER WA, 1987, LIGHT REACTIONS, P447; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; Deniau C, 2000, BIOCHEMISTRY-US, V39, P3304, DOI 10.1021/bi992445+; Dikanov SA, 2004, J BIOL CHEM, V279, P15814, DOI 10.1074/jbc.M313417200; DUTTON PL, 1972, EUR J BIOCHEM, V30, P495, DOI 10.1111/j.1432-1033.1972.tb02121.x; Elbehti A, 2000, J BACTERIOL, V182, P3602, DOI 10.1128/JB.182.12.3602-3606.2000; Finazzi G, 2002, BIOCHEMISTRY-US, V41, P7475, DOI 10.1021/bi025714w; FRANK K, 1995, PHOTOCHEM PHOTOBIOL, V61, P2, DOI 10.1111/j.1751-1097.1995.tb09237.x; FURBACHER PN, 1989, BIOCHEMISTRY-US, V28, P8990, DOI 10.1021/bi00449a006; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; Hamel P, 2000, J BIOL CHEM, V275, P17072, DOI 10.1074/jbc.M001468200; HAUSKA G, 1996, OXYGENIC PHOTOSYNTHE; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Hunte C, 2001, FEBS LETT, V504, P126, DOI 10.1016/S0014-5793(01)02744-2; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOLIOT P, 1986, BIOCHIM BIOPHYS ACTA, V849, P211, DOI 10.1016/0005-2728(86)90027-7; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; Joliot P, 2001, BBA-BIOENERGETICS, V1503, P369, DOI 10.1016/S0005-2728(00)00232-2; Joliot P, 1998, BIOCHEMISTRY-US, V37, P10404, DOI 10.1021/bi980546m; JONES RW, 1988, BIOCHIM BIOPHYS ACTA, V933, P258, DOI 10.1016/0005-2728(88)90033-3; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; KRAMER DM, 1994, BBA-BIOENERGETICS, V1184, P193, DOI 10.1016/0005-2728(94)90223-2; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Lee TX, 2001, BBA-BIOENERGETICS, V1504, P235, DOI 10.1016/S0005-2728(00)00253-X; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1102, P266, DOI 10.1016/0167-4838(92)90519-J; Osyczka A, 2004, NATURE, V427, P607, DOI 10.1038/nature02242; Paddock ML, 2003, FEBS LETT, V555, P45, DOI 10.1016/S0014-5793(03)01149-9; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Sacksteder CA, 2000, P NATL ACAD SCI USA, V97, P14283, DOI 10.1073/pnas.97.26.14283; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Soriano GM, 1999, J BIOENERG BIOMEMBR, V31, P201, DOI 10.1023/A:1005463527752; Soriano GM, 2001, BIOCHEMISTRY-US, V40, P15109, DOI 10.1021/bi011465k; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; Tandori J, 2001, J BIOL CHEM, V276, P45513, DOI 10.1074/jbc.C100537200; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WITT HT, 1979, BIOCHIM BIOPHYS ACTA, V505, P355, DOI 10.1016/0304-4173(79)90008-9; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yan JS, 2003, J BIOL CHEM, V278, P20925, DOI 10.1074/jbc.M212616200; ZHANG LL, 1994, J BIOL CHEM, V269, P5036; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zito F, 2002, J BIOL CHEM, V277, P12446, DOI 10.1074/jbc.M110914200	60	14	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10395	10402		10.1074/jbc.M410948200	http://dx.doi.org/10.1074/jbc.M410948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632120	hybrid			2022-12-27	WOS:000227559600080
J	Weng, CJ; Li, Y; Xu, D; Shi, Y; Tang, H				Weng, CJ; Li, Y; Xu, D; Shi, Y; Tang, H			Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY; DEATH RECEPTORS; TNF; MITOCHONDRIA; COMPLEX; ACTIVATION; DOMAIN; IDENTIFICATION; DEGRADATION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces programmed cell death through the caspase activation cascade and translocation of cleaved Bid (tBid) by the apical caspase-8 to mitochondria to induce oligomerization of multidomain Bax and Bak. However, the roles of prosurvival Bcl-2 family proteins in TRAIL apoptosis remain elusive. Here we showed that, besides the specific cleavage and activation of Bid by caspase-8 and caspase-3, TRAIL-induced apoptosis in Jurkat T cells required the specific cleavage of Mcl-1 at Asp-127 and Asp-157 by caspase-3, while other prototypic antiapoptotic factors such as Bcl- 2 or Bcl-XL seemed not to be affected. Mutation at Asp-127 and Asp-157 of Mcl-1 led to cellular resistance to TRAIL-induced apoptosis. In sharp contrast to cycloheximide-induced Mcl-1 dilapidation, TRAIL did not activate proteasomal degradation of Mcl-1 in Jurkat cells. We further established for the first time that the C-terminal domain of Mcl-1 became proapoptotic as a result of caspase-3 cleavage, and its physical interaction and cooperation with tBid, Bak, and voltage-dependent anion-selective channel 1 promoted mitochondrial apoptosis. These results suggested that removal of N-terminal domains of Bid by caspase-8 and Mcl-1 by caspase-3 enabled the maximal mitochondrial perturbation that potentiated TRAIL-induced apoptosis.	Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Beijing 100080, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China; Capital Normal Univ, Dept Biol Sci & Technol, Beijing 100037, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Capital Normal University	Tang, H (corresponding author), Chinese Acad Sci, Inst Biophys, Ctr Infect & Immun, Beijing 100101, Peoples R China.	tanghong@moon.ibp.ac.cn	weng, changjiang/HHR-8479-2022					Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng HC, 2002, J BIOL CHEM, V277, P33930, DOI 10.1074/jbc.M201206200; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MULLER KP, 1995, EUR J IMMUNOL, V25, P2996, DOI 10.1002/eji.1830251043; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Page DM, 1998, J IMMUNOL, V160, P120; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2000, GENE DEV, V14, P2060; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu Y, 2002, MOL BIOL CELL, V13, P3493, DOI 10.1091/mbc.E02-01-0004; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205	58	205	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10491	10500		10.1074/jbc.M412819200	http://dx.doi.org/10.1074/jbc.M412819200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637055	hybrid			2022-12-27	WOS:000227559600092
J	Woodring, PJ; Hunter, T; Wang, JYJ				Woodring, PJ; Hunter, T; Wang, JYJ			Mitotic phosphorylation rescues Abl from F-actin-mediated inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; C-ABL; PROTEIN-BINDING; BCR-ABL; CRK; ADAPTER; FAMILY; TRANSFORMATION; ACTIVATION; REQUIRES	We have previously shown that F-actin exerts a negative effect on Ab1 tyrosine kinase activity. This inhibition results from a direct association of F-actin with the C terminus of Ab1 and accounts, in part, for the loss of Ab1 activity in detached fibroblasts. We report here that Ab1 from mitotic cells or cells treated with the protein phosphatase inhibitor okadaic acid remains active when detached from the extracellular matrix. Aspartic acid substitution of Thr(566), which is phosphorylated in mitotic or okadaic acid-treated cells, is sufficient to abolish F-actin-mediated inhibition and to maintain Ab1 activity despite cell detachment. A recent crystal structure of the Ab1 N-terminal region has revealed autoinhibtory interactions among the Src homology 3 (SH3), SH2, and kinase domains. We found that deletion of the SH2 domain also abolished the negative effect of F-actin on kinase activity. Immediately following the kinase domain in Ab1 is a proline-rich linker (PRL) that binds to several SH3 adaptor proteins. Interestingly, binding of the Crk N-terminal SH3 domain to the PRL also disrupted F-actin-mediated inhibition of Ab1 kinase. These results suggest that F-actin may reinforce the autoinhibitory interactions to regulate Ab1 kinase and that inhibition can be relieved through phosphorylation and/or protein interactions with the Ab1 PRL region.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, JYJ (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jywang@ucsd.edu			NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054, F32CA076710] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, R37 CA043054, CA82863, CA76710] Funding Source: Medline; NHLBI NIH HHS [HL57900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Hernandez SE, 2004, CURR BIOL, V14, P691, DOI 10.1016/j.cub.2004.03.062; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MEISENHELDER J, 1999, CURRENT PROTOCOLS MO, V18; Miller AL, 2004, J CELL BIOL, V165, P407, DOI 10.1083/jcb.200308055; Moresco EMY, 2003, CURR OPIN NEUROBIOL, V13, P535, DOI 10.1016/j.conb.2003.08.002; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WANG JYJ, 2000, SIGNAL TRANSDUCTION, P303; Woodring PJ, 2004, J CELL BIOL, V165, P493, DOI 10.1083/jcb.200312171; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10318	10325		10.1074/jbc.M410658200	http://dx.doi.org/10.1074/jbc.M410658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632178	hybrid			2022-12-27	WOS:000227559600071
J	Iyer, GH; Moore, MJ; Taylor, SS				Iyer, GH; Moore, MJ; Taylor, SS			Consequences of lysine 72 mutation on the phosphorylation and activation state of cAMP-dependent kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; STRUCTURAL BASIS; BINDING-SITES; AUTOPHOSPHORYLATION; ADENOSINE; FAMILY; DOMAIN	General strategies to obtain inactive kinases have utilized mutation of key conserved residues in the kinase core, and the equivalent Lys(72) in cAMP-dependent kinase has often been used to generate a "dead" kinase. Here, we have analyzed the consequences of this mutation on kinase structure and function. Mutation of Lys(72) to histidine (K72H) generated an inactive enzyme, which was unphosphorylated. Treatment with an exogenous kinase (PDK-1) resulted in a mutant that was phosphorylated only at Thr(197) and remained inactive but nevertheless capable of binding ATP. Ser(338) in K72H cannot be autophosphorylated, nor can it be phosphorylated in an intermolecular process by active wild type C-subunit. The Lys(72) mutant, once phosphorylated on Thr(197), can bind with high affinity to the RIalpha subunits. Thus a dead kinase can still act as a scaffold for binding substrates and inhibitors; it is only phosphoryl transfer that is defective. Using a potent inhibitor of C-subunit activity, H-89, Escherichia coli-expressed C-subunit was also obtained in its unphosphorylated state. This protein is able to mature into its active form in the presence of PDK-1 and is able to undergo secondary autophosphorylation on Ser(338). Unlike the H-89-treated wild type protein, the mutant protein ( K72H) cannot undergo the subsequent cis autophosphorylation following phosphorylation at Thr(197). Using these two substrates and mammalian-expressed PDK-1, we can elucidate a possible two-step process for the activation of the C-subunit: initial phosphorylation on the activation loop at Thr(197) by PDK-1, or a PDK-1-like enzyme, followed by second cis autophosphorylation step at Ser(338).	Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, 9500 Gilman Dr 0654, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019301, R01GM019301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Batkin M, 2000, BIOCHEMISTRY-US, V39, P5366, DOI 10.1021/bi000153z; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; Bishop SM, 1999, BIOCHEMISTRY-US, V38, P3079, DOI 10.1021/bi982546s; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cauthron RD, 1998, MOL CELL BIOL, V18, P1416, DOI 10.1128/MCB.18.3.1416; Cheng XD, 1998, BIOCHEMISTRY-US, V37, P14005, DOI 10.1021/bi981057p; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GILL GN, 1970, BIOCHEM BIOPH RES CO, V39, P335, DOI 10.1016/0006-291X(70)90581-4; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Herberg FW, 1999, BIOCHEMISTRY-US, V38, P6352, DOI 10.1021/bi982672w; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JACOBSON MA, 1984, J BIOL CHEM, V259, P1454; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee SL, 1996, MOL CELL ENDOCRINOL, V116, P233, DOI 10.1016/0303-7207(95)03719-5; Liu GZ, 2002, J BIOL CHEM, V277, P20264, DOI 10.1074/jbc.M110999200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Moore MJ, 2002, J BIOL CHEM, V277, P47878, DOI 10.1074/jbc.M204970200; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P14002, DOI 10.1021/bi005116m; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SHOJI S, 1979, J BIOL CHEM, V254, P6211; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STEINBERG RA, 1991, MOL CELL BIOL, V11, P705, DOI 10.1128/MCB.11.2.705; TONERWEBB J, 1992, J BIOL CHEM, V267, P25174; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WEN W, 1994, J BIOL CHEM, V269, P8423; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; YONEMOTO WM, 1991, METHODS ENZYMOL, V200, P581; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	45	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8800	8807		10.1074/jbc.M407586200	http://dx.doi.org/10.1074/jbc.M407586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15618230	hybrid			2022-12-27	WOS:000227453100023
J	Diaz-Moreno, I; Diaz-Quintana, A; Molina-Heredia, FP; Nieto, PM; Hansson, O; De la Rosa, MA; Karlsson, BG				Diaz-Moreno, I; Diaz-Quintana, A; Molina-Heredia, FP; Nieto, PM; Hansson, O; De la Rosa, MA; Karlsson, BG			NMR analysis of the transient complex between membrane photosystem I and soluble cytochrome c(6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLASH ABSORPTION-SPECTROSCOPY; KINETIC-ANALYSIS; PCC 7119; PLASTOCYANIN; STATE; REDUCTION; BINDING	A structural analysis of the surface areas of cytochrome c(6), responsible for the transient interaction with photosystem I, was performed by NMR transverse relaxation-optimized spectroscopy. The hemeprotein was titrated by adding increasing amounts of the chlorophyllic photosystem, and the NMR spectra of the free and bound protein were analyzed in a comparative way. The NMR signals of cytochrome c(6) residues located at the hydrophobic and electrostatic patches, which both surround the heme cleft, were specifically modified by binding. The backbones of internal residues close to the hydrophobic patch of cytochrome c(6) were also affected, a fact that is ascribed to the conformational changes taking place inside the hemeprotein when interacting with photosystem I. To the best of our knowledge, this is the first structural analysis by NMR spectroscopy of a transient complex between soluble and membrane proteins.	Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; Univ Seville, Inst Invest Quim, Seville 41092, Spain; Univ Gothenburg, Dept Chem, S-40530 Gothenburg, Sweden; Chalmers, Dept Chem, S-40530 Gothenburg, Sweden; Chalmers, Dept Biosci, S-40530 Gothenburg, Sweden; Univ Gothenburg, Hasselblad Lab, Swedish NMR Ctr, S-40530 Gothenburg, Sweden	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-USE - Instituto de Investigaciones Quimicas (IIQ); University of Gothenburg; Chalmers University of Technology; Chalmers University of Technology; University of Gothenburg	De la Rosa, MA (corresponding author), Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio 49, Seville 41092, Spain.	marosa@us.es	Díaz-Moreno, Irene/E-7181-2010; Díaz-Quintana, Antonio/A-1946-2011; Hansson, Orjan/D-1282-2009; Karlsson, Göran/E-8686-2011; Molina-Heredia, Fernando P./F-7877-2015; De la Rosa, Miguel/B-2545-2014; Nieto, Pedro M/B-7869-2008	Díaz-Moreno, Irene/0000-0002-5318-7644; Díaz-Quintana, Antonio/0000-0001-8973-8009; Molina-Heredia, Fernando P./0000-0002-3637-0519; De la Rosa, Miguel/0000-0003-1187-5737; Nieto, Pedro M/0000-0002-4074-9011; Karlsson, Goran/0000-0002-1821-4715				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Bendall D. S., 1996, P43; Crowley PB, 2003, ACCOUNTS CHEM RES, V36, P723, DOI 10.1021/ar0200955; Crowley PB, 2002, J BIOL CHEM, V277, P48685, DOI 10.1074/jbc.M203983200; Danielsen E, 1999, BIOCHEMISTRY-US, V38, P11531, DOI 10.1021/bi990869y; Diaz-Quintana A, 2003, PHOTOSYNTH RES, V75, P97, DOI 10.1023/A:1022841513592; Diercks T, 2001, CURR OPIN CHEM BIOL, V5, P285, DOI 10.1016/S1367-5931(00)00204-0; Fiaux J, 2002, NATURE, V418, P207, DOI 10.1038/nature00860; FORD RC, 1987, BIOCHIM BIOPHYS ACTA, V893, P115, DOI 10.1016/0005-2728(87)90031-4; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; Fromme P, 2003, FEBS LETT, V555, P40, DOI 10.1016/S0014-5793(03)01124-4; Golbeck JH, 2003, ANNU REV BIOPH BIOM, V32, P237, DOI 10.1146/annurev.biophys.32.110601.142356; Goodman JL, 2000, J MOL BIOL, V295, P963, DOI 10.1006/jmbi.1999.3419; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Inooka H, 2001, NAT STRUCT BIOL, V8, P161, DOI 10.1038/84159; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KERFELD CA, 1995, J MOL BIOL, V250, P627, DOI 10.1006/jmbi.1995.0404; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MEDINA M, 1993, EUR J BIOCHEM, V213, P1133, DOI 10.1111/j.1432-1033.1993.tb17863.x; Molina-Heredia FP, 1998, BIOCHEM BIOPH RES CO, V243, P302, DOI 10.1006/bbrc.1997.7953; Molina-Heredia FP, 1999, J BIOL CHEM, V274, P33565, DOI 10.1074/jbc.274.47.33565; Navarro JA, 2000, PHOTOSYNTH RES, V65, P63, DOI 10.1023/A:1006404621724; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Rudiger S, 2002, P NATL ACAD SCI USA, V99, P11085, DOI 10.1073/pnas.132393699; Sahu SC, 2000, J BIOMOL NMR, V18, P107, DOI 10.1023/A:1008310402933; Stone MJ, 2001, ACCOUNTS CHEM RES, V34, P379, DOI 10.1021/ar000079c; Sun J, 1999, J BIOL CHEM, V274, P19048, DOI 10.1074/jbc.274.27.19048; Thompson LK, 2002, CURR OPIN STRUC BIOL, V12, P661, DOI 10.1016/S0959-440X(02)00374-3; Tugarinov V, 2002, J AM CHEM SOC, V124, P10025, DOI 10.1021/ja0205636; Watts A, 1999, CURR OPIN BIOTECH, V10, P48, DOI 10.1016/S0958-1669(99)80009-3	33	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7925	7931		10.1074/jbc.M412422200	http://dx.doi.org/10.1074/jbc.M412422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611120	hybrid, Green Published			2022-12-27	WOS:000227395700061
J	Li, J; O'Connor, KL; Greeley, GH; Blackshear, PJ; Townsend, CM; Evers, BM				Li, J; O'Connor, KL; Greeley, GH; Blackshear, PJ; Townsend, CM; Evers, BM			Myristoylated alanine-rich C kinase substrate-mediated neurotensin release via protein kinase C-delta downstream of the Rho/ROK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-SECRETION; MARCKS PROTEIN; PHORBOL ESTERS; PKC-ALPHA; GASTROINTESTINAL HORMONES; SEROTONIN RELEASE; RHO SUBFAMILY; PHOSPHORYLATION; EXOCYTOSIS; EPSILON	Myristoylated alanine- rich protein kinase C substrate (MARCKS) is a cellular substrate for protein kinase C (PKC). Recently, we have shown that PKC isoforms- alpha and - delta, as well as the Rho/ Rho kinase ( ROK) pathway, play a role in phorbol 12- myristate 13- acetate (PMA)mediated secretion of the gut peptide neurotensin (NT) in the BON human endocrine cell line. Here, we demonstrate that activation of MARCKS protein is important for PMA- and bombesin (BBS)- mediated NT secretion in BON cells. Small interfering RNA (siRNA) to MARCKS significantly inhibited, whereas overexpression of wildtype MARCKS significantly increased PMA- mediated NT secretion. Endogenous MARCKS and green fluorescent protein- tagged wild- type MARCKS were translocated from membrane to cytosol upon PMA treatment, further confirming MARCKS activation. MARCKS phosphorylation was inhibited by PKC- delta siRNA, ROK alpha siRNA, and C3 toxin (a Rho protein inhibitor), suggesting that the PKC- delta and the Rho/ ROK pathways are necessary for MARCKS activation. The phosphorylation of PKC- delta was inhibited by C3 toxin, demonstrating that the role of MARCKS in NT secretion was regulated by PKC- delta downstream of the Rho/ ROK pathway. BON cell clones stably transfected with the receptor for gastrin releasing peptide, a physiologic stimulant of NT, and treated with BBS, the amphibian equivalent of gastrin releasing peptide, demonstrated a similar MARCKS phosphorylation as noted with PMA. BBS- mediated NT secretion was attenuated by MARCKS siRNA. Collectively, these findings provide evidence for novel signaling pathways, including the sequential regulation of MARCKS activity by Rho/ ROK and PKC- delta proteins, in stimulated gut peptide secretion.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; NIEHS, Off Clin Res, Res Triangle Pk, NC 27709 USA; NIEHS, Neurobiol Lab, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu	O'Connor, Kathleen L/H-2569-2013; Blackshear, Perry J./C-6206-2019; Li, Jing/B-7206-2011	O'Connor, Kathleen L/0000-0002-1088-9734; Blackshear, Perry J./0000-0002-9561-8529; 	NCI NIH HHS [R21 CA10212] Funding Source: Medline; NIA NIH HHS [2R37 AG10885] Funding Source: Medline; NIDDK NIH HHS [P01 DK35608, R01 DK48489] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; Akita Y, 2000, ELECTROPHORESIS, V21, P452, DOI 10.1002/(SICI)1522-2683(20000101)21:2<452::AID-ELPS452>3.0.CO;2-L; AKITA Y, 1994, J BIOL CHEM, V269, P4653; Amin RH, 2003, ENDOCRINOLOGY, V144, P4508, DOI 10.1210/en.2003-0106; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; ARMSTRONG MJ, 1986, AM J PHYSIOL, V251, pG823, DOI 10.1152/ajpgi.1986.251.6.G823; Betancourt-Calle S, 1999, MOL CELL ENDOCRINOL, V154, P1, DOI 10.1016/S0303-7207(99)00111-2; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CALLE R, 1992, J BIOL CHEM, V267, P18723; CHUNG DH, 1992, GASTROENTEROLOGY, V103, P1254, DOI 10.1016/0016-5085(92)91512-3; CLARKE PR, 1993, FEBS LETT, V336, P37, DOI 10.1016/0014-5793(93)81604-X; Daniel S, 2002, BIOCHEMISTRY-US, V41, P9663, DOI 10.1021/bi025604p; Elzagallaai A, 2000, BLOOD, V95, P894, DOI 10.1182/blood.V95.3.894.003k15_894_902; Elzagallaai A, 2001, BRIT J HAEMATOL, V112, P593, DOI 10.1046/j.1365-2141.2001.02642.x; Evers BM, 2002, WORLD J SURG, V26, P799, DOI 10.1007/s00268-002-4055-3; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; EVERS BM, 1992, GASTROENTEROLOGY, V103, P86, DOI 10.1016/0016-5085(92)91099-P; Frantz C, 2002, EXP CELL RES, V273, P119, DOI 10.1006/excr.2001.5432; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; Goodall AR, 1997, J NEUROCHEM, V68, P392; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Guo YS, 1999, CONT ENDOCRINOL, V8, P189; GUYTON AC, 2000, TXB MED PHYSL, P738; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; HERGET T, 1994, EUR J BIOCHEM, V225, P539, DOI 10.1111/j.1432-1033.1994.00539.x; Ikenoya M, 2002, J NEUROCHEM, V81, P9, DOI 10.1046/j.1471-4159.2002.00801.x; JONES PM, 1989, BIOCHEM SOC T, V17, P61, DOI 10.1042/bst0170061; Just I, 2001, INT J MED MICROBIOL, V291, P243, DOI 10.1078/1438-4221-00127; Kowluru A, 1997, BIOCHEM PHARMACOL, V54, P1097, DOI 10.1016/S0006-2952(97)00314-6; Lee IS, 2003, CELL SIGNAL, V15, P529, DOI 10.1016/S0898-6568(02)00137-7; Li J, 2004, GASTROENTEROLOGY, V126, pA147; Li J, 2002, AM J PHYSIOL-GASTR L, V283, pG1197, DOI 10.1152/ajpgi.00177.2002; Li J, 2004, J BIOL CHEM, V279, P28466, DOI 10.1074/jbc.M314307200; Li QW, 2003, J PHYSIOL-LONDON, V550, P431, DOI 10.1113/jphysiol.2003.039073; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Littman ED, 2000, PANCREAS, V20, P256, DOI 10.1097/00006676-200004000-00006; LIU JP, 1994, MOL CELL ENDOCRINOL, V101, P247, DOI 10.1016/0303-7207(94)90241-0; LIU JP, 1994, MOL CELL ENDOCRINOL, V105, P217; Mendez CF, 2003, J BIOL CHEM, V278, P44753, DOI 10.1074/jbc.M308664200; Nagumo H, 2001, BIOCHEM BIOPH RES CO, V280, P605, DOI 10.1006/bbrc.2000.4179; Powis DA, 1996, CELL CALCIUM, V19, P419, DOI 10.1016/S0143-4160(96)90115-3; Ramsden JJ, 2000, INT J BIOCHEM CELL B, V32, P475, DOI 10.1016/S1357-2725(99)00152-1; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200; Salli U, 2003, BIOL REPROD, V69, P2053, DOI 10.1095/biolreprod.103.017640; Salli U, 2000, BIOL REPROD, V63, P12, DOI 10.1095/biolreprod63.1.12; Salli U, 2001, ENDOCRINE, V16, P83, DOI 10.1385/ENDO:16:2:083; SAS Institute Inc, 1999, SAS STAT US GUID VER; Sasaki Y, 2003, J PHARMACOL SCI, V93, P35, DOI 10.1254/jphs.93.35; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Spizz G, 2001, J BIOL CHEM, V276, P32264, DOI 10.1074/jbc.M103960200; Tfelt-Hansen J, 2003, AM J PHYSIOL-ENDOC M, V285, pE329, DOI 10.1152/ajpendo.00489.2002; Thomas RP, 2003, ENDOCR REV, V24, P571, DOI 10.1210/er.2002-0028; THOR K, 1986, GASTROENTEROLOGY, V90, P27, DOI 10.1016/0016-5085(86)90070-3; Tinsley JH, 2004, AM J PHYSIOL-CELL PH, V286, pC105, DOI 10.1152/ajpcell.00340.2003; TOWNSEND CM, 1994, SURG TODAY, V24, P772, DOI 10.1007/BF01636304; Trifaro JM, 2000, BIOCHIMIE, V82, P339, DOI 10.1016/S0300-9084(00)00193-0; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; Walaas SI, 2000, NEUROCHEM INT, V36, P581, DOI 10.1016/S0197-0186(99)00159-X; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Yaney GC, 2002, AM J PHYSIOL-ENDOC M, V283, pE880, DOI 10.1152/ajpendo.00474.2001; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989	63	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8351	8357		10.1074/jbc.M409431200	http://dx.doi.org/10.1074/jbc.M409431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623535	hybrid			2022-12-27	WOS:000227395700110
J	Lo, KWH; Kan, HM; Chan, LN; Xu, WG; Wang, KP; Wu, ZG; Sheng, M; Zhang, MJ				Lo, KWH; Kan, HM; Chan, LN; Xu, WG; Wang, KP; Wu, ZG; Sheng, M; Zhang, MJ			The 8-kDa dynein light chain binds to p53-binding protein 1 and mediates DNA damage-induced p53 nuclear accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-SUPPRESSOR P53; CELLULAR-PROTEINS; MOTOR COMPLEX; MYOSIN-V; 53BP1; LC8; DOMAIN; CHECKPOINT; FAMILY	The tumor suppressor protein p53 is known to undergo cytoplasmic dynein-dependent nuclear translocation in response to DNA damage. However, the molecular link between p53 and the minus end-directed microtubule motor dynein complex has not been described. We report here that the 8-kDa light chain (LC8) of dynein binds to p53-binding protein 1 (53BP1). The LC8-binding domain was mapped to a short peptide segment immediately N-terminal to the kinetochore localization region of 53BP1. The LC8-binding domain is completely separated from the p53-binding domain in 53BP1. Therefore, 53BP1 can potentially act as an adaptor to assemble p53 to the dynein complex. Unlike other known LC8-binding proteins, 53BP1 contains two distinct LC8-binding motifs that are arranged in tandem. We further showed that 53BP1 can directly associate with the dynein complex. Disruption of the interaction between LC8 and 53BP1 in vivo prevented DNA damage-induced nuclear accumulation of p53. These data illustrate that LC8 is able to function as a versatile acceptor to link a wide spectrum of molecular cargoes to the dynein motor.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; MIT, Howard Hughes Med Inst, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Hong Kong University of Science & Technology; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	mzhang@ust.hk	Wang, Kepeng/F-8363-2014	Wang, Kepeng/0000-0001-6428-4709; Zhang, Mingjie/0000-0001-9404-0190; Wu, Zhenguo/0000-0003-3049-8324				Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiBella LM, 2001, J BIOL CHEM, V276, P14366, DOI 10.1074/jbc.M011456200; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Fan JS, 2002, J BIOMOL NMR, V23, P103, DOI 10.1023/A:1016332918178; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Jacob Y, 2000, J VIROL, V74, P10217, DOI 10.1128/JVI.74.21.10217-10222.2000; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; KASTAN MB, 1991, CANCER RES, V51, P6304; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; MIYASHITA T, 1995, CELL, V80, P293; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Passafaro M, 1999, NAT NEUROSCI, V2, P1063, DOI 10.1038/15990; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; Rodriguez-Crespo I, 2001, FEBS LETT, V503, P135, DOI 10.1016/S0014-5793(01)02718-1; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753	45	91	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8172	8179		10.1074/jbc.M411408200	http://dx.doi.org/10.1074/jbc.M411408200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611139	Green Published, hybrid			2022-12-27	WOS:000227395700090
J	Isono, E; Saito, N; Kamata, N; Saeki, Y; Toh-e, A				Isono, E; Saito, N; Kamata, N; Saeki, Y; Toh-e, A			Functional analysis of Rpn6p, a lid component of the 26 S proteasome, using temperature-sensitive rpn6 mutants of the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME REGULATORY PARTICLE; UBIQUITIN-DEPENDENT PROTEOLYSIS; 26S PROTEASOME; DEGRADATION SIGNAL; COP9 SIGNALOSOME; 26-S PROTEASOME; PCI DOMAIN; SUBUNIT; PROTEINS; COMPLEX	Rpn6p is a component of the lid of the 26 S proteasome. We isolated and analyzed two temperature-sensitive rpn6 mutants in the yeast, Saccharomyces cerevisiae. Both mutants showed defects in protein degradation in vivo. However, the affinity-purified 26 S proteasome of the rpn6 mutants grown at the permissive temperature degraded polyubiquitinated Sic1p efficiently, even at a higher temperature. Interestingly, their enzyme activity was even higher at a higher temperature, indicating that once made mutant proteasomes are stable and have little defect in the proteolytic function. These results suggest that the deficiency in protein degradation observed in vivo is rather due to a defect in the assembly of a holoenzyme at the restrictive temperature. Indeed, both rpn6 mutants grown at the restrictive temperature were defective in assembling the 26 S proteasome. A striking feature of the rpn6 mutants at the restrictive temperature was that there appeared a protein complex composed of only four of the nine lid components, Rpn5p, Rpn8p, Rpn9p, and Rpn11p. Altogether, we conclude that Rpn6p is essential for the integrity/assembly of the lid in the sense that it is necessary for the incorporation of Rpn3p, Rpn7p, Rpn12p, and Sem1p (Rpn15p) into the lid, thereby playing an essential role in the proper function of the 26 S proteasome.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan	University of Tokyo	Toh-e, A (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, 7-3-1 Hongo, Tokyo 1130033, Japan.	toh-e@biol.s.u-tokyo.ac.jp						Bailly E, 1999, MOL CELL BIOL, V19, P6872; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; BURK D, 2000, METHODS YEAST GENETI; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cagney G, 2001, PHYSIOL GENOMICS, V7, P27, DOI 10.1152/physiolgenomics.2001.7.1.27; Ciccarelli FD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-64; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guterman A, 2004, J BIOL CHEM, V279, P1729, DOI 10.1074/jbc.M307050200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Isono E, 2004, J BIOL CHEM, V279, P27168, DOI 10.1074/jbc.M314231200; Jantti J, 1999, P NATL ACAD SCI USA, V96, P909, DOI 10.1073/pnas.96.3.909; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KAIS, 1994, METHODS YEAST GENETI, P169; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Lier S, 2002, GENE, V298, P109, DOI 10.1016/S0378-1119(02)00930-7; NISOGI H, 1992, EXP CELL RES, V200, P48, DOI 10.1016/S0014-4827(05)80070-9; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Saeki Y, 2000, BIOCHEM BIOPH RES CO, V273, P509, DOI 10.1006/bbrc.2000.2980; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200; Schwartz AL, 1999, ANNU REV MED, V50, P57; SHERMAN F, 1986, METHODS YEAST GENETI, P12; SIKORSKI RS, 1989, GENETICS, V122, P19; Smalle J, 2003, PLANT CELL, V15, P965, DOI 10.1105/tpc.009217; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Takeuchi J, 1999, MOL GEN GENET, V262, P145, DOI 10.1007/s004380051069; Takeuchi J, 2001, BIOCHIMIE, V83, P333, DOI 10.1016/S0300-9084(01)01238-X; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Toh-e A, 2000, GENES GENET SYST, V75, P33, DOI 10.1266/ggs.75.33; Tsuge T, 2001, J MOL BIOL, V305, P1, DOI 10.1006/jmbi.2000.4288; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yen HCS, 2003, J BIOL CHEM, V278, P30669, DOI 10.1074/jbc.M302093200	51	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6537	6547		10.1074/jbc.M409364200	http://dx.doi.org/10.1074/jbc.M409364200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611133	hybrid			2022-12-27	WOS:000227332700037
J	Xu, XM; Adams, S; Chua, NH; Moller, SG				Xu, XM; Adams, S; Chua, NH; Moller, SG			AtNAP1 represents an atypical SufB protein in Arabidopsis plastids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; FE-S CLUSTER; ABC TRANSPORTER; SALMONELLA-TYPHIMURIUM; GENE-CLUSTER; IN-VIVO; ATP; NIFS; BIOGENESIS; BACTERIA	The assembly of iron-sulfur (Fe-S) clusters involves several pathways and in prokaryotes the mobilization of the sulfur (SUF) system is paramount for Fe-S biogenesis and repair during oxidative stress. The prokaryotic SUF system consists of six proteins: SufC is an ABC/ATPase that forms a complex with SufB and SufD, SufA acts as a scaffold protein, and SufE and SufS, are involved in sulfur mobilization from cysteine. Despite the importance of Fe-S proteins in higher plant plastids, little is known regarding plastidic Fe-S cluster assembly. We have recently shown that Arabidopsis harbors an evolutionary conserved plastidic SufC protein (AtNAP7) capable of hydrolyzing ATP and interacting with the SufD homolog AtNAP6. Based on this and the prokaryotic SUF system we speculated that a SufB-like protein may exist in plastids. Here we demonstrate that the Arabidopsis plastid-localized SufB homolog AtNAP1 can complement SufB deficiency in Escherichia coli during oxidative stress. Furthermore, we demonstrate that AtNAP1 can interact with AtNAP7 inside living chloroplasts suggesting the presence of a plastidic AtNAP1(.)AtNAP6(.)AtNAP7 complex and remarkable evolutionary conservation of the SUF system. However, in contrast to prokaryotic SufB proteins with no associated ATPase activity we show that AtNAP1 is an iron-stimulated ATPase and that AtNAP1 is capable of forming homodimers. Our results suggest that AtNAP1 represents an atypical plastidic SufB-like protein important for Fe-S cluster assembly and for regulating iron homeostasis in Arabidopsis.	Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England; Rockefeller Univ, Lab Plant Mol Biol, New York, NY 10021 USA	University of Leicester; Rockefeller University	Moller, SG (corresponding author), Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England.	sgm5@le.ac.uk		Moller, Simon/0000-0002-0460-3592	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044640, R56GM044640] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM044640, GM-44640] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Garcia O, 2004, J MOL BIOL, V343, P249, DOI 10.1016/j.jmb.2004.07.093; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; Kapazoglou A, 2000, EUR J BIOCHEM, V267, P352, DOI 10.1046/j.1432-1327.2000.01006.x; Kost B, 1998, PLANT J, V16, P393, DOI 10.1046/j.1365-313x.1998.00304.x; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Leon S, 2002, BIOCHEM J, V366, P557, DOI 10.1042/BJ20020322; Lezhneva L, 2004, PLANT J, V37, P174, DOI 10.1046/j.1365-313X.2003.01952.x; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Ollagnier-De-Choudens S, 2003, FEBS LETT, V555, P263, DOI 10.1016/S0014-5793(03)01244-4; Olson JW, 2000, BIOCHEMISTRY-US, V39, P16213, DOI 10.1021/bi001744s; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Pilon-Smits EAH, 2002, PLANT PHYSIOL, V130, P1309, DOI 10.1104/pp.010280; Rangachari K, 2002, FEBS LETT, V514, P225, DOI 10.1016/S0014-5793(02)02369-4; Raven JA, 1999, PHOTOSYNTH RES, V60, P111, DOI 10.1023/A:1006282714942; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Sarin J, 2001, J BIOL CHEM, V276, P44590, DOI 10.1074/jbc.M105401200; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x; Xu XM, 2004, P NATL ACAD SCI USA, V101, P9143, DOI 10.1073/pnas.0400799101; Yabe T, 2004, PLANT CELL, V16, P993, DOI 10.1105/tpc.020511; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	36	78	82	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6648	6654		10.1074/jbc.M413082200	http://dx.doi.org/10.1074/jbc.M413082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611066	Green Accepted, hybrid			2022-12-27	WOS:000227332700051
J	Yang, CX; McPheeters, DS; Yu, YT				Yang, CX; McPheeters, DS; Yu, YT			Psi 35 in the branch site recognition region of U2 small nuclear RNA is important for Pre-mRNA splicing in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPENSATORY BASE CHANGE; U6 SNRNA; PAIRING INTERACTION; CROSS-LINKING; GUIDE RNA; YEAST; U5; PSEUDOURIDYLATION; SEQUENCES; NUCLEOTIDES	Pseudouridine 35 (psi35) in the branch site recognition region of yeast U2 small nuclear RNA is absolutely conserved in all eukaryotes examined. Pus7p catalyzes pseudouridylation at position 35 in Saccharomyces cerevisiae U2. The pus7 deletion strain, although viable in rich medium, is growth-disadvantaged under certain conditions. To clarify the function of U2 psi35 in yeast, we used this pus7 deletion strain to screen a collection of mutant U2 small nuclear RNAs, each containing a point mutation near the branch site recognition sequence, for a synthetic growth defect phenotype. The screen identified two U2 mutants, one containing a U40 --> G40 substitution (U40G) and another having a U40 deletion (U40Delta). Yeast strains carrying either of these U2 mutations grew as well as the wild-type strain in the selection medium, but they exhibited a temperature-sensitive growth defect phenotype when coupled with the pus7 deletion (pus7Delta). A subsequent temperature shift assay and a conditional pus7 depletion (via GAL promoter shutoff) in the U2-U40 mutant genetic background caused pre-mRNA accumulation, suggesting that psi35 is required for pre-mRNA splicing under certain conditions.	Univ Rochester, Ctr Med, Dept Biochem & Biophys, Rochester, NY 14642 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	University of Rochester; Case Western Reserve University	Yu, YT (corresponding author), Univ Rochester, Ctr Med, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	yitao_yu@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062937, R01GM064682] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM064682, GM62937] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandrov A, 2002, RNA, V8, P1253, DOI 10.1017/S1355838202024019; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Behm-Ansmant I, 2003, RNA, V9, P1371, DOI 10.1261/rna.5520403; Chang JS, 2000, RNA, V6, P1120, DOI 10.1017/S1355838200000133; Collins CA, 2001, RNA, V7, P1845; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; Donmez G, 2004, RNA, V10, P1925, DOI 10.1261/rna.7186504; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; Jady BE, 2001, EMBO J, V20, P541, DOI 10.1093/emboj/20.3.541; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; Ma XJ, 2003, EMBO J, V22, P1889, DOI 10.1093/emboj/cdg191; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Massenet S., 1998, MODIFICATION EDITING, P201; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; Newby MI, 2002, NAT STRUCT BIOL, V9, P958, DOI 10.1038/nsb873; Newby MI, 2001, RNA, V7, P833, DOI 10.1017/S1355838201002308; Newman AJ, 1995, RNA, V1, P968; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; Valadkhan S, 2003, RNA, V9, P892, DOI 10.1261/rna.5440303; Valadkhan S, 2001, NATURE, V413, P701, DOI 10.1038/35099500; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; Yan D, 1996, MOL CELL BIOL, V16, P818; Yu YT, 1998, EMBO J, V17, P5783, DOI 10.1093/emboj/17.19.5783; YU YT, 1999, RNA WORLD, V2, P487; YU YT, 2005, TOPICS CURRENT GENET; Zhao XL, 2004, RNA, V10, P681, DOI 10.1261/rna.5159504; Zhao XL, 2002, RNA, V8, P1515, DOI 10.1017/S1355838202022537; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	45	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6655	6662		10.1074/jbc.M413288200	http://dx.doi.org/10.1074/jbc.M413288200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611063	hybrid			2022-12-27	WOS:000227332700052
J	Filipek, R; Potempa, J; Bochtler, M				Filipek, R; Potempa, J; Bochtler, M			A comparison of staphostatin B with standard mechanism serine protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE STABILIZATION; PANCREATIC TRYPSIN-INHIBITOR; CYSTEINE PROTEASE; PROTEINASE-INHIBITORS; CATALYTIC MECHANISM; PAPAIN; SPECIFICITY; COMPLEXES; SITE; CHYMOTRYPSIN	Staphostatins are the endogenous, highly specific inhibitors of staphopains, the major secreted cysteine proteases from Staphylococcus aureus. We have previously shown that staphostatins A and B are competitive, active site-directed inhibitors that span the active site clefts of their target proteases in the same orientation as substrates. We now report the crystal structure of staphostatin B in complex with wild-type staphopain B at 1.9 angstrom resolution. In the complex structure, the catalytic residues are found in exactly the positions that would be expected for uncomplexed papain-type proteases. There is robust, continuous density for the staphostatin B binding loop and no indication for cleavage of the peptide bond that comes closest to the active site cysteine of staphopain B. The carbonyl carbon atom C of this peptide bond is 4.1 angstrom away from the active site cysteine sulfur S gamma atom. The carbonyl oxygen atom O of this peptide bond points away from the putative oxyanion hole and lies almost on a line from the S gamma atom to the C atom. The arrangement is strikingly similar to the "ion-molecule" arrangement for the complex of papain-type enzymes with their substrates but differs significantly from the arrangement conventionally assumed for the Michaelis complex of papain-type enzymes with their substrates and also from the arrangement that is crystallographically observed for complexes of standard mechanism inhibitors and their target serine proteases.	Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Max Planck Inst Mol Cell Biol & Genet, D-01309 Dresden, Germany; Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Max Planck Society; Jagiellonian University; University System of Georgia; University of Georgia	Bochtler, M (corresponding author), Int Inst Mol & Cell Biol, Ul Trojdena 4, PL-02109 Warsaw, Poland.	MBochtler@iimcb.gov.pl	Bochtler, Matthias/A-4514-2010	Bochtler, Matthias/0000-0001-7884-4463				Allen FH, 1997, ACTA CRYSTALLOGR B, V53, P696, DOI 10.1107/S0108768197002644; ARAD D, 1990, J AM CHEM SOC, V112, P491, DOI 10.1021/ja00158a004; ASBOTH B, 1985, BIOCHEMISTRY-US, V24, P606, DOI 10.1021/bi00324a010; ASBOTH B, 1983, BIOCHEMISTRY-US, V22, P117, DOI 10.1021/bi00270a017; BLOW DM, 1972, J MOL BIOL, V69, P137, DOI 10.1016/0022-2836(72)90028-9; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; BURGI HB, 1974, TETRAHEDRON, V30, P1563, DOI 10.1016/S0040-4020(01)90678-7; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Dubin G, 2004, BIOL CHEM, V385, P543, DOI 10.1515/BC.2004.064; Esposito L, 2000, PROTEIN SCI, V9, P2038; Filipek R, 2004, BIOCHEMISTRY-US, V43, P14306, DOI 10.1021/bi048661m; Filipek R, 2003, J BIOL CHEM, V278, P40959, DOI 10.1074/jbc.M302926200; Finkenstadt W. R., 1965, J BIOL CHEM, V240, P962; FINKENSTADT WR, 1967, J BIOL CHEM, V242, P771; Harrison MJ, 1997, J AM CHEM SOC, V119, P12285, DOI 10.1021/ja9711472; Helland R, 1999, ACTA CRYSTALLOGR D, V55, P139, DOI 10.1107/S090744499801052X; HOWARD AE, 1988, J AM CHEM SOC, V110, P7195, DOI 10.1021/ja00229a040; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krowarsch D, 2003, CELL MOL LIFE SCI, V60, P2427, DOI 10.1007/s00018-003-3120-x; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; LONGSTAFF C, 1990, BIOCHEMISTRY-US, V29, P7339, DOI 10.1021/bi00483a025; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; Massimi I, 2002, J BIOL CHEM, V277, P41770, DOI 10.1074/jbc.M207162200; MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perakyla M, 2000, J AM CHEM SOC, V122, P3436, DOI 10.1021/ja991602p; Radisky ES, 2002, P NATL ACAD SCI USA, V99, P10316, DOI 10.1073/pnas.112332899; Rzychon M, 2003, PROTEIN SCI, V12, P2252, DOI 10.1110/ps.03247703; Rzychon M, 2003, MOL MICROBIOL, V49, P1051, DOI 10.1046/j.1365-2958.2003.03613.x; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P714, DOI 10.1107/S0907444900003723; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Thompson SK, 1997, P NATL ACAD SCI USA, V94, P14249, DOI 10.1073/pnas.94.26.14249; Tsai J, 1999, J MOL BIOL, V290, P253, DOI 10.1006/jmbi.1999.2829; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wladyka B, 2005, BIOCHEM J, V385, P181, DOI 10.1042/BJ20040958	40	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14669	14674		10.1074/jbc.M411792200	http://dx.doi.org/10.1074/jbc.M411792200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15644332	hybrid			2022-12-27	WOS:000228236800042
J	Niimura, M; Isoo, N; Takasugi, N; Tsuruoka, M; Ui- Tei, K; Saigo, K; Morohashi, Y; Tomita, T; Iwatsubo, T				Niimura, M; Isoo, N; Takasugi, N; Tsuruoka, M; Ui- Tei, K; Saigo, K; Morohashi, Y; Tomita, T; Iwatsubo, T			Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE HELIX INTERACTIONS; ALZHEIMERS-DISEASE; MEMBRANE-PROTEINS; GXXXG MOTIF; C-TERMINUS; DROSOPHILA-MELANOGASTER; MUTANT PRESENILIN; PRECURSOR PROTEIN; RNA INTERFERENCE; BETA-APP	gamma-Secretase cleaves type I transmembrane proteins, including beta-amyloid precursor protein and Notch, and requires the formation of a protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2 for its activity. Aph-1 is implicated in the stabilization of this complex, although its precise mechanistic role remains unknown. Substitution of the first glycine within the transmembrane GXXXG motif of Aph-1 causes a loss-of-function phenotype in Caenorhabditis elegans. Here, using an untranslated region-targeted RNA interference/rescue strategy in Drosophila Schneider 2 cells, we show that Aph-1 contributes to the assembly of the gamma-secretase complex by multiple mechanisms involving intermolecular and intramolecular interactions depending on or independent of the conserved glycines. Aph-1 binds to nicastrin forming an early subcomplex independent of the conserved glycines within the endoplasmic reticulum. Certain mutations in the conserved GXXXG motif affect the interaction of the Aph-1(.)nicastrin subcomplex with presenilin that mediates trafficking of the presenilin(.)Aph-1(.)nicastrin tripartite complex to the Golgi. The same mutations decrease the stability of Aph-1 polypeptides themselves, possibly by affecting intramolecular associations through the transmembrane domains. Our data suggest that the proper assembly of the Aph-1(.)nicastrin subcomplex with presenilin is the prerequisite for the trafficking as well as the enzymatic activity of the gamma-secretase complex and that Aph-1 functions as a stabilizing scaffold in the assembly of this complex.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Tomita, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	taisuke@mol.f.u-tokyo.ac.jp; iwatsubo@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; TAKASUGI, NOBUMASA/0000-0002-6059-2082				Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; Celotto AM, 2002, RNA, V8, P718, DOI 10.1017/S1355838202021064; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2004, J BIOL CHEM, V279, P37311, DOI 10.1074/jbc.M406228200; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Fortna RR, 2004, J BIOL CHEM, V279, P3685, DOI 10.1074/jbc.M310505200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442; NATSUGARI H, 2003, J BIOL CHEM, V278, P18664; Nowotny P, 2000, MOL CELL NEUROSCI, V15, P88, DOI 10.1006/mcne.1999.0805; Nufer O, 2002, J CELL SCI, V115, P619; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Roignant JY, 2003, RNA, V9, P299, DOI 10.1261/rna.2154103; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 2004, DRUG NEWS PERSPECT, V17, P321, DOI 10.1358/dnp.2004.17.5.829036; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	68	75	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12967	12975		10.1074/jbc.M409829200	http://dx.doi.org/10.1074/jbc.M409829200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15644323	hybrid			2022-12-27	WOS:000227922000106
J	Liu, SW; Lu, H; Niu, J; Xu, YJ; Wu, SG; Jiang, SB				Liu, SW; Lu, H; Niu, J; Xu, YJ; Wu, SG; Jiang, SB			Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDE; HEPTAD REPEAT; POTENT INHIBITORS; CRYSTAL-STRUCTURE; ATOMIC-STRUCTURE; SPIKE PROTEIN; BINDING-SITE; COILED-COIL	Fuzeon (also known as T-20 or enfuvirtide), one of the C-peptides derived from the HIV-1 envelope glycoprotein transmembrane subunit gp41 C-terminal heptad repeat (CHR) region, is the first member of a new class of anti-HIV drugs known as HIV fusion inhibitors. It has been widely believed that T-20 shares the same mechanism of action with C34, another C-peptide. The C34 is known to compete with the CHR of gp41 to form a stable 6-helix bundle (6-HB) with the gp41 N-terminal heptad repeat (NHR) and prevent the formation of the fusogenic gp41 core between viral gp41 NHR and CHR, thereby inhibiting fusion between viral and target cell membranes. Here we present data to demonstrate that, contrary to this belief, T-20 cannot form stable 6-HB with N-peptides derived from the NHR region, nor can it inhibit the 6-HB formation of the fusogenic core. Instead, it may interact with N-peptides to form unstable or insoluble complexes. Our data suggest that T-20 has a different mechanism of action from C34. The interaction of T-20 with viral NHR region alone may not prevent the formation of the fusion active gp41 core. We also demonstrate that the T-20-mediated anti-HIV activity can be significantly abrogated by peptides derived from the membrane-spanning domain in gp41 and coreceptor binding site in gp120. These new findings imply that T-20 inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. Further elucidation of the mechanism of action of T-20 will provide new target(s) for development of novel HIV entry inhibitors.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA; So Med Univ, Inst Pharmaceut Sci, Guangzhou 510515, Guangdong, Peoples R China	New York Blood Center; City University of New York (CUNY) System; Hunter College (CUNY); Southern Medical University - China	Jiang, SB (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.	sjiang@nybloodcenter.org	Jiang, Shibo/L-4500-2014	Jiang, Shibo/0000-0001-8283-7135; Liu, Shuwen/0000-0001-6346-5006	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046221, R21AI046221] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46221] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam SM, 2004, AIDS RES HUM RETROV, V20, P836, DOI 10.1089/0889222041725181; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cooper DA, 2004, LANCET INFECT DIS, V4, P426, DOI 10.1016/S1473-3099(04)01058-8; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Dwyer JJ, 2003, BIOCHEMISTRY-US, V42, P4945, DOI 10.1021/bi027283n; Ernst JT, 2002, ANGEW CHEM INT EDIT, V41, P278, DOI 10.1002/1521-3773(20020118)41:2<278::AID-ANIE278>3.0.CO;2-A; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Greenberg ML, 2004, J ANTIMICROB CHEMOTH, V54, P333, DOI 10.1093/jac/dkh330; Hildinger M, 2001, J VIROL, V75, P3038, DOI 10.1128/JVI.75.6.3038-3042.2001; Ji H, 1999, J VIROL, V73, P8578, DOI 10.1128/JVI.73.10.8578-8586.1999; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG S, 2000, P SOC PHOTO-OPT INS, V3926, P212, DOI DOI 10.1117/12.380514; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5; Jones DK, 1998, BIOCHEM J, V330, P983; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013; Liu SW, 2003, J BIOMOL SCREEN, V8, P685, DOI 10.1177/1087057103259155; Lombardi S, 1996, VIROLOGY, V220, P274, DOI 10.1006/viro.1996.0315; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Mobley PW, 2001, AIDS RES HUM RETROV, V17, P311, DOI 10.1089/08892220150503681; Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100; MOORE JP, 1993, FUSION MECH, P233; Peisajovich SG, 2003, J BIOL CHEM, V278, P21012, DOI 10.1074/jbc.M212773200; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; Reeves JD, 2004, J VIROL, V78, P5476, DOI 10.1128/JVI.78.10.5476-5485.2004; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Ryu JR, 1999, BIOCHEM BIOPH RES CO, V265, P625, DOI 10.1006/bbrc.1999.1739; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Sista PR, 2004, AIDS, V18, P1787, DOI 10.1097/00002030-200409030-00007; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Xu L, 2002, AIDS, V16, P1684, DOI 10.1097/00002030-200208160-00016; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200; Xu YH, 2004, BIOCHEM BIOPH RES CO, V315, P664, DOI 10.1016/j.bbrc.2004.01.115; Xu YN, 2000, FEBS LETT, V487, P185, DOI 10.1016/S0014-5793(00)02336-X; Yuan W, 2004, J VIROL, V78, P5448, DOI 10.1128/JVI.78.10.5448-5457.2004	65	191	214	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11259	11273		10.1074/jbc.M411141200	http://dx.doi.org/10.1074/jbc.M411141200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15640162	hybrid			2022-12-27	WOS:000227761800046
J	Blander, G; Olejnik, J; Olejnik, EK; Mcdonagh, T; Haigis, M; Yaffe, MB; Guarente, L				Blander, G; Olejnik, J; Olejnik, EK; Mcdonagh, T; Haigis, M; Yaffe, MB; Guarente, L			SIRT1 shows no substrate specificity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; NUCLEAR-BODIES; CELL-SURVIVAL; DNA-DAMAGE; P53; PROTEIN; PML; NAD; ACETYLATION; DEACETYLASE	SIR2 is a key regulator of the aging process in many model organisms. The human ortholog SIRT1 plays a pivotal role in the regulation of cellular differentiation, metabolism, cell cycle, and apoptosis. SIRT1 is an NAD(+)-dependent deacetylase, and its enzymatic activity may be regulated by cellular energy. There is a growing number of known SIRT1 substrates that contain epsilon-acetyl lysine but for which no obvious consensus sequence has been defined. In this study, we developed a novel unbiased method to identify deacetylase sequence specificity using oriented peptide libraries containing acetylated lysine. Following incubation with SIRT1, the subset of deacetylated peptides was selectively captured using a photocleavable N-hydroxysuccinimide (NHS)-biotin linker and streptavidin beads and analyzed using mass spectrometry and Edman degradation. These studies revealed that substrate recognition by SIRT1 does not depend on the amino acid sequence proximate to the acetylated lysine. This result brings us one step closer to understanding how SIRT1 and possibly other protein deacetylases chose their substrate.	MIT, Dept Biol, Cambridge, MA 02139 USA; AmberGen Inc, Boston, MA 02215 USA; Elixir Pharmaceut, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG011119, F32AG022775, R01AG011119, R01AG015339, R01AG021150] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119, AG15339, AG22775, AG21150] Funding Source: Medline; NIGMS NIH HHS [GM60594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; FRY M, 2002, SCI AGING KNOWLEDGE, V13, pRE2; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; OLEJNIK J, 1995, P NATL ACAD SCI USA, V92, P7590, DOI 10.1073/pnas.92.16.7590; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X	31	62	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9780	9785		10.1074/jbc.M414080200	http://dx.doi.org/10.1074/jbc.M414080200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640142	hybrid			2022-12-27	WOS:000227559600006
J	Bromann, PA; Korkaya, H; Webb, CP; Miller, J; Calvin, TL; Courtneidge, SA				Bromann, PA; Korkaya, H; Webb, CP; Miller, J; Calvin, TL; Courtneidge, SA			Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASES; SMOOTH-MUSCLE-CELLS; C-MYC-GENE; BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; MAMMALIAN-CELLS; IDENTIFICATION; EXPRESSION; TRANSCRIPTION	The Src family of protein-tyrosine kinases (SFKs) participates in a variety of signal transduction pathways, including promotion of cell growth, prevention of apoptosis, and regulation of cell interactions and motility. In particular, SFKs are required for the mitogenic response to platelet-derived growth factor ( PDGF). However, it is not clear whether there is a discrete SFK-specific pathway leading to enhanced gene expression or whether SFKs act to generally enhance PDGF-stimulated gene expression. To examine this, we treated quiescent NIH3T3 cells with PDGF in the presence or absence of small molecule inhibitors of SFKs, phosphatidylinositol 3-kinase (PI3K), and MEK1/2. Global patterns of gene expression were analyzed by using Affymetrix Gene-Chip arrays, and data were validated by using reverse transcription-PCR and ribonuclease protection assay. We identified a discrete set of immediate early genes induced by PDGF and inhibited in the presence of the SFK-selective inhibitor SU6656. A subset of these SFK-dependent genes was induced by PDGF even in the presence of the MEK1/2 inhibitor U0126 or the PI3K inhibitor LY294002. By using ribonuclease protection assays and nuclear run-off assays, we further determined that PDGF did not stimulate the rate of transcription of these SFK-dependent immediate early genes but rather promoted mRNA stabilization. Our data suggest that PDGF regulates gene expression through an SFK-specific pathway that is distinct from the Ras-MAPK and PI3K pathways, and that SFKs signal gene expression by enhancing mRNA stability.	Van Andel Res Inst, Lab Signal Regulat & Canc, Grand Rapids, MI 49503 USA; Van Andel Res Inst, Lab Tumor Metastasis & Angiogenesis, Grand Rapids, MI 49503 USA	Van Andel Institute; Van Andel Institute	Courtneidge, SA (corresponding author), Van Andel Res Inst, Lab Signal Regulat & Canc, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	sara.courtneidge@vai.org	Korkaya, Hasan/GRY-1016-2022; Korkaya, Hasan/ABD-6282-2020; Webb, Craig/I-8123-2012; Korkaya, Hasan/C-2201-2009	Korkaya, Hasan/0000-0002-0719-5862; 				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; Bogdanov VY, 1998, J BIOL CHEM, V273, P24932, DOI 10.1074/jbc.273.38.24932; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chen WSV, 2004, NAT GENET, V36, P304, DOI 10.1038/ng1306; Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEAN M, 1986, J BIOL CHEM, V261, P9161; Demoulin JB, 2004, J BIOL CHEM, V279, P35392, DOI 10.1074/jbc.M405924200; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kakoki M, 2004, DEV CELL, V6, P597, DOI 10.1016/S1534-5807(04)00094-2; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; MILLER J, 2003, APPL GENOMICS PROTEO, V2, P253; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NEPVEU A, 1987, ONCOGENE, V1, P243; Poon M, 1999, MOL CELL BIOL, V19, P6471; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; Ren LQ, 2002, J PHARMACOL EXP THER, V303, P265, DOI 10.1124/jpet.102.035253; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; SACCA R, 1990, ONCOGENE, V5, P1499; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611	42	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10253	10263		10.1074/jbc.M413806200	http://dx.doi.org/10.1074/jbc.M413806200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15637050	hybrid, Green Accepted			2022-12-27	WOS:000227559600064
J	Bruckner, S; Rhamouni, S; Tautz, L; Denault, JB; Alonso, A; Becattini, B; Salvesen, GS; Mustelin, T				Bruckner, S; Rhamouni, S; Tautz, L; Denault, JB; Alonso, A; Becattini, B; Salvesen, GS; Mustelin, T			Yersinia phosphatase induces mitochondrially dependent apoptosis of T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; VIRULENCE DETERMINANT; ANTIGEN RECEPTOR; YOPH; PHOSPHORYLATION; SPECIFICITY; MACROPHAGES; SUPPRESSION; INHIBITION; UPSTREAM	To evade the immune system, the etiologic agent of plague, Yersinia pestis, injects an exceptionally active tyrosine phosphatase called YopH into host cells using a type III secretion system. We recently reported that YopH acutely inhibits T cell antigen receptor signaling by dephosphorylating the Lck tyrosine kinase. Here, we show that prolonged presence of YopH in primary T cells or Jurkat T leukemia cells causes apoptosis, detected by annexin V binding, mitochondrial breakdown, caspase activation, and internucleosomal fragmentation. YopH also causes cell death when expressed in HeLa cells, and this cell death was inhibited by YopH-specific small molecule inhibitors. Cell death induced by YopH was also prevented by caspase inhibition or coexpression of Bcl-xL. We conclude that YopH not only paralyzes T cells acutely, but also ensures that the cells will not recover to induce a protective immune response but instead undergo mitochondrially regulated programmed cell death.	Burnham Inst, Program Inflammat, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA; Burnham Inst, Programs Signal Transduct, La Jolla, CA 92037 USA; Burnham Inst, Ctr Canc, Program Apoptosis & Cell Death, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute	Mustelin, T (corresponding author), Burnham Inst, Program Inflammat, Infect & Inflammatory Dis Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Denault, Jean-Bernard/AAC-5945-2019; Alonso, Andrés/L-7523-2014; Tautz, Lutz/M-9989-2014	Alonso, Andrés/0000-0001-8674-9378; Tautz, Lutz/0000-0002-4075-6238; Mustelin, Tomas/0000-0001-5912-8840; Becattini, Barbara/0000-0002-1002-6891	NIAID NIH HHS [AI55789, AI53114] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053114, P01AI055789] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aepfelbacher M, 1999, BIOL CHEM, V380, P795, DOI 10.1515/BC.1999.099; Alonso A, 2004, J BIOL CHEM, V279, P4922, DOI 10.1074/jbc.M308978200; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Andersson K, 1996, MOL MICROBIOL, V20, P1057, DOI 10.1111/j.1365-2958.1996.tb02546.x; Black DS, 2000, CELL MICROBIOL, V2, P401, DOI 10.1046/j.1462-5822.2000.00061.x; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Cornelis GR, 2002, INT J MED MICROBIOL, V291, P455; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Denecker G, 2001, J BIOL CHEM, V276, P19706, DOI 10.1074/jbc.M101573200; Ernst JD, 2000, CELL MICROBIOL, V2, P379, DOI 10.1046/j.1462-5822.2000.00075.x; GREEN SP, 1995, J LEUKOCYTE BIOL, V57, P972, DOI 10.1002/jlb.57.6.972; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Hinnebusch BJ, 1997, J MOL MED, V75, P645, DOI 10.1007/s001090050148; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Montagna LG, 2001, J BIOL CHEM, V276, P5005, DOI 10.1074/jbc.M009045200; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Salvesen GS, 2002, ESSAYS BIOCHEM, V38, P9, DOI 10.1042/bse0380009; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; Titball RW, 1998, BRIT MED BULL, V54, P625, DOI 10.1093/oxfordjournals.bmb.a011715; Yao T, 1999, J EXP MED, V190, P1343, DOI 10.1084/jem.190.9.1343	30	24	26	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10388	10394		10.1074/jbc.M408829200	http://dx.doi.org/10.1074/jbc.M408829200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632192	hybrid			2022-12-27	WOS:000227559600079
J	Wu, WWH; Wong, JP; Kast, J; Molday, RS				Wu, WWH; Wong, JP; Kast, J; Molday, RS			RS1, a discoidin domain-containing retinal cell adhesion protein associated with X-linked retinoschisis, exists as a novel disulfide-linked octamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VIII; C2 DOMAIN; PHOTORECEPTOR; EXPRESSION; GENE; MUTATIONS; BIPOLAR	RS1, also known as retinoschisin, is an extracellular protein that plays a crucial role in the cellular organization of the retina. Mutations in RS1 are responsible for X-linked retinoschisis, a common, early-onset macular degeneration in males that results in a splitting of the inner layers of the retina and severe loss in vision. RS1 is assembled and secreted from photoreceptors and bipolar cells as a homo-oligomeric protein complex. Each subunit consists of a 157-amino acid discoidin domain flanked by two small segments of 39 and 5 amino acids. To begin to understand how the structure of RS1 relates to its role in retinal cell adhesion and X-linked retinoschisis, we have determined the subunit organization and disulfide bonding pattern of RS1 by SDS gel electrophoresis, velocity sedimentation, and mass spectrometry. Our results indicate that RS1 exists as a novel octamer in which the eight subunits are joined together by Cys(59)-Cys(223) intermolecular disulfide bonds. Subunits within the octamer are further organized into dimers mediated by Cys(40)-Cys(40) bonds. These cysteines lie just outside the discoidin domain indicating that these flanking segments primarily function in the octamerization of RS1. Within the discoidin domain, two cysteine pairs (Cys(63)-Cys(219) and Cys(110)-Cys(142)) form intramolecular disulfide bonds that are important in protein folding, and one cysteine (Cys(83)) exists in its reduced state. Because mutations that disrupt subunit assembly cause X-linked retinoschisis, the assembly of RS1 into a disulfide-linked homo-octamer appears to be critical for its function as a retinal cell adhesion protein.	Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Ctr Macular Res, Dept Ophthalmol & Visual Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Ctr Biomed Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@interchange.ubc.ca			NEI NIH HHS [EY 02422] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1998, Hum Mol Genet, V7, P1185; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Fraternali F, 2003, FEBS LETT, V544, P21, DOI 10.1016/S0014-5793(03)00433-2; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; GEORGE NDL, 1995, BRIT J OPHTHALMOL, V79, P697, DOI 10.1136/bjo.79.7.697; Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873; Hiriyanna KT, 1999, HUM MUTAT, V14, P423, DOI 10.1002/(SICI)1098-1004(199911)14:5<423::AID-HUMU8>3.0.CO;2-D; Hvarregaard J, 1996, EUR J BIOCHEM, V240, P628, DOI 10.1111/j.1432-1033.1996.0628h.x; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Matese JC, 1997, DEV BIOL, V186, P16, DOI 10.1016/S0012-1606(97)98585-7; Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Reid SNM, 1999, GENE, V227, P257, DOI 10.1016/S0378-1119(98)00578-2; Reid SNM, 2003, J NEUROSCI, V23, P6030, DOI 10.1523/JNEUROSCI.23-14-06030.2003; Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164; See Y., 1989, PROTEIN STRUCTURE PR, P1; Shur BD, 2004, CURR OPIN CELL BIOL, V16, P477, DOI 10.1016/j.ceb.2004.07.005; SIEVING PA, 1998, GENETIC DIS EYE; Tantri A, 2004, SURV OPHTHALMOL, V49, P214, DOI 10.1016/j.survophthal.2003.12.007; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Wang T, 2002, HUM MOL GENET, V11, P3097, DOI 10.1093/hmg/11.24.3097; Weber BHF, 2002, P NATL ACAD SCI USA, V99, P6222, DOI 10.1073/pnas.092528599; Wu WWH, 2003, J BIOL CHEM, V278, P28139, DOI 10.1074/jbc.M302464200; Yamakawa M, 1999, DEV COMP IMMUNOL, V23, P281, DOI 10.1016/S0145-305X(99)00011-7	25	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10721	10730		10.1074/jbc.M413117200	http://dx.doi.org/10.1074/jbc.M413117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644328	hybrid			2022-12-27	WOS:000227559600118
J	Cabib, E; Duran, A				Cabib, E; Duran, A			Synthase III-dependent chitin is bound to different acceptors depending on location on the cell wall of budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-STEP PURIFICATION; SACCHAROMYCES-CEREVISIAE; LITHIUM CHLORIDE-N,N-DIMETHYLACETAMIDE; SEPTATION APPARATUS; CYCLE; MORPHOGENESIS; ARCHITECTURE; SYSTEM; CHROMATOGRAPHY; CYTOKINESIS	In yeast, chitin is laid down at three locations: a ring at the mother-bud neck, the primary septum and, after cytokinesis, the cell wall of the daughter cell. Some of the chitin is free and the remainder attached to similar to( 1 3) glucan or beta(1-6) glucan. We recently reported that the chitin ring contributes to the prevention of growth at the mother-bud neck and hypothesized that this inhibition is achieved by a preferential binding of chitin to beta(1-3) glucan at that site. Here, we devised a novel strategy for the analysis of chitin cross-links in [C-14] glucosamine-labeled cell walls, involving solubilization in water of alkali-treated walls by carboxymethylation. Intact cell walls or their digestion products with similar to( 1 3) glucanase or similar to(1-6) glucanase were carboxymethylated and fractionated on size columns, and the percentage of chitin bound to different polysaccharides was calculated. Chitin dispersed in the wall was labeled in maturing unbudded cells and that of the ring in early budding cells. The former was mostly attached to beta( 1 6) glucan and the latter to beta( 1 - 3) glucan. This confirmed our hypothesis and indicated that the cell has mechanisms to attach chitin, a water-insoluble substance, synthesized here through chitin synthase III, to different acceptors, depending on location. In contrast, most of the chitin synthase II-dependent chitin of the primary septum was free, with the remainder linked to beta(1-3) glucan.	NIDDK, Lab Biochem & Genet, Dept Hllth & Human Serv, NIH, Rockville, MD 20852 USA; Univ Salamanca, Inst Microbiol Bioquim, CSIC, Salamanca 37007, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Cabib, E (corresponding author), NIDDK, Lab Biochem & Genet, Dept Hllth & Human Serv, NIH, Rockville, MD 20852 USA.	enricoc@bdg10.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK024945, Z01DK024945] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bom IJ, 1998, BBA-GEN SUBJECTS, V1425, P419, DOI 10.1016/S0304-4165(98)00096-8; BULAWA CE, 1990, P NATL ACAD SCI USA, V87, P7424, DOI 10.1073/pnas.87.19.7424; Cabib E, 2004, ARCH BIOCHEM BIOPHYS, V426, P201, DOI 10.1016/j.abb.2004.02.030; Cabib E, 2001, J BIOL CHEM, V276, P19679, DOI 10.1074/jbc.R000031200; CABIB E, 1992, J GEN MICROBIOL, V138, P97, DOI 10.1099/00221287-138-1-97; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; Crotti LB, 2001, ANAL BIOCHEM, V292, P8, DOI 10.1006/abio.2001.5051; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; Drgonova J, 1999, J CELL BIOL, V146, P373, DOI 10.1083/jcb.146.2.373; HASEGAWA M, 1993, J CHROMATOGR, V635, P334, DOI 10.1016/0021-9673(93)80377-K; HIRANO S, 1988, METHOD ENZYMOL, V161, P408; Just E. K., 1985, ENCY POLYM SCI ENG, V3, P226; KANG MS, 1984, J BIOL CHEM, V259, P4966; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; MANNERS DJ, 1973, BIOCHEM J, V135, P19, DOI 10.1042/bj1350019; MOL PC, 1987, FEMS MICROBIOL LETT, V41, P95; MOLANO J, 1980, J CELL BIOL, V85, P199, DOI 10.1083/jcb.85.2.199; Popolo L, 2001, MED MYCOL, V39, P111, DOI 10.1080/744118881; ROBERTS RL, 1982, ANAL BIOCHEM, V127, P402, DOI 10.1016/0003-2697(82)90194-4; ROBERTS RL, 1983, MOL CELL BIOL, V3, P922, DOI 10.1128/MCB.3.5.922; Roh DH, 2002, MOL BIOL CELL, V13, P2747, DOI 10.1091/mbc.E02-03-0158; Roh DH, 2002, MOL MICROBIOL, V44, P1167, DOI 10.1046/j.1365-2958.2002.02955.x; Roncero C, 2002, CURR GENET, V41, P367, DOI 10.1007/s00294-002-0318-7; Schmidt M, 2003, MOL BIOL CELL, V14, P2128, DOI 10.1091/mbc.E02-08-0547; Schmidt M, 2002, J CELL SCI, V115, P293; Schorr M, 2001, CURR BIOL, V11, P1421, DOI 10.1016/S0960-9822(01)00449-3; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SIKORSKI RS, 1989, GENETICS, V122, P19; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STRIEGEL AM, 1995, CARBOHYD RES, V267, P271, DOI 10.1016/0008-6215(94)00307-2; TERBOJEVICH M, 1988, CARBOHYD RES, V180, P73, DOI 10.1016/0008-6215(88)80065-X; Tolliday N, 2003, MOL BIOL CELL, V14, P798, DOI 10.1091/mbc.E02-09-0558; TREVELYAN WE, 1952, BIOCHEM J, V50, P298, DOI 10.1042/bj0500298; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	38	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9170	9179		10.1074/jbc.M414005200	http://dx.doi.org/10.1074/jbc.M414005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637060	hybrid			2022-12-27	WOS:000227453100066
J	Chetverin, AB; Kopein, DS; Chetverina, HV; Demidenko, AA; Ugarov, VI				Chetverin, AB; Kopein, DS; Chetverina, HV; Demidenko, AA; Ugarov, VI			Viral RNA-directed RNA polymerases use diverse mechanisms to promote recombination between RNA molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Q-BETA-REPLICASE; BACTERIOPHAGE-Q-BETA; CELL-FREE SYSTEM; IN-VITRO; GENETIC-RECOMBINATION; SINDBIS VIRUS; CDNA-CLONES; POLIOVIRUS; TEMPLATE; PRIMER	An earlier developed purified cell-free system was used to explore the potential of two RNA-directed RNA polymerases (RdRps), Qbeta phage replicase and the poliovirus 3Dpol protein, to promote RNA recombination through a primer extension mechanism. The substrates of recombination were fragments of complementary strands of a Qbeta phage-derived RNA, such that if aligned at complementary 3'-termini and extended using one another as a template, they would produce replicable molecules detectable as RNA colonies grown in a Qbeta replicase-containing agarose. The results show that while 3Dpol efficiently extends the aligned fragments to produce the expected homologous recombinant sequences, only nonhomologous recombinants are generated by Qbeta replicase at a much lower yield and through a mechanism not involving the extension of RNA primers. It follows that the mechanisms of RNA recombination by poliovirus and Qbeta RdRps are quite different. The data favor an RNA transesterification reaction catalyzed by a conformation acquired by Qbeta replicase during RNA synthesis and provide a likely explanation for the very low frequency of homologous recombination in Qbeta phage.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia	Russian Academy of Sciences	Chetverin, AB (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	alexch@vega.protres.ru	Chetverin, Alexander B/AAA-6511-2022; Ugarov, Victor/AAC-6502-2022; Ugarov, Victor/AAC-6454-2022	Kopein, Damir/0000-0003-1176-5829				Agol VI, 1997, SEMIN VIROL, V8, P77, DOI 10.1006/smvy.1997.0112; Arnold JJ, 1999, J BIOL CHEM, V274, P2706, DOI 10.1074/jbc.274.5.2706; Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; BERESTOWSKAYA NH, 1988, FEBS LETT, V228, P263, DOI 10.1016/0014-5793(88)80012-7; BIEBRICHER CK, 1992, EMBO J, V11, P5129, DOI 10.1002/j.1460-2075.1992.tb05620.x; BIEBRICHER CK, 1982, J MOL BIOL, V154, P629, DOI 10.1016/S0022-2836(82)80019-3; Blumenthal T, 1979, Methods Enzymol, V60, P628; Bujarski J, 1996, SEMIN VIROL, V7, P361, DOI 10.1006/smvy.1996.0043; Chetverin AB, 2004, FEBS LETT, V567, P35, DOI 10.1016/j.febslet.2004.03.066; Chetverin AB, 1997, CELL, V88, P503, DOI 10.1016/S0092-8674(00)81890-5; Chetverin AB, 1997, SEMIN VIROL, V8, P121, DOI 10.1006/smvy.1997.0113; CHETVERIN AB, 1991, J MOL BIOL, V222, P3, DOI 10.1016/0022-2836(91)90729-P; Chetverin AB, 1999, FEBS LETT, V460, P1, DOI 10.1016/S0014-5793(99)01282-X; Chetverina HV, 1999, FEBS LETT, V450, P89, DOI 10.1016/S0014-5793(99)00469-X; CHETVERINA HV, 1993, NUCLEIC ACIDS RES, V21, P2349, DOI 10.1093/nar/21.10.2349; Chetverina HV, 2002, BIOTECHNIQUES, V33, P150, DOI 10.2144/02331md03; COOPER PD, 1974, J GEN VIROL, V23, P41, DOI 10.1099/0022-1317-23-1-41; FEIX G, 1975, BIOCHEM BIOPH RES CO, V65, P503, DOI 10.1016/S0006-291X(75)80176-8; FLANEGAN JB, 1979, J VIROL, V32, P155, DOI 10.1128/JVI.32.1.155-161.1979; Gallei A, 2004, J VIROL, V78, P6271, DOI 10.1128/JVI.78.12.6271-6281.2004; Gmyl AP, 2003, RNA, V9, P1221, DOI 10.1261/rna.5111803; Gmyl AP, 1999, J VIROL, V73, P8958, DOI 10.1128/JVI.73.11.8958-8965.1999; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HIRST GK, 1962, COLD SPRING HARB SYM, V27, P303, DOI 10.1101/SQB.1962.027.001.028; IGLOI GL, 1983, ANAL BIOCHEM, V134, P184, DOI 10.1016/0003-2697(83)90281-6; JARVIS TC, 1991, TRENDS GENET, V7, P186, DOI 10.1016/0168-9525(91)90434-R; Kim MJ, 2001, P NATL ACAD SCI USA, V98, P4972, DOI 10.1073/pnas.081077198; King A.M.Q., 1988, RNA GENETICS, P149; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; KRAMER FR, 1978, P NATL ACAD SCI USA, V75, P5334, DOI 10.1073/pnas.75.11.5334; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; LEDINKO N, 1963, VIROLOGY, V20, P107, DOI 10.1016/0042-6822(63)90145-4; Lindner Peter, 1992, Methods (Orlando), V4, P41, DOI 10.1016/1046-2023(92)90055-D; MOROZOV IY, 1993, P NATL ACAD SCI USA, V90, P9325, DOI 10.1073/pnas.90.20.9325; MUNISHKIN AV, 1991, J MOL BIOL, V221, P463, DOI 10.1016/0022-2836(91)80067-5; Nagy PD, 1997, VIROLOGY, V235, P1, DOI 10.1006/viro.1997.8681; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; Olsthoorn RCL, 1996, J VIROL, V70, P729, DOI 10.1128/JVI.70.2.729-736.1996; PALASINGAM K, 1992, J VIROL, V66, P2435, DOI 10.1128/JVI.66.4.2435-2442.1992; Pierangeli A, 1999, J GEN VIROL, V80, P1889, DOI 10.1099/0022-1317-80-8-1889; RAJU R, 1995, J VIROL, V69, P7391, DOI 10.1128/JVI.69.12.7391-7401.1995; Richards OC, 1998, J BIOL CHEM, V273, P12832, DOI 10.1074/jbc.273.21.12832; Rodriguez-Wells V, 2001, NUCLEIC ACIDS RES, V29, P2715, DOI 10.1093/nar/29.13.2715; Sambrook J., 2001, MOL CLONING; SCHLESINGER S, 1988, RNA GENETICS, V2, P167; SHAKLEE PN, 1988, VIROLOGY, V163, P209, DOI 10.1016/0042-6822(88)90250-4; Spirin AS, 2002, FEBS LETT, V530, P4, DOI 10.1016/S0014-5793(02)03434-8; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2729, DOI 10.1021/bi00872a033; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Ugarov VI, 2003, J BIOL CHEM, V278, P44139, DOI 10.1074/jbc.M305992200; WEISS BG, 1991, J VIROL, V65, P4017, DOI 10.1128/JVI.65.8.4017-4025.1991; WEISSMAN.C, 1967, P NATL ACAD SCI USA, V57, P1870, DOI 10.1073/pnas.57.6.1870	52	27	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8748	8755		10.1074/jbc.M412684200	http://dx.doi.org/10.1074/jbc.M412684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611043	hybrid			2022-12-27	WOS:000227453100017
J	Chinen, A; Matsumoto, Y; Kawamura, S				Chinen, A; Matsumoto, Y; Kawamura, S			Spectral differentiation of blue opsins between phylogenetically close but ecologically distant goldfish and zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE VISUAL PIGMENTS; CHAMELEON ANOLIS-CAROLINENSIS; GREEN COLOR-VISION; MOLECULAR EVOLUTION; ULTRAVIOLET VISION; SENSITIVITY; RHODOPSIN; VERTEBRATES; GENE; EXPRESSION	Zebrafish and goldfish are both diurnal freshwater fish species belonging to the same family, Cyprinidae, but their visual ecological surroundings considerably differ. Zebrafish are surface swimmers in conditions of broad and shortwave-dominated background spectra and goldfish are generalized swimmers whose light environment extends to a depth of elevated short wavelength absorbance with turbidity. The peak absorption spectrum (lambda(max)) of the zebrafish blue (SWS2) visual pigment is consistently shifted to short wavelength (416 nm) compared with that of the goldfish SWS2 (443 nm). Among the amino acid differences between the two pigments, only one (alanine in zebrafish and serine in goldfish at residue 94) was previously known to cause a difference in absorption spectrum (14-nm lambda(max) shift in newt SWS2). In this study, we reconstructed the ancestral SWS2 pigment of the two species by applying likelihood-based Bayesian statistics and performing site-directed mutagenesis. The reconstituted ancestral photopigment had a lambda(max) of 430 nm, indicating that zebrafish and goldfish achieved short wavelength (-14 nm) and long wavelength (+13 nm) spectral shifts, respectively, from the ancestor. Unexpectedly, the S94A mutation resulted in only a -3-nm spectral shift when introduced into the goldfish SWS2 pigment. Nearly half of the long wavelength shift toward the goldfish pigment was achieved instead by T116L (6 nm). The S295C mutation toward zebrafish SWS2 contributed to creating a ridge of absorbance around 400 nm and broadening its spectral sensitivity in the short wavelength direction. These results indicate that the evolutionary engineering approach is very effective in deciphering the process of functional divergence of visual pigments.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan	University of Tokyo	Kawamura, S (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Seimeitou 502,5-1-5 Kashiwanoha, Chiba 2778562, Japan.	kawamura@k.u-tokyo.ac.jp						Bowmaker JK, 1995, PROG RETIN EYE RES, V15, P1; Cameron DA, 2002, VISUAL NEUROSCI, V19, P365, DOI 10.1017/S0952523802192121; Carleton KL, 2001, MOL BIOL EVOL, V18, P1540, DOI 10.1093/oxfordjournals.molbev.a003940; Chinen A, 2003, GENETICS, V163, P663; Cowing JA, 2002, BIOCHEMISTRY-US, V41, P6019, DOI 10.1021/bi025656e; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; GORRY PA, 1990, ANAL CHEM, V62, P570, DOI 10.1021/ac00205a007; Hisatomi O, 1999, FEBS LETT, V447, P44, DOI 10.1016/S0014-5793(99)00209-4; Hisatomi O, 1997, VISION RES, V37, P3089, DOI 10.1016/S0042-6989(97)00115-6; JOHNSON RL, 1993, BIOCHEMISTRY-US, V32, P208, DOI 10.1021/bi00052a027; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kawamura S, 1999, GENETICS, V153, P1839; Kawamura S, 1998, VISION RES, V38, P37, DOI 10.1016/S0042-6989(97)00160-0; Kawamura S, 1996, VISION RES, V36, P2797, DOI 10.1016/0042-6989(96)00034-X; KHORANA HG, 1988, P NATL ACAD SCI USA, V85, P7917, DOI 10.1073/pnas.85.21.7917; KUMAR S, 2001, MEGA2 MOL EVOLUTIONA; LEVINE JS, 1979, SENS PROCESS, V3, P95; LEVINE JS, 1982, SCI AM, V246, P140, DOI 10.1038/scientificamerican0282-140; Lin SW, 1998, J BIOL CHEM, V273, P24583, DOI 10.1074/jbc.273.38.24583; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NAWROCKI L, 1985, VISION RES, V25, P1569, DOI 10.1016/0042-6989(85)90127-0; Nei M., 2000, MOL EVOLUTION PHYLOG, P352; OKANO T, 1989, BIOCHEMISTRY-US, V28, P8848, DOI 10.1021/bi00448a025; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; Palacios AG, 1998, VISION RES, V38, P2135, DOI 10.1016/S0042-6989(97)00411-2; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parry JWL, 2000, VISION RES, V40, P2241, DOI 10.1016/S0042-6989(00)00101-2; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Saszik S, 1999, VISION RES, V39, P1051, DOI 10.1016/S0042-6989(98)00237-5; Shi YS, 2003, P NATL ACAD SCI USA, V100, P8308, DOI 10.1073/pnas.1532535100; Takahashi Y, 2003, BIOCHEMISTRY-US, V42, P6025, DOI 10.1021/bi020629+; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WHITMORE AV, 1989, J COMP PHYSIOL A, V166, P103; Xu L, 1998, Mol Vis, V4, P10; YANG ZH, 1995, GENETICS, V141, P1641; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; YOKOYAMA R, 1993, FEBS LETT, V334, P27, DOI 10.1016/0014-5793(93)81673-N; Yokoyama S, 2000, PROG RETIN EYE RES, V19, P385, DOI 10.1016/S1350-9462(00)00002-1; Yokoyama S, 1998, MOL BIOL EVOL, V15, P560, DOI 10.1093/oxfordjournals.molbev.a025956; Yokoyama S, 2003, GENE, V306, P91, DOI 10.1016/S0378-1119(03)00424-4; Yokoyama S, 2000, GENE, V259, P17, DOI 10.1016/S0378-1119(00)00435-2; Yokoyama S, 2001, GENETICS, V158, P1697; Yokoyama S, 2000, FEBS LETT, V486, P167, DOI 10.1016/S0014-5793(00)02269-9; Zhang JZ, 2003, P NATL ACAD SCI USA, V100, P8045, DOI 10.1073/pnas.1533183100	45	29	31	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9460	9466		10.1074/jbc.M413001200	http://dx.doi.org/10.1074/jbc.M413001200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623516	hybrid			2022-12-27	WOS:000227453100099
J	Freeman, C; Liu, LG; Banwell, MG; Brown, KJ; Bezos, A; Ferro, V; Parish, CR				Freeman, C; Liu, LG; Banwell, MG; Brown, KJ; Bezos, A; Ferro, V; Parish, CR			Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH; CATHEPSIN-G; PROTEOGLYCANS; METASTASIS; INHIBITION; PI-88	Heparin and heparan sulfate (HS) are structurally diverse glycosaminoglycans (GAG) that are known to interact, via unique structural motifs, with a wide range of functionally distinct proteins and modulate their biological activity. To define the GAG motifs that interact with proteins, we assessed the ability of 15 totally synthetic HS mimetics to interact with 10 functionally diverse proteins that bind heparin/HS. The HS mimetics consisted of cyclitol-based pseudo-sugars coupled by linkers of variable chain length, flexibility, orientation, and hydrophobicity, with variations in sulfation also being introduced into some molecules. Three of the proteins tested, namely hepatocyte growth factor, eotaxin, and elastase, failed to interact with any of the sulfated linked cyclitols. In contrast, each of the remaining seven proteins tested exhibited a unique reactivity pattern with the panel of HS mimetics, with tetrameric cyclitols linked by different length alkyl chains being particularly informative. Thus, compounds with short alkyl spacers (2-3 carbon atoms) effectively blocked the interaction of fibroblast growth factor-1 (FGF-1) and lipoprotein lipase with heparin/HS, whereas longer chain spacers (7-10 carbon atoms) were required for optimal inhibition of FGF-2 and vascular endothelial growth factor binding. This effect was most pronounced with the chemokine, interleukin-8, where alkyl-linked tetrameric cyclitols were essentially inactive unless a spacer of > 7 carbon atoms was used. The heparin-inhibitable enzymes heparanase and cathepsin G also displayed characteristic inhibition patterns, cathepsin G interacting promiscuously with most of the sulfated cyclitols but heparanase activity being inhibited most effectively by HS mimetics that structurally resemble a sulfated pentasaccharide. These data indicate that a simple panel of HS mimetics can be used to probe the HS binding specificity of proteins, with the position of anionic groups in the HS mimetics being critical.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canberra, ACT 2601, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 2601, Australia; Progen Ind Ltd, Drug Design Grp, Darra, Qld 4076, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Progen Pharmaceuticals - Australia	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, POB 334, Canberra, ACT 2601, Australia.	christopher.parish@anu.edu.au	Banwell, Martin G/H-8354-2014; liu, ligong/B-1690-2010; Ferro, Vito/A-4882-2010	Banwell, Martin G/0000-0002-0582-475X; liu, ligong/0000-0002-2693-1896; Ferro, Vito/0000-0003-3306-2550; Parish, Christopher/0000-0001-7740-0430				BAICI A, 1993, BIOCHEM PHARMACOL, V46, P1545, DOI 10.1016/0006-2952(93)90321-M; Banwell MG, 2003, PURE APPL CHEM, V75, P223, DOI 10.1351/pac200375020223; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Ferro V, 2001, CARBOHYD RES, V332, P183, DOI 10.1016/S0008-6215(01)00061-1; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Francis DJ, 2003, CIRC RES, V92, pE70, DOI 10.1161/01.RES.0000071345.76095.07; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Johnson R. A., 2004, ORG REACTIONS, V63, P117, DOI DOI 10.1002/EJOC.201800139; Khachigian LM, 2004, CARDIOVASC DRUG REV, V22, P1; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Nakato H, 2002, BBA-GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304-4165(02)00398-7; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; Shriver Z, 2002, TRENDS CARDIOVAS MED, V12, P71, DOI 10.1016/S1050-1738(01)00150-5; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Ying QL, 1997, AM J PHYSIOL-LUNG C, V272, pL533, DOI 10.1152/ajplung.1997.272.3.L533	37	51	54	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8842	8849		10.1074/jbc.M410769200	http://dx.doi.org/10.1074/jbc.M410769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632177	Green Published, hybrid			2022-12-27	WOS:000227453100028
J	Wu, JC; Chen, TY; Yu, CTR; Tsai, SJ; Hsu, JM; Tang, MJ; Chou, CK; Lin, WJ; Yuan, CJ; Huang, CYF				Wu, JC; Chen, TY; Yu, CTR; Tsai, SJ; Hsu, JM; Tang, MJ; Chou, CK; Lin, WJ; Yuan, CJ; Huang, CYF			Identification of V23RalA-Ser(194) as a critical mediator for aurora-A-induced cellular motility and transformation by small pool expression screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FOCAL ADHESION KINASE; EPITHELIAL-CELLS; CENTROSOME AMPLIFICATION; DISSOCIATION STIMULATOR; CHROMOSOME SEGREGATION; SIGNALING PATHWAY; MITOTIC KINASE; MESSENGER-RNA; RAL-GTPASES	Human Aurora kinases have three gene family members: Aurora-A, Aurora-B, and Aurora-C. It is not yet established what the specificity of these kinases are and what signals relayed by their reactions. Therefore, we employed small pool expression screening to search for downstream substrates of Aurora-A. Interestingly, all of the identified Aurora-A substrates were resistant to serve as substrates for Aurora-B or Aurora-C, suggesting that these Aurora family members may have distinct substrate specificity for propagation of diverse signaling pathways, even though they share a conserved catalytic kinase domain. Of the candidate substrates, Aurora-A could increase the functional activity of RalA. Mutational analysis revealed that RalA-Ser(194) was the phosphorylation site for Aurora-A. Ectopic expression of V23RalA-WT could enhance collagen I-induced cell migration and anchorage-independent growth in Madin-Darby canine kidney (MDCK) Aurora-A stable cell lines. In contrast, overexpression of V23RalA-S194A in MDCK Aurora-Astable cell lines abolished the intrinsic migration and transformation abilities of Aurora-A. To our knowledge, this is the first systematic search for the downstream substrates of Aurora-A kinase. Moreover, these results support the notion that Aurora-A may act in concert with V23RalA through protein phosphorylation on Ser(194) to promote collagen I-induced cell motility and anchorage-independent growth in MDCK epithelial cells.	Natl Hlth Res Inst, Div Mol & Genomic Med, Zhunan Town 350, Miaoli, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Natl Taiwan Univ, Dept Comp Sci & Informat Engn, Taipei 106, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Chang Gung Univ, Dept Life Sci, Taoyuan 333, Taiwan; Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 300, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center; National Yang Ming Chiao Tung University; National Taiwan University; National Cheng Kung University; Chang Gung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Huang, CYF (corresponding author), Natl Hlth Res Inst, Div Mol & Genomic Med, 35 Keyan Rd, Zhunan Town 350, Miaoli, Taiwan.	chiying@nhri.org.tw	Tsai, Shaw-Jenq/AAG-6569-2019; Huang, Chi-Ying/AAG-7672-2022; Huang, Chi-Ying/AFL-7729-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937; Tang, Ming-Jer/0000-0002-0883-4363				ABATE C, 1991, ONCOGENE, V6, P2179; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chan PC, 2002, J BIOL CHEM, V277, P50373, DOI 10.1074/jbc.M204691200; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Gildea JJ, 2002, CANCER RES, V62, P982; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Hsu JM, 2004, J BIOL CHEM, V279, P32592, DOI 10.1074/jbc.M404950200; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Mendez R, 2000, MOL CELL, V6, P1253, DOI 10.1016/S1097-2765(00)00121-0; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; PALEN E, 1987, J BIOL CHEM, V262, P3518; Park JB, 2001, EXP MOL MED, V33, P54, DOI 10.1038/emm.2001.10; Sakai H, 2002, J BIOL CHEM, V277, P48714, DOI 10.1074/jbc.M208461200; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Songster MF, 1997, METHOD ENZYMOL, V289, P126; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tatsuka M, 1998, CANCER RES, V58, P4811; Tien AC, 2004, MOL CELL PROTEOMICS, V3, P93, DOI 10.1074/mcp.M300072-MCP200; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; Yamaguchi H, 2002, CANCER RES, V62, P2503; Yang H, 2004, CANCER RES, V64, P463, DOI 10.1158/0008-5472.CAN-03-2907; Zhang DL, 2001, CELL BIOL INT, V25, P997, DOI 10.1006/cbir.2001.0745; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	51	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9013	9022		10.1074/jbc.M411068200	http://dx.doi.org/10.1074/jbc.M411068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637052	hybrid			2022-12-27	WOS:000227453100048
J	Adams, MA; Jia, ZC				Adams, MA; Jia, ZC			Structural and biochemical evidence for an enzymatic quinone redox cycle in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; DT-DIAPHORASE; OXIDATIVE STRESS; BIOSYNTHESIS; REDUCTASE; CRYSTALLOGRAPHY; MONOOXYGENASE; ACTINORHODIN; PURIFICATION; REFINEMENT	Naturally synthesized quinones perform a variety of important cellular functions. Escherichia coli produce both ubiquinone and menaquinone, which are involved in electron transport. However, semiquinone intermediates produced during the one- electron reduction of these compounds, as well as through auto- oxidation of the hydroxyquinone product, generate reactive oxygen species that stress the cell. Here, we present the crystal structure of YgiN, a protein of hitherto unknown function. The three- dimensional fold of YgiN is similar to that of ActVA- Orf6 monooxygenase, which acts on hydroxyquinone substrates. YgiN shares a promoter with " modulator of drug activity B," a protein with activity similar to that of mammalian DT- diaphorase capable of reducing mendione. YgiN was able to reoxidize menadiol, the product of the " modulator of drug activity B" ( MdaB) enzymatic reaction. We therefore refer to YgiN as quinol monooxygenase. Modulator of drug activity B is reported to be involved in the protection of cells from reactive oxygen species formed during single electron oxidation and reduction reactions. The enzymatic activities, together with the structural characterization of YgiN, lend evidence to the possible existence of a novel quinone redox cycle in E. coli.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Jia, ZC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	jia@post.queensu.ca						Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNMARK A, 1987, FREE RADICAL BIO MED, V3, P181, DOI 10.1016/0891-5849(87)90003-7; CHATTERJEE PK, 1995, P NATL ACAD SCI USA, V92, P8950, DOI 10.1073/pnas.92.19.8950; Cheary R.W., 1996, PROGRAMS XFIT FOURYA; Fujii I, 1997, CHEM REV, V97, P2511, DOI 10.1021/cr960019d; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; Hayashi M, 1996, BBA-BIOENERGETICS, V1273, P165, DOI 10.1016/0005-2728(95)00138-7; HAYASHI M, 1990, BIOCHIM BIOPHYS ACTA, V1035, P230, DOI 10.1016/0304-4165(90)90122-D; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; Kendrew SG, 2000, ACTA CRYSTALLOGR D, V56, P481, DOI 10.1107/S0907444900001189; Kendrew SG, 1997, J BACTERIOL, V179, P4305, DOI 10.1128/jb.179.13.4305-4310.1997; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; LIND C, 1990, METHOD ENZYMOL, V186, P287; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Salgado H, 2004, NUCLEIC ACIDS RES, V32, pD303, DOI 10.1093/nar/gkh140; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOR H, 1982, J BIOL CHEM, V257, P2419; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Wang G, 2004, INFECT IMMUN, V72, P1391, DOI 10.1128/IAI.72.3.1391-1396.2004; Wasinger VC, 1998, FEMS MICROBIOL LETT, V169, P375, DOI 10.1111/j.1574-6968.1998.tb13343.x	35	46	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8358	8363		10.1074/jbc.M412637200	http://dx.doi.org/10.1074/jbc.M412637200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15613473	hybrid			2022-12-27	WOS:000227395700111
J	Dauty, E; Verkman, AS				Dauty, E; Verkman, AS			Actin cytoskeleton as the principal determinant of size-dependent DNA mobility in cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; PLASMID DNA; TRANSLATIONAL DIFFUSION; BINDING PROTEIN; CELL CYTOPLASM; GENE-TRANSFER; NUCLEUS; DELIVERY; MACROMOLECULES; POLYMERIZATION	The cytosol of mammalian cells is a crowded environment containing soluble proteins and a network of cytoskeletal filaments. Gene delivery by synthetic vectors involves the endocytosis of DNA-polycation complexes, escape from endosomes, and diffusion of non-complexed DNA through the cytosol to reach the nucleus. We found previously that the translational diffusion of large DNAs (> 250 bp) in cytoplasm was greatly slowed compared with that of smaller DNAs (Lukacs, G. L., Haggie, P., Seksek, O., Lechardeur, D., Freedman, N., and Verkman, A. S. (2000) J. Biol. Chem. 275, 1625 - 1629). To determine the mechanisms responsible for size-dependent DNA diffusion, we used fluorescence correlation spectroscopy to measure the diffusion of single fluorophore-labeled DNAs in crowded solutions, cytosol extracts, actin network, and living cells. DNA diffusion (D) in solutions made crowded with Ficoll-70 (up to 40 weight percentage) or soluble cytosol extracts (up to 100 mg/ml) relative to diffusion of the same sized DNAs in saline (D/Do) was approximately independent of DNA size (20 - 4500 bp), quite different from the strong reduction in D/D-o in the cytoplasm of living cells. However, the reduced D/D-o with increasing DNA size was closely reproduced in solutions containing cross-linked actin filaments assembled with gelsolin, whereas soluble macromolecules of the same size and concentration did not reduce D/D-o. In intact cells microinjected with fluorescent DNAs and studied by fluorescence correlation spectroscopy or photobleaching methods, D/D-o was reduced by 5 - 150-fold ( 20 - 6000 bp); however, the size-dependent reduction in D/D-o was abolished after actin cytoskeleton disruption. Our results identify the actin cytoskeleton as a major barrier restricting cytoplasmic transport of non-complexed DNA in non-viral gene transfer.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL75856, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADBURY EM, 1992, BIOESSAYS, V14, P9; Dauty E, 2004, J MOL RECOGNIT, V17, P441, DOI 10.1002/jmr.709; Dauty E, 2001, J AM CHEM SOC, V123, P9227, DOI 10.1021/ja015867r; DAVIES WA, 1977, J CELL BIOL, V75, P941, DOI 10.1083/jcb.75.3.941; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Ellis RJ, 2003, NATURE, V425, P27, DOI 10.1038/425027a; FUSHIMI K, 1991, J CELL BIOL, V112, P719, DOI 10.1083/jcb.112.4.719; GAO X, 1993, NUCLEIC ACIDS RES, V21, P2867, DOI 10.1093/nar/21.12.2867; Haggie PM, 2002, J BIOL CHEM, V277, P40782, DOI 10.1074/jbc.M207456200; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HOU L, 1990, BIOPHYS J, V58, P31, DOI 10.1016/S0006-3495(90)82351-1; KAO HP, 1993, J CELL BIOL, V120, P175, DOI 10.1083/jcb.120.1.175; Kim SA, 2004, P NATL ACAD SCI USA, V101, P105, DOI 10.1073/pnas.2436461100; Larson DR, 2003, J CELL BIOL, V162, P1233, DOI 10.1083/jcb.200303200; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; LUBYPHELPS K, 1993, BIOPHYS J, V65, P236, DOI 10.1016/S0006-3495(93)81075-0; Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; NIEDERMAN R, 1983, J CELL BIOL, V96, P1400, DOI 10.1083/jcb.96.5.1400; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Schwille P, 1999, CYTOMETRY, V36, P176, DOI 10.1002/(SICI)1097-0320(19990701)36:3<176::AID-CYTO5>3.0.CO;2-F; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; STOSSEL T, 1984, J CELL BIOL S, V99, P15; TAIT JF, 1982, BIOCHEMISTRY-US, V21, P3666, DOI 10.1021/bi00258a022; TIRADO MM, 1979, J CHEM PHYS, V71, P2581, DOI 10.1063/1.438613; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; YAMAKAWA H, 1976, J CHEM PHYS, V64, P5222, DOI 10.1063/1.432197; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zuber G, 2001, ADV DRUG DELIVER REV, V52, P245, DOI 10.1016/S0169-409X(01)00213-7	38	155	162	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7823	7828		10.1074/jbc.M412374200	http://dx.doi.org/10.1074/jbc.M412374200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15632160	hybrid			2022-12-27	WOS:000227395700048
J	Kochupurakkal, BS; Harari, D; Di-Segni, AD; Maik-Rachline, G; Lyass, L; Gur, G; Kerber, G; Citri, A; Lavi, S; Eilam, R; Chalifa-Caspi, VC; Eshhar, Z; Pikarsky, E; Pinkas-Kramarski, RP; Bacus, SS; Yarden, Y				Kochupurakkal, BS; Harari, D; Di-Segni, AD; Maik-Rachline, G; Lyass, L; Gur, G; Kerber, G; Citri, A; Lavi, S; Eilam, R; Chalifa-Caspi, VC; Eshhar, Z; Pikarsky, E; Pinkas-Kramarski, RP; Bacus, SS; Yarden, Y			Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; CRYSTAL-STRUCTURE; FACTOR-ALPHA; CELL LINES; NULL MICE; HB-EGF; EPIREGULIN; EXPRESSION; PROTEIN	Four ErbB receptors and multiple growth factors sharing an epidermal growth factor (EGF) motif underlie transmembrane signaling by the ErbB family in development and cancer. Unlike other ErbB proteins, ErbB-2 binds no known EGF-like ligand. To address the existence of a direct ligand for ErbB-2, we applied algorithms based on genomic and cDNA structures to search sequence data bases. These searches reidentified all known EGF-like growth factors including Epigen (EPG), the least characterized ligand, but failed to identify novel factors. The precursor of EPG is a widely expressed transmembrane glycoprotein that undergoes cleavage at two sites to release a soluble EGF-like domain. A recombinant EPG cannot stimulate cells singly expressing ErbB-2, but it acts as a mitogen for cells expressing ErbB-1 and co-expressing ErbB-2 in combination with the other ErbBs. Interestingly, soluble EPG is more mitogenic than EGF, although its binding affinity is 100-fold lower. Our results attribute the anomalous mitogenic power of EPG to evasion of receptor-mediated depletion of ligand molecules, as well as to inefficient receptor ubiquitylation and down-regulation. In conclusion, EPG might represent the last EGF-like growth factor and define a category of low affinity ligands, whose bioactivity differs from the more extensively studied high affinity ligands.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Targeted Mol Diagnost, Westmont, IL 60559 USA; Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Tel Aviv University; Ben Gurion University; Hebrew University of Jerusalem	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, 1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Citri, Ami/R-8973-2019; YARDEN, YOSEF/K-1467-2012; pikarsky, eli/GXV-7099-2022	Citri, Ami/0000-0002-9914-0278; pikarsky, eli/0000-0003-4186-7105; Chalifa-Caspi, Vered/0000-0001-6030-5816; Pinkas-Kramarski, Ronit/0000-0002-1000-369X	NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACUS SS, 1993, CANCER RES, V53, P5251; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Lenferink AEG, 1997, BIOCHEM J, V327, P859; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICOSIA RF, 1990, LAB INVEST, V63, P115; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Pinthus JH, 2000, CANCER RES, V60, P6563; PORTA DG, 1997, EMBO J, V16, P1647; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stein RA, 2000, J MOL EVOL, V50, P397, DOI 10.1007/s002390010043; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Torring N, 2000, ANTICANCER RES, V20, P91; Toyoda H, 1995, FEBS LETT, V377, P403, DOI 10.1016/0014-5793(95)01403-9; Troyer KL, 2001, J MAMMARY GLAND BIOL, V6, P7, DOI 10.1023/A:1009560330359; Troyer KL, 2001, GASTROENTEROLOGY, V121, P68, DOI 10.1053/gast.2001.25478; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	46	65	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8503	8512		10.1074/jbc.M413919200	http://dx.doi.org/10.1074/jbc.M413919200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611079	hybrid			2022-12-27	WOS:000227395700127
J	Lieser, SA; Shindler, C; Aubol, BE; Lee, S; Sun, GQ; Adams, JA				Lieser, SA; Shindler, C; Aubol, BE; Lee, S; Sun, GQ; Adams, JA			Phosphoryl transfer step in the C-terminal Src kinase controls Src recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; KINETIC MECHANISM; CRYSTAL-STRUCTURE; TYROSINE KINASES; CATALYTIC MECHANISM; CSK; SUBSTRATE; SPECIFICITY; DOMAIN; STATE	All members of the Src family of nonreceptor protein tyrosine kinases are phosphorylated and subsequently down-regulated by the C-terminal Src kinase, Csk. Although the recognition of Src protein substrates is essential for a diverse set of signaling events linked to cellular growth and differentiation, the factors controlling this critical protein-protein interaction are not well known. To understand how Csk recognizes Src, the chemical/physical events that modulate apparent substrate affinity and turnover were investigated. Src is phosphorylated in a biphasic manner in rapid quench flow experiments, suggesting that the phosphoryl transfer step is fast and highly favorable and does not limit overall turnover. As opposed to other kinase-substrate pairs, turnover is not limited by the physical release of ADP based on stopped-flow fluorescence and catalytic trapping experiments, suggesting that other steps control net phosphorylation. The K-d for Src is considerably larger than the K-m based on single turnover kinetic and equilibrium sedimentation experiments. Taken together, the data are consistent with a mechanism whereby Csk achieves a low K-m for the substrate Src, not by stabilizing protein-protein interactions but rather by facilitating a fast phosphoryl transfer step. In this manner, the phosphoryl transfer step functions as a chemical clamp facilitating substrate recognition.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Rhode Island	Adams, JA (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	joeadams@ucsd.edu			NCRR NIH HHS [1P20 RR16457] Funding Source: Medline; NIGMS NIH HHS [GM 68168, GM 07752] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Aubol BE, 2004, J BIOL CHEM, V279, P30182, DOI 10.1074/jbc.M402797200; Aubol BE, 2003, BIOCHEMISTRY-US, V42, P12813, DOI 10.1021/bi035200c; BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Cole PA, 2003, CURR OPIN CHEM BIOL, V7, P580, DOI 10.1016/j.cbpa.2003.08.009; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; Hamuro Y, 2002, J MOL BIOL, V323, P871, DOI 10.1016/S0022-2836(02)01003-3; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Jan AY, 2000, BIOCHEMISTRY-US, V39, P9786, DOI 10.1021/bi9924922; Johnson KA, 1998, CURR OPIN BIOTECH, V9, P87, DOI 10.1016/S0958-1669(98)80089-X; Kim K, 1998, J AM CHEM SOC, V120, P6851, DOI 10.1021/ja9808393; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Lin XF, 2003, J BIOL CHEM, V278, P24072, DOI 10.1074/jbc.M210596200; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Murray BW, 2001, BIOCHEMISTRY-US, V40, P10243, DOI 10.1021/bi010959e; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; Ni DQ, 2000, PROTEIN SCI, V9, P1818, DOI 10.1110/ps.9.9.1818; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; OKADA M, 1991, J BIOL CHEM, V266, P24249; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; QAMAR R, 1992, BIOCHEMISTRY-US, V31, P9986, DOI 10.1021/bi00156a018; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; Shaffer J, 2001, BIOCHEMISTRY-US, V40, P11149, DOI 10.1021/bi011029y; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; Waas WF, 2003, BIOCHEMISTRY-US, V42, P12273, DOI 10.1021/bi0348617; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P1533, DOI 10.1021/bi952435i; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Werner DS, 1996, J BIOL CHEM, V271, P180, DOI 10.1074/jbc.271.1.180; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Wong L, 2004, J MOL BIOL, V341, P93, DOI 10.1016/j.jmb.2004.05.060; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhou J, 1997, BIOCHEMISTRY-US, V36, P15733, DOI 10.1021/bi971438n	44	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7769	7776		10.1074/jbc.M411736200	http://dx.doi.org/10.1074/jbc.M411736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15623523	Green Published, hybrid			2022-12-27	WOS:000227395700041
J	Holmqvist, T; Johansson, L; Ostman, M; Ammoun, S; Akerman, KEO; Kukkonen, JP				Holmqvist, T; Johansson, L; Ostman, M; Ammoun, S; Akerman, KEO; Kukkonen, JP			OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DEPENDENT SIGNALING CASCADE; ADENOSINE A(1) RECEPTOR; HAMSTER OVARY CELLS; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; ADRENOCORTICAL-CELLS; INDUCED STIMULATION; HYPOCRETIN OREXIN; PHORBOL ESTER	In this study, the mechanism of OX, orexin receptors to regulate adenylyl cyclase activity when recombinantly expressed in Chinese hamster ovary cells was investigated. In intact cells, stimulation with orexin-A led to two responses, a weak (21%), high potency (EC50 approximate to 1 nM) inhibition and a strong (4-fold), low potency (EC50 = approximate to300 nM) stimulation. The inhibition was reversed by pertussis toxin, suggesting the involvement of G(i/o). proteins. Orexin-B was, surprisingly, almost equally as potent as orexin-A in elevating cAMP (pEC(50) = approximate to500 nM). cAMP elevation was not caused by Ca2+ elevation or by Gbetagamma. In contrast, it relied in part on a novel protein kinase C (PKC) isoform, PKCdelta, as determined using pharmacological inhibitors. Yet, PKC stimulation alone only very weakly stimulated cAMP production (1.1-fold). In the presence of G(s) activity, orexins still elevated cAMP; however, the potencies were greatly increased (EC50 of orexin-A = approximate to10 nm and EC50 of orexin-B = approximate to100 nm), and the response was fully dependent on PKCdelta. In permeabilized cells, only a PKC-independent low potency component was seen. This component was sensitive to anti-Galpha(s). antibodies. We conclude that OX1 receptors stimulate adenylyl cyclase via a low potency G(s) coupling and a high potency phospholipase C --> PKC coupling. The former or some exogenous G(s) activation is essentially required for the PKC to significantly activate adenylyl cyclase. The results also suggest that orexin-B-activated OX1 receptors couple to G(s) almost as efficiently as the orexin-A-activated receptors, in contrast to Ca2+ elevation and phospholipase C activation, for which orexin-A is 10-fold more potent.	Univ Uppsala, Div Physiol, Dept Neurosci, SE-75123 Uppsala, Sweden; Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70210 Kuopio, Finland	Uppsala University; University of Eastern Finland	Kukkonen, JP (corresponding author), Univ Uppsala, Div Physiol, Dept Neurosci, BMC POB Box 572, SE-75123 Uppsala, Sweden.	jyrki.kukkonen@fysiologi.uu.se		Kukkonen, Jyrki/0000-0002-6989-1564				ALOUSI AA, 1991, FASEB J, V5, P2300, DOI 10.1096/fasebj.5.9.1650314; Ammoun S, 2003, J PHARMACOL EXP THER, V305, P507, DOI 10.1124/jpet.102.048025; Bernard R, 2003, EUR J NEUROSCI, V18, P1775, DOI 10.1046/j.1460-9568.2003.02905.x; Bernard R, 2002, NEUROREPORT, V13, P447, DOI 10.1097/00001756-200203250-00017; Burford NT, 1996, BIOCHEM J, V315, P883, DOI 10.1042/bj3150883; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Cote M, 2001, J CLIN ENDOCR METAB, V86, P4495, DOI 10.1210/jc.86.9.4495; DARGY R, 1990, J PHARMACOL METHOD, V24, P165, DOI 10.1016/0160-5402(90)90027-I; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dickenson JM, 1998, EUR J PHARMACOL, V355, P85, DOI 10.1016/S0014-2999(98)00468-3; Dorn GW, 1997, BIOCHEMISTRY-US, V36, P6415, DOI 10.1021/bi970080s; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Hill KJ, 2003, BRIT J PHARMACOL, V139, P721, DOI 10.1038/sj.bjp.0705294; Hoang QV, 2003, J NEUROPHYSIOL, V90, P693, DOI 10.1152/jn.00001.2003; Holmqvist T, 2002, FEBS LETT, V526, P11, DOI 10.1016/S0014-5793(02)03101-0; Holmqvist T, 2001, NEUROSCI LETT, V305, P177, DOI 10.1016/S0304-3940(01)01839-0; HORIE K, 1995, MOL PHARMACOL, V48, P392; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; Karteris E, 2004, J CLIN ENDOCR METAB, V89, P1957, DOI 10.1210/jc.2003-031778; KAWABE J, 1994, J BIOL CHEM, V269, P16554; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Kohlmeier KA, 2004, J NEUROPHYSIOL, V92, P221, DOI 10.1152/jn.00076.2004; Krjukova J, 2004, BRIT J PHARMACOL, V143, P3, DOI 10.1038/sj.bjp.0705911; Kukkonen JP, 2002, AM J PHYSIOL-CELL PH, V283, pC1567, DOI 10.1152/ajpcell.00055.2002; Kukkonen JP, 2001, BRIT J PHARMACOL, V132, P1477, DOI 10.1038/sj.bjp.0703964; Kukkonen JP, 2001, NEUROREPORT, V12, P2017, DOI 10.1097/00001756-200107030-00046; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; Larsson KP, 2003, BIOCHEM BIOPH RES CO, V309, P209, DOI 10.1016/S0006-291X(03)01563-8; Lin WW, 1998, BRIT J PHARMACOL, V125, P1601, DOI 10.1038/sj.bjp.0702219; Lund PE, 2000, J BIOL CHEM, V275, P30806, DOI 10.1074/jbc.M002603200; Malendowicz LK, 1999, J STEROID BIOCHEM, V70, P185, DOI 10.1016/S0960-0760(99)00110-7; Marjamaki A, 1997, J BIOL CHEM, V272, P16466, DOI 10.1074/jbc.272.26.16466; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mazzocchi G, 2001, J CLIN ENDOCR METAB, V86, P778, DOI 10.1210/jc.86.2.778; Mazzocchi G, 2001, J CLIN ENDOCR METAB, V86, P4818, DOI 10.1210/jc.86.10.4818; Nasman J, 2002, J NEUROCHEM, V83, P1252, DOI 10.1046/j.1471-4159.2002.01270.x; Okumura T, 2001, BIOCHEM BIOPH RES CO, V280, P976, DOI 10.1006/bbrc.2001.4235; Porter RA, 2001, BIOORG MED CHEM LETT, V11, P1907, DOI 10.1016/S0960-894X(01)00343-2; POST SR, 1995, BIOCHEM J, V311, P75, DOI 10.1042/bj3110075; Randeva HS, 2001, J CLIN ENDOCR METAB, V86, P4808, DOI 10.1210/jc.86.10.4808; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shen TS, 1997, ENDOCRINOLOGY, V138, P4591, DOI 10.1210/en.138.11.4591; Smart D, 1999, BRIT J PHARMACOL, V128, P1, DOI 10.1038/sj.bjp.0702780; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Uramura K, 2001, NEUROREPORT, V12, P1885, DOI 10.1097/00001756-200107030-00024; van den Pol AN, 2001, J COMP NEUROL, V433, P349, DOI 10.1002/cne.1144; van den Pol AN, 1998, J NEUROSCI, V18, P7962; van den Pol AN, 1999, J NEUROSCI, V19, P3171; Xu RW, 2002, ENDOCRINOLOGY, V143, P4609, DOI 10.1210/en.2002-220506; Yang B, 2003, J NEUROSCI, V23, P6215; Zhu Y, 2003, J PHARMACOL SCI, V92, P259	56	99	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6570	6579		10.1074/jbc.M407397200	http://dx.doi.org/10.1074/jbc.M407397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611118	hybrid			2022-12-27	WOS:000227332700041
J	Liu, CP; Perrett, S; Zhou, JM				Liu, CP; Perrett, S; Zhou, JM			Dimeric trigger factor stably binds folding-competent intermediates and cooperates with the DnaK-DnaJ-GrpE chaperone system to allow refolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ESCHERICHIA-COLI; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; FUNCTIONAL DISSECTION; NASCENT POLYPEPTIDES; DENATURED PROTEINS; SPECIFICITY; SUBSTRATE; RIBOSOME; AGGREGATION	Trigger factor (TF) is the first chaperone encountered by the nascent chain in bacteria and forms a stoichiometric complex with the ribosome. However, the functional significance of the high cytosolic concentration of uncomplexed TF, the majority of which is dimeric, is unknown. To gain insight into TF function, we investigated the TF concentration dependence of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) reactivation yield in the presence and absence of the DnaK-DnaJ-GrpE chaperone system in vitro. Cross-linking results indicate that the observed decrease in the reactivation yield of GAPDH at high concentrations of TF is due to the formation of a stable complex between TF dimer and GAPDH intermediates. In the absence of TF, or at low TF concentrations, the DnaK-DnaJ-GrpE chaperone system had negligible effect on the GAPDH refolding yield. However, GAPDH intermediates bound and held by dimeric TF could be specifically rescued by the DnaK-DnaJ-GrpE chaperone system in an ATP-dependent manner. This indicates the potential of TF, in its dimeric form, to act as a binding chaperone, maintaining non-native proteins in a refolding competent conformation and cooperating with downstream molecular chaperones to facilitate post-translational or post-stress protein folding.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Zhou, JM (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	zhoujm@sun5.ibp.ac.cn	Perrett, Sarah/AAS-9483-2020	Perrett, Sarah/0000-0003-0137-0997				Agashe VR, 2004, CELL, V117, P199, DOI 10.1016/S0092-8674(04)00299-5; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; CAI H, 1994, J BIOL CHEM, V269, P24550; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Huang GC, 2000, BBA-PROTEIN STRUCT M, V1480, P77, DOI 10.1016/S0167-4838(00)00094-7; Huang GC, 2000, PROTEIN SCI, V9, P1254, DOI 10.1110/ps.9.6.1254; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lee HC, 2002, J BIOL CHEM, V277, P43527, DOI 10.1074/jbc.M205950200; Li ZY, 2001, FEBS LETT, V506, P108, DOI 10.1016/S0014-5793(01)02896-4; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; Liu CP, 2004, BIOCHEM BIOPH RES CO, V313, P509, DOI 10.1016/j.bbrc.2003.11.142; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; MARANGOS PJ, 1974, BIOCHEMISTRY-US, V13, P904, DOI 10.1021/bi00702a012; Mujacic M, 2004, MOL MICROBIOL, V51, P849, DOI 10.1046/j.1365-2958.2003.03871.x; Nishihara K, 2000, APPL ENVIRON MICROB, V66, P884, DOI 10.1128/AEM.66.3.884-889.2000; Patzelt H, 2002, BIOL CHEM, V383, P1611, DOI 10.1515/BC.2002.182; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Penefsky H S, 1979, Methods Enzymol, V56, P527; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schaffitzel E, 2001, BIOL CHEM, V382, P1235, DOI 10.1515/BC.2001.154; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Wild J, 1996, J BACTERIOL, V178, P3608, DOI 10.1128/jb.178.12.3608-3613.1996; Zarnt T, 1997, J MOL BIOL, V271, P827, DOI 10.1006/jmbi.1997.1206; Zhang NX, 1999, EUR J BIOCHEM, V264, P1002, DOI 10.1046/j.1432-1327.1999.00723.x; Zhang NX, 2000, J PROTEIN CHEM, V19, P569, DOI 10.1023/A:1007146217946	42	37	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13315	13320		10.1074/jbc.M414151200	http://dx.doi.org/10.1074/jbc.M414151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15632130	hybrid			2022-12-27	WOS:000228095500017
J	Lin, Y; Kimpler, LA; Naismith, TV; Lauer, JM; Hanson, PI				Lin, Y; Kimpler, LA; Naismith, TV; Lauer, JM; Hanson, PI			Interaction of the mammalian endosomal sorting complex required for transport (ESCRT) III protein hSnf7-1 with itself, membranes, and the AAA(+) ATPase SKD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIVESICULAR BODY PATHWAY; ESCRT-II; VPS PROTEIN; TRAFFICKING; UBIQUITIN; COMPARTMENTS; BIOGENESIS; IDENTIFICATION; EXPRESSION; MACHINERY	SKD1/VPS4B is an AAA(+) (ATPase associated with a variety of cellular activities) protein involved in multivesicular body (MVB) biogenesis. In this study, we show that the impairment in MVB biogenesis caused by the ATP hydrolysis-deficient mutant SKD1(E235Q) is accompanied by assembly of a large detergent-insoluble protein complex that includes normally soluble endogenous components of mammalian endosomal sorting complex required for transport (ESCRT) I and ESCRT-III complexes. Membrane-bound ESCRT-III complex has been proposed to be the substrate that recruits SKD1 to nascent MVBs. To explore this relationship, we studied interactions among the human ESCRT-III components hSnf7-1 and hVps24, membranes, and SKD1. We found that a significant portion of overexpressed hSnf7-1 associated with membranes where it formed a large protein complex that recruited SKD1 and perturbed normal MVB biogenesis. Overexpressed hVps24 also associated with membranes and perturbed endosome structure but only when fused to green fluorescent protein. Domain analysis revealed that the basic N-terminal half of hSnf7-1 localized to membranes and formed detergent-resistant polymers, some of which looked like filopodia extending into the lumen of swollen endosomes or out from the plasma membrane. The C-terminal acidic half of hSnf7-1 did not associate with membranes and was required for interaction of hSnf7-1 with SKD1. Together with earlier studies, our work suggests that a variety of ESCRT-III-containing polymers can assemble on membranes and recruit SKD1 during formation of the MVB.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Hanson, PI (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Box 8228, St Louis, MO 63110 USA.	phanson@cellbiology.wustl.edu	Hanson, Phyllis/E-9420-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038058] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38058] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bache KG, 2004, MOL BIOL CELL, V15, P4337, DOI 10.1091/mbc.E04-03-0250; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Beyer A, 2003, GENE, V305, P47, DOI 10.1016/S0378-1119(02)01205-2; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; de Gassart A, 2004, TRAFFIC, V5, P896, DOI 10.1111/j.1600-0854.2004.00223.x; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FinkenEigen M, 1997, CURR GENET, V31, P469, DOI 10.1007/s002940050232; Fujita H, 2004, J CELL SCI, V117, P2997, DOI 10.1242/jcs.01170; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Hammond C, 1998, J IMMUNOL, V161, P3282; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hierro A, 2004, NATURE, V431, P221, DOI 10.1038/nature02914; Howard TL, 2001, J CELL SCI, V114, P2395; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Katoh K, 2003, J BIOL CHEM, V278, P39104, DOI 10.1074/jbc.M301604200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Luzio JP, 2003, MOL MEMBR BIOL, V20, P141, DOI 10.1080/0968768031000089546; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Murk JLAN, 2003, P NATL ACAD SCI USA, V100, P13332, DOI 10.1073/pnas.2232379100; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Peck JW, 2004, BIOCHEM J, V377, P693, DOI 10.1042/bj20031347; Pelham HRB, 2002, CURR OPIN CELL BIOL, V14, P454, DOI 10.1016/S0955-0674(02)00352-6; PERIER F, 1994, FEBS LETT, V351, P286, DOI 10.1016/0014-5793(94)00879-5; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Sachse M, 2004, J CELL SCI, V117, P1699, DOI 10.1242/jcs.00998; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shiflett SL, 2004, J BIOL CHEM, V279, P10982, DOI 10.1074/jbc.M312669200; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Teo H, 2004, DEV CELL, V7, P559, DOI 10.1016/j.devcel.2004.09.003; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Whitley P, 2003, J BIOL CHEM, V278, P38786, DOI 10.1074/jbc.M306864200; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751; YORIKAWA C, 2004, IN PRESS BIOCH J; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	61	115	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12799	12809		10.1074/jbc.M413968200	http://dx.doi.org/10.1074/jbc.M413968200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15632132	hybrid			2022-12-27	WOS:000227922000088
J	Tsukada, M; Prokscha, A; Ungewickell, E; Eichele, G				Tsukada, M; Prokscha, A; Ungewickell, E; Eichele, G			Doublecortin association with actin filaments is regulated by neurabin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; CROSS-LINKING; PHOSPHORYLATION; MUTATIONS; MIGRATION; MOTILITY; GUIDANCE; FAMILY; DCX	Mutations in the human Doublecortin (DCX) gene cause X-linked lissencephaly, a neuronal migration disorder affecting the neocortex and characterized by mental retardation and epilepsy. Because dynamic cellular asymmetries such as those seen in cell migration critically depend on a cooperation between the microtubule and actin cytoskeletal filament systems, we investigated whether Dcx, a microtubule-associated protein, is engaged in cytoskeletal cross-talk. We now demonstrate that Dcx co-sediments with actin filaments (F-actin), and using light and electron microscopy and spin down assays, we show that Dcx induces bundling and cross-linking of microtubules and F-actin in vitro. It has recently been shown that binding of Dcx to microtubules is negatively regulated by phosphorylation of the Dcx at Ser-47 or Ser-297. Although the phosphomimetic green fluorescent protein (GFP)-Dcx(S47E) transfected into COS-7 cells had a reduced affinity for microtubules, we found that pseudophosphorylation was not sufficient to cause Dcx to bind to F-actin. When cells were co-transfected with neurabin II, a protein that binds F-actin as well as Dcx, GFP-Dcx and to an even greater extent GFP-Dcx(S47E) became predominantly associated with filamentous actin. Thus Dcx phosphorylation and neurabin II combinatorially enhance Dcx binding to F-actin. Our findings raise the possibility that Dcx acts as a molecular link between microtubule and actin cytoskeletal filaments that is regulated by phosphorylation and neurabin II.	Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Cell Biol, Ctr Anat, D-30623 Hannover, Germany	Max Planck Society; Hannover Medical School	Tsukada, M (corresponding author), Max Planck Inst Expt Endocrinol, Feodor Lynen Str 7, D-30625 Hannover, Germany.	miki.tsukada@mpihan.mpg.de						Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Corbo JC, 2002, J NEUROSCI, V22, P7548; des Portes V, 1998, CELL, V92, P51; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Friocourt G, 2003, CEREB CORTEX, V13, P620, DOI 10.1093/cercor/13.6.620; Friocourt G, 2001, MOL CELL NEUROSCI, V18, P307, DOI 10.1006/mcne.2001.1022; Gdalyahu A, 2004, EMBO J, V23, P823, DOI 10.1038/sj.emboj.7600079; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Gordon-Weeks PR, 2004, J NEUROBIOL, V58, P70, DOI 10.1002/neu.10266; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Kim MH, 2003, NAT STRUCT BIOL, V10, P324, DOI 10.1038/nsb918; Kizhatil K, 2002, J NEUROSCI, V22, P7948; Leung CL, 1999, J CELL BIOL, V147, P1275, DOI 10.1083/jcb.147.6.1275; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; Moores CA, 2004, MOL CELL, V14, P833, DOI 10.1016/j.molcel.2004.06.009; Moores CA, 2003, NAT STRUCT BIOL, V10, P314, DOI 10.1038/nsb0503-314; Ozer RS, 2000, MOL BIOL CELL, V11, P3573, DOI 10.1091/mbc.11.10.3573; RIVAS RJ, 1995, J NEUROSCI, V15, P981; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Salmon WC, 2002, J CELL BIOL, V158, P31, DOI 10.1083/jcb.200203022; Sapir T, 2000, HUM MOL GENET, V9, P703, DOI 10.1093/hmg/9.5.703; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Schaar BT, 2004, NEURON, V41, P203, DOI 10.1016/S0896-6273(03)00843-2; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Sun DM, 2001, J CELL SCI, V114, P161; Sweeney KJ, 2001, MECH DEVELOP, V101, P21, DOI 10.1016/S0925-4773(00)00543-8; Tanaka T, 2004, NEURON, V41, P215, DOI 10.1016/S0896-6273(03)00852-3; Taylor KR, 2000, J BIOL CHEM, V275, P34442, DOI 10.1074/jbc.M007078200; Tsukada M, 2003, MECH DEVELOP, V120, P1033, DOI 10.1016/S0925-4773(03)00177-1; Ward M, 2003, J NEUROSCI, V23, P5170; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X	34	66	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11361	11368		10.1074/jbc.M405525200	http://dx.doi.org/10.1074/jbc.M405525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15632197	hybrid			2022-12-27	WOS:000227761800058
J	Babilonia, E; Wei, Y; Sterling, H; Kaminski, P; Wolin, M; Wang, WH				Babilonia, E; Wei, Y; Sterling, H; Kaminski, P; Wolin, M; Wang, WH			Superoxide anions are involved in mediating the effect of low K intake on c-Src expression and renal K secretion in the cortical collecting duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; HYDROGEN-PEROXIDE; REDOX REGULATION; CELLS; ACTIVATION; RECEPTOR; PHOSPHORYLATION; GENERATION; CHANNELS; INTERMEDIATE	We previously demonstrated that low K intake stimulated the expression of c-Src and that stimulation of protein tyrosine kinase inhibited ROMK channel activity (Wei, Y., Bloom, P., Lin, D. H., Gu, R. M., and Wang, W. H. (2001) Am. J. Physiol. 281, F206-F212). Decreases in dietary K content significantly increased O-2(.-) levels and the phosphorylation of c-Jun, a transcription factor, in renal cortex and outer medulla. The role of O-2(.-) and related products such as H2O2 in stimulating the expression of protein tyrosine kinase is suggested by the observation that addition of 50-200 mu M H2O2 increased the phosphorylation of c-Jun and the expression of c-Src in M1 cells, a mouse collecting duct principal cell line. The effect of H2O2 on c-Src expression was completely abolished with cyclohexamide or actinomycin D. The treatment of animals on a K-deficient (KD) diet with tempol for 7 days significantly decreased the production of O-2(.-), c-Jun phosphorylation, and c-Src expression. Moreover, low K intake decreased the activity of ROMK-like small conductance channels from 1.37 (control K diet) to 0.5 in the cortical collecting duct and increased the tyrosine phosphorylation of ROMK in the renal cortex and outer medulla. In contrast, the tempol treatment not only increased channel activity to 1.1 in the cortical collecting duct but also decreased the tyrosine phosphorylation of ROMK from rats on a KD diet. Finally, suppressing O-2(.-) production with tempol significantly increased renal K excretion measured with metabolic cage and lowered the plasma K concentration in comparison with those on a KD diet alone without tempol. We conclude that O-2(.-) and related products play a role in mediating the effect of low K intake on c-Src expression and in suppressing ROMK channel activity and renal K secretion.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Wang, WH (corresponding author), New York Med Coll, Dept Pharmacol, BSB Rm 537, Valhalla, NY 10595 USA.	wenhui_wang@nymc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047402, R01DK054983] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK047402, R01 DK054983-08, R01 DK047402-13, R01 DK054983] Funding Source: Medline; PHS HHS [47402, 54983] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD I, 1992, P NATL ACAD SCI USA, V89, P10262, DOI 10.1073/pnas.89.21.10262; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; EVAN AP, 1995, KIDNEY INT, V48, P1517, DOI 10.1038/ki.1995.442; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; Hsu FW, 1997, KIDNEY INT, V52, P363, DOI 10.1038/ki.1997.342; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KORBMACHER C, 1993, J GEN PHYSIOL, V102, P761, DOI 10.1085/jgp.102.4.761; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; LETZ B, 1995, J MEMBRANE BIOL, V148, P127; Lin DH, 2002, AM J PHYSIOL-RENAL, V283, pF671, DOI 10.1152/ajprenal.00160.2002; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MOHAZZAB HKM, 1994, AM J PHYSIOL, V267, pL815; MohazzabH KM, 1996, AM J PHYSIOL-HEART C, V270, pH1044, DOI 10.1152/ajpheart.1996.270.3.H1044; Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Schmid E, 1999, FASEB J, V13, P1491, DOI 10.1096/fasebj.13.12.1491; Sterling H, 2002, J BIOL CHEM, V277, P4317, DOI 10.1074/jbc.M109739200; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang WH, 2004, ANNU REV PHYSIOL, V66, P547, DOI 10.1146/annurev.physiol.66.032102.112025; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wei Y, 2001, AM J PHYSIOL-RENAL, V281, pF206, DOI 10.1152/ajprenal.2001.281.2.F206; Wei Y, 2000, J BIOL CHEM, V275, P20502, DOI 10.1074/jbc.M000783200; WINGO CS, 1993, ANNU REV PHYSIOL, V55, P323, DOI 10.1146/annurev.physiol.55.1.323; Woda CB, 2002, AM J PHYSIOL-RENAL, V283, pF437, DOI 10.1152/ajprenal.00316.2001; Woda CB, 2001, AM J PHYSIOL-RENAL, V280, pF786, DOI 10.1152/ajprenal.2001.280.5.F786; Yang BC, 1998, AM J PHYSIOL-HEART C, V274, pH1955, DOI 10.1152/ajpheart.1998.274.6.H1955	37	32	32	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10790	10796		10.1074/jbc.M414610200	http://dx.doi.org/10.1074/jbc.M414610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644319	Green Accepted, hybrid			2022-12-27	WOS:000227559600126
J	Messiha, HL; Munro, AW; Bruce, NC; Barsukov, I; Scrutton, NS				Messiha, HL; Munro, AW; Bruce, NC; Barsukov, I; Scrutton, NS			Reaction of morphinone reductase with 2-cyclohexen-1-one and 1-nitrocyclohexene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLD YELLOW ENZYME; PENTAERYTHRITOL TETRANITRATE REDUCTASE; PSEUDOMONAS-PUTIDA M10; TRIMETHYLAMINE DEHYDROGENASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; OVER-EXPRESSION; HALF-REACTION; ACTIVE-SITE; SEQUENCE	Morphinone reductase (MR) catalyzes the NADH-dependent reduction of alpha/beta unsaturated carbonyl compounds in a reaction similar to that catalyzed by Old Yellow Enzyme ( OYE1). The two enzymes are related at the sequence and structural levels, but key differences in active site architecture exist which have major implications for the reaction mechanism. We report detailed kinetic and solution NMR data for wild-type MR and two mutant forms in which residues His-186 and Asn-189 have been exchanged for alanine residues. We show that both residues are involved in the binding of the reducing nicotinamide coenzyme NADH and also the binding of the oxidizing substrates 2-cyclohexen-1-one and 1-nitrocyclohexene. Reduction of 2-cyclohexen-1-one by FMNH2 is concerted with proton transfer from an unknown proton donor in the active site. NMR spectroscopy and flavin reoxidation studies with 2-cyclohexen-1-one are consistent with His-186 being unprotonated in oxidized, reduced, and ligand-bound MR, suggesting that His-186 is not the key proton donor required for the reduction of 2-cyclohexen-1-one. Hydride transfer is decoupled from proton transfer with 1-nitrocyclohexene as oxidizing substrate, and unlike with OYE1 the intermediate nitronate species produced after hydride transfer from FMNH2 is not converted to 1-nitrocyclohexane. The work highlights key mechanistic differences in the reactions catalyzed by MR and OYE1 and emphasizes the need for caution in inferring mechanistic similarities in structurally related proteins.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ York, Ctr Novel Agr Prod, Dept Biol, York YO10 5YW, N Yorkshire, England	University of Leicester; University of York - UK	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X; Bruce, Neil Charles/0000-0003-0398-2997	Biotechnology and Biological Sciences Research Council [BBS/B/03572/2] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Barna T, 2002, J BIOL CHEM, V277, P30976, DOI 10.1074/jbc.M202846200; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Basran J, 2003, J BIOL CHEM, V278, P43973, DOI 10.1074/jbc.M305983200; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; BRUCE NC, 1995, TRENDS BIOTECHNOL, V13, P200, DOI 10.1016/S0167-7799(00)88946-5; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P411; Craig DH, 1998, BIOCHEMISTRY-US, V37, P7598, DOI 10.1021/bi980345i; Craig DH, 2001, BIOCHEM J, V359, P315, DOI 10.1042/0264-6021:3590315; Damblon C, 1999, J AM CHEM SOC, V121, P11575, DOI 10.1021/ja992896h; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; Dutton P L, 1978, Methods Enzymol, V54, P411; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; FRENCH CE, 1995, BIO-TECHNOL, V13, P674, DOI 10.1038/nbt0795-674; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; FRENCH CE, 1994, BIOCHEM J, V301, P97, DOI 10.1042/bj3010097; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Fujieda N, 2004, BIOCHEMISTRY-US, V43, P10800, DOI 10.1021/bi049061q; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Khan H, 2002, J BIOL CHEM, V277, P21906, DOI 10.1074/jbc.M200637200; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; LIU XL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P187, DOI 10.1016/0167-4781(93)90113-R; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; Meah Y, 2000, P NATL ACAD SCI USA, V97, P10733, DOI 10.1073/pnas.190345597; Moffat A.C, 1986, CLARKES ISOLATION ID, DOI DOI 10.1002/JPS.2600760520; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Schaller F, 1997, J BIOL CHEM, V272, P28066, DOI 10.1074/jbc.272.44.28066; SCRUTTON NS, 1994, BIOESSAYS, V16, P115, DOI 10.1002/bies.950160208; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; STANSKI DR, 1992, CLIN PHARM BASIC PRI, P721; STOTT K, 1993, J BIOL CHEM, V268, P6097; STRASSNER J, 1999, FLAVINS FLAVOPROTEIN, P655; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; WILLEY DL, 1993, BIOCHEM J, V290, P539, DOI 10.1042/bj2900539; Williams RE, 2004, APPL ENVIRON MICROB, V70, P3566, DOI 10.1128/AEM.70.6.3566-3574.2004; YANG CC, 1995, EUR J BIOCHEM, V232, P264, DOI 10.1111/j.1432-1033.1995.tb20808.x	40	21	22	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10695	10709		10.1074/jbc.M410595200	http://dx.doi.org/10.1074/jbc.M410595200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15632179	hybrid			2022-12-27	WOS:000227559600115
J	Ishii, S; Kihara, Y; Shimizu, T				Ishii, S; Kihara, Y; Shimizu, T			Identification of T cell death-associated gene 8 ( TDAG8) as a novel acid sensing G-protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR RECEPTOR; INDUCED APOPTOSIS; LYSOPHOSPHATIDYLCHOLINE; PSYCHOSINE; EXPRESSION; RHO; SPHINGOSYLPHOSPHORYLCHOLINE; LIGAND; GPR4; G2A	T cell death-associated gene 8 (TDAG8) is a G-protein-coupled receptor mainly expressed in lymphoid organs and cancer tissues. TDAG8 shares high amino acid sequence homologies with recently reported proton-sensing G-protein-coupled receptors, G2A, OGR1, and GPR4. Here we have identified TDAG8 as a novel proton-sensing receptor. Upon acid stimulation, stably expressed TDAG8 was internalized from the plasma membrane. As a signaling pathway downstream of TDAG8, accumulation of cyclic AMP was observed in response to solutions with a pH value lower than 7.2. Furthermore, RhoA activation and actin rearrangement were elicited by acid-stimulated TDAG8. These results suggest that TDAG8 may play biological roles in immune response and cellular transformation under conditions accompanying tissue acidosis.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Ishii, S (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.	mame@m.u-tokyo.ac.jp	Shimizu, Takao/AAV-7052-2021; Kihara, Yasuyuki/C-8801-2011	Kihara, Yasuyuki/0000-0001-7462-3006				Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; Gretz JE, 1996, J IMMUNOL, V157, P495; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IGISU H, 1988, LIPIDS, V23, P345, DOI 10.1007/BF02537346; Im DS, 2004, J LIPID RES, V45, P410, DOI 10.1194/jlr.R300006-JLR200; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Lynch KR, 1999, NATURE, V399, P789; Maghazachi AA, 2004, BIOCHEM BIOPH RES CO, V320, P810, DOI 10.1016/j.bbrc.2004.06.027; MAHADEVAN MS, 1995, GENOMICS, V30, P84, DOI 10.1006/geno.1995.0013; Malone MH, 2004, J BIOL CHEM, V279, P52850, DOI 10.1074/jbc.M408040200; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Myklebust JH, 1999, J CELL PHYSIOL, V180, P71; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sin WC, 2004, ONCOGENE, V23, P6299, DOI 10.1038/sj.onc.1207838; SVENNERHOLM L, 1980, J LIPID RES, V21, P53; Tosa N, 2003, INT IMMUNOL, V15, P741, DOI 10.1093/intimm/dxg070; Vermeulen M, 2004, J IMMUNOL, V172, P3196, DOI 10.4049/jimmunol.172.5.3196; Wang JQ, 2004, J BIOL CHEM, V279, P45626, DOI 10.1074/jbc.M406966200; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	35	140	145	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9083	9087		10.1074/jbc.M407832200	http://dx.doi.org/10.1074/jbc.M407832200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15618224	hybrid			2022-12-27	WOS:000227453100057
J	Kang, JY; Hong, YJ; Ashida, H; Shishioh, N; Murakami, Y; Morita, YS; Maeda, Y; Kinoshita, T				Kang, JY; Hong, YJ; Ashida, H; Shishioh, N; Murakami, Y; Morita, YS; Maeda, Y; Kinoshita, T			PIG-V involved in transferring the second mannose in glycosylphosphatidylinositol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL ANCHOR SYNTHESIS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GPI-ANCHOR; ENDOPLASMIC-RETICULUM; MANNOSYL-TRANSFERASE; MAMMALIAN-CELLS; 3RD MANNOSE; 4TH MANNOSE; YEAST	Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors many proteins to the eukaryotic cell surface. The biosynthetic pathway of GPI is mediated by sequential additions of sugars and other components to phosphatidylinositol. Four mannoses in the GPI are transferred from dolichol-phosphate-mannose (Dol-PMan) and are linked through different glycosidic linkages. Therefore, four Dol-P-Man-dependent mannosyl-transferases, GPI-MT-I, -MT-II, -MT-III, and -MT-IV for the first, second, third, and fourth mannoses, respectively, are required for generation of GPI. GPI-MT-I (PIG-M), GPI-MT-III (PIG-B), and GPI-MT-IV (SMP3) were previously reported, but GPI-MT-II remains to be identified. Here we report the cloning of PIG-V involved in transferring the second mannose in the GPI anchor. Human PIG-V encodes a 493-amino acid, endoplasmic reticulum (ER) resident protein with eight putative transmembrane regions. Saccharomyces cerevisiae protein encoded in open reading frame YBR004c, which we termed GPI18, has 25% amino acid identity to human PIG-V. Viability of the yeast gpi18 deletion mutant was restored by human PIG-V cDNA. PIG-V has two functionally important conserved regions facing the ER lumen. Taken together, we suggest that PIG-V is the second mannosyltransferase in GPI anchor biosynthesis.	Res Inst Microbial Dis, Dept Immunoregulat, Suita, Osaka 5650871, Japan; Chonnam Natl Univ, Sch Med, Genom Res Ctr Enteropathogen Bacteria, Dept Microbiol, Kwangju 501746, South Korea	Chonnam National University	Kinoshita, T (corresponding author), Res Inst Microbial Dis, Dept Immunoregulat, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009; Ashida, Hisashi/HCI-0293-2022	Ashida, Hisashi/0000-0001-5844-4075; Morita, Yasu/0000-0002-4514-9242				Abrami L, 2000, TRENDS MICROBIOL, V8, P168, DOI 10.1016/S0966-842X(00)01722-4; Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; ASHIDA H, 2005, IN PRESS MOL BIOL CE; BUCKLEY JT, 1999, COMPREHENSIVE SOURCE, P362; Burda P, 1996, P NATL ACAD SCI USA, V93, P7160, DOI 10.1073/pnas.93.14.7160; Chavan M, 2003, J BIOL CHEM, V278, P51441, DOI 10.1074/jbc.M310456200; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Girrbach V, 2000, J BIOL CHEM, V275, P19288, DOI 10.1074/jbc.M001771200; Grimme SJ, 2001, J BIOL CHEM, V276, P27731, DOI 10.1074/jbc.M101986200; Hazenbos WLW, 2004, BLOOD, V104, P2825, DOI 10.1182/blood-2004-02-0671; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Hong YJ, 2003, MOL BIOL CELL, V14, P1780, DOI 10.1091/mbc.E02-12-0794; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; Kinoshita T, 1995, ADV IMMUNOL, V60, P57, DOI 10.1016/S0065-2776(08)60584-2; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Naderer T, 2002, MOL BIOCHEM PARASIT, V125, P147, DOI 10.1016/S0166-6851(02)00236-0; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Nosjean O, 1997, BBA-REV BIOMEMBRANES, V1331, P153, DOI 10.1016/S0304-4157(97)00005-1; Nozaki M, 1999, LAB INVEST, V79, P293; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; Sutterlin C, 1998, BIOCHEM J, V332, P153; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; Tachado SD, 1996, J IMMUNOL, V156, P1897; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; Taron BW, 2004, J BIOL CHEM, V279, P36083, DOI 10.1074/jbc.M405081200; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Willer T, 2003, CURR OPIN STRUC BIOL, V13, P621, DOI 10.1016/j.sbi.2003.09.003; Zakrzewska A, 2003, CURR GENET, V43, P11, DOI 10.1007/s00294-003-0368-5	44	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9489	9497		10.1074/jbc.M413867200	http://dx.doi.org/10.1074/jbc.M413867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623507	hybrid			2022-12-27	WOS:000227453100103
J	Kim, DJ; Murray, IA; Burns, AM; Gonzalez, FJ; Perdew, GH; Peters, JM				Kim, DJ; Murray, IA; Burns, AM; Gonzalez, FJ; Perdew, GH; Peters, JM			Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; C-ALPHA; TARGETED DISRUPTION; GENE-EXPRESSION; PPAR-BETA/DELTA; CYCLIN-E; DELTA; DIFFERENTIATION; INFLAMMATION; DEGRADATION	Recent work has shown that peroxisome proliferator-activated receptor beta(PPARbeta) attenuates cell proliferation and skin carcinogenesis, and this is due in part to regulation of ubiquitin C expression. In these studies, the role of PPARbeta in modulating ubiquitin-dependent protein kinase Calpha (PKCalpha) levels and phosphorylation signaling pathways was evaluated. Intracellular phosphorylation analysis showed that phosphorylated PKCalpha and other kinases were lower in wild-type mouse skin treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) as compared with PPARbeta-null mouse skin. No differences in expression levels of other PKC isoforms present in skin were observed. Lower ubiquitination of PKCalpha was found in TPA-treated PPARbeta-null skin as compared with wild-type, and inhibition of ubiquitin-dependent proteasome degradation prevented TPA-induced down-regulation of PKCalpha. The activity of PKCalpha and downstream signaling kinases is enhanced, and expression of cyclooxygenase-2 (COX-2) is significantly greater, in PPARbeta-null mouse skin in response to TPA compared with wild-type mouse skin. Inhibition of PKCalpha or COX-2 reduced cell proliferation in TPA-treated PPARbeta-null keratinocytes in a dose-dependent manner, whereas it only slightly influenced cell proliferation in wild-type keratinocytes. Combined, these studies provide strong evidence that PPAR beta attenuates cell proliferation by modulating PKCalpha/Raf1/MEK/ERK activity that may be due in part to reduced ubiquitin-dependent turnover of PKCalpha.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Huck Inst Life Sci, Grad Program Mol Toxicol, University Pk, PA 16802 USA; NCI, NIH, Lab Metab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peters, JM (corresponding author), Penn State Univ, Dept Vet Sci, 312 Life Sci Bldg, University Pk, PA 16802 USA.	jmp21@psu.edu	Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998; KIM, DAE/0000-0002-7977-9955	NATIONAL CANCER INSTITUTE [R01CA097999, R01CA089607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004869, R29ES004869] Funding Source: NIH RePORTER; NCI NIH HHS [CA89607, CA97999] Funding Source: Medline; NIEHS NIH HHS [ES04869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akiyama TE, 2004, J BIOL CHEM, V279, P20874, DOI 10.1074/jbc.M312802200; Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Buitrago CG, 2003, J BIOL CHEM, V278, P2199, DOI 10.1074/jbc.M205732200; Cataisson C, 2003, J IMMUNOL, V171, P2703, DOI 10.4049/jimmunol.171.5.2703; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chang YY, 1998, BIOCHEM MOL BIOL INT, V45, P1139; Cheng LH, 2004, BIOCHEM BIOPH RES CO, V313, P277, DOI 10.1016/j.bbrc.2003.11.127; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim AL, 2002, BIOCHEM BIOPH RES CO, V298, P377, DOI 10.1016/S0006-291X(02)02435-X; Kim DJ, 2004, J BIOL CHEM, V279, P23719, DOI 10.1074/jbc.M312063200; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; Matsusue K, 2004, FASEB J, V18, P1477, DOI 10.1096/fj.04-1944fje; Matsuura H, 1999, MOL CELL ENDOCRINOL, V147, P85, DOI 10.1016/S0303-7207(98)00214-7; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Munger K, 2002, CANCER INVEST, V20, P71, DOI 10.1081/CNV-120000369; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Perelygin AA, 2002, J MOL EVOL, V55, P202, DOI 10.1007/s00239-002-2318-0; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Schmuth M, 2004, J INVEST DERMATOL, V122, P971, DOI 10.1111/j.0022-202X.2004.22412.x; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shearer BG, 2003, CURR MED CHEM, V10, P267, DOI 10.2174/0929867033368295; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Vosper Helen, 2003, Nucl Recept, V1, P9, DOI 10.1186/1478-1336-1-9; Wang HQ, 1999, J CELL SCI, V112, P3497; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Werling U, 2001, MOL PHARMACOL, V59, P1269, DOI 10.1124/mol.59.5.1269; Westergaard M, 2001, J INVEST DERMATOL, V116, P702, DOI 10.1046/j.1523-1747.2001.01329.x	58	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9519	9527		10.1074/jbc.M413808200	http://dx.doi.org/10.1074/jbc.M413808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632134	hybrid			2022-12-27	WOS:000227453100106
J	Mischo, HE; Hemmerich, P; Grosse, F; Zhang, SS				Mischo, HE; Hemmerich, P; Grosse, F; Zhang, SS			Actinomycin D induces histone gamma-H2AX foci and complex formation of gamma-H2AX with Ku70 and nuclear DNA helicase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; RNA-POLYMERASE-II; DOSAGE-COMPENSATION; H2AX PHOSPHORYLATION; MALELESS PROTEIN; GENOMIC INSTABILITY; ATM ACTIVATION; KINASE; CHROMATIN; DAMAGE	Formation of gamma-H2AX foci is a P.O. cellular response to genotoxic stress, such as DNA double strand breaks or stalled replication forks. Here we show that gamma-H2AX foci were also formed when cells were incubated with 0.5 mug/ ml DNA intercalating agent actinomycin D. In untreated cells, gamma-H2AX co-immunoprecipitated with Ku70, a subunit of DNA-dependent protein kinase, as well as with nuclear DNA helicase II ( NDH II), a DEXH family helicase also known as RNA helicase A or DHX9. This association was increased manifold after actinomycin D treatment. DNA degradation diminished the amount of Ku70 associated with gamma-H2AX but not that of NDH II. In vitro binding studies with recombinant NDH II and H2AX phosphorylated by DNA-dependent protein kinase confirmed a direct physical interaction between NDH II and gamma-H2AX. Thereby, the NDH II DEXH domain alone, i. e. its catalytic core, was able to support binding to gamma-H2AX. Congruently, after actinomycin D treatment, NDH II accumulated in RNA-containing nuclear bodies that predominantly co-localized with gamma-H2AX foci. Taken together, these results suggest that histone gamma-H2AX promotes binding of NDH II to transcriptionally stalled sites on chromosomal DNA.	Inst Mol Biotechnol, Dept Biochem, D-07708 Jena, Germany; Inst Mol Biotechnol, Dept Mol Biol, D-07708 Jena, Germany		Grosse, F (corresponding author), Inst Mol Biotechnol, Dept Biochem, Beutenbergstr 11, D-07745 Jena, Germany.	fgrosse@imb-jena.de						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Abraham RT, 2002, NAT CELL BIOL, V4, pE277, DOI 10.1038/ncb1202-e277; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Doherty AJ, 2001, CURR BIOL, V11, pR920, DOI 10.1016/S0960-9822(01)00555-3; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fujita H, 2003, MOL CELL BIOL, V23, P2645, DOI 10.1128/MCB.23.8.2645-2657.2003; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; JAXEL C, 1988, BIOCHEMISTRY-US, V27, P95, DOI 10.1021/bi00401a016; Jin Y, 2000, J CELL BIOL, V149, P1005, DOI 10.1083/jcb.149.5.1005; Kelley RL, 2000, CURR OPIN GENET DEV, V10, P555, DOI 10.1016/S0959-437X(00)00127-1; Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Meller VH, 2000, TRENDS CELL BIOL, V10, P54, DOI 10.1016/S0962-8924(99)01693-1; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Pannuti A, 2000, CURR OPIN GENET DEV, V10, P644, DOI 10.1016/S0959-437X(00)00136-2; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422; Zhang SS, 1997, J BIOL CHEM, V272, P11487; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933; Zhang SS, 1999, J CELL SCI, V112, P2693; Zhong XL, 2004, J BIOL CHEM, V279, P17134, DOI 10.1074/jbc.M311057200; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	62	79	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9586	9594		10.1074/jbc.M411444200	http://dx.doi.org/10.1074/jbc.M411444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15613478	hybrid			2022-12-27	WOS:000227453100113
J	Yu, LQ; Gupta, S; Xu, F; Liverman, ADB; Moschetta, A; Mangelsdorf, DJ; Repa, JJ; Hobbs, HH; Cohen, JC				Yu, LQ; Gupta, S; Xu, F; Liverman, ADB; Moschetta, A; Mangelsdorf, DJ; Repa, JJ; Hobbs, HH; Cohen, JC			Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTERS; DIETARY-CHOLESTEROL; BILE-ACIDS; MICE; ABSORPTION; LIVER; RAT; SITOSTEROLEMIA; ACCUMULATION; DISRUPTION	The major pathway for elimination of cholesterol in mammals is via secretion into bile. Biliary cholesterol secretion is mediated by the ATP-binding cassette (ABC) transporters ABCG5 (G5) and ABCG8 (G8) and is stimulated by cholesterol and by the non-cholesterol steroids cholate and diosgenin. To define the relationship between G5G8 expression and biliary cholesterol secretion, we measured G5 and G8 mRNA levels and biliary cholesterol concentrations in genetically manipulated mice expressing 0, 1, 2, 5, 10, or 16 copies of the two genes. Biliary cholesterol levels varied directly with G5G8 copy number and hepatic mRNA levels over a > 16-fold range. Thus neither delivery of cholesterol to the transporter nor levels of cholesterol acceptors in bile were limiting under these conditions. In wild-type mice, cholate and diosgenin both increased biliary cholesterol concentrations 2-3-fold. The increase in biliary cholesterol content was dependent on expression of G5 and G8; neither steroid increased biliary cholesterol levels in G5G8(-/-) mice. Cholate treatment was associated with a farnesoid X receptor (FXR)-dependent increase in hepatic mRNA and protein levels of G5 and G8. In contrast to cholate, diosgenin treatment did not affect G5G8 expression. Diosgenin increased the expression of several pregnane X receptor (PXR) target genes and the choleretic effect of diosgenin was reduced by similar to70% in PXR knock-out mice. Thus G5 and G8 are required to modulate biliary cholesterol secretion in response to cholate and diosgenin, but the choleretic effects of these two steroids are mediated by different mechanisms requiring FXR and PXR, respectively.	Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cohen, JC (corresponding author), Univ Texas, SW Med Ctr, Ctr Human Nutr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jonathan.cohen@utsouthwestern.edu	Moschetta, Antonio/K-6211-2016; Moschetta, Antonio/AAC-5295-2022	Mangelsdorf, David/0000-0002-4355-0796; Moschetta, Antonio/0000-0003-2123-6074; Repa, Joyce/0000-0001-5740-1954	NHLBI NIH HHS [HL20948, HL72304] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL072304, R37HL072304] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELAMARICH PF, 1990, PEDIATRICS, V86, P977; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Frijters CMG, 1997, BIOCHEM J, V321, P389, DOI 10.1042/bj3210389; FROMM H, 1980, J LIPID RES, V21, P259; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; GRUNDY SM, 1983, ANNU REV NUTR, V3, P71, DOI 10.1146/annurev.nu.03.070183.000443; Kamisako T, 2003, HEPATOL RES, V26, P348, DOI 10.1016/S1386-6346(03)00153-0; Kipp H, 2001, J BIOL CHEM, V276, P7218, DOI 10.1074/jbc.M007794200; Klett EL, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-5; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kosters A, 2003, J HEPATOL, V38, P710, DOI 10.1016/S0168-8278(03)00093-X; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x; NERVI F, 1988, J CLIN INVEST, V82, P1818, DOI 10.1172/JCI113797; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; TAKAYAMA M, 1977, Clinica Chimica Acta, V79, P93; Tauscher A, 2003, BIOCHEM BIOPH RES CO, V307, P1021, DOI 10.1016/S0006-291X(03)01296-8; TURLEY SD, 1978, J LIPID RES, V19, P924; TURLEY SD, 1991, METABOLISM, V40, P1063, DOI 10.1016/0026-0495(91)90131-F; TURLEY SD, 1984, GASTROENTEROLOGY, V87, P284; UCHIDA K, 1984, J LIPID RES, V25, P236; Wang DQH, 1997, J LIPID RES, V38, P1395; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751; Wittenburg H, 2002, J CLIN INVEST, V110, P605, DOI 10.1172/JCI200216548; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2004, J LIPID RES, V45, P301, DOI 10.1194/jlr.M300377-JLR200; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	32	170	176	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8742	8747		10.1074/jbc.M411080200	http://dx.doi.org/10.1074/jbc.M411080200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611112	hybrid			2022-12-27	WOS:000227453100016
J	En-Nia, A; Yilmaz, E; Klinge, U; Lovett, DH; Stefanidis, I; Mertens, PR				En-Nia, A; Yilmaz, E; Klinge, U; Lovett, DH; Stefanidis, I; Mertens, PR			Transcription factor YB-1 mediates DNA polymerase alpha gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y-BOX PROTEINS; BINDING-PROTEIN; REPLICATION; ACTIVATION; REGIONS; COMPLEX; FAMILY	Y-box protein-1 involvement in cyclin A and B1 gene regulation has recently been demonstrated. A more generalized role of this protein for cell replication is hypothesized as numerous regulatory sequences of cell cycle-related genes contain putative binding sites. In the present study the DNA polymerase alpha (DPA) gene is identified as another YB-1-responsive gene with a Y-box and 3' inverted repeat sequence, designated DPA RE-1, in the serum-responsive promoter region. Overexpressed YB-1 concentration-dependently trans-activated DPA gene expression in reporter assays and Southwestern blotting as well as DNA binding analyses revealed binding of distinct endogenous proteins to the RE-1 with molecular sizes of 26, 32 and 52 kDa. Among these, YB-1 binding was confirmed using recombinant as well as endogenous proteins, with preferential single-stranded DNA binding. Early serum growth response in mesangial cells was accompanied by a nuclear YB-1 shift and nucleocomplex formation at the RE-1. Fine mapping of the DPA RE-1 sequence unraveled a dependence on co-factors for trans-regulation with gene activation in the context of a heterologous SV40 promoter but suppression in the context of the abbreviated homologous promoter sequence. A YB-1 knock down resulted in decreased DPA transcription rates and abrogated the serum-dependent induction of DPA transcription. These results link YB-1 with serum responsiveness of DPA gene expression and provide insight into the required sequence and protein binding context.	Univ Hosp Aachen, Dept Nephrol & Clin Immunol, D-52057 Aachen, Germany; Univ Calif San Francisco, Vet Affairs Med Ctr, Div Nephrol, San Francisco, CA 94121 USA	RWTH Aachen University; RWTH Aachen University Hospital; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mertens, PR (corresponding author), Univ Hosp Aachen, Dept Nephrol & Clin Immunol, Pauwelsstr 30, D-52057 Aachen, Germany.	pmertens@ukaachen.de	Mertens, Peter/AAI-7310-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, R01DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYUSAWA D, 1986, J MOL BIOL, V190, P559, DOI 10.1016/0022-2836(86)90241-X; CAMPBELL JL, 1986, ANNU REV BIOCHEM, V55, P733, DOI 10.1146/annurev.bi.55.070186.003505; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; DURSO G, 1995, J CELL SCI, V108, P3109; En-Nia A, 2002, BIOCHEM J, V362, P693, DOI 10.1042/0264-6021:3620693; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; Gu CD, 2001, ANTICANCER RES, V21, P2357; HAYHURST GP, 1995, J VIROL, V69, P182, DOI 10.1128/JVI.69.1.182-188.1995; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Levenson VV, 2000, CANCER RES, V60, P5027; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Mertens PR, 1998, HYPERTENSION, V32, P945, DOI 10.1161/01.HYP.32.5.945; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Norman JT, 2001, J BIOL CHEM, V276, P29880, DOI 10.1074/jbc.M103145200; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Reisdorff J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015617.39974.FB; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; Swamynathan SK, 2000, BIOCHEM J, V348, P297, DOI 10.1042/0264-6021:3480297; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Wada MR, 1998, DEV GROWTH DIFFER, V40, P631; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	28	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7702	7711		10.1074/jbc.M413353200	http://dx.doi.org/10.1074/jbc.M413353200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615704	hybrid			2022-12-27	WOS:000227395700034
J	Ahr, B; Denizot, M; Robert-Hebmann, W; Brelot, A; Biard-Piechaczyk, M				Ahr, B; Denizot, M; Robert-Hebmann, W; Brelot, A; Biard-Piechaczyk, M			Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; HEMATOPOIETIC PROGENITOR CELLS; GROWTH-HORMONE RECEPTOR; SIGNAL TRANSDUCER GP130; JANUS KINASE/SIGNAL TRANSDUCER; PLATELET-ACTIVATING-FACTOR; PROTEIN-COUPLED RECEPTORS; COLONY-STIMULATING FACTOR; FOCAL ADHESION PROTEINS; II AT(1) RECEPTOR	The chemokine SDF-1alpha transduces G(i)-dependent and -independent signals through CXCR4. Activation of Jak2/STAT3, a G(i)-independent signaling pathway, which plays a major role in survival signals, is known to be activated after SDF-1alpha binding to CXCR4 but the domains of CXCR4 involved in this signaling remain unexplored. Using human embryonic kidney HEK-293 cells stably expressing wild-type or mutated forms of CXCR4, we demonstrated that STAT3 phosphorylation requires the N-terminal part of the third intracellular loop (ICL3) and the tyrosine 157 present at the end of the second intracellular loop (ICL2) of CXCR4. In contrast, neither the conserved Tyr(135) in the DRY motif at the N terminus of ICL2 nor the Tyr(65) and Tyr(76) in the first intracellular loop (ICL1) are involved in this activation. ICL3, which does not contain any tyrosine residues, is needed to activate Jak2. These results demonstrate that two separate domains of CXCR4 are involved in Jak2/ STAT3 signaling. The N-terminal part of ICL3 is needed to activate Jak2 after SDF-1alpha binding to CXCR4, leading to phosphorylation of only one cytoplasmic Tyr, present at the C terminus of ICL2, which triggers STAT3 activation. This work has profound implications for the understanding of CXCR4-transduced signaling.	CNRS, UMR 5121, Lab Infect Retrovirales & Signalisat Cellulaire, Inst Biol, F-34960 Montpellier 2, France; Inst Cochin, U567, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Biard-Piechaczyk, M (corresponding author), CNRS, UMR 5121, Lab Infect Retrovirales & Signalisat Cellulaire, Inst Biol, 4 Bd Henri IV,CS 89508, F-34960 Montpellier 2, France.	martine.biard@univ-montp1.fr	Brelot, Anne/P-4129-2017	Brelot, Anne/0000-0002-8095-4909				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bahrenberg G, 2002, MOL ENDOCRINOL, V16, P859, DOI 10.1210/me.16.4.859; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Carvalho CRO, 2003, ENDOCRINOLOGY, V144, P638, DOI 10.1210/en.2002-220706; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DASILVA L, 1994, J BIOL CHEM, V269, P18267; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; Gent J, 2003, MOL ENDOCRINOL, V17, P967, DOI 10.1210/me.2002-0261; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Hamada T, 1998, J EXP MED, V188, P539, DOI 10.1084/jem.188.3.539; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Kaczur V, 2003, MOL GENET METAB, V78, P275, DOI 10.1016/S1096-7192(03)00036-2; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Lee SP, 2003, LIFE SCI, V74, P173, DOI 10.1016/j.lfs.2003.09.028; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Mellado M, 1998, J IMMUNOL, V161, P805; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Schabath R, 1999, J LEUKOCYTE BIOL, V66, P996, DOI 10.1002/jlb.66.6.996; Soriano SF, 2002, J EXP MED, V196, P311, DOI 10.1084/jem.20012041; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; Soyer Orkun, 2002, Pac Symp Biocomput, P625; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Takeda K, 1998, J IMMUNOL, V161, P4652; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Toth PT, 2004, J PHARMACOL EXP THER, V310, P8, DOI 10.1124/jpet.103.064956; Trettel F, 2003, J BIOL CHEM, V278, P40980, DOI 10.1074/jbc.M306815200; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Velichko S, 2002, J BIOL CHEM, V277, P35635, DOI 10.1074/jbc.M204578200; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Wu EHT, 2003, BIOCHEM BIOPH RES CO, V303, P920, DOI 10.1016/S0006-291X(03)00451-0; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Zar J. H., 1996, BIOSTATISTICAL ANAL; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	84	57	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6692	6700		10.1074/jbc.M408481200	http://dx.doi.org/10.1074/jbc.M408481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15615703	hybrid			2022-12-27	WOS:000227332700057
J	Rosenberger, G; Gal, A; Kutsche, K				Rosenberger, G; Gal, A; Kutsche, K			alpha PIX associates with calpain 4, the small subunit of calpain, and has a dual role in integrin-mediated cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; BINDING PROTEIN RHO; ACTIN STRESS FIBERS; FOCAL ADHESIONS; LINKED KINASE; P21-ACTIVATED KINASES; SUBSTRATE INTERACTION; NEURITE OUTGROWTH; LD4 MOTIF; GTPASES	Binding of integrins to the extracellular matrix results in actin cytoskeletal rearrangements, e.g. during cell spreading, by regulating the activity of Rho GTPases. We have shown previously that alphaPIX (Cool-2 or ARHGEF6), a Rac1/Cdc42-specific guanine nucleotide exchange factor (GEF), binds to beta-parvin/affixin and colocalizes with integrin-linked kinase in actively spreading cells, suggesting that aPIX is involved in integrin-induced signaling leading to activation of Rac1/Cdc42. Here we report calpain 4, the small subunit of the proteases mu-calpain and m-calpain, as a novel binding partner of alphaPIX. This association was identified by the CytoTrap system and confirmed by coimmunoprecipitation and glutathione S-transferase pull-down assays. The alphaPIX triple domain SH3-DH-PH was found to be required for calpain 4 binding. During integrin-dependent spreading of CHO-K1 cells, aPIX colocalized with mu-and m-calpain, integrin-linked kinase, and beta1 integrin in early integrin-containing clusters. Overexpression of aPIX wild type but not the GEF-deficient mutant (L386R/L387S) resulted in enhanced formation of characteristic cellular protrusions during cell spreading, suggesting that alphaPIX GEF activity is necessary for this specific actin cytoskeletal reorganization. The calpain inhibitors calpeptin and calpain inhibitor IV significantly inhibited integrin-dependent cell spreading. However, concomitant overexpression of alphaPIX wild type or the L386RAL387S mutant restored cell spreading. Together, these data suggest that alphaPIX is a component of early integrin clusters and plays a dual role in integrin-dependent cell spreading. Whereas alphaPIX GEF activity contributes to enhanced formation of cellular protrusions, the GEF-independent association with calpain 4 leads to induction of a yet unknown signaling cascade resulting in cell spreading.	Univ Hamburg, Klinikum Eppendorf, Inst Human Genet, D-22529 Hamburg, Germany	University of Hamburg	Kutsche, K (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Human Genet, Butenfeld 42, D-22529 Hamburg, Germany.	kkutsche@uke.uni-hamburg.de						Aronheim A, 1997, NUCLEIC ACIDS RES, V25, P3373, DOI 10.1093/nar/25.16.3373; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ishii T, 2001, J BIOL CHEM, V276, P42994, DOI 10.1074/jbc.M105198200; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Koh CG, 2001, J CELL SCI, V114, P4239; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Kutsche K, 2000, NAT GENET, V26, P247, DOI 10.1038/80002; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Manabe R, 2002, J CELL SCI, V115, P1497; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Mills J, 2003, J NEUROSCI, V23, P1638; Mishima W, 2004, GENES CELLS, V9, P193, DOI 10.1111/j.1356-9597.2004.00717.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olski TM, 2001, J CELL SCI, V114, P525; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Premont RT, 2004, CELL SIGNAL, V16, P1001, DOI 10.1016/j.cellsig.2004.02.002; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Reddy KB, 2001, J BIOL CHEM, V276, P28300, DOI 10.1074/jbc.M102794200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rock MT, 2000, EXP CELL RES, V261, P260, DOI 10.1006/excr.2000.5048; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; VAN AL, 1997, GENE DEV, V11, P2295; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Yamaji S, 2004, J CELL BIOL, V165, P539, DOI 10.1083/jcb.200308141; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200	56	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6879	6889		10.1074/jbc.M412119200	http://dx.doi.org/10.1074/jbc.M412119200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611136	hybrid			2022-12-27	WOS:000227332700077
J	Oikawa, K; Nakamura, S; Sonoyama, T; Ohshima, A; Kobayashi, Y; Takayama, SJ; Yamamoto, Y; Uchiyama, S; Hasegawa, J; Sambongi, Y				Oikawa, K; Nakamura, S; Sonoyama, T; Ohshima, A; Kobayashi, Y; Takayama, SJ; Yamamoto, Y; Uchiyama, S; Hasegawa, J; Sambongi, Y			Five amino acid residues responsible for the high stability of Hydrogenobacter thermophilus cytochrome c(552) - Reciprocal mutation analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZING BACTERIUM; PROTEIN STABILITY; PERIPLASM; C-552; STABILIZATION; EXPRESSION; VARIANTS; SEQUENCE; C(552)	Five amino acid residues responsible for extreme stability have been identified in cytochrome c(552). (HT c(552.)) from a thermophilic bacterium, Hydrogenobacter thermophilus. The five residues, which are spatially distributed in three regions of HT C-552 were replaced with the corresponding residues in the homologous but less stable cytochrome C-551 (PA c(551)) from Pseudomonas aeruginosa. The quintuple HT c(552). variant (A7F/M13V/Y34F/Y43E/ 178V) showed the same stability against guanidine hydrochloride denaturation as that of PA C-511, suggesting that the five residues in HT C-552 necessarily and sufficiently contribute to the overall stability. In the three HT C551 variants carrying mutations in each of the three regions, the Y34F/Y43E mutations resulted in the greatest destabilization, by -13.3 kJ mol(-1), followed by A7F/M13V (-3.3 W mol(-1)) and then 178V (-1.5 W mol(-1)). The order of destabilization in HT C-552 was the same as that of stabilization in PA C-551 with reverse mutations such as F34Y/ E43Y, F7A/V13WL and V78I (13.4, 10.3, and 0.3 W mol(-1), respectively). The results of guanidine hydrochloride denaturation were consistent with those of thermal denaturation for the same variants. The present study established a method for reciprocal mutation analysis. The effects of side-chain contacts were experimentally evaluated by swapping the residues between the two homologous proteins that differ in stability. A comparative study of the two proteins was a useful tool for assessing the nmino acid contribution to the overall stability.	Hiroshima Univ, CREST Japan Sci & Technol Corp, Grad Sch Biosphere Sci, Hiroshima 7398528, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; Univ Tsukuba, Dept Chem, Tsukuba, Ibaraki 3058571, Japan; Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan; Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan	Hiroshima University; Japan Science & Technology Agency (JST); Osaka University; University of Tsukuba; Osaka University; Daiichi Sankyo Company Limited	Sambongi, Y (corresponding author), Hiroshima Univ, CREST Japan Sci & Technol Corp, Grad Sch Biosphere Sci, 1-4-4 Kagamiyama, Hiroshima 7398528, Japan.	sambongi@hiroshima-u.ac.jp	UCHIYAMA, Susumu/F-9590-2017; Nakamura, Shota/E-3033-2010	UCHIYAMA, Susumu/0000-0002-5181-179X; Nakamura, Shota/0000-0003-2058-5942				Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; Hasegawa J, 2000, J BIOL CHEM, V275, P37824, DOI 10.1074/jbc.M005861200; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Ishida M, 2004, BIOCHEMISTRY-US, V43, P9823, DOI 10.1021/bi049546e; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Jaenicke R, 2000, J BIOTECHNOL, V79, P193, DOI 10.1016/S0168-1656(00)00236-4; Karan EF, 2002, J BIOL INORG CHEM, V7, P260, DOI 10.1007/s007750100292; Kuroda Y, 2000, J MOL BIOL, V298, P493, DOI 10.1006/jmbi.2000.3622; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Perl D, 2000, NAT STRUCT BIOL, V7, P380; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; Sambongi Y, 2002, EUR J BIOCHEM, V269, P3355, DOI 10.1046/j.1432-1033.2002.03045.x; SAMBONGI Y, 1991, THESIS U TOKYO; SANBONGI Y, 1989, J BACTERIOL, V171, P65, DOI 10.1128/jb.171.1.65-69.1989; SANBONGI Y, 1989, BIOCHEMISTRY-US, V28, P9574, DOI 10.1021/bi00451a004; SANBONGI Y, 1991, EUR J BIOCHEM, V198, P7, DOI 10.1111/j.1432-1033.1991.tb15979.x; Terui N, 2003, J AM CHEM SOC, V125, P13650, DOI 10.1021/ja035682f; Uchiyama S, 2004, J AM CHEM SOC, V126, P14684, DOI 10.1021/ja046667t; Uchiyama S, 2002, PROTEIN ENG, V15, P455, DOI 10.1093/protein/15.6.455; Zhang Y, 1998, J FERMENT BIOENG, V85, P346, DOI 10.1016/S0922-338X(97)85688-7	24	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5527	5532		10.1074/jbc.M412392200	http://dx.doi.org/10.1074/jbc.M412392200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15598654	Green Published, hybrid			2022-12-27	WOS:000227217100052
J	Brouns, SJJ; Wu, H; Akerboom, J; Turnbull, AP; de Vos, WM; van der Oost, J				Brouns, SJJ; Wu, H; Akerboom, J; Turnbull, AP; de Vos, WM; van der Oost, J			Engineering a selectable marker for hyperthermophiles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLEOMYCIN-RESISTANCE DETERMINANT; THERMUS-THERMOPHILUS; STREPTOALLOTEICHUS-HINDUSTANUS; STREPTOMYCES-VERTICILLUS; EXTREME THERMOPHILE; DIRECTED EVOLUTION; CRYSTAL-STRUCTURE; BINDING PROTEIN; ALPHA-HELIX; ION-PAIRS	Limited thermostability of antibiotic resistance markers has restricted genetic research in the field of extremely thermophilic Archaea and bacteria. In this study, we used directed evolution and selection in the thermophilic bacterium Thermus thermophilus HB27 to find thermostable variants of a bleomycin-binding protein from the mesophilic bacterium Streptoalloteichus hindustanus. In a single selection round, we identified eight clones bearing five types of double mutated genes that provided T. thermophilus transformants with bleomycin resistance at 77 degrees C, while the wild-type gene could only do so up to 65 degrees C. Only six different amino acid positions were altered, three of which were glycine residues. All variant proteins were produced in Escherichia coli and analyzed biochemically for thermal stability and functionality at high temperature. A synthetic mutant resistance gene with low GC content was designed that combined four substitutions. The encoded protein showed up to 17 degrees C increased thermostability and unfolded at 85 degrees C in the absence of bleomycin, whereas in its presence the protein unfolded at 100 degrees C. Despite these highly thermophilic properties, this mutant was still able to function normally at mesophilic temperatures in vivo. The mutant protein was co-crystallized with bleomycin, and the structure of the binary complex was determined to a resolution of 1.5 angstrom. Detailed structural analysis revealed possible molecular mechanisms of thermostabilization and enhanced antibiotic binding, which included the introduction of an intersubunit hydrogen bond network, improved hydrophobic packing of surface indentations, reduction of loop flexibility, and alpha-helix stabilization. The potential applicability of the thermostable selection marker is discussed.	Univ Wageningen, Microbiol Lab, Dept Agrotechnol & Food Sci, NL-6703 CT Wageningen, Netherlands; Berliner Elecktronenspeicherring Gesell Synchrotr, Prot Strukturfabrik, D-12489 Berlin, Germany	Wageningen University & Research	Brouns, SJJ (corresponding author), Univ Wageningen, Microbiol Lab, Dept Agrotechnol & Food Sci, Hesselink Van Suchtelenweg 4, NL-6703 CT Wageningen, Netherlands.	stan.brouns@wur.nl	van+der+Oost, John/Y-2548-2019	Brouns, Stan/0000-0002-9573-1724				Akanuma S, 1998, PROTEIN SCI, V7, P698, DOI 10.1002/pro.5560070319; Arnold FH, 2001, TRENDS BIOCHEM SCI, V26, P100, DOI 10.1016/S0968-0004(00)01755-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; de Grado M, 1999, PLASMID, V42, P241, DOI 10.1006/plas.1999.1427; DROCOURT D, 1990, NUCLEIC ACIDS RES, V18, P4009, DOI 10.1093/nar/18.13.4009; DUMAS P, 1994, EMBO J, V13, P2483, DOI 10.1002/j.1460-2075.1994.tb06535.x; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; FernandezHerrero LA, 1997, MOL MICROBIOL, V24, P61, DOI 10.1046/j.1365-2958.1997.3191683.x; Fridjonsson O, 2002, J BACTERIOL, V184, P3385, DOI 10.1128/JB.184.12.3385-3391.2002; Friedrich A, 2002, APPL ENVIRON MICROB, V68, P745, DOI 10.1128/AEM.68.2.745-755.2002; GATIGNOL A, 1988, FEBS LETT, V230, P171, DOI 10.1016/0014-5793(88)80665-3; GENILLOUD O, 1984, GENE, V32, P225, DOI 10.1016/0378-1119(84)90050-7; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Gonzalez M, 1999, BIOMOL ENG, V16, P67, DOI 10.1016/S1050-3862(99)00041-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hoseki J, 1999, J BIOCHEM-TOKYO, V126, P951, DOI 10.1093/oxfordjournals.jbchem.a022539; Iqbalsyah TM, 2004, PROTEIN SCI, V13, P32, DOI 10.1110/ps.03341804; Jaswal SS, 2002, NATURE, V415, P343, DOI 10.1038/415343a; Karshikoff A, 2001, TRENDS BIOCHEM SCI, V26, P550, DOI 10.1016/S0968-0004(01)01918-1; Kawano Y, 2000, J MOL BIOL, V295, P915, DOI 10.1006/jmbi.1999.3404; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; Kumar S, 2001, CELL MOL LIFE SCI, V58, P1216, DOI 10.1007/PL00000935; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIAO H, 1986, P NATL ACAD SCI USA, V83, P576, DOI 10.1073/pnas.83.3.576; Machius M, 2003, J BIOL CHEM, V278, P11546, DOI 10.1074/jbc.M212618200; Martin A, 2001, J MOL BIOL, V309, P717, DOI 10.1006/jmbi.2001.4698; Maruyama M, 2001, J BIOL CHEM, V276, P9992, DOI 10.1074/jbc.M009874200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Noll KM, 1997, ARCH MICROBIOL, V168, P73, DOI 10.1007/s002030050472; Nuttall SD, 2000, BIOCHEM J, V346, P251, DOI 10.1042/0264-6021:3460251; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palackal N, 2004, PROTEIN SCI, V13, P494, DOI 10.1110/ps.03333504; Penel S, 1999, J MOL BIOL, V287, P127, DOI 10.1006/jmbi.1998.2549; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Poddevin B., 1991, BIOCHEM PHARMACOL, V42, pS67; RONDEAU JM, 1989, J MOL BIOL, V207, P645, DOI 10.1016/0022-2836(89)90476-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEMON D, 1987, PLASMID, V17, P46, DOI 10.1016/0147-619X(87)90007-2; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; Shafikhani S, 1997, BIOTECHNIQUES, V23, P304, DOI 10.2144/97232rr01; Sieber V, 1998, NAT BIOTECHNOL, V16, P955, DOI 10.1038/nbt1098-955; SIKIC BI, 1986, CANCER SURV, V5, P81; Smith JS, 1998, BIOCHEMISTRY-US, V37, P33, DOI 10.1021/bi972026h; Spiller B, 1999, P NATL ACAD SCI USA, V96, P12305, DOI 10.1073/pnas.96.22.12305; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; Sugiyama M, 2002, J BIOL CHEM, V277, P2311, DOI 10.1074/jbc.M103278200; SUGIYAMA M, 1994, GENE, V151, P11; Sugiyama M, 2002, J BIOSCI BIOENG, V93, P105, DOI 10.1263/jbb.93.105; TAMAKOSHI M, 1995, MOL MICROBIOL, V16, P1031, DOI 10.1111/j.1365-2958.1995.tb02328.x; Tamakoshi M, 2001, EXTREMOPHILES, V5, P17, DOI 10.1007/s007920000168; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOMITA K, 1987, INT J SYST BACTERIOL, V37, P211, DOI 10.1099/00207713-37-3-211; TURNER SL, 1992, PROTEIN ENG, V5, P535, DOI 10.1093/protein/5.6.535; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; van den Burg B, 2002, CURR OPIN BIOTECH, V13, P333, DOI 10.1016/S0958-1669(02)00325-7; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; Vanbelle C, 2003, BIOCHEMISTRY-US, V42, P651, DOI 10.1021/bi0267341; VANDENBURG B, 1994, EUR J BIOCHEM, V220, P981; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042	65	67	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11422	11431		10.1074/jbc.M413623200	http://dx.doi.org/10.1074/jbc.M413623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15640151	hybrid			2022-12-27	WOS:000227761800065
J	Grove, DE; Willcox, S; Griffith, JD; Bryant, FR				Grove, DE; Willcox, S; Griffith, JD; Bryant, FR			Differential single-stranded DNA binding properties of the paralogous SsbA and SsbB proteins from Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SSB; MECHANISM; RECOMBINATION; VISUALIZATION; COMPLEXES; EXCHANGE; GENES	The naturally transformable Gram-positive bacterium Streptococcus pneumoniae has two single-stranded DNA-binding (SSB) proteins, designated SsbA and SsbB. The SsbA protein is similar in size to the well characterized SSB protein from Escherichia coli (SsbEc). The SsbB protein, in contrast, is a smaller protein that is specifically induced during natural transformation and has no counterpart in E. coli. In this report, the single-stranded DNA (ssDNA) binding properties of the SsbA and SsbB proteins were examined and compared with those of the SsbEc protein. The ssDNA binding characteristics of the SsbA protein were similar to those of the SsbEc protein in every ssDNA binding assay used in this study. The SsbB protein differed from the SsbA and SsbEc proteins, however, both in its binding to short homopolymeric dT(n) oligomers (as judged by polyacrylamide gel-shift assays) and in its binding to the longer naturally occurring phi X and M13 ssDNAs (as judged by agarose gel-shift assays and electron microscopic analysis). The results indicate that an individual SsbB protein binds to ssDNA with an affinity that is similar or higher than that of the SsbA and SsbEc proteins. However, the manner in which multiple SsbB proteins assemble onto a ssDNA molecule differs from that observed with the SsbA and SsbEc proteins. These results represent the first analysis of paralogous SSB proteins from any bacterial species and provide a foundation for further investigations into the biological roles of these proteins.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bryant, FR (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 N Wolfe St, Baltimore, MD 21205 USA.	fbryant@jhsph.edu			NIEHS NIH HHS [ES07141] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; Claverys JP, 2000, MOL MICROBIOL, V35, P251, DOI 10.1046/j.1365-2958.2000.01718.x; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Hedayati MA, 2002, J BIOL CHEM, V277, P24863, DOI 10.1074/jbc.M202041200; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P11611, DOI 10.1021/bi020361m; Lindner C, 2004, J BACTERIOL, V186, P1097, DOI 10.1128/JB.186.4.1097-1105.2004; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Peterson SN, 2004, MOL MICROBIOL, V51, P1051, DOI 10.1046/j.1365-2958.2003.03907.x; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; Steffen SE, 2002, J BIOL CHEM, V277, P14493, DOI 10.1074/jbc.M112444200; Steffen SE, 2001, ARCH BIOCHEM BIOPHYS, V388, P165, DOI 10.1006/abbi.2001.2286	13	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11067	11073		10.1074/jbc.M414057200	http://dx.doi.org/10.1074/jbc.M414057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647253	Green Published, hybrid			2022-12-27	WOS:000227761800024
J	Hisatsune, C; Nakamura, K; Kuroda, Y; Nakamura, T; Mikoshiba, K				Hisatsune, C; Nakamura, K; Kuroda, Y; Nakamura, T; Mikoshiba, K			Amplification of Ca2+ signaling by diacylglycerol-mediated inositol 1,4,5-trisphosphate production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; TRANSIENT RECEPTOR; CALCIUM; PROTEIN; INHIBITION; ACTIVATION; CHANNEL; MECHANISM; ENTRY	Stimulation of various cell surface receptors leads to the production of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) through phospholipase C ( PLC) activation, and the IP3 and DAG in turn trigger Ca2+ release through IP3 receptors and protein kinase C activation, respectively. The amount of IP3 produced is particularly critical to determining the spatio-temporally coordinated Ca2+-signaling patterns. In this paper, we report a novel signal cross-talk between DAG and the IP3-mediated Ca2+-signaling pathway. We found that a DAG derivative, 1-oleoyl-2-acyl-sn-glycerol (OAG), induces Ca2+ oscillation in various types of cells independently of protein kinase C activity and extracellular Ca2+. The OAG-induced Ca2+ oscillation was completely abolished by depletion of Ca2+ stores or inhibition of PLC and IP3 receptors, indicating that OAG stimulates IP3 production through PLC activation and thereby induces IP3-induced Ca2+ release. Furthermore, intracellular accumulation of endogenous DAG by a DAG-lipase inhibitor greatly increased the number of cells responding to agonist stimulation at low doses. These results suggest a novel physiological function of DAG, i.e. amplification of Ca2+ signaling by enhancing IP3 production via its positive feedback effect on PLC activity.	RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; ICORP, Calcium Oscillat Project, Japan Sci & Technol Agcy, Chiyoda Ku, Tokyo 1020084, Japan; Univ Tokyo, Inst Med Sci, IMSUT, NTT,Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, IMSUT, NTT,Div Neural Signal Informat,Minato Ku, Tokyo 1088639, Japan	RIKEN; Japan Science & Technology Agency (JST); Nippon Telegraph & Telephone Corporation; University of Tokyo; Nippon Telegraph & Telephone Corporation; University of Tokyo	Hisatsune, C (corresponding author), RIKEN, Dev Neurobiol Lab, Brain Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	chihiro@brain.riken.jp	Hisatsune, Chihiro/C-6661-2017; Kuroda, Yukiko/L-6332-2013; Mikoshiba, Katsuhiko/N-7943-2015; Kuroda, Yukiko/L-6332-2013	Hisatsune, Chihiro/0000-0001-7811-7784; Kuroda, Yukiko/0000-0002-5335-4238; Kuroda, Yukiko/0000-0001-7713-9471				Andoh T, 2004, BRAIN RES, V1013, P125, DOI 10.1016/j.brainres.2004.04.012; Arai M, 2000, JPN HEART J, V41, P1, DOI 10.1536/jhj.41.1; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Bootman MD, 2001, J CELL SCI, V114, P2213; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Crary JI, 2000, J GEN PHYSIOL, V116, P755, DOI 10.1085/jgp.116.6.755; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; GORDON SE, 1995, BIOPHYS J, V69, P409, DOI 10.1016/S0006-3495(95)79913-1; Grimaldi M, 2003, J NEUROSCI, V23, P4737; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; JOSEPH SK, 1989, ARCH BIOCHEM BIOPHYS, V273, P1, DOI 10.1016/0003-9861(89)90156-2; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; MILLER S, 1995, J NEUROSCI, V15, P6103; Misquitta CM, 1999, CELL CALCIUM, V25, P277, DOI 10.1054/ceca.1999.0032; Nalaskowski MM, 2004, CURR MOL MED, V4, P277, DOI 10.2174/1566524043360726; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Ozdener F, 2002, MOL PHARMACOL, V62, P672, DOI 10.1124/mol.62.3.672; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; PREISS J, 1986, J BIOL CHEM, V261, P8597; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zhang L, 2001, J BIOL CHEM, V276, P13331, DOI 10.1074/jbc.M008914200	41	52	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11723	11730		10.1074/jbc.M409535200	http://dx.doi.org/10.1074/jbc.M409535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15637078	hybrid			2022-12-27	WOS:000227761800101
J	Shirokova, E; Schmiedeberg, K; Bedner, P; Niessen, H; Willecke, K; Raguse, JD; Meyerhof, W; Krautwurst, D				Shirokova, E; Schmiedeberg, K; Bedner, P; Niessen, H; Willecke, K; Raguse, JD; Meyerhof, W; Krautwurst, D			Identification of specific ligands for orphan olfactory receptors - G protein-dependent agonism and antagonisms of odorants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; FUNCTIONAL EXPRESSION; ADENYLYL-CYCLASE; RECONSTITUTION; SENSITIVITY; VOMERONASAL; SYSTEMS; GENES; CODES; CAMP	Olfactory receptors are the largest group of orphan G protein-coupled receptors with an infinitely small number of agonists identified out of thousands of odorants. The de-orphaning of olfactory receptor (OR) is complicated by its combinatorial odorant coding and thus requires large scale odorant and receptor screening and establishing receptor-specific odorant profiles. Here, we report on the stable reconstitution of OR-specific signaling in HeLa/Olf cells via G protein alpha olf and adenylyl cyclase type-III to the Ca2+ influx-mediating olfactory cyclic nucleotide-gated CNGA2 channel. We demonstrate the central role of G alpha olf in odorant-specific signaling out of OR. The employment of the non-typical G protein alpha 15 dramatically altered the odorant specificities of 3 of 7 receptors that had been characterized previously by different groups. We further show for two OR that an odorant may be an agonist or antagonist, depending on the G protein used. HeLa/Olf cells proved suitable for high-throughput screening in fluorescence-imaging plate reader experiments, resulting in the deorphaning of two new OR for the odorant (-)citronellal from an expression library of 93 receptors. To demonstrate the G protein dependence of its odorant response pattern, we screened the most sensitive (-)citronellal receptor Olfr43 versus 94 odorants simultaneously in the presence of G alpha 15 or G alpha olf. We finally established an EC50-ranking odorant profile for Olfr43 in HeLa/Olf cells. In summary, we conclude that, in heterologous systems, odorants may function as agonists or antagonists, depending on the G protein used. HeLa/Olf cells provide an olfactory model system for functional expression and de-orphaning of OR.	German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, D-14558 Nuthetal, Germany; Univ Bonn, D-53117 Bonn, Germany; Charite, Clin & Polylcin Oral & Maxillofacial Surg & Plast, D-13353 Berlin, Germany	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Krautwurst, D (corresponding author), German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, Arthur Scheunert Allee 114-116, D-14558 Nuthetal, Germany.	dietmark@mail.dife.de	Krautwurst, Dietmar/AAD-5579-2019	Krautwurst, Dietmar/0000-0002-3350-8682				Araneda RC, 2000, NAT NEUROSCI, V3, P1248, DOI 10.1038/81774; Araneda RC, 2004, J PHYSIOL-LONDON, V555, P743, DOI 10.1113/jphysiol.2003.058040; Barber RD, 2000, J NEUROSCI, V20, P3695, DOI 10.1523/JNEUROSCI.20-10-03695.2000; Bidlack Jean M., 2003, V237, P135; Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Fagan KA, 2001, FEBS LETT, V500, P85, DOI 10.1016/S0014-5793(01)02564-9; Finn JT, 1998, BIOPHYS J, V74, P1333, DOI 10.1016/S0006-3495(98)77846-4; Gaillard I, 2002, EUR J NEUROSCI, V15, P409, DOI 10.1046/j.0953-816x.2001.01871.x; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hamana H, 2003, CHEM SENSES, V28, P87, DOI 10.1093/chemse/28.2.87; Illing N, 2002, MOL CELL NEUROSCI, V20, P225, DOI 10.1006/mcne.2002.1106; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Kenakin T, 2002, TRENDS PHARMACOL SCI, V23, P403, DOI 10.1016/S0165-6147(02)02046-1; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Malnic B, 2004, P NATL ACAD SCI USA, V101, P2584, DOI 10.1073/pnas.0307882100; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MENCO BPM, 1994, J NEUROCYTOL, V23, P708, DOI 10.1007/BF01181645; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Murrell JR, 1999, J NEUROSCI, V19, P8260; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Oka Y, 2004, EMBO J, V23, P120, DOI 10.1038/sj.emboj.7600032; Pun RYK, 2003, BIOPHYS J, V84, P3425, DOI 10.1016/S0006-3495(03)70064-2; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Sanchez-Montanes MA, 2002, BIOSYSTEMS, V67, P229, DOI 10.1016/S0303-2647(02)00081-3; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; Zhang XM, 2004, GENOMICS, V83, P802, DOI 10.1016/j.ygeno.2003.10.009; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	36	111	116	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11807	11815		10.1074/jbc.M411508200	http://dx.doi.org/10.1074/jbc.M411508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15598656	hybrid			2022-12-27	WOS:000227761800110
J	Corvest, V; Sigalat, C; Venard, R; Falson, P; Mueller, DM; Haraux, F				Corvest, V; Sigalat, C; Venard, R; Falson, P; Mueller, DM; Haraux, F			The binding mechanism of the yeast F-1-ATPase inhibitory peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ATP SYNTHASE; ADENOSINE-TRIPHOSPHATASE INHIBITOR; NUCLEOTIDE-BINDING; CATALYTIC SITES; BETA-SUBUNIT; SUBMITOCHONDRIAL PARTICLES; ALPHA-SUBUNITS; HEART-MITOCHONDRIA; THIOL MODULATION; CARDIAC-MUSCLE	The mechanism of inhibition of yeast mitochondrial F-1-ATPase by its natural regulatory peptide, IF1, was investigated by correlating the rate of inhibition by IF1 with the nucleotide occupancy of the catalytic sites. Nucleotide occupancy of the catalytic sites was probed by fluorescence quenching of a tryptophan, which was engineered in the catalytic site (beta-Y345W). Fluorescence quenching of a beta-Trp345 indicates that the binding of MgADP to F-1 can be described as 3 binding sites with dissociation constants of K-d1 = 10 +/- 2 nM, K-d2 +/- 0.22 +/- 0.03 mu M, and K-d3 = 16.3 +/- 0.2 = mu M. In addition, the ATPase activity of the beta-Trp(345) enzyme followed simple Michaelis-Menten kinetics with a corresponding K-m of 55 mu M. Values for the K-d for MgATP were estimated and indicate that the K-m (55 mu M) for ATP hydrolysis corresponds to filling the third catalytic site on F1. IF1 binds very slowly to F-1-ATPase depleted of nucleotides and under unisite conditions. The rate of inhibition by IF1 increased with increasing concentration of MgATP to about 50 mu M, but decreased thereafter. The rate of inhibition was half-maximal at 5 mu M MgATP, which is 10-fold lower than the K-m for ATPase. The variations of the rate of IF1 binding are related to changes in the conformation of the IF1 binding site during the catalytic reaction cycle of ATP hydrolysis. A model is proposed that suggests that IF1 binds rapidly, but loosely to F1 with two or three catalytic sites filled, and is then locked in the enzyme during catalytic hydrolysis of ATP.	CEA Saclay, Dept Biol Joliot Curie, Serv Bioenerget, F-91191 Gif Sur Yvette, France; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Rosalin Franklin Univ Med & Sci, Dept Biochem & Mol Biol, Chicago Med Sch, Chicago, IL 60064 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Chicago Medical School; Rosalind Franklin University Medical & Science	Haraux, F (corresponding author), CEA Saclay, Dept Biol Joliot Curie, Serv Bioenerget, F-91191 Gif Sur Yvette, France.	francis.haraux@cea.fr		Falson, Pierre/0000-0002-9760-4577	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067091, R01GM066223] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM066223, R01-GM067091] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BAUBICHON H, 1981, BIOCHEM BIOPH RES CO, V100, P1032, DOI 10.1016/0006-291X(81)91927-6; BELTRAN C, 1984, EUR J BIOCHEM, V144, P151, DOI 10.1111/j.1432-1033.1984.tb08443.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Boyer PD, 2002, FEBS LETT, V512, P29, DOI 10.1016/S0014-5793(02)02293-7; Cabezon E, 2003, NAT STRUCT BIOL, V10, P744, DOI 10.1038/nsb966; DREYFUS G, 1981, BIOCHEM BIOPH RES CO, V100, P400, DOI 10.1016/S0006-291X(81)80110-6; FALSON P, 1986, J BIOL CHEM, V261, P7151; Galkin M, 2004, EUR J BIOCHEM, V271, P1963, DOI 10.1111/j.1432-1033.2004.04108.x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOMEZFERNANDEZ JC, 1978, BIOCHEM J, V176, P967, DOI 10.1042/bj1760967; Green DW, 2000, BBA-BIOENERGETICS, V1458, P343, DOI 10.1016/S0005-2728(00)00085-2; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; He XD, 2000, J BIOL CHEM, V275, P13250, DOI 10.1074/jbc.275.18.13250; HUSAIN I, 1985, BIOCHIM BIOPHYS ACTA, V806, P64, DOI 10.1016/0005-2728(85)90082-9; HUSAIN I, 1983, FEBS LETT, V160, P110, DOI 10.1016/0014-5793(83)80947-8; Ichikawa N, 1996, J BIOCHEM-TOKYO, V119, P193; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; JACKSON PJ, 1988, FEBS LETT, V229, P224, DOI 10.1016/0014-5793(88)80832-9; JAULT JM, 1993, J BIOL CHEM, V268, P1558; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KLEIN G, 1983, J BIOENERG BIOMEMBR, V15, P347, DOI 10.1007/BF00751055; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; KLEIN G, 1977, FEBS LETT, V84, P129, DOI 10.1016/0014-5793(77)81072-7; LIPPE G, 1988, BIOCHIM BIOPHYS ACTA, V933, P12, DOI 10.1016/0005-2728(88)90051-5; LIPPE G, 1988, BIOCHIM BIOPHYS ACTA, V933, P1, DOI 10.1016/0005-2728(88)90050-3; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; LOPEZMEDIAVILLA C, 1993, EUR J BIOCHEM, V215, P487, DOI 10.1111/j.1432-1033.1993.tb18058.x; MATSUBARA H, 1981, J BIOCHEM-TOKYO, V90, P1159, DOI 10.1093/oxfordjournals.jbchem.a133568; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Milgrom YM, 1998, BIOCHEM J, V330, P1037; MILGROM YM, 1989, FEBS LETT, V246, P202, DOI 10.1016/0014-5793(89)80283-2; MIMURA H, 1993, J BIOCHEM-TOKYO, V113, P350, DOI 10.1093/oxfordjournals.jbchem.a124050; Minauro-Sanmiguel F, 2002, J BIOENERG BIOMEMBR, V34, P433, DOI 10.1023/A:1022514008462; MUELLER DM, 1994, EUR J BIOCHEM, V222, P991, DOI 10.1111/j.1432-1033.1994.tb18950.x; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Nishizaka T, 2004, NAT STRUCT MOL BIOL, V11, P142, DOI 10.1038/nsmb721; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NORLING B, 1990, EUR J BIOCHEM, V188, P247, DOI 10.1111/j.1432-1033.1990.tb15396.x; PANCHENKO MV, 1986, EBEC SHORT REPORTS, V4, P267; POWER J, 1983, BIOCHIM BIOPHYS ACTA, V724, P128, DOI 10.1016/0005-2728(83)90034-8; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; ROUSLIN W, 1983, J BIOL CHEM, V258, P9657; ROUSLIN W, 1987, J BIOL CHEM, V262, P3472; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; SCHWERZMANN K, 1986, ARCH BIOCHEM BIOPHYS, V250, P1, DOI 10.1016/0003-9861(86)90695-8; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SHEN HG, 1994, J BIOL CHEM, V269, P9424; VANDESTADT RJ, 1973, BIOCHIM BIOPHYS ACTA, V292, P338, DOI 10.1016/0005-2728(73)90040-6; Venard R, 2003, BIOCHEMISTRY-US, V42, P7626, DOI 10.1021/bi034394t; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P12042, DOI 10.1021/bi981089c; Weber J, 2001, J BIOL CHEM, V276, P35422, DOI 10.1074/jbc.M104946200; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WONG SY, 1982, BIOCHEMISTRY-US, V21, P5781, DOI 10.1021/bi00266a009; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513	61	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9927	9936		10.1074/jbc.M414098200	http://dx.doi.org/10.1074/jbc.M414098200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640141	hybrid			2022-12-27	WOS:000227559600024
J	Li, YZ; Batra, S; Sassano, A; Majchrzak, B; Levy, DE; Gaestel, M; Fish, EN; Davis, RJ; Platanias, LC				Li, YZ; Batra, S; Sassano, A; Majchrzak, B; Levy, DE; Gaestel, M; Fish, EN; Davis, RJ; Platanias, LC			Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by Type I interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MEDIATES TYROSINE PHOSPHORYLATION; STAT1 SERINE PHOSPHORYLATION; CRKL ADAPTER PROTEIN; P38 MAP KINASE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TNF-ALPHA; JAK-STAT; PHOSPHATIDYLINOSITOL 3-KINASE	There is accumulating evidence that the p38 MAP kinase pathway plays important roles in Type I interferon (IFN) signaling, but the mechanisms regulating p38 activation during engagement of the Type I IFN receptor remain to be defined. We sought to identify the events that lead to activation of the p38 MAP kinase in response to Type I IFNs. Our data demonstrate that treatment of sensitive cell lines with IFN alpha results in activation of both MAP kinase kinase 3 (MKK3) and MAP kinase kinase 6 (MKK6). Such IFN-inducible activation of MKK3 and MKK6 is essential for downstream phosphorylation and activation of the p38 MAP kinase, as shown by studies using mouse embryonic fibroblasts (MEFs) with targeted disruption of the Mkk3 and Mkk6 genes (MKK3-/- MKK6-/-). Similarly, IFN-dependent activation of the downstream effectors of p38, MAPKAPK-2 and MAPKAPK-3, is not detectable in cells lacking Mkk3 and Mkk6, demonstrating that the function of these MAP kinase kinases is required for full activation of the p38 pathway. To define the functional relevance of MKK3/6 engagement in Type I IFN signaling, IFN-inducible gene transcription was evaluated in the MKK3/MKK6 double knock-out cells. IFN alpha- and IFN beta-dependent transcription via either interferon-stimulated response element or IFN gamma activated site elements was defective in MKK3 -/-/MKK6 -/- MEFs in luciferase reporter assays. In addition, IFN-dependent induction of two genes known to be of importance in the generation of IFN responses, Isg15 and Irf-9, was diminished in the absence of Mkk3 and Mkk6. The effects of Mkk3 and Mkk6 on IFN-dependent transcription were unrelated to any effects on the phosphorylation and activation of STAT proteins, indicating the presence of a STAT-independent mechanism. Altogether, our findings demonstrate that MKK3 and MKK6 are rapidly activated during engagement of the Type I IFN receptor and play important roles in Type I IFN signaling and the generation of IFN responses.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Lakeside Vet Affairs Med Ctr, Chicago, IL 60611 USA; Univ Hlth Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany; Univ Massachusetts, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Program Mol Med, Worcester, MA 01605 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; New York University; Hannover Medical School; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks St,Olson 8250, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Gaestel, Matthias/A-6560-2013; Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Gaestel, Matthias/0000-0002-4944-4652; Levy, David/0000-0002-7320-7788	NCI NIH HHS [CA77816, CA94079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094079, R01CA077816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Caraglia M, 1999, CELL DEATH DIFFER, V6, P773, DOI 10.1038/sj.cdd.4400550; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Doualla-Bell F, 2001, ENDOCRINOLOGY, V142, P5107, DOI 10.1210/en.142.12.5107; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Lekmine F, 2002, BIOCHEM BIOPH RES CO, V291, P744, DOI 10.1006/bbrc.2002.6516; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; MORIGUCHI T, 1996, J BIOL CHEM, V271, P13765; MORIGUCHI T, 1996, J BIOL CHEM, V271, P13775; Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salojin KV, 1999, J IMMUNOL, V163, P844; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Srivastava KK, 2004, J BIOL CHEM, V279, P29911, DOI 10.1074/jbc.M401997200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Verma A, 2002, LEUKEMIA LYMPHOMA, V43, P703, DOI 10.1080/10428190290016782; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; WEN Z, 1995, CELL, V28, P241; Winston BW, 1997, J IMMUNOL, V159, P4491; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	66	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10001	10010		10.1074/jbc.M410972200	http://dx.doi.org/10.1074/jbc.M410972200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644321	hybrid			2022-12-27	WOS:000227559600033
J	Cui, HJ; Li, T; Ding, HF				Cui, HJ; Li, T; Ding, HF			Linking of N-Myc to death receptor machinery in neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; P53 GENE-MUTATIONS; CYTOCHROME-C; CASPASE ACTIVATION; TRANSCRIPTIONAL TARGET; TUMOR; RESISTANCE; EXPRESSION; PATHWAY	The oncogene MYCN is amplified in aggressive neuroblastomas in which caspase-8, an essential component of death receptor pathways, is frequently inactivated, suggesting a critical role of death receptor-mediated apoptosis in suppression of N-Myc oncogenic activity. Elevated levels of N-Myc sensitize neuroblastoma cells to apoptosis induced by various death ligands. Using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis as a model, we define the mechanism underlying the sensitization effect. In neuroblastoma cells with increased expression of N-Myc, TRAIL triggers high levels of caspase-8 activation and Bid cleavage, leading to release of cytochrome c and Smac/DIABLO from mitochondria. However, the apoptotic process requires Smac/DIABLO, but not cytochrome c-mediated caspase-9 activation. N-Myc sensitizes neuroblastoma cells to TRAIL by up-regulating TRAIL receptor-2/DR5/KILLER and Bid. Moreover, DR5 mRNA is increased after N-Myc overexpression, and the human DR5 promoter contains two noncanonical E-boxes critical for the transcriptional activation by N-Myc. These findings establish a mechanistic link between N-Myc and death receptor machinery, which may serve as a checkpoint to guard the cell from N-Myc-initiated tumorigenesis.	Med Coll Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA		Ding, HF (corresponding author), Med Coll Ohio, Dept Biochem & Canc Biol, Hlth Sci Bldg,Rm 468,3035 Arlington Ave, Toledo, OH 43614 USA.	hding@mco.edu		Ding, Han-Fei/0000-0001-5702-3439				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cui HJ, 2002, MOL CANCER THER, V1, P679; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eggert A, 2001, CANCER RES, V61, P1314; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Goldman SC, 1996, AM J PATHOL, V148, P1381; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; IMAMURA J, 1993, CANCER RES, V53, P4053; Jasty R, 1998, MOL GENET METAB, V65, P155, DOI 10.1006/mgme.1998.2747; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Keshelava N, 2001, CANCER RES, V61, P6185; Kim KH, 2000, CLIN CANCER RES, V6, P335; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KOMURO H, 1993, CANCER RES, V53, P5284; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; McKenzie PP, 1999, CLIN CANCER RES, V5, P4199; Mitchell KO, 2000, CANCER RES, V60, P6318; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; Nesterov A, 2004, CANCER RES, V64, P3922, DOI 10.1158/0008-5472.CAN-03-2219; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Reichmann E, 2002, SEMIN CANCER BIOL, V12, P309, DOI 10.1016/S1044-579X(02)00017-2; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2002, ONCOGENE, V21, P1848, DOI 10.1038/sj.onc.1205180; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; VOGAN K, 1993, CANCER RES, V53, P5269; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	76	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9474	9481		10.1074/jbc.M410450200	http://dx.doi.org/10.1074/jbc.M410450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632181	hybrid			2022-12-27	WOS:000227453100101
J	Folgering, JHA; Moe, PC; Wolters, GKS; Blount, P; Poolman, B				Folgering, JHA; Moe, PC; Wolters, GKS; Blount, P; Poolman, B			Lactococcus lactis uses MscL as its principal mechanosensitive channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED GENE-EXPRESSION; ESCHERICHIA-COLI-CELLS; STREPTOCOCCUS-LACTIS; MEMBRANE-PROTEINS; LARGE-CONDUCTANCE; MYCOBACTERIUM-TUBERCULOSIS; GLYCINE BETAINE; SINGLE RESIDUE; IN-VIVO; TRANSPORT	The functions of the mechanosensitive channels from Lactococcus lactis were determined by biochemical, physiological, and electrophysiological methods. Patch-clamp studies showed that the genes yncB and mscL encode MscS and MscL-like channels, respectively, when expressed in Escherichia coli or if the gene products were purified and reconstituted in proteoliposomes. However, unless yncB was expressed in trans, wild type membranes of L. lactis displayed only MscL activity. Membranes prepared from an mscL disruption mutant did not show any mechanosensitive channel activity, irrespective of whether the cells had been grown on low or high osmolarity medium. In osmotic downshift assays, wild type cells survived and retained 20% of the glycine betaine internalized under external high salt conditions. On the other hand, the mscL disruption mutant retained 40% of internalized glycine betaine and was significantly compromised in its survival upon osmotic downshifts. The data strongly suggest that L. lactis uses MscL as the main mechanosensitive solute release system to protect the cells under conditions of osmotic downshift.	Univ Groningen, Dept Biochem, Groninger Biomol Sci, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biochem, Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biochem, Mat Sci Ctr, NL-9747 AG Groningen, Netherlands; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Groningen; University of Groningen; University of Groningen; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groninger Biomol Sci, NL-9747 AG Groningen, Netherlands.	B.Poolman@rug.nl	Poolman, Bert/D-1882-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60818] Funding Source: Medline; NIGMS NIH HHS [GM61028, R01 GM061028] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajouz B, 1998, J BIOL CHEM, V273, P26670, DOI 10.1074/jbc.273.41.26670; ALTINGMEES MA, 1989, NUCLEIC ACIDS RES, V17, P9494, DOI 10.1093/nar/17.22.9494; Bartlett JL, 2004, P NATL ACAD SCI USA, V101, P10161, DOI 10.1073/pnas.0402040101; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Batiza AF, 2002, P NATL ACAD SCI USA, V99, P5643, DOI 10.1073/pnas.082092599; Blount P, 1999, Methods Enzymol, V294, P458; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chiang CS, 2004, BIOPHYS J, V86, P2846, DOI 10.1016/S0006-3495(04)74337-4; CHOPIN A, 1984, PLASMID, V11, P260, DOI 10.1016/0147-619X(84)90033-7; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Drouault S, 2000, APPL ENVIRON MICROB, V66, P588, DOI 10.1128/AEM.66.2.588-598.2000; Folgering JHA, 2004, LANGMUIR, V20, P6985, DOI 10.1021/la048942v; GASSON MJ, 1983, J BACTERIOL, V154, P1; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hamoen LW, 2002, NUCLEIC ACIDS RES, V30, P5517, DOI 10.1093/nar/gkf698; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Kunji ERS, 2003, BBA-BIOMEMBRANES, V1610, P97, DOI 10.1016/S0005-2736(02)00712-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Maurer JA, 2000, J BIOL CHEM, V275, P22238, DOI 10.1074/jbc.M003056200; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; Morbach S, 2002, CHEMBIOCHEM, V3, P385, DOI 10.1002/1439-7633(20020503)3:5<384::AID-CBIC384>3.0.CO;2-H; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; PEARCE LE, 1969, NZ J DAIRY SCI TECHN, V4, P246; Poolman B, 2004, BBA-BIOMEMBRANES, V1666, P88, DOI 10.1016/j.bbamem.2004.06.013; Poolman B, 2002, MOL MICROBIOL, V44, P889, DOI 10.1046/j.1365-2958.2002.02894.x; POOLMAN B, 1988, J BACTERIOL, V170, P700, DOI 10.1128/jb.170.2.700-707.1988; Ruffert S, 1999, J BACTERIOL, V181, P1673, DOI 10.1128/JB.181.5.1673-1676.1999; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Stokes NR, 2003, P NATL ACAD SCI USA, V100, P15959, DOI 10.1073/pnas.2536607100; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; Sukharev SI, 1999, J GEN PHYSIOL, V113, P525, DOI 10.1085/jgp.113.4.525; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Van der Heide T, 2000, J BACTERIOL, V182, P203, DOI 10.1128/JB.182.1.203-206.2000; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; van Montfort BA, 2002, BBA-BIOENERGETICS, V1555, P111, DOI 10.1016/S0005-2728(02)00264-5; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Wood JM, 2001, COMP BIOCHEM PHYS A, V130, P437, DOI 10.1016/S1095-6433(01)00442-1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2; Yoshimura K, 2001, BIOPHYS J, V80, P2198, DOI 10.1016/S0006-3495(01)76192-9	45	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8784	8792		10.1074/jbc.M411732200	http://dx.doi.org/10.1074/jbc.M411732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15613476	Green Published, hybrid			2022-12-27	WOS:000227453100021
J	Marta, CB; Montano, MB; Taylor, CM; Taylor, AL; Bansal, R; Pfeiffer, SE				Marta, CB; Montano, MB; Taylor, CM; Taylor, AL; Bansal, R; Pfeiffer, SE			Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein - Potential implications for multiple sclerosis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; ANCHORED PROTEINS; LIPID RAFTS; ANNEXIN-VI; CELL; GROWTH; FYN; KINASE; DEMYELINATION	Antibody-induced demyelination is an important component of pathology in multiple sclerosis. In particular, antibodies to myelin oligodendrocyte glycoprotein (MOG) are elevated in multiple sclerosis patients, and they have been implicated as mediators of demyelination. We have shown previously that antibody cross-linking of MOG in oligodendrocytes results in the repartitioning of MOG into glycosphingolipid-cholesterol membrane microdomains ("lipid rafts"), followed by changes in the phosphorylation of specific proteins, including dephosphorylation of beta-tubulin and the beta subunit of the trimeric G protein and culminating in rapid and dramatic morphological alterations. In order to further elucidate the mechanism of anti-MOG-mediated demyelination, we have carried out a proteomic analysis to identify the set of proteins for which the phosphorylation states or expression levels are altered upon anti-MOG treatment. We demonstrate that treatment of oligodendrocytes with anti-MOG alone leads to an increase in calcium influx and activation of the MAPK/Akt pathways that is independent of MOG repartitioning. However, further cross-linking of anti-MOG.MOG complexes with a secondary anti-IgG results in the lipid raft-dependent phosphorylation of specific proteins related to cellular stress response and cytoskeletal stability. Oligodendrocyte survival is not compromised by these treatments. We discuss the possible significance of the anti-MOG-induced signaling cascade in relation to the initial steps of MOG-mediated demyelination.	Univ Connecticut, Sch Med, Dept Neurosci, Farmington, CT 06030 USA	University of Connecticut	Marta, CB (corresponding author), Univ Connecticut, Sch Med, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	Marta@up.uchc.edu			NINDS NIH HHS [NS41078, NS10861] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041078] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aquino DA, 1997, J NEUROPATH EXP NEUR, V56, P664; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; Bansal R, 1996, MOL CELL NEUROSCI, V7, P263, DOI 10.1006/mcne.1996.0020; BANSAL R, 1989, J NEUROSCI RES, V24, P548, DOI 10.1002/jnr.490240413; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Breithaupt C, 2003, P NATL ACAD SCI USA, V100, P9446, DOI 10.1073/pnas.1133443100; Casaccia-Bonnefil P, 1999, MICROSC RES TECHNIQ, V45, P217, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<217::AID-JEMT5>3.0.CO;2-5; Cross AH, 2000, NEUROLOGY, V54, P1214, DOI 10.1212/WNL.54.6.1214; DEROSBO NK, 1990, J NEUROCHEM, V55, P583; Diverse-Pierluissi M, 2000, J BIOL CHEM, V275, P28380, DOI 10.1074/jbc.M003571200; Fogli A, 2002, NEUROLOGY, V59, P1966, DOI 10.1212/01.WNL.0000041666.76863.47; Freye-Minks C, 2003, BIOCHEMISTRY-US, V42, P620, DOI 10.1021/bi026742h; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GARD AL, 1989, DEVELOPMENT, V106, P119; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; Iglesias A, 2001, GLIA, V36, P220, DOI 10.1002/glia.1111; JANEWAY C, 1994, IMMUNOBIOLOGY IMMUNE, P822; Johns TG, 1999, J NEUROCHEM, V72, P1, DOI 10.1046/j.1471-4159.1999.0720001.x; Johns TG, 1997, MOL IMMUNOL, V34, P33, DOI 10.1016/S0161-5890(97)00005-9; Kim T, 1999, J NEUROCYTOL, V28, P281, DOI 10.1023/A:1007001427597; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; Kramer EM, 1997, J BIOL CHEM, V272, P8937; Lassmann H, 2003, J NEUROL NEUROSUR PS, V74, P695, DOI 10.1136/jnnp.74.6.695; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319-03.2004; LININGTON C, 1988, AM J PATHOL, V130, P443; LINNINGTON C, 1984, J NEUROIMMUNOL, V6, P387, DOI 10.1016/0165-5728(84)90064-X; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; Liu HN, 1999, MOL BRAIN RES, V66, P50, DOI 10.1016/S0169-328X(99)00009-1; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; Marta CB, 2004, NEURON GLIA BIOL, V1, P35, DOI 10.1017/s1740925x04000067; Marta CB, 2003, J NEUROSCI, V23, P5461; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Niederost B, 2002, J NEUROSCI, V22, P10368; Oh LYS, 2003, J NEUROSCI, V23, P883; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Park SK, 2001, J CELL BIOL, V154, P1245, DOI 10.1083/jcb.200104025; Pedraza L, 2001, NEURON, V30, P335, DOI 10.1016/S0896-6273(01)00306-3; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; Reindl M, 1999, BRAIN, V122, P2047, DOI 10.1093/brain/122.11.2047; Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Rus HG, 2001, IMMUNOL REV, V180, P49, DOI 10.1034/j.1600-065X.2001.1800104.x; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; SCHLUESENER HJ, 1987, J IMMUNOL, V139, P4016; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Stariha RL, 2001, MICROSC RES TECHNIQ, V52, P680, DOI 10.1002/jemt.1052.abs; Taylor CM, 2004, P NATL ACAD SCI USA, V101, P4643, DOI 10.1073/pnas.0400922101; Taylor CM, 2003, PROTEOMICS, V3, P1303, DOI 10.1002/pmic.200300451; Viehover A, 2001, DEV NEUROSCI-BASEL, V23, P377, DOI 10.1159/000048721; Von Budingen HC, 2001, J CLIN IMMUNOL, V21, P155; WATANABE T, 1994, J BIOL CHEM, V269, P17656; Wolf RM, 2001, J NEUROBIOL, V49, P62, DOI 10.1002/neu.1066	58	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8985	8993		10.1074/jbc.M413174200	http://dx.doi.org/10.1074/jbc.M413174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15634682	hybrid			2022-12-27	WOS:000227453100045
J	Park, Y; Maizels, ET; Feiger, ZJ; Alam, H; Peters, CA; Woodruff, TK; Unterman, TG; Lee, EJ; Jameson, JL; Hunzicker-Dunn, M				Park, Y; Maizels, ET; Feiger, ZJ; Alam, H; Peters, CA; Woodruff, TK; Unterman, TG; Lee, EJ; Jameson, JL; Hunzicker-Dunn, M			Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FOLLICLE-STIMULATING-HORMONE; FORKHEAD TRANSCRIPTION FACTORS; STEROIDOGENIC FACTOR-I; PROTEIN-KINASE-B; ELEMENT-BINDING PROTEIN; HISTONE H3 PHOSPHORYLATION; NUCLEAR ANTIGEN PCNA; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; MESSENGER-RNA	Ovarian follicles undergo exponential growth in response to follicle-stimulating hormone (FSH), largely as a result of the proliferation of granulosa cells (GCs). In vitro under serum-free conditions, rat GCs differentiate in response to FSH but do not proliferate unless activin is also present. In the presence of FSH plus activin, GCs exhibit enhanced expression of cyclin D2 as well as inhibin-alpha, aromatase, steroidogenic factor-1 (SF-1), cholesterol side chain (SCC), and epiregulin. In this report we sought to identify the signaling pathways by which FSH and activin promote GC proliferation and differentiation. Our results show that these responses are associated with prolonged Akt phosphorylation relative to time-matched controls and are dependent on phosphatidylinositol 3- kinase (PI 3- kinase) and Smad2/3 signaling, based on the ability of the PI 3- kinase inhibitor LY294002 or infection with adenoviral dominant negative Smad3 ( DN- Smad3) mutant to attenuate induction of cyclin D2, inhibin-alpha, aromatase, SCC, SF-1, and epiregulin. The DN- Smad3 mutant also abolished prolonged Akt phosphorylation stimulated by FSH plus activin 24 h posttreatment. Infection with the adenoviral constitutively active forkhead box-containing protein, O subfamily (FOXO)1 mutant suppressed induction of cyclin D2, aromatase, inhibin-alpha, SF-1, and epiregulin. Transient transfections of GCs with constitutively active FOXO1 mutant also suppressed cyclin D2, inhibin-alpha, and epiregulin promoter-reporter activities. Chromatin immunoprecipitation results demonstrate in vivo the association of FOXO1 with the cyclin D2 promoter in untreated GCs and release of FOXO1 from the cyclin D2 promoter upon addition of FSH plus activin. These results suggest that proliferation and differentiation of GCs in response to FSH plus activin requires both removal of FOXO1- dependent repression and positive signaling from Smad2/ 3.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	mhd@Northwestern.edu		Woodruff, Teresa/0000-0002-1197-3399; Maizels, Evelyn/0000-0001-9072-1095; Jameson, James/0000-0001-9538-4059	NICHD NIH HHS [R01 HD044464, P01 HD21921, P01 HD021921] Funding Source: Medline; NIDDK NIH HHS [R01 DK041430, R01 DK41430] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam H, 2004, J BIOL CHEM, V279, P19431, DOI 10.1074/jbc.M401235200; Bai J, 2004, J BIOL CHEM, V279, P38710, DOI 10.1074/jbc.M403329200; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CARR DW, 1993, J BIOL CHEM, V268, P20729; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Cottom J, 2003, J BIOL CHEM, V278, P7167, DOI 10.1074/jbc.M203901200; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Cunningham MA, 2003, ENDOCRINOLOGY, V144, P5585, DOI 10.1210/en.2003-0678; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; DORRINGTON J, 1988, ENDOCRINOLOGY, V123, P353, DOI 10.1210/endo-123-1-353; El-Hefnawy T, 2001, ENDOCRINOLOGY, V142, P4357, DOI 10.1210/en.142.10.4357; Falender AE, 2003, ENDOCRINOLOGY, V144, P3598, DOI 10.1210/en.2002-0137; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Heckert LL, 2001, MOL ENDOCRINOL, V15, P704, DOI 10.1210/me.15.5.704; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; HIRSHFIELD AN, 1991, INT REV CYTOL, V124, P43, DOI 10.1016/s0074-7696(08)61524-7; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; Hu CL, 2004, MOL ENDOCRINOL, V18, P326, DOI 10.1210/me.2003-0178; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; Ishikawa T, 2004, MOL CELL BIOL, V24, P8323, DOI 10.1128/MCB.24.19.8323-8331.2004; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Khan SA, 2002, ENDOCRINOLOGY, V143, P2259, DOI 10.1210/en.143.6.2259; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kubo T, 1998, BIOL REPROD, V58, P712, DOI 10.1095/biolreprod58.3.712; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Lanuza GM, 1999, ENDOCRINOLOGY, V140, P2549, DOI 10.1210/en.140.6.2549; LAPOLT PS, 1989, MOL ENDOCRINOL, V3, P1666, DOI 10.1210/mend-3-10-1666; Lee EJ, 1999, J CLIN ENDOCR METAB, V84, P786, DOI 10.1210/jc.84.2.786; Lee EJ, 2000, NEUROSURGERY, V46, P1461, DOI 10.1097/00006123-200006000-00029; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI RH, 1995, ENDOCRINOLOGY, V136, P849, DOI 10.1210/en.136.3.849; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lutz M, 2002, CELL SIGNAL, V14, P977, DOI 10.1016/S0898-6568(02)00058-X; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; McMullen ML, 2001, ENDOCRINOLOGY, V142, P5005, DOI 10.1210/en.142.11.5005; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miro F, 1996, ENDOCRINOLOGY, V137, P464, DOI 10.1210/en.137.2.464; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ogawa T, 2003, MOL CELL ENDOCRINOL, V210, P31, DOI 10.1016/j.mce.2003.08.008; OLIVER JE, 1989, ENDOCRINOLOGY, V124, P2671, DOI 10.1210/endo-124-6-2671; Park Y, 2003, DIABETOLOGIA, V46, P365, DOI 10.1007/s00125-003-1037-4; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; RICHARDS J S, 1987, Steroids, V50, P393, DOI 10.1016/0039-128X(87)90027-4; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Roh JS, 2003, ENDOCRINOLOGY, V144, P172, DOI 10.1210/en.2002-220618; Rudolph S A, 1979, Adv Cyclic Nucleotide Res, V10, P107; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Saxena D, 2004, ENDOCRINOLOGY, V145, P3821, DOI 10.1210/en.2004-0423; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200; Sekiguchi T, 2002, ENDOCRINOLOGY, V143, P4718, DOI 10.1210/en.2002-220440; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shimasaki S, 2003, REPRODUCTION, P323; Shimasaki S, 2004, ENDOCR REV, V25, P72, DOI 10.1210/er.2003-0007; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Suszko MI, 2003, MOL ENDOCRINOL, V17, P318, DOI 10.1210/me.2002-0081; Takahashi-Yanaga F, 2003, J BIOL CHEM, V278, P9663, DOI 10.1074/jbc.M205768200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tomic D, 2004, MOL ENDOCRINOL, V18, P2224, DOI 10.1210/me.2003-0414; Tomic D, 2002, BIOL REPROD, V66, P917, DOI 10.1095/biolreprod66.4.917; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WOODRUFF TK, 1987, MOL ENDOCRINOL, V1, P561, DOI 10.1210/mend-1-8-561; XIAO S, 1992, ENDOCRINOLOGY, V131, P1009, DOI 10.1210/en.131.3.1009; Xu J, 2002, BIOL REPROD, V66, P1571, DOI 10.1095/biolreprod66.6.1571; Yazawa T, 2003, ENDOCRINOLOGY, V144, P1920, DOI 10.1210/en.2002-221070; Zeleznik AJ, 2003, ENDOCRINOLOGY, V144, P3985, DOI 10.1210/en.2003-0293; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450	110	128	139	1	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9135	9148		10.1074/jbc.M409486200	http://dx.doi.org/10.1074/jbc.M409486200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15613482	hybrid, Green Accepted			2022-12-27	WOS:000227453100063
J	Geurtsen, J; Steeghs, L; ten Hove, J; van der Ley, P; Tommassen, J				Geurtsen, J; Steeghs, L; ten Hove, J; van der Ley, P; Tommassen, J			Dissemination of lipid A deacylases (PagL) among gram-negative bacteria - Identification of active-site histidine and serine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STRUCTURAL-CHARACTERIZATION; MEMBRANE ENZYME; SALMONELLA; LIPOPOLYSACCHARIDE; RESISTANCE; COMPONENT; GENES; PHOSPHOLIPIDS; EXPRESSION	Lipopolysaccharide (LPS) is one of the main constituents of the Gram-negative bacterial outer membrane. It usually consists of a highly variable O-antigen, a less variable core oligosaccharide, and a highly conserved lipid moiety, designated lipid A. Several bacteria are capable of modifying their lipid A architecture in response to external stimuli. The outer membrane-localized lipid A 3-O-deacylase, encoded by the pagL gene of Salmonella enterica serovar Typhimurium, removes the fatty acyl chain from the 3 position of lipid A. Although a similar activity was reported in some other Gram-negative bacteria, the corresponding genes could not be identified. Here, we describe the presence of pagL homologs in a variety of Gram-negative bacteria. Although the overall sequence similarity is rather low, a conserved domain could be distinguished in the C-terminal region. The activity of the Pseudomonas aeruginosa and Bordetella bronchiseptica pagL homologs was confirmed upon expression in Escherichia coli, which resulted in the removal of an R-3-hydroxymyristoyl group from lipid A. Upon deacylation by PagL, E. coli lipid A underwent another modification, which was the result of the activity of the endogenous palmitoyl transferase PagP. Furthermore, we identified a conserved histidine-serine couple as active site residues, suggesting a catalytic mechanism similar to serine hydrolases. The biological function of PagL remains unclear. However, because PagL homologs were found in both pathogenic and nonpathogenic species, PagL-mediated deacylation of lipid A probably does not have a dedicated role in pathogenicity.	Univ Utrecht, Dept Mol Microbiol, NL-3584 CH Utrecht, Netherlands; Netherlands Vaccine Inst, NL-3720 AL Bilthoven, Netherlands; Univ Utrecht, Med Ctr, Lab Immunotherapy, NL-3508 AB Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, Lab Organ Analyt Chem, NL-3720 BA Bilthoven, Netherlands	Utrecht University; Utrecht University; Netherlands National Institute for Public Health & the Environment	Geurtsen, J (corresponding author), Univ Utrecht, Dept Mol Microbiol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	j.j.g.geurtsen@bio.uu.nl	Tommassen, Jan/I-1690-2016	Tommassen, Jan/0000-0001-7633-4945				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Caroff M, 2002, MICROBES INFECT, V4, P915, DOI 10.1016/S1286-4579(02)01612-X; DEKKER N, 1995, EUR J BIOCHEM, V232, P214, DOI 10.1111/j.1432-1033.1995.tb20801.x; Ernst RK, 1999, J INFECT DIS, V179, pS326, DOI 10.1086/513850; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 1998, MICROB PATHOGENESIS, V25, P77, DOI 10.1006/mpat.1998.0217; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HAAS D, 1976, MOL GEN GENET, V144, P243, DOI 10.1007/BF00341722; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; Kol MA, 2003, J BIOL CHEM, V278, P24586, DOI 10.1074/jbc.M301875200; KULSHIN VA, 1991, EUR J BIOCHEM, V198, P697, DOI 10.1111/j.1432-1033.1991.tb16069.x; KUMADA H, 1995, J BACTERIOL, V177, P2098, DOI 10.1128/jb.177.8.2098-2106.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Robey M, 2001, INFECT IMMUN, V69, P4276, DOI 10.1128/IAI.69.7.4276-4286.2001; Sambrook J., 1989, MOL CLONING, pA1; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; Steeghs L, 2002, CELL MICROBIOL, V4, P599, DOI 10.1046/j.1462-5822.2002.00214.x; Tanamoto K, 2000, J IMMUNOL, V164, P3149, DOI 10.4049/jimmunol.164.6.3149; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; TOMMASSEN J, 1988, NATO ASI SER, V16, P351; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WINKLER KC, 1948, ARCH BIOCHEM, V18, P97	49	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8248	8259		10.1074/jbc.M414235200	http://dx.doi.org/10.1074/jbc.M414235200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611102	hybrid			2022-12-27	WOS:000227395700098
J	Wang, LC; Okitsu, CY; Zandi, E				Wang, LC; Okitsu, CY; Zandi, E			Tumor necrosis factor alpha-dependent drug resistance to purine and pyrimidine analogues in human colon tumor cells mediated through IKK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GROWTH ARREST; CANCER-CELLS; EXPRESSION; ANTIMETABOLITES; PROLIFERATION; INTERLEUKIN-1; ACTIVATION; MECHANISMS; RECEPTORS	Development of drug resistance in cancer is one of the main challenges in chemotherapy, and many mechanisms are still unknown. In this study, we show that tumor necrosis factor alpha (TNFalpha) increases postdrug survival from 5-fluoro-2'-deoxyuridine (FdUrd) in two human colon tumor cell lines. This resulted in the development of drug-resistant cells in a TNFalpha-dependent manner. Interestingly, although the drug-resistant cells were selected using FdUrd, they are also resistant to a number of other antimetabolites in the DNA synthesis pathway in a TNFalpha-dependent manner. Only in the drug-resistant cells (p35- colo201) TNFalpha treatment resulted in G(0)-G(1) arrest but not in the parental colo201 and other cell types. Blocking TNFalpha-induced cell cycle arrest sensitized drug- resistant cells to FdUrd. TNFalpha-induced cell cycle arrest required IKK. IKK inhibition by a small molecule inhibitor or by the knockdown of IKKalpha, IKKbeta, or RelA/p65 using siRNA, but not the inhibition of JNK, MEK, p38, or caspase-8 pathways, blocked TNFalpha-induced G(0)-G(1) arrest and restored sensitivity to FdUrd of drug-resistant cells. TNFalpha reduced the transcripts and protein levels of phosphorylated retinoblastoma protein (Rb), Rb, E2F1, and Cdk4 only in drugresistant p35-colo201 cells. This effect of TNFalpha was reversed by IKK inhibitor, suggesting that TNFalpha-induced cell cycle arrest is probably due to the reduction of Rb, E2F1, and Cdk4. Taken together, this study shows that, in vitro, TNFalpha-induced cell cycle arrest through IKK can provide a mechanism for the development of drug resistance to anti-cancer drugs, purine and pyrimidine analogues.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Southern California	Zandi, E (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Mol Microbiol & Immunol, 1441 Eastlake Ave, Los Angeles, CA 90033 USA.	Zandi@usc.edu						Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; ARDIZZOIA A, 1992, J BIOL REG HOMEOS AG, V6, P103; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Borrelli E, 1996, CRIT CARE MED, V24, P392, DOI 10.1097/00003246-199603000-00006; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cheng Kang, 1994, Neurologia Medico-Chirurgica, V34, P274, DOI 10.2176/nmc.34.274; Chu E, 1994, Cancer Chemother Biol Response Modif, V15, P1; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; Hatse S, 1999, BIOCHEM PHARMACOL, V58, P539, DOI 10.1016/S0006-2952(99)00035-0; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kinsella AR, 1997, BRIT J CANCER, V75, P935, DOI 10.1038/bjc.1997.164; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Mader RM, 1998, GEN PHARMACOL, V31, P661, DOI 10.1016/S0306-3623(98)00191-8; Merli M, 1999, INT J ONCOL, V14, P1117; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Miwa M, 2001, CANCER BIOTHER RADIO, V16, P317, DOI 10.1089/108497801753131390; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; Nalca A, 1998, J BIOL CHEM, V273, P30517, DOI 10.1074/jbc.273.46.30517; Negus PRM, 1996, WORLD J UROL, V14, P157; Pinedo HM, 1997, LANCET, V349, pS7, DOI 10.1016/S0140-6736(97)90012-X; Pinedo HM, 1996, INT J CANCER, V65, P561; PREWITT TW, 1994, J THORAC CARDIOV SUR, V107, P43; SATTERWHITE DJ, 1994, INVAS METAST, V14, P309; Sherr C J, 2000, Harvey Lect, V96, P73; Skeel RT., 2003, HDB CANC CHEMOTHERAP, V6; SPEARS CP, 1995, HEMATOL ONCOL CLIN N, V9, P397; Takao J, 2003, BRIT J DERMATOL, V148, P680, DOI 10.1046/j.1365-2133.2003.05285.x; TAKEYAMA H, 1991, CANCER RES, V51, P4476; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tisdale MJ, 1999, J NUTR, V129, p243S, DOI 10.1093/jn/129.1.243S; Yamamoto M, 1999, CANCER CHEMOTH PHARM, V43, P43, DOI 10.1007/s002800050861; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	42	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7634	7644		10.1074/jbc.M413384200	http://dx.doi.org/10.1074/jbc.M413384200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611081	hybrid			2022-12-27	WOS:000227395700026
J	McMahon, S; Grondin, F; McDonal, PP; Richard, DE; Dubois, CM				McMahon, S; Grondin, F; McDonal, PP; Richard, DE; Dubois, CM			Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1 - Impact on the bioactivation of proproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 MATRIX-METALLOPROTEINASE; UBIQUITIN-PROTEASOME PATHWAY; FACTOR 1-ALPHA HIF-1-ALPHA; GROWTH-FACTOR EXPRESSION; GENE-EXPRESSION; RESPONSE ELEMENTS; MESSENGER-RNA; ENZYME FURIN; NITRIC-OXIDE; DNA-BINDING	Hypoxia is a common tumorigenesis enhancer, mostly owing to its impact on gene expression of many angiogenic and invasion-related mediators, some of which are natural substrates for the proprotein convertase furin. Analysis of furin promoters revealed the presence of putative binding sites for hypoxia-inducible factor-1 (HIF-1), a transcription complex that plays a pivotal role in cellular adaptation to hypoxia. In fact, we demonstrate herein that the levels of fur mRNA, encoding furin, are remarkably increased upon hypoxic challenge. Cotransfection of a HIF-1alpha dominant negative form in wild-type (WT) cells or transfection of a furin promoter-reporter gene in HIF-1-deficient cells indicated the requirement of HIF-1 for furin promoter activation by hypoxia. Direct HIF-1 action on the furin promoter was identified as a canonical hypoxia-responsive element site with enhancer capability. The hypoxic/HIF-1 regulation of furin correlated with an increased proteolytic activation of the substrates membrane-type 1 matrix metalloproteinase and transforming growth factor-beta1. Our findings unveil a new facet of the physiological consequences of hypoxia/HIF-1, through enhanced furin-induced proteolytic processing/activation of proproteins known to be involved in tumorigenesis.	Univ Sherbrooke, Fac Med, Immunol Div, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Pulm Div, Sherbrooke, PQ J1H 5N4, Canada; Hotel Dieu Quebec, Ctr Rech, Quebec City, PQ, Canada	University of Sherbrooke; University of Sherbrooke; Laval University	Dubois, CM (corresponding author), Univ Sherbrooke, Fac Med, Immunol Div, 3001,12th N Ave, Sherbrooke, PQ J1H 5N4, Canada.	Claire.M.Dubois@USherbrooke.ca	Richard, Darren E./K-6760-2019	Richard, Darren/0000-0003-2690-0480				AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; Bando M, 2002, J BIOCHEM, V132, P127, DOI 10.1093/oxfordjournals.jbchem.a003189; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Beasley NJP, 2002, CANCER RES, V62, P2493; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Blanchette F, 2001, J CELL PHYSIOL, V188, P264, DOI 10.1002/jcp.1116; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; DUGUAY SJ, 1995, J BIOL CHEM, V270, P17566, DOI 10.1074/jbc.270.29.17566; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Goodge KA, 1998, BIOCHEM J, V336, P353, DOI 10.1042/bj3360353; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hubbard FC, 1997, CANCER RES, V57, P5226; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jeong J W, 1999, Angiogenesis, V3, P167, DOI 10.1023/A:1009065709676; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Krishnamachary B, 2003, CANCER RES, V63, P1138; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Laprise MH, 2002, BLOOD, V100, P3578, DOI 10.1182/blood.V100.10.3578; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Lok CN, 2000, J BIOL CHEM, V275, P24185, DOI 10.1074/jbc.M000944200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDonald PP, 1999, J IMMUNOL, V163, P6164; Mercapide J, 2002, CLIN CANCER RES, V8, P1740; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Mori K, 1999, J BIOCHEM-TOKYO, V125, P627, DOI 10.1093/oxfordjournals.jbchem.a022329; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PATEL B, 1994, BIOCHEM MOL BIOL INT, V34, P639; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Posthaus H, 2003, FEBS LETT, V536, P203, DOI 10.1016/S0014-5793(02)03897-8; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rovere C, 1998, BIOCHEM BIOPH RES CO, V246, P155, DOI 10.1006/bbrc.1998.8506; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sasaki K, 1998, J BIOCHEM-TOKYO, V123, P431, DOI 10.1093/oxfordjournals.jbchem.a021955; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Sounni NE, 2003, MATRIX BIOL, V22, P55, DOI 10.1016/S0945-053X(03)00003-9; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Srour N, 2003, FEBS LETT, V554, P275, DOI 10.1016/S0014-5793(03)01159-1; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tsuji A, 1997, J BIOCHEM-TOKYO, V122, P438; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhong H, 1999, CANCER RES, V59, P5830; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598	73	138	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6561	6569		10.1074/jbc.M413248200	http://dx.doi.org/10.1074/jbc.M413248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611046	hybrid			2022-12-27	WOS:000227332700040
J	Yasumi, M; Sakisaka, T; Hoshino, T; Kimura, T; Sakamoto, Y; Yamanaka, T; Ohno, S; Takai, Y				Yasumi, M; Sakisaka, T; Hoshino, T; Kimura, T; Sakamoto, Y; Yamanaka, T; Ohno, S; Takai, Y			Direct binding of lg12 to LGN during mitosis and its requirement for normal cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; POLARITY; DROSOPHILA; NUMA; IDENTIFICATION; LOCALIZATION; MICROTUBULES; ORGANIZATION; NEUROBLAST; PATHWAYS	The Drosophila tumor suppressor protein lethal (2) giant larvae (1(2)gl) is involved in asymmetric cell division during development and epithelial cell polarity through interaction with the aPKC-Par-6 complex. We showed here that Lgl2, a mammalian homolog of 1(2)gl, directly bound to LGN, a mammalian homolog of Partner of inscuteable in HEK293 cells. The C-terminal tail of Lgl2 bound to LGN with a K-d value of about 56 nm. Endogenous Lgl2 formed a complex with aPKC, Par-6, and LGN. This complex formation was enhanced in metaphase of the synchronized cells by treatment with thymidine and nocodazole. Immunofluoreseence staining of the complex was the strongest at the cell periphery of the metaphase cells. Overexpression of the C-terminal tail of Lgl2 induced mis-localization of the nuclear mitotic apparatus protein NuMA and disorganization of the mitotic spindle during mitosis, eventually causing formation of multiple micronuclei. Knockdown of endogenous Lgl (Lgl1 and Lgl2) also induced disorganization of the mitotic spindle, thereby causing formation of multiple micronuclei. The binding between Lg12 and LGN played a role in the mitotic spindle organization through regulating formation of the LGN-NuMA complex. These results indicate that Lg12 forms a Lgl2(.)Par-6(.)aPKC(.)LGN complex, which responds to mitotic signaling to establish normal cell division.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Yokohama, Kanagawa 2360004, Japan	Osaka University; Yokohama City University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Yamanaka, Tomoyuki/0000-0002-5378-4326; Sakamoto, Yasuhisa/0000-0003-1833-6197				Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Du QS, 2002, CURR BIOL, V12, P1928, DOI 10.1016/S0960-9822(02)01298-8; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gordon MB, 2001, J CELL BIOL, V152, P425, DOI 10.1083/jcb.152.3.425; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; James P, 1996, GENETICS, V144, P1425; Justice NJ, 2003, NAT CELL BIOL, V5, P273, DOI 10.1038/ncb0403-273; Kaiser C., 1994, METHODS YEAST GENETI; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kaushik R, 2003, MOL BIOL CELL, V14, P3144, DOI 10.1091/mbc.E03-04-0212; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; PENG CY, 2000, NATURE, V419, P929; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Yamada A, 2005, J BIOL CHEM, V280, P6016, DOI 10.1074/jbc.M408215200; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	31	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6761	6765		10.1074/jbc.C400440200	http://dx.doi.org/10.1074/jbc.C400440200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15632202	hybrid			2022-12-27	WOS:000227332700065
J	Feraudet, C; Morel, N; Simon, S; Volland, H; Frobert, Y; Creminon, C; Vilette, D; Lehmann, S; Grassi, J				Feraudet, C; Morel, N; Simon, S; Volland, H; Frobert, Y; Creminon, C; Vilette, D; Lehmann, S; Grassi, J			Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRION PROTEIN; IMMUNOMETRIC ASSAYS; BLOOD-TRANSFUSION; MOLECULAR-BIOLOGY; VARIANT; TRANSMISSION; IMMUNIZATION; PROPAGATION; FORM	Prion diseases are transmissible neurodegenerative disorders affecting humans and animals for which no therapeutic or prophylactic regimens exist. During the last three years several studies have shown that anti-PrP monoclonal antibodies (mAbs) can antagonize prion propagation in vitro and in vivo, but the mechanisms of inhibition are not known so far. To identify the most powerful mAbs and characterize more precisely the therapeutic effect of anti-PrP antibodies, we have screened 145 different mAbs produced in our laboratory for their capacity to cure cells constitutively expressing PrPSc. Our results confirm for a very large series of antibodies that mAbs recognizing cell-surface native PrPc can efficiently clean and definitively cure infected cells. Antibodies having a cleaning effect are directed against linear epitopes located in at least four different regions of PrP, suggesting an epitope-independent inhibition mechanism. The consequence of antibody binding is the sequestration of PrPc at the cell surface, an increase of PrPc levels recovered in cell culture medium, and an internalization of antibodies. Taken together these data suggest that the cleaning process is more likely due to a global effect on the PrP trafficking and/or transconformation process. Two antibodies, Sha31 and BAR236, show an IC50 of 0.6 nM, thus appearing 10-fold more efficient than previous antibodies described in the literature. Finally, five co-treatments were also tested, and only one of them, described previously (SAF34 + SAF61), lowered PrPSc levels in the cells synergistically.	CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; INRA, F-78350 Jouy En Josas, France; CNRS, F-34396 Montpellier, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Grassi, J (corresponding author), CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France.	jacques.grassi@cea.fr	Lehmann, Sylvain/P-1301-2017; Simon, Stephanie/E-4289-2012; Morel, Nathalie/O-9012-2016	Lehmann, Sylvain/0000-0001-6117-562X; Simon, Stephanie/0000-0002-6071-8255; 				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Beringue V, 2004, J BIOL CHEM, V279, P39671, DOI 10.1074/jbc.M402270200; Brown P, 2002, NEUROLOGY, V58, P1720, DOI 10.1212/WNL.58.12.1720; Bruce ME, 2001, LANCET, V358, P208, DOI 10.1016/S0140-6736(01)05411-3; Cashman NR, 2004, NAT REV DRUG DISCOV, V3, P874, DOI 10.1038/nrd1525; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Gilch S, 2003, TRENDS MOL MED, V9, P367, DOI 10.1016/S1471-4914(03)00144-8; Gilch S, 2003, J BIOL CHEM, V278, P18524, DOI 10.1074/jbc.M210723200; Grassi J, 1996, CLIN CHEM, V42, P1532; Grassi J, 2000, Arch Virol Suppl, P197; GRASSI J, 1989, J IMMUNOL METHODS, V123, P193, DOI 10.1016/0022-1759(89)90223-8; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Hunter N, 2002, J GEN VIROL, V83, P2897, DOI 10.1099/0022-1317-83-11-2897; Kim CL, 2004, J GEN VIROL, V85, P3473, DOI 10.1099/vir.0.80113-0; Kocisko DA, 2003, J VIROL, V77, P10288, DOI 10.1128/JVI.77.19.10288-10294.2003; Krasemann S, 1996, J IMMUNOL METHODS, V199, P109, DOI 10.1016/S0022-1759(96)00165-2; Krasemann S, 1999, J BIOTECHNOL, V73, P119, DOI 10.1016/S0168-1656(99)00115-7; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Meggio F, 2000, BIOCHEM J, V352, P191, DOI 10.1042/0264-6021:3520191; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; Morel N, 2004, J BIOL CHEM, V279, P30143, DOI 10.1074/jbc.M403896200; Nakajima M, 2004, DEMENT GERIATR COGN, V17, P158, DOI 10.1159/000076350; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Nunziante M, 2003, CHEMBIOCHEM, V4, P1268, DOI 10.1002/cbic.200300704; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Otto M, 2004, NEUROLOGY, V62, P714, DOI 10.1212/01.WNL.0000113764.35026.EF; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Perrier V, 2004, J NEUROCHEM, V89, P454, DOI 10.1111/j.1471-4159.2004.02356.x; Polymenidou M, 2004, P NATL ACAD SCI USA, V101, P14670, DOI 10.1073/pnas.0404772101; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; REIK LM, 1987, J IMMUNOL METHODS, V100, P123, DOI 10.1016/0022-1759(87)90180-3; Rudyk H, 2000, J GEN VIROL, V81, P1155, DOI 10.1099/0022-1317-81-4-1155; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; Sigurdsson EM, 2002, AM J PATHOL, V161, P13, DOI 10.1016/S0002-9440(10)64151-X; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Supattapone S, 2002, BIOCHEM PHARMACOL, V63, P1383, DOI 10.1016/S0006-2952(02)00874-2; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; White AR, 2003, J NEUROCHEM, V87, P801, DOI 10.1046/j.1471-4159.2003.02064.x; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	55	255	266	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11247	11258		10.1074/jbc.M407006200	http://dx.doi.org/10.1074/jbc.M407006200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15618225	Green Published, hybrid			2022-12-27	WOS:000227761800045
J	Vance, JE; Vance, DE				Vance, JE; Vance, DE			Metabolic insights into phospholipid function using gene-targeted mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; TRANSFER PROTEIN; HIGH-DENSITY; TANGIER-DISEASE; TISSUE-CULTURE; PHOSPHATIDYLCHOLINE SYNTHESIS; CHOLINE; CHOLESTEROL; DISRUPTION; CELLS		Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca; dennis.vance@ualberta.ca						Alb JG, 2003, J BIOL CHEM, V278, P33501, DOI 10.1074/jbc.M303591200; Alb JG, 2002, MOL BIOL CELL, V13, P739, DOI 10.1091/mbc.01-09-0457; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bergo MO, 2002, J BIOL CHEM, V277, P47701, DOI 10.1074/jbc.M207734200; Best CH, 1932, J PHYSIOL-LONDON, V75, P405, DOI 10.1113/jphysiol.1932.sp002899; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V43, P477, DOI 10.1016/0006-3002(60)90470-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; FIELDING PE, 2002, BIOCH LIPIDS LIPOPRO, P527; GLASER M, 1974, P NATL ACAD SCI USA, V71, P4072, DOI 10.1073/pnas.71.10.4072; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Heinzer AK, 2002, J BIOL CHEM, V277, P28765, DOI 10.1074/jbc.M203053200; Jackowski S, 2004, MOL CELL BIOL, V24, P4720, DOI 10.1128/MCB.24.11.4720-4733.2004; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; KENNEDY EP, 1957, ANNU REV BIOCHEM, V26, P119, DOI 10.1146/annurev.bi.26.070157.001003; Kuipers F, 1997, Subcell Biochem, V28, P295; KUKSIS A, 1978, NUTR REV, V36, P201; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Noga AA, 2003, J BIOL CHEM, V278, P5952, DOI 10.1074/jbc.M212194200; Noga AA, 2003, J LIPID RES, V44, P1998, DOI 10.1194/jlr.M300226-JLR200; Noga AA, 2003, J BIOL CHEM, V278, P21851, DOI 10.1074/jbc.M301982200; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RUETZ S, 1995, J BIOL CHEM, V270, P25388, DOI 10.1074/jbc.270.43.25388; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHROEDER F, 1976, J BIOL CHEM, V251, P6747; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Stone SJ, 1999, BIOCHEM J, V342, P57, DOI 10.1042/0264-6021:3420057; Sturbois-Balcerzak B, 2001, J BIOL CHEM, V276, P8205, DOI 10.1074/jbc.M009776200; Tabas I, 1997, CURR OPIN LIPIDOL, V8, P263, DOI 10.1097/00041433-199710000-00004; van Helvoort A, 1999, P NATL ACAD SCI USA, V96, P11501, DOI 10.1073/pnas.96.20.11501; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VOELKER DR, 2002, BIOCH LIPIDS LIPOPRO, P449; Waite KA, 2004, BBA-MOL CELL BIOL L, V1636, P175, DOI 10.1016/j.bbalip.2003.10.014; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Wiedmer T, 2004, P NATL ACAD SCI USA, V101, P13296, DOI 10.1073/pnas.0405354101; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271	60	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10877	10880		10.1074/jbc.R400038200	http://dx.doi.org/10.1074/jbc.R400038200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15642727	hybrid			2022-12-27	WOS:000227761800002
J	Zhou, H; Wang, W; Luo, YZ				Zhou, H; Wang, W; Luo, YZ			Contributions of disulfide bonds in a nested pattern to the structure, stability, and biological functions of endostatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE HELIX; REDUCTIVE CLEAVAGE; PROTEIN; ANGIOGENESIS; INHIBITOR; ROLES; RIBONUCLEASE; EXPRESSION; MECHANISM; LYSOZYME	Endostatin can inhibit the proliferation and migration of endothelial cells. It contains two pairs of disulfide bonds in a nested pattern. We constructed three mutants, C33A/C173A, C135A/C165A, and all-Ala, to evaluate the contributions of individual disulfide bonds to the structure, stability, and biological functions of endostatin. Both tryptophan emission fluorescence spectrum and H-1 nuclear magnetic resonance spectrum show that C135A/C165A and all-Ala, the two mutants lacking disulfide bond Cys(135)-Cys(165), lost nearly their entire tertiary structure. Although C33A/C173A appears to retain some native-like structures, it is less stable and has a higher helical content, which confirms our earlier hypothesis that the polypeptide backbone of endostatin has a high helical propensity. C135A/C165A and all-Ala mutants lost most of their inhibitory activities both on the migration and proliferation of human microvascular endothelial cells, whereas C33A/C173A is partially active. The mutants without disulfide bond Cys(135)-Cys(165) can hardly be internalized and localized to cytoskeleton and nucleus in the cell, which probably contributes to their loss of inhibition on the migration and proliferation of endothelial cells. Our studies provide a structural basis for the two disulfide bonds on the biological functions of endostatin.	Tsinghua Univ, Dept Biol Sci & Biotechnol, Minist Educ, Lab Prot Sci,Lab Prot Chem, Beijing 100084, Peoples R China	Tsinghua University	Luo, YZ (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Minist Educ, Lab Prot Sci,Lab Prot Chem, Beijing 100084, Peoples R China.	protein@tsinghua.edu.cn						AKSAMIT RR, 1994, J BIOL CHEM, V269, P4084; ANFINSEN C, 1961, J BIOL CHEM, V236, P1361; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Carotti C, 2004, EUR J BIOCHEM, V271, P3635, DOI 10.1111/j.1432-1033.2004.04297.x; CREIGHTON TE, 1984, PROTEINS, P1; Darby N, 1995, Methods Mol Biol, V40, P219; Dhanabal M, 1999, CANCER RES, V59, P189; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Dixelius J, 2003, CANCER LETT, V196, P1, DOI 10.1016/S0304-3835(03)00267-2; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Firsov D, 1999, J BIOL CHEM, V274, P2743, DOI 10.1074/jbc.274.5.2743; Forrest LR, 1999, BIOPHYS J, V76, P1886, DOI 10.1016/S0006-3495(99)77347-9; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; Guez V, 2002, PROTEIN SCI, V11, P1136, DOI 10.1110/ps.3960102; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; HIRS CHW, 1956, J BIOL CHEM, V219, P611; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; Huang XJ, 2001, CANCER RES, V61, P478; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; KELLA NKD, 1988, J PROTEIN CHEM, V7, P535, DOI 10.1007/BF01024872; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KIM PS, 1984, NATURE, V307, P329, DOI 10.1038/307329a0; Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200; Li B, 2004, BIOCHEMISTRY-US, V43, P2550, DOI 10.1021/bi0357863; Luo YZ, 2001, BIOCHEMISTRY-US, V40, P5283, DOI 10.1021/bi010122j; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; Morbidelli L, 2003, CLIN CANCER RES, V9, P5358; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Oster LM, 2004, J MOL BIOL, V343, P157, DOI 10.1016/j.jmb.2004.07.049; OSWALD T, 1994, APPL MICROBIOL BIOT, V42, P73; PACE CN, 1988, J BIOL CHEM, V263, P11820; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; RESNICK H, 1959, J BIOL CHEM, V234, P1711; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SELA M, 1959, BIOCHIM BIOPHYS ACTA, V31, P417, DOI 10.1016/0006-3002(59)90016-2; SNOUWAERT JN, 1991, J BIOL CHEM, V266, P23097; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; SORENSON RC, 1995, P NATL ACAD SCI USA, V92, P7187, DOI 10.1073/pnas.92.16.7187; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Watkins SJ, 1997, GENE THER, V4, P1004, DOI 10.1038/sj.gt.3300511; WHITE FH, 1976, BIOCHEMISTRY-US, V15, P2906, DOI 10.1021/bi00658a032; Wickstrom SA, 2001, CANCER RES, V61, P6511; Wu XY, 2004, BIOCHEM BIOPH RES CO, V320, P973, DOI 10.1016/j.bbrc.2004.06.047; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Zhang HG, 2002, J VIROL, V76, P12023, DOI 10.1128/JVI.76.23.12023-12031.2002	55	25	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11303	11312		10.1074/jbc.M412072200	http://dx.doi.org/10.1074/jbc.M412072200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15634676	hybrid			2022-12-27	WOS:000227761800051
J	Foulon, V; Sniekers, M; Huysmans, E; Asselberghs, S; Mahieu, V; Mannaerts, GP; Van Veldhoven, PP; Casteels, M				Foulon, V; Sniekers, M; Huysmans, E; Asselberghs, S; Mahieu, V; Mannaerts, GP; Van Veldhoven, PP; Casteels, M			Breakdown of 2-hydroxylated straight chain fatty acids via peroxisomal 2-hydroxyphytanoyl-CoA lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTANOYL-COA HYDROXYLASE; ALPHA-OXIDATION; RAT-LIVER; BETA-OXIDATION; MOLECULAR-CLONING; PURIFICATION; EXPRESSION; PROTEIN; IDENTIFICATION; DECARBOXYLASE	Hydroxyfatty acids, constituents of brain cerebro-sides and sulfatides, were previously reported to be degraded by an alpha-oxidation system, generating fatty acids shortened by one carbon atom. In the current study we used labeled and unlabeled 2-hydroxyoctadecanoic acid to reinvestigate the degradation of this class of lipids. Both in intact and broken cell systems formate was identified as a main reaction product. Furthermore, the generation of an n-1 aldehyde was demonstrated. In permeabilized rat hepatocytes and liver homogenates, studies on cofactor requirements revealed a dependence on ATP, CoA, Mg2+, thiamine pyrophosphate, and NAD(+). Together with subcellular fractionation data and studies on recombinant enzymes, this led to the following picture. In a first step, the 2-hydroxyfatty acid is activated to an acyl-CoA; subsequently, the 2-hydroxy fatty acyl-CoA is cleaved by 2-hydroxyphytanoyl-CoA lyase, to formyl-CoA and an n-1 aldehyde. The severe inhibition of formate generation by oxythiamin treatment of intact fibroblasts indicates that cleavage through the thiamine pyrophosphate-dependent 2-hydroxyphytanoyl-CoA lyase is the main pathway for the degradation of 2-hydroxyfatty acids. The latter protein was initially characterized as an essential enzyme in the peroxisomal alpha-oxidation of 3-methyl-branched fatty acids such as phytanic acid. Our findings point to a new role for peroxisomes in mammals, i.e. the breakdown of 2-hydroxyfatty acids, at least the long chain 2-hydroxyfatty acids. Most likely, the more abundant very long chain 2-hydroxyfatty acids are degraded in a similar manner.	Catholic Univ Louvain, Fac Geneeskunde, Dept Celbiol, Afdeling Farmacol, B-3000 Louvain, Belgium	Universite Catholique Louvain	Casteels, M (corresponding author), Catholic Univ Louvain, Fac Geneeskunde, Dept Celbiol, Afdeling Farmacol, Herestr 49,Box 601,Campus Gasthuisberg, B-3000 Louvain, Belgium.	minne.casteels@med.kuleuven.ac.be	, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564; Foulon, Veerle/0000-0002-4053-3915				Alderson NL, 2004, J BIOL CHEM, V279, P48562, DOI 10.1074/jbc.M406649200; Ashton R, 1936, J CHEM SOC, P283, DOI 10.1039/jr9360000283; Baes M, 1997, NAT GENET, V17, P49, DOI 10.1038/ng0997-49; BELMOUDEN A, 1993, EUR J BIOCHEM, V214, P17, DOI 10.1111/j.1432-1033.1993.tb17891.x; Borge GIA, 1998, BBA-LIPID LIPID MET, V1394, P158, DOI 10.1016/S0005-2760(98)00113-1; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; CASTEELS M, 1994, BIOCHEM PHARMACOL, V48, P1973, DOI 10.1016/0006-2952(94)90596-7; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Croes K, 1996, EUR J BIOCHEM, V240, P674, DOI 10.1111/j.1432-1033.1996.0674h.x; Croes K, 2000, J LIPID RES, V41, P629; Croes K, 1999, J LIPID RES, V40, P601; Croes K, 1997, FEBS LETT, V407, P197, DOI 10.1016/S0014-5793(97)00343-8; Croes K, 1997, FEBS LETT, V412, P643, DOI 10.1016/S0014-5793(97)00856-9; CROES K, 1995, BBA-LIPID LIPID MET, V1255, P63, DOI 10.1016/0005-2760(94)00209-H; CROES K, 1998, THESIS; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; DIRKX R, 2005, IN PRESS HEPATOLOGY; Foulon V, 2003, J LIPID RES, V44, P2349, DOI 10.1194/jlr.M300230-JLR200; Foulon V, 1999, P NATL ACAD SCI USA, V96, P10039, DOI 10.1073/pnas.96.18.10039; FOULON V, 2001, THESIS; FULCO AJ, 1967, J BIOL CHEM, V242, P3608; GERHARDT B, 1992, PROG LIPID RES, V31, P417, DOI 10.1016/0163-7827(92)90004-3; HAJRA AK, 1963, J LIPID RES, V58, P270; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; Jones JM, 2000, J BIOL CHEM, V275, P12590, DOI 10.1074/jbc.275.17.12590; KAYA K, 1984, J BIOL CHEM, V259, P3548; KISHIMOTO Y, 1963, J LIPID RES, V4, P139; Koeduka T, 2002, J BIOL CHEM, V277, P22648, DOI 10.1074/jbc.M110420200; Kovacs WJ, 2001, EUR J BIOCHEM, V268, P4850, DOI 10.1046/j.0014-2956.2001.02409.x; Larson TR, 2001, PLANT J, V25, P115, DOI 10.1046/j.1365-313x.2001.00929.x; LEVIS GM, 1964, J BIOL CHEM, V239, P77; LIPPEL K, 1968, BIOCHIM BIOPHYS ACTA, V152, P669, DOI 10.1016/0005-2760(68)90113-6; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; Mukherji M, 2002, CHEM BIOL, V9, P597, DOI 10.1016/S1074-5521(02)00139-4; NOVIKOV DK, 1994, J BIOL CHEM, V269, P27125; Saito M, 1999, BBA-MOL CELL BIOL L, V1438, P55, DOI 10.1016/S1388-1981(99)00037-2; Sandhir R, 2000, LIPIDS, V35, P1127, DOI 10.1007/s11745-000-0628-5; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; SVENNERHOLM L, 1968, J LIPID RES, V9, P215; Tatsumi K, 2001, BBA-MOL BASIS DIS, V1535, P285, DOI 10.1016/S0925-4439(01)00027-8; Tittmann K, 1998, FEBS LETT, V441, P404, DOI 10.1016/S0014-5793(98)01594-4; Townsend CA, 2002, CURR OPIN CHEM BIOL, V6, P583, DOI 10.1016/S1367-5931(02)00392-7; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANVELDHOVEN PP, 1993, J INHERIT METAB DIS, V16, P381, DOI 10.1007/BF00710285; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; Verhoeven NM, 1998, FEBS LETT, V429, P225, DOI 10.1016/S0014-5793(98)00574-2	46	78	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9802	9812		10.1074/jbc.M413362200	http://dx.doi.org/10.1074/jbc.M413362200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644336	hybrid			2022-12-27	WOS:000227559600009
J	Levitin, F; Baruch, A; Weiss, M; Stiegman, K; Hartmann, ML; Yoeli-Lerner, M; Ziv, R; Zrihan-Licht, S; Shina, S; Gat, A; Lifschitz, B; Simha, M; Stadler, Y; Cholostoy, A; Gil, B; Greaves, D; Keydar, I; Zaretsky, J; Smorodinsky, N; Wreschner, DH				Levitin, F; Baruch, A; Weiss, M; Stiegman, K; Hartmann, ML; Yoeli-Lerner, M; Ziv, R; Zrihan-Licht, S; Shina, S; Gat, A; Lifschitz, B; Simha, M; Stadler, Y; Cholostoy, A; Gil, B; Greaves, D; Keydar, I; Zaretsky, J; Smorodinsky, N; Wreschner, DH			A novel protein derived from the MUC1 gene by alternative splicing and frameshifting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DF3/MUC1 CARCINOMA ANTIGEN; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; BETA-CATENIN; PREFERENTIAL EXPRESSION; MOLECULAR-CLONING; EPITHELIAL MUCIN; T-CELLS; C-SRC; BREAST	Genes that have been designated the name "MUC" code for proteins comprising mucin domains. These proteins may be involved in barrier and protective functions. The first such gene to be characterized and sequenced is the MUC1 gene. Here we report a novel small protein derived from the MUC1 gene by alternative splicing that does not contain the hallmark of mucin proteins, the mucin domain. This protein termed MUC1/ZD retains the same N-terminal MUC1 sequences as all of the other known MUC1 protein isoforms. The common N-terminal sequences comprise the signal peptide and a subsequent stretch of 30 amino acids. In contrast, the MUC1/ZDC-terminal 43 amino acids are novel and result from a reading frameshift engendered by a splicing event that forms MUC1/ZD. The expression of MUC1/ZD at the protein level in human tissues is demonstrated by Western blotting, immunohistochemistry, immunoprecipitation, and an ELISA. Utilization was made of affinity-purified MUC1/ZD-specific polyclonal antibodies as well as two different monoclonal antibodies that are monospecific for the MUC1/ZD protein. The MUC1/ZD protein is expressed in tissues as an oligomeric complex composed of monomers linked by disulfide bonds contributed by MUC1/ZD cysteine residues. MUC1/ZD protein expression did not parallel that of the tandem-repeat array-containing MUC1 protein. Results presented here demonstrate for the first time the expression of a novel MUC1 protein isoform MUC1/ZD, which is generated by an alternative splicing event that both deletes the tandem-repeat array and leads to a C-terminal reading frameshift.	Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel; Sourasky Ichilov Med Ctr, Dept Pathol, IL-64239 Tel Aviv, Israel; Sourasky Ichilov Med Ctr, Dept Surg A, IL-64239 Tel Aviv, Israel; Assaf Harofeh Med Ctr, Dept Endocrinol, IL-70300 Zerifin, Israel; Univ Oxford, Dept Pathol, Oxford OX1 RE, England	Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; University of Oxford	Wreschner, DH (corresponding author), Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel.	danielhw@post.tau.ac.il		Greaves, David/0000-0003-2856-9410; Wreschner, Daniel/0000-0003-2102-2164				Baruch A, 1999, CANCER RES, V59, P1552; Baruch A, 1997, INT J CANCER, V71, P741; Canbay E, 2003, CELL BIOL INT, V27, P477, DOI 10.1016/S1065-6995(03)00039-8; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Hartman ML, 1999, INT J CANCER, V82, P256, DOI 10.1002/(SICI)1097-0215(19990719)82:2<256::AID-IJC17>3.0.CO;2-C; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JENSEN J, 1967, SCIENCE, V155, P1122, DOI 10.1126/science.155.3766.1122; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; Li Q, 2004, BIOCHEM BIOPH RES CO, V315, P471, DOI 10.1016/j.bbrc.2004.01.075; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1991, NUCLEIC ACIDS RES, V19, P297, DOI 10.1093/nar/19.2.297; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Lillehoj EP, 2004, AM J PHYSIOL-LUNG C, V287, pL809, DOI 10.1152/ajplung.00385.2003; Meerzaman D, 2000, AM J PHYSIOL-LUNG C, V278, pL625, DOI 10.1152/ajplung.2000.278.3.L625; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Meyer B, 1996, PLANT PHYSIOL, V112, P615, DOI 10.1104/pp.112.2.615; Moniaux N, 2000, EUR J BIOCHEM, V267, P4536, DOI 10.1046/j.1432-1327.2000.01504.x; Mukherjee P, 2005, J LEUKOCYTE BIOL, V77, P90, DOI 10.1189/jlb.0604333; Obermair A, 2002, INT J CANCER, V100, P166, DOI 10.1002/ijc.10456; Obermair A, 2001, GYNECOL ONCOL, V83, P343, DOI 10.1006/gyno.2001.6396; Oosterkamp HM, 1997, INT J CANCER, V72, P87, DOI 10.1002/(SICI)1097-0215(19970703)72:1<87::AID-IJC13>3.0.CO;2-7; PANDEY P, 1995, CANCER RES, V55, P4000; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Rahn JJ, 2004, J BIOL CHEM, V279, P29386, DOI 10.1074/jbc.C400010200; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schmid BC, 2003, ONCOL REP, V10, P1981; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Vlad AM, 2004, ADV IMMUNOL, V82, P249, DOI 10.1016/S0065-2776(04)82006-6; Wang HH, 2004, BIOCHEM BIOPH RES CO, V321, P448, DOI 10.1016/j.bbrc.2004.06.167; Weber K, 1972, Methods Enzymol, V26, P3; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; WRESCHNER DH, 1994, ADV EXP MED BIOL, V353, P17; WRIGHT SD, 1995, J IMMUNOL, V155, P6; Wykes M, 2002, J LEUKOCYTE BIOL, V72, P692; Yoshii N, 2002, PATHOL INT, V52, P390, DOI 10.1046/j.1440-1827.2002.01364.x; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851; ZRIHANLICHT S, 1994, EUR J BIOCHEM, V224, P787, DOI 10.1111/j.1432-1033.1994.00787.x; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	46	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10655	10663		10.1074/jbc.M406943200	http://dx.doi.org/10.1074/jbc.M406943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15623537	hybrid			2022-12-27	WOS:000227559600111
J	Mayeur, GL; Kung, WJ; Martinez, A; Izumiya, C; Chen, DJ; Kung, HJ				Mayeur, GL; Kung, WJ; Martinez, A; Izumiya, C; Chen, DJ; Kung, HJ			Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RNA-POLYMERASE-II; STRAND-BREAK REPAIR; DIFFERENTIAL GENE-EXPRESSION; CREB-BINDING-PROTEIN; DNA-TOPOISOMERASE-I; V(D)J RECOMBINATION; GLIOMA-CELLS; COMPLEX; ANTIGEN	The androgen receptor (AR) dynamically assembles and disassembles multicomponent receptor complexes in order to respond rapidly and reversibly to fluctuations in androgen levels. We are interested in identifying the basal factors that compose the AR aporeceptor and holoreceptor complexes and impact the transcriptional process. Using tandem mass spectroscopy analysis, we identified the trimeric DNA-dependent protein kinase (DNA-PK) complex as the major AR-interacting proteins. AR directly interacts with both Ku70 and Ku80 in vivo and in vitro, as shown by co-immunoprecipitation, glutathione S-transferase pull-down, and Sf9 cell/baculovirus expression. The interaction was localized to the androgen receptor ligand binding domain and is independent of DNA interactions. Ku interacts with AR in the cytoplasm and nucleus regardless of the presence or absence of androgen. Ku acts as a coactivator of AR activity in a luciferase reporter assay employing both Ku-defective cells and Ku small interfering RNA knockdown in a prostate cancer cell line. DNA-PK catalytic subunit (DNA-PKcs) also acts as a coactivator of androgen receptor activity in a luciferase reporter assay employing DNA-PKcs defective cells. AR nuclear translocation is not affected in Ku defective cells, implying Ku functionality may be mainly nuclear. Chromatin immunoprecipitation experiments demonstrated that both Ku70 and Ku80 interact with the prostate-specific antigen promoter in an androgen-dependant manner. Finally, in vitro transcription assays demonstrated Ku involvement in transcriptional recycling with androgen dependent promoters.	Univ Calif Davis, UC Davis Canc Ctr, Dept Biol Chem, Sch Med, Sacramento, CA 95817 USA; Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA	University of California System; University of California Davis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kung, HJ (corresponding author), Univ Calif Davis, UC Davis Canc Ctr, Dept Biol Chem, Sch Med, Res Bldg 3,Rm 2400B,4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA86936, CA50519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050519, R01CA086936, R37CA050519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Ai R, 2003, GENE EXPRESSION, V11, P35, DOI 10.3727/000000003783992306; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Belenkov AI, 2002, CANCER RES, V62, P5888; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bertinato J, 2003, GENE, V302, P53, DOI 10.1016/S0378111902010892; Chan JYH, 2001, J RADIAT RES, V42, P371, DOI 10.1269/jrr.42.371; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; Errami A, 1996, MOL CELL BIOL, V16, P1519; Fan R, 2004, CANCER RES, V64, P8526, DOI 10.1158/0008-5472.CAN-04-1601; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HEINLEIN CA, 2002, ANDROGENS ANDROGEN R; Hu YC, 2004, J BIOL CHEM, V279, P33438, DOI 10.1074/jbc.M401781200; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Koike M, 2002, J RADIAT RES, V43, P223, DOI 10.1269/jrr.43.223; Koike M, 2001, J BIOL CHEM, V276, P11167, DOI 10.1074/jbc.M010902200; Konno S, 1996, ANTICANCER RES, V16, P1843; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; Mo XM, 2002, MOL CELL BIOL, V22, P8088, DOI 10.1128/MCB.22.22.8088-8099.2002; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Pang DL, 1997, CANCER RES, V57, P1412; Pirrotta V, 2003, SCIENCE, V299, P528, DOI 10.1126/science.1081520; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Sheppard HM, 2000, BBA-GENE STRUCT EXPR, V1493, P41, DOI 10.1016/S0167-4781(00)00155-X; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; Tazi J, 1997, J MOL MED, V75, P786, DOI 10.1007/s001090050168; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Woodard RL, 2001, J BIOL CHEM, V276, P15423, DOI 10.1074/jbc.M010752200; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	58	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10827	10833		10.1074/jbc.M413336200	http://dx.doi.org/10.1074/jbc.M413336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640154	hybrid			2022-12-27	WOS:000227559600130
J	Muller, I; Subert, N; Otto, H; Herbst, R; Ruhling, H; Maniak, M; Leippe, M				Muller, I; Subert, N; Otto, H; Herbst, R; Ruhling, H; Maniak, M; Leippe, M			A Dictyostelium mutant with reduced lysozyme levels compensates by increased phagocytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CHEDIAK-HIGASHI-SYNDROME; CATHEPSIN-D; ENTAMOEBA-HISTOLYTICA; SUGAR MODIFICATIONS; MOLECULAR-CLONING; DISCOIDEUM; CELLS; CYTOKINESIS; ENDOCYTOSIS	Lysozymes are bacteria-degrading enzymes and play a major role in the immune defense of animals. In free-living protozoa, lysozyme-like proteins are involved in the digestion of phagocytosed bacteria. Here, we purified a protein with lysozyme activity from Dictyostelium amoebae, which constitutes the founding member, a novel class of lysozymes. By tagging the protein with green fluorescent protein or the Myc epitope, a new type of lysozyme-containing vesicle was identified that was devoid of other known lysosomal enzymes. The most highly expressed isoform, encoded by the alyA gene, was knocked out by homologous recombination. The mutant cells had greatly reduced enzymatic activity and grew inefficiently when bacteria were the sole food source. Over time the mutant gained the ability to internalize bacteria more efficiently, so that the defect in digestion was compensated by increased uptake of food particles.	Univ Kassel, Abt Zellbiol, D-34132 Kassel, Germany; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Ruhr Univ Bochum, Dept Special Zool, D-44780 Bochum, Germany; Univ Kiel, Inst Zool, D-24098 Kiel, Germany	Universitat Kassel; Bernhard Nocht Institut fur Tropenmedizin; Ruhr University Bochum; University of Kiel	Maniak, M (corresponding author), Univ Kassel, Abt Zellbiol, Heinrich Plett Str 40, D-34132 Kassel, Germany.	maniak@uni-kassel.de	Leippe, Matthias/AAP-1677-2020	Maniak, Markus/0000-0001-6442-5372; Herbst, Rosa/0000-0002-2379-7433				ADACHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1808, DOI 10.1006/bbrc.1994.2880; Andra J, 1996, FEBS LETT, V385, P96, DOI 10.1016/0014-5793(96)00359-6; Bachali S, 2002, J MOL EVOL, V54, P652, DOI 10.1007/s00239-001-0061-6; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; BOMBLIES L, 1990, J CELL BIOL, V110, P669, DOI 10.1083/jcb.110.3.669; Bruckert F, 2000, PROTOPLASMA, V210, P108, DOI 10.1007/BF01276850; Buczynski G, 1997, MOL BIOL CELL, V8, P1343, DOI 10.1091/mbc.8.7.1343; Cornillon S, 2002, J CELL SCI, V115, P737; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DOBSON DE, 1984, J BIOL CHEM, V259, P1607; Drengk A, 2003, CURR BIOL, V13, P1814, DOI 10.1016/j.cub.2003.09.037; Faix J, 1996, FEBS LETT, V394, P251, DOI 10.1016/0014-5793(96)00963-5; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Hacker U, 1997, J CELL SCI, V110, P105; Hanakam F, 1996, EMBO J, V15, P2935, DOI 10.1002/j.1460-2075.1996.tb00656.x; Harris E, 2002, MOL BIOL CELL, V13, P656, DOI 10.1091/mbc.01-09-0454; Heringa J, 1999, COMPUT CHEM, V23, P341, DOI 10.1016/S0097-8485(99)00012-1; Huete-Perez JA, 1999, J BIOL CHEM, V274, P16249, DOI 10.1074/jbc.274.23.16249; JACOBS T, 1995, EUR J BIOCHEM, V231, P831, DOI 10.1111/j.1432-1033.1995.0831d.x; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; Journet A, 1999, J CELL SCI, V112, P3833; Konzok A, 1999, J CELL BIOL, V146, P453, DOI 10.1083/jcb.146.2.453; Maniak M, 2002, INT REV CYTOL, V221, P257; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Markart P, 2004, BIOCHEM J, V380, P385, DOI 10.1042/BJ20031810; Markart P, 2004, AM J RESP CRIT CARE, V169, P454, DOI 10.1164/rccm.200305-669OC; Maselli A, 2002, MICROBIOL-SGM, V148, P413, DOI 10.1099/00221287-148-2-413; MILLER GL, 1950, ARCH BIOCHEM, V29, P420; Moin K, 2000, ADV EXP MED BIOL, V477, P391; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; Neuhaus EM, 1998, J STRUCT BIOL, V121, P326, DOI 10.1006/jsbi.1998.3971; Nickel R, 1998, FEBS LETT, V437, P153, DOI 10.1016/S0014-5793(98)01220-4; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; OSSERMAN EF, 1966, J EXP MED, V124, P921, DOI 10.1084/jem.124.5.921; REISSIG JL, 1955, J BIOL CHEM, V217, P959; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seastone DJ, 1998, MOL BIOL CELL, V9, P2891, DOI 10.1091/mbc.9.10.2891; Seastone DJ, 1999, MOL BIOL CELL, V10, P393, DOI 10.1091/mbc.10.2.393; SHUGAR D, 1952, BIOCHIM BIOPHYS ACTA, V8, P302, DOI 10.1016/0006-3002(52)90045-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Souza GM, 1997, J CELL SCI, V110, P2239; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; Temesvari L, 2000, MOL BIOL CELL, V11, P2019, DOI 10.1091/mbc.11.6.2019; Tyynela J, 2000, EMBO J, V19, P2786, DOI 10.1093/emboj/19.12.2786; Walkley SU, 2001, CURR OPIN NEUROL, V14, P805, DOI 10.1097/00019052-200112000-00020; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; Wienke DC, 1999, MOL BIOL CELL, V10, P225, DOI 10.1091/mbc.10.1.225; Winchester B, 2000, BIOCHEM SOC T, V28, P150, DOI 10.1042/bst0280150; YAMADA H, 1981, CARBOHYD RES, V92, P160, DOI 10.1016/S0008-6215(00)85993-5; Yuan AD, 2000, EXP CELL RES, V261, P336, DOI 10.1006/excr.2000.5055	56	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10435	10443		10.1074/jbc.M411445200	http://dx.doi.org/10.1074/jbc.M411445200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640146	hybrid			2022-12-27	WOS:000227559600085
J	Johnsen, L; Fimland, G; Meyer, JN				Johnsen, L; Fimland, G; Meyer, JN			The C-terminal domain of pediocin-like antimicrobial peptides (class IIa bacteriocins) is involved in specific recognition of the C-terminal part of cognate immunity proteins and in determining the antimicrobial spectrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LISTERIA-MONOCYTOGENES; LACTOCOCCIN-A; 3-DIMENSIONAL STRUCTURE; ENTEROCOCCUS-FAECALIS; MUTATIONAL ANALYSIS; PTS PERMEASE; SAKACIN-P; EXPRESSION; LACTOBACILLUS; PA-1	The pediocin-like bacteriocins contain two domains: a cationic N-terminal beta-sheet domain that mediates binding of the bacteriocin to the target cell surface and a more hydrophobic C-terminal hairpin-like domain that penetrates into the hydrophobic part of the target cell membrane. The two domains are joined by a hinge, which enables movement of the domains relative to each other. In this study, 12 different hybrid bacteriocins were constructed by exchanging domains between 5 different bacteriocins. The hybrid bacteriocins were by and large highly potent (i.e. similar potencies as the parental bacteriocins) when constructed such that the recombination point was in the hinge region, indicating that the two domains function independently. The use of optimal recombination points was, however, crucial. Shifting the recombination point just one residue from the hinge could reduce the activity of the hybrid by 3-4 orders of magnitude. Most interestingly, the active hybrids displayed target cell specificities similar to those of the parental bacteriocin from which their membrane-penetrating C-terminal hairpin domain was derived. The results also indicate that the negatively charged aspartate reside in the hinge of most pediocin-like bacteriocins interacts with the C-terminal hairpin domain, perhaps by interacting with the positively charged residue that is present at one of the last three positions in the C-terminal end of most pediocin- like bacteriocins. Bacteria that produce pediocin- like bacteriocins also produce a cognate immunity protein that protects the producer from being killed by its own bacteriocin. Four different active hybrid immunity proteins constructed by exchanging regions between three different immunity proteins were tested for their ability to confer immunity to the hybrid bacteriocins. The results showed that the C-terminal half of the immunity proteins contains a region that directly or indirectly specifically recognizes the membrane-penetrating C-terminal hairpin domain of pediocin- like bacteriocins. The implications these results have on how pediocin- like bacteriocins and their immunity proteins interact with cellular specificity determinants (for instance a putative bacteriocin receptor) are discussed.	Univ Oslo, Dept Mol Biosci, Program Biochem & Mol Biol, N-0316 Oslo, Norway	University of Oslo	Johnsen, L (corresponding author), Univ Oslo, Dept Mol Biosci, Program Biochem & Mol Biol, Post Box 1041, N-0316 Oslo, Norway.	line.johnsen@biokjemi.uio.no	Nissen-Meyer, Jon/Y-8727-2019; Nissen-Meyer, Jon/A-5581-2008					Aukrust T W, 1995, Methods Mol Biol, V47, P201; AXELSSON L, 1995, J BACTERIOL, V177, P2125, DOI 10.1128/jb.177.8.2125-2137.1995; Axelsson L, 1998, FEMS MICROBIOL LETT, V168, P137, DOI 10.1016/S0378-1097(98)00431-5; Aymerich T, 1996, APPL ENVIRON MICROB, V62, P1676, DOI 10.1128/AEM.62.5.1676-1682.1996; Brurberg MB, 1997, MOL MICROBIOL, V26, P347, DOI 10.1046/j.1365-2958.1997.5821951.x; Chen YH, 1997, APPL ENVIRON MICROB, V63, P4770, DOI 10.1128/AEM.63.12.4770-4777.1997; CHIKINDAS ML, 1993, APPL ENVIRON MICROB, V59, P3577, DOI 10.1128/AEM.59.11.3577-3584.1993; CHIKINDAS ML, 1995, LETT APPL MICROBIOL, V21, P183, DOI 10.1111/j.1472-765X.1995.tb01037.x; Dalet K, 2001, MICROBIOL-SGM, V147, P3263, DOI 10.1099/00221287-147-12-3263; Dayem MA, 1996, FEMS MICROBIOL LETT, V138, P251, DOI 10.1016/0378-1097(96)00119-X; Eijsink VGH, 1998, APPL ENVIRON MICROB, V64, P3275; Ennahar S, 2000, FEMS MICROBIOL REV, V24, P85, DOI 10.1111/j.1574-6976.2000.tb00534.x; Fimland G, 2000, J BACTERIOL, V182, P2643, DOI 10.1128/JB.182.9.2643-2648.2000; Fimland G, 1998, APPL ENVIRON MICROB, V64, P5057; Fimland G, 1996, APPL ENVIRON MICROB, V62, P3313, DOI 10.1128/AEM.62.9.3313-3318.1996; Fimland G, 2002, BIOCHEMISTRY-US, V41, P9508, DOI 10.1021/bi025856q; Fimland G, 2002, MICROBIOL-SGM, V148, P3661, DOI 10.1099/00221287-148-11-3661; Gallagher NLF, 1997, BIOCHEMISTRY-US, V36, P15062, DOI 10.1021/bi971263h; Gravesen A, 2002, MICROBIOL-SGM, V148, P2361, DOI 10.1099/00221287-148-8-2361; Hechard Y, 2001, MICROBIOL-SGM, V147, P1575, DOI 10.1099/00221287-147-6-1575; Huhne K, 1996, MICROBIOL-SGM, V142, P1437, DOI 10.1099/13500872-142-6-1437; Johnsen L, 2004, APPL ENVIRON MICROB, V70, P2647, DOI 10.1128/AEM.70.5.2647-2652.2004; Kazazic M, 2002, MICROBIOL-SGM, V148, P2019, DOI 10.1099/00221287-148-7-2019; LOZANO JCN, 1992, J GEN MICROBIOL, V138, P1985, DOI 10.1099/00221287-138-9-1985; MARUGG JD, 1992, APPL ENVIRON MICROB, V58, P2360, DOI 10.1128/AEM.58.8.2360-2367.1992; Miller KW, 1998, APPL ENVIRON MICROB, V64, P1997; Moll GN, 1999, ANTON LEEUW INT J G, V76, P185, DOI 10.1023/A:1002002718501; NES IF, 2002, UNMODIFIED PEPTIDE B, P81; NISSENMEYER J, 1993, J GEN MICROBIOL, V139, P1503, DOI 10.1099/00221287-139-7-1503; NissenMeyer J, 1997, ARCH MICROBIOL, V167, P67, DOI 10.1007/s002030050418; NISSENMEYER J, 1992, J BACTERIOL, V174, P5686, DOI 10.1128/JB.174.17.5686-5692.1992; QUADRI LEN, 1995, J BACTERIOL, V177, P1144, DOI 10.1128/JB.177.5.1144-1151.1995; Quadri LEN, 1997, J BACTERIOL, V179, P6163, DOI 10.1128/jb.179.19.6163-6171.1997; Ramnath M, 2000, APPL ENVIRON MICROB, V66, P3098, DOI 10.1128/AEM.66.7.3098-3101.2000; Ramnath M, 2004, MICROBIOL-SGM, V150, P2663, DOI 10.1099/mic.0.27002-0; Saavedra L, 2004, ANTIMICROB AGENTS CH, V48, P2778, DOI 10.1128/AAC.48.7.2778-2781.2004; Sambrook J., 1989, MOL CLONING, pA1; Shepard B D, 1995, Methods Mol Biol, V47, P217; Sprules T, 2004, BIOCHEMISTRY-US, V43, P11740, DOI 10.1021/bi048854+; TICHACZEK PS, 1993, ARCH MICROBIOL, V160, P279, DOI 10.1007/BF00292077; Uteng M, 2003, BIOCHEMISTRY-US, V42, P11417, DOI 10.1021/bi034572i; Uteng M, 2002, APPL ENVIRON MICROB, V68, P952, DOI 10.1128/AEM.68.2.952-956.2002; VANDEGUCHTE M, 1989, APPL ENVIRON MICROB, V55, P224, DOI 10.1128/AEM.55.1.224-228.1989; Vaughan A, 2001, J APPL MICROBIOL, V91, P131, DOI 10.1046/j.1365-2672.2001.01365.x; VENEMA K, 1994, MOL MICROBIOL, V14, P521, DOI 10.1111/j.1365-2958.1994.tb02186.x; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x; Wang YJ, 1999, BIOCHEMISTRY-US, V38, P15438, DOI 10.1021/bi991351x	47	95	99	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9243	9250		10.1074/jbc.M412712200	http://dx.doi.org/10.1074/jbc.M412712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15611086	hybrid			2022-12-27	WOS:000227453100074
J	Trujillo, KM; Bunch, JT; Baumann, P				Trujillo, KM; Bunch, JT; Baumann, P			Extended DNA binding site in Pot1 broadens sequence specificity to allow recognition of heterogeneous fission yeast telomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; CATALYTIC SUBUNIT; HUMAN-CHROMOSOMES; LENGTH REGULATOR; END PROTECTION; IN-VITRO; PROTEIN; CDC13; EST1; DOMAIN	The Pot1 (protection of telomeres) protein binds to single-stranded telomeric DNA and is essential for the protection of chromosome ends from degradation and end-to-end fusions. The Pot1 amino-terminal DNA binding domain, Pot1N, adopts an oligonucleotide/oligosaccharide binding fold and binds GGTTAC motifs cooperatively and with exceptionally high sequence specificity. We have now examined DNA binding to naturally occurring telomeric substrates based on the analysis of 100 cloned chromosome ends and in the context of the full- length Pot1 protein. Here, we describe several important differences between Pot1 and Pot1N with apparent consequences for chromosome end protection. Specifically, full- length Pot1.DNA complexes are more stable, and the minimal binding site for a Pot1 monomer is extended into two adjacent telomeric repeats. We provide evidence that Pot1 contains a second DNA binding motif that recognizes DNA with reduced sequence specificity compared with the domain present in Pot1N. The two DNA binding motifs cooperate, whereby the amino-terminal oligonucleotide/oligosaccharide binding fold determines the registry of binding, and the internal DNA binding motif stabilizes the complex and expands the protected region toward the 3'-end. Consistent with a role in chromosome end capping, Pot1 prevents access of telomerase to the 3'-end and protects against exonucleolytic degradation.	Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Baumann, P (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	peb@stowers-institute.org		Baumann, Peter/0000-0003-4892-1485				Armbruster BN, 2004, MOL CELL BIOL, V24, P3552, DOI 10.1128/MCB.24.8.3552-3561.2004; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Beernink HTH, 2003, CURR BIOL, V13, P575, DOI 10.1016/S0960-9822(03)00169-6; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Grandin N, 2001, EMBO J, V20, P1173, DOI 10.1093/emboj/20.5.1173; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2004, J BIOL CHEM, V279, P13241, DOI 10.1074/jbc.M312309200; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Lue NF, 1997, NUCLEIC ACIDS RES, V25, P4331, DOI 10.1093/nar/25.21.4331; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Peersen OB, 2002, NAT STRUCT BIOL, V9, P182, DOI 10.1038/nsb761; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; Qi HY, 2000, GENE DEV, V14, P1777; Reichenbach P, 2003, CURR BIOL, V13, P568, DOI 10.1016/S0960-9822(03)00173-8; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Sugawara N., 1988, THESIS HARVARD U CAM; Theobald DL, 2004, STRUCTURE, V12, P1877, DOI 10.1016/j.str.2004.07.015; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WANG WL, 1992, NUCLEIC ACIDS RES, V20, P6621, DOI 10.1093/nar/20.24.6621; Wei C, 2004, MOL CELL BIOL, V24, P2091, DOI 10.1128/MCB.24.5.2091-2102.2004; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404	50	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9119	9128		10.1074/jbc.M414511200	http://dx.doi.org/10.1074/jbc.M414511200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15637058	hybrid			2022-12-27	WOS:000227453100061
J	Crevillen, P; Ventriglia, T; Pinto, F; Orea, A; Merida, A; Romero, JM				Crevillen, P; Ventriglia, T; Pinto, F; Orea, A; Merida, A; Romero, JM			Differential pattern of expression and sugar regulation of Arabidopsis thaliana ADP-glucose pyrophosphorylase-encoding genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; STARCH SYNTHESIS; POTATO-TUBERS; SMALL-SUBUNIT; ADPGLUCOSE PYROPHOSPHORYLASE; CDNA-CLONES; SUCROSE; MODULATION; INDUCTION; ENZYME	ADP-glucose pyrophoshorylase (ADP-Glc PPase) catalyzes the first and limiting step in starch biosynthesis. In plants, the enzyme is composed of two types of subunits ( small and large) and is allosterically regulated by 3-phosphoglycerate and phosphate. The pattern of expression and sugar regulation of the six Arabidopsis thaliana ADP-Glc PPase-encoding genes ( two small subunits, ApS1 and ApS2; and four large subunits, ApL1-ApL4) has been studied. Based on mRNA expression, ApS1 is the main small subunit or catalytic isoform responsible for ADP-Glc PPase activity in all tissues of the plant. Large subunits play a regulatory role, and the data presented define a clear functional distinction among them. ApL1 is the main large subunit in source tissues, whereas ApL3 and, to a lesser extent, ApL4 are the main isoforms present in sink tissues. Thus, in source tissues, ADP-Glc PPase would be finely regulated by the 3-phosphoglycerate/phosphate ratio, whereas in sink tissues, the enzyme would be dependent on the availability of substrates for starch synthesis. Sugar regulation of ADP-Glc PPase genes is restricted to ApL3 and ApL4 in leaves. Sugar induction of ApL3 and ApL4 transcription in leaves allows the establishment of heterotetramers less sensitive to the allosteric effectors, resembling the situation in sink tissues. The results presented on the expression pattern and sugar regulation allow us to propose a gene evolution model for the Arabidopsis ADP-Glc PPase gene family.	Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; Univ Seville, CSIC, Inst Invest Quim, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-USE - Instituto de Investigaciones Quimicas (IIQ)	Romero, JM (corresponding author), Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio 49, Seville 41092, Spain.	jmromero@ibvf.csic.es	Berlanga, Ángel Mérida/E-7623-2013; Pinto, Francisco M./P-4995-2014; Crevillén, Pedro/G-7113-2012; Romero, Jose M/D-5183-2009	Berlanga, Ángel Mérida/0000-0002-0880-2329; Pinto, Francisco M./0000-0001-9694-9816; Crevillén, Pedro/0000-0003-1276-9792; Romero, Jose M/0000-0002-4621-5934				[Anonymous], 1998, Adv Food Nutr Res, V41, P1; Bae JM, 1997, MOL GEN GENET, V254, P179, DOI 10.1007/s004380050406; Ballicora MA, 1998, PLANT PHYSIOL, V118, P265, DOI 10.1104/pp.118.1.265; Ballicora MA, 2004, PHOTOSYNTH RES, V79, P1, DOI 10.1023/B:PRES.0000011916.67519.58; Ballicora MA, 2000, J BIOL CHEM, V275, P1315, DOI 10.1074/jbc.275.2.1315; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; Blanc G, 2004, PLANT CELL, V16, P1679, DOI 10.1105/tpc.021410; Burgess D, 1997, PLANT MOL BIOL, V33, P431, DOI 10.1023/A:1005752311130; Burton RA, 2002, PLANT PHYSIOL, V130, P1464, DOI 10.1104/pp.010363; Cross JM, 2004, PLANT PHYSIOL, V135, P137, DOI 10.1104/pp.103.036699; Fritzius T, 2001, PLANT PHYSIOL, V126, P883, DOI 10.1104/pp.126.2.883; Geiger M, 1998, PLANTA, V206, P234, DOI 10.1007/s004250050395; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; Hendriks JHM, 2003, PLANT PHYSIOL, V133, P838, DOI 10.1104/pp.103.024513; Khoshnoodi J, 1998, PLANT SCI, V135, P183, DOI 10.1016/S0168-9452(98)00093-4; Kim KN, 1999, PLANT PHYSIOL, V121, P225, DOI 10.1104/pp.121.1.225; KLECZKOWSKI LA, 1993, PLANT PHYSIOL, V101, P179, DOI 10.1104/pp.101.1.179; Kleczkowski LA, 1999, Z NATURFORSCH C, V54, P353; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; Leonhardt N, 2004, PLANT CELL, V16, P596, DOI 10.1105/tpc.019000; Li XY, 2002, PLANT SCI, V162, P239, DOI 10.1016/S0168-9452(01)00565-9; LIN TP, 1988, PLANT PHYSIOL, V86, P1131, DOI 10.1104/pp.86.4.1131; Merida A, 1999, PLANT PHYSIOL, V120, P401, DOI 10.1104/pp.120.2.401; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; MULLERROBER BT, 1990, MOL GEN GENET, V224, P136, DOI 10.1007/BF00259460; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Pedro CN, 2003, J BIOL CHEM, V278, P28508, DOI 10.1074/jbc.M304280200; PRESCOTT A, 1987, PLANT MOL BIOL REP, V4, P219, DOI DOI 10.1007/BF02675414; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rook F, 2001, PLANT J, V26, P421, DOI 10.1046/j.1365-313X.2001.2641043.x; Siedlecka A, 2003, PLANTA, V217, P184, DOI 10.1007/s00425-003-0982-y; Simillion C, 2002, P NATL ACAD SCI USA, V99, P13627, DOI 10.1073/pnas.212522399; Sokolov LN, 1998, BIOCHEM J, V336, P681, DOI 10.1042/bj3360681; Sun CW, 1997, PLANT J, V11, P1017, DOI 10.1046/j.1365-313X.1997.11051017.x; Tiessen A, 2002, PLANT CELL, V14, P2191, DOI 10.1105/tpc.003640; VILLAND P, 1993, PLANT MOL BIOL, V23, P1279, DOI 10.1007/BF00042361; VISSER RGF, 1991, PLANT MOL BIOL, V17, P691, DOI 10.1007/BF00037054; WEBER H, 1995, PLANTA, V195, P352, DOI 10.1007/BF00202592; Wingler A, 2000, PLANT PHYSIOL, V124, P105, DOI 10.1104/pp.124.1.105; Zeeman SC, 2002, PLANT PHYSIOL, V129, P516, DOI 10.1104/pp.003756; Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8	41	78	81	2	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8143	8149		10.1074/jbc.M411713200	http://dx.doi.org/10.1074/jbc.M411713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15598655	Green Published, hybrid			2022-12-27	WOS:000227395700086
J	Hofmann, CS; Wang, XB; Sullivan, CP; Toselli, P; Stone, PJ; McLean, SE; Mecham, RP; Schreiber, BM; Sonenshein, GE				Hofmann, CS; Wang, XB; Sullivan, CP; Toselli, P; Stone, PJ; McLean, SE; Mecham, RP; Schreiber, BM; Sonenshein, GE			B-Myb represses elastin gene expression in aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HSP70 PROMOTER; C-MYB; MESSENGER-RNA; A-MYB; DNA-BINDING; EXTRACELLULAR-MATRIX; RAT; PHOSPHORYLATION; TRANSACTIVATION; TRANSCRIPTION	B-Myb represses collagen gene transcription in vascular smooth muscle cells (SMCs) in vitro and in vivo. Here we sought to determine whether elastin is similarly repressed by B-Myb. Levels of tropoelastin mRNA and protein were lower in aortas and isolated SMCs of adult transgenic mice expressing the human B-myb gene, driven by the basal cytomegalovirus promoter, compared with age-matched wild type (WT) animals. However, the vessel wall architecture and levels of insoluble elastin revealed no differences. Since elastin deposition occurs early in development, microarray analysis was performed using nontransgenic mice. Aortic levels of tropoelastin mRNA were low during embryonal growth and increased substantially in neonates, whereas B-myb levels varied inversely. Tropoelastin mRNA expression in aortas of 6-day-old neonatal transgenic and WT animals was comparable. Recently, we demonstrated that cyclin A-Cdk2 prevents B-Myb-mediated repression of collagen promoter activity. Cyclin A2 levels were higher in neonatal versus adult WT or transgenic mouse aortas. Ectopic cyclin A expression reversed the ability of B-Myb to repress elastin gene promoter activity in adult SMCs. These results demonstrate for the first time that B-Myb represses SMC elastin gene expression and that cyclin A plays a role in the developmental regulation of elastin gene expression in the aorta. Furthermore, the findings provide additional insight into the mechanism of B-myb-mediated resistance to femoral artery injury.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Boston University; Washington University (WUSTL); Washington University (WUSTL)	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	gsonensh@bu.edu	Wang, Xiaobo/A-8604-2011	McLean, Sean/0000-0002-9880-9654; Stone, Phillip/0000-0001-6220-690X; Schreiber, Barbara/0000-0001-8560-4249; Wang, Xiaobo/0000-0002-3311-1378	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL13262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BARONE LM, 1988, BIOCHEMISTRY-US, V27, P3175, DOI 10.1021/bi00409a008; BELDEKAS JC, 1982, J BIOL CHEM, V257, P2252; Bergholtz S, 2001, NUCLEIC ACIDS RES, V29, P3546, DOI 10.1093/nar/29.17.3546; Bessa M, 2001, BLOOD CELL MOL DIS, V27, P416, DOI 10.1006/bcmd.2001.0399; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; BROWN KE, 1991, J BIOL CHEM, V266, P23268; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHANG CJ, 1991, MATRIX, V11, P242, DOI 10.1016/S0934-8832(11)80231-3; Cicchillitti L, 2004, BIOCHEM J, V378, P609, DOI 10.1042/BJ20031110; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FOSTER JA, 1990, AM J PHYSIOL, V259, pL13, DOI 10.1152/ajplung.1990.259.2.L13; GOLAY J, 1991, BLOOD, V77, P149; HATA R, 1990, CELL BIOL INT REP, V14, P25, DOI 10.1016/0309-1651(90)90068-A; Hofmann CS, 2004, ARTERIOSCL THROM VAS, V24, P1608, DOI 10.1161/01.ATV.0000139010.71779.f3; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; James MF, 1998, DEV DYNAM, V213, P170, DOI 10.1002/(SICI)1097-0177(199810)213:2<170::AID-AJA2>3.0.CO;2-D; JOHNSON DJ, 1995, CIRC RES, V77, P1107, DOI 10.1161/01.RES.77.6.1107; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; KADAR A, 1971, J PATHOL, V104, P253, DOI 10.1002/path.1711040407; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KINDY MS, 1988, J BIOL CHEM, V263, P11426; Kypreos KE, 1999, MATRIX BIOL, V18, P275, DOI 10.1016/S0945-053X(99)00023-2; Kypreos KE, 1998, CELL GROWTH DIFFER, V9, P723; LAM EWF, 1992, ONCOGENE, V7, P1885; LANSING AI, 1952, ANAT RECORD, V114, P555, DOI 10.1002/ar.1091140404; LEFEVRE M, 1980, BIOCHIM BIOPHYS ACTA, V630, P519, DOI 10.1016/0304-4165(80)90006-9; Li DY, 1998, J CLIN INVEST, V102, P1783, DOI 10.1172/JCI4487; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; Luchetti MM, 2003, J BIOL CHEM, V278, P1533, DOI 10.1074/jbc.M204392200; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; Masselink H, 2001, CANCER LETT, V171, P87, DOI 10.1016/S0304-3835(01)00631-0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OLIVETTI G, 1980, CIRC RES, V47, P417, DOI 10.1161/01.RES.47.3.417; Perrin S, 1997, CRIT REV EUKAR GENE, V7, P1; Petrovas C, 2003, ONCOGENE, V22, P2011, DOI 10.1038/sj.onc.1206231; POLLOCK J, 1990, J BIOL CHEM, V265, P3697; QUAGLINO D, 1993, MATRIX, V13, P481, DOI 10.1016/S0934-8832(11)80114-9; Rich CB, 1999, J BIOL CHEM, V274, P33433, DOI 10.1074/jbc.274.47.33433; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1971, J CELL BIOL, V50, P159, DOI 10.1083/jcb.50.1.159; Rucker R B, 1977, Int Rev Exp Pathol, V17, P1; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; Santilli G, 2001, ONCOGENE, V20, P8167, DOI 10.1038/sj.onc.1204943; Saville MK, 1998, ADV CANCER RES, V72, P109; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STARCHER BC, 1976, ANAL BIOCHEM, V74, P441, DOI 10.1016/0003-2697(76)90224-4; STEPP MA, 1986, J BIOL CHEM, V261, P6542; Stone PJ, 1997, AM J RESP CELL MOL, V17, P289, DOI 10.1165/ajrcmb.17.3.2597; STONE PJ, 1987, IN VITRO CELL DEV B, V23, P663; Tajima Shingo, 1996, Keio Journal of Medicine, V45, P58; Tanno B, 2002, J BIOL CHEM, V277, P23172, DOI 10.1074/jbc.M200141200; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tatham AS, 2000, TRENDS BIOCHEM SCI, V25, P567, DOI 10.1016/S0968-0004(00)01670-4; TOSELLI P, 1992, MATRIX, V12, P321, DOI 10.1016/S0934-8832(11)80084-3; WACHI H, 1995, BIOCHEM J, V309, P575, DOI 10.1042/bj3090575; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WOLINSKY H, 1967, CIRC RES, V20, P99, DOI 10.1161/01.RES.20.1.99	72	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7694	7701		10.1074/jbc.M412501200	http://dx.doi.org/10.1074/jbc.M412501200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15615710	hybrid			2022-12-27	WOS:000227395700033
J	Nam, MJ; Kee, MK; Kuick, R; Hanash, SM				Nam, MJ; Kee, MK; Kuick, R; Hanash, SM			Identification of defensin alpha 6 as a potential biomarker in colon adenocarcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL PEPTIDE ANTIBIOTICS; BETA; EXPRESSION; GLANDS; FAMILY	There is substantial interest in the identification of circulating human tumor-derived proteins in serum for the purposes of early cancer diagnosis. We have implemented an approach based on the analysis of microarray data for the identification of tumor proteins that may have utility as biomarkers in colon cancer. Expression analysis of microarray data obtained from a variety of 283 tumors and normal tissues revealed that defensin alpha6 was maximally expressed in colon cancer. These findings were corroborated by reverse transcription-PCR, in which the colon cancer cell lines LoVo, Caco2, HCT15, SW480, and SW620 showed significantly higher levels of defensin alpha6 expression than did non-colon cancer cell lines. Moreover, our data were concordant with data obtained from the NCI, National Institutes of Health Cancer Genome Anatomy Project. To evaluate defensin alpha6 as a potential biomarker of colon cancer, a preliminary "training" set of serum from 91 healthy donors and 109 colon cancer patients was analyzed by enzyme-linked immunosorbent assay. The data pattern was confirmed by an independent set of 67 masked serum samples: 18 from healthy donors and 49 from colon cancer patients. This result yielded a sensitivity of 69.4% (95% CI 54.6-81.8), specificity of 83.3% (58.6-96.4), and positive predictive value of 91.9% (78.1-98.3). These findings justify a prospective assessment of serum defensin alpha6 protein as a screening tool for colon cancer.	Natl Inst Hlth, Seoul 122701, South Korea; Univ Michigan, Dept Pediat & Internal Med, Ann Arbor, MI 48109 USA	Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); University of Michigan System; University of Michigan	Nam, MJ (corresponding author), Natl Inst Hlth, Seoul 122701, South Korea.	genetx@hanmail.net						Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BATEMAN A, 1992, PEPTIDES, V13, P133, DOI 10.1016/0196-9781(92)90152-S; Berglund A, 2002, ANN ONCOL, V13, P1430, DOI 10.1093/annonc/mdf220; CARPELANHOLMSTROM M, 1995, BRIT J CANCER, V71, P868, DOI 10.1038/bjc.1995.167; CarpelanHolmstrom MA, 1996, DIS COLON RECTUM, V39, P799, DOI 10.1007/BF02054447; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Ganz T, 1997, SEMIN HEMATOL, V34, P343; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Inger DB, 1999, PRIMARY CARE, V26, P179, DOI 10.1016/S0095-4543(05)70108-1; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; Louhimo J, 2002, INT J CANCER, V101, P545, DOI 10.1002/ijc.90009; Mallow EB, 1996, J BIOL CHEM, V271, P4038; Mizukawa N, 2000, ANTICANCER RES, V20, P1125; Muller CA, 2002, AM J PATHOL, V160, P1311, DOI 10.1016/S0002-9440(10)62558-8; MURPHY CJ, 1993, J CELL PHYSIOL, V155, P408, DOI 10.1002/jcp.1041550223; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	21	42	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8260	8265		10.1074/jbc.M410054200	http://dx.doi.org/10.1074/jbc.M410054200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15613481	hybrid			2022-12-27	WOS:000227395700099
J	Taniguchi, S; Suzuki, N; Masuda, M; Hisanaga, S; Iwatsubo, T; Goedert, M; Hasegawa, M				Taniguchi, S; Suzuki, N; Masuda, M; Hisanaga, S; Iwatsubo, T; Goedert, M; Hasegawa, M			Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PAIRED HELICAL FILAMENTS; PRION PROTEIN-FORMATION; X-RAY-DIFFRACTION; IN-VITRO; AMYLOID FIBRILS; ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; MISSENSE MUTATIONS	Tau protein is the major component of the intraneuronal filamentous inclusions that constitute defining neuropathological characteristics of Alzheimer's disease and other tauopathies. The discovery of tau gene mutations in familial forms of frontotemporal dementia has established that dysfunction of the tau protein is sufficient to cause neurodegeneration and dementia. Here we have tested 42 compounds belonging to nine different chemical classes for their ability to inhibit heparin-induced assembly of tau into filaments in vitro. Several phenothiazines (methylene blue, azure A, azure B, and quinacrine mustard), polyphenols (myricetin, epicatechin 5-gallate, gossypetin, and 2,3,4,2',4'-penta-hydroxybenzophenone), and the porphyrin ferric dehydroporphyrin IX inhibited tau filament formation with IC50 values in the low micromolar range as assessed by thioflavin S fluorescence, electron microscopy, and Sarkosyl insolubility. Disassembly of tau filaments was observed in the presence of the porphyrin phthalocyanine. Compounds that inhibited tau filament assembly were also found to inhibit the formation of Abeta fibrils. Biochemical analysis revealed the formation of soluble oligomeric tau in the presence of the inhibitory compounds, suggesting that this may be the mechanism by which tau filament formation is inhibited. The compounds investigated did not affect the ability of tau to interact with microtubules. Identification of small molecule inhibitors of heparin-induced assembly of tau will form a starting point for the development of mechanismbased therapies for the tauopathies.	Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, Tokyo 1568585, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Lab 2, Edogawa Ku, Tokyo 1348630, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Mol Neurosci Lab, Hachioji, Tokyo 1920397, Japan; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Tokyo Institute of Psychiatry; Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Daiichi Sankyo Company Limited; Tokyo Metropolitan University; MRC Laboratory Molecular Biology	Hasegawa, M (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 1568585, Japan.	masato@prit.go.jp						Allen B, 2002, J NEUROSCI, V22, P9340; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; Cashman NR, 2004, NAT REV DRUG DISCOV, V3, P874, DOI 10.1038/nrd1525; Caughey WS, 1998, P NATL ACAD SCI USA, V95, P12117, DOI 10.1073/pnas.95.21.12117; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; DEES C, 1985, J GEN VIROL, V66, P845, DOI 10.1099/0022-1317-66-4-845; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; EANES ED, 1968, J HISTOCHEM CYTOCHEM, V16, P673, DOI 10.1177/16.11.673; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Hall GF, 2002, J MOL NEUROSCI, V19, P253; Hartsel SC, 2003, BIOCHEMISTRY-US, V42, P6228, DOI 10.1021/bi0270384; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Heiser V, 2002, P NATL ACAD SCI USA, V99, P16400, DOI 10.1073/pnas.182426599; Howlett D, 1997, FEBS LETT, V417, P249, DOI 10.1016/S0014-5793(97)01290-8; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; Klunk WE, 2003, J NEUROSCI, V23, P2086; Kocisko DA, 2003, J VIROL, V77, P10288, DOI 10.1128/JVI.77.19.10288-10294.2003; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Lee EN, 2004, BIOCHEMISTRY-US, V43, P3704, DOI 10.1021/bi0356707; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; NAIKI H, 1990, LAB INVEST, V62, P768; NGUYEN JT, 1995, J MOL BIOL, V252, P412, DOI 10.1006/jmbi.1995.0507; Ono K, 2004, BBA-MOL BASIS DIS, V1690, P193, DOI 10.1016/j.bbadis.2004.06.008; Ono K, 2003, J NEUROCHEM, V87, P172, DOI 10.1046/j.1471-4159.2003.01976.x; Paudel HK, 1999, J BIOL CHEM, V274, P8029, DOI 10.1074/jbc.274.12.8029; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Pickhardt M, 2005, J BIOL CHEM, V280, P3628, DOI 10.1074/jbc.M410984200; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Prusiner Stanley B., 2004, VVolume 41, P961; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROIKHEL VM, 1984, ACTA VIROL, V28, P321; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMITH MA, 1994, AM J PATHOL, V145, P42; Smith MJ, 2000, FEBS LETT, V484, P265, DOI 10.1016/S0014-5793(00)02169-4; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; STGEORGEHYSLOP PH, 2001, METABOLIC MOL BASES, P5875; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Wischik CM, 1996, P NATL ACAD SCI USA, V93, P11213, DOI 10.1073/pnas.93.20.11213; Zhu M, 2004, J BIOL CHEM, V279, P26846, DOI 10.1074/jbc.M403129200	53	422	453	5	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7614	7623		10.1074/jbc.M408714200	http://dx.doi.org/10.1074/jbc.M408714200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611092	hybrid			2022-12-27	WOS:000227395700024
J	Kang, KJ; Shibukawa, Y; Szerencsei, RT; Schnetkamp, PPM				Kang, KJ; Shibukawa, Y; Szerencsei, RT; Schnetkamp, PPM			Substitution of a single residue, AsP575, renders the NCKX2 K+-dependent Na+/Ca2+ exchanger independent of K+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL CONE; MOLECULAR-CLONING; CALCIUM EXCHANGE; INSECT CELLS; TRANSPORT; CA2+; STOICHIOMETRY; TOPOLOGY; SEGMENTS; MUTATION	The Na+/Ca+-K+ exchanger (NCKX) is a polytopic membrane protein that uses both the inward Na+ gradient and the outward K+ gradient to drive Ca2+ extrusion across the plasma membrane. NCKX1 is found in retinal rod photoreceptors, while NCKX2 is found in retinal cone photoreceptors and is also widely expressed in the brain. Here, we have identified a single residue (out of >100 tested) for which substitution removed the K+ dependence of NCKX-mediated Ca2+ transport. Charge-removing replacement of Asp(575) by either asparagine or cysteine rendered the mutant NCKX2 proteins independent of K+, whereas the charge-conservative substitution of Asp 171 to glutamate resulted in a nonfunctional mutant NCKX2 protein, accentuating the critical nature of this residue. Asp(575) is conserved in the NCKX1-5 genes, while an asparagine is found in this position in the three NCX genes, coding for the K+-independent Na+/Ca2+ exchanger.	Univ Calgary, Fac Med, Dept Physiol & Biophys, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada	University of Calgary	Schnetkamp, PPM (corresponding author), Univ Calgary, Fac Med, Dept Physiol & Biophys, Hotchkiss Brain Inst, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	pschnetk@ucalgary.ca		Kang, KyeongJin/0000-0003-0446-469X				Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai XJ, 2004, J BIOL CHEM, V279, P5867, DOI 10.1074/jbc.M310908200; Cooper CB, 2000, METHOD ENZYMOL, V315, P847; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Kang K, 2003, BIOCHEMISTRY-US, V42, P9438, DOI 10.1021/bi0342261; Kang KJ, 2005, J BIOL CHEM, V280, P6823, DOI 10.1074/jbc.M407933200; Kang TM, 2004, NATURE, V427, P544, DOI 10.1038/nature02271; Kinjo TG, 2004, BIOCHEMISTRY-US, V43, P7940, DOI 10.1021/bi049538y; Kinjo TG, 2003, BIOCHEMISTRY-US, V42, P2485, DOI 10.1021/bi0270788; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Palty R, 2004, J BIOL CHEM, V279, P25234, DOI 10.1074/jbc.M401229200; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Quednau BD, 2004, PFLUG ARCH EUR J PHY, V447, P543, DOI 10.1007/s00424-003-1065-4; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; Schnetkamp PPM, 2004, PFLUG ARCH EUR J PHY, V447, P683, DOI 10.1007/s00424-003-1069-0; SCHNETKAMP PPM, 1989, AM J PHYSIOL-CELL PH, V257, pG153; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Sheng JZ, 2000, BIOPHYS J, V79, P1945, DOI 10.1016/S0006-3495(00)76443-5; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Szerencsei RT, 2001, BIOCHEMISTRY-US, V40, P6009, DOI 10.1021/bi0102353; Winkfein RJ, 2003, BIOCHEMISTRY-US, V42, P543, DOI 10.1021/bi026982x	24	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6834	6839		10.1074/jbc.M412933200	http://dx.doi.org/10.1074/jbc.M412933200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15611132	hybrid			2022-12-27	WOS:000227332700072
J	Kresge, N; Simoni, RD; Hill, RL				Kresge, N; Simoni, RD; Hill, RL			Succeeding in science despite the odds; Studying metabolism with NMR by Mildred Cohn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							MAGNETIC-RESONANCE SPECTRA; TRIPHOSPHATE							Kresge, Nicole/0000-0003-1551-6627				COHN M, 1962, J BIOL CHEM, V237, P176; Cohn M, 2003, SCIENTIST, V17, P15; COHN M, 1953, J BIOL CHEM, V201, P735; COHN M, 1960, J BIOL CHEM, V235, P3250; Cori CF, 1928, J BIOL CHEM, V79, P321; CORI GERTY T., 1938, JOUR BIOL CHEM, V124, P543; Cori GT, 1939, J BIOL CHEM, V127, P771; Cori GT, 1943, J BIOL CHEM, V151, P31; Du Vigneaud V, 1941, J BIOL CHEM, V140, P625; Green AA, 1943, J BIOL CHEM, V151, P21; WASSERMAN E, 2000, DOOR DREAM CONVERSAT, P43	11	0	0	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53							e12					2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15615732				2022-12-27	WOS:000225960800131
J	Finkemeier, I; Goodman, M; Lamkemeyer, P; Kandlbinder, A; Sweetlove, LJ; Dietz, KJ				Finkemeier, I; Goodman, M; Lamkemeyer, P; Kandlbinder, A; Sweetlove, LJ; Dietz, KJ			The mitochondrial type II peroxiredoxin F is essential for redox homeostasis and root growth of Arabidopsis thaliana under stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBATE-GLUTATHIONE CYCLE; OXIDATIVE STRESS; ALTERNATIVE OXIDASE; HYDROGEN-PEROXIDE; GENE-EXPRESSION; THIOREDOXIN PEROXIDASE; 2-CYS PEROXIREDOXIN; PLANT-MITOCHONDRIA; HYDROPEROXIDE REDUCTASE; ELECTRON-TRANSPORT	Peroxiredoxins (Prx) have recently moved into the focus of plant and animal research in the context of development, adaptation, and disease, as they function both in antioxidant defense by reducing a broad range of toxic peroxides and in redox signaling relating to the adjustment of cell redox and antioxidant metabolism. At-PrxII F is one of six type II Prx identified in the genome of Arabidopsis thaliana and the only Prx that is targeted to the plant mitochondrion. Therefore, it might be assumed to have functions similar to the human 2-Cys Prx (PRDX3) and type II Prx (PRDX5) and yeast 1-Cys Prx that likewise have mitochondrial localizations. This paper presents a characterization of PrxII F at the level of subcellular distribution, activity, and reductive regeneration by mitochondrial thioredoxin and glutaredoxin. By employing tDNA insertion mutants of A. thaliana lacking expression of AtprxII F (KO-AtPrxII F), it is shown that under optimal environmental conditions the absence of PrxII F is almost fully compensated for, possibly by increases in activity of mitochondrial ascorbate peroxidase and glutathione-dependent peroxidase. However, a stronger inhibition of root growth in KO-AtPrxII F seedlings as compared with wild type is observed under stress conditions induced by CdCl2 as well as after administration of salicylhydroxamic acid, an inhibitor of cyanide-insensitive respiration. Simultaneously, major changes in the abundance of both nuclear and mitochondria-encoded transcripts were observed. These results assign a principal role to PrxII F in antioxidant defense and possibly redox signaling in plants cells.	Univ Bielefeld, Dept Plant Physiol & Biochem, D-33501 Bielefeld, Germany; Univ Oxford, Dept Plant Sci, Oxford OX1 3RP, England	University of Bielefeld; University of Oxford	Dietz, KJ (corresponding author), Univ Bielefeld, Dept Plant Physiol & Biochem, W5, D-33501 Bielefeld, Germany.	karl-josef.dietz@uni-bielefeld.de	Finkemeier, Iris/B-3034-2017; Dietz, Karl-Josef/B-6029-2009	Finkemeier, Iris/0000-0002-8972-4026; Dietz, Karl-Josef/0000-0003-0311-2182	Biotechnology and Biological Sciences Research Council [JF16984] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Balmer Y, 2004, P NATL ACAD SCI USA, V101, P2642, DOI 10.1073/pnas.0308583101; Bartoli CG, 2000, PLANT PHYSIOL, V123, P335, DOI 10.1104/pp.123.1.335; Brehelin C, 2003, PLANT PHYSIOL, V132, P2045, DOI 10.1104/pp.103.022533; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; Chew O, 2003, J BIOL CHEM, V278, P46869, DOI 10.1074/jbc.M307525200; CREISSEN G, 1995, PLANT J, V8, P167, DOI 10.1046/j.1365-313X.1995.08020167.x; DEVISSER R, 1984, PLANT PHYSIOL, V75, P813, DOI 10.1104/pp.75.3.813; Dietz KJ, 2003, INT REV CYTOL, V228, P141, DOI 10.1016/S0074-7696(03)28004-9; Dietz KJ, 2003, ANNU REV PLANT BIOL, V54, P93, DOI 10.1146/annurev.arplant.54.031902.134934; Dietz KJ, 2002, J EXP BOT, V53, P1321, DOI 10.1093/jexbot/53.372.1321; Dutilleul C, 2003, PLANT CELL, V15, P1212, DOI 10.1105/tpc.009464; Dutilleul C, 2003, PLANT PHYSIOL, V131, P264, DOI 10.1104/pp.011155; Finkemeier I, 2003, PLANT CELL ENVIRON, V26, P821, DOI 10.1046/j.1365-3040.2003.01014.x; Gelhaye E, 2004, P NATL ACAD SCI USA, V101, P14545, DOI 10.1073/pnas.0405282101; Hagemeyer J., 1999, HEAVY METAL STRESS P, P139, DOI 10.1007/978-3-662-07745-0_7; Heazlewood JL, 2004, PLANT CELL, V16, P241, DOI 10.1105/tpc.016055; Heazlewood JL, 2003, PLANT PHYSIOL, V132, P230, DOI 10.1104/pp.102.018986; Herbette S, 2002, EUR J BIOCHEM, V269, P2414, DOI 10.1046/j.1432-1033.2002.02905.x; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Horling F, 2003, PLANT PHYSIOL, V131, P317, DOI 10.1104/pp.010017; Horling F, 2002, PLANT PHYSIOL BIOCH, V40, P491, DOI 10.1016/S0981-9428(02)01396-7; Hourton-Cabassa U, 2004, PLANT PHYSIOL BIOCH, V42, P283, DOI 10.1016/j.plaphy.2004.01.007; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jenner HL, 2001, PLANT PHYSIOL, V126, P1139, DOI 10.1104/pp.126.3.1139; Jimenez A, 1997, PLANT PHYSIOL, V114, P275, DOI 10.1104/pp.114.1.275; Jones A, 2000, TRENDS PLANT SCI, V5, P225, DOI 10.1016/S1360-1385(00)01605-8; KAISER W, 1977, BIOCHIM BIOPHYS ACTA, V459, P337, DOI 10.1016/0005-2728(77)90035-4; Kandlbinder A, 2004, PHYSIOL PLANTARUM, V120, P63, DOI 10.1111/j.0031-9317.2004.0272.x; Kania A, 2003, PLANT SOIL, V248, P117, DOI 10.1023/A:1022371115788; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim SH, 2001, J NEURAL TRANSM-SUPP, P223; Konig J, 2003, J BIOL CHEM, V278, P24409, DOI 10.1074/jbc.M301145200; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Kruft V, 2001, PLANT PHYSIOL, V127, P1694, DOI 10.1104/pp.010474; LALOI C, 2001, P NATL ACAD SCI USA, V95, P3312; LEE KC, 1976, PHYSIOL PLANTARUM, V36, P4, DOI 10.1111/j.1399-3054.1976.tb05017.x; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; Millar AH, 2000, FEBS LETT, V481, P117, DOI 10.1016/S0014-5793(00)01976-1; Millenaar FF, 2003, PLANT BIOLOGY, V5, P2, DOI 10.1055/s-2003-37974; Mittova V, 2000, PHYSIOL PLANTARUM, V110, P42, DOI 10.1034/j.1399-3054.2000.110106.x; MOLLER IM, 1988, PHYSIOL PLANTARUM, V72, P642, DOI 10.1111/j.1399-3054.1988.tb09176.x; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; Monteiro G, 2004, ARCH BIOCHEM BIOPHYS, V425, P14, DOI 10.1016/j.abb.2004.03.005; Monteiro G, 2002, FREE RADICAL BIO MED, V32, P278, DOI 10.1016/S0891-5849(01)00801-2; Moon H, 2003, P NATL ACAD SCI USA, V100, P358, DOI 10.1073/pnas.252641899; Nast G, 1996, PLANT PHYSIOL, V112, P1219, DOI 10.1104/pp.112.3.1219; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Nonn L, 2003, MOL CANCER RES, V1, P682; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Pastori GM, 2003, PLANT CELL, V15, P939, DOI 10.1105/tpc.010538; Purvis AC, 1997, PHYSIOL PLANTARUM, V100, P165, DOI 10.1034/j.1399-3054.1997.1000119.x; Rasmusson AG, 2004, ANNU REV PLANT BIOL, V55, P23, DOI 10.1146/annurev.arplant.55.031903.141720; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Romano PGN, 2004, PLANT PHYSIOL, V134, P1268, DOI 10.1104/pp.103.022160; Rosso MG, 2003, PLANT MOL BIOL, V53, P247, DOI 10.1023/B:PLAN.0000009297.37235.4a; Rouhier N, 2004, PHYSIOL PLANTARUM, V120, P57, DOI 10.1111/j.0031-9317.2004.0203.x; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; ROUHIER N, 2004, IN PRESS ANTIOXID RE; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seaver LC, 2001, J BACTERIOL, V183, P7182, DOI 10.1128/JB.183.24.7182-7189.2001; Sessions A, 2002, PLANT CELL, V14, P2985, DOI 10.1105/tpc.004630; Siedlecka A, 1997, PLANT PHYSIOL BIOCH, V35, P951; Smith AMO, 2004, J BIOL CHEM, V279, P51944, DOI 10.1074/jbc.M408920200; Sweetlove LJ, 2001, FEBS LETT, V508, P272, DOI 10.1016/S0014-5793(01)03069-1; Sweetlove LJ, 2002, PLANT J, V32, P891, DOI 10.1046/j.1365-313X.2002.01474.x; Taylor NL, 2004, J EXP BOT, V55, P1, DOI 10.1093/jxb/erh001; VANASSCHE F, 1990, PLANT CELL ENVIRON, V13, P195, DOI 10.1111/j.1365-3040.1990.tb01304.x; Vandenabeele S, 2004, PLANT J, V39, P45, DOI 10.1111/j.1365-313X.2004.02105.x; Vanlerberghe GC, 1999, PLANT PHYSIOL, V121, P793, DOI 10.1104/pp.121.3.793; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; Wong CM, 2004, J BIOL CHEM, V279, P23207, DOI 10.1074/jbc.M402095200; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Yoshimura K, 2004, PLANT J, V37, P21, DOI 10.1046/j.1365-313X.2003.01930.x; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231	79	192	201	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12168	12180		10.1074/jbc.M413189200	http://dx.doi.org/10.1074/jbc.M413189200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15632145	hybrid			2022-12-27	WOS:000227922000015
J	Comayras, R; Jungas, C; Lavergne, J				Comayras, R; Jungas, C; Lavergne, J			Functional consequences of the organization of the photosynthetic apparatus in Rhodobacter sphaeroides - I. Quinone domains and excitation transfer in chromatophores and reaction center center dot antenna complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; CYTOCHROME-C OXIDOREDUCTASE; RESTRICTED ENERGY-TRANSFER; RADICAL-PAIR EQUILIBRIUM; PHOTOSYSTEM-II; PURPLE BACTERIA; RHODOPSEUDOMONAS-SPHAEROIDES; FLUORESCENCE INDUCTION; ELECTRON-TRANSFER; CORE COMPLEX	The purpose of this study was to gain information on the functional consequences of the supramolecular organization of the photosynthetic apparatus in the bacterium Rhodobacter sphaeroides. Isolated complexes of the reaction center ( RC) with its core antenna ring ( light- harvesting complex 1 ( LH1)) were studied in their dimeric ( native) form or as monomers with respect to excitation transfer and distribution of the quinone pool. Similar issues were examined in chromatophore membranes. The relationship between the fluorescence yield and the amount of closed centers is indicative of a very efficient excitation transfer between the two monomers in isolated dimeric complexes. A similar dependence was observed in chromatophores, suggesting that excitation transfer in vivo from a closed RC (.) LH1 unit is also essentially directed to its partner in the dimer. The isolated complexes were found to retain 25 - 30% of the endogenous quinone acceptor pool, and the distribution of this pool among the complexes suggests a cooperative character for the association of quinones with the protein complexes. In chromatophores, the decrease in the amount of photoreducible quinones when inhibiting a fraction of the centers implies a confinement of the quinone pool over small domains, including one to six reaction centers. We suggest that the crowding of membrane proteins may not be the sole reason for quinone confinement and that a quinone- rich region is formed around the RC (.) LH1 complexes.	CEA Cadarache, Dept Ecophysiol Vegetale & Microbiol, UMR 6191, CNRS Commissariat Energie Atom Aix Marseille 2, F-13108 St Paul Les Durance, France	CEA	Lavergne, J (corresponding author), CEA Cadarache, Dept Ecophysiol Vegetale & Microbiol, UMR 6191, CNRS Commissariat Energie Atom Aix Marseille 2, F-13108 St Paul Les Durance, France.	jerome.lavergne@cea.fr						Alric J, 2004, J BIOL CHEM, V279, P26090, DOI 10.1074/jbc.M400361200; Bahatyrova S, 2004, NATURE, V430, P1058, DOI 10.1038/nature02823; Bernhardt K, 1999, BBA-BIOENERGETICS, V1409, P125, DOI 10.1016/S0005-2728(98)00149-2; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; CLAYTON RK, 1960, BIOCHIM BIOPHYS ACTA, V37, P503, DOI 10.1016/0006-3002(60)90507-2; Cogdell RJ, 2004, PHOTOSYNTH RES, V81, P207, DOI 10.1023/B:PRES.0000036883.56959.a9; Comayras R, 2005, J BIOL CHEM, V280, P11214, DOI 10.1074/jbc.M412089200; CORNELL BA, 1987, BIOCHEMISTRY-US, V26, P7702, DOI 10.1021/bi00398a025; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Cuni A, 2004, PHYS CHEM CHEM PHYS, V6, P4825, DOI 10.1039/b407511k; DAINESE P, 1991, J BIOL CHEM, V266, P8136; DENHOLLANDER WTF, 1983, BIOCHIM BIOPHYS ACTA, V725, P492, DOI 10.1016/0005-2728(83)90190-1; DREPPER F, 1993, BIOCHEMISTRY-US, V32, P11915, DOI 10.1021/bi00095a022; Feniouk BA, 2001, BBA-BIOENERGETICS, V1506, P189, DOI 10.1016/S0005-2728(01)00213-4; Fotiadis D, 2004, J BIOL CHEM, V279, P2063, DOI 10.1074/jbc.M310382200; Francia F, 1999, BIOCHEMISTRY-US, V38, P6834, DOI 10.1021/bi982891h; Francia F, 2004, BIOCHEMISTRY-US, V43, P14199, DOI 10.1021/bi048629s; Francia F, 2002, EUR J BIOCHEM, V269, P1877, DOI 10.1046/j.1432-1033.2002.02834.x; Ginet N, 2001, BIOCHEMISTRY-US, V40, P1812, DOI 10.1021/bi001686a; GINET N, 2005, PHOTOSYNTHESIS FUNDA; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hauska G, 1982, FUNCTION QUINONES EN, P87; Hemelrijk PW, 1996, BBA-BIOENERGETICS, V1274, P31, DOI 10.1016/0005-2728(96)00006-0; HERON C, 1979, BIOCHEM J, V178, P415, DOI 10.1042/bj1780415; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HSU BD, 1992, BIOCHIM BIOPHYS ACTA, V1140, P30, DOI 10.1016/0005-2728(92)90016-U; Hu X, 1998, BIOPHYS J, V75, P683, DOI 10.1016/S0006-3495(98)77558-7; Hu XC, 2002, Q REV BIOPHYS, V35, P1, DOI 10.1017/S0033583501003754; Jamieson SJ, 2002, EMBO J, V21, P3927, DOI 10.1093/emboj/cdf410; JOLIOT A, 1964, CR HEBD ACAD SCI, V258, P4622; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; JOLIOT P, 1992, BIOCHIM BIOPHYS ACTA, V1101, P1, DOI 10.1016/0167-4838(92)90460-U; Joliot P, 1997, BBA-BIOENERGETICS, V1318, P374, DOI 10.1016/S0005-2728(96)00114-4; JOLIOT P, 1989, BIOCHIM BIOPHYS ACTA, V975, P336, DOI 10.1016/S0005-2728(89)80341-X; JOLIOT P, 1984, BIOCHIM BIOPHYS ACTA, V765, P210, DOI 10.1016/0005-2728(84)90015-X; JOLIOT P, 2005, IN PRESS BIOCH BIOPH; Jungas C, 1999, EMBO J, V18, P534, DOI 10.1093/emboj/18.3.534; KINGSLEY PB, 1981, BIOCHIM BIOPHYS ACTA, V635, P602, DOI 10.1016/0005-2728(81)90117-1; Kirchhoff H, 2002, BIOCHEMISTRY-US, V41, P4872, DOI 10.1021/bi011650y; Kirchhoff H, 2000, BBA-BIOENERGETICS, V1459, P148, DOI 10.1016/S0005-2728(00)00143-2; Lavergen J, 1999, BIOCHEMISTRY-US, V38, P4542, DOI 10.1021/bi9827621; LAVERGNE J, 1995, BIOPHYS J, V68, P2474, DOI 10.1016/S0006-3495(95)80429-7; LAVERGNE J, 1991, TRENDS BIOCHEM SCI, V16, P129, DOI 10.1016/0968-0004(91)90054-Y; LAVERGNE J, 1989, BIOCHIM BIOPHYS ACTA, V975, P346, DOI 10.1016/S0005-2728(89)80342-1; Lavergne J, 1996, PHOTOSYNTH RES, V48, P127, DOI 10.1007/BF00041003; LAVERGNE J, 1992, BIOCHIM BIOPHYS ACTA, V1101, P13, DOI 10.1016/0167-4838(92)90461-L; LENAZ G, 1982, FUNCTION QUINONES EN, P111; Mezzetti A, 2003, FEBS LETT, V537, P161, DOI 10.1016/S0014-5793(03)00118-2; MOSS D, 1990, EUR J BIOCHEM, V187, P565, DOI 10.1111/j.1432-1033.1990.tb15338.x; PAILLOTIN G, 1976, J THEOR BIOL, V58, P237, DOI 10.1016/0022-5193(76)90150-8; PAILLOTIN G, 1976, J THEOR BIOL, V58, P219, DOI 10.1016/0022-5193(76)90149-1; Papiz MZ, 1996, TRENDS PLANT SCI, V1, P198, DOI 10.1016/1360-1385(96)20005-6; RAGAN CI, 1978, BIOCHEM J, V174, P783, DOI 10.1042/bj1740783; RUTHERFORD AW, 1980, FEBS LETT, V110, P257, DOI 10.1016/0014-5793(80)80086-X; SAPHON S, 1975, BIOCHIM BIOPHYS ACTA, V408, P58, DOI 10.1016/0005-2728(75)90158-9; Scheuring S, 2004, J BIOL CHEM, V279, P3620, DOI 10.1074/jbc.M310050200; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; SEBBAN P, 1983, BIOCHIM BIOPHYS ACTA, V722, P436, DOI 10.1016/0005-2728(83)90059-2; Siebert CA, 2004, EMBO J, V23, P690, DOI 10.1038/sj.emboj.7600092; Sundstrom V, 1999, J PHYS CHEM B, V103, P2327, DOI 10.1021/jp983722+; SUNDSTROM V, 1986, BIOCHIM BIOPHYS ACTA, V851, P431, DOI 10.1016/0005-2728(86)90080-0; SUNDSTROM V, 1995, ADV PHOTOSYNTHESIS R, P00349; TAKAMIYA KI, 1979, BIOCHIM BIOPHYS ACTA, V546, P1, DOI 10.1016/0005-2728(79)90166-X; Tremmel IG, 2003, BBA-BIOENERGETICS, V1607, P97, DOI 10.1016/j.bbabio.2003.09.004; Trissl HW, 1999, BBA-BIOENERGETICS, V1412, P149, DOI 10.1016/S0005-2728(99)00056-0; Trissl HW, 1996, PHOTOSYNTH RES, V47, P175, DOI 10.1007/BF00016180; TRISSL HW, 1995, AUST J PLANT PHYSIOL, V22, P183, DOI 10.1071/PP9950183; ULRICH EL, 1985, BIOCHEMISTRY-US, V24, P2501, DOI 10.1021/bi00331a016; Vermeglio A, 2002, BBA-BIOENERGETICS, V1555, P60, DOI 10.1016/S0005-2728(02)00255-4; VERMEGLIO A, 1995, ANOXYGENIC PHOTOSYNT, P279; Walz T, 1998, J MOL BIOL, V282, P833, DOI 10.1006/jmbi.1998.2050; Westerhuis WHJ, 1998, BBA-BIOENERGETICS, V1366, P317, DOI 10.1016/S0005-2728(98)00132-7; WRAIGHT CA, 1979, PHOTOCHEM PHOTOBIOL, V30, P767, DOI 10.1111/j.1751-1097.1979.tb07211.x	73	63	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11203	11213		10.1074/jbc.M412088200	http://dx.doi.org/10.1074/jbc.M412088200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15632164	hybrid			2022-12-27	WOS:000227761800041
J	Sidhu, G; Li, W; Laryngakis, N; Bishai, E; Balla, T; Southwick, F				Sidhu, G; Li, W; Laryngakis, N; Bishai, E; Balla, T; Southwick, F			Phosphoinositide 3-kinase is required for intracellular Listeria monocytogenes actin-based motility and filopod formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; IN-VITRO; CYTOSKELETON; PI(3,4,5)P-3; PHAGOCYTOSIS; CHEMOTAXIS; CALCIUM; BINDING; PROTEIN; ROLES	Motile nonmuscle cells concentrate phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) in areas of new actin filament assembly. There is great interest in assessing the in vivo functional significance of these phosphoinositides, and we have used Listeria monocytogenes to explore the contribution of PtdIns( 3,4,5) P3 and PtdIns( 4,5) P2 to its actin-based motility. In Listeria-infected PtK2 cells Akt-pleckstrin homology (PH)-green fluorescent protein (GFP) and phospholipase C delta(PLC delta)-PH-GFP both first concentrate at the front of motile Listeria, subsequently surrounding the bacterium and then concentrating in the actin filament tail. Surprisingly, Listeria ActA mutant strains lacking the putative phosphoinositide binding site are also able to concentrate these probes. Reduction of available PtdIns( 3,4,5)P-3 by expression of Akt-PH-GFP and available PtdIns(4,5)P-2 by expression of PLC delta-PH-GFP both significantly slow Listeria actin-based movement. Treatment of cells with the PI 3-kinase inhibitor, LY294002, dissociates Akt-PH but not PLC delta-PH, from the bacterial surface and cell membranes, and results in near complete inhibition of Listeria actin-based motility and filopod formation. Removal of LY294002 results in rapid and full recovery of Akt-PH localization, Listeria actin-based motility, and filopod formation. These findings suggest that PtdIns(4,5)P-2 is concentrated at the surface of Listeria and serves as the substrate for PtdIns(3,4,5)P-3 production, indicating a central role for PI 3-kinases in Listeria intracellular actin-based motility and filopod formation.	Univ Florida, Coll Med, Div Infect Dis, Dept Med, Gainesville, FL 32610 USA; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20982 USA	State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Southwick, F (corresponding author), Univ Florida, Coll Med, Div Infect Dis, Dept Med, Box 100277, Gainesville, FL 32610 USA.	southfs@med.mac.ufl.edu		Balla, Tamas/0000-0002-9077-3335	NIAID NIH HHS [R01 AI034276, R01AI34276, R01AI-23262] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023262, R01AI034276] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Botelho RJ, 2004, CURR TOP MICROBIOL, V282, P1; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Cicchetti G, 1999, J BIOL CHEM, V274, P33616, DOI 10.1074/jbc.274.47.33616; Cossart P, 2000, CELL MICROBIOL, V2, P195, DOI 10.1046/j.1462-5822.2000.00053.x; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DILLON SB, 1987, J CELL BIOCHEM, V35, P345, DOI 10.1002/jcb.240350409; Hilpela P, 2004, CURR TOP MICROBIOL, V282, P117; LARSON L, 2005, IN PRESS P NATL ACAD; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; May RC, 1999, CURR BIOL, V9, P759, DOI 10.1016/S0960-9822(99)80337-6; Moreau V, 1998, FEBS LETT, V427, P353, DOI 10.1016/S0014-5793(98)00443-8; Pizarro-Cerda J, 2004, CR BIOL, V327, P115, DOI 10.1016/j.crvi.2003.11.007; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; Postma M, 2004, EMBO REP, V5, P35, DOI 10.1038/sj.embor.7400051; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; Skoble J, 2000, J CELL BIOL, V150, P527, DOI 10.1083/jcb.150.3.527; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Steffen P, 2000, CELL MOTIL CYTOSKEL, V45, P58; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zeile WL, 1996, J CELL BIOL, V133, P49, DOI 10.1083/jcb.133.1.49	26	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11379	11386		10.1074/jbc.M414533200	http://dx.doi.org/10.1074/jbc.M414533200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15642729	hybrid			2022-12-27	WOS:000227761800060
J	Rubotham, J; Woods, K; Garcia-Salcedo, JA; Pays, E; Nolan, DP				Rubotham, J; Woods, K; Garcia-Salcedo, JA; Pays, E; Nolan, DP			Characterization of two protein disulfide isomerases from the endocytic pathway of bloodstream forms of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; LYSOSOMAL MEMBRANE GLYCOPROTEIN; INDUCIBLE EXPRESSION SYSTEM; PROTIST GIARDIA-LAMBLIA; AFRICAN TRYPANOSOMES; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; BOND FORMATION; SURFACE; INTERFERENCE	Proteins from the endocytic pathway in bloodstream forms of Trypanosome brucei are modified by the addition of linear poly-N-acetyllactosamine side chains, which permits their isolation by tomato lectin affinity chromatography. Antibodies against this tomato lectin binding fraction were employed to screen a cDNA expression library from bloodstream forms of T. brucei. Two cDNAs were prominent among those selected. These cDNAs coded for two putative protein disulfide isomerases (PDIs) that respectively contained one and two double-cysteine redox-active sites and corresponded to a single domain PDI and a class 1 PDI. Assays of the purified recombinant proteins demonstrated that both proteins possess isomerase activity, but only the single domain PDI had a reducing activity. These PDIs possess a number of unusual features that distinguish them from previously characterized PDIs. The expression of both is developmentally regulated, they both co-localize with markers of the endocytic pathway, and both are modified by N-glycosylation. The larger PDI possesses N-glycans containing poly-N-acetyllactosamine, a modification that is indicative of processing in the Golgi and suggests the presence of a novel trafficking pathway for PDIs in trypanosomes. Although generally PDIs are considered essential, neither activity appeared to be essential for the growth of trypanosomes, at least in vitro.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Free Univ Brussels, Mol Parasitol Lab, Inst Mol Biol & Med, B-6041 Gosselies, Belgium	Trinity College Dublin	Nolan, DP (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.	denolan@tcd.ie	Garcia-Salcedo, Jose A/AAA-9434-2019	Garcia-Salcedo, Jose A/0000-0003-3399-1835; Woods, Katherine/0000-0003-3474-3104; Nolan, Derek/0000-0002-3742-4304				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; Bastin P, 2000, J CELL SCI, V113, P3321; Ben Achour Y, 2002, INFECT IMMUN, V70, P3576, DOI 10.1128/IAI.70.7.3576-3585.2002; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; BRICKMAN MJ, 1993, EXP PARASITOL, V76, P329, DOI 10.1006/expr.1993.1041; BRICKMAN MJ, 1994, J CELL SCI, V107, P3191; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; BRUN R, 1979, ACTA TROP, V36, P289; Desilva MG, 1996, DNA CELL BIOL, V15, P9, DOI 10.1089/dna.1996.15.9; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Field MC, 2004, TRAFFIC, V5, P905, DOI 10.1111/j.1600-0854.2004.00234.x; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Garcia-Salcedo JA, 2004, EMBO J, V23, P780, DOI 10.1038/sj.emboj.7600094; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HSU MP, 1989, BIOCHEMISTRY-US, V28, P6440, DOI 10.1021/bi00441a042; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; Kelley RJ, 1995, MOL BIOCHEM PARASIT, V74, P167, DOI 10.1016/0166-6851(95)02493-X; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LEE MGS, 1994, J BIOL CHEM, V269, P8408; McArthur AG, 2001, MOL BIOL EVOL, V18, P1455, DOI 10.1093/oxfordjournals.molbev.a003931; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; Morgan GW, 2002, TRENDS PARASITOL, V18, P540, DOI 10.1016/S1471-4922(02)02392-9; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Nolan DP, 1999, CURR BIOL, V9, P1169, DOI 10.1016/S0960-9822(00)80018-4; O'Beirne C, 1998, MOL BIOCHEM PARASIT, V91, P165, DOI 10.1016/S0166-6851(97)00191-6; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Padilla A, 2003, J BIOL CHEM, V278, P1872, DOI 10.1074/jbc.M210322200; PAYS E, 1980, NUCLEIC ACIDS RES, V8, P5965, DOI 10.1093/nar/8.24.5965; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	57	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10410	10418		10.1074/jbc.M409375200	http://dx.doi.org/10.1074/jbc.M409375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642735	hybrid			2022-12-27	WOS:000227559600082
J	Ward, DMV; Vaughn, MB; Shiflett, SL; White, PL; Pollock, AL; Hill, J; Schnegelberger, R; Sundquist, WI; Kaplan, J				Ward, DMV; Vaughn, MB; Shiflett, SL; White, PL; Pollock, AL; Hill, J; Schnegelberger, R; Sundquist, WI; Kaplan, J			The role of LIP5 and CHMP5 in multivesicular body formation and HIV-1 budding in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DOWN-REGULATION; SACCHAROMYCES-CEREVISIAE; ENDOCYTIC PATHWAY; ESCRT-I; PROTEIN; ENDOSOMES; COMPLEX; TRANSPORT; INTERACT; TRAFFICKING	We examined the function of LIP5 in mammalian cells, because the yeast homologue Vta1p was recently identified as a protein required for multivesicular body (MVB) formation. LIP5 is predominantly a cytosolic protein. Depletion of LIP5 by small inhibitory RNA (siRNA) does not affect the distribution or morphology of early endosomes, lysosomes, or Golgi but does reduce the degradation of internalized epidermal growth factor receptor ( EGFR), with EGFR accumulating in intracellular vesicles. Depletion of LIP5 by siRNA also decreases human immunodeficiency virus type 1 (HIV-1) budding by 70%. We identify CHMP5 as a LIP5-binding protein and show that CHMP5 is primarily cytosolic. Depletion of CHMP5 by siRNA does not affect the distribution or morphology of early endosomes, lysosomes, or Golgi but does result in reduced degradation of the EGFR similar to silencing of LIP5. Surprisingly, CHMP5 depletion results in an increase in the release of infectious HIV-1 particles. Overexpression of CHMP5 with a large carboxyl-terminal epitope affects the distribution of both early and late endocytic compartments, whereas overexpression of LIP5 does not alter the endocytic pathway. Comparison of overexpression and siRNA phenotypes suggests that the roles of these proteins in MVB formation may be more specifically addressed using RNA interference and that both LIP5 and CHMP5 function in MVB sorting, whereas only LIP5 is required for HIV release.	Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu			NHLBI NIH HHS [HL26922] Funding Source: Medline; NIAID NIH HHS [AI51174] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026922, R01HL026922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amara A, 2003, J CELL BIOL, V162, P371, DOI 10.1083/jcb.200307062; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2004, MOL BIOL CELL, V15, P4337, DOI 10.1091/mbc.E04-03-0250; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bishop NE, 2003, INT REV CYTOL, V232, P1, DOI 10.1016/S0074-7696(03)32001-7; Bright NA, 2001, TRAFFIC, V2, P631, DOI 10.1034/j.1600-0854.2001.20906.x; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Fujita H, 2004, J CELL SCI, V117, P2997, DOI 10.1242/jcs.01170; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Howard TL, 2001, J CELL SCI, V114, P2395; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kranz A, 2001, MOL BIOL CELL, V12, P711, DOI 10.1091/mbc.12.3.711; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Shiflett SL, 2004, J BIOL CHEM, V279, P10982, DOI 10.1074/jbc.M312669200; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Tchernev VT, 2002, MOL MED, V8, P56, DOI 10.1007/BF03402003; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751; YORIKAWA C, 2004, IN PRESS BIOCH J	37	86	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10548	10555		10.1074/jbc.M413734200	http://dx.doi.org/10.1074/jbc.M413734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644320	hybrid			2022-12-27	WOS:000227559600099
J	Yang, WH; Hammes, SR				Yang, WH; Hammes, SR			Xenopus laevis CYP17 regulates androgen biosynthesis independent of the cofactor cytochrome b(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED 17,20-LYASE DEFICIENCY; HUMAN P450C17; RECEPTOR; B(5); FEMALE; 17-ALPHA-HYDROXYLASE; EXPRESSION; MATURATION; OVARIES; CELLS	The enzyme CYP17 primarily regulates androgen production by mediating four reactions: conversion of pregnenolone and progesterone to 17-hydroxypregnenolone and 17-hydroxyprogesterone, respectively (17 alpha-hydroxylase activity), followed by conversion of the 17-hydroxylated steroids to dehydroepiandrosterone and androstenedione, respectively (17,20-lyase activity). Most mammalian CYP17 isoforms have high 17 alpha-hydroxylase relative to 17,20-lyase activities and preferentially mediate one of the two 17,20-lyase reactions. In contrast, Xenopus laevis CYP17 potently regulates all four reactions in the frog ovary. CYP17 isoforms generally rely on the cofactor cytochrome b(5) for the 17,20-lyase reaction, suggesting that the high lyase activity of Xenopus CYP17 might be due to a lesser dependence on b(5). The kinetics of Xenopus CYP17 expressed in yeast microsomes were therefore examined in the absence and presence of Xenopus on human b(5). Xenopus CYP17 mediated both 17,20-lyase reactions in the absence of b(5), confirming that the activity did not require b(5). However, both Xenopus and human b(5) slightly enhanced Xenopus CYP17-mediated lyase activity, indicating that the enzyme was still at least partially responsive to b(5). Surprisingly, only the human b(5) cofactor enhanced human CYP17-mediated lyase activity, implying that the human enzyme had more specific cofactor requirements than Xenopus CYP17. Studies using human/Xenopus chimeric b(5) proteins revealed that human b(5) residues 16-41 were important for the specific regulation of the lyase activity of HuCYP17, possibly serving as an interacting domain with the enzyme. CYP17 may therefore have evolved from a general producer of sex steroids in lower vertebrates to a more tightly regulated producer of both sex steroids and glucocorticoids in mammals.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammes, SR (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Endocrinol & Metab, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	stephen.hammes@utsouthwestern.edu		Yang, Wei-Hsiung/0000-0002-2904-1143	NIDDK NIH HHS [DK59913, R01 DK059913] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059913] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMOUR KJ, 1993, J MOL ENDOCRINOL, V10, P235, DOI 10.1677/jme.0.0100235; Auchus RJ, 2004, CLIN ENDOCRINOL, V60, P288, DOI 10.1046/j.1365-2265.2003.01858.x; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Cloutier M, 1997, DNA CELL BIOL, V16, P357, DOI 10.1089/dna.1997.16.357; DE L, 1998, J CLIN ENDOCR METAB, V83, P99; Geller DH, 1999, MOL ENDOCRINOL, V13, P167, DOI 10.1210/me.13.1.167; Gupta MK, 2001, J CLIN ENDOCR METAB, V86, P4416, DOI 10.1210/jc.86.9.4416; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hillier SG, 1997, BAILLIERE CLIN OB GY, V11, P249, DOI 10.1016/S0950-3552(97)80036-3; HOLMANS PL, 1994, ARCH BIOCHEM BIOPHYS, V312, P554, DOI 10.1006/abbi.1994.1345; Hu YC, 2004, P NATL ACAD SCI USA, V101, P11209, DOI 10.1073/pnas.0404372101; ITO Y, 1993, P NATL ACAD SCI USA, V90, P11673, DOI 10.1073/pnas.90.24.11673; KATAGIRI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P343, DOI 10.1006/abbi.1995.1173; KOH YC, 1993, J BIOL CHEM, V268, P18267; LIN D, 1993, ENDOCRINOLOGY, V132, P2498, DOI 10.1210/en.132.6.2498; Lutz LB, 2001, P NATL ACAD SCI USA, V98, P13728, DOI 10.1073/pnas.241471598; Lutz LB, 2003, MOL ENDOCRINOL, V17, P1106, DOI 10.1210/me.2003-0032; PACHE TD, 1991, HISTOPATHOLOGY, V19, P445, DOI 10.1111/j.1365-2559.1991.tb00235.x; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; Rainey WE, 2002, TRENDS ENDOCRIN MET, V13, P234, DOI 10.1016/S1043-2760(02)00609-4; REDSHAW MR, 1969, J ENDOCRINOL, V43, P47, DOI 10.1677/joe.0.0430047; SANDOR T, 1970, CAN J BIOCHEM CELL B, V48, P553, DOI 10.1139/o70-091; Sherbet DP, 2003, J BIOL CHEM, V278, P48563, DOI 10.1074/jbc.M307586200; Simpson E, 2000, TRENDS ENDOCRIN MET, V11, P184, DOI 10.1016/S1043-2760(00)00254-X; SIMPSON TH, 1970, J ENDOCRINOL, V46, P261, DOI 10.1677/joe.0.0460261; Speiser PW, 2001, J ENDOCRINOL INVEST, V24, P681, DOI 10.1007/BF03343913; TREMBLAY Y, 1995, ENDOCR RES, V21, P495, DOI 10.3109/07435809509030467; Yang WH, 2003, J BIOL CHEM, V278, P9552, DOI 10.1074/jbc.M212027200; YOUNGBLOOD GL, 1992, MOL ENDOCRINOL, V6, P927, DOI 10.1210/me.6.6.927; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	30	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10196	10201		10.1074/jbc.M411886200	http://dx.doi.org/10.1074/jbc.M411886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640159	Green Accepted, hybrid			2022-12-27	WOS:000227559600057
J	Cui, QL; Zheng, WH; Quirion, R; Almazan, G				Cui, QL; Zheng, WH; Quirion, R; Almazan, G			Inhibition of Src-like kinases reveals Akt-dependent and -independent pathways in insulin-like growth factor I-mediated oligodendrocyte progenitor survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FYN TYROSINE KINASE; PROTEIN-KINASE; CELL-SURVIVAL; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; NEURONAL SURVIVAL; MORPHOLOGICAL-DIFFERENTIATION; CASPASE-3 ACTIVATION; SIGNALING PATHWAYS; MAPK ACTIVATION	Insulin-like growth factor I (IGF-I) has been previously shown to promote survival of oligodendrocyte progenitors; however, the underlying mechanisms are not fully understood. Our aim was to investigate the involvement of phosphatidylinositol 3-kinase (PI3K), MEK1, and Src family tyrosine kinases in IGF-I-mediated oligodendrocyte progenitor survival. In agreement with previous studies, IGF-I promoted cell survival. We show that IGF-I prevented apoptosis induced by growth factor deprivation in a PI3K-dependent and MEK/ERK-independent manner. In addition, IGF-I activated Akt while inhibiting caspase-3 activation, and these effects were reversed by the PI3K inhibitors LY 294002 and wortmannin, but not by the MEK1 inhibitor PD 98059. Interestingly, PP2, a specific Src-like kinase inhibitor, blocked the tyrosine phosphorylation of Src, Fyn, and Lyn and IGF-I-stimulated Akt activation, yet had no significant effects on caspase-3 activation or progenitor survival. To further determine whether Akt is required for IGF-I-mediated survival, oligodendrocyte progenitors were transduced with defective Akt mutants or treated with an Akt inhibitor. Although the Akt mutants and inhibitor decreased Akt activity and reduced basal cell survival, IGF-I could partially rescue oligodendrocyte progenitors by decreasing caspase-3 activation. These results suggest that 1) PI3K is essential for IGF-I-promoted cell survival, 2) downstream activation of Akt-dependent and -independent pathways is involved, and 3) Src-like tyrosine kinases participate in IGF-I-induced Akt activation. Therefore, an unidentified effector(s) of PI3K appears to be involved in conferring complete IGF-I-mediated protection of oligodendrocyte progenitors.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Psychiat, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Almazan, G (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, Rm 1321,3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	guillermina.almazan@mcgill.ca	yang, chao/AAV-5929-2021; Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Campana WM, 1999, J NEUROSCI RES, V57, P332; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao Y, 2003, J CEREBR BLOOD F MET, V23, P739, DOI 10.1097/01.WCB.0000067720.12805.6F; Chattopadhyay A, 2002, J CELL SCI, V115, P2233; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; COHEN RI, 1994, EUR J NEUROSCI, V6, P1213, DOI 10.1111/j.1460-9568.1994.tb00620.x; Colognato H, 2004, J CELL BIOL, V167, P365, DOI 10.1083/jcb.200404076; Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200; Craparo A, 1997, J BIOL CHEM, V272, P11663; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Delaney CL, 1999, J NEUROBIOL, V41, P540, DOI 10.1002/(SICI)1097-4695(199912)41:4<540::AID-NEU9>3.0.CO;2-P; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ebner S, 2000, J NEUROSCI RES, V62, P336; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Flores AI, 2000, J NEUROSCI, V20, P7622; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Guan J, 2001, J CEREBR BLOOD F MET, V21, P493, DOI 10.1097/00004647-200105000-00003; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P10351, DOI 10.1021/bi026065r; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Khorchid A, 2002, GLIA, V40, P283, DOI 10.1002/glia.10123; Khorchid A, 1999, J NEUROSCI RES, V58, P765; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; Larocque D, 2002, NEURON, V36, P815, DOI 10.1016/S0896-6273(02)01055-3; Liu EM, 2003, PEDIATR RES, V54, P919, DOI 10.1203/01.PDR.0000088067.04673.1B; Liu HN, 1995, EUR J NEUROSCI, V7, P2355, DOI 10.1111/j.1460-9568.1995.tb01032.x; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Mason JL, 2000, J NEUROSCI, V20, P5703, DOI 10.1523/JNEUROSCI.20-15-05703.2000; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Ness JK, 2002, MOL CELL NEUROSCI, V20, P476, DOI 10.1006/mcne.2002.1149; Ness JK, 2002, DEV NEUROSCI-BASEL, V24, P437, DOI 10.1159/000069050; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peruzzi F, 2001, J BIOL CHEM, V276, P25990, DOI 10.1074/jbc.M103188200; POMERANCE M, 1994, CELL MOL BIOL, V40, P653; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rodgers EE, 2002, INT J DEV NEUROSCI, V20, P187, DOI 10.1016/S0736-5748(02)00047-3; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Shah OJ, 2002, BIOCHEM J, V366, P57, DOI 10.1042/BJ20020198; Soane L, 2001, J IMMUNOL, V167, P2305, DOI 10.4049/jimmunol.167.4.2305; Sperber BR, 2001, J NEUROSCI RES, V63, P303, DOI 10.1002/1097-4547(20010215)63:4<303::AID-JNR1024>3.0.CO;2-A; Sperber BR, 2001, J NEUROSCI, V21, P2039, DOI 10.1523/JNEUROSCI.21-06-02039.2001; Takano R, 2000, J BIOL CHEM, V275, P16360, DOI 10.1074/jbc.M910419199; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Umemori H, 1999, J NEUROSCI, V19, P1393; Vemuri GS, 1996, DEVELOPMENT, V122, P2529; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Webster HD, 1997, MULT SCLER J, V3, P113, DOI 10.1177/135245859700300210; Yamada M, 2001, J NEUROCHEM, V78, P940, DOI 10.1046/j.1471-4159.2001.00497.x; Ye P, 2000, J NEUROSCI RES, V62, P700, DOI 10.1002/1097-4547(20001201)62:5<700::AID-JNR9>3.0.CO;2-1; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	66	68	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8918	8928		10.1074/jbc.M414267200	http://dx.doi.org/10.1074/jbc.M414267200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632127	hybrid			2022-12-27	WOS:000227453100038
J	Fuenzalida, KM; Aguilera, MC; Piderit, DG; Ramos, PC; Contador, D; Quinones, V; Rigotti, A; Bronfman, FC; Bronfman, M				Fuenzalida, KM; Aguilera, MC; Piderit, DG; Ramos, PC; Contador, D; Quinones, V; Rigotti, A; Bronfman, FC; Bronfman, M			Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGODENDROCYTE-LIKE CELLS; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); PROTEIN-KINASE; ALZHEIMERS-DISEASE; TERMINAL DIFFERENTIATION; NEURITE OUTGROWTH; UP-REGULATION; AGONISTS; NEUROTROPHINS	Peroxisome proliferator- activated receptor gamma ( PPARgamma), a member of the nuclear receptor superfamily, is subject to considerable interest because of its role in adipocyte differentiation, metabolic control, and anti- inflammatory action. PPARgamma research in brain cells is presently focused on glial PPARgamma because of its potential as a pharmacological target in the treatment of neurodegenerative diseases with an inflammatory component. In neurons PPARgamma function is far from clear, and PPARgamma agonist-dependent and -independent effects on cell survival or differentiation have been reported. We used PC12 cells, widely used to study neuronal signaling, such as nerve growth factor (NGF)-induced differentiation and survival or epidermal growth factor-dependent cell proliferation to dissect the possible involvement of PPARgamma in these pathways. We show that NGF but not epidermal growth factor increases the transcriptional activity of PPARgamma, and modulates the expression of this transcription factor. Because NGF signals through the tyrosine kinase (TrkA) NGF receptor and/ or the p75(NTR) receptor, we used rescue experiments with a PC12 cell mutant lacking TrkA to show that NGF- induced PPARgamma activation is dependent on TrkA activation. Our results point out PPARgamma as a novel target of the TrkA-mediated neuronal cell survival and differentiating pathway and suggest a potential new inflammatory-independent therapeutic approach for pharmacological intervention in neurological disorders.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Regulac Celular & Patol, Dept Cellular & Mol Biol, Santiago, Chile; Pontificia Univ Catolica Chile, Fac Biol Sci, Millenium Inst Fundamental & Appl Biol, Santiago, Chile; Pontificia Univ Catolica Chile, Fac Med, Dept Gastroenterol, Santiago, Chile	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Bronfman, M (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Regulac Celular & Patol, Dept Cellular & Mol Biol, Casilla 114-D, Santiago, Chile.	mbronfma@bio.puc.cl	Ramos, Patricio/B-6665-2017; Ramos, Patricio/ABE-5961-2021	Ramos, Patricio/0000-0001-8341-314X; Fuenzalida, Karen/0000-0001-8829-7336; Contador, David/0000-0002-0383-214X				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Aoun P, 2003, EUR J PHARMACOL, V472, P65, DOI 10.1016/S0014-2999(03)01867-3; Camp HS, 1997, J BIOL CHEM, V272, P10811; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Conner JM, 2001, P NATL ACAD SCI USA, V98, P1941, DOI 10.1073/pnas.98.4.1941; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Feinstein DL, 2002, ANN NEUROL, V51, P694, DOI 10.1002/ana.10206; Feinstein Douglas L, 2003, Diabetes Technol Ther, V5, P67, DOI 10.1089/152091503763816481; FINK DW, 1990, J NEUROCHEM, V55, P1716, DOI 10.1111/j.1471-4159.1990.tb04961.x; Floyd ZE, 2002, J BIOL CHEM, V277, P4062, DOI 10.1074/jbc.M108473200; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Heneka MT, 2000, J NEUROSCI, V20, P6862, DOI 10.1523/JNEUROSCI.20-18-06862.2000; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; INESTROSA NC, 2005, IN PRESS EXP CELL RE; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; Jung KM, 2003, MOL PHARMACOL, V63, P607, DOI 10.1124/mol.63.3.607; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Landreth GE, 2001, NEUROBIOL AGING, V22, P937, DOI 10.1016/S0197-4580(01)00296-2; Leisewitz AV, 2003, J NEUROCHEM, V85, P135, DOI 10.1046/j.1471-4159.2003.01641.x; Lim SY, 2004, J BIOL CHEM, V279, P46263, DOI 10.1074/jbc.M406555200; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakashima S, 2003, BIOCHEM J, V376, P655, DOI 10.1042/BJ20030830; Nishijima C, 2001, J NEUROCHEM, V76, P383, DOI 10.1046/j.1471-4159.2001.00039.x; Park KS, 2004, EXP CELL RES, V297, P424, DOI 10.1016/j.yexcr.2004.03.034; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Rohn TT, 2001, NEUROREPORT, V12, P839, DOI 10.1097/00001756-200103260-00043; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Roth AD, 2003, J NEUROSCI RES, V72, P425, DOI 10.1002/jnr.10596; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Teng KK, 2004, CELL MOL LIFE SCI, V61, P35, DOI 10.1007/s00018-003-3099-3; Varley CL, 2004, J CELL SCI, V117, P2029, DOI 10.1242/jcs.01042; Watson GS, 2003, CNS DRUGS, V17, P27, DOI 10.2165/00023210-200317010-00003; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	43	36	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9604	9609		10.1074/jbc.M409447200	http://dx.doi.org/10.1074/jbc.M409447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632188	hybrid			2022-12-27	WOS:000227453100115
J	Funke, S; Knechten, T; Ollesch, J; Schunemann, D				Funke, S; Knechten, T; Ollesch, J; Schunemann, D			A unique sequence motif in the 54-kDa subunit of the chloroplast signal recognition particle mediates binding to the 43-kDa subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; THYLAKOID MEMBRANES; POSTTRANSLATIONAL INTEGRATION; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; HOMOLOG; ARABIDOPSIS; CPSRP54; CHAINS; SITE	Chloroplasts contain a novel type of signal recognition particle (cpSRP) that consists of two proteins, cpSRP54 and cpSRP43. cpSRP is involved in the post-translational targeting of the nuclear encoded light-harvesting chlorophyll-binding proteins (LHCPs) to the thylakoid membrane by forming a soluble cpSRP.LHCP transit complex in the stroma. Despite high sequence homology between chloroplast and cytosolic SRP54 proteins, the 54-kDa subunit of cpSRP is unique in its ability to bind cpSRP43. In this report, we identified a 10-amino acid long segment of cpSRP54 that forms the cpSRP43-binding site. This segment is located at position 530-539 close to the C terminus of cpSRP54. In addition, we demonstrate that arginine at position 537 is essential for binding cpSRP43 and that mutation of arginine 536 drastically reduced cpSRP43 binding. Mutations within the cpSRP43-binding site of cpSRP54 that reduced or completely abolished cpSRP complex formation also did inhibit transit complex formation and integration of LHCP into the thylakoid membrane, reflecting the importance of these residues for LHCP targeting. Alignment studies revealed that the cpSRP43-binding site is conserved in chloroplast SRP54 proteins and is not present in any SRP54 subunit of cytosolic SRPs.	Ruhr Univ Bochum, Lehrstuhl Allgemeine & Mol Bot, D-44780 Bochum, Germany; Rhein Westfal TH Aachen, Inst Biol 2, D-52074 Aachen, Germany; Ruhr Univ Bochum, Lehrstuhl Biophys, D-44780 Bochum, Germany	Ruhr University Bochum; RWTH Aachen University; Ruhr University Bochum	Schunemann, D (corresponding author), Ruhr Univ Bochum, Lehrstuhl Allgemeine & Mol Bot, D-44780 Bochum, Germany.	Danja.Schuenemann@ruhr-uni-bochum.de						Amin P, 1999, PLANT PHYSIOL, V121, P61, DOI 10.1104/pp.121.1.61; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Groves MR, 2001, J BIOL CHEM, V276, P27778, DOI 10.1074/jbc.M103470200; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; Jonas-Straube E, 2001, J BIOL CHEM, V276, P24654, DOI 10.1074/jbc.M100153200; Klimyuk VI, 1999, PLANT CELL, V11, P87, DOI 10.1105/tpc.11.1.87; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Nilsson R, 2002, FEBS LETT, V524, P127, DOI 10.1016/S0014-5793(02)03016-8; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; Pilgrim ML, 1998, PLANT J, V13, P177, DOI 10.1046/j.1365-313X.1998.00021.x; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Schuenemann D, 1999, BIOCHEM BIOPH RES CO, V254, P253, DOI 10.1006/bbrc.1998.9923; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	23	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8912	8917		10.1074/jbc.M409992200	http://dx.doi.org/10.1074/jbc.M409992200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632183	hybrid			2022-12-27	WOS:000227453100037
J	Olivero, AG; Eigenbrot, C; Goldsmith, R; Robarge, K; Artis, DR; Flygare, J; Rawson, T; Sutherlin, DP; Kadkhodayan, S; Beresini, M; Elliott, LO; DeGuzman, GG; Banner, DW; Ultsch, M; Marzec, U; Hanson, SR; Refino, C; Bunting, S; Kirchhofer, D				Olivero, AG; Eigenbrot, C; Goldsmith, R; Robarge, K; Artis, DR; Flygare, J; Rawson, T; Sutherlin, DP; Kadkhodayan, S; Beresini, M; Elliott, LO; DeGuzman, GG; Banner, DW; Ultsch, M; Marzec, U; Hanson, SR; Refino, C; Bunting, S; Kirchhofer, D			A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITISSUE FACTOR ANTIBODY; HEPATOCYTE GROWTH-FACTOR; TISSUE FACTOR MUTANT; EXFOLIATIVE TOXIN-B; CRYSTAL-STRUCTURE; COAGULATION-FACTOR; PYRAZINONE ANTITHROMBOTICS; ARTERIAL THROMBOSIS; SERINE-PROTEASE; FACTOR-X	The serine protease factor VIIa ( FVIIa) in complex with its cellular cofactor tissue factor ( TF) initiates the blood coagulation reactions. TF.FVIIa is also implicated in thrombosis-related disorders and constitutes an appealing therapeutic target for treatment of cardiovascular diseases. To this end, we generated the FVIIa active site inhibitor G17905, which displayed great potency toward TF.FVIIa (K-i = 0.35 +/- 0.11 nM). G17905 did not appreciably inhibit 12 of the 14 examined trypsin-like serine proteases, consistent with its TF.FVIIa- specific activity in clotting assays. The crystal structure of the FVIIa.G17905 complex provides insight into the molecular basis of the high selectivity. It shows that, compared with other serine proteases, FVIIa is uniquely equipped to accommodate conformational disturbances in the Gln(217) - Gly(219) region caused by the ortho-hydroxy group of the inhibitor's aminobenzamidine moiety located in the S1 recognition pocket. Moreover, the structure revealed a novel, nonstandard conformation of FVIIa active site in the region of the oxyanion hole, a "flipped" Lys(192)-Gly(193) peptide bond. Macromolecular substrate activation assays demonstrated that G17905 is a noncompetitive, slow-binding inhibitor. Nevertheless, G17905 effectively inhibited thrombus formation in a baboon arterio- venous shunt model, reducing platelet and fibrin deposition by similar to70% at 0.4 mg/ kg + 0.1 mg/ kg/ min infusion. Therefore, the in vitro potency of G17905, characterized by slow binding kinetics, correlated with efficacious antithrombotic activity in vivo.	Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA; Genentech Inc, Dept Med Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Res & Dev, San Francisco, CA 94080 USA; Emory Univ, Atlanta, GA 30322 USA; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Emory University; Roche Holding	Kirchhofer, D (corresponding author), Genentech Inc, Dept Physiol, 1 DNA Way, San Francisco, CA 94080 USA.	dak@gene.com						ALIAGAS IR, 2000, Patent No. 2000041531; Amagai M, 2000, NAT MED, V6, P1275, DOI 10.1038/81385; Amagai M, 2002, J INVEST DERMATOL, V118, P845, DOI 10.1046/j.1523-1747.2002.01751.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Belting M, 2004, NAT MED, V10, P502, DOI 10.1038/nm1037; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; BULLENS S, 2001, 18 C INT SOC THROM S; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Cavarelli J, 1997, STRUCTURE, V5, P813, DOI 10.1016/S0969-2126(97)00235-9; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P230; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Eigenbrot C, 2002, CURR PROTEIN PEPT SC, V3, P287, DOI 10.2174/1389203023380675; Eigenbrot C, 2002, TRENDS CARDIOVAS MED, V12, P19, DOI 10.1016/S1050-1738(01)00139-6; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; Erlich JH, 2000, AM J PATHOL, V157, P1849, DOI 10.1016/S0002-9440(10)64824-9; Erlich JH, 1997, AM J PATHOL, V150, P873; Falati S, 2003, J EXP MED, V197, P1585, DOI 10.1084/jem.20021868; FINGERLE J, 2001, 18 C INT SOC THROM S; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Gustafsson D, 2001, THROMB RES, V101, P171, DOI 10.1016/S0049-3848(00)00399-6; HARKER LA, 1991, CIRCULATION, V83, P41; Harker LA, 1996, HAEMOSTASIS, V26, P76; Hembrough TA, 2003, CANCER RES, V63, P2997; Himber J, 2003, J THROMB HAEMOST, V1, P889, DOI 10.1046/j.1538-7836.2003.00110.x; Himber J, 2001, THROMB HAEMOSTASIS, V85, P475; Himber J, 1997, THROMB HAEMOSTASIS, V78, P1142; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSH J, 1994, HEMOSTASIS THROMBOSI, P1567; Kaikita K, 1997, ARTERIOSCL THROM VAS, V17, P2232, DOI 10.1161/01.ATV.17.10.2232; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; Kelley RF, 1997, BLOOD, V89, P3219, DOI 10.1182/blood.V89.9.3219; Kemball-Cook G, 1999, J STRUCT BIOL, V127, P213, DOI 10.1006/jsbi.1999.4158; Kirchhofer D, 2003, J BIOL CHEM, V278, P36341, DOI 10.1074/jbc.M304643200; Kirchhofer D, 2000, BIOCHEMISTRY-US, V39, P7380, DOI 10.1021/bi000182+; Klingler O, 2004, BIOORG MED CHEM LETT, V14, P3715, DOI 10.1016/j.bmcl.2004.05.006; Klingler O, 2003, BIOORG MED CHEM LETT, V13, P1463, DOI 10.1016/S0960-894X(03)00168-9; Koopman MMW, 2003, J INTERN MED, V254, P335, DOI 10.1046/j.1365-2796.2003.01226.x; KRUPSKI WC, 1991, CIRCULATION, V84, P1749, DOI 10.1161/01.CIR.84.4.1749; Lazarus RA, 2004, CURR MED CHEM, V11, P2275, DOI 10.2174/0929867043364568; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; List K, 2003, J CELL BIOL, V163, P901, DOI 10.1083/jcb.200304161; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; Moll S, 2002, SEMIN HEMATOL, V39, P145, DOI 10.1053/shem.2002.34087; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papageorgiou AC, 2000, PROTEIN SCI, V9, P610; Parlow JJ, 2003, J MED CHEM, V46, P4696, DOI 10.1021/jm0301686; Parlow JJ, 2003, BIOORG MED CHEM LETT, V13, P3721, DOI 10.1016/j.bmcl.2003.08.002; Parlow JJ, 2003, J MED CHEM, V46, P4050, DOI 10.1021/jm030131l; Pawlinski R, 2002, P NATL ACAD SCI USA, V99, P15333, DOI 10.1073/pnas.242501899; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Persson E, 2004, BIOCHEM J, V379, P497, DOI 10.1042/BJ20031596; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Presta L, 2001, THROMB HAEMOSTASIS, V85, P379; Rauch U, 2000, BLOOD, V96, P170, DOI 10.1182/blood.V96.1.170.013k42_170_175; Rickles FR, 2003, CHEST, V124, p58S, DOI 10.1378/chest.124.3_suppl.58S; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; Sichler K, 2002, J MOL BIOL, V322, P591, DOI 10.1016/S0022-2836(02)00747-7; South MS, 2003, BIOORG MED CHEM LETT, V13, P2319, DOI 10.1016/S0960-894X(03)00410-4; Suleymanov OD, 2003, J PHARMACOL EXP THER, V306, P1115, DOI 10.1124/jpet.103.052779; Szalony JA, 2003, THROMB RES, V112, P167, DOI 10.1016/j.thromres.2003.10.017; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; Vath GM, 1999, BIOCHEMISTRY-US, V38, P10239, DOI 10.1021/bi990721e; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Weller T, 1996, J MED CHEM, V39, P3139, DOI 10.1021/jm9509298; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Zbinden KG, 2005, BIOORG MED CHEM LETT, V15, P817, DOI 10.1016/j.bmcl.2004.10.092	82	40	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9160	9169		10.1074/jbc.M409068200	http://dx.doi.org/10.1074/jbc.M409068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632123	hybrid			2022-12-27	WOS:000227453100065
J	Shulga, N; Hoek, JB; Pastorino, JG				Shulga, N; Hoek, JB; Pastorino, JG			Elevated PTEN levels account for the increased sensitivity of ethanol-exposed cells to tumor necrosis factor-induced cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-ALPHA; INDUCED APOPTOSIS; GLUTATHIONE DEPLETION; CYTOCHROME-C; P38 MAPK; AKT; ALCOHOL; DEATH; LIVER	Tumor necrosis factor alpha (TNF) is known to be one of the primary causative cytokines inflicting the characteristic damage to hepatocytes seen in alcoholic liver disease. TNF activates both cell survival and death-inducing signaling pathways. The balance between these two prongs determines the fate of the cell and the onset of disease. Ethanol exposure has been shown to alter mitochondrial function, decreasing their threshold for injury. Importantly, mitochondrial injury is a necessary end point of TNF-induced cell killing. It has been shown that ethanol exposure increases the sensitivity of hepatocytes and HepG2E47 cells to TNF-mediated death. The cumulative and terminal effect of the increased sensitivity to TNF caused by ethanol is an induction of a mitochondrial permeability transition. TNF brings about the mitochondrial permeability transition in ethanol-exposed cells due to amplification in the activity of the p38 stress kinase and a diminution in the activity of the antiapoptotic Akt/PKB kinase. The present report identifies an increase of PTEN expression in ethanol-exposed cells as the main causative factor in altering the balance between prosurvival and prodeath signals initiated by TNF. Suppression of the elevated PTEN levels found in ethanol-exposed HepG2E47 cells through the use of RNA interference reversed the ethanol-induced alterations to TNF signaling, resulting in a preservation of mitochondrial function and cell viability.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Pastorino, JG (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 272,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	John.Pastorino@jefferson.edu		Hoek, Jan/0000-0001-7127-4218	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K01AA000330] Funding Source: NIH RePORTER; NIAAA NIH HHS [K01-AA-00330-1] Funding Source: Medline; PHS HHS [1-R01-12897-01A2] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; Cahill A, 1999, HEPATOLOGY, V30, P881, DOI 10.1002/hep.510300434; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; DEACIUC IV, 1995, ALCOHOL CLIN EXP RES, V19, P332, DOI 10.1111/j.1530-0277.1995.tb01511.x; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; Diehl A M, 1997, Liver Transpl Surg, V3, P206, DOI 10.1002/lt.500030303; FELVER ME, 1990, ALCOHOL CLIN EXP RES, V14, P255, DOI 10.1111/j.1530-0277.1990.tb00482.x; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; LIEBER CS, 1994, METHOD ENZYMOL, V233, P585; LIEBER CS, 1994, GASTROENTEROLOGY, V106, P1085, DOI 10.1016/0016-5085(94)90772-2; Lin HZ, 1998, ALCOHOL CLIN EXP RES, V22, p231S, DOI 10.1111/j.1530-0277.1998.tb04008.x; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsumaru K, 2003, HEPATOLOGY, V37, P1425, DOI 10.1053/jhep.2003.50230; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Ozes ON, 1999, NATURE, V401, P82; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Pastorino JG, 1999, BIOCHEM BIOPH RES CO, V265, P405, DOI 10.1006/bbrc.1999.1696; Pastorino JG, 2000, HEPATOLOGY, V31, P1141, DOI 10.1053/he.2000.7013; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 2003, AM J PHYSIOL-GASTR L, V285, pG503, DOI 10.1152/ajpgi.00442.2002; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Slomiany BL, 1997, ALCOHOL CLIN EXP RES, V21, P1530; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Thurman RG, 1998, J GASTROEN HEPATOL, V13, pS39, DOI 10.1111/jgh.1998.13.s1.39; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yeon JE, 2003, HEPATOLOGY, V38, P703, DOI 10.1053/jhep.2003.50368; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9	50	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9416	9424		10.1074/jbc.M409505200	http://dx.doi.org/10.1074/jbc.M409505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15623531	hybrid			2022-12-27	WOS:000227453100094
J	Manno, S; Takakuwa, Y; Mohandas, N				Manno, S; Takakuwa, Y; Mohandas, N			Modulation of erythrocyte membrane mechanical function by protein 4.1 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELL; MARCKS-RELATED DOMAIN; KINASE-C; HEREDITARY ELLIPTOCYTOSIS; BINDING-PROTEIN; GLYCOPHORIN-C; ATTACHMENT SITES; BAND 4.1; SPECTRIN; ADDUCIN	Erythrocyte membrane mechanical function is regulated by the spectrin-based membrane skeleton composed of alpha-and beta-spectrin, actin, protein 4.1R (4.1R), and adducin. Post-translational modifications of these proteins have been suggested to modulate membrane mechanical function. Indeed, beta-spectrin phosphorylation by casein kinase I has been shown to decrease membrane mechanical stability. However, the effects of the phosphorylation of skeletal proteins by protein kinase C (PKC), a serine/threonine kinase, have not been elucidated. In the present study, we explored the functional consequences of the phosphorylation of 4.1R and adducin by PKC. We identified Ser-312 in 4.1R as the PKC phosphorylation site. Using antibodies raised against phosphopeptides of 4.1R and adducin, we documented significant differences in the time course of phosphorylation of adducin and 4.1R by PKC. Although adducin was phosphorylated rapidly by the activation of membrane-bound atypical PKC by phorbol 12-myristate 13-acetate stimulation, there was a significant delay in the phosphorylation of 4.1R because of delayed recruitment of conventional PKC from cytosol to the membrane. This differential time course in the phosphorylation of 4.1R and adducin in conjunction with membrane mechanical stability measurements enabled us to document that, although phosphorylation of adducin by PKC has little effect on membrane mechanical stability, additional phosphorylation of 4.1R results in a marked decrease in membrane mechanical stability. We further showed that the phosphorylation of 4.1R by PKC results in its decreased ability to form a ternary complex with spectrin and actin as well as dissociation of glycophorin C from the membrane skeleton. These findings have enabled us to define a regulatory role for 4.1R phosphorylation in dynamic regulation of red cell membrane properties.	Tokyo Womens Med Univ, Dept Biochem, Shinjuku Ku, Tokyo 1628666, Japan; New York Blood Ctr, New York, NY 10021 USA	Tokyo Women's Medical University; New York Blood Center	Mohandas, N (corresponding author), Red Cell Physiol Lab, 310 E 67th St, New York, NY 10021 USA.	MNarla@NYBloodcenter.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026263, R37DK026263, P01DK032094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32094, DK 26263] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD C, 1977, BLOOD CELLS, V3, P209; ALLOISIO N, 1985, BIOCHIM BIOPHYS ACTA, V816, P57, DOI 10.1016/0005-2736(85)90392-X; BENNETT V, 1988, J BIOL CHEM, V263, P60; BOIVIN P, 1988, BIOCHEM J, V256, P689, DOI 10.1042/bj2560689; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang SH, 2001, J BIOL CHEM, V276, P22223, DOI 10.1074/jbc.M100604200; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; COHEN CM, 1992, SEMIN HEMATOL, V29, P244; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; GALLAGHER PG, 1992, J CLIN INVEST, V89, P892, DOI 10.1172/JCI115669; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GASCARD P, 1994, BLOOD, V83, P1102; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; HORNE WC, 1990, BIOCHIM BIOPHYS ACTA, V1055, P87, DOI 10.1016/0167-4889(90)90095-U; HORNE WC, 1985, J BIOL CHEM, V260, P9073; JOSHI R, 1990, J BIOL CHEM, V265, P13130; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; LING E, 1988, J BIOL CHEM, V263, P2209; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; MANNO S, 1995, J BIOL CHEM, V270, P5659, DOI 10.1074/jbc.270.10.5659; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MOHANDAS N, 1982, BLOOD, V59, P768; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PINDER JC, 1995, BIOCHEM BIOPH RES CO, V210, P478, DOI 10.1006/bbrc.1995.1685; PINDER JC, 1993, BLOOD, V82, P3482; SHIMIZU T, 1995, HISTOCHEM CELL BIOL, V103, P363, DOI 10.1007/BF01457811; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; UNGEWICKELL E, 1979, NATURE, V280, P811, DOI 10.1038/280811a0; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143	43	162	170	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7581	7587		10.1074/jbc.M410650200	http://dx.doi.org/10.1074/jbc.M410650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15611095	hybrid			2022-12-27	WOS:000227395700020
